No_DT drug_NN ,_, nutritional_JJ supplement_NN ,_, food_NN or_CC herb_NN interactions_NNS have_VBP yet_RB been_VBN reported_VBN ._. No_DT formal_JJ drug/drug_NN interaction_NN studies_NNS with_IN Plenaxis_NNPS were_VBD performed_VBN ._. Cytochrome_NN P-450_NN is_VBZ not_RB known_VBN to_TO be_VB involved_VBN in_IN the_DT metabolism_NN of_IN Plenaxis_NNP ._. Plenaxis_NNP is_VBZ highly_RB bound_VBN to_TO plasma_NN proteins_NNS -LRB-_-LRB- 96_CD to_TO 99_CD %_NN -RRB-_-RRB- ._. Laboratory_NN Tests_NNS Response_NN to_TO Plenaxis_NNP should_MD be_VB monitored_VBN by_IN measuring_VBG serum_NN total_JJ testosterone_NN concentrations_NNS just_RB prior_RB to_TO administration_NN on_IN Day_NN 29_CD and_CC every_DT 8_CD weeks_NNS thereafter_RB ._. Serum_NN transaminase_NN levels_NNS should_MD be_VB obtained_VBN before_IN starting_VBG treatment_NN with_IN Plenaxis_NNPS and_CC periodically_RB during_IN treatment_NN ._. Periodic_JJ measurement_NN of_IN serum_NN PSA_NN levels_NNS may_MD also_RB be_VB considered_VBN ._. Formal_JJ drug_NN interaction_NN studies_NNS have_VBP not_RB been_VBN conducted_VBN with_IN ORENCIA_NN ._. Population_NNP pharmacokinetic_JJ analyses_NNS revealed_VBD that_IN MTX_NNP ,_, NSAIDs_NNS ,_, corticosteroids_NNS ,_, and_CC TNF_NN blocking_VBG agents_NNS did_VBD not_RB influence_VB abatacept_JJ clearance_NN ._. The_DT majority_NN of_IN patients_NNS in_IN RA_NN clinical_JJ studies_NNS received_VBD one_CD or_CC more_JJR of_IN the_DT following_VBG concomitant_JJ medications_NNS with_IN ORENCIA_NNP :_: MTX_NNP ,_, NSAIDs_NNS ,_, corticosteroids_NNS ,_, TNF_NN blocking_VBG agents_NNS ,_, azathioprine_NN ,_, chloroquine_NN ,_, gold_NN ,_, hydroxychloroquine_NN ,_, leflunomide_NN ,_, sulfasalazine_NN ,_, and_CC anakinra_NN ._. Concurrent_JJ administration_NN of_IN a_DT TNF_NN antagonist_NN with_IN ORENCIA_NNP has_VBZ been_VBN associated_VBN with_IN an_DT increased_VBN risk_NN of_IN serious_JJ infections_NNS and_CC no_DT significant_JJ additional_JJ efficacy_NN over_IN use_NN of_IN the_DT TNF_NN antagonists_NNS alone_RB ._. Concurrent_JJ therapy_NN with_IN ORENCIA_NN and_CC TNF_NN antagonists_NNS is_VBZ not_RB recommended_VBN ._. There_EX is_VBZ insufficient_JJ experience_NN to_TO assess_VB the_DT safety_NN and_CC efficacy_NN of_IN ORENCIA_NNP administered_VBN concurrently_RB with_IN anakinra_NN ,_, and_CC therefore_RB such_JJ use_NN is_VBZ not_RB recommended_VBN ._. Formal_JJ drug_NN interaction_NN studies_NNS with_IN Abciximab_NNP have_VBP not_RB been_VBN conducted_VBN ._. Abciximab_NNP has_VBZ been_VBN administered_VBN to_TO patients_NNS with_IN ischemic_JJ heart_NN disease_NN treated_VBN concomitantly_RB with_IN a_DT broad_JJ range_NN of_IN medications_NNS used_VBN in_IN the_DT treatment_NN of_IN angina_NN myocardial_JJ infarction_NN and_CC hypertension_NN ._. These_DT medications_NNS have_VBP included_VBN heparin_NN ,_, warfarin_NN ,_, beta-adrenergic_JJ receptor_NN blockers_NNS ,_, calcium_NN channel_NN antagonists_NNS ,_, angiotensin_NN converting_VBG enzyme_NN inhibitors_NNS ,_, intravenous_JJ and_CC oral_JJ nitrates_NNS ,_, ticlopidine_NN ,_, and_CC aspirin_NN ._. Heparin_NN ,_, other_JJ anticoagulants_NNS ,_, thrombolytics_NNS ,_, and_CC anti_JJ platelet_NN agents_NNS are_VBP associated_VBN with_IN an_DT increase_NN in_IN bleeding_NN ._. Patients_NNS with_IN HACA_NN titers_NNS may_MD have_VB allergic_JJ or_CC hypersensitivity_NN reactions_NNS when_WRB treated_VBN with_IN other_JJ diagnostic_JJ or_CC therapeutic_JJ monoclonal_JJ antibodies_NNS ._. The_DT concomitant_JJ intake_NN of_IN alcohol_NN and_CC Acamprosate_NN does_VBZ not_RB affect_VB the_DT pharmacokinetics_NNS of_IN either_CC alcohol_NN or_CC acamprosate_NN ._. Pharmacokinetic_JJ studies_NNS indicate_VBP that_IN administration_NN of_IN disulfiram_NN or_CC diazepam_NN does_VBZ not_RB affect_VB the_DT pharmacokinetics_NNS of_IN acamprosate_NN ._. Co-administration_NN of_IN naltrexone_NN with_IN Acamprosate_NNP produced_VBD a_DT 25_CD %_NN increase_NN in_IN AUC_NN and_CC a_DT 33_CD %_NN increase_NN in_IN the_DT Cmax_NN of_IN acamprosate_NN ._. No_DT adjustment_NN of_IN dosage_NN is_VBZ recommended_VBN in_IN such_JJ patients_NNS ._. The_DT pharmacokinetics_NNS of_IN naltrexone_NN and_CC its_PRP$ major_JJ metabolite_NN 6-beta-naltrexol_NN were_VBD unaffected_JJ following_VBG co-administration_NN with_IN Acamprosate_NNP ._. Other_JJ concomitant_JJ therapies_NNS :_: In_IN clinical_JJ trials_NNS ,_, the_DT safety_NN profile_NN in_IN subjects_NNS treated_VBN with_IN Acamprosate_NNP concomitantly_RB with_IN anxiolytics_NNS ,_, hypnotics_NNS and_CC sedatives_NNS -LRB-_-LRB- including_VBG benzodiazepines_NNS -RRB-_-RRB- ,_, or_CC non-opioid_JJ analgesics_NNS was_VBD similar_JJ to_TO that_DT of_IN subjects_NNS taking_VBG placebo_NN with_IN these_DT concomitant_JJ medications_NNS ._. Patients_NNS taking_VBG Acamprosate_NNP concomitantly_RB with_IN antidepressants_NNS more_RBR commonly_RB reported_VBD both_CC weight_NN gain_NN and_CC weight_NN loss_NN ,_, compared_VBN with_IN patients_NNS taking_VBG either_CC medication_NN alone_RB ._. Certain_JJ drugs_NNS tend_VBP to_TO produce_VB hyperglycemia_NN and_CC may_MD lead_VB to_TO loss_NN of_IN blood_NN glucose_NN control_NN ._. These_DT drugs_NNS include_VBP the_DT thiazides_NNS and_CC other_JJ diuretics_NNS ,_, corticosteroids_NNS ,_, phenothiazines_NNS ,_, thyroid_NN products_NNS ,_, estrogens_NNS ,_, oral_JJ contraceptives_NNS ,_, phenytoin_NN ,_, nicotinic_JJ acid_NN ,_, sympathomimetics_NNS ,_, calcium_NN channel-blocking_NN drugs_NNS ,_, and_CC isoniazid_NN ._. When_WRB such_JJ drugs_NNS are_VBP administered_VBN to_TO a_DT patient_NN receiving_VBG Acarbose_NNP ,_, the_DT patient_NN should_MD be_VB closely_RB observed_VBN for_IN loss_NN of_IN blood_NN glucose_NN control_NN ._. When_WRB such_JJ drugs_NNS are_VBP withdrawn_VBN from_IN patients_NNS receiving_VBG Acarbose_NNP in_IN combination_NN with_IN sulfonylureas_NNS or_CC insulin_NN ,_, patients_NNS should_MD be_VB observed_VBN closely_RB for_IN any_DT evidence_NN of_IN hypoglycemia_NN ._. Intestinal_JJ adsorbents_NNS -LRB-_-LRB- e._FW g._FW ,_, charcoal_NN -RRB-_-RRB- and_CC digestive_JJ enzyme_NN preparations_NNS containing_VBG carbohydrate-splitting_JJ enzymes_NNS -LRB-_-LRB- e._FW g._FW ,_, amylase_NN ,_, pancreatin_NN -RRB-_-RRB- may_MD reduce_VB the_DT effect_NN of_IN Acarbose_NNP and_CC should_MD not_RB be_VB taken_VBN concomitantly_RB ._. Acarbose_NNP has_VBZ been_VBN shown_VBN to_TO change_VB the_DT bioavailabillty_NN digoxin_NN when_WRB they_PRP are_VBP co-administered_JJ ,_, which_WDT may_MD require_VB digoxin_NN dose_NN adjustment_NN ._. Studies_NNS in_IN healthy_JJ volunteers_NNS have_VBP shown_VBN that_IN Acarbose_NNP has_VBZ no_DT effect_NN on_IN either_CC the_DT pharmacokinetics_NNS or_CC pharmacodynamics_NNS of_IN digoxin_NN ,_, nifedipine_NN ,_, propranolol_NN ,_, or_CC ranitidine_NN ._. Acarbose_NNP did_VBD not_RB interfere_VB with_IN the_DT absorption_NN or_CC disposition_NN of_IN the_DT sulfonylurea_NN glyburide_NN in_IN diabetic_JJ patients_NNS ._. Acarbose_NNP may_MD affect_VB digoxin_NN bioavailabillty_NN and_CC may_MD require_VB dose_NN adjustment_NN of_IN digoxin_NN by_IN 16_CD %_NN -LRB-_-LRB- 90_CD %_NN confidence_NN interval_NN :_: 8-23_CD %_NN -RRB-_-RRB- ,_, decrease_NN mean_NN C_NN max_NN digoxin_NN by_IN 26_CD %_NN -LRB-_-LRB- 90_CD %_NN confidence_NN interval_NN :_: 16-34_CD %_NN -RRB-_-RRB- and_CC decrease_VB mean_JJ trough_NN concentrations_NNS of_IN digoxin_NN by_IN 9_CD %_NN -LRB-_-LRB- 90_CD %_NN confidence_NN limit_NN :_: 19_CD %_NN decrease_NN to_TO 2_CD %_NN increase_NN -RRB-_-RRB- ._. The_DT amount_NN of_IN metformin_NN absorbed_VBN while_IN taking_VBG Acarbose_NNP was_VBD bioequivalent_JJ to_TO the_DT amount_NN absorbed_VBN when_WRB taking_VBG placebo_NN ,_, as_IN indicated_VBN by_IN the_DT plasma_NN AUC_NN values_NNS ._. However_RB ,_, the_DT peak_NN plasma_NN level_NN of_IN metformin_NN was_VBD reduced_VBN by_IN approximately_RB 20_CD %_NN when_WRB taking_VBG Acarbose_NNP due_JJ to_TO a_DT slight_JJ delay_NN in_IN the_DT absorption_NN of_IN metformin_NN ._. There_EX is_VBZ little_JJ if_IN any_DT clinically_RB significant_JJ interaction_NN between_IN Acarbose_NNP and_CC metformin_NN ._. Catecholamine-depleting_JJ drugs_NNS ,_, such_JJ as_IN reserpine_NN ,_, may_MD have_VB an_DT additive_JJ effect_NN when_WRB given_VBN with_IN beta-blocking_JJ agents_NNS ._. Patients_NNS treated_VBN with_IN acebutolol_NN plus_CC catecholamine_NN depletors_NNS should_MD ,_, therefore_RB ,_, be_VB observed_VBN closely_RB for_IN evidence_NN of_IN marked_JJ bradycardia_NN or_CC hypotension_NN which_WDT may_MD present_VB as_IN vertigo_NN ,_, syncope/presyncope_NN ,_, or_CC orthostatic_JJ changes_NNS in_IN blood_NN pressure_NN without_IN compensatory_JJ tachycardia_NN ._. Exaggerated_JJ hypertensive_JJ responses_NNS have_VBP been_VBN reported_VBN from_IN the_DT combined_VBN use_NN of_IN beta-adrenergic_JJ antagonists_NNS and_CC alpha-adrenergic_JJ stimulants_NNS ,_, including_VBG those_DT contained_VBN in_IN proprietary_JJ cold_JJ remedies_NNS and_CC vasoconstrictive_JJ nasal_JJ drops_NNS ._. Patients_NNS receiving_VBG beta-blockers_NNS should_MD be_VB warned_VBN of_IN this_DT potential_JJ hazard_NN ._. Blunting_VBG of_IN the_DT antihypertensive_JJ effect_NN of_IN beta-adrenoceptor_NN blocking_VBG agents_NNS by_IN nonsteroidal_JJ anti-inflammatory_JJ drugs_NNS has_VBZ been_VBN reported_VBN ._. No_DT significant_JJ interactions_NNS with_IN digoxin_NN ,_, hydrochlorothiazide_NN ,_, hydralazine_NN ,_, sulfinpyrazone_NN ,_, oral_JJ contraceptives_NNS ,_, tolbutamide_NN ,_, or_CC warfarin_NN have_VBP been_VBN observed_VBN ._. DIAMOX_NNP modifies_VBZ phenytoin_NN metabolism_NN with_IN increased_VBN serum_NN levels_NNS of_IN phenytoin_NN ._. This_DT may_MD increase_VB or_CC enhance_VB the_DT occurrence_NN of_IN osteomalacia_NN in_IN some_DT patients_NNS receiving_VBG chronic_JJ phenytoin_NN therapy_NN ._. Caution_NN is_VBZ advised_VBN in_IN patients_NNS receiving_VBG chronic_JJ concomitant_JJ therapy_NN ._. By_IN decreasing_VBG the_DT gastrointestinal_JJ absorption_NN of_IN primidone_NN ,_, DIAMOX_NNP may_MD decrease_VB serum_NN concentrations_NNS of_IN primidone_NN and_CC its_PRP$ metabolites_NNS ,_, with_IN a_DT consequent_JJ possible_JJ decrease_NN in_IN anticonvulsant_JJ effect_NN ._. Caution_NN is_VBZ advised_VBN when_WRB beginning_VBG ,_, discontinuing_VBG ,_, or_CC changing_VBG the_DT dose_NN of_IN DIAMOX_NNP in_IN patients_NNS receiving_VBG primidone_NN ._. Because_IN of_IN possible_JJ additive_JJ effects_NNS with_IN other_JJ carbonic_JJ anhydrase_NN inhibitors_NNS ,_, concomitant_JJ use_NN is_VBZ not_RB advisable_JJ ._. Acetazolamide_NNP may_MD increase_VB the_DT effects_NNS of_IN other_JJ folic_JJ acid_NN antagonists_NNS ._. Acetazolamide_NNP may_MD increase_VB or_CC decrease_VB blood_NN glucose_NN levels_NNS ._. Consideration_NN should_MD be_VB taken_VBN in_IN patients_NNS being_VBG treated_VBN with_IN antidiabetic_JJ agents_NNS ._. Acetazolamide_NN decreases_VBZ urinary_JJ excretion_NN of_IN amphetamine_NN and_CC may_MD enhance_VB the_DT magnitude_NN and_CC duration_NN of_IN their_PRP$ effect_NN ._. Acetazolamide_NNP reduces_VBZ urinary_JJ excretion_NN of_IN quinidine_NN and_CC may_MD enhance_VB its_PRP$ effect_NN ._. Acetazolamide_NNP may_MD prevent_VB the_DT urinary_JJ antiseptic_JJ effect_NN of_IN methenamine_NN ._. Acetazolamide_NNP increases_VBZ lithium_NN excretion_NN and_CC the_DT lithium_NN may_MD be_VB decreased_VBN ._. Acetazolamide_NNP and_CC sodium_NN bicarbonate_NN used_VBN concurrently_RB increases_VBZ the_DT risk_NN of_IN renal_JJ calculus_NN formation_NN ._. Acetazolamide_NNP may_MD elevate_VB cyclosporine_NN levels_NNS ._. Concomitant_JJ use_NN with_IN iron_NN supplements_NNS may_MD result_VB in_IN the_DT reduced_VBN absorption_NN of_IN iron_NN ._. Co-administration_NN of_IN probenecid_NN with_IN acyclovir_NN has_VBZ been_VBN shown_VBN to_TO increase_VB the_DT mean_NN half-life_NN and_CC the_DT area_NN under_IN the_DT concentration-time_JJ curve_NN ._. Urinary_JJ excretion_NN and_CC renal_JJ clearance_NN were_VBD correspondingly_RB reduced_VBN ._. The_DT clinical_JJ effects_NNS of_IN this_DT combination_NN have_VBP not_RB been_VBN studied_VBN ._. Ethanol_NN :_: Clinical_JJ evidence_NN has_VBZ shown_VBN that_IN etretinate_NN can_MD be_VB formed_VBN with_IN concurrent_JJ ingestion_NN of_IN acitretin_NN and_CC ethanol_NN ._. Glibenclamide_NNP :_: In_IN a_DT study_NN of_IN 7_CD healthy_JJ male_JJ volunteers_NNS ,_, acitretin_NN treatment_NN potentiated_VBD the_DT blood_NN glucose_NN lowering_VBG effect_NN of_IN glibenclamide_NN -LRB-_-LRB- a_DT sulfonylurea_NN similar_JJ to_TO chlorpropamide_NN -RRB-_-RRB- in_IN 3_CD of_IN the_DT 7_CD subjects_NNS ._. Repeating_VBG the_DT study_NN with_IN 6_CD healthy_JJ male_JJ volunteers_NNS in_IN the_DT absence_NN of_IN glibenclamide_NN did_VBD not_RB detect_VB an_DT effect_NN of_IN acitretin_NN on_IN glucose_NN tolerance_NN ._. Careful_JJ supervision_NN of_IN diabetic_JJ patients_NNS under_IN treatment_NN with_IN Soriatane_NN is_VBZ recommended_VBN ._. Hormonal_JJ Contraceptives_NNS :_: It_PRP has_VBZ not_RB been_VBN established_VBN if_IN there_EX is_VBZ a_DT pharmacokinetic_JJ interaction_NN between_IN acitretin_NN and_CC combined_VBN oral_JJ contraceptives_NNS ._. However_RB ,_, it_PRP has_VBZ been_VBN established_VBN that_IN acitretin_NN interferes_VBZ with_IN the_DT contraceptive_JJ effect_NN of_IN microdosed_JJ progestin_NN minipill_NN preparations_NNS ._. Microdosed_JJ minipill_NN progestin_NN preparations_NNS are_VBP not_RB recommended_VBN for_IN use_NN with_IN Soriatane_NN ._. It_PRP is_VBZ not_RB known_VBN whether_IN other_JJ progestational_JJ contraceptives_NNS ,_, such_JJ as_IN implants_NNS and_CC injectables_NNS ,_, are_VBP adequate_JJ methods_NNS of_IN contraception_NN during_IN acitretin_NN therapy_NN ._. Methotrexate_NNP :_: An_DT increased_VBN risk_NN of_IN hepatitis_NN has_VBZ been_VBN reported_VBN to_TO result_VB from_IN combined_VBN use_NN of_IN methotrexate_NN and_CC etretinate_NN ._. Consequently_RB ,_, the_DT combination_NN of_IN methotrexate_NN with_IN acitretin_NN is_VBZ also_RB contraindicated_VBN ._. Phenytoin_NNP :_: If_IN acitretin_NN is_VBZ given_VBN concurrently_RB with_IN phenytoin_NN ,_, the_DT protein_NN binding_NN of_IN phenytoin_NN may_MD be_VB reduced_VBN ._. Tetracyclines_NNS :_: Since_IN both_DT acitretin_NN and_CC tetracyclines_NNS can_MD cause_VB increased_VBN intracranial_JJ pressure_NN ,_, their_PRP$ combined_VBN use_NN is_VBZ contraindicated_VBN ._. Vitamin_NN A_NN and_CC oral_JJ retinoids_NNS :_: Concomitant_JJ administration_NN of_IN vitamin_NN A_NN and/or_CC other_JJ oral_JJ retinoids_NNS with_IN acitretin_NN must_MD be_VB avoided_VBN because_IN of_IN the_DT risk_NN of_IN hypervitaminosis_NN A._NN Other_JJ :_: There_EX appears_VBZ to_TO be_VB no_DT pharmacokinetic_JJ interaction_NN between_IN acitretin_NN and_CC cimetidine_NN ,_, digoxin_NN ,_, or_CC glyburide_NN ._. Investigations_NNS into_IN the_DT effect_NN of_IN acitretin_NN on_IN the_DT protein_NN binding_NN of_IN anticoagulants_NNS of_IN the_DT coumarin_NN type_NN -LRB-_-LRB- warfarin_NN -RRB-_-RRB- revealed_VBD no_DT interaction_NN ._. Laboratory_NN Tests_NNS If_IN significant_JJ abnormal_JJ laboratory_NN results_NNS are_VBP obtained_VBN ,_, either_CC dosage_NN reduction_NN with_IN careful_JJ monitoring_NN or_CC treatment_NN discontinuation_NN is_VBZ recommended_VBN ,_, depending_VBG on_IN clinical_JJ judgement_NN ._. Blood_NN Sugar_NNP :_: Some_DT patients_NNS receiving_VBG retinoids_NNS have_VBP experienced_VBN problems_NNS with_IN blood_NN sugar_NN control_NN ._. In_IN addition_NN ,_, new_JJ cases_NNS of_IN diabetes_NNS have_VBP been_VBN diagnosed_VBN during_IN retinoid_NN therapy_NN ,_, including_VBG diabetic_JJ ketoacidosis_NN ._. In_IN diabetics_NNS ,_, blood-sugar_JJ levels_NNS should_MD be_VB monitored_VBN very_RB carefully_RB ._. Lipids_NNS :_: In_IN clinical_JJ studies_NNS ,_, the_DT incidence_NN of_IN hypertriglyceridemia_NN was_VBD 66_CD %_NN ,_, hypercholesterolemia_NN was_VBD 33_CD %_NN and_CC that_IN of_IN decreased_VBN HDL_NN was_VBD 40_CD %_NN ._. Pretreatment_NN and_CC follow-up_NN measurements_NNS should_MD be_VB obtained_VBN under_IN fasting_NN conditions_NNS ._. It_PRP is_VBZ recommended_VBN that_IN these_DT tests_NNS be_VB performed_VBN weekly_JJ or_CC every_DT other_JJ week_NN until_IN the_DT lipid_NN response_NN to_TO Soriatane_NNP has_VBZ stabilized_VBN ._. Liver_NN Function_NN Tests_NNS :_: Elevations_NNS of_IN AST_NNP -LRB-_-LRB- SGOT_NNP -RRB-_-RRB- ,_, ALT_NN -LRB-_-LRB- SGPT_NN -RRB-_-RRB- or_CC LDH_NN were_VBD experienced_VBN by_IN approximately_RB 1_CD in_IN 3_CD patients_NNS treated_VBN with_IN Soriatane_NN ._. It_PRP is_VBZ recommended_VBN that_IN these_DT tests_NNS be_VB performed_VBN prior_RB to_TO initiation_NN of_IN Soriatane_NN therapy_NN ,_, at_IN 1_LS -_: to_TO 2-week_JJ intervals_NNS until_IN stable_JJ and_CC thereafter_RB at_IN intervals_NNS as_IN clinically_RB indicated_VBN ._. Methotrexate_NNP :_: HUMIRA_NNP has_VBZ been_VBN studied_VBN in_IN rheumatoid_JJ arthritis_NN patients_NNS taking_VBG concomitant_JJ MTX_NN ._. The_DT data_NNS do_VBP not_RB suggest_VB the_DT need_NN for_IN dose_NN adjustment_NN of_IN either_CC HUMIRA_NN or_CC MTX_NN ._. Anakinra_NNP :_: Concurrent_JJ administration_NN of_IN anakinra_NN -LRB-_-LRB- an_DT interleukin-1_NN antagonist_NN -RRB-_-RRB- and_CC another_DT TNF-blocking_JJ agent_NN has_VBZ been_VBN associated_VBN with_IN an_DT increased_VBN risk_NN of_IN serious_JJ infections_NNS ,_, an_DT increased_VBN risk_NN of_IN neutropenia_NN and_CC no_DT additional_JJ benefit_NN compared_VBN to_TO these_DT medicinal_JJ products_NNS alone_RB ._. The_DT safety_NN and_CC efficacy_NN of_IN anakinra_NN used_VBN in_IN combination_NN with_IN HUMIRA_NNP has_VBZ not_RB been_VBN studied_VBN ._. Therefore_RB the_DT ,_, combination_NN of_IN anakinra_NN with_IN other_JJ TNF-blocking_JJ agents_NNS ,_, including_VBG HUMIRA_NNP ,_, may_MD also_RB result_VB i_FW n_NN similar_JJ toxicities_NNS ._. As_IN DIFFERIN_NNP Gel_NN has_VBZ the_DT potential_JJ to_TO produce_VB local_JJ irritation_NN in_IN some_DT patients_NNS ,_, concomitant_JJ use_NN of_IN other_JJ potentially_RB irritating_JJ topical_JJ products_NNS -LRB-_-LRB- medicated_VBN or_CC abrasive_JJ soaps_NNS and_CC cleansers_NNS ,_, soaps_NNS and_CC cosmetics_NNS that_WDT have_VBP a_DT strong_JJ drying_VBG effect_NN ,_, and_CC products_NNS with_IN high_JJ concentrations_NNS of_IN alcohol_NN ,_, astringents_NNS ,_, spices_NNS or_CC lime_NN -RRB-_-RRB- should_MD be_VB approached_VBN with_IN caution_NN ._. Particular_JJ caution_NN should_MD be_VB exercised_VBN in_IN using_VBG preparations_NNS containing_VBG sulfur_NN ,_, resorcinol_NN ,_, or_CC salicylic_JJ acid_NN in_IN combination_NN with_IN DIFFERIN_NNP Gel_NN ._. If_IN these_DT preparations_NNS have_VBP been_VBN used_VBN it_PRP is_VBZ advisable_JJ not_RB to_TO start_VB therapy_NN with_IN DIFFERIN_NNP Gel_NN until_IN the_DT effects_NNS of_IN such_JJ preparations_NNS in_IN the_DT skin_NN have_VBP subsided_VBN ._. Before_IN using_VBG this_DT medication_NN ,_, tell_VB your_PRP$ doctor_NN or_CC pharmacist_NN of_IN all_DT prescription_NN and_CC nonprescription_NN products_NNS you_PRP may_MD use_VB ,_, especially_RB of_IN :_: aminoglycosides_NNS -LRB-_-LRB- e.g._FW ,_, gentamicin_NN ,_, amikacin_NN -RRB-_-RRB- ,_, amphotericin_NN B_NN ,_, cyclosporine_NN ,_, non-steroidal_JJ anti-inflammatory_JJ drugs_NNS -LRB-_-LRB- e.g._FW ,_, ibuprofen_NN -RRB-_-RRB- ,_, tacrolimus_NN ,_, vancomycin_NN ._. Do_VB not_RB start_VB or_CC stop_VB any_DT medicine_NN without_IN doctor_NN or_CC pharmacist_NN approval_NN ._. Intravenous_JJ Adenocard_NN -LRB-_-LRB- adenosine_NN -RRB-_-RRB- has_VBZ been_VBN effectively_RB administered_VBN in_IN the_DT presence_NN of_IN other_JJ cardioactive_JJ drugs_NNS ,_, such_JJ as_IN quinidine_NN ,_, beta-adrenergic_JJ blocking_VBG agents_NNS ,_, calcium_NN channel_NN blocking_VBG agents_NNS ,_, and_CC angiotensin_NN converting_NN enzyme_NN inhibitors_NNS ,_, without_IN any_DT change_NN in_IN the_DT adverse_JJ reaction_NN profile_NN ._. Digoxin_NN and_CC verapamil_NN use_NN may_MD be_VB rarely_RB associated_VBN with_IN ventricular_JJ fibrillation_NN when_WRB combined_VBN with_IN Adenocard_NNP ._. Because_IN of_IN the_DT potential_NN for_IN additive_JJ or_CC synergistic_JJ depressant_NN effects_NNS on_IN the_DT SA_NNP and_CC AV_NNP nodes_NNS ,_, however_RB ,_, Adenocard_NNP should_MD be_VB used_VBN with_IN caution_NN in_IN the_DT presence_NN of_IN these_DT agents_NNS ._. The_DT use_NN of_IN Adenocard_NNP in_IN patients_NNS receiving_VBG digitalis_NN may_MD be_VB rarely_RB associated_VBN with_IN ventricular_JJ fibrillation_NN ._. The_DT effects_NNS of_IN adenosine_NN are_VBP antagonized_VBN by_IN methylxanthines_NNS such_JJ as_IN caffeine_NN and_CC theophylline_NN ._. In_IN the_DT presence_NN of_IN these_DT methylxanthines_NNS ,_, larger_JJR doses_NNS of_IN adenosine_NN may_MD be_VB required_VBN or_CC adenosine_NN may_MD not_RB be_VB effective_JJ ._. Adenosine_NN effects_NNS are_VBP potentiated_VBN by_IN dipyridamole_NN ._. Thus_RB ,_, smaller_JJR doses_NNS of_IN adenosine_NN may_MD be_VB effective_JJ in_IN the_DT presence_NN of_IN dipyridamole_NN ._. Carbamazepine_NNP has_VBZ been_VBN reported_VBN to_TO increase_VB the_DT degree_NN of_IN heart_NN block_NN produced_VBN by_IN other_JJ agents_NNS ._. As_IN the_DT primary_JJ effect_NN of_IN adenosine_NN is_VBZ to_TO decrease_VB conduction_NN through_IN the_DT A-V_NN node_NN ,_, higher_JJR degrees_NNS of_IN heart_NN block_NN may_MD be_VB produced_VBN in_IN the_DT presence_NN of_IN carbamazepine_NN ._. Co-administration_NN with_IN antifungal_JJ agents_NNS such_JJ as_IN ketoconazole_NN or_CC itraconazole_NN is_VBZ not_RB recommended_VBN ._. Nafazodone_NNP ,_, fluvoxamine_NN ,_, cimetidine_NN -LRB-_-LRB- consider_VB Xanax_NNP dose_NN reduction_NN -RRB-_-RRB- ._. Fluoxetine_NNP ,_, OCs_NNP ,_, sertraline_NN ,_, diltiazem_NN ,_, macrolide_NN antibiotics_NNS -LRB-_-LRB- exercise_NN caution_NN -RRB-_-RRB- ._. No_DT drug_NN interaction_NN studies_NNS were_VBD performed_VBN ._. No_DT in_FW vitro_FW metabolism_NN studies_NNS were_VBD performed_VBN ._. Dexamethasone_NN :_: Steady-state_JJ trough_NN concentrations_NNS of_IN albendazole_NN sulfoxide_NN were_VBD about_IN 56_CD %_NN higher_JJR when_WRB 8_CD mg_NN dexamethasone_NN was_VBD coadministered_VBN with_IN each_DT dose_NN of_IN albendazole_NN -LRB-_-LRB- 15_CD mg/kg/day_NN -RRB-_-RRB- in_IN eight_CD neurocysticercosis_NN patients_NNS ._. Praziquantel_NNP :_: In_IN the_DT fed_NN state_NN ,_, praziquantel_NN -LRB-_-LRB- 40_CD mg/kg_NN -RRB-_-RRB- increased_VBD mean_JJ maximum_NN plasma_NN concentration_NN and_CC area_NN under_IN the_DT curve_NN of_IN albendazole_NN sulfoxide_NN by_IN about_IN 50_CD %_NN in_IN healthy_JJ subjects_NNS -LRB-_-LRB- n_NN =_JJ 10_CD -RRB-_-RRB- compared_VBN with_IN a_DT separate_JJ group_NN of_IN subjects_NNS -LRB-_-LRB- n_NN =_JJ 6_CD -RRB-_-RRB- given_VBN albendazole_NN alone_RB ._. Mean_NN T_NN max_NN and_CC mean_VB plasma_NN elimination_NN half-life_NN of_IN albendazole_NN sulfoxide_NN were_VBD unchanged_JJ ._. The_DT pharmacokinetics_NNS of_IN praziquantel_NN were_VBD unchanged_JJ following_VBG coadministration_NN with_IN albendazole_NN -LRB-_-LRB- 400_CD mg_NN -RRB-_-RRB- ._. Cimetidine_NNP :_: Albendazole_NNP sulfoxide_NN concentrations_NNS in_IN bile_NN and_CC cystic_JJ fluid_NN were_VBD increased_VBN -LRB-_-LRB- about_IN 2-fold_JJ -RRB-_-RRB- in_IN hydatid_NN cyst_NN patients_NNS treated_VBN with_IN cimetidine_NN -LRB-_-LRB- 10_CD mg/kg/day_NN -RRB-_-RRB- -LRB-_-LRB- n_NN =_JJ 7_CD -RRB-_-RRB- compared_VBN with_IN albendazole_NN -LRB-_-LRB- 20_CD mg/kg/day_NN -RRB-_-RRB- alone_RB -LRB-_-LRB- n_NN =_JJ 12_CD -RRB-_-RRB- ._. Albendazole_NNP sulfoxide_NN plasma_NN concentrations_NNS were_VBD unchanged_JJ 4_CD hours_NNS after_IN dosing_NN ._. Theophylline_NNP :_: The_DT pharmacokinetics_NNS of_IN theophylline_NN -LRB-_-LRB- aminophylline_NN 5.8_CD mg/kg_NN infused_VBD over_IN 20_CD minutes_NNS -RRB-_-RRB- were_VBD unchanged_JJ following_VBG a_DT single_JJ oral_JJ dose_NN of_IN albendazole_NN -LRB-_-LRB- 400_CD mg_NN -RRB-_-RRB- in_IN 6_CD healthy_JJ subjects_NNS ._. No_DT information_NN provided_VBN ._. PROLEUKIN_NNP may_MD affect_VB central_JJ nervous_JJ function_NN ._. Therefore_RB ,_, interactions_NNS could_MD occur_VB following_VBG concomitant_JJ administration_NN of_IN psychotropic_JJ drugs_NNS -LRB-_-LRB- e.g._FW ,_, narcotics_NNS ,_, analgesics_NNS ,_, antiemetics_NNS ,_, sedatives_NNS ,_, tranquilizers_NNS -RRB-_-RRB- ._. Concurrent_JJ administration_NN of_IN drugs_NNS possessing_VBG nephrotoxic_JJ -LRB-_-LRB- e.g._FW ,_, aminoglycosides_NNS ,_, indomethacin_NN -RRB-_-RRB- ,_, myelotoxic_JJ -LRB-_-LRB- e.g._FW ,_, cytotoxic_JJ chemotherapy_NN -RRB-_-RRB- ,_, cardiotoxic_JJ -LRB-_-LRB- e.g._FW ,_, doxorubicin_NN -RRB-_-RRB- or_CC hepatotoxic_JJ -LRB-_-LRB- e.g._FW ,_, methotrexate_NN ,_, asparaginase_NN -RRB-_-RRB- effects_NNS with_IN PROLEUKIN_NN may_MD increase_VB toxicity_NN in_IN these_DT organ_NN systems_NNS ._. The_DT safety_NN and_CC efficacy_NN of_IN PROLEUKIN_NNP in_IN combination_NN with_IN any_DT antineoplastic_JJ agents_NNS have_VBP not_RB been_VBN established_VBN ._. In_IN addition_NN ,_, reduced_VBD kidney_NN and_CC liver_NN function_NN secondary_JJ to_TO PROLEUKIN_NN treatment_NN may_MD delay_VB elimination_NN of_IN concomitant_JJ medications_NNS and_CC increase_VB the_DT risk_NN of_IN adverse_JJ events_NNS from_IN those_DT drugs_NNS ._. Hypersensitivity_NN reactions_NNS have_VBP been_VBN reported_VBN in_IN patients_NNS receiving_VBG combination_NN regimens_NNS containing_VBG sequential_JJ high_JJ dose_NN PROLEUKIN_NN and_CC antineoplastic_JJ agents_NNS ,_, specifically_RB ,_, dacarbazine_NN ,_, cis-platinum_NN ,_, tamoxifen_NN and_CC interferon-alfa_NN ._. These_DT reactions_NNS consisted_VBD of_IN erythema_NN ,_, pruritus_NN ,_, and_CC hypotension_NN and_CC occurred_VBD within_IN hours_NNS of_IN administration_NN of_IN chemotherapy_NN ._. These_DT events_NNS required_VBN medical_JJ intervention_NN in_IN some_DT patients_NNS ._. Myocardial_JJ injury_NN ,_, including_VBG myocardial_JJ infarction_NN ,_, myocarditis_NN ,_, ventricular_JJ hypokinesia_NN ,_, and_CC severe_JJ rhabdomyolysis_NN appear_VBP to_TO be_VB increased_VBN in_IN patients_NNS receiving_VBG PROLEUKIN_NNP and_CC interferon-alfa_JJ concurrently_RB ._. Exacerbation_NN or_CC the_DT initial_JJ presentation_NN of_IN a_DT number_NN of_IN autoimmune_JJ and_CC inflammatory_JJ disorders_NNS has_VBZ been_VBN observed_VBN following_VBG concurrent_JJ use_NN of_IN interferon-alfa_NN and_CC PROLEUKIN_NN ,_, including_VBG crescentic_JJ IgA_NN glomerulonephritis_NN ,_, oculo-bulbar_JJ myasthenia_NN gravis_NN ,_, inflammatory_JJ arthritis_NN ,_, thyroiditis_NN ,_, bullous_JJ pemphigoid_NN ,_, and_CC Stevens-Johnson_NN syndrome_NN ._. Although_IN glucocorticoids_NNS have_VBP been_VBN shown_VBN to_TO reduce_VB PROLEUKIN-induced_JJ side_JJ effects_NNS including_VBG fever_NN ,_, renal_JJ insufficiency_NN ,_, hyperbilirubinemia_NN ,_, confusion_NN ,_, and_CC dyspnea_NN ,_, concomitant_JJ administration_NN of_IN these_DT agents_NNS with_IN PROLEUKIN_NN may_MD reduce_VB the_DT antitumor_NN effectiveness_NN of_IN PROLEUKIN_NNP and_CC thus_RB should_MD be_VB avoided_VBN ._. 12_CD Beta-blockers_NNS and_CC other_JJ antihypertensives_NNS may_MD potentiate_VB the_DT hypotension_NN seen_VBN with_IN PROLEUKIN_NN ._. Delayed_VBN Adverse_JJ Reactions_NNS to_TO Iodinated_NNP Contrast_NNP Media_NNP :_: A_NNP review_NN of_IN the_DT literature_NN revealed_VBD that_IN 12.6_CD %_NN -LRB-_-LRB- range_NN 11-28_CD %_NN -RRB-_-RRB- of_IN 501_CD patients_NNS treated_VBN with_IN various_JJ interleukin-2_NN containing_VBG regimens_NNS who_WP were_VBD subsequently_RB administered_VBN radiographic_JJ iodinated_VBN contrast_NN media_NNS experienced_VBD acute_JJ ,_, atypical_JJ adverse_JJ reactions_NNS ._. The_DT onset_NN of_IN symptoms_NNS usually_RB occurred_VBD within_IN hours_NNS -LRB-_-LRB- most_RBS commonly_RB 1_CD to_TO 4_CD hours_NNS -RRB-_-RRB- following_VBG the_DT administration_NN of_IN contrast_NN media_NNS ._. These_DT reactions_NNS include_VBP fever_NN ,_, chills_NNS ,_, nausea_NN ,_, vomiting_VBG ,_, pruritus_NN ,_, rash_NN ,_, diarrhea_NN ,_, hypotension_NN ,_, edema_NN ,_, and_CC oliguria_NN ._. Some_DT clinicians_NNS have_VBP noted_VBN that_IN these_DT reactions_NNS resemble_VBP the_DT immediate_JJ side_JJ effects_NNS caused_VBN by_IN interleukin-2_NN administration_NN ,_, however_RB the_DT cause_NN of_IN contrast_NN reactions_NNS after_IN interleukin-2_NN therapy_NN is_VBZ unknown_JJ ._. Most_JJS events_NNS were_VBD reported_VBN to_TO occur_VB when_WRB contrast_NN media_NNS was_VBD given_VBN within_IN 4_CD weeks_NNS after_IN the_DT last_JJ dose_NN of_IN interleukin-2_NN ._. These_DT events_NNS were_VBD also_RB reported_VBN to_TO occur_VB when_WRB contrast_NN media_NNS was_VBD given_VBN several_JJ months_NNS after_IN interleukin-2_NN treatment_NN ._. No_DT formal_JJ interaction_NN studies_NNS have_VBP been_VBN performed_VBN ._. The_DT duration_NN of_IN the_DT period_NN following_VBG treatment_NN with_IN AMEVIVE_NN before_IN one_CD should_MD consider_VB starting_VBG other_JJ immunosuppressive_JJ therapy_NN has_VBZ not_RB been_VBN evaluated_VBN ._. Carcinogenesis_NN ,_, Mutagenesis_NN ,_, and_CC Fertility_NN ._. In_IN a_DT chronic_JJ toxicity_NN study_NN ,_, cynomolgus_NN monkeys_NNS were_VBD dosed_VBN weekly_RB for_IN 52_CD weeks_NNS with_IN intravenous_JJ alefacept_NN at_IN 1_CD mg/kg/dose_NN or_CC 20_CD mg/kg/dose_NN ._. One_CD animal_NN in_IN the_DT high_JJ dose_NN group_NN developed_VBD a_DT B-cell_NN lymphoma_NN that_WDT was_VBD detected_VBN after_IN 28_CD weeks_NNS of_IN dosing_NN ._. Additional_JJ animals_NNS in_IN both_DT dose_NN groups_NNS developed_VBD B-cell_NN hyperplasia_NN of_IN the_DT spleen_NN and_CC lymph_NN nodes_NNS ._. All_DT animals_NNS in_IN the_DT study_NN were_VBD positive_JJ for_IN an_DT endemic_JJ primate_JJ gammaherpes_NNS virus_NN also_RB known_VBN as_IN lymphocryptovirus_NN -LRB-_-LRB- LCV_NN -RRB-_-RRB- ._. Latent_JJ LCV_NN infection_NN is_VBZ generally_RB asymptomatic_JJ ,_, but_CC can_MD lead_VB to_TO B-cell_NN lymphomas_NNS when_WRB animals_NNS are_VBP immune_JJ suppressed_VBN ._. In_IN a_DT separate_JJ study_NN ,_, baboons_NNS given_VBN 3_CD doses_NNS of_IN alefacept_NN at_IN 1_CD mg/kg_NN every_DT 8_CD weeks_NNS were_VBD found_VBN to_TO have_VB centroblast_NN proliferation_NN in_IN B-cell_NN dependent_JJ areas_NNS in_IN the_DT germinal_JJ centers_NNS of_IN the_DT spleen_NN following_VBG a_DT 116-day_JJ washout_NN period_NN ._. The_DT role_NN of_IN AMEVIVE_NNP in_IN the_DT development_NN of_IN the_DT lymphoid_JJ malignancy_NN and_CC the_DT hyperplasia_NN observed_VBN in_IN non-human_JJ primates_NNS and_CC the_DT relevance_NN to_TO humans_NNS is_VBZ unknown_JJ ._. Immunodeficiency-associated_JJ lymphocyte_NN disorders_NNS -LRB-_-LRB- plasmacytic_JJ hyperplasia_NN ,_, polymorphic_JJ proliferation_NN ,_, and_CC B-cell_NN lymphomas_NNS -RRB-_-RRB- occur_VBP in_IN patients_NNS who_WP have_VBP congenital_JJ or_CC acquired_VBN immunodeficiencies_NNS including_VBG those_DT resulting_VBG from_IN immunosuppressive_JJ therapy_NN ._. No_DT carcinogenicity_NN or_CC fertility_NN studies_NNS were_VBD conducted_VBN ._. Mutagenicity_NN studies_NNS were_VBD conducted_VBN in_FW vitro_FW and_CC in_FW vivo_FW ;_: ._. no_DT evidence_NN of_IN mutagenicity_NN was_VBD observed_VBN ._. Pregnancy_NN -LRB-_-LRB- Category_NN B_NN -RRB-_-RRB- ._. Women_NNS of_IN childbearing_JJ potential_JJ make_VB up_RP a_DT considerable_JJ segment_NN of_IN the_DT patient_NN population_NN affected_VBN by_IN psoriasis_NN ._. Since_IN the_DT effect_NN of_IN AMEVIVE_NNP on_IN pregnancy_NN and_CC fetal_JJ development_NN ,_, including_VBG immune_JJ system_NN development_NN ,_, is_VBZ not_RB known_VBN ,_, health_NN care_NN providers_NNS are_VBP encouraged_VBN to_TO enroll_VB patients_NNS currently_RB taking_VBG AMEVIVE_NNP who_WP become_VBP pregnant_JJ into_IN the_DT Biogen_NNP Pregnancy_NNP Registry_NNP by_IN calling_VBG 1-866-AMEVIVE_NN -LRB-_-LRB- 1-866-263-8483_CD -RRB-_-RRB- ._. Reproductive_NNP toxicology_NN studies_NNS have_VBP been_VBN performed_VBN in_IN cynomolgus_NN monkeys_NNS at_IN doses_NNS up_RB to_TO 5_CD mg/kg/week_NN -LRB-_-LRB- about_IN 62_CD times_NNS the_DT human_JJ dose_NN based_VBN on_IN body_NN weight_NN -RRB-_-RRB- and_CC have_VBP revealed_VBN no_DT evidence_NN of_IN impaired_JJ fertility_NN or_CC harm_NN to_TO the_DT fetus_NN due_JJ to_TO AMEVIVE_NNP ._. No_DT abortifacient_NN or_CC teratogenic_JJ effects_NNS were_VBD observed_VBN in_IN cynomolgus_NN monkeys_NNS following_VBG intravenous_JJ bolus_NN injections_NNS of_IN AMEVIVE_NNP administered_VBN weekly_RB during_IN the_DT period_NN of_IN organogenesis_NN to_TO gestation_NN ._. AMEVIVE_NNP underwent_VBD trans-placental_JJ passage_NN and_CC produced_VBN in_IN utero_NN exposure_NN in_IN the_DT developing_VBG monkeys_NNS ._. In_IN utero_NN ,_, serum_NN levels_NNS of_IN exposure_NN in_IN these_DT monkeys_NNS were_VBD 23_CD %_NN of_IN maternal_JJ serum_NN levels_NNS ._. No_DT evidence_NN of_IN fetal_JJ toxicity_NN including_VBG adverse_JJ effects_NNS on_IN immune_JJ system_NN development_NN was_VBD observed_VBN in_IN any_DT of_IN these_DT animals_NNS ._. Animal_NN reproduction_NN studies_NNS ,_, however_RB ,_, are_VBP not_RB always_RB predictive_JJ of_IN human_JJ response_NN and_CC there_EX are_VBP no_DT adequate_JJ and_CC well-controlled_JJ studies_NNS in_IN pregnant_JJ women_NNS ._. Because_IN the_DT risk_NN to_TO the_DT development_NN of_IN the_DT fetal_JJ immune_JJ system_NN and_CC postnatal_JJ immune_JJ function_NN in_IN humans_NNS is_VBZ unknown_JJ ,_, AMEVIVE_NNP should_MD be_VB used_VBN during_IN pregnancy_NN only_RB if_IN clearly_RB needed_VBN ._. If_IN pregnancy_NN occurs_VBZ while_IN taking_VBG AMEVIVE_NNP ,_, continued_VBD use_NN of_IN the_DT drug_NN should_MD be_VB assessed_VBN ._. Nursing_NNP Mothers_NNP ._. It_PRP is_VBZ not_RB known_VBN whether_IN AMEVIVE_NNP is_VBZ excreted_VBN in_IN human_JJ milk_NN ._. Because_IN many_JJ drugs_NNS are_VBP excreted_VBN in_IN human_JJ milk_NN ,_, and_CC because_IN there_EX exists_VBZ the_DT potential_NN for_IN serious_JJ adverse_JJ reactions_NNS in_IN nursing_NN infants_NNS from_IN AMEVIVE_NNP ,_, a_DT decision_NN should_MD be_VB made_VBN whether_IN to_TO discontinue_VB nursing_NN while_IN taking_VBG the_DT drug_NN or_CC to_TO discontinue_VB the_DT use_NN of_IN the_DT drug_NN ,_, taking_VBG into_IN account_NN the_DT importance_NN of_IN the_DT drug_NN to_TO the_DT mother_NN ._. Geriatric_NNP Use_NNP ._. Of_IN the_DT 1357_CD patients_NNS who_WP received_VBD AMEVIVE_NNP in_IN clinical_JJ trials_NNS ,_, a_DT total_NN of_IN 100_CD patients_NNS wer_NN ._. 65_CD years_NNS of_IN age_NN and_CC 13_CD patients_NNS were_VBD ._. 75_CD years_NNS of_IN age_NN ._. No_DT differences_NNS in_IN safety_NN or_CC efficacy_NN were_VBD observed_VBN between_IN older_JJR and_CC younger_JJR patients_NNS ,_, but_CC there_EX were_VBD not_RB sufficient_JJ data_NNS to_TO exclude_VB important_JJ differences_NNS ._. Because_IN the_DT incidence_NN of_IN infections_NNS and_CC certain_JJ malignancies_NNS is_VBZ higher_JJR in_IN the_DT elderly_JJ population_NN ,_, in_IN general_JJ ,_, caution_NN should_MD be_VB used_VBN in_IN treating_VBG the_DT elderly_JJ ._. Pediatric_NNP Use_NNP ._. The_DT safety_NN and_CC efficacy_NN of_IN AMEVIVE_NNP in_IN pediatric_JJ patients_NNS have_VBP not_RB been_VBN studied_VBN ._. AMEVIVE_NNP is_VBZ not_RB indicated_VBN for_IN pediatric_JJ patients_NNS ._. Drug/Laboratory_NNP Interactions_NNS No_DT formal_JJ drug_NN interaction_NN studies_NNS have_VBP been_VBN performed_VBN with_IN Campath_NNP ._. An_DT immune_JJ response_NN to_TO Campath_NNP may_MD interfere_VB with_IN subsequent_JJ diagnostic_JJ serum_NN tests_NNS that_WDT utilize_VBP antibodie_NN ._. Intravenous_JJ ranitidine_NN was_VBD shown_VBN to_TO double_VB the_DT bioavailability_NN of_IN oral_JJ alendronate_NN ._. The_DT clinical_JJ significance_NN of_IN this_DT increased_VBN bioavailability_NN and_CC whether_IN similar_JJ increases_NNS will_MD occur_VB in_IN patients_NNS given_VBN oral_JJ H2-antagonists_NNS is_VBZ unknown_JJ ._. no_DT other_JJ specific_JJ drug_NN interaction_NN studies_NNS were_VBD performed_VBN ._. Products_NNPS containing_VBG calcium_NN and_CC other_JJ multivalent_JJ cations_NNS likely_RB will_MD interfere_VB with_IN absorption_NN of_IN alendronate_NN ._. Both_CC the_DT magnitude_NN and_CC duration_NN of_IN central_JJ nervous_JJ system_NN and_CC cardiovascular_JJ effects_NNS may_MD be_VB enhanced_VBN when_WRB ALFENTA_NNP is_VBZ administered_VBN in_IN combination_NN with_IN other_JJ CNS_NN depressants_NNS such_JJ as_IN barbiturates_NNS ,_, tranquilizers_NNS ,_, opioids_NNS ,_, or_CC inhalation_NN general_JJ anesthetics_NNS ._. Postoperative_JJ respiratory_JJ depression_NN may_MD be_VB enhanced_VBN or_CC prolonged_VBN by_IN these_DT agents_NNS ._. In_IN such_JJ cases_NNS of_IN combined_JJ treatment_NN ,_, the_DT dose_NN of_IN one_CD or_CC both_DT agents_NNS should_MD be_VB reduced_VBN ._. Limited_JJ clinical_JJ experience_NN indicates_VBZ that_IN requirements_NNS for_IN volatile_JJ inhalation_NN anesthetics_NNS are_VBP reduced_VBN by_IN 30_CD to_TO 50_CD %_NN for_IN the_DT first_JJ sixty_NN -LRB-_-LRB- 60_CD -RRB-_-RRB- minutes_NNS following_VBG ALFENTA_NNP induction_NN The_DT concomitant_JJ use_NN of_IN erythromycin_NN with_IN ALFENTA_NN can_MD significantly_RB inhibit_VB ALFENTA_NN clearance_NN and_CC may_MD increase_VB the_DT risk_NN of_IN prolonged_JJ or_CC delayed_VBN respiratory_JJ depression_NN ._. Cimetidine_NNP reduces_VBZ the_DT clearance_NN of_IN ALFENTA_NNP ._. Therefore_RB smaller_JJR ALFENTA_NN doses_NNS will_MD be_VB required_VBN with_IN prolonged_JJ administration_NN and_CC the_DT duration_NN of_IN action_NN of_IN ALFENTA_NNP my_PRP$ be_VB extended_VBN ._. Perioperative_NNP administration_NN of_IN drugs_NNS affecting_VBG hepatic_JJ blood_NN flow_NN or_CC enzyme_NN function_NN may_MD reduce_VB plasma_NN clearance_NN and_CC prolong_VB recovery_NN ._. Drug-Drug_NNP Interactions_NNS :_: The_DT pharmacokinetic_JJ and_CC pharmacodynamic_JJ interactions_NNS between_IN UROXATRAL_NNP and_CC other_JJ alpha-blockers_NNS have_VBP not_RB been_VBN determined_VBN ._. However_RB ,_, interactions_NNS may_MD be_VB expected_VBN ,_, and_CC UROXATRAL_NNP should_MD NOT_RB be_VB used_VBN in_IN combination_NN with_IN other_JJ alpha-blockers_NNS ._. No_DT drug_NN interaction_NN studies_NNS have_VBP been_VBN performed_VBN ._. Effects_NNS of_IN Other_JJ Drugs_NNS on_IN Aliskiren_NNP Based_VBD on_IN in-vitro_FW studies_NNS ,_, aliskiren_NN is_VBZ metabolized_VBN by_IN CYP_NN 3A4_NN ._. Co-administration_NN of_IN lovastatin_NN ,_, atenolol_NN ,_, warfarin_NN ,_, furosemide_NN ,_, digoxin_NN ,_, celecoxib_NN ,_, hydrochlorothiazide_NN ,_, ramipril_NN ,_, valsartan_NN ,_, metformin_NN and_CC amlodipine_NN did_VBD not_RB result_VB in_IN clinically_RB significant_JJ increases_NNS in_IN aliskiren_JJ exposure_NN ._. Co-administration_NN of_IN irbesartan_NN reduced_VBD aliskiren_JJ Cmax_NN up_IN to_TO 50_CD %_NN after_IN multiple_JJ dosing_NN ._. Co-administration_NN of_IN atorvastatin_NN resulted_VBD in_IN about_IN a_DT 50_CD %_NN increase_NN in_IN aliskiren_NN Cmax_NN and_CC AUC_NN after_IN multiple_JJ dosing_NN ._. Ketoconazole_NN :_: Co-administration_NN of_IN 200_CD mg_NN twice-daily_JJ ketoconazole_NN with_IN aliskiren_NN resulted_VBD in_IN an_DT approximate_JJ 80_CD %_NN increase_NN in_IN plasma_NN levels_NNS of_IN aliskiren_NN ._. A_DT 400_CD mg_NN once-daily_JJ dose_NN was_VBD not_RB studied_VBN but_CC would_MD be_VB expected_VBN to_TO increase_VB aliskiren_JJ blood_NN levels_NNS further_RB ._. Effects_NNS of_IN Aliskiren_NN on_IN Other_JJ Drugs_NNS Aliskiren_NN does_VBZ not_RB inhibit_VB the_DT CYP450_NN isoenzymes_NNS -LRB-_-LRB- CYP1A2_NN ,_, 2C8_NN ,_, 2C9_NN ,_, 2C19_NN ,_, 2D6_NN ,_, 2E1_NN ,_, and_CC CYP_NN 3A_NN -RRB-_-RRB- or_CC induce_VB CYP_NN 3A4_NN ._. Co-administration_NN of_IN aliskiren_NN did_VBD not_RB significantly_RB affect_VB the_DT pharmacokinetics_NNS of_IN lovastatin_NN ,_, digoxin_NN ,_, valsartan_NN ,_, amlodipine_NN ,_, metformin_NN ,_, celecoxib_NN ,_, atenolol_NN ,_, atorvastatin_NN ,_, ramipril_NN or_CC hydrochlorothiazide_NN ._. Warfarin_NNP :_: The_DT effects_NNS of_IN aliskiren_NN on_IN warfarin_NN pharmacokinetics_NNS have_VBP not_RB been_VBN evaluated_VBN in_IN a_DT well-controlled_JJ clinical_JJ trial_NN ._. Furosemide_NNP :_: When_WRB aliskiren_NN was_VBD co-administered_VBN with_IN furosemide_NN ,_, the_DT AUC_NN and_CC Cmax_NN of_IN furosemide_NN were_VBD reduced_VBN by_IN about_IN 30_CD %_NN and_CC 50_CD %_NN ,_, respectively_RB ._. Patients_NNS who_WP are_VBP applying_VBG Panretin_NNP gel_NN should_MD not_RB concurrently_RB use_VB products_NNS that_WDT contain_VBP DEET_NN -LRB-_-LRB- N_NN ,_, N-diethyl-m-toluamide_NN -RRB-_-RRB- ,_, a_DT common_JJ component_NN of_IN insect_JJ repellent_NN products_NNS ._. Animal_NN toxicology_NN studies_NNS showed_VBD increased_VBN DEET_NNP toxicity_NN when_WRB DEET_NNP was_VBD included_VBN as_IN proof_NN of_IN the_DT formulation_NN ._. Although_IN there_EX was_VBD no_DT clinical_JJ evidence_NN in_IN the_DT vehicle-controlled_JJ studies_NNS of_IN drug_NN interactions_NNS with_IN systemic_JJ antiretroviral_JJ agents_NNS ,_, including_VBG protease_NN inhibitors_NNS ,_, macrolide_NN antibiotics_NNS ,_, and_CC azole_NN antifungals_NNS ,_, the_DT effect_NN of_IN Panretin_NNP gel_NN on_IN the_DT steady-state_JJ concentrations_NNS of_IN these_DT drugs_NNS is_VBZ not_RB known_VBN ._. No_DT drug_NN interaction_NN data_NNS are_VBP available_JJ on_IN concomitant_JJ administration_NN of_IN Panretin_NNP gel_NN and_CC systemic_JJ anti-KS_JJ agents_NNS ._. The_DT following_VBG drug_NN interactions_NNS were_VBD observed_VBN in_IN some_DT patients_NNS undergoing_VBG treatment_NN with_IN oral_JJ allopurinol_NN ._. Although_IN the_DT pattern_NN of_IN use_NN for_IN oral_JJ allopurinol_NN includes_VBZ longer_JJR term_NN therapy_NN ,_, particularly_RB for_IN gout_NN and_CC renal_JJ calculi_NNS ,_, the_DT experience_NN gained_VBD may_MD be_VB relevant_JJ ._. Mercaptopurine/Azathioprine_NNP :_: Allopurinol_NN inhibits_VBZ the_DT enzymatic_JJ oxidation_NN of_IN mercaptopurine_NN and_CC azathioprine_NN to_TO 6-thiouric_JJ acid_NN ._. This_DT oxidation_NN ,_, which_WDT is_VBZ catalyzed_VBN by_IN xanthine_NN oxidase_NN ,_, inactivates_VBZ mercaptopurine_NN ._. In_IN patients_NNS receiving_VBG mercaptopurine_NN -LRB-_-LRB- Purinethol_NN -RRB-_-RRB- or_CC azathioprine_NN -LRB-_-LRB- Imuran_NN -RRB-_-RRB- ,_, the_DT concomitant_JJ administration_NN of_IN 300-600_CD mg_NN of_IN allopurinol_NN per_IN day_NN will_MD require_VB a_DT reduction_NN in_IN dose_NN to_TO approximately_RB one-third_JJ to_TO one-fourth_NN of_IN the_DT usual_JJ dose_NN of_IN mercaptopurine_NN or_CC azathioprine_NN ._. Subsequent_JJ adjustment_NN of_IN doses_NNS of_IN mercaptopurine_NN or_CC azathioprine_NN should_MD be_VB made_VBN on_IN the_DT basis_NN of_IN therapeutic_JJ response_NN and_CC the_DT appearance_NN of_IN toxic_JJ effects_NNS ._. Dicumarol_NNP :_: It_PRP has_VBZ been_VBN reported_VBN that_IN allopurinol_NN prolongs_VBZ the_DT half-life_NN of_IN the_DT anticoagulant_NN ,_, dicumarol_NN ._. The_DT clinical_JJ basis_NN of_IN this_DT drug_NN interaction_NN has_VBZ not_RB been_VBN established_VBN but_CC should_MD be_VB noted_VBN when_WRB allopurinol_NN is_VBZ given_VBN to_TO patients_NNS already_RB on_IN dicumarol_NN therapy_NN ._. Consequently_RB ,_, prothrombin_NN time_NN should_MD be_VB reassessed_VBN periodically_RB in_IN patients_NNS receiving_VBG both_CC drugs_NNS ._. Uricosuric_NNP Agents_NNPS :_: Since_IN the_DT excretion_NN of_IN oxipurinol_NN is_VBZ similar_JJ to_TO that_DT of_IN urate_NN ,_, uricosuric_JJ agents_NNS ,_, which_WDT increase_VBP the_DT excretion_NN of_IN urate_NN ,_, are_VBP also_RB likely_JJ to_TO increase_VB the_DT excretion_NN of_IN oxipurinol_NN and_CC thus_RB lower_JJR the_DT degree_NN of_IN inhibition_NN of_IN xanthine_NN oxidase_NN ._. The_DT concomitant_JJ administration_NN of_IN uricosuric_JJ agents_NNS and_CC allopurinol_NN has_VBZ been_VBN associated_VBN with_IN a_DT decrease_NN in_IN the_DT excretion_NN of_IN oxypurines_NNS -LRB-_-LRB- hypoxanthine_NN and_CC xanthine_NN -RRB-_-RRB- and_CC an_DT increase_NN in_IN urinary_JJ uric_JJ acid_NN excretion_NN compared_VBN with_IN that_DT observed_VBN with_IN allopurinol_NN alone_RB ._. Although_IN clinical_JJ evidence_NN to_TO date_NN has_VBZ not_RB demonstrated_VBN renal_JJ precipitation_NN of_IN oxypurines_NNS in_IN patients_NNS either_CC on_IN allopurinol_NN alone_RB or_CC in_IN combination_NN with_IN uricosuric_JJ agents_NNS ,_, the_DT possibility_NN should_MD be_VB kept_VBN in_IN mind_NN ._. Thiazide_NNP Diuretics_NNPS :_: The_DT reports_NNS that_IN the_DT concomitant_JJ use_NN of_IN allopurinol_NN and_CC thiazide_JJ diuretics_NNS may_MD contribute_VB to_TO the_DT enhancement_NN of_IN allopurinol_NN toxicity_NN in_IN some_DT patients_NNS have_VBP been_VBN reviewed_VBN in_IN an_DT attempt_NN to_TO establish_VB a_DT cause-and-effect_JJ relationship_NN and_CC a_DT mechanism_NN of_IN causation_NN ._. Review_NN of_IN these_DT case_NN reports_VBZ indicates_VBZ that_IN the_DT patients_NNS were_VBD mainly_RB receiving_VBG thiazide_JJ diuretics_NNS for_IN hypertension_NN and_CC that_IN tests_NNS to_TO rule_VB out_RP decreased_VBN renal_JJ function_NN secondary_JJ to_TO hypertensive_JJ nephropathy_NN were_VBD not_RB often_RB performed_VBN ._. In_IN those_DT patients_NNS in_IN whom_WP renal_JJ insufficiency_NN was_VBD documented_VBN ,_, however_RB ,_, the_DT recommendation_NN to_TO lower_VB the_DT dose_NN of_IN allopurinol_NN was_VBD not_RB followed_VBN ._. Although_IN a_DT causal_JJ mechanism_NN and_CC a_DT cause-and-effect_JJ relationship_NN have_VBP not_RB been_VBN established_VBN ,_, current_JJ evidence_NN suggests_VBZ that_IN renal_JJ function_NN should_MD be_VB monitored_VBN in_IN patients_NNS on_IN thiazide_JJ diuretics_NNS and_CC allopurinol_NN even_RB in_IN the_DT absence_NN of_IN renal_JJ failure_NN ,_, and_CC dosage_NN levels_NNS should_MD be_VB even_RB more_RBR conservatively_RB adjusted_VBN in_IN those_DT patients_NNS on_IN such_JJ combined_JJ therapy_NN if_IN diminished_VBN renal_JJ function_NN is_VBZ detected_VBN ._. Ampicillin/Amoxicillin_NNP :_: An_DT increase_NN in_IN the_DT frequency_NN of_IN skin_NN rash_NN has_VBZ been_VBN reported_VBN among_IN patients_NNS receiving_VBG ampicillin_NN or_CC amoxicillin_NNP concurrently_RB with_IN allopurinol_NN compared_VBN to_TO patients_NNS who_WP are_VBP not_RB receiving_VBG both_CC drugs_NNS ._. The_DT cause_NN of_IN the_DT reported_VBN association_NN has_VBZ not_RB been_VBN established_VBN ._. Cytotoxic_JJ Agents_NNS :_: Enhanced_VBN bone_NN marrow_NN suppression_NN by_IN cyclophosphamide_NN and_CC other_JJ cytotoxic_JJ agents_NNS has_VBZ been_VBN reported_VBN among_IN patients_NNS with_IN neoplastic_JJ disease_NN ,_, except_IN leukemia_NN ,_, in_IN the_DT presence_NN of_IN allopurinol_NN ._. However_RB ,_, in_IN a_DT well-controlled_JJ study_NN of_IN patients_NNS with_IN lymphoma_NN on_IN combination_NN therapy_NN ,_, allopurinol_NN did_VBD not_RB increase_VB the_DT marrow_NN toxicity_NN of_IN patients_NNS treated_VBN with_IN cyclophosphamide_NN ,_, doxorubicin_NN ,_, bleomycin_NN ,_, procarbazine_NN and/or_CC mechlorethamine_NN ._. Chlorpropamide_NNP :_: Chlorpropamides_NNP plasma_NN half-life_NN may_MD be_VB prolonged_VBN by_IN allopurinol_NN ,_, since_IN allopurinol_NN and_CC chlorpropamide_NN may_MD compete_VB for_IN excretion_NN in_IN the_DT renal_JJ tubule_NN ._. The_DT risk_NN of_IN hypoglycemia_NN secondary_JJ to_TO this_DT mechanism_NN may_MD be_VB increased_VBN if_IN allopurinol_NN and_CC chlorpropamide_NN are_VBP given_VBN concomitantly_RB in_IN the_DT presence_NN of_IN renal_JJ insufficiency_NN ._. Cyclosporin_NN :_: Reports_NNS indicate_VBP that_IN cyclosporine_NN levels_NNS may_MD be_VB increased_VBN during_IN concomitant_JJ treatment_NN with_IN allopurinol_NN sodium_NN for_IN injection_NN ._. Monitoring_NN of_IN cyclosporine_NN levels_NNS and_CC possible_JJ adjustment_NN of_IN cyclosporine_NN dosage_NN should_MD be_VB considered_VBN when_WRB these_DT drugs_NNS are_VBP co-administered_JJ ._. Tolbutamides_NNS conversion_NN to_TO inactive_JJ metabolites_NNS has_VBZ been_VBN shown_VBN to_TO be_VB catalyzed_VBN by_IN xanthine_NN oxidase_NN from_IN rat_NN liver_NN ._. The_DT clinical_JJ significance_NN ,_, if_IN any_DT ,_, of_IN these_DT observations_NNS is_VBZ unknown_JJ ._. Ergot-Containing_JJ Drugs_NNS :_: These_DT drugs_NNS have_VBP been_VBN reported_VBN to_TO cause_VB prolonged_JJ vasospastic_JJ reactions_NNS ._. Because_IN there_EX is_VBZ a_DT theoretical_JJ basis_NN that_IN these_DT effects_NNS may_MD be_VB additive_JJ ,_, use_NN of_IN ergotamine-containing_JJ or_CC ergot-type_JJ medications_NNS -LRB-_-LRB- like_IN dihydroergotamine_NN or_CC methysergide_NN -RRB-_-RRB- and_CC AXERT_NN within_IN 24_CD hours_NNS of_IN each_DT other_JJ should_MD be_VB avoided_VBN ._. Monoamine_NNP Oxidase_NNP Inhibitors_NNS :_: Coadministration_NN of_IN moclobemide_NN resulted_VBD in_IN a_DT 27_CD %_NN decrease_NN in_IN almotriptan_NN clearance_NN and_CC an_DT increase_NN in_IN Cmax_NN of_IN approximately_RB 6_CD %_NN ._. No_DT dose_NN adjustment_NN is_VBZ necessary_JJ ._. Other_JJ 5-HT1B_NN /_: 1D_NN Agonists_NNS Concomitant_JJ use_NN of_IN other_JJ 5-HT1B_NN /_: 1D_NN agonists_NNS within_IN 24_CD hours_NNS of_IN treatment_NN with_IN AXERT_NN is_VBZ contraindicated_VBN ._. Propanolol_NNP :_: The_DT pharmacokinetics_NNS of_IN almotriptan_NN were_VBD not_RB affected_VBN by_IN coadministration_NN of_IN propranolol_NN ._. Selective_JJ Serotonin_NN Reuptake_NNP Inhibitors_NNS -LRB-_-LRB- SSRIs_NNS -RRB-_-RRB- :_: SSRIs_NNS -LRB-_-LRB- e.g._FW ,_, fluoxetine_NN ,_, fluvoxamine_NN ,_, paroxetine_NN ,_, sertraline_NN -RRB-_-RRB- have_VBP been_VBN rarely_RB reported_VBN to_TO cause_VB weakness_NN ,_, hyperreflexia_NN ,_, and_CC incoordination_NN when_WRB coadministered_VBN with_IN 5-HT1_NN agonists_NNS ._. If_IN concomitant_JJ treatment_NN with_IN AXERT_NN and_CC an_DT SSRI_NNP is_VBZ clinically_RB warranted_VBN ,_, appropriate_JJ observation_NN of_IN the_DT patient_NN is_VBZ advised_VBN ._. Verapamil_NNP :_: Coadministration_NNP of_IN almotriptan_NN and_CC verapamil_NN resulted_VBD in_IN a_DT 24_CD %_NN increase_NN in_IN plasma_NN concentrations_NNS of_IN almotriptan_NN ._. No_DT dose_NN adjustment_NN is_VBZ necessary_JJ ._. Coadministration_NN of_IN almotriptan_NN and_CC the_DT potent_JJ CYP3A4_NN inhibitor_NN ketoconazole_NN -LRB-_-LRB- 400_CD mg_NN q.d._NN for_IN 3_CD days_NNS -RRB-_-RRB- resulted_VBD in_IN an_DT approximately_RB 60_CD %_NN increase_NN in_IN the_DT area_NN under_IN the_DT plasma_NN concentration-time_NN curve_NN and_CC maximal_JJ plasma_NN concentrations_NNS of_IN almotriptan_NN ._. Although_IN the_DT interaction_NN between_IN almotriptan_NN and_CC other_JJ potent_JJ CYP3A4_NN inhibitors_NNS -LRB-_-LRB- e.g._FW ,_, itraconazole_NN ,_, ritonavir_NN ,_, and_CC erythromycin_NN -RRB-_-RRB- has_VBZ not_RB been_VBN studied_VBN ,_, increased_VBD exposures_NNS to_TO almotriptan_NN may_MD be_VB expected_VBN when_WRB almotriptan_NN is_VBZ used_VBN concomitantly_RB with_IN these_DT medications_NNS ._. AXERT_NNP is_VBZ not_RB known_VBN to_TO interfere_VB with_IN commonly_RB employed_VBN clinical_JJ laboratory_NN tests_NNS ._. Because_IN alosetron_NN is_VBZ metabolized_VBN by_IN a_DT variety_NN of_IN hepatic_JJ CYP_NN drug-metabolizing_JJ enzymes_NNS ,_, inducers_NNS or_CC inhibitors_NNS of_IN these_DT enzymes_NNS may_MD change_VB the_DT clearance_NN of_IN alosetron_NN ._. Fluvoxamine_NN is_VBZ a_DT known_JJ strong_JJ inhibitor_NN of_IN CYP1A2_NN and_CC also_RB inhibits_VBZ CYP3A4_NN ,_, CYP2C9_NN ,_, and_CC CYP2C19_NN ._. In_IN a_DT pharmacokinetic_JJ study_NN ,_, 40_CD healthy_JJ female_JJ subjects_NNS received_VBD fluvoxamine_NN in_IN escalating_VBG doses_NNS from_IN 50_CD to_TO 200_CD mg_NN per_IN day_NN for_IN 16_CD days_NNS ,_, with_IN coadministration_NN of_IN alosetron_NN 1_CD mg_NN on_IN the_DT last_JJ day_NN ._. Fluvoxamine_NN increased_VBD mean_JJ alosetron_NN plasma_NN concentrations_NNS -LRB-_-LRB- AUC_NN -RRB-_-RRB- approximately_RB 6-fold_RB and_CC prolonged_VBD the_DT half-life_NN by_IN approximately_RB 3-fold_RB ._. Concomitant_JJ administration_NN of_IN alosetron_NN and_CC fluvoxamine_NN is_VBZ contraindicated_VBN ._. Concomitant_JJ administration_NN of_IN alosetron_NN and_CC moderate_JJ CYP1A2_NN inhibitors_NNS ,_, including_VBG quinolone_JJ antibiotics_NNS and_CC cimetidine_NN ,_, has_VBZ not_RB been_VBN evaluated_VBN ,_, but_CC should_MD be_VB avoided_VBN unless_IN clinically_RB necessary_JJ because_IN of_IN similar_JJ potential_JJ drug_NN interactions_NNS ._. Ketoconazole_NN is_VBZ a_DT known_JJ strong_JJ inhibitor_NN of_IN CYP3A4_NN ._. In_IN a_DT pharmacokinetic_JJ study_NN ,_, 38_CD healthy_JJ female_JJ subjects_NNS received_VBD ketoconazole_NN 200_CD mg_NN twice_RB daily_RB for_IN 7_CD days_NNS ,_, with_IN coadministration_NN of_IN alosetron_NN 1_CD mg_NN on_IN the_DT last_JJ day_NN ._. Ketoconazole_NN increased_VBD mean_JJ alosetron_NN plasma_NN concentrations_NNS -LRB-_-LRB- AUC_NN -RRB-_-RRB- by_IN 29_CD %_NN ._. Caution_NN should_MD be_VB used_VBN when_WRB alosetron_NN and_CC ketoconazole_NN are_VBP administered_VBN concomitantly_RB ._. Coadministration_NN of_IN alosetron_NN and_CC strong_JJ CYP3A4_NN inhibitors_NNS ,_, such_JJ as_IN clarithromycin_NN ,_, telithromycin_NN ,_, protease_NN inhibitors_NNS ,_, voriconazole_NN ,_, and_CC itraconazole_NN has_VBZ not_RB been_VBN evaluated_VBN but_CC should_MD be_VB undertaken_VBN with_IN caution_NN because_IN of_IN similar_JJ potential_JJ drug_NN interactions_NNS ._. The_DT effect_NN of_IN induction_NN or_CC inhibition_NN of_IN other_JJ pathways_NNS on_IN exposure_NN to_TO alosetron_NN and_CC its_PRP$ metabolites_NNS is_VBZ not_RB known_VBN ._. In_FW vitro_FW human_JJ liver_NN microsome_NN studies_NNS and_CC an_DT in_FW vivo_FW metabolic_JJ probe_NN study_NN demonstrated_VBD that_IN alosetron_NN did_VBD not_RB inhibit_VB CYP_NN enzymes_NNS 2D6_NN ,_, 3A4_NN ,_, 2C9_NN ,_, or_CC 2C19_NN ._. In_FW vitro_FW ,_, at_IN total_JJ drug_NN concentrations_NNS 27-fold_RB higher_JJR than_IN peak_JJ plasma_NN concentrations_NNS observed_VBN with_IN the_DT 1-mg_JJ dosage_NN ,_, alosetron_NN inhibited_VBD CYP_NN enzymes_NNS 1A2_NN -LRB-_-LRB- 60_CD %_NN -RRB-_-RRB- and_CC 2E1_NN -LRB-_-LRB- 50_CD %_NN -RRB-_-RRB- ._. In_IN an_DT in_FW vivo_FW metabolic_JJ probe_NN study_NN ,_, alosetron_NN did_VBD not_RB inhibit_VB CYP2E1_NN but_CC did_VBD produce_VB 30_CD %_NN inhibition_NN of_IN both_CC CYP1A2_NN and_CC N-acetyltransferase_NN ._. Although_IN not_RB studied_VBN with_IN alosetron_NN ,_, inhibition_NN of_IN N-acetyltransferase_NN may_MD have_VB clinically_RB relevant_JJ consequences_NNS for_IN drugs_NNS such_JJ as_IN isoniazid_NN ,_, procainamide_NN ,_, and_CC hydralazine_NN ._. The_DT effect_NN on_IN CYP1A2_NN was_VBD explored_VBN further_RB in_IN a_DT clinical_JJ interaction_NN study_NN with_IN theophylline_NN and_CC no_DT effect_NN on_IN metabolism_NN was_VBD observed_VBN ._. Another_DT study_NN showed_VBD that_IN alosetron_NN had_VBD no_DT clinically_RB significant_JJ effect_NN on_IN plasma_NN concentrations_NNS of_IN the_DT oral_JJ contraceptive_JJ agents_NNS ethinyl_NN estradiol_NN and_CC levonorgestrel_NN -LRB-_-LRB- CYP3A4_NN substrates_NNS -RRB-_-RRB- ._. A_DT clinical_JJ interaction_NN study_NN was_VBD also_RB conducted_VBN with_IN alosetron_NN and_CC the_DT CYP3A4_NN substrate_NN cisapride_NN ._. No_DT significant_JJ effects_NNS on_IN cisapride_NN metabolism_NN or_CC QT_NN interval_NN were_VBD noted_VBN ._. The_DT effect_NN of_IN alosetron_NN on_IN monoamine_NN oxidases_NNS and_CC on_IN intestinal_JJ first_JJ pass_NN secondary_JJ to_TO high_JJ intraluminal_JJ concentrations_NNS have_VBP not_RB been_VBN examined_VBN ._. Based_VBN on_IN the_DT above_JJ data_NNS from_IN in_FW vitro_FW and_CC in_FW vivo_FW studies_NNS ,_, it_PRP is_VBZ unlikely_JJ that_IN alosetron_NN will_MD inhibit_VB the_DT hepatic_JJ metabolic_JJ clearance_NN of_IN drugs_NNS metabolized_VBN by_IN the_DT major_JJ CYP_NN enzyme_NN 3A4_NN ,_, as_RB well_RB as_IN the_DT CYP_NN enzymes_NNS 2D6_NN ,_, 2C9_NN ,_, 2C19_NN ,_, 2E1_NN ,_, or_CC 1A2_NN ._. Alosetron_NNP does_VBZ not_RB appear_VB to_TO induce_VB the_DT major_JJ cytochrome_NN P450_NN -LRB-_-LRB- CYP_NN -RRB-_-RRB- drug_NN metabolizing_VBG enzyme_NN 3A_NN ._. Alosetron_NNP also_RB does_VBZ not_RB appear_VB to_TO induce_VB CYP_NN enzymes_NNS 2E1_NN or_CC 2C19_NN ._. It_PRP is_VBZ not_RB known_VBN whether_IN alosetron_NN might_MD induce_VB other_JJ enzymes_NNS ._. The_DT benzodiazepines_NNS ,_, including_VBG alprazolam_NN ,_, produce_VBP additive_JJ CNS_NNS depressant_NN effects_NNS when_WRB co-administered_VBN with_IN other_JJ psychotropic_JJ medications_NNS ,_, anticonvulsants_NNS ,_, antihistaminics_NNS ,_, ethanol_NN ,_, and_CC other_JJ drugs_NNS which_WDT themselves_PRP produce_VBP CNS_NN depression_NN ._. The_DT steady_JJ state_NN plasma_NN concentrations_NNS of_IN imipramine_NN and_CC desipramine_NN have_VBP been_VBN reported_VBN to_TO be_VB increased_VBN an_DT average_NN of_IN 31_CD %_NN and_CC 20_CD %_NN ,_, respectively_RB ,_, by_IN the_DT concomitant_JJ administration_NN of_IN alprazolam_NN tablets_NNS in_IN doses_NNS up_RB to_TO 4_CD mg/day_NN ._. The_DT clinical_JJ significance_NN of_IN these_DT changes_NNS is_VBZ unknown_JJ ._. Drugs_NNS That_WDT Inhibit_VBP Alprazolam_NNP Metabolism_NNP Via_NNP Cytochrome_NNP P450_NN 3A_NN :_: The_DT initial_JJ step_NN in_IN alprazolam_NN metabolism_NN is_VBZ hydroxylation_NN catalyzed_VBN by_IN cytochrome_NN P450_NN 3A_NN -LRB-_-LRB- CYP_NN 3A_NN -RRB-_-RRB- ._. Drugs_NNS which_WDT inhibit_VBP this_DT metabolic_JJ pathway_NN may_MD have_VB a_DT profound_JJ effect_NN on_IN the_DT clearance_NN of_IN alprazolam_NN ._. Drugs_NNS Demonstrated_VBN to_TO be_VB CYP_NN 3A_NN Inhibitors_NNS of_IN Possible_JJ Clinical_JJ Significance_NN on_IN the_DT Basis_NN of_IN Clinical_JJ Studies_NNS Involving_VBG Alprazolam_NN -LRB-_-LRB- caution_NN is_VBZ recommended_VBN during_IN coadministration_NN with_IN alprazolam_NN -RRB-_-RRB- :_: Coadministration_NN of_IN fluoxetine_NN with_IN alprazolam_NN increased_VBD the_DT maximum_NN plasma_NN concentration_NN of_IN alprazolam_NN by_IN 46_CD %_NN ,_, decreased_VBD clearance_NN by_IN 21_CD %_NN ,_, increased_VBD half-life_NN by_IN 17_CD %_NN ,_, and_CC decreased_VBD measured_VBN psychomotor_NN performance_NN ._. Coadministration_NN of_IN propoxyphene_NN decreased_VBD the_DT maximum_NN plasma_NN concentration_NN of_IN alprazolam_NN by_IN 6_CD %_NN ,_, decreased_VBD clearance_NN by_IN 38_CD %_NN ,_, and_CC increased_VBD half-life_NN by_IN 58_CD %_NN ._. Coadministration_NN of_IN oral_JJ contraceptives_NNS increased_VBD the_DT maximum_NN plasma_NN concentration_NN of_IN alprazolam_NN by_IN 18_CD %_NN ,_, decreased_VBD clearance_NN by_IN 22_CD %_NN ,_, and_CC increased_VBD half-life_NN by_IN 29_CD %_NN ._. Drugs_NNS and_CC other_JJ substances_NNS demonstrated_VBD to_TO be_VB CYP_NN 3A_NN inhibitors_NNS on_IN the_DT basis_NN of_IN clinical_JJ studies_NNS involving_VBG benzodiazepines_NNS metabolized_VBN similarly_RB to_TO alprazolam_NN or_CC on_IN the_DT basis_NN of_IN in_FW vitro_FW studies_NNS with_IN alprazolam_NN or_CC other_JJ benzodiazepines_NNS -LRB-_-LRB- caution_NN is_VBZ recommended_VBN during_IN coadministration_NN with_IN alprazolam_NN -RRB-_-RRB- :_: Available_JJ data_NNS from_IN clinical_JJ studies_NNS of_IN benzodiazepines_NNS other_JJ than_IN alprazolam_NN suggest_VBP a_DT possible_JJ drug_NN interaction_NN with_IN alprazolam_NN for_IN the_DT following_NN :_: diltiazem_NN ,_, isoniazid_NN ,_, macrolide_NN antibiotics_NNS such_JJ as_IN erythromycin_NN and_CC clarithromycin_NN ,_, and_CC grapefruit_NN juice_NN ._. Data_NNS from_IN in_FW vitro_FW studies_NNS of_IN alprazolam_NN suggest_VBP a_DT possible_JJ drug_NN interaction_NN with_IN alprazolam_NN for_IN the_DT following_NN :_: sertraline_NN and_CC paroxetine_NN ._. Data_NNS from_IN in_FW vitro_FW studies_NNS of_IN benzodiazepines_NNS other_JJ than_IN alprazolam_NN suggest_VBP a_DT possible_JJ drug_NN interaction_NN for_IN the_DT following_NN :_: ergotamine_NN ,_, cyclosporine_NN ,_, amiodarone_NN ,_, nicardipine_NN ,_, and_CC nifedipine_NN ._. Caution_NN is_VBZ recommended_VBN during_IN the_DT coadministration_NN of_IN any_DT of_IN these_DT with_IN alprazolam_NN ._. No_DT drug_NN interactions_NNS have_VBP been_VBN reported_VBN between_IN Prostin_NNP VR_NN Pediatric_NNP and_CC the_DT therapy_NN standard_NN in_IN neonates_NNS with_IN restricted_JJ pulmonary_JJ or_CC systemic_JJ blood_NN flow_NN ._. Standard_JJ therapy_NN includes_VBZ antibiotics_NNS ,_, such_JJ as_IN penicillin_NN and_CC gentamicin_NN ._. vasopressors_NNS ,_, such_JJ as_IN dopamine_NN and_CC isoproterenol_NN ._. cardiac_JJ glycosides_NNS ._. and_CC diuretics_NNS ,_, such_JJ as_IN furosemide_NN ._. Caverject_NNP :_: The_DT potential_NN for_IN pharmacokinetic_JJ drug-drug_NN interactions_NNS between_IN alprostadil_NN and_CC other_JJ agents_NNS has_VBZ not_RB been_VBN formally_RB studied_VBN ._. The_DT interaction_NN of_IN Activase_NN with_IN other_JJ cardioactive_JJ or_CC cerebroactive_JJ drugs_NNS has_VBZ not_RB been_VBN studied_VBN ._. In_IN addition_NN to_TO bleeding_NN associated_VBN with_IN heparin_NN and_CC vitamin_NN K_NN antagonists_NNS ,_, drugs_NNS that_WDT alter_VBP platelet_NN function_NN -LRB-_-LRB- such_JJ as_IN acetylsalicylic_JJ acid_NN ,_, dipyridamole_NN and_CC Abciximab_NNP -RRB-_-RRB- may_MD increase_VB the_DT risk_NN of_IN bleeding_VBG if_IN administered_VBN prior_RB to_TO ,_, during_IN ,_, or_CC after_IN Activase_NN therapy_NN ._. Use_NN of_IN Antithrombotics_NNP Aspirin_NNP and_CC heparin_NN have_VBP been_VBN administered_VBN concomitantly_RB with_IN and_CC following_VBG infusions_NNS of_IN Activase_NNP in_IN the_DT management_NN of_IN acute_JJ myocardial_JJ infarction_NN or_CC pulmonary_JJ embolism_NN ._. Because_IN heparin_NN ,_, aspirin_NN ,_, or_CC Activase_NNP may_MD cause_VB bleeding_JJ complications_NNS ,_, careful_JJ monitoring_NN for_IN bleeding_NN is_VBZ advised_VBN ,_, especially_RB at_IN arterial_JJ puncture_NN sites_NNS ._. The_DT concomitant_JJ use_NN of_IN heparin_NN or_CC aspirin_NN during_IN the_DT first_JJ 24_CD hours_NNS following_VBG symptom_NN onset_NN were_VBD prohibited_VBN in_IN The_DT NINDS_NN t-PA_NN Stroke_NNP Trial_NNP ._. The_DT safety_NN of_IN such_JJ concomitant_JJ use_NN with_IN Activase_NN for_IN the_DT management_NN of_IN acute_JJ ischemic_JJ stroke_NN is_VBZ unknown_JJ ._. Concurrent_JJ administration_NN of_IN HEXALEN_NN and_CC antidepressants_NNS of_IN the_DT MAO_NNP inhibitor_NN class_NN may_MD cause_VB severe_JJ orthostatic_JJ hypotension.Cimetidine_NN ,_, an_DT inhibitor_NN of_IN microsomal_JJ drug_NN metabolism_NN ,_, increased_VBD altretamines_NNS half-life_NN and_CC toxicity_NN in_IN a_DT rat_NN model_NN ._. Data_NNS from_IN a_DT randomized_JJ trial_NN of_IN HEXALEN_NN and_CC cisplatin_NN plus_CC or_CC minus_CC pyridoxine_NN in_IN ovarian_JJ cancer_NN indicated_VBD that_IN pyridoxine_NN significantly_RB reduced_VBD neurotoxicity_NN ._. however_RB ,_, it_PRP adversely_RB affected_VBD response_NN duration_NN suggesting_VBG that_IN pyridoxine_NN should_MD not_RB be_VB administered_VBN with_IN HEXALEN_NN and/or_CC cisplatin_NN ._. Careful_JJ observation_NN is_VBZ required_VBN when_WRB amantadine_NN is_VBZ administered_VBN concurrently_RB with_IN central_JJ nervous_JJ system_NN stimulants_NNS ._. Coadministration_NN of_IN thioridazine_NN has_VBZ been_VBN reported_VBN to_TO worsen_VB the_DT tremor_NN in_IN elderly_JJ patients_NNS with_IN Parkinsons_NNPS disease_NN ._. however_RB ,_, it_PRP is_VBZ not_RB known_VBN if_IN other_JJ phenothiazines_NNS produce_VBP a_DT similar_JJ response_NN ._. Special_JJ consideration_NN should_MD be_VB given_VBN to_TO the_DT administration_NN of_IN ETHYOL_NNP in_IN patients_NNS receiving_VBG antihypertensive_JJ medications_NNS or_CC other_JJ drugs_NNS that_WDT could_MD cause_VB or_CC potentiate_VB hypotension_NN ._. When_WRB amiloride_NN HCl_NN is_VBZ administered_VBN concomitantly_RB with_IN an_DT angiotensin-converting_JJ enzyme_NN inhibitor_NN ,_, the_DT risk_NN of_IN hyperkalemia_NN may_MD be_VB increased_VBN ._. Therefore_RB ,_, if_IN concomitant_JJ use_NN of_IN these_DT agents_NNS is_VBZ indicated_VBN because_IN of_IN demonstrated_VBN hypokalemia_NN ,_, they_PRP should_MD be_VB used_VBN with_IN caution_NN and_CC with_IN frequent_JJ monitoring_NN of_IN serum_NN potassium_NN ._. Lithium_NN generally_RB should_MD not_RB be_VB given_VBN with_IN diuretics_NNS because_IN they_PRP reduce_VBP its_PRP$ renal_JJ clearance_NN and_CC add_VB a_DT high_JJ risk_NN of_IN lithium_NN toxicity_NN ._. Read_VB circulars_NNS for_IN lithium_NN preparations_NNS before_IN use_NN of_IN such_JJ concomitant_JJ therapy_NN ._. In_IN some_DT patients_NNS ,_, the_DT administration_NN of_IN a_DT non-steroidal_JJ anti-inflammatory_JJ agent_NN can_MD reduce_VB the_DT diuretic_JJ ,_, natriuretic_JJ ,_, and_CC antihypertensive_JJ effects_NNS of_IN loop_NN ,_, potassium-sparing_NN and_CC thiazide_JJ diuretics_NNS ._. Therefore_RB ,_, when_WRB MIDAMOR_NN and_CC non-steroidal_JJ anti-inflammatory_JJ agents_NNS are_VBP used_VBN concomitantly_RB ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB to_TO determine_VB if_IN the_DT desired_VBN effect_NN of_IN the_DT diuretic_JJ is_VBZ obtained_VBN ._. Since_IN indomethacin_NN and_CC potassium-sparing_JJ diuretics_NNS ,_, including_VBG MIDAMOR_NNP ,_, may_MD each_DT be_VB associated_VBN with_IN increased_VBN serum_NN potassium_NN levels_NNS ,_, the_DT potential_JJ effects_NNS on_IN potassium_NN kinetics_NNS and_CC renal_JJ function_NN should_MD be_VB considered_VBN when_WRB these_DT agents_NNS are_VBP administered_VBN concurrently_RB ._. Drug_NNP Laboratory_NNP Test_NNP Interactions_NNS :_: Prolongation_NN of_IN the_DT template_NN bleeding_NN time_NN has_VBZ been_VBN reported_VBN during_IN continuous_JJ intravenous_JJ infusion_NN of_IN AMICAR_NN at_IN dosages_NNS exceeding_VBG 24_CD g/day_NN ._. Platelet_NN function_NN studies_NNS in_IN these_DT patients_NNS have_VBP not_RB demonstrated_VBN any_DT significant_JJ platelet_NN dysfunction_NN ._. However_RB ,_, in_FW vitro_FW studies_NNS have_VBP shown_VBN that_IN at_IN high_JJ concentrations_NNS -LRB-_-LRB- 7.4_CD mMol/L_NN or_CC 0.97_CD mg/mL_NN and_CC greater_JJR -RRB-_-RRB- EACA_NN inhibits_VBZ ADP_NN and_CC collagen-induced_JJ platelet_NN aggregation_NN ,_, the_DT release_NN of_IN ATP_NN and_CC serotonin_NN ,_, and_CC the_DT binding_NN of_IN fibrinogen_NN to_TO the_DT platelets_NNS in_IN a_DT concentration-response_JJ manner_NN ._. Following_VBG a_DT 10_CD g_NN bolus_NN of_IN AMICAR_NNP ,_, transient_JJ peak_NN plasma_NN concentrations_NNS of_IN 4.6_CD mMol/L_NN or_CC 0.60_CD mg/mL_NN have_VBP been_VBN obtained_VBN ._. The_DT concentration_NN of_IN AMICAR_NNP necessary_JJ to_TO maintain_VB inhibition_NN of_IN fibrinolysis_NN is_VBZ 0.99_CD mMol/L_NN or_CC 0.13_CD mg/mL_NN ._. Administration_NN of_IN a_DT 5_CD g_NN bolus_NN followed_VBN by_IN 1_CD to_TO 1.25_CD g/hr_NN should_MD achieve_VB and_CC sustain_VB plasma_NN levels_NNS of_IN 0.13_CD mg/mL_NN ._. Thus_RB ,_, concentrations_NNS which_WDT have_VBP been_VBN obtained_VBN in_FW vivo_FW clinically_RB in_IN patients_NNS with_IN normal_JJ renal_JJ function_NN are_VBP considerably_RB lower_JJR than_IN the_DT in_FW vitro_FW concentrations_NNS found_VBN to_TO induce_VB abnormalities_NNS in_IN platelet_NN function_NN tests_NNS ._. However_RB ,_, higher_JJR plasma_NN concentrations_NNS of_IN AMICAR_NN may_MD occur_VB in_IN patients_NNS with_IN severe_JJ renal_JJ failure_NN ._. Cytadren_NN accelerates_VBZ the_DT metabolism_NN of_IN dexamethasone_NN ._. therefore_RB ,_, if_IN glucocorticoid_NN replacement_NN is_VBZ needed_VBN ,_, hydrocortisone_NN should_MD be_VB prescribed_VBN ._. Aminoglutethimide_NNP diminishes_VBZ the_DT effect_NN of_IN coumarin_NN and_CC warfarin_NN ._. Renal_JJ clearance_NN measurements_NNS of_IN PAH_NN can_MD not_RB be_VB made_VBN with_IN any_DT significant_JJ accuracy_NN in_IN patients_NNS receiving_VBG sulfonamides_NNS ,_, procaine_NN ,_, or_CC thiazolesulfone_NN ._. These_DT compounds_NNS interfere_VBP with_IN chemical_NN color_NN development_NN essential_JJ to_TO the_DT analytical_JJ procedures_NNS ._. Probenecid_NNP depresses_VBZ tubular_JJ secretion_NN of_IN certain_JJ weak_JJ acids_NNS such_JJ as_IN PAH_NN ._. Therefore_RB ,_, patients_NNS receiving_VBG probenecid_NN will_MD have_VB erroneously_RB low_JJ ERPF_NN and_CC Tm_NN PAH_NN values_NNS ._. There_EX have_VBP been_VBN no_DT formal_JJ studies_NNS of_IN the_DT interaction_NN of_IN LEVULAN_NNP KERASTICK_NNP for_IN Topical_NNP Solution_NN with_IN any_DT other_JJ drugs_NNS ,_, and_CC no_DT drug-specific_JJ interactions_NNS were_VBD noted_VBN during_IN any_DT of_IN the_DT controlled_JJ clinical_JJ trials_NNS ._. It_PRP is_VBZ ,_, however_RB ,_, possible_JJ that_IN concomitant_JJ use_NN of_IN other_JJ known_JJ photosensitizing_JJ agents_NNS such_JJ as_IN griseofulvin_NN ,_, thiazide_JJ diuretics_NNS ,_, sulfonylureas_NNS ,_, phenothiazines_NNS ,_, sulfonamides_NNS and_CC tetracyclines_NNS might_MD increase_VB the_DT photosensitivity_NN reaction_NN of_IN actinic_JJ keratoses_NNS treated_VBN with_IN the_DT LEVULAN_NNP KERASTICK_NNP for_IN Topical_NNP Solution_NN ._. Aminosalicylic_JJ acid_NN may_MD decrease_VB the_DT amount_NN of_IN digoxin_NN -LRB-_-LRB- Lanoxin_NN ,_, Lanoxicaps_NN -RRB-_-RRB- that_WDT gets_VBZ absorbed_VBN into_IN your_PRP$ body_NN ._. In_IN the_DT case_NN that_IN you_PRP are_VBP taking_VBG digoxin_NN while_IN taking_VBG aminosalicylic_JJ acid_NN ,_, higher_JJR doses_NNS of_IN digoxin_NN may_MD be_VB needed_VBN ._. Aminosalicylic_JJ acid_NN may_MD also_RB decrease_VB the_DT absorption_NN of_IN vitamin_NN B12_NN ,_, which_WDT can_MD lead_VB to_TO a_DT deficiency_NN ._. Therefore_RB you_PRP may_MD need_VB to_TO take_VB a_DT vitamin_NN B12_NN supplement_NN while_IN taking_VBG aminosalicylic_JJ acid_NN ._. Amiodarone_NNP is_VBZ metabolized_VBN to_TO desethylamiodarone_VBN by_IN the_DT cytochrome_NN P450_NN -LRB-_-LRB- CYP450_NN -RRB-_-RRB- enzyme_NN group_NN ,_, specifically_RB cytochromes_VBZ P450_NN 3A4_NN -LRB-_-LRB- CYP3A4_NN -RRB-_-RRB- and_CC CYP2C8_NN ._. The_DT CYP3A4_NN isoenzyme_NN is_VBZ present_JJ in_IN both_CC the_DT liver_NN and_CC intestines_NNS ._. Amiodarone_NNP is_VBZ also_RB known_VBN to_TO be_VB an_DT inhibitor_NN of_IN CYP3A4_NN ._. Therefore_RB ,_, amiodarone_NN has_VBZ the_DT potential_NN for_IN interactions_NNS with_IN drugs_NNS or_CC substances_NNS that_WDT may_MD be_VB substrates_NNS ,_, inhibitors_NNS or_CC inducers_NNS of_IN CYP3A4_NN ._. While_IN only_RB a_DT limited_JJ number_NN of_IN in_FW vivo_FW drug-drug_JJ interactions_NNS with_IN amiodarone_NN have_VBP been_VBN reported_VBN ,_, chiefly_RB with_IN the_DT oral_JJ formulation_NN ,_, the_DT potential_NN for_IN other_JJ interactions_NNS should_MD be_VB anticipated_VBN ._. This_DT is_VBZ especially_RB important_JJ for_IN drugs_NNS associated_VBN with_IN serious_JJ toxicity_NN ,_, such_JJ as_IN other_JJ antiarrhythmics_NNS ._. If_IN such_JJ drugs_NNS are_VBP needed_VBN ,_, their_PRP$ dose_NN should_MD be_VB reassessed_VBN and_CC ,_, where_WRB appropriate_JJ ,_, plasma_NN concentration_NN measured_VBN ._. In_IN view_NN of_IN the_DT long_JJ and_CC variable_JJ half-life_NN of_IN amiodarone_NN ,_, potential_NN for_IN drug_NN interactions_NNS exists_VBZ not_RB only_RB with_IN concomitant_JJ medication_NN but_CC also_RB with_IN drugs_NNS administered_VBN after_IN discontinuation_NN of_IN amiodarone_NN ._. Since_IN amiodarone_NN is_VBZ a_DT substrate_NN for_IN CYP3A4_NN and_CC CYP2C8_NN ,_, drugs/substances_NNS that_WDT inhibit_VBP these_DT isoenzymes_NNS may_MD decrease_VB the_DT metabolism_NN and_CC increase_NN serum_NN concentration_NN of_IN amiodarone_NN ._. Reported_VBN examples_NNS include_VBP the_DT following_NN :_: Protease_NN Inhibitors_NNS :_: Protease_NN inhibitors_NNS are_VBP known_VBN to_TO inhibit_VB CYP3A4_NN to_TO varying_VBG degrees_NNS ._. A_DT case_NN report_NN of_IN one_CD patient_NN taking_VBG amiodarone_NN 200_CD mg_NN and_CC indinavir_NN 800_CD mg_NN three_CD times_NNS a_DT day_NN resulted_VBD in_IN increases_NNS in_IN amiodarone_NN concentrations_NNS from_IN 0.9_CD mg/L_NN to_TO 1.3_CD mg/L_NN ._. DEA_NNP concentrations_NNS were_VBD not_RB affected_VBN ._. There_EX was_VBD no_DT evidence_NN of_IN toxicity_NN ._. Monitoring_VBG for_IN amiodarone_NN toxicity_NN and_CC serial_NN measurement_NN of_IN amiodarone_NN serum_NN concentration_NN during_IN concomitant_JJ protease_NN inhibitor_NN therapy_NN should_MD be_VB considered_VBN ._. Histamine_NN H2_NN antagonists_NNS :_: Cimetidine_NN inhibits_VBZ CYP3A4_NN and_CC can_MD increase_VB serum_NN amiodarone_NN levels_NNS ._. Other_JJ substances_NNS :_: Grapefruit_NN juice_NN given_VBN to_TO healthy_JJ volunteers_NNS increased_VBD amiodarone_NN AUC_NN by_IN 50_CD %_NN and_CC Cmax_NN by_IN 84_CD %_NN ,_, resulting_VBG in_IN increased_VBN plasma_NN levels_NNS of_IN amiodarone_NN ._. Grapefruit_NN juice_NN should_MD not_RB be_VB taken_VBN during_IN treatment_NN with_IN oral_JJ amiodarone_NN ._. This_DT information_NN should_MD be_VB considered_VBN when_WRB changing_VBG from_IN intravenous_JJ amiodarone_NN to_TO oral_JJ amiodarone_NN ._. Amiodarone_NNP may_MD suppress_VB certain_JJ CYP450_NN enzymes_NNS ,_, including_VBG CYP1A2_NN ,_, CYP2C9_NN ,_, CYP2D6_NN ,_, and_CC CYP3A4_NN ._. This_DT inhibition_NN can_MD result_VB in_IN unexpectedly_RB high_JJ plasma_NN levels_NNS of_IN other_JJ drugs_NNS which_WDT are_VBP metabolized_VBN by_IN those_DT CYP450_NN enzymes_NNS ._. Reported_VBN examples_NNS of_IN this_DT interaction_NN include_VBP the_DT following_NN :_: Immunosuppressives_NNS :_: Cyclosporine_NN -LRB-_-LRB- CYP3A4_NN substrate_NN -RRB-_-RRB- administered_VBN in_IN combination_NN with_IN oral_JJ amiodarone_NN has_VBZ been_VBN reported_VBN to_TO produce_VB persistently_RB elevated_JJ plasma_NN concentrations_NNS of_IN cyclosporine_NN resulting_VBG in_IN elevated_JJ creatinine_NN ,_, despite_IN reduction_NN in_IN dose_NN of_IN cyclosporine_NN ._. HMG-CoA_NN Reductase_NN Inhibitors_NNS :_: Simvastatin_NN -LRB-_-LRB- CYP3A4_NN substrate_NN -RRB-_-RRB- in_IN combination_NN with_IN amiodarone_NN has_VBZ been_VBN associated_VBN with_IN reports_NNS of_IN myopathy/rhabdomyolysis_NN ._. Cardiovasculars_NNP :_: Cardiac_JJ glycosides_NNS :_: In_IN patients_NNS receiving_VBG digoxin_NN therapy_NN ,_, administration_NN of_IN oral_JJ amiodarone_NN regularly_RB results_VBZ in_IN an_DT increase_NN in_IN serum_NN digoxin_NN concentration_NN that_WDT may_MD reach_VB toxic_JJ levels_NNS with_IN resultant_JJ clinical_JJ toxicity_NN ._. Amiodarone_NNP taken_VBN concomitantly_RB with_IN digoxin_NN increases_VBZ the_DT serum_NN digoxin_NN concentration_NN by_IN 70_CD %_NN after_IN one_CD day_NN ._. On_IN administration_NN of_IN oral_JJ amiodarone_NN ,_, the_DT need_NN for_IN digitalis_NN therapy_NN should_MD be_VB reviewed_VBN and_CC the_DT dose_NN reduced_VBN by_IN approximately_RB 50_CD %_NN or_CC discontinued_VBN ._. If_IN digitalis_NN treatment_NN is_VBZ continued_VBN ,_, serum_NN levels_NNS should_MD be_VB closely_RB monitored_VBN and_CC patients_NNS observed_VBN for_IN clinical_JJ evidence_NN of_IN toxicity_NN ._. These_DT precautions_NNS probably_RB should_MD apply_VB to_TO digitoxin_NN administration_NN as_RB well_RB ._. Antiarrhythmics_NNS :_: Other_JJ antiarrhythmic_JJ drugs_NNS ,_, such_JJ as_IN quinidine_NN ,_, procainamide_NN ,_, disopyramide_NN ,_, and_CC phenytoin_NN ,_, have_VBP been_VBN used_VBN concurrently_RB with_IN amiodarone_NN ._. There_EX have_VBP been_VBN case_NN reports_NNS of_IN increased_VBN steady-state_JJ levels_NNS of_IN quinidine_NN ,_, procainamide_NN ,_, and_CC phenytoin_NN during_IN concomitant_JJ therapy_NN with_IN amiodarone_NN ._. Phenytoin_NN decreases_VBZ serum_NN amiodarone_NN levels_NNS ._. Amiodarone_NNP taken_VBN concomitantly_RB with_IN quinidine_NN increases_VBZ quinidine_NN serum_NN concentration_NN by_IN 33_CD %_NN after_IN two_CD days_NNS ._. Amiodarone_NNP taken_VBN concomitantly_RB with_IN procainamide_NN for_IN less_JJR than_IN seven_CD days_NNS increases_VBZ plasma_NN concentrations_NNS of_IN procainamide_NN and_CC n-acetyl_NN procainamide_NN by_IN 55_CD %_NN and_CC 33_CD %_NN ,_, respectively_RB ._. Quinidine_NN and_CC procainamide_NN doses_NNS should_MD be_VB reduced_VBN by_IN one-third_NN when_WRB either_CC is_VBZ administered_VBN with_IN amiodarone_NN ._. Plasma_NN levels_NNS of_IN flecainide_NN have_VBP been_VBN reported_VBN to_TO increase_VB in_IN the_DT presence_NN of_IN oral_JJ amiodarone_NN ._. because_IN of_IN this_DT ,_, the_DT dosage_NN of_IN flecainide_NN should_MD be_VB adjusted_VBN when_WRB these_DT drugs_NNS are_VBP administered_VBN concomitantly_RB ._. In_IN general_JJ ,_, any_DT added_VBD antiarrhythmic_JJ drug_NN should_MD be_VB initiated_VBN at_IN a_DT lower_JJR than_IN usual_JJ dose_NN with_IN careful_JJ monitoring_NN ._. Combination_NN of_IN amiodarone_NN with_IN other_JJ antiarrhythmic_JJ therapy_NN should_MD be_VB reserved_VBN for_IN patients_NNS with_IN life-threatening_JJ ventricular_JJ arrhythmias_NNS who_WP are_VBP incompletely_RB responsive_JJ to_TO a_DT single_JJ agent_NN or_CC incompletely_RB responsive_JJ to_TO amiodarone_NN ._. During_IN transfer_NN to_TO oral_JJ amiodarone_NN ,_, the_DT dose_NN levels_NNS of_IN previously_RB administered_VBN agents_NNS should_MD be_VB reduced_VBN by_IN 30_CD to_TO 50_CD %_NN several_JJ days_NNS after_IN the_DT addition_NN of_IN oral_JJ amiodarone_NN ._. The_DT continued_JJ need_NN for_IN the_DT other_JJ antiarrhythmic_JJ agent_NN should_MD be_VB reviewed_VBN after_IN the_DT effects_NNS of_IN amiodarone_NN have_VBP been_VBN established_VBN ,_, and_CC discontinuation_NN ordinarily_RB should_MD be_VB attempted_VBN ._. If_IN the_DT treatment_NN is_VBZ continued_VBN ,_, these_DT patients_NNS should_MD be_VB particularly_RB carefully_RB monitored_VBN for_IN adverse_JJ effects_NNS ,_, especially_RB conduction_NN disturbances_NNS and_CC exacerbation_NN of_IN tachyarrhythmias_NNS ,_, as_IN amiodarone_NN is_VBZ continued_VBN ._. In_IN amiodarone-treated_JJ patients_NNS who_WP require_VBP additional_JJ antiarrhythmic_JJ therapy_NN ,_, the_DT initial_JJ dose_NN of_IN such_JJ agents_NNS should_MD be_VB approximately_RB half_NN of_IN the_DT usual_JJ recommended_VBN dose_NN ._. Antihypertensives_NNS :_: Amiodarone_NN should_MD be_VB used_VBN with_IN caution_NN in_IN patients_NNS receiving_VBG -_: receptor_NN blocking_VBG agents_NNS -LRB-_-LRB- e.g._FW ,_, propranolol_NN ,_, a_DT CYP3A4_NN inhibitor_NN -RRB-_-RRB- or_CC calcium_NN channel_NN antagonists_NNS -LRB-_-LRB- e.g._FW ,_, verapamil_NN ,_, a_DT CYP3A4_NN substrate_NN ,_, and_CC diltiazem_NN ,_, a_DT CYP3A4_NN inhibitor_NN -RRB-_-RRB- because_IN of_IN the_DT possible_JJ potentiation_NN of_IN bradycardia_NN ,_, sinus_NN arrest_NN ,_, and_CC AV_NN block_NN ._. if_IN necessary_JJ ,_, amiodarone_NN can_MD continue_VB to_TO be_VB used_VBN after_IN insertion_NN of_IN a_DT pacemaker_NN in_IN patients_NNS with_IN severe_JJ bradycardia_NN or_CC sinus_NN arrest_NN ._. Anticoagulants_NNPS :_: Potentiation_NN of_IN warfarin-type_JJ -LRB-_-LRB- CYP2C9_NN and_CC CYP3A4_NN substrate_NN -RRB-_-RRB- anticoagulant_JJ response_NN is_VBZ almost_RB always_RB seen_VBN in_IN patients_NNS receiving_VBG amiodarone_NN and_CC can_MD result_VB in_IN serious_JJ or_CC fatal_JJ bleeding_NN ._. Since_IN the_DT concomitant_JJ administration_NN of_IN warfarin_NN with_IN amiodarone_NN increases_VBZ the_DT prothrombin_NN time_NN by_IN 100_CD %_NN after_IN 3_CD to_TO 4_CD days_NNS ,_, the_DT dose_NN of_IN the_DT anticoagulant_NN should_MD be_VB reduced_VBN by_IN one-third_NN to_TO one-half_NN ,_, and_CC prothrombin_NN times_NNS should_MD be_VB monitored_VBN closely_RB ._. Some_DT drugs/substances_NNS are_VBP known_VBN to_TO accelerate_VB the_DT metabolism_NN of_IN amiodarone_NN by_IN stimulating_VBG the_DT synthesis_NN of_IN CYP3A4_NN -LRB-_-LRB- enzyme_NN induction_NN -RRB-_-RRB- ._. This_DT may_MD lead_VB to_TO low_JJ amiodarone_NN serum_NN levels_NNS and_CC potential_JJ decrease_NN in_IN efficacy_NN ._. Reported_VBN examples_NNS of_IN this_DT interaction_NN include_VBP the_DT following_NN :_: Antibiotics_NNS :_: Rifampin_NNP is_VBZ a_DT potent_JJ inducer_NN of_IN CYP3A4_NN ._. Administration_NN of_IN rifampin_NN concomitantly_RB with_IN oral_JJ amiodarone_NN has_VBZ been_VBN shown_VBN to_TO result_VB in_IN decreases_NNS in_IN serum_NN concentrations_NNS of_IN amiodarone_NN and_CC desethylamiodarone_NN ._. Other_JJ substances_NNS ,_, including_VBG herbal_JJ preparations_NNS :_: St._NNP John_NNP s_VBZ Wort_NNP -LRB-_-LRB- Hypericum_NNP perforatum_NN -RRB-_-RRB- induces_VBZ CYP3A4_NN ._. Since_IN amiodarone_NN is_VBZ a_DT substrate_NN for_IN CYP3A4_NN ,_, there_EX is_VBZ the_DT potential_NN that_IN the_DT use_NN of_IN St._NNP John_NNP s_VBZ Wort_NNP in_IN patients_NNS receiving_VBG amiodarone_NN could_MD result_VB in_IN reduced_VBN amiodarone_NN levels_NNS ._. Other_JJ reported_VBN interactions_NNS with_IN amiodarone_NN :_: Fentanyl_NN -LRB-_-LRB- CYP3A4_NN substrate_NN -RRB-_-RRB- in_IN combination_NN with_IN amiodarone_NN may_MD cause_VB hypotension_NN ,_, bradycardia_NN ,_, and_CC decreased_VBD cardiac_JJ output_NN ._. Sinus_NN bradycardia_NN has_VBZ been_VBN reported_VBN with_IN oral_JJ amiodarone_NN in_IN combination_NN with_IN lidocaine_NN -LRB-_-LRB- CYP3A4_NN substrate_NN -RRB-_-RRB- given_VBN for_IN local_JJ anesthesia_NN ._. Seizure_NN ,_, associated_VBN with_IN increased_VBN lidocaine_NN concentrations_NNS ,_, has_VBZ been_VBN reported_VBN with_IN concomitant_JJ administration_NN of_IN intravenous_JJ amiodarone_NN ._. Dextromethorphan_NNP is_VBZ a_DT substrate_NN for_IN both_DT CYP2D6_NN and_CC CYP3A4_NN ._. Amiodarone_NN inhibits_VBZ CYP2D6_NN ._. Cholestyramine_NNP increases_VBZ enterohepatic_JJ elimination_NN of_IN amiodarone_NN and_CC may_MD reduce_VB its_PRP$ serum_NN levels_NNS and_CC t1/2_NN ._. Disopyramide_NNP increases_VBZ QT_NNP prolongation_NN which_WDT could_MD cause_VB arrhythmia_NN ._. Fluoroquinolones_NNP ,_, macrolide_NN antibiotics_NNS ,_, and_CC azoles_NNS are_VBP known_VBN to_TO cause_VB QTc_NN prolongation_NN ._. There_EX have_VBP been_VBN reports_NNS of_IN QTc_NN prolongation_NN ,_, with_IN or_CC without_IN TdP_NN ,_, in_IN patients_NNS taking_VBG amiodarone_NN when_WRB fluoroquinolones_NNS ,_, macrolide_NN antibiotics_NNS ,_, or_CC azoles_NNS were_VBD administered_VBN concomitantly_RB ._. Hemodynamic_JJ and_CC electrophysiologic_JJ interactions_NNS have_VBP also_RB been_VBN observed_VBN after_IN concomitant_JJ administration_NN with_IN propranolol_NN ,_, diltiazem_NN ,_, and_CC verapamil_NN ._. Volatile_JJ Anesthetic_NNP Agents_NNPS :_: ._. In_IN addition_NN to_TO the_DT interactions_NNS noted_VBD above_RB ,_, chronic_JJ -LRB-_-LRB- 2_CD weeks_NNS -RRB-_-RRB- oral_JJ Cordarone_NNP administration_NN impairs_VBZ metabolism_NN of_IN phenytoin_NN ,_, dextromethorphan_NN ,_, and_CC methotrexate_NN ._. Electrolyte_NNP Disturbances_NNPS Patients_NNPS with_IN hypokalemia_NN or_CC hypomagnesemia_NN should_MD have_VB the_DT condition_NN corrected_VBN whenever_WRB possible_JJ before_IN being_VBG treated_VBN with_IN Cordarone_JJ I.V._NNP ,_, as_IN these_DT disorders_NNS can_MD exaggerate_VB the_DT degree_NN of_IN QTc_NN prolongation_NN and_CC increase_VB the_DT potential_NN for_IN TdP_NN ._. Special_JJ attention_NN should_MD be_VB given_VBN to_TO electrolyte_NN and_CC acid-base_NN balance_NN in_IN patients_NNS experiencing_VBG severe_JJ or_CC prolonged_JJ diarrhea_NN or_CC in_IN patients_NNS receiving_VBG concomitant_JJ diuretics_NNS ._. Drugs_NNS Metabolized_VBN by_IN P450_NN 2D6_NN -_: The_DT biochemical_JJ activity_NN of_IN the_DT drug_NN metabolizing_VBG isozyme_NN cytochrome_NN P450_NN 2D6_NN -LRB-_-LRB- debrisoquin_NN hydroxylase_NN -RRB-_-RRB- is_VBZ reduced_VBN in_IN a_DT subset_NN of_IN the_DT caucasian_JJ population_NN -LRB-_-LRB- about_IN 7-10_CD %_NN of_IN caucasians_NNS are_VBP so_RB called_VBN poor_JJ metabolizers_NNS -RRB-_-RRB- ;_: ._. reliable_JJ estimates_NNS of_IN the_DT prevalence_NN of_IN reduced_VBN P450_NN 2D6_NN isozyme_NN activity_NN among_IN Asian_JJ ,_, African_JJ and_CC other_JJ populations_NNS are_VBP not_RB yet_RB available_JJ ._. Poor_NNP metabolizers_NNS have_VBP higher_JJR than_IN expected_VBN plasma_NN concentrations_NNS of_IN tricyclic_JJ antidepressants_NNS -LRB-_-LRB- TCAs_NNS -RRB-_-RRB- when_WRB given_VBN usual_JJ doses_NNS ._. Depending_VBG on_IN the_DT fraction_NN of_IN drug_NN metabolized_VBN by_IN P450_NN 2D6_NN ,_, the_DT increase_NN in_IN plasma_NN concentration_NN may_MD be_VB small_JJ ,_, or_CC quite_RB large_JJ -LRB-_-LRB- 8-fold_JJ increase_NN in_IN plasma_NN AUC_NN of_IN the_DT TCA_NNP -RRB-_-RRB- ._. In_IN addition_NN ,_, certain_JJ drugs_NNS inhibit_VBP the_DT activity_NN of_IN this_DT isozyme_NN and_CC make_VB normal_JJ metabolizers_NNS resemble_VBP poor_JJ metabolizers_NNS ._. An_DT individual_NN who_WP is_VBZ stable_JJ on_IN a_DT given_VBN dose_NN of_IN TCA_NNP may_MD become_VB abruptly_RB toxic_JJ when_WRB given_VBN one_CD of_IN these_DT inhibiting_VBG drugs_NNS as_IN concomitant_JJ therapy_NN ._. The_DT drugs_NNS that_WDT inhibit_VBP cytochrome_NN P450_NN 2D6_NN include_VBP some_DT that_WDT are_VBP not_RB metabolized_VBN by_IN the_DT enzyme_NN -LRB-_-LRB- quinidine_NN ._. cimetidine_NN -RRB-_-RRB- and_CC many_JJ that_WDT are_VBP substrates_NNS for_IN P450_NN 2D6_NN -LRB-_-LRB- many_JJ other_JJ antidepressants_NNS ,_, phenothiazines_NNS ,_, and_CC the_DT Type_NN 1C_NN antiarrhythmics_NNS propafenone_NN and_CC flecainide_NN -RRB-_-RRB- ._. While_IN all_PDT the_DT selective_JJ serotonin_NN reuptake_NN inhibitors_NNS -LRB-_-LRB- SSRIs_NNS -RRB-_-RRB- ,_, e.g._FW ,_, fluoxetine_NN ,_, sertraline_NN ,_, and_CC paroxetine_NN ,_, inhibit_VBP P450_NN 2D6_NN ,_, they_PRP may_MD vary_VB in_IN the_DT extent_NN of_IN inhibition_NN ._. The_DT extent_NN to_TO which_WDT SSRI-TCA_NNP interactions_NNS may_MD pose_VB clinical_JJ problems_NNS will_MD depend_VB on_IN the_DT degree_NN of_IN inhibition_NN and_CC the_DT pharmacokinetics_NNS of_IN the_DT SSRI_NNP involved_VBN ._. Nevertheless_RB ,_, caution_NN is_VBZ indicated_VBN in_IN the_DT coadministration_NN of_IN TCAs_NNS with_IN any_DT of_IN the_DT SSRIs_NNS and_CC also_RB in_IN switching_NN from_IN one_CD class_NN to_TO the_DT other_JJ ._. Of_IN particular_JJ importance_NN ,_, sufficient_JJ time_NN must_MD elapse_VB before_IN initiating_VBG TCA_NNP treatment_NN in_IN a_DT patient_NN being_VBG withdrawn_VBN from_IN fluoxetine_NN ,_, given_VBN the_DT long_JJ half-life_NN of_IN the_DT parent_NN and_CC active_JJ metabolite_NN -LRB-_-LRB- at_IN least_JJS 5_CD weeks_NNS may_MD be_VB necessary_JJ -RRB-_-RRB- ._. Concomitant_JJ use_NN of_IN tricyclic_JJ antidepressants_NNS with_IN drugs_NNS that_WDT can_MD inhibit_VB cytochrome_NN P450_NN 2D6_NN may_MD require_VB lower_JJR doses_NNS than_IN usually_RB prescribed_VBN for_IN either_CC the_DT tricyclic_JJ antidepressant_JJ or_CC the_DT other_JJ drug_NN ._. Furthermore_RB ,_, whenever_WRB one_CD of_IN these_DT other_JJ drugs_NNS is_VBZ withdrawn_VBN from_IN co-therapy_JJ ,_, an_DT increased_VBN dose_NN of_IN tricyclic_JJ antidepressant_JJ may_MD be_VB required_VBN ._. It_PRP is_VBZ desirable_JJ to_TO monitor_VB TCA_NNP plasma_NN levels_NNS whenever_WRB a_DT TCA_NNP is_VBZ going_VBG to_TO be_VB coadministered_VBN with_IN another_DT drug_NN known_VBN to_TO be_VB an_DT inhibitor_NN of_IN P450_NN 2D6_NN ._. Monoamine_NNP Oxidase_NNP Inhibitors_NNS :_: Guanethidine_NN or_CC similarly_RB acting_VBG compounds_NNS ._. thyroid_NN medication_NN ._. alcohol_NN ,_, barbiturates_NNS and_CC other_JJ CNS_NN depressants_NNS ._. and_CC disulfiram_NN When_WRB amitriptyline_NNP HCl_NN is_VBZ given_VBN with_IN anticholinergic_JJ agents_NNS or_CC sympathomimetic_JJ drugs_NNS ,_, including_VBG epinephrine_NN combined_VBN with_IN local_JJ anesthetics_NNS ,_, close_JJ supervision_NN and_CC careful_JJ adjustment_NN of_IN dosages_NNS are_VBP required_VBN ._. Hyperpyrexia_NNP has_VBZ been_VBN reported_VBN when_WRB amitriptyline_NNP HCl_NN is_VBZ administered_VBN with_IN anticholinergic_JJ agents_NNS or_CC with_IN neuroleptic_JJ drugs_NNS ,_, particularly_RB during_IN hot_JJ weather_NN ._. Paralytic_JJ ileus_NN may_MD occur_VB in_IN patients_NNS taking_VBG tricyclic_JJ antidepressants_NNS in_IN combination_NN with_IN anticholinergic-type_JJ drugs_NNS ._. Cimetidine_NNP is_VBZ reported_VBN to_TO reduce_VB hepatic_JJ metabolism_NN of_IN certain_JJ tricyclic_JJ antidepressants_NNS ,_, thereby_RB delaying_VBG elimination_NN and_CC increasing_VBG steady-state_JJ concentrations_NNS of_IN these_DT drugs_NNS ._. Clinically_RB significant_JJ effects_NNS have_VBP been_VBN reported_VBN with_IN the_DT tricyclic_JJ antidepressants_NNS when_WRB used_VBN concomitantly_RB with_IN cimetidine_NN ._. Increases_NNS in_IN plasma_NN levels_NNS of_IN tricyclic_JJ antidepressants_NNS ,_, and_CC in_IN the_DT frequency_NN and_CC severity_NN of_IN side_JJ effects_NNS ,_, particularly_RB anticholinergic_JJ ,_, have_VBP been_VBN reported_VBN when_WRB cimetidine_NN was_VBD added_VBN to_TO the_DT drug_NN regimen_NN ._. Discontinuation_NN of_IN cimetidine_NN in_IN well-controlled_JJ patients_NNS receiving_VBG tricyclic_JJ antidepressants_NNS and_CC cimetidine_NN may_MD decrease_VB the_DT plasma_NN levels_NNS and_CC efficacy_NN of_IN the_DT antidepressants_NNS ._. Caution_NN is_VBZ advised_VBN if_IN patients_NNS receive_VBP large_JJ doses_NNS of_IN ethchlorvynol_NN concurrently_RB ._. Transient_JJ delirium_NN has_VBZ been_VBN reported_VBN in_IN patients_NNS who_WP were_VBD treated_VBN with_IN one_CD gram_NN of_IN ethchlorvynol_NN and_CC 75_CD -_: 150_CD mg_NN of_IN amitriptyline_NNP HCl_NN ._. When_WRB administered_VBN concurrently_RB ,_, the_DT following_VBG drugs_NNS may_MD interact_VB with_IN amphotericin_NN B_NN :_: Antineoplastic_JJ agents_NNS :_: may_MD enhance_VB the_DT potential_NN for_IN renal_JJ toxicity_NN ,_, bronchospasm_NN and_CC hypotension_NN ._. Antineoplastic_JJ agents_NNS -LRB-_-LRB- e._FW g._FW ,_, nitrogen_NN mustard_NN ,_, etc._FW -RRB-_-RRB- should_MD be_VB given_VBN concomitantly_RB only_RB with_IN great_JJ caution_NN ._. Corticosteroids_NNS and_CC Corticotropin_NN -LRB-_-LRB- ACTH_NN -RRB-_-RRB- :_: may_MD potentiate_VB amphotericin_NN B_NN -_: induced_VBN hypokalemia_NN which_WDT may_MD predispose_VB the_DT patient_NN to_TO cardiac_JJ dysfunction_NN ._. Avoid_VB concomitant_JJ use_NN unless_IN necessary_JJ to_TO control_VB side_JJ effects_NNS of_IN amphotericin_NN B_NN ._. If_IN used_VBN concomitantly_RB ,_, closely_RB monitor_VB serum_NN electrolytes_NNS and_CC cardiac_JJ function_NN ._. Digitalis_NN glycosides_NNS :_: amphotericin_NN B-induced_JJ hypokalemia_NN may_MD potentiate_VB digitalis_NN toxicity_NN ._. Serum_NN potassium_NN levels_NNS and_CC cardiac_JJ function_NN should_MD be_VB closely_RB monitored_VBN and_CC any_DT deficit_NN promptly_RB corrected_VBN ._. Flucytosine_NNP :_: while_IN a_DT synergistic_JJ relationship_NN with_IN amphotericin_NN B_NN has_VBZ been_VBN reported_VBN ,_, concomitant_JJ use_NN may_MD increase_VB the_DT toxicity_NN of_IN flucytosine_NN by_IN possibly_RB increasing_VBG its_PRP$ cellular_JJ uptake_NN and/or_CC impairing_VBG its_PRP$ renal_JJ excretion_NN ._. Imidazoles_NNS -LRB-_-LRB- e._FW g._FW ,_, ketoconazole_NN ,_, miconazole_NN ,_, clotrimazole_NN ,_, fluconazole_NN ,_, etc._FW -RRB-_-RRB- :_: in_FW vitro_FW and_CC animal_JJ studies_NNS with_IN the_DT combination_NN of_IN amphotericin_NN B_NN and_CC imidazoles_NNS suggest_VBP that_IN imidazoles_NNS may_MD induce_VB fungal_JJ resistance_NN to_TO amphotericin_NN B._NNP Combination_NNP therapy_NN should_MD be_VB administered_VBN with_IN caution_NN ,_, especially_RB in_IN immunocompromised_JJ patients_NNS ._. Other_JJ nephrotoxic_JJ medications_NNS :_: agents_NNS such_JJ as_IN aminoglycosides_NNS ,_, cyclosporine_NN ,_, and_CC pentamidine_NN may_MD enhance_VB the_DT potential_NN for_IN drug-induced_JJ renal_JJ toxicity_NN ,_, and_CC should_MD be_VB used_VBN concomitantly_RB only_RB with_IN great_JJ caution_NN ._. Intensive_JJ monitoring_NN of_IN renal_JJ function_NN is_VBZ recommended_VBN in_IN patients_NNS requiring_VBG any_DT combination_NN of_IN nephrotoxic_JJ medications_NNS ._. Skeletal_JJ muscle_NN relaxants_NNS :_: amphotericin_NN B-induced_JJ hypokalemia_NN may_MD enhance_VB the_DT curariform_NN effect_NN of_IN skeletal_JJ muscle_NN relaxants_NNS -LRB-_-LRB- e.g._FW ,_, tubocurarine_NN -RRB-_-RRB- ._. Serum_NN potassium_NN levels_NNS should_MD be_VB monitored_VBN and_CC deficiencies_NNS corrected_VBN ._. Leukocyte_NN transfusions_NNS :_: acute_JJ pulmonary_JJ toxicity_NN has_VBZ been_VBN reported_VBN in_IN patients_NNS receiving_VBG intravenous_JJ amphotericin_NN B_NN and_CC leukocyte_NN transfusions_NNS ._. When_WRB administered_VBN concurrently_RB ,_, the_DT following_VBG drugs_NNS may_MD interact_VB with_IN ampicillin_NN ._. Allopurinol_NNP :_: Increased_VBN possibility_NN of_IN skin_NN rash_NN ,_, particularly_RB in_IN hyperuricemic_JJ patients_NNS may_MD occur_VB ._. Bacteriostatic_JJ Antibiotics_NNS :_: Chloramphenicol_NN ,_, erythromycins_NNS ,_, sulfonamides_NNS ,_, or_CC tetracyclines_NNS may_MD interfere_VB with_IN the_DT bactericidal_JJ effect_NN of_IN penicillins_NNS ._. This_DT has_VBZ been_VBN demonstrated_VBN in_IN view_NN ,_, however_RB ,_, the_DT clinical_JJ significance_NN of_IN this_DT interaction_NN is_VBZ not_RB well_RB documented_VBN ._. Oral_JJ Contraceptives_NNS :_: May_MD be_VB less_RBR effective_JJ and_CC increased_VBD breakthrough_NN bleeding_NN may_MD occur_VB ._. Probenecid_NNP :_: May_NNP decrease_VB renal_JJ tubular_JJ secretion_NN of_IN ampicillin_NN resulting_VBG in_IN increased_VBN blood_NN levels_NNS and/or_CC ampicillin_NN toxicity_NN ._. Drug/Laboratory_JJ Test_NN Interaction_NN After_IN treatment_NN with_IN ampicillin_NN ,_, a_DT false-positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN may_MD occur_VB with_IN copper_NN sulfate_NN tests_NNS -LRB-_-LRB- Benedicts_NNS solution_NN ,_, Fehlings_NNP solution_NN ,_, or_CC Clinitest_NNP tablets_NNS -RRB-_-RRB- but_CC not_RB with_IN enzyme_NN based_VBN tests_NNS such_JJ as_IN Clinistix_NNP and_CC Glucose_NNP Enzymatic_JJ Test_NN Strip_NNP USP_NNP ._. Amprenavir_NNP is_VBZ metabolized_VBN in_IN the_DT liver_NN by_IN the_DT cytochrome_NN P450_NN enzyme_NN system_NN ._. Amprenavir_NN inhibits_VBZ CYP3A4_NN ._. Caution_NN should_MD be_VB used_VBN when_WRB coadministering_VBG medications_NNS that_WDT are_VBP substrates_NNS ,_, inhibitors_NNS ,_, or_CC inducers_NNS of_IN CYP3A4_NN ,_, or_CC potentially_RB toxic_JJ medications_NNS that_WDT are_VBP metabolized_VBN by_IN CYP3A4_NN ._. Amprenavir_NNP does_VBZ not_RB inhibit_VB CYP2D6_NN ,_, CYP1A2_NN ,_, CYP2C9_NN ,_, CYP2C19_NN ,_, CYP2E1_NN ,_, or_CC uridine_NN glucuronosyltransferase_NN -LRB-_-LRB- UDPGT_NN -RRB-_-RRB- ._. HIV_NN Protease_NN Inhibitors_NNS :_: The_DT effect_NN of_IN amprenavir_NN on_IN total_JJ drug_NN concentrations_NNS of_IN other_JJ HIV_NN protease_NN inhibitors_NNS in_IN subjects_NNS receiving_VBG both_CC agents_NNS was_VBD evaluated_VBN using_VBG comparisons_NNS to_TO historical_JJ data_NNS ._. Indinavir_NNP steady-state_JJ Cmax_NNP ,_, A.C._NNP and_CC Cmin_NNP were_VBD decreased_VBN by_IN 22_CD %_NN ,_, 38_CD %_NN ,_, and_CC 27_CD %_NN ,_, respectively_RB ,_, by_IN concomitant_JJ amprenavir_NN ._. Similar_JJ decreases_NNS in_IN Cmax_NN and_CC AUC_NN were_VBD seen_VBN after_IN the_DT first_JJ dose_NN ._. Saquinavir_NNP steady-state_JJ Cmax_NNP ,_, A.C._NNP and_CC Cmin_NNP were_VBD increased_VBN 21_CD %_NN ,_, decreased_VBD 19_CD %_NN ,_, and_CC decreased_VBD 48_CD %_NN ,_, respectively_RB ,_, by_IN concomitant_JJ amprenavir_NN ._. Nelfinavir_NNP steady-state_JJ Cmax_NNP ,_, A.C._NNP and_CC Cmin_NNP were_VBD increased_VBN by_IN 12_CD %_NN ,_, 15_CD %_NN ,_, and_CC 14_CD %_NN ,_, respectively_RB ,_, by_IN concomitant_JJ amprenavir_NN ._. Methadone_NNP :_: Coadministration_NNP of_IN amprenavir_NN and_CC methadone_NN can_MD decrease_VB plasma_NN levels_NNS of_IN methadone_NN ._. Coadministration_NN of_IN amprenavir_NN and_CC methadone_NN as_IN compared_VBN to_TO a_DT non-matched_JJ historicalcontrol_NN group_NN resulted_VBD in_IN a_DT 30_CD %_NN ,_, 27_CD %_NN ,_, and_CC 25_CD %_NN decrease_NN in_IN serum_NN amprenavir_NN AUC_NN ,_, Cmax_NN ,_, andCmin_NN ,_, respectively_RB ._. Amprenavir_NNP is_VBZ an_DT inhibitor_NN of_IN cytochrome_NN P450_NN C.P.A._NN metabolism_NN and_CC therefore_RB should_MD not_RB be_VB administered_VBN concurrently_RB with_IN medications_NNS with_IN narrow_JJ therapeutic_JJ windows_NNS that_WDT are_VBP substrates_NNS of_IN CYP3A4_NN ._. There_EX are_VBP other_JJ agents_NNS that_WDT may_MD result_VB in_IN serious_JJ and/or_CC life-threatening_JJ drug_NN interactions_NNS ._. Laboratory_NN Tests_NNS :_: The_DT combination_NN of_IN Amprenavir_NNP and_CC low-dose_JJ ritonavir_NN has_VBZ been_VBN associated_VBN with_IN elevations_NNS of_IN cholesterol_NN and_CC triglycerides_NNS ,_, SGOT_NN -LRB-_-LRB- AST_NNP -RRB-_-RRB- ,_, and_CC SGPT_NN -LRB-_-LRB- ALT_NN -RRB-_-RRB- in_IN some_DT patients_NNS ._. Appropriate_JJ laboratory_NN testing_NN should_MD be_VB considered_VBN prior_RB to_TO initiating_VBG combination_NN therapy_NN with_IN Amprenavir_NN and_CC ritonavir_NN and_CC at_IN periodic_JJ intervals_NNS or_CC if_IN any_DT clinical_JJ signs_NNS or_CC symptoms_NNS of_IN hyperlipidemia_NN or_CC elevated_JJ liver_NN function_NN tests_NNS occur_VBP during_IN therapy_NN ._. For_IN comprehensive_JJ information_NN concerning_VBG laboratory_NN test_NN alterations_NNS associated_VBN with_IN ritonavir_NN ,_, physicians_NNS should_MD refer_VB to_TO the_DT complete_JJ prescribing_VBG information_NN for_IN NORVIR_NN -LRB-_-LRB- ritonavir_NN -RRB-_-RRB- ._. Taking_VBG amyl_NN nitrite_NN after_IN drinking_VBG alcohol_NN may_MD worsen_VB side_JJ effects_NNS and_CC may_MD cause_VB severe_JJ hypotension_NN and_CC cardiovascular_JJ collapse_NN ._. Limited_JJ PK_NN and/or_CC PD_NN studies_NNS investigating_VBG possible_JJ interactions_NNS between_IN anagrelide_NN and_CC other_JJ medicinal_JJ products_NNS have_VBP been_VBN conducted_VBN ._. In_FW vivo_FW interaction_NN studies_NNS in_IN humans_NNS have_VBP demonstrated_VBN that_IN digoxin_NN and_CC warfarin_NN do_VBP not_RB affect_VB the_DT PK_NN properties_NNS of_IN anagrelide_NN ,_, nor_CC does_VBZ anagrelide_NN affect_VB the_DT PK_NN properties_NNS of_IN digoxin_NN or_CC warfarin_NN ._. Although_IN additional_JJ drug_NN interaction_NN studies_NNS have_VBP not_RB been_VBN conducted_VBN ,_, the_DT most_RBS common_JJ medications_NNS used_VBN concomitantly_RB with_IN anagrelide_NN in_IN clinical_JJ trials_NNS were_VBD aspirin_NN ,_, acetaminophen_NN ,_, furosemide_NN ,_, iron_NN ,_, ranitidine_NN ,_, hydroxyurea_NN ,_, and_CC allopurinol_NN ._. There_EX is_VBZ no_DT clinical_JJ evidence_NN to_TO suggest_VB that_IN anagrelide_NN interacts_VBZ with_IN any_DT of_IN these_DT compounds_NNS ._. An_DT in_FW vivo_FW interaction_NN study_NN in_IN humans_NNS demonstrated_VBD that_IN a_DT single_JJ 1mg_JJ dose_NN of_IN anagrelide_NN administered_VBN concomitantly_RB with_IN a_DT single_JJ 900_CD mg_NN dose_NN of_IN aspirin_NN was_VBD generally_RB well_RB tolerated_VBN ._. There_EX was_VBD no_DT effect_NN on_IN bleeding_JJ time_NN ,_, PT_NN or_CC aPTT_NN ._. No_DT clinically_RB relevant_JJ pharmacokinetic_JJ interactions_NNS between_IN anagrelide_NN and_CC acetylsalicylic_JJ acid_NN were_VBD observed_VBN ._. In_IN that_DT same_JJ study_NN ,_, aspirin_NN alone_RB produced_VBD a_DT marked_JJ inhibition_NN in_IN platelet_NN aggregation_NN ex_FW vivo_FW ._. Anagrelide_NN alone_RB had_VBD no_DT effect_NN on_IN platelet_NN aggregation_NN ,_, but_CC did_VBD slightly_RB enhance_VB the_DT inhibition_NN of_IN platelet_NN aggregation_NN by_IN aspirin_NN ._. Anagrelide_NNP is_VBZ metabolized_VBN at_IN least_JJS in_IN part_NN by_IN CYP1A2_NN ._. It_PRP is_VBZ known_VBN that_IN CYP1A2_NN is_VBZ inhibited_VBN by_IN several_JJ medicinal_JJ products_NNS ,_, including_VBG fluvoxamine_NN ,_, and_CC such_JJ medicinal_JJ products_NNS could_MD theoretically_RB adversely_RB influence_VB the_DT clearance_NN of_IN anagrelide_NN ._. Anagrelide_NNP demonstrates_VBZ some_DT limited_JJ inhibitory_JJ activity_NN towards_IN CYP1A2_NN which_WDT may_MD present_VB a_DT theoretical_JJ potential_NN for_IN interaction_NN with_IN other_JJ coadministered_JJ medicinal_JJ products_NNS sharing_VBG that_IN clearance_NN mechanism_NN e.g._FW Anagrelide_FW demonstrates_VBZ some_DT limited_JJ inhibitory_JJ activity_NN towards_IN CYP1A2_NN which_WDT may_MD present_VB a_DT theoretical_JJ potential_NN for_IN interaction_NN with_IN other_JJ coadministered_JJ medicinal_JJ products_NNS sharing_VBG that_IN clearance_NN mechanism_NN e.g._FW theophylline_FW ._. Anagrelide_NNP is_VBZ an_DT inhibitor_NN of_IN cyclic_JJ AMP_NN PDE_NN III_CD ._. The_DT effects_NNS of_IN medicinal_JJ products_NNS with_IN similar_JJ properties_NNS such_JJ as_IN inotropes_NNS milrinone_NN ,_, enoximone_NN ,_, amrinone_NN ,_, olprinone_NN and_CC cilostazol_NN may_MD be_VB exacerbated_VBN by_IN anagrelide_NN ._. There_EX is_VBZ a_DT single_JJ case_NN report_NN ,_, which_WDT suggests_VBZ that_IN sucralfate_NN may_MD interfere_VB with_IN anagrelide_NN absorption_NN ._. Food_NNP has_VBZ no_DT clinically_RB significant_JJ effect_NN on_IN the_DT bioavailability_NN of_IN anagrelide_NN ._. No_DT drug-drug_NN interaction_NN studies_NNS in_IN human_JJ subjects_NNS have_VBP been_VBN conducted_VBN ._. Toxicologic_JJ and_CC toxicokinetic_JJ studies_NNS in_IN rats_NNS did_VBD not_RB demonstrate_VB any_DT alterations_NNS in_IN the_DT clearance_NN or_CC toxicologic_JJ profile_NN of_IN either_CC methotrexate_NN or_CC Kineret_NN when_WRB the_DT two_CD agents_NNS were_VBD administered_VBN together_RB ._. In_IN a_DT study_NN in_IN which_WDT patients_NNS with_IN active_JJ RA_NN were_VBD treated_VBN for_IN up_RB to_TO 24_CD weeks_NNS with_IN concurrent_JJ Kineret_NN and_CC etanercept_NN therapy_NN ,_, a_DT 7_CD %_NN rate_NN of_IN serious_JJ infections_NNS was_VBD observed_VBN ,_, which_WDT was_VBD higher_JJR than_IN that_DT observed_VBN with_IN etanercept_NN alone_RB -LRB-_-LRB- 0_CD %_NN -RRB-_-RRB- ._. Two_CD percent_NN of_IN patients_NNS treated_VBN concurrently_RB with_IN Kineret_NN and_CC etanercept_NN developed_VBD neutropenia_NN -LRB-_-LRB- ANC_NNP 1_CD x_CC 109/L_CD -RRB-_-RRB- ._. Anastrozole_NNP inhibited_VBD in_FW vitro_FW metabolic_JJ reactions_NNS catalyzed_VBN by_IN cytochromes_NNS P450_NN 1A2_NN ,_, 2C8/9_NN ,_, and_CC 3A4_NN but_CC only_RB at_IN relatively_RB high_JJ concentrations_NNS ._. Anastrozole_NNP did_VBD not_RB inhibit_VB P450_NN 2A6_NN or_CC the_DT polymorphic_JJ P450_NN 2D6_NN in_IN human_JJ liver_NN microsomes_NNS ._. Anastrozole_NNP did_VBD not_RB alter_VB the_DT pharmacokinetics_NNS of_IN antipyrine_NN ._. Although_IN there_EX have_VBP been_VBN no_DT formal_JJ interaction_NN studies_NNS other_JJ than_IN with_IN antipyrine_NN ,_, based_VBN on_IN these_DT in_FW vivo_FW and_CC in_FW vitro_FW studies_NNS ,_, it_PRP is_VBZ unlikely_JJ that_IN co-administration_NN of_IN a_DT 1_CD mg_NN dose_NN of_IN ARIMIDEX_NN with_IN other_JJ drugs_NNS will_MD result_VB in_IN clinically_RB significant_JJ drug_NN inhibition_NN of_IN cytochrome_NN P450-mediated_JJ metabolism_NN of_IN the_DT other_JJ drugs_NNS ._. An_DT interaction_NN study_NN with_IN warfarin_NN showed_VBD no_DT clinically_RB significant_JJ effect_NN of_IN anastrozole_NN on_IN warfarin_NN pharmacokinetics_NNS or_CC anticoagulant_JJ activity_NN ._. At_IN a_DT median_JJ follow-up_NN of_IN 33_CD months_NNS ,_, the_DT combination_NN of_IN ARIMIDEX_NNP and_CC tamoxifen_NN did_VBD not_RB demonstrate_VB any_DT efficacy_NN benefit_NN when_WRB compared_VBN with_IN tamoxifen_NN in_IN all_DT patients_NNS as_RB well_RB as_IN in_IN the_DT hormone_NN receptor-positive_JJ subpopulation_NN ._. This_DT treatment_NN arm_NN was_VBD discontinued_VBN from_IN the_DT trial_NN ._. Based_VBN on_IN clinical_JJ and_CC pharmacokinetic_JJ results_NNS from_IN the_DT ATAC_NN trial_NN ,_, tamoxifen_NN should_MD not_RB be_VB administered_VBN with_IN anastrozole_NN -LRB-_-LRB- see_VB CLINICAL_NNP PHARMACOLOGY_NNP Drug_NNP Interactions_NNS and_CC CLINICAL_JJ PHARMACOLOGY_NN -_: Clinical_JJ Studies_NNS -_: Adjuvant_JJ Treatment_NN of_IN Breast_NN Cancer_NN in_IN Postmenopausal_NNP Women_NNP subsections_NNS -RRB-_-RRB- ._. Co-administration_NN of_IN anastrozole_NN and_CC tamoxifen_NN resulted_VBD in_IN a_DT reduction_NN of_IN anastrozole_NN plasma_NN levels_NNS by_IN 27_CD %_NN compared_VBN with_IN those_DT achieved_VBN with_IN anastrozole_NN alone_RB ._. Estrogen-containing_JJ therapies_NNS should_MD not_RB be_VB used_VBN with_IN ARIMIDEX_NN as_IN they_PRP may_MD diminish_VB its_PRP$ pharmacologic_JJ action_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS No_DT clinically_RB significant_JJ changes_NNS in_IN the_DT results_NNS of_IN clinical_JJ laboratory_NN tests_NNS have_VBP been_VBN observed_VBN ._. No_DT clinically_RB relevant_JJ drug-drug_JJ interactions_NNS have_VBP been_VBN observed_VBN with_IN drugs_NNS likely_JJ to_TO be_VB co-administered_VBN with_IN anidulafungin_NN ._. Caution_NN should_MD be_VB observed_VBN when_WRB anileridine_NN is_VBZ coadministered_VBN with_IN other_JJ opioids_NNS ,_, sedatives_NNS ,_, phenothiazines_NNS ,_, or_CC anesthetics_NNS ,_, as_IN these_DT agents_NNS may_MD increase_VB respiratory_JJ and_CC circulatory_JJ depression_NN ._. Addition_NN or_CC deletion_NN of_IN any_DT drug_NN from_IN the_DT therapeutic_JJ regimen_NN of_IN patients_NNS receiving_VBG oral_JJ anticoagulants_NNS may_MD affect_VB patient_NN response_NN to_TO the_DT anticoagulant_NN ._. Frequent_JJ determination_NN of_IN prothrombin_NN time_NN and_CC close_JJ monitoring_NN of_IN the_DT patient_NN is_VBZ essential_JJ to_TO ascertain_VB when_WRB adjustment_NN of_IN dosage_NN of_IN anticoagulant_NN may_MD be_VB needed_VBN ._. Because_IN of_IN the_DT variability_NN of_IN individual_JJ patient_NN response_NN ,_, multiple_JJ interacting_VBG mechanisms_NNS with_IN some_DT drugs_NNS ,_, the_DT dependency_NN of_IN the_DT extent_NN of_IN the_DT interaction_NN on_IN the_DT dosage_NN and_CC duration_NN of_IN therapy_NN ,_, and_CC the_DT possible_JJ administration_NN of_IN several_JJ interacting_VBG drugs_NNS simultaneously_RB ,_, it_PRP is_VBZ difficult_JJ to_TO predict_VB the_DT direction_NN and_CC degree_NN of_IN the_DT ultimate_JJ effect_NN of_IN concomitant_JJ medications_NNS on_IN anticoagulant_JJ response_NN ._. For_IN example_NN ,_, since_IN cholestyramine_NN may_MD reduce_VB the_DT gastrointestinal_JJ absorption_NN of_IN both_CC the_DT oral_JJ anticoagulants_NNS and_CC vitamin_NN K_NN ,_, the_DT net_JJ effects_NNS are_VBP unpredictable_JJ ._. Chloral_JJ hydrate_NN may_MD cause_VB an_DT increased_VBN prothrombin_NN response_NN by_IN displacing_VBG the_DT anticoagulant_NN from_IN protein_NN binding_NN sites_NNS or_CC a_DT diminished_VBN prothrombin_NN response_NN through_IN increased_VBN metabolism_NN of_IN the_DT unbound_JJ drug_NN by_IN hepatic_JJ enzyme_NN induction_NN ,_, thus_RB leading_VBG to_TO inter-patient_JJ variation_NN in_IN ultimate_JJ prothrombin_NN effect_NN ._. An_DT interacting_VBG drug_NN which_WDT leads_VBZ to_TO a_DT decrease_NN in_IN prothrombin_NN time_NN necessitating_VBG an_DT increased_VBN dose_NN of_IN oral_JJ anticoagulant_NN to_TO maintain_VB an_DT adequate_JJ degree_NN of_IN anticoagulation_NN may_MD ,_, if_IN abruptly_RB discontinued_VBN ,_, increase_VB the_DT risk_NN of_IN subsequent_JJ bleeding_NN ._. Drugs_NNS that_WDT have_VBP been_VBN reported_VBN to_TO diminish_VB oral_JJ anticoagulant_JJ response_NN ,_, ie_FW ,_, decreased_VBD prothrom-bin_NN time_NN response_NN ,_, in_IN man_NN significantly_RB include_VBP :_: adrenocortical_JJ steroids_NNS ._. alcohol_NN *_SYM ._. antacids_NNS ._. antihistamines_NNS ._. barbiturates_NNS ._. carbamazepine_NN ._. chloral_JJ hydrate_NN *_NN ._. chlordiazepoxide_NN ._. cholestyramine_NN ._. diet_NN high_JJ in_IN vitamin_NN K._NNP diuretics_NNS *_SYM ._. ethchlorvynol_NN ._. glutethimide_NN ._. griseofulvin_NN ._. haloperidol_NN ._. meprobamate_NN ._. oral_JJ contraceptives_NNS ._. paraldehyde_NN ._. primidone_NN ._. ranitidine_NN *_SYM ._. rifampin_NN ._. unreliable_JJ prothrombin_NN time_NN determinations_NNS ;_: ._. vitamin_NN C._NN Drugs_NNS that_WDT have_VBP been_VBN reported_VBN to_TO diminish_VB oral_JJ anticoagulant_JJ response_NN ,_, ie_FW ,_, decreased_VBD prothrom-bin_NN time_NN response_NN ,_, in_IN man_NN significantly_RB include_VBP :_: adrenocortical_JJ steroids_NNS ;_: alcohol_NN *_SYM ;_: antacids_NNS ;_: antihistamines_NNS ;_: barbiturates_NNS ;_: carbamazepine_NN ;_: chloral_JJ hydrate_NN *_NN ;_: chlordiazepoxide_NN ;_: cholestyramine_NN ;_: diet_NN high_JJ in_IN vitamin_NN K_NN ;_: diuretics_NNS *_SYM ;_: ethchlorvynol_NN ;_: glutethimide_NN ;_: griseofulvin_NN ;_: haloperidol_NN ;_: meprobamate_NN ;_: oral_JJ contraceptives_NNS ;_: paraldehyde_NN ;_: primidone_NN ;_: ranitidine_NN *_SYM ;_: rifampin_NN ;_: unreliable_JJ prothrombin_NN time_NN determinations_NNS ;_: vitamin_NN C_NN ;_: warfarin_NN sodium_NN under-dosage_NN ._. Drugs_NNS that_WDT reportedly_RB may_MD increase_VB oral_JJ anticoagulant_JJ response_NN ,_, ie_FW ,_, increased_VBD prothrombin_NN response_NN ,_, in_IN man_NN include_VBP :_: alcohol_NN *_NN ._. allopurinol_NN ._. aminosalicylic_JJ acid_NN ._. amiodarone_NN ._. anabolic_JJ steroids_NNS ._. antibiotics_NNS ._. bromelains_NNS ._. chloral_JJ hydrate_NN *_NN ._. chlorpropamide_NN ._. chymotrypsin_NN ._. cimetidine_NN ._. cinchophen_NN ._. clofibrate_NN ._. dextran_NN ._. dextrothyroxine_NN ._. diazoxide_NN ._. dietary_JJ deficiencies_NNS ;_: ._. diflunisal_NN ._. diuretics_NNS *_SYM ._. disulfiram_NN ._. drugs_NNS affecting_VBG blood_NN elements_NNS ;_: ._. ethacrynic_JJ acid_NN ._. fenoprofen_NN ._. glucagon_NN ._. hepatotoxic_JJ drugs_NNS ;_: ._. ibuprofen_NN ._. indomethacin_NN ._. influenza_NN virus_NN vaccine_NN ._. inhalation_NN anesthetics_NNS ._. mefenamic_JJ acid_NN ._. methyldopa_NN ._. methylphenidate_NN ._. metronidazole_NN ._. miconazole_NN ._. monoamine_NN oxidase_NN inhibitors_NNS ._. nalidixic_JJ acid_NN ._. naproxen_NN ._. oxolinic_JJ acid_NN ._. oxyphenbutazone_NN ._. pentoxifylline_NN ._. phenylbutazone_NN ._. phenyramidol_NN ._. phenytoin_NN ._. prolonged_JJ hot_JJ weather_NN ;_: ._. prolonged_JJ narcotics_NNS ._. pyrazolones_NNS ._. quinidine_NN ._. quinine_NN ._. ranitidine_NN *_SYM ._. salicylates_NNS ;_: sulfinpyrazone_NN ._. sulfonamides_NNS ,_, long_RB acting_VBG ._. sulindac_NN ._. thyroid_NN drugs_NNS ._. tolbutamide_NN ._. triclofos_NNS sodium_NN ._. trimethoprim/sulfamethoxazole_NN ._. unreliable_JJ prothrombin_NN time_NN determinations_NNS ;_: ._. Drugs_NNS that_WDT reportedly_RB may_MD increase_VB oral_JJ anticoagulant_JJ response_NN ,_, ie_FW ,_, increased_VBD prothrombin_NN response_NN ,_, in_IN man_NN include_VBP :_: alcohol_NN *_SYM ;_: allopurinol_NN ;_: aminosalicylic_JJ acid_NN ;_: amiodarone_NN ;_: anabolic_JJ steroids_NNS ;_: antibiotics_NNS ;_: bromelains_NNS ;_: chloral_JJ hydrate_NN *_NN ;_: chlorpropamide_NN ;_: chymotrypsin_NN ;_: cimetidine_NN ;_: cinchophen_NN ;_: clofibrate_NN ;_: dextran_NN ;_: dextrothyroxine_NN ;_: diazoxide_NN ;_: dietary_JJ deficiencies_NNS ;_: diflunisal_NN ;_: disulfiram_NN ;_: drugs_NNS affecting_VBG blood_NN elements_NNS ;_: ethacrynic_JJ acid_NN ;_: fenoprofen_NN ;_: glucagon_NN ;_: hepatotoxic_JJ drugs_NNS ;_: ibuprofen_NN ;_: indomethacin_NN ;_: influenza_NN virus_NN vaccine_NN ;_: inhalation_NN anesthetics_NNS ;_: mefenamic_JJ acid_NN ;_: methyldopa_NN ;_: methylphenidate_NN ;_: metronidazole_NN ;_: miconazole_NN ;_: monoamine_NN oxidase_NN inhibitors_NNS ;_: nalidixic_JJ acid_NN ;_: naproxen_NN ;_: oxolinic_JJ acid_NN ;_: oxyphenbutazone_NN ;_: pentoxifylline_NN ;_: phenylbutazone_NN ;_: phenyramidol_NN ;_: phenytoin_NN ;_: prolonged_JJ hot_JJ weather_NN ;_: prolonged_JJ narcotics_NNS ;_: pyrazolones_NNS ;_: quinidine_NN ;_: quinine_NN ;_: ranitidine_NN *_SYM ;_: salicylates_NNS ;_: sulfinpyrazone_NN ;_: sulfonamides_NNS ,_, long_RB acting_VBG ;_: sulindac_NN ;_: thyroid_NN drugs_NNS ;_: tolbutamide_NN ;_: triclofos_NNS sodium_NN ;_: trimethoprim/sulfamethoxazole_NN ;_: unreliable_JJ prothrombin_NN time_NN determinations_NNS ;_: warfarin_NN sodium_NN overdosage_NN ._. Oral_JJ anticoagulants_NNS may_MD potentiate_VB the_DT hypoglycemic_JJ action_NN of_IN hypoglycemic_JJ agents_NNS ,_, eg_FW ,_, tolbutamide_NN and_CC chlorpropamide_NN ,_, by_IN inhibiting_VBG their_PRP$ metabolism_NN in_IN the_DT liver_NN ._. Because_IN oral_JJ anticoagulants_NNS may_MD interfere_VB with_IN the_DT hepatic_JJ metabolism_NN of_IN phenytoin_NN ,_, toxic_JJ levels_NNS of_IN the_DT anticonvulsant_NN may_MD occur_VB when_WRB an_DT oral_JJ anticoagulant_NN and_CC phenytoin_NN are_VBP administered_VBN concurrently_RB ._. Drugs_NNS that_WDT reduce_VBP the_DT number_NN of_IN blood_NN platelets_NNS by_IN causing_VBG bone_NN marrow_NN depression_NN -LRB-_-LRB- such_JJ as_IN antineoplastic_JJ agents_NNS -RRB-_-RRB- or_CC drugs_NNS which_WDT inhibit_VBP platelet_NN function_NN -LRB-_-LRB- eg_FW ,_, aspirin_NN and_CC other_JJ non-steroidal_JJ anti-inflammatory_JJ drugs_NNS ,_, dipyridamole_NN ,_, hydrochloroquine_NN ,_, clofibrate_NN ,_, dextran_NN -RRB-_-RRB- may_MD increase_VB the_DT bleeding_NN tendency_NN produced_VBN by_IN anticoagulants_NNS without_IN altering_VBG prothrombin_NN time_NN determinations_NNS ._. The_DT beneficial_JJ effects_NNS on_IN arterial_JJ thrombus_NN formation_NN from_IN combined_JJ therapy_NN with_IN antiplatelet_JJ and_CC anticoagulant_JJ medication_NN must_MD be_VB weighed_VBN against_IN an_DT increased_VBN risk_NN of_IN inducing_VBG hemorrhage_NN ._. *_SYM Increased_VBN and_CC decreased_VBN prothrombin_NN time_NN responses_NNS have_VBP been_VBN reported_VBN ._. Drug/Laboratory_JJ Test_NN Interferences_NNS :_: Dicumarol_NN and_CC indanedione_NN anticoagulants_NNS ,_, including_VBG anisindione_NN ,_, or_CC their_PRP$ metabolites_NNS may_MD color_VB alkaline_NN urine_NN red-orange_NN ,_, which_WDT may_MD interfere_VB with_IN spectrophotometrically_RB determined_VBN urinary_JJ laboratory_NN tests_NNS ._. The_DT color_NN reverses_VBZ when_WRB the_DT test_NN sample_NN is_VBZ acidified_VBN in_FW vitro_FW to_TO a_DT pH_NN below_IN 4_CD ._. 5HT3_NN Antagonists_NNS :_: Based_VBN on_IN reports_NNS of_IN profound_JJ hypotension_NN and_CC loss_NN of_IN consciousness_NN when_WRB apomorphine_NN was_VBD administered_VBN with_IN ondansetron_NN ,_, the_DT concomitant_JJ use_NN of_IN apomorphine_NN with_IN drugs_NNS of_IN the_DT 5HT3_NN antagonist_NN class_NN -LRB-_-LRB- including_VBG ,_, for_IN example_NN ,_, ondansetron_NN ,_, granisetron_NN ,_, dolasetron_NN ,_, palonosetron_NN ,_, and_CC alosetron_NN -RRB-_-RRB- is_VBZ contraindicated_VBN ._. Antihypertensive_JJ Medications_NNS and_CC Vasodilators_NNS :_: The_DT following_VBG adverse_JJ events_NNS were_VBD experienced_VBN more_RBR commonly_RB in_IN patients_NNS receiving_VBG concomitant_JJ antihypertensive_JJ medications_NNS or_CC vasodilators_NNS -LRB-_-LRB- n_NN =_JJ 94_CD -RRB-_-RRB- compared_VBN to_TO patients_NNS not_RB receiving_VBG these_DT concomitant_JJ drugs_NNS -LRB-_-LRB- n_NN =_JJ 456_CD -RRB-_-RRB- :_: hypotension_NN 10_CD %_NN vs_CC 4_CD %_NN ,_, myocardial_JJ infarction_NN 3_CD %_NN vs_CC 1_CD %_NN ,_, serious_JJ pneumonia_NN 5_CD %_NN vs_CC 3_CD %_NN ,_, serious_JJ falls_VBZ 9_CD %_NN vs_CC 3_CD %_NN ,_, and_CC bone_NN and_CC joint_JJ injuries_NNS 6_CD %_NN vs_CC 2_CD %_NN ._. The_DT mechanism_NN underlying_VBG many_JJ of_IN these_DT events_NNS is_VBZ unknown_JJ ,_, but_CC may_MD represent_VB increased_VBN hypotension_NN ._. Dopamine_NN Antagonists_NNS :_: Since_IN apomorphine_NN is_VBZ a_DT dopamine_NN agonist_NN ,_, it_PRP is_VBZ possible_JJ that_IN dopamine_NN antagonists_NNS ,_, such_JJ as_IN the_DT neuroleptics_NNS -LRB-_-LRB- phenothiazines_NNS ,_, butyrophenones_NNS ,_, thioxanthenes_NNS -RRB-_-RRB- or_CC metoclopramide_NN ,_, may_MD diminish_VB the_DT effectiveness_NN of_IN APOKYN_NNP ._. Patients_NNS with_IN major_JJ psychotic_JJ disorders_NNS ,_, treated_VBN with_IN neuroleptics_NNS ,_, should_MD be_VB treated_VBN with_IN dopamine_NN agonists_NNS only_RB if_IN the_DT potential_JJ benefits_NNS outweigh_VBP the_DT risks_NNS ._. Drugs_NNS Prolonging_VBG the_DT QT/QTc_NNP Interval_NNP Caution_NN should_MD be_VB exercised_VBN when_WRB prescribing_VBG apomorphine_NN concomitantly_RB with_IN drugs_NNS that_WDT prolong_VBP the_DT QT/QTc_JJ interval_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS There_EX are_VBP no_DT known_JJ interactions_NNS between_IN APOKYN_NNP and_CC laboratory_NN tests_NNS ._. Apraclonidine_NN should_MD not_RB be_VB used_VBN in_IN patients_NNS receiving_VBG MAO_NNP inhibitors_NNS ._. Although_IN no_DT specific_JJ drug_NN interactions_NNS with_IN topical_JJ glaucoma_NN drugs_NNS or_CC systemic_JJ medications_NNS were_VBD identified_VBN in_IN clinical_JJ studies_NNS of_IN IOPIDINE_NNP 0.5_CD %_NN Ophthalmic_JJ Solution_NN ,_, the_DT possibility_NN of_IN an_DT additive_JJ or_CC potentiating_NN effect_NN with_IN CNS_NN depressants_NNS -LRB-_-LRB- alcohol_NN ,_, barbiturates_NNS ,_, opiates_NNS ,_, sedatives_NNS ,_, anesthetics_NNS -RRB-_-RRB- should_MD be_VB considered_VBN ._. Tricyclic_JJ antidepressants_NNS have_VBP been_VBN reported_VBN to_TO blunt_VB the_DT hypotensive_JJ effect_NN of_IN systemic_JJ clonidine_NN ._. It_PRP is_VBZ not_RB known_VBN whether_IN the_DT concurrent_JJ use_NN of_IN these_DT agents_NNS with_IN apraclonidine_NN can_MD lead_VB to_TO a_DT reduction_NN in_IN IOP_NNP lowering_VBG effect_NN ._. No_DT data_NNS on_IN the_DT level_NN of_IN circulating_VBG catecholamines_NNS after_IN apraclonidine_NN withdrawal_NN are_VBP available_JJ ._. Caution_NN ,_, however_RB ,_, is_VBZ advised_VBN in_IN patients_NNS taking_VBG tricyclic_JJ antidepressants_NNS which_WDT can_MD affect_VB the_DT metabolism_NN and_CC uptake_NN of_IN circulating_VBG amines_NNS ._. An_DT additive_JJ hypotensive_JJ effect_NN has_VBZ been_VBN reported_VBN with_IN the_DT combination_NN of_IN systemic_JJ clonidine_NN and_CC neuroleptic_JJ therapy_NN ._. Systemic_JJ clonidine_NN may_MD inhibit_VB the_DT production_NN of_IN catecholamines_NNS in_IN response_NN to_TO insulin-induced_JJ hypoglycemia_NN and_CC mask_NN the_DT signs_NNS and_CC symptoms_NNS of_IN hypoglycemia_NN ._. Since_IN apraclonidine_NN may_MD reduce_VB pulse_NN and_CC blood_NN pressure_NN ,_, caution_NN in_IN using_VBG drugs_NNS such_JJ as_IN beta-blockers_NNS -LRB-_-LRB- ophthalmic_JJ and_CC systemic_JJ -RRB-_-RRB- ,_, antihypertensives_NNS ,_, and_CC cardiac_JJ glycosides_NNS is_VBZ advised_VBN ._. Patients_NNS using_VBG cardiovascular_JJ drugs_NNS concurrently_RB with_IN IOPIDINE_NN 0.5_CD %_NN Ophthalmic_JJ Solution_NN should_MD have_VB pulse_NN and_CC blood_NN pressures_NNS frequently_RB monitored_VBD ._. Caution_NN should_MD be_VB exercised_VBN with_IN simultaneous_JJ use_NN of_IN clonidine_NN and_CC other_JJ similar_JJ pharmacologic_JJ agent_NN ._. Aprepitant_NN is_VBZ a_DT substrate_NN ,_, a_DT moderate_JJ inhibitor_NN ,_, and_CC an_DT inducer_NN of_IN CYP3A4_NN ._. Aprepitant_NN is_VBZ also_RB an_DT inducer_NN of_IN CYP2C9_NN ._. Effect_NN of_IN aprepitant_NN on_IN the_DT pharmacokinetics_NNS of_IN other_JJ agent_NN ._. As_IN a_DT moderate_JJ inhibitor_NN of_IN CYP3A4_NN ,_, aprepitant_NN can_MD increase_VB plasma_NN concentrations_NNS of_IN coadministered_JJ medicinal_JJ products_NNS that_WDT are_VBP metabolized_VBN through_IN CYP3A4_NN ._. Aprepitant_NN has_VBZ been_VBN shown_VBN to_TO induce_VB the_DT metabolism_NN of_IN S_NN -LRB-_-LRB- -_: -RRB-_-RRB- warfarin_NN and_CC tolbutamide_NN ,_, which_WDT are_VBP metabolized_VBN through_IN CYP2C9_NN ._. Coadministration_NN of_IN Aprepitant_JJ with_IN these_DT drugs_NNS or_CC other_JJ drugs_NNS that_WDT are_VBP known_VBN to_TO be_VB metabolized_VBN by_IN CYP2C9_NN ,_, such_JJ as_IN phenytoin_NN ,_, may_MD result_VB in_IN lower_JJR plasma_NN concentrations_NNS of_IN these_DT drugs_NNS ._. Aprepitant_NN is_VBZ unlikely_JJ to_TO interact_VB with_IN drugs_NNS that_WDT are_VBP substrates_NNS for_IN the_DT P-glycoprotein_NN transporter_NN ,_, as_IN demonstrated_VBN by_IN the_DT lack_NN of_IN interaction_NN of_IN Aprepitant_JJ with_IN digoxin_NN in_IN a_DT clinical_JJ drug_NN interaction_NN study_NN ._. 5-HT3_NN antagonists_NNS :_: In_IN clinical_JJ drug_NN interaction_NN studies_NNS ,_, aprepitant_NN did_VBD not_RB have_VB clinically_RB important_JJ effects_NNS on_IN the_DT pharmacokinetics_NNS of_IN ondansetron_NN or_CC granisetron_NN ._. No_DT clinical_JJ or_CC drug_NN interaction_NN study_NN was_VBD conducted_VBN with_IN dolasetron_NN ._. Corticosteroids_NNS :_: Dexamethasone_NN :_: Aprepitant_NN ,_, when_WRB given_VBN as_IN a_DT regimen_NN of_IN 125mg_NN with_IN dexamethasone_NN coadministered_VBN orally_RB as_IN 20_CD mg_NN on_IN Day_NN 1_CD ,_, and_CC Aprepitant_NN when_WRB given_VBN as_IN 80_CD mg/day_NN with_IN dexamethasone_NN coadministered_VBN orally_RB as_IN 8_CD mg_NN on_IN Days_NNS 2_CD through_IN 5_CD ,_, increased_VBD the_DT AUC_NN of_IN dexamethasone_NN ,_, a_DT CYP3A4_NN substrate_NN by_IN 2.2-fold_JJ ,_, on_IN Days_NNS 1_CD and_CC 5_CD ._. The_DT oral_JJ dexamethasone_NN doses_NNS should_MD be_VB reduced_VBN by_IN approximately_RB 50_CD %_NN when_WRB coadministered_VBN with_IN Aprepitant_NN ,_, to_TO achieve_VB exposures_NNS of_IN dexamethasone_NN similar_JJ to_TO those_DT obtained_VBN when_WRB it_PRP is_VBZ given_VBN without_IN Aprepitant_NN ._. The_DT daily_JJ dose_NN of_IN dexamethasone_NN administered_VBN in_IN clinical_JJ studies_NNS with_IN Aprepitant_NN reflects_VBZ an_DT approximate_JJ 50_CD %_NN reduction_NN of_IN the_DT dose_NN of_IN dexamethasone_NN ._. Methylprednisolon_NNP ._. Aprepitant_NNP ,_, when_WRB given_VBN as_IN a_DT regimen_NN of_IN 125_CD mg_NN on_IN Day_NN 1_CD and_CC 80_CD mg/day_NN on_IN Days_NNS 2_CD and_CC 3_CD ,_, increased_VBD the_DT AUC_NN of_IN methylprednisolone_NN ,_, a_DT CYP3A4_NN substrate_NN ,_, by_IN 1.34-fold_JJ on_IN Day_NN 1_CD and_CC by_IN 2.5-fold_RB on_IN Day_NN 3_CD ,_, when_WRB methylprednisolone_NN was_VBD coadministered_VBN intravenously_RB as_IN 125_CD mg_NN on_IN Day_NN 1_CD and_CC orally_RB as_IN 40_CD mg_NN on_IN Days_NNS 2_CD and_CC 3_CD ._. The_DT IV_CD methylprednisolone_NN dose_NN should_MD be_VB reduced_VBN by_IN approximately_RB 25_CD %_NN ,_, and_CC the_DT oral_JJ methylprednisolone_NN dose_NN should_MD be_VB reduced_VBN by_IN approximately_RB 50_CD %_NN when_WRB coadministered_VBN with_IN Aprepitant_NN to_TO achieve_VB exposures_NNS of_IN methylprednisolone_NN similar_JJ to_TO those_DT obtained_VBN when_WRB it_PRP is_VBZ given_VBN without_IN Aprepitant_NN ._. Warfarin_NNP :_: A_NNP single_JJ 125-mg_JJ dose_NN of_IN Aprepitant_NN was_VBD administered_VBN on_IN Day_NN 1_CD and_CC 80_CD mg/day_NN on_IN Days_NNS 2_CD and_CC 3_CD to_TO healthy_JJ subjects_NNS who_WP were_VBD stabilized_VBN on_IN chronic_JJ warfarin_NN therapy_NN ._. Although_IN there_EX was_VBD no_DT effect_NN of_IN Aprepitant_NN on_IN the_DT plasma_NN AUC_NN of_IN R_NN -LRB-_-LRB- +_CC -RRB-_-RRB- or_CC S_NN -LRB-_-LRB- -_: -RRB-_-RRB- warfarin_NN determined_VBN on_IN Day_NN 3_CD ,_, there_EX was_VBD a_DT 34_CD %_NN decrease_NN in_IN S_NN -LRB-_-LRB- -_: -RRB-_-RRB- warfarin_NN -LRB-_-LRB- a_DT CYP2C9_NN substrate_NN -RRB-_-RRB- trough_NN concentration_NN accompanied_VBN by_IN a_DT 14_CD %_NN decrease_NN in_IN the_DT prothrombin_NN time_NN -LRB-_-LRB- reported_VBN as_IN International_NNP Normalized_NNP Ratio_NNP or_CC INR_NNP -RRB-_-RRB- 5_CD days_NNS after_IN completion_NN of_IN dosing_NN with_IN Aprepitant_NN ._. In_IN patients_NNS on_IN chronic_JJ warfarin_NN therapy_NN ,_, the_DT prothrombin_NN time_NN -LRB-_-LRB- INR_NN -RRB-_-RRB- should_MD be_VB closely_RB monitored_VBN in_IN the_DT 2-week_JJ period_NN ,_, particularly_RB at_IN 7_CD to_TO 10_CD days_NNS ,_, following_VBG initiation_NN of_IN the_DT 3-day_JJ regimen_NN of_IN Aprepitant_JJ with_IN each_DT chemotherapy_NN cycle_NN ._. Tolbutamide_NNP :_: Aprepitant_NN ,_, when_WRB given_VBN as_IN 125_CD mg_NN on_IN Day_NN 1_CD and_CC 80_CD mg/day_NN on_IN Days_NNS 2_CD and_CC 3_CD ,_, decreased_VBD the_DT AUC_NN of_IN tolbutamide_NN -LRB-_-LRB- a_DT CYP2C9_NN substrate_NN -RRB-_-RRB- by_IN 23_CD %_NN on_IN Day_NN 4_CD ,_, 28_CD %_NN on_IN Day_NN 8_CD ,_, and_CC 15_CD %_NN on_IN Day_NN 15_CD ,_, when_WRB a_DT single_JJ dose_NN of_IN tolbutamide_NN 500_CD mg_NN was_VBD admini_JJ ,_, stered_JJ orally_RB prior_RB to_TO the_DT administration_NN of_IN the_DT 3-day_JJ regimen_NN of_IN Aprepitant_NN and_CC on_IN Days_NNS 4,8_CD ,_, and_CC 15_CD ._. Oral_JJ contraceptives_NNS :_: Aprepitant_JJ ,_, when_WRB given_VBN once_RB daily_RB for_IN 14_CD days_NNS as_IN a_DT 100-mg_JJ capsule_NN with_IN an_DT oral_JJ contraceptive_NN containing_VBG 35_CD mcg_NN of_IN ethinyl_NN estradiol_NN and_CC 1_CD mg_NN of_IN norethindrone_NN ,_, decreased_VBD the_DT AUC_NN of_IN ethinyl_NN estradiol_NN by_IN 43_CD %_NN ,_, and_CC decreased_VBD the_DT AUC_NN of_IN norethindrone_NN by_IN 8_CD %_NN ._. therefore_RB ,_, the_DT efficacy_NN of_IN oral_JJ contraceptives_NNS during_IN administration_NN of_IN Aprepitant_NN may_MD be_VB reduced_VBN ._. Although_IN a_DT 3-day_JJ regimen_NN of_IN Aprepitant_JJ given_VBN concomitantly_RB with_IN oral_JJ contraceptives_NNS has_VBZ not_RB been_VBN studied_VBN ,_, alternative_JJ or_CC back-up_JJ methods_NNS of_IN contraception_NN should_MD be_VB used_VBN ._. Midazolam_NNP :_: Aprepitant_NN increased_VBD the_DT AUC_NN of_IN midazolam_NN ,_, a_DT sensitive_JJ CYP3A4_NN substrate_NN ,_, by_IN 2.3-fold_JJ on_IN Day_NN 1_CD and_CC 3.3-fold_RB on_IN Day_NN 5_CD ,_, when_WRB a_DT single_JJ oral_JJ dose_NN of_IN midazolam_NN 2_CD mg_NN was_VBD coadministered_VBN on_IN Day_NN 1_CD and_CC Day_NNP 5_CD of_IN a_DT regimen_NN of_IN Aprepitant_JJ 125_CD mg_NN on_IN Day_NN 1_CD and_CC 80_CD mg/day_NN on_IN Days_NNS 2_CD through_IN 5_CD ._. The_DT potential_JJ effects_NNS of_IN increased_VBN plasma_NN concentrations_NNS of_IN midazolam_NN or_CC other_JJ benzodiazepines_NNS metabolized_VBN via_IN CYP3A4_NN -LRB-_-LRB- alprazolam_NN ,_, triazolam_NN -RRB-_-RRB- should_MD be_VB considered_VBN when_WRB coadministering_VBG these_DT agents_NNS with_IN Aprepitant_NN ._. In_IN another_DT study_NN with_IN intravenous_JJ administration_NN of_IN midazolam_NN ,_, Aprepitant_NN was_VBD given_VBN as_IN 125_CD mg_NN on_IN Day_NN 1_CD and_CC 80_CD mg/day_NN on_IN Days_NNS 2_CD and_CC 3_CD ,_, and_CC midazolam_NN 2_CD mg_NN IV_CD was_VBD given_VBN prior_RB to_TO the_DT administration_NN of_IN the_DT 3-day_JJ regimen_NN of_IN Aprepitant_NN and_CC on_IN Days_NNS 4_CD ,_, 8_CD ,_, and_CC 15_CD ._. Aprepitant_NN increased_VBD the_DT AUC_NN of_IN midazolam_NN by_IN 25_CD %_NN on_IN Day_NN 4_CD and_CC decreased_VBD the_DT AUC_NN of_IN midazolam_NN by_IN 19_CD %_NN on_IN Day_NN 8_CD relative_JJ to_TO the_DT dosing_NN of_IN Aprepitant_NN on_IN Days_NNS 1_CD through_IN 3_CD ._. These_DT effects_NNS were_VBD not_RB considered_VBN clinically_RB important_JJ ._. The_DT AUC_NN of_IN midazolam_NN on_IN Day_NN 15_CD was_VBD similar_JJ to_TO that_DT observed_VBN at_IN baseline_NN ._. Effect_NN of_IN other_JJ agents_NNS on_IN the_DT pharmacokinefics_NNS of_IN aprepitan_NN ._. Aprepitant_NN is_VBZ a_DT substrate_NN for_IN CYP3A4_NN ._. therefore_RB ,_, coadministration_NN of_IN Aprepitant_JJ with_IN drugs_NNS that_WDT inhibit_VBP CYP3A4_NN activity_NN may_MD result_VB in_IN increased_VBN plasma_NN concentrations_NNS of_IN aprepitant_NN ._. Consequently_RB ,_, concomitant_JJ administration_NN of_IN Aprepitant_JJ with_IN strong_JJ CYP3A4_NN inhibitors_NNS -LRB-_-LRB- e.g._FW ,_, ketoconazole_NN ,_, itraconazole_NN ,_, nefazodone_NN ,_, troleandomycin_NN ,_, clarithromycin_NN ,_, ritonavir_NN ,_, nelfinavir_NN -RRB-_-RRB- should_MD be_VB approached_VBN with_IN caution_NN ._. Because_IN moderate_JJ CYP3A4_NN inhibitors_NNS -LRB-_-LRB- e.g._FW ,_, diltiazem_NN -RRB-_-RRB- result_VBP in_IN 2-fold_JJ increase_NN in_IN plasma_NN concentrations_NNS of_IN aprepitant_NN ,_, concomitant_JJ administration_NN should_MD also_RB be_VB approached_VBN with_IN caution_NN ._. Aprepitant_NN is_VBZ a_DT substrate_NN for_IN CYP3A4_NN ._. therefore_RB ,_, coadministration_NN of_IN Aprepitant_JJ with_IN drugs_NNS that_WDT strongly_RB induce_VBP CYP3A4_NN activity_NN -LRB-_-LRB- e.g._FW ,_, rifampin_NN ,_, carbamazepine_NN ,_, phenytoin_NN -RRB-_-RRB- may_MD result_VB in_IN reduced_VBN plasma_NN concentrations_NNS of_IN aprepitant_NN that_WDT may_MD result_VB in_IN decreased_VBN efficacy_NN of_IN Aprepitant_NN ._. Ketoconazole_NN :_: When_WRB a_DT single_JJ 125-mg_JJ dose_NN of_IN Aprepitant_NN was_VBD administered_VBN on_IN Day5_NN of_IN ._. Ketoconazole_NN :_: When_WRB a_DT single_JJ 125-mg_JJ dose_NN of_IN Aprepitant_NN was_VBD administered_VBN on_IN Day5_NN of_IN a_DT 10-day_JJ regimen_NN of_IN 400_CD mg/day_NN of_IN ketoconazole_NN ,_, a_DT strong_JJ CYP3A4_NN inhibitor_NN ,_, the_DT AUC_NN of_IN aprepitant_NN increased_VBD approximately_RB 5-fold_RB and_CC the_DT mean_JJ terminal_JJ half-life_NN of_IN aprepitant_NN increased_VBD approximately_RB 3-fold_RB ._. Concomitant_JJ administration_NN of_IN Aprepitant_JJ with_IN strong_JJ CYP3A4_NN inhibitors_NNS should_MD be_VB approached_VBN cautiously_RB ._. Rifampin_NNP :_: When_WRB a_DT single_JJ 375-mg_JJ dose_NN of_IN Aprepitant_NN was_VBD administered_VBN on_IN Day9_NN of_IN a_DT 14-day_JJ regimen_NN of_IN 600_CD mg/day_NN of_IN rifampin_NN ,_, a_DT strong_JJ CYP3A4_NN inducer_NN ,_, the_DT AUC_NN of_IN aprepitant_NN decreased_VBD approximately_RB 11-fold_JJ and_CC the_DT mean_JJ terminal_JJ half-life_NN decreased_VBD approximately_RB 3-fold_RB ._. Coadministration_NN of_IN Aprepitant_JJ with_IN drugs_NNS that_WDT induce_VBP CYP3A4_NN activity_NN may_MD result_VB in_IN reduced_VBN plasma_NN concentrations_NNS and_CC decreased_VBD efficacy_NN of_IN Aprepitant_NN ._. Additional_JJ interactions_NNS ._. Diltiazem_NNP :_: In_IN patients_NNS with_IN mild_JJ to_TO moderate_JJ hypertension_NN ,_, administration_NN of_IN aprepitant_NN once_RB daily_RB ,_, as_IN a_DT tablet_JJ formulation_NN comparable_JJ to_TO 230_CD mg_NN of_IN the_DT capsule_NN formulation_NN ,_, with_IN diltiazem_NN 120_CD mg_NN 3_CD times_NNS daily_RB for_IN 5_CD days_NNS ,_, resulted_VBD in_IN a_DT 2-fold_JJ increase_NN of_IN aprepitant_JJ AUC_NN and_CC a_DT simultaneous_JJ 1.7-fold_JJ increase_NN of_IN diltiazem_NN AUC_NN ._. These_DT pharmacokinetic_JJ effects_NNS did_VBD not_RB result_VB in_IN clinically_RB meaningful_JJ changes_NNS in_IN ECG_NN ,_, heart_NN rate_NN or_CC blood_NN pressure_NN beyond_IN those_DT changes_NNS induced_VBN by_IN diltiazem_NN alone_RB ._. Paroxetine_NNP :_: Coadministration_NNP of_IN once_RB daily_JJ doses_NNS of_IN aprepitant_NN ,_, as_IN a_DT tablet_JJ formulation_NN comparable_JJ to_TO 85_CD mg_NN or_CC 170_CD mg_NN of_IN the_DT capsule_NN formulation_NN ,_, with_IN paroxetine_NN 20_CD mg_NN once_RB daily_RB ,_, resulted_VBD in_IN a_DT decrease_NN in_IN AUC_NN by_IN approximately_RB 25_CD %_NN and_CC Cmax_NN ,_, by_IN approximately_RB 20_CD %_NN of_IN both_CC aprepitant_JJ and_CC paroxetine_NN ._. Beta-adrenergic_JJ blocking_VBG agents_NNS :_: concurrent_JJ use_NN may_MD blunt_VB the_DT response_NN to_TO arbutamine_NN ._. Beta-adrenergic_JJ blocking_VBG agents_NNS should_MD be_VB withdrawn_VBN at_IN least_JJS 48_CD hours_NNS before_IN conducting_VBG an_DT arbutamine-mediated_JJ stress_NN test_NN ._. Antiarrhythmic_JJ agents_NNS ,_, class_NN I_CD -LRB-_-LRB- such_JJ as_IN flecainide_NN ,_, lidocaine_NN ,_, or_CC quinidine_NN -RRB-_-RRB- :_: concurrent_JJ use_NN with_IN arbutamine_NN may_MD have_VB a_DT proarrhythmic_JJ effect_NN ._. Antidepressants_NNS -LRB-_-LRB- tricyclic_JJ -RRB-_-RRB- ,_, atropine_NN or_CC other_JJ anticholinergic_JJ agents_NNS ,_, or_CC digitalis_NN glycosides_NNS :_: concurrent_JJ use_NN with_IN arbutamine_NN may_MD produce_VB additive_JJ inotropic_JJ and/or_CC chronotropic_JJ effects_NNS ._. Anticoagulants_NNS including_VBG coumarin_NN derivatives_NNS ,_, indandione_NN derivatives_NNS ,_, and_CC platelet_NN aggregation_NN inhibitors_NNS such_JJ as_IN nonsteroidal_JJ anti-inflammatory_JJ drugs_NNS -LRB-_-LRB- NSAIDs_NNS -RRB-_-RRB- ,_, and_CC aspirin_NN may_MD increase_VB the_DT risk_NN of_IN bleeding_VBG when_WRB administered_VBN concomitantly_RB with_IN ardeparin_NN ._. If_IN additional_JJ adrenergic_JJ drugs_NNS are_VBP to_TO be_VB administered_VBN by_IN any_DT route_NN ,_, they_PRP should_MD be_VB used_VBN with_IN caution_NN because_IN the_DT pharmacologically_RB predictable_JJ sympathetic_JJ effects_NNS of_IN BROVANA_NN may_MD be_VB potentiated_VBN ._. When_WRB paroxetine_NN ,_, a_DT potent_JJ inhibitor_NN of_IN CYP2D6_NN ,_, was_VBD co-administered_VBN with_IN BROVANA_NN at_IN steady-state_JJ ,_, exposure_NN to_TO either_CC drug_NN was_VBD not_RB altered_VBN ._. Dosage_NN adjustments_NNS of_IN BROVANA_NNP are_VBP not_RB necessary_JJ when_WRB the_DT drug_NN is_VBZ given_VBN concomitantly_RB with_IN potent_JJ CYP2D6_NN inhibitors_NNS ._. Concomitant_JJ treatment_NN with_IN methylxanthines_NNS -LRB-_-LRB- aminophylline_NN ,_, theophylline_NN -RRB-_-RRB- ,_, steroids_NNS ,_, or_CC diuretics_NNS may_MD potentiate_VB any_DT hypokalemic_JJ effect_NN of_IN adrenergic_JJ agonists_NNS ._. The_DT ECG_NN changes_NNS and/or_CC hypokalemia_NN that_WDT may_MD result_VB from_IN the_DT administration_NN of_IN non-potassium_JJ sparing_NN diuretics_NNS -LRB-_-LRB- such_JJ as_IN loop_NN or_CC thiazide_JJ diuretics_NNS -RRB-_-RRB- can_MD be_VB acutely_RB worsened_VBN by_IN beta-agonists_NNS ,_, especially_RB when_WRB the_DT recommended_VBN dose_NN of_IN the_DT beta-agonist_NN is_VBZ exceeded_VBN ._. Although_IN the_DT clinical_JJ significance_NN of_IN these_DT effects_NNS is_VBZ not_RB known_VBN ,_, caution_NN is_VBZ advised_VBN in_IN the_DT co-administration_NN of_IN beta-agonists_NNS with_IN non-potassium_JJ sparing_NN diuretics_NNS ._. BROVANA_NNP ,_, as_IN with_IN other_JJ beta2-agonists_NNS ,_, should_MD be_VB administered_VBN with_IN extreme_JJ caution_NN to_TO patients_NNS being_VBG treated_VBN with_IN monoamine_NN oxidase_NN inhibitors_NNS ,_, tricyclic_JJ antidepressants_NNS ,_, or_CC drugs_NNS known_VBN to_TO prolong_VB the_DT QTc_NN interval_NN because_IN the_DT action_NN of_IN adrenergic_JJ agonists_NNS on_IN the_DT cardiovascular_JJ system_NN may_MD be_VB potentiated_VBN by_IN these_DT agents_NNS ._. Drugs_NNS that_WDT are_VBP known_VBN to_TO prolong_VB the_DT QTc_NN interval_NN have_VBP an_DT increased_VBN risk_NN of_IN ventricular_JJ arrhythmias_NNS ._. The_DT concurrent_JJ use_NN of_IN intravenously_RB or_CC orally_RB administered_VBN methylxanthines_NNS -LRB-_-LRB- e.g._FW ,_, aminophylline_NN ,_, theophylline_NN -RRB-_-RRB- by_IN patients_NNS receiving_VBG BROVANA_NNP has_VBZ not_RB been_VBN completely_RB evaluated_VBN ._. In_IN two_CD combined_JJ 12-week_JJ placebo_NN controlled_VBN trials_NNS that_WDT included_VBD BROVANA_NN doses_NNS of_IN 15_CD mcg_NN twice_RB daily_RB ,_, 25_CD mcg_NN twice_RB daily_RB ,_, and_CC 50_CD mcg_NN once_RB daily_RB ,_, 54_CD of_IN 873_CD BROVANA_NN -_: treated_JJ subjects_NNS received_VBD concomitant_JJ theophylline_NN at_IN study_NN entry_NN ._. In_IN a_DT 12-month_JJ controlled_JJ trial_NN that_WDT included_VBD a_DT 50_CD mcg_NN once_RB daily_JJ BROVANA_NNP dose_NN ,_, 30_CD of_IN the_DT 528_CD BROVANA_NN -_: treated_JJ subjects_NNS received_VBD concomitant_JJ theophylline_NN at_IN study_NN entry_NN ._. In_IN these_DT trials_NNS ,_, heart_NN rate_NN and_CC systolic_JJ blood_NN pressure_NN were_VBD approximately_RB 2-3_CD bpm_NN and_CC 6-8_CD mm_NN Hg_NN higher_JJR ,_, respectively_RB ,_, in_IN subjects_NNS on_IN concomitant_JJ theophylline_NN compared_VBN with_IN the_DT overall_JJ population_NN ._. Beta-adrenergic_JJ receptor_NN antagonists_NNS -LRB-_-LRB- beta-blockers_NNS -RRB-_-RRB- and_CC BROVANA_NN may_MD interfere_VB with_IN the_DT effect_NN of_IN each_DT other_JJ when_WRB administered_VBN concurrently_RB ._. Beta-blockers_NNS not_RB only_RB block_VB the_DT therapeutic_JJ effects_NNS of_IN beta-agonists_NNS ,_, but_CC may_MD produce_VB severe_JJ bronchospasm_NN in_IN COPD_NN patients_NNS ._. Therefore_RB ,_, patients_NNS with_IN COPD_NN should_MD not_RB normally_RB be_VB treated_VBN with_IN beta-blockers_NNS ._. However_RB ,_, under_IN certain_JJ circumstances_NNS ,_, e.g._FW ,_, as_IN prophylaxis_NN after_IN myocardial_JJ infarction_NN ,_, there_EX may_MD be_VB no_DT acceptable_JJ alternatives_NNS to_TO the_DT use_NN of_IN beta-blockers_NNS in_IN patients_NNS with_IN COPD_NN ._. In_IN this_DT setting_NN ,_, cardioselective_JJ beta-blockers_NNS could_MD be_VB considered_VBN ,_, although_IN they_PRP should_MD be_VB administered_VBN with_IN caution_NN ._. Heparin_NN :_: Since_IN heparin_NN is_VBZ contraindicated_VBN in_IN patients_NNS with_IN heparin-induced_JJ thrombocytopenia_NN ,_, the_DT co-administration_NN of_IN Argatroban_NN and_CC heparin_NN is_VBZ unlikely_JJ for_IN this_DT indication_NN ._. However_RB ,_, if_IN Argatroban_NN is_VBZ to_TO be_VB initiated_VBN after_IN cessation_NN of_IN heparin_NN therapy_NN ,_, allow_VBP sufficient_JJ time_NN for_IN heparins_NNS effect_NN on_IN the_DT aPTT_NN to_TO decrease_VB prior_RB to_TO initiation_NN of_IN Argatroban_NN therapy_NN ._. Aspirin/Acetaminophen_NNP :_: Pharmacokinetic_JJ or_CC pharmacodynamic_JJ drug-drug_NN interactions_NNS have_VBP not_RB been_VBN demonstrated_VBN between_IN Argatroban_NN and_CC concomitantly_RB administered_VBN aspirin_NN -LRB-_-LRB- 162.5_CD mg_NN orally_RB given_VBN 26_CD and_CC 2_CD hours_NNS prior_RB to_TO initiation_NN of_IN Argatroban_NN 1_CD g/kg/min_NN ._. over_IN 4_CD hours_NNS -RRB-_-RRB- or_CC acetaminophen_NN -LRB-_-LRB- 1000_CD mg_NN orally_RB given_VBN 12_CD ,_, 6_CD and_CC 0_CD hours_NNS prior_RB to_TO ,_, and_CC 6_CD and_CC 12_CD hours_NNS subsequent_JJ to_TO ,_, initiation_NN of_IN Argatroban_JJ 1.5_CD g/kg/min_NN ._. over_IN 18_CD hours_NNS -RRB-_-RRB- ._. Oral_JJ anticoagulant_JJ agents_NNS :_: Pharmacokinetic_JJ drug-drug_JJ interactions_NNS between_IN Argatroban_NN and_CC warfarin_NN -LRB-_-LRB- 7.5_CD mg_NN single_JJ oral_JJ dose_NN -RRB-_-RRB- have_VBP not_RB been_VBN demonstrated_VBN ._. However_RB ,_, the_DT concomitant_JJ use_NN of_IN Argatroban_NN and_CC warfarin_NN -LRB-_-LRB- 5-7_CD .5_CD mg_NN initial_JJ oral_JJ dose_NN followed_VBN by_IN 2.5-6_CD mg/day_NN orally_RB for_IN 6-10_CD days_NNS -RRB-_-RRB- results_VBZ in_IN prolongation_NN of_IN the_DT prothrombin_NN time_NN -LRB-_-LRB- PT_NN -RRB-_-RRB- and_CC International_NNP Normalized_NNP Ratio_NNP -LRB-_-LRB- INR_NNP -RRB-_-RRB- ._. Thrombolytic_JJ agents_NNS :_: The_DT safety_NN and_CC effectiveness_NN of_IN Argatroban_NN with_IN thrombolytic_JJ agents_NNS have_VBP not_RB been_VBN established_VBN ._. Co-administration_NN :_: Concomitant_JJ use_NN of_IN Argatroban_NN with_IN antiplatelet_JJ agents_NNS ,_, thrombolytics_NNS ,_, and_CC other_JJ anticoagulants_NNS may_MD increase_VB the_DT risk_NN of_IN bleeding_NN ._. Drug-drug_JJ interactions_NNS have_VBP not_RB been_VBN observed_VBN between_IN Argatroban_NN and_CC digoxin_NN or_CC erythromycin_NN ._. Drug-Drug_NNP Interactions_NNS Given_VBN the_DT primary_JJ CNS_NN effects_NNS of_IN aripiprazole_NN ,_, caution_NN should_MD be_VB used_VBN when_WRB ABILIFY_NNP is_VBZ taken_VBN in_IN combination_NN with_IN other_JJ centrally_RB acting_VBG drugs_NNS and_CC alcohol_NN ._. Due_JJ to_TO its_PRP$ ._. 1_LS -_: adrenergic_JJ receptor_NN antagonism_NN ,_, aripiprazole_NN has_VBZ the_DT potential_JJ to_TO enhance_VB the_DT effect_NN of_IN certain_JJ antihypertensive_JJ agents_NNS ._. Potential_JJ for_IN Other_JJ Drugs_NNS to_TO Affect_VB ABILIFY_NNP Aripiprazole_NNP is_VBZ not_RB a_DT substrate_NN of_IN CYP1A1_NN ,_, CYP1A2_NN ,_, CYP2A6_NN ,_, CYP2B6_NN ,_, CYP2C8_NN ,_, CYP2C9_NN ,_, CYP2C19_NN ,_, or_CC CYP2E1_NN enzymes_NNS ._. Aripiprazole_NNP also_RB does_VBZ not_RB undergo_VB direct_JJ glucuronidation_NN ._. This_DT suggests_VBZ that_IN an_DT interaction_NN of_IN aripiprazole_NN with_IN inhibitors_NNS or_CC inducers_NNS of_IN these_DT enzymes_NNS ,_, or_CC other_JJ factors_NNS ,_, like_IN smoking_NN ,_, is_VBZ unlikely_JJ ._. Both_DT CYP3A4_NN and_CC CYP2D6_NN are_VBP responsible_JJ for_IN aripiprazole_NN metabolism_NN ._. Agents_NNS that_WDT induce_VBP CYP3A4_NN -LRB-_-LRB- eg_FW ,_, carbamazepine_NN -RRB-_-RRB- could_MD cause_VB an_DT increase_NN in_IN aripiprazole_JJ clearance_NN and_CC lower_JJR blood_NN levels_NNS ._. Inhibitors_NNS of_IN CYP3A4_NN -LRB-_-LRB- eg_FW ,_, ketoconazole_NN -RRB-_-RRB- or_CC CYP2D6_NN -LRB-_-LRB- eg_FW ,_, quinidine_NN ,_, fluoxetine_NN ,_, or_CC paroxetine_NN -RRB-_-RRB- can_MD inhibit_VB aripiprazole_NN elimination_NN and_CC cause_VB increased_VBN blood_NN levels_NNS ._. Ketoconazole_NN :_: Coadministration_NN of_IN ketoconazole_NN -LRB-_-LRB- 200_CD mg/day_NN for_IN 14_CD days_NNS -RRB-_-RRB- with_IN a_DT 15-mg_JJ single_JJ dose_NN of_IN aripiprazole_NN increased_VBD the_DT AUC_NN of_IN aripiprazole_NN and_CC its_PRP$ active_JJ metabolite_NN by_IN 63_CD %_NN and_CC 77_CD %_NN ,_, respectively_RB ._. The_DT effect_NN of_IN a_DT higher_JJR ketoconazole_NN dose_NN -LRB-_-LRB- 400_CD mg/day_NN -RRB-_-RRB- has_VBZ not_RB been_VBN studied_VBN ._. When_WRB concomitant_JJ administration_NN of_IN ketoconazole_NN with_IN aripiprazole_NN occurs_VBZ ,_, aripiprazole_NN dose_NN should_MD be_VB reduced_VBN to_TO one-half_NN of_IN its_PRP$ normal_JJ dose_NN ._. Other_JJ strong_JJ inhibitors_NNS of_IN CYP3A4_NN -LRB-_-LRB- itraconazole_NN -RRB-_-RRB- would_MD be_VB expected_VBN to_TO have_VB similar_JJ effects_NNS and_CC need_VBP similar_JJ dose_NN reductions_NNS ._. weaker_JJR inhibitors_NNS -LRB-_-LRB- erythromycin_NN ,_, grapefruit_NN juice_NN -RRB-_-RRB- have_VBP not_RB been_VBN studied_VBN ._. When_WRB the_DT CYP3A4_NN inhibitor_NN is_VBZ withdrawn_VBN from_IN the_DT combination_NN therapy_NN ,_, aripiprazole_NN dose_NN should_MD then_RB be_VB increased_VBN ._. Quinidine_NNP :_: Coadministration_NNP of_IN a_DT 10-mg_JJ single_JJ dose_NN of_IN aripiprazole_NN with_IN quinidine_NN -LRB-_-LRB- 166_CD mg/day_NN for_IN 13_CD days_NNS -RRB-_-RRB- ,_, a_DT potent_JJ inhibitor_NN of_IN CYP2D6_NN ,_, increased_VBD the_DT AUC_NN of_IN aripiprazole_NN by_IN 112_CD %_NN but_CC decreased_VBD the_DT AUC_NN of_IN its_PRP$ active_JJ metabolite_NN ,_, dehydroaripiprazole_NN ,_, by_IN 35_CD %_NN ._. Aripiprazole_NNP dose_NN should_MD be_VB reduced_VBN to_TO one-half_NN of_IN its_PRP$ normal_JJ dose_NN when_WRB concomitant_JJ administration_NN of_IN quinidine_NN with_IN aripiprazole_NN occurs_VBZ ._. Other_JJ significant_JJ inhibitors_NNS of_IN CYP2D6_NN ,_, such_JJ as_IN fluoxetine_NN or_CC paroxetine_NN ,_, would_MD be_VB expected_VBN to_TO have_VB similar_JJ effects_NNS and_CC ,_, therefore_RB ,_, should_MD be_VB accompanied_VBN by_IN similar_JJ dose_NN reductions_NNS ._. When_WRB the_DT CYP2D6_NN inhibitor_NN is_VBZ withdrawn_VBN from_IN the_DT combination_NN therapy_NN ,_, aripiprazole_NN dose_NN should_MD then_RB be_VB increased_VBN ._. Carbamazepine_NNP :_: Coadministration_NNP of_IN carbamazepine_NN -LRB-_-LRB- 200_CD mg_NN BID_NNP -RRB-_-RRB- ,_, a_DT potent_JJ CYP3A4_NN inducer_NN ,_, with_IN aripiprazole_NN -LRB-_-LRB- 30_CD mg_NN QD_NN -RRB-_-RRB- resulted_VBD in_IN an_DT approximate_JJ 70_CD %_NN decrease_NN in_IN Cmax_NN and_CC AUC_NN values_NNS of_IN both_DT aripiprazole_NN and_CC its_PRP$ active_JJ metabolite_NN ,_, dehydro-aripiprazole_NN ._. When_WRB carbamazepine_NN is_VBZ added_VBN to_TO aripiprazole_NN therapy_NN ,_, aripiprazole_NN dose_NN should_MD be_VB doubled_VBN ._. Additional_JJ dose_NN increases_NNS should_MD be_VB based_VBN on_IN clinical_JJ evaluation_NN ._. When_WRB carbamazepine_NN is_VBZ withdrawn_VBN from_IN the_DT combination_NN therapy_NN ,_, aripiprazole_NN dose_NN should_MD then_RB be_VB reduced_VBN ._. No_DT clinically_RB significant_JJ effect_NN of_IN famotidine_NN ,_, valproate_NN ,_, or_CC lithium_NN was_VBD seen_VBN on_IN the_DT pharmacokinetics_NNS of_IN aripiprazole_NN -LRB-_-LRB- see_VB CLINICAL_NNP PHARMACOLOGY_NNP :_: Drug_NN -_: Drug_NN Interactions_NNS -RRB-_-RRB- ._. Potential_JJ for_IN ABILIFY_NNP to_TO Affect_VB Other_JJ Drugs_NNS Aripiprazole_NN is_VBZ unlikely_JJ to_TO cause_VB clinically_RB important_JJ pharmacokinetic_JJ interactions_NNS with_IN drugs_NNS metabolized_VBN by_IN cytochrome_NN P450_NN enzymes_NNS ._. In_IN in_FW vivo_FW studies_NNS ,_, 10_CD -_: to_TO 30-mg/day_JJ doses_NNS of_IN aripiprazole_NN had_VBD no_DT significant_JJ effect_NN on_IN metabolism_NN by_IN CYP2D6_NN -LRB-_-LRB- dextromethorphan_NN -RRB-_-RRB- ,_, CYP2C9_NN -LRB-_-LRB- warfarin_NN -RRB-_-RRB- ,_, CYP2C19_NN -LRB-_-LRB- omeprazole_NN ,_, warfarin_NN -RRB-_-RRB- ,_, and_CC CYP3A4_NN -LRB-_-LRB- dextromethorphan_NN -RRB-_-RRB- substrates_NNS ._. Additionally_RB ,_, aripiprazole_NN and_CC dehydroaripiprazole_NN did_VBD not_RB show_VB potential_JJ for_IN altering_VBG CYP1A2-mediated_JJ metabolism_NN in_FW vitro_FW ._. Alcohol_NN :_: There_EX was_VBD no_DT significant_JJ difference_NN between_IN aripiprazole_NN coadministered_VBN with_IN ethanol_NN and_CC placebo_NN coadministered_VBN with_IN ethanol_NN on_IN performance_NN of_IN gross_JJ motor_NN skills_NNS or_CC stimulus_NN response_NN in_IN healthy_JJ subjects_NNS ._. As_IN with_IN most_JJS psychoactive_JJ medications_NNS ,_, patients_NNS should_MD be_VB advised_VBN to_TO avoid_VB alcohol_NN while_IN taking_VBG ABILIF_NNP ._. No_DT formal_JJ assessments_NNS of_IN pharmacokinetic_JJ drug-drug_NN interactions_NNS between_IN TRISENOX_NN and_CC other_JJ agents_NNS have_VBP been_VBN conducted_VBN ._. Caution_NN is_VBZ advised_VBN when_WRB TRISENOX_NN is_VBZ coadministered_VBN with_IN other_JJ medications_NNS that_WDT can_MD prolong_VB the_DT QT_NNP interval_NN -LRB-_-LRB- e.g._FW certain_JJ antiarrhythmics_NNS or_CC thioridazine_NN -RRB-_-RRB- or_CC lead_VB to_TO electrolyte_NN abnormalities_NNS -LRB-_-LRB- such_JJ as_IN diuretics_NNS or_CC amphotericin_NN B_NN -RRB-_-RRB- ._. Tissue_NN culture_NN and_CC animal_NN studies_NNS indicate_VBP that_IN ELSPAR_NN can_MD diminish_VB or_CC abolish_VB the_DT effect_NN of_IN methotrexate_NN on_IN malignant_JJ cells_NNS .14_CD This_DT effect_NN on_IN methotrexate_NN activity_NN persists_VBZ as_RB long_JJ as_IN plasma_NN asparagine_NN levels_NNS are_VBP suppressed_VBN ._. These_DT results_NNS would_MD seem_VB to_TO dictate_VB against_IN the_DT clinical_JJ use_NN of_IN methotrexate_NN with_IN ELSPAR_NN ,_, or_CC during_IN the_DT period_NN following_VBG ELSPAR_NN therapy_NN when_WRB plasma_NN asparagine_NN levels_NNS are_VBP below_IN normal_JJ ._. Uricosuric_NNP Agents_NNPS :_: Aspirin_NN may_MD decrease_VB the_DT effects_NNS of_IN probenecid_NN ,_, sulfinpyrazone_NN ,_, and_CC phenylbutazone_NN ._. Alcohol_NN :_: Has_VBZ a_DT synergistic_JJ effect_NN with_IN aspirin_NN in_IN causing_VBG gastrointestinal_JJ bleeding_NN ._. Corticosteroids_NNS :_: Concomitant_JJ administration_NN with_IN aspirin_NN may_MD increase_VB the_DT risk_NN of_IN gastrointestinal_JJ ulceration_NN and_CC may_MD reduce_VB serum_NN salicylate_NN levels_NNS ._. Pyrazolone_NNP Derivatives_NNS -LRB-_-LRB- phenylbutazone_NN ,_, oxyphenbutazone_NN ,_, and_CC possibly_RB dipyrone_NN -RRB-_-RRB- :_: Concomitant_JJ administration_NN with_IN aspirin_NN may_MD increase_VB the_DT risk_NN of_IN gastrointestinal_JJ ulceration_NN ._. Nonsteroidal_JJ Antiinflammatory_JJ Agents_NNS :_: Aspirin_NN is_VBZ contraindicated_VBN in_IN patients_NNS who_WP are_VBP hypersensitive_JJ to_TO nonsteroidal_JJ anti-inflammatory_JJ agents_NNS ._. Urinary_JJ Alkalinizers_NNS :_: Decrease_NN aspirin_NN effectiveness_NN by_IN increasing_VBG the_DT rate_NN of_IN salicylate_NN renal_JJ excretion_NN ._. Phenobarbital_NNP :_: Decreases_VBZ aspirin_NN effectiveness_NN by_IN enzyme_NN induction_NN ._. Phenytoin_NNP :_: Serum_NN phenytoin_NN levels_NNS may_MD be_VB increased_VBN by_IN aspirin_NN ._. Propranolol_NN :_: May_NNP decrease_VB aspirins_NNS anti-inflammatory_JJ action_NN by_IN competing_VBG for_IN the_DT same_JJ receptors_NNS ._. Antacids_NNS :_: Enteric_JJ Coated_JJ Aspirin_NN should_MD not_RB be_VB given_VBN concurrently_RB with_IN antacids_NNS ,_, since_IN an_DT increase_NN in_IN the_DT pH_NN of_IN the_DT stomach_NN may_MD effect_VB the_DT enteric_JJ coating_NN of_IN the_DT tablets_NNS ._. Ketoconazole/Itraconazole_NNP ,_, Macrolides_NNP ,_, Including_VBG Erythromyci_NNP ._. Catecholamine-depleting_JJ drugs_NNS -LRB-_-LRB- eg_FW ,_, reserpine_NN -RRB-_-RRB- may_MD have_VB an_DT additive_JJ effect_NN when_WRB given_VBN with_IN beta-blocking_JJ agents_NNS ._. Patients_NNS treated_VBN with_IN TENORMIN_NN plus_CC a_DT catecholamine_NN depletor_NN should_MD therefore_RB be_VB closely_RB observed_VBN for_IN evidence_NN of_IN hypotension_NN and/or_CC marked_JJ bradycardia_NN which_WDT may_MD produce_VB vertigo_NN ,_, syncope_NN ,_, or_CC postural_JJ hypotension_NN ._. Calcium_NN channel_NN blockers_NNS may_MD also_RB have_VB an_DT additive_JJ effect_NN when_WRB given_VBN with_IN TENORMIN_NN ._. Beta_NN blockers_NNS may_MD exacerbate_VB the_DT rebound_NN hypertension_NN which_WDT can_MD follow_VB the_DT withdrawal_NN of_IN clonidine_NN ._. If_IN the_DT two_CD drugs_NNS are_VBP coadministered_VBN ,_, the_DT beta_NN blocker_NN should_MD be_VB withdrawn_VBN several_JJ days_NNS before_IN the_DT gradual_JJ withdrawal_NN of_IN clonidine_NN ._. If_IN replacing_VBG clonidine_NN by_IN beta-blocker_NN therapy_NN ,_, the_DT introduction_NN of_IN beta_NN blockers_NNS should_MD be_VB delayed_VBN for_IN several_JJ days_NNS after_IN clonidine_NN administration_NN has_VBZ stopped_VBN ._. Concomitant_JJ use_NN of_IN prostaglandin_NN synthase_NN inhibiting_VBG drugs_NNS ,_, eg_FW ,_, indomethacin_NN ,_, may_MD decrease_VB the_DT hypotensive_JJ effects_NNS of_IN beta_NN blockers_NNS ._. Information_NN on_IN concurrent_JJ usage_NN of_IN atenolol_NN and_CC aspirin_NN is_VBZ limited_VBN ._. Data_NNS from_IN several_JJ studies_NNS ,_, ie_FW ,_, TIMI-II_NN ,_, ISIS-2_NN ,_, currently_RB do_VBP not_RB suggest_VB any_DT clinical_JJ interaction_NN between_IN aspirin_NN and_CC beta_NN blockers_NNS in_IN the_DT acute_JJ myocardial_JJ infarction_NN setting_NN ._. While_IN taking_VBG beta_NN blockers_NNS ,_, patients_NNS with_IN a_DT history_NN of_IN anaphylactic_JJ reaction_NN to_TO a_DT variety_NN of_IN allergens_NNS may_MD have_VB a_DT more_RBR severe_JJ reaction_NN on_IN repeated_VBN challenge_NN ,_, either_CC accidental_JJ ,_, diagnostic_JJ or_CC therapeutic_JJ ._. Such_JJ patients_NNS may_MD be_VB unresponsive_JJ to_TO the_DT usual_JJ doses_NNS of_IN epinephrine_NN used_VBN to_TO treat_VB the_DT allergic_JJ reaction_NN ._. Drug-Drug_NNP Interactions_NNS Albuterol_NNP -_: STRATTERA_NN should_MD be_VB administered_VBN with_IN caution_NN to_TO patients_NNS being_VBG treated_VBN with_IN systemically-administered_JJ -LRB-_-LRB- oral_JJ or_CC intravenous_JJ -RRB-_-RRB- albuterol_NN -LRB-_-LRB- or_CC other_JJ beta2_NN agonists_NNS -RRB-_-RRB- because_IN the_DT action_NN of_IN albuterol_NN on_IN the_DT cardiovascular_JJ system_NN can_MD be_VB potentiated_JJ resulting_VBG in_IN increases_NNS in_IN heart_NN rate_NN and_CC blood_NN pressure_NN ._. CYP2D6_NN inhibitors_NNS -_: Atomoxetine_NN is_VBZ primarily_RB metabolized_VBN by_IN the_DT CYP2D6_NN pathway_NN to_TO 4-hydroxyatomoxetine_NN ._. In_IN EMs_NNS ,_, selective_JJ inhibitors_NNS of_IN CYP2D6_NN increase_NN atomoxetine_NN steady-state_JJ plasma_NN concentrations_NNS to_TO exposures_NNS similar_JJ to_TO those_DT observed_VBN in_IN PMs_NNS ._. Dosage_NN adjustment_NN of_IN STRATTERA_NNP may_MD be_VB necessary_JJ when_WRB coadministered_VBN with_IN CYP2D6_NN inhibitors_NNS ,_, e.g._FW ,_, paroxetine_NN ,_, fluoxetine_NN ,_, and_CC quinidine_NN ._. In_IN EM_NN individuals_NNS treated_VBN with_IN paroxetine_NN or_CC fluoxetine_NN ,_, the_DT AUC_NN of_IN atomoxetine_NN is_VBZ approximately_RB 6_CD -_: to_TO 8-fold_JJ and_CC Css_NN ,_, max_NN is_VBZ about_IN 3_CD -_: to_TO 4-fold_RB greater_JJR than_IN atomoxetine_NN alone_RB ._. In_FW vitro_FW studies_NNS suggest_VBP that_IN coadministration_NN of_IN cytochrome_NN P450_NN inhibitors_NNS to_TO PMs_NNS will_MD not_RB increase_VB the_DT plasma_NN concentrations_NNS of_IN atomoxetine_NN ._. Pressor_NNP agents_NNS -_: Because_IN of_IN possible_JJ effects_NNS on_IN blood_NN pressure_NN ,_, STRATTERA_NN should_MD be_VB used_VBN cautiously_RB with_IN pressor_NN agents_NNS ._. The_DT risk_NN of_IN myopathy_NN during_IN treatment_NN with_IN drugs_NNS of_IN this_DT class_NN is_VBZ increased_VBN with_IN concurrent_JJ administration_NN of_IN cyclosporine_NN ,_, fibric_JJ acid_NN derivatives_NNS ,_, niacin_NN -LRB-_-LRB- nicotinic_JJ acid_NN -RRB-_-RRB- ,_, erythromycin_NN ,_, azole_NN antifungals_NNS ._. Antacid_NN :_: When_WRB atorvastatin_NN and_CC Maalox_NNP TC_NNP suspension_NN were_VBD coadministered_VBN ,_, plasma_NN concentrations_NNS of_IN atorvastatin_NN decreased_VBD approximately_RB 35_CD %_NN ._. However_RB ,_, LDL-C_NN reduction_NN was_VBD not_RB altered_VBN ._. Antipyrine_NNP :_: Because_IN atorvastatin_NN does_VBZ not_RB affect_VB the_DT pharmacokinetics_NNS of_IN antipyrine_NN ,_, interactions_NNS with_IN other_JJ drugs_NNS metabolized_VBN via_IN the_DT same_JJ cytochrome_NN isozymes_NNS are_VBP not_RB expected_VBN ._. Colestipol_NNP :_: Plasma_NN concentrations_NNS of_IN atorvastatin_NN decreased_VBD approximately_RB 25_CD %_NN when_WRB colestipol_NN and_CC atorvastatin_NN were_VBD coadministered_VBN ._. However_RB ,_, LDL-C_NN reduction_NN was_VBD greater_JJR when_WRB atorvastatin_NN and_CC colestipol_NN were_VBD coadministered_VBN than_IN when_WRB either_CC drug_NN was_VBD given_VBN alone_RB ._. Cimetidine_NNP :_: Atorvastatin_NNP plasma_NN concentrations_NNS and_CC LDL-C_NN reduction_NN were_VBD not_RB altered_VBN by_IN coadministration_NN of_IN cimetidine_NN ._. Digoxin_NNP :_: When_WRB multiple_JJ doses_NNS of_IN atorvastatin_NN and_CC digoxin_NN were_VBD coadministered_VBN ,_, steady-state_JJ plasma_NN digoxin_NN concentrations_NNS increased_VBN by_IN approximately_RB 20_CD %_NN ._. Patients_NNS taking_VBG digoxin_NN should_MD be_VB monitored_VBN appropriately_RB ._. Erythromycin_NNP :_: In_IN healthy_JJ individuals_NNS ,_, plasma_NN concentrations_NNS of_IN atorvastatin_NN increased_VBD approximately_RB 40_CD %_NN with_IN coadministration_NN of_IN atorvastatin_NN and_CC erythromycin_NN ,_, a_DT known_JJ inhibitor_NN of_IN cytochrome_NN P450_NN 3A4_NN ._. Oral_JJ Contraceptives_NNS :_: Coadministration_NN of_IN atorvastatin_NN and_CC an_DT oral_JJ contraceptive_NN increased_VBD AUC_NN values_NNS for_IN norethindrone_NN and_CC ethinyl_NN estradiol_NN by_IN approximately_RB 30_CD %_NN and_CC 20_CD %_NN ._. These_DT increases_NNS should_MD be_VB considered_VBN when_WRB selecting_VBG an_DT oral_JJ contraceptive_NN for_IN a_DT woman_NN taking_VBG atorvastatin_NN ._. Warfarin_NNP :_: Atorvastatin_NNP had_VBD no_DT clinically_RB significant_JJ effect_NN on_IN prothrombin_NN time_NN when_WRB administered_VBN to_TO patients_NNS receiving_VBG chronic_JJ warfarin_NN treatment_NN ._. Endocrine_JJ Function_NN HMG-CoA_NN reductase_NN inhibitors_NNS interfere_VBP with_IN cholesterol_NN synthesis_NN and_CC theoretically_RB might_MD blunt_VB adrenal_JJ and/or_CC gonadal_JJ steroid_NN production_NN ._. Clinical_JJ studies_NNS have_VBP shown_VBN that_IN atorvastatin_NN does_VBZ not_RB reduce_VB basal_JJ plasma_NN cortisol_NN concentration_NN or_CC impair_VB adrenal_JJ reserve_NN ._. The_DT effects_NNS of_IN HMG-CoA_NN reductase_NN inhibitors_NNS on_IN male_JJ fertility_NN have_VBP not_RB been_VBN studied_VBN in_IN adequate_JJ numbers_NNS of_IN patients_NNS ._. The_DT effects_NNS ,_, if_IN any_DT ,_, on_IN the_DT pituitary-gonadal_JJ axis_NN in_IN premenopausal_JJ women_NNS are_VBP unknown_JJ ._. Caution_NN should_MD be_VB exercised_VBN if_IN an_DT HMG-CoA_NN reductase_NN inhibitor_NN is_VBZ administered_VBN concomitantly_RB with_IN drugs_NNS that_WDT may_MD decrease_VB the_DT levels_NNS or_CC activity_NN of_IN endogenous_JJ steroid_NN hormones_NNS ,_, such_JJ as_IN ketoconazole_NN ,_, spironolactone_NN ,_, and_CC cimetidine_NN ._. CNS_NN Toxicity_NN Brain_NN hemorrhage_NN was_VBD seen_VBN in_IN a_DT female_JJ dog_NN treated_VBN for_IN 3_CD months_NNS at_IN 120_CD mg/kg/day_NN ._. Brain_NN hemorrhage_NN and_CC optic_JJ nerve_NN vacuolation_NN were_VBD seen_VBN in_IN another_DT female_JJ dog_NN that_WDT was_VBD sacrificed_VBN in_IN moribund_JJ condition_NN after_IN 11_CD weeks_NNS of_IN escalating_VBG doses_NNS up_RB to_TO 280_CD mg/kg/day_NN ._. The_DT 120_CD mg/kg_NN dose_NN resulted_VBD in_IN a_DT systemic_JJ exposure_NN approximately_RB 16_CD times_NNS the_DT human_JJ plasma_NN area-under-the-curve_NN -LRB-_-LRB- AUC_NN ,_, 0-24_CD hours_NNS -RRB-_-RRB- based_VBN on_IN the_DT maximum_NN human_JJ dose_NN of_IN 80_CD mg/day_NN ._. A_DT single_JJ tonic_JJ convulsion_NN was_VBD seen_VBN in_IN each_DT of_IN 2_CD male_JJ dogs_NNS -LRB-_-LRB- one_CD treated_VBN at_IN 10_CD mg/kg/day_NN and_CC one_CD at_IN 120_CD mg/kg/day_NN -RRB-_-RRB- in_IN a_DT 2-year_JJ study_NN ._. No_DT CNS_NN lesions_NNS have_VBP been_VBN observed_VBN in_IN mice_NNS after_IN chronic_JJ treatment_NN for_IN up_RB to_TO 2_CD years_NNS at_IN doses_NNS up_RB to_TO 400_CD mg/kg/day_NN or_CC in_IN rats_NNS at_IN doses_NNS up_RB to_TO 100_CD mg/kg/day_NN ._. These_DT doses_NNS were_VBD 6_CD to_TO 11_CD times_NNS -LRB-_-LRB- mouse_NN -RRB-_-RRB- and_CC 8_CD to_TO 16_CD times_NNS -LRB-_-LRB- rat_NN -RRB-_-RRB- the_DT human_JJ AUC_NN -LRB-_-LRB- 0-24_CD -RRB-_-RRB- based_VBN on_IN the_DT maximum_NN recommended_VBD human_JJ dose_NN of_IN 80_CD mg/day_NN ._. CNS_NN vascular_JJ lesions_NNS ,_, characterized_VBN by_IN perivascular_JJ hemorrhages_NNS ,_, edema_NN ,_, and_CC mononuclear_JJ cell_NN infiltration_NN of_IN perivascular_JJ spaces_NNS ,_, have_VBP been_VBN observed_VBN in_IN dogs_NNS treated_VBN with_IN other_JJ members_NNS of_IN this_DT class_NN ._. A_DT chemically_RB similar_JJ drug_NN in_IN this_DT class_NN produced_VBD optic_JJ nerve_NN degeneration_NN -LRB-_-LRB- Wallerian_JJ degeneration_NN of_IN retinogeniculate_NN fibers_NNS -RRB-_-RRB- in_IN clinically_RB normal_JJ dogs_NNS in_IN a_DT dose-dependent_JJ fashion_NN at_IN a_DT dose_NN that_WDT produced_VBD plasma_NN drug_NN levels_NNS about_IN 30_CD times_NNS higher_JJR than_IN the_DT mean_NN drug_NN level_NN in_IN humans_NNS taking_VBG the_DT highest_JJS recommended_VBN dose_NN ._. Atovaquone_NNP is_VBZ highly_RB bound_VBN to_TO plasma_NN protein_NN -LRB-_-LRB- 99.9_CD %_NN -RRB-_-RRB- ._. Therefore_RB ,_, caution_NN should_MD be_VB used_VBN when_WRB administering_VBG MEPRON_NNP concurrently_RB with_IN other_JJ highly_RB plasma_NN protein_NN -_: bound_VBN drugs_NNS with_IN narrow_JJ therapeutic_JJ indices_NNS ,_, as_IN competition_NN for_IN binding_VBG sites_NNS may_MD occur_VB ._. The_DT extent_NN of_IN plasma_NN protein_NN binding_NN of_IN atovaquone_NN in_IN human_JJ plasma_NN is_VBZ not_RB affected_VBN by_IN the_DT presence_NN of_IN therapeutic_JJ concentrations_NNS of_IN phenytoin_NN -LRB-_-LRB- 15_CD mcg_NN /_: mL_NN -RRB-_-RRB- ,_, nor_CC is_VBZ the_DT binding_NN of_IN phenytoin_NN affected_VBN by_IN the_DT presence_NN of_IN atovaquone_NN ._. Rifampin_NNP :_: Coadministration_NNP of_IN rifampin_NN and_CC MEPRON_NNP Suspension_NNP results_VBZ in_IN a_DT significant_JJ decrease_NN in_IN average_JJ steady_JJ -_: state_NN plasma_NN atovaquone_NN concentrations_NNS ._. Alternatives_NNP to_TO rifampin_NN should_MD be_VB considered_VBN during_IN the_DT course_NN of_IN PCP_NN treatment_NN with_IN MEPRON_NN ._. Rifabutin_NNP ,_, another_DT rifamycin_NN ,_, is_VBZ structurally_RB similar_JJ to_TO rifampin_NN and_CC may_MD possibly_RB have_VB some_DT of_IN the_DT same_JJ drug_NN interactions_NNS as_IN rifampin_NN ._. No_DT interaction_NN trials_NNS have_VBP been_VBN conducted_VBN with_IN MEPRON_NN and_CC rifabutin_NN ._. Drug_NN /_: Laboratory_NNP Test_NNP Interactions_NNS :_: It_PRP is_VBZ not_RB known_VBN if_IN MEPRON_NN interferes_VBZ with_IN clinical_JJ laboratory_NN test_NN or_CC assay_NN results_NNS ._. Drugs_NNS which_WDT may_MD enhance_VB the_DT neuromuscular_JJ blocking_VBG action_NN of_IN TRACRIUM_NN include_VBP :_: enflurane_NN ._. isoflurane_NN ._. halothane_NN ._. certain_JJ antibiotics_NNS ,_, especially_RB the_DT aminoglycosides_NNS and_CC polymyxins_NNS ._. lithium_NN ._. magnesium_NN salts_NNS ._. procainamide_NN ._. Drugs_NNS which_WDT may_MD enhance_VB the_DT neuromuscular_JJ blocking_VBG action_NN of_IN TRACRIUM_NN include_VBP :_: enflurane_NN ;_: isoflurane_NN ;_: halothane_NN ;_: certain_JJ antibiotics_NNS ,_, especially_RB the_DT aminoglycosides_NNS and_CC polymyxins_NNS ;_: lithium_NN ;_: magnesium_NN salts_NNS ;_: procainamide_NN ;_: and_CC quinidine_NN ._. If_IN other_JJ muscle_NN relaxants_NNS are_VBP used_VBN during_IN the_DT same_JJ procedure_NN ,_, the_DT possibility_NN of_IN a_DT synergistic_JJ or_CC antagonist_NN effect_NN should_MD be_VB considered_VBN ._. The_DT prior_JJ administration_NN of_IN succinylcholine_NN does_VBZ not_RB enhance_VB the_DT duration_NN ,_, but_CC quickens_VBZ the_DT onset_NN and_CC may_MD increase_VB the_DT depth_NN ,_, of_IN neuromuscular_JJ block_NN induced_VBN by_IN TRACRIUM_NN ._. TRACRIUM_NN should_MD not_RB be_VB administered_VBN until_IN a_DT patient_NN has_VBZ recovered_VBN from_IN succinylcholine-induced_JJ neuromuscular_JJ block_NN ._. When_WRB atropine_NN and_CC pralidoxime_NN are_VBP used_VBN together_RB ,_, the_DT signs_NNS of_IN atropinization_NN -LRB-_-LRB- flushing_NN ,_, mydriasis_NN ,_, tachycardia_NN ,_, dryness_NN of_IN the_DT mouth_NN and_CC nose_NN -RRB-_-RRB- may_MD occur_VB earlier_JJR than_IN might_MD be_VB expected_VBN than_IN when_WRB atropine_NN is_VBZ used_VBN alone_RB because_IN pralidoxime_NN may_MD potentiate_VB the_DT effect_NN of_IN atropine_NN ._. The_DT following_VBG precautions_NNS should_MD be_VB kept_VBN in_IN mind_NN in_IN the_DT treatment_NN of_IN anticholinesterase_JJ poisoning_NN although_IN they_PRP do_VBP not_RB bear_VB directly_RB on_IN the_DT use_NN of_IN atropine_NN and_CC pralidoxime_NN ._. Since_IN barbiturates_NNS are_VBP potentiated_VBN by_IN the_DT anticholinesterases_NNS ,_, they_PRP should_MD be_VB used_VBN cautiously_RB in_IN the_DT treatment_NN of_IN convulsions_NNS ._. Auranofin_NNP should_MD be_VB avoided_VBN by_IN patients_NNS with_IN a_DT history_NN of_IN serious_JJ reaction_NN to_TO any_DT gold_NN medication_NN ,_, including_VBG Solganal_NNP and_CC Myochrysine_NNP ._. Auranofin_NNP should_MD not_RB be_VB used_VBN together_RP with_IN penicillamine_NN -LRB-_-LRB- Depen_NN ,_, Cuprimine_NN -RRB-_-RRB- ,_, another_DT arthritis_NN medication_NN ._. It_PRP should_MD also_RB be_VB avoided_VBN in_IN patients_NNS with_IN blood_NN ,_, liver_NN or_CC kidney_NN diseases_NNS ,_, recent_JJ radiation_NN treatment_NN ,_, or_CC uncontrolled_JJ diabetes_NN ._. Patients_NNS should_MD report_VB to_TO their_PRP$ practitioners_NNS any_DT new_JJ rashes_NNS ,_, itching_VBG ,_, mouth_NN sores_NNS ,_, or_CC unusual_JJ taste_NN while_IN taking_VBG auranofin_NN ._. Gold_NN is_VBZ excreted_VBN slowly_RB from_IN the_DT body_NN ._. Safety_NN and_CC effectiveness_NN in_IN children_NNS has_VBZ not_RB been_VBN established_VBN ._. No_DT formal_JJ assessments_NNS of_IN drug-drug_JJ interactions_NNS between_IN Vidaza_NNP and_CC other_JJ agents_NNS have_VBP been_VBN conducte_NN ._. MAO_NN inhibitors_NNS prolong_VB and_CC intensify_VB the_DT effects_NNS of_IN antihistamines_NNS ._. Concomitant_JJ use_NN of_IN antihistamines_NNS with_IN alcohol_NN ,_, tricyclic_JJ antidepressants_NNS ,_, barbiturates_NNS ,_, or_CC other_JJ central_JJ nervous_JJ system_NN depressants_NNS may_MD have_VB an_DT additive_JJ effect_NN ._. When_WRB sympathomimetic_JJ drugs_NNS are_VBP given_VBN to_TO patients_NNS receiving_VBG monoamine_NN oxidase_NN inhibitors_NNS ,_, hypertensive_JJ reactions_NNS ,_, including_VBG hypertensive_JJ crises_NNS ,_, may_MD occur_VB ._. The_DT antihypertensive_JJ effects_NNS of_IN methyldopa_NN ,_, mecamylamine_NN ,_, reserpine_NN ,_, and_CC veratrum_NN alkaloids_NNS may_MD be_VB reduced_VBN by_IN sympathomimetics_NNS ._. Beta-adrenergic_JJ blocking_VBG agents_NNS may_MD also_RB interact_VB with_IN sympathomimetics_NNS ._. Increased_VBN ectopic_JJ pacemaker_NN activity_NN can_MD occur_VB when_WRB pseudoephedrine_NN is_VBZ used_VBN concomitantly_RB with_IN digitalis_NN ._. Antacids_NNS increase_VBP the_DT rate_NN of_IN absorption_NN of_IN pseudoephedrine_NN ,_, while_IN kaolin_NN decreases_VBZ it_PRP ._. Use_NN with_IN Allopurinol_NNP :_: The_DT principal_JJ pathway_NN for_IN detoxification_NN of_IN azathioprine_NN is_VBZ inhibited_VBN by_IN allopurinol_NN ._. Patients_NNS receiving_VBG azathioprine_NN and_CC allopurinol_NN concomitantly_RB should_MD have_VB a_DT dose_NN reduction_NN of_IN azathioprine_NN ,_, to_TO approximately_RB 1/3_CD to_TO 1/4_CD the_DT usual_JJ dose_NN ._. Use_NN with_IN Other_JJ Agents_NNS Affecting_VBG Myelopoesis_NNP :_: Drugs_NNS which_WDT may_MD affect_VB leukocyte_NN production_NN ,_, including_VBG co-trimoxazole_NN ,_, may_MD lead_VB to_TO exaggerated_JJ leukopenia_NN ,_, especially_RB in_IN renal_JJ transplant_NN recipients_NNS ._. Use_NN with_IN Angiotensln_NNP Converting_NNP Enzyme_NNP Inhibitors_NNS :_: The_DT use_NN of_IN angiotensin_NN converting_VBG enzyme_NN inhibitors_NNS to_TO control_VB hypertension_NN in_IN patients_NNS on_IN azathioprine_NN has_VBZ been_VBN reported_VBN to_TO induce_VB severe_JJ leukopenia_NN ._. No_DT information_NN provided_VBN ._. Co-administration_NN of_IN nelfinavir_NN at_IN steady-state_JJ with_IN a_DT single_JJ dose_NN of_IN azithromycin_NN ._. Co-administration_NN of_IN nelfinavir_NN at_IN steady-state_JJ with_IN a_DT single_JJ dose_NN of_IN azithromycin_NN -LRB-_-LRB- 2_CD x_CC 600_CD mg_NN tablets_NNS -RRB-_-RRB- results_VBZ in_IN increased_VBN azithromycin_NN serum_NN concentrations_NNS ._. Although_IN a_DT dose_NN adjustment_NN of_IN azithromycin_NN is_VBZ not_RB recommended_VBN when_WRB administered_VBN in_IN combination_NN with_IN nelfinavir_NN ,_, close_JJ monitoring_NN for_IN known_JJ side_JJ effects_NNS of_IN azithromycin_NN ,_, such_JJ as_IN liver_NN enzyme_NN abnormalities_NNS and_CC hearing_VBG impairment_NN ,_, is_VBZ warranted_VBN ._. Azithromycin_NNP did_VBD not_RB affect_VB the_DT prothrombin_NN time_NN response_NN to_TO a_DT single_JJ dose_NN of_IN warfarin_NN ._. However_RB ,_, prudent_JJ medical_JJ practice_NN dictates_VBZ careful_JJ monitoring_NN of_IN prothrombin_NN time_NN in_IN all_DT patients_NNS treated_VBN with_IN azithromycin_NN and_CC warfarin_NN concomitantly_RB ._. Concurrent_JJ use_NN of_IN macrolides_NNS and_CC warfarin_NN in_IN clinical_JJ practice_NN has_VBZ been_VBN associated_VBN with_IN increased_VBN anticoagulant_JJ effects_NNS ._. Drug_NN interaction_NN studies_NNS were_VBD performed_VBN with_IN azithromycin_NN and_CC other_JJ drugs_NNS likely_JJ to_TO be_VB co-administered_VBN ._. When_WRB used_VBN in_IN therapeutic_JJ doses_NNS ,_, azithromycin_NN had_VBD a_DT modest_JJ effect_NN on_IN the_DT pharmacokinetics_NNS of_IN atorvastatin_NN ,_, carbamazepine_NN ,_, cetirizine_NN ,_, didanosine_NN ,_, efavirenz_NN ,_, fluconazole_NN ,_, indinavir_NN ,_, midazolam_NN ,_, rifabutin_NN ,_, sildenafil_NN ,_, theophylline_NN -LRB-_-LRB- intravenous_JJ and_CC oral_JJ -RRB-_-RRB- ,_, triazolam_NN ,_, trimethoprim/sulfamethoxazole_NN or_CC zidovudine_NN ._. Co-administration_NN with_IN efavirenz_NN or_CC fluconazole_NN had_VBD a_DT modest_JJ effect_NN on_IN the_DT pharmacokinetics_NNS of_IN azithromycin_NN ._. No_DT dosage_NN adjustment_NN of_IN either_CC drug_NN is_VBZ recommended_VBN when_WRB azithromycin_NN is_VBZ co_NN administered_VBN with_IN any_DT of_IN the_DT above_JJ agents_NNS ._. Interactions_NNS with_IN the_DT drugs_NNS listed_VBN below_RB have_VBP not_RB been_VBN reported_VBN in_IN clinical_JJ trials_NNS with_IN azithromycin_NN ._. however_RB ,_, no_DT specific_JJ drug_NN interaction_NN studies_NNS have_VBP been_VBN performed_VBN to_TO evaluate_VB potential_JJ drug-drug_JJ interaction_NN ._. Nonetheless_RB ,_, they_PRP have_VBP been_VBN observed_VBN with_IN macrolide_NN products_NNS ._. Until_IN further_JJ data_NNS are_VBP developed_VBN regarding_VBG drug_NN interactions_NNS when_WRB azithromycin_NN and_CC these_DT drugs_NNS are_VBP used_VBN concomitantly_RB ,_, careful_JJ monitoring_NN of_IN patients_NNS is_VBZ advised_VBN :_: Digoxin_NN elevated_JJ digoxin_NN concentrations_NNS ._. Ergotamine_NN or_CC dihydroergotamine_NN acute_JJ ergot_NN toxicity_NN characterized_VBN by_IN severe_JJ peripheral_JJ vasospasm_NN and_CC dysesthesia_NN ._. Cyclosporine_NN ,_, hexobarbital_NN and_CC phenytoin_NN concentrations_NNS ._. Laboratory_NNP Test_NNP Interactions_NNS There_EX are_VBP no_DT reported_VBN laboratory_NN test_NN interactions_NNS ._. Repeat_NN Treatment_NN Studies_NNS evaluating_VBG the_DT use_NN of_IN repeated_VBN courses_NNS of_IN Zmax_NNP have_VBP not_RB been_VBN conducted_VBN ._. Azlocillin_NN should_MD not_RB be_VB administered_VBN concomitantly_RB with_IN amikacin_NN ,_, ciprofloxacin_NN ,_, gentamicin_NN ,_, netilmicin_NN ,_, or_CC tobramycin_NN ._. Injection_NN There_EX is_VBZ inadequate_JJ systematic_JJ experience_NN with_IN the_DT use_NN of_IN baclofen_NN injection_NN in_IN combination_NN with_IN other_JJ medications_NNS to_TO predict_VB specific_JJ drug-drug_JJ interactions_NNS ._. Interactions_NNS attributed_VBD to_TO the_DT combined_VBN use_NN of_IN baclofen_NN injection_NN and_CC epidural_JJ morphine_NN include_VBP hypotension_NN and_CC dyspnea_NN ._. SIDE_NNP EFFECTS_NNP -LRB-_-LRB- KEMSTRO_NNP -RRB-_-RRB- The_DT most_RBS common_JJ adverse_JJ reaction_NN during_IN treatment_NN with_IN baclofen_NN is_VBZ transient_JJ drowsiness_NN -LRB-_-LRB- 10-63_CD %_NN -RRB-_-RRB- ._. In_IN one_CD controlled_JJ study_NN of_IN 175_CD patients_NNS ,_, transient_JJ drowsiness_NN was_VBD observed_VBN in_IN 63_CD %_NN of_IN those_DT receiving_VBG baclofen_NN tablets_NNS compared_VBN to_TO 36_CD %_NN of_IN those_DT in_IN the_DT placebo_NN group_NN ._. Other_JJ common_JJ adverse_JJ reactions_NNS are_VBP dizziness_NN -LRB-_-LRB- 5-15_CD %_NN -RRB-_-RRB- ,_, weakness_NN -LRB-_-LRB- 5-15_CD %_NN -RRB-_-RRB- and_CC fatigue_NN -LRB-_-LRB- 2-4_CD %_NN -RRB-_-RRB- ._. Others_NNS reported_VBD :_: Neuropsychiatric_NNP :_: Confusion_NN -LRB-_-LRB- 1-11_CD %_NN -RRB-_-RRB- ,_, headache_NN -LRB-_-LRB- 4-8_CD %_NN -RRB-_-RRB- ,_, insomnia_NN -LRB-_-LRB- 2-7_CD %_NN -RRB-_-RRB- ;_: ._. and_CC ,_, rarely_RB ,_, euphoria_NN ,_, excitement_NN ,_, depression_NN ,_, hallucinations_NNS ,_, paresthesia_NN ,_, muscle_NN pain_NN ,_, tinnitus_NN ,_, slurred_VBD speech_NN ,_, coordination_NN disorder_NN ,_, tremor_NN ,_, rigidity_NN ,_, dystonia_NN ,_, ataxia_NN ,_, blurred_VBD vision_NN ,_, nystagmus_NN ,_, strabismus_NN ,_, miosis_NN ,_, mydriasis_NN ,_, diplopia_NN ,_, dysarthria_NN ,_, epileptic_JJ seizure_NN ._. Cardiovascular_NNP :_: Hypotension_NN -LRB-_-LRB- 0-9_CD %_NN -RRB-_-RRB- ._. Rare_JJ instances_NNS of_IN dyspnea_NN ,_, palpitation_NN ,_, chest_NN pain_NN ,_, syncope_NN ._. Gastrointestinal_JJ :_: Nausea_NN -LRB-_-LRB- 4-12_CD %_NN -RRB-_-RRB- ,_, constipation_NN -LRB-_-LRB- 2-6_CD %_NN -RRB-_-RRB- ;_: ._. and_CC ,_, rarely_RB ,_, dry_JJ mouth_NN ,_, anorexia_NN ,_, taste_VBP disorder_NN ,_, abdominal_JJ pain_NN ,_, vomiting_VBG ,_, diarrhea_NN ,_, and_CC positive_JJ test_NN for_IN occult_VBN blood_NN in_IN stool_NN ._. Genitourinary_NNP :_: Urinary_JJ frequency_NN -LRB-_-LRB- 2-6_CD %_NN -RRB-_-RRB- ;_: ._. and_CC ,_, rarely_RB ,_, enuresis_NN ,_, urinary_JJ retention_NN ,_, dysuria_NN ,_, impotence_NN ,_, inability_NN to_TO ejaculate_VB ,_, nocturia_NN ,_, hematuria_NN ._. Other_JJ :_: Instances_NNS of_IN rash_NN ,_, pruritus_NN ,_, ankle_NN edema_NN ,_, excessive_JJ perspiration_NN ,_, weight_NN gain_NN ,_, nasal_JJ congestion_NN ._. Some_DT of_IN the_DT CNS_NN and_CC genitourinary_JJ symptoms_NNS may_MD be_VB related_VBN to_TO the_DT underlying_VBG disease_NN rather_RB than_IN to_TO drug_NN therapy_NN ._. The_DT following_VBG laboratory_NN tests_NNS have_VBP been_VBN found_VBN to_TO be_VB abnormal_JJ in_IN a_DT few_JJ patients_NNS receiving_VBG baclofen_NN :_: increased_VBN SGOT_NNP ,_, elevated_JJ alkaline_NN phosphatase_NN ,_, and_CC elevation_NN of_IN blood_NN sugar_NN ._. The_DT adverse_JJ experience_NN profile_NN seen_VBN with_IN KEMSTROTM_NN was_VBD similar_JJ to_TO that_DT seen_VBN with_IN baclofen_NN tablets_NNS ._. No_DT drug_NN interaction_NN studies_NNS have_VBP been_VBN conducted_VBN for_IN COLAZAL_NNP ,_, however_RB the_DT use_NN of_IN orally_RB administered_VBN antibiotics_NNS could_MD ,_, theoretically_RB ,_, interfere_VBP with_IN the_DT release_NN of_IN mesalamine_NN in_IN the_DT colon_NN ._. No_DT dose_NN adjustment_NN is_VBZ necessary_JJ when_WRB Simulect_NNP is_VBZ added_VBN to_TO triple-immunosuppression_JJ regimens_NNS including_VBG cyclosporine_NN ,_, corticosteroids_NNS ,_, and_CC either_CC azathioprine_NN or_CC mycophenolate_JJ mofetil_NN ._. Three_CD clinical_JJ trials_NNS have_VBP investigated_VBN Simulect_NNP use_NN in_IN combination_NN with_IN triple-therapy_JJ regimens_NNS ._. Pharmacokinetics_NNS were_VBD assessed_VBN in_IN two_CD of_IN these_DT trials_NNS ._. Total_JJ body_NN clearance_NN of_IN Simulect_NNP was_VBD reduced_VBN by_IN an_DT average_JJ 22_CD %_NN and_CC 51_CD %_NN when_WRB azathioprine_NN and_CC mycophenolate_JJ mofetil_NN ,_, respectively_RB ,_, were_VBD added_VBN to_TO a_DT regimen_NN consisting_VBG of_IN cyclosporine_NN ,_, USP_NN -LRB-_-LRB- MODIFIED_VBN -RRB-_-RRB- and_CC corticosteroids_NNS ._. Nonetheless_RB ,_, the_DT range_NN of_IN individual_JJ Simulect_JJ clearance_NN values_NNS in_IN the_DT presence_NN of_IN azathioprine_NN -LRB-_-LRB- 12-57_CD mL/h_NN -RRB-_-RRB- or_CC mycophenolate_JJ mofetil_NN -LRB-_-LRB- 7-54_CD mL/h_NN -RRB-_-RRB- did_VBD not_RB extend_VB outside_IN the_DT range_NN observed_VBN with_IN dual_JJ therapy_NN -LRB-_-LRB- 10-78_CD mL/h_NN -RRB-_-RRB- ._. The_DT following_VBG medications_NNS have_VBP been_VBN administered_VBN in_IN clinical_JJ trials_NNS with_IN Simulect_NN with_IN no_DT increase_NN in_IN adverse_JJ reactions_NNS :_: ATG/ALG_NN ,_, azathioprine_NN ,_, corticosteroids_NNS ,_, cyclosporine_NN ,_, mycophenolate_JJ mofetil_NN ,_, and_CC muromonab-CD3_NN ._. It_PRP is_VBZ not_RB known_VBN if_IN REGRANEX_NNP Gel_NN interacts_VBZ with_IN other_JJ topical_JJ medications_NNS applied_VBD to_TO the_DT ulcer_NN site_NN ._. The_DT use_NN of_IN REGRANEX_NNP Gel_NN with_IN other_JJ topical_JJ drugs_NNS has_VBZ not_RB been_VBN studied_VBN ._. Albuterol_NNP ,_, Antihistamines_NNP ,_, antidiabetic_JJ drugs_NNS ,_, diuretics_NNS ,_, digitalis_NN ._. Diuretics_NNS :_: Patients_NNS on_IN diuretics_NNS ,_, especially_RB those_DT in_IN whom_WP diuretic_JJ therapy_NN was_VBD recently_RB instituted_VBN ,_, may_MD occasionally_RB experience_VB an_DT excessive_JJ reduction_NN of_IN blood_NN pressure_NN after_IN initiation_NN of_IN therapy_NN with_IN Lotensin_NN ._. The_DT possibility_NN of_IN hypotensive_JJ effects_NNS with_IN Lotensin_NN can_MD be_VB minimized_VBN by_IN either_CC discontinuing_VBG the_DT diuretic_JJ or_CC increasing_VBG the_DT salt_NN intake_NN prior_RB to_TO initiation_NN of_IN treatment_NN with_IN Lotensin_NN ._. If_IN this_DT is_VBZ not_RB possible_JJ ,_, the_DT starting_VBG dose_NN should_MD be_VB reduced_VBN ._. Potassium_NN Supplements_NNS and_CC Potassium-Sparing_NNP Diuretics_NNP Lotensin_NNP can_MD attenuate_VB potassium_NN loss_NN caused_VBN by_IN thiazide_JJ diuretics_NNS ._. Potassium-sparing_JJ diuretics_NNS -LRB-_-LRB- spironolactone_NN ,_, amiloride_NN ,_, triamterene_NN ,_, and_CC others_NNS -RRB-_-RRB- or_CC potassium_NN supplements_NNS can_MD increase_VB the_DT risk_NN of_IN hyperkalemia_NN ._. Therefore_RB ,_, if_IN concomitant_JJ use_NN of_IN such_JJ agents_NNS is_VBZ indicated_VBN ,_, they_PRP should_MD be_VB given_VBN with_IN caution_NN ,_, and_CC the_DT patient_NN 's_POS serum_NN potassium_NN should_MD be_VB monitored_VBN frequently_RB ._. Oral_JJ Anticoagulants_NNPS Interaction_NN studies_NNS with_IN warfarin_NN and_CC acenocoumarol_NN failed_VBD to_TO identify_VB any_DT clinically_RB important_JJ effects_NNS on_IN the_DT serum_NN concentrations_NNS or_CC clinical_JJ effects_NNS of_IN these_DT anticoagulants_NNS ._. Lithium_NN :_: Increased_VBN serum_NN lithium_NN levels_NNS and_CC symptoms_NNS of_IN lithium_NN toxicity_NN have_VBP been_VBN reported_VBN in_IN patients_NNS receiving_VBG ACE_NN inhibitors_NNS during_IN therapy_NN with_IN lithium_NN ._. These_DT drugs_NNS should_MD be_VB coadministered_VBN with_IN caution_NN ,_, and_CC frequent_JJ monitoring_NN of_IN serum_NN lithium_NN levels_NNS is_VBZ recommended_VBN ._. If_IN a_DT diuretic_JJ is_VBZ also_RB used_VBN ,_, the_DT risk_NN of_IN lithium_NN toxicity_NN may_MD be_VB increased_VBN ._. Other_JJ No_DT clinically_RB important_JJ pharmacokinetic_JJ interactions_NNS occurred_VBD when_WRB Lotensin_NNP was_VBD administered_VBN concomitantly_RB with_IN hydrochlorothiazide_NN ,_, chlorthalidone_NN ,_, furosemide_NN ,_, digoxin_NN ,_, propranolol_NN ,_, atenolol_NN ,_, naproxen_NN ,_, or_CC cimetidine_NN ._. Lotensin_NNP has_VBZ been_VBN used_VBN concomitantly_RB with_IN beta-adrenergic-blocking_JJ agents_NNS ,_, calcium-channel-blocking_JJ agents_NNS ,_, diuretics_NNS ,_, digoxin_NN ,_, and_CC hydralazine_NN ,_, without_IN evidence_NN of_IN clinically_RB important_JJ adverse_JJ interactions_NNS ._. Benazepril_NNP ,_, like_IN other_JJ ACE_NN inhibitors_NNS ,_, has_VBZ had_VBN less_JJR than_IN additive_JJ effects_NNS with_IN beta-adrenergic_JJ blockers_NNS ,_, presumably_RB because_IN both_DT drugs_NNS lower_JJR blood_NN pressure_NN by_IN inhibiting_VBG parts_NNS of_IN the_DT renin-angiotensin_JJ syste_NN ._. May_NNP interact_VBP with_IN the_DT following_NN :_: cholestyramine_NN ,_, colestipol_NN -LRB-_-LRB- use_NN with_IN thiazide_JJ diuretics_NNS may_MD prevent_VB the_DT diuretic_JJ from_IN working_VBG properly_RB ._. Bentiromide_NNP may_MD interact_VB with_IN acetaminophen_NN -LRB-_-LRB- e.g._FW ,_, Tylenol_NNP -RRB-_-RRB- ,_, chloramphenicol_NN -LRB-_-LRB- e.g._FW ,_, Chloromycetin_NN -RRB-_-RRB- ,_, local_JJ anesthetics_NNS -LRB-_-LRB- e.g._FW ,_, benzocaine_NN and_CC lidocaine_NN -RRB-_-RRB- ,_, para-aminobenzoic_JJ acid_NN -LRB-_-LRB- PABA_NN -RRB-_-RRB- -_: containing_VBG preparations_NNS -LRB-_-LRB- e.g._FW ,_, sunscreens_NNS and_CC some_DT multivitamins_NNS -RRB-_-RRB- ,_, procainamide_NN -LRB-_-LRB- e.g._FW ,_, Pronestyl_NNP -RRB-_-RRB- ,_, sulfonamides_NNS -LRB-_-LRB- sulfa_NN medicines_NNS -RRB-_-RRB- ,_, thiazide_JJ diuretics_NNS -LRB-_-LRB- use_NN of_IN these_DT medicines_NNS during_IN the_DT test_NN period_NN will_MD affect_VB the_DT test_NN results_VBZ -RRB-_-RRB- ,_, and_CC pancreatic_JJ supplements_NNS -LRB-_-LRB- use_NN of_IN pancreatic_JJ supplements_NNS may_MD give_VB false_JJ test_NN results_NNS -RRB-_-RRB- ._. May_NNP interact_VBP with_IN other_JJ creams_NNS ,_, lotions_NNS ,_, or_CC skin_NN medicines_NNS when_WRB placed_VBN on_IN the_DT same_JJ areas_NNS of_IN your_PRP$ skin_NN that_IN you_PRP are_VBP using_VBG bentoquatam_NN ._. No_DT information_NN is_VBZ available_JJ ._. Hypertensive_JJ crises_NNS have_VBP resulted_VBN when_WRB sympathomimetic_JJ amines_NNS have_VBP been_VBN used_VBN concomitantly_RB within14_CD days_NNS following_VBG use_NN of_IN monoamine_NN oxidase_NN inhibitors_NNS ._. DIDREX_NNP should_MD not_RB be_VB used_VBN concomitantly_RB with_IN other_JJ CNS_NN stimulants_NNS ._. Amphetamines_NNS may_MD decrease_VB the_DT hypotensive_JJ effect_NN of_IN antihypertensives_NNS ._. Amphetamines_NNS may_MD enhance_VB the_DT effects_NNS of_IN tricyclic_JJ antidepressants_NNS ._. Urinary_JJ alkalinizing_JJ agents_NNS increase_VBP blood_NN levels_NNS and_CC decrease_VB excretion_NN of_IN amphetamines_NNS ._. Urinary_JJ acidifying_VBG agents_NNS decrease_VB blood_NN levels_NNS and_CC increase_VB excretion_NN of_IN amphetamines_NNS ._. Benzthiazide_NNP may_MD interact_VB with_IN alcohol_NN ,_, blood_NN thinners_NNS ,_, decongestant_NN drugs_NNS -LRB-_-LRB- allergy_NN ,_, cold_JJ ,_, and_CC sinus_NN medicines_NNS -RRB-_-RRB- ,_, diabetic_JJ drugs_NNS ,_, lithium_NN ,_, norepinephrine_NN ,_, NSAIDs_NNS like_IN Aleve_NNP or_CC Ibuprofen_NNP ,_, and_CC high_JJ blood_NN pressure_NN medications_NNS ._. Antipsychotic_JJ drugs_NNS such_JJ as_IN phenothiazines_NNS or_CC haloperidol_NN ._. tricyclic_JJ antidepressants_NNS ._. Nitrates_NNS :_: The_DT concomitant_JJ use_NN of_IN Bepridil_NN with_IN long_JJ -_: and_CC short-acting_JJ nitrates_NNS has_VBZ been_VBN safely_RB tolerated_VBN in_IN patients_NNS with_IN stable_JJ angina_NN pectoris_NN ._. Sublingual_JJ nitroglycerin_NN may_MD be_VB taken_VBN if_IN necessary_JJ for_IN the_DT control_NN of_IN acute_JJ angina_NN attacks_NNS during_IN Bepridil_NN therapy_NN ._. Beta-blocking_JJ Agents_NNS :_: The_DT concomitant_JJ use_NN of_IN Bepridil_NNP and_CC beta-blocking_JJ agents_NNS has_VBZ been_VBN well_RB tolerated_VBN in_IN patients_NNS with_IN stable_JJ angina_NN ._. Available_JJ data_NNS are_VBP not_RB sufficient_JJ ,_, however_RB ,_, to_TO predict_VB the_DT effects_NNS of_IN concomitant_JJ medication_NN on_IN patients_NNS with_IN impaired_JJ ventricular_JJ function_NN or_CC cardiac_JJ conduction_NN abnormalities_NNS ._. Digoxin_NNP :_: In_IN controlled_JJ studies_NNS in_IN healthy_JJ volunteers_NNS ,_, bepridil_NN hydrochloride_NN either_CC had_VBD no_DT effect_NN -LRB-_-LRB- one_CD study_NN -RRB-_-RRB- or_CC was_VBD associated_VBN with_IN modest_JJ increases_NNS ,_, about_IN 30_CD %_NN -LRB-_-LRB- two_CD studies_NNS -RRB-_-RRB- in_IN steady-state_JJ serum_NN digoxin_NN concentrations_NNS ._. Limited_JJ clinical_JJ data_NNS in_IN angina_NN patients_NNS receiving_VBG concomitant_JJ bepridil_NN hydrochloride_NN and_CC digoxin_NN therapy_NN indicate_VBP no_DT discernible_JJ changes_NNS in_IN serum_NN digoxin_NN levels_NNS ._. Available_JJ data_NNS are_VBP neither_DT sufficient_JJ to_TO rule_VB out_RP possible_JJ increases_NNS in_IN serum_NN digoxin_NN with_IN concomitant_JJ treatment_NN in_IN some_DT patients_NNS ,_, nor_CC other_JJ possible_JJ interactions_NNS ,_, particularly_RB in_IN patients_NNS with_IN cardiac_JJ conduction_NN abnormalities_NNS -LRB-_-LRB- Also_RB see_VB WARNINGS_NNP Congestive_JJ Heart_NNP Failure_NN -RRB-_-RRB- ._. Oral_JJ Hypoglycemics_NNS :_: Bepridil_NNP has_VBZ been_VBN safely_RB used_VBN in_IN diabetic_JJ patients_NNS without_IN significantly_RB lowering_VBG their_PRP$ blood_NN glucose_NN levels_NNS or_CC altering_VBG their_PRP$ need_NN for_IN insulin_NN or_CC oral_JJ hypoglycemic_JJ agents_NNS ._. General_NNP Interactions_NNS :_: Certain_JJ drugs_NNS could_MD increase_VB the_DT likelihood_NN of_IN potentially_RB serious_JJ adverse_JJ effects_NNS with_IN bepridil_NN hydrochloride_NN ._. In_IN general_JJ ,_, these_DT are_VBP drugs_NNS that_WDT have_VBP one_CD or_CC more_JJR pharmacologic_JJ activities_NNS similar_JJ to_TO bepridil_NN hydrochloride_NN ,_, including_VBG anti-arrhythmic_JJ agents_NNS such_JJ as_IN quinidine_NN and_CC procainamide_NN ,_, cardiac_JJ glycosides_NNS and_CC tricyclic_JJ anti-depressants_NNS ._. Anti-arrhythmics_NNS and_CC tricyclic_JJ anti-depressants_NNS could_MD exaggerate_VB the_DT prolongation_NN of_IN the_DT QT_NNP interval_NN observed_VBN with_IN bepridil_NN hydrochloride_NN ._. Cardiac_JJ glycosides_NNS could_MD exaggerate_VB the_DT depression_NN of_IN AV_NN nodal_JJ conduction_NN observed_VBN with_IN bepridil_NN hydrochloride_NN ._. The_DT following_VBG drugs_NNS have_VBP been_VBN coadministered_VBN with_IN Kerlone_NNP and_CC have_VBP not_RB altered_VBN its_PRP$ pharmacokinetics_NNS :_: cimetidine_NN ,_, nifedipine_NN ,_, chlorthalidone_NN ,_, and_CC hydrochlorothiazide_NN ._. Concomitant_JJ administration_NN of_IN Kerlone_NNP with_IN the_DT oral_JJ anticoagulant_JJ warfarin_NN has_VBZ been_VBN shown_VBN not_RB to_TO potentiate_VB the_DT anticoagulant_JJ effect_NN of_IN warfarin_NN ._. Catecholamine-depleting_JJ drugs_NNS -LRB-_-LRB- e.g._FW ,_, reserpine_NN -RRB-_-RRB- may_MD have_VB an_DT additive_JJ effect_NN when_WRB given_VBN with_IN beta-blocking_JJ agents_NNS ._. Patients_NNS treated_VBN with_IN a_DT beta-adrenergic_JJ receptor_NN blocking_VBG agent_NN plus_CC a_DT catecholamine_NN depletor_NN should_MD therefore_RB be_VB closely_RB observed_VBN for_IN evidence_NN of_IN hypotension_NN or_CC marked_JJ bradycardia_NN ,_, which_WDT may_MD produce_VB vertigo_NN ,_, syncope_NN ,_, or_CC postural_JJ hypotension_NN ._. Should_MD it_PRP be_VB decided_VBN to_TO discontinue_VB therapy_NN in_IN patients_NNS receiving_VBG beta-blockers_NNS and_CC clonidine_NN concurrently_RB ,_, the_DT beta-blocker_NN should_MD be_VB discontinued_VBN slowly_RB over_IN several_JJ days_NNS before_IN the_DT gradual_JJ withdrawal_NN of_IN clonidine_NN ._. Literature_NN reports_NNS suggest_VBP that_IN oral_JJ calcium_NN antagonists_NNS may_MD be_VB used_VBN in_IN combination_NN with_IN beta-adrenergic_JJ blocking_VBG agents_NNS when_WRB heart_NN function_NN is_VBZ normal_JJ ,_, but_CC should_MD be_VB avoided_VBN in_IN patients_NNS with_IN impaired_JJ cardiac_JJ function_NN ._. Hypotension_NN ,_, AV_NN conduction_NN disturbances_NNS ,_, and_CC left_VBD ventricular_JJ failure_NN have_VBP been_VBN reported_VBN in_IN some_DT patients_NNS receiving_VBG beta-adrenergic_JJ blocking_VBG agents_NNS when_WRB an_DT oral_JJ calcium_NN antagonist_NN was_VBD added_VBN to_TO the_DT treatment_NN regimen_NN ._. Hypotension_NN was_VBD more_RBR likely_JJ to_TO occur_VB if_IN the_DT calcium_NN antagonist_NN were_VBD a_DT dihydropyridine_NN derivative_NN ,_, e.g._FW ,_, nifedipine_NN ,_, while_IN left_VBN ventricular_JJ failure_NN and_CC AV_NN conduction_NN disturbances_NNS ,_, including_VBG complete_JJ heart_NN block_NN ,_, were_VBD more_RBR likely_JJ to_TO occur_VB with_IN either_CC verapamil_NN or_CC diltiazem_NN ._. Risk_NN of_IN Anaphylactic_NNP Reaction_NNP :_: Although_IN it_PRP is_VBZ known_VBN that_IN patients_NNS on_IN beta-blockers_NNS may_MD be_VB refractory_JJ to_TO epinephrine_NN in_IN the_DT treatment_NN of_IN anaphylactic_JJ shock_NN ,_, beta-blockers_NNS can_MD ,_, in_IN addition_NN ,_, interfere_VBP with_IN the_DT modulation_NN of_IN allergic_JJ reaction_NN and_CC lead_VB to_TO an_DT increased_VBN severity_NN and/or_CC frequency_NN of_IN attacks_NNS ._. Severe_JJ allergic_JJ reactions_NNS including_VBG anaphylaxis_NN have_VBP been_VBN reported_VBN in_IN patients_NNS exposed_VBN to_TO a_DT variety_NN of_IN allergens_NNS either_CC by_IN repeated_VBN challenge_NN ,_, or_CC accidental_JJ contact_NN ,_, and_CC with_IN diagnostic_JJ or_CC therapeutic_JJ agents_NNS while_IN receiving_VBG beta-blockers_NNS ._. Such_JJ patients_NNS may_MD be_VB unresponsive_JJ to_TO the_DT usual_JJ doses_NNS of_IN epinephrine_NN used_VBN to_TO treat_VB allergic_JJ reaction_NN ._. Special_JJ care_NN is_VBZ required_VBN if_IN this_DT drug_NN is_VBZ given_VBN to_TO patients_NNS receiving_VBG ganglion_NN blocking_VBG compounds_NNS because_IN a_DT critical_JJ fall_NN in_IN blood_NN pressure_NN may_MD occur_VB ._. Usually_RB ,_, severe_JJ abdominal_JJ symptoms_NNS appear_VBP before_IN there_EX is_VBZ such_JJ a_DT fall_NN in_IN the_DT blood_NN pressure_NN ._. No_DT formal_JJ drug_NN interaction_NN studies_NNS with_IN anti-neoplastic_JJ agents_NNS have_VBP been_VBN conducted_VBN ._. In_IN Study_NNP 1_CD ,_, patients_NNS with_IN colorectal_JJ cancer_NN were_VBD given_VBN irinotecan/5-FU/leucovorin_NN -LRB-_-LRB- bolus-IFL_NN -RRB-_-RRB- with_IN or_CC without_IN AVASTIN_NNP ._. Irinotecan_JJ concentrations_NNS were_VBD similar_JJ in_IN patients_NNS receiving_VBG bolus-IFL_NN alone_RB and_CC in_IN combination_NN with_IN AVASTIN_NNP ._. The_DT concentrations_NNS of_IN SN38_NN ,_, the_DT active_JJ metabolite_NN of_IN irinotecan_NN ,_, were_VBD on_IN average_JJ 33_CD %_NN higher_JJR in_IN patients_NNS receiving_VBG bolus-IFL_NN in_IN combination_NN with_IN AVASTIN_NN when_WRB compared_VBN with_IN bolus-IFL_NN alone_RB ._. In_IN Study_NNP 1_CD ,_, patients_NNS receiving_VBG bolus-IFL_NN plus_CC AVASTIN_NNP had_VBD a_DT higher_JJR incidence_NN of_IN Grade_NNP 3-4_CD diarrhea_NN and_CC neutropenia_NN ._. Due_JJ to_TO high_JJ inter-patient_JJ variability_NN and_CC limited_JJ sampling_NN ,_, the_DT extent_NN of_IN the_DT increase_NN in_IN SN38_NN levels_NNS in_IN patients_NNS receiving_VBG concurrent_JJ irinotecan_NN and_CC AVASTIN_NN is_VBZ uncertain_JJ ._. No_DT formal_JJ studies_NNS to_TO evaluate_VB drug_NN interactions_NNS with_IN bexarotene_NN have_VBP been_VBN conducted_VBN ._. Bexarotene_NNP oxidative_JJ metabolites_NNS appear_VBP to_TO be_VB formed_VBN by_IN cytochrome_NN P450_NN 3A4_NN ._. On_IN the_DT basis_NN of_IN the_DT metabolism_NN of_IN bexarotene_NN by_IN cytochrome_NN P450_NN 3A4_NN ,_, ketoconazole_NN ,_, itraconazole_NN ,_, erythromycin_NN ,_, gemfibrozil_NN ,_, grapefruit_NN juice_NN ,_, and_CC other_JJ inhibitors_NNS of_IN cytochrome_NN P450_NN 3A4_NN would_MD be_VB expected_VBN to_TO lead_VB to_TO an_DT increase_NN in_IN plasma_NN bexarotene_NN concentrations_NNS ._. Furthermore_RB ,_, rifampin_NN ,_, phenytoin_NN ,_, phenobarbital_NN ,_, and_CC other_JJ inducers_NNS of_IN cytochrome_NN P450_NN 3A4_NN may_MD cause_VB a_DT reduction_NN in_IN plasma_NN bexarotene_NN concentrations_NNS ._. Concomitant_JJ administration_NN of_IN Targretin_NNP capsules_NNS and_CC gemfibrozil_NN resulted_VBD in_IN substantial_JJ increases_NNS in_IN plasma_NN concentrations_NNS of_IN bexarotene_NN ,_, probably_RB at_IN least_JJS partially_RB related_JJ to_TO cytochrome_NN P450_NN 3A4_NN inhibition_NN by_IN gemfibrozil_NN ._. Under_IN similar_JJ conditions_NNS ,_, bexarotene_NN concentrations_NNS were_VBD not_RB affected_VBN by_IN concomitant_JJ atorvastatin_NN administration_NN ._. Concomitant_JJ administration_NN of_IN gemfibrozil_NN with_IN Targretin_NNP capsules_NNS is_VBZ not_RB recommended_VBN ._. When_WRB Bezalip_NNP or_CC Bezalip_NNP retard_VBP is_VBZ used_VBN at_IN the_DT same_JJ time_NN as_IN other_JJ medicines_NNS or_CC substances_NNS the_DT following_JJ interactions_NNS must_MD be_VB taken_VBN into_IN account_NN :_: -_: Bezalip_NN and_CC Bezalip_NN retard_VBP may_MD enhance_VB the_DT action_NN of_IN anticoagulants_NNS of_IN the_DT coumarin_NN type_NN ._. For_IN this_DT reason_NN ,_, the_DT dose_NN of_IN the_DT anticoagulant_NN should_MD be_VB reduced_VBN by_IN 30_CD -_: 50_CD %_NN at_IN the_DT start_NN of_IN treatment_NN with_IN Bezalip_NN or_CC Bezalip_JJ retard_VB and_CC then_RB titrated_VBD according_VBG to_TO the_DT blood_NN clotting_NN parameter_NN ._. -_: The_DT action_NN of_IN sulphonylureas_NNS and_CC insulin_NN may_MD be_VB enhanced_VBN by_IN Bezalip_NNP or_CC Bezalip_NNP retard_VBP ._. This_DT may_MD be_VB due_JJ to_TO an_DT improved_VBN glucose_NN utilization_NN with_IN simultaneous_JJ reduction_NN in_IN insulin_NN requiremen_NN ._. -_: In_IN isolated_VBN cases_NNS ,_, a_DT pronounced_JJ though_IN reversible_JJ ,_, impairment_NN of_IN renal_JJ function_NN -LRB-_-LRB- accompanied_VBN by_IN a_DT corresponding_JJ increase_NN in_IN the_DT serum_NN creatinine_NN level_NN -RRB-_-RRB- has_VBZ been_VBN reported_VBN in_IN organ_NN transplant_NN patients_NNS receiving_VBG immuno-suppressant_JJ therapy_NN and_CC concomitant_JJ bezafibrate_NN ._. Accordingly_RB ,_, renal_JJ function_NN should_MD be_VB closely_RB monitored_VBN in_IN these_DT patients_NNS and_CC ,_, in_IN the_DT event_NN of_IN relevant_JJ significant_JJ changes_NNS in_IN laboratory_NN parameters_NNS ,_, bezafibrate_NN should_MD ,_, if_IN necessary_JJ ,_, be_VB discontinue_VB ._. -_: When_WRB Bezalip_NNP or_CC Bezalip_NNP retard_VBP is_VBZ used_VBN concurrently_RB with_IN anion-exchange_JJ resins_NNS -LRB-_-LRB- e.g._FW cholestryramine_FW -RRB-_-RRB- ,_, an_DT interval_NN of_IN at_IN least_JJS 2_CD hours_NNS should_MD be_VB maintained_VBN between_IN the_DT two_CD medicines_NNS ,_, since_IN the_DT absorption_NN of_IN Bezalip_NNP or_CC Bezalip_NNP retard_VBP is_VBZ impaire_NN ._. -_: Perhexiline_NN hydrogen_NN maleate_NN or_CC MAO-inhibitors_NNS -LRB-_-LRB- with_IN hepatotoxic_JJ potential_NN -RRB-_-RRB- must_MD not_RB be_VB administered_VBN together_RB with_IN Bezalip_NN or_CC Bezalip_NN retard_VBP ._. In_FW vitro_FW studies_NNS have_VBP shown_VBN CASODEX_NNP can_MD displace_VB coumarin_NN anticoagulants_NNS ,_, such_JJ as_IN warfarin_NN ,_, from_IN their_PRP$ protein-binding_JJ sites_NNS ._. It_PRP is_VBZ recommended_VBN that_IN if_IN CASODEX_NNP is_VBZ started_VBN in_IN patients_NNS already_RB receiving_VBG coumarin_NN anticoagulants_NNS ,_, prothrombin_NN times_NNS should_MD be_VB closely_RB monitored_VBN and_CC adjustment_NN of_IN the_DT anticoagulant_JJ dose_NN may_MD be_VB necessary_JJ ._. No_DT Information_NN Provided_VBN ._. Drug_NN Interactions_NNS :_: The_DT central_JJ anticholinergic_JJ syndrome_NN can_MD occur_VB when_WRB anticholinergic_JJ agents_NNS such_JJ as_IN AKINETON_NNP are_VBP administered_VBN concomitantly_RB with_IN drugs_NNS that_WDT have_VBP secondary_JJ anticholinergic_JJ actions_NNS ,_, e.g._FW ,_, certain_JJ narcotic_JJ analgesics_NNS such_JJ as_IN meperidine_NN ,_, the_DT phenothiazines_NNS and_CC other_JJ antipsychotics_NNS ,_, tricyclic_JJ antidepressants_NNS ,_, certain_JJ antiarrhythmics_NNS such_JJ as_IN the_DT quinidine_NN salts_NNS ,_, and_CC antihistamines_NNS ._. ZEBETA_NN should_MD not_RB be_VB combined_VBN with_IN other_JJ beta-blocking_JJ agents_NNS ._. Patients_NNS receiving_VBG catecholamine-depleting_JJ drugs_NNS ,_, such_JJ as_IN reserpine_NN or_CC guanethidine_NN ,_, should_MD be_VB closely_RB monitored_VBN ,_, because_IN the_DT added_VBN beta-adrenergic_JJ blocking_VBG action_NN of_IN ZEBETA_NNP may_MD produce_VB excessive_JJ reduction_NN of_IN sympathetic_JJ activity_NN ._. In_IN patients_NNS receiving_VBG concurrent_JJ therapy_NN with_IN clonidine_NN ,_, if_IN therapy_NN is_VBZ to_TO be_VB discontinued_VBN ,_, it_PRP is_VBZ suggested_VBN that_IN ZEBETA_NNP be_VB discontinued_VBN for_IN several_JJ days_NNS before_IN the_DT withdrawal_NN of_IN clonidine_NN ._. ZEBETA_NN should_MD be_VB used_VBN with_IN care_NN when_WRB myocardial_JJ depressants_NNS or_CC inhibitors_NNS of_IN AV_NN conduction_NN ,_, such_JJ as_IN certain_JJ calcium_NN antagonists_NNS -LRB-_-LRB- particularly_RB of_IN the_DT phenylalkylamine_NN -LSB-_-LRB- verapamil_NN -RSB-_-RRB- and_CC benzothiazepine_NN -LSB-_-LRB- diltiazem_NN -RSB-_-RRB- classes_NNS -RRB-_-RRB- ,_, or_CC antiarrhythmic_JJ agents_NNS ,_, such_JJ as_IN disopyramide_NN ,_, are_VBP used_VBN concurrently_RB ._. Concurrent_JJ use_NN of_IN rifampin_NN increases_VBZ the_DT metabolic_JJ clearance_NN of_IN ZEBETA_NNP ,_, resulting_VBG in_IN a_DT shortened_VBN elimination_NN half-life_NN of_IN ZEBETA_NN ._. However_RB ,_, initial_JJ dose_NN modification_NN is_VBZ generally_RB not_RB necessary_JJ ._. Pharmacokinetic_JJ studies_NNS document_VBP no_DT clinically_RB relevant_JJ interactions_NNS with_IN other_JJ agents_NNS given_VBN concomitantly_RB ,_, including_VBG thiazide_JJ diuretics_NNS ,_, digoxin_NN ,_, and_CC cimetidine_NN ._. There_EX was_VBD no_DT effect_NN of_IN ZEBETA_NN on_IN prothrombin_NN time_NN in_IN patients_NNS on_IN stable_JJ doses_NNS of_IN warfarin_NN ._. Risk_NN of_IN Anaphylactic_NNP Reaction_NNP :_: While_IN taking_VBG beta-blockers_NNS ,_, patients_NNS with_IN a_DT history_NN of_IN severe_JJ anaphylactic_JJ reaction_NN to_TO a_DT variety_NN of_IN allergens_NNS may_MD be_VB more_RBR reactive_JJ to_TO repeated_VBN challenge_NN ,_, either_CC accidental_JJ ,_, diagnostic_JJ ,_, or_CC therapeutic_JJ ._. Such_JJ patients_NNS may_MD be_VB unresponsive_JJ to_TO the_DT usual_JJ doses_NNS of_IN epinephrine_NN used_VBN to_TO treat_VB allergic_JJ reactions_NNS ._. Use_NN of_IN MAO_NN inhibitors_NNS may_MD cause_VB an_DT excessive_JJ increase_NN in_IN blood_NN pressure_NN and_CC heart_NN stimulation_NN ._. If_IN you_PRP are_VBP also_RB using_VBG a_DT steroid_NN inhaler_NN ,_, take_VB bitolterol_NN first_JJ and_CC then_RB wait_VB about_RB 15_CD minutes_NNS before_IN using_VBG the_DT steroid_NN inhaler_NN ._. This_DT allows_VBZ bitolterol_NN to_TO open_VB air_NN passages_NNS ,_, increasing_VBG the_DT effectiveness_NN of_IN the_DT steroid_NN ._. Angiomax_NN does_VBZ not_RB exhibit_VB binding_VBG to_TO plasma_NN proteins_NNS -LRB-_-LRB- other_JJ than_IN thrombin_NN -RRB-_-RRB- or_CC red_JJ blood_NN cells_NNS ._. In_IN clinical_JJ trials_NNS in_IN patients_NNS undergoing_VBG PTCA/PCI_NN ,_, co-administration_NN of_IN Angiomax_NN with_IN heparin_NN ,_, warfarin_NN ,_, thrombolytics_NNS or_CC glycoprotein_NN IIb/IIIa_NN inhibitors_NNS was_VBD associated_VBN with_IN increased_VBN risks_NNS of_IN major_JJ bleeding_JJ events_NNS compared_VBN to_TO patients_NNS not_RB receiving_VBG these_DT concomitant_JJ medications_NNS ._. There_EX is_VBZ no_DT experience_NN with_IN co-administration_NN of_IN Angiomax_NN and_CC plasma_NN expanders_NNS such_JJ as_IN dextran_NN ._. Angiomax_NN should_MD be_VB used_VBN with_IN caution_NN in_IN patients_NNS with_IN disease_NN states_NNS associated_VBN with_IN an_DT increased_VBN risk_NN of_IN bleeding_NN ._. Immunogenicity/Re-exposure_NN :_: In_IN in_FW vitro_FW studies_NNS ,_, Angiomax_NN exhibited_VBD no_DT platelet_NN aggregation_NN response_NN against_IN sera_NNS from_IN patients_NNS with_IN a_DT history_NN of_IN HIT/HITTS_NN ._. Among_IN 494_CD subjects_NNS who_WP received_VBD Angiomax_NNP in_IN clinical_JJ trials_NNS and_CC were_VBD tested_VBN for_IN antibodies_NNS ,_, 2_CD subjects_NNS had_VBD treatment-emergent_JJ positive_JJ bivalirudin_NN antibody_NN tests_NNS ._. Neither_DT subject_JJ demonstrated_VBD clinical_JJ evidence_NN of_IN allergic_JJ or_CC anaphylactic_JJ reactions_NNS and_CC repeat_NN testing_NN was_VBD not_RB performed_VBN ._. Nine_CD additional_JJ patients_NNS who_WP had_VBD initial_JJ positive_JJ tests_NNS were_VBD negative_JJ on_IN repeat_NN testing_NN ._. Certain_JJ antibiotic_JJ ,_, cisplatin_NN ,_, cyclosporine_NN ,_, diuretic_JJ ,_, foscarnet_NN ,_, and_CC vaccines_NNS ._. No_DT formal_JJ drug_NN interaction_NN studies_NNS have_VBP been_VBN conducted_VBN with_IN VELCADE_NN ._. In_FW vitro_FW studies_NNS with_IN human_JJ liver_NN microsomes_NNS indicate_VBP that_IN bortezomib_NN is_VBZ primarily_RB a_DT substrate_NN for_IN cytochrome_NN P450_NN 3A4_NN ,_, 2C19_NN ,_, and_CC 1A2_NN ._. Patients_NNS who_WP are_VBP concomitantly_RB receiving_VBG VELCADE_NNP and_CC drugs_NNS that_WDT are_VBP inhibitors_NNS or_CC inducers_NNS of_IN cytochrome_NN P450_NN 3A4_NN should_MD be_VB closely_RB monitored_VBN for_IN either_CC toxicities_NNS or_CC reduced_VBN efficacy_NN ._. During_IN clinical_JJ trials_NNS ,_, hypoglycemia_NN and_CC hyperglycemia_NN were_VBD reported_VBN in_IN diabetic_JJ patients_NNS receiving_VBG oral_JJ hypoglycemics_NNS ._. Patients_NNS on_IN oral_JJ antidiabetic_JJ agents_NNS receiving_VBG VELCADE_NNP treatment_NN may_MD require_VB close_JJ monitoring_NN of_IN their_PRP$ blood_NN glucose_NN levels_NNS and_CC adjustment_NN of_IN the_DT dose_NN of_IN their_PRP$ antidiabetic_JJ medication_NN ._. Drug_NNP Laboratory_NNP Test_NNP Interactions_NNS None_NN known_VBN ._. Bosentan_NNP is_VBZ metabolized_VBN by_IN CYP2C9_NN and_CC CYP3A4_NN ._. Inhibition_NN of_IN these_DT isoenzymes_NNS may_MD increase_VB the_DT plasma_NN concentration_NN of_IN bosentan_NN ._. Bosentan_NNP is_VBZ an_DT inducer_NN of_IN CYP3A4_NN and_CC CYP2C9_NN ._. Consequently_RB ,_, plasma_NN concentrations_NNS of_IN drugs_NNS metabolized_VBN by_IN these_DT two_CD isoenzymes_NNS will_MD be_VB decreased_VBN when_WRB TRACLEER_NN is_VBZ co-administered_JJ ._. Bosentan_NNP had_VBD no_DT relevant_JJ inhibitory_JJ effect_NN on_IN any_DT CYP_NN isoenzymes_NNS tested_VBN -LRB-_-LRB- CYP1A2_NN ,_, CYP2C9_NN ,_, CYP2C19_NN ,_, CYP2D6_NN ,_, CYP3A4_NN -RRB-_-RRB- ._. Consequently_RB ,_, TRACLEER_NN is_VBZ not_RB expected_VBN to_TO increase_VB the_DT plasma_NN concentrations_NNS of_IN drugs_NNS metabolized_VBN by_IN these_DT enzymes_NNS ._. Hormonal_JJ Contraceptives_NNS ,_, Including_VBG Oral_JJ ,_, Injectable_JJ ,_, Transdermal_JJ ,_, and_CC Implantable_JJ Contraceptives_NNS :_: An_DT interaction_NN study_NN demonstrated_VBD that_IN co-administration_NN of_IN bosentan_NN and_CC the_DT oral_JJ hormonal_JJ contraceptive_JJ Ortho-Novum_NNP produced_VBN average_JJ decreases_NNS of_IN norethindrone_NN and_CC ethinyl_NN estradiol_NN levels_NNS of_IN 14_CD %_NN and_CC 31_CD %_NN ,_, respectively_RB ._. However_RB ,_, decreases_VBZ in_IN exposure_NN were_VBD as_RB much_JJ as_IN 56_CD %_NN and_CC 66_CD %_NN ,_, respectively_RB ,_, in_IN individual_JJ subjects_NNS ._. Therefore_RB ,_, hormonal_JJ contraceptives_NNS ,_, including_VBG oral_JJ ,_, injectable_JJ ,_, transdermal_JJ ,_, and_CC implantable_JJ forms_NNS ,_, may_MD not_RB be_VB reliable_JJ when_WRB TRACLEER_NN is_VBZ co-administered_JJ ._. Women_NNS should_MD practice_VB additional_JJ methods_NNS of_IN contraception_NN and_CC not_RB rely_VB on_IN hormonal_JJ contraception_NN alone_RB when_WRB taking_VBG TRACLEER_NN ._. Specific_JJ interaction_NN studies_NNS have_VBP demonstrated_VBN the_DT following_NN :_: Cyclosporine_NN A_NN :_: During_IN the_DT first_JJ day_NN of_IN concomitant_JJ administration_NN ,_, trough_NN concentrations_NNS of_IN bosentan_NN were_VBD increased_VBN by_IN about_IN 30-fold_RB ._. Steady-state_JJ bosentan_NN plasma_NN concentrations_NNS were_VBD 3_LS -_: to_TO 4-fold_RB higher_JJR than_IN in_IN the_DT absence_NN of_IN cyclosporine_NN A_NN ._. The_DT concomitant_JJ administration_NN of_IN bosentan_NN and_CC cyclosporine_NN A_NN is_VBZ contraindicated_VBN ._. Co-administration_NN of_IN bosentan_NN decreased_VBD the_DT plasma_NN concentrations_NNS of_IN cyclosporine_NN A_NN -LRB-_-LRB- a_DT CYP3A4_NN substrate_NN -RRB-_-RRB- by_IN approximately_RB 50_CD %_NN ._. Tacrolimus_NN :_: Co-administration_NN of_IN tacrolimus_NN and_CC bosentan_NN has_VBZ not_RB been_VBN studied_VBN in_IN man_NN ._. Co-administration_NN of_IN tacrolimus_NN and_CC bosentan_NN resulted_VBD in_IN markedly_RB increased_VBN plasma_NN concentrations_NNS of_IN bosentan_NN in_IN animals_NNS ._. Caution_NN should_MD be_VB exercised_VBN if_IN tacrolimus_NN and_CC bosentan_NN are_VBP used_VBN together_RB ._. Glyburide_NNP :_: An_DT increased_VBN risk_NN of_IN elevated_JJ liver_NN aminotransferases_NNS was_VBD observed_VBN in_IN patients_NNS receiving_VBG concomitant_JJ therapy_NN with_IN glyburide_NN ._. Therefore_RB ,_, the_DT concomitant_JJ administration_NN of_IN TRACLEER_NN and_CC glyburide_NN is_VBZ contraindicated_VBN ,_, and_CC alternative_JJ hypoglycemic_JJ agents_NNS should_MD be_VB considered_VBN ._. Co-administration_NN of_IN bosentan_NN decreased_VBD the_DT plasma_NN concentrations_NNS of_IN glyburide_NN by_IN approximately_RB 40_CD %_NN ._. The_DT plasma_NN concentrations_NNS of_IN bosentan_NN were_VBD also_RB decreased_VBN by_IN approximately_RB 30_CD %_NN ._. Bosentan_NNP is_VBZ also_RB expected_VBN to_TO reduce_VB plasma_NN concentrations_NNS of_IN other_JJ oral_JJ hypoglycemic_JJ agents_NNS that_WDT are_VBP predominantly_RB metabolized_VBN by_IN CYP2C9_NN or_CC CYP3A4_NN ._. The_DT possibility_NN of_IN worsened_VBN glucose_NN control_NN in_IN patients_NNS using_VBG these_DT agents_NNS should_MD be_VB considered_VBN ._. Ketoconazole_NN :_: Co-administration_NN of_IN bosentan_NN 125_CD mg_NN b.i.d._NN and_CC ketoconazole_NN ,_, a_DT potent_JJ CYP3A4_NN inhibitor_NN ,_, increased_VBD the_DT plasma_NN concentrations_NNS of_IN bosentan_NN by_IN approximately_RB 2-fold_RB ._. No_DT dose_NN adjustment_NN of_IN bosentan_NN is_VBZ necessary_JJ ,_, but_CC increased_VBD effects_NNS of_IN bosentan_NN should_MD be_VB considered_VBN ._. Simvastatin_NNP and_CC Other_JJ Statins_NNS :_: Co-administration_NN of_IN bosentan_NN decreased_VBD the_DT plasma_NN concentrations_NNS of_IN simvastatin_NN -LRB-_-LRB- a_DT CYP3A4_NN substrate_NN -RRB-_-RRB- ,_, and_CC its_PRP$ active_JJ -_: hydroxy_NN acid_NN metabolite_NN ,_, by_IN approximately_RB 50_CD %_NN ._. The_DT plasma_NN concentrations_NNS of_IN bosentan_NN were_VBD not_RB affected_VBN ._. Bosentan_NNP is_VBZ also_RB expected_VBN to_TO reduce_VB plasma_NN concentrations_NNS of_IN other_JJ statins_NNS that_WDT have_VBP significant_JJ metabolism_NN by_IN CYP3A4_NN ,_, such_JJ as_IN lovastatin_NN and_CC atorvastatin_NN ._. The_DT possibility_NN of_IN reduced_VBN statin_NN efficacy_NN should_MD be_VB considered_VBN ._. Patients_NNS using_VBG CYP3A4_NN metabolized_VBN statins_NNS should_MD have_VB cholesterol_NN levels_NNS monitored_VBD after_IN TRACLEER_NN is_VBZ initiated_VBN to_TO see_VB whether_IN the_DT statin_NN dose_NN needs_VBZ adjustment_NN ._. Warfarin_NNP :_: Co-administration_NN of_IN bosentan_NN 500_CD mg_NN b.i.d._NN for_IN 6_CD days_NNS decreased_VBD the_DT plasma_NN concentrations_NNS of_IN both_DT S-warfarin_NN -LRB-_-LRB- a_DT CYP2C9_NN substrate_NN -RRB-_-RRB- and_CC R-warfarin_NN -LRB-_-LRB- a_DT CYP3A4_NN substrate_NN -RRB-_-RRB- by_IN 29_CD and_CC 38_CD %_NN ,_, respectively_RB ._. Clinical_JJ experience_NN with_IN concomitant_JJ administration_NN of_IN bosentan_NN and_CC warfarin_NN in_IN patients_NNS with_IN pulmonary_JJ arterial_JJ hypertension_NN did_VBD not_RB show_VB clinically_RB relevant_JJ changes_NNS in_IN INR_NN or_CC warfarin_NN dose_NN -LRB-_-LRB- baseline_NN vs._CC end_NN of_IN the_DT clinical_JJ studies_NNS -RRB-_-RRB- ,_, and_CC the_DT need_NN to_TO change_VB the_DT warfarin_NN dose_NN during_IN the_DT trials_NNS due_JJ to_TO changes_NNS in_IN INR_NN or_CC due_JJ to_TO adverse_JJ events_NNS was_VBD similar_JJ among_IN bosentan_NN -_: and_CC placebo-treated_JJ patients_NNS ._. Digoxin_NNP ,_, Nimodipine_NNP and_CC Losartan_NNP :_: Bosentan_NNP has_VBZ no_DT significant_JJ pharmacokinetic_JJ interactions_NNS with_IN digoxin_NN and_CC nimodipine_NN ,_, and_CC losartan_NN has_VBZ no_DT significant_JJ effect_NN on_IN plasma_NN levels_NNS of_IN bosentan_NN ._. Co-administration_NN of_IN BOTOX_NNP and_CC aminoglycosides_NNS or_CC other_JJ agents_NNS interfering_VBG with_IN neuromuscular_JJ transmission_NN -LRB-_-LRB- e.g._FW ,_, curare-like_JJ compounds_NNS -RRB-_-RRB- should_MD only_RB be_VB performed_VBN with_IN caution_NN as_IN the_DT effect_NN of_IN the_DT toxin_NN may_MD be_VB potentiated_VBN ._. The_DT effect_NN of_IN administering_VBG different_JJ botulinum_NN neurotoxin_NN serotypes_NNS at_IN the_DT same_JJ time_NN or_CC within_IN several_JJ months_NNS of_IN each_DT other_JJ is_VBZ unknown_JJ ._. Excessive_JJ neuromuscular_JJ weakness_NN may_MD be_VB exacerbated_VBN by_IN administration_NN of_IN another_DT botulinum_NN toxin_NN prior_RB to_TO the_DT resolution_NN of_IN the_DT effects_NNS of_IN a_DT previously_RB administered_VBN botulinum_NN toxin_NN ._. Co-administration_NN of_IN MYOBLOC_NNP and_CC aminoglycosides_NNS or_CC other_JJ agents_NNS interfering_VBG with_IN neuromuscular_JJ transmission_NN -LRB-_-LRB- e.g._FW ,_, curare-like_JJ compounds_NNS -RRB-_-RRB- should_MD only_RB be_VB performed_VBN with_IN caution_NN as_IN the_DT effect_NN of_IN the_DT toxin_NN may_MD be_VB potentiated_VBN ._. The_DT effect_NN of_IN administering_VBG different_JJ botulinum_NN neurotoxin_NN serotypes_NNS at_IN the_DT same_JJ time_NN or_CC within_IN less_JJR than_IN 4_CD months_NNS of_IN each_DT other_JJ is_VBZ unknown_JJ ._. However_RB ,_, neuromuscular_JJ paralysis_NN may_MD be_VB potentiated_VBN by_IN co-administration_NN or_CC overlapping_VBG administration_NN of_IN different_JJ botulinum_NN toxin_NN serotypes_NNS ._. Digitalis_NN toxicity_NN may_MD be_VB aggravated_VBN by_IN the_DT initial_JJ release_NN of_IN norepinephrine_NN caused_VBN by_IN Bretylium_NNP Tosylate_NNP Injection_NN ._. The_DT pressor_JJ effects_NNS of_IN catecholamines_NNS such_JJ as_IN dopamine_NN or_CC norepinephrine_NN are_VBP enhanced_VBN by_IN Bretylium_NNP Tosylate_NNP ._. When_WRB catecholamines_NNS are_VBP administered_VBN ,_, dilute_VB solutions_NNS should_MD be_VB used_VBN and_CC blood_NN pressure_NN should_MD be_VB monitored_VBN closely_RB ._. 
Although_IN there_EX is_VBZ little_JJ published_VBN information_NN on_IN concomitant_JJ administration_NN of_IN lidocaine_NN and_CC Bretylium_NNP Tosylate_NNP ,_, these_DT drugs_NNS are_VBP often_RB administered_VBN concurrently_RB without_IN any_DT evidence_NN of_IN interactions_NNS resulting_VBG in_IN adverse_JJ effects_NNS or_CC diminished_VBN efficacy_NN ._. Although_IN specific_JJ drug_NN interaction_NN studies_NNS have_VBP not_RB been_VBN conducted_VBN with_IN ALPHAGAN_NN P_NN ,_, the_DT possibility_NN of_IN an_DT additive_JJ or_CC potentiating_NN effect_NN with_IN CNS_NN depressants_NNS -LRB-_-LRB- alcohol_NN ,_, barbiturates_NNS ,_, opiates_NNS ,_, sedatives_NNS ,_, or_CC anesthetics_NNS -RRB-_-RRB- should_MD be_VB considered_VBN ._. Alpha-agonists_NNS ,_, as_IN a_DT class_NN ,_, may_MD reduce_VB pulse_NN and_CC blood_NN pressure_NN ._. Caution_NN in_IN using_VBG concomitant_JJ drugs_NNS such_JJ as_IN beta-blockers_NNS -LRB-_-LRB- ophthalmic_JJ and_CC systemic_JJ -RRB-_-RRB- ,_, anti-hypertensives_JJ and/or_CC cardiac_JJ glycosides_NNS is_VBZ advised_VBN ._. Tricyclic_JJ antidepressants_NNS have_VBP been_VBN reported_VBN to_TO blunt_VB the_DT hypotensive_JJ effect_NN of_IN systemic_JJ clonidine.It_NN is_VBZ not_RB known_VBN whether_IN the_DT concurrent_JJ use_NN of_IN these_DT agents_NNS with_IN ALPHAGAN_NN P_NN in_IN humans_NNS can_MD lead_VB to_TO resulting_VBG interference_NN with_IN the_DT IOP_NN lowering_NN effect_NN ._. No_DT data_NNS on_IN the_DT level_NN of_IN circulating_VBG catecholamines_NNS after_IN ALPHAGAN_NNP P_NN administration_NN are_VBP available_JJ ._. Caution_NN ,_, however_RB ,_, is_VBZ advised_VBN in_IN patients_NNS taking_VBG tricyclic_JJ antidepressants_NNS which_WDT can_MD affect_VB the_DT metabolism_NN and_CC uptake_NN of_IN circulating_VBG amines_NNS ._. AZOPT_NN -LRB-_-LRB- brinzolamide_NN ophthalmic_JJ suspension_NN -RRB-_-RRB- 1_CD %_NN contains_VBZ a_DT carbonic_JJ anhydrase_NN inhibitor_NN ._. Acid-base_NN and_CC electrolyte_NN alterations_NNS were_VBD not_RB reported_VBN in_IN the_DT clinical_JJ trials_NNS with_IN brinzolamide_NN ._. However_RB ,_, in_IN patients_NNS treated_VBN with_IN oral_JJ carbonic_JJ anhydrase_NN inhibitors_NNS ,_, rare_JJ instances_NNS of_IN drug_NN interactions_NNS have_VBP occurred_VBN with_IN high-dose_JJ salicylate_NN therapy_NN ._. Therefore_RB ,_, the_DT potential_NN for_IN such_JJ drug_NN interaction_NN should_MD be_VB considered_VBN in_IN patients_NNS receiving_VBG AZOPT_NNP -LRB-_-LRB- brinzolamide_JJ ophthalmic_JJ suspension_NN -RRB-_-RRB- 1_CD %_NN ._. The_DT risk_NN of_IN using_VBG bromocriptine_NN mesylate_NN in_IN combination_NN with_IN other_JJ drugs_NNS has_VBZ not_RB been_VBN systematically_RB evaluated_VBN ,_, but_CC alcohol_NN may_MD potentiate_VB the_DT side_JJ effects_NNS of_IN bromocriptine_NN mesylate_NN ._. Bromocriptine_NN mesylate_NN may_MD interact_VB with_IN dopamine_NN antagonists_NNS ,_, butyrophenones_NNS ,_, and_CC certain_JJ other_JJ agents_NNS ._. Compounds_NNS in_IN these_DT categories_NNS result_VBP in_IN a_DT decreased_VBN efficacy_NN of_IN bromocriptine_NN mesylate_NN :_: phenothiazines_NNS ,_, haloperidol_NN ,_, metoclopramide_NN ,_, pimozide_NN ._. Concomitant_JJ use_NN of_IN bromocriptine_NN mesylate_NN with_IN other_JJ ergot_NN alkaloids_NNS is_VBZ not_RB recommended_VBN ._. Dexbrompheniramine_NN can_MD interact_VB with_IN alcohol_NN or_CC other_JJ CNS_NN depressants_NNS -LRB-_-LRB- may_MD potentiate_VB the_DT CNS_NN depressant_NN effects_NNS of_IN either_CC these_DT medications_NNS or_CC antihistamines_NNS -RRB-_-RRB- ,_, anticholinergics_NNS or_CC other_JJ medications_NNS with_IN anticholinergic_JJ activity_NN -LRB-_-LRB- anticholinergic_JJ effects_NNS may_MD be_VB potentiated_VBN when_WRB these_DT medications_NNS are_VBP used_VBN concurrently_RB with_IN antihistamines_NNS -RRB-_-RRB- ,_, and_CC monoamine_NN oxidase_NN -LRB-_-LRB- MAO_NN -RRB-_-RRB- inhibitors_NNS -LRB-_-LRB- concurrent_JJ use_NN with_IN antihistamines_NNS may_MD prolong_VB and_CC intensify_VB the_DT anticholinergic_JJ and_CC CNS_NN depressant_NN effects_NNS of_IN antihistamines_NNS -RRB-_-RRB- ._. This_DT drug_NN may_MD interact_VB with_IN alcohol_NN or_CC other_JJ CNS_NN depressants_NNS -LRB-_-LRB- may_MD potentiate_VB the_DT CNS_NN depressant_NN effects_NNS of_IN either_CC these_DT medications_NNS or_CC antihistamines_NNS -RRB-_-RRB- ,_, anticholinergics_NNS or_CC other_JJ medications_NNS with_IN anticholinergic_JJ activity_NN -LRB-_-LRB- anticholinergic_JJ effects_NNS may_MD be_VB potentiated_VBN when_WRB these_DT medications_NNS are_VBP used_VBN concurrently_RB with_IN antihistamines_NNS -RRB-_-RRB- ,_, and_CC monoamine_NN oxidase_NN -LRB-_-LRB- MAO_NN -RRB-_-RRB- inhibitors_NNS -LRB-_-LRB- concurrent_JJ use_NN with_IN antihistamines_NNS may_MD prolong_VB and_CC intensify_VB the_DT anticholinergic_JJ and_CC CNS_NN depressant_NN effects_NNS of_IN antihistamines_NNS -RRB-_-RRB- ._. Concomitant_JJ oral_JJ administration_NN of_IN ketoconazole_NN -LRB-_-LRB- a_DT known_JJ inhibitor_NN of_IN CYP3A4_NN activity_NN in_IN the_DT liver_NN and_CC in_IN the_DT intestinal_JJ mucosa_NN -RRB-_-RRB- caused_VBD an_DT eight-fold_JJ increase_NN of_IN the_DT systemic_JJ exposure_NN to_TO oral_JJ budesonide_NN ._. If_IN treatment_NN with_IN inhibitors_NNS of_IN CYP3A4_NN activity_NN -LRB-_-LRB- such_JJ as_IN ketoconazole_NN ,_, intraconazole_NN ,_, ritonavir_NN ,_, indinavir_NN ,_, saquinavir_NN ,_, erythromycin_NN ,_, etc._FW -RRB-_-RRB- is_VBZ indicated_VBN ,_, reduction_NN of_IN the_DT budesonide_NN dose_NN should_MD be_VB considered_VBN ._. After_IN extensive_JJ intake_NN of_IN grapefruit_NN juice_NN -LRB-_-LRB- which_WDT inhibits_VBZ CYP3A4_NN activity_NN predominantly_RB in_IN the_DT intestinal_JJ mucosa_NN -RRB-_-RRB- ,_, the_DT systemic_JJ exposure_NN for_IN oral_JJ budesonide_NN increased_VBD about_IN two_CD times_NNS ._. As_IN with_IN other_JJ drugs_NNS primarily_RB being_VBG metabolized_VBN through_IN CYP3A4_NN ,_, ingestion_NN of_IN grapefruit_NN or_CC grapefruit_NN juice_NN should_MD be_VB avoided_VBN in_IN connection_NN with_IN budesonide_NN administration_NN ._. -_: Drugs_NNS with_IN ototoxic_JJ potential_NN :_: Especially_RB in_IN the_DT presence_NN of_IN impaired_JJ renal_JJ function_NN ,_, the_DT use_NN of_IN parenterally_RB administered_VBN bumetanide_NN in_IN patients_NNS to_TO whom_WP aminoglycoside_RB antibiotics_NNS are_VBP also_RB being_VBG given_VBN should_MD be_VB avoided_VBN ,_, except_IN in_IN life-threatening_JJ conditions_NNS ._. -_: Drugs_NNS with_IN nephrotoxic_JJ potential_NN :_: There_EX has_VBZ been_VBN no_DT experience_NN on_IN the_DT concurrent_JJ use_NN of_IN bumetanide_NN with_IN drugs_NNS known_VBN to_TO have_VB a_DT nephrotoxic_JJ potential_NN ._. Therefore_RB ,_, the_DT simultaneous_JJ administration_NN of_IN these_DT drugs_NNS should_MD be_VB avoided_VBN ._. -_: Lithium_NN :_: Lithium_NN should_MD generally_RB not_RB be_VB given_VBN with_IN diuretics_NNS -LRB-_-LRB- such_JJ as_IN bumetanide_NN -RRB-_-RRB- because_IN they_PRP reduce_VBP its_PRP$ renal_JJ clearance_NN and_CC add_VB a_DT high_JJ risk_NN of_IN lithium_NN toxicity_NN ._. -_: Probenecid_NNP :_: Pretreatment_NN with_IN probenecid_NN reduces_VBZ both_CC the_DT natriuresis_NN and_CC hyperreninemia_NN produced_VBN by_IN bumetanide_NN ._. This_DT antagonistic_JJ effect_NN of_IN probenecid_NN on_IN bumetanide_NN natriuresis_NN is_VBZ not_RB due_JJ to_TO a_DT direct_JJ action_NN on_IN sodium_NN excretion_NN but_CC is_VBZ probably_RB secondary_JJ to_TO its_PRP$ inhibitory_JJ effect_NN on_IN renal_JJ tubular_JJ secretion_NN of_IN bumetanide_NN ._. Thus_RB ,_, probenecid_NN should_MD not_RB be_VB administered_VBN concurrently_RB with_IN bumetanide_NN ._. -_: Indomethacin_NN :_: Indomethacin_NN blunts_VBZ the_DT increases_NNS in_IN urine_NN volume_NN and_CC sodium_NN excretion_NN seen_VBN during_IN bumetanide_NN treatment_NN and_CC inhibits_VBZ the_DT bumetanide-induced_JJ increase_NN in_IN plasma_NN renin_NN activity_NN ._. Concurrent_JJ therapy_NN with_IN bumetanide_NN is_VBZ thus_RB not_RB recommended_VBN ._. -_: Antihypertensives_NNS :_: Bumetanide_NNP may_MD potentiate_VB the_DT effect_NN of_IN various_JJ antihypertensive_JJ drugs_NNS ,_, necessitating_VBG a_DT reduction_NN in_IN the_DT dosage_NN of_IN these_DT drugs_NNS ._. -_: Digoxin_NN :_: Interaction_NN studies_NNS in_IN humans_NNS have_VBP shown_VBN no_DT effect_NN on_IN digoxin_NN blood_NN levels_NNS ._. -_: Anticoagulants_NNPS :_: Interaction_NN studies_NNS in_IN humans_NNS have_VBP shown_VBN bumetanide_NN to_TO have_VB no_DT effect_NN on_IN warfarin_NN metabolism_NN or_CC on_IN plasma_NN prothrombin_NN activity_NN ._. The_DT administration_NN of_IN local_JJ anesthetic_JJ solutions_NNS containing_VBG epinephrine_NN or_CC norepinephrine_NN to_TO patients_NNS receiving_VBG monoamine_NN oxidase_NN inhibitors_NNS or_CC tricyclic_JJ antidepressants_NNS may_MD produce_VB severe_JJ ,_, prolonged_JJ hypertension_NN ._. Concurrent_JJ use_NN of_IN these_DT agents_NNS should_MD generally_RB be_VB avoided_VBN ._. In_IN situations_NNS in_IN which_WDT concurrent_JJ therapy_NN is_VBZ necessary_JJ ,_, careful_JJ patient_NN monitoring_NN is_VBZ essential_JJ ._. Concurrent_JJ administration_NN of_IN vasopressor_NN drugs_NNS and_CC of_IN ergot-type_JJ oxytocic_JJ drugs_NNS may_MD cause_VB severe_JJ ,_, persistent_JJ hypertension_NN or_CC cerebrovascular_JJ accidents_NNS ._. Phenothiazines_NNS and_CC butyrophenones_NNS may_MD reduce_VB or_CC reverse_VB the_DT pressor_NN effect_NN of_IN epinephrine_NN ._. Buprenorphine_NNP is_VBZ metabolized_VBN to_TO norbuprenorphine_NN by_IN cytochrome_NN CYP_NN 3A4_NN ._. Because_IN CYP_NN 3A4_NN inhibitors_NNS may_MD increase_VB plasma_NN concentrations_NNS of_IN buprenorphine_NN ,_, patients_NNS already_RB on_IN CYP_NN 3A4_NN inhibitors_NNS such_JJ as_IN azole_NN antifungals_NNS -LRB-_-LRB- e.g._FW ketoconazole_NN -RRB-_-RRB- ,_, macrolide_NN antibiotics_NNS -LRB-_-LRB- e.g._FW erythromycin_NN -RRB-_-RRB- ,_, and_CC HIV_NN protease_NN inhibitors_NNS -LRB-_-LRB- e.g._FW ritonavir_FW ,_, indinavir_NN and_CC saquinavir_NN -RRB-_-RRB- should_MD have_VB their_PRP$ dose_NN of_IN SUBUTEX_NNP or_CC SUBOXONE_NNP adjusted_VBN ._. Based_VBN on_IN anecdotal_JJ reports_NNS ,_, there_EX may_MD be_VB an_DT interaction_NN between_IN buprenorphine_NN and_CC benzodiazepines_NNS ._. There_EX have_VBP been_VBN a_DT number_NN of_IN reports_NNS in_IN the_DT post-marketing_JJ experience_NN of_IN coma_NN and_CC death_NN associated_VBN with_IN the_DT concomitant_JJ intravenous_JJ misuse_NN of_IN buprenorphine_NN and_CC benzodiazepines_NNS by_IN addicts_NNS ._. In_IN many_JJ of_IN these_DT cases_NNS ,_, buprenorphine_NN was_VBD misused_VBN by_IN self-injection_NN of_IN crushed_JJ SUBUTEX_NNP tablets_NNS ._. SUBUTEX_NNP and_CC SUBOXONE_NNP should_MD be_VB prescribed_VBN with_IN caution_NN to_TO patients_NNS on_IN benzodiazepines_NNS or_CC other_JJ drugs_NNS that_WDT act_VBP on_IN the_DT central_JJ nervous_JJ system_NN ,_, regardless_RB of_IN whether_IN these_DT drugs_NNS are_VBP taken_VBN on_IN the_DT advice_NN of_IN a_DT physician_NN or_CC are_VBP taken_VBN as_IN drugs_NNS of_IN abuse_NN ._. Patients_NNS should_MD be_VB warned_VBN of_IN the_DT potential_JJ danger_NN of_IN the_DT intravenous_JJ self-administration_NN of_IN benzodiazepines_NNS while_IN under_IN treatment_NN with_IN SUBOXONE_NN or_CC SUBUTEX_NN ._. Few_JJ systemic_JJ data_NNS have_VBP been_VBN collected_VBN on_IN the_DT metabolism_NN of_IN WELLBUTRIN_NNP following_VBG concomitant_JJ administration_NN with_IN other_JJ drugs_NNS or_CC ,_, alternatively_RB ,_, the_DT effect_NN of_IN concomitant_JJ administration_NN of_IN WELLBUTRIN_NNP on_IN the_DT metabolism_NN of_IN other_JJ drugs_NNS ._. Because_IN bupropion_NN is_VBZ extensively_RB metabolized_VBN ,_, the_DT coadministration_NN of_IN other_JJ drugs_NNS may_MD affect_VB its_PRP$ clinical_JJ activity_NN ._. In_FW vitro_FW studies_NNS indicate_VBP that_IN bupropion_NN is_VBZ primarily_RB metabolized_VBN to_TO hydroxybupropion_NN by_IN the_DT CYP2B6_NN isoenzyme_NN ._. Therefore_RB ,_, the_DT potential_JJ exists_VBZ for_IN a_DT drug_NN interaction_NN between_IN WELLBUTRIN_NNP and_CC drugs_NNS that_WDT affect_VBP the_DT CYP2B6_NN isoenzyme_NN -LRB-_-LRB- e.g._FW ,_, orphenadrine_NN and_CC cyclophosphamide_NN -RRB-_-RRB- ._. The_DT threohydrobupropion_NN metabolite_NN of_IN bupropion_NN does_VBZ not_RB appear_VB to_TO be_VB produced_VBN by_IN the_DT cytochrome_NN P450_NN isoenzymes_NNS ._. The_DT effects_NNS of_IN concomitant_JJ administration_NN of_IN cimetidine_NN on_IN the_DT pharmacokinetics_NNS of_IN bupropion_NN and_CC its_PRP$ active_JJ metabolites_NNS were_VBD studied_VBN in_IN 24_CD healthy_JJ young_JJ male_JJ volunteers_NNS ._. Following_VBG oral_JJ administration_NN of_IN two_CD 150-mg_JJ sustained-release_JJ tablets_NNS with_IN and_CC without_IN 800_CD mg_NN of_IN cimetidine_NN ,_, the_DT pharmacokinetics_NNS of_IN bupropion_NN and_CC hydroxybupropion_NN were_VBD unaffected_JJ ._. However_RB ,_, there_EX were_VBD 16_CD %_NN and_CC 32_CD %_NN increases_NNS in_IN the_DT AUC_NN and_CC Cmax_NN ,_, respectively_RB ,_, of_IN the_DT combined_JJ moieties_NNS of_IN threohydrobupropion_NN and_CC erythrohydrobupropion_NN ._. While_IN not_RB systematically_RB studied_VBN ,_, certain_JJ drugs_NNS may_MD induce_VB the_DT metabolism_NN of_IN bupropion_NN -LRB-_-LRB- e.g._FW ,_, carbamazepine_NN ,_, phenobarbital_NN ,_, phenytoin_NN -RRB-_-RRB- ._. Animal_NN data_NNS indicated_VBD that_IN bupropion_NN may_MD be_VB an_DT inducer_NN of_IN drug-metabolizing_JJ enzymes_NNS in_IN humans_NNS ._. In_IN one_CD study_NN ,_, following_VBG chronic_JJ administration_NN of_IN bupropion_NN ,_, 100_CD mg_NN 3_CD times_NNS daily_JJ to_TO 8_CD healthy_JJ male_JJ volunteers_NNS for_IN 14_CD days_NNS ,_, there_EX was_VBD no_DT evidence_NN of_IN induction_NN of_IN its_PRP$ own_JJ metabolism_NN ._. Nevertheless_RB ,_, there_EX may_MD be_VB the_DT potential_NN for_IN clinically_RB important_JJ alterations_NNS of_IN blood_NN levels_NNS of_IN coadministered_JJ drugs_NNS ._. Drugs_NNS Metabolized_VBN by_IN Cytochrome_NN P450IID6_NN -LRB-_-LRB- CYP2D6_NN -RRB-_-RRB- :_: Many_JJ drugs_NNS ,_, including_VBG most_RBS antidepressants_NNS -LRB-_-LRB- SSRIs_NNS ,_, many_JJ tricyclics_NNS -RRB-_-RRB- ,_, beta-blockers_NNS ,_, antiarrhythmics_NNS ,_, and_CC antipsychotics_NNS are_VBP metabolized_VBN by_IN the_DT CYP2D6_NN isoenzyme_NN ._. Although_IN bupropion_NN is_VBZ not_RB metabolized_VBN by_IN this_DT isoenzyme_NN ,_, bupropion_NN and_CC hydroxybupropion_NN are_VBP inhibitors_NNS of_IN the_DT CYP2D6_NN isoenzyme_NN in_FW vitro_FW ._. In_IN a_DT study_NN of_IN 15_CD male_JJ subjects_NNS -LRB-_-LRB- ages_NNS 19_CD to_TO 35_CD years_NNS -RRB-_-RRB- who_WP were_VBD extensive_JJ metabolizers_NNS of_IN the_DT CYP2D6_NN isoenzyme_NN ,_, daily_JJ doses_NNS of_IN bupropion_NN given_VBN as_IN 150_CD mg_NN twice_RB daily_JJ followed_VBN by_IN a_DT single_JJ dose_NN of_IN 50_CD mg_NN desipramine_NN increased_VBD the_DT Cmax_NNP ,_, AUC_NN ,_, and_CC t1/2_NN of_IN desipramine_NN by_IN an_DT average_NN of_IN approximately_RB 2_LS -_: ,_, 5_LS -_: and_CC 2-fold_RB ,_, respectively_RB ._. The_DT effect_NN was_VBD present_JJ for_IN at_IN least_JJS 7_CD days_NNS after_IN the_DT last_JJ dose_NN of_IN bupropion_NN ._. Concomitant_JJ use_NN of_IN bupropion_NN with_IN other_JJ drugs_NNS metabolized_VBN by_IN CYP2D6_NN has_VBZ not_RB been_VBN formally_RB studied_VBN ._. Therefore_RB ,_, co-administration_NN of_IN bupropion_NN with_IN drugs_NNS that_WDT are_VBP metabolized_VBN by_IN CYP2D6_NN isoenzyme_NN including_VBG certain_JJ antidepressants_NNS -LRB-_-LRB- e.g._FW ,_, nortriptyline_NN ,_, imipramine_NN ,_, desipramine_NN ,_, paroxetine_NN ,_, fluoxetine_NN ,_, sertraline_NN -RRB-_-RRB- ,_, antipsychotics_NNS -LRB-_-LRB- e.g._FW ,_, haloperidol_NN ,_, risperidone_NN ,_, thioridazine_NN -RRB-_-RRB- ,_, beta-blockers_NNS -LRB-_-LRB- e.g._FW ,_, metoprolol_NN -RRB-_-RRB- ,_, and_CC Type_NN 1C_NN antiarrhythmics_NNS -LRB-_-LRB- e.g._FW ,_, propafenone_NN ,_, flecainide_NN -RRB-_-RRB- ,_, should_MD be_VB approached_VBN with_IN caution_NN and_CC should_MD be_VB initiated_VBN at_IN the_DT lower_JJR end_NN of_IN the_DT dose_NN range_NN of_IN the_DT concomitant_JJ medication_NN ._. If_IN bupropion_NN is_VBZ added_VBN to_TO the_DT treatment_NN regimen_NN of_IN a_DT patient_NN already_RB receiving_VBG a_DT drug_NN metabolized_VBN by_IN CYP2D6_NN ,_, the_DT need_NN to_TO decrease_VB the_DT dose_NN of_IN the_DT original_JJ medication_NN should_MD be_VB considered_VBN ,_, particularly_RB for_IN those_DT concomitant_JJ medications_NNS with_IN a_DT narrow_JJ therapeutic_JJ index_NN ._. MAO_NNP Inhibitors_NNS :_: Studies_NNS in_IN animals_NNS demonstrate_VBP that_IN the_DT acute_JJ toxicity_NN of_IN bupropion_NN is_VBZ enhanced_VBN by_IN the_DT MAO_NNP inhibitor_NN phenelzine_NN ._. Levodopa_NN and_CC Amantadine_NNP :_: Limited_NNP clinical_JJ data_NNS suggest_VBP a_DT higher_JJR incidence_NN of_IN adverse_JJ experiences_NNS in_IN patients_NNS receiving_VBG bupropion_NN concurrently_RB with_IN either_CC levodopa_NN or_CC amantadine_NN ._. Administration_NN of_IN WELLBUTRIN_NNP Tablets_NNPS to_TO patients_NNS receiving_VBG either_CC levodopa_NN or_CC amantadine_NN concurrently_RB should_MD be_VB undertaken_VBN with_IN caution_NN ,_, using_VBG small_JJ initial_JJ doses_NNS and_CC small_JJ gradual_JJ dose_NN increases_NNS ._. Drugs_NNS that_WDT Lower_NNP Seizure_NNP Threshold_NNP :_: Concurrent_JJ administration_NN of_IN WELLBUTRIN_NNP and_CC agents_NNS -LRB-_-LRB- e.g._FW ,_, antipsychotics_NNS ,_, other_JJ antidepressants_NNS ,_, theophylline_NN ,_, systemic_JJ steroids_NNS ,_, etc._FW -RRB-_-RRB- that_WDT lower_JJR seizure_NN threshold_NN should_MD be_VB undertaken_VBN only_RB with_IN extreme_JJ caution_NN ._. Low_JJ initial_JJ dosing_NN and_CC small_JJ gradual_JJ dose_NN increases_NNS should_MD be_VB employed_VBN ._. Nicotine_NN Transdermal_NNP System_NNP :_: ._. Alcohol_NN :_: In_IN post-marketing_JJ experience_NN ,_, there_EX have_VBP been_VBN rare_JJ reports_NNS of_IN adverse_JJ neuropsychiatric_JJ events_NNS or_CC reduced_VBN alcohol_NN tolerance_NN in_IN patients_NNS who_WP were_VBD drinking_VBG alcohol_NN during_IN treatment_NN with_IN WELLBUTRIN_NNP ._. The_DT consumption_NN of_IN alcohol_NN during_IN treatment_NN with_IN WELLBUTRIN_NN should_MD be_VB minimized_VBN or_CC avoided_VBN -LRB-_-LRB- also_RB see_VB a_DT href_NN =_JJ bupropz_NN ._. 
htm_NN #CI_NN CONTRAINDICATIONS_NNS ._. It_PRP is_VBZ recommended_VBN that_IN buspirone_NN hydrochloride_NN not_RB be_VB used_VBN concomitantly_RB with_IN MAO_NN inhibitors_NNS Because_IN the_DT effects_NNS of_IN concomitant_JJ administration_NN of_IN buspirone_NN HCl_NN with_IN most_JJS other_JJ psychotropic_JJ drugs_NNS have_VBP not_RB been_VBN studied_VBN ,_, the_DT concomitant_JJ use_NN of_IN buspirone_NN HCl_NN with_IN other_JJ CNS-active_JJ drugs_NNS should_MD be_VB approached_VBN with_IN caution_NN ._. There_EX is_VBZ one_CD report_NN suggesting_VBG that_IN the_DT concomitant_JJ use_NN of_IN trazodone_NN hydrochloride_NN -LRB-_-LRB- Desyrel_NN -RRB-_-RRB- and_CC buspirone_NN HCl_NN may_MD have_VB caused_VBN 3_LS -_: to_TO 6-fold_RB elevations_NNS on_IN SGPT_NN -LRB-_-LRB- ALT_NN -RRB-_-RRB- in_IN a_DT few_JJ patients_NNS ._. In_IN a_DT similar_JJ study_NN ,_, attempting_VBG to_TO replicate_VB this_DT finding_NN ,_, no_DT interactive_JJ effect_NN on_IN hepatic_JJ transaminases_NNS was_VBD identified_VBN ._. In_IN a_DT study_NN in_IN normal_JJ volunteers_NNS ,_, concomitant_JJ administration_NN of_IN buspirone_NN HCl_NN and_CC haloperidol_NN resulted_VBD in_IN increased_VBN serum_NN haloperidol_NN concentrations_NNS ._. The_DT clinical_JJ significance_NN of_IN this_DT finding_NN is_VBZ not_RB clear_JJ ._. In_FW vitro_FW ,_, buspirone_NN does_VBZ not_RB displace_VB tightly_RB bound_VBN drugs_NNS like_IN phenytoin_NN ,_, propranolol_NN ,_, and_CC warfarin_NN from_IN serum_NN proteins_NNS ._. However_RB ,_, there_EX has_VBZ been_VBN one_CD report_NN of_IN prolonged_JJ prothrombin_NN time_NN when_WRB buspirone_NN was_VBD added_VBN to_TO the_DT regimen_NN of_IN a_DT patient_NN treated_VBN with_IN warfarin_NN ._. The_DT patient_NN was_VBD also_RB chronically_RB receiving_VBG phenytoin_NN ,_, phenobarbital_NN ,_, digoxin_NN ,_, and_CC levothyroxine_NN sodium_NN ._. In_FW vitro_FW ,_, buspirone_NN may_MD displace_VB less_JJR firmly_RB bound_VBN drugs_NNS like_IN digoxin_NN ._. The_DT clinical_JJ significance_NN of_IN this_DT property_NN is_VBZ unknown_JJ ._. Itraconazole_NN decreases_VBZ busulfan_JJ clearance_NN by_IN up_RB to_TO 25_CD %_NN ,_, and_CC may_MD produce_VB AUCs_NNS 1500_CD M_NN min_NN in_IN some_DT patients_NNS ._. Fluconazole_NNP ,_, and_CC the_DT 5-HT3_NN antiemetics_NNS ondansetron_NN -LRB-_-LRB- Zofran_NN -RRB-_-RRB- and_CC granisetron_NN -LRB-_-LRB- Kytril_NN -RRB-_-RRB- have_VBP all_DT been_VBN used_VBN with_IN BUSULFEX_NN ._. Phenytoin_NNP increases_VBZ the_DT clearance_NN of_IN busulfan_NN by_IN 15_CD %_NN or_CC more_JJR ,_, possibly_RB due_JJ to_TO the_DT induction_NN of_IN glutathione-S-transferase_NN ._. Since_IN the_DT pharmacokinetics_NNS of_IN BUSULFEX_NNP were_VBD studied_VBN in_IN patients_NNS treated_VBN with_IN phenytoin_NN ,_, the_DT clearance_NN of_IN BUSULFEX_NNP at_IN the_DT recommended_VBN dose_NN may_MD be_VB lower_JJR and_CC exposure_NN -LRB-_-LRB- AUC_NN -RRB-_-RRB- higher_JJR in_IN patients_NNS not_RB treated_VBN with_IN phenytoin_NN ._. Because_IN busulfan_NN is_VBZ eliminated_VBN from_IN the_DT body_NN via_IN conjugation_NN with_IN glutathione_NN ,_, use_NN of_IN acetaminophen_NN prior_RB to_TO -LRB-_-LRB- 72_CD hours_NNS -RRB-_-RRB- or_CC concurrent_JJ with_IN BUSULFEX_NN may_MD result_VB in_IN reduced_VBN busulfan_JJ clearance_NN based_VBN upon_IN the_DT known_JJ property_NN of_IN acetaminophen_NN to_TO decrease_VB glutathione_NN levels_NNS in_IN the_DT blood_NN and_CC tissues_NNS ._. Interactions_NNS may_MD occur_VB with_IN the_DT following_NN :_: adrenocorticoids_NNS -LRB-_-LRB- cortisone-like_JJ medicine_NN -RRB-_-RRB- ,_, anticoagulants_NNS -LRB-_-LRB- blood_NN thinners_NNS -RRB-_-RRB- ,_, carbamazepine_NN ,_, corticotropin_NN -LRB-_-LRB- barbiturates_NNS may_MD decrease_VB the_DT effects_NNS of_IN these_DT medicines_NNS -RRB-_-RRB- ,_, central_JJ nervous_JJ system_NN -LRB-_-LRB- CNS_NN -RRB-_-RRB- depressants_NNS -LRB-_-LRB- using_VBG these_DT medicines_NNS with_IN barbiturates_NNS may_MD result_VB in_IN increased_VBN CNS_NN depressant_NN effects_NNS -RRB-_-RRB- ,_, divalproex_NN sodium_NN ,_, valproic_JJ acid_NN -LRB-_-LRB- using_VBG these_DT medicines_NNS with_IN barbiturates_NNS may_MD change_VB the_DT amount_NN of_IN either_CC medicine_NN that_IN you_PRP need_VBP to_TO take_VB -RRB-_-RRB- ,_, and_CC oral_JJ contraceptives_NNS containing_VBG estrogens_NNS -LRB-_-LRB- barbiturates_NNS may_MD decrease_VB the_DT effectiveness_NN of_IN these_DT oral_JJ contraceptives_NNS ,_, and_CC you_PRP may_MD need_VB to_TO change_VB to_TO a_DT different_JJ type_NN of_IN birth_NN control_NN -RRB-_-RRB- ._. The_DT CNS_NN effects_NNS of_IN butalbital_NN may_MD be_VB enhanced_VBN by_IN monoamine_NN oxidase_NN -LRB-_-LRB- MAO_NN -RRB-_-RRB- inhibitors_NNS ._. Butalbital_NNP ,_, acetaminophen_NN and_CC caffeine_NN may_MD enhance_VB the_DT effects_NNS of_IN :_: other_JJ narcotic_JJ analgesics_NNS ,_, alcohol_NN ,_, general_JJ anesthetics_NNS ,_, tranquilizers_NNS such_JJ as_IN chlordiazepoxide_NN ,_, sedative-hypnotics_NNS ,_, or_CC other_JJ CNS_NN depressants_NNS ,_, causing_VBG increased_VBN CNS_NN depression_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS Acetaminophen_NN may_MD produce_VB false-positive_JJ test_NN results_VBZ for_IN urinary_JJ 5-hydroxyindoleacetic_JJ acid_NN ._. Potential_JJ drug_NN interactions_NNS between_IN Mentax_NN -LRB-_-LRB- butenafine_NN HCl_NN cream_NN -RRB-_-RRB- Cream_NN ,_, 1_CD %_NN ,_, and_CC other_JJ drugs_NNS have_VBP not_RB been_VBN systematically_RB evaluated_VBN ._. Concurrent_JJ use_NN of_IN butorphanol_NN with_IN central_JJ nervous_JJ system_NN depressants_NNS -LRB-_-LRB- e.g._FW ,_, alcohol_NN ,_, barbiturates_NNS ,_, tranquilizers_NNS ,_, and_CC antihistamines_NNS -RRB-_-RRB- may_MD result_VB in_IN increased_VBN central_JJ nervous_JJ system_NN depressant_NN effects_NNS ._. When_WRB used_VBN concurrently_RB with_IN such_JJ drugs_NNS ,_, the_DT dose_NN of_IN butorphanol_NN should_MD be_VB the_DT smallest_JJS effective_JJ dose_NN and_CC the_DT frequency_NN of_IN dosing_NN reduced_VBD as_RB much_JJ as_IN possible_JJ when_WRB administered_VBN concomitantly_RB with_IN drugs_NNS that_WDT potentiate_VBP the_DT action_NN of_IN opioids_NNS ._. In_IN healthy_JJ volunteers_NNS ,_, the_DT pharmacokinetics_NNS of_IN a_DT 1-mg_JJ dose_NN of_IN butorphanol_NN administered_VBN as_IN STADOL_NN NS_NN were_VBD not_RB affected_VBN by_IN the_DT coadministration_NN of_IN a_DT single_JJ 6-mg_JJ subcutaneous_JJ dose_NN of_IN sumatriptan_NN ._. However_RB ,_, in_IN another_DT study_NN in_IN healthy_JJ volunteers_NNS ,_, the_DT pharmacokinetics_NNS of_IN butorphanol_NN were_VBD significantly_RB altered_JJ -LRB-_-LRB- 29_CD %_NN decrease_NN in_IN AUC_NN and_CC 38_CD %_NN decrease_NN in_IN Cmax_NN -RRB-_-RRB- when_WRB a_DT 1-mg_JJ dose_NN of_IN STADOL_NN NS_NN was_VBD administered_VBN 1_CD minute_NN after_IN a_DT 20-mg_JJ dose_NN of_IN sumatriptan_NN nasal_JJ spray_NN ._. -LRB-_-LRB- The_DT two_CD drugs_NNS were_VBD administered_VBN in_IN opposite_JJ nostrils_NNS ._. -RRB-_-RRB- ._. When_WRB the_DT STADOL_NN NS_NN was_VBD administered_VBN 30_CD minutes_NNS after_IN the_DT sumatriptan_NN nasal_JJ spray_NN ,_, the_DT AUC_NN of_IN butorphanol_NN increased_VBD 11_CD %_NN and_CC Cmax_NN decreased_VBD 18_CD %_NN ._. In_IN neither_DT case_NN were_VBD the_DT pharmacokinetics_NNS of_IN sumatriptan_NN affected_VBN by_IN coadministration_NN with_IN STADOL_NN NS_NN ._. These_DT results_NNS suggest_VBP that_IN the_DT analgesic_JJ effect_NN of_IN STADOL_NN NS_NN may_MD be_VB diminished_VBN when_WRB it_PRP is_VBZ administered_VBN shortly_RB after_IN sumatriptan_NN nasal_JJ spray_NN ,_, but_CC by_IN 30_CD minutes_NNS any_DT such_JJ reduction_NN in_IN effect_NN should_MD be_VB minimal_JJ ._. The_DT safety_NN of_IN using_VBG STADOL_NN NS_NN and_CC IMITREX_NN -LRB-_-LRB- sumatriptan_NN -RRB-_-RRB- Nasal_JJ Spray_NN during_IN the_DT same_JJ episode_NN of_IN migraine_NN has_VBZ not_RB been_VBN established_VBN ._. However_RB ,_, it_PRP should_MD be_VB noted_VBN that_IN both_CC products_NNS are_VBP capable_JJ of_IN producing_VBG transient_JJ increases_NNS in_IN blood_NN pressure_NN ._. The_DT pharmacokinetics_NNS of_IN a_DT 1-mg_JJ dose_NN of_IN butorphanol_NN administered_VBN as_IN STADOL_NN NS_NN were_VBD not_RB affected_VBN by_IN the_DT coadministration_NN of_IN cimetidine_NN -LRB-_-LRB- 300_CD mg_NN QID_NN -RRB-_-RRB- ._. Conversely_RB ,_, the_DT administration_NN of_IN STADOL_NN NS_NN -LRB-_-LRB- 1_CD mg_NN butorphanol_NN QID_NN -RRB-_-RRB- did_VBD not_RB alter_VB the_DT pharmacokinetics_NNS of_IN a_DT 300-mg_JJ dose_NN of_IN cimetidine_NN ._. It_PRP is_VBZ not_RB known_VBN if_IN the_DT effects_NNS of_IN butorphanol_NN are_VBP altered_VBN by_IN concomitant_JJ medications_NNS that_WDT affect_VBP hepatic_JJ metabolism_NN of_IN drugs_NNS -LRB-_-LRB- erythromycin_NN ,_, etc._FW -RRB-_-RRB- ,_, but_CC physicians_NNS should_MD be_VB alert_JJ to_TO the_DT possibility_NN that_IN a_DT smaller_JJR initial_JJ dose_NN and_CC longer_JJR intervals_NNS between_IN doses_NNS may_MD be_VB needed_VBN ._. The_DT fraction_NN of_IN STADOL_NN NS_NN absorbed_VBN is_VBZ unaffected_JJ by_IN the_DT concomitant_JJ administration_NN of_IN a_DT nasal_JJ vasoconstrictor_NN -LRB-_-LRB- oxymetazoline_NN -RRB-_-RRB- ,_, but_CC the_DT rate_NN of_IN absorption_NN is_VBZ decreased_VBN ._. Therefore_RB ,_, a_DT slower_JJR onset_NN can_MD be_VB anticipated_VBN if_IN STADOL_NN NS_NN is_VBZ administered_VBN concomitantly_RB with_IN ,_, or_CC immediately_RB following_VBG ,_, a_DT nasal_JJ vasoconstrictor_NN ._. No_DT information_NN is_VBZ available_JJ about_IN the_DT use_NN of_IN butorphanol_NN concurrently_RB with_IN MAO_NN inhibitors_NNS ._. DOSTINEX_NNP should_MD not_RB be_VB administered_VBN concurrently_RB with_IN D2-antagonists_NNS ,_, such_JJ as_IN phenothiazines_NNS ,_, butyrophenones_NNS ,_, thioxanthines_NNS ,_, or_CC metoclopramide_NN ._. Cytochrome_NN P450_NN 1A2_NN -LRB-_-LRB- CYP1A2_NN -RRB-_-RRB- is_VBZ known_VBN to_TO be_VB the_DT major_JJ enzyme_NN involved_VBN in_IN the_DT metabolism_NN of_IN caffeine_NN ._. Therefore_RB ,_, caffeine_NN has_VBZ the_DT potential_JJ to_TO interact_VB with_IN drugs_NNS that_WDT are_VBP substrates_NNS for_IN CYP1A2_NN ,_, inhibit_VBP CYP1A2_NN ,_, or_CC induce_VB CYP1A2_NN ._. Few_JJ data_NNS exist_VBP on_IN drug_NN interactions_NNS with_IN caffeine_NN in_IN preterm_JJ neonates_NNS ._. Based_VBN on_IN adult_JJ data_NNS ,_, lower_JJR doses_NNS of_IN caffeine_NN may_MD be_VB needed_VBN following_VBG coadministration_NN of_IN drugs_NNS which_WDT are_VBP reported_VBN to_TO decrease_VB caffeine_NN elimination_NN -LRB-_-LRB- e.g._FW ,_, cimetidine_NN and_CC ketoconazole_NN -RRB-_-RRB- and_CC higher_JJR caffeine_NN doses_NNS may_MD be_VB needed_VBN following_VBG coadministration_NN of_IN drugs_NNS that_WDT increase_VBP caffeine_NN elimination_NN -LRB-_-LRB- e.g._FW ,_, phenobarbital_JJ and_CC phenytoin_NN -RRB-_-RRB- ._. Caffeine_NN administered_VBN concurrently_RB with_IN ketoprofen_NN reduced_VBD the_DT urine_NN volume_NN in_IN 4_CD healthy_JJ volunteers_NNS ._. The_DT clinical_JJ significance_NN of_IN this_DT interaction_NN in_IN preterm_JJ neonates_NNS is_VBZ not_RB known_VBN ._. Interconversion_NN between_IN caffeine_NN and_CC theophylline_NN has_VBZ been_VBN reported_VBN in_IN preterm_JJ neonates_NNS ._. The_DT concurrent_JJ use_NN of_IN these_DT drugs_NNS is_VBZ not_RB recommended_VBN ._. Interactions_NNS for_IN vitamin_NN D_NN analogues_NNS -LRB-_-LRB- Vitamin_NN D2_NN ,_, Vitamin_NN D3_NN ,_, Calcitriol_NN ,_, and_CC Calcidiol_NN -RRB-_-RRB- :_: Cholestyramine_NNP :_: Cholestyramine_NNP has_VBZ been_VBN reported_VBN to_TO reduce_VB intestinal_JJ absorption_NN of_IN fat_JJ soluble_JJ vitamins_NNS ._. as_IN such_JJ it_PRP may_MD impair_VB intestinal_JJ absorption_NN of_IN any_DT of_IN vitamin_NN D._NNP Phenytoin/Phenobarbital_NNP :_: The_DT coadministration_NN of_IN phenytoin_NN or_CC phenobarbital_NN will_MD not_RB affect_VB plasma_NN concentrations_NNS of_IN vitamin_NN D_NN ,_, but_CC may_MD reduce_VB endogenous_JJ plasma_NN levels_NNS of_IN calcitriol/ergocalcitriol_NN by_IN accelerating_VBG metabolism_NN ._. Since_IN blood_NN level_NN of_IN calcitriol/ergocalcitriol_NN will_MD be_VB reduced_VBN ,_, higher_JJR doses_NNS of_IN Rocaltrol_NNP may_MD be_VB necessary_JJ if_IN these_DT drugs_NNS are_VBP administered_VBN simultaneously_RB ._. Thiazides_NNP :_: Thiazides_NNS are_VBP known_VBN to_TO induce_VB hypercalcemia_NN by_IN the_DT reduction_NN of_IN calcium_NN excretion_NN in_IN urine_NN ._. Some_DT reports_NNS have_VBP shown_VBN that_IN the_DT concomitant_JJ administration_NN of_IN thiazides_NNS with_IN vitamin_NN D_NN causes_VBZ hypercalcemia_NN ._. Therefore_RB ,_, precaution_NN should_MD be_VB taken_VBN when_WRB coadministration_NN is_VBZ necessary_JJ ._. Digitalis_NNP :_: Vitamin_NN D_NN dosage_NN must_MD be_VB determined_VBN with_IN care_NN in_IN patients_NNS undergoing_VBG treatment_NN with_IN digitalis_NN ,_, as_IN hypercalcemia_NN in_IN such_JJ patients_NNS may_MD precipitate_VB cardiac_JJ arrhythmias_NNS ._. Ketoconazole_NN :_: Ketoconazole_NN may_MD inhibit_VB both_DT synthetic_JJ and_CC catabolic_JJ enzymes_NNS of_IN vitamin_NN D._NNP Reductions_NNPS in_IN serum_NN endogenous_JJ vitamin_NN D_NN concentrations_NNS have_VBP been_VBN observed_VBN following_VBG the_DT administration_NN of_IN 300_CD mg/day_NN to_TO 1200_CD mg/day_NN ketoconazole_NN for_IN a_DT week_NN to_TO healthy_JJ men_NNS ._. However_RB ,_, in_FW vivo_FW drug_NN interaction_NN studies_NNS of_IN ketoconazole_NN with_IN vitamin_NN D_NN have_VBP not_RB been_VBN investigated_VBN ._. Corticosteroids_NNS :_: A_DT relationship_NN of_IN functional_JJ antagonism_NN exists_VBZ between_IN vitamin_NN D_NN analogues_NNS ,_, which_WDT promote_VBP calcium_NN absorption_NN ,_, and_CC corticosteroids_NNS ,_, which_WDT inhibit_VBP calcium_NN absorption_NN ._. Phosphate-Binding_JJ Agents_NNS :_: Since_IN vitamin_NN D_NN also_RB has_VBZ an_DT effect_NN on_IN phosphate_NN transport_NN in_IN the_DT intestine_NN ,_, kidneys_NNS and_CC bones_NNS ,_, the_DT dosage_NN of_IN phosphate-binding_JJ agents_NNS must_MD be_VB adjusted_VBN in_IN accordance_NN with_IN the_DT serum_NN phosphate_NN concentration_NN ._. Vitamin_NN D_NN :_: The_DT coadministration_NN of_IN any_DT of_IN the_DT vitamin_NN D_NN analogues_NNS should_MD be_VB avoided_VBN as_IN this_DT could_MD create_VB possible_JJ additive_JJ effects_NNS and_CC hypercalcemia_NN ._. Calcium_NN Supplements_NNS :_: Uncontrolled_JJ intake_NN of_IN additional_JJ calcium-containing_JJ preparations_NNS should_MD be_VB avoided_VBN ._. Magnesium_NN :_: Magnesium-containing_JJ preparations_NNS -LRB-_-LRB- eg_FW ,_, antacids_NNS -RRB-_-RRB- may_MD cause_VB hypermagnesemia_NN and_CC should_MD therefore_RB not_RB be_VB taken_VBN during_IN therapy_NN with_IN vitamin_NN D_NN by_IN patients_NNS on_IN chronic_JJ renal_JJ dialysis_NN ._. Interactions_NNS for_IN vitamin_NN D_NN analogues_NNS -LRB-_-LRB- Vitamin_NN D2_NN ,_, Vitamin_NN D3_NN ,_, Calcitriol_NN ,_, and_CC Calcidiol_NN -RRB-_-RRB- :_: Cholestyramine_NNP :_: Cholestyramine_NNP has_VBZ been_VBN reported_VBN to_TO reduce_VB intestinal_JJ absorption_NN of_IN fat_JJ soluble_JJ vitamins_NNS ._. as_IN such_JJ it_PRP may_MD impair_VB intestinal_JJ absorption_NN of_IN any_DT of_IN vitamin_NN D._NNP Phenytoin/Phenobarbital_NNP :_: The_DT coadministration_NN of_IN phenytoin_NN or_CC phenobarbital_NN will_MD not_RB affect_VB plasma_NN concentrations_NNS of_IN vitamin_NN D_NN ,_, but_CC may_MD reduce_VB endogenous_JJ plasma_NN levels_NNS of_IN calcitriol/ergocalcitriol_NN by_IN accelerating_VBG metabolism_NN ._. Since_IN blood_NN level_NN of_IN calcitriol/ergocalcitriol_NN will_MD be_VB reduced_VBN ,_, higher_JJR doses_NNS of_IN Rocaltrol_NNP may_MD be_VB necessary_JJ if_IN these_DT drugs_NNS are_VBP administered_VBN simultaneously_RB ._. Thiazides_NNP :_: Thiazides_NNS are_VBP known_VBN to_TO induce_VB hypercalcemia_NN by_IN the_DT reduction_NN of_IN calcium_NN excretion_NN in_IN urine_NN ._. Some_DT reports_NNS have_VBP shown_VBN that_IN the_DT concomitant_JJ administration_NN of_IN thiazides_NNS with_IN vitamin_NN D_NN causes_VBZ hypercalcemia_NN ._. Therefore_RB ,_, precaution_NN should_MD be_VB taken_VBN when_WRB coadministration_NN is_VBZ necessary_JJ ._. Digitalis_NNP :_: Vitamin_NN D_NN dosage_NN must_MD be_VB determined_VBN with_IN care_NN in_IN patients_NNS undergoing_VBG treatment_NN with_IN digitalis_NN ,_, as_IN hypercalcemia_NN in_IN such_JJ patients_NNS may_MD precipitate_VB cardiac_JJ arrhythmias_NNS ._. Ketoconazole_NN :_: Ketoconazole_NN may_MD inhibit_VB both_DT synthetic_JJ and_CC catabolic_JJ enzymes_NNS of_IN vitamin_NN D._NNP Reductions_NNPS in_IN serum_NN endogenous_JJ vitamin_NN D_NN concentrations_NNS have_VBP been_VBN observed_VBN following_VBG the_DT administration_NN of_IN 300_CD mg/day_NN to_TO 1200_CD mg/day_NN ketoconazole_NN for_IN a_DT week_NN to_TO healthy_JJ men_NNS ._. However_RB ,_, in_FW vivo_FW drug_NN interaction_NN studies_NNS of_IN ketoconazole_NN with_IN vitamin_NN D_NN have_VBP not_RB been_VBN investigated_VBN ._. Corticosteroids_NNS :_: A_DT relationship_NN of_IN functional_JJ antagonism_NN exists_VBZ between_IN vitamin_NN D_NN analogues_NNS ,_, which_WDT promote_VBP calcium_NN absorption_NN ,_, and_CC corticosteroids_NNS ,_, which_WDT inhibit_VBP calcium_NN absorption_NN ._. Phosphate-Binding_JJ Agents_NNS :_: Since_IN vitamin_NN D_NN also_RB has_VBZ an_DT effect_NN on_IN phosphate_NN transport_NN in_IN the_DT intestine_NN ,_, kidneys_NNS and_CC bones_NNS ,_, the_DT dosage_NN of_IN phosphate-binding_JJ agents_NNS must_MD be_VB adjusted_VBN in_IN accordance_NN with_IN the_DT serum_NN phosphate_NN concentration_NN ._. Vitamin_NN D_NN :_: The_DT coadministration_NN of_IN any_DT of_IN the_DT vitamin_NN D_NN analogues_NNS should_MD be_VB avoided_VBN as_IN this_DT could_MD create_VB possible_JJ additive_JJ effects_NNS and_CC hypercalcemia_NN ._. Calcium_NN Supplements_NNS :_: Uncontrolled_JJ intake_NN of_IN additional_JJ calcium-containing_JJ preparations_NNS should_MD be_VB avoided_VBN ._. Magnesium_NN :_: Magnesium-containing_JJ preparations_NNS -LRB-_-LRB- eg_FW ,_, antacids_NNS -RRB-_-RRB- may_MD cause_VB hypermagnesemia_NN and_CC should_MD therefore_RB not_RB be_VB taken_VBN during_IN therapy_NN with_IN vitamin_NN D_NN by_IN patients_NNS on_IN chronic_JJ renal_JJ dialysis_NN ._. Concomitant_JJ use_NN with_IN other_JJ calcium-containing_JJ medicines_NNS -LRB-_-LRB- including_VBG antacids_NNS -RRB-_-RRB- may_MD cause_VB too_RB much_JJ calcium_NN in_IN the_DT blood_NN or_CC urine_NN ,_, which_WDT may_MD increase_VB the_DT chance_NN of_IN side_JJ effects_NNS ._. Using_VBG calcium_NN acetate_NN with_IN digitalis_NN glycosides_NNS -LRB-_-LRB- heart_NN medicine_NN -RRB-_-RRB- may_MD cause_VB hypercalcemia_NN -LRB-_-LRB- too_RB much_JJ calcium_NN in_IN the_DT blood_NN -RRB-_-RRB- ,_, which_WDT could_MD increase_VB the_DT chance_NN of_IN developing_VBG an_DT irregular_JJ heartbeat_NN ._. May_NNP interact_VBP with_IN cefamandole_NN naftate_NN ,_, cephalothin_NN sodium_NN ,_, magnesium_NN sulfate_NN ,_, prednisolone_JJ sodium_NN succinate_NN ,_, and_CC prochlorperazine_NN edisylate_NN ._. No_DT significant_JJ drug_NN interactions_NNS have_VBP been_VBN reported_VBN in_IN studies_NNS of_IN candesartan_NN cilexetil_NN given_VBN with_IN other_JJ drugs_NNS such_JJ as_IN glyburide_NN ,_, nifedipine_NN ,_, digoxin_NN ,_, warfarin_NN ,_, hydrochlorothiazide_NN ,_, and_CC oral_JJ contraceptives_NNS in_IN healthy_JJ volunteers_NNS ,_, or_CC given_VBN with_IN enalapril_NN to_TO patients_NNS with_IN heart_NN failure_NN -LRB-_-LRB- NYHA_NN class_NN II_CD and_CC III_CD -RRB-_-RRB- ._. Because_IN candesartan_NN is_VBZ not_RB significantly_RB metabolized_VBN by_IN the_DT cytochrome_NN P450_NN system_NN and_CC at_IN therapeutic_JJ concentrations_NNS has_VBZ no_DT effects_NNS on_IN P450_NN enzymes_NNS ,_, interactions_NNS with_IN drugs_NNS that_WDT inhibit_VBP or_CC are_VBP metabolized_VBN by_IN those_DT enzymes_NNS would_MD not_RB be_VB expected_VBN ._. Lithium_NN Reversible_JJ increases_NNS in_IN serum_NN lithium_NN concentrations_NNS and_CC toxicity_NN have_VBP been_VBN reported_VBN during_IN concomitant_JJ administration_NN of_IN lithium_NN with_IN ACE_NN inhibitors_NNS ,_, and_CC with_IN some_DT angiotensin_NN II_CD receptor_NN antagonists_NNS ._. An_DT increase_NN in_IN serum_NN lithium_NN concentration_NN has_VBZ been_VBN reported_VBN during_IN concomitant_JJ administration_NN of_IN lithium_NN with_IN ATACAND_NN ,_, so_RB careful_JJ monitoring_NN of_IN serum_NN lithium_NN levels_NNS is_VBZ recommended_VBN during_IN concomitant_JJ use_NN ._. Antacid_NN :_: The_DT effect_NN of_IN an_DT aluminum_NN hydroxide_NN -_: and_CC magnesium_NN hydroxide-containing_JJ antacid_NN -LRB-_-LRB- Maalox_NNP -RRB-_-RRB- *_SYM on_IN the_DT pharmacokinetics_NNS of_IN capecitabine_NN was_VBD investigated_VBN in_IN 12_CD cancer_NN patients_NNS ._. There_EX was_VBD a_DT small_JJ increase_NN in_IN plasma_NN concentrations_NNS of_IN capecitabine_NN and_CC one_CD metabolite_NN -LRB-_-LRB- 5-DFCR_NN -RRB-_-RRB- ._. there_EX was_VBD no_DT effect_NN on_IN the_DT 3_CD major_JJ metabolites_NNS -LRB-_-LRB- 5-DFUR_NN ,_, 5-FU_NN and_CC FBAL_NN -RRB-_-RRB- ._. Coumarin_NNP Anticoagulants_NNPS Altered_JJ coagulation_NN parameters_NNS and/or_CC bleeding_VBG have_VBP been_VBN reported_VBN in_IN patients_NNS taking_VBG capecitabine_NN concomitantly_RB with_IN coumarin-derivative_JJ anticoagulants_NNS such_JJ as_IN warfarin_NN and_CC phenprocoumon_NN ._. Patients_NNS taking_VBG coumarin-derivative_JJ anticoagulants_NNS concomitantly_RB with_IN capecitabine_NN should_MD be_VB monitored_VBN regularly_RB for_IN alterations_NNS in_IN their_PRP$ coagulation_NN parameters_NNS -LRB-_-LRB- PT_NN or_CC INR_NN -RRB-_-RRB- ._. Leucovorin_NNP :_: The_DT concentration_NN of_IN 5-fluorouracil_NN is_VBZ increased_VBN and_CC its_PRP$ toxicity_NN may_MD be_VB enhanced_VBN by_IN leucovorin_NN ._. Deaths_NNS from_IN severe_JJ enterocolitis_NN ,_, diarrhea_NN ,_, and_CC dehydration_NN have_VBP been_VBN reported_VBN in_IN elderly_JJ patients_NNS receiving_VBG weekly_JJ leucovorin_NN and_CC fluorouracil_NN ._. Hypotension_NN Patients_NNS on_IN Diuretic_JJ Therapy_NN :_: Patients_NNS on_IN diuretics_NNS and_CC especially_RB those_DT in_IN whom_WP diuretic_JJ therapy_NN was_VBD recently_RB instituted_VBN ,_, as_RB well_RB as_IN those_DT on_IN severe_JJ dietary_JJ salt_NN restriction_NN or_CC dialysis_NN ,_, may_MD occasionally_RB experience_VB a_DT precipitous_JJ reduction_NN of_IN blood_NN pressure_NN usually_RB within_IN the_DT first_JJ hour_NN after_IN receiving_VBG the_DT initial_JJ dose_NN of_IN captopril_NN ._. The_DT possibility_NN of_IN hypotensive_JJ effects_NNS with_IN captopril_NN can_MD be_VB minimized_VBN by_IN either_CC discontinuing_VBG the_DT diuretic_JJ or_CC increasing_VBG the_DT salt_NN intake_NN approximately_RB one_CD week_NN prior_RB to_TO initiation_NN of_IN treatment_NN with_IN captopril_NN -LRB-_-LRB- captopril_NN tablets_NNS ,_, USP_NN -RRB-_-RRB- or_CC initiating_VBG therapy_NN with_IN small_JJ doses_NNS -LRB-_-LRB- 6.25_CD or_CC 12.5_CD mg_NN -RRB-_-RRB- ._. Alternatively_RB ,_, provide_VBP medical_JJ supervision_NN for_IN at_IN least_JJS one_CD hour_NN after_IN the_DT initial_JJ dose_NN ._. If_IN hypotension_NN occurs_VBZ ,_, the_DT patient_NN should_MD be_VB placed_VBN in_IN a_DT supine_NN position_NN and_CC ,_, if_IN necessary_JJ ,_, receive_VBP an_DT intravenous_JJ infusion_NN of_IN normal_JJ saline_NN ._. This_DT transient_JJ hypotensive_JJ response_NN is_VBZ not_RB a_DT contraindication_NN to_TO further_JJ doses_NNS which_WDT can_MD be_VB given_VBN without_IN difficulty_NN once_IN the_DT blood_NN pressure_NN has_VBZ increased_VBN after_IN volume_NN expansion_NN ._. Agents_NNS Having_VBG Vasodilator_NN Activity_NN :_: Data_NNS on_IN the_DT effect_NN of_IN concomitant_JJ use_NN of_IN other_JJ vasodilators_NNS in_IN patients_NNS receiving_VBG captopril_NN for_IN heart_NN failure_NN are_VBP not_RB available_JJ ._. therefore_RB ,_, nitroglycerin_NN or_CC other_JJ nitrates_NNS -LRB-_-LRB- as_IN used_VBN for_IN management_NN of_IN angina_NN -RRB-_-RRB- or_CC other_JJ drugs_NNS having_VBG vasodilator_NN activity_NN should_MD ,_, if_IN possible_JJ ,_, be_VB discontinued_VBN before_IN starting_VBG captopril_NN ._. If_IN resumed_VBN during_IN captopril_NN therapy_NN ,_, such_JJ agents_NNS should_MD be_VB administered_VBN cautiously_RB ,_, and_CC perhaps_RB at_IN lower_JJR dosage_NN ._. Agents_NNS Causing_VBG Renin_NNP Release_NNP Captopril_NNP 's_POS effect_NN will_MD be_VB augmented_VBN by_IN antihypertensive_JJ agents_NNS that_WDT cause_VBP renin_NN release_NN ._. For_IN example_NN ,_, diuretics_NNS -LRB-_-LRB- e.g._FW ,_, thiazides_NNS -RRB-_-RRB- may_MD activate_VB the_DT renin-angiotensin-aldosterone_NN system_NN ._. Agents_NNS Affecting_VBG Sympathetic_JJ Activity_NN The_DT sympathetic_JJ nervous_JJ system_NN may_MD be_VB especially_RB important_JJ in_IN supporting_VBG blood_NN pressure_NN in_IN patients_NNS receiving_VBG captopril_NN alone_RB or_CC with_IN diuretics_NNS ._. Therefore_RB ,_, agents_NNS affecting_VBG sympathetic_JJ activity_NN -LRB-_-LRB- e.g._FW ,_, ganglionic_JJ blocking_VBG agents_NNS or_CC adrenergic_JJ neuron_NN blocking_VBG agents_NNS -RRB-_-RRB- should_MD be_VB used_VBN with_IN caution_NN ._. Beta-adrenergic_JJ blocking_NN drugs_NNS add_VBP some_DT further_JJ antihypertensive_JJ effect_NN to_TO captopril_NN ,_, but_CC the_DT overall_JJ response_NN is_VBZ less_JJR than_IN additive_JJ ._. Agents_NNS Increasing_VBG Serum_NN Potassium_NN Since_IN captopril_NN decreases_VBZ aldosterone_NN production_NN ,_, elevation_NN of_IN serum_NN potassium_NN may_MD occur_VB ._. Potassium-sparing_JJ diuretics_NNS such_JJ as_IN spironolactone_NN ,_, triamterene_NN ,_, or_CC amiloride_NN ,_, or_CC potassium_NN supplements_NNS should_MD be_VB given_VBN only_RB for_IN documented_VBN hypokalemia_NN ,_, and_CC then_RB with_IN caution_NN ,_, since_IN they_PRP may_MD lead_VB to_TO a_DT significant_JJ increase_NN of_IN serum_NN potassium_NN ._. Salt_NNP substitutes_VBZ containing_VBG potassium_NN should_MD also_RB be_VB used_VBN with_IN caution_NN ._. Inhibitors_NNS Of_IN Endogenous_JJ Prostaglandin_NN Synthesis_NN It_PRP has_VBZ been_VBN reported_VBN that_IN indomethacin_NN may_MD reduce_VB the_DT antihypertensive_JJ effect_NN of_IN captopril_NN ,_, especially_RB in_IN cases_NNS of_IN low_JJ renin_NN hypertension_NN ._. Other_JJ nonsteroidal_JJ anti-inflammatory_JJ agents_NNS -LRB-_-LRB- e.g._FW ,_, aspirin_NN -RRB-_-RRB- may_MD also_RB have_VB this_DT effect_NN ._. Lithium_NN :_: Increased_VBN serum_NN lithium_NN levels_NNS and_CC symptoms_NNS of_IN lithium_NN toxicity_NN have_VBP been_VBN reported_VBN in_IN patients_NNS receiving_VBG concomitant_JJ lithium_NN and_CC ACE_NN inhibitor_NN therapy_NN ._. These_DT drugs_NNS should_MD be_VB coad-ministered_JJ with_IN caution_NN and_CC frequent_JJ monitoring_NN of_IN serum_NN lithium_NN levels_NNS is_VBZ recommended_VBN ._. If_IN a_DT diuretic_JJ is_VBZ also_RB used_VBN ,_, it_PRP may_MD increase_VB the_DT risk_NN of_IN lithium_NN toxicity_NN ._. Cardiac_JJ Glycosides_NNS :_: In_IN a_DT study_NN of_IN young_JJ healthy_JJ male_JJ subjects_NNS no_DT evidence_NN of_IN a_DT direct_JJ pharmacokinetic_JJ captopril-digoxin_NN interaction_NN could_MD be_VB found_VBN ._. Loop_NNP Diuretics_NNPS :_: Furosemide_NN administered_VBN concurrently_RB with_IN captopril_NN does_VBZ not_RB alter_VB the_DT pharmacokinetics_NNS of_IN captopril_NN in_IN renally_RB impaired_JJ hypertensive_JJ patients_NNS ._. Allopurinol_NNP :_: In_IN a_DT study_NN of_IN healthy_JJ male_JJ volunteers_NNS no_DT significant_JJ pharmacokinetic_JJ interaction_NN occurred_VBD when_WRB captopril_NN and_CC allopurinol_NN were_VBD administered_VBN concomitantly_RB for_IN 6_CD days_NNS ._. Drug/Laboratory_JJ Test_NN Interaction_NN Captopril_NN may_MD cause_VB a_DT false-positive_JJ urine_NN test_NN for_IN acetone_NN ._. Clinically_RB meaningful_JJ drug_NN interactions_NNS have_VBP occurred_VBN with_IN concomitant_JJ medications_NNS and_CC include_VBP ,_, but_CC are_VBP not_RB limited_VBN to_TO the_DT following_NN :_: Agents_NNS Highly_RB Bound_VBN to_TO Plasma_NN Protein_NN Carbamazepine_NN is_VBZ not_RB highly_RB bound_VBN to_TO plasma_NN proteins_NNS ._. therefore_RB ,_, administration_NN of_IN EQUETROTM_NNP to_TO a_DT patient_NN taking_VBG another_DT drug_NN that_WDT is_VBZ highly_RB protein_NN bound_VBD should_MD not_RB cause_VB increased_VBN free_JJ concentrations_NNS of_IN the_DT other_JJ drug_NN ._. Agents_NNS that_WDT Inhibit_VBP Cytochrome_NN P450_NN Isoenzymes_NNS and/or_CC Epoxide_NNP Hydrolase_NNP Carbamazepine_NNP is_VBZ metabolized_VBN mainly_RB by_IN cytochrome_NN P450_NN -LRB-_-LRB- CYP_NN -RRB-_-RRB- 3A4_NN to_TO the_DT active_JJ carbamazepine_NN 10,11-epoxide_NN ,_, which_WDT is_VBZ further_JJ metabolized_VBN to_TO the_DT trans-diol_NN by_IN epoxide_NN hydrolase_NN ._. Therefore_RB ,_, the_DT potential_JJ exists_VBZ for_IN interaction_NN between_IN carbamazepine_NN and_CC any_DT agent_NN that_WDT inhibits_VBZ CYP3A4_NN and/or_CC epoxide_NN hydrolase_NN ._. Agents_NNS that_WDT are_VBP CYP3A4_NN inhibitors_NNS that_WDT have_VBP been_VBN found_VBN ,_, or_CC are_VBP expected_VBN ,_, to_TO increase_VB plasma_NN levels_NNS of_IN EQUETROTM_NNP are_VBP the_DT following_NN :_: Acetazolamide_NNP ,_, azole_NN antifungals_NNS ,_, cimetidine_NN ,_, clarithromycin_NN -LRB-_-LRB- 1_CD -RRB-_-RRB- ,_, dalfopristin_NN ,_, danazol_NN ,_, delavirdine_NN ,_, diltiazem_NN ,_, erythromycin_NN -LRB-_-LRB- 1_CD -RRB-_-RRB- ,_, fluoxetine_NN ,_, fluvoxamine_NN ,_, grapefruit_NN juice_NN ,_, isoniazid_NN ,_, itraconazole_NN ,_, ketoconazole_NN ,_, loratadine_NN ,_, nefazodone_NN ,_, niacinamide_NN ,_, nicotinamide_NN ,_, protease_NN inhibitors_NNS ,_, propoxyphene_NN ,_, quinine_NN ,_, quinupristin_NN ,_, troleandomycin_NN ,_, valproate_NN -LRB-_-LRB- 1_CD -RRB-_-RRB- ,_, verapamil_NN ,_, zileuton_NN ._. Thus_RB ,_, if_IN a_DT patient_NN has_VBZ been_VBN titrated_VBN to_TO a_DT stable_JJ dosage_NN of_IN EQUETROTM_NNP ,_, and_CC then_RB begins_VBZ a_DT course_NN of_IN treatment_NN with_IN one_CD of_IN these_DT CYP3A4_NN or_CC epoxide_NN hydrolase_NN inhibitors_NNS ,_, it_PRP is_VBZ reasonable_JJ to_TO expect_VB that_IN a_DT dose_NN reduction_NN for_IN EQUETROTM_NNP may_MD be_VB necessary_JJ ._. Agents_NNS that_WDT Induce_VBP Cytochrome_NN P450_NN Isoenzymes_NNS Carbamazepine_NN is_VBZ metabolized_VBN by_IN CYP3A4_NN ._. Therefore_RB ,_, the_DT potential_JJ exists_VBZ for_IN interaction_NN between_IN carbamazepine_NN and_CC any_DT agent_NN that_WDT induces_VBZ CYP3A4_NN ._. Agents_NNS that_WDT are_VBP CYP_NNP inducers_NNS that_WDT have_VBP been_VBN found_VBN ,_, or_CC are_VBP expected_VBN ,_, to_TO decrease_VB plasma_NN levels_NNS of_IN EQUETROTM_NNP are_VBP the_DT following_NN :_: Cisplatin_NNP ,_, doxorubicin_NN HCL_NNP ,_, felbamate_NN ,_, rifampin_NN ,_, phenobarbital_NN ,_, Phenytoin_NN -LRB-_-LRB- 2_CD -RRB-_-RRB- ,_, primidone_NN ,_, methsuximide_NN ,_, and_CC theophylline_NN Thus_RB ,_, if_IN a_DT patient_NN has_VBZ been_VBN titrated_VBN to_TO a_DT stable_JJ dosage_NN on_IN EQUETROTM_NNP ,_, and_CC then_RB begins_VBZ a_DT course_NN of_IN treatment_NN with_IN one_CD of_IN these_DT CYP3A4_NN inducers_NNS ,_, it_PRP is_VBZ reasonable_JJ to_TO expect_VB that_IN a_DT dose_NN increase_NN for_IN EQUETROTM_NNP may_MD be_VB necessary_JJ ._. Agents_NNS with_IN Decreased_VBN Levels_NNS in_IN the_DT Presence_NN of_IN Carbamazepine_NNP due_JJ to_TO Induction_NN of_IN Cytochrome_NN P450_NN Enzymes_NNS Carbamazepine_NN is_VBZ known_VBN to_TO induce_VB CYP1A2_NN and_CC CYP3A4_NN ._. Therefore_RB ,_, the_DT potential_JJ exists_VBZ for_IN interaction_NN between_IN carbamazepine_NN and_CC any_DT agent_NN metabolized_VBN by_IN one_CD -LRB-_-LRB- or_CC more_JJR -RRB-_-RRB- of_IN these_DT enzymes_NNS ._. Agents_NNS that_WDT have_VBP been_VBN found_VBN ,_, or_CC are_VBP expected_VBN to_TO have_VB decreased_VBN plasma_NN levels_NNS in_IN the_DT presence_NN of_IN EQUETROTM_NNP due_JJ to_TO induction_NN of_IN CYP_NN enzymes_NNS are_VBP the_DT following_NN :_: Acetaminophen_NNP ,_, alprazolam_NN ,_, amitriptyline_NNP ,_, bupropion_NN ,_, buspirone_NN ,_, citalopram_NN ,_, clobazam_NN ,_, clonazepam_NN ,_, clozapine_NN ,_, cyclosporin_NN ,_, delavirdine_NN ,_, desipramine_NN ,_, diazepam_NN ,_, dicumarol_NN ,_, doxycycline_NN ,_, ethosuximide_NN ,_, felbamate_NN ,_, felodipine_NN ,_, glucocorticoids_NNS ,_, haloperidol_NN ,_, itraconazole_NN ,_, lamotrigine_NN ,_, levothyroxine_NN ,_, lorazepam_NN ,_, methadone_NN ,_, midazolam_NN ,_, mirtazapine_NN ,_, nortriptyline_NN ,_, olanzapine_NN ,_, oral_JJ contraceptives_NNS -LRB-_-LRB- 3_CD -RRB-_-RRB- ,_, oxcarbazepine_NN ,_, Phenytoin_NN -LRB-_-LRB- 4_CD -RRB-_-RRB- ,_, praziquantel_NN ,_, protease_NN inhibitors_NNS ,_, quetiapine_NN ,_, risperidone_NN ,_, theophylline_NN ,_, topiramate_NN ,_, tiagabine_NN ,_, tramadol_NN ,_, triazolam_NN ,_, valproate_NN ,_, warfarin_NN -LRB-_-LRB- 5_CD -RRB-_-RRB- ,_, ziprasidone_NN ,_, and_CC zonisamide_NN ._. Thus_RB ,_, if_IN a_DT patient_NN has_VBZ been_VBN titrated_VBN to_TO a_DT stable_JJ dosage_NN on_IN one_CD of_IN the_DT agents_NNS in_IN this_DT category_NN ,_, and_CC then_RB begins_VBZ a_DT course_NN of_IN treatment_NN with_IN EQUETROTM_NN ,_, it_PRP is_VBZ reasonable_JJ to_TO expect_VB that_IN a_DT dose_NN increase_NN for_IN the_DT concomitant_JJ agent_NN may_MD be_VB necessary_JJ ._. Agents_NNS with_IN Increased_VBN Levels_NNS in_IN the_DT Presence_NN of_IN Carbamazepine_NNP :_: EQUETROTM_NNP increases_VBZ the_DT plasma_NN levels_NNS of_IN the_DT following_VBG agents_NNS :_: Clomipramine_NNP HCl_NN ,_, Phenytoin_NNP -LRB-_-LRB- 6_CD -RRB-_-RRB- ,_, and_CC primidone_NN Thus_RB ,_, if_IN a_DT patient_NN has_VBZ been_VBN titrated_VBN to_TO a_DT stable_JJ dosage_NN on_IN one_CD of_IN the_DT agents_NNS in_IN this_DT category_NN ,_, and_CC then_RB begins_VBZ a_DT course_NN of_IN the_DT treatment_NN with_IN EQUETROTM_NN ,_, it_PRP is_VBZ reasonable_JJ to_TO expect_VB that_IN a_DT dose_NN decrease_NN for_IN the_DT concomitant_JJ agent_NN may_MD be_VB necessary_JJ ._. Pharmacological/Pharmacodynamic_JJ Interactions_NNS with_IN Carbamazepine_NNP Concomitant_JJ administration_NN of_IN carbamazepine_NN and_CC lithium_NN may_MD increase_VB the_DT risk_NN of_IN neurotoxic_JJ side_JJ effects_NNS ._. Given_VBN the_DT anticonvulsant_JJ properties_NNS of_IN carbamazepine_NN ,_, EQUETROTM_NN may_MD reduce_VB the_DT thyroid_NN function_NN as_IN has_VBZ been_VBN reported_VBN with_IN other_JJ anticonvulsants_NNS ._. Additionally_RB ,_, anti-malarial_JJ drugs_NNS ,_, such_JJ as_IN chloroquine_NN and_CC mefloquine_NN ,_, may_MD antagonize_VB the_DT activity_NN of_IN carbamazepine_NN ._. Thus_RB if_IN a_DT patient_NN has_VBZ been_VBN titrated_VBN to_TO a_DT stable_JJ dosage_NN on_IN one_CD of_IN the_DT agents_NNS in_IN this_DT category_NN ,_, and_CC then_RB begins_VBZ a_DT course_NN of_IN treatment_NN with_IN EQUETROTM_NN ,_, it_PRP is_VBZ reasonable_JJ to_TO expect_VB that_IN a_DT dose_NN adjustment_NN may_MD be_VB necessary_JJ ._. Because_IN of_IN its_PRP$ primary_JJ CNS_NN effect_NN ,_, caution_NN should_MD be_VB used_VBN when_WRB EQUETROTM_NNP is_VBZ taken_VBN with_IN other_JJ centrally_RB acting_VBG drugs_NNS and_CC alcohol_NN ._. Geocillin_NN -LRB-_-LRB- carbenicillin_NN indanyl_NN sodium_NN -RRB-_-RRB- blood_NN levels_NNS may_MD be_VB increased_VBN and_CC prolonged_VBN by_IN concurrent_JJ administration_NN of_IN probenecid_NN ._. Caution_NN should_MD be_VB exercised_VBN when_WRB the_DT following_VBG drugs_NNS are_VBP administered_VBN concomitantly_RB with_IN LODOSYN_NN -LRB-_-LRB- Carbidopa_NN -RRB-_-RRB- given_VBN with_IN levodopa_NN or_CC carbidopa-levodopa_NN combination_NN products_NNS ._. For_IN patients_NNS receiving_VBG monoamine_NN oxidase_NN inhibitors_NNS ,_, see_VBP CONTRAINDICATIONS_NNS ._. Dopamine_NN D2_NN receptor_NN antagonists_NNS -LRB-_-LRB- e.g._FW ,_, phenothiazines_NNS ,_, butyrophenones_NNS ,_, risperidone_NN -RRB-_-RRB- and_CC isoniazid_NN may_MD reduce_VB the_DT therapeutic_JJ effects_NNS of_IN levodopa_NN ._. In_IN addition_NN ,_, the_DT beneficial_JJ effects_NNS of_IN levodopa_NN in_IN Parkinsons_NNPS disease_NN have_VBP been_VBN reported_VBN to_TO be_VB reversed_VBN by_IN phenytoin_NN and_CC papaverine_NN ._. Patients_NNS taking_VBG these_DT drugs_NNS with_IN LODOSYN_NN and_CC levodopa_NN or_CC carbidopa-levodopa_NN combination_NN products_NNS should_MD be_VB carefully_RB observed_VBN for_IN loss_NN of_IN therapeutic_JJ response_NN ._. Iron_NNP salts_NNS may_MD reduce_VB the_DT bioavailability_NN of_IN carbidopa_NN and_CC levodopa_NN ._. The_DT clinical_JJ relevance_NN is_VBZ unclear_JJ ._. Although_IN metoclopramide_NN may_MD increase_VB the_DT bioavailability_NN of_IN levodopa_NN by_IN increasing_VBG gastric_JJ emptying_NN ,_, metoclopramide_NN may_MD also_RB adversely_RB affect_VB disease_NN control_NN by_IN its_PRP$ dopamine_NN receptor_NN antagonistic_JJ properties_NNS ._. Iodine_NN or_CC iodine_NN excess_NN may_MD decrease_VB the_DT effect_NN of_IN Carbimazole_NNP ,_, and_CC an_DT iodine_NN deficiency_NN can_MD increase_VB the_DT effect_NN of_IN Carbimazole_NN ._. Serum_NN concentration_NN of_IN digoxin_NN and_CC digitoxin_NN may_MD increase_VB when_WRB patients_NNS take_VBP antithyroid_JJ agents_NNS ._. A_DT decrease_NN of_IN the_DT dosage_NN may_MD be_VB necessary_JJ when_WRB patient_NN becomes_VBZ euthyroid_JJ ._. Antithyroid_JJ agents_NNS may_MD decrease_VB thyroidal_JJ uptake_NN of_IN sodium_NN iodide_NN I131_NN ,_, a_DT rebound_NN in_IN uptake_NN may_MD occur_VB up_RP to_TO 5_CD days_NNS after_IN sudden_JJ withdrawal_NN of_IN Carbimazole_NN ._. Patients_NNS response_NN to_TO oral_JJ anticoagulants_NNS may_MD be_VB affected_VBN by_IN his/her_NN thyroid_NN and_CC metabolic_JJ status_NN ._. An_DT evaluation_NN of_IN prothrombin_NN time_NN and_CC an_DT adjustment_NN of_IN anticoagulant_JJ dosage_NN are_VBP recommende_NN ._. Antihistamines_NNS may_MD enhance_VB the_DT effects_NNS of_IN tricyclic_JJ antidepressants_NNS ,_, barbiturates_NNS ,_, alcohol_NN ,_, and_CC other_JJ CNS_NN depressants_NNS ._. MAO_NN inhibitors_NNS prolong_VB and_CC intensify_VB the_DT anticholinergic_JJ effects_NNS of_IN antihistamines_NNS ._. Sympathomimetic_JJ amines_NNS may_MD reduce_VB the_DT antihypertensive_JJ effects_NNS of_IN reserpine_NN ,_, veratrum_NN alkaloids_NNS ,_, methyldopa_NN and_CC mecamylamine_NN ._. Effects_NNS of_IN sympathomimetics_NNS are_VBP increased_VBN with_IN MAO_NN inhibitors_NNS and_CC beta_NN adrenergic_JJ blockers_NNS ._. The_DT renal_JJ effects_NNS of_IN nephrotoxic_JJ compounds_NNS may_MD be_VB potentiated_VBN by_IN Carboplatin_NNP ._. HEMABATE_NN may_MD augment_VB the_DT activity_NN of_IN other_JJ oxytocic_JJ agents_NNS ._. Concomitant_JJ use_NN with_IN other_JJ oxytocic_JJ agents_NNS is_VBZ not_RB recommende_NN ._. Ocupress_NN should_MD be_VB used_VBN with_IN caution_NN in_IN patients_NNS who_WP are_VBP receiving_VBG a_DT beta-adrenergic_JJ blocking_VBG agent_NN orally_RB because_IN of_IN the_DT potential_NN for_IN additive_JJ effects_NNS on_IN systemic_JJ beta-blockade_NN ._. Close_JJ observation_NN of_IN the_DT patient_NN is_VBZ recommended_VBN when_WRB a_DT beta-blocker_NN is_VBZ administered_VBN to_TO patients_NNS receiving_VBG catecholamine-depleting_JJ drugs_NNS such_JJ as_IN reserpine_NN ,_, because_IN of_IN possible_JJ additive_JJ effects_NNS and_CC the_DT production_NN of_IN hypotension_NN and/or_CC marked_JJ bradycardia_NN ,_, which_WDT may_MD produce_VB vertigo_NN ,_, syncope_NN ,_, or_CC postural_JJ hypotension_NN ._. Inhibitors_NNS of_IN CYP2D6_NN ;_: ._. poor_JJ metabolizers_NNS of_IN debrisoquin_NN :_: Interactions_NNS of_IN carvedilol_NN with_IN strong_JJ inhibitors_NNS of_IN CYP2D6_NN -LRB-_-LRB- such_JJ as_IN quinidine_NN ,_, fluoxetine_NN ,_, paroxetine_NN ,_, and_CC propafenone_NN -RRB-_-RRB- have_VBP not_RB been_VBN studied_VBN ,_, but_CC these_DT drugs_NNS would_MD be_VB expected_VBN to_TO increase_VB blood_NN levels_NNS of_IN the_DT R_NN -LRB-_-LRB- +_CC -RRB-_-RRB- enantiomer_NN of_IN carvedilol_NN ._. Retrospective_JJ analysis_NN of_IN side_JJ effects_NNS in_IN clinical_JJ trials_NNS showed_VBD that_IN poor_JJ 2D6_NN metabolizers_NNS had_VBD a_DT higher_JJR rate_NN of_IN dizziness_NN during_IN up-titration_NN ,_, presumably_RB resulting_VBG from_IN vasodilating_VBG effects_NNS of_IN the_DT higher_JJR concentrations_NNS of_IN the_DT a-blocking_NN R_NN -LRB-_-LRB- +_CC -RRB-_-RRB- enantiomer_NN ._. Catecholamine-depleting_JJ Agents_NNS :_: Patients_NNS taking_VBG both_CC agents_NNS with_IN b-blocking_NN properties_NNS and_CC a_DT drug_NN that_WDT can_MD deplete_VB catecholamines_NNS -LRB-_-LRB- e.g._FW ,_, reserpine_NN and_CC monoamine_NN oxidase_NN inhibitors_NNS -RRB-_-RRB- should_MD be_VB observed_VBN closely_RB for_IN signs_NNS of_IN hypotension_NN and/or_CC severe_JJ bradycardia_NN ._. Clonidine_NNP :_: Concomitant_JJ administration_NN of_IN clonidine_NN with_IN agents_NNS with_IN b-blocking_NN properties_NNS may_MD potentiate_VB blood-pressure_NN -_: and_CC heart-rate-lowering_JJ effects_NNS ._. When_WRB concomitant_JJ treatment_NN with_IN agents_NNS with_IN b-blocking_NN properties_NNS and_CC clonidine_NN is_VBZ to_TO be_VB terminated_VBN ,_, the_DT b-blocking_JJ agent_NN should_MD be_VB discontinued_VBN first_RB ._. Clonidine_NN therapy_NN can_MD then_RB be_VB discontinued_VBN several_JJ days_NNS later_RB by_IN gradually_RB decreasing_VBG the_DT dosage_NN ._. Cyclosporine_NN :_: Modest_JJ increases_NNS in_IN mean_JJ trough_NN cyclosporine_NN concentrations_NNS were_VBD observed_VBN following_VBG initiation_NN of_IN carvedilol_NN treatment_NN in_IN 21_CD renal_JJ transplant_NN patients_NNS suffering_VBG from_IN chronic_JJ vascular_JJ rejection_NN ._. In_IN about_RB 30_CD %_NN of_IN patients_NNS ,_, the_DT dose_NN of_IN cyclosporine_NN had_VBD to_TO be_VB reduced_VBN in_IN order_NN to_TO maintain_VB cyclosporine_NN concentrations_NNS within_IN the_DT therapeutic_JJ range_NN ,_, while_IN in_IN the_DT remainder_NN no_DT adjustment_NN was_VBD needed_VBN ._. On_IN the_DT average_NN for_IN the_DT group_NN ,_, the_DT dose_NN of_IN cyclosporine_NN was_VBD reduced_VBN about_IN 20_CD %_NN in_IN these_DT patients_NNS ._. Due_JJ to_TO wide_JJ interindividual_JJ variability_NN in_IN the_DT dose_NN adjustment_NN required_VBN ,_, it_PRP is_VBZ recommended_VBN that_IN cyclosporine_NN concentrations_NNS be_VB monitored_VBN closely_RB after_IN initiation_NN of_IN carvedilol_NN therapy_NN and_CC that_IN the_DT dose_NN of_IN cyclosporine_NN be_VB adjusted_VBN as_IN appropriate_JJ ._. Digoxin_NNP :_: Digoxin_NN concentrations_NNS are_VBP increased_VBN by_IN about_RB 15_CD %_NN when_WRB digoxin_NN and_CC carvedilol_NN are_VBP administered_VBN concomitantly_RB ._. Both_DT digoxin_NN and_CC COREG_NNP slow_JJ AV_NN conduction_NN ._. Therefore_RB ,_, increased_VBD monitoring_NN of_IN digoxin_NN is_VBZ recommended_VBN when_WRB initiating_VBG ,_, adjusting_VBG ,_, or_CC discontinuing_VBG COREG_NNP ._. Inducers_NNS and_CC Inhibitors_NNS of_IN Hepatic_JJ Metabolism_NN :_: Rifampin_NNP reduced_VBD plasma_NN concentrations_NNS of_IN carvedilol_NN by_IN about_RB 70_CD %_NN ._. Cimetidine_NN increased_VBD AUC_NN by_IN about_IN 30_CD %_NN but_CC caused_VBD no_DT change_NN in_IN Cmax_NNP ._. Calcium_NN Channel_NNP Blockers_NNPS :_: Isolated_VBN cases_NNS of_IN conduction_NN disturbance_NN -LRB-_-LRB- rarely_RB with_IN hemodynamic_JJ compromise_NN -RRB-_-RRB- have_VBP been_VBN observed_VBN when_WRB COREG_NNP is_VBZ co-administered_VBN with_IN diltiazem_NN ._. As_IN with_IN other_JJ agents_NNS with_IN b-blocking_NN properties_NNS ,_, if_IN COREG_NNP is_VBZ to_TO be_VB administered_VBN orally_RB with_IN calcium_NN channel_NN blockers_NNS of_IN the_DT verapamil_NN or_CC diltiazem_NN type_NN ,_, it_PRP is_VBZ recommended_VBN that_IN ECG_NN and_CC blood_NN pressure_NN be_VB monitored_VBN ._. Insulin_NN or_CC Oral_JJ Hypoglycemics_NNS :_: Agents_NNS with_IN b-blocking_NN properties_NNS may_MD enhance_VB the_DT blood-sugar-reducing_JJ effect_NN of_IN insulin_NN and_CC oral_JJ hypoglycemics_NNS ._. Therefore_RB ,_, in_IN patients_NNS taking_VBG insulin_NN or_CC oral_JJ hypoglycemics_NNS ,_, regular_JJ monitoring_NN of_IN blood_NN glucose_NN is_VBZ recommended_VBN ._. Studies_NNS in_FW vitro_FW show_VBP that_IN caspofungin_NN acetate_NN is_VBZ not_RB an_DT inhibitor_NN of_IN any_DT enzyme_NN in_IN the_DT cytochrome_NN P450_NN -LRB-_-LRB- CYP_NN -RRB-_-RRB- system_NN ._. In_IN clinical_JJ studies_NNS ,_, caspofungin_NN did_VBD not_RB induce_VB the_DT CYP3A4_NN metabolism_NN of_IN other_JJ drugs_NNS ._. Caspofungin_NNP is_VBZ not_RB a_DT substrate_NN for_IN P-glycoprotein_NN and_CC is_VBZ a_DT poor_JJ substrate_NN for_IN cytochrome_NN P450_NN enzymes_NNS ._. Clinical_JJ studies_NNS in_IN healthy_JJ volunteers_NNS show_VBP that_IN the_DT pharmacokinetics_NNS of_IN CANCIDAS_NNP are_VBP not_RB altered_VBN by_IN itraconazole_NN ,_, amphotericin_NN B_NN ,_, mycophenolate_NN ,_, nelfinavir_NN ,_, or_CC tacrolimus_NN ._. CANCIDAS_NNP has_VBZ no_DT effect_NN on_IN the_DT pharmacokinetics_NNS of_IN itraconazole_NN ,_, amphotericin_NN B_NN ,_, or_CC the_DT active_JJ metabolite_NN of_IN mycophenolate_NN ._. CANCIDAS_NNP reduced_VBD the_DT blood_NN AUC0-12_NN of_IN tacrolimus_NN by_IN approximately_RB 20_CD %_NN ,_, peak_JJ blood_NN concentration_NN -LRB-_-LRB- Cmax_NN -RRB-_-RRB- by_IN 16_CD %_NN ,_, and_CC 12-hour_JJ blood_NN concentration_NN -LRB-_-LRB- C12hr_NN -RRB-_-RRB- by_IN 26_CD %_NN in_IN healthy_JJ subjects_NNS when_WRB tacrolimus_NN -LRB-_-LRB- 2_CD doses_NNS of_IN 0.1_CD mg/kg_NN 12_CD hours_NNS apart_RB -RRB-_-RRB- was_VBD administered_VBN on_IN the_DT 10th_JJ day_NN of_IN CANCIDAS_NNP 70_CD mg_NN daily_RB ,_, as_IN compared_VBN to_TO results_NNS from_IN a_DT control_NN period_NN in_IN which_WDT tacrolimus_NN was_VBD administered_VBN alone_RB ._. For_IN patients_NNS receiving_VBG both_CC therapies_NNS ,_, standard_JJ monitoring_NN of_IN tacrolimus_NN blood_NN concentrations_NNS and_CC appropriate_JJ tacrolimus_NN dosage_NN adjustments_NNS are_VBP recommended_VBN ._. In_IN two_CD clinical_JJ studies_NNS ,_, cyclosporine_NN -LRB-_-LRB- one_CD 4_CD mg/kg_NN dose_NN or_CC two_CD 3_CD mg/kg_NN doses_NNS -RRB-_-RRB- increased_VBD the_DT AUC_NN of_IN caspofungin_NN by_IN approximately_RB 35_CD %_NN ._. CANCIDAS_NNP did_VBD not_RB increase_VB the_DT plasma_NN levels_NNS of_IN cyclosporine_NN ._. There_EX were_VBD transient_JJ increases_NNS in_IN liver_NN ALT_NN and_CC AST_NNP when_WRB CANCIDAS_NNP and_CC cyclosporine_NN were_VBD co-administered_VBN ._. A_DT drug-drug_JJ interaction_NN study_NN with_IN rifampin_NN in_IN healthy_JJ volunteers_NNS has_VBZ shown_VBN a_DT 30_CD %_NN decrease_NN in_IN caspofungin_NN trough_NN concentrations_NNS ._. Patients_NNS on_IN rifampin_NN should_MD receive_VB 70_CD mg_NN of_IN CANCIDAS_NNP daily_RB ._. In_IN addition_NN ,_, results_VBZ from_IN regression_NN analyses_NNS of_IN patient_NN pharmacokinetic_JJ data_NNS suggest_VBP that_IN co-administration_NN of_IN other_JJ inducers_NNS of_IN drug_NN clearance_NN -LRB-_-LRB- efavirenz_NN ,_, nevirapine_NN ,_, phenytoin_NN ,_, dexamethasone_NN ,_, or_CC carbamazepine_NN -RRB-_-RRB- with_IN CANCIDAS_NNS may_MD result_VB in_IN clinically_RB meaningful_JJ reductions_NNS in_IN caspofungin_NN concentrations_NNS ._. It_PRP is_VBZ not_RB known_VBN which_WDT drug_NN clearance_NN mechanism_NN involved_VBN in_IN caspofungin_NN disposition_NN may_MD be_VB inducible_JJ ._. When_WRB CANCIDAS_NNP is_VBZ co-administered_VBN with_IN inducers_NNS of_IN drug_NN clearance_NN ,_, such_JJ as_IN efavirenz_NN ,_, nevirapine_NN ,_, phenytoin_NN ,_, dexamethasone_NN ,_, or_CC carbamazepine_NN ,_, use_NN of_IN a_DT daily_JJ dose_NN of_IN 70_CD mg_NN of_IN CANCIDAS_NNP should_MD be_VB considere_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS Positive_JJ direct_JJ Coombs_NNP tests_NNS have_VBP been_VBN reported_VBN during_IN treatment_NN with_IN the_DT cephalosporin_NN antibiotics_NNS ._. In_IN hematologic_JJ studies_NNS or_CC in_IN transfusion_NN cross-matching_NN procedures_NNS when_WRB anti-globulin_JJ tests_NNS are_VBP performed_VBN on_IN the_DT minor_JJ side_NN or_CC in_IN Coombs_NNP testing_NN of_IN newborns_NNS whose_WP$ mothers_NNS have_VBP received_VBN cephalosporin_NN antibiotics_NNS before_IN parturition_NN ,_, it_PRP should_MD be_VB recognized_VBN that_IN a_DT positive_JJ Coombs_NNP test_NN may_MD be_VB due_JJ to_TO the_DT drug_NN ._. Probenecid_NNP may_MD decrease_VB renal_JJ tubular_JJ secretion_NN of_IN cephalosporins_NNS when_WRB used_VBN concurrently_RB ,_, resulting_VBG in_IN increased_VBN and_CC more_RBR prolonged_JJ cephalosporin_NN blood_NN levels_NNS ._. Drug/Laboratory_JJ Test_NN Interactions_NNS A_DT false_JJ positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN may_MD occur_VB with_IN Benedicts_NNS solution_NN ,_, Fehlings_NNP solution_NN or_CC with_IN CLINITEST_NN tablets_NNS ,_, but_CC not_RB with_IN enzyme-based_JJ tests_NNS such_JJ as_IN CLINISTIX_NN ._. Positive_JJ direct_JJ and_CC indirect_JJ antiglobulin_NN -LRB-_-LRB- Coombs_NNS -RRB-_-RRB- tests_NNS have_VBP occurred_VBN ;_: ._. these_DT may_MD also_RB occur_VB in_IN neonates_NNS whose_WP$ mothers_NNS received_VBD cephalosporins_NNS before_IN delivery_NN ._. Antacids_NNS -LRB-_-LRB- aluminum_NN -_: or_CC magnesium-containing_JJ -RRB-_-RRB- :_: Concomitant_JJ administration_NN of_IN 300-mg_JJ cefdinir_NN capsules_NNS with_IN 30_CD mL_NN Maalox_NNP TC_NNP suspension_NN reduces_VBZ the_DT rate_NN -LRB-_-LRB- Cmax_NN -RRB-_-RRB- and_CC extent_NN -LRB-_-LRB- AUC_NN -RRB-_-RRB- of_IN absorption_NN by_IN approximately_RB 40_CD %_NN ._. Time_NNP to_TO reach_VB Cmax_NNP is_VBZ also_RB prolonged_VBN by_IN 1_CD hour_NN ._. There_EX are_VBP no_DT significant_JJ effects_NNS on_IN cefdinir_NN pharmacokinetics_NNS if_IN the_DT antacid_NN is_VBZ administered_VBN 2_CD hours_NNS before_IN or_CC 2_CD hours_NNS after_IN cefdinir_NN ._. If_IN antacids_NNS are_VBP required_VBN during_IN OMNICEF_NN therapy_NN ,_, OMNICEF_NN should_MD be_VB taken_VBN at_IN least_JJS 2_CD hours_NNS before_IN or_CC after_IN the_DT antacid_NN ._. Probenecid_NNP :_: As_IN with_IN other_JJ b-lactam_NN antibiotics_NNS ,_, probenecid_NN inhibits_VBZ the_DT renal_JJ excretion_NN of_IN cefdinir_NN ,_, resulting_VBG in_IN an_DT approximate_JJ doubling_NN in_IN A.C._NNP a_DT 54_CD %_NN increase_NN in_IN peak_JJ cefdinir_NN plasma_NN levels_NNS ,_, and_CC a_DT 50_CD %_NN prolongation_NN in_IN the_DT apparent_JJ elimination_NN half-life_NN ._. Iron_NNP Supplements_NNP and_CC Foods_NNP Fortified_VBD With_IN Iron_NNP Concomitant_JJ administration_NN of_IN cefdinir_NN with_IN a_DT therapeutic_JJ iron_NN supplement_NN containing_VBG 60_CD mg_NN of_IN elemental_JJ iron_NN -LRB-_-LRB- as_IN FeSO4_NN -RRB-_-RRB- or_CC vitamins_NNS supplemented_VBN with_IN 10_CD mg_NN of_IN elemental_JJ iron_NN reduced_VBD extent_NN of_IN absorption_NN by_IN 80_CD %_NN and_CC 31_CD %_NN ,_, respectively_RB ._. If_IN iron_NN supplements_NNS are_VBP required_VBN during_IN OMNICEF_NN therapy_NN ,_, OMNICEF_NN should_MD be_VB taken_VBN at_IN least_JJS 2_CD hours_NNS before_IN or_CC after_IN the_DT supplement_NN ._. The_DT effect_NN of_IN foods_NNS highly_RB fortified_VBD with_IN elemental_JJ iron_NN -LRB-_-LRB- primarily_RB iron-fortified_JJ breakfast_NN cereals_NNS -RRB-_-RRB- on_IN cefdinir_NN absorption_NN has_VBZ not_RB been_VBN studied_VBN ._. Concomitantly_RB administered_VBN iron-fortified_JJ infant_NN formula_NN -LRB-_-LRB- 2.2_CD mg_NN elemental_JJ iron/6_NN oz_NN -RRB-_-RRB- has_VBZ no_DT significant_JJ effect_NN on_IN cefdinir_NN pharmacokinetics_NNS ._. Therefore_RB ,_, OMNICEF_NN for_IN Oral_NNP Suspension_NNP can_MD be_VB administered_VBN with_IN iron-fortified_JJ infant_NN formula_NN ._. There_EX have_VBP been_VBN rare_JJ reports_NNS of_IN reddish_JJ stools_NNS in_IN patients_NNS who_WP have_VBP received_VBN cefdinir_NN in_IN Japan_NNP ._. The_DT reddish_JJ color_NN is_VBZ due_JJ to_TO the_DT formation_NN of_IN a_DT nonabsorbable_JJ complex_NN between_IN cefdinir_NN or_CC its_PRP$ breakdown_NN products_NNS and_CC iron_NN in_IN the_DT gastrointestinal_JJ tract_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS A_DT false-positive_JJ reaction_NN for_IN ketones_NNS in_IN the_DT urine_NN may_MD occur_VB with_IN tests_NNS using_VBG nitroprusside_NN ,_, but_CC not_RB with_IN those_DT using_VBG nitroferricyanide_NN ._. The_DT administration_NN of_IN cefdinir_NN may_MD result_VB in_IN a_DT false-positive_JJ reaction_NN for_IN glucose_NN in_IN urine_NN using_VBG Clinitest_NNP ,_, Benedict_NNP s_VBZ solution_NN ,_, or_CC Fehlings_NNP solution_NN ._. It_PRP is_VBZ recommended_VBN that_IN glucose_NN tests_NNS based_VBN on_IN enzymatic_JJ glucose_NN oxidase_NN reactions_NNS -LRB-_-LRB- such_JJ as_IN Clinistix_NNP or_CC Tes-Tape_NNP -RRB-_-RRB- be_VB used_VBN ._. Cephalosporins_NNS are_VBP known_VBN to_TO occasionally_RB induce_VB a_DT positive_JJ direct_JJ Coombs_NNS test_NN ._. Oral_JJ Contraceptives_NNS Multiple_JJ doses_NNS of_IN cefditoren_NN pivoxil_NN had_VBD no_DT effect_NN on_IN the_DT pharmacokinetics_NNS of_IN ethinyl_NN estradiol_NN ,_, the_DT estrogenic_JJ component_NN in_IN most_JJS oral_JJ contraceptives_NNS ._. Although_IN the_DT clinical_JJ significance_NN is_VBZ not_RB known_VBN ,_, it_PRP is_VBZ not_RB recommended_VBN that_IN cefditoren_NN pivoxil_NN be_VB taken_VBN concomitantly_RB with_IN antacids_NNS ._. H2-Receptor_NN Antagonists_NNS :_: Co-administration_NN of_IN a_DT single_JJ dose_NN of_IN intravenously_RB administered_VBN famotidine_NN -LRB-_-LRB- 20_CD mg_NN -RRB-_-RRB- reduced_VBD the_DT oral_JJ absorption_NN of_IN a_DT single_JJ 400_CD mg_NN dose_NN of_IN cefditoren_NN pivoxil_NN administered_VBN following_VBG a_DT meal_NN ,_, as_IN evidenced_VBN by_IN a_DT 27_CD %_NN decrease_NN in_IN mean_JJ Cmax_NN and_CC a_DT 22_CD %_NN decrease_NN in_IN mean_JJ AUC_NN ._. Although_IN the_DT clinical_JJ significance_NN is_VBZ not_RB known_VBN ,_, it_PRP is_VBZ not_RB recommended_VBN that_IN cefditoren_NN pivoxil_NN be_VB taken_VBN concomitantly_RB with_IN H2_NN receptor_NN antagonists_NNS ._. Probenecid_NNP :_: As_IN with_IN other_JJ b-lactam_NN antibiotics_NNS ,_, co-administration_NN of_IN probenecid_NN with_IN cefditoren_NN pivoxil_NN resulted_VBD in_IN an_DT increase_NN in_IN the_DT plasma_NN exposure_NN of_IN cefditoren_NNS ,_, with_IN a_DT 49_CD %_NN increase_NN in_IN mean_NN Cmax_NN ,_, a_DT 122_CD %_NN increase_NN in_IN mean_JJ AUC_NN ,_, and_CC a_DT 53_CD %_NN increase_NN in_IN half-life_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS Cephalosporins_NNS are_VBP known_VBN to_TO occasionally_RB induce_VB a_DT positive_JJ direct_JJ Coombs_NNS test_NN ._. A_DT false-positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN may_MD occur_VB with_IN copper_NN reduction_NN tests_NNS -LRB-_-LRB- Benedicts_NNS or_CC Fehlings_NNS solution_NN or_CC with_IN CLINITEST_NN tablets_NNS -RRB-_-RRB- ,_, but_CC not_RB with_IN enzyme-based_JJ tests_NNS for_IN glycosuria_NN -LRB-_-LRB- e.g._FW ,_, CLINISTIX_NN ,_, TES-TAPE_NN -RRB-_-RRB- ._. As_IN a_DT false-negative_JJ result_NN may_MD occur_VB in_IN the_DT ferricyanide_JJ test_NN ,_, it_PRP is_VBZ recommended_VBN that_IN either_CC the_DT glucose_NN oxidase_NN or_CC hexokinase_NN method_NN be_VB used_VBN to_TO determine_VB blood/plasma_NN glucose_NN levels_NNS in_IN patients_NNS receiving_VBG cefditoren_NN pivoxil_NN ._. Renal_JJ function_NN should_MD be_VB monitored_VBN carefully_RB if_IN high_JJ doses_NNS of_IN aminoglycosides_NNS are_VBP to_TO be_VB administered_VBN with_IN MAXIPIME_NN because_IN of_IN the_DT increased_VBN potential_NN of_IN nephrotoxicity_NN and_CC ototoxicity_NN of_IN aminoglycoside_NN antibiotics_NNS ._. Nephrotoxicity_NN has_VBZ been_VBN reported_VBN following_VBG concomitant_JJ administration_NN of_IN other_JJ cephalosporins_NNS with_IN potent_JJ diuretics_NNS such_JJ as_IN furosemide_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS The_DT administration_NN of_IN cefepime_NN may_MD result_VB in_IN a_DT false-positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN when_WRB using_VBG Clinitest_NNP tablets_NNS ._. It_PRP is_VBZ recommended_VBN that_IN glucose_NN tests_NNS based_VBN on_IN enzymatic_JJ glucose_NN oxidase_NN reactions_NNS -LRB-_-LRB- such_JJ as_IN Clinistix_NNP or_CC Tes-Tape_NNP -RRB-_-RRB- be_VB used_VBN ._. Carbamazepine_NNP :_: Elevated_JJ carbamazepine_NN levels_NNS have_VBP been_VBN reported_VBN in_IN postmarketing_VBG experience_NN when_WRB SUPRAX_NNP is_VBZ administered_VBN concomitantly_RB ._. Drug_NN monitoring_NN may_MD be_VB of_IN assistance_NN in_IN detecting_VBG alterations_NNS in_IN carbamazepine_NN plasma_NN concentrations_NNS ._. Warfarin_NNP and_CC Anticoagulants_NNPS :_: Increased_VBN prothrombin_NN time_NN ,_, with_IN or_CC without_IN clinical_JJ bleeding_NN ,_, has_VBZ been_VBN reported_VBN when_WRB cefixime_NN is_VBZ administered_VBN concomitantly_RB ._. Drug/Laboratory_JJ Test_NN Interactions_NNS A_DT false-positive_JJ reaction_NN for_IN ketones_NNS in_IN the_DT urine_NN may_MD occur_VB with_IN tests_NNS using_VBG nitroprusside_NN but_CC not_RB with_IN those_DT using_VBG nitroferricyanide_NN ._. The_DT administration_NN of_IN SUPRAX_NNP may_MD result_VB in_IN a_DT false-positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN using_VBG Clinitest_NNP **_SYM ,_, Benedict_NNP s_VBZ solution_NN ,_, or_CC Fehling_NN s_NNS solution_NN ._. It_PRP is_VBZ recommended_VBN that_IN glucose_NN tests_NNS based_VBN on_IN enzymatic_JJ glucose_NN oxidase_NN reactions_NNS -LRB-_-LRB- such_JJ as_IN Clinistix_NNP **_SYM or_CC Tes-Tape_JJ **_SYM -RRB-_-RRB- be_VB used_VBN ._. A_DT false-positive_JJ direct_JJ Coombs_NNS test_NN has_VBZ been_VBN reported_VBN during_IN treatment_NN with_IN other_JJ cephalosporin_NN antibiotics_NNS ._. therefore_RB ,_, it_PRP should_MD be_VB recognized_VBN that_IN a_DT positive_JJ Coombs_NNP test_NN may_MD be_VB due_JJ to_TO the_DT drug_NN ._. Increased_VBN nephrotoxicity_NN has_VBZ been_VBN reported_VBN following_VBG concomitant_JJ administration_NN of_IN cephalosporins_NNS and_CC aminoglycoside_NN antibiotics_NNS ._. Drug/Laboratory_JJ Test_NN Interactions_NNS Cephalosporins_NNS ,_, including_VBG cefotaxime_NN sodium_NN ,_, are_VBP known_VBN to_TO occasionally_RB induce_VB a_DT positive_JJ direct_JJ Coombs_NNS test_NN ._. Increases_NNS in_IN serum_NN creatinine_NN have_VBP occurred_VBN when_WRB CEFOTAN_NNP was_VBD given_VBN alone_RB ._. If_IN CEFOTAN_NNP and_CC an_DT aminoglycoside_NN are_VBP used_VBN concomitantly_RB ,_, renal_JJ function_NN should_MD be_VB carefully_RB monitored_VBN ,_, because_IN nephrotoxicity_NN may_MD be_VB potentiated_VBN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS :_: The_DT administration_NN of_IN CEFOTAN_NNP may_MD result_VB in_IN a_DT false_JJ positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN using_VBG Clinitest_NNP ,_, Benedicts_NNP solution_NN ,_, or_CC Fehlings_NNP solution_NN ._. It_PRP is_VBZ recommended_VBN that_IN glucose_NN tests_NNS based_VBN on_IN enzymatic_JJ glucose_NN oxidase_NN be_VB used_VBN ._. As_IN with_IN other_JJ cephalosporins_NNS ,_, high_JJ concentrations_NNS of_IN cefotetan_NN may_MD interfere_VB with_IN measurement_NN of_IN serum_NN and_CC urine_NN creatinine_NN levels_NNS by_IN Jaffe_NNP reaction_NN and_CC produce_VBP false_JJ increases_NNS in_IN the_DT levels_NNS of_IN creatinine_NN reported_VBD ._. Increased_VBN nephrotoxicity_NN has_VBZ been_VBN reported_VBN following_VBG concomitant_JJ administration_NN of_IN cephalosporins_NNS and_CC aminoglycoside_NN antibiotics_NNS ._. Drug/Laboratory_JJ Test_NN Interactions_NNS As_IN with_IN cephalothin_NN ,_, high_JJ concentrations_NNS of_IN cefoxitin_NN -LRB-_-LRB- 100_CD micrograms/mL_NNS -RRB-_-RRB- may_MD interfere_VB with_IN measurement_NN of_IN serum_NN and_CC urine_NN creatinine_NN levels_NNS by_IN the_DT Jaff_NNP reaction_NN ,_, and_CC produce_VBP false_JJ increases_NNS of_IN modest_JJ degree_NN in_IN the_DT levels_NNS of_IN creatinine_NN reported_VBD ._. Serum_NN samples_NNS from_IN patients_NNS treated_VBN with_IN cefoxitin_NN should_MD not_RB be_VB analyzed_VBN for_IN creatinine_NN if_IN withdrawn_VBN within_IN 2_CD hours_NNS of_IN drug_NN administration_NN ._. High_JJ concentrations_NNS of_IN cefoxitin_NN in_IN the_DT urine_NN may_MD interfere_VB with_IN measurement_NN of_IN urinary_JJ 17-hydroxy-corticosteroids_NNS by_IN the_DT Porter-Silber_NNP reaction_NN ,_, and_CC produce_VBP false_JJ increases_NNS of_IN modest_JJ degree_NN in_IN the_DT levels_NNS reported_VBD ._. A_DT false-positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN may_MD occur_VB ._. This_DT has_VBZ been_VBN observed_VBN with_IN CLINITEST_NN reagent_NN tablets_NNS ._. Registered_NNP trademark_NN of_IN Ames_NNP Company_NNP ,_, Division_NNP of_IN Miles_NNP Laboratories_NNPS ,_, Inc._NNP ._. Nephrotoxicity_NN has_VBZ been_VBN reported_VBN following_VBG concomitant_JJ administration_NN of_IN aminoglycoside_NN antibiotics_NNS and_CC cephalosporin_NN antibiotics_NNS ._. Concomitant_JJ administration_NN of_IN probenecid_NN doubled_VBD the_DT AUC_NN for_IN cefprozil_NN ._. The_DT bioavailability_NN of_IN the_DT capsule_NN formulation_NN of_IN cefprozil_NN was_VBD not_RB affected_VBN when_WRB administered_VBN 5_CD minutes_NNS following_VBG an_DT antacid_NN ._. Nephrotoxicity_NN has_VBZ been_VBN reported_VBN following_VBG concomitant_JJ administration_NN of_IN cephalosporins_NNS with_IN aminoglycoside_NN antibiotics_NNS or_CC potent_JJ diuretics_NNS such_JJ as_IN furosemide_NN ._. Renal_JJ function_NN should_MD be_VB carefully_RB monitored_VBN ,_, especially_RB if_IN higher_JJR dosages_NNS of_IN the_DT aminoglycosides_NNS are_VBP to_TO be_VB administered_VBN or_CC if_IN therapy_NN is_VBZ prolonged_VBN ,_, because_IN of_IN the_DT potential_JJ nephrotoxicity_NN and_CC ototoxicity_NN of_IN aminoglycosidic_JJ antibiotics_NNS ._. Nephrotoxicity_NN and_CC ototoxicity_NN were_VBD not_RB noted_VBN when_WRB ceftazidime_NN was_VBD given_VBN alone_RB in_IN clinical_JJ trials_NNS ._. Chloramphenicol_NN has_VBZ been_VBN shown_VBN to_TO be_VB antagonistic_JJ to_TO beta-lactam_JJ antibiotics_NNS ,_, including_VBG ceftazidime_NN ,_, based_VBN on_IN in_FW vitro_FW studies_NNS and_CC time_NN kill_VBP curves_NNS with_IN enteric_JJ gram-negative_JJ bacilli_NNS ._. Due_JJ to_TO the_DT possibility_NN of_IN antagonism_NN in_FW vivo_FW ,_, particularly_RB when_WRB bactericidal_JJ activity_NN is_VBZ desired_VBN ,_, this_DT drug_NN combination_NN should_MD be_VB avoided_VBN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS The_DT administration_NN of_IN ceftazidime_NN may_MD result_VB in_IN a_DT false-positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN when_WRB using_VBG CLINITEST_NN tablets_NNS ,_, Benedicts_NNP solution_NN ,_, or_CC Fehlings_NNP solution_NN ._. It_PRP is_VBZ recommended_VBN that_IN glucose_NN tests_NNS based_VBN on_IN enzymatic_JJ glucose_NN oxidase_NN reactions_NNS -LRB-_-LRB- such_JJ as_IN CLINISTIX_NN or_CC TES-TAPE_NN -RRB-_-RRB- be_VB used_VBN ._. Theophylline_NNP :_: Twelve_CD healthy_JJ male_JJ volunteers_NNS were_VBD administered_VBN one_CD 200-mg_JJ ceftibuten_NN capsule_NN twice_RB daily_RB for_IN 6_CD days_NNS ._. With_IN the_DT morning_NN dose_NN of_IN ceftibuten_NN on_IN day_NN 6_CD ,_, each_DT volunteer_NN received_VBD a_DT single_JJ intravenous_JJ infusion_NN of_IN theophylline_NN -LRB-_-LRB- 4_CD mg/kg_NN -RRB-_-RRB- ._. The_DT pharmacokinetics_NNS of_IN theophylline_NN were_VBD not_RB altered_VBN ._. The_DT effect_NN of_IN ceftibuten_NN on_IN the_DT pharmacokinetics_NNS of_IN theophylline_NN administered_VBN orally_RB has_VBZ not_RB been_VBN investigated_VBN ._. Antacids_NNS or_CC H_NN 2_CD -_: receptor_NN antagonists_NNS :_: The_DT effect_NN of_IN increased_VBN gastric_JJ pH_NN on_IN the_DT bioavailability_NN of_IN ceftibuten_NN was_VBD evaluated_VBN in_IN 18_CD healthy_JJ adult_JJ volunteers_NNS ._. Each_DT volunteer_NN was_VBD administered_VBN one_CD 400-mg_JJ ceftibuten_NN capsule_NN ._. A_DT single_JJ dose_NN of_IN liquid_JJ antacid_NN did_VBD not_RB affect_VB the_DT C_NN max_NN or_CC AUC_NN of_IN ceftibuten_NN ._. however_RB ,_, 150_CD mg_NN of_IN ranitidine_NN q12h_NN for_IN 3_CD days_NNS increased_VBD the_DT ceftibuten_NN C_NN max_NN by_IN 23_CD %_NN and_CC ceftibuten_NN AUC_NN by_IN 16_CD %_NN ._. The_DT clinical_JJ relevance_NN of_IN these_DT increases_NNS is_VBZ not_RB known_VBN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS :_: There_EX have_VBP been_VBN no_DT chemical_NN or_CC laboratory_NN test_NN interactions_NNS with_IN ceftibuten_NN noted_VBD to_TO date_NN ._. False-positive_JJ direct_JJ Coombs_NNP tests_NNS have_VBP been_VBN reported_VBN during_IN treatment_NN with_IN other_JJ cephalosporins_NNS ._. Therefore_RB ,_, it_PRP should_MD be_VB recognized_VBN that_IN a_DT positive_JJ Coombs_NNP test_NN could_MD be_VB due_JJ to_TO the_DT drug_NN ._. The_DT results_NNS of_IN assays_NNS using_VBG red_JJ cells_NNS from_IN healthy_JJ subjects_NNS to_TO determine_VB whether_IN ceftibuten_NN would_MD cause_VB direct_JJ Coombs_NNP reactions_NNS in_FW vitro_FW showed_VBD no_DT positive_JJ reaction_NN at_IN ceftibuten_NN concentrations_NNS as_IN high_JJ as_IN 40_CD g/mL_NN ._. Although_IN the_DT occurrence_NN has_VBZ not_RB been_VBN reported_VBN with_IN Cefizox_NN ,_, nephrotoxicity_NN has_VBZ been_VBN reported_VBN following_VBG concomitant_JJ administration_NN of_IN other_JJ cephalosporins_NNS and_CC aminoglycosides_NNS ._. Drug/Laboratory_JJ Test_NN Interactions_NNS :_: A_DT false-positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN may_MD occur_VB with_IN copper_NN reduction_NN tests_NNS -LRB-_-LRB- Benedict_NNP s_NNS or_CC Fehling_NN s_NNS solution_NN or_CC with_IN Clinitest_NNP tablets_NNS -RRB-_-RRB- but_CC not_RB with_IN enzyme-based_JJ tests_NNS for_IN glycosuria_NN ._. As_IN a_DT false-negative_JJ result_NN may_MD occur_VB in_IN the_DT ferricyanide_JJ test_NN ,_, it_PRP is_VBZ recommended_VBN that_IN either_CC the_DT glucose_NN oxidase_NN or_CC hexokinase_NN method_NN be_VB used_VBN to_TO determine_VB blood_NN plasma_NN glucose_NN levels_NNS in_IN patients_NNS receiving_VBG cefuroxime_NN ._. Cefuroxime_RB does_VBZ not_RB interfere_VB with_IN the_DT assay_NN of_IN serum_NN and_CC urine_NN creatinine_NN by_IN the_DT alkaline_NN picrate_NN method_NN ._. General_NNP :_: Significant_JJ interactions_NNS may_MD occur_VB when_WRB celecoxib_NN is_VBZ administered_VBN together_RB with_IN drugs_NNS that_WDT inhibit_VBP P450_NN 2C9_NN ._. Celecoxib_NNP metabolism_NN is_VBZ predominantly_RB mediated_VBN via_IN cytochrome_NN P450_NN 2C9_NN in_IN the_DT liver_NN ._. Co-administration_NN of_IN celecoxib_NN with_IN drugs_NNS that_WDT are_VBP known_VBN to_TO inhibit_VB 2C9_NN should_MD be_VB done_VBN with_IN caution_NN ._. In_FW vitro_FW studies_NNS indicate_VBP that_IN celecoxib_NN is_VBZ not_RB an_DT inhibitor_NN of_IN cytochrome_NN P450_NN 2C9_NN ,_, 2C19_NN or_CC 3A4_NN ._. In_FW vitro_FW studies_NNS also_RB indicate_VBP that_IN celecoxib_NN ,_, although_IN not_RB a_DT substrate_NN ,_, is_VBZ an_DT inhibitor_NN of_IN cytochrome_NN P450_NN 2D6_NN ._. Therefore_RB ,_, there_EX is_VBZ a_DT potential_NN for_IN an_DT in_FW vivo_FW drug_NN interaction_NN with_IN drugs_NNS that_WDT are_VBP metabolized_VBN by_IN P450_NN 2D6_NN ._. Clinical_JJ studies_NNS with_IN celecoxib_NNS have_VBP identified_VBN potentially_RB significant_JJ interactions_NNS with_IN fluconazole_NN and_CC lithium_NN ._. Experience_NN with_IN nonsteroidal_JJ anti-inflammatory_JJ drugs_NNS -LRB-_-LRB- NSAIDs_NNS -RRB-_-RRB- suggests_VBZ the_DT potential_NN for_IN interactions_NNS with_IN furosemide_NN and_CC ACE_NN inhibitors_NNS ._. The_DT effects_NNS celecoxib_VBP on_IN the_DT pharmacokinetics_NNS and/or_CC pharmacodynamics_NNS of_IN glyburide_NN ,_, ketoconazole_NN ,_, methotrexate_NN ,_, phenytoin_NN ,_, tolbutamide_NN ,_, and_CC warfarin_NN have_VBP been_VBN studied_VBN in_FW vivo_FW and_CC clinically_RB important_JJ interactions_NNS have_VBP not_RB been_VBN found_VBN ._. ACE_NN inhibitors_NNS :_: Reports_NNS suggest_VBP that_IN NSAIDs_NNS may_MD diminish_VB the_DT antihypertensive_JJ effect_NN of_IN Angiotensin_NN Converting_VBG Enzyme_NN -LRB-_-LRB- ACE_NN -RRB-_-RRB- inhibitors_NNS ._. This_DT interaction_NN should_MD be_VB given_VBN consideration_NN in_IN patients_NNS taking_VBG CELEBREX_NNP concomitantly_RB with_IN ACE-inhibitors_NNS ._. Furosemide_NNP :_: Clinical_JJ studies_NNS ,_, as_RB well_RB as_IN post_NN marketing_NN observations_NNS ,_, have_VBP shown_VBN that_IN NSAIDs_NNS can_MD reduce_VB the_DT natriuretic_JJ effect_NN of_IN furosemide_NN and_CC thiazides_NNS in_IN some_DT patients_NNS ._. This_DT response_NN has_VBZ been_VBN attributed_VBN to_TO inhibition_NN of_IN renal_JJ prostaglandin_NN synthesis_NN ._. Aspirin_NN :_: CELEBREX_NNP can_MD be_VB used_VBN with_IN low_JJ dose_NN aspirin_NN ._. However_RB ,_, concomitant_JJ administration_NN of_IN aspirin_NN with_IN CELEBREX_NNP may_MD result_VB in_IN an_DT increased_VBN rate_NN of_IN GI_NN ulceration_NN or_CC other_JJ complications_NNS ,_, compared_VBN to_TO use_VB of_IN CELEBREX_NNP alone_RB ._. Because_IN of_IN its_PRP$ lack_NN of_IN platelet_NN effects_NNS ,_, CELEBREX_NNP is_VBZ not_RB a_DT substitute_NN for_IN aspirin_NN for_IN cardiovascular_JJ prophylaxis_NN ._. Fluconazole_NNP :_: Concomitant_JJ administration_NN of_IN fluconazole_NN at_IN 200_CD mg_NN QD_NN resulted_VBD in_IN a_DT two-fold_JJ increase_NN in_IN celecoxib_NN plasma_NN concentration_NN ._. This_DT increase_NN is_VBZ due_JJ to_TO the_DT inhibition_NN of_IN celecoxib_NN metabolism_NN via_IN P450_NN 2C9_NN by_IN fluconazole_NN -LRB-_-LRB- see_VB CLINICAL_NNP PHARMACOLOGY_NNP -_: Pharmacokinetics_NNS :_: Metabolism_NN -RRB-_-RRB- ._. CELEBREX_NNP should_MD be_VB introduced_VBN at_IN the_DT lowest_JJS recommended_VBN dose_NN in_IN patients_NNS receiving_VBG fluconazole_NN ._. Lithium_NN :_: In_IN a_DT study_NN conducted_VBN in_IN healthy_JJ subjects_NNS ,_, mean_VB steady-state_JJ lithium_NN plasma_NN levels_NNS increased_VBD approximately_RB 17_CD %_NN in_IN subjects_NNS receiving_VBG lithium_NN 450_CD mg_NN BID_NNP with_IN CELEBREX_NNP 200_CD mg_NN BID_NNP as_IN compared_VBN to_TO subjects_NNS receiving_VBG lithium_NN alone_RB ._. Patients_NNS on_IN lithium_NN treatment_NN should_MD be_VB closely_RB monitored_VBN when_WRB CELEBREX_NNP is_VBZ introduced_VBN or_CC withdrawn_VBN ._. Methotrexate_NNP :_: In_IN an_DT interaction_NN study_NN of_IN rheumatoid_JJ arthritis_NN patients_NNS taking_VBG methotrexate_NN ,_, CELEBREX_NNP did_VBD not_RB have_VB a_DT significant_JJ effect_NN on_IN the_DT pharmacokinetics_NNS of_IN methotrexate_NN ._. Warfarin_NNP :_: The_DT effect_NN of_IN celecoxib_NN on_IN the_DT anti-coagulant_JJ effect_NN of_IN warfarin_NN was_VBD studied_VBN in_IN a_DT group_NN of_IN healthy_JJ subjects_NNS receiving_VBG daily_JJ doses_NNS of_IN 2-5_CD mg_NN of_IN warfarin_NN ._. In_IN these_DT subjects_NNS ,_, celecoxib_NN did_VBD not_RB alter_VB the_DT anticoagulant_JJ effect_NN of_IN warfarin_NN as_IN determined_VBN by_IN prothrombin_NN time_NN ._. However_RB ,_, caution_NN should_MD be_VB used_VBN when_WRB administering_VBG CELEBREX_NN with_IN warfarin_NN since_IN these_DT patients_NNS are_VBP at_IN increased_VBN risk_NN of_IN bleeding_VBG complications_NNS ._. Metformin_NNP :_: In_IN healthy_JJ subjects_NNS given_VBN single_JJ 500_CD mg_NN doses_NNS of_IN cephalexin_NN and_CC metformin_NN ,_, plasma_NN metformin_NN mean_VB cmax_NN and_CC AUC_NN increased_VBN by_IN an_DT average_NN of_IN 34_CD %_NN and_CC 24_CD %_NN ,_, respectively_RB ,_, and_CC metformin_NN mean_VBP renal_JJ clearance_NN decreased_VBN by_IN 14_CD %_NN ._. No_DT information_NN is_VBZ available_JJ about_IN the_DT interaction_NN of_IN cephalexin_NN and_CC metformin_NN following_VBG multiple_JJ doses_NNS of_IN either_CC drug_NN ._. Although_IN not_RB observed_VBN in_IN this_DT study_NN ,_, adverse_JJ effects_NNS could_MD potentially_RB arise_VB from_IN co-administration_NN of_IN cephalexin_NN and_CC metformin_NN by_IN inhibition_NN of_IN tubular_JJ secretion_NN via_IN organic_JJ cationic_JJ transporter_NN systems_NNS ._. Accordingly_RB ,_, careful_JJ patient_NN monitoring_NN and_CC dose_NN adjustment_NN of_IN metformin_NN is_VBZ recommended_VBN in_IN patients_NNS concomitantly_RB taking_VBG cephalexin_NN and_CC metformin_NN ._. Probenecid_NNP :_: As_IN with_IN other_JJ b-lactams_NNS ,_, the_DT renal_JJ excretion_NN of_IN cephalexin_NN is_VBZ inhibited_VBN by_IN probenecid_NN ._. Drug_NN /_: Laboratory_NNP Test_NNP Interactions_NNS As_IN a_DT result_NN of_IN administration_NN of_IN Keflex_NNP ,_, a_DT false-positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN may_MD occur_VB ._. This_DT has_VBZ been_VBN observed_VBN with_IN Benedict_NNP s_NNS and_CC Fehling_NN s_NNS solutions_NNS and_CC also_RB with_IN Clinitest_NNP tablets_NNS ._. Immunosuppressive_JJ Drugs_NNS ,_, Fibric_JJ Acid_NN Derivatives_NNS ,_, Niacin_NN -LRB-_-LRB- Nicotinic_JJ Acid_NN ,_, Erythromycin_NNP ,_, Azole_NNP Antifungals_NNPS :_: Skeletal_JJ Muscle_NN ._. ANTACID_NN -LRB-_-LRB- Magnesium-Aluminum_NNP Hydroxide_NNP -RRB-_-RRB- :_: Cerivastatin_NNP plasma_NN concentrations_NNS were_VBD not_RB affected_VBN by_IN co-administration_NN of_IN antacid_NN ._. CIMETlDINE_NNP :_: Cerivastatin_NNP plasma_NN concentrations_NNS were_VBD not_RB affected_VBN by_IN co-administration_NN of_IN cimetidine_NN ._. CHOLESTYRAMINE_NNP :_: The_DT influence_NN of_IN the_DT bile-acidsequestering_JJ agent_NN cholestyramine_NN on_IN the_DT pharmacokinetits_NNS of_IN cerivastatin_NN sodium_NN was_VBD evaluated_VBN in_IN 12_CD healthy_JJ males_NNS in_IN 2_CD separate_JJ randomized_JJ crossover_NN studies_NNS ._. In_IN the_DT first_JJ study_NN ,_, concomitant_JJ administration_NN of_IN 0.2_CD mg_NN cerivastatin_NN sodium_NN and_CC 12_CD g_NN cholestyramine_NN resulted_VBD in_IN decreases_NNS of_IN more_JJR than_IN 22_CD %_NN for_IN AUC_NN and_CC 40_CD %_NN for_IN Cmax_NNP when_WRB compared_VBN to_TO dosing_NN cerivastatin_NN sodium_NN alone_RB ._. However_RB ,_, in_IN the_DT second_JJ study_NN ,_, administration_NN of_IN 12_CD g_NN cholestyramine_NN 1_CD hour_NN before_IN the_DT evening_NN meal_NN and_CC 0.3_CD mg_NN cerivastatin_NN sodium_NN approximately_RB 4_CD hours_NNS after_IN the_DT same_JJ evening_NN meal_NN resulted_VBD in_IN a_DT decrease_NN in_IN the_DT cerivastatin_NN AUC_NN of_IN less_JJR than_IN 8_CD %_NN ,_, and_CC a_DT decrease_NN in_IN Cmax_NN of_IN about_IN 30_CD %_NN when_WRB compared_VBN to_TO dosing_NN cerivastatin_NN sodium_NN alone_RB ._. Therefore_RB ,_, it_PRP would_MD be_VB expected_VBN that_IN a_DT dosing_NN schedule_NN of_IN cerivastatin_NN sodium_NN given_VBN at_IN bedtime_NN and_CC cholestyramine_NN given_VBN before_IN the_DT evening_NN meal_NN would_MD not_RB result_VB in_IN a_DT significant_JJ decrease_NN in_IN the_DT clinical_JJ effect_NN of_IN cerivastatin_NN sodium_NN ._. DIGOXIN_NNP :_: Plasma_NN digoxin_NN levels_NNS and_CC digoxin_NN clearance_NN at_IN steady-state_JJ were_VBD not_RB affected_VBN by_IN co-administration_NN of_IN 0.2_CD mg_NN cerivastatin_NN sodium_NN ._. Cerivastatin_NNP plasma_NN concentrations_NNS were_VBD also_RB not_RB affected_VBN by_IN co-administration_NN of_IN digoxin_NN ._. WARFARIN_NNP :_: Co_NNP -_: administration_NN of_IN warfarin_NN and_CC cerivastatin_NN to_TO healthy_JJ volunteers_NNS did_VBD not_RB result_VB in_IN any_DT changes_NNS in_IN prothrombin_NN time_NN or_CC clotting_NN factor_NN VII_NN when_WRB compared_VBN to_TO co-administration_NN of_IN warfarin_NN and_CC placebo_NN ._. The_DT AUC_NN and_CC Cmax_NN of_IN both_CC the_DT -LRB-_-LRB- R_NN -RRB-_-RRB- and_CC -LRB-_-LRB- S_NN -RRB-_-RRB- isomers_NNS of_IN warfarin_NN were_VBD unaffected_JJ by_IN concurrent_JJ dosing_NN of_IN 0.3_CD mg_NN cerivastatin_NN sodium_NN ._. Co-administration_NN of_IN warfarin_NN and_CC cerivastatin_NN did_VBD not_RB alter_VB the_DT pharmacokinetics_NNS of_IN cerivastatin_NN sodium_NN ._. ERYTHROMYCIN_NNP :_: In_IN hypercholesterolemic_JJ patients_NNS ,_, steady-state_JJ cerivastatin_NN AUC_NN and_CC Cmax_NN increased_VBD approximately_RB 50_CD %_NN and_CC 24_CD %_NN respectively_RB after_IN 10_CD days_NNS with_IN co-administration_NN of_IN erythromycin_NN ,_, a_DT known_JJ inhibitor_NN of_IN cytochrome_NN P450_NN 3A4_NN ._. OTHER_JJ CONCOMITANT_JJ THERAPY_NN :_: Although_IN specific_JJ interaction_NN studies_NNS were_VBD not_RB performed_VBN ,_, in_IN clinical_JJ studies_NNS ,_, cerivastatin_NN sodium_NN was_VBD used_VBN concomitantly_RB with_IN angiotensin_NN -_: converting_VBG enzyme_NN -LRB-_-LRB- ACE_NN -RRB-_-RRB- inhibitors_NNS ,_, betablockers_NNS ,_, calcium-channel_JJ blockers_NNS ,_, diuretics_NNS ,_, and_CC nonsteroidal_JJ anti-inflammatory_JJ drugs_NNS -LRB-_-LRB- NSAIDs_NNS -RRB-_-RRB- without_IN evidence_NN of_IN clinically_RB significant_JJ adverse_JJ interactions_NNS ._. Pharmacokinetic_JJ interaction_NN studies_NNS with_IN cetirizine_NN in_IN adults_NNS were_VBD conducted_VBN with_IN pseudoephedrine_NN ,_, antipyrine_NN ,_, ketoconazole_NN ,_, erythromycin_NN and_CC azithromycin_NN ._. No_DT interactions_NNS were_VBD observed_VBN ._. In_IN a_DT multiple_JJ dose_NN study_NN of_IN theophylline_NN -LRB-_-LRB- 400_CD mg_NN once_RB daily_RB for_IN 3_CD days_NNS -RRB-_-RRB- and_CC cetirizine_NN -LRB-_-LRB- 20_CD mg_NN once_RB daily_RB for_IN 3_CD days_NNS -RRB-_-RRB- ,_, a_DT 16_CD %_NN decrease_NN in_IN the_DT clearance_NN of_IN cetirizine_NN was_VBD observed_VBN ._. The_DT disposition_NN of_IN theophylline_NN was_VBD not_RB altered_VBN by_IN concomitant_JJ cetirizine_NN administration_NN ._. Drug-Drug_NNP Interactions_NNS :_: No_DT clinically_RB significant_JJ drug_NN interactions_NNS have_VBP been_VBN found_VBN with_IN theophylline_NN at_IN a_DT low_JJ dose_NN ,_, azithromycin_NN ,_, pseudoephedrine_NN ,_, ketoconazole_NN ,_, or_CC erythromycin_NN ._. There_EX was_VBD a_DT small_JJ decrease_NN in_IN the_DT clearance_NN of_IN cetirizine_NN caused_VBN by_IN a_DT 400-mg_JJ dose_NN of_IN theophylline_NN ._. it_PRP is_VBZ possible_JJ that_IN larger_JJR theophylline_NN doses_NNS could_MD have_VB a_DT greater_JJR effect_NN ._. No_DT formal_JJ drug_NN interaction_NN studies_NNS have_VBP been_VBN performed_VBN with_IN Cetrotide_NN ._. A_DT drug_NN interaction_NN study_NN was_VBD performed_VBN in_IN which_WDT ERBITUX_NNP was_VBD administered_VBN in_IN combination_NN with_IN irinotecan_NN ._. There_EX was_VBD no_DT evidence_NN of_IN any_DT pharmacokinetic_JJ interactions_NNS between_IN ERBITUX_NNP and_CC irinotecan_NN ._. Cevimeline_NNP should_MD be_VB administered_VBN with_IN caution_NN to_TO patients_NNS taking_VBG beta_NN adrenergic_JJ antagonists_NNS ,_, because_IN of_IN the_DT possibility_NN of_IN conduction_NN disturbances_NNS ._. Drugs_NNS with_IN parasympathomimetic_JJ effects_NNS administered_VBN concurrently_RB with_IN cevimeline_NN can_MD be_VB expected_VBN to_TO have_VB additive_JJ effects_NNS ._. Cevimeline_NNP might_MD interfere_VB with_IN desirable_JJ antimuscarinic_JJ effects_NNS of_IN drugs_NNS used_VBN concomitantly_RB ._. Drugs_NNS which_WDT inhibit_VBP CYP2D6_NN and_CC CYP3A3/4_NN also_RB inhibit_VBP the_DT metabolism_NN of_IN cevimeline_NN ._. Cevimeline_NNP should_MD be_VB used_VBN with_IN caution_NN in_IN individuals_NNS known_VBN or_CC suspected_VBN to_TO be_VB deficient_JJ in_IN CYP2D6_NN activity_NN ,_, based_VBN on_IN previous_JJ experience_NN ,_, as_IN they_PRP may_MD be_VB at_IN a_DT higher_JJR risk_NN of_IN adverse_JJ events_NNS ._. In_IN an_DT in_FW vitro_FW study_NN ,_, cytochrome_NN P450_NN isozymes_NNS 1A2_NN ,_, 2A6_NN ,_, 2C9_NN ,_, 2C19_NN ,_, 2D6_NN ,_, 2E1_NN ,_, and_CC 3A4_NN were_VBD not_RB inhibited_VBN by_IN exposure_NN to_TO cevimeline_NN ._. There_EX are_VBP no_DT known_JJ drug/drug_NN interactions_NNS with_IN chlorambucil_NN ._. Although_IN clinical_JJ studies_NNS have_VBP not_RB established_VBN a_DT cause_NN and_CC effect_NN relationship_NN ,_, physicians_NNS should_MD be_VB aware_JJ that_IN variable_JJ effects_NNS an_DT blood_NN coagulation_NN have_VBP been_VBN reported_VBN very_RB rarely_RB in_IN patients_NNS receiving_VBG oral_JJ anticoagulants_NNS and_CC chlordiazepoxide_NN ._. The_DT concomitant_JJ use_NN of_IN alcohol_NN or_CC other_JJ central_JJ nervous_JJ system_NN depressants_NNS may_MD have_VB an_DT additive_JJ effect_NN ._. The_DT administration_NN of_IN local_JJ anesthetic_JJ solutions_NNS containing_VBG epinephrine_NN or_CC norepinephrine_NN to_TO patients_NNS receiving_VBG monoamine_NN oxidase_NN inhibitors_NNS ,_, tricyclic_JJ antidepressants_NNS or_CC phenothiazines_NNS may_MD produce_VB severe_JJ ,_, prolonged_JJ hypotension_NN or_CC hypertension_NN ._. Concurrent_JJ use_NN of_IN these_DT agents_NNS should_MD generally_RB be_VB avoided_VBN ._. In_IN situations_NNS when_WRB concurrent_JJ therapy_NN is_VBZ necessary_JJ ,_, careful_JJ patient_NN monitoring_NN is_VBZ essential_JJ ._. Concurrent_JJ administration_NN of_IN vasopressor_NN drugs_NNS -LRB-_-LRB- for_IN the_DT treatment_NN of_IN hypotension_NN related_JJ to_TO obstetric_JJ blocks_NNS -RRB-_-RRB- and_CC ergot-type_JJ oxytocic_JJ drugs_NNS may_MD cause_VB severe_JJ ,_, persistent_JJ hypertension_NN or_CC cerebrovascular_JJ accidents_NNS ._. The_DT para-aminobenzoic_JJ acid_NN metabolite_NN of_IN chloroprocaine_NN inhibits_VBZ the_DT action_NN of_IN sulfonamides_NNS ._. Therefore_RB ,_, chloroprocaine_NN should_MD not_RB be_VB used_VBN in_IN any_DT condition_NN in_IN which_WDT a_DT sulfonamide_NN drug_NN is_VBZ being_VBG employed_VBN ._. Antacids_NNS and_CC kaolin_NN :_: Antacids_NNS and_CC kaolin_NN can_MD reduce_VB absorption_NN of_IN chloroquine_NN ._. an_DT interval_NN of_IN at_IN least_JJS 4_CD hours_NNS between_IN intake_NN of_IN these_DT agents_NNS and_CC chloroquine_NN should_MD be_VB observed_VBN ._. Cimetidine_NNP :_: Cimetidine_NNP can_MD inhibit_VB the_DT metabolism_NN of_IN chloroquine_NN ,_, increasing_VBG its_PRP$ plasma_NN level_NN ._. Concomitant_JJ use_NN of_IN cimetidine_NN should_MD be_VB avoided_VBN ._. Ampicillin_NNP :_: In_IN a_DT study_NN of_IN healthy_JJ volunteers_NNS ,_, chloroquine_NN significantly_RB reduced_VBD the_DT bioavailability_NN of_IN ampicillin_NN ._. An_DT interval_NN of_IN at_IN least_JJS two_CD hours_NNS between_IN intake_NN of_IN this_DT agent_NN and_CC chloroquine_NN should_MD be_VB observed_VBN ._. Cyclosporin_NN :_: After_IN introduction_NN of_IN chloroquine_NN -LRB-_-LRB- oral_JJ form_NN -RRB-_-RRB- ,_, a_DT sudden_JJ increase_NN in_IN serum_NN cyclosporin_NN level_NN has_VBZ been_VBN reported_VBN ._. Therefore_RB ,_, close_JJ monitoring_NN of_IN serum_NN cyclosporin_NN level_NN is_VBZ recommended_VBN and_CC ,_, if_IN necessary_JJ ,_, chloroquine_NN should_MD be_VB discontinued_VBN ._. When_WRB given_VBN concurrently_RB the_DT following_VBG drugs_NNS may_MD interact_VB with_IN thiazide_JJ diuretics_NNS ._. -_: Alcohol_NN ,_, barbiturates_NNS ,_, or_CC narcotics_NNS :_: Potentiation_NN of_IN otthostatic_JJ hypotension_NN may_MD occu_VB ._. -_: Antidiabetic_JJ drugs_NNS :_: -LRB-_-LRB- Oral_JJ agents_NNS and_CC insulin_NN -RRB-_-RRB- Dosage_NN adjustment_NN of_IN the_DT antidiabetic_JJ drug_NN may_MD be_VB require_VB ._. -_: Other_JJ antihypertensive_JJ drugs_NNS :_: Additive_JJ effect_NN or_CC potentiatio_NN ._. -_: Cholestyramine_NN and_CC colestipol_NN resins_NNS :_: Cholestytamine_NN and_CC colestipol_NN resins_NNS have_VBP the_DT potential_NN of_IN binding_VBG thiazide_JJ diuretics_NNS and_CC reducing_VBG diuretic_JJ absorption_NN from_IN the_DT gastrointestinal_JJ trac_NN ._. -_: Corticosteroids_NNS ,_, ACTH_NN :_: Intensified_VBN electrolyte_NN depletion_NN ,_, particularly_RB hypokalemi_NN ._. -_: Pressor_NN amines_NNS -LRB-_-LRB- e.g._FW ,_, norepinephrine_NN -RRB-_-RRB- :_: Possible_JJ decreased_VBN response_NN to_TO pressor_NN amines_NNS but_CC not_RB sufficient_JJ to_TO preclude_VB their_PRP$ us_PRP ._. -_: Skeletal_JJ muscle_NN relaxants_NNS ,_, nondepolarizing_JJ -LRB-_-LRB- e.g._FW ,_, tubocurarine_NN -RRB-_-RRB- :_: Possible_JJ increased_VBN responsiveness_NN to_TO the_DT muscle_NN relaxan_NN ._. -_: Lithium_NN :_: Generally_RB should_MD not_RB be_VB given_VBN with_IN diuretics_NNS ._. Diuretic_JJ agents_NNS reduce_VB the_DT renal_JJ clearance_NN of_IN lithium_NN and_CC add_VB a_DT high_JJ risk_NN of_IN lithium_NN toxicity_NN ._. Refer_VB to_TO the_DT package_NN insert_NN for_IN lithium_NN preparations_NNS before_IN use_NN of_IN such_JJ preparations_NNS with_IN chlorothiazid_NN ._. -_: Non-steroidal_JJ Anti-inflammatory_JJ Drugs_NNS :_: In_IN some_DT patients_NNS ,_, the_DT administration_NN of_IN a_DT non-steroidal_JJ anti-inflammatory_JJ agent_NN can_MD reduce_VB the_DT diuretic_JJ ,_, natriuretic_JJ ,_, and_CC antihypertensive_JJ effects_NNS of_IN loop_NN ,_, potassium-sparing_NN and_CC thiazide_JJ diuretics_NNS ._. Therefore_RB ,_, when_WRB chlorothiazide_NN and_CC non-steroidal_JJ anti-inflammatory_JJ agents_NNS are_VBP used_VBN concomitantly_RB ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB to_TO determine_VB if_IN the_DT desired_VBN effect_NN of_IN the_DT diuretic_JJ is_VBZ obtaine_NN ._. -_: Drug/Laboratory_NN Test_NN Interactions_NNS :_: Thiazides_NNS should_MD be_VB discontinued_VBN before_IN carrying_VBG out_RP tests_NNS for_IN parathyroid_JJ function_NN ._. Chlorotrianisene_NN may_MD interact_VB with_IN antidepressants_NNS ,_, aspirin_NN ,_, barbiturates_NNS ,_, bromocriptine_NN ,_, calcium_NN supplements_NNS ,_, corticosteroids_NNS ,_, corticotropin_NN ,_, cyclosporine_NN ,_, dantrolene_NN ,_, nicotine_NN ,_, somatropin_NN ,_, tamoxifen_NN ,_, and_CC warfarin_NN ._. May_NNP interact_VBP with_IN skin_NN products_NNS or_CC shampoos_NNS for_IN dandruff_NN or_CC psoriasis_NN ._. Substrate_NN of_IN CYP2D6_NN -LRB-_-LRB- minor_JJ -RRB-_-RRB- ,_, 3A4_NN -LRB-_-LRB- major_JJ -RRB-_-RRB- ;_: ._. Inhibits_VBZ CYP2D6_NN -LRB-_-LRB- weak_JJ -RRB-_-RRB- ._. Increased_VBN toxicity_NN -LRB-_-LRB- CNS_NN depression_NN -RRB-_-RRB- :_: CNS_NN depressants_NNS ,_, MAO_NN inhibitors_NNS ,_, tricyclic_JJ antidepressants_NNS ,_, phenothiazines_NNS ._. CYP3A4_NN inhibitors_NNS :_: May_NNP increase_VB the_DT levels/effects_NNS of_IN chlorpheniramine_NN ._. Example_NN inhibitors_NNS include_VBP azole_NN antifungals_NNS ,_, ciprofloxacin_NN ,_, clarithromycin_NN ,_, diclofenac_NN ,_, doxycycline_NN ,_, erythromycin_NN ,_, imatinib_NN ,_, isoniazid_NN ,_, nefazodone_NN ,_, nicardipine_NN ,_, propofol_NN ,_, protease_NN inhibitors_NNS ,_, quinidine_NN ,_, and_CC verapamil_NN ._. The_DT concurrent_JJ use_NN of_IN two_CD or_CC more_JJR drugs_NNS with_IN anticholinergic_JJ activity_NN --_: such_JJ as_IN an_DT antipsychotic_JJ drug_NN -LRB-_-LRB- eg_FW ,_, chlorpromazine_NN -RRB-_-RRB- ,_, an_DT antiparkinsonian_JJ drug_NN -LRB-_-LRB- eg_FW ,_, trihexyphenidyl_NN -RRB-_-RRB- ,_, and/or_CC a_DT tricyclic_JJ antidepressant_JJ -LRB-_-LRB- eg_FW ,_, amitriptyline_NNP -RRB-_-RRB- --_: commonly_RB results_VBZ in_IN excessive_JJ anticholinergic_JJ effects_NNS ,_, including_VBG dry_JJ mouth_NN and_CC associated_VBN dental_JJ complications_NNS ,_, blurred_VBD vision_NN ,_, and_CC ,_, in_IN patients_NNS exposed_VBN to_TO high_JJ temperature_NN and_CC humidity_NN ,_, hyperpyrexia_NN ._. Interactions_NNS may_MD also_RB occur_VB with_IN the_DT following_NN :_: anti-depressants/anti-anxiety_JJ drugs_NNS ,_, drugs_NNS used_VBN to_TO treat_VB an_DT overactive_JJ thyroid_NN ,_, beta-blockers_NNS -LRB-_-LRB- e.g._FW ,_, propranolol_NN -RRB-_-RRB- ,_, sparfloxacin_NN ,_, grepafloxacin_NN ,_, guanethidine_NN ,_, guanadrel_NN ,_, metrizamide_NN ,_, cabergoline_NN ,_, lithium_NN ,_, narcotic_JJ pain_NN medication_NN -LRB-_-LRB- e.g._FW ,_, codeine_NN -RRB-_-RRB- ,_, drugs_NNS used_VBN to_TO aid_VB sleep_NN ,_, drowsiness-causing_JJ antihistamines_NNS -LRB-_-LRB- e.g._FW ,_, diphenhydramine_NN -RRB-_-RRB- ,_, any_DT other_JJ drugs_NNS that_WDT may_MD make_VB you_PRP drowsy_JJ ._. The_DT hypoglycemic_JJ action_NN of_IN sulfonylurea_NN may_MD be_VB potentiated_VBN by_IN certain_JJ drugs_NNS including_VBG nonsteroidal_JJ anti-inflammatory_JJ agents_NNS and_CC other_JJ drugs_NNS that_WDT are_VBP highly_RB protein_NN bound_VBD ,_, salicylates_NNS ,_, sulfonamides_NNS ,_, chloramphenicol_NN ,_, probenecid_NN ,_, coumarins_NNS ,_, monoamine_NN oxidase_NN inhibitors_NNS ,_, and_CC beta_NN adrenergic_JJ blocking_VBG agents_NNS ._. When_WRB such_JJ drugs_NNS are_VBP administered_VBN to_TO a_DT patient_NN receiving_VBG DIABINESE_NNP ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB for_IN hypoglycemia_NN ._. When_WRB such_JJ drugs_NNS are_VBP withdrawn_VBN from_IN a_DT patient_NN receiving_VBG DIABINESE_NNP ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB for_IN loss_NN of_IN control_NN ._. Certain_JJ drugs_NNS tend_VBP to_TO produce_VB hyperglycemia_NN and_CC may_MD lead_VB to_TO loss_NN of_IN control_NN ._. These_DT drugs_NNS include_VBP the_DT thiazides_NNS and_CC other_JJ diuretics_NNS ,_, corticosteroids_NNS ,_, phenothiazines_NNS ,_, thyroid_NN products_NNS ,_, estrogens_NNS ,_, oral_JJ contraceptives_NNS ,_, phenytoin_NN ,_, nicotinic_JJ acid_NN ,_, sympathomimetics_NNS ,_, calcium_NN channel_NN blocking_VBG drugs_NNS ,_, and_CC isoniazid_NN ._. When_WRB such_JJ drugs_NNS are_VBP administered_VBN to_TO a_DT patient_NN receiving_VBG DIABINESE_NNP ,_, the_DT patient_NN should_MD be_VB closely_RB observed_VBN for_IN loss_NN of_IN control_NN ._. When_WRB such_JJ drugs_NNS are_VBP withdrawn_VBN from_IN a_DT patient_NN receiving_VBG DIABINESE_NNP ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB for_IN hypoglycemia_NN ._. Since_IN animal_NN studies_NNS suggest_VBP that_IN the_DT action_NN of_IN barbiturates_NNS may_MD be_VB prolonged_VBN by_IN therapy_NN with_IN chlorpropamide_NN ,_, barbiturates_NNS should_MD be_VB employed_VBN with_IN caution_NN ._. In_IN some_DT patients_NNS ,_, a_DT disulfiram-like_JJ reaction_NN may_MD be_VB produced_VBN by_IN the_DT ingestion_NN of_IN alcohol_NN ._. A_DT potential_JJ interaction_NN between_IN oral_JJ miconazole_NN and_CC oral_JJ hypoglycemic_JJ agents_NNS leading_VBG to_TO severe_JJ hypoglycemia_NN has_VBZ been_VBN reported_VBN ._. Whether_IN this_DT interaction_NN also_RB occurs_VBZ with_IN the_DT intravenous_JJ ,_, topical_JJ ,_, or_CC vaginal_JJ preparations_NNS of_IN miconazole_NN is_VBZ not_RB known_VBN ._. Chlorprothixene_NN may_MD increase_VB the_DT plasma-level_NN of_IN concomitantly_RB given_VBN lithium_NN ._. In_IN order_NN to_TO avoid_VB lithium_NN intoxication_NN ,_, lithium_NN plasma_NN levels_NNS should_MD be_VB monitored_VBN closely_RB ._. If_IN chlorprothixene_NN is_VBZ given_VBN concomitantly_RB with_IN opioids_NNS ,_, the_DT opioid_JJ dose_NN should_MD be_VB reduced_VBN -LRB-_-LRB- by_IN approx_RB ._. 50_CD %_NN -RRB-_-RRB- ,_, because_IN chlorprothixene_NN amplifies_VBZ the_DT therapeutic_JJ actions_NNS and_CC side-effects_NNS of_IN opioids_NNS massively_RB ._. Avoid_VB the_DT concomitant_JJ use_NN of_IN chlorprothixene_NN and_CC tramadol_NN -LRB-_-LRB- Ultram_NN -RRB-_-RRB- ._. Massive_JJ seizures_NNS may_MD be_VB encountered_VBN with_IN this_DT combination_NN ._. Consider_VB additive_JJ sedative_JJ effects_NNS and_CC confusional_JJ states_NNS to_TO emerge_VB ,_, if_IN chlorprothixene_NN is_VBZ given_VBN with_IN benzodiazepines_NNS or_CC barbituates_NNS ._. Choose_VB particular_JJ low_JJ doses_NNS of_IN these_DT drugs_NNS ._. Exert_VB particular_JJ caution_NN in_IN combining_VBG chlorprothixene_NN with_IN other_JJ anticholinergic_JJ drugs_NNS -LRB-_-LRB- tricyclic_JJ antidepressants_NNS and_CC antiparkinsonian_JJ agents_NNS -RRB-_-RRB- :_: Particularly_RB the_DT elderly_JJ may_MD develop_VB delirium_NN ,_, high_JJ fever_NN ,_, severe_JJ obstipation_NN ,_, even_RB ileus_NN and_CC glaucoma_NN ._. Chlorthalidone_NNP may_MD add_VB to_TO or_CC potentiate_VB the_DT action_NN of_IN other_JJ antihypertensive_JJ drugs_NNS ._. Potentiation_NN occurs_VBZ with_IN ganglionic_JJ peripheral_JJ adrenergic_JJ blocking_NN drugs_NNS ._. Medication_NN such_JJ as_IN digitalis_NN may_MD also_RB influence_VB serum_NN electrolytes_NNS ._. Warning_NN signs_NNS ,_, irrespective_RB of_IN cause_NN ,_, are_VBP :_: dryness_NN of_IN mouth_NN ,_, thirst_NN ,_, weakness_NN ,_, lethargy_NN ,_, drowsiness_NN ,_, restlessness_NN ,_, muscle_NN pains_NNS or_CC cramps_NNS ,_, muscular_JJ fatigue_NN ,_, hypotension_NN ,_, oliguria_NN ,_, tachycardia_NN ,_, and_CC gastrointestinal_JJ disturbances_NNS such_JJ as_IN nausea_NN and_CC vomiting_NN ._. Insulin_NN requirements_NNS in_IN diabetic_JJ patients_NNS may_MD be_VB increased_VBN ,_, decreased_VBN ,_, or_CC unchanged_JJ ._. Higher_JJR dosage_NN of_IN oral_JJ hypoglycemic_JJ agents_NNS may_MD be_VB required_VBN ._. Latent_JJ diabetes_NN mellitus_NN may_MD become_VB manifest_JJ during_IN chlorthalidone_NN administration_NN ._. Chlorthalidone_NNP and_CC related_JJ drugs_NNS may_MD increase_VB the_DT responsiveness_NN to_TO tubocurarine_NN ._. Chlorthalidone_NNP and_CC related_JJ drugs_NNS may_MD decrease_VB arterial_JJ responsiveness_NN to_TO norepinephrine_NN ._. This_DT diminution_NN is_VBZ not_RB sufficient_JJ to_TO preclude_VB effectiveness_NN of_IN the_DT pressor_NN agent_NN for_IN therapeutic_JJ use_NN ._. The_DT concomitant_JJ use_NN of_IN alcohol_NN or_CC other_JJ central_JJ nervous_JJ system_NN depressants_NNS may_MD have_VB an_DT additive_JJ effect_NN ._. Interactions_NNS for_IN vitamin_NN D_NN analogues_NNS -LRB-_-LRB- Vitamin_NN D2_NN ,_, Vitamin_NN D3_NN ,_, Calcitriol_NN ,_, and_CC Calcidiol_NN -RRB-_-RRB- :_: Cholestyramine_NNP :_: Cholestyramine_NNP has_VBZ been_VBN reported_VBN to_TO reduce_VB intestinal_JJ absorption_NN of_IN fat_JJ soluble_JJ vitamins_NNS ._. as_IN such_JJ it_PRP may_MD impair_VB intestinal_JJ absorption_NN of_IN any_DT of_IN vitamin_NN D._NNP Phenytoin/Phenobarbital_NNP :_: The_DT coadministration_NN of_IN phenytoin_NN or_CC phenobarbital_NN will_MD not_RB affect_VB plasma_NN concentrations_NNS of_IN vitamin_NN D_NN ,_, but_CC may_MD reduce_VB endogenous_JJ plasma_NN levels_NNS of_IN calcitriol/ergocalcitriol_NN by_IN accelerating_VBG metabolism_NN ._. Since_IN blood_NN level_NN of_IN calcitriol/ergocalcitriol_NN will_MD be_VB reduced_VBN ,_, higher_JJR doses_NNS of_IN Rocaltrol_NNP may_MD be_VB necessary_JJ if_IN these_DT drugs_NNS are_VBP administered_VBN simultaneously_RB ._. Thiazides_NNP :_: Thiazides_NNS are_VBP known_VBN to_TO induce_VB hypercalcemia_NN by_IN the_DT reduction_NN of_IN calcium_NN excretion_NN in_IN urine_NN ._. Some_DT reports_NNS have_VBP shown_VBN that_IN the_DT concomitant_JJ administration_NN of_IN thiazides_NNS with_IN vitamin_NN D_NN causes_VBZ hypercalcemia_NN ._. Therefore_RB ,_, precaution_NN should_MD be_VB taken_VBN when_WRB coadministration_NN is_VBZ necessary_JJ ._. Digitalis_NNP :_: Vitamin_NN D_NN dosage_NN must_MD be_VB determined_VBN with_IN care_NN in_IN patients_NNS undergoing_VBG treatment_NN with_IN digitalis_NN ,_, as_IN hypercalcemia_NN in_IN such_JJ patients_NNS may_MD precipitate_VB cardiac_JJ arrhythmias_NNS ._. Ketoconazole_NN :_: Ketoconazole_NN may_MD inhibit_VB both_DT synthetic_JJ and_CC catabolic_JJ enzymes_NNS of_IN vitamin_NN D._NNP Reductions_NNPS in_IN serum_NN endogenous_JJ vitamin_NN D_NN concentrations_NNS have_VBP been_VBN observed_VBN following_VBG the_DT administration_NN of_IN 300_CD mg/day_NN to_TO 1200_CD mg/day_NN ketoconazole_NN for_IN a_DT week_NN to_TO healthy_JJ men_NNS ._. However_RB ,_, in_FW vivo_FW drug_NN interaction_NN studies_NNS of_IN ketoconazole_NN with_IN vitamin_NN D_NN have_VBP not_RB been_VBN investigated_VBN ._. Corticosteroids_NNS :_: A_DT relationship_NN of_IN functional_JJ antagonism_NN exists_VBZ between_IN vitamin_NN D_NN analogues_NNS ,_, which_WDT promote_VBP calcium_NN absorption_NN ,_, and_CC corticosteroids_NNS ,_, which_WDT inhibit_VBP calcium_NN absorption_NN ._. Phosphate-Binding_JJ Agents_NNS :_: Since_IN vitamin_NN D_NN also_RB has_VBZ an_DT effect_NN on_IN phosphate_NN transport_NN in_IN the_DT intestine_NN ,_, kidneys_NNS and_CC bones_NNS ,_, the_DT dosage_NN of_IN phosphate-binding_JJ agents_NNS must_MD be_VB adjusted_VBN in_IN accordance_NN with_IN the_DT serum_NN phosphate_NN concentration_NN ._. Vitamin_NN D_NN :_: The_DT coadministration_NN of_IN any_DT of_IN the_DT vitamin_NN D_NN analogues_NNS should_MD be_VB avoided_VBN as_IN this_DT could_MD create_VB possible_JJ additive_JJ effects_NNS and_CC hypercalcemia_NN ._. Calcium_NN Supplements_NNS :_: Uncontrolled_JJ intake_NN of_IN additional_JJ calcium-containing_JJ preparations_NNS should_MD be_VB avoided_VBN ._. Magnesium_NN :_: Magnesium-containing_JJ preparations_NNS -LRB-_-LRB- eg_FW ,_, antacids_NNS -RRB-_-RRB- may_MD cause_VB hypermagnesemia_NN and_CC should_MD therefore_RB not_RB be_VB taken_VBN during_IN therapy_NN with_IN vitamin_NN D_NN by_IN patients_NNS on_IN chronic_JJ renal_JJ dialysis_NN ._. Cholestyramine_NNP resin_NN may_MD delay_VB or_CC reduce_VB the_DT absorption_NN of_IN concomitant_JJ oral_JJ medication_NN such_JJ as_IN phenylbutazone_NN ,_, warfarin_NN ,_, thiazide_JJ diuretics_NNS -LRB-_-LRB- acidic_JJ -RRB-_-RRB- or_CC propranolol_NN -LRB-_-LRB- basic_JJ -RRB-_-RRB- ,_, as_RB well_RB as_IN tetracycline_NN penicillin_NN G_NN ,_, phenobarbital_NN ,_, thyroid_NN and_CC thyroxine_NN preparations_NNS ,_, estrogens_NNS and_CC progestins_NNS ,_, and_CC digitalis_NN ._. Interference_NN with_IN the_DT absorption_NN of_IN oral_JJ phosphate_NN supplements_NNS has_VBZ been_VBN observed_VBN with_IN another_DT positively-charged_JJ bile_NN acid_NN sequestrant_NN ._. Cholestyramine_NNP resin_NN may_MD interfere_VB with_IN the_DT pharmacokinetics_NNS of_IN drugs_NNS that_WDT undergo_VBP enterohepatic_JJ circulation_NN ,_, The_DT discontinuance_NN of_IN cholestyramine_NN resin_NN could_MD pose_VB a_DT hazard_NN to_TO health_NN if_IN a_DT potentially_RB toxic_JJ drug_NN such_JJ as_IN digitalis_NN has_VBZ been_VBN filtrated_VBN to_TO a_DT maintenance_NN level_NN while_IN the_DT patient_NN was_VBD taking_VBG cholestyramine_NN resin_NN ._. Because_IN cholestyramine_NN binds_VBZ bile_NN acids_NNS ,_, cholestyramine_NN resin_NN may_MD interfere_VB with_IN normal_JJ fat_JJ digestion_NN and_CC absorption_NN and_CC thus_RB may_MD prevent_VB absorption_NN of_IN fat_JJ soluble_JJ vitamins_NNS such_JJ as_IN A_DT ,_, D_NN ,_, E_NN ,_, and_CC K_NN ._. When_WRB cholestyramine_NN resin_NN is_VBZ given_VBN for_IN long_JJ periods_NNS of_IN time_NN ,_, concomitant_JJ supplementation_NN with_IN water-miscible_JJ -LRB-_-LRB- or_CC parenteral_JJ -RRB-_-RRB- forms_NNS of_IN fat-soluble_JJ vitamins_NNS should_MD be_VB considered_VBN ._. SINCE_IN CHOLESTYRAMINE_NNP RESIN_NNP MAY_NNP BIND_VBP OTHER_JJ DRUGS_NNS GIVEN_VBP CONCURRENTLY_RB ,_, IT_PRP IS_VBZ RECOMMENDED_NNP THAT_WDT PATIENTS_NNS TAKE_VBP OTHER_JJ DRUGS_NNS AT_IN LEAST_NN 1_CD HOUR_NN BEFORE_IN OR_NN 4_CD TO_TO 6_CD HOURS_NNS AFTER_IN CHOLESTYRAMINE_NNP RESIN_NNP -LRB-_-LRB- OR_NN AT_IN AS_JJ GREAT_JJ AN_DT INTERVAL_NNP AS_NNP POSSIBLE_NN -RRB-_-RRB- TO_TO AVOID_VB IMPEDING_NNP THEIR_NNP ABSORPTION_NNP ._. Based_VBN on_IN in_FW vitro_FW studies_NNS in_IN human_JJ liver_NN microsomes_NNS ,_, des-ciclesonide_NN appears_VBZ to_TO have_VB no_DT inhibitory_JJ or_CC induction_NN potential_NN on_IN the_DT metabolism_NN of_IN other_JJ drugs_NNS metabolized_VBN by_IN CYP_NN 450_CD enzymes_NNS ._. The_DT inhibitory_JJ potential_NN of_IN ciclesonide_NN on_IN CYP450_NN isoenzymes_NNS has_VBZ not_RB been_VBN studied_VBN ._. In_FW vitro_FW studies_NNS demonstrated_VBD that_IN the_DT plasma_NN protein_NN binding_NN of_IN des-ciclesonide_NN was_VBD not_RB affected_VBN by_IN warfarin_NN or_CC salicylic_JJ acid_NN ,_, indicating_VBG no_DT potential_NN for_IN protein_NN binding-based_JJ drug_NN interactions_NNS ._. In_IN a_DT drug_NN interaction_NN study_NN ,_, co-administration_NN of_IN orally_RB inhaled_VBN ciclesonide_NN and_CC oral_JJ erythromycin_NN ,_, an_DT inhibitor_NN of_IN cytochrome_NN P450_NN 3A4_NN ,_, had_VBD no_DT effect_NN on_IN the_DT pharmacokinetics_NNS of_IN either_CC des-ciclesonide_NN or_CC erythromycin_NN ._. In_IN another_DT drug_NN interaction_NN study_NN ,_, co-administration_NN of_IN orally_RB inhaled_VBN ciclesonide_NN and_CC oral_JJ ketoconazole_NN ,_, a_DT potent_JJ inhibitor_NN of_IN cytochrome_NN P450_NN 3A4_NN ,_, increased_VBD the_DT exposure_NN -LRB-_-LRB- AUC_NN -RRB-_-RRB- of_IN des-ciclesonide_NN by_IN approximately_RB 3.6-fold_RB at_IN steady_JJ state_NN ,_, while_IN levels_NNS of_IN ciclesonide_NN remained_VBD unchanged_JJ ._. Therefore_RB ,_, ketoconazole_NN should_MD be_VB administered_VBN with_IN caution_NN with_IN intranasal_JJ ciclesonide_NN ._. Probenecid_NNP :_: Probenecid_NNP is_VBZ known_VBN to_TO interact_VB with_IN the_DT metabolism_NN or_CC renal_JJ tubular_JJ excretion_NN of_IN many_JJ drugs_NNS -LRB-_-LRB- e.g._FW ,_, acetaminophen_NN ,_, acyclovir_NN ,_, angiotensin-converting_JJ enzyme_NN inhibitors_NNS ,_, aminosalicylic_JJ acid_NN ,_, barbiturates_NNS ,_, benzodiazepines_NNS ,_, bumetanide_NN ,_, clofibrate_NN ,_, methotrexate_NN ,_, famotidine_NN ,_, furosemide_NN ,_, nonsteroidal_JJ anti-inflammatory_JJ agents_NNS ,_, theophylline_NN ,_, and_CC zidovudine_NN -RRB-_-RRB- ._. Concomitant_JJ medications_NNS should_MD be_VB carefully_RB assessed_VBN ._. Zidovudine_NN should_MD either_RB be_VB temporarily_RB discontinued_VBN or_CC decreased_VBN by_IN 50_CD %_NN when_WRB coadministered_VBN with_IN probenecid_NN on_IN the_DT day_NN of_IN VISTIDE_NNP infusion_NN ._. Nephrotoxic_JJ agents_NNS :_: Concomitant_JJ administration_NN of_IN VISTIDE_NNP and_CC agents_NNS with_IN nephrotoxic_JJ potential_JJ -LSB-_-LRB- e.g._FW ,_, intravenous_JJ aminoglycosides_NNS -LRB-_-LRB- e.g._FW ,_, tobramycin_NN ,_, gentamicin_NN ,_, and_CC amikacin_NN -RRB-_-RRB- ,_, amphotericin_NN B_NN ,_, foscarnet_NN ,_, intravenous_JJ pentamidine_NN ,_, vancomycin_NN ,_, and_CC non-steroidal_JJ anti-inflammatory_JJ agents_NNS -RSB-_-RRB- is_VBZ contraindicated_VBN ._. Such_JJ agents_NNS must_MD be_VB discontinued_VBN at_IN least_JJS seven_CD days_NNS prior_RB to_TO starting_VBG therapy_NN with_IN VISTIDE_NN ._. Since_IN PLETAL_NN is_VBZ extensively_RB metabolized_VBN by_IN cytochrome_NN P-450_NN isoenzymes_NNS ,_, caution_NN should_MD be_VB exercised_VBN when_WRB PLETAL_NNP is_VBZ coadministered_VBN with_IN inhibitors_NNS of_IN C.P.A._NNP such_JJ as_IN ketoconazole_NN and_CC erythromycin_NN or_CC inhibitors_NNS of_IN CYP2C19_NN such_JJ as_IN omeprazole_NN ._. Pharmacokinetic_JJ studies_NNS have_VBP demonstrated_VBN that_IN omeprazole_NN and_CC erythromycin_NN significantly_RB increased_VBD the_DT systemic_JJ exposure_NN of_IN cilostazol_NN and/or_CC its_PRP$ major_JJ metabolites_NNS ._. Population_NNP pharmacokinetic_JJ studies_NNS showed_VBD higher_JJR concentrations_NNS of_IN cilostazol_NN among_IN patients_NNS concurrently_RB treated_VBN with_IN diltiazem_NN ,_, an_DT inhibitor_NN of_IN C.P.A._NNP Pletal_NNP does_VBZ not_RB ,_, however_RB ,_, appear_VBP to_TO cause_VB increased_VBN blood_NN levels_NNS of_IN drugs_NNS metabolized_VBN by_IN CYP3A4_NN ,_, as_IN it_PRP had_VBD no_DT effect_NN on_IN lovastatin_NN ,_, a_DT drug_NN with_IN metabolism_NN very_RB sensitive_JJ to_TO C.P.A._NNP inhibition_NN ._. Tagamet_NNP ,_, apparently_RB through_IN an_DT effect_NN on_IN certain_JJ microsomal_JJ enzyme_NN systems_NNS ,_, has_VBZ been_VBN reported_VBN to_TO reduce_VB the_DT hepatic_JJ metabolism_NN of_IN warfarin-type_JJ anticoagulants_NNS ,_, phenytoin_NN ,_, propranolol_NN ,_, nifedipine_NN ,_, chlordiazepoxide_NN ,_, diazepam_NN ,_, certain_JJ tricyclic_JJ antidepressants_NNS ,_, lidocaine_NN ,_, theophylline_NN and_CC metronidazole_NN ,_, thereby_RB delaying_VBG elimination_NN and_CC increasing_VBG blood_NN levels_NNS of_IN these_DT drugs_NNS ._. Clinically_RB significant_JJ effects_NNS have_VBP been_VBN reported_VBN with_IN the_DT warfarin_NN anticoagulants_NNS ._. therefore_RB ,_, close_JJ monitoring_NN of_IN prothrombin_NN time_NN is_VBZ recommended_VBN ,_, and_CC adjustment_NN of_IN the_DT anticoagulant_JJ dose_NN may_MD be_VB necessary_JJ when_WRB Tagamet_NNP is_VBZ administered_VBN concomitantly_RB ._. Interaction_NN with_IN phenytoin_NN ,_, lidocaine_NN and_CC theophylline_NN has_VBZ also_RB been_VBN reported_VBN to_TO produce_VB adverse_JJ clinical_JJ effects_NNS ._. However_RB ,_, a_DT crossover_NN study_NN in_IN healthy_JJ subjects_NNS receiving_VBG either_CC Tagamet_NNP 300_CD mg_NN q.i.d._NN or_CC 800_CD mg_NN h.s._NN concomitantly_RB with_IN a_DT 300_CD mg_NN b.i.d._NN dosage_NN of_IN theophylline_NN -LRB-_-LRB- Theo-Dur_NNP ,_, Key_NNP Pharmaceuticals_NNP ,_, Inc._NNP -RRB-_-RRB- demonstrated_VBD less_JJR alteration_NN in_IN steady-state_JJ theophylline_NN peak_NN serum_NN levels_NNS with_IN the_DT 800_CD mg_NN h.s._NN regimen_NN ,_, particularly_RB in_IN subjects_NNS aged_JJ 54_CD years_NNS and_CC older_JJR ._. Data_NNS beyond_IN 10_CD days_NNS are_VBP not_RB available_JJ ._. -LRB-_-LRB- Note_NN :_: All_DT patients_NNS receiving_VBG theophylline_NN should_MD be_VB monitored_VBN appropriately_RB ,_, regardless_RB of_IN concomitant_JJ drug_NN therapy_NN ._. Dosage_NN of_IN the_DT drugs_NNS mentioned_VBN above_IN and_CC other_JJ similarly_RB metabolized_VBN drugs_NNS ,_, particularly_RB those_DT of_IN low_JJ therapeutic_JJ ratio_NN or_CC in_IN patients_NNS with_IN renal_JJ and/or_CC hepatic_JJ impairment_NN ,_, may_MD require_VB adjustment_NN when_WRB starting_VBG or_CC stopping_VBG concomitantly_RB administered_VBN Tagamet_NNP to_TO maintain_VB optimum_JJ therapeutic_JJ blood_NN levels_NNS ._. Alteration_NN of_IN pH_NN may_MD affect_VB absorption_NN of_IN certain_JJ drugs_NNS -LRB-_-LRB- e.g._FW ,_, ketoconazole_NN -RRB-_-RRB- ._. If_IN these_DT products_NNS are_VBP needed_VBN ,_, they_PRP should_MD be_VB given_VBN at_IN least_JJS 2_CD hours_NNS before_IN cimetidine_NN administration_NN ._. Additional_JJ clinical_JJ experience_NN may_MD reveal_VB other_JJ drugs_NNS affected_VBN by_IN the_DT concomitant_JJ administration_NN of_IN Tagamet_NNP ._. and/or_CC Drug/Laboratory_JJ Test_NN Interactions_NNS See_VB CLINICAL_NNP PHARMACOLOGY_NNP ,_, Pharmacokinetics_NNP and_CC Drug_NNP Interactions_NNS ._. Effect_NN of_IN Sensipar_NN on_IN other_JJ drugs_NNS :_: Drugs_NNS metabolized_VBN by_IN cytochrome_NN P450_NN 2D6_NN -LRB-_-LRB- CYP2D6_NN -RRB-_-RRB- :_: Sensipar_NN is_VBZ a_DT strong_JJ in_FW vitro_FW inhibitor_NN of_IN CYP2D6_NN ._. Therefore_RB ,_, dose_NN adjustments_NNS of_IN concomitant_JJ medications_NNS that_WDT are_VBP predominantly_RB metabolized_VBN by_IN CYP2D6_NN and_CC have_VBP a_DT narrow_JJ therapeutic_JJ index_NN -LRB-_-LRB- e.g._FW ,_, flecainide_NN ,_, vinblastine_NN ,_, thioridazine_NN and_CC most_RBS tricyclic_JJ antidepressants_NNS -RRB-_-RRB- may_MD be_VB required_VBN ._. Amitriptyline_NNP :_: Concurrent_JJ administration_NN of_IN 25_CD mg_NN or_CC 100_CD mg_NN cinacalcet_NN with_IN 50_CD mg_NN amitriptyline_NNP increased_VBD amitriptyline_NNP exposure_NN and_CC nortriptyline_NN -LRB-_-LRB- active_JJ metabolite_NN -RRB-_-RRB- exposure_NN by_IN approximately_RB 20_CD %_NN in_IN CYP2D6_NN extensive_JJ metabolizers_NNS ._. Effect_NN of_IN other_JJ drugs_NNS on_IN Sensipar_NNP :_: Sensipar_NNP is_VBZ metabolized_VBN by_IN multiple_JJ cytochrome_NN P450_NN enzymes_NNS ,_, primarily_RB CYP3A4_NN ,_, CYP2D6_NN ,_, and_CC CYP1A2_NN ._. Ketoconazole_NN :_: Sensipar_NN is_VBZ metabolized_VBN in_IN part_NN by_IN CYP3A4_NN ._. Co-administration_NN of_IN ketoconazole_NN ,_, a_DT strong_JJ inhibitor_NN of_IN CYP3A4_NN ,_, increased_VBD cinacalcet_NN exposure_NN following_VBG a_DT single_JJ 90_CD mg_NN dose_NN of_IN Sensipar_NN by_IN 2.3_CD fold_NN ._. Dose_NN adjustment_NN of_IN Sensipar_NN may_MD be_VB required_VBN and_CC PTH_NN and_CC serum_NN calcium_NN concentrations_NNS should_MD be_VB closely_RB monitored_VBN if_IN a_DT patient_NN initiates_VBZ or_CC discontinues_VBZ therapy_NN with_IN a_DT strong_JJ CYP3A4_NN inhibitor_NN -LRB-_-LRB- e.g._FW ,_, ketoconazole_NN ,_, erythromycin_NN ,_, itraconazole_NN ._. see_VB DOSAGE_NNP AND_CC ADMINISTRATION_NNP -RRB-_-RRB- ._. Elevated_JJ plasma_NN levels_NNS of_IN theophylline_NN have_VBP been_VBN reported_VBN with_IN concomitant_JJ use_NN of_IN some_DT quinolones_NNS ._. There_EX have_VBP been_VBN reports_NNS of_IN theophylline-related_JJ side-effects_NNS in_IN patients_NNS on_IN concomitant_JJ theophylline-quinolone_JJ therapy_NN ._. Therefore_RB ,_, monitoring_NN of_IN theophylline_NN plasma_NN levels_NNS should_MD be_VB considered_VBN and_CC dosage_NN of_IN theophylline_NN adjusted_VBN as_IN required_VBN ._. Quinolones_NNS have_VBP also_RB been_VBN shown_VBN to_TO interfere_VB with_IN the_DT metabolism_NN of_IN caffeine_NN ._. This_DT may_MD lead_VB to_TO reduced_VBN clearance_NN of_IN caffeine_NN and_CC a_DT prolongation_NN of_IN its_PRP$ plasma_NN half-life_NN ._. Although_IN this_DT interaction_NN has_VBZ not_RB been_VBN reported_VBN with_IN cinoxacin_NN ,_, caution_NN should_MD be_VB exercised_VBN when_WRB cinoxacin_NN is_VBZ given_VBN concomitantly_RB with_IN caffeine-containing_JJ products_NNS ._. Antacids_NNS or_CC sucralfate_NN substantially_RB interfere_VBP with_IN the_DT absorption_NN of_IN some_DT quinolones_NNS ,_, resulting_VBG in_IN low_JJ urine_NN levels_NNS ._. Also_RB ,_, concomitant_JJ administration_NN of_IN quinolones_NNS with_IN products_NNS containing_VBG iron_NN ,_, multivitamins_NNS containing_VBG zinc_NN ,_, or_CC Videx_NNP -LRB-_-LRB- didanosine_NN -RRB-_-RRB- chewable/buffered_VBD tablets_NNS or_CC the_DT pediatric_JJ powder_NN for_IN oral_JJ solution_NN may_MD result_VB in_IN low_JJ urine_NN levels_NNS ._. Quinolones_NNP ,_, including_VBG cinoxacin_NN ,_, may_MD enhance_VB the_DT effects_NNS of_IN oral_JJ anticoagulants_NNS ,_, such_JJ as_IN warfarin_NN or_CC its_PRP$ derivatives_NNS ._. When_WRB these_DT products_NNS are_VBP administered_VBN concomitantly_RB ,_, prothrombin_NN time_NN or_CC other_JJ suitable_JJ coagulation_NN tests_NNS should_MD be_VB closely_RB monitored_VBN ._. Seizures_NNS have_VBP been_VBN reported_VBN in_IN patients_NNS taking_VBG another_DT quinolone_NN class_NN antimicrobial_JJ and_CC the_DT nonsteroidal_JJ anti-inflammatory_JJ drug_NN fenbufen_NN concurrently_RB ._. Animal_NN studies_NNS also_RB suggest_VBP an_DT increased_VBN potential_NN for_IN seizures_NNS when_WRB these_DT 2_CD drugs_NNS are_VBP given_VBN concomitantly_RB ._. Fenbufen_NNP is_VBZ not_RB approved_VBN in_IN the_DT United_NNP States_NNPS at_IN this_DT time_NN ._. Physicians_NNP are_VBP provided_VBN this_DT information_NN to_TO increase_VB awareness_NN of_IN the_DT potential_NN for_IN serious_JJ interactions_NNS when_WRB cinoxacin_NN and_CC certain_JJ nonsteroidal_JJ anti-inflammatory_JJ agents_NNS are_VBP administered_VBN concomitantly_RB ._. Elevated_JJ cyclosporine_NN serum_NN levels_NNS have_VBP been_VBN reported_VBN with_IN the_DT concomitant_JJ use_NN of_IN quinolones_NNS and_CC cyclosporine_NN ._. Some_DT quinolones_NNS ,_, including_VBG ciprofloxacin_NN ,_, have_VBP also_RB been_VBN shown_VBN to_TO interfere_VB with_IN the_DT metabolism_NN of_IN caffeine_NN ._. This_DT may_MD lead_VB to_TO reduced_VBN clearance_NN of_IN caffeine_NN and_CC a_DT prolongation_NN of_IN its_PRP$ serum_NN half-life_NN ._. Some_DT quinolones_NNS ,_, including_VBG ciprofloxacin_NN ,_, have_VBP been_VBN associated_VBN with_IN transient_JJ elevations_NNS in_IN serum_NN creatinine_NN in_IN patients_NNS receiving_VBG cyclosporine_NN concomitantly_RB ._. Glyburide_NNP :_: The_DT concomitant_JJ administration_NN of_IN ciprofloxacin_NN with_IN the_DT sulfonylurea_NN glyburide_NN has_VBZ ,_, on_IN rare_JJ occasions_NNS ,_, resulted_VBD in_IN severe_JJ hypoglycemia_NN ._. Histamine_NN H2-receptor_NN antagonists_NNS :_: Histamine_NN H2-receptor_NN antagonists_NNS appear_VBP to_TO have_VB no_DT significant_JJ effect_NN on_IN the_DT bioavailability_NN of_IN ciprofloxacin_NN ._. Methotrexate_NNP Renal_JJ tubular_JJ transport_NN of_IN methotrexate_NN may_MD be_VB inhibited_VBN by_IN concomitant_JJ administration_NN of_IN ciprofloxacin_NN ,_, potentially_RB leading_VBG to_TO increased_VBN plasma_NN levels_NNS of_IN methotrexate_NN ._. This_DT might_MD increase_VB the_DT risk_NN of_IN methotrexate_NN toxic_JJ reactions_NNS ._. Therefore_RB ,_, patients_NNS under_IN methotrexate_NN therapy_NN should_MD be_VB carefully_RB monitored_VBN when_WRB concomitant_JJ ciprofloxacin_NN therapy_NN is_VBZ indicated_VBN ._. Multivalent_JJ Cation-Containing_NNP Products_NNPS :_: Concurrent_JJ administration_NN of_IN a_DT quinolone_NN ,_, including_VBG ciprofloxacin_NN ,_, with_IN multivalent_JJ cation-containing_JJ products_NNS such_JJ as_IN magnesium_NN or_CC aluminum_NN antacids_NNS ,_, sucralfate_NN ,_, VIDEX_NNP chewable/buffered_VBD tablets_NNS or_CC pediatric_JJ powder_NN ,_, or_CC products_NNS containing_VBG calcium_NN ,_, iron_NN ,_, or_CC zinc_NN may_MD substantially_RB decrease_VB the_DT absorption_NN of_IN ciprofloxacin_NN ,_, resulting_VBG in_IN serum_NN and_CC urine_NN levels_NNS considerably_RB lower_JJR than_IN desired_VBN ._. Proquin_NNP XR_NNP should_MD be_VB administered_VBN at_IN least_JJS 4_CD hours_NNS before_IN or_CC 2_CD hours_NNS after_IN these_DT products_NNS ._. This_DT time_NN window_NN is_VBZ different_JJ than_IN for_IN other_JJ oral_JJ formulations_NNS of_IN ciprofloxacin_NN ,_, which_WDT are_VBP usually_RB administered_VBN 2_CD hours_NNS before_IN or_CC 6_CD hours_NNS after_IN antacids_NNS ._. Non-steroidal_JJ anti-inflammatory_JJ drugs_NNS -LRB-_-LRB- but_CC not_RB aspirin_NN -RRB-_-RRB- :_: These_DT drugs_NNS in_IN combination_NN with_IN very_RB high_JJ doses_NNS of_IN quinolones_NNS have_VBP been_VBN shown_VBN to_TO provoke_VB convulsions_NNS in_IN pre-clinical_JJ studies_NNS ._. Omeprazole_NNP :_: The_DT rate_NN and_CC extent_NN of_IN absorption_NN of_IN ciprofloxacin_NN was_VBD bioequivalent_JJ when_WRB Proquin_NNP XR_NNP was_VBD given_VBN alone_RB or_CC when_WRB Proquin_NNP XR_NNP was_VBD given_VBN 2_CD hours_NNS after_IN omeprazole_NN at_IN the_DT dose_NN that_WDT maximally_RB suppresses_VBZ gastric_JJ acid_NN secretion_NN ._. Omeprazole_NNP should_MD be_VB taken_VBN as_IN directed_VBN and_CC Proquin_NNP XR_NN should_MD be_VB taken_VBN with_IN a_DT main_JJ meal_NN of_IN the_DT day_NN ,_, preferably_RB the_DT evening_NN meal_NN ._. Phenytoin_NNP :_: Altered_JJ serum_NN levels_NNS of_IN phenytoin_NN -LRB-_-LRB- increased_VBN and_CC decreased_VBN -RRB-_-RRB- have_VBP been_VBN reported_VBN in_IN patients_NNS receiving_VBG concomitant_JJ ciprofloxacin_NN ._. Probenecid_NNP :_: Probenecid_NNP interferes_VBZ with_IN renal_JJ tubular_JJ secretion_NN of_IN ciprofloxacin_NN and_CC produces_VBZ an_DT increase_NN in_IN the_DT level_NN of_IN ciprofloxacin_NN in_IN serum_NN ._. Theophylline_NNP :_: As_IN with_IN some_DT other_JJ quinolones_NNS ,_, concurrent_JJ administration_NN of_IN ciprofloxacin_NN with_IN theophylline_NN may_MD lead_VB to_TO elevated_JJ serum_NN concentrations_NNS of_IN theophylline_NN and_CC prolongation_NN of_IN its_PRP$ elimination_NN half-life_NN ._. This_DT may_MD result_VB in_IN increased_VBN risk_NN of_IN theophylline-related_JJ adverse_JJ reactions_NNS ._. If_IN concomitant_JJ use_NN can_MD not_RB be_VB avoided_VBN ,_, serum_NN levels_NNS of_IN theophylline_NN should_MD be_VB monitored_VBN and_CC dosage_NN adjustments_NNS made_VBN as_IN appropriate_JJ ._. Warfarin_NNP :_: Quinolones_NNS have_VBP been_VBN reported_VBN to_TO enhance_VB the_DT effects_NNS of_IN the_DT oral_JJ anticoagulant_JJ warfarin_NN or_CC its_PRP$ derivatives_NNS ._. When_WRB these_DT products_NNS are_VBP administered_VBN concomitantly_RB ,_, prothrombin_NN time_NN or_CC other_JJ suitable_JJ coagulation_NN tests_NNS should_MD be_VB monitored_VBN ._. Cisapride_NNP is_VBZ metabolized_VBN mainly_RB via_IN the_DT cytochrome_NN P450_NN 3A4_NN enzyme_NN ._. In_IN some_DT cases_NNS where_WRB serious_JJ ventricular_JJ arrhythmias_NNS ,_, QT_NN prolongation_NN ,_, and_CC torsades_NNS de_IN pointes_NNS have_VBP occurred_VBN when_WRB cisapride_NN was_VBD taken_VBN in_IN conjunction_NN with_IN one_CD of_IN the_DT cytochrome_NN P450_NN 3A4_NN inhibitors_NNS ,_, elevated_JJ blood_NN cisapride_NN levels_NNS were_VBD noted_VBN at_IN the_DT time_NN of_IN the_DT QT_NNP prolongation_NN ._. Antibiotics_NNS :_: In_FW vitro_FW and/or_CC in_FW vivo_FW data_NNS show_VBP that_IN clarithromycin_NN ,_, erythromycin_NN ,_, and_CC troleandomycin_NN markedly_RB inhibit_VBP the_DT metabolism_NN of_IN cisapride_NN ,_, which_WDT can_MD result_VB in_IN an_DT increase_NN in_IN plasma_NN cisapride_NN levels_NNS and_CC prolongation_NN of_IN the_DT QT_NNP interval_NN on_IN the_DT ECG_NN ._. Anticholinergics_NNP :_: Concurrent_JJ administration_NN of_IN certain_JJ anticholinergic_JJ compounds_NNS ,_, such_JJ as_IN belladonna_NN alkaloids_NNS and_CC dicyclomine_NN ,_, would_MD be_VB expected_VBN to_TO compromise_VB the_DT beneficial_JJ effects_NNS of_IN cisapride_NN ._. Anticoagulants_NNS -LRB-_-LRB- Oral_JJ -RRB-_-RRB- :_: In_IN patients_NNS receiving_VBG oral_JJ anticoagulants_NNS ,_, the_DT coagulation_NN times_NNS were_VBD increased_VBN in_IN some_DT cases_NNS ._. It_PRP is_VBZ advisable_JJ to_TO check_VB coagulation_NN time_NN within_IN the_DT first_JJ few_JJ days_NNS after_IN the_DT start_NN and_CC discontinuation_NN of_IN cisapride_NN therapy_NN ,_, with_IN an_DT appropriate_JJ adjustment_NN of_IN the_DT anticoagulant_JJ dose_NN ,_, if_IN necessary_JJ ._. Antidepressants_NNS :_: In_FW vitro_FW data_NNS indicate_VBP that_IN nefazodone_NN inhibits_VBZ the_DT metabolism_NN of_IN cisapride_NN ,_, which_WDT can_MD result_VB in_IN an_DT increase_NN in_IN plasma_NN cisapride_NN levels_NNS and_CC prolongation_NN of_IN the_DT QT_NNP interval_NN on_IN the_DT ECG_NN ._. Antifungals_NNS :_: In_FW vitro_FW and/or_CC in_FW vivo_FW data_NNS indicate_VBP that_IN fluconazole_NN ,_, itraconazole_NN ,_, and_CC oral_JJ ketoconazole_NN markedly_RB inhibit_VBP the_DT metabolism_NN of_IN cisapride_NN ,_, which_WDT can_MD result_VB in_IN an_DT increase_NN in_IN plasma_NN cisapride_NN levels_NNS and_CC prolongation_NN of_IN the_DT QT_NNP interval_NN on_IN the_DT ECG_NN ._. Human_JJ pharmacokinetic_JJ data_NNS indicate_VBP that_IN oral_JJ ketoconazole_NN markedly_RB inhibits_VBZ the_DT metabolism_NN of_IN cisapride_NN ,_, resulting_VBG in_IN a_DT mean_NN eight-fold_JJ increase_NN in_IN AUC_NN of_IN cisapride_NN ._. A_DT study_NN in_IN 14_CD normal_JJ male_NN and_CC female_JJ volunteers_NNS suggests_VBZ that_IN coadministration_NN of_IN cisapride_NN and_CC ketoconazole_NN can_MD result_VB in_IN prolongation_NN of_IN the_DT QT_NNP interval_NN on_IN the_DT ECG_NN ._. H2_NN Receptor_NN Antagonists_NNS :_: Cimetidine_NN coadministration_NN leads_VBZ to_TO an_DT increased_VBN peak_NN plasma_NN concentration_NN and_CC AUC_NN of_IN cisapride_NN ,_, there_EX is_VBZ no_DT effect_NN on_IN cisapride_NN absorption_NN when_WRB it_PRP is_VBZ coadministered_VBN with_IN ranitidine_NN ._. The_DT gastrointestinal_JJ absorption_NN of_IN cimetidine_NN and_CC ranitidine_NN is_VBZ accelerated_VBN when_WRB they_PRP are_VBP coadministered_VBN with_IN cisapride_NN ._. Protease_NN Inhibitors_NNS :_: In_FW vitro_FW data_NNS indicate_VBP that_IN indinavir_NN and_CC ritonavir_NN markedly_RB inhibit_VBP the_DT metabolism_NN of_IN cisapride_NN which_WDT can_MD result_VB in_IN an_DT increase_NN in_IN plasma_NN cisapride_NN levels_NNS and_CC prolongation_NN of_IN the_DT QT_NNP interval_NN on_IN the_DT ECG_NN ._. Other_JJ :_: Coadministration_NN of_IN grapefruit_NN juice_NN with_IN cisapride_NN increases_VBZ the_DT bioavailability_NN of_IN cisapride_NN and_CC concomitant_JJ use_NN should_MD be_VB avoided_VBN ._. Cisapride_NNP should_MD not_RB be_VB used_VBN concomitantly_RB with_IN other_JJ drugs_NNS known_VBN to_TO prolong_VB the_DT QT_NNP interval_NN :_: certain_JJ antiarrhythmics_NNS ,_, including_VBG those_DT of_IN Class_NNP IA_NNP -LRB-_-LRB- such_JJ as_IN quinidine_NN and_CC procainamide_NN -RRB-_-RRB- and_CC Class_NN III_CD -LRB-_-LRB- such_JJ as_IN sotalol_NN -RRB-_-RRB- ._. tricyclic_JJ antidepressants_NNS -LRB-_-LRB- such_JJ as_IN amitriptyline_NNP -RRB-_-RRB- ._. certain_JJ tetracyclic_JJ antidepressants_NNS -LRB-_-LRB- such_JJ as_IN maprotiline_NN -RRB-_-RRB- ._. certain_JJ antipsychotic_JJ medications_NNS -LRB-_-LRB- such_JJ as_IN sertindole_NN -RRB-_-RRB- ._. astemizole_NN ,_, bepridil_NN ,_, sparfloxacin_NN ,_, and_CC terodiline_NN ._. The_DT preceding_VBG lists_NNS of_IN drugs_NNS are_VBP not_RB comprehensive_JJ ._. The_DT acceleration_NN of_IN gastric_JJ emptying_NN by_IN cisapride_NN could_MD affect_VB the_DT rate_NN of_IN absorption_NN of_IN other_JJ drugs_NNS ._. Patients_NNS receiving_VBG narrow_JJ therapeutic_JJ ratio_NN drugs_NNS or_CC other_JJ drugs_NNS that_WDT require_VBP careful_JJ titration_NN should_MD be_VB followed_VBN closely_RB ;_: ._. if_IN plasma_NN levels_NNS are_VBP being_VBG monitored_VBN ,_, they_PRP should_MD be_VB reassessed_VBN ._. Administration_NN of_IN 0.1-mg_JJ /_: kg_NN -LRB-_-LRB- 2_CD x_CC ED95_NN -RRB-_-RRB- NIMBEX_NN at_IN 10_CD %_NN or_CC 95_CD %_NN recovery_NN following_VBG an_DT intubating_VBG dose_NN of_IN succinylcholine_NN -LRB-_-LRB- 1_CD mg/kg_NN -RRB-_-RRB- produced_VBD 95_CD %_NN neuromuscular_JJ block_NN ._. The_DT time_NN to_TO onset_NN of_IN maximum_NN block_NN following_VBG NIMBEX_NNP is_VBZ approximately_RB 2_CD minutes_NNS faster_RBR with_IN prior_JJ administration_NN of_IN succinylcholine_NN ._. Prior_RB administration_NN of_IN succinylcholine_NN had_VBD no_DT effect_NN on_IN the_DT duration_NN of_IN neuromuscular_JJ block_NN following_VBG initial_JJ or_CC maintenance_NN bolus_NN doses_NNS of_IN NIMBEX_NNP ._. Infusion_NN requirements_NNS of_IN NIMBEX_NNP in_IN patients_NNS administered_VBN succinylcholine_NN prior_RB to_TO infusions_NNS of_IN NIMBEX_NNP were_VBD comparable_JJ to_TO or_CC slightly_RB greater_JJR than_IN when_WRB succinylcholine_NN was_VBD not_RB administered_VBN ._. The_DT use_NN of_IN NIMBEX_NN before_IN succinylcholine_NN to_TO attenuate_VB some_DT of_IN the_DT side_JJ effects_NNS of_IN succinylcholine_NN has_VBZ not_RB been_VBN studied_VBN ._. Although_IN not_RB studied_VBN systematically_RB in_IN clinical_JJ trials_NNS ,_, no_DT drug_NN interactions_NNS were_VBD observed_VBN when_WRB vecuronium_NN ,_, pancuronium_NN ,_, or_CC atracurium_NN were_VBD administered_VBN following_VBG varying_VBG degrees_NNS of_IN recovery_NN from_IN single_JJ doses_NNS or_CC infusions_NNS of_IN NIMBEX_NNP ._. Isoflurane_NN or_CC enflurane_NN administered_VBN with_IN nitrous_JJ oxide/oxygen_NN to_TO achieve_VB 1.25_CD MAC_NNP -LSB-_-LRB- Minimum_NNP Alveolar_JJ Concentration_NN -RSB-_-RRB- may_MD prolong_VB the_DT clinically_RB effective_JJ duration_NN of_IN action_NN of_IN initial_JJ and_CC maintenance_NN doses_NNS of_IN NIMBEX_NNP and_CC decrease_VB the_DT required_VBN infusion_NN rate_NN of_IN NIMBEX_NNP ._. The_DT magnitude_NN of_IN these_DT effects_NNS may_MD depend_VB on_IN the_DT duration_NN of_IN administration_NN of_IN the_DT volatile_JJ agents_NNS ._. Fifteen_CD to_TO 30_CD minutes_NNS of_IN exposure_NN to_TO 1.25_CD MAC_NNP isoflurane_NN or_CC enflurane_NN had_VBD minimal_JJ effects_NNS on_IN the_DT duration_NN of_IN action_NN of_IN initial_JJ doses_NNS of_IN NIMBEX_NNP and_CC therefore_RB ,_, no_DT adjustment_NN to_TO the_DT initial_JJ dose_NN should_MD be_VB necessary_JJ when_WRB NIMBEX_NNP is_VBZ administered_VBN shortly_RB after_IN initiation_NN of_IN volatile_JJ agents_NNS ._. In_IN long_JJ surgical_JJ procedures_NNS during_IN enflurane_NN or_CC isoflurane_NN anesthesia_NN ,_, less_JJR frequent_JJ maintenance_NN dosing_NN ,_, lower_JJR maintenance_NN doses_NNS ,_, or_CC reduced_VBN infusion_NN rates_NNS of_IN NIMBEX_NNP may_MD be_VB necessary_JJ ._. The_DT average_JJ infusion_NN rate_NN requirement_NN may_MD be_VB decreased_VBN by_IN as_RB much_JJ as_IN 30_CD %_NN to_TO 40_CD %_NN ._. In_IN clinical_JJ studies_NNS propofol_NN had_VBD no_DT effect_NN on_IN the_DT duration_NN of_IN action_NN or_CC dosing_NN requirements_NNS for_IN NIMBEX_NNP ._. Other_JJ drugs_NNS which_WDT may_MD enhance_VB the_DT neuromuscular_JJ blocking_VBG action_NN of_IN nondepolarizing_JJ agents_NNS such_JJ as_IN NIMBEX_NNP include_VBP certain_JJ antibiotics_NNS -LRB-_-LRB- e._FW g._FW ,_, aminoglycosides_NNS ,_, tetracyclines_NNS ,_, bacitracin_NN ,_, polymyxins_NNS ,_, lincomycin_NN ,_, clindamycin_NN ,_, colistin_NN ,_, and_CC sodium_NN colistemethate_NN -RRB-_-RRB- ,_, magnesium_NN salts_NNS ,_, lithium_NN ,_, local_JJ anesthetics_NNS ,_, procainamide_NN ,_, and_CC quinidine_NN ._. Resistance_NN to_TO the_DT neuromuscular_JJ blocking_VBG action_NN of_IN nondepolarizing_JJ neuromuscular_JJ blocking_VBG agents_NNS has_VBZ been_VBN demonstrated_VBN in_IN patients_NNS chronically_RB administered_VBN phenytoin_NN or_CC carbamazepine_NN ._. While_IN the_DT effects_NNS of_IN chronic_JJ phenytoin_NN or_CC carbamazepine_NN therapy_NN on_IN the_DT action_NN of_IN NIMBEX_NNP are_VBP unknown_JJ ,_, slightly_RB shorter_JJR durations_NNS of_IN neuromuscular_JJ block_NN may_MD be_VB anticipated_VBN and_CC infusion_NN rate_NN requirements_NNS may_MD be_VB higher_JJR ._. Drug/Laboratory_JJ Test_NN Interactions_NNS None_NN known_VBN ._. Plasma_NN levels_NNS of_IN anticonvulsant_JJ agents_NNS may_MD become_VB subtherapeutic_JJ during_IN cisplatin_NN therapy_NN ._. Central_NNP nervous_JJ system_NN depressant_NN -LRB-_-LRB- CNS_NN -RRB-_-RRB- drugs_NNS including_VBG alcohol_NN ,_, antidepressants_NNS ,_, antihistamines_NNS ,_, antipsychotics_NNS ,_, blood_NN pressure_NN medications_NNS -LRB-_-LRB- reserpine_NN ,_, methyldopa_NN ,_, beta-blockers_NNS -RRB-_-RRB- ,_, motion_NN sickness_NN medications_NNS ,_, muscle_NN relaxants_NNS ,_, narcotics_NNS ,_, sedatives_NNS ,_, sleeping_VBG pills_NNS and_CC tranquilizer_NN ._. There_EX are_VBP no_RB known_VBN drug_NN interactions_NNS with_IN LEUSTATIN_NNP Injection_NN ._. Caution_NN should_MD be_VB exercised_VBN if_IN LEUSTATIN_NNP Injection_NN is_VBZ administered_VBN before_RB ,_, after_IN ,_, or_CC in_IN conjunction_NN with_IN other_JJ drugs_NNS known_VBN to_TO cause_VB immunosuppression_NN or_CC myelosuppression_NN ._. The_DT concurrent_JJ administration_NN of_IN allopurinol_NN and_CC ampicillin_NN increases_NNS substantially_RB the_DT incidence_NN of_IN rashes_NNS in_IN patients_NNS receiving_VBG both_CC drugs_NNS as_IN compared_VBN to_TO patients_NNS receiving_VBG ampicillin_NN alone_RB ._. It_PRP is_VBZ not_RB known_VBN whether_IN this_DT potentiation_NN of_IN ampicillin_NN rashes_NNS is_VBZ due_JJ to_TO allopurinol_NN or_CC the_DT hyperuricemia_NN present_JJ in_IN these_DT patients_NNS ._. In_IN controlled_JJ clinical_JJ trials_NNS of_IN AUGMENTIN_NNP XR_NNP ,_, 22_CD patients_NNS received_VBD concomitant_JJ allopurinol_NN and_CC AUGMENTIN_NNP XR_NNP ._. No_DT rashes_NNS were_VBD reported_VBN in_IN these_DT patients_NNS ._. However_RB ,_, this_DT sample_NN size_NN is_VBZ too_RB small_JJ to_TO allow_VB for_IN any_DT conclusions_NNS to_TO be_VB drawn_VBN regarding_VBG the_DT risk_NN of_IN rashes_NNS with_IN concomitant_JJ AUGMENTIN_NNP XR_NN and_CC allopurinol_NN use_NN ._. In_IN common_JJ with_IN other_JJ broad-spectrum_JJ antibiotics_NNS ,_, AUGMENTIN_NNP XR_NNP may_MD reduce_VB the_DT efficacy_NN of_IN oral_JJ contraceptive_NN ._. Additive_JJ CNS_NN depression_NN may_MD occur_VB when_WRB antihistamines_NNS are_VBP administered_VBN concomitantly_RB with_IN other_JJ CNS_NN depressants_NNS including_VBG barbiturates_NNS ,_, tranquilizers_NNS ,_, and_CC alcohol_NN ._. Patients_NNS receiving_VBG antihistamines_NNS should_MD be_VB advised_VBN against_IN the_DT concurrent_JJ use_NN of_IN other_JJ CNS_NNS depressant_NN drugs_NNS ._. Monoamine_NN oxidase_NN -LRB-_-LRB- MAO_NN -RRB-_-RRB- inhibitors_NNS prolong_VB and_CC intensify_VB the_DT anticholinergic_JJ effects_NNS of_IN antihistamines_NNS ._. Amantadine_NNP ,_, tricyclic_JJ antidepressants_NNS ,_, and_CC MAOIs_NNS may_MD increase_VB anticholinergic_JJ effect_NN of_IN clidinium_NN ._. Clidinium_NNP may_MD decrease_VB the_DT effect_NN of_IN phenothiazines_NNS ,_, levodopa_NN ,_, and_CC ketoconazole_NN ._. Clindamycin_NNP has_VBZ been_VBN shown_VBN to_TO have_VB neuromuscular_JJ blocking_VBG properties_NNS that_WDT may_MD enhance_VB the_DT action_NN of_IN other_JJ neuromuscular_JJ blocking_VBG agents_NNS ._. Therefore_RB ,_, it_PRP should_MD be_VB used_VBN with_IN caution_NN in_IN patients_NNS receiving_VBG such_JJ agents_NNS ._. Antagonism_NN has_VBZ been_VBN demonstrated_VBN between_IN clindamycin_NN and_CC erythromycin_NN in_FW vitro_FW ._. Because_IN of_IN possible_JJ clinical_JJ significance_NN ,_, these_DT two_CD drugs_NNS should_MD not_RB be_VB administered_VBN concurrently_RB ._. Alcohol_NN -LRB-_-LRB- increases_NNS bioavailability_NN by_IN 50_CD %_NN -RRB-_-RRB- ,_, cimetidine_NN ,_, and_CC valproates_NNS ._. No_DT separate_JJ information_NN available_JJ ._. Although_IN no_DT clinical_JJ drug-drug_JJ interaction_NN studies_NNS have_VBP been_VBN conducted_VBN to_TO date_NN ,_, on_IN the_DT basis_NN of_IN the_DT in_FW vitro_FW studies_NNS ,_, cytochrome_NN p450_NN inhibitors_NNS and_CC inducers_NNS are_VBP unlikely_JJ to_TO affect_VB the_DT metabolism_NN of_IN clofarabine_NN ._. The_DT effect_NN of_IN clofarabine_NN on_IN the_DT metabolism_NN of_IN cytochrome_NN p450_NN substrates_NNS has_VBZ not_RB been_VBN studied_VBN ._. Drug/Laboratory_NNP Tests_NNP Interactions_NNS There_EX are_VBP no_DT known_JJ clinically_RB significant_JJ interactions_NNS of_IN CLOLAR_NN with_IN other_JJ medications_NNS or_CC laboratory_NN tests_NNS ._. No_DT formal_JJ drug/laboratory_JJ test_NN interaction_NN studies_NNS have_VBP been_VBN conducted_VBN with_IN CLOLAR_NN ._. Preliminary_JJ data_NNS which_WDT suggest_VBP that_IN dapsone_NN may_MD inhibit_VB the_DT anti-inflammatory_JJ activity_NN of_IN Lamprene_NNP have_VBP not_RB been_VBN confirmed_VBN ._. If_IN leprosy-associated_JJ inflammatory_JJ reactions_NNS develop_VBP in_IN patients_NNS being_VBG treated_VBN with_IN dapsone_NN and_CC clofazimine_NN ,_, it_PRP is_VBZ still_RB advisable_JJ to_TO continue_VB treatment_NN with_IN both_CC drugs_NNS ._. Caution_NN should_MD be_VB exercised_VBN when_WRB anticoagulants_NNS are_VBP given_VBN in_IN conjunction_NN with_IN Atromid-S_NN ._. Usually_RB ,_, the_DT dosage_NN of_IN the_DT anticoagulant_NN should_MD be_VB reduced_VBN by_IN one-half_NN -LRB-_-LRB- depending_VBG on_IN the_DT individual_JJ case_NN -RRB-_-RRB- to_TO maintain_VB the_DT prothrombin_NN time_NN at_IN the_DT desired_VBN level_NN to_TO prevent_VB bleeding_JJ complications_NNS ._. Frequent_JJ prothrombin_NN determinations_NNS are_VBP advisable_JJ until_IN it_PRP has_VBZ been_VBN determined_VBN definitely_RB that_IN the_DT prothrombin_NN level_NN has_VBZ been_VBN stabilized_VBN ._. Atromid-S_NN may_MD displace_VB acidic_JJ drugs_NNS such_JJ as_IN phenytoin_NN or_CC tolbutamide_NN from_IN their_PRP$ binding_NN sites_NNS ._. Caution_NN should_MD be_VB exercised_VBN when_WRB treating_VBG patients_NNS with_IN either_DT of_IN these_DT drugs_NNS or_CC other_JJ highly_RB protein-bound_JJ drugs_NNS and_CC Atromid-S_NN ._. The_DT hypoglycemic_JJ effect_NN of_IN tolbutamide_NN has_VBZ been_VBN reported_VBN to_TO increase_VB when_WRB Atromid-S_NN is_VBZ given_VBN concurrently_RB ._. Fulminant_JJ rhabdomyolysis_NN has_VBZ been_VBN seen_VBN as_IN early_JJ as_IN three_CD weeks_NNS after_IN initiation_NN of_IN combined_JJ therapy_NN with_IN another_DT fibrate_NN and_CC lovastatin_NN but_CC may_MD be_VB seen_VBN after_IN several_JJ months_NNS ._. For_IN these_DT reasons_NNS ,_, it_PRP is_VBZ felt_VBN that_IN ,_, in_IN most_JJS subjects_NNS who_WP have_VBP had_VBD an_DT unsatisfactory_JJ lipid_NN response_NN to_TO either_CC drug_NN alone_RB ,_, the_DT possible_JJ benefits_NNS of_IN combined_JJ therapy_NN with_IN lovastatin_NN and_CC a_DT fibrate_NN do_VBP not_RB outweigh_VB the_DT risks_NNS of_IN severe_JJ myopathy_NN ,_, rhabdomyolysis_NN ,_, and_CC acute_JJ renal_JJ failure_NN ._. While_IN it_PRP is_VBZ not_RB known_VBN whether_IN this_DT interaction_NN occurs_VBZ with_IN fibrates_NNS other_JJ than_IN gemfibrozil_NN ,_, myopathy_NN and_CC rhabdomyolysis_NN have_VBP occasionally_RB been_VBN associated_VBN with_IN the_DT use_NN of_IN fibrates_NNS alone_RB ,_, including_VBG clofibrate_NN ._. Therefore_RB ,_, the_DT combined_VBN use_NN of_IN lovastatin_NN with_IN fibrates_NNS should_MD generally_RB be_VB avoided_VBN ._. Drug_NN interactions_NNS with_IN clomiphene_NN citrate_NN tablets_NNS USP_NNP have_VBP not_RB been_VBN documented_VBN ._. The_DT risks_NNS of_IN using_VBG Anafranil_NNP in_IN combination_NN with_IN other_JJ drugs_NNS have_VBP not_RB been_VBN systematically_RB evaluated_VBN ._. Given_VBN the_DT primary_JJ CNS_NN effects_NNS of_IN Anafranil_NNP ,_, caution_NN is_VBZ advised_VBN in_IN using_VBG it_PRP concomitantly_RB with_IN other_JJ CNS-active_JJ drugs_NNS ._. Anafranil_NNP should_MD not_RB be_VB used_VBN with_IN MAO_NN inhibitors_NNS ._. Close_JJ supervision_NN and_CC careful_JJ adjustment_NN of_IN dosage_NN are_VBP required_VBN when_WRB Anafranil_NNP is_VBZ administered_VBN with_IN anticholinergic_JJ or_CC sympathomimetic_JJ drugs_NNS ._. Several_JJ tricyclic_JJ antidepressants_NNS have_VBP been_VBN reported_VBN to_TO block_VB the_DT pharmacologic_JJ effects_NNS of_IN guanethidine_NN ,_, clonidine_NN ,_, or_CC similar_JJ agents_NNS ,_, and_CC such_PDT an_DT effect_NN may_MD be_VB anticipated_VBN with_IN CMI_NN because_IN of_IN its_PRP$ structural_JJ similarity_NN to_TO other_JJ tricyclic_JJ antidepressants_NNS ._. The_DT plasma_NN concentration_NN of_IN CMI_NNP has_VBZ been_VBN reported_VBN to_TO be_VB increased_VBN by_IN the_DT concomitant_JJ administration_NN of_IN haloperidol_NN ._. plasma_NN levels_NNS of_IN several_JJ closely_RB related_JJ tricyclic_JJ antidepressants_NNS have_VBP been_VBN reported_VBN to_TO be_VB increased_VBN by_IN the_DT concomitant_JJ administration_NN of_IN methylphenidate_NN or_CC hepatic_JJ enzyme_NN inhibitors_NNS -LRB-_-LRB- e.g._FW ,_, cimetidine_NN ,_, fluoxetine_NN -RRB-_-RRB- and_CC decreased_VBN by_IN the_DT concomitant_JJ administration_NN of_IN hepatic_JJ enzyme_NN inducers_NNS -LRB-_-LRB- e.g._FW ,_, barbiturates_NNS ,_, phenytoin_NN -RRB-_-RRB- ,_, and_CC such_PDT an_DT effect_NN may_MD be_VB anticipated_VBN with_IN CMI_NNP as_RB well_RB ._. Administration_NN of_IN CMI_NNP has_VBZ been_VBN reported_VBN to_TO increase_VB the_DT plasma_NN levels_NNS of_IN phenobarbital_NN ,_, if_IN given_VBN concomitantly_RB ._. Drugs_NNS Metabolized_VBN by_IN P450_NN 2D6_NN :_: The_DT biochemical_JJ activity_NN of_IN the_DT drug_NN metabolizing_VBG isozyme_NN cytochrome_NN P450_NN 2D6_NN -LRB-_-LRB- debrisoquin_NN hydroxylase_NN -RRB-_-RRB- is_VBZ reduced_VBN in_IN a_DT subset_NN of_IN the_DT aucasian_JJ population_NN -LRB-_-LRB- about_IN 7_CD %_NN -10_CD %_NN of_IN Caucasians_NNPS are_VBP so-called_JJ poor_JJ metabolizers_NNS -RRB-_-RRB- ;_: ._. reliable_JJ estimates_NNS of_IN the_DT prevalence_NN of_IN reduced_VBN P450_NN 2D6_NN isozyme_NN activity_NN among_IN Asian_JJ ,_, African_JJ and_CC other_JJ populations_NNS are_VBP not_RB yet_RB available_JJ ._. Poor_NNP metabolizers_NNS have_VBP higher_JJR than_IN expected_VBN lasma_NN concentrations_NNS of_IN tricyclic_JJ antidepressants_NNS -LRB-_-LRB- TCAs_NNS -RRB-_-RRB- when_WRB given_VBN usual_JJ doses_NNS ._. Depending_VBG on_IN the_DT fraction_NN of_IN drug_NN metabolized_VBN by_IN P450_NN 2D6_NN ,_, the_DT increase_NN in_IN plasma_NN concentration_NN may_MD be_VB small_JJ ,_, or_CC quite_RB large_JJ -LRB-_-LRB- 8_CD fold_JJ increase_NN in_IN plasma_NN AUC_NN of_IN the_DT TCA_NNP -RRB-_-RRB- ._. In_IN addition_NN ,_, certain_JJ drugs_NNS inhibit_VBP the_DT activity_NN of_IN this_DT isozyme_NN and_CC make_VB normal_JJ metabolizers_NNS resemble_VBP poor_JJ metabolizers_NNS ._. An_DT individual_NN who_WP is_VBZ stable_JJ on_IN a_DT given_VBN dose_NN of_IN TCAmay_NN become_VBP abruptly_RB toxic_JJ when_WRB given_VBN one_CD of_IN these_DT inhibiting_VBG drugs_NNS as_IN concomitant_JJ therapy_NN ._. The_DT drugs_NNS that_WDT inhibit_VBP cytochrome_NN P450_NN 2D6_NN include_VBP some_DT that_WDT are_VBP not_RB metabolized_VBN by_IN the_DT enzyme_NN -LRB-_-LRB- quinidine_NN ._. cimetidine_NN -RRB-_-RRB- and_CC many_JJ that_WDT are_VBP substrates_NNS for_IN P450_NN 2D6_NN -LRB-_-LRB- many_JJ other_JJ antidepressants_NNS ,_, phenothiazines_NNS ,_, and_CC the_DT Type_NN 1C_NN antiarrhythmics_NNS propafenone_NN and_CC flecainide_NN -RRB-_-RRB- ._. While_IN all_PDT the_DT selective_JJ serotonin_NN reuptake_NN inhibitors_NNS -LRB-_-LRB- SSRIs_NNS -RRB-_-RRB- ,_, e.g._FW ,_, fluoxetine_NN ,_, sertraline_NN ,_, paroxetine_NN ,_, and_CC fluvoxamine_NN ,_, inhibit_VBP P450_NN 2D6_NN ,_, they_PRP may_MD vary_VB in_IN the_DT extent_NN of_IN inhibition_NN ._. Fluvoxamine_NNP has_VBZ also_RB been_VBN shown_VBN to_TO inhibit_VB P450_NN 1A2_NN ,_, an_DT isoform_NN also_RB involved_VBN in_IN TCAmetabolism_NN ._. The_DT extent_NN to_TO which_WDT SSRI-TCAinteractions_NNS may_MD pose_VB clinical_JJ problems_NNS will_MD depend_VB on_IN the_DT degree_NN of_IN inhibition_NN and_CC the_DT pharmacokinetics_NNS of_IN the_DT SSRI_NNP involved_VBN ._. Nevertheless_RB ,_, caution_NN is_VBZ indicated_VBN in_IN the_DT co-administration_NN of_IN TCAs_NNS with_IN any_DT of_IN the_DT SSRIs_NNS and_CC also_RB in_IN switching_NN from_IN one_CD class_NN to_TO the_DT other_JJ ._. Of_IN particular_JJ importance_NN ,_, sufficient_JJ time_NN must_MD elapse_VB before_IN initiating_VBG TCAtreatment_NN in_IN a_DT patient_NN being_VBG withdrawn_VBN from_IN fluoxetine_NN ,_, given_VBN the_DT long_JJ half-life_NN of_IN the_DT parent_NN and_CC active_JJ metabolite_NN -LRB-_-LRB- at_IN least_JJS 5_CD weeks_NNS may_MD be_VB necessary_JJ -RRB-_-RRB- ._. Concomitant_JJ use_NN of_IN agents_NNS in_IN the_DT tricyclic_JJ antidepressant_JJ class_NN -LRB-_-LRB- which_WDT includes_VBZ Anafranil_NNP -RRB-_-RRB- with_IN drugs_NNS that_WDT can_MD inhibit_VB cytochrome_NN P450_NN 2D6_NN may_MD require_VB lower_JJR doses_NNS than_IN usually_RB prescribed_VBN for_IN either_CC the_DT tricyclic_JJ antidepressant_JJ agent_NN or_CC the_DT other_JJ drug_NN ._. Furthermore_RB ,_, whenever_WRB one_CD of_IN these_DT drugs_NNS is_VBZ withdrawn_VBN from_IN co-therapy_JJ ,_, an_DT increased_VBN dose_NN of_IN tricyclic_JJ antidepressant_JJ agent_NN may_MD be_VB required_VBN ._. It_PRP is_VBZ desirable_JJ to_TO monitor_VB TCAplasma_NN levels_NNS whenever_WRB an_DT agent_NN of_IN the_DT tricyclic_JJ antidepressant_JJ class_NN including_VBG Anafranil_NNP is_VBZ going_VBG to_TO be_VB co-administered_VBN with_IN another_DT drug_NN known_VBN to_TO be_VB an_DT inhibitor_NN of_IN P450_NN 2D6_NN -LRB-_-LRB- and/or_CC P450_NN 1A2_NN -RRB-_-RRB- ._. Because_IN Anafranil_NNP is_VBZ highly_RB bound_VBN to_TO serum_NN protein_NN ,_, the_DT administration_NN of_IN Anafranil_NNP to_TO patients_NNS taking_VBG other_JJ drugs_NNS that_WDT are_VBP highly_RB bound_VBN to_TO protein_NN -LRB-_-LRB- e.g._FW ,_, warfarin_NN ,_, digoxin_NN -RRB-_-RRB- may_MD cause_VB an_DT increase_NN in_IN plasma_NN concentrations_NNS of_IN these_DT drugs_NNS ,_, potentially_RB resulting_VBG in_IN adverse_JJ effects_NNS ._. Conversely_RB ,_, adverse_JJ effects_NNS may_MD result_VB from_IN displacement_NN of_IN protein-bound_JJ Anafranil_NNP by_IN other_JJ highly_RB bound_VBN drugs_NNS ._. Effect_NN of_IN Clonazepam_NNP on_IN the_DT Pharmacokinetics_NNS of_IN Other_JJ Drugs_NNS :_: Clonazepam_NN does_VBZ not_RB appear_VB to_TO alter_VB the_DT pharmacokinetics_NNS of_IN phenytoin_NN ,_, carbamazepine_NN ,_, or_CC phenobarbital_NN ._. The_DT effect_NN of_IN clonazepam_NN on_IN the_DT metabolism_NN of_IN other_JJ drugs_NNS has_VBZ not_RB been_VBN investigated_VBN ._. Effect_NN of_IN Other_JJ Drugs_NNS on_IN the_DT Pharmacokinetics_NNS of_IN Clonazepam_NNP :_: Literature_NNP reports_NNS suggest_VBP that_IN ranitidine_NN ,_, an_DT agent_NN that_WDT decreases_VBZ stomach_NN acidity_NN ,_, does_VBZ not_RB greatly_RB alter_VB clonazepam_NN pharmacokinetics_NNS ._. In_IN a_DT study_NN in_IN which_WDT the_DT 2_CD mg_NN clonazepam_NN orally_RB disintegrating_VBG tablet_NN was_VBD administered_VBN with_IN and_CC without_IN propantheline_NN -LRB-_-LRB- an_DT anticholinergic_JJ agent_NN with_IN multiple_JJ effects_NNS on_IN the_DT GI_NN tract_NN -RRB-_-RRB- to_TO healthy_JJ volunteers_NNS ,_, the_DT AUC_NN of_IN clonazepam_NN was_VBD 10_CD %_NN lower_JJR and_CC the_DT Cmax_NN of_IN clonazepam_NN was_VBD 20_CD %_NN lower_JJR when_WRB the_DT orally_RB disintegrating_VBG tablet_NN was_VBD given_VBN with_IN propantheline_NN compared_VBN to_TO when_WRB it_PRP was_VBD given_VBN alone_RB ._. Fluoxetine_NN does_VBZ not_RB affect_VB the_DT pharmacokinetics_NNS of_IN clonazepam_NN ._. Cytochrome_NN P-450_NN inducers_NNS ,_, such_JJ as_IN phenytoin_NN ,_, carbamazepine_NN and_CC phenobarbital_NN ,_, induce_VBP clonazepam_NN metabolism_NN ,_, causing_VBG an_DT approximately_RB 30_CD %_NN decrease_NN in_IN plasma_NN clonazepam_NN levels_NNS ._. Although_IN clinical_JJ studies_NNS have_VBP not_RB been_VBN performed_VBN ,_, based_VBN on_IN the_DT involvement_NN of_IN the_DT cytochrome_NN P-450_NN 3A_NN family_NN in_IN clonazepam_NN metabolism_NN ,_, inhibitors_NNS of_IN this_DT enzyme_NN system_NN ,_, notably_RB oral_JJ antifungal_JJ agents_NNS ,_, should_MD be_VB used_VBN cautiously_RB in_IN patients_NNS receiving_VBG clonazepam_NN ._. Pharmacodynamic_JJ Interactions_NNS :_: The_DT CNS-depressant_JJ action_NN of_IN the_DT benzodiazepine_NN class_NN of_IN drugs_NNS may_MD be_VB potentiated_VBN by_IN alcohol_NN ,_, narcotics_NNS ,_, barbiturates_NNS ,_, nonbarbiturate_JJ hypnotics_NNS ,_, antianxiety_JJ agents_NNS ,_, the_DT phenothiazines_NNS ,_, thioxanthene_NN and_CC butyrophenone_NN classes_NNS of_IN antipsychotic_JJ agents_NNS ,_, monoamine_NN oxidase_NN inhibitors_NNS and_CC the_DT tricyclic_JJ antidepressants_NNS ,_, and_CC by_IN other_JJ anticonvulsant_JJ drugs_NNS ._. Tablet_NNP If_IN a_DT patient_NN receiving_VBG clonidine_NN hydrochloride_NN is_VBZ also_RB taking_VBG tricyclic_JJ antidepressants_NNS ,_, the_DT effect_NN of_IN clonidine_NN may_MD be_VB reduced_VBN ,_, thus_RB necessitating_VBG an_DT increase_NN in_IN dosage_NN ._. Clonidine_NN hydrochloride_NN may_MD enhance_VB the_DT CNS-depressive_JJ effects_NNS of_IN alcohol_NN ,_, barbiturates_NNS or_CC other_JJ sedatives_NNS ._. Amitriptyline_NNP in_IN combination_NN with_IN clonidine_NN enhances_VBZ the_DT manifestation_NN of_IN corneal_NN lesions_NNS in_IN rats_NNS Epidural_JJ Injection_NN Clonidine_NN may_MD potentiate_VB the_DT CNS-depressive_JJ effect_NN of_IN alcohol_NN ,_, barbiturates_NNS or_CC other_JJ sedating_VBG drugs_NNS ._. Narcotic_JJ analgesics_NNS may_MD potentiate_VB the_DT hypotensive_JJ effects_NNS of_IN clonidine_NN ._. Tricyclic_JJ antidepressants_NNS may_MD antagonize_VB the_DT hypotensive_JJ effects_NNS of_IN clonidine_NN ._. The_DT effects_NNS of_IN tricyclic_JJ antidepressants_NNS on_IN clonidines_NNS analgesic_JJ actions_NNS are_VBP not_RB known_VBN ._. Beta_NN blockers_NNS may_MD exacerbate_VB the_DT hypertensive_JJ response_NN seen_VBN with_IN clonidine_NN withdrawl_NN ._. Also_RB ,_, due_JJ to_TO the_DT potential_NN for_IN additive_JJ effects_NNS such_JJ as_IN bradycardia_NN and_CC AV_NN block_NN ,_, caution_NN is_VBZ warranted_VBN in_IN patients_NNS receiving_VBG clonidine_NN with_IN agents_NNS known_VBN to_TO affect_VB sinus_NN node_NN function_NN or_CC AV_NN nodal_JJ conduction_NN -LRB-_-LRB- e.g._FW ,_, digitalis_NN ,_, calcium_NN channel_NN blockers_NNS ,_, and_CC beta-blockers_NNS ._. There_EX is_VBZ one_CD reported_VBD case_NN of_IN a_DT patient_NN with_IN acute_JJ delirium_NN associated_VBN with_IN the_DT simultaneous_JJ use_NN of_IN fluphenazine_NN and_CC oral_JJ clonidine_NN ._. Symptoms_NNS resolved_VBN when_WRB clonidine_NN was_VBD withdrawn_VBN and_CC recurred_VBN when_WRB the_DT patient_NN was_VBD rechallenged_VBN with_IN clonidine_NN ._. Epidural_JJ clonidine_NN may_MD prolong_VB the_DT duration_NN of_IN pharmacologic_JJ effects_NNS of_IN epidural_JJ local_JJ anesthetics_NNS ,_, including_VBG both_DT sensory_JJ and_CC motor_NN blockade_NN ._. Aspirin_NN ,_, warfarin_NN ,_, heparin_NN ,_, NSAID_NN ._. If_IN TRANXENE_NN is_VBZ to_TO be_VB combined_VBN with_IN other_JJ drugs_NNS acting_VBG on_IN the_DT central_JJ nervous_JJ system_NN ,_, careful_JJ consideration_NN should_MD be_VB given_VBN to_TO the_DT pharmacology_NN of_IN the_DT agents_NNS to_TO be_VB employed_VBN ._. Animal_NN experience_NN indicates_VBZ that_IN clorazepate_NN dipotassium_NN prolongs_VBZ the_DT sleeping_VBG time_NN after_IN hexobarbital_JJ or_CC after_IN ethyl_NN alcohol_NN ,_, increases_VBZ the_DT inhibitory_JJ effects_NNS of_IN chlorpromazine_NN ,_, but_CC does_VBZ not_RB exhibit_VB monoamine_NN oxidase_NN inhibition_NN ._. Clinical_JJ studies_NNS have_VBP shown_VBN increased_VBN sedation_NN with_IN concurrent_JJ hypnotic_JJ medications_NNS ._. The_DT actions_NNS of_IN the_DT benzodiazepines_NNS may_MD be_VB potentiated_VBN by_IN barbiturates_NNS ,_, narcotics_NNS ,_, phenothiazines_NNS ,_, monoamine_NN oxidase_NN inhibitors_NNS or_CC other_JJ antidepressants_NNS ._. If_IN TRANXENE_NN tablets_NNS are_VBP used_VBN to_TO treat_VB anxiety_NN associated_VBN with_IN somatic_JJ disease_NN states_NNS ,_, careful_JJ attention_NN must_MD be_VB paid_VBN to_TO possible_JJ drug_NN interaction_NN with_IN concomitant_JJ medication_NN ._. In_IN bioavailability_NN studies_NNS with_IN normal_JJ subjects_NNS ,_, the_DT concurrent_JJ administration_NN of_IN antacids_NNS at_IN therapeutic_JJ levels_NNS did_VBD not_RB significantly_RB influence_VB the_DT bioavailability_NN of_IN TRANXENE_NNP tablets_NNS ._. The_DT risks_NNS of_IN using_VBG Clozapine_NNP in_IN combination_NN with_IN other_JJ drugs_NNS have_VBP not_RB been_VBN systematically_RB evaluated_VBN ._. Pharmacodynamic-related_JJ Interactions_NNS :_: The_DT mechanism_NN of_IN Clozapine_NN induced_VBD agranulocytosis_NN is_VBZ unknown_JJ ._. nonetheless_RB ,_, the_DT possibility_NN that_IN causative_JJ factors_NNS may_MD interact_VB synergistically_RB to_TO increase_VB the_DT risk_NN and/or_CC severity_NN of_IN bone_NN marrow_NN suppression_NN warrants_NNS consideration_NN ._. Therefore_RB ,_, Clozapine_NNP should_MD not_RB be_VB used_VBN with_IN other_JJ agents_NNS having_VBG a_DT well-known_JJ potential_NN to_TO suppress_VB bone_NN marrow_NN function_NN ._. Given_VBN the_DT primary_JJ CNS_NN effects_NNS of_IN Clozapine_NNP ,_, caution_NN is_VBZ advised_VBN in_IN using_VBG it_PRP concomitantly_RB with_IN other_JJ CNS-active_JJ drugs_NNS or_CC alcohol_NN ._. Orthostatic_JJ hypotension_NN in_IN patients_NNS taking_VBG clozapine_NN can_MD ,_, in_IN rare_JJ cases_NNS -LRB-_-LRB- approximately_RB 1_CD case_NN per_IN 3,000_CD patients_NNS -RRB-_-RRB- ,_, be_VB accompanied_VBN by_IN profound_JJ collapse_NN and_CC respiratory_JJ and/or_CC cardiac_JJ arrest_NN ._. Some_DT of_IN the_DT cases_NNS of_IN collapse/respiratory_JJ arrest/cardiac_JJ arrest_NN during_IN initial_JJ treatment_NN occurred_VBD in_IN patients_NNS who_WP were_VBD being_VBG administered_VBN benzodiazepines_NNS ._. similar_JJ events_NNS have_VBP been_VBN reported_VBN in_IN patients_NNS taking_VBG other_JJ psychotropic_JJ drugs_NNS or_CC even_RB Clozapine_NNP by_IN itself_PRP ._. Although_IN it_PRP has_VBZ not_RB been_VBN established_VBN that_IN there_EX is_VBZ an_DT interaction_NN between_IN Clozapine_NNP and_CC benzodiazepines_NNS or_CC other_JJ psychotropics_NNS ,_, caution_NN is_VBZ advised_VBN when_WRB clozapine_NN is_VBZ initiated_VBN in_IN patients_NNS taking_VBG a_DT benzodiazepine_NN or_CC any_DT other_JJ psychotropic_JJ drug_NN ._. Clozapine_NNP may_MD potentiate_VB the_DT hypotensive_JJ effects_NNS of_IN antihypertensive_JJ drugs_NNS and_CC the_DT anticholinergic_JJ effects_NNS of_IN atropine-type_JJ drugs_NNS ._. The_DT administration_NN of_IN epinephrine_NN should_MD be_VB avoided_VBN in_IN the_DT treatment_NN of_IN drug_NN induced_VBD hypotension_NN because_IN of_IN a_DT possible_JJ reverse_JJ epinephrine_NN effect_NN ._. Pharmacokinetic-related_JJ Interactions_NNS :_: Clozapine_NNP is_VBZ a_DT substrate_NN for_IN many_JJ CYP_NN 450_CD isozymes_NNS ,_, in_IN particular_JJ 1A2_NN ,_, 2D6_NN ,_, and_CC 3A4_NN ._. The_DT risk_NN of_IN metabolic_JJ interactions_NNS caused_VBN by_IN an_DT effect_NN on_IN an_DT individual_JJ isoform_NN is_VBZ therefore_RB minimized_VBN ._. Nevertheless_RB ,_, caution_NN should_MD be_VB used_VBN in_IN patients_NNS receiving_VBG concomitant_JJ treatment_NN with_IN other_JJ drugs_NNS that_WDT are_VBP either_DT inhibitors_NNS or_CC inducers_NNS of_IN these_DT enzymes_NNS ._. Concomitant_JJ administration_NN of_IN drugs_NNS known_VBN to_TO induce_VB cytochrome_NN P450_NN enzymes_NNS may_MD decrease_VB the_DT plasma_NN levels_NNS of_IN clozapine_NN ._. Phenytoin_NNP ,_, nicotine_NN ,_, and_CC rifampin_NN may_MD decrease_VB Clozapine_NNP plasma_NN levels_NNS ,_, resulting_VBG in_IN a_DT decrease_NN in_IN effectiveness_NN of_IN a_DT previously_RB effective_JJ Clozapine_NNP dose_NN ._. Concomitant_JJ administration_NN of_IN drugs_NNS known_VBN to_TO inhibit_VB the_DT activity_NN of_IN cytochrome_NN P450_NN isozymes_NNS may_MD increase_VB the_DT plasma_NN levels_NNS of_IN clozapine_NN ._. Cimetidine_NNP ,_, caffeine_NN ,_, and_CC erythromycin_NN may_MD increase_VB plasma_NN levels_NNS of_IN Clozapine_NNP ,_, potentially_RB resulting_VBG in_IN adverse_JJ effects_NNS ._. Although_IN concomitant_JJ use_NN of_IN Clozapine_NNP and_CC carbamazepine_NN is_VBZ not_RB recommended_VBN ,_, it_PRP should_MD be_VB noted_VBN that_IN discontinuation_NN of_IN concomitant_JJ carbamazepine_NN administration_NN may_MD result_VB in_IN an_DT increase_NN in_IN Clozapine_NNP plasma_NN levels_NNS ._. In_IN a_DT study_NN of_IN schizophrenic_JJ patients_NNS who_WP received_VBD clozapine_NN under_IN steady_JJ state_NN conditions_NNS ,_, fluvoxamine_NN or_CC paroxetine_NN was_VBD added_VBN in_IN 16_CD and_CC 14_CD patients_NNS ,_, respectively_RB ._. After_IN 14_CD days_NNS of_IN co-administration_NN ,_, mean_VB trough_NN concentrations_NNS of_IN clozapine_NN and_CC its_PRP$ metabolites_NNS ,_, N-desmethylclozapine_NN and_CC clozapine_NN N-oxide_NN ,_, were_VBD elevated_JJ with_IN fluvoxamine_NN by_IN about_IN three-fold_JJ compared_VBN to_TO baseline_NN concentrations_NNS ._. Paroxetine_NNP produced_VBD only_RB minor_JJ changes_NNS in_IN the_DT levels_NNS of_IN clozapine_NN and_CC its_PRP$ metabolites_NNS ._. However_RB ,_, other_JJ published_VBN reports_NNS describe_VBP modest_JJ elevations_NNS -LRB-_-LRB- less_JJR than_IN two-fold_JJ -RRB-_-RRB- of_IN clozapine_NN and_CC metabolite_NN concentrations_NNS when_WRB clozapine_NN was_VBD taken_VBN with_IN paroxetine_NN ,_, fluoxetine_NN ,_, and_CC sertraline_NN ._. Therefore_RB ,_, such_JJ combined_JJ treatment_NN should_MD be_VB approached_VBN with_IN caution_NN and_CC patients_NNS should_MD be_VB monitored_VBN closely_RB when_WRB Clozapine_NNP is_VBZ combined_VBN with_IN these_DT drugs_NNS ,_, particularly_RB with_IN fluvoxamine_NN ._. A_DT reduced_VBN Clozapine_NNP dose_NN should_MD be_VB considered_VBN ._. A_DT subset_NN -LRB-_-LRB- 3_CD %_NN -10_CD %_NN -RRB-_-RRB- of_IN the_DT population_NN has_VBZ reduced_VBN activity_NN of_IN certain_JJ drug_NN metabolizing_VBG enzymes_NNS such_JJ as_IN the_DT cytochrome_NN P450_NN isozyme_NN P450_NN 2D6_NN ._. Such_JJ individuals_NNS are_VBP referred_VBN to_TO as_IN poor_JJ metabolizers_NNS of_IN drugs_NNS such_JJ as_IN debrisoquin_NN ,_, dextromethorphan_NN ,_, the_DT tricyclic_JJ antidepressants_NNS ,_, and_CC clozapine_NN ._. These_DT individuals_NNS may_MD develop_VB higher_JJR than_IN expected_VBN plasma_NN concentrations_NNS of_IN clozapine_NN when_WRB given_VBN usual_JJ doses_NNS ._. In_IN addition_NN ,_, certain_JJ drugs_NNS that_WDT are_VBP metabolized_VBN by_IN this_DT isozyme_NN ,_, including_VBG many_JJ antidepressants_NNS -LRB-_-LRB- clozapine_NN ,_, selective_JJ serotonin_NN reuptake_NN inhibitors_NNS ,_, and_CC others_NNS -RRB-_-RRB- ,_, may_MD inhibit_VB the_DT activity_NN of_IN this_DT isozyme_NN ,_, and_CC thus_RB may_MD make_VB normal_JJ metabolizers_NNS resemble_VBP poor_JJ metabolizers_NNS with_IN regard_NN to_TO concomitant_JJ therapy_NN with_IN other_JJ drugs_NNS metabolized_VBN by_IN this_DT enzyme_NN system_NN ,_, leading_VBG to_TO drug_NN interaction_NN ._. Concomitant_JJ use_NN of_IN clozapine_NN with_IN other_JJ drugs_NNS metabolized_VBN by_IN cytochrome_NN P450_NN 2D6_NN may_MD require_VB lower_JJR doses_NNS than_IN usually_RB prescribed_VBN for_IN either_CC clozapine_NN or_CC the_DT other_JJ drug_NN ._. Therefore_RB ,_, co-administration_NN of_IN clozapine_NN with_IN other_JJ drugs_NNS that_WDT are_VBP metabolized_VBN by_IN this_DT isozyme_NN ,_, including_VBG antidepressants_NNS ,_, phenothiazines_NNS ,_, carbamazepine_NN ,_, and_CC Type_NN 1C_NN antiarrhythmics_NNS -LRB-_-LRB- e.g._FW ,_, propafenone_NN ,_, flecainide_NN and_CC encainide_NN -RRB-_-RRB- ,_, or_CC that_IN inhibit_VBP this_DT enzyme_NN -LRB-_-LRB- e.g._FW ,_, quinidine_NN -RRB-_-RRB- ,_, should_MD be_VB approached_VBN with_IN caution_NN ._. The_DT risk_NN of_IN a_DT potential_JJ interaction_NN between_IN NovoSeven_NNP and_CC coagulation_NN factor_NN concentrates_VBZ has_VBZ not_RB been_VBN adequately_RB evaluated_VBN in_IN preclinical_JJ or_CC clinical_JJ studies_NNS ._. Simultaneous_JJ use_NN of_IN activated_VBN prothrombin_NN complex_NN concentrates_VBZ or_CC prothrombin_NN complex_NN concentrates_VBZ should_MD be_VB avoided_VBN ._. Although_IN the_DT specific_JJ drug_NN interaction_NN was_VBD not_RB studied_VBN in_IN a_DT clinical_JJ trial_NN ,_, there_EX have_VBP been_VBN more_JJR than_IN 50_CD episodes_NNS of_IN concomitant_JJ use_NN of_IN antifibrinolytic_JJ therapies_NNS -LRB-_-LRB- i.e._FW ,_, tranexamic_JJ acid_NN ,_, aminocaproic_JJ acid_NN -RRB-_-RRB- and_CC NovoSeven_NNP ._. NovoSeven_NNP should_MD not_RB be_VB mixed_VBN with_IN infusion_NN solutions_NNS until_IN clinical_JJ data_NNS are_VBP available_JJ to_TO direct_VB this_DT use_NN ._. Codeine_NNP in_IN combination_NN with_IN other_JJ narcotic_JJ analgesics_NNS ,_, general_JJ anesthetics_NNS ,_, phenothiazines_NNS ,_, tranquilizers_NNS ,_, sedative-hypnotics_NNS ,_, or_CC other_JJ CNS_NN depressants_NNS -LRB-_-LRB- including_VBG alcohol_NN -RRB-_-RRB- has_VBZ additive_JJ depressant_NN effects_NNS ._. When_WRB s.c._NN combination_NN therapy_NN is_VBZ contemplated_VBN ,_, the_DT dosage_NN of_IN one_CD or_CC both_DT agents_NNS should_MD be_VB reduced_VBN ._. Colchicine_NNP is_VBZ inhibited_VBN by_IN acidifying_VBG agents_NNS ._. The_DT action_NN of_IN colchicine_NN is_VBZ potentiated_VBN by_IN alkalinizing_VBG agents_NNS ._. Colchicine_NNP may_MD increase_VB sensitivity_NN to_TO the_DT CNS_NN depressants_NNS ._. Response_NN to_TO sympathomimetic_JJ agents_NNS may_MD be_VB enhanced_VBN by_IN colchicine_NN ._. WelChol_NNP has_VBZ been_VBN studied_VBN in_IN several_JJ human_JJ drug_NN interaction_NN studies_NNS in_IN which_WDT it_PRP was_VBD administered_VBN with_IN a_DT meal_NN and_CC the_DT test_NN drug_NN ._. WelChol_NNP was_VBD found_VBN to_TO have_VB no_DT significant_JJ effect_NN on_IN the_DT bioavailability_NN of_IN digoxin_NN ,_, lovastatin_NN ,_, metoprolol_NN ,_, quinidine_NN ,_, valproic_JJ acid_NN ,_, and_CC warfarin_NN ._. WelChol_NNP decreased_VBD the_DT Cmax_NN and_CC AUC_NN of_IN sustained-release_JJ verapamil_NN -LRB-_-LRB- Calan_JJ SR_NN -RRB-_-RRB- by_IN approximately_RB 31_CD %_NN and_CC 11_CD %_NN ,_, respectively_RB ._. Since_IN there_EX is_VBZ a_DT high_JJ degree_NN of_IN variability_NN in_IN the_DT bioavailability_NN of_IN verapamil_NN ,_, the_DT clinical_JJ significance_NN of_IN this_DT finding_NN is_VBZ unclear_JJ ._. In_IN clinical_JJ studies_NNS ,_, coadministration_NN of_IN WelChol_NN with_IN atorvastatin_NN ,_, lovastatin_NN ,_, or_CC simvastatin_NN did_VBD not_RB interfere_VB with_IN the_DT lipid-lowering_JJ activity_NN of_IN the_DT HMG-CoA_NN reductase_NN inhibitor_NN ._. Other_JJ drugs_NNS have_VBP not_RB been_VBN studied_VBN ._. When_WRB administering_VBG other_JJ drugs_NNS for_IN which_WDT alterations_NNS in_IN blood_NN levels_NNS could_MD have_VB a_DT clinically_RB significant_JJ effect_NN on_IN safety_NN or_CC efficacy_NN ,_, physicians_NNS should_MD consider_VB monitoring_VBG drug_NN levels_NNS or_CC effects_NNS ._. Since_IN colestipol_NN hydrochloride_NN is_VBZ an_DT anion_NN exchange_NN resin_NN ,_, it_PRP may_MD have_VB a_DT strong_JJ affinity_NN for_IN anions_NNS other_JJ than_IN the_DT bile_NN acids_NNS ._. In_FW vitro_FW studies_NNS have_VBP indicated_VBN that_IN colestipol_NN hydrochloride_NN binds_VBZ a_DT number_NN of_IN drugs_NNS ._. Therefore_RB ,_, COLESTlD_NNP Tablets_NNPS may_MD delay_VB or_CC reduce_VB the_DT absorption_NN of_IN concomitant_JJ oral_JJ medication_NN ._. The_DT interval_NN between_IN the_DT administration_NN of_IN COLESTID_NNP Tablets_NNPS and_CC any_DT other_JJ medication_NN should_MD be_VB as_RB long_RB as_IN possible_JJ ._. Patients_NNS should_MD take_VB other_JJ drugs_NNS at_IN least_JJS one_CD hour_NN before_IN or_CC four_CD hours_NNS after_IN COLESTID_NNP Tablets_NNPS to_TO avoid_VB impeding_VBG their_PRP$ absorption_NN ._. Repeated_JJ doses_NNS of_IN colestipol_NN hydrochloride_NN given_VBN prior_RB to_TO a_DT single_JJ dose_NN of_IN propranolol_NN in_IN human_JJ trials_NNS have_VBP been_VBN reported_VBN to_TO decrease_VB propranolol_NN absorption_NN ._. However_RB ,_, in_IN a_DT follow-up_JJ study_NN in_IN normal_JJ subjects_NNS ,_, single-dose_JJ administration_NN of_IN colestipol_NN hydrochloride_NN and_CC propranolol_NN and_CC twice-a-day_JJ administration_NN for_IN 5_CD days_NNS of_IN both_DT agents_NNS did_VBD not_RB affect_VB the_DT extent_NN of_IN propranolol_NN absorption_NN ,_, but_CC had_VBD a_DT small_JJ yet_RB statistically_RB significant_JJ effect_NN on_IN its_PRP$ rate_NN of_IN absorption_NN ._. the_DT time_NN to_TO reach_VB maximum_NN concentration_NN was_VBD delayed_VBN approximately_RB 30_CD minutes_NNS ._. Effects_NNS on_IN the_DT absorption_NN of_IN other_JJ beta-blockers_NNS have_VBP not_RB been_VBN determined_VBN ._. Therefore_RB ,_, patients_NNS on_IN propranolol_NN should_MD be_VB observed_VBN when_WRB COLESTID_NNP Tablets_NNS are_VBP either_RB added_VBN or_CC deleted_VBN from_IN a_DT therapeutic_JJ regimen_NN ._. Studies_NNS in_IN humans_NNS show_VBP that_IN the_DT absorption_NN of_IN chlorothiazide_NN as_IN reflected_VBN in_IN urinary_JJ excretion_NN is_VBZ markedly_RB decreased_VBN even_RB when_WRB administered_VBN one_CD hour_NN before_IN colestipol_NN hydrochloride_NN ._. The_DT absorption_NN of_IN tetracycline_NN ,_, furosemide_NN ,_, penicillin_NN G_NN ,_, hydrochlorothiazide_NN ,_, and_CC gemfibrozil_NN was_VBD significantly_RB decreased_VBN when_WRB given_VBN simultaneously_RB with_IN colestipol_NN hydrochloride_NN ._. these_DT drugs_NNS were_VBD not_RB tested_VBN to_TO determine_VB the_DT effect_NN of_IN administration_NN one_CD hour_NN before_IN colestipol_NN hydrochloride_NN ._. No_DT depressant_NN effect_NN on_IN blood_NN levels_NNS in_IN humans_NNS was_VBD noted_VBN when_WRB colestipol_NN hydrochloride_NN was_VBD administered_VBN with_IN any_DT of_IN the_DT following_VBG drugs_NNS :_: aspirin_NN ,_, clindamycin_NN ,_, clofibrate_NN ,_, methyldopa_NN ,_, nicotinic_JJ acid_NN -LRB-_-LRB- niacin_NN -RRB-_-RRB- ,_, tolbutamide_NN ,_, phenytoin_NN or_CC warfarin_NN ._. Particular_JJ caution_NN should_MD be_VB observed_VBN with_IN digitalis_NN preparations_NNS since_IN there_EX are_VBP conflicting_VBG results_NNS for_IN the_DT effect_NN of_IN colestipol_NN hydrochloride_NN on_IN the_DT availability_NN of_IN digoxin_NN and_CC digitoxin_NN ._. The_DT potential_NN for_IN binding_NN of_IN these_DT drugs_NNS if_IN given_VBN concomitantly_RB is_VBZ present_JJ ._. Discontinuing_VBG colestipol_NN hydrochloride_NN could_MD pose_VB a_DT hazard_NN to_TO health_NN if_IN a_DT potentially_RB toxic_JJ drug_NN that_WDT is_VBZ significantly_RB bound_VBN to_TO the_DT resin_NN has_VBZ been_VBN titrated_VBN to_TO a_DT maintenance_NN level_NN while_IN the_DT patient_NN was_VBD taking_VBG colestipol_NN hydrochloride_NN ._. Bile_NN acid_NN binding_NN resins_NNS may_MD also_RB interfere_VB with_IN the_DT absorption_NN of_IN oral_JJ phosphate_NN supplements_NNS and_CC hydrocortisone_NN ._. Certain_JJ other_JJ antibiotics_NNS -LRB-_-LRB- aminoglycosides_NNS and_CC polymyxin_NN -RRB-_-RRB- have_VBP also_RB been_VBN reported_VBN to_TO interfere_VB with_IN the_DT nerve_NN transmission_NN at_IN the_DT neuromuscular_JJ junction_NN ._. Based_VBN on_IN this_DT reported_VBN activity_NN ,_, they_PRP should_MD not_RB be_VB given_VBN concomitantly_RB with_IN Coly-Mycin_NN M_NN Parenteral_JJ except_IN with_IN the_DT greatest_JJS caution_NN ._. Curariform_JJ muscle_NN relaxants_NNS -LRB-_-LRB- eg_FW ,_, tubocurarine_NN -RRB-_-RRB- and_CC other_JJ drugs_NNS ,_, including_VBG ether_NN ,_, succinylcholine_NN ,_, gallamine_NN ,_, decamethonium_NN and_CC sodium_NN citrate_NN ,_, potentiate_VB the_DT neuromuscular_JJ blocking_NN effect_NN and_CC should_MD be_VB used_VBN with_IN extreme_JJ caution_NN in_IN patients_NNS being_VBG treated_VBN with_IN Coly-Mycin_NN M_NN Parenteral_NN ._. Sodium_NN cephalothin_NN may_MD enhance_VB the_DT nephrotoxicity_NN of_IN Coly-Mycin_NNP M_NN Parenteral_NN ._. The_DT concomitant_JJ use_NN of_IN sodium_NN cephalothin_NN and_CC Coly-Mycin_NN M_NN Parenteral_NN should_MD be_VB avoided_VBN ._. Digoxin_NNP :_: Coadministration_NNP of_IN digoxin_NN ,_, a_DT P-glycoprotein_NN substrate_NN ,_, with_IN oral_JJ conivaptan_NN resulted_VBD in_IN a_DT reduction_NN in_IN clearance_NN and_CC an_DT increase_NN in_IN digoxin_NN Cmax_NN and_CC AUC_NN values_NNS ._. Therefore_RB ,_, if_IN digoxin_NN is_VBZ administered_VBN with_IN VAPRISOL_NN ,_, the_DT clinician_NN should_MD be_VB alert_JJ to_TO the_DT possibility_NN of_IN increases_NNS in_IN digoxin_NN levels_NNS ._. DRUG/LABORATORY_NN TEST_NN INTERACTIONS_NNS 1_CD ._. Accelerated_VBN prothrombin_NN time_NN ,_, partial_JJ thromboplastin_NN time_NN ,_, and_CC platelet_NN aggregation_NN time_NN ;_: ._. increased_VBN platelet_NN count_NN ;_: ._. increased_VBN factors_NNS II_CD ,_, VII_NN antigen_NN ,_, VIII_CD antigen_NN ,_, VIII_CD coagulant_NN activity_NN ,_, IX_CD ,_, X_NN ,_, XII_NNP ,_, VII-X_NN complex_NN ,_, II-VII-X_NN complex_NN ,_, and_CC beta-thromboglobulin_NN ;_: ._. decreased_VBN levels_NNS of_IN anti-factor_JJ Xa_NN and_CC antithrombin_NN III_CD ,_, decreased_VBD antithrombin_NN III_CD activity_NN ._. increased_VBN levels_NNS of_IN fibrinogen_NN and_CC fibrinogen_NN activity_NN ._. increased_VBN plasminogen_NN antigen_NN and_CC activity_NN ._. 2_LS ._. Increased_VBN thyroid-binding_JJ globulin_NN -LRB-_-LRB- TBG_NN -RRB-_-RRB- levels_NNS leading_VBG to_TO increased_VBN circulating_VBG total_JJ thyroid_NN hormone_NN levels_NNS as_IN measured_VBN by_IN protein-bound_JJ iodine_NN -LRB-_-LRB- PBI_NN -RRB-_-RRB- ,_, T4_NN levels_NNS -LRB-_-LRB- by_IN column_NN or_CC by_IN radioimmunoassay_NN -RRB-_-RRB- or_CC T3_NN levels_NNS by_IN radioimmunoassay_NN ._. T3_NN resin_NN uptake_NN is_VBZ decreased_VBN ,_, reflecting_VBG the_DT elevated_JJ TBG_NN ._. Free_NNP T4_NN and_CC free_JJ T3_NN concentrations_NNS are_VBP unaltered_JJ ._. Patients_NNS on_IN thyroid_NN replacement_NN therapy_NN may_MD require_VB higher_JJR doses_NNS of_IN thyroid_NN hormone_NN ._. 3_LS ._. Other_JJ binding_NN proteins_NNS may_MD be_VB elevated_JJ in_IN serum_NN ,_, -LRB-_-LRB- i.e._FW ,_, corticosteroid_NN binding_NN globulin_NN -LRB-_-LRB- CBG_NN -RRB-_-RRB- ,_, sex_NN hormone_NN binding_NN globulin_NN -LRB-_-LRB- SHBG_NN -RRB-_-RRB- -RRB-_-RRB- leading_VBG to_TO increased_VBN total_JJ circulating_VBG corticosteroids_NNS and_CC sex_NN steroids_NNS ,_, respectively_RB ._. Free_NNP hormone_NN concentrations_NNS may_MD be_VB decreased_VBN ._. Other_JJ plasma_NN proteins_NNS may_MD be_VB increased_VBN -LRB-_-LRB- angiotensinogen/renin_NN substrate_NN ,_, alpha-1-antitrypsin_NN ,_, ceruloplasmin_NN -RRB-_-RRB- ._. 4_LS ._. Increased_VBN plasma_NN HDL_NN and_CC HDL2_NN cholesterol_NN subfraction_NN concentrations_NNS ,_, reduced_VBD LDL_NN cholesterol_NN concentration_NN ,_, increased_VBD triglyceride_NN levels_NNS ._. 5_CD ._. Impaired_JJ glucose_NN tolerance_NN ._. 6_CD ._. Reduced_VBN response_NN to_TO metyrapone_NN test_NN ._. Corticotropin_NNP may_MD accentuate_VB the_DT electrolyte_NN loss_NN associated_VBN with_IN diuretic_JJ therapy_NN ._. The_DT pharmacokinetic_JJ interactions_NNS listed_VBN below_RB are_VBP potentially_RB clinically_RB important_JJ ._. Drugs_NNS that_WDT induce_VBP hepatic_JJ enzymes_NNS such_JJ as_IN phenobarbital_NN ,_, phenytoin_NN and_CC rifampin_NN may_MD increase_VB the_DT clearance_NN of_IN corticosteroids_NNS and_CC may_MD require_VB increases_NNS in_IN corticosteroid_NN dose_NN to_TO achieve_VB the_DT desired_VBN response_NN ._. Drugs_NNS such_JJ as_IN troleandomycin_NN and_CC ketoconazole_NN may_MD inhibit_VB the_DT metabolism_NN of_IN corticosteroids_NNS and_CC thus_RB decrease_VB their_PRP$ clearance_NN ._. Therefore_RB ,_, the_DT dose_NN of_IN corticosteroid_NN should_MD be_VB titrated_VBN to_TO avoid_VB steroid_NN toxicity_NN ._. Corticosteroids_NNS may_MD increase_VB the_DT clearance_NN of_IN chronic_JJ high_JJ dose_NN aspirin_NN ._. This_DT could_MD lead_VB to_TO decreased_VBN salicylate_NN serum_NN levels_NNS or_CC increase_VB the_DT risk_NN of_IN salicylate_NN toxicity_NN when_WRB corticosteroid_NN is_VBZ withdrawn_VBN ._. Aspirin_NN should_MD be_VB used_VBN cautiously_RB in_IN conjunction_NN with_IN cortico-steroids_NNS in_IN patients_NNS suffering_VBG from_IN hypopro-thrombinemia_JJ ._. The_DT effect_NN of_IN corticosteroids_NNS on_IN oral_JJ anticoagulants_NNS is_VBZ variable_JJ ._. There_EX are_VBP reports_NNS of_IN enhanced_VBN as_RB well_RB as_IN diminished_JJ effects_NNS of_IN anticoagulants_NNS when_WRB given_VBN concurrently_RB with_IN corticosteroids_NNS ._. Therefore_RB ,_, coagulation_NN indices_NNS should_MD be_VB monitored_VBN to_TO maintain_VB the_DT desired_VBN anticoagulant_JJ effect_NN ._. Corticotropin_NNP may_MD accentuate_VB the_DT electrolyte_NN loss_NN associated_VBN with_IN diuretic_JJ therapy_NN ._. Drug_NN Interaction_NN During_IN Pregnancy_NNP :_: Cromolyn_NNP sodium_NN and_CC isoproterenol_NN were_VBD studied_VBN following_VBG subcutaneous_JJ injections_NNS in_IN pregnant_JJ mice_NNS ._. Cromolyn_NNP sodium_NN alone_RB in_IN doses_NNS up_RB to_TO 540_CD mg/kg/day_NN -LRB-_-LRB- approximately_RB 340_CD times_NNS the_DT maximum_NN recommended_VBD daily_JJ inhalation_NN dose_NN in_IN adults_NNS on_IN a_DT mg/m2_NN basis_NN -RRB-_-RRB- did_VBD not_RB cause_VB significant_JJ increases_NNS in_IN resorptions_NNS or_CC major_JJ malformations_NNS ._. Isoproterenol_NN alone_RB at_IN a_DT dose_NN of_IN 2.7_CD mg/kg/day_NN -LRB-_-LRB- approximately_RB 7_CD times_NNS the_DT maximum_NN recommended_VBD daily_JJ inhalation_NN dose_NN in_IN adults_NNS on_IN a_DT mg/m2_NN basis_NN -RRB-_-RRB- increased_VBD both_DT resorptions_NNS and_CC malformations_NNS ._. The_DT addition_NN of_IN 540_CD mg/kg/day_NN of_IN cromolyn_NN sodium_NN -LRB-_-LRB- approximately_RB 340_CD times_NNS the_DT maximum_NN recommended_VBD daily_JJ inhalation_NN dose_NN in_IN adults_NNS on_IN a_DT mg/m2_NN basis_NN -RRB-_-RRB- to_TO 2.7_CD mg/kg/day_NN of_IN isoproterenol_NN -LRB-_-LRB- approximately_RB 7_CD times_NNS the_DT maximum_NN recommended_VBD daily_JJ inhalation_NN dose_NN in_IN adults_NNS on_IN a_DT mg/m2_NN basis_NN -RRB-_-RRB- appears_VBZ to_TO have_VB increased_VBN the_DT incidence_NN of_IN both_DT resorptions_NNS and_CC malformations_NNS ._. None_NN known_VBN ._. Persons_NNS taking_VBG most_RBS antibiotics_NNS ,_, methotrexate_NN and_CC pyrimethamine_NN invalidate_VBP folic_JJ acid_NN and_CC vitamin_NN B12_NN diagnostic_JJ blood_NN assays_NNS ._. Colchicine_NNP para-aminosalicylic_JJ acid_NN and_CC heavy_JJ alcohol_NN intake_NN for_IN longer_JJR than_IN 2_CD weeks_NNS may_MD produce_VB malabsorption_NN of_IN vitamin_NN B12_NN ._. FLEXERIL_NNP may_MD have_VB life-threatening_JJ interactions_NNS with_IN MAO_NN inhibitors_NNS ._. FLEXERIL_NNP may_MD enhance_VB the_DT effects_NNS of_IN alcohol_NN ,_, barbiturates_NNS ,_, and_CC other_JJ CNS_NN depressants_NNS ._. Tricyclic_JJ antidepressants_NNS may_MD block_VB the_DT antihypertensive_JJ action_NN of_IN guanethidine_NN and_CC similarly_RB acting_VBG compounds_NNS ._. Tricyclic_JJ antidepressants_NNS may_MD enhance_VB the_DT seizure_NN risk_NN in_IN patients_NNS taking_VBG tramado_NN ._. Cyclopentolate_NNP may_MD interfere_VB with_IN the_DT anti-glaucoma_JJ action_NN of_IN carbachol_NN or_CC pilocarpine_NN ._. also_RB ,_, concurrent_JJ use_NN of_IN this_DT medication_NN may_MD antagonise_VB the_DT anti-glaucoma_JJ and_CC miotic_JJ actions_NNS of_IN ophthalmic_JJ cholinesterase_NN inhibitors_NNS ._. The_DT rate_NN of_IN metabolism_NN and_CC the_DT leukopenic_JJ activity_NN of_IN cyclophosphamide_NN reportedly_RB are_VBP increased_VBN by_IN chronic_JJ administration_NN of_IN high_JJ doses_NNS of_IN phenobarbital_NN ._. The_DT physician_NN should_MD be_VB alert_JJ for_IN possible_JJ combined_VBN drug_NN actions_NNS ,_, desirable_JJ or_CC undesirable_JJ ,_, involving_VBG cyclophosphamide_NN even_RB though_IN cyclophosphamide_NN has_VBZ been_VBN used_VBN successfully_RB concurrently_RB with_IN other_JJ drugs_NNS ,_, including_VBG other_JJ cytotoxic_JJ drugs_NNS ._. Cyclophosphamide_NN treatment_NN ,_, which_WDT causes_VBZ a_DT marked_JJ and_CC persistent_JJ inhibition_NN of_IN cholinesterase_NN activity_NN ,_, potentiates_VBZ the_DT effect_NN of_IN succinylcholine_NN chloride_NN ._. If_IN a_DT patient_NN has_VBZ been_VBN treated_VBN with_IN cyclophosphamide_NN within_IN 10_CD days_NNS of_IN general_JJ anesthesia_NN ,_, the_DT anesthesiologist_NN should_MD be_VB alerted_VBN ._. May_NNP interact_VBP with_IN wthionamide_NN -LRB-_-LRB- Trecator-SC_NN -RRB-_-RRB- and_CC isoniazid_NN -LRB-_-LRB- Nydrazid_NN -RRB-_-RRB- ._. MAO_NN inhibitors_NNS prolong_VB and_CC intensify_VB the_DT anticholinergic_JJ effects_NNS of_IN antihistamines_NNS ._. Antihistamines_NNS may_MD have_VB additive_JJ effects_NNS with_IN alcohol_NN and_CC other_JJ CNS_NN depressants_NNS ,_, e.g._FW ,_, hypnotics_NNS ,_, sedatives_NNS ,_, tranquilizers_NNS ,_, antianxiety_JJ agents_NNS ._. No_DT drug_NN interactions_NNS have_VBP been_VBN reported_VBN ._. Steady_JJ state_NN plasma_NN digitoxin_NN concentrations_NNS did_VBD not_RB appear_VB to_TO change_VB ._. Therefore_RB ,_, monitoring_NN of_IN plasma_NN digoxin_NN levels_NNS may_MD be_VB indicated_VBN in_IN patients_NNS receiving_VBG similar_JJ combination_NN chemotherapy_NN regimens_NNS ._. The_DT utilization_NN of_IN digitoxin_NN for_IN such_JJ patients_NNS may_MD be_VB considered_VBN as_IN an_DT alternative_NN ._. Also_RB flucytosine_NN ._. Drug/LaboratoryTest_NNP Interactions_NNS Dactinomycin_NN may_MD interfere_VB with_IN bioassay_NN procedures_NNS for_IN the_DT determination_NN of_IN antibacterial_JJ drug_NN levels_NNS ._. Dantrium_NNP is_VBZ metabolized_VBN by_IN the_DT liver_NN ,_, and_CC it_PRP is_VBZ theoretically_RB possible_JJ that_IN its_PRP$ metabolism_NN may_MD be_VB enhanced_VBN by_IN drugs_NNS known_VBN to_TO induce_VB hepatic_JJ microsomal_JJ enzymes_NNS ._. However_RB ,_, neither_DT phenobarbital_JJ nor_CC diazepam_NN appears_VBZ to_TO affect_VB Dantrium_NNP metabolism_NN ._. Binding_NN to_TO plasma_NN protein_NN is_VBZ not_RB significantly_RB altered_VBN by_IN diazepam_NN ,_, diphenylhydantoin_NN ,_, or_CC phenylbutazone_NN ._. Binding_NN to_TO plasma_NN proteins_NNS is_VBZ reduced_VBN by_IN warfarin_NN and_CC clotibrate_NN and_CC increased_VBN by_IN tolbutamide_NN ._. Cardiovascular_NNP collapse_NN in_IN patients_NNS treated_VBN simultaneously_RB with_IN varapamil_NN and_CC dantrolene_JJ sodium_NN is_VBZ rare_JJ ._. The_DT combination_NN of_IN therapeutic_JJ doses_NNS of_IN intravenous_JJ dantrolene_JJ sodium_NN and_CC verapamil_NN in_IN halothane_NN a-chloralose_NN anesthetized_JJ swine_NNS has_VBZ resulted_VBN in_IN ventricular_JJ fibrillation_NN and_CC cardiovascular_JJ collapse_NN in_IN association_NN with_IN marked_JJ hyperkalemia_NN ._. It_PRP is_VBZ recommended_VBN that_IN the_DT combination_NN of_IN intravenous_JJ dantrolene_JJ sodium_NN and_CC calcium_NN channel_NN blockers_NNS ,_, such_JJ as_IN verapamil_NN ,_, not_RB be_VB used_VBN together_RB during_IN the_DT management_NN of_IN malignant_JJ hyperthermia_NN crisis_NN until_IN the_DT relevance_NN of_IN these_DT findings_NNS to_TO humans_NNS is_VBZ established_VBN ._. Administration_NN of_IN dantrolene_NN may_MD potentiate_VB vecuronium-induced_JJ neuromuscular_JJ block_NN ._. A_DT drug-drug_JJ interaction_NN study_NN evaluated_VBD the_DT effect_NN of_IN the_DT use_NN of_IN ACZONE_NNP Gel_NN ,_, 5_CD %_NN ,_, in_IN combination_NN with_IN double_JJ strength_NN -LRB-_-LRB- 160_CD mg/800_NN mg_NN -RRB-_-RRB- trimethoprim/sulfamethoxazole_NN -LRB-_-LRB- TMP/SMX_NN -RRB-_-RRB- ._. During_IN co-administration_NN ,_, systemic_JJ levels_NNS of_IN TMP_NNP and_CC SMX_NN were_VBD essentially_RB unchanged_JJ ._. Notably_RB ,_, systemic_JJ exposure_NN -LRB-_-LRB- AUC0-12_NN -RRB-_-RRB- of_IN dapsone_NN hydroxylamine_NN -LRB-_-LRB- DHA_NN -RRB-_-RRB- was_VBD more_JJR than_IN doubled_VBN in_IN the_DT presence_NN of_IN TMP/SMX_NN ._. Exposure_NN from_IN the_DT proposed_VBN topical_JJ dose_NN is_VBZ about_IN 1_CD %_NN of_IN that_DT from_IN the_DT 100_CD mg_NN oral_JJ dose_NN ,_, even_RB when_WRB co-administered_VBN with_IN TMP/SMX_NN ._. Certain_JJ concomitant_JJ medications_NNS -LRB-_-LRB- such_JJ as_IN rifampin_NN ,_, anticonvulsants_NNS ,_, St._NNP John_NNP s_VBZ wort_NN -RRB-_-RRB- may_MD increase_VB the_DT formation_NN of_IN dapsone_NN hydroxylamine_NN ,_, a_DT metabolite_NN of_IN dapsone_NN associated_VBN with_IN hemolysis_NN ._. With_IN oral_JJ dapsone_NN treatment_NN ,_, folic_JJ acid_NN antagonists_NNS such_JJ as_IN pyrimethamine_NN have_VBP been_VBN noted_VBN to_TO possibly_RB increase_VB the_DT likelihood_NN of_IN hematologic_JJ reaction_NN ._. Warfarin_NNP :_: Concomitant_JJ administration_NN of_IN daptomycin_NN -LRB-_-LRB- 6_CD mg/kg_NN once_RB every_DT 24_CD hours_NNS for_IN 5_CD days_NNS -RRB-_-RRB- and_CC warfarin_NN -LRB-_-LRB- 25_CD mg_NN single_JJ oral_JJ dose_NN -RRB-_-RRB- had_VBD no_DT significant_JJ effect_NN on_IN the_DT pharmacokinetics_NNS of_IN either_CC drug_NN ,_, and_CC the_DT INR_NN was_VBD not_RB significantly_RB altered_VBN ._. HMG-CoA_NN Reductase_NN Inhibitors_NNS :_: Inhibitors_NNS of_IN HMG-CoA_NN reductase_NN may_MD cause_VB myopathy_NN ,_, which_WDT is_VBZ manifested_VBN as_IN muscle_NN pain_NN or_CC weakness_NN associated_VBN with_IN elevated_JJ levels_NNS of_IN CPK_NNP ._. There_EX were_VBD no_DT reports_NNS of_IN skeletal_JJ myopathy_NN in_IN a_DT placebo-controlled_JJ Phase_NN I_PRP trial_NN in_IN which_WDT 10_CD healthy_JJ subjects_NNS on_IN stable_JJ simvastatin_NN therapy_NN were_VBD treated_VBN concurrently_RB with_IN daptomycin_NN -LRB-_-LRB- 4_CD mg/kg_NN once_RB every_DT 24_CD hours_NNS -RRB-_-RRB- for_IN 14_CD days_NNS ._. Experience_NN with_IN co-administration_NN of_IN HMG-CoA_NN reductase_NN inhibitors_NNS and_CC Fentanyl_NNP in_IN patients_NNS is_VBZ limited_VBN ,_, therefore_RB ,_, consideration_NN should_MD be_VB given_VBN to_TO temporarily_RB suspending_VBG use_NN of_IN HMG-CoA_NN reductase_NN inhibitors_NNS in_IN patients_NNS receiving_VBG Fentanyl_NNP ._. Drug-Laboratory_JJ Test_NN Interactions_NNS :_: There_EX are_VBP no_DT reported_VBN drug-laboratory_JJ test_NN interactions_NNS ._. No_DT formal_JJ drug_NN interaction_NN studies_NNS of_IN Aranesp_NNP have_VBP been_VBN performed_VBN ._. The_DT daily_JJ dose_NN of_IN ENABLEX_NNP should_MD not_RB exceed_VB 7.5_CD mg_NN when_WRB coadministered_VBN with_IN potent_JJ CYP3A4_NN inhibitors_NNS -LRB-_-LRB- e.g._FW ,_, ketoconazole_NN ,_, itraconazole_NN ,_, ritonavir_NN ,_, nelfinavir_NN ,_, clarithromycin_NN and_CC nefazadone_NN -RRB-_-RRB- ._. Caution_NN should_MD be_VB taken_VBN when_WRB ENABLEX_NNP is_VBZ used_VBN concomitantly_RB with_IN medications_NNS that_WDT are_VBP predominantly_RB metabolized_VBN by_IN CYP2D6_NN and_CC which_WDT have_VBP a_DT narrow_JJ therapeutic_JJ window_NN ,_, such_JJ as_IN flecainide_NN ,_, thioridazine_NN and_CC tricyclic_JJ antidepressants_NNS -LRB-_-LRB- see_VB CLINICAL_NNP PHARMACOLOGY_NNP -RRB-_-RRB- ._. The_DT concomitant_JJ use_NN of_IN ENABLEX_NN with_IN other_JJ anticholinergic_JJ agents_NNS may_MD increase_VB the_DT frequency_NN and/or_CC severity_NN of_IN dry_JJ mouth_NN ,_, constipation_NN ,_, blurred_VBD vision_NN and_CC other_JJ anticholinergic_JJ pharmacological_JJ effects_NNS ._. Anticholinergic_JJ agents_NNS may_MD potentially_RB alter_VB the_DT absorption_NN of_IN some_DT concomitantly_RB administered_VBN drugs_NNS due_JJ to_TO effects_NNS on_IN gastrointestinal_JJ motility_NN ._. Drug_NNP Laboratory_NNP Test_NNP Interactions_NNS Interactions_NNS between_IN darifenacin_NN and_CC laboratory_NN tests_NNS have_VBP not_RB been_VBN studied_VBN ._. Drugs_NNS that_WDT may_MD increase_VB dasatinib_JJ plasma_NN concentrations_NNS CYP3A4_NN Inhibitors_NNS :_: Dasatinib_NN is_VBZ a_DT CYP3A4_NN substrate_NN ._. Concomitant_JJ use_NN of_IN SPRYCEL_NN and_CC drugs_NNS that_WDT inhibit_VBP CYP3A4_NN -LRB-_-LRB- eg_FW ,_, ketoconazole_NN ,_, itraconazole_NN ,_, erythromycin_NN ,_, clarithromycin_NN ,_, ritonavir_NN ,_, atazanavir_NN ,_, indinavir_NN ,_, nefazodone_NN ,_, nelfinavir_NN ,_, saquinavir_NN ,_, telithromycin_NN -RRB-_-RRB- may_MD increase_VB exposure_NN to_TO dasatinib_NN and_CC should_MD be_VB avoided_VBN ._. In_IN patients_NNS receiving_VBG treatment_NN with_IN SPRYCEL_NN ,_, close_JJ monitoring_NN for_IN toxicity_NN and_CC a_DT SPRYCEL_NNP dose_NN reduction_NN should_MD be_VB considered_VBN if_IN systemic_JJ administration_NN of_IN a_DT potent_JJ CYP3A4_NN inhibitor_NN can_MD not_RB be_VB avoided_VBN ._. Drugs_NNS that_WDT may_MD decrease_VB dasatinib_JJ plasma_NN concentrations_NNS CYP3A4_NN Inducers_NNS :_: Drugs_NNS that_WDT induce_VBP CYP3A4_NN activity_NN may_MD decrease_VB dasatinib_JJ plasma_NN concentrations_NNS ._. In_IN patients_NNS in_IN whom_WP CYP3A4_NN inducers_NNS -LRB-_-LRB- eg_FW ,_, dexamethasone_NN ,_, phenytoin_NN ,_, carbamazepine_NN ,_, rifampicin_NN ,_, phenobarbital_NN -RRB-_-RRB- are_VBP indicated_VBN ,_, alternative_JJ agents_NNS with_IN less_JJR enzyme_NN induction_NN potential_NN should_MD be_VB used_VBN ._. If_IN SPRYCEL_NNP must_MD be_VB administered_VBN with_IN a_DT CYP3A4_NN inducer_NN ,_, a_DT dose_NN increase_NN in_IN SPRYCEL_NN should_MD be_VB considered_VBN ._. St._NNP Johns_NNP wort_NN -LRB-_-LRB- Hypericum_NN perforatum_NN -RRB-_-RRB- may_MD decrease_VB SPRYCEL_NNP plasma_NN concentrations_NNS unpredictably_RB ._. Patients_NNS receiving_VBG SPRYCEL_NN should_MD not_RB take_VB St._NNP Johns_NNP wort_NN ._. Antacids_NNS :_: Nonclinical_JJ data_NNS demonstrate_VBP that_IN the_DT solubility_NN of_IN dasatinib_NN is_VBZ pH_NN dependent_JJ ._. Simultaneous_JJ administration_NN of_IN SPRYCEL_NN with_IN antacids_NNS should_MD be_VB avoided_VBN ._. If_IN antacid_NN therapy_NN is_VBZ needed_VBN ,_, the_DT antacid_NN dose_NN should_MD be_VB administered_VBN at_IN least_JJS 2_CD hours_NNS prior_RB to_TO or_CC 2_CD hours_NNS after_IN the_DT dose_NN of_IN SPRYCEL_NN ._. H2_NN Blockers/Proton_NN Pump_NN Inhibitors_NNS :_: Long-term_JJ suppression_NN of_IN gastric_JJ acid_NN secretion_NN by_IN H2_NN blockers_NNS or_CC proton_NN pump_NN inhibitors_NNS -LRB-_-LRB- eg_FW ,_, famotidine_NN and_CC omeprazole_NN -RRB-_-RRB- is_VBZ likely_JJ to_TO reduce_VB dasatinib_NN exposure_NN ._. The_DT concomitant_JJ use_NN of_IN H2_NN blockers_NNS or_CC proton_NN pump_NN inhibitors_NNS with_IN SPRYCEL_NN is_VBZ not_RB recommended_VBN ._. The_DT use_NN of_IN antacids_NNS should_MD be_VB considered_VBN in_IN place_NN of_IN H2_NN blockers_NNS or_CC proton_NN pump_NN inhibitors_NNS in_IN patients_NNS receiving_VBG SPRYCEL_NN therapy_NN ._. Drugs_NNS that_WDT may_MD have_VB their_PRP$ plasma_NN concentration_NN altered_VBN by_IN dasatinib_NN CYP3A4_NN Substrates_NNS :_: Dasatinib_NN is_VBZ a_DT time-dependent_JJ inhibitor_NN of_IN CYP3A4_NN ._. Therefore_RB ,_, CYP3A4_NN substrates_NNS known_VBN to_TO have_VB a_DT narrow_JJ therapeutic_JJ index_NN such_JJ as_IN alfentanil_NN ,_, astemizole_NN ,_, terfenadine_NN ,_, cisapride_NN ,_, cyclosporine_NN ,_, fentanyl_NN ,_, pimozide_NN ,_, quinidine_NN ,_, sirolimus_NN ,_, tacrolimus_NN ,_, or_CC ergot_NN alkaloids_NNS -LRB-_-LRB- ergotamine_NN ,_, dihydroergotamine_NN -RRB-_-RRB- should_MD be_VB administered_VBN with_IN caution_NN in_IN patients_NNS receiving_VBG SPRYCEL_NNP ._. Hepatic_JJ Impairment_NN There_EX are_VBP currently_RB no_DT clinical_JJ studies_NNS with_IN SPRYCEL_NN in_IN patients_NNS with_IN impaired_JJ liver_NN function_NN -LRB-_-LRB- clinical_JJ studies_NNS have_VBP excluded_VBN patients_NNS with_IN ALT_NN and/or_CC AST_NNP 2.5_CD times_NNS the_DT upper_JJ limit_NN of_IN the_DT normal_JJ range_NN and/or_CC total_JJ bilirubin_NN 2_CD times_NNS the_DT upper_JJ limit_NN of_IN the_DT normal_JJ range_NN -RRB-_-RRB- ._. Metabolism_NN of_IN dasatinib_NN is_VBZ mainly_RB hepatic_JJ ._. Caution_NN is_VBZ recommended_VBN in_IN patients_NNS with_IN hepatic_JJ impairment_NN ._. Renal_JJ Impairment_NN There_EX are_VBP currently_RB no_DT clinical_JJ studies_NNS with_IN SPRYCEL_NN in_IN patients_NNS with_IN impaired_JJ renal_JJ function_NN -LRB-_-LRB- clinical_JJ studies_NNS have_VBP excluded_VBN patients_NNS with_IN serum_NN creatinine_NN concentration_NN 1.5_CD times_NNS the_DT upper_JJ limit_NN of_IN the_DT normal_JJ range_NN -RRB-_-RRB- ._. Dasatinib_NNP and_CC its_PRP$ metabolites_NNS are_VBP minimally_RB excreted_VBN via_IN the_DT kidney_NN ._. Since_IN the_DT renal_JJ excretion_NN of_IN unchanged_JJ dasatinib_NN and_CC its_PRP$ metabolites_NNS is_VBZ 4_CD %_NN ,_, a_DT decrease_NN in_IN total_JJ body_NN clearance_NN is_VBZ not_RB expected_VBN in_IN patients_NNS with_IN renal_JJ insufficiency_NN ._. Use_NN of_IN Cerubidine_NNP in_IN a_DT patient_NN who_WP has_VBZ previously_RB received_VBN doxorubicin_NN increases_VBZ the_DT risk_NN of_IN cardiotoxicity_NN ._. Cerubidine_NN should_MD not_RB be_VB used_VBN in_IN patients_NNS who_WP have_VBP previously_RB received_VBN the_DT recommended_VBN maximum_NN cumulative_JJ doses_NNS of_IN doxorubicin_NN or_CC Cerubidine_NN ._. Cyclophosphamide_NNP used_VBD concurrently_RB with_IN Cerubidine_NN may_MD also_RB result_VB in_IN increased_VBN cardiotoxicity_NN ._. Dosage_NN reduction_NN of_IN Cerubidine_NN may_MD be_VB required_VBN when_WRB used_VBN concurrently_RB with_IN other_JJ myelosuppressive_JJ agents_NNS ._. Hepatotoxic_JJ medications_NNS ,_, such_JJ as_IN high-dose_JJ methotrexate_NN ,_, may_MD impair_VB liver_NN function_NN and_CC increase_VB the_DT risk_NN of_IN toxicity_NN ._. Potentially_RB fatal_JJ drug_NN interactions_NNS may_MD occur_VB when_WRB coadministered_VBN with_IN digoxin_NN ,_, as_IN this_DT may_MD enhance_VB cardiovascular_JJ depression_NN and_CC bradyarrhythmias_NNS may_MD occur_VB ._. Anticholinesterases_NNS -LRB-_-LRB- neostgmine_NN ,_, physostigmine_NN -RRB-_-RRB- ,_, lignocaine_NN ,_, quinine_NN ,_, procainamide_NN can_MD enhance_VB toxicity_NN and_CC cause_VB cardio_NN respiratory_JJ depression_NN ._. In_IN addition_NN ,_, neuromuscular_JJ blocking_VBG action_NN is_VBZ enhanced_VBN by_IN general_JJ anesthetics_NNS ,_, local_JJ anesthetics_NNS like_IN lidocaine_NN ,_, procaine_NN ,_, beta-blockers_NNS ,_, metaclopramide_NN ,_, lithium_NN carbonate_NN ,_, and_CC terbutaline_NN ._. Drug_NN interaction_NN studies_NNS with_IN decitabine_NN have_VBP not_RB been_VBN conducted_VBN ._. In_FW vitro_FW studies_NNS in_IN human_JJ liver_NN microsomes_NNS suggest_VBP that_IN decitabine_NN is_VBZ unlikely_JJ to_TO inhibit_VB or_CC induce_VB cytochrome_NN P450_NN enzymes_NNS ._. In_FW vitro_FW metabolism_NN studies_NNS have_VBP suggested_VBN that_IN decitabine_NN is_VBZ not_RB a_DT substrate_NN for_IN the_DT human_JJ liver_NN cytochrome_NN P450_NN enzymes_NNS ._. As_IN plasma_NN protein_NN binding_NN of_IN decitabine_NN is_VBZ negligible_JJ -LRB-_-LRB- 1_CD %_NN -RRB-_-RRB- ,_, interactions_NNS due_JJ to_TO displacement_NN of_IN more_RBR highly_RB protein_NN bound_VBD drugs_NNS from_IN plasma_NN proteins_NNS are_VBP not_RB expected_VBN ._. The_DT concomitant_JJ administration_NN of_IN Exjade_NNP and_CC aluminum-containing_JJ antacid_NN preparations_NNS has_VBZ not_RB been_VBN formally_RB studied_VBN ._. Although_IN deferasirox_NN has_VBZ a_DT lower_JJR affinity_NN for_IN aluminum_NN than_IN for_IN iron_NN ,_, Exjade_NN should_MD not_RB be_VB taken_VBN with_IN aluminum-containing_JJ antacid_NN preparations_NNS ._. In_IN healthy_JJ volunteers_NNS ,_, Exjade_NNP had_VBD no_DT effect_NN on_IN the_DT pharmacokinetics_NNS of_IN digoxin_NN ._. The_DT effect_NN of_IN digoxin_NN on_IN Exjade_NNP pharmacokinetics_NNS has_VBZ not_RB been_VBN studied_VBN ._. The_DT concomitant_JJ administration_NN of_IN Exjade_NNP and_CC vitamin_NN C_NN has_VBZ not_RB been_VBN formally_RB studied_VBN ._. Doses_NNS of_IN vitamin_NN C_NN up_IN to_TO 200_CD mg_NN were_VBD allowed_VBN in_IN clinical_JJ studies_NNS without_IN negative_JJ consequences_NNS ._. The_DT interaction_NN of_IN Exjade_NN with_IN hydroxyurea_NN has_VBZ not_RB been_VBN formally_RB studied_VBN ._. No_DT inhibition_NN of_IN deferasirox_NN metabolism_NN by_IN hydroxyurea_NN is_VBZ expected_VBN based_VBN on_IN the_DT results_NNS of_IN an_DT in_FW vitro_FW study_NN ._. Exjade_NN should_MD not_RB be_VB combined_VBN with_IN other_JJ iron_NN chelator_NN therapies_NNS ,_, as_IN safety_NN of_IN such_JJ combinations_NNS has_VBZ not_RB been_VBN established_VBN ._. Drug/Food_NNP Interactions_NNS The_DT bioavailability_NN -LRB-_-LRB- AUC_NN -RRB-_-RRB- of_IN deferasirox_NN was_VBD variably_RB increased_VBN when_WRB taken_VBN with_IN a_DT meal_NN ._. Deferasirox_NN should_MD be_VB taken_VBN on_IN an_DT empty_JJ stomach_NN 30_CD minutes_NNS before_IN eating_VBG ._. Exjade_NNP tablets_NNS for_IN oral_JJ suspension_NN can_MD be_VB dispersed_VBN in_IN water_NN ,_, orange_JJ juice_NN ,_, or_CC apple_NN juice_NN ._. Antiacid_NNP ,_, clarithromycin_NN ,_, Didanosine_NNP ,_, Fluconazole_NNP ,_, Fluoxetine_NNP ,_, Indanavir_NNP ,_, Ketoconazole_NNP ,_, Phenytoin_NNP ,_, Phenobarbitol_NNP ,_, carbamazepine_NN ,_, Rifabutin_NN ,_, Rifampin_NNP ,_, Ritanovir_NNP ,_, Saquinavir_NNP ._. Possible_JJ drug_NN interactions_NNS of_IN HUMORSOL_NN with_IN succinylcholine_NN or_CC with_IN other_JJ anticholinesterase_JJ agents_NNS ._. Because_IN the_DT tetracyclines_NNS have_VBP been_VBN shown_VBN to_TO depress_VB plasma_NN prothrombin_NN activity_NN ,_, patients_NNS who_WP are_VBP on_IN anticoagulant_JJ therapy_NN may_MD require_VB downward_JJ adjustment_NN of_IN their_PRP$ anticoagulant_JJ dosage_NN ._. Since_IN bacteriostatic_JJ drugs_NNS ,_, such_JJ as_IN the_DT tetracycline_NN class_NN of_IN antibiotics_NNS ,_, may_MD interfere_VB with_IN the_DT bactericidal_JJ action_NN of_IN penicillins_NNS ,_, it_PRP is_VBZ not_RB advisable_JJ to_TO administer_VB these_DT drugs_NNS concomitantly_RB ._. Concurrent_JJ use_NN of_IN tetracyclines_NNS with_IN oral_JJ contraceptives_NNS may_MD render_VB oral_JJ contraceptives_NNS less_RBR effective_JJ ._. Breakthrough_NN bleeding_NN has_VBZ been_VBN reported_VBN ._. No_DT clinical_JJ drug_NN interaction_NN studies_NNS have_VBP been_VBN conducted_VBN ._. However_RB ,_, in_IN a_DT single_JJ in_FW vivo_FW rodent_JJ study_NN denileukin_NN diftitox_NN had_VBD no_DT effect_NN on_IN P450_NN levels_NNS ._. Taking_VBG a_DT rauwolfia_NN alkaloid_NN while_IN you_PRP are_VBP taking_VBG or_CC within_IN 2_CD weeks_NNS of_IN taking_VBG MAO_NNP inhibitors_NNS may_MD increase_VB the_DT risk_NN of_IN central_JJ nervous_JJ system_NN depression_NN or_CC may_MD cause_VB a_DT severe_JJ high_JJ blood_NN pressure_NN reaction_NN ._. No_DT clinically_RB significant_JJ adverse_JJ interactions_NNS with_IN commonly_RB used_VBN preanesthetic_JJ drugs_NNS ,_, or_CC drugs_NNS used_VBN during_IN anesthesia_NN -LRB-_-LRB- muscle_NN relaxants_NNS ,_, intravenous_JJ agents_NNS ,_, and_CC local_JJ anesthetic_JJ agents_NNS -RRB-_-RRB- were_VBD reported_VBN in_IN clinical_JJ trials_NNS ._. The_DT effect_NN of_IN desflurane_NN on_IN the_DT disposition_NN of_IN other_JJ drugs_NNS has_VBZ not_RB been_VBN determined_VBN ._. Like_IN isoflurane_NN ,_, desflurane_NN does_VBZ not_RB predispose_VB to_TO premature_JJ ventricular_JJ arrhythmias_NNS in_IN the_DT presence_NN of_IN exogenously_RB infused_VBN epinephrine_NN in_IN swine_NNS ._. 1_LS ._. Drugs_NNS Metabolized_VBN by_IN P450_NN 2D6_NN :_: The_DT biochemical_JJ activity_NN of_IN the_DT drug_NN metabolizing_VBG isozyme_NN cytochrome_NN P450_NN 2D6_NN -LRB-_-LRB- debrisoquin_NN hydroxylase_NN -RRB-_-RRB- is_VBZ reduced_VBN in_IN a_DT subset_NN of_IN the_DT caucasian_JJ population_NN -LRB-_-LRB- about_IN 7_CD to_TO 10_CD %_NN of_IN caucasians_NNS are_VBP so_RB called_VBN poor_JJ metabolizers_NNS -RRB-_-RRB- ;_: ._. reliable_JJ estimates_NNS of_IN the_DT prevalence_NN of_IN reduced_VBN P450_NN 2D6_NN isozyme_NN activity_NN among_IN Asian_JJ ,_, African_JJ and_CC other_JJ populations_NNS are_VBP not_RB yet_RB available_JJ ._. Poor_NNP metabolizers_NNS have_VBP higher_JJR than_IN expected_VBN plasma_NN concentrations_NNS of_IN tricyclic_JJ antidepressants_NNS -LRB-_-LRB- TCAs_NNS -RRB-_-RRB- when_WRB given_VBN usual_JJ doses_NNS ._. Depending_VBG on_IN the_DT traction_NN of_IN drug_NN metabolized_VBN by_IN P450_NN 2D6_NN ,_, the_DT increase_NN in_IN plasma_NN concentration_NN may_MD be_VB small_JJ ,_, or_CC quite_RB large_JJ -LRB-_-LRB- 8_CD fold_JJ increase_NN in_IN plasma_NN AUC_NN of_IN the_DT TCA_NNP -RRB-_-RRB- ._. In_IN addition_NN ,_, certain_JJ drugs_NNS inhibit_VBP the_DT activity_NN of_IN this_DT isozyme_NN and_CC make_VB normal_JJ metabolizers_NNS resemble_VBP p.o._NN metabolizers_NNS ._. An_DT individual_NN who_WP is_VBZ stable_JJ on_IN a_DT given_VBN dose_NN of_IN TCA_NNP may_MD become_VB abruptly_RB toxic_JJ when_WRB given_VBN one_CD of_IN these_DT inhibiting_VBG drugs_NNS as_IN concomitant_JJ therapy_NN ._. The_DT drugs_NNS that_WDT inhibit_VBP cytochrome_NN P450_NN 2D6_NN include_VBP some_DT that_WDT are_VBP not_RB metabolized_VBN by_IN the_DT enzyme_NN -LRB-_-LRB- quinidine_NN ._. cimetidine_NN -RRB-_-RRB- and_CC many_JJ that_WDT are_VBP substrates_NNS for_IN P450_NN 2D6_NN -LRB-_-LRB- many_JJ other_JJ antidepressants_NNS ,_, phenothiazines_NNS ,_, and_CC the_DT Type_NN 1C_NN antiarrhythrnics_NNS propatenone_NN and_CC flecainide_NN -RRB-_-RRB- ._. While_IN all_PDT the_DT selective_JJ serotonin_NN reuptake_NN inhibitors_NNS -LRB-_-LRB- SSRIs_NNS -RRB-_-RRB- ,_, e.g._FW ,_, fluoxetine_NN ,_, seriraline_NN ,_, and_CC paroxetine_NN ,_, inhibit_VBP P450_NN 2D6_NN ,_, they_PRP may_MD vary_VB in_IN the_DT extent_NN of_IN inhibition_NN ._. The_DT extent_NN to_TO which_WDT SSRI-TCA_NNP interactions_NNS may_MD pose_VB clinical_JJ problems_NNS will_MD depend_VB on_IN the_DT degree_NN of_IN inhibition_NN and_CC the_DT pharmacokinetics_NNS of_IN the_DT SSRI_NNP involved_VBN ._. Nevertheless_RB ,_, caution_NN is_VBZ indicated_VBN in_IN the_DT co-administration_NN of_IN T.A._NN with_IN any_DT of_IN the_DT SSRIs_NNS and_CC also_RB in_IN switching_NN from_IN one_CD class_NN to_TO the_DT other_JJ ._. Of_IN particular_JJ importance_NN ,_, sufficient_JJ time_NN must_MD elapse_VB before_IN initiating_VBG TCA_NNP treatment_NN in_IN a_DT patient_NN being_VBG withdrawn_VBN from_IN fluoxetine_NN ,_, given_VBN the_DT long_JJ half-life_NN of_IN the_DT parent_NN and_CC active_JJ metabolite_NN -LRB-_-LRB- at_IN least_JJS 5_CD weeks_NNS may_MD be_VB necessary_JJ -RRB-_-RRB- ._. Concomitant_JJ use_NN of_IN tricyclic_JJ antidepressants_NNS with_IN drugs_NNS that_WDT can_MD inhibit_VB cytochrome_NN P450_NN 2D6_NN may_MD require_VB lower_JJR doses_NNS than_IN usually_RB prescribed_VBN for_IN either_CC the_DT tricyclic_JJ antidepressant_JJ or_CC the_DT other_JJ drug_NN ._. Furthermore_RB ,_, whenever_WRB one_CD of_IN these_DT other_JJ drugs_NNS is_VBZ withdrawn_VBN from_IN co-therapy_JJ ,_, an_DT increased_VBN dose_NN of_IN tricyclic_JJ antidepressant_JJ may_MD be_VB required_VBN ._. It_PRP is_VBZ desirable_JJ to_TO monitor_VB TCA_NNP plasma_NN levels_NNS whenever_WRB a_DT TCA_NNP is_VBZ going_VBG to_TO be_VB co-administered_VBN with_IN another_DT drug_NN known_VBN to_TO be_VB an_DT inhibitor_NN of_IN P450_NN 2D6_NN ._. 2_LS ._. Close_JJ supervision_NN and_CC careful_JJ adjustment_NN of_IN dosage_NN are_VBP required_VBN when_WRB this_DT drug_NN is_VBZ given_VBN concomitantly_RB with_IN anticholinergic_JJ or_CC sympathomimetic_JJ drugs_NNS ._. 3_LS ._. Clinical_JJ experience_NN in_IN the_DT concurrent_JJ administration_NN of_IN ECT_NNP and_CC antidepressant_JJ drugs_NNS is_VBZ limited_VBN ._. Thus_RB ,_, if_IN such_JJ treatment_NN is_VBZ essential_JJ ,_, the_DT possibility_NN of_IN increased_VBN risk_NN relative_JJ to_TO benefits_NNS should_MD be_VB considered_VBN ._. 4_LS ._. If_IN desipramine_NN hydrochloride_NN is_VBZ to_TO be_VB combined_VBN with_IN other_JJ psychotropic_JJ agents_NNS such_JJ as_IN tranquilizers_NNS or_CC sedative/hypnotics_NNS ,_, careful_JJ consideration_NN should_MD be_VB given_VBN to_TO the_DT pharmacology_NN of_IN the_DT agents_NNS employed_VBN since_IN the_DT sedative_JJ effects_NNS of_IN desipramine_NN and_CC benzodiazepines_NNS -LRB-_-LRB- e.g._FW ,_, chlordiazepoxide_NN or_CC diazepam_NN -RRB-_-RRB- are_VBP additive_JJ ._. Both_CC the_DT sedative_NN and_CC anticholinergic_JJ effects_NNS of_IN the_DT major_JJ tranquilizers_NNS are_VBP also_RB additive_JJ to_TO those_DT of_IN desipramine_NN ._. 5_CD ._. Concurrent_JJ administration_NN of_IN cimetidine_NN and_CC tricyclic_JJ antidepressants_NNS can_MD produce_VB clinically_RB significant_JJ increases_NNS in_IN the_DT plasma_NN levels_NNS of_IN the_DT tricyclic_JJ antidepressants_NNS ._. Conversely_RB ,_, decreases_VBZ in_IN plasma_NN levels_NNS of_IN the_DT tricyclic_JJ antidepressants_NNS have_VBP been_VBN reported_VBN upon_IN discontinuation_NN of_IN cimetidine_NN which_WDT may_MD result_VB in_IN the_DT loss_NN of_IN the_DT therapeutic_JJ efficacy_NN of_IN the_DT tricyclic_JJ antidepressant_JJ 6_CD ._. There_EX have_VBP been_VBN greater_JJR than_IN two-fold_JJ increases_NNS of_IN previously_RB stable_JJ plasma_NN levels_NNS of_IN tricyclic_JJ antidepressants_NNS when_WRB fluoxetine_NN has_VBZ been_VBN administered_VBN in_IN combination_NN with_IN these_DT agents_NNS ._. In_IN two_CD controlled_JJ crossover_NN clinical_JJ pharmacology_NN studies_NNS in_IN healthy_JJ male_NN -LRB-_-LRB- n_NN =_JJ 12_CD in_IN each_DT study_NN -RRB-_-RRB- a_DT nd_NN female_NN -LRB-_-LRB- n_NN =_JJ 12_CD in_IN each_DT study_NN -RRB-_-RRB- volunteers_NNS ,_, desloratadine_NN 7.5_CD mg_NN -LRB-_-LRB- 1.5_CD times_NNS the_DT daily_JJ dose_NN -RRB-_-RRB- once_RB daily_RB was_VBD coadministered_VBN with_IN erythromycin_NN 500_CD mg_NN every_DT 8_CD hours_NNS or_CC ketoconazole_NN 200_CD mg_NN every_DT 12_CD hours_NNS for_IN 10_CD days_NNS ._. In_IN three_CD separate_JJ controlled_JJ ,_, parallel_JJ group_NN clinical_JJ pharmacology_NN studies_NNS ,_, desloratadine_NN at_IN the_DT clinical_JJ dose_NN of_IN 5_CD mg_NN has_VBZ been_VBN coadministered_VBN with_IN azithromycin_NN 500_CD mg_NN followed_VBN by_IN 250_CD mg_NN once_RB daily_RB for_IN 4_CD days_NNS -LRB-_-LRB- n_NN =_JJ 18_CD -RRB-_-RRB- or_CC with_IN fluoxetine_NN 20_CD mg_NN once_RB daily_RB for_IN 7_CD days_NNS after_IN a_DT 23_CD day_NN pretreatment_NN period_NN with_IN fluoxetine_NN -LRB-_-LRB- n_NN =_JJ 18_CD -RRB-_-RRB- or_CC with_IN cimetidine_NN 600_CD mg_NN every_DT 12_CD hours_NNS for_IN 14_CD days_NNS -LRB-_-LRB- n_NN =_JJ 18_CD -RRB-_-RRB- under_IN steady_JJ state_NN conditions_NNS to_TO normal_JJ healthy_JJ male_NN and_CC female_JJ volunteers_NNS ._. Although_IN increased_VBN plasma_NN concentrations_NNS -LRB-_-LRB- C_NN max_NN and_CC AUC_NN 0-24_CD hrs_NNS -RRB-_-RRB- of_IN desloratadine_NN and_CC 3-hydroxydesloratadine_NN were_VBD observed_VBN ,_, there_EX were_VBD no_DT clinically_RB relevant_JJ changes_NNS in_IN the_DT safety_NN profile_NN of_IN desloratadine_NN ,_, as_IN assessed_VBN by_IN electrocardiographic_JJ parameters_NNS -LRB-_-LRB- including_VBG the_DT corrected_VBN QT_NN interval_NN -RRB-_-RRB- ,_, clinical_JJ laboratory_NN tests_NNS ,_, vital_JJ signs_NNS ,_, and_CC adverse_JJ events_NNS ._. Table_NNP 1_CD Changes_NNS in_IN Desloratadine_NN and_CC 3-Hydroxydesloratadine_NN Pharmacokinetics_NNS in_IN Healthy_JJ Male_NN and_CC Female_JJ Volunteer_NN ._. Desloratadine_NN 3-Hydroxydesloratadin_NN ._. C_NN max_NN AUC_NN 0-24_CD hrs_NNS C_NN max_NN AUC_NN 0-24_CD hrs_NNS ._. Erythromyci_NNP ._. -LRB-_-LRB- 500_CD mg_NN Q8h_NN -RRB-_-RRB- ._. +24_CD %_NN +14_CD %_NN +43_CD %_NN +40_CD %_NN ._. Ketoconazol_NNP ._. -LRB-_-LRB- 200_CD mg_NN Q12h_NN -RRB-_-RRB- ._. +45_CD %_NN +39_CD %_NN +43_CD %_NN +72_CD %_NN ._. Azithromyci_NNP ._. -LRB-_-LRB- 500_CD mg_NN day_NN 1_CD ,_, 250_CD mg_NN QD_NN 4_CD days_NNS -RRB-_-RRB- ._. +15_CD %_NN +5_CD %_NN +15_CD %_NN +4_CD %_NN ._. Fluoxetin_NNP ._. -LRB-_-LRB- 20_CD mg_NN QD_NN -RRB-_-RRB- ._. +15_CD %_NN +0_CD %_NN +17_CD %_NN +13_CD %_NN ._. Cimetidin_NNP ._. -LRB-_-LRB- 600_CD mg_NN Q12h_NN -RRB-_-RRB- ._. +12_CD %_NN +19_CD %_NN -11_CD %_NN -3_CD %_NN ._. Although_IN the_DT pressor_NN activity_NN of_IN Desmopressin_NN is_VBZ very_RB low_JJ compared_VBN to_TO its_PRP$ antidiuretic_JJ activity_NN ,_, large_JJ doses_NNS of_IN Desmopressin_NNP Tablets_NNS should_MD be_VB used_VBN with_IN other_JJ pressor_NN agents_NNS only_RB with_IN careful_JJ patient_NN monitoring_NN ._. Reduced_VBN efficacy_NN and_CC increased_VBD incidence_NN of_IN breakthrough_NN bleeding_NN and_CC menstrual_JJ irregularities_NNS have_VBP been_VBN associated_VBN with_IN concomitant_JJ use_NN of_IN rifampin_NN ._. A_DT similar_JJ association_NN ,_, though_IN less_JJR marked_JJ ,_, has_VBZ been_VBN suggested_VBN with_IN barbiturates_NNS ,_, phenyl-butazone_NN ,_, phenytoin_NN sodium_NN ,_, carbamazepine_NN and_CC possibly_RB with_IN griseofulvin_NN ,_, ampicillin_NN ,_, and_CC tetracyclines_NNS -LRB-_-LRB- 72_CD ._. No_DT specific_JJ information_NN available_JJ ._. Aminoglutethimide_NNP :_: Aminoglutethimide_NNP may_MD diminish_VB adrenal_JJ suppression_NN by_IN corticosteroids_NNS ._. Amphotericin_NN B_NN injection_NN and_CC potassium-depleting_JJ agents_NNS :_: When_WRB corticosteroids_NNS are_VBP administered_VBN concomitantly_RB with_IN potassium-depleting_JJ agents_NNS -LRB-_-LRB- e.g._FW ,_, amphotericin_NN B_NN ,_, diuretics_NNS -RRB-_-RRB- ,_, patients_NNS should_MD be_VB observed_VBN closely_RB for_IN development_NN of_IN hypokalemia_NN ._. In_IN addition_NN ,_, there_EX have_VBP been_VBN cases_NNS reported_VBD in_IN which_WDT concomitant_JJ use_NN of_IN amphotericin_NN B_NN and_CC hydrocortisone_NN was_VBD followed_VBN by_IN cardiac_JJ enlargement_NN and_CC congestive_JJ heart_NN failure_NN ._. Antibiotics_NNS :_: Macrolide_NNP antibiotics_NNS have_VBP been_VBN reported_VBN to_TO cause_VB a_DT significant_JJ decrease_NN in_IN corticosteroid_NN clearance_NN ._. Anticholinesterases_NNP :_: Concomitant_JJ use_NN of_IN anticholinesterase_JJ agents_NNS and_CC corticosteroids_NNS may_MD produce_VB severe_JJ weakness_NN in_IN patients_NNS with_IN myasthenia_NN gravis_NN ._. If_IN possible_JJ ,_, anticholinesterase_JJ agents_NNS should_MD be_VB withdrawn_VBN at_IN least_JJS 24_CD hours_NNS before_IN initiating_VBG corticosteroid_NN therapy_NN ._. Anticoagulants_NNPS ,_, oral_JJ :_: Co-administration_NN of_IN corticosteroids_NNS and_CC warfarin_NN usually_RB results_VBZ in_IN inhibition_NN of_IN response_NN to_TO warfarin_NN ,_, although_IN there_EX have_VBP been_VBN some_DT conflicting_VBG reports_NNS ._. Therefore_RB ,_, coagulation_NN indices_NNS should_MD be_VB monitored_VBN frequently_RB to_TO maintain_VB the_DT desired_VBN anticoagulant_JJ effect_NN ._. Antidiabetics_NNS :_: Because_IN corticosteroids_NNS may_MD increase_VB blood_NN glucose_NN concentrations_NNS ,_, dosage_NN adjustments_NNS of_IN antidiabetic_JJ agents_NNS may_MD be_VB required_VBN ._. Antitubercular_JJ drugs_NNS :_: Serum_NN concentrations_NNS of_IN isoniazid_NN may_MD be_VB decreased_VBN ._. Cholestyramine_NNP :_: Cholestyramine_NNP may_MD increase_VB the_DT clearance_NN of_IN corticosteroids_NNS ._. Cyclosporine_NN :_: Increased_VBN activity_NN of_IN both_DT cyclosporine_NN and_CC corticosteroids_NNS may_MD occur_VB when_WRB the_DT two_CD are_VBP used_VBN concurrently_RB ._. Convulsions_NNS have_VBP been_VBN reported_VBN with_IN this_DT concurrent_JJ use_NN ._. Dexamethasone_NN suppression_NN test_NN -LRB-_-LRB- DST_NN -RRB-_-RRB- :_: False-negative_JJ results_NNS in_IN the_DT dexamethasone_NN suppression_NN test_NN -LRB-_-LRB- DST_NN -RRB-_-RRB- in_IN patients_NNS being_VBG treated_VBN with_IN indomethacin_NN have_VBP been_VBN reported_VBN ._. Thus_RB ,_, results_NNS of_IN the_DT DST_NNP should_MD be_VB interpreted_VBN with_IN caution_NN in_IN these_DT patients_NNS ._. Digitalis_NN glycosides_NNS :_: Patients_NNS on_IN digitalis_NN glycosides_NNS may_MD be_VB at_IN increased_VBN risk_NN of_IN arrhythmias_NNS due_JJ to_TO hypokalemia_NN ._. Ephedrine_NN :_: Ephedrine_NN may_MD enhance_VB the_DT metabolic_JJ clearance_NN of_IN corticosteroids_NNS ,_, resulting_VBG in_IN decreased_VBN blood_NN levels_NNS and_CC lessened_VBD physiologic_JJ activity_NN ,_, thus_RB requiring_VBG an_DT increase_NN in_IN corticosteroid_NN dosage_NN ._. Estrogens_NNS ,_, including_VBG oral_JJ contraceptives_NNS :_: Estrogens_NNS may_MD decrease_VB the_DT hepatic_JJ metabolism_NN of_IN certain_JJ corticosteroids_NNS ,_, thereby_RB increasing_VBG their_PRP$ effect_NN ._. Hepatic_JJ Enzyme_NN Inducers_NNS ,_, Inhibitors_NNS and_CC Substrates_NNS :_: Drugs_NNS which_WDT induce_VBP cytochrome_NN P450_NN 3A4_NN -LRB-_-LRB- CYP_NN 3A4_NN -RRB-_-RRB- enzyme_NN activity_NN -LRB-_-LRB- e.g._FW ,_, barbiturates_NNS ,_, phenytoin_NN ,_, carbamazepine_NN ,_, rifampin_NN -RRB-_-RRB- may_MD enhance_VB the_DT metabolism_NN of_IN corticosteroids_NNS and_CC require_VBP that_IN the_DT dosage_NN of_IN the_DT corticosteroid_NN be_VB increased_VBN ._. Drugs_NNS which_WDT inhibit_VBP CYP_NN 3A4_NN -LRB-_-LRB- e.g._FW ,_, ketoconazole_NN ,_, macrolide_NN antibiotics_NNS such_JJ as_IN erythromycin_NN -RRB-_-RRB- have_VBP the_DT potential_JJ to_TO result_VB in_IN increased_VBN plasma_NN concentrations_NNS of_IN corticosteroids_NNS ._. Dexamethasone_NN is_VBZ a_DT moderate_JJ inducer_NN of_IN CYP_NN 3A4_NN ._. Co-administration_NN with_IN other_JJ drugs_NNS that_WDT are_VBP metabolized_VBN by_IN CYP_NN 3A4_NN -LRB-_-LRB- e.g._FW ,_, indinavir_NN ,_, erythromycin_NN -RRB-_-RRB- may_MD increase_VB their_PRP$ clearance_NN ,_, resulting_VBG in_IN decreased_VBN plasma_NN concentration_NN ._. Ketoconazole_NN :_: Ketoconazole_NNP has_VBZ been_VBN reported_VBN to_TO decrease_VB the_DT metabolism_NN of_IN certain_JJ corticosteroids_NNS by_IN up_RB to_TO 60_CD %_NN ,_, leading_VBG to_TO increased_VBN risk_NN of_IN corticosteroid_NN side_NN effects_NNS ._. In_IN addition_NN ,_, ketoconazole_NN alone_RB can_MD inhibit_VB adrenal_JJ corticosteroid_NN synthesis_NN and_CC may_MD cause_VB adrenal_JJ insufficiency_NN during_IN corticosteroid_NN withdrawal_NN ._. 
Nonsteroidal_JJ anti-inflammatory_JJ agents_NNS -LRB-_-LRB- NSAIDS_NNS -RRB-_-RRB- :_: Concomitant_JJ use_NN of_IN aspirin_NN -LRB-_-LRB- or_CC other_JJ nonsteroidal_JJ antiinflammatory_JJ agents_NNS -RRB-_-RRB- and_CC corticosteroids_NNS increases_VBZ the_DT risk_NN of_IN gastrointestinal_JJ side_JJ effects_NNS ._. Aspirin_NN should_MD be_VB used_VBN cautiously_RB in_IN conjunction_NN with_IN corticosteroids_NNS in_IN hypoprothrombinemia_NN ._. The_DT clearance_NN of_IN salicylates_NNS may_MD be_VB increased_VBN with_IN concurrent_JJ use_NN of_IN corticosteroids_NNS ._. Phenytoin_NNP :_: In_IN post-marketing_JJ experience_NN ,_, there_EX have_VBP been_VBN reports_NNS of_IN both_DT increases_NNS and_CC decreases_VBZ in_IN phenytoin_NN levels_NNS with_IN dexamethasone_NN co-administration_NN ,_, leading_VBG to_TO alterations_NNS in_IN seizure_NN control_NN ._. Skin_NN tests_NNS :_: Corticosteroids_NNS may_MD suppress_VB reactions_NNS to_TO skin_NN tests_NNS ._. Thalidomide_NNP :_: Co-administration_NN with_IN thalidomide_NN should_MD be_VB employed_VBN cautiously_RB ,_, as_IN toxic_JJ epidermal_JJ necrolysis_NN has_VBZ been_VBN reported_VBN with_IN concomitant_JJ use_NN ._. Vaccines_NNS :_: Patients_NNS on_IN corticosteroid_NN therapy_NN may_MD exhibit_VB a_DT diminished_JJ response_NN to_TO toxoids_NNS and_CC live_VB or_CC inactivated_VBN vaccines_NNS due_JJ to_TO inhibition_NN of_IN antibody_NN response_NN ._. Corticosteroids_NNS may_MD also_RB potentiate_VB the_DT replication_NN of_IN some_DT organisms_NNS contained_VBD in_IN live_JJ attenuated_VBN vaccines_NNS ._. Routine_JJ administration_NN of_IN vaccines_NNS or_CC toxoids_NNS should_MD be_VB deferred_VBN until_IN corticosteroid_NN therapy_NN is_VBZ discontinued_VBN if_IN possible_JJ ._. Dexbrompheniramine_NN can_MD interact_VB with_IN alcohol_NN or_CC other_JJ CNS_NN depressants_NNS -LRB-_-LRB- may_MD potentiate_VB the_DT CNS_NN depressant_NN effects_NNS of_IN either_CC these_DT medications_NNS or_CC antihistamines_NNS -RRB-_-RRB- ,_, anticholinergics_NNS or_CC other_JJ medications_NNS with_IN anticholinergic_JJ activity_NN -LRB-_-LRB- anticholinergic_JJ effects_NNS may_MD be_VB potentiated_VBN when_WRB these_DT medications_NNS are_VBP used_VBN concurrently_RB with_IN antihistamines_NNS -RRB-_-RRB- ,_, and_CC monoamine_NN oxidase_NN -LRB-_-LRB- MAO_NN -RRB-_-RRB- inhibitors_NNS -LRB-_-LRB- concurrent_JJ use_NN with_IN antihistamines_NNS may_MD prolong_VB and_CC intensify_VB the_DT anticholinergic_JJ and_CC CNS_NN depressant_NN effects_NNS of_IN antihistamines_NNS -RRB-_-RRB- ._. In_IN patients_NNS receiving_VBG nonselective_JJ monoamine_NN oxidase_NN inhibitors_NNS -LRB-_-LRB- MAOIs_NNS -RRB-_-RRB- -LRB-_-LRB- e.g._FW ,_, selegiline_NN hydrochloride_NN -RRB-_-RRB- in_IN combination_NN with_IN serotoninergic_JJ agents_NNS -LRB-_-LRB- e.g._FW ,_, fluoxetine_NN ,_, fluvoxamine_NN ,_, paroxetine_NN ,_, sertraline_NN ,_, venlafaxine_NN -RRB-_-RRB- ,_, there_EX have_VBP been_VBN reports_NNS of_IN serious_JJ ,_, sometimes_RB fatal_JJ ,_, reactions_NNS ._. Because_IN dexfenfluramine_NN is_VBZ a_DT serotonin_NN releaser_NN and_CC reuptake_NN inhibitor_NN ,_, dexfenfluramine_NN should_MD not_RB be_VB used_VBN concomitantly_RB with_IN a_DT MAO_NNP inhibitor_NN ._. At_IN least_JJS 14_CD days_NNS should_MD elapse_VB between_IN discontinuation_NN of_IN a_DT MAO_NNP inhibitor_NN and_CC initiation_NN of_IN treatment_NN with_IN dexfenfluramine_NN ._. At_IN least_JJS 3_CD weeks_NNS should_MD elapse_VB between_IN discontinuation_NN of_IN dexfenfluramine_NN and_CC initiation_NN of_IN treatment_NN with_IN a_DT MAO_NNP inhibitor_NN ._. A_DT rare_JJ ,_, but_CC serious_JJ ,_, constellation_NN of_IN symptoms_NNS ,_, termed_VBN serotonin_NN syndrome_NN ,_, has_VBZ been_VBN reported_VBN with_IN the_DT concomitant_JJ use_NN of_IN selective_JJ serotonin_NN reuptake_NN inhibitors_NNS -LRB-_-LRB- SSRIs_NNS -RRB-_-RRB- and_CC agents_NNS for_IN migraine_NN therapy_NN ,_, such_JJ as_IN Imitrex_NN -LRB-_-LRB- sumatriptan_NN succinate_NN -RRB-_-RRB- and_CC dihydroergotamine_NN ._. The_DT syndrome_NN requires_VBZ immediate_JJ medical_JJ attention_NN and_CC may_MD include_VB one_CD or_CC more_JJR of_IN the_DT following_VBG symptoms_NNS :_: excitement_NN ,_, hypomania_NN ,_, restlessness_NN ,_, loss_NN of_IN consciousness_NN ,_, confusion_NN ,_, disorientation_NN ,_, anxiety_NN ,_, agitation_NN ,_, motor_NN weakness_NN ,_, myoclonus_NN ,_, tremor_NN ,_, hemiballismus_NN ,_, hyperreflexia_NN ,_, ataxia_NN ,_, dysarthria_NN ,_, incoordination_NN ,_, hyperthermia_NN ,_, shivering_VBG ,_, pupillary_JJ dilation_NN ,_, diaphoresis_NN ,_, emesis_NN ,_, and_CC tachycardia_NN ._. Dexfenfluramine_NN should_MD not_RB be_VB administered_VBN with_IN other_JJ serotoninergic_JJ agents_NNS ._. The_DT appropriate_JJ interval_NN between_IN administration_NN of_IN these_DT agents_NNS and_CC dexfenfluramine_NN has_VBZ not_RB been_VBN established_VBN ._. The_DT use_NN of_IN dexfenfluramine_NN with_IN other_JJ CNS-active_JJ drugs_NNS has_VBZ not_RB been_VBN systematically_RB evaluated_VBN ._. consequently_RB ,_, caution_NN is_VBZ advised_VBN if_IN dexfenfluramine_NN and_CC such_JJ drugs_NNS are_VBP prescribed_VBN concurrently_RB ._. General_NNP In_FW vitro_FW studies_NNS in_IN human_JJ liver_NN microsomes_NNS demonstrated_VBD no_DT evidence_NN of_IN cytochrome_NN P450-mediated_JJ drug_NN interactions_NNS that_WDT are_VBP likely_JJ to_TO be_VB of_IN clinical_JJ relevance_NN ._. Anesthetics/Sedatives/Hypnotics_NNS /_: Opioids_NNS :_: Co-administration_NN of_IN PRECEDEX_NN with_IN anesthetics_NNS ,_, sedatives_NNS ,_, hypnotics_NNS ,_, and_CC opioids_NNS is_VBZ likely_JJ to_TO lead_VB to_TO an_DT enhancement_NN of_IN effects_NNS ._. Specific_JJ studies_NNS have_VBP confirmed_VBN these_DT effects_NNS with_IN sevoflurane_NN ,_, isoflurane_NN ,_, propofol_NN ,_, alfentanil_NN ,_, and_CC midazolam_NN ._. No_DT pharmacokinetic_JJ interactions_NNS between_IN dexmedetomidine_NN and_CC isoflurane_NN ,_, propofol_NN ,_, alfentanil_NN ,_, and_CC midazolam_NN have_VBP been_VBN demonstrated_VBN ._. However_RB ,_, due_JJ to_TO possible_JJ pharmacodynamic_JJ interactions_NNS ,_, when_WRB co-administered_VBN with_IN PRECEDEX_NN ,_, a_DT reduction_NN in_IN dosage_NN of_IN PRECEDEX_NNP on_IN the_DT concomitant_JJ anesthetic_NN ,_, sedative_NN ,_, hypnotic_JJ or_CC opioid_NN may_MD be_VB required_VBN ._. Neuromuscular_JJ Blockers_NNS :_: In_IN one_CD study_NN of_IN 10_CD healthy_JJ volunteers_NNS ,_, administration_NN of_IN PRECEDEX_NNP for_IN 45_CD minutes_NNS at_IN a_DT plasma_NN concentration_NN of_IN 1_CD -LRB-_-LRB- one_CD -RRB-_-RRB- ng/mL_NN resulted_VBD in_IN no_DT clinically_RB meaningful_JJ increases_NNS in_IN the_DT magnitude_NN or_CC neuromuscular_JJ blockade_NN associated_VBN with_IN rocuronium_NN administration_NN ._. ZINECARD_NN does_VBZ not_RB influence_VB the_DT pharmacokinetics_NNS of_IN doxorubicin_NN ._. Carcinogenesis_NN ,_, Mutagenesis_NN ,_, Impairment_NN of_IN Fertility_NNP No_NNP long-term_JJ carcinogenicity_NN studies_NNS have_VBP been_VBN carried_VBN out_RP with_IN dexrazoxane_NN in_IN animals_NNS ._. Dexrazoxane_NN was_VBD not_RB mutagenic_JJ in_IN the_DT Ames_NNP test_NN but_CC was_VBD found_VBN to_TO be_VB clastogenic_JJ to_TO human_JJ lymphocytes_NNS in_FW vitro_FW and_CC to_TO mouse_NN bone_NN marrow_NN erythrocytes_NNS in_FW vivo_FW -LRB-_-LRB- micronucleus_NN test_NN -RRB-_-RRB- ._. The_DT possible_JJ adverse_JJ effects_NNS of_IN ZINECARD_NN on_IN the_DT fertility_NN of_IN humans_NNS and_CC experimental_JJ animals_NNS ,_, male_JJ or_CC female_JJ ,_, have_VBP not_RB been_VBN adequately_RB studied_VBN ._. Testicular_JJ atrophy_NN was_VBD seen_VBN with_IN dexrazoxane_NN administration_NN at_IN doses_NNS as_RB low_JJ as_IN 30_CD mg/kg_NN weekly_JJ for_IN 6_CD weeks_NNS in_IN rats_NNS -LRB-_-LRB- 1/3_CD the_DT human_JJ dose_NN on_IN a_DT mg/m_NN 2_CD basis_NN -RRB-_-RRB- and_CC as_RB low_JJ as_IN 20_CD mg/kg_NN weekly_JJ for_IN 13_CD weeks_NNS in_IN dogs_NNS -LRB-_-LRB- approximately_RB equal_JJ to_TO the_DT human_JJ dose_NN on_IN a_DT mg/m_NN 2_CD basis_NN -RRB-_-RRB- ._. Acidifying_VBG agents_NNS :_: Gastrointestinal_JJ acidifying_VBG agents_NNS -LRB-_-LRB- guanethidine_NN ,_, reserpine_NN ,_, glutamic_JJ acid_NN HCl_NN ,_, ascorbic_JJ acid_NN ,_, fruit_NN juices_NNS ,_, etc._FW -RRB-_-RRB- lower_JJR absorption_NN of_IN amphetamines_NNS ._. Urinary_JJ acidifying_VBG agents_NNS -LRB-_-LRB- ammonium_NN chloride_NN ,_, sodium_NN acid_NN phosphate_NN ,_, etc._FW -RRB-_-RRB- increase_VBP the_DT concentration_NN of_IN the_DT ionized_VBN species_NNS of_IN the_DT amphetamine_NN molecule_NN ,_, thereby_RB increasing_VBG urinary_JJ excretion_NN ._. Both_DT groups_NNS of_IN agents_NNS lower_JJR blood_NN levels_NNS and_CC efficacy_NN of_IN amphetamines_NNS ._. Adrenergic_JJ blockers_NNS :_: Adrenergic_JJ blockers_NNS are_VBP inhibited_VBN by_IN amphetamines_NNS ._. Alkalinizing_JJ agents_NNS :_: Gastrointestinal_JJ alkalinizing_JJ agents_NNS -LRB-_-LRB- sodium_NN bicarbonate_NN ,_, etc._FW -RRB-_-RRB- increase_NN absorption_NN of_IN amphetamines_NNS ._. Urinary_JJ alkalinizing_JJ agents_NNS -LRB-_-LRB- acetazolamide_NN ,_, some_DT thiazides_NNS -RRB-_-RRB- increase_VBP the_DT concentration_NN of_IN the_DT non-ionized_JJ species_NNS of_IN the_DT amphetamine_NN molecule_NN ,_, thereby_RB decreasing_VBG urinary_JJ excretion_NN ._. Both_DT groups_NNS of_IN agents_NNS increase_VBP blood_NN levels_NNS and_CC therefore_RB potentiate_VB the_DT actions_NNS of_IN amphetamines_NNS ._. Antidepressants_NNS ,_, tricyclic_JJ :_: Amphetamines_NNS may_MD enhance_VB the_DT activity_NN of_IN tricyclic_JJ or_CC sympathomimetic_JJ agents_NNS ._. d-amphetamine_NN with_IN desipramine_NN or_CC protriptyline_NN and_CC possibly_RB other_JJ tricyclics_NNS cause_VBP striking_JJ and_CC sustained_JJ increases_NNS in_IN the_DT concentration_NN of_IN d-amphetamine_NN in_IN the_DT brain_NN ._. cardiovascular_JJ effects_NNS can_MD be_VB potentiated_VBN ._. MAO_NN inhibitors_NNS :_: MAOI_NNP antidepressants_NNS ,_, as_RB well_RB as_IN a_DT metabolite_NN of_IN furazolidone_NN ,_, slow_JJ amphetamine_NN metabolism_NN ._. This_DT slowing_VBG potentiates_VBZ amphetamines_NNS ,_, increasing_VBG their_PRP$ effect_NN on_IN the_DT release_NN of_IN norepinephrine_NN and_CC other_JJ monoamines_NNS from_IN adrenergic_JJ nerve_NN endings_NNS ._. this_DT can_MD cause_VB headaches_NNS and_CC other_JJ signs_NNS of_IN hypertensive_JJ crisis_NN ._. A_DT variety_NN of_IN neurological_JJ toxic_JJ effects_NNS and_CC malignant_JJ hyperpyrexia_NN can_MD occur_VB ,_, sometimes_RB with_IN fatal_JJ results_NNS ._. Antihistamines_NNS :_: Amphetamines_NNS may_MD counteract_VB the_DT sedative_JJ effect_NN of_IN antihistamines_NNS ._. Antihypertensives_NNS :_: Amphetamines_NNS may_MD antagonize_VB the_DT hypotensive_JJ effects_NNS of_IN antihypertensives_NNS ._. Chlorpromazine_NNP :_: Chlorpromazine_NNP blocks_VBZ dopamine_NN and_CC norepinephrine_NN reuptake_NN ,_, thus_RB inhibiting_VBG the_DT central_JJ stimulant_NN effects_NNS of_IN amphetamines_NNS ,_, and_CC can_MD be_VB used_VBN to_TO treat_VB amphetamine_NN poisoning_NN ._. Ethosuximide_NNP :_: Amphetamines_NNS may_MD delay_VB intestinal_JJ absorption_NN of_IN ethosuximide_NN ._. Haloperidol_NNP :_: Haloperidol_NNP blocks_VBZ dopamine_NN and_CC norepinephrine_NN reuptake_NN ,_, thus_RB inhibiting_VBG the_DT central_JJ stimulant_NN effects_NNS of_IN amphetamines_NNS ._. Lithium_NN carbonate_NN :_: The_DT stimulatory_JJ effects_NNS of_IN amphetamines_NNS may_MD be_VB inhibited_VBN by_IN lithium_NN carbonate_NN ._. Meperidine_NNP :_: Amphetamines_NNS potentiate_VBP the_DT analgesic_JJ effect_NN of_IN meperidine_NN ._. Methenamine_NN therapy_NN :_: Urinary_JJ excretion_NN of_IN amphetamines_NNS is_VBZ increased_VBN ,_, and_CC efficacy_NN is_VBZ reduced_VBN ,_, by_IN acidifying_VBG agents_NNS used_VBN in_IN methenamine_NN therapy_NN ._. Norepinephrine_NN :_: Amphetamines_NNS enhance_VBP the_DT adrenergic_JJ effect_NN of_IN norepinephrine_NN ._. Phenobarbital_NNP :_: Amphetamines_NNS may_MD delay_VB intestinal_JJ absorption_NN of_IN phenobarbital_NN ._. co-administration_NN of_IN phenobarbital_NN may_MD produce_VB a_DT synergistic_JJ anticonvulsant_JJ action_NN ._. Phenytoin_NNP :_: Amphetamines_NNS may_MD delay_VB intestinal_JJ absorption_NN of_IN phenytoin_NN ._. co-administration_NN of_IN phenytoin_NN may_MD produce_VB a_DT synergistic_JJ anticonvulsant_JJ action_NN ._. Propoxyphene_NNP :_: In_IN cases_NNS of_IN propoxyphene_NN overdosage_NN ,_, amphetamine_NN CNS_NN stimulation_NN is_VBZ potentiated_JJ and_CC fatal_JJ convulsions_NNS can_MD occur_VB ._. Veratrum_NNP alkaloids_NNS :_: Amphetamines_NNS inhibit_VBP the_DT hypotensive_JJ effect_NN of_IN veratrum_NN alkaloids_NNS ._. Drug/Laboratory_JJ Test_NN Interactions_NNS :_: Amphetamines_NNS can_MD cause_VB a_DT significant_JJ elevation_NN in_IN plasma_NN corticosteroid_NN levels_NNS ._. This_DT increase_NN is_VBZ greatest_JJS in_IN the_DT evening_NN ._. Amphetamines_NNS may_MD interfere_VB with_IN urinary_JJ steroid_NN determinations_NNS ._. Additive_JJ depressant_NN effect_NN when_WRB used_VBN with_IN general_JJ anesthetics_NNS ,_, sedatives_NNS ,_, antianxiety_JJ drugs_NNS ,_, hypnotics_NNS ,_, alcohol_NN ,_, and_CC other_JJ opiate_JJ analgesics_NNS ._. May_NNP interact_VBP with_IN thyroid_NN medication_NN -LRB-_-LRB- e.g._FW ,_, levothyroxine_NN -RRB-_-RRB- ,_, iodine-containing_JJ products_NNS ,_, antacids_NNS ,_, H2-antagonists_NNS -LRB-_-LRB- e.g._FW ,_, famotidine_NN ,_, ranitidine_NN -RRB-_-RRB- ,_, and_CC proton_NN pump_NN inhibitors_NNS -LRB-_-LRB- e.g._FW ,_, lansoprazole_NN ,_, omeprazole_NN -RRB-_-RRB- ._. This_DT product_NN can_MD affect_VB the_DT results_NNS of_IN certain_JJ lab_NN tests_NNS ._. Caution_NN is_VBZ advised_VBN in_IN patients_NNS receiving_VBG concomitant_JJ high-dose_JJ aspirin_NN and_CC carbonic_JJ anhydrase_NN inhibitors_NNS ,_, as_IN anorexia_NN ,_, tachypnea_NN ,_, lethargy_NN and_CC coma_NN have_VBP been_VBN rarely_RB reported_VBN due_JJ to_TO a_DT possible_JJ drug_NN interaction_NN ._. Aspirin_NN :_: Concomitant_JJ administration_NN of_IN diclofenac_NN and_CC aspirin_NN is_VBZ not_RB recommended_VBN because_IN diclofenac_NN is_VBZ displaced_VBN from_IN its_PRP$ binding_NN sites_NNS during_IN the_DT concomitant_JJ administration_NN of_IN aspirin_NN ,_, resulting_VBG in_IN lower_JJR plasma_NN concentrations_NNS ,_, peak_JJ plasma_NN levels_NNS ,_, and_CC AUC_NN values_NNS ._. Anticoagulants_NNPS :_: While_IN studies_NNS have_VBP not_RB shown_VBN diclofenac_NN to_TO interact_VB with_IN anticoagulants_NNS of_IN the_DT warfarin_NN type_NN ,_, caution_NN should_MD be_VB exercised_VBN ,_, nonetheless_RB ,_, since_IN interactions_NNS have_VBP been_VBN seen_VBN with_IN other_JJ NSAIDs_NNS ._. Because_IN prostaglandins_NNS play_VBP an_DT important_JJ role_NN in_IN hemostasis_NN ,_, and_CC NSAIDs_NNS affect_VBP platelet_NN function_NN as_RB well_RB ,_, concurrent_JJ therapy_NN with_IN all_DT NSAIDs_NNS ,_, including_VBG diclofenac_NN ,_, and_CC warfarin_NN requires_VBZ close_JJ monitoring_NN of_IN patients_NNS to_TO be_VB certain_JJ that_IN no_DT change_NN in_IN their_PRP$ anticoagulant_JJ dosage_NN is_VBZ required_VBN ._. Digoxin_NNP ,_, Methotrexate_NNP ,_, Cyclosporine_NNP :_: Diclofenac_NNP ,_, like_IN other_JJ NSAIDs_NNS ,_, may_MD affect_VB renal_JJ prostaglandins_NNS and_CC increase_VB the_DT toxicity_NN of_IN certain_JJ drugs_NNS ._. Ingestion_NN of_IN diclofenac_NN may_MD increase_VB serum_NN concentrations_NNS of_IN digoxin_NN and_CC methotrexate_NN and_CC increase_NN cyclosporine_NN s_VBZ nephrotoxicity_NN ._. Patients_NNS who_WP begin_VBP taking_VBG diclofenac_NN or_CC who_WP increase_VBP their_PRP$ diclofenac_NN dose_NN or_CC any_DT other_JJ NSAID_NN while_IN taking_VBG digoxin_NN ,_, methotrexate_NN ,_, or_CC cyclosporine_NN may_MD develop_VB toxicity_NN characteristics_NNS for_IN these_DT drugs_NNS ._. They_PRP should_MD be_VB observed_VBN closely_RB ,_, particularly_RB if_IN renal_JJ function_NN is_VBZ impaired_JJ ._. In_IN the_DT case_NN of_IN digoxin_NN ,_, serum_NN levels_NNS should_MD be_VB monitored_VBN ._. Lithium_NN :_: Diclofenac_NNP decreases_VBZ lithium_NN renal_JJ clearance_NN and_CC increases_VBZ lithium_NN plasma_NN levels_NNS ._. In_IN patients_NNS taking_VBG diclofenac_NN and_CC lithium_NN concomitantly_RB ,_, lithium_NN toxicity_NN may_MD develop_VB ._. Oral_JJ Hypoglycemics_NNS :_: Diclofenac_NNP does_VBZ not_RB alter_VB glucose_NN metabolism_NN in_IN normal_JJ subjects_NNS nor_CC does_VBZ it_PRP alter_VB the_DT effects_NNS of_IN oral_JJ hypoglycemic_JJ agents_NNS ._. There_EX are_VBP rare_JJ reports_NNS ,_, however_RB ,_, from_IN marketing_NN experiences_NNS ,_, of_IN changes_NNS in_IN effects_NNS of_IN insulin_NN or_CC oral_JJ hypoglycemic_JJ agents_NNS in_IN the_DT presence_NN of_IN diclofenac_NN that_WDT necessitated_VBD changes_NNS in_IN the_DT doses_NNS of_IN such_JJ agents_NNS ._. Both_DT hypo_NN -_: and_CC hyperglycemic_JJ effects_NNS have_VBP been_VBN reported_VBN ._. A_DT direct_JJ causal_JJ relationship_NN has_VBZ not_RB been_VBN established_VBN ,_, but_CC physicians_NNS should_MD consider_VB the_DT possibility_NN that_IN diclofenac_NN may_MD alter_VB a_DT diabetic_JJ patient_NN s_NNS response_NN to_TO insulin_NN or_CC oral_JJ hypoglycemic_JJ agents_NNS ._. Diuretics_NNS :_: Diclofenac_NNP and_CC other_JJ NSAIDs_NNS can_MD inhibit_VB the_DT activity_NN of_IN diuretics_NNS ._. Concomitant_JJ treatment_NN with_IN potassium-sparing_JJ diuretics_NNS may_MD be_VB associated_VBN with_IN increased_VBN serum_NN potassium_NN levels_NNS ._. Other_JJ Drugs_NNS :_: In_IN small_JJ groups_NNS of_IN patients_NNS -LRB-_-LRB- 7-10_CD /_: interaction_NN study_NN -RRB-_-RRB- ,_, the_DT concomitant_JJ administration_NN of_IN azathioprine_NN ,_, gold_NN ,_, chloroquine_NN ,_, D-penicillamine_NN ,_, prednisolone_NN ,_, doxycycline_NN ,_, or_CC digitoxin_NN did_VBD not_RB significantly_RB affect_VB the_DT peak_NN levels_NNS and_CC AUC_NN values_NNS of_IN diclofenac_NN ._. Phenobarbital_JJ toxicity_NN has_VBZ been_VBN reported_VBN to_TO have_VB occurred_VBN in_IN a_DT patient_NN on_IN chronic_JJ phenobarbital_JJ treatment_NN following_VBG the_DT initiation_NN of_IN diclofenac_NN therapy_NN ._. Protein_NN Binding_NN In_FW vitro_FW ,_, diclofenac_NN interferes_VBZ minimally_RB or_CC not_RB at_IN all_DT with_IN the_DT protein_NN binding_NN of_IN salicylic_JJ acid_NN -LRB-_-LRB- 20_CD %_NN decrease_NN in_IN binding_NN -RRB-_-RRB- ,_, tolbutamide_NN ,_, prednisolone_NN -LRB-_-LRB- 10_CD %_NN decrease_NN in_IN binding_NN -RRB-_-RRB- ,_, or_CC warfarin_NN ._. Benzylpenicillin_NNP ,_, ampicillin_NN ,_, oxacillin_NN ,_, chlortetracycline_NN ,_, doxycycline_NN ,_, cephalothin_NN ,_, erythromycin_NN ,_, and_CC sulfamethoxazole_NN have_VBP no_DT influence_NN in_FW vitro_FW on_IN the_DT protein_NN binding_NN of_IN diclofenac_NN in_IN human_JJ serum_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS Effect_NN on_IN Blood_NN Coagulation_NN :_: Diclofenac_NNP increases_VBZ platelet_NN aggregation_NN time_NN but_CC does_VBZ not_RB affect_VB bleeding_JJ time_NN ,_, plasma_NN thrombin_NN clotting_NN time_NN ,_, plasma_NN fibrinogen_NN ,_, or_CC factors_NNS V_NN and_CC VII_NN to_TO XII_NNP ._. Statistically_RB significant_JJ changes_NNS in_IN prothrombin_NN and_CC partial_JJ thromboplastin_NN times_NNS have_VBP been_VBN reported_VBN in_IN normal_JJ volunteers_NNS ._. The_DT mean_JJ changes_NNS were_VBD observed_VBN to_TO be_VB less_JJR than_IN 1_CD second_JJ in_IN both_CC instances_NNS ,_, however_RB ,_, and_CC are_VBP unlikely_JJ to_TO be_VB clinically_RB important_JJ ._. Diclofenac_NNP is_VBZ a_DT prostaglandin_NN synthetase_NN inhibitor_NN ,_, however_RB ,_, and_CC all_DT drugs_NNS that_WDT inhibit_VBP prostaglandin_NN synthesis_NN interfere_VBP with_IN platelet_NN function_NN to_TO some_DT degree_NN ._. therefore_RB ,_, patients_NNS who_WP may_MD be_VB adversely_RB affected_VBN by_IN such_PDT an_DT action_NN should_MD be_VB carefully_RB observed_VBN ._. Tetracycline_NN ,_, a_DT bacteriostatic_JJ antibiotic_JJ ,_, may_MD antagonize_VB the_DT bactercidal_JJ effect_NN of_IN penicillin_NN and_CC concurrent_JJ use_NN of_IN these_DT drugs_NNS should_MD be_VB avoided_VBN ._. The_DT following_VBG agents_NNS may_MD increase_VB certain_JJ actions_NNS or_CC side_JJ effects_NNS of_IN anticholinergic_JJ drugs_NNS ._. amantadine_NN antiarrhythmic_JJ agents_NNS of_IN class_NN -LRB-_-LRB- e.g._FW quinidine_FW -RRB-_-RRB- ,_, antihistamines_NNS antipsychotic_JJ agents_NNS -LRB-_-LRB- e.g._FW phenothiazines_NNS -RRB-_-RRB- ,_, benzodiazepines_NNS ._. MAO_NN inhibitors_NNS ,_, narcotic_JJ analgesics_NNS -LRB-_-LRB- e.g._FW ,_, meperidine_NN -RRB-_-RRB- ,_, nitrates_NNS and_CC nitrites_NNS ,_, sympathomimetic_JJ agents_NNS ,_, tricyclic_JJ antidepressants_NNS ,_, and_CC other_JJ drugs_NNS having_VBG anticholinergic_JJ activity_NN ._. Anticholinergics_NNS antagonize_VBP the_DT effects_NNS of_IN antiglaucoma_NN agents_NNS ._. Anticholinergic_JJ drugs_NNS in_IN the_DT presence_NN of_IN increased_VBN intraocular_JJ pressure_NN may_MD be_VB hazardous_JJ when_WRB taken_VBN concurrently_RB with_IN agents_NNS such_JJ as_IN corti_NN costeroids_NNS ._. Anticholinergic_JJ agents_NNS may_MD affect_VB gastrointestinal_JJ absorption_NN of_IN various_JJ drugs_NNS ,_, such_JJ as_IN slowly_RB dissolving_VBG dosage_JJ forms_NNS of_IN digoxin_NN ._. increased_VBN serum_NN digoxin_NN concentrations_NNS may_MD result_VB ._. Anticholinergic_JJ drugs_NNS may_MD antagonize_VB the_DT effects_NNS of_IN the_DT drugs_NNS that_WDT alter_VBP gastrointestinal_JJ motility_NN ,_, such_JJ as_IN metoclopramide_NN ._. Because_IN antacids_NNS may_MD interfere_VB with_IN the_DT absorption_NN of_IN anticholinergic_JJ agents_NNS ,_, simultaneous_JJ use_NN of_IN these_DT drugs_NNS should_MD be_VB avoided_VBN ._. The_DT inhibiting_JJ effects_NNS of_IN anticholinergic_JJ drugs_NNS on_IN gastric_JJ hydrochloric_JJ acid_NN secretion_NN are_VBP antagonized_VBN by_IN agents_NNS used_VBN to_TO treat_VB achlorhydria_NN and_CC those_DT used_VBN to_TO test_VB gastric_JJ secretion_NN ._. Coadministration_NN of_IN VIDEX_NN with_IN drugs_NNS that_WDT are_VBP known_VBN to_TO cause_VB pancreatitis_NN may_MD increase_VB the_DT risk_NN of_IN this_DT toxicity_NN -LRB-_-LRB- see_VB WARNINGS_NNS -RRB-_-RRB- and_CC should_MD be_VB done_VBN with_IN extreme_JJ caution_NN ,_, only_RB if_IN other_JJ alternatives_NNS are_VBP not_RB available_JJ ,_, and_CC only_RB if_IN clearly_RB indicated_VBN ._. Neuropathy_NN has_VBZ occurred_VBN more_RBR frequently_RB in_IN patients_NNS with_IN a_DT history_NN of_IN neuropathy_NN or_CC neurotoxic_JJ drug_NN therapy_NN ,_, including_VBG stavudine_NN ,_, and_CC these_DT patients_NNS may_MD be_VB at_IN increased_VBN risk_NN of_IN neuropathy_NN during_IN VIDEX_NN therapy_NN -LRB-_-LRB- see_VB ADVERSE_JJ REACTIONS_NNS -RRB-_-RRB- ._. Allopurinol_NNP :_: The_DT AUC_NN of_IN didanosine_NN was_VBD increased_VBN about_IN 4-fold_RB when_WRB allopurinol_NN at_IN 300_CD mg/day_NN was_VBD coadministered_VBN with_IN a_DT single_JJ 200-mg_JJ dose_NN of_IN VIDEX_NNP to_TO two_CD patients_NNS with_IN renal_JJ impairment_NN -LRB-_-LRB- CLcr_NN =_JJ 15_CD and_CC 18_CD mL/min_NN -RRB-_-RRB- ._. The_DT effects_NNS of_IN allopurinol_NN on_IN didanosine_NN pharmacokinetics_NNS in_IN subjects_NNS with_IN normal_JJ renal_JJ function_NN are_VBP not_RB known_VBN ._. Antacids_NNS :_: Concomitant_JJ administration_NN of_IN antacids_NNS containing_VBG magnesium_NN or_CC aluminum_NN with_IN VIDEX_NNP Chewable/Dispersible_NNP Buffered_NNP Tablets_NNPS or_CC Pediatric_NNP Powder_NNP for_IN Oral_NNP Solution_NN may_MD potentiate_VB adverse_JJ events_NNS associated_VBN with_IN the_DT antacid_NN components_NNS ._. Drugs_NNS Whose_WP$ Absorption_NN Can_MD Be_VB Affected_VBN by_IN the_DT Level_NN of_IN Acidity_NN in_IN the_DT Stomach_NNP :_: Drugs_NNS such_JJ as_IN ketoconazole_NN and_CC itraconazole_NN should_MD be_VB administered_VBN at_IN least_JJS 2_CD hours_NNS prior_RB to_TO dosing_NN with_IN VIDEX_NN ._. Ganciclovir_NNP :_: Administration_NNP of_IN VIDEX_NNP 2_CD hours_NNS prior_RB to_TO or_CC concurrent_JJ with_IN oral_JJ ganciclovir_NN was_VBD associated_VBN with_IN a_DT 111_CD -LRB-_-LRB- 114_CD -RRB-_-RRB- %_NN increase_NN in_IN the_DT steady-state_JJ AUC_NN of_IN didanosine_NN -LRB-_-LRB- n_NN =_JJ 12_CD -RRB-_-RRB- ._. A_DT 21_CD -LRB-_-LRB- 17_CD -RRB-_-RRB- %_NN decrease_NN in_IN the_DT steady-state_JJ AUC_NN of_IN ganciclovir_NN was_VBD observed_VBN when_WRB VIDEX_NNP was_VBD administered_VBN 2_CD hours_NNS prior_RB to_TO ganciclovir_NN ,_, but_CC not_RB when_WRB the_DT two_CD drugs_NNS were_VBD administered_VBN simultaneously_RB -LRB-_-LRB- n_NN =_JJ 12_CD -RRB-_-RRB- ._. Quinolone_NNP Antibiotics_NNPS :_: VIDEX_NN should_MD be_VB administered_VBN at_IN least_JJS 2_CD hours_NNS after_IN or_CC 6_CD hours_NNS before_IN dosing_NN with_IN ciprofloxacin_NN because_IN plasma_NN concentrations_NNS of_IN ciprofloxacin_NN are_VBP decreased_VBN when_WRB administered_VBN with_IN antacids_NNS containing_VBG magnesium_NN ,_, calcium_NN ,_, or_CC aluminum_NN ._. In_IN eight_CD HIV-infected_JJ patients_NNS ,_, the_DT steady-state_JJ AUC_NN of_IN ciprofloxacin_NN was_VBD decreased_VBN an_DT average_NN of_IN 26_CD %_NN -LRB-_-LRB- 95_CD %_NN CI_NN =_JJ 14_CD %_NN ,_, 37_CD %_NN -RRB-_-RRB- when_WRB ciprofloxacin_NN was_VBD administered_VBN 2_CD hours_NNS prior_RB to_TO a_DT marketed_VBN chewable/dispersible_JJ tablet_NN formulation_NN of_IN VIDEX_NNP ._. The_DT AUC_NN of_IN ciprofloxacin_NN was_VBD decreased_VBN an_DT average_NN of_IN 15-fold_JJ in_IN 12_CD healthy_JJ subjects_NNS given_VBN ciprofloxacin_NN and_CC didanosine-placebo_JJ tablets_NNS concurrently_RB ._. In_IN a_DT single_JJ subject_JJ given_VBN one_CD dose_NN of_IN ciprofloxacin_NN 2_CD hours_NNS after_IN a_DT dose_NN of_IN didanosine-placebo_JJ tablets_NNS ,_, a_DT greater_JJR than_IN 50_CD %_NN reduction_NN in_IN the_DT AUC_NN of_IN ciprofloxacin_NN was_VBD observed_VBN ._. Plasma_NN concentrations_NNS of_IN quinolone_JJ antibiotics_NNS are_VBP decreased_VBN when_WRB administered_VBN with_IN antacids_NNS containing_VBG magnesium_NN ,_, calcium_NN ,_, or_CC aluminum_NN ._. The_DT optimal_JJ dosing_NN interval_NN for_IN coadministration_NN with_IN VIDEX_NN should_MD be_VB determined_VBN by_IN consulting_VBG the_DT appropriate_JJ quinolone_NN package_NN insert_NN ._. Interactions_NNS with_IN Other_JJ Antiretroviral_JJ Drugs_NNS :_: Significant_JJ decreases_NNS in_IN the_DT AUC_NN of_IN delavirdine_NN -LRB-_-LRB- 20_CD %_NN -RRB-_-RRB- and_CC indinavir_NN -LRB-_-LRB- 84_CD %_NN -RRB-_-RRB- occurred_VBD following_VBG simultaneous_JJ administration_NN of_IN these_DT agents_NNS with_IN VIDEX_NN ._. To_TO avoid_VB this_DT interaction_NN ,_, delavirdine_NN or_CC indinavir_NN should_MD be_VB given_VBN 1_CD hour_NN prior_RB to_TO dosing_NN with_IN VIDEX_NN ._. The_DT pharmacokinetics_NNS of_IN nelfinavir_NN are_VBP not_RB altered_VBN to_TO a_DT clinically_RB significant_JJ degree_NN when_WRB it_PRP is_VBZ administered_VBN with_IN a_DT light_JJ meal_NN 1_CD hour_NN after_IN VIDEX_NNP ._. Drug_NN /_: Laboratory_NNP Test_NNP Interactions_NNS Certain_JJ endocrine_NN and_CC liver_NN function_NN tests_NNS may_MD be_VB affected_VBN by_IN estrogen-containing_JJ oral_JJ contraceptives_NNS ._. The_DT following_VBG similar_JJ changes_NNS may_MD be_VB expected_VBN with_IN larger_JJR doses_NNS of_IN estrogen_NN :_: -_: Increased_VBN sulfobromophthalein_NN retentio_NN ._. -_: Increased_VBN prothrombin_NN and_CC factors_NNS VII_NNP ,_, VIII_NNP ,_, IX_CD ,_, and_CC X_NN ;_: ._. decreased_VBN antithrombin_NN 3_CD ._. increased_VBN norepinephrine-induced_JJ platelet_NN aggregability_NN ._. -_: Increased_VBN thyroid-binding_JJ globulin_NN -LRB-_-LRB- TBG_NN -RRB-_-RRB- leading_VBG to_TO in-creased_JJ circulating_VBG total_JJ thyroid_NN hormone_NN ;_: ._. as_IN measured_VBN by_IN PBI_NN ,_, T4_NN by_IN column_NN ,_, or_CC T4_NN by_IN radioimmunoassay_NN ._. Free_NNP T3_NN resin_NN uptake_NN is_VBZ decreased_VBN ,_, reflecting_VBG the_DT elevated_JJ TBG_NN ;_: ._. free_JJ T4_NN concentration_NN is_VBZ unaltered_JJ ._. -_: Impaired_JJ glucose_NN tolerance_NN ._. -_: Decreased_VBN pregnanediol_NN excretion_NN ._. -_: Reduced_VBN response_NN to_TO metyrapone_NN test_NN ._. -_: Reduced_VBN serum_NN folate_VBP concentration_NN ._. -_: Increased_VBN serum_NN triglyceride_NN and_CC phospholipid_JJ concentration_NN ._. Antidiabetic_JJ drug_NN requirements_NNS -LRB-_-LRB- i.e._FW ,_, insulin_NN -RRB-_-RRB- may_MD be_VB altered_VBN ._. Concurrent_JJ use_NN with_IN general_JJ anesthetics_NNS may_MD result_VB in_IN arrhythmias_NNS ._. The_DT pressor_JJ effects_NNS of_IN diethylpropion_NN and_CC those_DT of_IN other_JJ drugs_NNS may_MD be_VB additive_JJ when_WRB the_DT drugs_NNS are_VBP used_VBN concomitantly_RB ._. conversely_RB ,_, diethylpropion_NN may_MD interfere_VB with_IN antihypertensive_JJ drugs_NNS -LRB-_-LRB- i.e._FW ,_, guanethidine_NN ,_, a-methyldopa_NN -RRB-_-RRB- ._. Concurrent_JJ use_NN of_IN phenothiazines_NNS may_MD antagonize_VB the_DT anorectic_NN effect_NN of_IN diethylpropion_NN ._. May_NNP interact_VBP anticoagulants_NNS -LRB-_-LRB- altered_JJ hypo-prothrombinemic_JJ effect_NN -RRB-_-RRB- ,_, barbiturates_NNS ,_, rifampin_NN and_CC other_JJ inducers_NNS of_IN hepatic_JJ microsomal_JJ enzyme_NN oxidation_NN system_NN -LRB-_-LRB- decreased_VBN effect_NN of_IN diethylstilbestrol_NN -RRB-_-RRB- ,_, corticosteroids_NNS -LRB-_-LRB- increased_VBN effect_NN of_IN corticosteroids_NNS -RRB-_-RRB- ._. Oral_JJ Anticoagulants_NNPS :_: In_IN some_DT normal_JJ volunteers_NNS ,_, the_DT concomitant_JJ administration_NN of_IN diflunisal_NN and_CC warfarin_NN ,_, acenocoumarol_NN ,_, or_CC phenprocoumon_NN resulted_VBD in_IN prolongation_NN of_IN prothrombin_NN time_NN ._. This_DT may_MD occur_VB because_IN diflunisal_JJ competitively_RB displaces_VBZ coumarins_NNS from_IN protein_NN binding_NN sites_NNS ._. Accordingly_RB ,_, when_WRB diflunisal_NN is_VBZ administered_VBN with_IN oral_JJ anticoagulants_NNS ,_, the_DT prothrombin_NN time_NN should_MD be_VB closely_RB monitored_VBN during_IN and_CC for_IN several_JJ days_NNS after_IN concomitant_JJ drug_NN administration_NN ._. Adjustment_NNP of_IN dosage_NN of_IN oral_JJ anticoagulants_NNS may_MD be_VB required_VBN ._. Tolbutamide_NNP :_: In_IN diabetic_JJ patients_NNS receiving_VBG diflunisal_JJ and_CC tolbutamide_NN ,_, no_DT significant_JJ effects_NNS were_VBD seen_VBN on_IN tolbutamide_NN plasma_NN levels_NNS or_CC fasting_JJ blood_NN glucose_NN ._. Hydrochlorothiazide_NN :_: In_IN normal_JJ volunteers_NNS ,_, concomitant_JJ administration_NN of_IN diflunisal_NN and_CC hydrochlorothiazide_NN resulted_VBD in_IN significantly_RB increased_VBN plasma_NN levels_NNS of_IN hydrochlorothiazide_NN ._. Diflunisal_NNP decreased_VBD the_DT hyperuricemic_JJ effect_NN of_IN hydrochlorothiazide_NN ._. Furosemide_NNP :_: In_IN normal_JJ volunteers_NNS ,_, the_DT concomitant_JJ administration_NN of_IN diflunisal_NN and_CC furosemide_NN had_VBD no_DT effect_NN on_IN the_DT diuretic_JJ activity_NN of_IN furosemide_NN ._. Diflunisal_NNP decreased_VBD the_DT hyperuricemic_JJ effect_NN of_IN furosemide_NN ._. Antacids_NNS :_: Concomitant_JJ administration_NN of_IN antacids_NNS may_MD reduce_VB plasma_NN levels_NNS of_IN diflunisal_NN ._. This_DT effect_NN is_VBZ small_JJ with_IN occasional_JJ doses_NNS of_IN antacids_NNS ,_, but_CC may_MD be_VB clinically_RB significant_JJ when_WRB antacids_NNS are_VBP used_VBN on_IN a_DT continuous_JJ schedule_NN ._. Acetaminophen_NN :_: In_IN normal_JJ volunteers_NNS ,_, concomitant_JJ administration_NN of_IN diflunisal_NN and_CC acetaminophen_NN resulted_VBD in_IN an_DT approximate_JJ 50_CD %_NN increase_NN in_IN plasma_NN levels_NNS of_IN acetaminophen_NN ._. Acetaminophen_NN had_VBD no_DT effect_NN on_IN plasma_NN levels_NNS of_IN diflunisal_NN ._. Since_IN acetaminophen_NN in_IN high_JJ doses_NNS has_VBZ been_VBN associated_VBN with_IN hepatotoxicity_NN ,_, concomitant_JJ administration_NN of_IN diflunisal_NN and_CC acetaminophen_NN should_MD be_VB used_VBN cautiously_RB ,_, with_IN careful_JJ monitoring_NN of_IN patients_NNS ._. Concomitant_JJ administration_NN of_IN diflunisal_NN and_CC acetaminophen_NN in_IN dogs_NNS ,_, but_CC not_RB in_IN rats_NNS ,_, at_IN approximately_RB 2_CD times_NNS the_DT recommended_VBN maximum_NN human_JJ therapeutic_JJ dose_NN of_IN each_DT -LRB-_-LRB- 40_CD to_TO 52_CD mg/kg/day_NN of_IN diflunisal/acetaminophen_NN -RRB-_-RRB- resulted_VBD in_IN greater_JJR gastrointestinal_JJ toxicity_NN than_IN when_WRB either_CC drug_NN was_VBD administered_VBN alone_RB ._. The_DT clinical_JJ significance_NN of_IN these_DT findings_NNS has_VBZ not_RB been_VBN established_VBN ._. Methotrexate_NNP :_: Caution_NN should_MD be_VB used_VBN if_IN diflunisal_NN is_VBZ administered_VBN concomitantly_RB with_IN methotrexate_NN ._. Nonsteroidal_JJ anti-inflammatory_JJ drugs_NNS have_VBP been_VBN reported_VBN to_TO decrease_VB the_DT tubular_JJ secretion_NN of_IN methotrexate_NN and_CC to_TO potentiate_VB its_PRP$ toxicity_NN ._. Cyclosporine_NN :_: Administration_NN of_IN nonsteroial_JJ anti-inflammatory_JJ drugs_NNS concomitantly_RB with_IN cyclosporine_NN has_VBZ been_VBN associated_VBN with_IN an_DT increase_NN in_IN cyclosporine-induced_JJ toxicity_NN ,_, possibly_RB due_JJ to_TO decreased_VBN synthesis_NN of_IN renal_JJ prostacyclin_NN ._. NSAIDs_NNS should_MD be_VB used_VBN with_IN caution_NN in_IN patients_NNS taking_VBG cyclosporine_NN ,_, and_CC renal_JJ function_NN should_MD be_VB carefully_RB monitored_VBN ._. Nonsteroidal_JJ Anti-Inflammatory_JJ Drugs_NNS :_: The_DT administration_NN of_IN diflunisal_NN to_TO normal_JJ volunteers_NNS receiving_VBG indomethacin_NN decreased_VBD the_DT renal_JJ clearance_NN and_CC significantly_RB increased_VBD the_DT plasma_NN levels_NNS of_IN indomethacin_NN ._. In_IN some_DT patients_NNS the_DT combined_JJ use_NN of_IN indomethacin_NN and_CC diflunisal_NN has_VBZ been_VBN associated_VBN with_IN fatal_JJ gastrointestinal_JJ hemorrhage_NN ._. Therefore_RB ,_, indomethacin_NN and_CC diflunisal_NN should_MD not_RB be_VB used_VBN concomitantly_RB ._. The_DT concomitant_JJ use_NN of_IN diflunisal_JJ tablets_NNS and_CC other_JJ NSAIDs_NNS is_VBZ not_RB recommended_VBN due_JJ to_TO the_DT increased_VBN possibility_NN of_IN gastrointestinal_JJ toxicity_NN ,_, with_IN little_JJ or_CC no_DT increase_NN in_IN efficacy_NN ._. The_DT following_VBG information_NN was_VBD obtained_VBN from_IN studies_NNS in_IN normal_JJ volunteers_NNS ._. Aspirin_NN :_: In_IN normal_JJ volunteers_NNS ,_, a_DT small_JJ decrease_NN in_IN diflunisal_JJ levels_NNS was_VBD observed_VBN when_WRB multiple_JJ doses_NNS of_IN diflunisal_NN and_CC aspirin_NN were_VBD administered_VBN concomitantly_RB ._. Sulindac_NN :_: The_DT concomitant_JJ administration_NN of_IN diflunisal_NN and_CC sulindac_NN in_IN normal_JJ volunteers_NNS resulted_VBD in_IN lowering_NN of_IN the_DT plasma_NN levels_NNS of_IN the_DT active_JJ sulindac_NN sulfide_NN metabolite_NN by_IN approximately_RB one-third_JJ ._. Naproxen_NN :_: The_DT concomitant_JJ administration_NN of_IN diflunisal_NN and_CC naproxen_NN in_IN normal_JJ volunteers_NNS had_VBD no_DT effect_NN on_IN the_DT plasma_NN levels_NNS of_IN naproxen_NN ,_, but_CC significantly_RB decreased_VBD the_DT urinary_JJ excretion_NN of_IN naproxen_NN and_CC its_PRP$ glucuronide_NN metabolite_NN ._. Naproxen_NN had_VBD no_DT effect_NN on_IN plasma_NN levels_NNS of_IN diflunisal_NN ._. Drug_NN laboratory_NN Test_NN Interactions_NNS Serum_NN Salicylate_NNP Assays_NNS :_: Caution_NN should_MD be_VB used_VBN in_IN interpreting_VBG the_DT results_NNS of_IN serum_NN salicylate_NN assays_NNS when_WRB diflunisal_NN is_VBZ present_JJ ._. Salicylate_NN levels_NNS have_VBP been_VBN found_VBN to_TO be_VB falsely_RB elevated_JJ with_IN some_DT assay_NN methods_NNS ._. Potassium-depleting_JJ diuretics_NNS are_VBP a_DT major_JJ contributing_JJ factor_NN to_TO digitalis_NN toxicity_NN ._. Calcium_NN ,_, particularly_RB if_IN administered_VBN rapidly_RB by_IN the_DT intravenous_JJ route_NN ,_, may_MD produce_VB serious_JJ arrhythmias_NNS in_IN digitalized_JJ patients_NNS ._. Quinidine_NNP ,_, verapamil_NN ,_, amiodarone_NN ,_, propafenone_NN ,_, indomethacin_NN ,_, itraconazole_NN ,_, alprazolam_NN ,_, and_CC spironolactone_NN raise_VBP the_DT serum_NN digoxin_NN concentration_NN due_JJ to_TO a_DT reduction_NN in_IN clearance_NN and/or_CC in_IN volume_NN of_IN distribution_NN of_IN the_DT drug_NN ,_, with_IN the_DT implication_NN that_WDT digitalis_NN intoxication_NN may_MD result_VB ._. Erythromycin_NN and_CC clarithromycin_NN -LRB-_-LRB- and_CC possibly_RB other_JJ macrolide_NN antibiotics_NNS -RRB-_-RRB- and_CC tetracycline_NN may_MD increase_VB digoxin_NN absorption_NN in_IN patients_NNS who_WP inactivate_VBP digoxin_NN by_IN bacterial_JJ metabolism_NN in_IN the_DT lower_JJR intestine_NN ,_, so_RB that_IN digitalis_NN intoxication_NN may_MD result_VB ._. The_DT risk_NN of_IN this_DT interaction_NN may_MD be_VB reduced_VBN if_IN digoxin_NN is_VBZ given_VBN as_IN capsules_NNS ._. Propantheline_NNP and_CC diphenoxylate_NN ,_, by_IN decreasing_VBG gut_NN motility_NN ,_, may_MD increase_VB digoxin_NN absorption_NN ._. Antacids_NNS ,_, kaolin-pectin_NN ,_, sulfasalazine_NN ,_, neomycin_NN ,_, cholestyramine_NN ,_, certain_JJ anticancer_JJ drugs_NNS ,_, and_CC metoclopramide_NN may_MD interfere_VB with_IN intestinal_JJ digoxin_NN absorption_NN ,_, resulting_VBG in_IN unexpectedly_RB low_JJ serum_NN concentrations_NNS ._. Rifampin_NNP may_MD decrease_VB serum_NN digoxin_NN concentration_NN ,_, especially_RB in_IN patients_NNS with_IN renal_JJ dysfunction_NN ,_, by_IN increasing_VBG the_DT non-renal_JJ clearance_NN of_IN digoxin_NN ._. There_EX have_VBP been_VBN inconsistent_JJ reports_NNS regarding_VBG the_DT effects_NNS of_IN other_JJ drugs_NNS -LRB-_-LRB- e.g._FW ,_, quinine_NN ,_, penicillamine_NN -RRB-_-RRB- on_IN serum_NN digoxin_NN concentration_NN ._. Thyroid_NN administration_NN to_TO a_DT digitalized_JJ ,_, hypothyroid_JJ patient_NN may_MD increase_VB the_DT dose_NN requirement_NN of_IN digoxin_NN ._. Concomitant_JJ use_NN of_IN digoxin_NN and_CC sympathomimetics_NNS increases_VBZ the_DT risk_NN of_IN cardiac_JJ arrhythmias_NNS ._. Succinylcholine_NNP may_MD cause_VB a_DT sudden_JJ extrusion_NN of_IN potassium_NN from_IN muscle_NN cells_NNS ,_, and_CC may_MD thereby_RB cause_VB arrhythmias_NNS in_IN digitalized_JJ patients_NNS ._. Although_IN beta-adrenergic_JJ blockers_NNS or_CC calcium_NN channel_NN blockers_NNS and_CC digoxin_NN may_MD be_VB useful_JJ in_IN combination_NN to_TO control_VB atrial_JJ fibrillation_NN ,_, their_PRP$ additive_JJ effects_NNS on_IN AV_NN node_NN conduction_NN can_MD result_VB in_IN advanced_JJ or_CC complete_JJ heart_NN block_NN ._. Due_JJ to_TO the_DT considerable_JJ variability_NN of_IN these_DT interactions_NNS ,_, the_DT dosage_NN of_IN digoxin_NN should_MD be_VB individualized_VBN when_WRB patients_NNS receive_VBP these_DT medications_NNS concurrently_RB ._. Furthermore_RB ,_, caution_NN should_MD be_VB exercised_VBN when_WRB combining_VBG digoxin_NN with_IN any_DT drug_NN that_WDT may_MD cause_VB a_DT significant_JJ deterioration_NN in_IN renal_JJ function_NN ,_, since_IN a_DT decline_NN in_IN glomerular_JJ filtration_NN or_CC tubular_JJ secretion_NN may_MD impair_VB the_DT excretion_NN of_IN digoxin_NN ._. Vasoconstrictors_NNP :_: D.H.E._NNP 45_CD -LRB-_-LRB- dihydroergotamine_NN mesylate_NN -RRB-_-RRB- Injection_NN ,_, USP_NN should_MD not_RB be_VB used_VBN with_IN peripheral_JJ vasoconstrictors_NNS because_IN the_DT combination_NN may_MD cause_VB synergistic_JJ elevation_NN of_IN blood_NN pressure_NN ._. Sumatriptan_NNP :_: Sumatriptan_NNP has_VBZ been_VBN reported_VBN to_TO cause_VB coronary_JJ artery_NN vasospasm_NN ,_, and_CC its_PRP$ effect_NN could_MD be_VB additive_JJ with_IN D.H.E._NNP 45_CD -LRB-_-LRB- dihydroergotamine_NN mesylate_NN -RRB-_-RRB- Injection_NN ,_, USP_NN ._. Sumatriptan_NNP and_CC D.H.E._NNP 45_CD -LRB-_-LRB- dihydroergotamine_NN mesylate_NN -RRB-_-RRB- Injection_NN ,_, USP_NN should_MD not_RB be_VB taken_VBN within_IN 24_CD hours_NNS of_IN each_DT other_JJ ._. Beta_NN Blockers_NNS :_: Although_IN the_DT results_NNS of_IN a_DT clinical_JJ study_NN did_VBD not_RB indicate_VB a_DT safe_JJ problem_NN associated_VBN with_IN the_DT administration_NN of_IN D.H.E._NNP 45_CD -LRB-_-LRB- dihydroergotamine_NN mesylate_NN -RRB-_-RRB- Injection_NN ,_, USP_NN to_TO subjects_NNS already_RB receiving_VBG propranolol_NN ,_, there_EX have_VBP been_VBN reports_NNS that_IN propranolol_NN may_MD potentiate_VB the_DT vasoconstrictive_JJ action_NN of_IN ergotamine_NN by_IN blocking_VBG the_DT vasodilating_VBG property_NN of_IN epinephrine_NN ._. Nicotine_NN :_: Nicotine_NN may_MD provoke_VB vasoconstriction_NN in_IN some_DT patients_NNS ,_, predisposing_VBG to_TO a_DT greater_JJR ischemic_JJ response_NN to_TO ergot_NN therapy_NN ._. Macrolide_NNP Antibiotics_NNP -LRB-_-LRB- e._FW g._FW erythromycin_NN and_CC troleandomycin_NN -RRB-_-RRB- :_: Agents_NNS of_IN the_DT ergot_NN alkaloid_NN class_NN ,_, of_IN which_WDT D.H.E._NNP 45_CD -LRB-_-LRB- dihydroergotamine_NN mesylate_NN -RRB-_-RRB- Injection_NN ,_, USP_NN is_VBZ a_DT member_NN ,_, have_VBP been_VBN shown_VBN to_TO interact_VB with_IN antibiotics_NNS of_IN the_DT macrolide_NN class_NN ,_, resulting_VBG in_IN increased_VBN plasma_NN levels_NNS of_IN unchanged_JJ alkaloids_NNS and_CC peripheral_JJ vasoconstriction_NN ._. Vasospastic_JJ reactions_NNS have_VBP been_VBN reported_VBN with_IN therapeutic_JJ doses_NNS of_IN ergotamine-containing_JJ drugs_NNS when_WRB co-administered_VBN with_IN these_DT antibiotics_NNS ._. SSRIs_NNS :_: Weakness_NN hyperreflexia_NN ,_, and_CC incoordination_NN have_VBP been_VBN reported_VBN rarely_RB when_WRB 5-HT1_NN agonists_NNS have_VBP been_VBN co-administered_VBN with_IN SSRIs_NNS -LRB-_-LRB- e._FW g._FW fluoxetine_NN ,_, fluvoxamine_NN ,_, paroxetine_NN ,_, sertraline_NN -RRB-_-RRB- ._. There_EX have_VBP been_VBN no_DT reported_VBN cases_NNS from_IN spontaneous_JJ reports_NNS of_IN drug_NN interaction_NN between_IN SSRIs_NNS and_CC D.H.E._NNP 45_CD -LRB-_-LRB- dihydroergotamine_NN mesylate_NN -RRB-_-RRB- Injection_NN ,_, USP_NN ._. Oral_JJ Contraceptives_NNS :_: The_DT effect_NN of_IN oral_JJ contraceptives_NNS on_IN the_DT pharmacokinetics_NNS of_IN D.H.E._NNP 45_CD -LRB-_-LRB- dihydroergotamine_NN mesylate_NN -RRB-_-RRB- Injection_NN ,_, USP_NNP has_VBZ not_RB been_VBN studied_VBN ._. Administration_NN of_IN thiazide_JJ diuretics_NNS to_TO hypoparathyroid_JJ patients_NNS who_WP are_VBP concurrently_RB being_VBG treated_VBN with_IN dihydrotachysterol_NN may_MD cause_VB hypercalcemia_NN ._. Due_JJ to_TO the_DT potential_NN for_IN additive_JJ effects_NNS ,_, caution_NN and_CC careful_JJ titration_NN are_VBP warranted_VBN in_IN patients_NNS receiving_VBG diltiazem_NN hydrochloride_NN concomitantly_RB with_IN other_JJ agents_NNS known_VBN to_TO affect_VB cardiac_JJ contractility_NN and/or_CC conduction_NN ._. Pharmacologic_JJ studies_NNS indicate_VBP that_IN there_EX may_MD be_VB additive_JJ effects_NNS in_IN prolonging_VBG AV_NN conduction_NN when_WRB using_VBG beta-blockers_NNS or_CC digitalis_NN concomitantly_RB with_IN Tiazac_NNP ._. As_IN with_IN all_DT drugs_NNS ,_, care_NN should_MD be_VB exercised_VBN when_WRB treating_VBG patients_NNS with_IN multiple_JJ medications_NNS ._. Diltiazem_NNP is_VBZ both_CC a_DT substrate_NN and_CC an_DT inhibitor_NN of_IN the_DT cytochrome_NN P-450_NN 3A4_NN enzyme_NN system_NN ._. Other_JJ drugs_NNS that_WDT are_VBP specific_JJ substrates_NNS ,_, inhibitors_NNS ,_, or_CC inducers_NNS of_IN the_DT enzyme_NN system_NN may_MD have_VB a_DT significant_JJ impact_NN on_IN the_DT efficacy_NN and_CC side_NN effect_NN profile_NN of_IN diltiazem_NN ._. Patients_NNS taking_VBG other_JJ drugs_NNS that_WDT are_VBP substrates_NNS of_IN CYP450_NN 3A4_NN ,_, especially_RB patients_NNS with_IN renal_JJ and/or_CC hepatic_JJ impairment_NN ,_, may_MD require_VB dosage_NN adjustment_NN when_WRB starting_VBG or_CC stopping_VBG concomitantly_RB administered_VBN diltiazem_NN in_IN order_NN to_TO maintain_VB optimum_JJ therapeutic_JJ blood_NN levels_NNS ._. Beta_NN Blocker_NN ._. Controlled_VBN and_CC uncontrolled_JJ domestic_JJ studies_NNS suggest_VBP that_IN concomitant_JJ use_NN of_IN diltiazem_NN hydrochloride_NN and_CC beta-blockers_NNS is_VBZ usually_RB well_RB tolerated_VBD ,_, but_CC available_JJ data_NNS are_VBP not_RB sufficient_JJ to_TO predict_VB the_DT effects_NNS of_IN concomitant_JJ treatment_NN in_IN patients_NNS with_IN left_JJ ventricular_JJ dysfunction_NN or_CC cardiac_JJ conduction_NN abnormalities_NNS ._. Administration_NN of_IN diltiazem_NN hydrochloride_NN concomitantly_RB with_IN propranolol_NN in_IN five_CD normal_JJ volunteers_NNS resulted_VBD in_IN increased_VBN propranolol_NN levels_NNS in_IN all_DT subjects_NNS and_CC bioavailability_NN of_IN propranolol_NN was_VBD increased_VBN approximately_RB 50_CD %_NN ._. In_FW vitro_FW ,_, propranolol_NN appears_VBZ to_TO be_VB displaced_VBN from_IN its_PRP$ binding_NN sites_NNS by_IN diltiazem_NN ._. If_IN combination_NN therapy_NN is_VBZ initiated_VBN or_CC withdrawn_VBN in_IN conjunction_NN with_IN propranolol_NN ,_, an_DT adjustment_NN in_IN the_DT propranolol_NN dose_NN may_MD be_VB warranted_VBN ._. Cimetidin_NNP ._. A_DT study_NN in_IN six_CD healthy_JJ volunteers_NNS has_VBZ shown_VBN a_DT significant_JJ increase_NN in_IN peak_JJ diltiazem_NN plasma_NN levels_NNS -LRB-_-LRB- 58_CD %_NN -RRB-_-RRB- and_CC AUC_NN -LRB-_-LRB- 53_CD %_NN -RRB-_-RRB- after_IN a_DT 1-week_JJ course_NN of_IN cimetidine_NN 1200_CD mg/day_NN and_CC a_DT single_JJ dose_NN of_IN diltiazem_NN 60mg_NN ._. Ranitidine_NN produced_VBD smaller_JJR ,_, nonsignificant_JJ increases_NNS ._. The_DT effect_NN may_MD be_VB mediated_VBN by_IN cimetidines_NNS known_VBN inhibition_NN of_IN hepatic_JJ cytochrome_NN P-450_NN ,_, the_DT enzyme_NN system_NN responsible_JJ for_IN the_DT first-pass_JJ metabolism_NN of_IN diltiazem_NN ._. Patients_NNS currently_RB receiving_VBG diltiazem_NN therapy_NN should_MD be_VB carefully_RB monitored_VBN for_IN a_DT change_NN in_IN pharmacological_JJ effect_NN when_WRB initiating_VBG and_CC discontinuing_VBG therapy_NN with_IN cimetidine_NN ._. An_DT adjustment_NN in_IN the_DT diltiazem_NN dose_NN may_MD be_VB warranted_VBN ._. Digitali_NNP ._. Administration_NN of_IN diltiazem_NN hydrochloride_NN with_IN digoxin_NN in_IN 24_CD healthy_JJ male_JJ subjects_NNS increased_VBN plasma_NN digoxin_NN concentrations_NNS approximately_RB 20_CD %_NN ._. Another_DT investigator_NN found_VBD no_DT increase_NN in_IN digoxin_NN levels_NNS in_IN 12_CD patients_NNS with_IN coronary_JJ artery_NN disease_NN ._. Since_IN there_EX have_VBP been_VBN conflicting_JJ results_NNS regarding_VBG the_DT effect_NN of_IN digoxin_NN levels_NNS ,_, it_PRP is_VBZ recommended_VBN that_IN digoxin_NN levels_NNS be_VB monitored_VBN when_WRB initiating_VBG ,_, adjusting_VBG ,_, and_CC discontinuing_VBG diltiazem_NN hydrochloride_NN therapy_NN to_TO avoid_VB possible_JJ over_IN -_: or_CC under-digitalization_NN ._. Anesthetic_NNP ._. The_DT depression_NN of_IN cardiac_JJ contractility_NN ,_, conductivity_NN ,_, and_CC automaticity_NN as_RB well_RB as_IN the_DT vascular_JJ dilation_NN associated_VBN with_IN anesthetics_NNS may_MD be_VB potentiated_VBN by_IN calcium_NN channel_NN blockers_NNS ._. When_WRB used_VBN concomitantly_RB ,_, anesthetics_NNS and_CC calcium_NN channel_NN blockers_NNS should_MD be_VB titrated_VBN carefully_RB ._. Cyclosporin_NN ._. A_DT pharmacokinetic_JJ interaction_NN between_IN diltiazem_NN and_CC cyclosporine_NN has_VBZ been_VBN observed_VBN during_IN studies_NNS involving_VBG renal_JJ and_CC cardiac_JJ transplant_NN patients_NNS ._. In_IN renal_JJ and_CC cardiac_JJ transplant_NN recipients_NNS ,_, a_DT reduction_NN of_IN cyclosporine_NN dose_NN ranging_VBG from_IN 15_CD %_NN to_TO 48_CD %_NN was_VBD necessary_JJ to_TO maintain_VB cyclosporine_NN trough_NN concentrations_NNS similar_JJ to_TO those_DT seen_VBN prior_JJ to_TO the_DT addition_NN of_IN diltiazem_NN ._. If_IN these_DT agents_NNS are_VBP to_TO be_VB administered_VBN concurrently_RB ,_, cyclosporine_NN concentrations_NNS should_MD be_VB monitored_VBN ,_, especially_RB when_WRB diltiazem_NN therapy_NN is_VBZ initiated_VBN ,_, adjusted_VBN ,_, or_CC discontinued_VBN ._. The_DT effect_NN of_IN cyclosporine_NN on_IN diltiazem_NN plasma_NN concentrations_NNS has_VBZ not_RB been_VBN evaluated_VBN ._. Carbamazepin_NNP ._. Concomitant_JJ administration_NN of_IN diltiazem_NN with_IN carbamazepine_NN has_VBZ been_VBN reported_VBN to_TO result_VB in_IN elevated_JJ serum_NN levels_NNS of_IN carbamazepine_NN -LRB-_-LRB- 40_CD %_NN to_TO 72_CD %_NN increase_NN -RRB-_-RRB- ,_, resulting_VBG in_IN toxicity_NN in_IN some_DT cases_NNS ._. Patients_NNS receiving_VBG these_DT drugs_NNS concurrently_RB should_MD be_VB monitored_VBN for_IN a_DT potential_JJ drug_NN interaction_NN ._. Benzodiazepine_NN ._. Studies_NNS showed_VBD that_IN diltiazem_NN increased_VBD the_DT AUC_NN of_IN midazolam_NN and_CC triazolam_NN by_IN 3-4_CD fold_NN and_CC the_DT Cmax_NN by_IN 2-fold_RB ,_, compared_VBN to_TO placebo_NN ._. The_DT elimination_NN half_NN life_NN of_IN midazolam_NN and_CC triazolam_NN also_RB increased_VBD -LRB-_-LRB- 1.5-2_CD .5_CD fold_NN -RRB-_-RRB- during_IN coadministration_NN with_IN diltiazem_NN ._. These_DT pharmacokinetic_JJ effects_NNS seen_VBN during_IN diltiazem_NN coadministration_NN can_MD result_VB in_IN increased_VBN clinical_JJ effects_NNS -LRB-_-LRB- e.g._FW ,_, prolonged_JJ sodation_NN -RRB-_-RRB- of_IN both_DT midazolam_NN and_CC triazolam_NN ._. Lovastati_NNP ._. In_IN a_DT ten-subject_JJ study_NN ,_, coadministration_NN of_IN diltiazem_NN -LRB-_-LRB- 120_CD mg_NN bid_NN -RRB-_-RRB- with_IN lovastatin_NN resulted_VBD in_IN a_DT 3-4_CD times_NNS increase_VBP in_IN mean_JJ lovastatin_NN AUC_NN and_CC Cmax_NN vs._CC lovastatin_NN alone_RB ._. no_DT change_NN in_IN pravastatin_NN AUC_NN and_CC Cmax_NN was_VBD observed_VBN during_IN diltiazem_NN coadministration_NN ._. Diltiazem_NNP plasma_NN levels_NNS were_VBD not_RB significantly_RB affected_VBN by_IN lovastatin_NN or_CC pravastatin_NN ._. Rifampi_NNP ._. Coadministration_NN of_IN rifampin_NN with_IN diltiazem_NN lowered_VBD the_DT diltiazem_NN plasma_NN concentrations_NNS to_TO undetectable_JJ levels_NNS ._. Coadministration_NN of_IN diltiazem_NN with_IN rifampin_NN or_CC any_DT known_JJ CYP3A4_NN inducer_NN should_MD be_VB avoided_VBN when_WRB possible_JJ ,_, and_CC alternative_JJ therapy_NN considered_VBN ._. Dimenhydrinate_NNP may_MD decrease_VB emetic_JJ response_NN to_TO apomorphine_NN ._. Oxytocin_NN or_CC other_JJ oxytocics_NNS -LRB-_-LRB- concurrent_JJ use_NN with_IN dinoprost_NN may_MD result_VB in_IN uterine_JJ hypertonus_NN ,_, possibly_RB causing_VBG uterine_JJ rupture_NN or_CC cervical_JJ laceration_NN ,_, especially_RB in_IN the_DT absence_NN of_IN adequate_JJ cervical_JJ dilatation_NN ._. although_IN combinations_NNS are_VBP sometimes_RB used_VBN for_IN therapeutic_JJ advantage_NN ,_, when_WRB used_VBN concurrently_RB ,_, patient_NN should_MD be_VB closely_RB monitored_VBN ._. PROSTIN_NNP E2_NN may_MD augment_VB the_DT activity_NN of_IN other_JJ oxytocic_JJ drugs_NNS ._. Concomitant_JJ use_NN with_IN other_JJ oxytocic_JJ agents_NNS is_VBZ not_RB recommended_VBN ._. Diphenhydramine_NN hydrochloride_NN has_VBZ additive_JJ effects_NNS with_IN alcohol_NN and_CC other_JJ CNS_NN depressants_NNS -LRB-_-LRB- hypnotics_NNS ,_, sedatives_NNS ,_, tranquilizers_NNS ,_, etc_FW -RRB-_-RRB- ._. MAO_NN inhibitors_NNS prolong_VB and_CC intensify_VB the_DT anticholinergic_JJ -LRB-_-LRB- drying_VBG -RRB-_-RRB- effects_NNS of_IN antihistamines_NNS ._. CNS_NN depression_NN producing_VBG medications_NNS -_: concurrent_JJ use_NN may_MD potentiate_VB the_DT effects_NNS of_IN either_CC these_DT medications_NNS or_CC diphenidol_NN ._. anticholinergics_NNS or_CC other_JJ medications_NNS with_IN anticholinergic_JJ activity_NN -_: anticholinergic_JJ effects_NNS may_MD be_VB potentiated_VBN when_WRB these_DT medications_NNS are_VBP used_VBN concurrently_RB with_IN diphenidol_NN ._. apomorphine_NN -_: prior_RB ingestion_NN of_IN diphenidol_NN may_MD decrease_VB the_DT emetic_JJ response_NN to_TO apomorphine_NN in_IN the_DT treatment_NN of_IN poisoning_NN ._. Known_VBN drug_NN interactions_NNS include_VBP barbiturates_NNS ,_, tranquilizers_NNS ,_, and_CC alcohol_NN ._. Diphenoxylate_NNP HCl_NN and_CC atropine_NN sulfate_NN may_MD interact_VB with_IN MAO_NN inhibitors_NNS In_IN studies_NNS with_IN male_JJ rats_NNS ,_, diphenoxylate_NN hydrochloride_NN was_VBD found_VBN to_TO inhibit_VB the_DT hepatic_JJ microsomal_JJ enzyme_NN system_NN at_IN a_DT dose_NN of_IN 2_CD mg/kg/day_NN ._. Therefore_RB ,_, diphenoxylate_NN has_VBZ the_DT potential_JJ to_TO prolong_VB the_DT biological_JJ half-lives_NNS of_IN drugs_NNS for_IN which_WDT the_DT rate_NN of_IN elimination_NN is_VBZ dependent_JJ on_IN the_DT microsomal_JJ drug_NN metabolizing_VBG enzyme_NN system_NN ._. This_DT drug_NN may_MD interact_VB with_IN alcohol_NN or_CC other_JJ CNS_NN depressants_NNS -LRB-_-LRB- may_MD potentiate_VB the_DT CNS_NN depressant_NN effects_NNS of_IN either_CC these_DT medications_NNS or_CC antihistamines_NNS -RRB-_-RRB- ,_, anticholinergics_NNS or_CC other_JJ medications_NNS with_IN anticholinergic_JJ activity_NN -LRB-_-LRB- anticholinergic_JJ effects_NNS may_MD be_VB potentiated_VBN when_WRB these_DT medications_NNS are_VBP used_VBN concurrently_RB with_IN antihistamines_NNS -RRB-_-RRB- ,_, and_CC monoamine_NN oxidase_NN -LRB-_-LRB- MAO_NN -RRB-_-RRB- inhibitors_NNS -LRB-_-LRB- concurrent_JJ use_NN with_IN antihistamines_NNS may_MD prolong_VB and_CC intensify_VB the_DT anticholinergic_JJ and_CC CNS_NN depressant_NN effects_NNS of_IN antihistamines_NNS -RRB-_-RRB- ._. No_DT pharmacokinetic_JJ drug-drug_NN interaction_NN studies_NNS were_VBD conducted_VBN with_IN PERSANTINE_NN -LRB-_-LRB- dipyridamole_NN USP_NN -RRB-_-RRB- Tablets_NNS ._. The_DT following_VBG information_NN was_VBD obtained_VBN from_IN the_DT literature_NN ._. Adenosine_NN :_: Dipyridamole_NNP has_VBZ been_VBN reported_VBN to_TO increase_VB the_DT plasma_NN levels_NNS and_CC cardiovascular_JJ effects_NNS of_IN adenosine_NN ._. Adjustment_NNP of_IN adenosine_NN dosage_NN may_MD be_VB necessary_JJ ._. Cholinesterase_NNP Inhibitors_NNS :_: Dipyridamole_NNP may_MD counteract_VB the_DT anticholinesterase_NN effect_NN of_IN cholinesterase_NN inhibitors_NNS ,_, thereby_RB potentially_RB aggravating_JJ myasthenia_NN gravis_NN ._. Terfenadine_NNP :_: In_IN a_DT prospective_JJ study_NN involving_VBG six-healthy-male_JJ volunteers_NNS ,_, dirithromycin_NN did_VBD not_RB affect_VB the_DT metabolism_NN of_IN terfenadine_NN ._. These_DT six_CD volunteers_NNS received_VBD terfenadine_NN alone_RB -LRB-_-LRB- 60_CD mg_NN twice_RB daily_RB -RRB-_-RRB- for_IN 8_CD days_NNS ,_, followed_VBN by_IN terfenadine_NN in_IN combination_NN with_IN dirithromycin_NN -LRB-_-LRB- 500_CD mg_NN once_RB daily_JJ -RRB-_-RRB- for_IN 10_CD days_NNS ._. -LRB-_-LRB- Both_CC drugs_NNS were_VBD thus_RB dosed_VBN to_TO steady_JJ state_NN ._. -RRB-_-RRB- ._. The_DT pharmacokinetics_NNS of_IN terfenadine_NN and_CC its_PRP$ acid_NN metabolite_NN and_CC the_DT electrocardiographic_JJ QT_NN c_NN interval_NN were_VBD measured_VBN during_IN both_DT periods_NNS :_: with_IN terfenadine_NN alone_RB ,_, and_CC with_IN terfenadine_NN plus_CC dirithromycin_NN ._. In_IN five_CD men_NNS ,_, terfenadine_NN levels_NNS were_VBD undetectable_JJ -LRB-_-LRB- 5_CD ng/mL_NN -RRB-_-RRB- throughout_IN the_DT study_NN ._. in_IN one_CD man_NN ,_, the_DT C_NN max_NN of_IN terfenadine_NN was_VBD 8.1_CD ng/mL_NN with_IN terfenadine_NN alone_RB and_CC 7.2_CD ng/mL_NN with_IN terfenadine_NN plus_CC dirithromycin_NN ._. The_DT mean_NN C_NN max_NN ,_, T_NN max_NN ,_, and_CC AUC_NN of_IN the_DT acid_NN metabolite_NN of_IN terfenadine_NN were_VBD not_RB significantly_RB changed_VBD ._. The_DT mean_NN QT_NN c_NN interval_NN -LRB-_-LRB- msec_NN -RRB-_-RRB- was_VBD 369_CD with_IN terfenadine_NN alone_RB and_CC 367_CD with_IN terfenadine_NN plus_CC dirithromycin_NN ._. Also_RB ,_, in_FW vitro_FW experiments_NNS demonstrated_VBD a_DT lack_NN of_IN interaction_NN between_IN dirithromycin_NN and_CC terfenadine_NN ._. Thus_RB ,_, the_DT interaction_NN observed_VBN between_IN erythromycin_NN and_CC terfenadine_NN is_VBZ not_RB expected_VBN for_IN dirithromycin_NN ._. Serious_JJ cardiac_JJ dysrhythmias_NNS ,_, some_DT resulting_VBG in_IN death_NN ,_, have_VBP occurred_VBN in_IN patients_NNS receiving_VBG terfenadine_NN concomitantly_RB with_IN other_JJ macrolide_NN antibiotics_NNS ._. In_IN addition_NN ,_, most_JJS macrolides_NNS are_VBP contraindicated_VBN in_IN patients_NNS receiving_VBG terfenadine_NN therapy_NN who_WP have_VBP pre-existing_JJ cardiac_JJ abnormalities_NNS -LRB-_-LRB- arrhythmia_NN ,_, bradycardia_NN ,_, QT_NN c_NN interval_NN prolongation_NN ,_, ischemic_JJ heart_NN disease_NN ,_, congestive_JJ heart_NN failure_NN ,_, etc._FW -RRB-_-RRB- or_CC electrolyte_NN disturbances_NNS ._. Theophylline_NNP :_: Following_VBG co-administration_NN of_IN two_CD 250-mg_JJ dirithromycin_NN tablets_NNS administered_VBN once_RB daily_RB with_IN 200-mg_JJ theophylline_NN tablets_NNS administered_VBN twice_RB daily_RB for_IN 10_CD days_NNS to_TO 14_CD healthy_JJ subjects_NNS ,_, the_DT steady-state_JJ plasma_NN concentration_NN of_IN theophylline_NN was_VBD not_RB significantly_RB altered_VBN ._. In_IN general_JJ ,_, most_JJS patients_NNS treated_VBN with_IN dirithromycin_NN who_WP are_VBP receiving_VBG concomitant_JJ theophylline_NN therapy_NN may_MD not_RB require_VB empiric_JJ adjustment_NN of_IN theophylline_NN dosage_NN or_CC monitoring_NN of_IN theophylline_NN plasma_NN concentrations_NNS ._. However_RB ,_, theophylline_NN plasma_NN concentrations_NNS should_MD be_VB monitored_VBN ,_, with_IN dosage_NN adjustment_NN as_IN appropriate_JJ ,_, in_IN patients_NNS whose_WP$ pulmonary_JJ disease_NN requires_VBZ maintaining_VBG a_DT given_VBN theophylline_NN plasma_NN concentration_NN for_IN optimal_JJ pulmonary_JJ function_NN or_CC in_IN patients_NNS with_IN theophylline_NN concentrations_NNS at_IN the_DT higher_JJR end_NN of_IN the_DT therapeutic_JJ range_NN ._. Antacids_NNS or_CC H_NN 2_CD receptor_NN antagonists_NNS :_: When_WRB dirithromycin_NN is_VBZ administered_VBN immediately_RB following_VBG antacids_NNS or_CC H_NN 2_CD -_: receptor_NN antagonists_NNS ,_, the_DT absorption_NN of_IN dirithromycin_NN is_VBZ slightly_RB enhanced_VBN ._. The_DT following_VBG drug_NN interactions_NNS have_VBP been_VBN reported_VBN with_IN erythromycin_NN products_NNS ._. It_PRP is_VBZ presently_RB not_RB known_VBN whether_IN these_DT same_JJ drug_NN interactions_NNS occur_VBP with_IN dirithromycin_NN ._. Until_IN further_JJ data_NNS are_VBP available_JJ regarding_VBG the_DT potential_JJ interaction_NN of_IN dirithromycin_NN with_IN these_DT compounds_NNS ,_, caution_NN should_MD be_VB used_VBN during_IN coadministration_NN ._. Triazolam_NNP :_: Erythromycin_NNP has_VBZ been_VBN reported_VBN to_TO decrease_VB the_DT clearance_NN of_IN triazolam_NN and_CC ,_, thus_RB ,_, may_MD increase_VB the_DT pharmacologic_JJ effect_NN of_IN triazolam_NN ._. Digoxin_NNP :_: Concomitant_JJ administration_NN of_IN erythromycin_NN and_CC digoxin_NN has_VBZ been_VBN reported_VBN to_TO result_VB in_IN elevated_JJ digoxin_NN serum_NN levels_NNS ._. Anticoagulants_NNPS :_: There_EX have_VBP been_VBN reports_NNS of_IN increased_VBN anticoagulant_JJ effects_NNS when_WRB erythromycin_NN and_CC oral_JJ anticoagulants_NNS were_VBD used_VBN concomitantly_RB ._. Increased_VBN anticoagulation_JJ effects_NNS due_JJ to_TO a_DT drug_NN interaction_NN with_IN erythromycin_NN may_MD be_VB more_RBR pronounced_JJ in_IN the_DT elderly_JJ ._. Ergotamine_NNP :_: Concurrent_JJ use_NN of_IN erythromycin_NN and_CC ergotamine_NN or_CC dihydroergotamine_NN has_VBZ been_VBN associated_VBN in_IN some_DT patients_NNS with_IN acute_JJ ergot_NN toxicity_NN characterized_VBN by_IN severe_JJ peripheral_JJ vasospasm_NN and_CC dysesthesia_NN ._. Other_JJ drugs_NNS Drug_NN interactions_NNS have_VBP been_VBN reported_VBN with_IN concomitant_JJ administration_NN of_IN erythromycin_NN and_CC other_JJ medications_NNS ,_, including_VBG cyclosporine_NN ,_, hexobarbital_NN ,_, carbamazepine_NN ,_, alfentanil_NN ,_, disopyramide_NN ,_, phenytoin_NN ,_, bromocriptine_NN ,_, valproate_NN ,_, astemizole_NN ,_, and_CC lovastatin_NN ._. If_IN phenytoin_NN or_CC other_JJ hepatic_JJ enzyme_NN inducers_NNS are_VBP taken_VBN concurrently_RB with_IN Norpace_NNP or_CC Norpace_NNP CR_NN ,_, lower_JJR plasma_NN levels_NNS of_IN disopyramide_NN may_MD occur_VB ._. Monitoring_NN of_IN disopyramide_NN plasma_NN levels_NNS is_VBZ recommended_VBN in_IN such_JJ concurrent_JJ use_NN to_TO avoid_VB ineffective_JJ therapy_NN ._. Other_JJ antiarrhythmic_JJ drugs_NNS -LRB-_-LRB- eg_FW ,_, quinidine_NN ,_, procainamide_NN ,_, lidocaine_NN ,_, propranolol_NN -RRB-_-RRB- have_VBP occasionally_RB been_VBN used_VBN concurrently_RB with_IN Norpace_NNP ._. Excessive_JJ widening_NN of_IN the_DT QRS_NNP complex_NN and/or_CC prolongation_NN of_IN the_DT Q-T_JJ interval_NN may_MD occur_VB in_IN these_DT situations_NNS ._. In_IN healthy_JJ subjects_NNS ,_, no_DT significant_JJ drug-drug_JJ interaction_NN was_VBD observed_VBN when_WRB Norpace_NNP was_VBD coadministered_VBN with_IN either_CC propranolol_NN or_CC diazepam_NN ._. Concomitant_JJ administration_NN of_IN Norpace_NNP and_CC quinidine_NN resulted_VBD in_IN slight_JJ increases_NNS in_IN plasma_NN disopyramide_NN levels_NNS and_CC slight_JJ decreases_NNS in_IN plasma_NN quinidine_NN levels_NNS ._. Norpace_NNP does_VBZ not_RB increase_VB serum_NN digoxin_NN levels_NNS ._. Patients_NNS taking_VBG disopyramide_JJ phosphate_NN and_CC erythromycin_NN concomitantly_RB may_MD develop_VB increased_VBN serum_NN concentrations_NNS of_IN disopyramide_NN resulting_VBG in_IN excessive_JJ widening_NN of_IN the_DT QRS_NNP complex_NN and/or_CC prolongation_NN of_IN the_DT Q-T_JJ interval_NN ._. Patients_NNS taking_VBG disopyramide_JJ phosphate_NN and_CC hepatic_JJ enzyme_NN inhibitors_NNS concomitantly_RB should_MD be_VB closely_RB monitored_VBN ._. Until_IN data_NNS on_IN possible_JJ interactions_NNS between_IN verapamil_NN and_CC disopyramide_NN phosphate_NN are_VBP obtained_VBN ,_, disopyramide_NN should_MD not_RB be_VB administered_VBN within_IN 48_CD hours_NNS before_IN or_CC 24_CD hours_NNS after_IN verapamil_NN administration_NN ._. Disulfiram_NNP appears_VBZ to_TO decrease_VB the_DT rate_NN at_IN which_WDT certain_JJ drugs_NNS are_VBP metabolized_VBN and_CC therefore_RB may_MD increase_VB the_DT blood_NN levels_NNS and_CC the_DT possibility_NN of_IN clinical_JJ toxicity_NN of_IN drugs_NNS given_VBN concomitantly_RB ._. DISULFIRAM_NNP SHOULD_MD BE_VB USED_JJ WITH_IN CAUTION_NN IN_IN THOSE_DT PATIENTS_NNS REVEIVING_VBG PHENYTOIN_NN AND_CC ITS_NNS CONGENERS_NNS ._. SINCE_IN THE_DT CONCOMITANT_JJ ADMINISTRATION_NN OF_IN THESE_NN TWO_CD DRUGS_NNS CAN_JJ LEAD_NN TO_TO PHENYTOIN_NNP INTOXICATION_NNP ,_, PRIOR_NNP TO_TO ADMINISTERING_NNP DISULFIRAM_NNP TO_TO A_DT PATIENT_NN ON_IN PHENYTOIN_NNP THERAPY_NNP ,_, A_NNP BASELINE_NNP PHENYTOIN_NNP SERUM_NNP LEVEL_NNP SHOULD_MD BE_VB OBTAINED_NNP ._. SUBSEQUENT_JJ TO_TO INITIATION_NNP OF_IN DISULFIRAM_NNP THERAPY_NNP ._. SERUM_NN LEVELS_NNS OF_IN PHENYTOIN_NNP SHOULD_MD BE_VB DETERMINED_VBN ON_IN DIFFERENT_JJ DAYS_NNS FOR_IN EVIDENCE_NNS OF_IN AN_DT INCREASE_NN OR_NN FOR_IN A_DT CONTINUING_NNP RISE_NNP IN_IN LEVELS_NNP ._. INCREASED_VBN PHENYTOIN_NNP LEVELS_NNP SHOULD_MD BE_VB TREATED_VBN WITH_IN APPROPRIATE_JJ DOSAGE_NN ADJUSTMENT_NN ._. It_PRP may_MD be_VB necessary_JJ to_TO adjust_VB the_DT dosage_NN of_IN oral_JJ anticoagulants_NNS upon_IN beginning_VBG or_CC stopping_VBG disulfiram_NN ._. since_IN disulfiram_NN may_MD prolong_VB prothrombin_NN time_NN ._. Patients_NNS taking_VBG isoniazid_NN when_WRB disulfiram_NN is_VBZ given_VBN should_MD be_VB observed_VBN for_IN the_DT appearance_NN of_IN unsteady_JJ gait_NN or_CC marked_JJ changes_NNS in_IN mental_JJ status_NN ._. the_DT disulfiram_NN should_MD be_VB discontinued_VBN if_IN such_JJ signs_NNS appear_VBP ._. In_IN rats_NNS ,_, simultaneous_JJ ingestion_NN of_IN disulfiram_NN and_CC nitrite_NN in_IN the_DT diet_NN for_IN 78_CD weeks_NNS has_VBZ been_VBN reported_VBN to_TO cause_VB tumors_NNS ,_, and_CC it_PRP has_VBZ been_VBN suggested_VBN that_IN disulfiram_NN may_MD react_VB with_IN nitrites_NNS in_IN the_DT rat_NN stomach_NN to_TO form_VB a_DT nitrosamine_NN ,_, which_WDT is_VBZ tumorigenic_JJ ._. Disulfiram_NNP alone_RB in_IN the_DT rat_NN s_VBZ diet_NN did_VBD not_RB lead_VB to_TO such_JJ tumors_NNS ._. The_DT relevance_NN of_IN this_DT finding_NN to_TO humans_NNS is_VBZ not_RB known_VBN at_IN this_DT time_NN ._. Animal_NN studies_NNS indicate_VBP that_IN dobutamine_NN may_MD be_VB ineffective_JJ if_IN the_DT patient_NN has_VBZ recently_RB received_VBN a_DT b-blocking_NN drug_NN ._. In_IN such_PDT a_DT case_NN ,_, the_DT peripheral_JJ vascular_JJ resistance_NN may_MD increase_VB ._. Preliminary_JJ studies_NNS indicate_VBP that_IN the_DT concomitant_JJ use_NN of_IN dobutamine_NN and_CC nitroprusside_JJ results_NNS in_IN a_DT higher_JJR cardiac_JJ output_NN and_CC ,_, usually_RB ,_, a_DT lower_JJR pulmonary_JJ wedge_NN pressure_NN than_IN when_WRB either_CC drug_NN is_VBZ used_VBN alone_RB ._. There_EX was_VBD no_DT evidence_NN of_IN drug_NN interactions_NNS in_IN clinical_JJ studies_NNS in_IN which_WDT dobutamine_NN was_VBD administered_VBN concurrently_RB with_IN other_JJ drugs_NNS ,_, including_VBG digitalis_NN preparations_NNS ,_, furosemide_NN ,_, spironolactone_NN ,_, lidocaine_NN ,_, glyceryl_NN trinitrate_NN ,_, isosorbide_NN dinitrate_NN ,_, morphine_NN ,_, atropine_NN ,_, heparin_NN ,_, protamine_NN ,_, potassium_NN chloride_NN ,_, folic_JJ acid_NN ,_, and_CC acetaminophen_NN ._. There_EX have_VBP been_VBN no_DT formal_JJ clinical_JJ studies_NNS to_TO evaluate_VB the_DT drug_NN interactions_NNS of_IN TAXOTERE_NN with_IN other_JJ medications_NNS ._. In_FW vitro_FW studies_NNS have_VBP shown_VBN that_IN the_DT metabolism_NN of_IN docetaxel_NN may_MD be_VB modified_VBN by_IN the_DT concomitant_JJ administration_NN of_IN compounds_NNS that_WDT induce_VBP ,_, inhibit_VBP ,_, or_CC are_VBP metabolized_VBN by_IN cytochrome_NN P450_NN 3A4_NN ,_, such_JJ as_IN cyclosporine_NN ,_, terfenadine_NN ,_, ketoconazole_NN ,_, erythromycin_NN ,_, and_CC troleandomycin_NN ._. Caution_NN should_MD be_VB exercised_VBN with_IN these_DT drugs_NNS when_WRB treating_VBG patients_NNS receiving_VBG TAXOTERE_NN as_IN there_EX is_VBZ a_DT potential_NN for_IN a_DT significant_JJ interaction_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS None_NN known_VBN ._. Drug-Drug_NNP Interactions_NNS Cimetidine_NNP :_: Concomitant_JJ use_NN of_IN cimetidine_NN is_VBZ contraindicated_VBN ._. Cimetidine_NN at_IN 400_CD mg_NN BID_NNP -LRB-_-LRB- the_DT usual_JJ prescription_NN dose_NN -RRB-_-RRB- co-administered_JJ with_IN TIKOSYN_NN -LRB-_-LRB- 500_CD mcg_NN BID_NNP -RRB-_-RRB- for_IN 7_CD days_NNS has_VBZ been_VBN shown_VBN to_TO increase_VB dofetilide_NN plasma_NN levels_NNS by_IN 58_CD %_NN ._. Cimetidine_NN at_IN doses_NNS of_IN 100_CD mg_NN BID_NNP -LRB-_-LRB- OTC_NNP dose_NN -RRB-_-RRB- resulted_VBD in_IN a_DT 13_CD %_NN increase_NN in_IN dofetilide_NN plasma_NN levels_NNS -LRB-_-LRB- 500_CD mcg_NN single_JJ dose_NN -RRB-_-RRB- ._. No_DT studies_NNS have_VBP been_VBN conducted_VBN at_IN intermediate_JJ doses_NNS of_IN cimetidine_NN ._. If_IN a_DT patient_NN requires_VBZ TIKOSYN_NNP and_CC anti-ulcer_JJ therapy_NN ,_, it_PRP is_VBZ suggested_VBN that_IN omeprazole_NN ,_, ranitidine_NN ,_, or_CC antacids_NNS -LRB-_-LRB- aluminum_NN and_CC magnesium_NN hydroxides_NNS -RRB-_-RRB- be_VB used_VBN as_IN alternatives_NNS to_TO cimetidine_NN ,_, as_IN these_DT agents_NNS have_VBP no_DT effect_NN on_IN the_DT pharmacokinetic_JJ profile_NN of_IN TIKOSYN_NNP ._. Verapamil_NNP :_: Concomitant_JJ use_NN of_IN verapamil_NN is_VBZ contraindicated_VBN ._. Co-administration_NN of_IN TIKOSYN_NN with_IN verapamil_NN resulted_VBD in_IN increases_NNS in_IN dofetilide_NN peak_NN plasma_NN levels_NNS of_IN 42_CD %_NN ,_, although_IN overall_JJ exposure_NN to_TO dofetilide_NN was_VBD not_RB significantly_RB increased_VBN ._. In_IN an_DT analysis_NN of_IN the_DT supraventricular_JJ arrhythmia_NN and_CC DIAMOND_NN patient_NN populations_NNS ,_, the_DT concomitant_JJ administration_NN of_IN verapamil_NN with_IN dofetilide_NN was_VBD associated_VBN with_IN a_DT higher_JJR occurrence_NN of_IN torsade_FW de_FW pointes_FW ._. Ketoconazole_NN :_: Concomitant_JJ use_NN of_IN ketoconazole_NN is_VBZ contraindicated_VBN ._. Ketoconazole_NN at_IN 400_CD mg_NN daily_JJ -LRB-_-LRB- the_DT maximum_NN approved_VBD prescription_NN dose_NN -RRB-_-RRB- co-administered_JJ with_IN TIKOSYN_NN -LRB-_-LRB- 500_CD mcg_NN BID_NNP -RRB-_-RRB- for_IN 7_CD days_NNS has_VBZ been_VBN shown_VBN to_TO increase_VB dofetilide_NN Cmax_NN by_IN 53_CD %_NN in_IN males_NNS and_CC 97_CD %_NN in_IN females_NNS ,_, and_CC AUC_NN by_IN 41_CD %_NN in_IN males_NNS and_CC 69_CD %_NN in_IN females_NNS ._. Trimethoprim_NNP Alone_RB or_CC in_IN Combination_NN with_IN Sulfamethoxazole_NNP :_: Concomitant_JJ use_NN of_IN trimethoprim_NN alone_RB or_CC in_IN combination_NN with_IN sulfamethoxazole_NN is_VBZ contraindicated_VBN ._. Hydrochlorothiazide_NN -LRB-_-LRB- HCTZ_NN -RRB-_-RRB- Alone_RB or_CC in_IN Combination_NN with_IN Triamterene_NN :_: Concomitant_JJ use_NN of_IN HCTZ_NN alone_RB or_CC in_IN combination_NN with_IN triamterene_NN is_VBZ contraindicated_VBN ._. HCTZ_NN 50_CD mg_NN QD_NN or_CC HCTZ/triamterene_NN 50/100_CD mg_NN QD_NN was_VBD co-administered_VBN with_IN TIKOSYN_NN -LRB-_-LRB- 500_CD mcg_NN BID_NNP -RRB-_-RRB- for_IN 5_CD days_NNS -LRB-_-LRB- following_VBG 2_CD days_NNS of_IN diuretic_JJ use_NN at_IN half_NN dose_NN -RRB-_-RRB- ._. In_IN patients_NNS receiving_VBG HCTZ_NN alone_RB ,_, dofetilide_NN AUC_NN increased_VBN by_IN 27_CD %_NN and_CC Cmax_NN by_IN 21_CD %_NN ._. However_RB ,_, the_DT pharmacodynamic_JJ effect_NN increased_VBN by_IN 197_CD %_NN -LRB-_-LRB- QTc_NN increase_NN over_IN time_NN -RRB-_-RRB- and_CC by_IN 95_CD %_NN -LRB-_-LRB- maximum_NN QTc_NN increase_NN -RRB-_-RRB- ._. However_RB ,_, the_DT pharmacodynamic_JJ effect_NN increased_VBN by_IN 190_CD %_NN -LRB-_-LRB- QTc_NN increase_NN over_IN time_NN -RRB-_-RRB- and_CC by_IN 84_CD %_NN -LRB-_-LRB- Maximum_NNP QTc_NNP increase_NN -RRB-_-RRB- ._. The_DT pharmacodynamic_JJ effects_NNS can_MD be_VB explained_VBN by_IN a_DT combination_NN of_IN the_DT increase_NN in_IN dofetilide_NN exposure_NN and_CC the_DT reductions_NNS in_IN serum_NN potassium_NN ._. In_IN the_DT DIAMOND_NN trials_NNS ,_, 1252_CD patients_NNS were_VBD treated_VBN with_IN TIKOSYN_NN and_CC diuretics_NNS concomitantly_RB of_IN whom_WP 493_CD died_VBD compared_VBN to_TO 508_CD deaths_NNS among_IN the_DT 1248_CD patients_NNS receiving_VBG placebo_NN and_CC diuretics_NNS ._. Of_IN the_DT 229_CD patients_NNS who_WP had_VBD potassium_NN depleting_VBG diuretics_NNS added_VBD to_TO their_PRP$ concomitant_JJ medications_NNS in_IN the_DT DIAMOND_NN trials_NNS ,_, the_DT patients_NNS on_IN TIKOSYN_NNP had_VBD a_DT non-significantly_JJ reduced_VBN relative_JJ risk_NN for_IN death_NN of_IN 0.68_CD -LRB-_-LRB- 95_CD %_NN CI_NN 0.376_CD ,_, 1.230_CD -RRB-_-RRB- ._. Potential_JJ Drug_NN Interactions_NNS Dofetilide_NNP is_VBZ eliminated_VBN in_IN the_DT kidney_NN by_IN cationic_JJ secretion_NN ._. Inhibitors_NNS of_IN renal_JJ cationic_JJ secretion_NN are_VBP contraindicated_VBN with_IN TIKOSYN_NN ._. In_IN addition_NN ,_, drugs_NNS that_WDT are_VBP actively_RB secreted_VBN via_IN this_DT route_NN -LRB-_-LRB- e.g._FW ,_, triamterene_NN ,_, metformin_NN and_CC amiloride_NN -RRB-_-RRB- should_MD be_VB co-administered_VBN with_IN care_NN as_IN they_PRP might_MD increase_VB dofetilide_NN levels_NNS ._. Dofetilide_NNP is_VBZ metabolized_VBN to_TO a_DT small_JJ extent_NN by_IN the_DT CYP3A4_NN isoenzyme_NN of_IN the_DT cytochrome_NN P450_NN system_NN ._. Inhibitors_NNS of_IN the_DT CYP3A4_NN isoenzyme_NN could_MD increase_VB systemic_JJ dofetilide_NN exposure_NN ._. Inhibitors_NNS of_IN this_DT isoenzyme_NN -LRB-_-LRB- e.g._FW ,_, macrolide_NN antibiotics_NNS ,_, azole_JJ antifungal_JJ agents_NNS ,_, protease_NN inhibitors_NNS ,_, serotonin_NN reuptake_NN inhibitors_NNS ,_, amiodarone_NN ,_, cannabinoids_NNS ,_, diltiazem_NN ,_, grapefruit_NN juice_NN ,_, nefazadone_NN ,_, norfloxacin_NN ,_, quinine_NN ,_, zafirlukast_NN -RRB-_-RRB- should_MD be_VB cautiously_RB coadministered_VBN with_IN TIKOSYN_NN as_IN they_PRP can_MD potentially_RB increase_VB dofetilide_NN levels_NNS ._. Dofetilide_NNP is_VBZ not_RB an_DT inhibitor_NN of_IN CYP3A4_NN nor_CC of_IN other_JJ cytochrome_NN P450_NN isoenzymes_NNS -LRB-_-LRB- e.g._FW ,_, CYP2C9_NN ,_, CYP2D6_NN -RRB-_-RRB- and_CC is_VBZ not_RB expected_VBN to_TO increase_VB levels_NNS of_IN drugs_NNS metabolized_VBN by_IN CYP3A4_NN ._. Other_JJ Drug_NN Interaction_NN Information_NN Digoxin_NNP :_: Studies_NNS in_IN healthy_JJ volunteers_NNS have_VBP shown_VBN that_IN TIKOSYN_NN does_VBZ not_RB affect_VB the_DT pharmacokinetics_NNS of_IN digoxin_NN ._. In_IN patients_NNS ,_, the_DT concomitant_JJ administration_NN of_IN digoxin_NN with_IN dofetilide_NN was_VBD associated_VBN with_IN a_DT higher_JJR occurrence_NN of_IN torsade_FW de_FW pointes_FW ._. It_PRP is_VBZ not_RB clear_JJ whether_IN this_DT represents_VBZ an_DT interaction_NN with_IN TIKOSYN_NN or_CC the_DT presence_NN of_IN more_RBR severe_JJ structural_JJ heart_NN disease_NN in_IN patients_NNS on_IN digoxin_NN ._. structural_JJ heart_NN disease_NN is_VBZ a_DT known_JJ risk_NN factor_NN for_IN arrhythmia_NN ._. No_DT increase_NN in_IN mortality_NN was_VBD observed_VBN in_IN patients_NNS taking_VBG digoxin_NN as_IN concomitant_JJ medication_NN ._. Other_JJ Drugs_NNS :_: In_IN healthy_JJ volunteers_NNS ,_, amlodipine_NN ,_, phenytoin_NN ,_, glyburide_NN ,_, ranitidine_NN ,_, omeprazole_NN ,_, hormone_NN replacement_NN therapy_NN -LRB-_-LRB- a_DT combination_NN of_IN conjugated_VBN estrogens_NNS and_CC medroxyprogesterone_NN -RRB-_-RRB- ,_, antacid_NN -LRB-_-LRB- aluminum_NN and_CC magnesium_NN hydroxides_NNS -RRB-_-RRB- and_CC theophylline_NN did_VBD not_RB affect_VB the_DT pharmacokinetics_NNS of_IN TIKOSYN_NN ._. In_IN addition_NN ,_, studies_NNS in_IN healthy_JJ volunteers_NNS have_VBP shown_VBN that_IN TIKOSYN_NN does_VBZ not_RB affect_VB the_DT pharmacokinetics_NNS or_CC pharmacodynamics_NNS of_IN warfarin_NN ,_, or_CC the_DT pharmacokinetics_NNS of_IN propranolol_NN -LRB-_-LRB- 40_CD mg_NN twice_RB daily_RB -RRB-_-RRB- ,_, phenytoin_NN ,_, theophylline_NN ,_, or_CC oral_JJ contraceptives_NNS ._. Population_NNP pharmacokinetic_JJ analyses_NNS were_VBD conducted_VBN on_IN plasma_NN concentration_NN data_NNS from_IN 1445_CD patients_NNS in_IN clinical_JJ trials_NNS to_TO examine_VB the_DT effects_NNS of_IN concomitant_JJ medications_NNS on_IN clearance_NN or_CC volume_NN of_IN distribution_NN of_IN dofetilide_NN ._. Concomitant_JJ medications_NNS were_VBD grouped_VBN as_IN ACE_NN inhibitors_NNS ,_, oral_JJ anticoagulants_NNS ,_, calcium_NN channel_NN blockers_NNS ,_, beta_NN blockers_NNS ,_, cardiac_JJ glycosides_NNS ,_, inducers_NNS of_IN CYP3A4_NN ,_, substrates_NNS and_CC inhibitors_NNS of_IN CYP3A4_NN ,_, substrates_NNS and_CC inhibitors_NNS of_IN P-glycoprotein_NN ,_, nitrates_NNS ,_, sulphonylureas_NNS ,_, loop_NN diuretics_NNS ,_, potassium_NN sparing_VBG diuretics_NNS ,_, thiazide_JJ diuretics_NNS ,_, substrates_NNS and_CC inhibitors_NNS of_IN tubular_JJ organic_JJ cation_NN transport_NN ,_, and_CC QTc-prolonging_JJ drugs_NNS ._. Differences_NNS in_IN clearance_NN between_IN patients_NNS on_IN these_DT medications_NNS -LRB-_-LRB- at_IN any_DT occasion_NN in_IN the_DT study_NN -RRB-_-RRB- and_CC those_DT off_IN medications_NNS varied_VBD between_IN -16_CD %_NN and_CC +3_CD %_NN ._. The_DT mean_NN clearances_NNS of_IN dofetilide_NN were_VBD 16_CD %_NN and_CC 15_CD %_NN lower_JJR in_IN patients_NNS on_IN thiazide_JJ diuretics_NNS and_CC inhibitors_NNS of_IN tubular_JJ organic_JJ cation_NN transport_NN ,_, respectively_RB ._. The_DT potential_NN for_IN clinically_RB significant_JJ drug-drug_JJ interactions_NNS posed_VBN by_IN dolasetron_NN and_CC hydrodolasetron_NN appears_VBZ to_TO be_VB low_JJ for_IN drugs_NNS commonly_RB used_VBN in_IN chemotherapy_NN or_CC surgery_NN ,_, because_IN hydrodolasetron_NN is_VBZ eliminated_VBN by_IN multiple_JJ routes_NNS ._. Blood_NN levels_NNS of_IN hydrodolasetron_NN increased_VBD 24_CD %_NN when_WRB dolasetron_NN was_VBD coadministered_VBN with_IN cimetidine_NN -LRB-_-LRB- nonselective_JJ inhibitor_NN of_IN cytochrome_NN P-450_NN -RRB-_-RRB- for_IN 7_CD days_NNS ,_, and_CC decreased_VBD 28_CD %_NN with_IN coadministration_NN of_IN rifampin_NN -LRB-_-LRB- potent_JJ inducer_NN of_IN cytochrome_NN P-450_NN -RRB-_-RRB- for_IN 7_CD days_NNS ._. Dolasetron_NNP has_VBZ been_VBN safely_RB coadministered_VBN with_IN drugs_NNS used_VBN in_IN chemotherapy_NN and_CC surgery_NN ._. As_IN with_IN other_JJ agents_NNS which_WDT prolong_VBP ECG_NN intervals_NNS ,_, caution_NN should_MD be_VB exercised_VBN in_IN patients_NNS taking_VBG drugs_NNS which_WDT prolong_VBP ECG_NN intervals_NNS ,_, particularly_RB QTc_NN ._. In_IN patients_NNS taking_VBG furosemide_NN ,_, nifedipine_NN ,_, diltiazem_NN ,_, ACE_NN inhibitors_NNS ,_, verapamil_NN ,_, glyburide_NN ,_, propranolol_NN ,_, and_CC various_JJ chemotherapy_NN agents_NNS ,_, no_DT effect_NN was_VBD shown_VBN on_IN the_DT clearance_NN of_IN hydrodolasetron_NN ._. Clearance_NN of_IN hydrodolasetron_NN decreased_VBN by_IN about_IN 27_CD %_NN when_WRB dolasetron_NN mesylate_NN was_VBD administered_VBN intravenously_RB concomitantly_RB with_IN atenolol_NN ._. Dolasetron_NNP does_VBZ not_RB influence_VB anesthesia_NN recovery_NN time_NN in_IN patients_NNS ._. Dolasetron_NNP mesylate_NN did_VBD not_RB inhibit_VB the_DT antitumor_NN activity_NN of_IN four_CD chemotherapeutic_JJ agents_NNS -LRB-_-LRB- cisplatin_NN ,_, 5-fluorouracil_NN ,_, doxorubicin_NN ,_, cyclophosphamide_NN -RRB-_-RRB- in_IN four_CD murine_JJ models_NNS ._. Drugs_NNS that_WDT inhibit_VBP or_CC Induce_VBP CYP_NN 2D6_NN and_CC CYP_NN 3A4_NN may_MD affect_VB the_DT concentration_NN on_IN Aricept_NNP ._. Because_IN dopamine_NN is_VBZ metabolized_VBN by_IN monoamine_NN oxidase_NN -LRB-_-LRB- MAO_NN -RRB-_-RRB- ,_, inhibition_NN of_IN this_DT enzyme_NN prolongs_VBZ and_CC potentiates_VBZ the_DT effect_NN of_IN dopamine_NN ._. Patients_NNS who_WP have_VBP been_VBN treated_VBN with_IN MAO_NN inhibitors_NNS within_IN two_CD to_TO three_CD weeks_NNS prior_RB to_TO the_DT administration_NN of_IN dopamine_NN HCl_NN should_MD receive_VB initial_JJ doses_NNS of_IN dopamine_NN HCl_NN no_RB greater_JJR than_IN one-tenth_JJ -LRB-_-LRB- 1/10_CD -RRB-_-RRB- of_IN the_DT usual_JJ dose_NN ._. Concurrent_JJ administration_NN of_IN low-dose_JJ dopamine_NN HCl_NN and_CC diuretic_JJ agents_NNS may_MD produce_VB an_DT additive_JJ or_CC potentiating_NN effect_NN on_IN urine_NN flow_NN ._. Tricyclic_JJ antidepressants_NNS may_MD potentiate_VB the_DT cardiovascular_JJ effects_NNS of_IN adreneric_JJ agents_NNS ._. Cardiac_JJ effects_NNS of_IN dopamine_NN are_VBP antagonized_VBN by_IN beta-adrenergic_JJ blocking_VBG agents_NNS ,_, such_JJ as_IN propranolol_NN and_CC metoprolol_NN ._. The_DT peripheral_JJ vasoconstriction_NN caused_VBN by_IN high_JJ doses_NNS of_IN dopamine_NN HCl_NN is_VBZ antagonized_VBN by_IN alpha-adrenergic_JJ blocking_VBG agents_NNS ._. Dopamine-induced_JJ renal_JJ and_CC mesenteric_JJ vasodilation_NN is_VBZ not_RB antagonized_VBN by_IN either_CC alpha_NN -_: or_CC beta-adrenergic_JJ blocking_VBG agents_NNS ._. Butyrophenones_NNS -LRB-_-LRB- such_JJ as_IN haloperidol_NN -RRB-_-RRB- and_CC phenothiazines_NNS can_MD suppress_VB the_DT dopaminergic_JJ renal_JJ and_CC mesenteric_JJ vasodilation_NN induced_VBN with_IN low_JJ dose_NN dopamine_NN infusion_NN ._. Cyclopropane_NN or_CC halogenated_VBN hydrocarbon_NN anesthetics_NNS increase_VBP cardiac_JJ autonomic_JJ irritability_NN and_CC may_MD sensitize_VB the_DT myocardium_NN to_TO the_DT action_NN of_IN certain_JJ intravenously_RB administered_VBN catecholamines_NNS ,_, such_JJ as_IN dopamine_NN ._. This_DT interaction_NN appears_VBZ to_TO be_VB related_VBN both_DT to_TO pressor_NN activity_NN and_CC to_TO beta-adrenergic_JJ stimulating_NN properties_NNS of_IN these_DT catecholamines_NNS and_CC may_MD produce_VB ventricular_JJ arrhythmias_NNS and_CC hypertension_NN ._. Therefore_RB ,_, EXTREME_JJ CAUTION_NN should_MD be_VB exercised_VBN when_WRB administering_VBG dopamine_NN HCl_NN to_TO patients_NNS receiving_VBG cyclopropane_NN or_CC halogenated_VBN hydrocarbon_NN anesthetics_NNS ._. It_PRP has_VBZ been_VBN reported_VBN that_IN results_NNS of_IN studies_NNS in_IN animals_NNS indicate_VBP that_IN dopamine-induced_JJ ventricular_JJ arrhythmias_NNS during_IN anesthesia_NN can_MD be_VB reversed_VBN by_IN propranolol_NN ._. The_DT concomitant_JJ use_NN of_IN vasopressors_NNS ,_, vasoconstricting_VBG agents_NNS -LRB-_-LRB- such_JJ as_IN ergonovine_NN -RRB-_-RRB- and_CC some_DT oxytocic_JJ drugs_NNS may_MD result_VB in_IN severe_JJ hypertension_NN ._. Administration_NN of_IN phenytoin_NN to_TO patients_NNS receiving_VBG dopamine_NN HCl_NN has_VBZ been_VBN reported_VBN to_TO lead_VB to_TO hypotension_NN and_CC bradycardia_NN ._. It_PRP is_VBZ suggested_VBN that_IN in_IN patients_NNS receiving_VBG dopamine_NN HCl_NN ,_, alternatives_NNS to_TO phenytoin_NN should_MD be_VB used_VBN if_IN anticonvulsant_JJ therapy_NN is_VBZ needed_VBN ._. Clinical_JJ trials_NNS have_VBP indicated_VBN that_IN Pulmozyme_NNP can_MD be_VB effectively_RB and_CC safely_RB used_VBN in_IN conjunction_NN with_IN standard_JJ cystic_JJ fibrosis_NN therapies_NNS including_VBG oral_JJ ,_, inhaled_VBD and/or_CC parenteral_JJ antibiotics_NNS ,_, bronchodilators_NNS ,_, enzyme_NN supplements_NNS ,_, vitamins_NNS ,_, oral_JJ or_CC inhaled_VBN corticosteroids_NNS ,_, and_CC analgesics_NNS ._. No_DT formal_JJ drug_NN interaction_NN studies_NNS have_VBP been_VBN performed_VBN ._. Although_IN acid-base_NN and_CC electrolyte_NN disturbances_NNS were_VBD not_RB reported_VBN in_IN the_DT clinical_JJ trials_NNS with_IN dorzolamide_NN ,_, these_DT disturbances_NNS have_VBP been_VBN reported_VBN with_IN oral_JJ carbonic_JJ anhydrase_NN inhibitors_NNS and_CC have_VBP ,_, in_IN some_DT instances_NNS ,_, resulted_VBD in_IN drug_NN interactions_NNS -LRB-_-LRB- e.g._FW ,_, toxicity_NN associated_VBN with_IN high-dose_JJ salicylate_NN therapy_NN -RRB-_-RRB- ._. Therefore_RB ,_, the_DT potential_NN for_IN such_JJ drug_NN interactions_NNS should_MD be_VB considered_VBN in_IN patients_NNS receiving_VBG dorzolamide_NN ._. Prior_RB administration_NN of_IN succinylcholine_NN has_VBZ no_DT clinically_RB important_JJ effect_NN on_IN the_DT neuromuscular_JJ blocking_VBG action_NN of_IN NUROMAX_NNP ._. The_DT use_NN of_IN NUROMAX_NN before_IN succinylcholine_NN to_TO attenuate_VB some_DT of_IN the_DT side_JJ effects_NNS of_IN succinylcholine_NN has_VBZ not_RB been_VBN studied_VBN ._. There_EX are_VBP no_DT clinical_JJ data_NNS on_IN concomitant_JJ use_NN of_IN NUROMAX_NNP and_CC other_JJ nondepolarizing_JJ neuromuscular_JJ blocking_VBG agents_NNS ._. Isoflurane_NNP ,_, enflurane_NN ,_, and_CC halothane_NN decrease_VBP the_DT ED50_NN of_IN NUROMAX_NN by_IN 30_CD %_NN to_TO 45_CD %_NN ._. These_DT agents_NNS may_MD also_RB prolong_VB the_DT clinically_RB effective_JJ duration_NN of_IN action_NN by_IN up_RB to_TO 25_CD %_NN ._. Other_JJ drugs_NNS which_WDT may_MD enhance_VB the_DT neuromuscular_JJ blocking_VBG action_NN of_IN nondepolarizing_JJ agents_NNS such_JJ as_IN NUROMAX_NNP include_VBP certain_JJ antibiotics_NNS -LRB-_-LRB- e._FW g._FW ,_, aminoglycosides_NNS ,_, tetracyclines_NNS ,_, bacitracin_NN ,_, polymyxins_NNS ,_, lincomycin_NN ,_, clindamycin_NN ,_, colistin_NN ,_, and_CC sodium_NN colistimethate_NN -RRB-_-RRB- ,_, magnesium_NN salts_NNS ,_, lithium_NN ,_, local_JJ anesthetics_NNS ,_, procainamide_NN ,_, and_CC quinidine_NN ._. As_IN with_IN some_DT other_JJ nondepolarizing_JJ neuromuscular_JJ blocking_VBG agents_NNS ,_, the_DT time_NN of_IN onset_NN of_IN neuromuscular_JJ block_NN induced_VBN by_IN NUROMAX_NNP is_VBZ lengthened_VBN and_CC the_DT duration_NN of_IN block_NN is_VBZ shortened_VBN in_IN patients_NNS receiving_VBG phenytoin_NN or_CC carbamazepine_NN ._. Administration_NN of_IN doxapram_NN to_TO patients_NNS who_WP are_VBP receiving_VBG sympathomimetic_JJ or_CC monoamine_NN oxidase_NN inhibiting_VBG drugs_NNS may_MD result_VB in_IN an_DT additive_JJ pressor_NN effect_NN ._. In_IN patients_NNS who_WP have_VBP received_VBN muscle_NN relaxants_NNS ,_, doxapram_NN may_MD temporarily_RB mask_NN the_DT residual_JJ effects_NNS of_IN muscle_NN relaxant_NN drugs_NNS ._. In_IN patients_NNS who_WP have_VBP received_VBN general_JJ anesthesia_NN utilizing_VBG a_DT volatile_JJ agent_NN known_VBN to_TO sensitize_VB the_DT myocardium_NN to_TO catecholamines_NNS ,_, administration_NN of_IN doxapram_NN should_MD be_VB delayed_VBN until_IN the_DT volatile_JJ agent_NN has_VBZ been_VBN excreted_VBN in_IN order_NN to_TO lessen_VB the_DT potential_NN for_IN arrhythmias_NNS ,_, including_VBG ventricular_JJ tachycardia_NN and_CC ventricular_JJ fibrillation_NN ._. Most_JJS -LRB-_-LRB- 98_CD %_NN -RRB-_-RRB- of_IN plasma_NN doxazosin_NN is_VBZ protein_NN bound_VBN ._. In_FW vitro_FW data_NNS in_IN human_JJ plasma_NN indicate_VBP that_IN doxazosin_NN mesylate_NN has_VBZ no_DT effect_NN on_IN protein_NN binding_NN of_IN digoxin_NN ,_, warfarin_NN ,_, phenytoin_NN or_CC indomethacin_NN ._. There_EX is_VBZ no_DT information_NN on_IN the_DT effect_NN of_IN other_JJ highly_RB plasma_NN protein_NN bound_VBD drugs_NNS on_IN doxazosin_NN binding_NN ._. Doxazosin_NN mesylate_NN has_VBZ been_VBN administered_VBN without_IN any_DT evidence_NN of_IN an_DT adverse_JJ drug_NN interaction_NN to_TO patients_NNS receiving_VBG thiazide_JJ diuretics_NNS ,_, beta-blocking_JJ agents_NNS ,_, and_CC nonsteroidal_JJ anti-inflammatory_JJ drugs_NNS ._. In_IN a_DT placebo-controlled_JJ trial_NN in_IN normal_JJ volunteers_NNS ,_, the_DT administration_NN of_IN a_DT single_JJ 1_CD mg_NN dose_NN of_IN doxazosin_NN on_IN day_NN 1_CD of_IN a_DT four-day_JJ regimen_NN of_IN oral_JJ cimetidine_NN -LRB-_-LRB- 400_CD mg_NN twice_RB daily_RB -RRB-_-RRB- resulted_VBD in_IN a_DT 10_CD %_NN increase_NN in_IN mean_JJ AUC_NN of_IN doxazosin_NN -LRB-_-LRB- p_NN =_JJ 0.006_CD -RRB-_-RRB- ,_, and_CC a_DT slight_JJ but_CC not_RB statistically_RB significant_JJ increase_NN in_IN mean_JJ Cmax_NN and_CC mean_VB half-life_NN of_IN doxazosin_NN ._. The_DT clinical_JJ significance_NN of_IN this_DT increase_NN in_IN doxazosin_NN AUC_NN is_VBZ unknown_JJ ._. In_IN clinical_JJ trials_NNS ,_, doxazosin_NN mesylate_NN tablets_NNS have_VBP been_VBN administered_VBN to_TO patients_NNS on_IN a_DT variety_NN of_IN concomitant_JJ medications_NNS ._. while_IN no_DT formal_JJ interaction_NN studies_NNS have_VBP been_VBN conducted_VBN ,_, no_DT interactions_NNS were_VBD observed_VBN ._. Doxazosin_NN mesylate_NN tablets_NNS have_VBP been_VBN used_VBN with_IN the_DT following_VBG drugs_NNS or_CC drug_NN classes_NNS :_: 1_CD ._. Analgesic/anti-inflammatory_JJ -LRB-_-LRB- e.g._FW ,_, acetaminophen_NN ,_, aspirin_NN ,_, codeine_NN and_CC codeine_NN combinations_NNS ,_, ibuprofen_NN ,_, indomethacin_NN -RRB-_-RRB- ._. 2_LS ._. Antibiotics_NNS -LRB-_-LRB- e.g._FW ,_, erythromycin_NN ,_, trimethoprim_NN and_CC sulfamethoxazole_NN ,_, amoxicillin_NNP -RRB-_-RRB- ._. 3_LS ._. Antihistamines_NNS -LRB-_-LRB- e.g._FW ,_, chlorpheniramine_NN -RRB-_-RRB- ._. 4_LS ._. Cardiovascular_NNP agents_NNS -LRB-_-LRB- e.g._FW ,_, atenolol_NN ,_, hydrochlorothiazide_NN ,_, propranolol_NN -RRB-_-RRB- ._. 5_CD ._. Corticosteroids_NNS ._. 6_CD ._. Gastrointestinal_JJ agents_NNS -LRB-_-LRB- e.g._FW ,_, antacids_NNS -RRB-_-RRB- ._. 7_CD ._. Hypoglycemics_NNS and_CC endocrine_JJ drugs_NNS ._. 8_CD ._. Sedatives_NNS and_CC tranquilizers_NNS -LRB-_-LRB- e.g._FW ,_, diazepam_NN -RRB-_-RRB- ._. 9_CD ._. Cold_NNP and_CC flu_NN remedies_NNS ._. Drugs_NNS Metabolized_VBN by_IN P450_NN 2D6_NN :_: The_DT biochemical_JJ activity_NN of_IN the_DT drug_NN metabolizing_VBG isozyme_NN cytochrome_NN P450_NN 2D6_NN -LRB-_-LRB- debrisoquin_NN hydroxylase_NN -RRB-_-RRB- is_VBZ reduced_VBN in_IN a_DT subset_NN of_IN the_DT Caucasian_JJ population_NN -LRB-_-LRB- about_IN 7-10_CD %_NN of_IN Caucasians_NNPS are_VBP so-called_JJ poor_JJ metabolizers_NNS -RRB-_-RRB- ;_: ._. reliable_JJ estimates_NNS of_IN the_DT prevalence_NN of_IN reduced_VBN P450_NN 2D6_NN isozyme_NN activity_NN among_IN Asian_JJ ,_, African_JJ and_CC other_JJ populations_NNS are_VBP not_RB yet_RB available_JJ ._. Poor_NNP metabolizers_NNS have_VBP higher_JJR than_IN expected_VBN plasma_NN concentrations_NNS of_IN tricyclic_JJ antidepressants_NNS -LRB-_-LRB- TCAs_NNS -RRB-_-RRB- when_WRB given_VBN usual_JJ doses_NNS ._. Depending_VBG on_IN the_DT fraction_NN of_IN drug_NN metabolized_VBN by_IN P450_NN 2D6_NN ,_, the_DT increase_NN in_IN plasma_NN concentration_NN may_MD be_VB small_JJ ,_, or_CC quite_RB large_JJ -LRB-_-LRB- 8-fold_JJ increase_NN in_IN plasma_NN AUC_NN of_IN the_DT TCA_NNP -RRB-_-RRB- ._. In_IN addition_NN ,_, certain_JJ drugs_NNS inhibit_VBP the_DT activity_NN of_IN this_DT isozyme_NN and_CC make_VB normal_JJ metabolizers_NNS resemble_VBP poor_JJ metabolizers_NNS ._. An_DT individual_NN who_WP is_VBZ stable_JJ on_IN a_DT given_VBN dose_NN of_IN TCA_NNP may_MD become_VB abruptly_RB toxic_JJ when_WRB given_VBN one_CD of_IN these_DT inhibiting_VBG drugs_NNS as_IN concomitant_JJ therapy_NN ._. The_DT drugs_NNS that_WDT inhibit_VBP cytochrome_NN P450_NN 2D6_NN include_VBP some_DT that_WDT are_VBP not_RB metabolized_VBN by_IN the_DT enzyme_NN -LRB-_-LRB- quinidine_NN ._. cimetidine_NN -RRB-_-RRB- and_CC many_JJ that_WDT are_VBP substrates_NNS for_IN P450_NN 2D6_NN -LRB-_-LRB- many_JJ other_JJ antidepressants_NNS ,_, phenothiazines_NNS ,_, and_CC the_DT Type_NN 1C_NN antiarrhythmics_NNS propafenone_NN and_CC flecainide_NN -RRB-_-RRB- ._. While_IN all_PDT the_DT selective_JJ serotonin_NN reuptake_NN inhibitors_NNS -LRB-_-LRB- SSRIs_NNS -RRB-_-RRB- ,_, e.g._FW ,_, citalopram_NN ,_, escitalopram_NN ,_, fluoxetine_NN ,_, sertraline_NN ,_, and_CC paroxetine_NN ,_, inhibit_VBP P450_NN 2D6_NN ,_, they_PRP may_MD vary_VB in_IN the_DT extent_NN of_IN inhibition_NN ._. The_DT extent_NN to_TO which_WDT SSRI-TCA_NNP interactions_NNS may_MD pose_VB clinical_JJ problems_NNS will_MD depend_VB on_IN the_DT degree_NN of_IN inhibition_NN and_CC the_DT pharmacokinetics_NNS of_IN the_DT SSRI_NNP involved_VBN ._. Nevertheless_RB ,_, caution_NN is_VBZ indicated_VBN in_IN the_DT co-administration_NN of_IN TCAs_NNS with_IN any_DT of_IN the_DT SSRIs_NNS and_CC also_RB in_IN switching_NN from_IN one_CD class_NN to_TO the_DT other_JJ ._. Of_IN particular_JJ importance_NN ,_, sufficient_JJ time_NN must_MD elapse_VB before_IN initiating_VBG TCA_NNP treatment_NN in_IN a_DT patient_NN being_VBG withdrawn_VBN from_IN fluoxetine_NN ,_, given_VBN the_DT long_JJ half-life_NN of_IN the_DT parent_NN and_CC active_JJ metabolite_NN -LRB-_-LRB- at_IN least_JJS 5_CD weeks_NNS may_MD be_VB necessary_JJ -RRB-_-RRB- ._. Concomitant_JJ use_NN of_IN tricyclic_JJ antidepressants_NNS with_IN drugs_NNS that_WDT can_MD inhibit_VB cytochrome_NN P450_NN 2D6_NN may_MD require_VB lower_JJR doses_NNS than_IN usually_RB prescribed_VBN for_IN either_CC the_DT tricyclic_JJ antidepressant_JJ or_CC the_DT other_JJ drug_NN ._. Furthermore_RB ,_, whenever_WRB one_CD of_IN these_DT other_JJ drugs_NNS is_VBZ withdrawn_VBN from_IN co-therapy_JJ ,_, an_DT increased_VBN dose_NN of_IN tricyclic_JJ antidepressant_JJ may_MD be_VB required_VBN ._. It_PRP is_VBZ desirable_JJ to_TO monitor_VB TCA_NNP plasma_NN levels_NNS whenever_WRB a_DT TCA_NNP is_VBZ going_VBG to_TO be_VB co-administered_VBN with_IN another_DT drug_NN known_VBN to_TO be_VB an_DT inhibitor_NN of_IN P450_NN 2D6_NN ._. Doxepin_NN is_VBZ primarily_RB metabolized_VBN by_IN CYP2D6_NN -LRB-_-LRB- with_IN CYP1A2_NN and_CC CYP3A4_NN as_IN minor_JJ pathways_NNS -RRB-_-RRB- ._. Inhibitors_NNS or_CC substrates_NNS of_IN CYP2D6_NN -LRB-_-LRB- i.e._FW ,_, quinidine_NN ,_, selective_JJ serotonin_NN reuptake_NN inhibitors_NNS -LSB-_-LRB- SSRIs_NNS -RSB-_-RRB- -RRB-_-RRB- may_MD increase_VB the_DT plasma_NN concentration_NN of_IN doxepin_NN when_WRB administered_VBN concomitantly_RB ._. The_DT extent_NN of_IN interaction_NN depends_VBZ on_IN the_DT variability_NN of_IN effect_NN on_IN CYP2D6_NN ._. The_DT clinical_JJ significance_NN of_IN this_DT interaction_NN with_IN doxepin_NN has_VBZ not_RB been_VBN systematically_RB evaluated_VBN ._. MAO_NNP Inhibitors_NNS :_: Serious_JJ side_JJ effects_NNS and_CC even_RB death_NN have_VBP been_VBN reported_VBN following_VBG the_DT concomitant_JJ use_NN of_IN certain_JJ drugs_NNS with_IN MAO_NN inhibitors_NNS ._. Therefore_RB ,_, MAO_NN inhibitors_NNS should_MD be_VB discontinued_VBN at_IN least_JJS two_CD weeks_NNS prior_RB to_TO the_DT cautious_JJ initiation_NN of_IN therapy_NN with_IN SINEQUAN_NNP ._. The_DT exact_JJ length_NN of_IN time_NN may_MD vary_VB and_CC is_VBZ dependent_JJ upon_IN the_DT particular_JJ MAO_NNP inhibitor_NN being_VBG used_VBN ,_, the_DT length_NN of_IN time_NN it_PRP has_VBZ been_VBN administered_VBN ,_, and_CC the_DT dosage_NN involved_VBN ._. Cimetidine_NNP :_: Cimetidine_NNP has_VBZ been_VBN reported_VBN to_TO produce_VB clinically_RB significant_JJ fluctuations_NNS in_IN steady-state_JJ serum_NN concentrations_NNS of_IN various_JJ tricyclic_JJ antidepressants_NNS ._. Serious_JJ anticholinergic_JJ symptoms_NNS -LRB-_-LRB- i.e._FW ,_, severe_JJ dry_JJ mouth_NN ,_, urinary_JJ retention_NN and_CC blurred_VBD vision_NN -RRB-_-RRB- have_VBP been_VBN associated_VBN with_IN elevations_NNS in_IN the_DT serum_NN levels_NNS of_IN tricyclic_JJ antidepressant_JJ when_WRB cimetidine_NN therapy_NN is_VBZ initiated_VBN ._. Additionally_RB ,_, higher_JJR than_IN expected_VBN tricyclic_JJ antidepressant_JJ levels_NNS have_VBP been_VBN observed_VBN when_WRB they_PRP are_VBP begun_VBN in_IN patients_NNS already_RB taking_VBG cimetidine_NN ._. In_IN patients_NNS who_WP have_VBP been_VBN reported_VBN to_TO be_VB well_RB controlled_VBN on_IN tricyclic_JJ antidepressants_NNS receiving_VBG concurrent_JJ cimetidine_NN therapy_NN ,_, discontinuation_NN of_IN cimetidine_NN has_VBZ been_VBN reported_VBN to_TO decrease_VB established_JJ steady-state_JJ serum_NN tricyclic_JJ antidepressant_JJ levels_NNS and_CC compromise_VB their_PRP$ therapeutic_JJ effects_NNS ._. Alcohol_NN :_: It_PRP should_MD be_VB borne_VBN in_IN mind_NN that_WDT alcohol_NN ingestion_NN may_MD increase_VB the_DT danger_NN inherent_JJ in_IN any_DT intentional_JJ or_CC unintentional_JJ SINEQUAN_NN overdosage_NN ._. This_DT is_VBZ especially_RB important_JJ in_IN patients_NNS who_WP may_MD use_VB alcohol_NN excessively_RB ._. Tolazamide_NNP :_: A_DT case_NN of_IN severe_JJ hypoglycemia_NN has_VBZ been_VBN reported_VBN in_IN a_DT type_NN II_CD diabetic_JJ patient_NN maintained_VBD on_IN tolazamide_NN -LRB-_-LRB- 1_CD gm/day_NN -RRB-_-RRB- 11_CD days_NNS after_IN the_DT addition_NN of_IN doxepin_NN -LRB-_-LRB- 75_CD mg/day_NN -RRB-_-RRB- ._. No_DT formal_JJ drug_NN interaction_NN studies_NNS have_VBP been_VBN conducted_VBN with_IN DOXIL_NN ._. Until_IN specific_JJ compatibility_NN data_NNS are_VBP available_JJ ,_, it_PRP is_VBZ not_RB recommended_VBN that_IN DOXIL_NNP be_VB mixed_VBN with_IN other_JJ drugs_NNS ._. DOXIL_NN may_MD interact_VB with_IN drugs_NNS known_VBN to_TO interact_VB with_IN the_DT conventional_JJ formulation_NN of_IN doxorubicin_NN HCl_NN ._. Because_IN tetracyclines_NNS have_VBP been_VBN shown_VBN to_TO depress_VB plasma_NN prothrombin_NN activity_NN ,_, patients_NNS who_WP are_VBP on_IN anticoagulant_JJ therapy_NN may_MD require_VB downward_JJ adjustment_NN of_IN their_PRP$ anticoagulant_JJ dosage_NN ._. Since_IN bacteriostatic_JJ drugs_NNS may_MD interfere_VB with_IN the_DT bactericidal_JJ action_NN of_IN penicillin_NN ,_, it_PRP is_VBZ advisable_JJ to_TO avoid_VB giving_VBG tetracyclines_NNS in_IN conjunction_NN with_IN penicillin_NN ._. Absorption_NN of_IN tetracyclines_NNS is_VBZ impaired_VBN by_IN antacids_NNS containing_VBG aluminum_NN ,_, calcium_NN ,_, or_CC magnesium_NN ,_, and_CC iron-containing_JJ preparations_NNS ._. Absorption_NN of_IN tetracycline_NN is_VBZ impaired_VBN by_IN bismuth_NN subsalicylate_NN ._. Barbiturates_NNP ,_, carbamazepine_NN ,_, and_CC phenytoin_NN decrease_VBP the_DT half-life_NN of_IN doxycycline_NN ._. The_DT concurrent_JJ use_NN of_IN tetracycline_NN and_CC Penthrane_NN -LRB-_-LRB- methoxyflurane_NN -RRB-_-RRB- has_VBZ been_VBN reported_VBN to_TO result_VB in_IN fatal_JJ renal_JJ toxicity_NN ._. Concurrent_JJ use_NN of_IN tetracycline_NN may_MD render_VB oral_JJ contraceptives_NNS less_RBR effective_JJ ._. Drug/Laboratory_JJ Test_NN Interactions_NNS False_JJ elevations_NNS of_IN urinary_JJ catecholamine_NN levels_NNS may_MD occur_VB due_JJ to_TO interference_NN with_IN the_DT fluorescence_NN test_NN ._. Potential_JJ drug_NN interactions_NNS for_IN doxylamine_NN include_VBP ,_, increased_VBD sedation_NN if_IN doxylamine_NN is_VBZ combined_VBN with_IN other_JJ CNS_NNS depressant_NN drugs_NNS ._. Antihistamines_NNS may_MD partially_RB counteract_VB the_DT anticoagulation_JJ effects_NNS of_IN heparin_NN or_CC warfarin_NN ._. Doxylamine_NN may_MD enhance_VB the_DT effects_NNS of_IN epinephrine_NN ._. Androgens_NNS may_MD increase_VB sensitivity_NN to_TO oral_JJ anticoagulahts_NNS ._. Dosage_NN of_IN the_DT anticoagulant_NN may_MD require_VB reduction_NN in_IN order_NN to_TO maintain_VB satisfactory_JJ therapeutic_JJ hypoprothrombinemia_NN ._. Concurrent_JJ administration_NN of_IN oxyphenbutazone_NN and_CC androgens_NNS may_MD result_VB in_IN elevated_JJ serum_NN levels_NNS of_IN oxyphenbutazone_NN ._. In_IN diabetic_JJ patients_NNS ,_, the_DT metabolic_JJ effects_NNS of_IN androgens_NNS may_MD decrease_VB blood_NN glucose_NN and_CC therefore_RB ,_, insulin_NN requirements_NNS ._. Other_JJ CNS_NNS depressant_NN drugs_NNS -LRB-_-LRB- e.g._FW barbiturates_FW ,_, tranquilizers_NNS ,_, opioids_NNS and_CC general_JJ anesthetics_NNS -RRB-_-RRB- have_VBP additive_JJ or_CC potentiating_NN effects_NNS with_IN INAPSINE_NN ._. When_WRB patients_NNS have_VBP received_VBN such_JJ drugs_NNS ,_, the_DT dose_NN of_IN INAPSINE_NN required_VBN will_MD be_VB less_JJR than_IN usual_JJ ._. Following_VBG the_DT administration_NN of_IN INAPSINE_NNP ,_, the_DT dose_NN of_IN other_JJ CNS_NNS depressant_NN drugs_NNS should_MD be_VB reduced_VBN ._. Drug_NN interaction_NN studies_NNS with_IN Xigris_NNP have_VBP not_RB been_VBN performed_VBN in_IN patients_NNS with_IN severe_JJ sepsis_NN ._. However_RB ,_, since_IN there_EX is_VBZ an_DT increased_VBN risk_NN of_IN bleeding_VBG with_IN Xigris_NNP ,_, caution_NN should_MD be_VB employed_VBN when_WRB Xigris_NNP is_VBZ used_VBN with_IN other_JJ drugs_NNS that_WDT affect_VBP hemostasis_NN ._. Approximately_RB 2/3_CD of_IN the_DT patients_NNS in_IN the_DT Phase_NN 3_CD study_NN received_VBD either_CC prophylactic_NN low_JJ dose_NN heparin_NN -LRB-_-LRB- unfractionated_JJ heparin_NN up_IN to_TO 15,000_CD units/day_NNS -RRB-_-RRB- or_CC prophylactic_NN doses_NNS of_IN low_JJ molecular_JJ weight_NN heparins_NNS as_IN indicated_VBN in_IN the_DT prescribing_VBG information_NN for_IN the_DT specific_JJ products_NNS ._. Concomitant_JJ use_NN of_IN prophylactic_NN low_JJ dose_NN heparin_NN did_VBD not_RB appear_VB to_TO affect_VB safety_NN ,_, however_RB ,_, its_PRP$ effects_NNS on_IN the_DT efficacy_NN of_IN Xigris_NNP have_VBP not_RB been_VBN evaluated_VBN in_IN an_DT adequate_JJ and_CC well-controlled_JJ clinical_JJ trial_NN ._. Drug/Laboratory_JJ Test_NN Interaction_NN Because_IN Xigris_NNP may_MD affect_VB the_DT APTT_NN assay_NN ,_, Xigris_NNP present_JJ in_IN plasma_NN samples_NNS may_MD interfere_VB with_IN one-stage_JJ coagulation_NN assays_NNS based_VBN on_IN the_DT APTT_NNP -LRB-_-LRB- such_JJ as_IN factor_NN VIII_CD ,_, IX_CD ,_, and_CC XI_NN assays_NNS -RRB-_-RRB- ._. This_DT interference_NN may_MD result_VB in_IN an_DT apparent_JJ factor_NN concentration_NN that_WDT is_VBZ lower_JJR than_IN the_DT true_JJ concentration_NN ._. Xigris_NNP present_JJ in_IN plasma_NN samples_NNS does_VBZ not_RB interfere_VB with_IN one-stage_JJ factor_NN assays_NNS based_VBN on_IN the_DT PT_NN -LRB-_-LRB- such_JJ as_IN factor_NN II_CD ,_, V_NN ,_, VII_NN ,_, and_CC X_NN assays_NNS -RRB-_-RRB- ._. Potential_JJ for_IN Other_JJ Drugs_NNS to_TO Affect_VB Duloxetine_NNP :_: Both_CC CYP1A2_NN and_CC CYP2D6_NN are_VBP responsible_JJ for_IN duloxetine_NN metabolism_NN ._. Inhibitors_NNS of_IN CYP1A2_NN :_: Concomitant_JJ use_NN of_IN duloxetine_NN with_IN fluvoxamine_NN ,_, an_DT inhibitor_NN of_IN CYP1A2_NN ,_, results_VBZ in_IN approximately_RB a_DT 6-fold_RB increase_NN in_IN AUC_NN and_CC about_IN a_DT 2.5-fold_JJ increase_NN in_IN Cmax_NN of_IN duloxetine_NN ._. Some_DT quinolone_JJ antibiotics_NNS would_MD be_VB expected_VBN to_TO have_VB similar_JJ effects_NNS and_CC these_DT combinations_NNS should_MD be_VB avoided_VBN ._. Inhibitors_NNS of_IN CYP2D6_NN :_: Because_IN CYP2D6_NN is_VBZ involved_VBN in_IN duloxetine_NN metabolism_NN ,_, concomitant_JJ use_NN of_IN duloxetine_NN with_IN potent_JJ inhibitors_NNS of_IN CYP2D6_NN may_MD result_VB in_IN higher_JJR concentrations_NNS of_IN duloxetine_NN ._. Paroxetine_NNP -LRB-_-LRB- 20_CD mg_NN QD_NN -RRB-_-RRB- increased_VBD the_DT concentration_NN of_IN duloxetine_NN -LRB-_-LRB- 40_CD mg_NN QD_NN -RRB-_-RRB- by_IN about_RB 60_CD %_NN ,_, and_CC greater_JJR degrees_NNS of_IN inhibition_NN are_VBP expected_VBN with_IN higher_JJR doses_NNS of_IN paroxetine_NN ._. Similar_JJ effects_NNS would_MD be_VB expected_VBN with_IN other_JJ potent_JJ CYP2D6_NN inhibitors_NNS -LRB-_-LRB- e.g._FW ,_, fluoxetine_NN ,_, quinidine_NN -RRB-_-RRB- ._. Potential_JJ for_IN Duloxetine_NNP to_TO Affect_VB Other_JJ Drugs_NNS :_: Drugs_NNS Metabolized_VBN by_IN CYP1A2_NN :_: In_FW vitro_FW drug_NN interaction_NN studies_NNS demonstrate_VBP that_IN duloxetine_NN does_VBZ not_RB induce_VB CYP1A2_NN activity_NN ,_, and_CC it_PRP is_VBZ unlikely_JJ to_TO have_VB a_DT clinically_RB significant_JJ effect_NN on_IN the_DT metabolism_NN of_IN CYP1A2_NN substrates_NNS ._. Drugs_NNS Metabolized_VBN by_IN CYP2D6_NN :_: Duloxetine_NNP is_VBZ a_DT moderate_JJ inhibitor_NN of_IN CYP2D6_NN ._. When_WRB duloxetine_NN was_VBD administered_VBN -LRB-_-LRB- at_IN a_DT dose_NN of_IN 60_CD mg_NN BID_NNP -RRB-_-RRB- in_IN conjunction_NN with_IN a_DT single_JJ 50-mg_JJ dose_NN of_IN desipramine_NN ,_, a_DT CYP2D6_NN substrate_NN ,_, the_DT AUC_NN of_IN desipramine_NN increased_VBD 3-fold_RB ._. Therefore_RB ,_, co-administration_NN of_IN Duloxetine_NN with_IN other_JJ drugs_NNS that_WDT are_VBP extensively_RB metabolized_VBN by_IN this_DT isozyme_NN and_CC which_WDT have_VBP a_DT narrow_JJ therapeutic_JJ index_NN ,_, including_VBG certain_JJ antidepressants_NNS -LRB-_-LRB- tricyclic_JJ antidepressants_NNS -LSB-_-LRB- TCAs_NNS -RSB-_-RRB- ,_, such_JJ as_IN nortriptyline_NN ,_, amitriptyline_NNP ,_, and_CC imipramine_NN -RRB-_-RRB- ,_, phenothiazines_NNS and_CC Type_NN 1C_NN antiarrhythmics_NNS -LRB-_-LRB- e.g._FW ,_, propafenone_NN ,_, flecainide_NN -RRB-_-RRB- ,_, should_MD be_VB approached_VBN with_IN caution_NN ._. Plasma_NN TCA_NN concentrations_NNS may_MD need_VB to_TO be_VB monitored_VBN and_CC the_DT dose_NN of_IN the_DT TCA_NNP may_MD need_VB to_TO be_VB reduced_VBN if_IN a_DT TCA_NNP is_VBZ co-administered_VBN with_IN Duloxetine_NN ._. Because_IN of_IN the_DT risk_NN of_IN serious_JJ ventricular_JJ arrhythmias_NNS and_CC sudden_JJ death_NN potentially_RB associated_VBN with_IN elevated_JJ plasma_NN levels_NNS of_IN thioridazine_NN ,_, Duloxetine_NNP and_CC thioridazine_NN should_MD not_RB be_VB co-administered_VBN ._. Drugs_NNS Metabolized_VBN by_IN CYP3A_NN :_: Results_NNS of_IN in_FW vitro_FW studies_NNS demonstrate_VBP that_IN duloxetine_NN does_VBZ not_RB inhibit_VB or_CC induce_VB CYP3A_NN activity_NN ._. Duloxetine_NNP May_NNP Have_VBP a_DT Clinically_RB Important_JJ Interaction_NN with_IN the_DT Following_VBG Other_JJ Drugs_NNS :_: Alcohol_NNP :_: When_WRB Duloxetine_NNP and_CC ethanol_NN were_VBD administered_VBN several_JJ hours_NNS apart_RB so_RB that_IN peak_JJ concentrations_NNS of_IN each_DT would_MD coincide_VB ,_, Duloxetine_NNP did_VBD not_RB increase_VB the_DT impairment_NN of_IN mental_JJ and_CC motor_NN skills_NNS caused_VBN by_IN alcohol_NN ._. In_IN the_DT Duloxetine_NNP clinical_JJ trials_NNS database_NN ,_, three_CD Duloxetine-treated_JJ patients_NNS had_VBD liver_NN injury_NN as_IN manifested_VBN by_IN ALT_NNP and_CC total_JJ bilirubin_NN elevations_NNS ,_, with_IN evidence_NN of_IN obstruction_NN ._. Substantial_JJ intercurrent_JJ ethanol_NN use_NN was_VBD present_JJ in_IN each_DT of_IN these_DT cases_NNS ,_, and_CC this_DT may_MD have_VB contributed_VBN to_TO the_DT abnormalities_NNS seen_VBN ._. CNS_NN Acting_NN Drugs_NNS :_: Given_VBN the_DT primary_JJ CNS_NN effects_NNS of_IN Duloxetine_NNP ,_, it_PRP should_MD be_VB used_VBN with_IN caution_NN when_WRB it_PRP is_VBZ taken_VBN in_IN combination_NN with_IN or_CC substituted_VBN for_IN other_JJ centrally_RB acting_VBG drugs_NNS ,_, including_VBG those_DT with_IN a_DT similar_JJ mechanism_NN of_IN action_NN ._. Potential_JJ for_IN Interaction_NN with_IN Drugs_NNS that_WDT Affect_VBP Gastric_JJ Acidity_NN :_: Duloxetine_NNP has_VBZ an_DT enteric_JJ coating_NN that_WDT resists_VBZ dissolution_NN until_IN reaching_VBG a_DT segment_NN of_IN the_DT gastrointestinal_JJ tract_NN where_WRB the_DT pH_NN exceeds_VBZ 5.5_CD ._. In_IN extremely_RB acidic_JJ conditions_NNS ,_, Duloxetine_NNP ,_, unprotected_JJ by_IN the_DT enteric_JJ coating_NN ,_, may_MD undergo_VB hydrolysis_NN to_TO form_VB naphthol_NN ._. Caution_NN is_VBZ advised_VBN in_IN using_VBG Duloxetine_NNP in_IN patients_NNS with_IN conditions_NNS that_WDT may_MD slow_VB gastric_JJ emptying_NN -LRB-_-LRB- e.g._FW ,_, some_DT diabetics_NNS -RRB-_-RRB- ._. Drugs_NNS that_WDT raise_VBP the_DT gastrointestinal_JJ pH_NN may_MD lead_VB to_TO an_DT earlier_JJR release_NN of_IN duloxetine_NN ._. However_RB ,_, co-administration_NN of_IN Duloxetine_NN with_IN aluminum_NN -_: and_CC magnesium-containing_JJ antacids_NNS -LRB-_-LRB- 51_CD mEq_NN -RRB-_-RRB- or_CC Duloxetine_NN with_IN famotidine_NN ,_, had_VBD no_DT significant_JJ effect_NN on_IN the_DT rate_NN or_CC extent_NN of_IN duloxetine_NN absorption_NN after_IN administration_NN of_IN a_DT 40-mg_JJ oral_JJ dose_NN ._. It_PRP is_VBZ unknown_JJ whether_IN the_DT concomitant_JJ administration_NN of_IN proton_NN pump_NN inhibitors_NNS affects_VBZ duloxetine_NN absorption_NN ._. Synergism_NN between_IN xanthine_NN bronchodilators_NNS -LRB-_-LRB- e.g._FW ,_, theophylline_NN -RRB-_-RRB- ,_, ephedrine_NN ,_, and_CC other_JJ sympathomimetic_JJ bronchodilators_NNS has_VBZ been_VBN reported_VBN ._. This_DT should_MD be_VB considered_VBN whenever_WRB these_DT agents_NNS are_VBP prescribed_VBN concomitantly_RB ._. Concurrent_JJ administration_NN of_IN dyphylline_NN and_CC probenecid_NN ,_, which_WDT competes_VBZ for_IN tubular_JJ secretion_NN ,_, has_VBZ been_VBN shown_VBN to_TO increase_VB the_DT plasma_NN half-life_NN of_IN dyphylline_NN ._. Phospholine_NN Iodide_NN potentiates_VBZ other_JJ cholinesterase_NN inhibitors_NNS such_JJ as_IN succinylcholine_NN or_CC organophosphate_NN and_CC carbamate_NN insecticides_NNS ._. Patients_NNS undergoing_VBG systemic_JJ anticholinesterase_NN treatment_NN should_MD be_VB warned_VBN of_IN the_DT possible_JJ additive_JJ effects_NNS of_IN Phospholine_NNP Iodide_NNP ._. Drug_NN interaction_NN studies_NNS have_VBP not_RB been_VBN performed_VBN with_IN Soliris_NNP ._. There_EX is_VBZ no_DT known_JJ drug_NN interference_NN with_IN standard_JJ clinical_JJ laboratory_NN tests_NNS ._. Steroids_NNS enhance_VBP the_DT renal_JJ toxicity_NN of_IN edetate_NN calcium_NN disodium_NN in_IN animals_NNS ._. 7_CD Edetate_NNP calcium_NN disodium_NN interferes_VBZ with_IN the_DT action_NN of_IN zinc_NN insulin_NN preparations_NNS by_IN chelating_VBG the_DT zinc_NN ._. ._. Care_NNP should_MD be_VB given_VBN when_WRB administering_VBG this_DT drug_NN to_TO patients_NNS with_IN symptoms_NNS of_IN myasthenic_JJ weakness_NN who_WP are_VBP also_RB on_IN anticholinesterase_JJ drugs_NNS ._. Since_IN symptoms_NNS of_IN anticholinesterase_NN overdose_NN -LRB-_-LRB- cholinergic_JJ crisis_NN -RRB-_-RRB- may_MD mimic_VB underdosage_NN -LRB-_-LRB- myasthenic_JJ weakness_NN -RRB-_-RRB- ,_, their_PRP$ condition_NN may_MD be_VB worsened_VBN by_IN the_DT use_NN of_IN this_DT drug_NN ._. No_DT formal_JJ drug_NN interaction_NN studies_NNS have_VBP been_VBN performed_VBN with_IN RAPTIVA_NN ._. RAPTIVA_NN should_MD not_RB be_VB used_VBN with_IN other_JJ immunosuppressive_JJ drugs_NNS ._. Acellular_JJ ,_, live_JJ and_CC live-attenuated_JJ vaccines_NNS should_MD not_RB be_VB administered_VBN during_IN RAPTIVA_NN treatment_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS Increases_NNS in_IN lymphocyte_NN counts_VBZ related_JJ to_TO the_DT pharmacologic_JJ mechanism_NN of_IN action_NN are_VBP frequently_RB observed_VBN during_IN RAPTIVA_NN treatment_NN ._. Efavirenz_NNP has_VBZ been_VBN shown_VBN in_FW vivo_FW to_TO induce_VB CYP3A4_NN ._. Other_JJ compounds_NNS that_WDT are_VBP substrates_NNS of_IN CYP3A4_NN may_MD have_VB decreased_VBN plasma_NN concentrations_NNS when_WRB coadministered_VBN with_IN SUSTIVA_NN -LRB-_-LRB- efavirenz_NN -RRB-_-RRB- ._. In_FW vitro_FW studies_NNS have_VBP demonstrated_VBN that_IN efavirenz_NN inhibits_VBZ 2C9_NN ,_, 2C19_NN ,_, and_CC 3A4_NN isozymes_NNS in_IN the_DT range_NN of_IN observed_VBN efavirenz_NN plasma_NN concentrations_NNS ._. Coadministration_NN of_IN efavirenz_NN with_IN drugs_NNS primarily_RB metabolized_VBN by_IN these_DT isozymes_NNS may_MD result_VB in_IN altered_JJ plasma_NN concentrations_NNS of_IN the_DT coadministered_VBN drug_NN ._. Therefore_RB ,_, appropriate_JJ dose_NN adjustments_NNS may_MD be_VB necessary_JJ for_IN these_DT drugs_NNS ._. Drugs_NNS which_WDT induce_VBP CYP3A4_NN activity_NN -LRB-_-LRB- eg_FW ,_, phenobarbital_JJ ,_, rifampin_NN ,_, rifabutin_NN -RRB-_-RRB- would_MD be_VB expected_VBN to_TO increase_VB the_DT clearance_NN of_IN efavirenz_NN resulting_VBG in_IN lowered_JJ plasma_NN concentrations_NNS ._. Drug_NN interactions_NNS with_IN SUSTIVA_NN are_VBP summarized_VBN in_IN Table_NNP 5_CD ._. Table_NNP 5a_NN :_: Drugs_NNS That_WDT Should_MD Not_RB Be_VB Coadministered_JJ With_IN SUSTIV_NN ._. Drug_NN Class_NN ._. Drugs_NNS Within_IN Class_NNP Not_RB To_TO Be_VB Coadministered_JJ With_IN SUSTIV_NN ._. Antihistamines_NNS :_: Benzodiazepines_NNPS GI_NNP Motility_NNP Agents_NNPS Anti-Migraine_NNP Antifunga_NNP ._. astemizole_NN midazolam_NN ,_, triazolam_NN cisapride_NN ergot_NN derivatives_NNS voriconazol_NN ._. Established_VBN Drug_NN Interactions_NNS ._. Drug_NN Name_VB ._. Effect_NN ._. Clinical_JJ Comment_NN ._. Atazanavi_NNP ._. atazanavi_NN ._. When_WRB coadministered_VBN with_IN SUSTIVA_NN in_IN treatment-naive_JJ patients_NNS ,_, the_DT recommended_VBN dose_NN of_IN atazanavir_NN is_VBZ 300_CD mg_NN with_IN ritonavir_NN 100_CD mg_NN and_CC SUSTIVA_NN 600_CD mg_NN -LRB-_-LRB- all_DT once_RB daily_JJ -RRB-_-RRB- ._. Dosing_NN recommendations_NNS for_IN SUSTIVA_NNP and_CC atazanavir_NN in_IN treatment-experienced_JJ patients_NNS have_VBP not_RB been_VBN established_VBN ._. Established_VBN Drug_NN Interactions_NNS -LRB-_-LRB- continued_VBN -RRB-_-RRB- ._. Drug_NN Name_VB ._. Effect_NN ._. Clinical_JJ Comment_NN ._. Clarithromyci_NNP ._. clarithromycin_NN concentratio_NN ._. Plasma_NN concentrations_NNS decreased_VBN by_IN SUSTIVA_NNP ._. clinical_JJ significance_NN unknown_NN ._. In_IN uninfected_JJ volunteers_NNS ,_, 46_CD %_NN developed_VBD rash_NN while_IN receiving_VBG SUSTIVA_NNP and_CC clarithromycin_NN ._. No_DT dose_NN adjustment_NN of_IN SUSTIVA_NNP is_VBZ recommended_VBN when_WRB given_VBN with_IN clarithromycin_NN ._. Alternatives_NNP to_TO clarithromycin_NN ,_, such_JJ as_IN azithromycin_NN ,_, should_MD be_VB considered_VBN ._. Other_JJ macrolide_NN antibiotics_NNS ,_, such_JJ as_IN erythromycin_NN ,_, have_VBP not_RB been_VBN studied_VBN in_IN combination_NN with_IN SUSTIVA_NN ._. 14-OH_JJ metabolite_NN concentration_NN ._. Indinavi_NNP ._. indinavir_NN concentratio_NN ._. The_DT optimal_JJ dose_NN of_IN indinavir_NN ,_, when_WRB given_VBN in_IN combination_NN with_IN SUSTIVA_NNP ,_, is_VBZ not_RB known_VBN ._. Increasing_VBG the_DT indinavir_NN dose_NN to_TO 1000_CD mg_NN every_DT 8_CD hours_NNS does_VBZ not_RB compensate_VB for_IN the_DT increased_VBN indinavir_NN metabolism_NN due_JJ to_TO SUSTIVA_NNP ._. When_WRB indinavir_NN at_IN an_DT increased_VBN dose_NN -LRB-_-LRB- 1000_CD mg_NN every_DT 8_CD hours_NNS -RRB-_-RRB- was_VBD given_VBN with_IN SUSTIVA_NN -LRB-_-LRB- 600_CD mg_NN once_RB daily_JJ -RRB-_-RRB- ,_, the_DT indinavir_NN AUC_NN and_CC Cmin_NN were_VBD decreased_VBN on_IN average_NN by_IN 33-46_CD %_NN and_CC 39-57_CD %_NN ,_, respectively_RB ,_, compared_VBN to_TO when_WRB indinavir_NN -LRB-_-LRB- 800_CD mg_NN every_DT 8_CD hours_NNS -RRB-_-RRB- was_VBD given_VBN alone_RB ._. Lopinavir/ritonavi_NN ._. lopinavir_NN concentratio_NN ._. A_DT dose_NN increase_NN of_IN lopinavir/ritonavir_NN to_TO 533/133_CD mg_NN -LRB-_-LRB- 4_CD capsules_NNS or_CC 6.5_CD mL_NN -RRB-_-RRB- twice_RB daily_JJ taken_VBN with_IN food_NN is_VBZ recommended_VBN when_WRB used_VBN in_IN combination_NN with_IN SUSTIVA_NN ._. Methadon_NNP ._. methadone_NN concentratio_NN ._. Coadministration_NNP in_IN HIV-infected_JJ individuals_NNS with_IN a_DT history_NN of_IN injection_NN drug_NN use_NN resulted_VBD in_IN decreased_VBN plasma_NN levels_NNS of_IN methadone_NN and_CC signs_NNS of_IN opiate_JJ withdrawal_NN ._. Methadone_NNP dose_NN was_VBD increased_VBN by_IN a_DT mean_NN of_IN 22_CD %_NN to_TO alleviate_VB withdrawal_NN symptoms_NNS ._. Patients_NNS should_MD be_VB monitored_VBN for_IN signs_NNS of_IN withdrawal_NN and_CC their_PRP$ methadone_NN dose_NN increased_VBD as_IN required_VBN to_TO alleviate_VB withdrawal_NN symptoms_NNS ._. Ethinyl_NN estradio_NN ._. ethinyl_NN estradiol_NN concentratio_NN ._. Plasma_NN concentrations_NNS increased_VBN by_IN SUSTIVA_NN -LRB-_-LRB- efavirenz_NN -RRB-_-RRB- ._. clinical_JJ significance_NN unknown_NN ._. Because_IN the_DT potential_JJ interaction_NN of_IN efavirenz_NN with_IN oral_JJ contraceptives_NNS has_VBZ not_RB been_VBN fully_RB characterized_VBN ,_, a_DT reliable_JJ method_NN of_IN barrier_NN contraception_NN should_MD be_VB used_VBN in_IN addition_NN to_TO oral_JJ contraceptives_NNS ._. Rifabuti_NNP ._. rifabutin_NN concentratio_NN ._. Increase_NN daily_RB dose_NN of_IN rifabutin_NN by_IN 50_CD %_NN ._. Consider_VB doubling_VBG the_DT rifabutin_NN dose_NN in_IN regimens_NNS where_WRB rifabutin_NN is_VBZ given_VBN 2_CD or_CC 3_CD times_NNS a_DT week_NN ._. Rifampi_NNP ._. efavirenz_NN concentratio_NN ._. Clinical_JJ significance_NN of_IN reduced_VBN efavirenz_NN concentrations_NNS unknown_JJ ._. Ritonavi_NNP ._. ritonavir_NN concentratio_NN ._. Combination_NN was_VBD associated_VBN with_IN a_DT higher_JJR frequency_NN of_IN adverse_JJ clinical_JJ experiences_NNS -LRB-_-LRB- eg_FW ,_, dizziness_NN ,_, nausea_NN ,_, paresthesia_NN -RRB-_-RRB- and_CC laboratory_NN abnormalities_NNS -LRB-_-LRB- elevated_JJ liver_NN enzymes_NNS -RRB-_-RRB- ._. Monitoring_NN of_IN liver_NN enzymes_NNS is_VBZ recommended_VBN when_WRB SUSTIVA_NNP is_VBZ used_VBN in_IN combination_NN with_IN ritonavir_NN ._. efavirenz_NN concentratio_NN ._. Saquinavi_NNP ._. saquinavir_NN concentratio_NN ._. Should_MD not_RB be_VB used_VBN as_IN sole_JJ protease_NN inhibitor_NN in_IN combination_NN with_IN SUSTIVA_NN ._. Sertralin_NN ._. sertraline_NN concentratio_NN ._. Increases_NNS in_IN sertraline_NN dose_NN should_MD be_VB guided_VBN by_IN clinical_JJ response_NN ._. Other_JJ Potentially_RB Clinically_RB Significant_JJ Drug_NN or_CC Herbal_NNP Product_NNP Interactions_NNS With_IN SUSTIVAb_NN ._. Anticoagulants_NNPS :_: Warfari_NNS ._. Plasma_NN concentrations_NNS and_CC effects_NNS potentially_RB increased_VBD or_CC decreased_VBN by_IN SUSTIVA_NNP ._. Anticonvulsants_NNPS :_: Phenytoin_NNP Phenobarbital_NNP Carbamazepin_NNP ._. Potential_JJ for_IN reduction_NN in_IN anticonvulsant_JJ and/or_CC efavirenz_JJ plasma_NN levels_NNS ._. periodic_JJ monitoring_NN of_IN anticonvulsant_JJ plasma_NN levels_NNS should_MD be_VB conducted_VBN ._. Antifungals_NNS :_: Itraconazole_NNP Ketoconazol_NNP ._. Drug_NN interaction_NN studies_NNS with_IN SUSTIVA_NN and_CC these_DT imidazole_NN and_CC triazole_NN antifungals_NNS have_VBP not_RB been_VBN conducted_VBN ._. SUSTIVA_NNP has_VBZ the_DT potential_JJ to_TO decrease_VB plasma_NN concentrations_NNS of_IN itraconazole_NN and_CC ketoconazole_NN ._. Anti-HIV_JJ protease_NN inhibitors_NNS :_: Saquinavir/ritonavir_NN combinatio_NN ._. No_DT pharmacokinetic_JJ data_NNS are_VBP available_JJ ._. Amprenavi_NNP ._. SUSTIVAhas_NNS the_DT potential_JJ to_TO decrease_VB serum_NN concentrations_NNS of_IN amprenavir_NN ._. Non-nucleoside_JJ reverse_JJ transcriptase_NN inhibitor_NN ._. No_DT studies_NNS have_VBP been_VBN performed_VBN with_IN other_JJ NNRTIs_NNS ._. St._NNP John_NNP s_VBZ wort_NN -LRB-_-LRB- Hypericum_NN perforatum_NN -RRB-_-RRB- ._. Expected_VBN to_TO substantially_RB decrease_VB plasma_NN levels_NNS of_IN efavirenz_NN ;_: has_VBZ not_RB been_VBN studied_VBN in_IN combination_NN with_IN SUSTIVA_NN ._. a_DT See_NNP Tables_NNP 1_CD and_CC 2_CD ._. b_NN This_DT table_NN is_VBZ not_RB all-inclusive_JJ ._. Other_JJ Drugs_NNS :_: Based_VBN on_IN the_DT results_NNS of_IN drug_NN interaction_NN studies_NNS ,_, no_DT dosage_NN adjustment_NN is_VBZ recommended_VBN when_WRB SUSTIVA_NNP -LRB-_-LRB- efavirenz_NN -RRB-_-RRB- is_VBZ given_VBN with_IN the_DT following_NN :_: aluminum/magnesium_NN hydroxide_NN antacids_NNS ,_, azithromycin_NN ,_, cetirizine_NN ,_, famotidine_NN ,_, fluconazole_NN ,_, lamivudine_NN ,_, lorazepam_NN ,_, nelfinavir_NN ,_, paroxetine_NN ,_, and_CC zidovudine_NN ._. Specific_JJ drug_NN interaction_NN studies_NNS have_VBP not_RB been_VBN performed_VBN with_IN SUSTIVA_NN and_CC NRTIs_NNS other_JJ than_IN lamivudine_NN and_CC zidovudine_NN ._. Clinically_RB significant_JJ interactions_NNS would_MD not_RB be_VB expected_VBN since_IN the_DT NRTIs_NNS are_VBP metabolized_VBN via_IN a_DT different_JJ route_NN than_IN efavirenz_NN and_CC would_MD be_VB unlikely_JJ to_TO compete_VB for_IN the_DT same_JJ metabolic_JJ enzymes_NNS and_CC elimination_NN pathways_NNS ._. The_DT potential_NN for_IN drug_NN interactions_NNS with_IN EMTRIVA_NNP has_VBZ been_VBN studied_VBN in_IN combination_NN with_IN indinavir_NN ,_, stavudine_NN ,_, famciclovir_NN ,_, and_CC tenofovir_NN disoproxil_NN fumarate_NN ._. There_EX were_VBD no_DT clinically_RB significant_JJ drug_NN interactions_NNS for_IN any_DT of_IN these_DT drugs_NNS ._. Hypotension_NN :_: Patients_NNS on_IN Diuretic_JJ Therapy_NN :_: Patients_NNS on_IN diuretics_NNS and_CC especially_RB those_DT in_IN whom_WP diuretic_JJ therapy_NN was_VBD recently_RB instituted_VBN ,_, may_MD occasionally_RB experience_VB an_DT excessive_JJ reduction_NN of_IN blood_NN pressure_NN after_IN initiation_NN of_IN therapy_NN with_IN enalapril_NN or_CC enalaprilat_NN ._. The_DT possibility_NN of_IN hypotensive_JJ effects_NNS with_IN enalapril_NN or_CC enalaprilat_NN can_MD be_VB minimized_VBN by_IN either_CC discontinuing_VBG the_DT diuretic_JJ or_CC increasing_VBG the_DT salt_NN intake_NN prior_RB to_TO initiation_NN of_IN treatment_NN with_IN enalapril_NN or_CC enalaprilat_NN ._. If_IN it_PRP is_VBZ necessary_JJ to_TO continue_VB the_DT diuretic_JJ ,_, provide_VBP close_JJ medical_JJ supervision_NN after_IN the_DT initial_JJ dose_NN for_IN at_IN least_JJS two_CD hours_NNS and_CC until_IN blood_NN pressure_NN has_VBZ stabilized_VBN for_IN at_IN least_JJS an_DT additional_JJ hour_NN ._. Agents_NNS Causing_VBG Renin_NNP Release_NNP :_: The_DT antihypertensive_JJ effect_NN of_IN enalapril_NN and_CC enalapril_NN IV_CD is_VBZ augmented_VBN by_IN antihypertensive_JJ agents_NNS that_WDT cause_VBP renin_NN release_NN -LRB-_-LRB- e.g._FW ,_, diuretics_NNS -RRB-_-RRB- ._. Non-steroidal_JJ Anti-inflammatory_JJ Agents_NNS :_: In_IN some_DT patients_NNS with_IN compromised_VBN renal_JJ function_NN who_WP are_VBP being_VBG treated_VBN with_IN nonsteroidal_JJ anti-inflammatory_JJ drugs_NNS ,_, the_DT co-administration_NN of_IN enalapril_NN may_MD result_VB in_IN a_DT further_JJ deterioration_NN of_IN renal_JJ function_NN ._. These_DT effects_NNS are_VBP usually_RB reversible_JJ ._. In_IN a_DT clinical_JJ pharmacology_NN study_NN ,_, indomethacin_NN or_CC sulindac_NN was_VBD administered_VBN to_TO hypertensive_JJ patients_NNS receiving_VBG VASOTEC_NNP ._. In_IN this_DT study_NN there_EX was_VBD no_DT evidence_NN of_IN a_DT blunting_NN of_IN the_DT antihypertensive_JJ action_NN of_IN VASOTEC_NNP ._. However_RB ,_, reports_NNS suggest_VBP that_IN NSAIDs_NNS may_MD diminish_VB the_DT antihypertensive_JJ effect_NN of_IN ACE_NN inhibitors_NNS ._. This_DT interaction_NN should_MD be_VB given_VBN consideration_NN in_IN patients_NNS taking_VBG NSAIDs_NNS concomitantly_RB with_IN ACE_NN inhibitors_NNS ._. Other_JJ Cardiovascular_NNP Agents_NNPS :_: Enalapril_NN and_CC enalapril_NN IV_CD have_VBP been_VBN used_VBN concomitantly_RB with_IN beta_NN adrenergic-blocking_JJ agents_NNS ,_, methyldopa_NN ,_, nitrates_NNS ,_, calcium-blocking_JJ agents_NNS ,_, hydralazine_NN ,_, prazosin_NN and_CC digoxin_NN without_IN evidence_NN of_IN clinically_RB significant_JJ adverse_JJ interactions_NNS ._. Enalapril_NNP IV_NNP has_VBZ been_VBN used_VBN concomitantly_RB with_IN digitalis_NN without_IN evidence_NN of_IN clinically_RB significant_JJ adverse_JJ reactions_NNS ._. Agents_NNS Increasing_VBG Serum_NN Potassium_NN :_: Enalapril_NNP and_CC enalapril_NN IV_CD attenuate_VBP potassium_NN loss_NN caused_VBN by_IN thiazide-type_JJ diuretics_NNS ._. Potassium-sparing_JJ diuretics_NNS -LRB-_-LRB- e.g._FW ,_, spironolactone_NN ,_, triamterene_NN ,_, or_CC amiloride_NN -RRB-_-RRB- ,_, potassium_NN supplements_NNS ,_, or_CC potassium-containing_JJ salt_NN substitutes_NNS may_MD lead_VB to_TO significant_JJ increases_NNS in_IN serum_NN potassium_NN ._. Therefore_RB ,_, if_IN concomitant_JJ use_NN of_IN these_DT agents_NNS is_VBZ indicated_VBN because_IN of_IN demonstrated_VBN hypokalemia_NN ,_, they_PRP should_MD be_VB used_VBN with_IN caution_NN and_CC with_IN frequent_JJ monitoring_NN of_IN serum_NN potassium_NN ._. Potassium_NN sparing_NN agents_NNS should_MD generally_RB not_RB be_VB used_VBN in_IN patients_NNS with_IN heart_NN failure_NN receiving_VBG enalapril_NN ._. Lithium_NN :_: Lithium_NN toxicity_NN has_VBZ been_VBN reported_VBN in_IN patients_NNS receiving_VBG lithium_NN concomitantly_RB with_IN drugs_NNS which_WDT cause_VBP elimination_NN of_IN sodium_NN ,_, including_VBG ACE_NN inhibitors_NNS ._. It_PRP is_VBZ recommended_VBN that_IN serum_NN lithium_NN levels_NNS be_VB monitored_VBN frequently_RB if_IN enalapril_NN is_VBZ administered_VBN concomitantly_RB with_IN lithium_NN ._. The_DT action_NN of_IN nondepolarizing_JJ relaxants_NNS is_VBZ augmented_VBN by_IN Enflurane_NN ._. Less_RBR than_IN the_DT usual_JJ amounts_NNS of_IN these_DT medicines_NNS should_MD be_VB used_VBN ._. If_IN the_DT usual_JJ amounts_NNS of_IN nondepolarizing_JJ relaxants_NNS are_VBP given_VBN ,_, the_DT time_NN for_IN recovery_NN from_IN neuromuscular_JJ blockade_NN will_MD be_VB longer_RBR in_IN the_DT presence_NN of_IN Enflurane_NN than_IN when_WRB halothane_NN or_CC nitrous_JJ oxide_NN with_IN a_DT balanced_JJ technique_NN are_VBP used_VBN ._. CYP450_NN Metabolized_VBN Drugs_NNS Results_NNS from_IN in_FW vitro_FW and_CC in_FW vivo_FW studies_NNS suggest_VBP that_IN enfuvirtide_NN is_VBZ unlikely_JJ to_TO have_VB significant_JJ drug_NN interactions_NNS with_IN concomitantly_RB administered_VBN drugs_NNS metabolized_VBN by_IN CYP450_NN enzymes_NNS ._. Antiretroviral_JJ Agents_NNS :_: No_DT drug_NN interactions_NNS with_IN other_JJ antiretroviral_JJ medications_NNS have_VBP been_VBN identified_VBN that_WDT would_MD warrant_VB alteration_NN of_IN either_CC the_DT enfuvirtide_NN dose_NN or_CC the_DT dose_NN of_IN the_DT other_JJ antiretroviral_JJ medication_NN ._. Bismuth_NNP :_: Bismuth_NNP subsalicylate_NNP ,_, given_VBN concomitantly_RB with_IN enoxacin_NN or_CC 60_CD minutes_NNS following_VBG enoxacin_NN administration_NN ,_, decreased_VBD enoxacin_NN bioavailability_NN by_IN approximately_RB 25_CD %_NN ._. Thus_RB ,_, concomitant_JJ administration_NN of_IN enoxacin_NN and_CC bismuth_NN subsalicylate_NN should_MD be_VB avoided_VBN ._. Caffeine_NN :_: Enoxacin_NN is_VBZ a_DT potent_JJ inhibitor_NN of_IN the_DT cytochrome_NN P-450_NN isozymes_NNS responsible_JJ for_IN the_DT metabolism_NN of_IN methylxanthines_NNS ._. In_IN a_DT multiple-dose_JJ study_NN ,_, enoxacin_NN caused_VBD a_DT dose-related_JJ increase_NN in_IN the_DT mean_NN elimination_NN half-life_NN of_IN caffeine_NN ,_, thereby_RB decreasing_VBG the_DT clearance_NN of_IN caffeine_NN by_IN up_RB to_TO 80_CD %_NN and_CC leading_VBG to_TO a_DT five-fold_JJ increase_NN in_IN the_DT AUC_NN and_CC the_DT half-life_NN of_IN caffeine_NN ._. Trough_NN plasma_NN enoxacin_NN levels_NNS were_VBD also_RB 20_CD %_NN higher_JJR when_WRB caffeine_NN and_CC enoxacin_NN were_VBD administered_VBN concomitantly_RB ._. Caffeine-related_JJ adverse_JJ effects_NNS have_VBP occurred_VBN in_IN patients_NNS consuming_VBG caffeine_NN while_IN on_IN therapy_NN with_IN enoxacin_NN ._. Cyclosporine_NN :_: Elevated_JJ serum_NN levels_NNS of_IN cyclosporine_NN have_VBP been_VBN reported_VBN with_IN concomitant_JJ use_NN of_IN cyclosporine_NN with_IN other_JJ members_NNS of_IN the_DT quinolone_NN class_NN ._. Digoxin_NNP :_: Enoxacin_NN may_MD raise_VB serum_NN digoxin_NN levels_NNS in_IN some_DT individuals_NNS ._. If_IN signs_NNS and_CC symptoms_NNS suggestive_JJ of_IN digoxin_NN toxicity_NN occur_VBP when_WRB enoxacin_NN and_CC digoxin_NN are_VBP given_VBN concomitantly_RB ,_, physicians_NNS are_VBP advised_VBN to_TO obtain_VB serum_NN digoxin_NN levels_NNS and_CC adjust_VBP digoxin_NN doses_NNS appropriately_RB ._. Non-steroidal_JJ anti-inflammatory_JJ agents_NNS :_: Seizures_NNS have_VBP been_VBN reported_VBN in_IN patients_NNS taking_VBG enoxacin_NN concomitantly_RB with_IN the_DT nonsteroidal_JJ anti-inflammatory_JJ drug_NN fenbufen_NN ._. Animal_NN studies_NNS also_RB suggest_VBP an_DT increased_VBN potential_NN for_IN seizures_NNS when_WRB these_DT two_CD drugs_NNS are_VBP given_VBN concomitantly_RB ._. Fenbufen_NNP is_VBZ not_RB approved_VBN in_IN the_DT United_NNP States_NNPS at_IN this_DT time_NN ._. Sucralfate_NNP and_CC antacids_NNS :_: Quinolones_NNS form_VBP chelates_NNS with_IN metal_NN cations_NNS ._. Therefore_RB ,_, administration_NN of_IN quinolones_NNS with_IN antacids_NNS containing_VBG calcium_NN ,_, magnesium_NN ,_, or_CC aluminum_NN ._. with_IN sucralfate_NN ._. with_IN divalent_JJ or_CC trivalent_JJ cations_NNS such_JJ as_IN iron_NN ._. or_CC with_IN multivitamins_NNS containing_VBG zinc_NN may_MD substantially_RB interfere_VB with_IN drug_NN absorption_NN and_CC result_NN in_IN insufficient_JJ plasma_NN and_CC tissue_NN quinolone_NN concentrations_NNS ._. Antacids_NNS containing_VBG aluminum_NN hydroxide_NN and_CC magnesium_NN hydroxide_NN reduce_VB the_DT oral_JJ absorption_NN of_IN enoxacin_NN by_IN 75_CD %_NN ._. The_DT oral_JJ bioavailability_NN of_IN enoxacin_NN is_VBZ reduced_VBN by_IN 60_CD %_NN with_IN coadministration_NN of_IN ranitidine_NN ._. These_DT agents_NNS should_MD not_RB be_VB taken_VBN for_IN 8_CD hours_NNS before_IN or_CC for_IN 2_CD hours_NNS after_IN enoxacin_NN administration_NN ._. Theophylline_NNP :_: Enoxacin_NN is_VBZ a_DT potent_JJ inhibitor_NN of_IN the_DT cytochrome_NN P-450_NN isozymes_NNS responsible_JJ for_IN the_DT metabolism_NN of_IN methylxanthines_NNS ._. Enoxacin_NN interferes_VBZ with_IN the_DT metabolism_NN of_IN theophylline_NN resulting_VBG in_IN a_DT 42_CD %_NN to_TO 74_CD %_NN dose-related_JJ decrease_NN in_IN theophylline_NN clearance_NN and_CC a_DT subsequent_JJ 260_CD %_NN to_TO 350_CD %_NN increase_NN in_IN serum_NN theophylline_NN levels_NNS ._. Theophylline-related_JJ adverse_JJ effects_NNS have_VBP occurred_VBN in_IN patients_NNS when_WRB theophylline_NN and_CC enoxacin_NN were_VBD coadministered_VBN ._. Warfarin_NNP :_: Quinolones_NNS ,_, including_VBG enoxacin_NN ,_, decrease_VB the_DT clearance_NN of_IN R-warfarin_NN ,_, the_DT less_RBR active_JJ isomer_NN of_IN racemic_JJ warfarin_NN ._. Enoxacin_NN does_VBZ not_RB affect_VB the_DT clearance_NN of_IN the_DT active_JJ S-isomer_NN ,_, and_CC changes_NNS in_IN clotting_VBG time_NN have_VBP not_RB been_VBN observed_VBN when_WRB enoxacin_NN and_CC warfarin_NN were_VBD coadministered_VBN ._. Nevertheless_RB ,_, the_DT prothrombin_NN time_NN or_CC other_JJ suitable_JJ coagulation_NN test_NN should_MD be_VB monitored_VBN when_WRB warfarin_NN or_CC its_PRP$ derivatives_NNS and_CC enoxacin_NN are_VBP given_VBN concomitantly_RB ._. Unless_IN really_RB needed_VBN ,_, agents_NNS which_WDT may_MD enhance_VB the_DT risk_NN of_IN hemorrhage_NN should_MD be_VB discontinued_VBN prior_RB to_TO initiation_NN of_IN Lovenox_NNP Injection_NN therapy_NN ._. These_DT agents_NNS include_VBP medications_NNS such_JJ as_IN :_: anticoagulants_NNS ,_, platelet_NN inhibitors_NNS including_VBG acetylsalicylic_JJ acid_NN ,_, sali-cylates_NNS ,_, NSAIDs_NNS -LRB-_-LRB- including_VBG ketorolac_NN tromethamine_NN -RRB-_-RRB- ,_, dipyridamole_NN ,_, or_CC sulfinpyrazone_NN ._. If_IN co-administration_NN is_VBZ essential_JJ ,_, conduct_VB close_JJ clinical_JJ and_CC laboratory_JJ monitoring_NN ._. In_FW vitro_FW studies_NNS of_IN human_JJ CYP_NN enzymes_NNS showed_VBD that_IN entacapone_NN inhibited_VBD the_DT CYP_NN enzymes_NNS 1A2_NN ,_, 2A6_NN ,_, 2C9_NN ,_, 2C19_NN ,_, 2D6_NN ,_, 2E1_NN and_CC 3A_NN only_RB at_IN very_RB high_JJ concentrations_NNS -LRB-_-LRB- IC50_NN from_IN 200_CD to_TO over_IN 1000_CD uM_NN ._. an_DT oral_JJ 200_CD mg_NN dose_NN achieves_VBZ a_DT highest_JJS level_NN of_IN approximately_RB 5_CD uM_NN in_IN people_NNS -RRB-_-RRB- ;_: ._. these_DT enzymes_NNS would_MD therefore_RB not_RB be_VB expected_VBN to_TO be_VB inhibited_VBN in_IN clinical_JJ use_NN ._. Protein_NN Binding_NN :_: Entacapone_NNP is_VBZ highly_RB protein_NN bound_VBD -LRB-_-LRB- 98_CD %_NN -RRB-_-RRB- ._. In_FW vitro_FW studies_NNS have_VBP shown_VBN no_DT binding_NN displacement_NN between_IN entacapone_NN and_CC other_JJ highly_RB bound_VBN drugs_NNS ,_, such_JJ as_IN warfarin_NN ,_, salicylic_JJ acid_NN ,_, phenylbutazone_NN ,_, and_CC diazepam_NN ._. Drugs_NNS Metabolized_VBN by_IN Catechol-O-methyltransferase_NN -LRB-_-LRB- COMT_NN -RRB-_-RRB- :_: Hormone_NN levels_NNS :_: Levodopa_NN is_VBZ known_VBN to_TO depress_VB prolactin_NN secretion_NN and_CC increase_NN growth_NN hormone_NN levels_NNS ._. Treatment_NN with_IN entacapone_NN coadministered_VBN with_IN levodopa/dopa_NN decarboxylase_NN inhibitor_NN does_VBZ not_RB change_VB these_DT effects_NNS ._. No_DT interaction_NN was_VBD noted_VBN with_IN the_DT MAO-B_NN inhibitor_NN selegiline_NN in_IN two_CD multiple-dose_JJ interaction_NN studies_NNS when_WRB entacapone_NN was_VBD coadministered_VBN with_IN a_DT levodopa/dopa_NN decarboxylase_NN inhibitor_NN -LRB-_-LRB- n_NN =_JJ 29_CD -RRB-_-RRB- ._. More_JJR than_IN 600_CD Parkinsons_NNPS disease_NN patients_NNS in_IN clinical_JJ trials_NNS have_VBP used_VBN selegiline_NN in_IN combination_NN with_IN entacapone_NN and_CC levodopa/dopa_NN decarboxylase_NN inhibitor_NN ._. As_IN most_JJS entacapone_JJ excretion_NN is_VBZ via_IN the_DT bile_NN ,_, caution_NN should_MD be_VB exercised_VBN when_WRB drugs_NNS known_VBN to_TO interfere_VB with_IN biliary_JJ excretion_NN ,_, glucuronidation_NN ,_, and_CC intestinal_JJ beta-glucuronidase_NN are_VBP given_VBN concurrently_RB with_IN entacapone_NN ._. These_DT include_VBP probenecid_NN ,_, cholestyramine_NN ,_, and_CC some_DT antibiotics_NNS -LRB-_-LRB- e.g._FW erythromycin_FW ,_, rifamipicin_NN ,_, ampicillin_NN and_CC chloramphenicol_NN -RRB-_-RRB- ._. No_DT interaction_NN with_IN the_DT tricyclic_JJ antidepressant_JJ imipramine_NN was_VBD shown_VBN in_IN a_DT single-dose_JJ study_NN with_IN entacapone_NN without_IN coadministered_VBN levodopa/dopa-decarboxylase_NN inhibitor_NN ._. Since_IN entecavir_NN is_VBZ primarily_RB eliminated_VBN by_IN the_DT kidneys_NNS ,_, coadministration_NN of_IN BARACLUDE_NN with_IN drugs_NNS that_WDT reduce_VBP renal_JJ function_NN or_CC compete_VB for_IN active_JJ tubular_JJ secretion_NN may_MD increase_VB serum_NN concentrations_NNS of_IN either_CC entecavir_NN or_CC the_DT coadministered_VBN drug_NN ._. Coadministration_NN of_IN entecavir_NN with_IN lamivudine_NN ,_, adefovir_NN dipivoxil_NN ,_, or_CC tenofovir_NN disoproxil_NN fumarate_NN did_VBD not_RB result_VB in_IN significant_JJ drug_NN interactions_NNS ._. The_DT effects_NNS of_IN coadministration_NN of_IN BARACLUDE_NN with_IN other_JJ drugs_NNS that_WDT are_VBP renally_RB eliminated_VBN or_CC are_VBP known_VBN to_TO affect_VB renal_JJ function_NN have_VBP not_RB been_VBN evaluated_VBN ,_, and_CC patients_NNS should_MD be_VB monitored_VBN closely_RB for_IN adverse_JJ events_NNS when_WRB BARACLUDE_NNP is_VBZ coadministered_VBN with_IN such_JJ drugs_NNS ._. None_NN Reported_VBN ._. Epinephrine_NN should_MD be_VB used_VBN cautiously_RB in_IN patients_NNS with_IN hyperthyroidism_NN ,_, hypertension_NN and_CC cardiac_JJ arrhythmias_NNS ._. All_DT vasopressors_NNS should_MD be_VB used_VBN cautiously_RB in_IN patients_NNS taking_VBG monoamine_NN oxidase_NN -LRB-_-LRB- MAO_NN -RRB-_-RRB- inhibitors_NNS ._. Epinephrine_NN should_MD not_RB be_VB administered_VBN concomitantly_RB with_IN other_JJ sympathomimetic_JJ drugs_NNS -LRB-_-LRB- such_JJ as_IN isoproterenol_NN -RRB-_-RRB- because_IN of_IN possible_JJ additive_JJ effects_NNS and_CC increased_VBD toxicity_NN ._. Combined_JJ effects_NNS may_MD induce_VB serious_JJ cardiac_JJ arrhythmias_NNS ._. They_PRP may_MD be_VB administered_VBN alternately_RB when_WRB the_DT preceding_JJ effect_NN of_IN other_JJ such_JJ drug_NN has_VBZ subsided_VBN ._. Administration_NN of_IN epinephrine_NN to_TO patients_NNS receiving_VBG cyclopropane_NN or_CC halogenated_VBN hydrocarbon_NN general_JJ anesthetics_NNS such_JJ as_IN halothane_NN which_WDT sensitize_VBP the_DT myocardium_NN ,_, may_MD induce_VB cardiac_JJ arrhythmia_NN ._. When_WRB encountered_VBN ,_, such_JJ arrhythmias_NNS may_MD respond_VB to_TO administration_NN of_IN a_DT beta-adrenergic_JJ blocking_VBG drug_NN ._. Epinephrine_NN also_RB should_MD be_VB used_VBN cautiously_RB with_IN other_JJ drugs_NNS -LRB-_-LRB- e.g._FW ,_, digitalis_NN ,_, glycosides_NNS -RRB-_-RRB- that_WDT sensitize_VBP the_DT myocardium_NN to_TO the_DT actions_NNS of_IN sympathomimetic_JJ drugs_NNS ._. Diuretic_JJ agents_NNS may_MD decrease_VB vascular_JJ response_NN to_TO pressor_NN drugs_NNS such_JJ as_IN epinephrine_NN ._. Epinephrine_NN may_MD antagonize_VB the_DT neuron_NN blockade_NN produced_VBN by_IN guanethidine_NN resulting_VBG in_IN decreased_VBN antihypertensive_JJ effect_NN and_CC requiring_VBG increased_VBN dosage_NN of_IN the_DT latter_JJ ._. ELLENCE_NN when_WRB used_VBN in_IN combination_NN with_IN other_JJ cytotoxic_JJ drugs_NNS may_MD show_VB on-treatment_JJ additive_JJ toxicity_NN ,_, especially_RB hematologic_JJ and_CC gastrointestinal_JJ effects_NNS ._. Concomitant_JJ use_NN of_IN ELLENCE_NN with_IN other_JJ cardioactive_JJ compounds_NNS that_WDT could_MD cause_VB heart_NN failure_NN -LRB-_-LRB- e.g._FW ,_, calcium_NN channel_NN blockers_NNS -RRB-_-RRB- ,_, requires_VBZ close_JJ monitoring_NN of_IN cardiac_JJ function_NN throughout_IN treatment_NN ._. There_EX are_VBP few_JJ data_NNS regarding_VBG the_DT coadministration_NN of_IN radiation_NN therapy_NN and_CC epirubicin_NN ._. In_IN adjuvant_JJ trials_NNS of_IN epirubicin-containing_JJ CEF-120_NN or_CC FEC-100_NN chemotherapies_NNS ,_, breast_NN irradiation_NN was_VBD delayed_VBN until_IN after_IN chemotherapy_NN was_VBD completed_VBN ._. This_DT practice_NN resulted_VBD in_IN no_DT apparent_JJ increase_NN in_IN local_JJ breast_NN cancer_NN recurrence_NN relative_JJ to_TO published_VBN accounts_NNS in_IN the_DT literature_NN ._. A_DT small_JJ number_NN of_IN patients_NNS received_VBD epirubicin-based_JJ chemotherapy_NN concomitantly_RB with_IN radiation_NN therapy_NN but_CC had_VBD chemotherapy_NN interrupted_JJ in_IN order_NN to_TO avoid_VB potential_JJ overlapping_VBG toxicities_NNS ._. It_PRP is_VBZ likely_JJ that_IN use_NN of_IN epirubicin_NN with_IN radiotherapy_NN may_MD sensitize_VB tissues_NNS to_TO the_DT cytotoxic_JJ actions_NNS of_IN irradiation_NN ._. Administration_NN of_IN ELLENCE_NN after_IN previous_JJ radiation_NN therapy_NN may_MD induce_VB an_DT inflammatory_JJ recall_NN reaction_NN at_IN the_DT site_NN of_IN the_DT irradiation_NN ._. Epirubicin_NN is_VBZ extensively_RB metabolized_VBN by_IN the_DT liver_NN ._. Changes_NNS in_IN hepatic_JJ function_NN induced_VBN by_IN concomitant_JJ therapies_NNS may_MD affect_VB epirubicin_NN metabolism_NN ,_, pharmacokinetics_NNS ,_, therapeutic_JJ efficacy_NN ,_, and/or_CC toxicity_NN ._. Cimetidine_NN increased_VBD the_DT AUC_NN of_IN epirubicin_NN by_IN 50_CD %_NN ._. Cimetidine_NN treatment_NN should_MD be_VB stopped_VBN during_IN treatment_NN with_IN ELLENCE_NN ._. Drug-Laboratory_JJ Test_NN Interactions_NNS There_EX are_VBP no_DT known_JJ interactions_NNS between_IN ELLENCE_NNP and_CC laboratory_NN tests_NNS ._. Inhibitors_NNS of_IN CYP3A4-Eplerenone_NN metabolism_NN is_VBZ predominantly_RB mediated_VBN via_IN CYP3A4_NN ._. A_DT pharmacokinetic_JJ study_NN evaluating_VBG the_DT administration_NN of_IN a_DT single_JJ dose_NN of_IN INSPRA_NN 100_CD mg_NN with_IN ketoconazole_NN 200_CD mg_NN BID_NNP ,_, a_DT potent_JJ inhibitor_NN of_IN the_DT CYP3A4_NN pathway_NN ,_, showed_VBD a_DT 1.7-fold_JJ increase_NN in_IN Cmax_NN of_IN eplerenone_NN and_CC a_DT 5.4-fold_JJ increase_NN in_IN AUC_NN of_IN eplerenone_NN ._. INSPRA_NN should_MD not_RB be_VB used_VBN with_IN drugs_NNS described_VBN as_IN strong_JJ inhibitors_NNS of_IN CYP3A4_NN in_IN their_PRP$ labeling_NN ._. Administration_NN of_IN eplerenone_NN with_IN other_JJ CYP3A4_NN inhibitors_NNS -LRB-_-LRB- e.g._FW ,_, erythromycin_NN 500_CD mg_NN BID_NNP ,_, verapamil_NN 240_CD mg_NN QD_NN ,_, saquinavir_NN 1200_CD mg_NN TID_NN ,_, fluconazole_NN 200_CD mg_NN QD_NN -RRB-_-RRB- resulted_VBD in_IN increases_NNS in_IN Cmax_NN of_IN eplerenone_NN ranging_VBG from_IN 1.4_CD -_: to_TO 1.6_CD -_: fold_JJ and_CC AUC_NN from_IN 2.0_CD -_: to_TO 2.9_CD -_: fold_NN ._. ACE_NN Inhibitors_NNS and_CC Angiotensin_NN II_CD Receptor_NN Antagonists_NNS -LRB-_-LRB- Congestive_JJ Heart_NNP Failure_NN Post-Myocardial_JJ Infarction_NN -RRB-_-RRB- -_: In_IN EPHESUS_NNP ,_, 3020_CD -LRB-_-LRB- 91_CD %_NN -RRB-_-RRB- patients_NNS receiving_VBG INSPRA_NNP 25_CD to_TO 50_CD mg_NN also_RB received_VBD ACE_NN inhibitors_NNS or_CC angiotensin_NN II_CD receptor_NN antagonists_NNS -LRB-_-LRB- ACEI/ARB_NN -RRB-_-RRB- ._. Rates_NNS of_IN patients_NNS with_IN maximum_NN potassium_NN levels_NNS 5.5_CD mEq/L_NN were_VBD similar_JJ regardless_RB of_IN the_DT use_NN of_IN ACEI/ARB_NN ._. ACE_NN Inhibitors_NNS and_CC Angiotensin_NN II_CD Receptor_NN Antagonists_NNS -LRB-_-LRB- Hypertension_NN -RRB-_-RRB- -_: In_IN clinical_JJ studies_NNS of_IN patients_NNS with_IN hypertension_NN ,_, the_DT addition_NN of_IN INSPRA_NNP 50_CD to_TO 100_CD mg_NN to_TO ACE_NN inhibitors_NNS and_CC angiotensin_NN II_CD receptor_NN antagonists_NNS increased_VBD mean_JJ serum_NN potassium_NN slightly_RB -LRB-_-LRB- about_IN 0.09-0_CD .13_CD mEq/L_NN -RRB-_-RRB- ._. In_IN a_DT study_NN in_IN diabetics_NNS with_IN microalbuminuria_NN INSPRA_NN 200_CD mg_NN combined_VBN with_IN the_DT ACE_NN inhibitor_NN enalapril_NN 10_CD mg_NN increased_VBD the_DT frequency_NN of_IN hyperkalemia_NN -LRB-_-LRB- serum_NN potassium_NN 5.5_CD mEq/L_NN -RRB-_-RRB- from_IN 17_CD %_NN on_IN enalapril_NN alone_RB to_TO 38_CD %_NN ._. Lithium-A_NN drug_NN interaction_NN study_NN of_IN eplerenone_NN with_IN lithium_NN has_VBZ not_RB been_VBN conducted_VBN ._. Serum_NN lithium_NN levels_NNS should_MD be_VB monitored_VBN frequently_RB if_IN INSPRA_NN is_VBZ administered_VBN concomitantly_RB with_IN lithium_NN ._. Nonsteroidal_JJ Anti-Inflammatory_JJ Drugs_NNS -LRB-_-LRB- NSAIDs_NNS -RRB-_-RRB- -_: A_DT drug_NN interaction_NN study_NN of_IN eplerenone_NN with_IN an_DT NSAID_NN has_VBZ not_RB been_VBN conducted_VBN ._. The_DT administration_NN of_IN other_JJ potassium-sparing_JJ antihypertensives_NNS with_IN NSAIDs_NNS has_VBZ been_VBN shown_VBN to_TO reduce_VB the_DT antihypertensive_JJ effect_NN in_IN some_DT patients_NNS and_CC result_VBP in_IN severe_JJ hyperkalemia_NN in_IN patients_NNS with_IN impaired_JJ renal_JJ function_NN ._. Therefore_RB ,_, when_WRB INSPRA_NNP and_CC NSAIDs_NNS are_VBP used_VBN concomitantly_RB ,_, patients_NNS should_MD be_VB observed_VBN to_TO determine_VB whether_IN the_DT desired_VBN effect_NN on_IN blood_NN pressure_NN is_VBZ obtained_VBN ._. No_DT evidence_NN of_IN interaction_NN of_IN PROCRIT_NN with_IN other_JJ drugs_NNS was_VBD observed_VBN in_IN the_DT course_NN of_IN clinical_JJ trials_NNS ._. Additional_JJ reductions_NNS in_IN blood_NN pressure_NN may_MD occur_VB when_WRB FLOLAN_NNP is_VBZ administered_VBN with_IN diuretics_NNS ,_, antihypertensive_JJ agents_NNS ,_, or_CC other_JJ vasodilators_NNS ._. When_WRB other_JJ antiplatelet_JJ agents_NNS or_CC anticoagulants_NNS are_VBP used_VBN concomitantly_RB ,_, there_EX is_VBZ the_DT potential_NN for_IN FLOLAN_NNP to_TO increase_VB the_DT risk_NN of_IN bleeding_NN ._. However_RB ,_, patients_NNS receiving_VBG infusions_NNS of_IN FLOLAN_NNP in_IN clinical_JJ trials_NNS were_VBD maintained_VBN on_IN anticoagulants_NNS without_IN evidence_NN of_IN increased_VBN bleeding_NN ._. In_IN clinical_JJ trials_NNS ,_, FLOLAN_NNP was_VBD used_VBN with_IN digoxin_NN ,_, diuretics_NNS ,_, anticoagulants_NNS ,_, oral_JJ vasodilators_NNS ,_, and_CC supplemental_JJ oxygen.In_NN a_DT pharmacokinetic_JJ substudy_NN in_IN patients_NNS with_IN congestive_JJ heart_NN failure_NN receiving_VBG furosemide_NN or_CC digoxin_NN in_IN whom_WP therapy_NN with_IN FLOLAN_NN was_VBD initiated_VBN ,_, apparent_JJ oral_JJ clearance_NN values_NNS for_IN furosemide_NN -LRB-_-LRB- n_NN =_JJ 23_CD -RRB-_-RRB- and_CC digoxin_NN -LRB-_-LRB- n_NN =_JJ 30_CD -RRB-_-RRB- were_VBD decreased_VBN by_IN 13_CD %_NN and_CC 15_CD %_NN ,_, respectively_RB ,_, on_IN the_DT second_JJ day_NN of_IN therapy_NN and_CC had_VBD returned_VBN to_TO baseline_NN values_NNS by_IN day_NN 87_CD ._. The_DT change_NN in_IN furosemide_NN clearance_NN value_NN is_VBZ not_RB likely_JJ to_TO be_VB clinically_RB significant_JJ ._. However_RB ,_, patients_NNS on_IN digoxin_NN may_MD show_VB elevations_NNS of_IN digoxin_NN concentrations_NNS after_IN initiation_NN of_IN therapy_NN with_IN FLOLAN_NNP ,_, which_WDT may_MD be_VB clinically_RB significant_JJ in_IN patients_NNS prone_JJ to_TO digoxin_NN toxicity_NN ._. Eprosartan_NNP has_VBZ been_VBN shown_VBN to_TO have_VB no_DT effect_NN on_IN the_DT pharmacokinetics_NNS of_IN digoxin_NN and_CC the_DT pharmacodynamics_NNS of_IN warfarin_NN and_CC glyburide_NN ._. Thus_RB no_DT dosing_NN adjustments_NNS are_VBP necessary_JJ during_IN concomitant_JJ use_NN with_IN these_DT agents_NNS ._. Because_IN eprosartan_NN is_VBZ not_RB metabolized_VBN by_IN the_DT cytochrome_NN P450_NN system_NN ,_, inhibitors_NNS of_IN CYP450_NN enzyme_NN would_MD not_RB be_VB expected_VBN to_TO affect_VB its_PRP$ metabolism_NN ,_, and_CC ketoconazole_NN and_CC fluconazole_NN ,_, potent_JJ inhibitors_NNS of_IN CYP3A_NN and_CC 2C9_NN ,_, respectively_RB ,_, have_VBP been_VBN shown_VBN to_TO have_VB no_DT effect_NN on_IN eprosartan_NN pharmacokinetics_NNS ._. Ranitidine_NN also_RB has_VBZ no_DT effect_NN on_IN eprosartan_NN pharmacokinetics_NNS ._. Eprosartan_NN -LRB-_-LRB- up_RB to_TO 400_CD mg_NN b.i.d._NN or_CC 800_CD mg_NN q.d._NN -RRB-_-RRB- doses_NNS have_VBP been_VBN safely_RB used_VBN concomitantly_RB with_IN a_DT thiazide_JJ diuretic_JJ -LRB-_-LRB- hydrochlorothiazide_NN -RRB-_-RRB- ._. Eprosartan_NN doses_NNS of_IN up_RB to_TO 300_CD mg_NN b.i.d._NN have_VBP been_VBN safely_RB used_VBN concomitantly_RB with_IN sustained-release_JJ calcium_NN channel_NN blockers_NNS -LRB-_-LRB- sustained-release_JJ nifedipine_NN -RRB-_-RRB- with_IN no_DT clinically_RB significant_JJ adverse_JJ interactions_NNS ._. Enoxaparin_NNP dosed_VBD as_IN a_DT 1.0_CD mg/kg_NN subcutaneous_JJ injection_NN q12h_NN for_IN four_CD doses_NNS did_VBD not_RB alter_VB the_DT pharmacokinetics_NNS of_IN eptifibatide_NN or_CC the_DT level_NN of_IN platelet_NN aggregation_NN in_IN healthy_JJ adults_NNS ._. Mineral_JJ oil_NN interferes_VBZ with_IN the_DT absorption_NN of_IN fat-soluble_JJ vitamins_NNS ,_, including_VBG vitamin_NN D_NN preparations_NNS ._. Administration_NN of_IN thiazide_JJ diuretics_NNS to_TO hypoparathyroid_JJ patients_NNS who_WP are_VBP concurrently_RB being_VBG treated_VBN with_IN ergocalciferol_NN may_MD cause_VB hypercalcemia_NN ._. No_DT reported_VBN interactions_NNS ._. The_DT effects_NNS of_IN ERGOMAR_NN may_MD be_VB potentiated_VBN by_IN triacetyloleandomycin_NN which_WDT inhibits_VBZ the_DT metabolism_NN of_IN ergotamine_NN ._. The_DT pressor_JJ effects_NNS of_IN ERGOMAR_NN and_CC other_JJ vasoconstrictor_NN drugs_NNS can_MD combine_VB to_TO cause_VB dangerous_JJ hypertension_NN ._. Co-treatment_NN with_IN the_DT potent_JJ CYP3A4_NN inhibitor_NN ketoconazole_NN increases_VBZ erlotinib_JJ AUC_NN by_IN 2/3_CD ._. Caution_NN should_MD be_VB used_VBN when_WRB administering_VBG or_CC taking_VBG TARCEVA_NN with_IN ketoconazole_NN and_CC other_JJ strong_JJ CYP3A4_NN inhibitors_NNS such_JJ as_IN ,_, but_CC not_RB limited_VBN to_TO ,_, atazanavir_NN ,_, clarithromycin_NN ,_, indinavir_NN ,_, itraconazole_NN ,_, nefazodone_NN ,_, nelfinavir_NN ,_, ritonavir_NN ,_, saquinavir_NN ,_, telithromycin_NN ,_, troleandomycin_NN -LRB-_-LRB- TAO_NN -RRB-_-RRB- ,_, and_CC voriconazole_NN ._. Pre-treatment_NN with_IN the_DT CYP3A4_NN inducer_NN rifampicin_NN decreased_VBD erlotinib_NN AUC_NN by_IN about_IN 2/3_CD ._. Alternate_JJ treatments_NNS lacking_VBG CYP3A4_NN inducing_NN activity_NN should_MD be_VB considered_VBN ._. If_IN an_DT alternative_JJ treatment_NN is_VBZ unavailable_JJ ,_, a_DT TARCEVA_NNP dose_NN greater_JJR than_IN 150_CD mg_NN should_MD be_VB considered_VBN for_IN NSCLC_NN patients_NNS ,_, and_CC greater_JJR than_IN 100_CD mg_NN considered_VBN for_IN pancreatic_JJ cancer_NN patients_NNS ._. If_IN the_DT TARCEVA_NNP dose_NN is_VBZ adjusted_VBN upward_RB ,_, the_DT dose_NN will_MD need_VB to_TO be_VB reduced_VBN upon_IN discontinuation_NN of_IN rifampicin_NN or_CC other_JJ inducers_NNS ._. Other_JJ CYP3A4_NN inducers_NNS include_VBP ,_, but_CC are_VBP not_RB limited_VBN to_TO ,_, rifabutin_NN ,_, rifapentine_NN ,_, phenytoin_NN ,_, carbamazepine_NN ,_, phenobarbital_NN and_CC St._NNP Johns_NNP Wort_NNP ._. Hepatotoxicity_NN Asymptomatic_JJ increases_NNS in_IN liver_NN transaminases_NNS have_VBP been_VBN observed_VBN in_IN TARCEVA_NN treated_JJ patients_NNS ._. therefore_RB ,_, periodic_JJ liver_NN function_NN testing_NN -LRB-_-LRB- transaminases_NNS ,_, bilirubin_NN ,_, and_CC alkaline_NN phosphatase_NN -RRB-_-RRB- should_MD be_VB considered_VBN ._. Dose_NN reduction_NN or_CC interruption_NN of_IN TARCEVA_NN should_MD be_VB considered_VBN if_IN changes_NNS in_IN liver_NN function_NN are_VBP severe_JJ ._. Patients_NNS with_IN Hepatic_JJ Impairment_NN In_FW vitro_FW and_CC in_FW vivo_FW evidence_NN suggest_VBP that_IN erlotinib_NN is_VBZ cleared_VBN primarily_RB by_IN the_DT liver_NN ._. Therefore_RB ,_, erlotinib_JJ exposure_NN may_MD be_VB increased_VBN in_IN patients_NNS with_IN hepatic_JJ dysfunction_NN ._. Elevated_JJ International_NNP Normalized_NNP Ratio_NNP and_CC Potential_JJ Bleeding_NNP International_NNP Normalized_NNP Ratio_NNP -LRB-_-LRB- INR_NNP -RRB-_-RRB- elevations_NNS and_CC infrequent_JJ reports_NNS of_IN bleeding_VBG events_NNS including_VBG gastrointestinal_JJ and_CC non-gastrointestinal_JJ bleedings_NNS have_VBP been_VBN reported_VBN in_IN clinical_JJ studies_NNS ,_, some_DT associated_VBN with_IN concomitant_JJ warfarin_NN administration_NN ._. Patients_NNS taking_VBG warfarin_NN or_CC other_JJ coumarin-derivative_JJ anticoagulants_NNS should_MD be_VB monitored_VBN regularly_RB for_IN changes_NNS in_IN prothrombin_NN time_NN or_CC IN_IN ._. When_WRB ertapenem_NN is_VBZ co-administered_VBN with_IN probenecid_NN -LRB-_-LRB- 500_CD mg_NN p.o._NN every_DT 6_CD hours_NNS -RRB-_-RRB- ,_, probenecid_NN competes_VBZ for_IN active_JJ tubular_JJ secretion_NN and_CC reduces_VBZ the_DT renal_JJ clearance_NN of_IN ertapenem_NN ._. Based_VBN on_IN total_JJ ertapenem_NN concentrations_NNS ,_, probenecid_NN increased_VBD the_DT AUC_NN by_IN 25_CD %_NN and_CC reduced_VBD the_DT plasma_NN and_CC renal_JJ clearances_NNS by_IN 20_CD %_NN and_CC 35_CD %_NN ,_, respectively_RB ._. The_DT half-life_NN increased_VBN from_IN 4.0_CD to_TO 4.8_CD hours_NNS ._. Because_IN of_IN the_DT small_JJ effect_NN on_IN half-life_NN ,_, the_DT coadministration_NN with_IN probenecid_NN to_TO extend_VB the_DT half-life_NN of_IN ertapenem_NN is_VBZ not_RB recommended_VBN ._. In_FW vitro_FW studies_NNS indicate_VBP that_IN ertapenem_NN does_VBZ not_RB inhibit_VB P-glycoprotein-mediated_JJ transport_NN of_IN digoxin_NN or_CC vinblastine_NN and_CC that_IN ertapenem_NN is_VBZ not_RB a_DT substrate_NN for_IN P-glycoprotein-mediated_JJ transport_NN ._. In_FW vitro_FW studies_NNS in_IN human_JJ liver_NN microsomes_NNS indicate_VBP that_IN ertapenem_NN does_VBZ not_RB inhibit_VB metabolism_NN mediated_VBN by_IN any_DT of_IN the_DT following_VBG six_CD cytochrome_NN p450_NN -LRB-_-LRB- CYP_NN -RRB-_-RRB- isoforms_NNS :_: 1A2_NN ,_, 2C9_NN ,_, 2C19_NN ,_, 2D6_NN ,_, 2E1_NN and_CC 3A4_NN ._. Drug_NN interactions_NNS caused_VBN by_IN inhibition_NN of_IN P-glycoprotein-mediated_JJ drug_NN clearance_NN or_CC CYP-mediated_JJ drug_NN clearance_NN with_IN the_DT listed_VBN isoforms_NNS are_VBP unlikely_JJ ._. Other_JJ than_IN with_IN probenecid_NN ,_, no_DT specific_JJ clinical_JJ drug_NN interaction_NN studies_NNS have_VBP been_VBN conducte_NN ._. Erythromycin_NNP use_NN in_IN patients_NNS who_WP are_VBP receiving_VBG high_JJ doses_NNS of_IN theophylline_NN may_MD be_VB associated_VBN with_IN an_DT increase_NN in_IN serum_NN theophylline_NN levels_NNS and_CC potential_JJ theophylline_NN toxicity_NN ._. In_IN case_NN of_IN theophylline_NN toxicity_NN and/or_CC elevated_JJ serum_NN theophylline_NN levels_NNS ,_, the_DT dose_NN of_IN theophylline_NN should_MD be_VB reduced_VBN while_IN the_DT patient_NN is_VBZ receiving_VBG concomitant_JJ erythromycin_NN therapy_NN ._. Concomitant_JJ administration_NN of_IN erythromycin_NN and_CC digoxin_NN has_VBZ been_VBN reported_VBN to_TO result_VB in_IN elevated_JJ digoxin_NN serum_NN levels_NNS ._. There_EX have_VBP been_VBN reports_NNS of_IN increased_VBN anticoagulant_JJ effects_NNS when_WRB erythromycin_NN and_CC oral_JJ anticoagulants_NNS were_VBD used_VBN concomitantly_RB ._. Increased_VBN anticoagulation_JJ effects_NNS due_JJ to_TO interactions_NNS of_IN erythromycin_NN with_IN various_JJ oral_JJ anticoagulents_NNS may_MD be_VB more_RBR pronounced_JJ in_IN the_DT elderly_JJ ._. Concurrent_JJ use_NN of_IN erythromycin_NN and_CC ergotamine_NN or_CC dihydroergotamine_NN has_VBZ been_VBN associated_VBN in_IN some_DT patients_NNS with_IN acute_JJ ergot_NN toxicity_NN characterized_VBN by_IN severe_JJ peripheral_JJ vasospasm_NN and_CC dysesthesia_NN ._. Erythromycin_NNP has_VBZ been_VBN reported_VBN to_TO decrease_VB the_DT clearance_NN of_IN triazolam_NN and_CC midazolam_NN and_CC thus_RB may_MD increase_VB the_DT pharmacologic_JJ effect_NN of_IN these_DT benzodiazepines_NNS ._. The_DT use_NN of_IN erythromycin_NN in_IN patients_NNS concurrently_RB taking_VBG drugs_NNS metabolized_VBN by_IN the_DT cytochrome_NN P450_NN system_NN may_MD be_VB associated_VBN with_IN elevations_NNS in_IN serum_NN levels_NNS of_IN these_DT other_JJ drugs_NNS ._. There_EX have_VBP been_VBN reports_NNS of_IN interactions_NNS of_IN erythromycin_NN with_IN carbamazepine_NN ,_, cyclosporine_NN ,_, tacrolimus_NN ,_, hexobarbital_NN ,_, phenytoin_NN ,_, alfentanil_NN ,_, cisapride_NN ,_, disopyramide_NN ,_, lovastatin_NN ,_, bromocriptine_NN ,_, valproate_NN ,_, terfenadine_NN ,_, and_CC astemizole_NN ._. Serum_NN concentrations_NNS of_IN drugs_NNS metabolized_VBN by_IN the_DT cytochrome_NN P450_NN system_NN should_MD be_VB monitored_VBN closely_RB in_IN patients_NNS concurrently_RB receiving_VBG erythromycin_NN ._. Erythromycin_NNP has_VBZ been_VBN reported_VBN to_TO significantly_RB alter_VB the_DT metabolism_NN of_IN nonsedating_JJ antihistamines_NNS terfenadine_NN and_CC astemizole_NN when_WRB taken_VBN concomitantly_RB ._. Rare_JJ cases_NNS of_IN serious_JJ cardiovascular_JJ adverse_JJ events_NNS ,_, including_VBG electrocardiographic_JJ QT/QTc_NN interval_NN prolongation_NN ,_, cardiac_JJ arrest_NN ,_, torsades_NNS de_IN pointes_NNS ,_, and_CC other_JJ ventricular_JJ arrhythmias_NNS have_VBP been_VBN observed_VBN ._. In_IN addition_NN ,_, deaths_NNS have_VBP been_VBN reported_VBN rarely_RB with_IN concomitant_JJ administration_NN of_IN terfenadine_NN and_CC erythromycin_NN ._. There_EX have_VBP been_VBN postmarketing_VBG reports_NNS of_IN drug_NN interactions_NNS when_WRB erythromycin_NN is_VBZ coadministered_VBN with_IN cisapride_NN ,_, resulting_VBG in_IN QT_NNP prolongation_NN ,_, cardiac_JJ arrythmias_NNS ,_, ventricular_JJ tachycardia_NN ,_, ventricular_JJ fibrulation_NN ,_, and_CC torsades_NNS de_IN pointes_NNS ,_, most_JJS like_IN due_JJ to_TO inhibition_NN of_IN hepatic_JJ metabolism_NN of_IN cisapride_NN by_IN erythromycin_NN ._. Fatalities_NNS have_VBP been_VBN reported_VBN ._. Patients_NNS receiving_VBG concomitant_JJ lovastatin_NN and_CC erythromycin_NN should_MD be_VB carefully_RB monitored_VBN ._. cases_NNS of_IN rhabdomyolysis_NN have_VBP been_VBN reported_VBN in_IN seriously_RB ill_JJ patients_NNS ._. CNS_NN Drugs_NNS -_: Given_VBN the_DT primary_JJ CNS_NN effects_NNS of_IN escitalopram_NN ,_, caution_NN should_MD be_VB used_VBN when_WRB it_PRP is_VBZ taken_VBN in_IN combination_NN with_IN other_JJ centrally_RB acting_VBG drugs_NNS ._. Alcohol_NN -_: Although_IN LEXAPRO_NN did_VBD not_RB potentiate_VB the_DT cognitive_JJ and_CC motor_NN effects_NNS of_IN alcohol_NN in_IN a_DT clinical_JJ trial_NN ,_, as_IN with_IN other_JJ psychotropic_JJ medications_NNS ,_, the_DT use_NN of_IN alcohol_NN by_IN patients_NNS taking_VBG LEXAPRO_NNP is_VBZ not_RB recommended_VBN ._. Monoamine_NNP Oxidase_NNP Inhibitors_NNS -LRB-_-LRB- MAOIs_NNS ._. Drugs_NNS That_WDT Interfere_VBP With_IN Hemostasis_NN -LRB-_-LRB- NSAIDs_NNS ,_, Aspirin_NNP ,_, Warfarin_NNP ,_, etc._FW ._. Serotonin_NN release_NN by_IN platelets_NNS plays_VBZ an_DT important_JJ role_NN in_IN hemostasis_NN ._. Epidemiological_JJ studies_NNS of_IN the_DT case-control_JJ and_CC cohort_NN design_NN that_WDT have_VBP demonstrated_VBN an_DT association_NN between_IN use_NN of_IN psychotropic_JJ drugs_NNS that_WDT interfere_VBP with_IN serotonin_NN reuptake_NN and_CC the_DT occurrence_NN of_IN upper_JJ gastrointestinal_JJ bleeding_NN have_VBP also_RB shown_VBN that_IN concurrent_JJ use_NN of_IN an_DT NSAID_NN or_CC aspirin_NN potentiated_VBD the_DT risk_NN of_IN bleeding_NN ._. Thus_RB ,_, patients_NNS should_MD be_VB cautioned_VBN about_IN the_DT use_NN of_IN such_JJ drugs_NNS concurrently_RB with_IN LEXAPRO_NN ._. Cimetidine_NN -_: In_IN subjects_NNS who_WP had_VBD received_VBN 21_CD days_NNS of_IN 40_CD mg/day_NN racemic_JJ citalopram_NN ,_, combined_VBN administration_NN of_IN 400_CD mg/day_NN cimetidine_NN for_IN 8_CD days_NNS resulted_VBD in_IN an_DT increase_NN in_IN citalopram_NN AUC_NN and_CC Cmax_NN of_IN 43_CD %_NN and_CC 39_CD %_NN ,_, respectively_RB ._. The_DT clinical_JJ significance_NN of_IN these_DT findings_NNS is_VBZ unknown_JJ ._. Digoxin_NN -_: In_IN subjects_NNS who_WP had_VBD received_VBN 21_CD days_NNS of_IN 40_CD mg/day_NN racemic_JJ citalopram_NN ,_, combined_VBN administration_NN of_IN citalopram_NN and_CC digoxin_NN -LRB-_-LRB- single_JJ dose_NN of_IN 1_CD mg_NN -RRB-_-RRB- did_VBD not_RB significantly_RB affect_VB the_DT pharmacokinetics_NNS of_IN either_CC citalopram_NN or_CC digoxin_NN ._. Lithium_NN -_: Coadministration_NN of_IN racemic_JJ citalopram_NN -LRB-_-LRB- 40_CD mg/day_NN for_IN 10_CD days_NNS -RRB-_-RRB- and_CC lithium_NN -LRB-_-LRB- 30_CD mmol/day_NN for_IN 5_CD days_NNS -RRB-_-RRB- had_VBD no_DT significant_JJ effect_NN on_IN the_DT pharmacokinetics_NNS of_IN citalopram_NN or_CC lithium_NN ._. Nevertheless_RB ,_, plasma_NN lithium_NN levels_NNS should_MD be_VB monitored_VBN with_IN appropriate_JJ adjustment_NN to_TO the_DT lithium_NN dose_NN in_IN accordance_NN with_IN standard_JJ clinical_JJ practice_NN ._. Because_IN lithium_NN may_MD enhance_VB the_DT serotonergic_JJ effects_NNS of_IN escitalopram_NN ,_, caution_NN should_MD be_VB exercised_VBN when_WRB LEXAPRO_NNP and_CC lithium_NN are_VBP coadministered_VBN ._. Pimozide_NNP and_CC Celexa_NNP -_: In_IN a_DT controlled_JJ study_NN ,_, a_DT single_JJ dose_NN of_IN pimozide_NN 2_CD mg_NN co-administered_VBN with_IN racemic_JJ citalopram_NN 40_CD mg_NN given_VBN once_RB daily_RB for_IN 11_CD days_NNS was_VBD associated_VBN with_IN a_DT mean_JJ increase_NN in_IN QTc_NN values_NNS of_IN approximately_RB 10_CD msec_NN compared_VBN to_TO pimozide_VB given_VBN alone_RB ._. Racemic_JJ citalopram_NN did_VBD not_RB alter_VB the_DT mean_NN AUC_NN or_CC Cmax_NN of_IN pimozide_NN ._. The_DT mechanism_NN of_IN this_DT pharmacodynamic_JJ interaction_NN is_VBZ not_RB known_VBN ._. Sumatriptan_NNP -_: There_EX have_VBP been_VBN rare_JJ postmarketing_VBG reports_NNS describing_VBG patients_NNS with_IN weakness_NN ,_, hyperreflexia_NN ,_, and_CC incoordination_NN following_VBG the_DT use_NN of_IN a_DT selective_JJ serotonin_NN reuptake_NN inhibitor_NN -LRB-_-LRB- SSRI_NN -RRB-_-RRB- and_CC sumatriptan_NN ._. If_IN concomitant_JJ treatment_NN with_IN sumatriptan_NN and_CC an_DT SSRI_NN -LRB-_-LRB- e.g._FW ,_, fluoxetine_NN ,_, fluvoxamine_NN ,_, paroxetine_NN ,_, sertraline_NN ,_, citalopram_NN ,_, escitalopram_NN -RRB-_-RRB- is_VBZ clinically_RB warranted_VBN ,_, appropriate_JJ observation_NN of_IN the_DT patient_NN is_VBZ advised_VBN ._. Theophylline_NNP -_: Combined_VBN administration_NN of_IN racemic_JJ citalopram_NN -LRB-_-LRB- 40_CD mg/day_NN for_IN 21_CD days_NNS -RRB-_-RRB- and_CC the_DT CYP1A2_NN substrate_NN theophylline_NN -LRB-_-LRB- single_JJ dose_NN of_IN 300_CD mg_NN -RRB-_-RRB- did_VBD not_RB affect_VB the_DT pharmacokinetics_NNS of_IN theophylline_NN ._. The_DT effect_NN of_IN theophylline_NN on_IN the_DT pharmacokinetics_NNS of_IN citalopram_NN was_VBD not_RB evaluated_VBN ._. Warfarin_NNP -_: Administration_NN of_IN 40_CD mg/day_NN racemic_JJ citalopram_NN for_IN 21_CD days_NNS did_VBD not_RB affect_VB the_DT pharmacokinetics_NNS of_IN warfarin_NN ,_, a_DT CYP3A4_NN substrate_NN ._. Prothrombin_NNP time_NN was_VBD increased_VBN by_IN 5_CD %_NN ,_, the_DT clinical_JJ significance_NN of_IN which_WDT is_VBZ unknown_JJ ._. Carbamazepine_NNP -_: Combined_VBN administration_NN of_IN racemic_JJ citalopram_NN -LRB-_-LRB- 40_CD mg/day_NN for_IN 14_CD days_NNS -RRB-_-RRB- and_CC carbamazepine_NN -LRB-_-LRB- titrated_VBN to_TO 400_CD mg/day_NN for_IN 35_CD days_NNS -RRB-_-RRB- did_VBD not_RB significantly_RB affect_VB the_DT pharmacokinetics_NNS of_IN carbamazepine_NN ,_, a_DT CYP3A4_NN substrate_NN ._. Although_IN trough_NN citalopram_NN plasma_NN levels_NNS were_VBD unaffected_JJ ,_, given_VBN the_DT enzyme-inducing_JJ properties_NNS of_IN carbamazepine_NN ,_, the_DT possibility_NN that_IN carbamazepine_NN might_MD increase_VB the_DT clearance_NN of_IN escitalopram_NN should_MD be_VB considered_VBN if_IN the_DT two_CD drugs_NNS are_VBP coadministered_VBN ._. Triazolam_NN -_: Combined_VBN administration_NN of_IN racemic_JJ citalopram_NN -LRB-_-LRB- titrated_VBN to_TO 40_CD mg/day_NN for_IN 28_CD days_NNS -RRB-_-RRB- and_CC the_DT CYP3A4_NN substrate_NN triazolam_NN -LRB-_-LRB- single_JJ dose_NN of_IN 0.25_CD mg_NN -RRB-_-RRB- did_VBD not_RB significantly_RB affect_VB the_DT pharmacokinetics_NNS of_IN either_CC citalopram_NN or_CC triazolam_NN ._. Ketoconazole_NN -_: Combined_VBN administration_NN of_IN racemic_JJ citalopram_NN -LRB-_-LRB- 40_CD mg_NN -RRB-_-RRB- and_CC ketoconazole_NN -LRB-_-LRB- 200_CD mg_NN -RRB-_-RRB- decreased_VBD the_DT Cmax_NN and_CC AUC_NN of_IN ketoconazole_NN by_IN 21_CD %_NN and_CC 10_CD %_NN ,_, respectively_RB ,_, and_CC did_VBD not_RB significantly_RB affect_VB the_DT pharmacokinetics_NNS of_IN citalopram_NN ._. Ritonavir_NNP -_: Combined_VBN administration_NN of_IN a_DT single_JJ dose_NN of_IN ritonavir_NN -LRB-_-LRB- 600_CD mg_NN -RRB-_-RRB- ,_, both_CC a_DT CYP3A4_NN substrate_NN and_CC a_DT potent_JJ inhibitor_NN of_IN CYP3A4_NN ,_, and_CC escitalopram_NN -LRB-_-LRB- 20_CD mg_NN -RRB-_-RRB- did_VBD not_RB affect_VB the_DT pharmacokinetics_NNS of_IN either_CC ritonavir_NN or_CC escitalopram_NN ._. CYP3A4_NN and_CC -2_CD C19_NN Inhibitors_NNS -_: In_FW vitro_FW studies_NNS indicated_VBD that_IN CYP3A4_NN and_CC -2_CD C19_NN are_VBP the_DT primary_JJ enzymes_NNS involved_VBN in_IN the_DT metabolism_NN of_IN escitalopram_NN ._. However_RB ,_, coadministration_NN of_IN escitalopram_NN -LRB-_-LRB- 20_CD mg_NN -RRB-_-RRB- and_CC ritonavir_NN -LRB-_-LRB- 600_CD mg_NN -RRB-_-RRB- ,_, a_DT potent_JJ inhibitor_NN of_IN CYP3A4_NN ,_, did_VBD not_RB significantly_RB affect_VB the_DT pharmacokinetics_NNS of_IN escitalopram_NN ._. Because_IN escitalopram_NN is_VBZ metabolized_VBN by_IN multiple_JJ enzyme_NN systems_NNS ,_, inhibition_NN of_IN a_DT single_JJ enzyme_NN may_MD not_RB appreciably_RB decrease_VB escitalopram_JJ clearance_NN ._. Drugs_NNS Metabolized_VBN by_IN Cytochrome_NN P4502D6_NN -_: In_FW vitro_FW studies_NNS did_VBD not_RB reveal_VB an_DT inhibitory_JJ effect_NN of_IN escitalopram_NN on_IN CYP2D6_NN ._. In_IN addition_NN ,_, steady_JJ state_NN levels_NNS of_IN racemic_JJ citalopram_NN were_VBD not_RB significantly_RB different_JJ in_IN poor_JJ metabolizers_NNS and_CC extensive_JJ CYP2D6_NN metabolizers_NNS after_IN multiple-dose_JJ administration_NN of_IN citalopram_NN ,_, suggesting_VBG that_IN coadministration_NN ,_, with_IN escitalopram_NN ,_, of_IN a_DT drug_NN that_WDT inhibits_VBZ CYP2D6_NN ,_, is_VBZ unlikely_JJ to_TO have_VB clinically_RB significant_JJ effects_NNS on_IN escitalopram_NN metabolism_NN ._. However_RB ,_, there_EX are_VBP limited_JJ in_FW vivo_FW data_NNS suggesting_VBG a_DT modest_JJ CYP2D6_NN inhibitory_JJ effect_NN for_IN escitalopram_NN ,_, i.e._FW ,_, coadministration_NN of_IN escitalopram_NN -LRB-_-LRB- 20_CD mg/day_NN for_IN 21_CD days_NNS -RRB-_-RRB- with_IN the_DT tricyclic_JJ antidepressant_JJ desipramine_NN -LRB-_-LRB- single_JJ dose_NN of_IN 50_CD mg_NN -RRB-_-RRB- ,_, a_DT substrate_NN for_IN CYP2D6_NN ,_, resulted_VBD in_IN a_DT 40_CD %_NN increase_NN in_IN Cmax_NNP and_CC a_DT 100_CD %_NN increase_NN in_IN AUC_NN of_IN desipramine_NN ._. The_DT clinical_JJ significance_NN of_IN this_DT finding_NN is_VBZ unknown_JJ ._. Nevertheless_RB ,_, caution_NN is_VBZ indicated_VBN in_IN the_DT coadministration_NN of_IN escitalopram_NN and_CC drugs_NNS metabolized_VBN by_IN CYP2D6_NN ._. Metoprolol_NNP -_: Administration_NN of_IN 20_CD mg/day_NN LEXAPRO_NN for_IN 21_CD days_NNS in_IN healthy_JJ volunteers_NNS resulted_VBD in_IN a_DT 50_CD %_NN increase_NN in_IN Cmax_NNP and_CC 82_CD %_NN increase_NN in_IN AUC_NN of_IN the_DT beta-adrenergic_JJ blocker_NN metoprolol_NN -LRB-_-LRB- given_VBN in_IN a_DT single_JJ dose_NN of_IN 100_CD mg_NN -RRB-_-RRB- ._. Increased_VBN metoprolol_NN plasma_NN levels_NNS have_VBP been_VBN associated_VBN with_IN decreased_VBN cardioselectivity_NN ._. Coadministration_NNP of_IN LEXAPRO_NNP and_CC metoprolol_NN had_VBD no_DT clinically_RB significant_JJ effects_NNS on_IN blood_NN pressure_NN or_CC heart_NN rate_NN ._. Electroconvulsive_JJ Therapy_NN -LRB-_-LRB- ECT_NN -RRB-_-RRB- -_: There_EX are_VBP no_DT clinical_JJ studies_NNS of_IN the_DT combined_VBN use_NN of_IN ECT_NNP and_CC escitalopram_NN ._. Concomitant_JJ Administration_NN with_IN Racemic_JJ Citalopram_NNP Citalopram_NNP -_: Since_IN escitalopram_NN is_VBZ the_DT active_JJ isomer_NN of_IN racemic_JJ citalopram_NN -LRB-_-LRB- Celexa_NN -RRB-_-RRB- ,_, the_DT two_CD agents_NNS should_MD not_RB be_VB coadministered_VBN ._. Catecholamine-depleting_JJ drugs_NNS ,_, e.g._FW ,_, reserpine_NN ,_, may_MD have_VB an_DT additive_JJ effect_NN when_WRB given_VBN with_IN beta_NN blocking_VBG agents_NNS ._. Patients_NNS treated_VBN concurrently_RB with_IN BREVIBLOC_NN -LRB-_-LRB- esmolol_NN HCl_NN -RRB-_-RRB- and_CC a_DT catecholamine_NN depletor_NN should_MD therefore_RB be_VB closely_RB observed_VBN for_IN evidence_NN of_IN hypotension_NN or_CC marked_JJ bradycardia_NN ,_, which_WDT may_MD result_VB in_IN vertigo_NN ,_, syncope_NN ,_, or_CC postural_JJ hypotension_NN ._. A_DT study_NN of_IN interaction_NN between_IN BREVIBLOC_NNP and_CC warfarin_NN showed_VBD that_IN concomitant_JJ administration_NN of_IN BREVIBLOC_NNP and_CC warfarin_NN does_VBZ not_RB alter_VB warfarin_NN plasma_NN levels_NNS ._. BREVIBLOC_NN concentrations_NNS were_VBD equivocally_RB higher_JJR when_WRB given_VBN with_IN warfarin_NN ,_, but_CC this_DT is_VBZ not_RB likely_JJ to_TO be_VB clinically_RB important_JJ ._. When_WRB digoxin_NN and_CC BREVIBLOC_NN were_VBD concomitantly_RB administered_VBN intravenously_RB to_TO normal_JJ volunteers_NNS ,_, there_EX was_VBD a_DT 10-20_CD %_NN increase_NN in_IN digoxin_NN blood_NN levels_NNS at_IN some_DT time_NN points_NNS ._. Digoxin_NN did_VBD not_RB affect_VB BREVIBLOC_NNP pharmacokinetics_NNS ._. When_WRB intravenous_JJ morphine_NN and_CC BREVIBLOC_NN were_VBD concomitantly_RB administered_VBN in_IN normal_JJ subjects_NNS ,_, no_DT effect_NN on_IN morphine_NN blood_NN levels_NNS was_VBD seen_VBN ,_, but_CC BREVIBLOC_NNP steady-state_JJ blood_NN levels_NNS were_VBD increased_VBN by_IN 46_CD %_NN in_IN the_DT presence_NN of_IN morphine_NN ._. No_DT other_JJ pharmacokinetic_JJ parameters_NNS were_VBD changed_VBN ._. The_DT effect_NN of_IN BREVIBLOC_NN on_IN the_DT duration_NN of_IN succinylcholine-induced_JJ neuromuscular_JJ blockade_NN was_VBD studied_VBN in_IN patients_NNS undergoing_VBG surgery_NN ._. The_DT onset_NN of_IN neuromuscular_JJ blockade_NN by_IN succinylcholine_NN was_VBD unaffected_JJ by_IN BREVIBLOC_NNP ,_, but_CC the_DT duration_NN of_IN neuromuscular_JJ blockade_NN was_VBD prolonged_VBN from_IN 5_CD minutes_NNS to_TO 8_CD minutes_NNS ._. Although_IN the_DT interactions_NNS observed_VBN in_IN these_DT studies_NNS do_VBP not_RB appear_VB to_TO be_VB of_IN major_JJ clinical_JJ importance_NN ,_, BREVIBLOC_NN should_MD be_VB titrated_VBN with_IN caution_NN in_IN patients_NNS being_VBG treated_VBN concurrently_RB with_IN digoxin_NN ,_, morphine_NN ,_, succinylcholine_NN or_CC warfarin_NN ._. While_IN taking_VBG beta_NN blockers_NNS ,_, patients_NNS with_IN a_DT history_NN of_IN severe_JJ anaphylactic_JJ reaction_NN to_TO a_DT variety_NN of_IN allergens_NNS may_MD be_VB more_RBR reactive_JJ to_TO repeated_VBN challenge_NN ,_, either_CC accidental_JJ ,_, diagnostic_JJ ,_, or_CC therapeutic_JJ ._. Such_JJ patients_NNS may_MD be_VB unresponsive_JJ to_TO the_DT usual_JJ doses_NNS of_IN epinephrine_NN used_VBN to_TO treat_VB allergic_JJ reaction_NN ._. Caution_NN should_MD be_VB exercised_VBN when_WRB considering_VBG the_DT use_NN of_IN BREVIBLOC_NN and_CC verapamil_NN in_IN patients_NNS with_IN depressed_JJ myocardial_JJ function_NN ._. Fatal_JJ cardiac_JJ arrests_NNS have_VBP occurred_VBN in_IN patients_NNS receiving_VBG both_CC drugs_NNS ._. Additionally_RB ,_, BREVIBLOC_NN should_MD not_RB be_VB used_VBN to_TO control_VB supraventricular_JJ tachycardia_NN in_IN the_DT presence_NN of_IN agents_NNS which_WDT are_VBP vasoconstrictive_JJ and_CC inotropic_JJ such_JJ as_IN dopamine_NN ,_, epinephrine_NN ,_, and_CC norepinephrine_NN because_IN of_IN the_DT danger_NN of_IN blocking_VBG cardiac_JJ contractility_NN when_WRB systemic_JJ vascular_JJ resistance_NN is_VBZ high_JJ ._. Esomeprazole_NNP is_VBZ extensively_RB metabolized_VBN in_IN the_DT liver_NN by_IN CYP2C19_NN and_CC CYP3A4_NN ._. In_FW vitro_FW and_CC in_FW vivo_FW studies_NNS have_VBP shown_VBN that_IN esomeprazole_NN is_VBZ not_RB likely_JJ to_TO inhibit_VB CYPs_NNS 1A2_NN ,_, 2A6_NN ,_, 2C9_NN ,_, 2D6_NN ,_, 2E1_NN and_CC 3A4_NN ._. No_DT clinically_RB relevant_JJ interactions_NNS with_IN drugs_NNS metabolized_VBN by_IN these_DT CYP_NN enzymes_NNS would_MD be_VB expected_VBN ._. Drug_NN interaction_NN studies_NNS have_VBP shown_VBN that_IN esomeprazole_NN does_VBZ not_RB have_VB any_DT clinically_RB significant_JJ interactions_NNS with_IN phenytoin_NN ,_, warfarin_NN ,_, quinidine_NN ,_, clarithromycin_NN or_CC amoxicillin_NNP ._. Post-marketing_JJ reports_NNS of_IN changes_NNS in_IN prothrombin_NN measures_NNS have_VBP been_VBN received_VBN among_IN patients_NNS on_IN concomitant_JJ warfarin_NN and_CC esomeprazole_NN therapy_NN ._. Increases_NNS in_IN INR_NN and_CC prothrombin_NN time_NN may_MD lead_VB to_TO abnormal_JJ bleeding_NN and_CC even_RB death_NN ._. Patients_NNS treated_VBN with_IN proton_NN pump_NN inhibitors_NNS and_CC warfarin_NN concomitantly_RB may_MD need_VB to_TO be_VB monitored_VBN for_IN increases_NNS in_IN INR_NN and_CC prothrombin_NN time_NN ._. Esomeprazole_NNP may_MD potentially_RB interfere_VB with_IN CYP2C19_NN ,_, the_DT major_JJ esomeprazole_NN metabolizing_VBG enzyme_NN ._. Coadministration_NN of_IN esomeprazole_NN 30_CD mg_NN and_CC diazepam_NN ,_, a_DT CYP2C19_NN substrate_NN ,_, resulted_VBD in_IN a_DT 45_CD %_NN decrease_NN in_IN clearance_NN of_IN diazepam_NN ._. Increased_VBN plasma_NN levels_NNS of_IN diazepam_NN were_VBD observed_VBN 12_CD hours_NNS after_IN dosing_NN and_CC onwards_NNS ._. However_RB ,_, at_IN that_DT time_NN ,_, the_DT plasma_NN levels_NNS of_IN diazepam_NN were_VBD below_IN the_DT therapeutic_JJ interval_NN ,_, and_CC thus_RB this_DT interaction_NN is_VBZ unlikely_JJ to_TO be_VB of_IN clinical_JJ relevance_NN ._. Esomeprazole_NN inhibits_VBZ gastric_JJ acid_NN secretion_NN ._. Therefore_RB ,_, esomeprazole_NN may_MD interfere_VB with_IN the_DT absorption_NN of_IN drugs_NNS where_WRB gastric_JJ pH_NN is_VBZ an_DT important_JJ determinant_NN of_IN bioavailability_NN -LRB-_-LRB- eg_FW ,_, ketoconazole_NN ,_, iron_NN salts_NNS and_CC digoxin_NN -RRB-_-RRB- ._. Coadministration_NN of_IN oral_JJ contraceptives_NNS ,_, diazepam_NN ,_, phenytoin_NN ,_, or_CC quinidine_NN did_VBD not_RB seem_VB to_TO change_VB the_DT pharmacokinetic_JJ profile_NN of_IN esomeprazole_NN ._. Concomitant_JJ administration_NN of_IN clarithromycin_NN with_IN pimozide_NN is_VBZ contraindicated_VBN ._. If_IN ProSom_NNP is_VBZ given_VBN concomitantly_RB with_IN other_JJ drugs_NNS acting_VBG on_IN the_DT central_JJ nervous_JJ system_NN ,_, careful_JJ consideration_NN should_MD be_VB given_VBN to_TO the_DT pharmacology_NN of_IN all_DT agents_NNS ._. The_DT action_NN of_IN the_DT benzodiazepines_NNS may_MD be_VB potentiated_VBN by_IN anticonvulsants_NNS ,_, antihistamines_NNS ,_, alcohol_NN ,_, barbiturates_NNS ,_, monoamine_NN oxidase_NN inhibitors_NNS ,_, narcotics_NNS ,_, phenothiazines_NNS ,_, psychotropic_JJ medications_NNS ,_, or_CC other_JJ drugs_NNS that_WDT produce_VBP CNS_NN depression_NN ._. Smokers_NNS have_VBP an_DT increased_VBN clearance_NN of_IN benzodiazepines_NNS as_IN compared_VBN to_TO nonsmokers_NNS ._. this_DT was_VBD seen_VBN in_IN studies_NNS with_IN estazolam_NN ._. While_IN no_DT in_FW vivo_FW drug-drug_JJ interaction_NN studies_NNS were_VBD conducted_VBN between_IN estazolam_NN and_CC inducers_NNS of_IN CYP3A_NN ,_, compounds_NNS that_WDT are_VBP potent_JJ CYP3A_NN inducers_NNS -LRB-_-LRB- such_JJ as_IN carbamazepine_NN ,_, phenytoin_NN ,_, rifampin_NN ,_, and_CC barbiturates_NNS -RRB-_-RRB- would_MD be_VB expected_VBN to_TO decrease_VB estazolam_NN concentrations_NNS ._. Estazolam_NNP :_: Interaction_NN with_IN Drugs_NNS that_WDT Inhibit_VBP Metabolism_NN via_IN Cytochrome_NNP P450_NN 3A_NN -LRB-_-LRB- CYP3A_NN -RRB-_-RRB- :_: The_DT metabolism_NN of_IN estazolam_NN to_TO the_DT major_JJ circulating_VBG metabolite_NN 4-hydroxy-estazolam_NN and_CC the_DT metabolism_NN of_IN other_JJ triazolobenzodiazepines_NNS is_VBZ catalyzed_VBN by_IN CYP3A_NN ._. Consequently_RB ,_, estazolam_NN should_MD be_VB avoided_VBN in_IN patients_NNS receiving_VBG ketoconazole_NN and_CC itraconazole_NN ,_, which_WDT are_VBP very_RB potent_JJ inhibitors_NNS of_IN CYP3A_NN ._. With_IN drugs_NNS inhibiting_VBG CYP3A_NN to_TO a_DT lesser_JJR ,_, but_CC still_RB significant_JJ degree_NN ,_, estazolam_NN should_MD be_VB used_VBN only_RB with_IN caution_NN and_CC consideration_NN of_IN appropriate_JJ dosage_NN reduction_NN ._. The_DT following_VBG are_VBP examples_NNS of_IN drugs_NNS known_VBN to_TO inhibit_VB the_DT metabolism_NN of_IN other_JJ related_JJ benzodiazepines_NNS ,_, presumably_RB through_IN inhibition_NN of_IN CYP3A_NN :_: nefazodone_NN ,_, fluvoxamine_NN ,_, cimetidine_NN ,_, diltiazem_NN ,_, isoniazide_NN ,_, and_CC some_DT macrolide_NN antibiotics_NNS ._. Drug_NN Interaction_NN with_IN Fluoxetine_NN :_: A_DT multiple-dose_JJ study_NN was_VBD conducted_VBN to_TO assess_VB the_DT effect_NN of_IN fluoxetine_NN 20_CD mg_NN BID_NNP on_IN the_DT pharmacokinetics_NNS of_IN estazolam_NN 2_CD mg_NN QHS_NN after_IN seven_CD days_NNS ._. The_DT pharmacokinetics_NNS of_IN estazolam_NN -LRB-_-LRB- Cmax_NN and_CC AUC_NN -RRB-_-RRB- were_VBD not_RB affected_VBN during_IN multiple-dose_JJ fluoxetine_NN ,_, suggesting_VBG no_DT clinically_RB significant_JJ pharmacokinetic_JJ interaction_NN ._. Estazolam_NNP :_: Interaction_NN with_IN Other_JJ Drugs_NNS that_WDT are_VBP Metabolized_VBN by_IN Cytochrome_NN P450_NN -LRB-_-LRB- CYP_NN -RRB-_-RRB- :_: At_IN clinically_RB relevant_JJ concentrations_NNS ,_, in_FW vitro_FW studies_NNS indicate_VBP that_IN estazolam_NN -LRB-_-LRB- 0.6_CD M_NN -RRB-_-RRB- was_VBD not_RB inhibitory_JJ towards_IN the_DT major_JJ cytochrome_NN P450_NN isoforms_NNS CYP1A2_NN ,_, CYP2A6_NN ,_, CYP2C9_NN ,_, CYP2C19_NN ,_, CYP2D6_NN ,_, CYP2E1_NN ,_, and_CC CYP3A_NN ._. Therefore_RB ,_, based_VBN on_IN these_DT in_FW vitro_FW data_NNS ,_, estazolam_NN is_VBZ very_RB unlikely_JJ to_TO inhibit_VB the_DT biotransformation_NN of_IN other_JJ drugs_NNS metabolized_VBN by_IN these_DT CYP_NN isoform_NN ._. D._NNP Drug_NNP and_CC Laboratory_NNP Test_NNP Interactions_NNS 1_CD ._. Accelerated_VBN prothrombin_NN time_NN ,_, partial_JJ thromboplastin_NN time_NN ,_, and_CC platelet_NN aggregation_NN time_NN ;_: ._. increased_VBN platelet_NN count_NN ;_: ._. increased_VBN factors_NNS II_CD ,_, VII_NN antigen_NN ,_, VIII_CD antigen_NN ,_, VIII_CD coagulant_NN activity_NN ,_, IX_CD ,_, X_NN ,_, XII_NNP ,_, VII-X_NN complex_NN ,_, II-VII-X_NN complex_NN ,_, and_CC beta-thromboglobulin_NN ;_: ._. decreased_VBN levels_NNS of_IN anti-factor_JJ Xa_NN and_CC antithrombin_NN III_CD ,_, decreased_VBD antithrombin_NN III_CD activity_NN ;_: ._. increased_VBN levels_NNS of_IN fibrinogen_NN and_CC fibrinogen_NN activity_NN ;_: ._. increased_VBN plasminogen_NN antigen_NN and_CC activity_NN ._. 2_LS ._. Increased_VBN thyroid-binding_JJ globulin_NN -LRB-_-LRB- TBG_NN -RRB-_-RRB- leading_VBG to_TO increased_VBN circulating_VBG total_JJ thyroid_NN hormone_NN levels_NNS ,_, as_IN measured_VBN by_IN protein-bound_JJ iodine_NN -LRB-_-LRB- PBI_NN -RRB-_-RRB- ,_, T4_NN levels_NNS -LRB-_-LRB- by_IN column_NN or_CC by_IN radioimmunoassay_NN -RRB-_-RRB- or_CC T3_NN levels_NNS by_IN radioimmunoassay_NN ._. T3_NN resin_NN uptake_NN is_VBZ decreased_VBN ,_, reflecting_VBG the_DT elevated_JJ TBG_NN ._. Free_NNP T4_NN and_CC T3_NN concentrations_NNS are_VBP unaltered_JJ ._. Patients_NNS on_IN thyroid_NN replacement_NN therapy_NN may_MD require_VB higher_JJR doses_NNS of_IN thyroid_NN hormone_NN ._. 3_LS ._. Other_JJ binding_NN proteins_NNS may_MD be_VB elevated_JJ in_IN serum_NN ,_, i.e._FW ,_, corticosteroid_NN binding_NN globulin_NN -LRB-_-LRB- CBG_NN -RRB-_-RRB- ,_, sex_NN hormone-binding_JJ globulin_NN -LRB-_-LRB- SHBG_NN -RRB-_-RRB- ,_, leading_VBG to_TO increased_VBN total_JJ circulating_VBG corticosteroids_NNS and_CC sex_NN steroids_NNS ,_, respectively_RB ._. Free_NNP hormone_NN concentrations_NNS may_MD be_VB decreased_VBN ._. Other_JJ plasma_NN proteins_NNS may_MD be_VB increased_VBN -LRB-_-LRB- angiotensinogen/renin_NN substrate_NN ,_, alpha-1-antitrypsin_NN ,_, ceruloplasmin_NN -RRB-_-RRB- ._. 4_LS ._. Increased_VBN plasma_NN HDL_NN and_CC HDL2_NN cholesterol_NN subfraction_NN concentrations_NNS ,_, reduced_VBD LDL_NN cholesterol_NN concentration_NN ,_, increased_VBD triglyceride_NN levels_NNS ._. 5_CD ._. Impaired_JJ glucose_NN tolerance_NN ._. 6_CD ._. Reduced_VBN response_NN to_TO metyrapone_NN test_NN ._. Milk_NN ,_, milk_NN products_NNS ,_, and_CC calcium-rich_JJ foods_NNS or_CC drugs_NNS may_MD impair_VB the_DT absorption_NN of_IN EMCYT_NNP ._. CNS-Active_JJ Drugs_NNS Ethanol_NN An_DT additive_JJ effect_NN on_IN psychomotor_NN performance_NN was_VBD seen_VBN with_IN coadministration_NN of_IN eszopiclone_NN and_CC ethanol_NN 0.70_CD g/kg_NN for_IN up_RB to_TO 4_CD hours_NNS after_IN ethanol_NN administration_NN ._. Paroxetine_NNP :_: Coadministration_NNP of_IN single_JJ doses_NNS of_IN eszopiclone_NN 3_CD mg_NN and_CC paroxetine_NN 20_CD mg_NN daily_RB for_IN 7_CD days_NNS produced_VBD no_DT pharmacokinetic_JJ or_CC pharmacodynamic_JJ interaction_NN ._. Lorazepam_NNP :_: Coadministration_NNP of_IN single_JJ doses_NNS of_IN eszopiclone_NN 3_CD mg_NN and_CC lorazepam_NN 2_CD mg_NN did_VBD not_RB have_VB clinically_RB relevant_JJ effects_NNS on_IN the_DT pharmacodynamics_NNS or_CC pharmacokinetics_NNS of_IN either_CC drug_NN ._. Olanzapine_NNP :_: Coadministration_NNP of_IN eszopiclone_NN 3_CD mg_NN and_CC olanzapine_NN 10_CD mg_NN produced_VBD a_DT decrease_NN in_IN DSST_NN scores_NNS ._. The_DT interaction_NN was_VBD pharmacodynamic_JJ ;_: ._. there_EX was_VBD no_DT alteration_NN in_IN the_DT pharmacokinetics_NNS of_IN either_CC drug_NN ._. Drugs_NNS That_WDT Inhibit_VBP CYP3A4_NN -LRB-_-LRB- Ketoconazole_NN -RRB-_-RRB- CYP3A4_NN is_VBZ a_DT major_JJ metabolic_JJ pathway_NN for_IN elimination_NN of_IN eszopiclone_NN ._. The_DT AUC_NN of_IN eszopiclone_NN was_VBD increased_VBN 2.2-fold_RB by_IN coadministration_NN of_IN ketoconazole_NN ,_, a_DT potent_JJ inhibitor_NN of_IN CYP3A4_NN ,_, 400_CD mg_NN daily_RB for_IN 5_CD days_NNS ._. Cmax_NN and_CC t1/2_NN were_VBD increased_VBN 1.4-fold_RB and_CC 1.3-fold_RB ,_, respectively_RB ._. Other_JJ strong_JJ inhibitors_NNS of_IN CYP3A4_NN -LRB-_-LRB- e.g._FW ,_, itraconazole_NN ,_, clarithromycin_NN ,_, nefazodone_NN ,_, troleandomycin_NN ,_, ritonavir_NN ,_, nelfinavir_NN -RRB-_-RRB- would_MD be_VB expected_VBN to_TO behave_VB similarly_RB ._. Drugs_NNS That_WDT Induce_VBP CYP3A4_NN -LRB-_-LRB- Rifampicin_NN -RRB-_-RRB- Racemic_JJ zopiclone_NN exposure_NN was_VBD decreased_VBN 80_CD %_NN by_IN concomitant_JJ useof_JJ rifampicin_NN ,_, a_DT potent_JJ inducer_NN of_IN CYP3A4_NN ._. A_DT similar_JJ effect_NN would_MD be_VB expected_VBN with_IN eszopiclone_NN ._. Drugs_NNS Highly_RB Bound_VBN To_TO Plasma_NN Protein_NN Eszopiclone_NN is_VBZ not_RB highly_RB bound_VBN to_TO plasma_NN proteins_NNS -LRB-_-LRB- 52-59_CD %_NN bound_VBN -RRB-_-RRB- ._. therefore_RB ,_, the_DT disposition_NN of_IN eszopiclone_NN is_VBZ not_RB expected_VBN to_TO be_VB sensitive_JJ to_TO alterations_NNS in_IN protein_NN binding_NN ._. Administration_NN of_IN eszopiclone_NN 3_CD mg_NN to_TO a_DT patient_NN taking_VBG another_DT drug_NN that_WDT is_VBZ highly_RB protein-bound_JJ would_MD not_RB be_VB expected_VBN to_TO cause_VB an_DT alteration_NN in_IN the_DT free_JJ concentration_NN of_IN either_CC drug_NN ._. Drugs_NNS With_IN A_DT Narrow_JJ Therapeutic_JJ Index_NN Digoxin_NN A_NN single_JJ dose_NN of_IN eszopiclone_NN 3_CD mg_NN did_VBD not_RB affect_VB the_DT pharmacokinetics_NNS of_IN digoxin_NN measured_VBN at_IN steady_JJ state_NN following_VBG dosing_NN of_IN 0.5_CD mg_NN twice_RB daily_RB for_IN one_CD day_NN and_CC 0.25_CD mg_NN daily_RB for_IN the_DT next_JJ 6_CD days_NNS ._. Warfarin_NNP :_: Eszopiclone_NNP 3_CD mg_NN administered_VBN daily_RB for_IN 5_CD days_NNS did_VBD not_RB affect_VB the_DT pharmacokinetics_NNS of_IN -LRB-_-LRB- R_NN -RRB-_-RRB- -_: or_CC -LRB-_-LRB- S_NN -RRB-_-RRB- -_: warfarin_NN ,_, nor_CC were_VBD there_EX any_DT changes_NNS in_IN the_DT pharmacodynamic_JJ profile_NN -LRB-_-LRB- prothrombin_NN time_NN -RRB-_-RRB- following_VBG a_DT single_JJ 25_CD mg_NN oral_JJ dose_NN of_IN warfari_NN ._. Specific_JJ drug_NN interaction_NN studies_NNS have_VBP not_RB been_VBN conducted_VBN with_IN ENBREL_NN ._. However_RB ,_, it_PRP was_VBD observed_VBN that_IN the_DT pharmacokinetics_NNS of_IN ENBREL_NNP was_VBD unaltered_JJ by_IN concomitant_JJ methotrexate_NN in_IN rheumatoid_JJ arthritis_NN patients_NNS ._. In_IN a_DT study_NN in_IN which_WDT patients_NNS with_IN active_JJ RA_NN were_VBD treated_VBN for_IN up_RB to_TO 24_CD weeks_NNS with_IN concurrent_JJ ENBREL_NN and_CC anakinra_NN therapy_NN ,_, a_DT 7_CD %_NN rate_NN of_IN serious_JJ infections_NNS was_VBD observed_VBN ,_, which_WDT was_VBD higher_JJR than_IN that_DT observed_VBN with_IN ENBREL_NN alone_RB -LRB-_-LRB- 0_CD %_NN -RRB-_-RRB- ._. Two_CD percent_NN of_IN patients_NNS treated_VBN concurrently_RB with_IN ENBREL_NN and_CC anakinra_NN developed_VBD neutropenia_NN -LRB-_-LRB- ANC_NNP 1_CD x_CC 109/L_CD -RRB-_-RRB- ._. Patients_NNS in_IN a_DT clinical_JJ study_NN who_WP were_VBD on_IN established_JJ therapy_NN with_IN sulfasalazine_NN ,_, to_TO which_WDT ENBREL_NNP was_VBD added_VBN ,_, were_VBD noted_VBN to_TO develop_VB a_DT mild_JJ decrease_NN in_IN mean_JJ neutrophil_NN counts_NNS in_IN comparison_NN to_TO groups_NNS treated_VBN with_IN either_CC ENBREL_NN CI_NN or_CC sulfasalazine_NN alone_RB ._. The_DT clinical_JJ significance_NN of_IN this_DT observation_NN is_VBZ unknown_JJ ._. Lithium_NN generally_RB should_MD not_RB be_VB given_VBN with_IN diuretics_NNS because_IN they_PRP reduce_VBP its_PRP$ renal_JJ clearance_NN and_CC add_VB a_DT high_JJ risk_NN of_IN lithium_NN toxicity_NN ._. Read_VB circulars_NNS for_IN lithium_NN preparations_NNS before_IN use_NN of_IN such_JJ concomitant_JJ therapy_NN ._. EDECRIN_NN may_MD increase_VB the_DT ototoxic_JJ potential_NN of_IN other_JJ drugs_NNS such_JJ as_IN aminoglycoside_NN and_CC some_DT cephalosporin_NN antibiotics_NNS ._. Their_PRP$ concurrent_JJ use_NN should_MD be_VB avoided_VBN ._. A_DT number_NN of_IN drugs_NNS ,_, including_VBG ethacrynic_JJ acid_NN ,_, have_VBP been_VBN shown_VBN to_TO displace_VB warfarin_NN from_IN plasma_NN protein_NN ._. a_DT reduction_NN in_IN the_DT usual_JJ anticoagulant_JJ dosage_NN may_MD be_VB required_VBN in_IN patients_NNS receiving_VBG both_CC drugs_NNS ._. In_IN some_DT patients_NNS ,_, the_DT administration_NN of_IN a_DT non_JJ -_: steroidal_JJ antiinflammatory_JJ agent_NN can_MD reduce_VB the_DT diuretic_JJ ,_, natriuretic_JJ ,_, and_CC antihypertensive_JJ effects_NNS of_IN loop_NN ,_, potassium_NN -_: sparing_NN and_CC thiazide_JJ diuretics_NNS ._. Therefore_RB ,_, when_WRB EDECRIN_NNP and_CC non_JJ -_: steroidal_JJ anti-_JJ inflammatory_JJ agents_NNS are_VBP used_VBN concomitantly_RB ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB to_TO determine_VB if_IN the_DT desired_VBN effect_NN of_IN the_DT diuretic_JJ is_VBZ obtained_VBN ._. The_DT results_NNS of_IN a_DT study_NN of_IN coadministration_NN of_IN ethambutol_NN -LRB-_-LRB- 50_CD mg/kg_NN -RRB-_-RRB- with_IN an_DT aluminum_NN hydroxide_NN containing_VBG antacid_NN to_TO 13_CD patients_NNS with_IN tuberculosis_NN showed_VBD a_DT reduction_NN of_IN mean_JJ serum_NN concentrations_NNS and_CC urinary_JJ excretion_NN of_IN ethambutol_NN of_IN approximately_RB 20_CD %_NN and_CC 13_CD %_NN ,_, respectively_RB ,_, suggesting_VBG that_IN the_DT oral_JJ absorption_NN of_IN ethambutol_NN may_MD be_VB reduced_VBN by_IN these_DT antacid_NN products_NNS ._. It_PRP is_VBZ recommended_VBN to_TO avoid_VB concurrent_JJ administration_NN of_IN ethambutol_NN with_IN aluminum_NN hydroxide_NN containing_VBG antacids_NNS for_IN at_IN least_JJS 4_CD hours_NNS following_VBG ethambutol_NN administration_NN ._. Dicumarol_NNP and_CC warfarin_NN may_MD decrease_VB hypoprothrombinemic_JJ effect_NN ._. Other_JJ depressasnts_NNS such_JJ as_IN alcohol_NN ,_, barbiturates_NNS ,_, and_CC MAOIs_NNS may_MD enhance_VB CNS_NN depression_NN when_WRB administered_VBN with_IN ethchlorvynol_NN ._. May_NNP interact_VBP with_IN addictive_JJ medications_NNS ,_, especially_RB central_JJ nervous_JJ system_NN -LRB-_-LRB- CNS_NN -RRB-_-RRB- depressants_NNS with_IN habituating_VBG potential_JJ -LRB-_-LRB- prolonged_JJ concurrent_JJ use_NN may_MD increase_VB the_DT risk_NN of_IN habituation_NN -RRB-_-RRB- ,_, alcohol_NN or_CC CNS_NN depression_NN producing_VBG medications_NNS -LRB-_-LRB- concurrent_JJ use_NN may_MD increase_VB the_DT CNS_NN depressant_NN effects_NNS of_IN either_CC these_DT medications_NNS or_CC ethinamate_NN -RRB-_-RRB- ._. Certain_JJ endocrine_NN and_CC liver_NN function_NN tests_NNS may_MD be_VB affected_VBN by_IN estrogen-containing_JJ oral_JJ contraceptives_NNS ._. The_DT following_VBG similar_JJ changes_NNS may_MD be_VB expected_VBN with_IN larger_JJR doses_NNS of_IN estrogen_NN :_: Increased_VBN sulfobromophthalein_NN retention_NN ._. increased_VBN prothrombin_NN and_CC factors_NNS VII_NNP ,_, VIII_NNP ,_, IX_CD ,_, and_CC X_NN ;_: ._. decreased_VBN antithrombin_NN 3_CD ;_: ._. increased_VBN norepinephrine-induced_JJ platel_NN et_FW aggregation_NN ;_: ._. increased_VBN thyroid_NN binding_NN globulin_NN -LRB-_-LRB- TBG_NN -RRB-_-RRB- leading_VBG to_TO increased_VBN circulating_VBG total_JJ thyroid_NN hormone_NN ,_, as_IN measured_VBN by_IN PBI_NN ,_, T4_NN by_IN column_NN ,_, or_CC T4_NN by_IN radioimmunoassay_NN ._. Free_NNP T3_NN resin_NN uptake_NN is_VBZ decreased_VBN ,_, reflecting_VBG the_DT elevated_JJ TBG_NN ;_: ._. free_JJ T4_NN concentration_NN is_VBZ unaltered_JJ :_: impaired_JJ glucose_NN tolerance_NN ;_: ._. decreased_VBN pregnanediol_NN excretion_NN ;_: ._. reduced_VBN response_NN to_TO metyrapone_NN test_NN ;_: ._. reduced_VBN serum_NN folate_VBP concentration_NN ;_: ._. increased_VBN serum_NN triglyceride_NN and_CC phospholipid_JJ concentration_NN ._. Trecator_NNP has_VBZ been_VBN found_VBN to_TO temporarily_RB raise_VB serum_NN concentrations_NNS of_IN isoniazid_NN ._. Trecator_NNP may_MD potentiate_VB the_DT adverse_JJ effects_NNS of_IN other_JJ antituberculous_JJ drugs_NNS administered_VBN concomitantly_RB ._. In_IN particular_JJ ,_, convulsions_NNS have_VBP been_VBN reported_VBN when_WRB ethionamide_NN is_VBZ administered_VBN with_IN cycloserine_NN and_CC special_JJ care_NN should_MD be_VB taken_VBN when_WRB the_DT treatment_NN regimen_NN includes_VBZ both_DT of_IN these_DT drugs_NNS ._. Excessive_JJ ethanol_NN ingestion_NN should_MD be_VB avoided_VBN because_IN a_DT psychotic_JJ reaction_NN has_VBZ been_VBN reported_VBN ._. Ethopropazine_NN may_MD interact_VB with_IN alcohol_NN or_CC other_JJ CNS_NN depressants_NNS ,_, causing_VBG increased_VBN sedative_JJ effects_NNS ._. It_PRP may_MD also_RB interact_VB with_IN amantadine_NN or_CC other_JJ anticholinergic_JJ drugs_NNS or_CC MAOIs_NNS ,_, which_WDT may_MD intensify_VB the_DT anticholinergic_JJ action_NN ._. Ethopropazine_NN can_MD interact_VB with_IN chlorpromazine_NN ,_, increasing_VBG the_DT metabolism_NN of_IN chlorpromazine_NN ._. Since_IN Zarontin_NN -LRB-_-LRB- ethosuximide_NN -RRB-_-RRB- may_MD interact_VB with_IN concurrently_RB administered_VBN antiepileptic_JJ drugs_NNS ,_, periodic_JJ serum_NN level_NN determinations_NNS of_IN these_DT drugs_NNS may_MD be_VB necessary_JJ -LRB-_-LRB- eg_FW ,_, ethosuximide_NN may_MD elevate_VB phenytoin_NN serum_NN levels_NNS and_CC valproic_JJ acid_NN has_VBZ been_VBN reported_VBN to_TO both_DT increase_NN and_CC decrease_VB ethosuximide_NN levels_NNS -RRB-_-RRB- ._. PEGANONE_NNP used_VBD in_IN combination_NN with_IN other_JJ drugs_NNS known_VBN to_TO adversely_RB affect_VB the_DT hematopoietic_JJ system_NN should_MD be_VB avoided_VBN if_IN possible_JJ ._. Considerable_JJ caution_NN should_MD be_VB exercised_VBN if_IN PEGANONE_NN is_VBZ administered_VBN concurrently_RB with_IN Phenurone_NN -LRB-_-LRB- phenacemide_NN -RRB-_-RRB- since_IN paranoid_JJ symptoms_NNS have_VBP been_VBN reported_VBN during_IN therapy_NN with_IN this_DT combination_NN ._. A_DT two-way_JJ interaction_NN between_IN the_DT hydantoin_NN antiepileptic_JJ ,_, phenytoin_NN ,_, and_CC the_DT coumarin_NN anticoagulants_NNS has_VBZ been_VBN suggested_VBN ._. Presumably_RB ,_, phenytoin_NN acts_VBZ as_IN a_DT stimulator_NN of_IN coumarin_NN metabolism_NN and_CC has_VBZ been_VBN reported_VBN to_TO cause_VB decreased_VBN serum_NN levels_NNS of_IN the_DT coumarin_NN anticoagulants_NNS and_CC increased_VBD prothrombin-proconvertin_JJ concentrations_NNS ._. Conversely_RB ,_, the_DT coumarin_NN anticoagulants_NNS have_VBP been_VBN reported_VBN to_TO increase_VB the_DT serum_NN levels_NNS and_CC prolong_VB the_DT serum_NN half-life_NN of_IN phenytoin_NN by_IN inhibiting_VBG its_PRP$ metabolism_NN ._. Although_IN there_EX is_VBZ no_DT documentation_NN of_IN such_JJ ,_, a_DT similar_JJ interaction_NN between_IN ethotoin_NN and_CC the_DT coumarin_NN anticoagulants_NNS may_MD occur_VB ._. Caution_NN is_VBZ therefore_RB advised_VBN when_WRB administering_VBG PEGANONE_NN to_TO patients_NNS receiving_VBG coumarin_NN anticoagulants_NNS ._. Ethoxzolamide_NN may_MD increase_VB the_DT action_NN of_IN tricyclics_NNS ,_, amphetamines_NNS ,_, procainamide_NN ,_, and_CC quinidine_NN ._. It_PRP may_MD increase_VB excretion_NN of_IN barbiturates_NNS ,_, lithium_NN ,_, and_CC ASA_NN and_CC may_MD also_RB increase_VB the_DT toxicity_NN of_IN salicylates_NNS ._. Coadministration_NN of_IN ethoxzolamide_NN with_IN other_JJ diuretics_NNS ,_, amphotericin_NN B_NN ,_, and_CC corticosteroids_NNS may_MD cause_VB hypokalemia_NN ._. Ethinyl_NN estradiol_NN :_: Substrate_NN of_IN CYP3A4_NN -LRB-_-LRB- major_JJ -RRB-_-RRB- ,_, 3A5-7_NN -LRB-_-LRB- minor_JJ -RRB-_-RRB- ._. Inhibits_VBZ CYP1A2_NN -LRB-_-LRB- weak_JJ -RRB-_-RRB- ,_, 2B6_NN -LRB-_-LRB- weak_JJ -RRB-_-RRB- ,_, 2C19_NN -LRB-_-LRB- weak_JJ -RRB-_-RRB- ,_, 3A4_NN -LRB-_-LRB- weak_JJ -RRB-_-RRB- ._. Acetaminophen_NN :_: May_NNP increase_NN plasma_NN concentration_NN of_IN synthetic_JJ estrogens_NNS ,_, possibly_RB by_IN inhibiting_VBG conjugation_NN ._. Combination_NN hormonal_JJ contraceptives_NNS may_MD also_RB decrease_VB the_DT plasma_NN concentration_NN of_IN acetaminophen_NN ._. Acitretin_NNP :_: Interferes_NNS with_IN the_DT contraceptive_JJ effect_NN of_IN microdosed_JJ progestin-containing_JJ minipill_NN preparations_NNS ._. The_DT effect_NN on_IN other_JJ progestational_JJ contraceptives_NNS -LRB-_-LRB- eg_FW ,_, implants_NNS ,_, injectables_NNS -RRB-_-RRB- is_VBZ unknown_JJ ._. Aminoglutethimide_NNP :_: May_NNP increase_NN CYP_NN metabolism_NN of_IN progestins_NNS leading_VBG to_TO possible_JJ decrease_NN in_IN contraceptive_JJ effectiveness_NN ._. Use_NN of_IN a_DT nonhormonal_JJ contraceptive_JJ product_NN is_VBZ recommended_VBN ._. Antibiotics_NNS -LRB-_-LRB- ampicillin_NN ,_, tetracycline_NN -RRB-_-RRB- :_: Pregnancy_NN has_VBZ been_VBN reported_VBN following_VBG concomitant_JJ use_NN ,_, however_RB ,_, pharmacokinetic_JJ studies_NNS have_VBP not_RB shown_VBN consistent_JJ effects_NNS with_IN these_DT antibiotics_NNS on_IN plasma_NN concentrations_NNS of_IN synthetic_JJ steroids_NNS ._. Use_NN of_IN a_DT nonhormonal_JJ contraceptive_JJ product_NN is_VBZ recommended_VBN ._. Anticoagulants_NNPS :_: Combination_NN hormonal_JJ contraceptives_NNS may_MD increase_VB or_CC decrease_VB the_DT effects_NNS of_IN coumarin_NN derivatives_NNS ._. Combination_NN hormonal_JJ contraceptives_NNS may_MD also_RB increase_VB risk_NN of_IN thromboembolic_JJ disorders_NNS ._. Anticonvulsants_NNS -LRB-_-LRB- carbamazepine_NN ,_, felbamate_NN ,_, phenobarbital_NN ,_, phenytoin_NN ,_, topiramate_NN -RRB-_-RRB- :_: Increase_VB the_DT metabolism_NN of_IN ethinyl_NN estradiol_NN and/or_CC some_DT progestins_NNS ,_, leading_VBG to_TO possible_JJ decrease_NN in_IN contraceptive_JJ effectiveness_NN ._. Use_NN of_IN a_DT nonhormonal_JJ contraceptive_JJ product_NN is_VBZ recommended_VBN ._. Ascorbic_JJ acid_NN :_: Doses_NNS of_IN ascorbic_JJ acid_NN -LRB-_-LRB- vitamin_NN C_NN -RRB-_-RRB- 1_CD g/day_NN have_VBP been_VBN reported_VBN to_TO increase_VB plasma_NN concentration_NN of_IN synthetic_JJ estrogens_NNS by_IN ~_NN 47_CD %_NN ,_, possibly_RB by_IN inhibiting_VBG conjugation_NN ._. clinical_JJ implications_NNS are_VBP unclear_JJ ._. Atorvastatin_NNP :_: Atorvastatin_NNP increases_VBZ the_DT AUC_NN for_IN norethindrone_NN and_CC ethinyl_NN estradiol_NN ._. Benzodiazepines_NNS :_: Combination_NN hormonal_JJ contraceptives_NNS may_MD decrease_VB the_DT clearance_NN of_IN some_DT benzodiazepines_NNS -LRB-_-LRB- alprazolam_NN ,_, chlordiazepoxide_NN ,_, diazepam_NN -RRB-_-RRB- and_CC increase_VB the_DT clearance_NN of_IN others_NNS -LRB-_-LRB- lorazepam_NN ,_, oxazepam_NN ,_, temazepam_NN -RRB-_-RRB- ._. Clofibric_JJ acid_NN :_: Combination_NN hormonal_JJ contraceptives_NNS may_MD increase_VB the_DT clearance_NN of_IN clofibric_JJ acid_NN ._. Cyclosporine_NN :_: Combination_NN hormonal_JJ contraceptives_NNS may_MD inhibit_VB the_DT metabolism_NN of_IN cyclosporine_NN ,_, leading_VBG to_TO increased_VBN plasma_NN concentrations_NNS ._. monitor_NN cyclosporine_NN levels_NNS ._. CYP3A4_NN inducers_NNS :_: CYP3A4_NN inducers_NNS may_MD decrease_VB the_DT levels/effects_NNS of_IN ethinyl_NN estradiol_NN ._. Example_NN inducers_NNS include_VBP aminoglutethimide_NN ,_, carbamazepine_NN ,_, nafcillin_NN ,_, nevirapine_NN ,_, phenobarbital_NN ,_, phenytoin_NN ,_, and_CC rifamycins_NNS ._. Griseofulvin_NNP :_: Griseofulvin_NNP may_MD induce_VB the_DT metabolism_NN of_IN combination_NN hormonal_JJ contraceptives_NNS causing_VBG menstrual_JJ changes_NNS ._. pregnancies_NNS have_VBP been_VBN reported_VBN ._. Use_NN of_IN barrier_NN form_NN of_IN contraception_NN is_VBZ suggested_VBN while_IN on_IN griseofulvin_NN therapy_NN ._. Morphine_NNP :_: Combination_NN hormonal_JJ contraceptives_NNS may_MD increase_VB the_DT clearance_NN of_IN morphine_NN ._. Non-nucleoside_JJ reverse_JJ transcriptase_NN inhibitors_NNS -LRB-_-LRB- NNRTIs_NNS -RRB-_-RRB- :_: Nevirapine_NN may_MD decrease_VB plasma_NN levels_NNS of_IN combination_NN hormonal_JJ contraceptives_NNS ._. use_NN of_IN a_DT nonhormonal_JJ contraceptive_JJ product_NN is_VBZ recommended_VBN ._. No_DT data_NNS for_IN delavirdine_NN ._. incomplete_JJ data_NNS for_IN efavirenz_NN ._. Prednisolone_NN :_: Ethinyl_NN estradiol_NN may_MD inhibit_VB the_DT metabolism_NN of_IN prednisolone_NN ,_, leading_VBG to_TO increased_VBN plasma_NN concentrations_NNS ._. Protease_NN inhibitors_NNS :_: Amprenavir_NNP ,_, lopinavir_NN ,_, nelfinavir_NN ,_, and_CC ritonavir_NN have_VBP been_VBN shown_VBN to_TO decrease_VB plasma_NN levels_NNS of_IN combination_NN hormonal_JJ contraceptives_NNS ._. use_NN of_IN a_DT nonhormonal_JJ contraceptive_JJ product_NN is_VBZ recommended_VBN ._. Indinavir_NNP has_VBZ been_VBN shown_VBN to_TO increase_VB plasma_NN levels_NNS of_IN combination_NN hormonal_JJ contraceptives_NNS ._. No_DT data_NNS for_IN saquinavir_NN ._. Rifampin_NNP :_: Rifampin_NNP increases_VBZ the_DT metabolism_NN of_IN ethinyl_NN estradiol_NN and_CC some_DT progestins_NNS -LRB-_-LRB- norethindrone_NN -RRB-_-RRB- resulting_VBG in_IN decreased_VBN contraceptive_JJ effectiveness_NN and_CC increased_VBD menstrual_JJ irregularities_NNS ._. Use_NN of_IN a_DT nonhormonal_JJ contraceptive_JJ product_NN is_VBZ recommended_VBN ._. Salicylic_JJ acid_NN :_: Combination_NN hormonal_JJ contraceptives_NNS may_MD increase_VB the_DT clearance_NN of_IN salicylic_JJ acid_NN ._. Selegiline_NNP :_: Combination_NN hormonal_JJ contraceptives_NNS may_MD increase_VB the_DT serum_NN concentration_NN of_IN selegiline_NN ._. Theophylline_NNP :_: Ethinyl_NNP estradiol_NN may_MD inhibit_VB the_DT metabolism_NN of_IN theophylline_NN ,_, leading_VBG to_TO increased_VBN plasma_NN concentrations_NNS ._. Tricyclic_JJ antidepressants_NNS -LRB-_-LRB- amitriptyline_NNP ,_, imipramine_NN ,_, nortriptyline_NN -RRB-_-RRB- :_: Metabolism_NN may_MD be_VB inhibited_VBN by_IN combination_NN hormonal_JJ contraceptives_NNS ,_, increasing_VBG plasma_NN levels_NNS of_IN antidepressant_JJ ._. use_NN caution_NN ._. ETHANOL_NN /_: NUTRITION_NNP /_: HERB_NNP INTERACTIONS_NNPS :_: Food_NNP :_: CNS_NN effects_NNS of_IN caffeine_NN may_MD be_VB enhanced_VBN if_IN combination_NN hormonal_JJ contraceptives_NNS are_VBP used_VBN concurrently_RB with_IN caffeine_NN ._. Grapefruit_NN juice_NN increases_VBZ ethinyl_NN estradiol_NN concentrations_NNS and_CC would_MD be_VB expected_VBN to_TO increase_VB progesterone_NN serum_NN levels_NNS as_RB well_RB ._. clinical_JJ implications_NNS are_VBP unclear_JJ ._. Herb/Nutraceutical_NNP :_: St_NNP Johns_NNP wort_NN may_MD decrease_VB the_DT effectiveness_NN of_IN combination_NN hormonal_JJ contraceptives_NNS by_IN inducing_VBG hepatic_JJ enzymes_NNS ._. Avoid_VB dong_FW quai_FW and_CC black_JJ cohosh_NN -LRB-_-LRB- have_VB estrogen_NN activity_NN -RRB-_-RRB- ._. Avoid_VB saw_NN palmetto_NN ,_, red_JJ clover_NN ,_, ginseng_NN ._. There_EX have_VBP been_VBN isolated_VBN reports_NNS of_IN patients_NNS experiencing_VBG increases_NNS in_IN their_PRP$ prothrombin_NN times_NNS when_WRB etidronate_NN was_VBD added_VBN to_TO warfarin_NN therapy_NN ._. The_DT majority_NN of_IN these_DT reports_NNS concerned_VBN variable_JJ elevations_NNS in_IN prothrombin_NN times_NNS without_IN clinically_RB significant_JJ sequelae_NN ._. Although_IN the_DT relevance_NN of_IN these_DT reports_NNS and_CC any_DT mechanism_NN of_IN coagulation_NN alterations_NNS is_VBZ unclear_JJ ,_, patients_NNS on_IN warfarin_NN should_MD have_VB their_PRP$ prothrombin_NN time_NN monitored_VBD ._. ACE-inhibitors_NNS Reports_NNS suggest_VBP that_IN NSAIDs_NNS may_MD diminish_VB the_DT antihypertensive_JJ effect_NN of_IN ACE-inhibitors_NNS ._. This_DT interaction_NN should_MD be_VB given_VBN consideration_NN in_IN patients_NNS taking_VBG NSAIDs_NNS concomitantly_RB with_IN ACE-inhibitors_NNS ._. Antacids_NNS :_: The_DT concomitant_JJ administration_NN of_IN antacids_NNS has_VBZ no_DT apparent_JJ effect_NN on_IN the_DT extent_NN of_IN absorption_NN of_IN Lodine_NNP ._. However_RB ,_, antacids_NNS can_MD decrease_VB the_DT peak_NN concentration_NN reached_VBN by_IN 15_CD %_NN to_TO 20_CD %_NN but_CC have_VBP no_DT detectable_JJ effect_NN on_IN the_DT time-to-peak_NN ._. Aspirin_NN :_: When_WRB Lodine_NNP is_VBZ administered_VBN with_IN aspirin_NN ,_, its_PRP$ protein_NN binding_NN is_VBZ reduced_VBN ,_, although_IN the_DT clearance_NN of_IN free_JJ etodolac_NN is_VBZ not_RB altered_VBN ._. The_DT clinical_JJ significance_NN of_IN this_DT interaction_NN is_VBZ not_RB known_VBN ;_: ._. however_RB ,_, as_IN with_IN other_JJ NSAIDs_NNS ,_, concomitant_JJ administration_NN of_IN Lodine_NNP and_CC aspirin_NN is_VBZ not_RB generally_RB recommended_VBN because_IN of_IN the_DT potential_NN of_IN increased_VBN adverse_JJ effects_NNS ._. Cyclosporine_NN ,_, Digoxin_NNP ,_, Methotrexate_NNP Lodine_NNP ,_, like_IN other_JJ NSAIDs_NNS ,_, through_IN effects_NNS on_IN renal_JJ prostaglandins_NNS ,_, may_MD cause_VB changes_NNS in_IN the_DT elimination_NN of_IN these_DT drugs_NNS leading_VBG to_TO elevated_JJ serum_NN levels_NNS of_IN cyclosporine_NN ,_, digoxin_NN ,_, methotrexate_NN ,_, and_CC increased_VBD toxicity_NN ._. Nephrotoxicity_NN associated_VBN with_IN cyclosporine_NN may_MD also_RB be_VB enhanced_VBN ._. Patients_NNS receiving_VBG these_DT drugs_NNS who_WP are_VBP given_VBN Lodine_NNP ,_, or_CC any_DT other_JJ NSAID_NN ,_, and_CC particularly_RB those_DT patients_NNS with_IN altered_JJ renal_JJ function_NN ,_, should_MD be_VB observed_VBN for_IN the_DT development_NN of_IN the_DT specific_JJ toxicities_NNS of_IN these_DT drugs_NNS ._. Diuretics_NNS :_: Etodolac_NNP has_VBZ no_DT apparent_JJ pharmacokinetic_JJ interaction_NN when_WRB administered_VBN with_IN furosemide_NN or_CC hydrochlorothiazide_NN ._. Nevertheless_RB ,_, clinical_JJ studies_NNS ,_, as_RB well_RB as_IN postmarketing_VBG observations_NNS have_VBP shown_VBN that_IN Lodine_NNP can_MD reduce_VB the_DT natriuretic_JJ effect_NN of_IN furosemide_NN and_CC thiazides_NNS in_IN some_DT patients_NNS ._. This_DT response_NN has_VBZ been_VBN attributed_VBN to_TO inhibition_NN of_IN renal_JJ prostaglandin_NN synthesis_NN ._. During_IN concomitant_JJ therapy_NN with_IN NSAIDs_NNS ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB for_IN signs_NNS of_IN renal_JJ failure_NN ,_, as_RB well_RB as_IN to_TO assure_VB diuretic_JJ efficacy_NN ._. Glyburide_NNP :_: Etodolac_NNP has_VBZ no_DT apparent_JJ pharmacokinetic_JJ interaction_NN when_WRB administered_VBN with_IN glyburide_NN ._. Lithium_NN :_: NSAIDs_NNS have_VBP produced_VBN an_DT elevation_NN of_IN plasma_NN lithium_NN levels_NNS and_CC a_DT reduction_NN in_IN renal_JJ lithium_NN clearance_NN ._. The_DT mean_NN minimum_JJ lithium_NN concentration_NN increased_VBD 15_CD %_NN and_CC the_DT renal_JJ clearance_NN was_VBD decreased_VBN by_IN approximately_RB 20_CD %_NN ._. These_DT effects_NNS have_VBP been_VBN attributed_VBN to_TO inhibition_NN of_IN renal_JJ prostaglandin_NN synthesis_NN by_IN the_DT NSAID_NN ._. Thus_RB ,_, when_WRB NSAIDs_NNS and_CC lithium_NN are_VBP administered_VBN concurrently_RB ,_, subjects_NNS should_MD be_VB observed_VBN carefully_RB for_IN signs_NNS of_IN lithium_NN toxicity_NN ._. Phenylbutazone_NNP :_: Phenylbutazone_NNP causes_VBZ increase_NN -LRB-_-LRB- by_IN about_IN 80_CD %_NN -RRB-_-RRB- in_IN the_DT free_JJ fraction_NN of_IN etodolac_NN ._. Although_IN in_FW vivo_FW studies_NNS have_VBP not_RB been_VBN done_VBN to_TO see_VB if_IN etodolac_NN clearance_NN is_VBZ changed_VBN by_IN coadministration_NN of_IN phenylbutazone_NN ,_, it_PRP is_VBZ not_RB recommended_VBN that_IN they_PRP be_VB coadministered_VBN ._. Phenytoin_NNP :_: Etodolac_NNP has_VBZ no_DT apparent_JJ pharmacokinetic_JJ interaction_NN when_WRB administered_VBN with_IN phenytoin_NN ._. Warfarin_NNP :_: The_DT effects_NNS of_IN warfarin_NN and_CC NSAIDs_NNS on_IN GI_NN bleeding_NN are_VBP synergistic_JJ ,_, such_JJ that_IN users_NNS of_IN both_DT drugs_NNS together_RB have_VBP a_DT risk_NN of_IN serious_JJ GI_NN bleeding_VBG higher_JJR than_IN that_DT of_IN users_NNS of_IN either_CC drug_NN alone_RB ._. Short-term_JJ pharmacokinetic_JJ studies_NNS have_VBP demonstrated_VBN that_IN concomitant_JJ administration_NN of_IN warfarin_NN and_CC Lodine_NN -LRB-_-LRB- etodolac_NN capsules_NNS and_CC tablets_NNS -RRB-_-RRB- results_VBZ in_IN reduced_VBN protein_NN binding_NN of_IN warfarin_NN ,_, but_CC there_EX was_VBD no_DT change_NN in_IN the_DT clearance_NN of_IN free_JJ warfarin_NN ._. There_EX was_VBD no_DT significant_JJ difference_NN in_IN the_DT pharmacodynamic_JJ effect_NN of_IN warfarin_NN administered_VBN alone_RB and_CC warfarin_NN administered_VBN with_IN Lodine_NN as_IN measured_VBN by_IN prothrombin_NN time_NN ._. Thus_RB ,_, concomitant_JJ therapy_NN with_IN warfarin_NN and_CC Lodine_NN should_MD not_RB require_VB dosage_NN adjustment_NN of_IN either_CC drug_NN ._. However_RB ,_, caution_NN should_MD be_VB exercised_VBN because_IN there_EX have_VBP been_VBN a_DT few_JJ spontaneous_JJ reports_NNS of_IN prolonged_JJ prothrombin_NN times_NNS ,_, with_IN or_CC without_IN bleeding_NN ,_, in_IN etodolac-treated_JJ patients_NNS receiving_VBG concomitant_JJ warfarin_NN therapy_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS The_DT urine_NN of_IN patients_NNS who_WP take_VBP Lodine_NN can_MD give_VB a_DT false-positive_JJ reaction_NN for_IN urinary_JJ bilirubin_NN -LRB-_-LRB- urobilin_NN -RRB-_-RRB- due_JJ to_TO the_DT presence_NN of_IN phenolic_JJ metabolites_NNS of_IN etodolac_NN ._. Diagnostic_JJ dip-stick_NN methodology_NN ,_, used_VBN to_TO detect_VB ketone_NN bodies_NNS in_IN urine_NN ,_, has_VBZ resulted_VBN in_IN false-positive_JJ findings_NNS in_IN some_DT patients_NNS treated_VBN with_IN Lodine_NN ._. Generally_RB ,_, this_DT phenomenon_NN has_VBZ not_RB been_VBN associated_VBN with_IN other_JJ clinically_RB significant_JJ events_NNS ._. No_DT dose_NN relationship_NN has_VBZ been_VBN observed_VBN ._. Lodine_NN treatment_NN is_VBZ associated_VBN with_IN a_DT small_JJ decrease_NN in_IN serum_NN uric_JJ acid_NN levels_NNS ._. In_IN clinical_JJ trials_NNS ,_, mean_VB decreases_NNS of_IN 1_CD to_TO 2_CD mg/dL_NN were_VBD observed_VBN in_IN arthritic_JJ patients_NNS receiving_VBG etodolac_NN -LRB-_-LRB- 600_CD mg_NN to_TO 1000_CD mg/day_NN -RRB-_-RRB- after_IN 4_CD weeks_NNS of_IN therapy_NN ._. These_DT levels_NNS then_RB remained_VBD stable_JJ for_IN up_RB to_TO 1_CD year_NN of_IN therapy_NN ._. The_DT following_VBG drug_NN interactions_NNS have_VBP been_VBN reported_VBN with_IN etomidate_NN ._. Drug_NN Effect_NN ._. Probenecid_NNP Prolonged_JJ action_NN of_IN etomidat_NN ._. Diazoxide_NNP Hypotensio_NNP ._. Zimelidine_NN etomidate_NN antagonis_NN ._. Opioid_JJ analgesics_NNS Decreased_VBN antinociceptive_JJ actio_NN ._. Aminophylline_NNP Etomidate_NNP antagonis_NN ._. Midazolam_NNP Synergis_NNP ._. Etonogestrel_NN may_MD interact_VB with_IN the_DT following_VBG medications_NNS :_: acetaminophen_NN -LRB-_-LRB- Tylenol_NNP -RRB-_-RRB- ,_, antibiotics_NNS such_JJ as_IN ampicillin_NN and_CC tetracycline_NN ,_, anticonvulsants_NNS -LRB-_-LRB- Dilantin_NNP ,_, Phenobarbital_NNP ,_, Tegretol_NNP ,_, Trileptal_NNP ,_, Topamax_NNP ,_, Felbatol_NNP -RRB-_-RRB- ,_, antifungals_NNS -LRB-_-LRB- Gris-PEG_NNP ,_, Nizoral_NNP ,_, Sporanox_NNP -RRB-_-RRB- ,_, atorvastatin_NN -LRB-_-LRB- Lipitor_NN -RRB-_-RRB- ,_, clofibrate_NN -LRB-_-LRB- Atromid-S_NN -RRB-_-RRB- ,_, cyclosporine_NN -LRB-_-LRB- Neoral_NNP ,_, Sandimmune_NNP -RRB-_-RRB- ,_, HIV_NN drugs_NNS classified_VBN as_IN protease_NN inhibitors_NNS -LRB-_-LRB- Agenerase_NN ,_, Crixivan_NNP ,_, Fortovase_NNP ,_, Invirase_NNP ,_, Kaletra_NNP ,_, Norvir_NNP ,_, Viracept_NNP -RRB-_-RRB- ,_, morphine_NN -LRB-_-LRB- Astramorph_NNP ,_, Kadian_NNP ,_, MS_NN Contin_NN -RRB-_-RRB- ,_, phenylbutazone_NN ,_, prednisolone_NN -LRB-_-LRB- Prelone_NN -RRB-_-RRB- ,_, rifadin_NN -LRB-_-LRB- rifampin_NN -RRB-_-RRB- ,_, St._NNP Johns_NNP wort_NN ,_, temazepam_NN ,_, theophylline_NN -LRB-_-LRB- Theo-Dur_NN -RRB-_-RRB- ,_, and_CC vitamin_NN C._NN Caution_NN should_MD be_VB exercised_VBN when_WRB administering_VBG ETOPOPHOS_NNS with_IN drugs_NNS that_WDT are_VBP known_VBN to_TO inhibit_VB phosphatase_NN activities_NNS -LRB-_-LRB- e.g._FW ,_, levamisole_NN hydrochloride_NN -RRB-_-RRB- ._. High-dose_JJ cyclosporin_NN A_NN resulting_VBG in_IN concentrations_NNS above_IN 2000_CD ng/mL_NN administered_VBN with_IN oral_JJ etoposide_NN has_VBZ led_VBN to_TO an_DT 80_CD %_NN increase_NN in_IN etoposide_NN exposure_NN with_IN a_DT 38_CD %_NN decrease_NN in_IN total_JJ body_NN clearance_NN of_IN etoposide_NN compared_VBN to_TO etoposide_NN alone_RB ._. Exemestane_NN is_VBZ extensively_RB metabolized_VBN by_IN CYP_NN 3A4_NN ,_, but_CC coadministration_NN of_IN ketoconazole_NN ,_, a_DT potent_JJ inhibitor_NN of_IN CYP_NN 3A4_NN ,_, has_VBZ no_DT significant_JJ effect_NN on_IN exemestane_NN pharmacokinetics_NNS ._. Significant_JJ pharmacokinetic_JJ interactions_NNS mediated_VBN by_IN inhibition_NN of_IN CYP_NN isoenzymes_NNS therefore_RB appear_VBP unlikely_JJ ._. Co-medications_NNS that_WDT induce_VBP CYP_NN 3A4_NN -LRB-_-LRB- e.g._FW ,_, rifampicin_NN ,_, phenytoin_NN ,_, carbamazepine_NN ,_, phenobarbital_NN ,_, or_CC St._NNP John_NNP s_VBZ wort_NN -RRB-_-RRB- may_MD significantly_RB decrease_VB exposure_NN to_TO exemestane_NN ._. Dose_NN modification_NN is_VBZ recommended_VBN for_IN patients_NNS who_WP are_VBP also_RB receiving_VBG a_DT potent_JJ CYP_NN 3A4_NN inducer_NN ._. Drug/Laboratory_NNP Tests_NNP Interactions_NNS No_DT clinically_RB relevant_JJ changes_NNS in_IN the_DT results_NNS of_IN clinical_JJ laboratory_NN tests_NNS have_VBP been_VBN observed_VBN ._. Concurrent_JJ use_NN with_IN probenecid_NN or_CC other_JJ drugs_NNS significantly_RB eliminated_VBN by_IN active_JJ renal_JJ tubular_JJ secretion_NN may_MD result_VB in_IN increased_VBN plasma_NN concentrations_NNS of_IN penciclovir_NN ._. The_DT conversion_NN of_IN 6-deoxy_JJ penciclovir_NN to_TO penciclovir_NN is_VBZ catalyzed_VBN by_IN aldehyde_NN oxidase_NN ._. Interactions_NNS with_IN other_JJ drugs_NNS metabolized_VBN by_IN this_DT enzyme_NN could_MD potentially_RB occur_VB ._. No_DT drug_NN interactions_NNS have_VBP been_VBN identified_VBN ._. Studies_NNS with_IN famotidine_NN in_IN man_NN ,_, in_IN animal_NN models_NNS ,_, and_CC in_FW vitro_FW have_VBP shown_VBN no_DT significant_JJ interference_NN with_IN the_DT disposition_NN of_IN compounds_NNS metabolized_VBN by_IN the_DT hepatic_JJ microsomal_JJ enzymes_NNS ,_, e.g._FW ,_, cytochrome_NN P450_NN system_NN ._. Compounds_NNS tested_VBN in_IN man_NN include_VBP warfarin_NN ,_, theophylline_NN ,_, phenytoin_NN ,_, diazepam_NN ,_, aminopyrine_NN and_CC antipyrine_NN ._. Indocyanine_JJ green_JJ as_IN an_DT index_NN of_IN hepatic_JJ drug_NN extraction_NN has_VBZ been_VBN tested_VBN and_CC no_DT significant_JJ effects_NNS have_VBP been_VBN found_VBN ._. The_DT drug_NN interaction_NN data_NNS described_VBN in_IN this_DT section_NN were_VBD obtained_VBN from_IN controlled_JJ clinical_JJ trials_NNS and_CC studies_NNS involving_VBG otherwise_RB healthy_JJ adults_NNS with_IN epilepsy_NN ._. Use_NN in_IN Conjunction_NN with_IN Other_JJ Antiepileptic_JJ Drugs_NNS :_: The_DT addition_NN of_IN Felbatol_NNP to_TO antiepileptic_JJ drugs_NNS -LRB-_-LRB- AEDs_NNS -RRB-_-RRB- affects_VBZ the_DT steady-state_JJ plasma_NN concentrations_NNS of_IN AEDs_NNS ._. The_DT net_JJ effect_NN of_IN these_DT interactions_NNS is_VBZ summarized_VBN in_IN the_DT following_VBG table_NN :_: AED_NNP AED_NNP Felbato_NNP ._. Coadministered_JJ Concentration_NN Concentration_NN ._. Phenytoi_NNP ._. Valproate_NNP *_SYM ._. Carbamazepine_NNP -LRB-_-LRB- CBZ_NNP -RRB-_-RRB- ._. *_SYM CBZ_NN epoxide_NN ._. Phenobarbita_NNP ._. *_SYM Not_RB administered_VBN ,_, but_CC an_DT active_JJ metabolite_NN of_IN carbamazepine_NN ._. **_SYM No_DT significant_JJ effect_NN ._. Specific_JJ Effects_NNS of_IN Felbatol_NN on_IN Other_JJ Antiepileptic_JJ Drugs_NNS Phenytoin_NNP :_: Felbatol_NNP causes_VBZ an_DT increase_NN in_IN steady-state_JJ phenytoin_NN plasma_NN concentrations_NNS ._. In_IN 10_CD otherwise_RB healthy_JJ subjects_NNS with_IN epilepsy_NN ingesting_VBG phenytoin_NN ,_, the_DT steadystate_NN trough_NN -LRB-_-LRB- Cmin_NN -RRB-_-RRB- phenytoin_NN plasma_NN concentration_NN was_VBD 17_CD 5_CD micrograms/mL_NNS ._. The_DT steady-state_JJ Cmin_NN increased_VBD to_TO 21_CD 5_CD micrograms/mL_NNS when_WRB 1200_CD mg/day_NN of_IN felbamate_NN was_VBD coadministered_VBN ._. Increasing_VBG the_DT felbamate_NN dose_NN to_TO 1800_CD mg/day_NN in_IN six_CD of_IN these_DT subjects_NNS increased_VBD the_DT steady-state_JJ phenytoin_NN Cmin_NN to_TO 25_CD 7_CD micrograms/mL_NNS ._. In_IN order_NN to_TO maintain_VB phenytoin_NN levels_NNS ,_, limit_NN adverse_JJ experiences_NNS ,_, and_CC achieve_VB the_DT felbamate_NN dose_NN of_IN 3600_CD mg/day_NN ,_, a_DT phenytoin_NN dose_NN reduction_NN of_IN approximately_RB 40_CD %_NN was_VBD necessary_JJ for_IN eight_CD of_IN these_DT 10_CD subjects_NNS ._. In_IN a_DT controlled_JJ clinical_JJ trial_NN ,_, a_DT 20_CD %_NN reduction_NN of_IN the_DT phenytoin_NN dose_NN at_IN the_DT initiation_NN of_IN Felbatol_NN therapy_NN resulted_VBD in_IN phenytoin_NN levels_NNS comparable_JJ to_TO those_DT prior_JJ to_TO Felbatol_NNP administration_NN ._. Carbamazepine_NNP :_: Felbatol_NNP causes_VBZ a_DT decrease_NN in_IN the_DT steady-state_JJ carbamazepine_NN plasma_NN concentrations_NNS and_CC an_DT increase_NN in_IN the_DT steady-state_JJ carbamazepine_NN epoxide_NN plasma_NN concentration_NN ._. In_IN nine_CD otherwise_RB healthy_JJ subjects_NNS with_IN epilepsy_NN ingesting_VBG carbamazepine_NN ,_, the_DT steady-state_JJ trough_NN -LRB-_-LRB- Cmin_NN -RRB-_-RRB- carbamazepine_NN concentration_NN was_VBD 8_CD 2_CD micrograms/mL_NNS ._. The_DT carbamazepine_NN steady-state_JJ Cmin_NN decreased_VBD 31_CD %_NN to_TO 5_CD 1_CD micrograms/mL_NNS when_WRB felbamate_NN -LRB-_-LRB- 3000_CD mg/day_NN ,_, divided_VBN into_IN three_CD doses_NNS -RRB-_-RRB- was_VBD coadministered_VBN ._. Carbamazepine_NN epoxide_NN steady-state_JJ Cmin_JJ concentrations_NNS increased_VBD 57_CD %_NN from_IN 1.0_CD 0.3_CD to_TO 1.6_CD 0.4_CD micrograms/mL_NNS with_IN the_DT addition_NN of_IN felbamate_NN ._. In_IN clinical_JJ trials_NNS ,_, similar_JJ changes_NNS in_IN carbamazepine_NN and_CC carbamazepine_NN epoxide_NN were_VBD seen_VBN ._. Valproate_NNP :_: Felbatol_NNP causes_VBZ an_DT increase_NN in_IN steady-state_JJ valproate_NN concentrations_NNS ._. In_IN four_CD subjects_NNS with_IN epilepsy_NN ingesting_VBG valproate_NN ,_, the_DT steady-state_JJ trough_NN -LRB-_-LRB- Cmin_NN -RRB-_-RRB- valproate_NN plasma_NN concentration_NN was_VBD 63_CD 16_CD micrograms/mL_NNS ._. The_DT steady-state_JJ Cmin_NN increased_VBD to_TO 78_CD 14_CD micrograms/mL_NNS when_WRB 1200_CD mg/day_NN of_IN felbamate_NN was_VBD coadministered_VBN ._. Increasing_VBG the_DT felbamate_NN dose_NN to_TO 2400_CD mg/day_NN increased_VBD the_DT steadystate_NN valproate_NN Cmin_NN to_TO 96_CD 25_CD micrograms/mL_NNS ._. Corresponding_VBG values_NNS for_IN free_JJ valproate_NN Cmin_NN concentrations_NNS were_VBD 7_CD 3_CD ,_, 9_CD 4_CD ,_, and_CC 11_CD 6_CD micrograms/mL_NNS for_IN 0_CD ,_, 1200_CD ,_, and_CC 2400_CD mg/day_NN Felbatol_NN ,_, respectively_RB ._. The_DT ratios_NNS of_IN the_DT AUCs_NNS of_IN unbound_JJ valproate_NN to_TO the_DT AUCs_NNS of_IN the_DT total_JJ valproate_NN were_VBD 11.1_CD %_NN ,_, 13.0_CD %_NN ,_, and_CC 11.5_CD %_NN ,_, with_IN coadministration_NN of_IN 0_CD ,_, 1200_CD ,_, and_CC 2400_CD mg/day_NN of_IN Felbatol_NNP ,_, respectively_RB ._. Phenobarbital_NNP :_: Coadministration_NNP of_IN felbamate_NN with_IN phenobarbital_JJ causes_NNS an_DT increase_NN in_IN phenobarbital_JJ plasma_NN concentrations_NNS ,_, In_IN 12_CD otherwise_RB healthy_JJ male_JJ volunteers_NNS ingesting_VBG phenobarbital_JJ ,_, the_DT steady-state_JJ trough_NN -LRB-_-LRB- Cmin_NN -RRB-_-RRB- phenobarbital_JJ concentration_NN was_VBD 14.2_CD micrograms/mL_NNS ._. The_DT steady-state_JJ Cmin_JJ concentration_NN increased_VBD to_TO 17.8_CD micrograms/mL_NNS when_WRB 2400_CD mg/day_NN of_IN felbamate_NN was_VBD coadministered_VBN for_IN one_CD week_NN ._. Effects_NNS of_IN Other_JJ Antiepileptic_JJ Drugs_NNS on_IN Felbatol_NNP Phenytoin_NNP :_: Phenytoin_NNP causes_VBZ an_DT approximate_JJ doubling_NN of_IN the_DT clearance_NN of_IN Felbatol_NN -LRB-_-LRB- felbamate_NN -RRB-_-RRB- at_IN steady_JJ state_NN and_CC ,_, therefore_RB ,_, the_DT addition_NN of_IN phenytoin_NN causes_VBZ an_DT approximate_JJ 45_CD %_NN decrease_NN in_IN the_DT steady-state_JJ trough_NN concentrations_NNS of_IN Felbatol_NNP as_IN compared_VBN to_TO the_DT same_JJ dose_NN of_IN Felbatol_NNP given_VBN as_IN monotherapy_NN ._. Carbamazepine_NNP :_: Carbamazepine_NNP causes_VBZ an_DT approximate_JJ 50_CD %_NN increase_NN in_IN the_DT clearance_NN of_IN Felbatol_NNP at_IN steady_JJ state_NN and_CC ,_, therefore_RB ,_, the_DT addition_NN of_IN carbamazepine_NN results_VBZ in_IN an_DT approximate_JJ 40_CD %_NN decrease_NN in_IN the_DT steady-state_JJ trough_NN concentrations_NNS of_IN Felbatol_NNP as_IN compared_VBN to_TO the_DT same_JJ dose_NN of_IN Felbatol_NNP given_VBN as_IN monotherapy_NN ._. Valproate_NNP :_: Available_JJ data_NNS suggest_VBP that_IN there_EX is_VBZ no_DT significant_JJ effect_NN of_IN valproate_NN on_IN the_DT clearance_NN of_IN Felbatol_NNP at_IN steady_JJ state_NN ,_, Therefore_RB ,_, the_DT addition_NN of_IN valproate_NN is_VBZ not_RB expected_VBN to_TO cause_VB a_DT clinically_RB important_JJ effect_NN on_IN Felbatol_NN -LRB-_-LRB- felbamate_NN -RRB-_-RRB- plasma_NN concentrations_NNS ._. Phenobarbital_NNP :_: It_PRP appears_VBZ that_IN phenobarbital_NN may_MD reduce_VB plasma_NN felbamate_NN concentrations_NNS ._. Steady-state_JJ plasma_NN felbamate_NN concentrations_NNS were_VBD found_VBN to_TO be_VB 29_CD %_NN lower_JJR than_IN the_DT mean_JJ concentrations_NNS of_IN a_DT group_NN of_IN newly_RB diagnosed_VBN subjects_NNS with_IN epilepsy_NN also_RB receiving_VBG 2400_CD mg_NN of_IN felbamate_NN a_DT day_NN ._. Effects_NNS of_IN Antacids_NNS on_IN Felbatol_NNP The_DT rate_NN and_CC extent_NN of_IN absorption_NN of_IN a_DT 2400_CD mg_NN dose_NN of_IN Felbatol_NNP as_IN monotherapy_JJ given_VBN as_IN tablets_NNS was_VBD not_RB affected_VBN when_WRB coadministered_VBN with_IN antacids_NNS ._. Effects_NNS of_IN Erythromycin_NN on_IN Felbatol_NNP The_DT coadministration_NN of_IN erythromycin_NN -LRB-_-LRB- 1000_CD mg/day_NN -RRB-_-RRB- for_IN 10_CD days_NNS did_VBD not_RB alter_VB the_DT pharmacokinetic_JJ parameters_NNS of_IN Cmax_NNP ,_, Cmin_NNP ,_, AUC_NN ,_, CI/kg_NN or_CC tmax_NN at_IN felbamate_NN daily_JJ doses_NNS of_IN 3000_CD or_CC 3600_CD mg/day_NN in_IN 10_CD otherwise_RB healthy_JJ subjects_NNS with_IN epilepsy_NN ._. Effects_NNS of_IN Felbatol_NNP on_IN Low-Dose_NNP Combination_NNP Oral_NNP Contraceptives_NNPS A_DT group_NN of_IN 24_CD nonsmoking_JJ ,_, healthy_JJ white_JJ female_JJ volunteers_NNS established_VBN on_IN an_DT oral_JJ contraceptive_JJ regimen_NN containing_VBG 30_CD mg_NN ethinyl_NN estradiol_NN and_CC 75_CD mg_NN gestodene_NN for_IN at_IN least_JJS 3_CD months_NNS received_VBD 2400_CD mg/day_NN of_IN felbamate_NN from_IN midcycle_NN -LRB-_-LRB- day_NN 15_CD -RRB-_-RRB- to_TO midcycle_NN -LRB-_-LRB- day_NN 14_CD -RRB-_-RRB- of_IN two_CD consecutive_JJ oral_JJ contraceptive_JJ cycles_NNS ._. Felbamate_NN treatment_NN resulted_VBD in_IN a_DT 42_CD %_NN decrease_NN in_IN the_DT gestodene_NN AUC_NN 0-24_CD ,_, but_CC no_DT clinically_RB relevant_JJ effect_NN was_VBD observed_VBN on_IN the_DT pharmacokinetic_JJ parameters_NNS of_IN ethinyl_NN estradiol_NN ._. No_DT volunteer_NN showed_VBD hormonal_JJ evidence_NN of_IN ovulation_NN ,_, but_CC one_CD volunteer_NN reported_VBD intermenstrual_JJ bleeding_NN during_IN felbamate_NN treatment_NN ._. CYP3A4_NN Inhibitors_NNS Felodipine_NN is_VBZ metabolized_VBN by_IN CYP3A4_NN ._. Co-administration_NN of_IN CYP3A4_NN inhibitors_NNS -LRB-_-LRB- eg_FW ,_, ketoconazole_NN ,_, itraconazole_NN ,_, erythromycin_NN ,_, grapefruit_NN juice_NN ,_, cimetidine_NN -RRB-_-RRB- with_IN felodipine_NN may_MD lead_VB to_TO several_JJ -_: fold_JJ increases_NNS in_IN the_DT plasma_NN levels_NNS of_IN felodipine_NN ,_, either_CC due_JJ to_TO an_DT increase_NN in_IN bioavailability_NN or_CC due_JJ to_TO a_DT decrease_NN in_IN metabolism_NN ._. These_DT increases_NNS in_IN concentration_NN may_MD lead_VB to_TO increased_VBN effects_NNS ,_, -LRB-_-LRB- lower_JJR blood_NN pressure_NN and_CC increased_VBD heart_NN rate_NN -RRB-_-RRB- ._. These_DT effects_NNS have_VBP been_VBN observed_VBN with_IN co-administration_NN of_IN itraconazole_NN -LRB-_-LRB- a_DT potent_JJ CYP3A4_NN inhibitor_NN -RRB-_-RRB- ._. Caution_NN should_MD be_VB used_VBN when_WRB CYP3A4_NN inhibitors_NNS are_VBP co-administered_VBN with_IN felodipine_NN ._. A_DT conservative_JJ approach_NN to_TO dosing_NN felodipine_NN should_MD be_VB taken_VBN ._. The_DT following_VBG specific_JJ interactions_NNS have_VBP been_VBN reported_VBN :_: Itraconazole_NNP Co-administration_NN of_IN another_DT extended_VBN release_NN formulation_NN of_IN felodipine_NN with_IN itraconazole_NN resulted_VBD in_IN approximately_RB 8-fold_JJ increase_NN in_IN the_DT AUC_NN ,_, more_JJR than_IN 6_CD -_: fold_JJ increase_NN in_IN the_DT Cmax_NNP ,_, and_CC 2-fold_JJ prolongation_NN in_IN the_DT half_NN -_: life_NN of_IN felodipine_NN ._. Erythromycin_NN Co-administration_NN of_IN felodipine_NN -LRB-_-LRB- PLENDIL_NN -RRB-_-RRB- with_IN erythromycin_NN resulted_VBD in_IN approximately_RB 2.5_CD -_: fold_JJ increase_NN in_IN the_DT AUC_NN and_CC Cmax_NN ,_, and_CC about_IN 2_CD -_: fold_JJ prolongation_NN in_IN the_DT half_NN -_: life_NN of_IN felodipine_NN ._. Grapefruit_NN juice_NN Co-administration_NN of_IN felodipine_NN with_IN grapefruit_NN juice_NN resulted_VBD in_IN more_JJR than_IN 2-fold_JJ increase_NN in_IN the_DT AUC_NN and_CC Cmax_NN ,_, but_CC no_DT prolongation_NN in_IN the_DT half_NN -_: life_NN of_IN felodipine_NN ._. Cimetidine_NN Co-administration_NN of_IN felodipine_NN with_IN cimetidine_NN -LRB-_-LRB- a_DT non-specific_JJ CYP-450_NN inhibitor_NN -RRB-_-RRB- resulted_VBD in_IN an_DT increase_NN of_IN approximately_RB 50_CD %_NN in_IN the_DT AUC_NN and_CC the_DT Cmax_NNP ,_, of_IN felodipine_NN ._. Beta-Blocking_JJ Agents_NNPS A_DT pharmacokinetic_JJ study_NN of_IN felodipine_NN in_IN conjunction_NN with_IN metoprolol_NN demonstrated_VBD no_DT significant_JJ effects_NNS on_IN the_DT pharmacokinetics_NNS of_IN felodipine_NN ._. The_DT AUC_NN and_CC Cmax_NN of_IN metoprolol_NN ,_, however_RB ,_, were_VBD increased_VBN approximately_RB 31_CD and_CC 38_CD %_NN ,_, respectively_RB ._. In_IN controlled_JJ clinical_JJ trials_NNS ,_, however_RB ,_, beta_NN blockers_NNS including_VBG metoprolol_NN were_VBD concurrently_RB administered_VBN with_IN felodipine_NN and_CC were_VBD well_RB tolerated_VBN ._. Digoxin_NNP When_WRB given_VBN concomitantly_RB with_IN PLENDIL_NN the_DT pharmacokinetics_NNS of_IN digoxin_NN in_IN patients_NNS with_IN heart_NN failure_NN were_VBD not_RB significantly_RB altered_VBN ._. Anticonvulsants_NNPS :_: In_IN a_DT pharmacokinetic_JJ study_NN ,_, maximum_NN plasma_NN concentrations_NNS of_IN felodipine_NN were_VBD considerably_RB lower_JJR in_IN epileptic_JJ patients_NNS on_IN long-term_JJ anticonvulsant_JJ therapy_NN -LRB-_-LRB- eg_FW ,_, phenytoin_NN ,_, carbamazepine_NN ,_, or_CC phenobarbital_NN -RRB-_-RRB- than_IN in_IN healthy_JJ volunteers_NNS ._. In_IN such_JJ patients_NNS ,_, the_DT mean_JJ area_NN under_IN the_DT felodipine_NN plasma_NN concentration-time_NN curve_NN was_VBD also_RB reduced_VBN to_TO approximately_RB 6_CD %_NN of_IN that_DT observed_VBN in_IN healthy_JJ volunteers_NNS ._. Since_IN a_DT clinically_RB significant_JJ interaction_NN may_MD be_VB anticipated_VBN ,_, alternative_JJ antihypertensive_JJ therapy_NN should_MD be_VB considered_VBN in_IN these_DT patients_NNS ._. Tacrolimus_NN Felodipine_NN may_MD increase_VB the_DT blood_NN concentration_NN of_IN tacrolimus_NN ._. When_WRB given_VBN concomitantly_RB with_IN felodipine_NN ,_, the_DT tacrolimus_NN blood_NN concentration_NN should_MD be_VB followed_VBN and_CC the_DT tacrolimus_NN dose_NN may_MD need_VB to_TO be_VB adjusted_VBN ._. Other_JJ Concomitant_JJ Therapy_NN In_IN healthy_JJ subjects_NNS there_EX were_VBD no_DT clinically_RB significant_JJ interactions_NNS when_WRB felodipine_NN was_VBD given_VBN concomitantly_RB with_IN indomethacin_NN or_CC spironolactone_NN ._. Interaction_NN with_IN Food_NNP See_VB CLINICAL_NNP PHARMACOLOGY_NNP ,_, Pharmacokinetics_NNP and_CC Metabolism_NNP ._. Fenfluramine_NN may_MD increase_VB slightly_RB the_DT effect_NN of_IN antihypertensive_JJ drugs_NNS ,_, e.g._FW ,_, guanethidine_NN ,_, methyldopa_NN ,_, reserpine_NN ._. Other_JJ CNS_NNS depressant_NN drugs_NNS should_MD be_VB used_VBN with_IN caution_NN in_IN patients_NNS taking_VBG fenfluramine_NN ,_, since_IN the_DT effects_NNS may_MD be_VB additive_JJ ._. Oral_JJ Anticoagulants_NNPS CAUTION_NNP SHOULD_MD BE_VB EXERCISED_VBN WHEN_WRB COUMARIN_NNP ANTICOAGULANTS_NNP ARE_VBP GIVEN_NNP IN_IN CONJUNCTION_NNP WITH_IN TRICOR_NNP ._. THE_DT DOSAGE_NN OF_IN THE_DT ANTICOAGULANTS_NNS SHOULD_MD BE_VB REDUCED_NNP TO_TO MAINTAIN_VB THE_DT PROTHROMBIN_NN TIME/INR_NN AT_IN THE_DT DESIRED_JJ LEVEL_NN TO_TO PREVENT_VB BLEEDING_VBG COMPLICATIONS_NNS ._. FREQUENT_JJ PROTHROMBIN_NN TIME/INR_NN DETERMINATIONS_NNS ARE_VBP ADVISABLE_JJ UNTIL_IN IT_PRP HAS_VBZ BEEN_NNP DEFINITELY_NNP DETERMINED_NNP THAT_WDT THE_DT PROTHROMBIN_NN TIME/INR_NN HAS_VBZ STABILIZED_VBN ._. HMG-CoA_NN reductase_NN inhibitors_NNS :_: The_DT combined_VBN use_NN of_IN TRICOR_NN and_CC HMG-CoA_NN reductase_NN inhibitors_NNS should_MD be_VB avoided_VBN unless_IN the_DT benefit_NN of_IN further_JJ alterations_NNS in_IN lipid_NN levels_NNS is_VBZ likely_JJ to_TO outweigh_VB the_DT increased_VBN risk_NN of_IN this_DT drug_NN combination_NN ._. Resins_NNS :_: Since_IN bile_NN acid_NN sequestrants_NNS may_MD bind_VB other_JJ drugs_NNS given_VBN concurrently_RB ,_, patients_NNS should_MD take_VB TRICOR_NNP at_IN least_JJS 1_CD hour_NN before_IN or_CC 4-6_CD hours_NNS after_IN a_DT bile_NN acid_NN binding_NN resin_NN to_TO avoid_VB impeding_VBG its_PRP$ absorption_NN ._. Cyclosporine_NN :_: Because_IN cyclosporine_NN can_MD produce_VB nephrotoxicity_NN with_IN decreases_NNS in_IN creatinine_NN clearance_NN and_CC rises_VBZ in_IN serum_NN creatinine_NN ,_, and_CC because_IN renal_JJ excretion_NN is_VBZ the_DT primary_JJ elimination_NN route_NN of_IN fibrate_JJ drugs_NNS including_VBG TRICOR_NNP ,_, there_EX is_VBZ a_DT risk_NN that_IN an_DT interaction_NN will_MD lead_VB to_TO deterioration_NN ._. The_DT benefits_NNS and_CC risks_NNS of_IN using_VBG TRICOR_NN with_IN immunosuppressants_NNS and_CC other_JJ potentially_RB nephrotoxic_JJ agents_NNS should_MD be_VB carefully_RB considered_VBN ,_, and_CC the_DT lowest_JJS effective_JJ dose_NN employe_NN ._. Drug-drug_JJ interactions_NNS In_FW vitro_FW studies_NNS using_VBG human_JJ liver_NN microsomes_NNS indicate_VBP that_IN fenofibrate_NN and_CC fenofibric_JJ acid_NN are_VBP not_RB inhibitors_NNS of_IN cytochrome_NN -LRB-_-LRB- CYP_NN -RRB-_-RRB- P450_NN isoforms_NNS CYP3A4_NN ,_, CYP2D6_NN ,_, CYP2E1_NN ,_, or_CC CYP1A2_NN ._. They_PRP are_VBP weak_JJ inhibitors_NNS of_IN CYP2C19_NN and_CC CYP2A6_NN ,_, and_CC mild-to-moderate_JJ inhibitors_NNS of_IN CYP2C9_NN at_IN therapeutic_JJ concentrations_NNS ._. Potentiation_NN of_IN coumarin-type_JJ anticoagulants_NNS has_VBZ been_VBN observed_VBN with_IN prolongation_NN of_IN the_DT prothrombin_NN time/INR_NN ._. Bile_NN acid_NN sequestrants_NNS have_VBP been_VBN shown_VBN to_TO bind_VB other_JJ drugs_NNS given_VBN concurrently_RB ._. Therefore_RB ,_, fenofibrate_NN should_MD be_VB taken_VBN at_IN least_JJS 1_CD hour_NN before_IN or_CC 4-6_CD hours_NNS after_IN a_DT bile_NN acid_NN binding_NN resin_NN to_TO avoid_VB impeding_VBG its_PRP$ absorption_NN ._. Concomitant_JJ administration_NN of_IN fenofibrate_NN -LRB-_-LRB- equivalent_JJ to_TO 145mg_JJ TRICOR_NN -RRB-_-RRB- with_IN pravastatin_NN -LRB-_-LRB- 40_CD mg_NN -RRB-_-RRB- once_RB daily_RB for_IN 10_CD days_NNS has_VBZ been_VBN shown_VBN to_TO increase_VB the_DT mean_NN Cmax_NN and_CC AUC_NN values_NNS for_IN pravastatin_NN by_IN 36_CD %_NN -LRB-_-LRB- range_NN from_IN 69_CD %_NN decrease_NN to_TO 321_CD %_NN increase_NN -RRB-_-RRB- and_CC 28_CD %_NN -LRB-_-LRB- range_NN from_IN 54_CD %_NN decrease_NN to_TO 128_CD %_NN increase_NN -RRB-_-RRB- ,_, respectively_RB ,_, and_CC for_IN 3_LS -_: hydroxy-iso-pravastatin_NN by_IN 55_CD %_NN -LRB-_-LRB- range_NN from_IN 32_CD %_NN decrease_NN to_TO 314_CD %_NN increase_NN -RRB-_-RRB- and_CC 39_CD %_NN -LRB-_-LRB- range_NN from_IN 24_CD %_NN decrease_NN to_TO 261_CD %_NN increase_NN -RRB-_-RRB- ,_, respectively_RB in_IN 23_CD healthy_JJ adults_NNS ._. A_DT single_JJ dose_NN of_IN pravastatin_NN had_VBD no_DT clinically_RB important_JJ effect_NN on_IN the_DT pharmacokinetics_NNS of_IN fenofibric_JJ acid_NN ._. Concomitant_JJ administration_NN of_IN fenofibrate_NN -LRB-_-LRB- equivalent_JJ to_TO 145_CD mg_NN TRICOR_NN -RRB-_-RRB- with_IN atorvastatin_NN -LRB-_-LRB- 20_CD mg_NN -RRB-_-RRB- once_RB daily_RB for_IN 10_CD days_NNS resulted_VBD in_IN approximately_RB 17_CD %_NN decrease_NN -LRB-_-LRB- range_NN from_IN 67_CD %_NN decrease_NN to_TO 44_CD %_NN increase_NN -RRB-_-RRB- in_IN atorvastatin_NN AUC_NN values_NNS in_IN 22_CD healthy_JJ males_NNS ._. The_DT atorvastatin_NN Cmax_NN values_NNS were_VBD not_RB significantly_RB affected_VBN by_IN fenofibrate_NN ._. The_DT pharmacokinetics_NNS of_IN fenofibric_JJ acid_NN were_VBD not_RB significantly_RB affected_VBN by_IN atorvastati_NN ._. Drug_NN Interactions_NNS with_IN Beta-Blockers_NNPS :_: Concomitant_JJ use_NN of_IN fenoldopam_NN with_IN beta-blockers_NNS should_MD be_VB avoided_VBN ._. If_IN the_DT drugs_NNS are_VBP used_VBN together_RB ,_, caution_NN should_MD be_VB exercised_VBN because_IN unexpected_JJ hypotension_NN could_MD result_VB from_IN beta-blocker_NN inhibition_NN of_IN the_DT sympathetic_JJ reflex_JJ response_NN to_TO fenoldopam_NN ._. Drug_NN Interactions_NNS ,_, General_NNP :_: Although_IN there_EX have_VBP been_VBN no_DT formal_JJ interaction_NN studies_NNS ,_, intravenous_JJ fenoldopam_NN has_VBZ been_VBN administered_VBN safely_RB with_IN drugs_NNS such_JJ as_IN digitalis_NN and_CC sublingual_JJ nitroglycerin_NN ._. There_EX is_VBZ limited_JJ experience_NN with_IN concomitant_JJ antihypertensive_JJ agents_NNS such_JJ as_IN alpha-blockers_NNS ,_, calcium_NN channel-blockers_NNS ,_, ACE_NN inhibitors_NNS ,_, and_CC diuretics_NNS -LRB-_-LRB- both_CC thiazide-like_JJ and_CC loop_NN -RRB-_-RRB- ._. The_DT coadministration_NN of_IN aspirin_NN decreases_VBZ the_DT biologic_JJ half-life_NN of_IN fenoprofen_NN because_IN of_IN an_DT increase_NN in_IN metabolic_JJ clearance_NN that_WDT results_VBZ in_IN a_DT greater_JJR amount_NN of_IN hydroxylated_VBN fenoprofen_NN in_IN the_DT urine_NN ._. Although_IN the_DT mechanism_NN of_IN interaction_NN between_IN fenoprofen_NN and_CC aspirin_NN is_VBZ not_RB totally_RB known_VBN ,_, enzyme_NN induction_NN and_CC displacement_NN of_IN fenoprofen_NN from_IN plasma_NN albumin_NN binding_VBG sites_NNS are_VBP possibilities_NNS ._. Because_IN Nalfon_NNP has_VBZ not_RB been_VBN shown_VBN to_TO produce_VB any_DT additional_JJ effect_NN beyond_IN that_DT obtained_VBN with_IN aspirin_NN alone_RB and_CC because_RB aspirin_NN increases_VBZ the_DT rate_NN of_IN excretion_NN of_IN Nalfon_NNP ,_, the_DT concomitant_JJ use_NN of_IN Nalfon_NNP and_CC salicylates_NNS is_VBZ not_RB recommended_VBN ._. Chronic_JJ administration_NN of_IN phenobarbital_NN ,_, a_DT known_JJ enzyme_NN inducer_NN ,_, may_MD be_VB associated_VBN with_IN a_DT decrease_NN in_IN the_DT plasma_NN half-life_NN of_IN fenoprofen_NN ._. When_WRB phenobarbital_NN is_VBZ added_VBN to_TO or_CC withdrawn_VBN from_IN treatment_NN ,_, dosage_NN adjustment_NN of_IN Nalfon_NNP may_MD be_VB required_VBN ._. In_FW vitro_FW studies_NNS have_VBP shown_VBN that_IN fenoprofen_NN ,_, because_IN of_IN its_PRP$ affinity_NN for_IN albumin_NN ,_, may_MD displace_VB from_IN their_PRP$ binding_NN sites_NNS other_JJ drugs_NNS that_WDT are_VBP also_RB albumin_NN bound_VBD ,_, and_CC this_DT may_MD lead_VB to_TO drug_NN interaction_NN ._. Theoretically_RB ,_, fenoprofen_NN could_MD likewise_RB be_VB displaced_VBN ._. Patients_NNS receiving_VBG hydantoins_NNS ,_, sulfonamides_NNS ,_, or_CC sulfonylureas_NNS should_MD be_VB observed_VBN for_IN increased_VBN activity_NN of_IN these_DT drugs_NNS and_CC ,_, therefore_RB ,_, signs_NNS of_IN toxicity_NN from_IN these_DT drugs_NNS ._. In_IN patients_NNS receiving_VBG coumarin-type_JJ anticoagulants_NNS ,_, the_DT addition_NN of_IN Nalfon_NNP to_TO therapy_NN could_MD prolong_VB the_DT prothrombin_NN time_NN ._. Patients_NNS receiving_VBG both_CC drugs_NNS should_MD be_VB under_IN careful_JJ observation_NN ._. Patients_NNS treated_VBN with_IN Nalfon_NN may_MD be_VB resistant_JJ to_TO the_DT effects_NNS of_IN loop_NN diuretics_NNS ._. In_IN patients_NNS receiving_VBG Nalfon_NNP and_CC a_DT steroid_NN concomitantly_RB ,_, any_DT reduction_NN in_IN steroid_NN dosage_NN should_MD be_VB gradual_JJ in_IN order_NN to_TO avoid_VB the_DT possible_JJ complications_NNS of_IN sudden_JJ steroid_NN withdrawal_NN ._. Agents_NNS Affecting_VBG Cytochrome_NN P450_NN 3A4_NN Isoenzyme_NNP System_NNP Fentanyl_NNP is_VBZ metabolized_VBN mainly_RB via_IN the_DT human_JJ cytochrome_NN P450_NN 3A4_NN isoenzyme_NN system_NN -LRB-_-LRB- CYP3A4_NN -RRB-_-RRB- ,_, therefore_RB potential_JJ interactions_NNS may_MD occur_VB when_WRB DURAGESIC_NN is_VBZ given_VBN concurrently_RB with_IN agents_NNS that_WDT affect_VBP CYP3A4_NN activity_NN ._. Coadminstration_NN with_IN agents_NNS that_WDT induce_VBP 3A4_NN activity_NN may_MD reduce_VB the_DT efficacy_NN of_IN DURAGESIC_NN ._. The_DT concomitant_JJ use_NN of_IN transdermal_JJ fentanyl_NN with_IN ritonavir_NN or_CC other_JJ potent_JJ 3A4_NN inhibitors_NNS such_JJ as_IN ketoconazole_NN ,_, itraconazole_NN ,_, troleandomycin_NN ,_, clarithromycin_NN ,_, nelfinavir_NN ,_, and_CC nefazadone_NN may_MD result_VB in_IN an_DT increase_NN in_IN fentanyl_NN plasma_NN concentrations_NNS ._. The_DT concomitant_JJ use_NN of_IN other_JJ CYP3A4_NN inhibitors_NNS such_JJ as_IN diltiazem_NN and_CC erythromycin_NN with_IN transdermal_JJ fentanyl_NN may_MD also_RB result_VB in_IN an_DT increase_NN in_IN fentanyl_NN plasma_NN concentrations_NNS ,_, which_WDT could_MD increase_VB or_CC prolong_VB adverse_JJ drug_NN effects_NNS and_CC may_MD cause_VB serious_JJ respiratory_JJ depression_NN ._. In_IN this_DT situation_NN ,_, special_JJ patient_NN care_NN and_CC observation_NN are_VBP appropriate_JJ ._. Central_NNP Nervous_NNP System_NNP Depressants_NNPS :_: The_DT concomitant_JJ use_NN of_IN DURAGESIC_NN -LRB-_-LRB- fentanyl_NN transdermal_JJ system_NN -RRB-_-RRB- with_IN other_JJ central_JJ nervous_JJ system_NN depressants_NNS ,_, including_VBG but_CC not_RB limited_VBN to_TO other_JJ opioids_NNS ,_, sedatives_NNS ,_, hypnotics_NNS ,_, tranquilizers_NNS -LRB-_-LRB- e.g._FW ,_, benzodiazepines_NNS -RRB-_-RRB- ,_, general_JJ anesthetics_NNS ,_, phenothiazines_NNS ,_, skeletal_JJ muscle_NN relaxants_NNS ,_, and_CC alcohol_NN ,_, may_MD cause_VB respiratory_JJ depression_NN ,_, hypotension_NN ,_, and_CC profound_JJ sedation_NN ,_, or_CC potentially_RB result_VBP in_IN coma_NN or_CC death_NN ._. When_WRB such_JJ combined_JJ therapy_NN is_VBZ contemplated_VBN ,_, the_DT dose_NN of_IN one_CD or_CC both_DT agents_NNS should_MD be_VB significantly_RB reduced_VBN ._. MAO_NNP Inhibitors_NNS :_: DURAGESIC_NN is_VBZ not_RB recommended_VBN for_IN use_NN in_IN patients_NNS who_WP have_VBP received_VBN MAOI_NNP within_IN 14_CD days_NNS because_IN severe_JJ and_CC unpredictable_JJ potentiation_NN by_IN MAO_NN inhibitors_NNS has_VBZ been_VBN reported_VBN with_IN opioid_JJ analgesic_JJ ._. Drug_NN Interaction_NN with_IN Erythromycin_NN and_CC Ketoconazole_NNP Fexofenadine_NNP has_VBZ been_VBN shown_VBN to_TO exhibit_VB minimal_JJ -LRB-_-LRB- ca._FW 5_CD %_NN -RRB-_-RRB- metabolism_NN ._. However_RB ,_, co_NN administration_NN of_IN fexofenadine_NN hydrochloride_NN with_IN either_CC ketoconazole_NN or_CC erythromycin_NN led_VBD to_TO increased_VBN plasma_NN concentrations_NNS of_IN fexofenadine_NN ._. Fexofenadine_NNP had_VBD no_DT effect_NN on_IN the_DT pharmacokinetics_NNS of_IN either_CC erythromycin_NN or_CC ketoconazole_NN ._. In_IN 2_CD separate_JJ studies_NNS ,_, fexofenadine_NN hydrochloride_NN 120_CD mg_NN twice_RB daily_RB -LRB-_-LRB- 240_CD mg_NN total_JJ daily_JJ dose_NN -RRB-_-RRB- was_VBD co-administered_VBN with_IN either_CC erythromycin_NN 500_CD mg_NN every_DT 8_CD hours_NNS or_CC ketoconazole_NN 400_CD mg_NN once_RB daily_RB under_IN steady-state_JJ conditions_NNS to_TO healthy_JJ volunteers_NNS -LRB-_-LRB- n_NN =_JJ 24_CD ,_, each_DT study_NN -RRB-_-RRB- ._. No_DT differences_NNS in_IN adverse_JJ events_NNS or_CC QTc_NN interval_NN were_VBD observed_VBN when_WRB subjects_NNS were_VBD administered_VBN fexofenadine_NN hydrochloride_NN alone_RB or_CC in_IN combination_NN with_IN either_CC erythromycin_NN or_CC ketoconazole_NN ._. The_DT findings_NNS of_IN these_DT studies_NNS are_VBP summarized_VBN in_IN the_DT following_VBG table_NN :_: Effects_NNS on_IN steady-state_JJ fexofenadine_NN pharmacokinetics_NNS after_IN 7_CD days_NNS of_IN co-administration_NN with_IN fexofenadine_NN hydrochloride_NN 120_CD mg_NN every_DT 12_CD hours_NNS -LRB-_-LRB- two_CD times_NNS the_DT recommended_VBN twice_RB daily_RB dose_NN -RRB-_-RRB- in_IN healthy_JJ volunteers_NNS -LRB-_-LRB- n_NN =_JJ 24_CD ._. Concomitant_JJ Drug_NN ._. cmaxSS_NN -LRB-_-LRB- Peak_JJ plasma_NN concentration_NN -RRB-_-RRB- ._. AUCss_NN -LRB-_-LRB- 0-12h_NN -RRB-_-RRB- -LRB-_-LRB- Extent_NN of_IN systemic_JJ exposure_NN -RRB-_-RRB- ._. Erythromycin_NN -LRB-_-LRB- 500_CD mg_NN every_DT 8_CD hrs_NNS ._. +82_CD %_NN ._. +109_CD %_NN ._. Ketoconazole_NN -LRB-_-LRB- 400_CD mg_NN once_RB daily_RB ._. +135_CD %_NN ._. +164_CD %_NN ._. The_DT changes_NNS in_IN plasma_NN levels_NNS were_VBD within_IN the_DT range_NN of_IN plasma_NN levels_NNS achieved_VBN in_IN adequate_JJ and_CC well-controlled_JJ clinical_JJ trials_NNS ._. The_DT mechanism_NN of_IN these_DT interactions_NNS has_VBZ been_VBN evaluated_VBN in_IN in_FW vitro_FW ,_, in_FW situ_FW ,_, and_CC in_FW vivo_FW animal_NN models_NNS ._. These_DT studies_NNS indicate_VBP that_IN ketoconazole_NN or_CC erythromycin_NN co-administration_NN enhances_VBZ fexofenadine_NN gastrointestinal_JJ absorption_NN ._. This_DT observed_VBN increase_NN in_IN the_DT bioavailability_NN of_IN fexofenadine_NN may_MD be_VB due_JJ to_TO transport-related_JJ effects_NNS ,_, such_JJ as_IN p-glycoprotein_NN ._. in_FW vivo_FW animal_NN studies_NNS also_RB suggest_VBP that_IN in_IN addition_NN to_TO enhancing_VBG absorption_NN ,_, ketoconazole_NN decreases_VBZ fexofenadine_NN gastrointestinal_JJ secretion_NN ,_, while_IN erythromycin_NN may_MD also_RB decrease_VB biliary_JJ excretion_NN ._. Drug_NN Interactions_NNS with_IN Antacids_NNPS Administration_NNP of_IN 120_CD mg_NN of_IN fexofenadine_NN hydrochloride_NN -LRB-_-LRB- 2_CD x_CC 60_CD mg_NN capsule_NN -RRB-_-RRB- within_IN 15_CD minutes_NNS of_IN an_DT aluminum_NN and_CC magnesium_NN containing_VBG antacid_NN -LRB-_-LRB- Maalox_NNP -RRB-_-RRB- decreased_VBD fexofenadine_NN AUC_NN by_IN 41_CD %_NN and_CC cmax_NN by_IN 43_CD %_NN ._. ALLEGRA_NNP should_MD not_RB be_VB taken_VBN closely_RB in_IN time_NN with_IN aluminum_NN and_CC magnesium_NN containing_VBG antacids_NNS ._. Interactions_NNS with_IN Fruit_NNP Juices_NNP Fruit_NNP juices_NNS such_JJ as_IN grapefruit_NN ,_, orange_NN and_CC apple_NN may_MD reduce_VB the_DT bioavailability_NN and_CC exposure_NN of_IN fexofenadine_NN ._. This_DT is_VBZ based_VBN on_IN the_DT results_NNS from_IN 3_CD clinical_JJ studies_NNS using_VBG histamine_NN induced_VBD skin_NN wheals_NNS and_CC flares_NNS coupled_VBN with_IN population_NN pharmacokinetic_JJ analysis_NN ._. The_DT size_NN of_IN wheal_NN and_CC flare_NN were_VBD significantly_RB larger_JJR when_WRB fexofenadine_NN hydrochloride_NN was_VBD administered_VBN with_IN either_CC grapefruit_NN or_CC orange_JJ juices_NNS compared_VBN to_TO water_NN ._. Based_VBN on_IN the_DT literature_NN reports_NNS ,_, the_DT same_JJ effects_NNS may_MD be_VB extrapolated_VBN to_TO other_JJ fruit_NN juices_NNS such_JJ as_IN apple_NN juice_NN ._. The_DT clinical_JJ significance_NN of_IN these_DT observations_NNS is_VBZ unknown_JJ ._. In_IN addition_NN ,_, based_VBN on_IN the_DT population_NN pharmacokinetics_NNS analysis_NN of_IN the_DT combined_JJ data_NNS from_IN grapefruit_NN and_CC orange_JJ juices_NNS studies_NNS with_IN the_DT data_NNS from_IN a_DT bioequivalence_NN study_NN ,_, the_DT bioavailability_NN of_IN fexofenadine_NN was_VBD reduced_VBN by_IN 36_CD %_NN ._. Therefore_RB ,_, to_TO maximize_VB the_DT effects_NNS of_IN fexofenadine_NN ,_, it_PRP is_VBZ recommended_VBN that_IN ALLEGRA_NNP should_MD be_VB taken_VBN with_IN wate_NN ._. Drug_NN interactions_NNS between_IN NEUPOGEN_NNP and_CC other_JJ drugs_NNS have_VBP not_RB been_VBN fully_RB evaluated_VBN ._. Drugs_NNS which_WDT may_MD potentiate_VB the_DT release_NN of_IN neutrophils_NNS ,_, such_JJ as_IN lithium_NN ,_, should_MD be_VB used_VBN with_IN caution_NN ._. No_DT drug_NN interactions_NNS of_IN clinical_JJ importance_NN have_VBP been_VBN identified_VBN ._. Finasteride_NN does_VBZ not_RB appear_VB to_TO affect_VB the_DT cytochrome_NN P450-linked_JJ drug-metabolizing_JJ enzyme_NN system_NN ._. Compounds_NNS that_WDT have_VBP been_VBN tested_VBN in_IN man_NN include_VBP antipyrine_NN ,_, digoxin_NN ,_, propranolol_NN ,_, theophylline_NN ,_, and_CC warfarin_NN and_CC no_DT clinically_RB meaningful_JJ interactions_NNS were_VBD found_VBN ._. Other_JJ concomitant_JJ therapy_NN Although_IN specific_JJ interaction_NN studies_NNS were_VBD not_RB performed_VBN ,_, finasteride_NN doses_NNS of_IN 1_CD mg_NN or_CC more_JJR were_VBD concomitantly_RB used_VBN in_IN clinical_JJ studies_NNS with_IN acetaminophen_NN ,_, acetylsalicylic_JJ acid_NN ,_, a-blockers_NNS ,_, analgesics_NNS ,_, angiotensin-converting_JJ enzyme_NN -LRB-_-LRB- ACE_NN -RRB-_-RRB- inhibitors_NNS ,_, anticonvulsants_NNS ,_, benzodiazepines_NNS ,_, beta_NN blockers_NNS ,_, calcium-channel_JJ blockers_NNS ,_, cardiac_JJ nitrates_NNS ,_, diuretics_NNS ,_, H2_NN antagonists_NNS ,_, HMG-CoA_NN reductase_NN inhibitors_NNS ,_, prostaglandin_NN synthetase_NN inhibitors_NNS -LRB-_-LRB- also_RB referred_VBN to_TO as_IN NSAIDs_NNS -RRB-_-RRB- ,_, and_CC quinolone_NN anti-infectives_NNS without_IN evidence_NN of_IN clinically_RB significant_JJ adverse_JJ interactions_NNS ._. Drug/Laboratory_JJ Test_NN Interactions_NNS Finasteride_NNP had_VBD no_DT effect_NN on_IN circulating_VBG levels_NNS of_IN cortisol_NN ,_, thyroid-stimulating_JJ hormone_NN ,_, or_CC thyroxine_NN ,_, nor_CC did_VBD it_PRP affect_VB the_DT plasma_NN lipid_NN profile_NN -LRB-_-LRB- e.g._FW ,_, total_JJ cholesterol_NN ,_, low-density_JJ lipoproteins_NNS ,_, high-density_JJ lipoproteins_NNS and_CC triglycerides_NNS -RRB-_-RRB- or_CC bone_NN mineral_NN density_NN ._. In_IN studies_NNS with_IN finasteride_NN ,_, no_DT clinically_RB meaningful_JJ changes_NNS in_IN luteinizing_VBG hormone_NN -LRB-_-LRB- LH_NN -RRB-_-RRB- ,_, follicle-stimulating_JJ hormone_NN -LRB-_-LRB- FSH_NN -RRB-_-RRB- or_CC prolactin_NN were_VBD detected_VBN ._. In_IN healthy_JJ volunteers_NNS ,_, treatment_NN with_IN finasteride_NN did_VBD not_RB alter_VB the_DT response_NN of_IN LH_NN and_CC FSH_NN to_TO gonadotropin-releasing_NN hormone_NN indicating_VBG that_IN the_DT hypothalamic-pituitary-testicular_JJ axis_NN was_VBD not_RB affected_VBN ._. In_IN clinical_JJ studies_NNS with_IN PROPECIA_NN -LRB-_-LRB- finasteride_NN ,_, 1_CD mg_NN -RRB-_-RRB- in_IN men_NNS 18-41_CD years_NNS of_IN age_NN ,_, the_DT mean_JJ value_NN of_IN serum_NN prostate-specific_JJ antigen_NN -LRB-_-LRB- PSA_NN -RRB-_-RRB- decreased_VBD from_IN 0.7_CD ng/mL_NN at_IN baseline_NN to_TO 0.5_CD ng/mL_NN at_IN Month_NNP 12_CD ._. Further_RB ,_, in_IN clinical_JJ studies_NNS with_IN PROSCAR_NN -LRB-_-LRB- finasteride_NN ,_, 5_CD mg_NN -RRB-_-RRB- when_WRB used_VBN in_IN older_JJR men_NNS who_WP have_VBP benign_JJ prostatic_JJ hyperplasia_NN -LRB-_-LRB- BPH_NNP -RRB-_-RRB- ,_, PSA_NN levels_NNS are_VBP decreased_VBN by_IN approximately_RB 50_CD %_NN ._. These_DT findings_NNS should_MD be_VB taken_VBN into_IN account_NN for_IN proper_JJ interpretation_NN of_IN serum_NN PSA_NN when_WRB evaluating_VBG men_NNS treated_VBN with_IN finasteride_NN ._. Drug_NN Interactions_NNS ._. TAMBOCOR_NN has_VBZ been_VBN administered_VBN to_TO patients_NNS receiving_VBG digitalis_NN preparations_NNS or_CC beta-adrenergic_JJ blocking_VBG agents_NNS without_IN adverse_JJ effects_NNS ._. During_IN administration_NN of_IN multiple_JJ oral_JJ doses_NNS of_IN TAMBOCOR_NN to_TO healthy_JJ subjects_NNS stabilized_VBD on_IN a_DT maintenance_NN dose_NN of_IN digoxin_NN ,_, a_DT 13_CD %_NN -19_CD %_NN increase_NN in_IN plasma_NN digoxin_NN levels_NNS occurred_VBD at_IN six_CD hours_NNS postdose_NN ._. In_IN a_DT study_NN involving_VBG healthy_JJ subjects_NNS receiving_VBG TAMBOCOR_NN and_CC propranolol_NN concurrently_RB ,_, plasma_NN flecainide_NN levels_NNS were_VBD increased_VBN about_RB 20_CD %_NN and_CC propranolol_NN levels_NNS were_VBD increased_VBN about_IN 30_CD %_NN compared_VBN to_TO control_VB values_NNS ._. In_IN this_DT formal_JJ interaction_NN study_NN ,_, TAMBOCOR_NN and_CC propranolol_NN were_VBD each_DT found_VBN to_TO have_VB negative_JJ inotropic_JJ effects_NNS ._. when_WRB the_DT drugs_NNS were_VBD administered_VBN together_RB ,_, the_DT effects_NNS were_VBD additive_JJ ._. The_DT effects_NNS of_IN concomitant_JJ administration_NN of_IN TAMBOCOR_NN and_CC propranolol_NN on_IN the_DT PR_NN interval_NN were_VBD less_JJR than_IN additive_JJ ._. In_IN TAMBOCOR_NN clinical_JJ trials_NNS ,_, patients_NNS who_WP were_VBD receiving_VBG beta_NN blockers_NNS concurrently_RB did_VBD not_RB experience_VB an_DT increased_VBN incidence_NN of_IN side_JJ effects_NNS ._. Nevertheless_RB ,_, the_DT possibility_NN of_IN additive_JJ negative_JJ inotropic_JJ effects_NNS of_IN beta_NN blockers_NNS and_CC flecainide_NN should_MD be_VB recognized_VBN ._. Flecainide_NNP is_VBZ not_RB extensively_RB bound_VBN to_TO plasma_NN proteins_NNS ._. In_FW vitro_FW studies_NNS with_IN several_JJ drugs_NNS which_WDT may_MD be_VB administered_VBN concomitantly_RB showed_VBD that_IN the_DT extent_NN of_IN flecainide_NN binding_NN to_TO human_JJ plasma_NN proteins_NNS is_VBZ either_CC unchanged_JJ or_CC only_RB slightly_RB less_RBR ._. Consequently_RB ,_, interactions_NNS with_IN other_JJ drugs_NNS which_WDT are_VBP highly_RB protein_NN bound_VBD -LRB-_-LRB- e.g._FW ,_, anticoagulants_NNS -RRB-_-RRB- would_MD not_RB be_VB expected_VBN ._. TAMBOCOR_NN has_VBZ been_VBN used_VBN in_IN a_DT large_JJ number_NN of_IN patients_NNS receiving_VBG diuretics_NNS without_IN apparent_JJ interaction_NN ._. Limited_JJ data_NNS in_IN patients_NNS receiving_VBG known_JJ enzyme_NN inducers_NNS -LRB-_-LRB- phenytoin_NN ,_, phenobarbital_NN ,_, carbamazepine_NN -RRB-_-RRB- indicate_VBP only_RB a_DT 30_CD %_NN increase_NN in_IN the_DT rate_NN of_IN flecainide_NN elimination_NN ._. In_IN healthy_JJ subjects_NNS receiving_VBG cimetidine_NN -LRB-_-LRB- 1_CD gm_NN daily_JJ -RRB-_-RRB- for_IN one_CD week_NN ,_, plasma_NN flecainide_NN levels_NNS increased_VBN by_IN about_IN 30_CD %_NN and_CC half-life_NN increased_VBN by_IN about_RB 10_CD %_NN ._. When_WRB amiodarone_NN is_VBZ added_VBN to_TO flecainide_NN therapy_NN ,_, plasma_NN flecainide_NN levels_NNS may_MD increase_VB two-fold_RB or_CC more_RBR in_IN some_DT patients_NNS ,_, if_IN flecainide_NN dosage_NN is_VBZ not_RB reduced_VBN ._. Drugs_NNS that_WDT inhibit_VBP cytochrome_NN P450IID6_NN ,_, such_JJ as_IN quinidine_NN ,_, might_MD increase_VB the_DT plasma_NN concentrations_NNS of_IN flecainide_NN in_IN patients_NNS that_WDT are_VBP on_IN chronic_JJ flecainide_NN therapy_NN ._. especially_RB if_IN these_DT patients_NNS are_VBP extensive_JJ metabolizers_NNS ._. There_EX has_VBZ been_VBN little_JJ experience_NN with_IN the_DT coadministration_NN of_IN TAMBOCOR_NN and_CC either_CC disopyramide_NN or_CC verapamil_NN ._. Because_IN both_DT of_IN these_DT drugs_NNS have_VBP negative_JJ inotropic_JJ properties_NNS and_CC the_DT effects_NNS of_IN coadministration_NN with_IN TAMBOCOR_NN are_VBP unknown_JJ ,_, neither_CC disopyramide_NN nor_CC verapamil_NN should_MD be_VB administered_VBN concurrently_RB with_IN TAMBOCOR_NN unless_IN ,_, in_IN the_DT judgment_NN of_IN the_DT physician_NN ,_, the_DT benefits_NNS of_IN this_DT combination_NN outweigh_VBP the_DT risks_NNS ._. There_EX has_VBZ been_VBN too_RB little_JJ experience_NN with_IN the_DT coadministration_NN of_IN TAMBOCOR_NN with_IN nifedipine_NN or_CC diltiazem_NN to_TO recommend_VB concomitant_JJ use_NN ._. Combination_NN Therapy_NN :_: Any_DT form_NN of_IN therapy_NN which_WDT adds_VBZ to_TO the_DT stress_NN of_IN the_DT patient_NN ,_, interferes_VBZ with_IN nutrition_NN or_CC depresses_VBZ bone_NN marrow_NN function_NN will_MD increase_VB the_DT toxicity_NN of_IN Floxuridine_NN ._. Cytosine_NN arabinoside_NN ,_, a_DT cytostatic_JJ agent_NN ,_, has_VBZ been_VBN reported_VBN to_TO inactivate_VB the_DT antifungal_JJ activity_NN of_IN flucytosine_NN by_IN competitive_JJ inhibition_NN ._. Drugs_NNS which_WDT impair_VBP glomerular_JJ filtration_NN may_MD prolong_VB the_DT biological_JJ half-life_NN of_IN flucytosine_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS :_: Measurement_NN of_IN serum_NN creatinine_NN levels_NNS should_MD be_VB determined_VBN by_IN the_DT Jaffe_NNP reaction_NN ,_, since_IN Ancobon_NNP does_VBZ not_RB interfere_VB with_IN the_DT determination_NN of_IN creatinine_NN values_NNS by_IN this_DT method_NN ._. Most_JJS automated_JJ equipment_NN for_IN measurement_NN of_IN creatinine_NN makes_VBZ use_NN of_IN the_DT Jaffe_NNP reaction_NN ._. The_DT use_NN of_IN FLUDARA_NNP FOR_IN INJECTION_NNP in_IN combination_NN with_IN pentostatin_NN is_VBZ not_RB recommended_VBN due_JJ to_TO the_DT risk_NN of_IN severe_JJ pulmonary_JJ toxicity_NN ._. When_WRB administered_VBN concurrently_RB ,_, the_DT following_VBG drugs_NNS may_MD interact_VB with_IN adrenal_JJ corticosteroids_NNS ._. Amphotericin_NN B_NN or_CC potassium-depleting_JJ diuretics_NNS -LRB-_-LRB- benzothiadiazines_NNS and_CC related_JJ drugs_NNS ,_, ethacrynic_JJ acid_NN and_CC furosemide_NN -RRB-_-RRB- enhanced_VBD hypokalemia_NN ._. Check_VB serum_NN potassium_NN levels_NNS at_IN frequent_JJ intervals_NNS ;_: ._. use_NN potassium_NN supplements_NNS if_IN necessary_JJ ._. Digitalis_NN glycosides_NNS enhanced_VBD possibility_NN of_IN arrhythmias_NNS or_CC digitalis_NN toxicity_NN associated_VBN with_IN hypokalemia_NN ._. Monitor_NNP serum_NN potassium_NN levels_NNS ;_: ._. use_NN potassium_NN supplements_NNS if_IN necessary_JJ ._. Oral_JJ anticoagulants_NNS decreased_VBD prothrombin_NN time_NN response_NN ._. Monitor_NNP prothrombin_NN levels_NNS and_CC adjust_VBP anticoagulant_JJ dosage_NN accordingly_RB ._. Antidiabetic_JJ drugs_NNS -LRB-_-LRB- oral_JJ agents_NNS and_CC insulin_NN -RRB-_-RRB- diminished_VBD antidiabetic_JJ effect_NN ._. Monitor_NNP for_IN symptoms_NNS of_IN hyperglycemia_NN ;_: ._. adjust_VBP dosage_NN of_IN antidiabetic_JJ drug_NN upward_RB if_IN necessary_JJ ._. Aspirin_NN increased_VBD ulcerogenic_JJ effect_NN ._. decreased_VBN pharmacologic_JJ effect_NN of_IN aspirin_NN ._. Rarely_RB salicylate_NN toxicity_NN may_MD occur_VB in_IN patients_NNS who_WP discontinue_VBP steroids_NNS after_IN concurrent_JJ high-dose_JJ aspirin_NN therapy_NN ._. Monitor_NNP salicylate_NN levels_NNS or_CC the_DT therapeutic_JJ effect_NN for_IN which_WDT aspirin_NN is_VBZ given_VBN ._. adjust_VBP salicylate_NN dosage_NN accordingly_RB if_IN effect_NN is_VBZ altered_VBN ._. Barbiturates_NNP ,_, phenytoin_NN ,_, or_CC rifampin_NN increased_VBD metabolic_JJ clearance_NN of_IN fludrocortisone_NN acetate_NN because_IN of_IN the_DT induction_NN of_IN hepatic_JJ enzymes_NNS ._. Observe_VB the_DT patient_NN for_IN possible_JJ diminished_JJ effect_NN of_IN steroid_NN and_CC increase_VB the_DT steroid_NN dosage_NN accordingly_RB ._. Anabolic_JJ steroids_NNS -LRB-_-LRB- particularly_RB C-17_JJ alkylated_VBN androgens_NNS such_JJ as_IN oxymetholone_NN ,_, methandrostenolone_NN ,_, norethandrolone_NN ,_, and_CC similar_JJ compounds_NNS -RRB-_-RRB- enhanced_VBD tendency_NN toward_IN edema_NN ._. Use_NNP caution_NN when_WRB giving_VBG these_DT drugs_NNS together_RB ,_, especially_RB in_IN patients_NNS with_IN hepatic_JJ or_CC cardiac_JJ disease_NN ._. Vaccines_NNS neurological_JJ complications_NNS and_CC lack_NN of_IN antibody_NN response_NN ._. Estrogen_NN increased_VBD levels_NNS of_IN corticosteroid-binding_JJ globulin_NN ,_, thereby_RB increasing_VBG the_DT bound_VBN -LRB-_-LRB- inactive_JJ -RRB-_-RRB- fraction_NN ._. this_DT effect_NN is_VBZ at_IN least_JJS balanced_VBN by_IN decreased_VBN metabolism_NN of_IN corticosteroids_NNS ._. When_WRB estrogen_NN therapy_NN is_VBZ initiated_VBN ,_, a_DT reduction_NN in_IN corticosteroid_NN dosage_NN may_MD be_VB required_VBN ,_, and_CC increased_VBD amounts_NNS may_MD be_VB required_VBN when_WRB estrogen_NN is_VBZ terminated_VBN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS Corticosteroids_NNS may_MD affect_VB the_DT nitrobluetetrazolium_JJ test_NN for_IN bacterial_JJ infection_NN and_CC produce_VBP false-negative_JJ result_NN ._. Interaction_NN with_IN central_JJ nervous_JJ system_NN depressants_NNS other_JJ than_IN benzodiazepines_NNS has_VBZ not_RB been_VBN specifically_RB studied_VBN ._. however_RB ,_, no_DT deleterious_JJ interactions_NNS were_VBD seen_VBN when_WRB ROMAZICON_NNP was_VBD administered_VBN after_IN narcotics_NNS ,_, inhalational_JJ anesthetics_NNS ,_, muscle_NN relaxants_NNS and_CC muscle_NN relaxant_NN antagonists_NNS administered_VBN in_IN conjunction_NN with_IN sedation_NN or_CC anesthesia_NN ._. Particular_JJ caution_NN is_VBZ necessary_JJ when_WRB using_VBG ROMAZICON_NNP in_IN cases_NNS of_IN mixed_JJ drug_NN overdosage_NN since_IN the_DT toxic_JJ effects_NNS -LRB-_-LRB- such_JJ as_IN convulsions_NNS and_CC cardiac_JJ dysrhythmias_NNS -RRB-_-RRB- of_IN other_JJ drugs_NNS taken_VBN in_IN overdose_NN -LRB-_-LRB- especially_RB cyclic_JJ antidepressants_NNS -RRB-_-RRB- may_MD emerge_VB with_IN the_DT reversal_NN of_IN the_DT benzodiazepine_NN effect_NN by_IN flumazenil_NN ._. The_DT use_NN of_IN ROMAZICON_NNP is_VBZ not_RB recommended_VBN in_IN epileptic_JJ patients_NNS who_WP have_VBP been_VBN receiving_VBG benzodiazepine_NN treatment_NN for_IN a_DT prolonged_JJ period_NN ._. Although_IN ROMAZICON_NN exerts_VBZ a_DT slight_JJ intrinsic_JJ anticonvulsant_JJ effect_NN ,_, its_PRP$ abrupt_JJ suppression_NN of_IN the_DT protective_JJ effect_NN of_IN a_DT benzodiazepine_NN agonist_NN can_MD give_VB rise_VB to_TO convulsions_NNS in_IN epileptic_JJ patients_NNS ._. ROMAZICON_NN blocks_VBZ the_DT central_JJ effects_NNS of_IN benzodiazepines_NNS by_IN competitive_JJ interaction_NN at_IN the_DT receptor_NN level_NN ._. The_DT effects_NNS of_IN nonbenzodiazepine_JJ agonists_NNS at_IN benzodiazepine_NN receptors_NNS ,_, such_JJ as_IN zopiclone_NN ,_, triazolopyridazines_NNS and_CC others_NNS ,_, are_VBP also_RB blocked_VBN by_IN ROMAZICON_NN ._. The_DT pharmacokinetics_NNS of_IN benzodiazepines_NNS are_VBP unaltered_JJ in_IN the_DT presence_NN of_IN flumazenil_NN and_CC vice_NN versa_RB ._. There_EX is_VBZ no_DT pharmacokinetic_JJ interaction_NN between_IN ethanol_NN and_CC flumazenil_NN ._. Use_NN in_IN Ambulatory_JJ Patients_NNS The_DT effects_NNS of_IN ROMAZICON_NN may_MD wear_VB off_RP before_IN a_DT long-acting_JJ benzodiazepine_NN is_VBZ completely_RB cleared_VBN from_IN the_DT body_NN ._. In_IN general_JJ ,_, if_IN a_DT patient_NN shows_VBZ no_DT signs_NNS of_IN sedation_NN within_IN 2_CD hours_NNS after_IN a_DT 1-mg_JJ dose_NN of_IN flumazenil_NN ,_, serious_JJ resedation_NN at_IN a_DT later_JJ time_NN is_VBZ unlikely_JJ ._. An_DT adequate_JJ period_NN of_IN observation_NN must_MD be_VB provided_VBN for_IN any_DT patient_NN in_IN whom_WP either_CC long-acting_JJ benzodiazepines_NNS -LRB-_-LRB- such_JJ as_IN diazepam_NN -RRB-_-RRB- or_CC large_JJ doses_NNS of_IN short-acting_JJ benzodiazepines_NNS -LRB-_-LRB- such_JJ as_IN 10_CD mg_NN of_IN midazolam_NN -RRB-_-RRB- have_VBP been_VBN used_VBN ._. Because_IN of_IN the_DT increased_VBN risk_NN of_IN adverse_JJ reactions_NNS in_IN patients_NNS who_WP have_VBP been_VBN taking_VBG benzodiazepines_NNS on_IN a_DT regular_JJ basis_NN ,_, it_PRP is_VBZ particularly_RB important_JJ that_IN physicians_NNS query_NN patients_NNS or_CC their_PRP$ guardians_NNS carefully_RB about_IN benzodiazepine_NN ,_, alcohol_NN and_CC sedative_NN use_VBP as_IN part_NN of_IN the_DT history_NN prior_RB to_TO any_DT procedure_NN in_IN which_WDT the_DT use_NN of_IN ROMAZICON_NNP is_VBZ planned_VBN ._. No_DT information_NN available_JJ ._. Do_VB not_RB take_VB this_DT medicine_NN with_IN thioridizine_NN ,_, or_CC within_IN 5_CD weeks_NNS of_IN taking_VBG fluoxetine_NN ._. Talk_NN to_TO your_PRP$ doctor_NN if_IN you_PRP are_VBP taking_VBG certain_JJ antibiotics_NNS such_JJ as_IN erythromycin_NN ,_, clarithromycin_NN or_CC azithromycin_NN ._. This_DT medicine_NN should_MD not_RB be_VB taken_VBN with_IN MAO_NN inhibitors_NNS ._. Caution_NN should_MD be_VB exercised_VBN when_WRB taking_VBG this_DT medicine_NN certain_JJ antibiotics_NNS ,_, such_JJ as_IN erythromycin_NN ,_, clarithromycin_NN ,_, or_CC azithromycin_NN ._. This_DT medicine_NN should_MD not_RB be_VB taken_VBN with_IN MAO_NN inhibitors_NNS ._. If_IN you_PRP think_VBP you_PRP are_VBP taking_VBG an_DT MAO_NNP inhibitor_NN talk_NN to_TO your_PRP$ doctor_NN or_CC pharmacist_NN ._. Do_VB not_RB take_VB this_DT medicine_NN with_IN St._NNP Johns_NNP Wort_NNP because_IN of_IN the_DT additive_JJ effects_NNS of_IN sertonin_NN ._. This_DT medication_NN should_MD not_RB be_VB taken_VBN with_IN MAO_NN inhibitors_NNS ._. Your_PRP$ doctor_NN or_CC pharmacist_NN can_MD give_VB you_PRP more_JJR information_NN on_IN MAO_NN inhibitors_NNS ._. Wait_VB 5_CD weeks_NNS after_IN stopping_VBG escitalopram_NN before_IN starting_VBG a_DT non-selective_JJ MAO_NNP inhibitor_NN ._. Wait_VB 2_CD weeks_NNS after_IN stopping_VBG an_DT MAO_NNP inhibitor_NN before_IN starting_VBG escitalopram_NN ._. If_IN you_PRP are_VBP taking_VBG medications_NNS for_IN migraines_NNS such_JJ as_IN Imitrex_NNP ,_, talk_NN to_TO your_PRP$ doctor_NN before_IN starting_VBG this_DT medicine_NN ._. If_IN you_PRP are_VBP taking_VBG a_DT tricyclic_JJ antidepressant_JJ ,_, talk_NN to_TO your_PRP$ doctor_NN before_IN taking_VBG this_DT medicine_NN ._. St._NNP John_NNP s_VBZ Wort_NNP should_MD be_VB avoided_VBN while_IN taking_VBG this_DT medicine_NN due_JJ to_TO the_DT additive_JJ effects_NNS of_IN serotonin_NN ._. Tell_VB your_PRP$ doctor_NN if_IN you_PRP are_VBP taking_VBG any_DT of_IN the_DT following_VBG drugs_NNS :_: blood_NN thinners_NNS -LRB-_-LRB- Coumadin_NN -RRB-_-RRB- other_JJ antidepressants_NNS metoprolol_NN antihistamines_NNS carbamazepine_NN -LRB-_-LRB- Tegretol_NN -RRB-_-RRB- cimetidine_NN -LRB-_-LRB- Tagamet_NN -RRB-_-RRB- estrogens_NNS fluoxetine_NN -LRB-_-LRB- Prozac_NNP -RRB-_-RRB- intraconazole_NN -LRB-_-LRB- Sporanox_NN -RRB-_-RRB- ketoconazole_NN -LRB-_-LRB- Nizoral_NN -RRB-_-RRB- levodopa_NN lithium_NN muscle_NN relaxants_NNS birth_NN control_NN pills_NNS sleeping_VBG pills_NNS thyroid_NN medication_NN ._. Androgens_NNS may_MD increase_VB sensitivity_NN to_TO oral_JJ anticoagulahts_NNS ._. Dosage_NN of_IN the_DT anticoagulant_NN may_MD require_VB reduction_NN in_IN order_NN to_TO maintain_VB satisfactory_JJ therapeutic_JJ hypoprothrombinemia_NN ._. Concurrent_JJ administration_NN of_IN oxyphenbutazone_NN and_CC androgens_NNS may_MD result_VB in_IN elevated_JJ serum_NN levels_NNS of_IN oxyphenbutazone_NN ._. In_IN diabetic_JJ patients_NNS ,_, the_DT metabolic_JJ effects_NNS of_IN androgens_NNS may_MD decrease_VB blood_NN glucose_NN and_CC therefore_RB ,_, insulin_NN requirements_NNS ._. Drug_NN Interactions_NNS :_: Flupenthixol_NN may_MD interact_VB with_IN some_DT drugs_NNS ,_, like_IN Monoamine_NN oxidase_NN inhibitors_NNS -LRB-_-LRB- MAOI_NN -RRB-_-RRB- :_: MAOI_NNP could_MD theoretically_RB affect_VB flupenthixol_NN pharmacodynamics_NNS -_: Arecoline_NN -_: Eproxindine_NN -_: Ethanol_NN :_: Flupenthixol_NN and_CC Ethanol_NN cause_VBP additive_JJ CNS_NN depression_NN -_: Tricyclic_JJ antidepressants_NNS :_: Flupenthixol_NN increases_VBZ the_DT effect_NN of_IN Tricyclic_JJ antidepressant_JJ ._. Antacids_NNS :_: Administration_NN of_IN flurbiprofen_NN to_TO volunteers_NNS under_IN fasting_NN conditions_NNS ,_, or_CC with_IN antacid_NN suspension_NN yielded_VBD similar_JJ serum_NN flurbiprofen_NN time_NN profiles_NNS in_IN young_JJ subjects_NNS -LRB-_-LRB- n_NN =_JJ 12_CD -RRB-_-RRB- ._. In_IN geriatric_JJ subjects_NNS -LRB-_-LRB- n_NN =_JJ 7_CD -RRB-_-RRB- there_EX was_VBD a_DT reduction_NN in_IN the_DT rate_NN but_CC not_RB the_DT extent_NN of_IN flurbiprofen_NN absorption_NN ._. Anticoagulants_NNPS :_: Flurbiprofen_NNP like_IN other_JJ nonsteroidal_JJ anti-inflammatory_JJ drugs_NNS ,_, has_VBZ been_VBN shown_VBN to_TO affect_VB bleeding_VBG parameters_NNS in_IN patients_NNS receiving_VBG anti-coagulants_NNS ,_, and_CC serious_JJ clinical_JJ bleeding_NN has_VBZ been_VBN reported_VBN ._. The_DT physician_NN should_MD be_VB cautious_JJ when_WRB administering_VBG flurbiprofen_NN to_TO patients_NNS taking_VBG anticoagulants_NNS ._. Aspirin_NN :_: Concurrent_JJ administration_NN of_IN aspirin_NN and_CC flurbiprofen_NN resulted_VBD in_IN 50_CD %_NN lower_JJR serum_NN flurbiprofen_NN concentrations_NNS ._. This_DT effect_NN of_IN aspirin_NN -LRB-_-LRB- which_WDT also_RB lowers_VBZ serum_NN concentrations_NNS of_IN other_JJ nonsteroidal_JJ anti-inflammatory_JJ drugs_NNS given_VBN with_IN it_PRP -RRB-_-RRB- has_VBZ been_VBN demonstrated_VBN in_IN patients_NNS with_IN rheumatoid_JJ arthritis_NN -LRB-_-LRB- n_NN =_JJ 15_CD -RRB-_-RRB- as_RB well_RB as_IN normal_JJ volunteers_NNS -LRB-_-LRB- n_NN =_JJ 16_CD -RRB-_-RRB- ._. Concurrent_JJ use_NN of_IN flurbiprofen_NN and_CC aspirin_NN is_VBZ therefore_RB not_RB recommended_VBN ._. Beta-adrenergic_JJ Blocking_NN Agents_NNS :_: The_DT effect_NN of_IN flurbiprofen_NN on_IN blood_NN pressure_NN response_NN to_TO propranolol_NN and_CC atenolol_NN was_VBD evaluated_VBN in_IN men_NNS with_IN mild_JJ uncomplicated_JJ hypertension_NN -LRB-_-LRB- n_NN =_JJ 10_CD -RRB-_-RRB- ._. Flurbiprofen_NNP pretreatment_NN attenuated_VBD the_DT hypotensive_JJ effect_NN of_IN a_DT single_JJ dose_NN of_IN propranolol_NN but_CC not_RB atenolol_NN ._. Flurbiprofen_NNP did_VBD not_RB appear_VB to_TO affect_VB the_DT beta-blocker-mediated_JJ reduction_NN in_IN heart_NN rate_NN ._. Flurbiprofen_NNP did_VBD not_RB affect_VB the_DT pharmacokinetic_JJ profile_NN of_IN either_CC drug_NN ,_, and_CC the_DT mechanism_NN under_IN lying_VBG the_DT interference_NN with_IN propranolols_NNS hypotensive_JJ effect_NN is_VBZ unknown_JJ ._. Patients_NNS taking_VBG both_CC flurbiprofen_NN and_CC a_DT beta-blocker_NN should_MD be_VB monitored_VBN to_TO ensure_VB that_IN a_DT satisfactory_JJ hypotensive_JJ effect_NN is_VBZ achieved_VBN ._. Cimetidine_NNP ,_, Ranitidine_NNP :_: In_IN normal_JJ volunteers_NNS -LRB-_-LRB- n_NN =_JJ 9_CD -RRB-_-RRB- ,_, pretreatment_NN with_IN cimetidine_NN or_CC ranitidine_NN did_VBD not_RB affect_VB flurbiprofen_JJ pharmacokinetics_NNS except_IN that_IN a_DT small_JJ -LRB-_-LRB- 13_CD %_NN -RRB-_-RRB- but_CC statistically_RB significant_JJ increase_NN in_IN the_DT area_NN under_IN the_DT serum_NN concentration_NN curve_NN of_IN flurbiprofen_NN resulted_VBD with_IN cimetidine_NN ._. Digoxin_NNP :_: Studies_NNS of_IN concomitant_JJ administration_NN of_IN flurbiprofen_NN and_CC digoxin_NN to_TO healthy_JJ men_NNS -LRB-_-LRB- n_NN =_JJ 14_CD -RRB-_-RRB- did_VBD not_RB show_VB a_DT change_NN in_IN the_DT steady_JJ state_NN serum_NN levels_NNS of_IN either_CC drug_NN ._. Diuretics_NNS :_: Studies_NNS in_IN normal_JJ volunteers_NNS have_VBP shown_VBN that_IN flurbiprofen_NN like_IN other_JJ nonsteroidal_JJ anti-inflammatory_JJ drugs_NNS ,_, can_MD interfere_VB with_IN the_DT effects_NNS of_IN furosemide_NN ._. Although_IN results_NNS have_VBP varied_VBN from_IN study_NN to_TO study_VB ,_, effects_NNS have_VBP been_VBN shown_VBN on_IN furosemide-stimulated_JJ diuresis_NN ,_, natriuresis_NN ,_, and_CC kaliuresis_NN ._. Other_JJ nonsteroidal_JJ anti-inflammatory_JJ drugs_NNS that_WDT inhibit_VBP prostaglandin_NN synthesis_NN have_VBP been_VBN shown_VBN to_TO interfere_VB with_IN thiazide_JJ diuretics_NNS in_IN some_DT studies_NNS and_CC with_IN potassium-sparing_JJ diuretics_NNS ._. Patients_NNS receiving_VBG flurbiprofen_NN and_CC furosemide_NN or_CC other_JJ diuretics_NNS should_MD be_VB observed_VBN closely_RB to_TO determine_VB if_IN the_DT desired_VBN effect_NN is_VBZ obtained_VBN ._. Oral_JJ Hypoglycemic_JJ Agents_NNS :_: In_IN one_CD study_NN ,_, flurbiprofen_NN was_VBD given_VBN to_TO adult_JJ diabetics_NNS who_WP were_VBD already_RB receiving_VBG glyburide_NN -LRB-_-LRB- n_NN =_JJ 4_CD -RRB-_-RRB- ,_, metformin_NN -LRB-_-LRB- n_NN =_JJ 2_CD -RRB-_-RRB- chlorpropamide_NN with_IN phenformin_NN -LRB-_-LRB- n_NN =_JJ 3_CD -RRB-_-RRB- or_CC glyburide_NN with_IN phenformin_NN -LRB-_-LRB- n_NN =_JJ 6_CD -RRB-_-RRB- ._. Although_IN there_EX was_VBD a_DT slight_JJ reduction_NN in_IN blood_NN sugar_NN concentrations_NNS during_IN concomitant_JJ administration_NN of_IN flurbiprofen_NN and_CC hypoglycemic_JJ agents_NNS ,_, there_EX were_VBD no_DT signs_NNS or_CC symptoms_NNS of_IN hypoglycemia_NN ._. Increases_NNS in_IN prothrombin_NN time_NN have_VBP been_VBN noted_VBN in_IN patients_NNS receiving_VBG long_JJ -_: term_NN warfarin_NN therapy_NN after_IN flutamide_NN was_VBD initiated_VBN ._. Therefore_RB ,_, close_JJ monitoring_NN of_IN prothrombin_NN time_NN is_VBZ recommended_VBN and_CC adjustment_NN of_IN the_DT anticoagulant_JJ dose_NN may_MD be_VB necessary_JJ when_WRB EULEXIN_NNP Capsules_NNPS are_VBP administered_VBN concomitantly_RB with_IN warfarin_NN ._. Potential_JJ for_IN Interaction_NN with_IN Monoamine_NNP Oxidase_NNP Inhibitor_NNP ._. In_IN patients_NNS receiving_VBG another_DT serotonin_NN reuptake_NN inhibitor_NN drug_NN in_IN combination_NN with_IN monoamine_NN oxidase_NN inhibitors_NNS -LRB-_-LRB- MAOI_NN -RRB-_-RRB- ,_, there_EX have_VBP been_VBN reports_NNS of_IN serious_JJ ,_, sometimes_RB fatal_JJ ,_, reactions_NNS including_VBG hyperthermia_NN ,_, rigidity_NN ,_, myoclonus_NN ,_, autonomic_JJ instability_NN with_IN possible_JJ rapid_JJ fluctuations_NNS of_IN vital_JJ signs_NNS ,_, and_CC mental_JJ status_NN changes_NNS that_WDT include_VBP extreme_JJ agitation_NN progressing_VBG to_TO delirium_NN and_CC coma_NN ._. These_DT reactions_NNS have_VBP also_RB been_VBN reported_VBN in_IN patients_NNS who_WP have_VBP discontinued_VBN that_IN drug_NN and_CC have_VBP been_VBN started_VBN on_IN a_DT MAOI_NNP ._. Some_DT cases_NNS presented_VBN with_IN features_NNS resembling_VBG neuroleptic_JJ malignant_JJ syndrome_NN ._. Therefore_RB ,_, it_PRP is_VBZ recommended_VBN that_IN Fluvoxamine_NNP Tablets_NNPS not_RB be_VB used_VBN in_IN combination_NN with_IN MAOIs_NNS ,_, or_CC within_IN 14_CD days_NNS of_IN discontinuing_VBG treatment_NN with_IN a_DT MAOI_NNP ._. After_IN stopping_VBG Fluvoxamine_NNP Tablets_NNPS ,_, at_IN least_JJS 2_CD weeks_NNS should_MD be_VB allowed_VBN before_IN starting_VBG a_DT MAOI_NNP ._. Potential_JJ Terfenadine_NN ,_, Astemizole_NNP ,_, and_CC Cisapride_NNP Interaction_NN ._. Terfenadine_NNP ,_, astemizole_NN and_CC cisapride_NN are_VBP all_DT metabolized_VBN by_IN the_DT cytochrome_NN P450IIIA4_NN isozyme_NN ,_, and_CC it_PRP has_VBZ been_VBN demonstrated_VBN that_IN ketoconazole_NN ,_, a_DT potent_JJ inhibitor_NN of_IN IIIA4_NN ,_, blocks_VBZ the_DT metabolism_NN of_IN these_DT drugs_NNS ,_, resulting_VBG in_IN increased_VBN plasma_NN concentrations_NNS of_IN parent_NN drug_NN ._. Increased_VBN plasma_NN concentrations_NNS of_IN terfenadine_NN ,_, astemizole_NN ,_, and_CC cisapride_NN cause_VBP QT_NNP prolongation_NN and_CC have_VBP been_VBN associated_VBN with_IN torsades_NNS de_IN pointes-type_JJ ventricular_JJ tachycardia_NN ,_, sometimes_RB fatal_JJ ._. As_IN noted_VBN below_IN ,_, a_DT sub_NN -_: for_IN fluvoxamine_NN in_IN combination_NN with_IN alprazolam_NN ,_, a_DT drug_NN that_WDT is_VBZ known_VBN to_TO be_VB metabolized_VBN by_IN the_DT IIIA4_NN isozyme_NN ._. Although_IN it_PRP has_VBZ not_RB been_VBN definitively_RB demonstrated_VBN that_IN fluvoxamine_NN is_VBZ a_DT potent_JJ IIIA4_NN inhibitor_NN ,_, it_PRP is_VBZ likely_JJ to_TO be_VB ,_, given_VBN the_DT substantial_JJ interaction_NN of_IN fluvoxamine_NN with_IN alprazolam_NN ._. Consequently_RB ,_, it_PRP is_VBZ recommended_VBN that_IN fluvoxamine_NN not_RB be_VB used_VBN in_IN combination_NN with_IN either_CC terbinafine_NN ,_, astemizole_NN ,_, or_CC cisapride_NN ._. Other_JJ Potentially_RB Important_JJ Drug_NN Interactions_NNS :_: Benzodiazepines_NNS :_: Benzodiazepines_NNS metabolized_VBN by_IN hepatic_JJ oxidation_NN -LRB-_-LRB- e.g._FW ,_, alprazolam_NN ,_, midazolam_NN ,_, triazolam_NN elc_NN ._. -RRB-_-RRB- should_MD be_VB used_VBN with_IN caution_NN because_IN the_DT clearance_NN of_IN these_DT drugs_NNS is_VBZ likely_JJ to_TO be_VB reduced_VBN by_IN fluvoxamine_NN ._. The_DT clearance_NN of_IN benzodiazepines_NNS metabolized_VBN by_IN glucuronidation_NN -LRB-_-LRB- e._FW g._FW ,_, lorazepam_NN ,_, oxazepam_NN ,_, temazepam_NN -RRB-_-RRB- is_VBZ unlikely_JJ to_TO be_VB affected_VBN by_IN fluvoxamine_NN ._. Alprazolam_NNP :_: When_WRB fluvoxamine_NN maleate_NN -LRB-_-LRB- 100_CD mg_NN qd_NN -RRB-_-RRB- and_CC alprazolam_NN -LRB-_-LRB- 1_CD mg_NN q.d._NN were_VBD co-administered_VBN to_TO steady_JJ state_NN ,_, plasma_NN concentration_NN and_CC other_JJ pharmacokinetics_NNS parameters_NNS -LRB-_-LRB- AUC_NN ,_, Cmax_NN ,_, T1/2_NN ,_, -RRB-_-RRB- of_IN alprazolam_NN were_VBD approximately_RB twice_RB those_DT observed_VBN when_WRB alprazolam_NN was_VBD administered_VBN alone_RB ._. oral_JJ clearance_NN was_VBD reduced_VBN by_IN about_IN 50_CD %_NN ._. The_DT elevated_JJ plasma_NN alprazolam_NN concentrations_NNS resulted_VBD in_IN decreased_VBN psychomotor_NN performance_NN and_CC memory_NN ._. This_DT interaction_NN ,_, which_WDT has_VBZ not_RB been_VBN investigated_VBN using_VBG higher_JJR doses_NNS of_IN fluvoxamine_NN ,_, may_MD be_VB more_RBR pronounced_JJ if_IN a_DT 300_CD mg_NN daily_JJ dose_NN is_VBZ co-administered_JJ ,_, particularly_RB since_IN fluvoxamine_NN exhibits_VBZ non-linear_JJ pharmacokinetics_NNS over_IN the_DT dosage_NN range_NN 100-300_CD mg_NN ._. If_IN alprazolam_NN is_VBZ co-administered_VBN with_IN Fluvoxamine_NNP Tablets_NNPS ,_, the_DT initial_JJ alprazolam_NN dosage_NN should_MD be_VB at_IN least_JJS halved_JJ and_CC titration_NN to_TO the_DT lowest_JJS effective_JJ dose_NN is_VBZ recommended_VBN ._. No_DT dosage_NN adjustment_NN is_VBZ required_VBN for_IN Fluvoxamine_NNP Tablets_NNPS ._. Diazepam_NN :_: The_DT co-administration_NN of_IN Fluvoxamine_NNP Tablets_NNPS and_CC diazepam_NN is_VBZ generally_RB not_RB advisable_JJ ._. Because_IN fluvoxamine_NN reduces_VBZ the_DT clearance_NN of_IN both_CC diazepam_NN and_CC its_PRP$ active_JJ metabolite_NN ,_, N-desmethyldiazepam_NN ,_, there_EX is_VBZ a_DT strong_JJ likelihood_NN of_IN substantial_JJ accumulation_NN of_IN both_DT species_NNS during_IN chronic_JJ co-administration_NN ._. Evidence_NN supporting_VBG the_DT conclusion_NN that_IN it_PRP is_VBZ inadvisable_JJ to_TO co-administer_NN fluvoxamine_NN and_CC diazepam_NN is_VBZ derived_VBN from_IN a_DT study_NN in_IN which_WDT healthy_JJ volunteers_NNS taking_VBG 150_CD mg/day_NN of_IN fluvoxamine_NN were_VBD administered_VBN a_DT single_JJ oral_JJ dose_NN of_IN 10_CD mg_NN of_IN diazepam_NN ._. In_IN these_DT subjects_NNS -LRB-_-LRB- R_NN =_JJ B_NN -RRB-_-RRB- ,_, the_DT clearance_NN of_IN diazepam_NN was_VBD reduced_VBN by_IN 65_CD %_NN and_CC that_IN of_IN N-desmethyldiazepam_NN to_TO a_DT level_NN that_WDT was_VBD too_RB low_JJ to_TO measure_VB over_IN the_DT course_NN of_IN the_DT 2_CD week_NN long_JJ study_NN ._. It_PRP is_VBZ likely_JJ that_IN experience_NN significantly_RB underestimates_VBZ the_DT degree_NN of_IN accumulation_NN that_WDT might_MD occur_VB with_IN repealed_VBN diazepam_NN administration_NN ._. Moreover_RB ,_, as_IN noted_VBN with_IN alprazolam_NN ,_, the_DT effect_NN of_IN fluvoxamine_NN may_MD even_RB be_VB more_RBR pronounced_JJ when_WRB it_PRP is_VBZ administered_VBN at_IN higher_JJR doses_NNS ._. Accordingly_RB ,_, diazepam_NN and_CC fluvoxamine_NN should_MD not_RB ordinarily_RB be_VB co-administered_VBN ._. Theophylline_NNP :_: The_DT effect_NN of_IN steady-state_JJ fluvoxamine_NN l50_NN mg_NN bid_NN on_IN the_DT pharmacokinetics_NNS of_IN a_DT single_JJ dose_NN of_IN Theophylline_NNP -LRB-_-LRB- 375_CD mg_NN -RRB-_-RRB- as_IN 442_CD mg_NN aminophylline_NN was_VBD evaluated_VBN in_IN 12_CD healthy_JJ non-smoking_JJ ,_, male_JJ volunteers_NNS ._. The_DT clearance_NN of_IN theophylline_NN was_VBD decreased_VBN approximately_RB 3-fold_RB ._. Therefore_RB ,_, if_IN theophylline_NN is_VBZ co-administered_VBN with_IN fluvoxamine_NN maleate_NN ,_, its_PRP$ dose_NN should_MD be_VB reduced_VBN to_TO one_CD third_NN of_IN the_DT usual_JJ daily_JJ maintenance_NN dose_NN and_CC plasma_NN concentrations_NNS of_IN theophylline_NN should_MD to_TO monitored_VBN ._. No_DT dosage_NN adjustment_NN is_VBZ required_VBN for_IN Fluvoxamine_NNP Tablets_NNPS ._. Warfarin_NNP :_: When_WRB fluvoxamine_NN maleate_NN -LRB-_-LRB- 50_CD mg_NN tid_NN -RRB-_-RRB- was_VBD administered_VBN concomitantly_RB with_IN warfarin_NN for_IN two_CD weeks_NNS ,_, warfarin_NN plasma_NN concentrations_NNS increased_VBN by_IN 98_CD %_NN and_CC prothrombin_NN times_NNS were_VBD prolonged_VBN ._. Thus_RB patients_NNS receiving_VBG oral_JJ anticoagulants_NNS and_CC Fluvoxamine_NNP Tablets_NNS should_MD have_VB their_PRP$ prothrombin_NN time_NN monitored_VBD and_CC their_PRP$ anticoagulant_JJ dose_NN adjusted_VBN accordingly_RB ._. No_DT dosage_NN adjustment_NN is_VBZ required_VBN for_IN Fluvoxamine_NNP Tablets_NNPS ._. Medications_NNS that_WDT interfere_VBP with_IN your_PRP$ bodys_NNS ability_NN to_TO use_VB folate_NN may_MD also_RB increase_VB the_DT need_NN for_IN this_DT vitamin_NN ._. Medications_NNS can_MD interfere_VB with_IN folate_NN utilization_NN ,_, including_VBG :_: anticonvulsant_JJ medications_NNS -LRB-_-LRB- such_JJ as_IN phenytoin_NN ,_, and_CC primidone_NN -RRB-_-RRB- metformin_NN -LRB-_-LRB- sometimes_RB prescribed_VBN to_TO control_VB blood_NN sugar_NN in_IN type_NN 2_CD diabetes_NN -RRB-_-RRB- sulfasalazine_NN -LRB-_-LRB- used_VBN to_TO control_VB inflammation_NN associated_VBN with_IN Crohns_NN disease_NN and_CC ulcerative_JJ colitis_NN -RRB-_-RRB- triamterene_NN -LRB-_-LRB- a_DT diuretic_JJ -RRB-_-RRB- Methotrexate_NNP There_EX has_VBZ been_VBN concern_NN about_IN the_DT interaction_NN between_IN vitamin_NN B12_NN and_CC folic_JJ acid_NN ._. Folic_JJ acid_NN supplements_NNS can_MD correct_VB the_DT anemia_NN associated_VBN with_IN vitamin_NN B12_NN deficiency_NN ._. Unfortunately_RB ,_, folic_JJ acid_NN will_MD not_RB correct_VB changes_NNS in_IN the_DT nervous_JJ system_NN that_WDT result_VBP from_IN vitamin_NN B12_NN deficiency_NN ._. Permanent_JJ nerve_NN damage_NN could_MD theoretically_RB occur_VB if_IN vitamin_NN B12_NN deficiency_NN is_VBZ not_RB treated_VBN ._. Therefore_RB ,_, intake_NN of_IN supplemental_JJ folic_JJ acid_NN should_MD not_RB exceed_VB 1000_CD micrograms_NNS -LRB-_-LRB- g_NN ,_, sometimes_RB mcg_NN -RRB-_-RRB- per_IN day_NN to_TO prevent_VB folic_JJ acid_NN from_IN masking_VBG symptoms_NNS of_IN vitamin_NN B12_NN deficiency_NN ._. It_PRP is_VBZ important_JJ for_IN older_JJR adults_NNS to_TO be_VB aware_JJ of_IN the_DT relationship_NN between_IN folic_JJ acid_NN and_CC vitamin_NN B12_NN because_IN they_PRP are_VBP at_IN greater_JJR risk_NN of_IN having_VBG a_DT vitamin_NN B12_NN deficiency_NN ._. If_IN you_PRP are_VBP 50_CD years_NNS of_IN age_NN or_CC older_JJR ,_, ask_VB your_PRP$ physician_NN to_TO check_VB your_PRP$ B12_NN status_NN before_IN you_PRP take_VBP a_DT supplement_NN that_WDT contains_VBZ folic_JJ acid_NN ._. No_DT drug/drug_NN interaction_NN studies_NNS have_VBP been_VBN performed_VBN ._. Oral_JJ doses_NNS of_IN Antizol_NNP -LRB-_-LRB- 10-20_CD mg/kg_NN -RRB-_-RRB- ,_, via_IN alcohol_NN dehydrogenase_NN inhibition_NN ,_, significantly_RB reduced_VBD the_DT rate_NN of_IN elimination_NN of_IN ethanol_NN -LRB-_-LRB- by_IN approximately_RB 40_CD %_NN -RRB-_-RRB- given_VBN to_TO healthy_JJ volunteers_NNS in_IN moderate_JJ doses_NNS ._. Similarly_RB ,_, ethanol_NN decreased_VBD the_DT rate_NN of_IN elimination_NN of_IN Antizol_NNP -LRB-_-LRB- by_IN approximately_RB 50_CD %_NN -RRB-_-RRB- by_IN the_DT same_JJ mechanism_NN ._. Reciprocal_JJ interactions_NNS may_MD occur_VB with_IN concomitant_JJ use_NN of_IN Antizol_NNP and_CC drugs_NNS that_WDT increase_VBP or_CC inhibit_VBP the_DT cytochrome_NN P450_NN system_NN -LRB-_-LRB- e.g._FW ,_, phenytoin_NN ,_, carbamazepine_NN ,_, cimetidine_NN ,_, ketoconazole_NN -RRB-_-RRB- ,_, though_IN this_DT has_VBZ not_RB been_VBN studie_NN ._. In_IN clinical_JJ studies_NNS performed_VBN with_IN Fondaparinux_NN ,_, the_DT concomitant_JJ use_NN of_IN oral_JJ anticoagulants_NNS -LRB-_-LRB- warfarin_NN -RRB-_-RRB- ,_, platelet_NN inhibitors_NNS -LRB-_-LRB- acetylsalicylic_JJ acid_NN -RRB-_-RRB- ,_, NSAIDs_NNS -LRB-_-LRB- piroxicam_NN -RRB-_-RRB- ,_, and_CC digoxin_NN did_VBD not_RB significantly_RB affect_VB the_DT pharmacokinetics/pharmacodynamics_NNS of_IN fondaparinux_NN sodium_NN ._. In_IN addition_NN ,_, Fondaparinux_NN neither_CC influenced_VBD the_DT pharmacodynamics_NNS of_IN warfarin_NN ,_, acetylsalicylic_JJ acid_NN ,_, piroxicam_NN ,_, and_CC digoxin_NN ,_, nor_CC the_DT pharmacokinetics_NNS of_IN digoxin_NN at_IN steady_JJ state_NN ._. Agents_NNS that_WDT may_MD enhance_VB the_DT risk_NN of_IN hemorrhage_NN should_MD be_VB discontinued_VBN prior_RB to_TO initiation_NN of_IN Fondaparinux_NN therapy_NN ._. If_IN co-administration_NN is_VBZ essential_JJ ,_, close_JJ monitoring_NN may_MD be_VB appropriate_JJ ._. In_IN an_DT in_FW vitro_FW study_NN in_IN human_JJ liver_NN microsomes_NNS ,_, inhibition_NN of_IN CYP2A6_NN hydroxylation_NN of_IN coumarin_NN by_IN fondaparinux_NN -LRB-_-LRB- 200_CD m_NN m_NN M_NN i.e._FW ,_, 350_CD mg/L_NN -RRB-_-RRB- was_VBD 17-28_CD %_NN ._. Inhibition_NN of_IN the_DT other_JJ isozymes_NNS evaluated_VBN -LRB-_-LRB- CYPs_NNS 2A1_NN ,_, 2C9_NN ,_, 2C19_NN ,_, 2D6_NN ,_, 3A4_NN ,_, and_CC 3E1_NN -RRB-_-RRB- was_VBD 0-16_CD %_NN ._. Since_IN fondaparinux_NN does_VBZ not_RB markedly_RB inhibit_VB CYP450s_NN -LRB-_-LRB- CYP1A2_NN ,_, CYP2A6_NN ,_, CYP2C9_NN ,_, CYP2C19_NN ,_, CYP2D6_NN ,_, CYP2E1_NN ,_, or_CC CYP3A4_NN -RRB-_-RRB- in_FW vitro_FW ,_, fondaparinux_NN sodium_NN is_VBZ not_RB expected_VBN to_TO significantly_RB interact_VB with_IN other_JJ drugs_NNS in_FW vivo_FW by_IN inhibition_NN of_IN metabolism_NN mediated_VBN by_IN these_DT isozymes_NNS ._. Since_IN fondaparinux_NN sodium_NN does_VBZ not_RB bind_VB significantly_RB to_TO plasma_NN proteins_NNS other_JJ than_IN ATIII_NN ,_, no_DT drug_NN interactions_NNS by_IN protein-binding_JJ displacement_NN are_VBP expected_VBN ._. Short-Acting_JJ beta2-agonists_NNS :_: Aerosol_NN bronchodilators_NNS of_IN the_DT short-acting_JJ adrenergic_JJ stimulant_NN type_NN may_MD be_VB used_VBN for_IN relief_NN of_IN breakthrough_NN symptoms_NNS while_IN using_VBG formoterol_NN ._. However_RB ,_, increasing_VBG use_NN of_IN such_JJ preparations_NNS to_TO control_VB symptoms_NNS indicates_VBZ deterioration_NN of_IN asthma_NN control_NN and_CC the_DT need_NN to_TO reassess_NN the_DT patient_NN s_VBZ therapy_NN ._. Concomitant_JJ administration_NN of_IN other_JJ sympathomimetic_JJ agents_NNS may_MD potentiate_VB the_DT undesirable_JJ effects_NNS of_IN FORADIL_NNP ._. Monoamine_NNP Oxidase_NNP Inhibitors_NNS and_CC Tricyclic_JJ Antidepressants_NNS :_: FORADIL_NN should_MD be_VB administered_VBN with_IN extreme_JJ caution_NN in_IN patients_NNS being_VBG treated_VBN with_IN monoamine_NN oxidase_NN inhibitors_NNS or_CC tricyclic_JJ antidepressants_NNS because_IN the_DT action_NN of_IN formoterol_NN on_IN the_DT cardiovascular_JJ system_NN may_MD be_VB potentiated_VBN by_IN these_DT agents_NNS ._. Corticosteroids_NNS ,_, Methylxanthines_NNS and_CC Diuretics_NNS :_: Concomitant_JJ treatment_NN with_IN xanthine_NN derivatives_NNS ,_, steroids_NNS ,_, or_CC diuretics_NNS may_MD potentiate_VB a_DT possible_JJ hypokalemic_JJ effect_NN of_IN beta2-agonists_NNS ._. Hypokalemia_NN may_MD increase_VB susceptibility_NN to_TO cardiac_JJ arrhythmias_NNS in_IN patients_NNS treated_VBN with_IN digitalis_NN ._. -_: adrenergic_JJ Blockers_NNS :_: -_: adrenergic_JJ blockers_NNS may_MD weaken_VB or_CC antagonise_VB the_DT effect_NN of_IN FORADIL_NNP ._. Therefore_RB FORADIL_NNP should_MD not_RB be_VB given_VBN together_RP with_IN -_: adrenergic_JJ blockers_NNS -LRB-_-LRB- including_VBG eye_NN drops_NNS -RRB-_-RRB- unless_IN there_EX are_VBP compelling_JJ reasons_NNS for_IN their_PRP$ use_NN ._. Other_JJ Drugs_NNS :_: Drugs_NNS such_JJ as_IN quinidine_NN ,_, disopyramide_NN ,_, procainamide_NN ,_, phenothiazines_NNS ,_, antihistamines_NNS ,_, and_CC tricyclic_JJ antidepressants_NNS may_MD be_VB associated_VBN with_IN QT-interval_JJ prolongation_NN and_CC an_DT increased_VBN risk_NN of_IN ventricular_JJ arrhythmia_NN ._. INFORMATION_NN TO_TO BE_VB PROVIDED_VBN TO_TO THE_DT PATIENT_NN OR_NN GUARDIAN_NNP See_NNP illustrated_VBD Information_NN For_IN The_DT Patient_NN or_CC Guardian_NNP section_NN ._. It_PRP is_VBZ important_JJ that_IN patients_NNS understand_VBP how_WRB to_TO use_VB FORADIL_NNP -LRB-_-LRB- formoterol_NN fumarate_NN -RRB-_-RRB- capsules_NNS with_IN the_DT supplied_VBN AerolizerTM_NN inhalation_NN device_NN and_CC how_WRB it_PRP should_MD be_VB used_VBN in_IN relation_NN to_TO other_JJ asthma_NN or_CC COPD_NN medications_NNS they_PRP are_VBP taking_VBG ._. Patients/Guardians_NN should_MD be_VB given_VBN the_DT following_VBG information_NN :_: i_LS ._. The_DT recommended_VBN dosage_NN -LRB-_-LRB- one_CD or_CC two_CD capsules_NNS twice_RB daily_RB ,_, morning_NN and_CC evening_NN -RRB-_-RRB- should_MD not_RB be_VB exceeded_VBN ._. ii_LS ._. FORADIL_NNP is_VBZ not_RB meant_VBN to_TO relieve_VB acute_JJ asthma_NN or_CC COPD_NN symptoms_NNS and_CC extra_JJ doses_NNS should_MD not_RB be_VB used_VBN for_IN that_DT purpose_NN ._. Acute_JJ symptoms_NNS should_MD be_VB treated_VBN with_IN a_DT short-acting_JJ ,_, inhaled_VBN beta2-agonist_NN such_JJ as_IN salbutamol_NN -LRB-_-LRB- the_DT physician_NN should_MD provide_VB the_DT patient_NN with_IN such_JJ medication_NN and_CC instruct_VB the_DT patient_NN in_IN how_WRB it_PRP should_MD be_VB used_VBN -RRB-_-RRB- ._. iii_LS ._. The_DT physician_NN should_MD be_VB notified_VBN immediately_RB if_IN any_DT of_IN the_DT following_VBG situations_NNS occur_VBP ,_, which_WDT may_MD be_VB a_DT sign_NN of_IN seriously_RB worsening_VBG asthma_NN :_: Decreased_VBN effectiveness_NN of_IN short-acting_JJ ,_, inhaled_VBD beta2-agonists_NNS ._. Need_VBN for_IN more_JJR inhalations_NNS than_IN usual_JJ of_IN short-acting_JJ ,_, inhaled_VBD beta2-agonists_NNS ._. iv_NN ._. FORADIL_NNP should_MD not_RB be_VB used_VBN as_IN a_DT substitute_NN for_IN oral_JJ or_CC inhaled_VBN corticosteroids_NNS ._. The_DT dosage_NN of_IN these_DT medications_NNS should_MD not_RB be_VB changed_VBN and_CC they_PRP should_MD not_RB be_VB stopped_VBN without_IN consulting_VBG the_DT physician_NN ,_, even_RB if_IN the_DT patient_NN feels_VBZ better_RB after_IN initiating_VBG treatment_NN with_IN FORADIL_NN ._. v._CC Patients_NNS should_MD be_VB cautioned_VBN regarding_VBG potential_JJ adverse_JJ cardiovascular_JJ effects_NNS ,_, such_JJ as_IN palpitations_NNS or_CC chest_NN pain_NN ._. vi_LS ._. In_IN patients_NNS receiving_VBG FORADIL_NNP ,_, other_JJ inhaled_VBN medications_NNS should_MD be_VB used_VBN only_RB as_IN directed_VBN by_IN the_DT physician_NN ._. vii_LS ._. Guardians_NNS of_IN children_NNS who_WP have_VBP been_VBN prescribed_VBN FORADIL_NNP should_MD be_VB alerted_VBN to_TO the_DT general_JJ concern_NN regarding_VBG asthma_NN therapy_NN compliance_NN ,_, especially_RB neglect_NN of_IN anti-inflammatory_JJ therapy_NN and_CC overuse_NN of_IN short-acting_JJ beta2-agonists_NNS ._. A_DT possible_JJ drug_NN interaction_NN of_IN FOSCAVIR_NNP and_CC intravenous_JJ pentamidine_NN has_VBZ been_VBN described_VBN ._. Concomitant_JJ treatment_NN of_IN four_CD patients_NNS in_IN the_DT United_NNP Kingdom_NNP with_IN FOSCAVIR_NNP and_CC intravenous_JJ pentamidine_NN may_MD have_VB caused_VBN hypocalcemia_NN ._. one_CD patient_NN died_VBD with_IN severe_JJ hypocalcemia_NN ._. Toxicity_NN associated_VBN with_IN concomitant_JJ use_NN of_IN aerosolized_JJ pentamidine_NN has_VBZ not_RB been_VBN reported_VBN ._. Because_IN of_IN foscarnets_NNS tendency_NN to_TO cause_VB renal_JJ impairment_NN ,_, the_DT use_NN of_IN FOSCAVIR_NNP should_MD be_VB avoided_VBN in_IN combination_NN with_IN potentially_RB nephrotoxic_JJ drugs_NNS such_JJ as_IN aminoglycosides_NNS ,_, amphotericin_NN B_NN and_CC intravenous_JJ pentamidine_NN unless_IN the_DT potential_JJ benefits_NNS outweigh_VBP the_DT risks_NNS to_TO the_DT patient_NN ._. Since_IN FOSCAVIR_NN decreases_VBZ serum_NN concentrations_NNS of_IN ionized_VBN calcium_NN ,_, concurrent_JJ treatment_NN with_IN other_JJ drugs_NNS known_VBN to_TO influence_VB serum_NN calcium_NN concentrations_NNS should_MD be_VB used_VBN with_IN particular_JJ caution_NN ._. Ganciclovir_NNP :_: The_DT pharmacokinetics_NNS of_IN foscarnet_NN and_CC ganciclovir_NN were_VBD not_RB altered_VBN in_IN 13_CD patients_NNS receiving_VBG either_CC concomitant_JJ therapy_NN or_CC daily_JJ alternating_VBG therapy_NN for_IN maintenance_NN of_IN CMV_NN disease_NN ._. Metoclopramide_NNP :_: When_WRB coadministered_VBN with_IN MONUROL_NN ,_, metoclopramide_NN ,_, a_DT drug_NN which_WDT increases_VBZ gastrointestinal_JJ motility_NN ,_, lowers_VBZ the_DT serum_NN concentration_NN and_CC urinary_JJ excretion_NN of_IN fosfomycin_NN ._. Other_JJ drugs_NNS that_WDT increase_VBP gastrointestinal_JJ motility_NN may_MD produce_VB similar_JJ effects_NNS ._. Cimetidine_NNP :_: Cimetidine_NN does_VBZ not_RB affect_VB the_DT pharmacokinetics_NNS of_IN fosfomycin_NN when_WRB coadministered_VBN with_IN MONUROL_NN ._. Diuretics_NNS :_: Patients_NNS on_IN diuretics_NNS ,_, especially_RB those_DT with_IN intravascular_JJ volume_NN depletion_NN ,_, may_MD occasionally_RB experience_VB an_DT excessive_JJ reduction_NN of_IN blood_NN pressure_NN after_IN initiation_NN of_IN therapy_NN with_IN fosinopril_NN sodium_NN ._. The_DT possibility_NN of_IN hypotensive_JJ effects_NNS can_MD be_VB minimized_VBN by_IN either_CC discontinuing_VBG the_DT diuretic_JJ or_CC increasing_VBG salt_NN intake_NN prior_RB to_TO initiation_NN of_IN treatment_NN with_IN fosinopril_NN sodium_NN ._. If_IN this_DT is_VBZ not_RB possible_JJ ,_, the_DT starting_VBG dose_NN should_MD be_VB reduced_VBN and_CC the_DT patient_NN should_MD be_VB observed_VBN closely_RB for_IN several_JJ hours_NNS following_VBG an_DT initial_JJ dose_NN and_CC until_IN blood_NN pressure_NN has_VBZ stabilized_VBN -LRB-_-LRB- see_VB DOSAGE_NNP AND_CC ADMINISTRATION_NNP ._. -RRB-_-RRB- ._. Potassium_NN Supplements_NNS and_CC Potassium-Sparing_NNP Diuretics_NNPS :_: Fosinopril_NN sodium_NN can_MD attenuate_VB potassium_NN loss_NN caused_VBN by_IN thiazide_JJ diuretics_NNS ._. Potassium-sparing_JJ diuretics_NNS -LRB-_-LRB- spironolactone_NN ,_, amiloride_NN ,_, triamterene_NN ,_, and_CC others_NNS -RRB-_-RRB- or_CC potassium_NN supplements_NNS can_MD increase_VB the_DT risk_NN of_IN hyperkalemia_NN ._. Therefore_RB ,_, if_IN concomitant_JJ use_NN of_IN such_JJ agents_NNS is_VBZ indicated_VBN ,_, they_PRP should_MD be_VB given_VBN with_IN caution_NN ,_, and_CC the_DT patients_NNS serum_NN potassium_NN should_MD be_VB monitored_VBN frequently_RB ._. Lithium_NN :_: Increased_VBN serum_NN lithium_NN levels_NNS and_CC symptoms_NNS of_IN lithium_NN toxicity_NN have_VBP been_VBN reported_VBN in_IN patients_NNS receiving_VBG ACE_NN inhibitors_NNS during_IN therapy_NN with_IN lithium_NN ._. These_DT drugs_NNS should_MD be_VB coadministered_VBN with_IN caution_NN ,_, and_CC frequent_JJ monitoring_NN of_IN serum_NN lithium_NN levels_NNS is_VBZ recommended_VBN ._. If_IN a_DT diuretic_JJ is_VBZ also_RB used_VBN ,_, the_DT risk_NN of_IN lithium_NN toxicity_NN may_MD be_VB increased_VBN ._. Antacids_NNS :_: In_IN a_DT clinical_JJ pharmacology_NN study_NN ,_, coadministration_NN of_IN an_DT antacid_NN -LRB-_-LRB- aluminum_NN hydroxide_NN ,_, magnesium_NN hydroxide_NN ,_, and_CC simethicone_NN -RRB-_-RRB- with_IN fosinopril_NN reduced_VBD serum_NN levels_NNS and_CC urinary_JJ excretion_NN of_IN fosinoprilat_NN as_IN compared_VBN with_IN fosinopril_NN administered_VBN alone_RB ,_, suggesting_VBG that_IN antacids_NNS may_MD impair_VB absorption_NN of_IN fosinopril_NN ._. Therefore_RB ,_, if_IN concomitant_JJ administration_NN of_IN these_DT agents_NNS is_VBZ indicated_VBN ,_, dosing_NN should_MD be_VB separated_VBN by_IN 2_CD hours_NNS ._. Other_JJ :_: Neither_DT fosinopril_NN sodium_NN nor_CC its_PRP$ metabolites_NNS have_VBP been_VBN found_VBN to_TO interact_VB with_IN food_NN ._. In_IN separate_JJ single_JJ or_CC multiple_JJ dose_NN pharmacokinetic_JJ interaction_NN studies_NNS with_IN chlorthalidone_NN ,_, nifedipine_NN ,_, propanolol_NN ,_, hydrochlorothiazide_NN ,_, cimetidine_NN ,_, metoclopramide_NN ,_, propantheline_NN ,_, digoxin_NN ,_, and_CC warfarin_NN ,_, the_DT bioavailability_NN of_IN fosinoprilat_NN was_VBD not_RB altered_VBN by_IN coadministration_NN of_IN fosinopril_NN with_IN any_DT one_CD of_IN these_DT drugs_NNS ._. In_IN a_DT study_NN with_IN concomitant_JJ administration_NN of_IN aspirin_NN and_CC fosinopril_NN sodium_NN ,_, the_DT bioavailability_NN of_IN unbound_JJ fosinoprilat_NN was_VBD not_RB altered_VBN ._. In_IN a_DT pharmacokinetic_JJ interaction_NN study_NN with_IN warfarin_NN ,_, bioavailability_NN parameters_NNS ,_, the_DT degree_NN of_IN protein_NN binding_NN ,_, and_CC the_DT anticoagulant_JJ effect_NN -LRB-_-LRB- measured_VBN by_IN prothrombin_NN time_NN -RRB-_-RRB- of_IN warfarin_NN were_VBD not_RB significantly_RB changed_VBD ._. Drug/Laboratory_JJ Test_NN Interaction_NN Fosinopril_NN may_MD cause_VB a_DT false_JJ low_JJ measurement_NN of_IN serum_NN digoxin_NN levels_NNS with_IN the_DT Digi_NNP -_: Tab_NNP RIA_NN Kit_NN for_IN Digoxin_NNP ._. Other_JJ kits_NNS ,_, such_JJ as_IN the_DT Coat-A-Count_NNP RIA_NN Kit_NN ,_, may_MD be_VB used_VBN ._. No_DT drugs_NNS are_VBP known_VBN to_TO interfere_VB with_IN the_DT conversion_NN of_IN fosphenytoin_NN to_TO phenytoin_NN ._. Conversion_NN could_MD be_VB affected_VBN by_IN alterations_NNS in_IN the_DT level_NN of_IN phosphatase_NN activity_NN ,_, but_CC given_VBN the_DT abundance_NN and_CC wide_JJ distribution_NN of_IN phosphatases_NNS in_IN the_DT body_NN it_PRP is_VBZ unlikely_JJ that_IN drugs_NNS would_MD affect_VB this_DT activity_NN enough_RB to_TO affect_VB conversion_NN of_IN fosphenytoin_NN to_TO phenytoin_NN ._. Drugs_NNS highly_RB bound_VBD to_TO albumin_NN could_MD increase_VB the_DT unbound_JJ fraction_NN of_IN fosphenytoin_NN ._. Although_IN ,_, it_PRP is_VBZ unknown_JJ whether_IN this_DT could_MD result_VB in_IN clinically_RB significant_JJ effects_NNS ,_, caution_NN is_VBZ advised_VBN when_WRB administering_VBG Cerebyx_NN with_IN other_JJ drugs_NNS that_WDT significantly_RB bind_VBP to_TO serum_NN albumin_NN ._. The_DT pharmacokinetics_NNS and_CC protein_NN binding_NN of_IN fosphenytoin_NN ,_, phenytoin_NN ,_, and_CC diazepam_NN were_VBD not_RB altered_VBN when_WRB diazepam_NN and_CC Cerebyx_NN were_VBD concurrently_RB administered_VBN in_IN single_JJ submaximal_JJ doses_NNS ._. The_DT most_RBS significant_JJ drug_NN interactions_NNS following_VBG administration_NN of_IN Cerebyx_NNP are_VBP expected_VBN to_TO occur_VB with_IN drugs_NNS that_WDT interact_VBP with_IN phenytoin_NN ._. Phenytoin_NNP is_VBZ extensively_RB bound_VBN to_TO serum_NN plasma_NN proteins_NNS and_CC is_VBZ prone_JJ to_TO competitive_JJ displacement_NN ._. Phenytoin_NNP is_VBZ metabolized_VBN by_IN hepatic_JJ cytochrome_NN P450_NN enzymes_NNS and_CC is_VBZ particularly_RB susceptible_JJ to_TO inhibitory_JJ drug_NN interactions_NNS because_IN it_PRP is_VBZ subject_JJ to_TO saturable_JJ metabolism_NN ._. Inhibition_NN of_IN metabolism_NN may_MD produce_VB significant_JJ increases_NNS in_IN circulating_VBG phenytoin_NN concentrations_NNS and_CC enhance_VBP the_DT risk_NN of_IN drug_NN toxicity_NN ._. Phenytoin_NNP is_VBZ a_DT potent_JJ inducer_NN of_IN hepatic_JJ drug-metabolizing_JJ enzymes_NNS ._. The_DT most_RBS commonly_RB occurring_VBG drug_NN interactions_NNS are_VBP listed_VBN below_IN :_: -_: Drugs_NNS that_WDT may_MD increase_VB plasma_NN phenytoin_NN concentrations_NNS include_VBP :_: acute_JJ alcohol_NN intake_NN ,_, amiodarone_NN ,_, chboramphenicol_NN ,_, chlordiazepoxide_NN ,_, cimetidine_NN ,_, diazepam_NN ,_, dicumarol_NN ,_, disulfiram_NN ,_, estrogens_NNS ,_, ethosuximide_NN ,_, fluoxetine_NN ,_, H2-antagonists_NNS ,_, halothane_NN ,_, isoniazid_NN ,_, methylphenidate_NN ,_, phenothiazines_NNS ,_, phenylbutazone_NN ,_, salicylates_NNS ,_, succinimides_NNS ,_, sulfonamides_NNS ,_, tolbutamide_NN ,_, trazodon_NN ._. -_: Drugs_NNS that_WDT may_MD decrease_VB plasma_NN phenytoin_NN concentrations_NNS include_VBP :_: carbamazepine_NN ,_, chronic_JJ alcohol_NN abuse_NN ,_, reserpin_NN ._. -_: Drugs_NNS that_WDT may_MD either_RB increase_VB or_CC decrease_VB plasma_NN phenytoin_NN concentrations_NNS include_VBP :_: phenobarbital_NN ,_, vaiproic_JJ acid_NN ,_, and_CC sodium_NN valproate_NN ._. Similarly_RB ,_, the_DT effects_NNS of_IN phenytoin_NN on_IN phenobarbital_NN ,_, valproic_JJ acid_NN and_CC sodium_NN plasma_NN valproate_NN concentrations_NNS are_VBP unpredictabl_NN ._. -_: Although_IN not_RB a_DT true_JJ drug_NN interaction_NN ,_, tricyclic_JJ antidepressants_NNS may_MD precipitate_VB seizures_NNS in_IN susceptible_JJ patients_NNS and_CC Cerebyx_NN dosage_NN may_MD need_VB to_TO be_VB adjuste_JJ ._. -_: Drugs_NNS whose_WP$ efficacy_NN is_VBZ impaired_VBN by_IN phenytoin_NN include_VBP :_: anticoagulants_NNS ,_, corticosteroids_NNS ,_, coumarin_NN ,_, digitoxin_NN ,_, doxycycline_NN ,_, estrogens_NNS ,_, furosemide_NN ,_, oral_JJ contraceptives_NNS ,_, rifampin_NN ,_, quinidine_NN ,_, theophylline_NN ,_, vitamin_NN D._NNP Monitoring_NN of_IN plasma_NN phenytoin_NN concentrations_NNS may_MD be_VB helpful_JJ when_WRB possible_JJ drug_NN interactions_NNS are_VBP suspected_VBN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS Phenytoin_NNP may_MD decrease_VB serum_NN concentrations_NNS of_IN 14_CD ._. It_PRP may_MD also_RB produce_VB artifactually_RB low_JJ results_NNS in_IN dexamethasone_NN or_CC metyrapone_NN tests_NNS ._. Phenytoin_NNP may_MD also_RB cause_VB increased_VBN serum_NN concentrations_NNS of_IN glucose_NN ,_, alkaline_NN phosphatase_NN ,_, and_CC gamma_NN glutamyl_NN transpeptidase_NN -LRB-_-LRB- GGT_NN -RRB-_-RRB- ._. Care_NNP should_MD be_VB taken_VBN when_WRB using_VBG immunoanalytical_JJ methods_NNS to_TO measure_VB plasma_NN phenytoin_NN concentrations_NNS following_VBG Cerebyx_NNP administration_NN ._. Ergot-containing_JJ drugs_NNS have_VBP been_VBN reported_VBN to_TO cause_VB prolonged_JJ vasospastic_JJ reactions_NNS ._. Due_JJ to_TO a_DT theoretical_JJ risk_NN of_IN a_DT pharmacodynamic_JJ interaction_NN ,_, use_NN of_IN ergotamine-containing_JJ or_CC ergot-type_JJ medications_NNS -LRB-_-LRB- like_IN dihydroergotamine_NN or_CC methysergide_NN -RRB-_-RRB- and_CC FROVA_NN within_IN 24_CD hours_NNS of_IN each_DT other_JJ should_MD be_VB avoided_VBN -LRB-_-LRB- see_VB a_DT href_NN =_JJ frova_NN ._. htm_NN #CI_NN CONTRAINDICATIONS_NNS -RRB-_-RRB- ._. Concomitant_JJ use_NN of_IN other_JJ 5-HT1B_NN /_: 1D_NN agonists_NNS within_IN 24_CD hours_NNS of_IN FROVA_NN treatment_NN is_VBZ not_RB recommended_VBN ._. Selective_JJ serotonin_NN reuptake_NN inhibitors_NNS -LRB-_-LRB- SSRIs_NNS -RRB-_-RRB- -LRB-_-LRB- e.g._FW ,_, fluoxetine_NN ,_, fluvoxamine_NN ,_, paroxetine_NN ,_, sertraline_NN -RRB-_-RRB- have_VBP been_VBN reported_VBN ,_, rarely_RB ,_, to_TO cause_VB weakness_NN ,_, hyperreflexia_NN ,_, and_CC incoordination_NN when_WRB coadministered_VBN with_IN 5-HT1_NN agonists_NNS ._. If_IN concomitant_JJ treatment_NN with_IN frovatriptan_NN and_CC an_DT SSRI_NNP is_VBZ clinically_RB warranted_VBN ,_, appropriate_JJ observation_NN of_IN the_DT patient_NN is_VBZ advised_VBN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS FROVA_NN is_VBZ not_RB known_VBN to_TO interfere_VB with_IN commonly_RB employed_VBN clinical_JJ laboratory_NN tests_NNS ._. Fulvestrant_NNP is_VBZ metabolized_VBN by_IN CYP_NN 3A4_NN in_FW vitro_FW ._. Clinical_JJ studies_NNS of_IN the_DT effect_NN of_IN strong_JJ CYP_NN 3A4_NN inhibitors_NNS on_IN the_DT pharmacokinetics_NNS of_IN fulvestrant_NN have_VBP not_RB been_VBN performed_VBN ._. Carcinogenesis_NN ,_, Mutagenesis_NN and_CC Impairment_NN of_IN Fertility_NN A_NN two-year_JJ carcinogenesis_NN study_NN was_VBD conducted_VBN in_IN female_JJ and_CC male_JJ rats_NNS ,_, at_IN intramuscular_JJ doses_NNS of_IN 15_CD mg/kg/30_CD days_NNS ,_, 10_CD mg/rat/30_CD days_NNS and_CC 10_CD mg/rat/15_CD days_NNS ._. These_DT doses_NNS correspond_VBP to_TO approximately_RB 1_CD -_: ,_, 3_LS -_: ,_, and_CC 5-fold_RB -LRB-_-LRB- in_IN females_NNS -RRB-_-RRB- and_CC 1.3_CD -_: ,_, 1.3_CD -_: ,_, and_CC 1.6-fold_RB -LRB-_-LRB- in_IN males_NNS -RRB-_-RRB- the_DT systemic_JJ exposure_NN -LSB-_-LRB- AUC0-30_CD days_NNS -RSB-_-RRB- -RSB-_-RRB- achieved_VBN in_IN women_NNS receiving_VBG the_DT recommended_VBN dose_NN of_IN 250_CD mg/month_NN ._. An_DT increased_VBN incidence_NN of_IN benign_JJ ovarian_JJ granulosa_NN cell_NN tumors_NNS and_CC testicular_JJ Leydig_NN cell_NN tumors_NNS was_VBD evident_JJ ,_, in_IN females_NNS dosed_VBN at_IN 10_CD mg/rat/15_CD days_NNS and_CC males_NNS dosed_VBN at_IN 15_CD mg/rat/30_CD days_NNS ,_, respectively_RB ._. Induction_NN of_IN such_JJ tumors_NNS is_VBZ consistent_JJ with_IN the_DT pharmacology-related_JJ endocrine_JJ feedback_NN alterations_NNS in_IN gonadotropin_NN levels_NNS caused_VBN by_IN an_DT antiestrogen_NN ._. Fulvestrant_NN was_VBD not_RB mutagenic_JJ or_CC clastogenic_JJ in_IN multiple_JJ in_FW vitro_FW tests_NNS with_IN and_CC without_IN the_DT addition_NN of_IN a_DT mammalian_JJ liver_NN metabolic_JJ activation_NN factor_NN -LRB-_-LRB- bacterial_JJ mutation_NN assay_NN in_IN strains_NNS of_IN Salmonella_FW typhimurium_FW and_CC Escherichia_FW coli_FW ,_, in_FW vitro_FW cytogenetics_NNS study_NN in_IN human_JJ lymphocytes_NNS ,_, mammalian_JJ cell_NN mutation_NN assay_NN in_IN mouse_NN lymphoma_NN cells_NNS and_CC in_FW vivo_FW micronucleus_FW test_NN in_IN rat_NN ._. In_IN female_JJ rats_NNS ,_, fulvestrant_JJ administered_VBN at_IN doses_NNS 0.01_CD mg/kg/day_NN -LRB-_-LRB- approximately_RB one-hundredth_JJ of_IN the_DT human_JJ recommended_VBN dose_NN based_VBN on_IN body_NN surface_NN area_NN -LSB-_-LRB- BSA_NN -RSB-_-RRB- ,_, for_IN 2_CD weeks_NNS prior_RB to_TO and_CC for_IN 1_CD week_NN following_VBG mating_NN ,_, caused_VBD a_DT reduction_NN in_IN fertility_NN and_CC embryonic_JJ survival_NN ._. No_DT adverse_JJ effects_NNS on_IN female_JJ fertility_NN and_CC embryonic_JJ survival_NN were_VBD evident_JJ in_IN female_JJ animals_NNS dosed_VBN at_IN 0.001_CD mg/kg/day_NN -LRB-_-LRB- approximately_RB one-thousandth_JJ of_IN the_DT human_JJ dose_NN based_VBN on_IN BSA_NN -RRB-_-RRB- ._. Restoration_NN of_IN female_JJ fertility_NN to_TO values_NNS similar_JJ to_TO controls_NNS was_VBD evident_JJ following_VBG a_DT 29-day_JJ withdrawal_NN period_NN after_IN dosing_NN at_IN 2_CD mg/kg/day_NN -LRB-_-LRB- twice_RB the_DT human_JJ dose_NN based_VBN on_IN BSA_NN -RRB-_-RRB- ._. The_DT effects_NNS of_IN fulvestrant_NN on_IN the_DT fertility_NN of_IN female_JJ rats_NNS appear_VBP to_TO be_VB consistent_JJ with_IN its_PRP$ anti-estrogenic_JJ activity_NN ._. The_DT potential_JJ effects_NNS of_IN fulvestrant_NN on_IN the_DT fertility_NN of_IN male_JJ animals_NNS were_VBD not_RB studied_VBN but_CC in_IN a_DT 6-month_JJ toxicology_NN study_NN ,_, male_JJ rats_NNS treated_VBN with_IN intramuscular_JJ doses_NNS of_IN 15_CD mg/kg/30_CD days_NNS ,_, 10_CD mg/rat/30_CD days_NNS ,_, or_CC 10_CD mg/rat/15_CD days_NNS fulvestrant_JJ showed_VBD a_DT loss_NN of_IN spermatozoa_NN from_IN the_DT seminiferous_JJ tubules_NNS ,_, seminiferous_JJ tubular_JJ atrophy_NN ,_, and_CC degenerative_JJ changes_NNS in_IN the_DT epididymides_NNS ._. Changes_NNS in_IN the_DT testes_NNS and_CC epididymides_NNS had_VBD not_RB recovered_VBN 20_CD weeks_NNS after_IN cessation_NN of_IN dosing_NN ._. These_DT fulvestrant_JJ doses_NNS correspond_VBP to_TO approximately_RB 2_CD -_: ,_, 3_LS -_: ,_, and_CC 3-fold_RB the_DT systemic_JJ exposure_NN -LSB-_-LRB- AUC0-30_CD days_NNS -RSB-_-RRB- achieved_VBN in_IN women_NNS ._. Pregnancy_NNP Pregnancy_NNP Category_NNP D_NNP :_: ._. In_IN studies_NNS in_IN female_JJ rats_NNS at_IN doses_NNS 0.01_CD mg/kg/day_NN -LRB-_-LRB- IM_NN ;_: ._. approximately_RB one-hundredth_NN of_IN the_DT human_JJ recommended_VBN dose_NN based_VBN on_IN body_NN surface_NN area_NN -LSB-_-LRB- BSA_NN -RSB-_-RRB- -RRB-_-RRB- ,_, fulvestrant_NN caused_VBD a_DT reversible_JJ reduction_NN in_IN female_JJ fertility_NN ,_, as_RB well_RB as_IN effects_NNS on_IN embryo/fetal_JJ development_NN consistent_JJ with_IN its_PRP$ anti-estrogenic_JJ activity_NN ._. Fulvestrant_NN caused_VBD an_DT increased_VBN incidence_NN of_IN fetal_JJ abnormalities_NNS in_IN rats_NNS -LRB-_-LRB- tarsal_JJ flexure_NN of_IN the_DT hind_JJ paw_NN at_IN 2_CD mg/kg/day_NN IM_NN ._. twice_RB the_DT human_JJ dose_NN on_IN BSA_NN -RRB-_-RRB- and_CC non-ossification_NN of_IN the_DT odontoid_NN and_CC ventral_JJ tubercle_NN of_IN the_DT first_JJ cervical_JJ vertebra_NN at_IN doses_NNS 0.1_CD mg/kg/day_NN IM_NN -LRB-_-LRB- approximately_RB one-tenth_NN of_IN the_DT human_JJ dose_NN on_IN BSA_NN -RRB-_-RRB- when_WRB administered_VBN during_IN the_DT period_NN of_IN organogenesis_NN ._. Rabbits_NNS failed_VBD to_TO maintain_VB pregnancy_NN when_WRB dosed_VBN with_IN 1_CD mg/kg/day_NN fulvestrant_JJ IM_NN -LRB-_-LRB- twice_RB the_DT human_JJ dose_NN on_IN BSA_NN -RRB-_-RRB- during_IN the_DT period_NN of_IN organogenesis_NN ._. Further_RB ,_, in_IN rabbits_NNS dosed_VBN at_IN 0.25_CD mg/kg/day_NN -LRB-_-LRB- about_IN one-half_NN the_DT human_JJ dose_NN on_IN BSA_NN -RRB-_-RRB- ,_, increases_VBZ in_IN placental_JJ weight_NN and_CC post-implantation_JJ loss_NN were_VBD observed_VBN but_CC ,_, there_EX were_VBD no_DT observed_VBN effects_NNS on_IN fetal_JJ development_NN ._. Fulvestrant_NN was_VBD associated_VBN with_IN an_DT increased_VBN incidence_NN of_IN fetal_JJ variations_NNS in_IN rabbits_NNS -LRB-_-LRB- backwards_RB displacement_NN of_IN the_DT pelvic_JJ girdle_NN ,_, and_CC 27_CD pre-sacral_JJ vertebrae_NNS at_IN 0.25_CD mg/kg/day_NN IM_NN ._. one-half_NN the_DT human_JJ dose_NN on_IN BSA_NN -RRB-_-RRB- when_WRB administered_VBN during_IN the_DT period_NN of_IN organogenesis_NN ._. Because_IN pregnancy_NN could_MD not_RB be_VB maintained_VBN in_IN the_DT rabbit_NN following_VBG doses_NNS of_IN fulvestrant_NN of_IN 1_CD mg/kg/day_NN and_CC above_RB ,_, this_DT study_NN was_VBD inadequate_JJ to_TO fully_RB define_VB the_DT possible_JJ adverse_JJ effects_NNS on_IN fetal_JJ development_NN at_IN clinically_RB relevant_JJ exposures_NNS ._. Nursing_NNP Mothers_NNP Fulvestrant_NNP is_VBZ found_VBN in_IN rat_NN milk_NN at_IN levels_NNS significantly_RB higher_JJR -LRB-_-LRB- approximately_RB 12-fold_RB -RRB-_-RRB- than_IN plasma_NN after_IN administration_NN of_IN 2_CD mg/kg_NN ._. Drug_NN exposure_NN in_IN rodent_JJ pups_NNS from_IN fulvestrant-treated_JJ lactating_NN dams_NNS was_VBD estimated_VBN as_IN 10_CD %_NN of_IN the_DT administered_VBN dose_NN ._. It_PRP is_VBZ not_RB known_VBN if_IN fulvestrant_NN is_VBZ excreted_VBN in_IN human_JJ milk_NN ._. Because_IN many_JJ drugs_NNS are_VBP excreted_VBN in_IN human_JJ milk_NN ,_, and_CC because_IN of_IN the_DT potential_NN for_IN serious_JJ adverse_JJ reactions_NNS from_IN FASLODEX_NNP in_IN nursing_NN infants_NNS ,_, a_DT decision_NN should_MD be_VB made_VBN whether_IN to_TO discontinue_VB nursing_NN or_CC to_TO discontinue_VB the_DT drug_NN taking_VBG into_IN account_NN the_DT importance_NN of_IN the_DT drug_NN to_TO the_DT mother_NN ._. Pediatric_NNP Use_NNP The_NNP safety_NN and_CC efficacy_NN of_IN FASLODEX_NNP in_IN pediatric_JJ patients_NNS have_VBP not_RB been_VBN established_VBN ._. Geriatric_NNP Use_NNP When_WRB tumor_NN response_NN was_VBD considered_VBN by_IN age_NN ,_, objective_JJ responses_NNS were_VBD seen_VBN in_IN 24_CD %_NN and_CC 22_CD %_NN of_IN patients_NNS under_IN 65_CD years_NNS of_IN age_NN and_CC in_IN 16_CD %_NN and_CC 11_CD %_NN of_IN patients_NNS 65_CD years_NNS of_IN age_NN and_CC older_JJR ,_, who_WP were_VBD treated_VBN with_IN FASLODEX_NNP in_IN the_DT European_JJ and_CC North_JJ American_JJ trials_NNS ,_, respectively_RB ._. Furosemide_NN may_MD increase_VB the_DT ototoxic_JJ potential_NN of_IN aminoglycoside_NN antibiotics_NNS ,_, especially_RB in_IN the_DT presence_NN of_IN impaired_JJ renal_JJ function_NN ._. Except_IN in_IN life-threatening_JJ situations_NNS ,_, avoid_VB this_DT combination_NN ._. Furosemide_NN should_MD not_RB be_VB used_VBN concomitantly_RB with_IN ethacrynic_JJ acid_NN because_IN of_IN the_DT possibility_NN of_IN ototoxicity_NN ._. Patients_NNS receiving_VBG high_JJ doses_NNS of_IN salicylates_NNS concomitantly_RB with_IN furosemide_NN ,_, as_IN in_IN rheumatic_JJ disease_NN ,_, may_MD experience_VB salicylate_NN toxicity_NN at_IN lower_JJR doses_NNS because_IN of_IN competitive_JJ renal_JJ excretory_NN sites_NNS ._. Furosemide_NNP has_VBZ a_DT tendency_NN to_TO antagonize_VB the_DT skeletal_JJ muscle_NN relaxing_NN effect_NN of_IN tubocurarine_NN and_CC may_MD potentiate_VB the_DT action_NN of_IN succinylcholine_NN ._. Lithium_NN generally_RB should_MD not_RB be_VB given_VBN with_IN diuretics_NNS because_IN they_PRP reduce_VBP lithiums_NNS renal_JJ clearance_NN and_CC add_VB a_DT high_JJ risk_NN of_IN lithium_NN toxicity_NN ._. Furosemide_NN may_MD add_VB to_TO or_CC potentiate_VB the_DT therapeutic_JJ effect_NN of_IN other_JJ antihypertensive_JJ drugs_NNS ._. Potentiation_NN occurs_VBZ with_IN ganglionic_JJ or_CC peripheral_JJ adrenergic_JJ blocking_NN drugs_NNS ._. Furosemide_NN may_MD decrease_VB arterial_JJ responsiveness_NN to_TO norepinephrine_NN ._. However_RB ,_, norepinephrine_NN may_MD still_RB be_VB used_VBN effectively_RB ._. Tablets_NNS Simultaneous_JJ administration_NN of_IN sucralfate_NN and_CC furosemide_NN tablets_NNS may_MD reduce_VB the_DT natriuretic_JJ and_CC antihypertensive_JJ effects_NNS of_IN furosemide_NN ._. Patients_NNS receiving_VBG both_CC drugs_NNS should_MD be_VB observed_VBN closely_RB to_TO determine_VB if_IN the_DT desired_VBN diuretic_JJ and/or_CC antihypertensive_JJ effect_NN of_IN furosemide_NN is_VBZ achieved_VBN ._. The_DT intake_NN of_IN furosemide_NN and_CC sucralfate_NN should_MD be_VB separated_VBN by_IN at_IN least_JJS two_CD hours_NNS ._. Tablets_NNS ,_, Injection_NN ,_, and_CC Oral_NNP Solution_NN One_CD study_NN in_IN six_CD subjects_NNS demonstrated_VBD that_IN the_DT combination_NN of_IN furosemide_NN and_CC acetylsalicylic_JJ acid_NN temporarily_RB reduced_VBD creatinine_NN clearance_NN in_IN patients_NNS with_IN chronic_JJ renal_JJ insufficiency_NN ._. There_EX are_VBP case_NN reports_NNS of_IN patients_NNS who_WP developed_VBD increased_VBN BUN_NN ,_, serum_NN creatinine_NN and_CC serum_NN potassium_NN levels_NNS ,_, and_CC weight_NN gain_NN when_WRB furosemide_NN was_VBD used_VBN in_IN conjunction_NN with_IN NSAIDs_NNS ._. Literature_NN reports_NNS indicate_VBP that_IN coadministration_NN of_IN indomethacin_NN may_MD reduce_VB the_DT natriuretic_JJ and_CC antihypertensive_JJ effects_NNS of_IN furosemide_NN in_IN some_DT patients_NNS by_IN inhibiting_VBG prostaglandin_NN synthesis_NN ._. Indomethacin_NN may_MD also_RB affect_VB plasma_NN renin_NN levels_NNS ,_, aldosterone_NN excretion_NN ,_, and_CC renin_NN profile_NN evaluation_NN ._. Patients_NNS receiving_VBG both_CC indomethacin_NN and_CC furosemide_NN should_MD be_VB observed_VBN closely_RB to_TO determine_VB if_IN the_DT desired_VBN diuretic_JJ and/or_CC antihypertensive_JJ effect_NN of_IN furosemide_NN is_VBZ achieved_VBN ._. In_FW vitro_FW studies_NNS were_VBD conducted_VBN to_TO investigate_VB the_DT potential_NN of_IN gabapentin_NN to_TO inhibit_VB the_DT major_JJ cytochrome_NN P450_NN enzymes_NNS -LRB-_-LRB- CYP1A2_NN ,_, CYP2A6_NN ,_, CYP2C9_NN ,_, CYP2C19_NN ,_, CYP2D6_NN ,_, CYP2E1_NN ,_, and_CC CYP3A4_NN -RRB-_-RRB- that_WDT mediate_VBP drug_NN and_CC xenobiotic_JJ metabolism_NN using_VBG isoform_NN selective_JJ marker_NN substrates_NNS and_CC human_JJ liver_NN microsomal_JJ preparations_NNS ._. Only_RB at_IN the_DT highest_JJS concentration_NN tested_VBN -LRB-_-LRB- 171_CD ._. g/mL_NN ;_: ._. 1_CD mM_NN -RRB-_-RRB- was_VBD a_DT slight_JJ degree_NN of_IN inhibition_NN -LRB-_-LRB- 14_CD %_NN -30_CD %_NN -RRB-_-RRB- of_IN isoform_NN CYP2A6_NN observed_VBN ._. No_DT inhibition_NN of_IN any_DT of_IN the_DT other_JJ isoforms_NNS tested_VBN was_VBD observed_VBN at_IN gabapentin_NN concentrations_NNS up_IN to_TO 171_CD mg/mL_NN -LRB-_-LRB- approximately_RB 15_CD times_NNS the_DT Cmax_NN at_IN 3600_CD mg/day_NN -RRB-_-RRB- ._. Gabapentin_NNP is_VBZ not_RB appreciably_RB metabolized_VBN nor_CC does_VBZ it_PRP interfere_VB with_IN the_DT metabolism_NN of_IN commonly_RB coadministered_VBN antiepileptic_JJ drugs_NNS ._. The_DT drug_NN interaction_NN data_NNS described_VBN in_IN this_DT section_NN were_VBD obtained_VBN from_IN studies_NNS involving_VBG healthy_JJ adults_NNS and_CC adult_JJ patients_NNS with_IN epilepsy_NN ._. Phenytoin_NNP :_: In_IN a_DT single_JJ -LRB-_-LRB- 400_CD mg_NN -RRB-_-RRB- and_CC multiple_JJ dose_NN -LRB-_-LRB- 400_CD mg_NN TID_NN -RRB-_-RRB- study_NN of_IN Neurontin_NNP in_IN epileptic_JJ patients_NNS -LRB-_-LRB- N_NN =_JJ 8_CD -RRB-_-RRB- maintained_VBN on_IN phenytoin_NN monotherapy_NN for_IN at_IN least_JJS 2_CD months_NNS ,_, gabapentin_NN had_VBD no_DT effect_NN on_IN the_DT steady-state_JJ trough_NN plasma_NN concentrations_NNS of_IN phenytoin_NN and_CC phenytoin_NN had_VBD no_DT effect_NN on_IN gabapentin_NN pharmacokinetics_NNS ._. Carbamazepine_NNP :_: Steady-state_JJ trough_NN plasma_NN carbamazepine_NN and_CC carbamazepine_NN 10_CD ,_, 11_CD epoxide_NN concentrations_NNS were_VBD not_RB affected_VBN by_IN concomitant_JJ gabapentin_NN -LRB-_-LRB- 400_CD mg_NN TID_NN ._. N_NN =_JJ 12_CD -RRB-_-RRB- administration_NN ._. Likewise_RB ,_, gabapentin_NN pharmacokinetics_NNS were_VBD unaltered_JJ by_IN carbamazepine_NN administration_NN ._. Valproic_JJ Acid_NN :_: The_DT mean_NN steady-state_JJ trough_NN serum_NN valproic_JJ acid_NN concentrations_NNS prior_RB to_TO and_CC during_IN concomitant_JJ gabapentin_NN administration_NN -LRB-_-LRB- 400_CD mg_NN TID_NN ._. N_NN =_JJ 17_CD -RRB-_-RRB- were_VBD not_RB different_JJ and_CC neither_CC were_VBD gabapentin_NN pharmacokinetic_JJ parameters_NNS affected_VBN by_IN valproic_JJ acid_NN ._. Phenobarbital_NNP :_: Estimates_NNS of_IN steady-state_JJ pharmacokinetic_JJ parameters_NNS for_IN phenobarbital_NN or_CC gabapentin_NN -LRB-_-LRB- 300_CD mg_NN TID_NN ._. N_NN =_JJ 12_CD -RRB-_-RRB- are_VBP identical_JJ whether_IN the_DT drugs_NNS are_VBP administered_VBN alone_RB or_CC together_RB ._. Naproxen_NN :_: Coadministration_NN -LRB-_-LRB- N_NN =_JJ 18_CD -RRB-_-RRB- of_IN naproxen_NN sodium_NN capsules_NNS -LRB-_-LRB- 250_CD mg_NN -RRB-_-RRB- with_IN Neurontin_NN -LRB-_-LRB- 125_CD mg_NN -RRB-_-RRB- appears_VBZ to_TO increase_VB the_DT amount_NN of_IN gabapentin_NN absorbed_VBN by_IN 12_CD %_NN to_TO 15_CD %_NN ._. Gabapentin_NNP had_VBD no_DT effect_NN on_IN naproxen_NN pharmacokinetic_JJ parameters_NNS ._. These_DT doses_NNS are_VBP lower_JJR than_IN the_DT therapeutic_JJ doses_NNS for_IN both_DT drugs_NNS ._. The_DT magnitude_NN of_IN interaction_NN within_IN the_DT recommended_VBN dose_NN ranges_NNS of_IN either_CC drug_NN is_VBZ not_RB known_VBN ._. Hydrocodone_NNP :_: Coadministration_NNP of_IN Neurontin_NNP -LRB-_-LRB- 125_CD to_TO 500_CD mg_NN ._. N_NN =_JJ 48_CD -RRB-_-RRB- decreases_VBZ hydrocodone_NN -LRB-_-LRB- 10_CD mg_NN ._. N_NN =_JJ 50_CD -RRB-_-RRB- Cmax_NN and_CC AUC_NN values_NNS in_IN a_DT dose-dependent_JJ manner_NN relative_JJ to_TO administration_NN of_IN hydrocodone_NN alone_RB ._. Cmax_NN and_CC AUC_NN values_NNS are_VBP 3_CD %_NN to_TO 4_CD %_NN lower_JJR ,_, respectively_RB ,_, after_IN administration_NN of_IN 125_CD mg_NN Neurontin_NN and_CC 21_CD %_NN to_TO 22_CD %_NN lower_JJR ,_, respectively_RB ,_, after_IN administration_NN of_IN 500_CD mg_NN Neurontin_NN ._. The_DT mechanism_NN for_IN this_DT interaction_NN is_VBZ unknown_JJ ._. Hydrocodone_NN increases_VBZ gabapentin_NN AUC_NN values_NNS by_IN 14_CD %_NN ._. The_DT magnitude_NN of_IN interaction_NN at_IN other_JJ doses_NNS is_VBZ not_RB known_VBN ._. Morphine_NNP :_: A_NNP literature_NN article_NN reported_VBD that_IN when_WRB a_DT 60-mg_JJ controlled-release_NN morphine_NN capsule_NN was_VBD administered_VBN 2_CD hours_NNS prior_RB to_TO a_DT 600-mg_JJ Neurontin_NNP capsule_NN -LRB-_-LRB- N_NN =_JJ 12_CD -RRB-_-RRB- ,_, mean_VB gabapentin_NN AUC_NN increased_VBN by_IN 44_CD %_NN compared_VBN to_TO gabapentin_NN administered_VBN without_IN morphine_NN ._. Morphine_NNP pharmacokinetic_JJ parameter_NN values_NNS were_VBD not_RB affected_VBN by_IN administration_NN of_IN Neurontin_NNP 2_CD hours_NNS after_IN morphine_NN ._. The_DT magnitude_NN of_IN interaction_NN at_IN other_JJ doses_NNS is_VBZ not_RB known_VBN ._. Cimetidine_NNP :_: In_IN the_DT presence_NN of_IN cimetidine_NN at_IN 300_CD mg_NN QID_NN -LRB-_-LRB- N_NN =_JJ 12_CD -RRB-_-RRB- the_DT mean_NN apparent_JJ oral_JJ clearance_NN of_IN gabapentin_NN fell_VBD by_IN 14_CD %_NN and_CC creatinine_NN clearance_NN fell_VBD by_IN 10_CD %_NN ._. Thus_RB cimetidine_NN appeared_VBD to_TO alter_VB the_DT renal_JJ excretion_NN of_IN both_CC gabapentin_NN and_CC creatinine_NN ,_, an_DT endogenous_JJ marker_NN of_IN renal_JJ function_NN ._. This_DT small_JJ decrease_NN in_IN excretion_NN of_IN gabapentin_NN by_IN cimetidine_NN is_VBZ not_RB expected_VBN to_TO be_VB of_IN clinical_JJ importance_NN ._. The_DT effect_NN of_IN gabapentin_NN on_IN cimetidine_NN was_VBD not_RB evaluated_VBN ._. Oral_JJ Contraceptive_NNP :_: Based_VBN on_IN AUC_NN and_CC half-life_NN ,_, multiple-dose_JJ pharmacokinetic_JJ profiles_NNS of_IN norethindrone_NN and_CC ethinyl_NN estradiol_NN following_VBG administration_NN of_IN tablets_NNS containing_VBG 2.5_CD mg_NN of_IN norethindrone_NN acetate_NN and_CC 50_CD mcg_NN of_IN ethinyl_NN estradiol_NN were_VBD similar_JJ with_IN and_CC without_IN coadministration_NN of_IN gabapentin_NN -LRB-_-LRB- 400_CD mg_NN TID_NN ._. N_NN =_JJ 13_CD -RRB-_-RRB- ._. The_DT Cmax_NN of_IN norethindrone_NN was_VBD 13_CD %_NN higher_JJR when_WRB it_PRP was_VBD coadministered_VBN with_IN gabapentin_NN ._. this_DT interaction_NN is_VBZ not_RB expected_VBN to_TO be_VB of_IN clinical_JJ importance_NN ._. Antacid_NN -LRB-_-LRB- Maalox_NNP -RRB-_-RRB- :_: Maalox_NNP reduced_VBD the_DT bioavailability_NN of_IN gabapentin_NN -LRB-_-LRB- N_NN =_JJ 16_CD -RRB-_-RRB- by_IN about_RB 20_CD %_NN ._. This_DT decrease_NN in_IN bioavailability_NN was_VBD about_IN 5_CD %_NN when_WRB gabapentin_NN was_VBD administered_VBN 2_CD hours_NNS after_IN Maalox_NNP ._. It_PRP is_VBZ recommended_VBN that_IN gabapentin_NN be_VB taken_VBN at_IN least_JJS 2_CD hours_NNS following_VBG Maalox_NNP administration_NN ._. Effect_NN of_IN Probenecid_NNP :_: Probenecid_NNP is_VBZ a_DT blocker_NN of_IN renal_JJ tubular_JJ secretion_NN ._. Gabapentin_NNP pharmacokinetic_JJ parameters_NNS without_IN and_CC with_IN probenecid_NN were_VBD comparable_JJ ._. This_DT indicates_VBZ that_IN gabapentin_NN does_VBZ not_RB undergo_VB renal_JJ tubular_JJ secretion_NN by_IN the_DT pathway_NN that_WDT is_VBZ blocked_VBN by_IN probenecid_NN ._. Drug/Laboratory_NNP Tests_NNP Interactions_NNS Because_IN false_JJ positive_JJ readings_NNS were_VBD reported_VBN with_IN the_DT Ames_NNP N-Multistix_NNP SG_NNP dipstick_NN test_NN for_IN urinary_JJ protein_NN when_WRB gabapentin_NN was_VBD added_VBN to_TO other_JJ antiepileptic_JJ drugs_NNS ,_, the_DT more_RBR specific_JJ sulfosalicylic_JJ acid_NN precipitation_NN procedure_NN is_VBZ recommended_VBN to_TO determine_VB the_DT presence_NN of_IN urine_NN protei_NN ._. LABORATORY_NN TEST_NN FINDINGS_VBZ Asymptomatic_JJ ,_, transitory_JJ changes_NNS in_IN serum_NN iron_NN have_VBP been_VBN observed_VBN ._. The_DT clinical_JJ significance_NN is_VBZ unknown_JJ ._. Omniscan_NN interferes_VBZ with_IN serum_NN calcium_NN measurements_NNS with_IN some_DT colorimetric_JJ -LRB-_-LRB- complexometric_JJ -RRB-_-RRB- methods_NNS commonly_RB used_VBN in_IN hospitals_NNS ,_, resulting_VBG in_IN serum_NN calcium_NN concentrations_NNS lower_JJR than_IN the_DT true_JJ values_NNS ._. Thus_RB ,_, it_PRP is_VBZ recommended_VBN not_RB to_TO use_VB such_JJ methods_NNS for_IN 12-24_CD hours_NNS after_IN administration_NN of_IN Omniscan_NNP ._. If_IN such_JJ measurements_NNS are_VBP necessary_JJ ,_, the_DT use_NN of_IN other_JJ methods_NNS is_VBZ recommended_VBN ._. All_DT patients_NNS in_IN whom_WP this_DT effect_NN was_VBD observed_VBN remained_VBD asymptomatic_JJ ._. No_DT formal_JJ drug_NN interaction_NN studies_NNS have_VBP been_VBN conducted_VBN ._. No_DT drug_NN interactions_NNS have_VBP been_VBN observed_VBN with_IN the_DT Vitrasert_NN Implant_NN ._. There_EX is_VBZ limited_JJ experience_NN with_IN use_NN of_IN retinal_JJ tamponades_NNS in_IN conjunction_NN with_IN the_DT Vitrasert_NN Implant_NN ._. Substances_NNS that_WDT are_VBP inducers_NNS of_IN CYP3A4_NN activity_NN increase_VBP the_DT metabolism_NN of_IN gefitinib_NN and_CC decrease_VB its_PRP$ plasma_NN concentrations_NNS ._. In_IN patients_NNS receiving_VBG a_DT potent_JJ CYP3A4_NN inducer_NN such_JJ as_IN rifampicin_NN or_CC phenytoin_NN ,_, a_DT dose_NN increase_NN to_TO 500_CD mg_NN daily_RB should_MD be_VB considered_VBN in_IN the_DT absence_NN of_IN severe_JJ adverse_JJ drug_NN reaction_NN ,_, and_CC clinical_JJ response_NN and_CC adverse_JJ events_NNS should_MD be_VB carefully_RB monitored_VBN -LRB-_-LRB- see_VB CLINICAL_NNP PHARMACOLOGY-Pharmacokinetics-Drug-Drug_NNP Interactions_NNS and_CC DOSAGE_NN AND_CC ADMINISTRATION-Dosage_NN Adjustment_NNP sections_NNS -RRB-_-RRB- ._. International_NNP Normalized_NNP Ratio_NNP -LRB-_-LRB- INR_NNP -RRB-_-RRB- elevations_NNS and/or_CC bleeding_VBG events_NNS have_VBP been_VBN reported_VBN in_IN some_DT patients_NNS taking_VBG warfarin_NN while_IN on_IN IRESSA_NN therapy_NN ._. Patients_NNS taking_VBG warfarin_NN should_MD be_VB monitored_VBN regularly_RB for_IN changes_NNS in_IN prothrombin_NN time_NN or_CC INR_NN ._. Substances_NNS that_WDT are_VBP potent_JJ inhibitors_NNS of_IN CYP3A4_NN activity_NN -LRB-_-LRB- eg_FW ,_, ketoconazole_NN and_CC itraconazole_NN -RRB-_-RRB- decrease_NN gefitinib_NN metabolism_NN and_CC increase_NN gefitinib_NN plasma_NN concentrations_NNS ._. This_DT increase_NN may_MD be_VB clinically_RB relevant_JJ as_IN adverse_JJ experiences_NNS are_VBP related_JJ to_TO dose_NN and_CC exposure_NN ;_: ._. therefore_RB ,_, caution_NN should_MD be_VB used_VBN when_WRB administering_VBG CYP3A4_NN inhibitors_NNS with_IN IRESSA_NN ._. Drugs_NNS that_WDT cause_VBP significant_JJ sustained_JJ elevation_NN in_IN gastric_JJ pH_NN -LRB-_-LRB- histamine_NN H2-receptor_NN antagonists_NNS such_JJ as_IN ranitidine_NN or_CC cimetidine_NN -RRB-_-RRB- may_MD reduce_VB plasma_NN concentrations_NNS of_IN IRESSA_NNP and_CC therefore_RB potentially_RB may_MD reduce_VB efficacy_NN ._. Phase_NN II_CD clinical_JJ trial_NN data_NNS ,_, where_WRB IRESSA_NNP and_CC vinorelbine_NN have_VBP been_VBN used_VBN concomitantly_RB ,_, indicate_VBP that_IN IRESSA_NNP may_MD exacerbate_VB the_DT neutropenic_JJ effect_NN of_IN vinorelbine_NN ._. No_DT specific_JJ drug_NN interaction_NN studies_NNS have_VBP been_VBN conducted_VBN ._. For_IN information_NN on_IN the_DT pharmacokinetics_NNS of_IN Gemzar_NNP and_CC cisplatin_NN in_IN combination_NN ,_, see_VBP Drug_NN Interactions_NNS under_IN CLINICAL_NNP PHARMACOLOGY_NNP section_NN ._. -RRB-_-RRB- ._. Clinical_JJ Laboratory_NN ._. increased_VBN creatine_NN ._. positive_JJ antinuclear_JJ ._. phosphokinase_NN ._. antibody_NN ._. increased_VBN bilirubin_NN ._. increased_VBN liver_NN ._. transaminases_NNS -LRB-_-LRB- AST_NNP ._. -LRB-_-LRB- SGOT_NN -RRB-_-RRB- ,_, ALT_NN -LRB-_-LRB- SGPT_NN -RRB-_-RRB- ._. increased_VBN alkaline_NN ._. phophatase_NN ._. Hematopoietic_JJ ._. anemia_NN ._. thrombocytopenia_NN ._. leukopenia_NN ._. bone_NN marrow_NN hypoplasia_NN ._. eosinophilia_NN ._. Immunologic_JJ ._. angioedema_NN ._. anaphylaxis_NN ._. laryngeal_JJ edema_NN ._. Lupus-like_JJ syndrome_NN ._. urticaria_NN ._. vasculitis_NN ._. Integumentary_NNP ._. exfoliative_JJ dermatitis_NN ._. alopecia_NN ._. rash_NN ._. dermatitis_NN ._. pruritus_NN ._. Administration_NN of_IN repeat_NN doses_NNS of_IN FACTIVE_NNP had_VBD no_DT effect_NN on_IN the_DT repeat_NN dose_NN pharmacokinetics_NNS of_IN theophylline_NN ,_, digoxin_NN or_CC an_DT ethinylestradiol/levonorgestrol_NN oral_JJ contraceptive_JJ product_NN in_IN healthy_JJ subjects_NNS ._. Concomitant_JJ administration_NN of_IN FACTIVE_NN and_CC calcium_NN carbonate_NN ,_, cimetidine_NN ,_, omeprazole_NN ,_, or_CC an_DT estrogen/progesterone_JJ oral_JJ contraceptive_NN produced_VBD minor_JJ changes_NNS in_IN the_DT pharmacokinetics_NNS of_IN gemifloxacin_NN ,_, which_WDT were_VBD considered_VBN to_TO be_VB without_IN clinical_JJ significance_NN ._. Concomitant_JJ administration_NN of_IN FACTIVE_NN with_IN probenecid_NN resulted_VBD in_IN a_DT 45_CD %_NN increase_NN in_IN systemic_JJ exposure_NN to_TO gemifloxacin_NN ._. FACTIVE_NNP had_VBD no_DT significant_JJ effect_NN on_IN the_DT anticoagulant_JJ effect_NN of_IN warfarin_NN in_IN healthy_JJ subjects_NNS on_IN stable_JJ warfarin_NN therapy_NN ._. However_RB ,_, because_IN some_DT quinolones_NNS have_VBP been_VBN reported_VBN to_TO enhance_VB the_DT anticoagulant_JJ effects_NNS of_IN warfarin_NN or_CC its_PRP$ derivatives_NNS in_IN patients_NNS ,_, the_DT prothrombin_NN time_NN or_CC other_JJ suitable_JJ coagulation_NN test_NN should_MD be_VB closely_RB monitored_VBN if_IN a_DT quinolone_JJ antimicrobial_JJ is_VBZ administered_VBN concomitantly_RB with_IN warfarin_NN or_CC its_PRP$ derivatives_NNS ._. Quinolones_NNS form_VBP chelates_NNS with_IN alkaline_NN earth_NN and_CC transition_NN metals_NNS ._. The_DT absorption_NN of_IN oral_JJ gemifloxacin_NN is_VBZ significantly_RB reduced_VBN by_IN the_DT concomitant_JJ administration_NN of_IN an_DT antacid_NN containing_VBG aluminum_NN and_CC magnesium_NN ._. Magnesium_NN -_: and/or_CC aluminum-containing_JJ antacids_NNS ,_, products_NNS containing_VBG ferrous_JJ sulfate_NN -LRB-_-LRB- iron_NN -RRB-_-RRB- ,_, multivitamin_JJ preparations_NNS containing_VBG zinc_NN or_CC other_JJ metal_NN cations_NNS ,_, or_CC Videx_NNP -LRB-_-LRB- didanosine_NN -RRB-_-RRB- chewable/buffered_VBD tablets_NNS or_CC the_DT pediatric_JJ powder_NN for_IN oral_JJ solution_NN should_MD not_RB be_VB taken_VBN within_IN 3_CD hours_NNS before_IN or_CC 2_CD hours_NNS after_IN FACTIVE_NNP ._. Sucralfate_NNP should_MD not_RB be_VB taken_VBN within_IN 2_CD hours_NNS of_IN FACTIVE_NN ._. There_EX have_VBP been_VBN no_DT formal_JJ drug-interaction_NN studies_NNS performed_VBN with_IN Mylotarg_NN ._. The_DT potential_NN for_IN drug-drug_JJ interaction_NN with_IN drugs_NNS affected_VBN by_IN cytochrome_NN P450_NN enzymes_NNS may_MD not_RB be_VB ruled_VBN out_RP ._. Laboratory_NNP Test_NNP Interactions_NNS ._. Mylotarg_NNP is_VBZ not_RB known_VBN to_TO interfere_VB with_IN any_DT routine_JJ diagnostic_JJ tests_NNS ._. Interactions_NNS between_IN COPAXONE_NNP and_CC other_JJ drugs_NNS have_VBP not_RB been_VBN fully_RB evaluated_VBN ._. Results_NNS from_IN existing_VBG clinical_JJ trials_NNS suggest_VBP no_DT significant_JJ interactions_NNS between_IN COPAXONE_NNP and_CC other_JJ therapies_NNS commonly_RB used_VBN in_IN MS_NN patients_NNS ,_, including_VBG the_DT concurrent_JJ use_NN of_IN corticosteroids_NNS for_IN up_RB to_TO 28_CD days_NNS ._. COPAXONE_NNP has_VBZ not_RB been_VBN formally_RB evaluated_VBN in_IN combination_NN with_IN Interferon_NN beta_NN ._. However_RB ,_, 10_CD patients_NNS who_WP switched_VBD from_IN therapy_NN with_IN Interferon_NN beta_NN to_TO COPAXONE_NNP did_VBD not_RB report_VB any_DT serious_JJ and_CC unexpected_JJ adverse_JJ reactions_NNS thought_VBD to_TO be_VB related_VBN to_TO treatment_NN ._. The_DT hypoglycemic_JJ action_NN of_IN sulfonylureas_NNS may_MD be_VB potentiated_VBN by_IN certain_JJ drugs_NNS including_VBG nonsteroidal_JJ anti-inflammatory_JJ agents_NNS and_CC other_JJ drugs_NNS that_WDT are_VBP highly_RB protein_NN bound_VBD ,_, salicylates_NNS ,_, sulfonamides_NNS ,_, chloramphenicol_NN ,_, probenecid_NN ,_, coumarins_NNS ,_, monoamine_NN oxidase_NN inhibitors_NNS ,_, and_CC beta_NN adrenergic_JJ blocking_VBG agents_NNS ._. When_WRB such_JJ drugs_NNS are_VBP administered_VBN to_TO a_DT patient_NN receiving_VBG MICRONASE_NNP ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB for_IN hypoglycemia_NN ._. When_WRB such_JJ drugs_NNS are_VBP withdrawn_VBN from_IN a_DT patient_NN receiving_VBG MICRONASE_NNP ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB for_IN loss_NN of_IN control_NN ._. Certain_JJ drugs_NNS tend_VBP to_TO produce_VB hyperglycemia_NN and_CC may_MD lead_VB to_TO loss_NN of_IN control_NN ._. These_DT drugs_NNS include_VBP the_DT thiazides_NNS and_CC other_JJ diuretics_NNS ,_, corticosteroids_NNS ,_, phe-nothiazines_NNS ,_, thyroid_NN products_NNS ,_, estrogens_NNS ,_, oral_JJ contraceptives_NNS ,_, phenytoin_NN ,_, nicotinic_JJ acid_NN ,_, sympathomimet-ics_NNS ,_, calcium_NN channel_NN blocking_VBG drugs_NNS ,_, and_CC isoniazid_NN ._. When_WRB such_JJ drugs_NNS are_VBP administered_VBN to_TO a_DT patient_NN receiving_VBG MICRONASE_NNP ,_, the_DT patient_NN should_MD be_VB closely_RB observed_VBN for_IN loss_NN of_IN control_NN ._. When_WRB such_JJ drugs_NNS are_VBP withdrawn_VBN from_IN a_DT patient_NN receiving_VBG MICRONASE_NNP ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB for_IN hypoglycemia_NN ._. A_DT possible_JJ interaction_NN between_IN glyburide_NN and_CC ciprofloxacin_NN ,_, a_DT fluoroquinolone_JJ antibiotic_JJ ,_, has_VBZ been_VBN reported_VBN ,_, resulting_VBG in_IN a_DT potentiation_NN of_IN the_DT hypoglycemic_JJ action_NN of_IN glyburide_NN ._. The_DT mechanism_NN for_IN this_DT interaction_NN is_VBZ not_RB known_VBN ._. A_DT potential_JJ interaction_NN between_IN oral_JJ miconazole_NN and_CC oral_JJ hypoglycemic_JJ agents_NNS leading_VBG to_TO severe_JJ hypoglycemia_NN has_VBZ been_VBN reported_VBN ._. Whether_IN this_DT interaction_NN also_RB occurs_VBZ with_IN the_DT intravenous_JJ ,_, topical_JJ or_CC vaginal_JJ preparations_NNS of_IN miconazole_NN is_VBZ not_RB known_VBN ._. Metformin_NNP :_: In_IN a_DT single-dose_JJ interaction_NN study_NN in_IN NIDDM_NNP subjects_NNS ,_, decreases_VBZ in_IN glyburide_NN AUC_NN and_CC Cmax_NN were_VBD observed_VBN ,_, but_CC were_VBD highly_RB variable_JJ ._. The_DT single-dose_JJ nature_NN of_IN this_DT study_NN and_CC the_DT lack_NN of_IN correlation_NN between_IN glyburide_NN blood_NN levels_NNS and_CC pharmaco-dynamic_JJ effects_NNS ,_, makes_VBZ the_DT clinical_JJ significance_NN of_IN this_DT interaction_NN uncertain_JJ ._. Coadministration_NN of_IN gly-buride_NN and_CC metformin_NN did_VBD not_RB result_VB in_IN any_DT changes_NNS in_IN either_CC metformin_NN pharmacokinetics_NNS or_CC pharmaco-dynamics_NNS ._. Many_JJ other_JJ medicines_NNS may_MD increase_VB or_CC decrease_VB the_DT effects_NNS of_IN glimepiride_NN or_CC affect_VB your_PRP$ condition_NN ._. Before_IN taking_VBG glimepiride_NN ,_, tell_VB your_PRP$ doctor_NN if_IN you_PRP are_VBP taking_VBG any_DT of_IN the_DT following_VBG medicines_NNS :_: -_: aspirin_NN or_CC another_DT salicylate_NN such_JJ as_IN magnesium/choline_NN salicylate_NN -LRB-_-LRB- Trilisate_NN -RRB-_-RRB- ,_, salsalate_NN -LRB-_-LRB- Disalcid_NNP ,_, others_NNS -RRB-_-RRB- ,_, choline_NN salicylate_NN -LRB-_-LRB- Arthropan_NN -RRB-_-RRB- ,_, magnesium_NN salicylate_NN -LRB-_-LRB- Magan_NN -RRB-_-RRB- ,_, or_CC bismuth_NN subsalicylate_NN -LRB-_-LRB- Pepto-Bismol_NN -RRB-_-RRB- ._. -_: a_DT nonsteroidal_JJ anti-inflammatory_JJ drug_NN -LRB-_-LRB- NSAID_NN -RRB-_-RRB- such_JJ as_IN ibuprofen_NN -LRB-_-LRB- Motrin_NN ,_, Advil_NNP ,_, Nuprin_NNP ,_, others_NNS -RRB-_-RRB- ,_, ketoprofen_NN -LRB-_-LRB- Orudis_NNP ,_, Orudis_NNP KT_NNP ,_, Oruvail_NNP -RRB-_-RRB- ,_, diclofenac_NN -LRB-_-LRB- Voltaren_NN ,_, Cataflam_NN -RRB-_-RRB- ,_, etodolac_NN -LRB-_-LRB- Lodine_NN -RRB-_-RRB- ,_, indomethacin_NN -LRB-_-LRB- Indocin_NN -RRB-_-RRB- ,_, nabumetone_NN -LRB-_-LRB- Relafen_NN -RRB-_-RRB- ,_, oxaprozin_NN -LRB-_-LRB- Daypro_NN -RRB-_-RRB- ,_, and_CC naproxen_NN -LRB-_-LRB- Anaprox_NNP ,_, Naprosyn_NNP ,_, Aleve_NNP -RRB-_-RRB- ._. -_: a_DT sulfa-based_JJ drug_NN such_JJ as_IN sulfamethoxazole-trimethoprim_NN -LRB-_-LRB- Bactrim_NN ,_, Septra_NNP -RRB-_-RRB- ,_, sulfisoxazole_NN -LRB-_-LRB- Gantrisin_NN -RRB-_-RRB- ,_, or_CC sulfasalazine_NN -LRB-_-LRB- Azulfidine_NN -RRB-_-RRB- ._. -_: a_DT monoamine_NN oxidase_NN inhibitor_NN -LRB-_-LRB- MAOI_NN -RRB-_-RRB- such_JJ as_IN isocarboxazid_NN -LRB-_-LRB- Marplan_NN -RRB-_-RRB- ,_, tranylcypromine_NN -LRB-_-LRB- Parnate_NN -RRB-_-RRB- ,_, or_CC phenelzine_NN -LRB-_-LRB- Nardil_NN -RRB-_-RRB- ._. -_: a_DT beta-blocker_NN such_JJ as_IN propranolol_NN -LRB-_-LRB- Inderal_NN -RRB-_-RRB- ,_, atenolol_NN -LRB-_-LRB- Tenormin_NN -RRB-_-RRB- ,_, acebutolol_NN -LRB-_-LRB- Sectral_JJ -RRB-_-RRB- ,_, metoprolol_NN -LRB-_-LRB- Lopressor_NN -RRB-_-RRB- ,_, and_CC others_NNS ._. -_: a_DT diuretic_JJ -LRB-_-LRB- water_NN pill_NN -RRB-_-RRB- such_JJ as_IN hydrochlorothiazide_NN -LRB-_-LRB- HCTZ_NN ,_, Hydrodiuril_NN -RRB-_-RRB- ,_, chlorothiazide_NN -LRB-_-LRB- Diuril_NN -RRB-_-RRB- ,_, and_CC others_NNS ._. -_: a_DT steroid_NN medicine_NN such_JJ as_IN prednisone_NN -LRB-_-LRB- Deltasone_NNP ,_, Orasone_NNP ,_, others_NNS -RRB-_-RRB- ,_, methylprednisolone_NN -LRB-_-LRB- Medrol_NNP ,_, others_NNS -RRB-_-RRB- ,_, prednisolone_NN -LRB-_-LRB- Prelone_NNP ,_, Pediapred_NNP ,_, others_NNS -RRB-_-RRB- ,_, and_CC others_NNS ._. -_: a_DT phenothiazine_NN such_JJ as_IN chlorpromazine_NN -LRB-_-LRB- Thorazine_NN -RRB-_-RRB- ,_, fluphenazine_NN -LRB-_-LRB- Prolixin_NN ,_, Permitil_NN -RRB-_-RRB- ,_, prochlorperazine_NN -LRB-_-LRB- Compazine_NN -RRB-_-RRB- ,_, promethazine_NN -LRB-_-LRB- Phenergan_NN -RRB-_-RRB- ,_, and_CC others_NNS ._. -_: phenytoin_NN -LRB-_-LRB- Dilantin_NN -RRB-_-RRB- ._. -_: isoniazid_NN -LRB-_-LRB- Nydrazid_NN -RRB-_-RRB- ._. -_: rifampin_NN -LRB-_-LRB- Rifadin_NNP ,_, Rifamate_NNP -RRB-_-RRB- ._. or_CC -_: over-the-counter_JJ cough_NN ,_, cold_JJ ,_, allergy_NN ,_, or_CC weight_NN loss_NN medications_NNS ._. You_PRP may_MD require_VB a_DT dosage_NN adjustment_NN or_CC special_JJ monitoring_NN if_IN you_PRP are_VBP taking_VBG any_DT of_IN the_DT medicines_NNS listed_VBN above_RB ._. Drugs_NNS other_JJ than_IN those_DT listed_VBN here_RB may_MD also_RB interact_VB with_IN glimepiride_NN or_CC affect_VB your_PRP$ condition_NN ._. Talk_NN to_TO your_PRP$ doctor_NN and_CC pharmacist_NN before_IN taking_VBG any_DT prescription_NN or_CC over-the-counter_JJ medicines_NNS ,_, including_VBG herbal_JJ products_NNS ._. Immediate_NNP and_CC Extended_NNP Release_NNP Tablets_NNPS The_DT hypoglycemic_JJ action_NN of_IN sulfonylureas_NNS may_MD be_VB potentiated_VBN by_IN certain_JJ drugs_NNS including_VBG nonsteroidal_JJ anti-inflammatory_JJ agents_NNS ,_, some_DT azoles_NNS and_CC other_JJ drugs_NNS that_WDT are_VBP highly_RB protein_NN bound_VBD ,_, salicylates_NNS ,_, sulfonamides_NNS ,_, chloramphenicol_NN ,_, probenecid_NN ,_, coumarins_NNS ,_, monoamine_NN oxidase_NN inhibitors_NNS ,_, and_CC beta_NN adrenergic_JJ blocking_VBG agents_NNS ._. When_WRB such_JJ drugs_NNS are_VBP administered_VBN to_TO a_DT patient_NN receiving_VBG glipizide_NN ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB for_IN hypoglycemia_NN ._. When_WRB such_JJ drugs_NNS are_VBP withdrawn_VBN from_IN a_DT patient_NN receiving_VBG glipizide_NN ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB for_IN loss_NN of_IN control_NN ._. In_FW vitro_FW binding_NN studies_NNS with_IN human_JJ serum_NN proteins_NNS indicate_VBP that_IN glipizide_NN binds_VBZ differently_RB than_IN tolbutamide_NN and_CC does_VBZ not_RB interact_VB with_IN salicylate_NN or_CC dicumarol_NN ._. However_RB ,_, caution_NN must_MD be_VB exercised_VBN in_IN extrapolating_VBG these_DT findings_NNS to_TO the_DT clinical_JJ situation_NN and_CC in_IN the_DT use_NN of_IN glipizide_NN with_IN these_DT drugs_NNS ._. Certain_JJ drugs_NNS tend_VBP to_TO produce_VB hyperglycemia_NN and_CC may_MD lead_VB to_TO loss_NN of_IN control_NN ._. These_DT drugs_NNS include_VBP the_DT thiazides_NNS and_CC other_JJ diuretics_NNS ,_, corticosteroids_NNS ,_, phenothiazines_NNS ,_, thyroid_NN products_NNS ,_, estrogens_NNS ,_, oral_JJ contraceptives_NNS ,_, phenytoin_NN ,_, nicotinic_JJ acid_NN ,_, sympathomimetics_NNS ,_, calcium_NN channel_NN blocking_VBG drugs_NNS ,_, and_CC isoniazid_NN ._. When_WRB such_JJ drugs_NNS are_VBP administered_VBN to_TO a_DT patient_NN receiving_VBG glipizide_NN ,_, the_DT patient_NN should_MD be_VB closely_RB observed_VBN for_IN loss_NN of_IN control_NN ._. When_WRB such_JJ drugs_NNS are_VBP withdrawn_VBN from_IN a_DT patient_NN receiving_VBG glipizide_NN ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB for_IN hypoglycemia_NN ._. A_DT potential_JJ interaction_NN between_IN oral_JJ miconazole_NN and_CC oral_JJ hypoglycemic_JJ agents_NNS leading_VBG to_TO severe_JJ hypoglycemia_NN has_VBZ been_VBN reported_VBN ._. Whether_IN this_DT interaction_NN also_RB occurs_VBZ with_IN the_DT intravenous_JJ ,_, topical_JJ ,_, or_CC vaginal_JJ preparations_NNS of_IN miconazole_NN is_VBZ not_RB known_VBN ._. The_DT effect_NN of_IN concomitant_JJ administration_NN of_IN fluconazole_NN and_CC glipizide_NN has_VBZ been_VBN demonstrated_VBN in_IN a_DT placebo-controlled_JJ crossover_NN study_NN in_IN normal_JJ volunteers_NNS ._. All_DT subjects_NNS received_VBD glipizide_NN alone_RB and_CC following_VBG treatment_NN with_IN 100_CD mg_NN of_IN fluconazole_NN as_IN a_DT single_JJ daily_JJ oral_JJ dose_NN for_IN seven_CD days_NNS ._. The_DT mean_JJ percentage_NN increase_NN in_IN the_DT glipizide_NN AUC_NN after_IN fluconazole_NN administration_NN was_VBD 56.9_CD %_NN -LRB-_-LRB- range_NN :_: 35_CD to_TO 81_CD -RRB-_-RRB- ._. The_DT concurrent_JJ use_NN of_IN Robinul_NNP Injection_NN with_IN other_JJ anticholinergics_NNS or_CC medications_NNS with_IN anticholinergic_JJ activity_NN ,_, such_JJ as_IN phenothiazines_NNS ,_, antiparkinson_JJ drugs_NNS ,_, or_CC tricyclic_JJ antidepressants_NNS ,_, may_MD intensify_VB the_DT antimuscarinic_JJ effects_NNS and_CC may_MD result_VB in_IN an_DT increase_NN in_IN anticholinergic_JJ side_JJ effects_NNS ._. Concomitant_JJ administration_NN of_IN Robinul_NNP Injection_NN and_CC potassium_NN chloride_NN in_IN a_DT wax_NN matrix_NN may_MD increase_VB the_DT severity_NN of_IN potassium_NN chloride-induced_JJ gastrointestinal_JJ lesions_NNS as_IN a_DT result_NN of_IN a_DT slower_JJR gastrointestinal_JJ transit_NN time_NN ._. The_DT Factrel_NNP test_NN should_MD be_VB conducted_VBN in_IN the_DT absence_NN of_IN other_JJ drugs_NNS which_WDT directly_RB affect_VBP the_DT pituitary_JJ secretion_NN of_IN the_DT gonadotropins_NNS ._. These_DT would_MD include_VB a_DT variety_NN of_IN preparations_NNS which_WDT contain_VBP androgens_NNS ,_, estrogens_NNS ,_, progestins_NNS ,_, or_CC glucocorticoids_NNS ._. The_DT gonadotropin_NN levels_NNS may_MD be_VB transiently_RB elevated_JJ by_IN spironolactone_NN ,_, minimally_RB elevated_JJ by_IN levodopa_NN ,_, and_CC suppressed_VBN by_IN oral_JJ contraceptives_NNS and_CC digoxin_NN ._. The_DT response_NN to_TO Factrel_NNP may_MD be_VB blunted_VBN by_IN phenothiazines_NNS and_CC dopamine_NN antagonists_NNS which_WDT cause_VBP a_DT rise_NN in_IN prolactin_NN ._. No_DT formal_JJ drug-drug_JJ interaction_NN studies_NNS have_VBP been_VBN performed_VBN ._. No_DT confirmed_VBD interactions_NNS have_VBP been_VBN reported_VBN between_IN ZOLADEX_NNP and_CC other_JJ drug_NN ._. Antacids_NNS ,_, Sucralfate_NNP ,_, Metal_NNP Cations_NNPS ,_, Multivitamins_NNPS Quinolones_NNPS form_VBP chelates_NNS with_IN alkaline_NN earth_NN and_CC transition_NN metal_NN cations_NNS ._. Administration_NN of_IN quinolones_NNS with_IN antacids_NNS containing_VBG aluminum_NN ,_, magnesium_NN ,_, or_CC calcium_NN ,_, with_IN sucralfate_NN ,_, with_IN metal_NN cations_NNS such_JJ as_IN iron_NN ,_, or_CC with_IN multivitamins_NNS containing_VBG iron_NN or_CC zinc_NN ,_, or_CC with_IN formulations_NNS containing_VBG divalent_JJ and_CC trivalent_JJ cations_NNS such_JJ as_IN VIDEX_NN -LRB-_-LRB- didanosine_NN -RRB-_-RRB- chewable/buffered_VBD tablets_NNS or_CC the_DT pediatric_JJ powder_NN for_IN oral_JJ solution_NN ,_, may_MD substantially_RB interfere_VB with_IN the_DT absorption_NN of_IN quinolones_NNS ,_, resulting_VBG in_IN systemic_JJ concentrations_NNS considerably_RB lower_JJR than_IN desired_VBN ._. These_DT agents_NNS should_MD not_RB be_VB taken_VBN within_IN 4_CD hours_NNS before_IN or_CC 4_CD hours_NNS after_IN grepafloxacin_NN administration_NN ._. Caffeine_NNP Theobromine_NNP Grepafloxacin_NNP ,_, like_IN other_JJ quinolones_NNS ,_, may_MD inhibit_VB the_DT metabolism_NN of_IN caffeine_NN and_CC theobromine_NN ._. These_DT stimulants_NNS are_VBP commonly_RB found_VBN in_IN coffee_NN and_CC tea_NN ,_, respectively_RB ._. In_IN some_DT patients_NNS ,_, this_DT may_MD lead_VB to_TO reduced_VBN clearance_NN ,_, prolongation_NN of_IN plasma_NN half-life_NN ,_, and_CC enhanced_VBD effects_NNS of_IN caffeine_NN and_CC theobromine_NN ._. Theophylline_NNP :_: Grepafloxacin_NNP is_VBZ a_DT competitive_JJ inhibitor_NN of_IN the_DT metabolism_NN of_IN theophylline_NN ._. Serum_NN theophylline_NN concentrations_NNS increase_VBP when_WRB grepafloxacin_NN is_VBZ initiated_VBN in_IN a_DT patient_NN maintained_VBD on_IN theophylline_NN ._. When_WRB initiating_VBG a_DT multi-day_JJ course_NN of_IN grepafloxacin_NN in_IN a_DT patient_NN maintained_VBD on_IN theophylline_NN ,_, the_DT theophylline_NN maintenance_NN dose_NN should_MD be_VB halved_VBN for_IN the_DT period_NN of_IN concurrent_JJ use_NN of_IN grepafloxacin_NN and_CC monitoring_NN of_IN serum_NN theophylline_NN concentrations_NNS should_MD be_VB initiated_VBN as_IN a_DT guide_NN to_TO further_JJ dosage_NN adjustments_NNS ._. Warfarin_NNP :_: In_IN subjects_NNS receiving_VBG warfarin_NN ,_, no_DT significant_JJ change_NN in_IN clotting_VBG time_NN was_VBD observed_VBN when_WRB grepafloxacin_NN was_VBD coadministered_VBN ._. However_RB ,_, because_IN some_DT quinolones_NNS have_VBP been_VBN reported_VBN to_TO enhance_VB the_DT effects_NNS of_IN warfarin_NN or_CC its_PRP$ derivatives_NNS ,_, prothrombin_NN time_NN or_CC other_JJ suitable_JJ anticoagulation_JJ test_NN should_MD be_VB monitored_VBN closely_RB if_IN a_DT quinolone_JJ antimicrobial_JJ is_VBZ administered_VBN with_IN warfarin_NN or_CC its_PRP$ derivatives_NNS ._. Drugs_NNS Metabolized_VBN by_IN Cytochrome_NN P450_NN Enzymes_NNS The_DT drug_NN interaction_NN study_NN evaluating_VBG the_DT effect_NN of_IN grepafloxacin_NN on_IN theophylline_NN indicates_VBZ that_IN grepafloxacin_NN inhibits_VBZ theophylline_NN metabolism_NN ,_, which_WDT is_VBZ mediated_VBN by_IN CYP1A2_NN ._. While_IN no_DT clinical_JJ studies_NNS have_VBP been_VBN conducted_VBN to_TO evaluate_VB the_DT effect_NN of_IN grepafloxacin_NN on_IN the_DT metabolism_NN of_IN C.P.A._NNP substrates_NNS ,_, in_FW vitro_FW data_NNS suggest_VBP similar_JJ effects_NNS of_IN grepafloxacin_NN in_IN CYP3A4_NN mediated_VBD metabolism_NN and_CC theophylline_NN metabolism_NN ._. In_IN addition_NN ,_, other_JJ quinolones_NNS have_VBP been_VBN reported_VBN to_TO decrease_VB the_DT CYP3A4-mediated_JJ metabolism_NN of_IN cyclosporine_NN ._. Other_JJ drugs_NNS metabolized_VBN by_IN C.P.A._NNP include_VBP terfenadine_NN ,_, astemizole_NN ,_, cisapride_NN ,_, midazolam_NN ,_, and_CC triazolam_NN ._. The_DT clinical_JJ relevance_NN of_IN the_DT potential_JJ effect_NN of_IN grepafloxacin_NN on_IN the_DT metabolism_NN of_IN C.P.A._NNP substrates_NNS is_VBZ not_RB known_VBN ._. Patients_NNS receiving_VBG concurrent_JJ administration_NN of_IN substrates_NNS of_IN C.P.A._NNP were_VBD not_RB excluded_VBN from_IN clinical_JJ trials_NNS of_IN grepafloxacin_NN ._. Nonsteroidal_JJ Anti-inflammatory_JJ Drugs_NNS -LRB-_-LRB- NSAIDs_NNS -RRB-_-RRB- :_: The_DT concomitant_JJ administration_NN of_IN a_DT nonsteroidal_JJ anti_JJ inflammatory_JJ drug_NN with_IN a_DT quinolone_NN may_MD increase_VB the_DT risks_NNS of_IN CNS_NN stimulation_NN and_CC convulsions_NNS ._. Antidiabetic_JJ Agents_NNS :_: Disturbances_NNS of_IN blood_NN glucose_NN ,_, including_VBG hyperglycemia_NN and_CC hypoglycemia_NN ,_, have_VBP been_VBN reported_VBN in_IN patients_NNS treated_VBN concomitantly_RB with_IN quinolones_NNS and_CC an_DT antidiabetic_JJ agent_NN ._. Therefore_RB ,_, careful_JJ monitoring_NN of_IN blood_NN glucose_NN is_VBZ recommended_VBN when_WRB these_DT agents_NNS are_VBP coadministered_VBN ._. Patients_NNS on_IN warfarin-type_JJ anticoagulant_JJ therapy_NN may_MD require_VB dosage_NN adjustment_NN of_IN the_DT anticoagulant_JJ during_IN and_CC after_IN griseofulvin_NN therapy_NN ._. Concomitant_JJ use_NN of_IN barbiturates_NNS usually_RB depresses_VBZ griseofulvin_NN activity_NN and_CC may_MD necessitate_VB raising_VBG the_DT dosage_NN ._. The_DT concomitant_JJ administration_NN of_IN griseofulvin_NN has_VBZ been_VBN reported_VBN to_TO reduce_VB the_DT efficacy_NN of_IN oral_JJ contraceptives_NNS and_CC to_TO increase_VB the_DT incidence_NN of_IN breakthrough_NN bleeding_NN ._. The_DT use_NN of_IN codeine_NN may_MD result_VB in_IN additive_JJ CNS_NN depressant_NN effects_NNS when_WRB coadministered_VBN with_IN alcohol_NN ,_, antihistamines_NNS ,_, psychotropics_NNS or_CC other_JJ drugs_NNS that_WDT produce_VBP CNS_NN depression_NN ._. Serious_JJ toxicity_NN may_MD result_VB if_IN dextromethorphan_NN is_VBZ coadministered_VBN with_IN monoamine_NN oxidase_NN inhibitors_NNS -LRB-_-LRB- MAOIs_NNS -RRB-_-RRB- ._. The_DT use_NN of_IN dextromethorphan_NN hydrobromide_NN may_MD result_VB in_IN additive_JJ CNS_NN depressant_NN effects_NNS when_WRB coadministered_VBN with_IN alcohol_NN ,_, antihistamines_NNS ,_, psychotropics_NNS or_CC other_JJ drugs_NNS that_WDT produce_VBP CNS_NN depression_NN ._. http://www.rxlist.com/cgi/generic3/guanethidine_NN ._. The_DT potential_NN for_IN increased_VBN sedation_NN when_WRB guanfacine_NN is_VBZ given_VBN with_IN other_JJ CNS-depressant_JJ drug_NN should_MD be_VB appreciated_VBN ._. The_DT administration_NN of_IN guanfacine_NN concomitantly_RB with_IN known_JJ microsomal_JJ enzyme_NN inducer_NN -LRB-_-LRB- phenobarbital_NN or_CC phenytoin_NN -RRB-_-RRB- to_TO two_CD patients_NNS with_IN renal_JJ impairment_NN reportedly_RB resulted_VBD in_IN significant_JJ reductions_NNS in_IN elimination_NN half-life_NN and_CC plasma_NN concentration_NN ._. In_IN such_JJ cases_NNS ,_, therefore_RB ,_, more_JJR frequent_JJ dosing_NN may_MD be_VB required_VBN to_TO achieve_VB or_CC maintain_VB the_DT desired_VBN hypotensive_NN response_NN ._. Further_RB ,_, if_IN guanfacine_NN is_VBZ to_TO be_VB discontinued_VBN in_IN such_JJ patients_NNS ,_, careful_JJ tapering_VBG of_IN the_DT dosage_NN may_MD be_VB necessary_JJ in_IN order_NN to_TO avoid_VB rebound_NN phenomena_NNS ._. TCAs_NNS decrease_VBP the_DT hypotensive_JJ effect_NN of_IN guanfacine_NN ._. Noncardioselective_JJ beta-blockers_NNS -LRB-_-LRB- nadolol_NN ,_, porpranolol_NN ,_, timolol_NN -RRB-_-RRB- may_MD exacerbate_VB rebound_VB hypertension_NN when_WRB guanfacine_NN is_VBZ withdrawn_VBN ._. The_DT beta-blocker_NN should_MD be_VB withdrawn_VBN first_RB ._. The_DT gradual_JJ withdrawal_NN of_IN guafacine_NN or_CC a_DT cardioselective_JJ beta-blocker_NN could_MD be_VB substituted_VBN ._. Anticoagulants_NNPS :_: Ten_CD patients_NNS who_WP were_VBD stabilized_VBN on_IN oral_JJ anticoagulants_NNS were_VBD given_VBN guanfacine_NN ,_, 1-2_CD mg/day_NN ,_, for_IN 4_CD weeks_NNS ._. No_DT changes_NNS were_VBD observed_VBN in_IN the_DT degree_NN of_IN anticoagulation_NN ._. In_IN several_JJ well-controlled_JJ studies_NNS ,_, guanfacine_NN was_VBD administered_VBN together_RB with_IN diuretics_NNS with_IN no_DT drug_NN interactions_NNS reported_VBD ._. In_IN the_DT long-term_JJ safety_NN studies_NNS ,_, guanfacine_NN was_VBD given_VBN concomitantly_RB with_IN many_JJ drugs_NNS without_IN evidence_NN of_IN any_DT interactions_NNS ._. The_DT principal_JJ drugs_NNS given_VBN -LRB-_-LRB- number_NN of_IN patients_NNS in_IN parentheses_NNS -RRB-_-RRB- were_VBD :_: cardiac_JJ glycosides_NNS -LRB-_-LRB- 115_CD -RRB-_-RRB- ,_, sedatives_NNS and_CC hypnotics_NNS -LRB-_-LRB- 103_CD -RRB-_-RRB- ,_, coronary_JJ vasodilators_NNS -LRB-_-LRB- 52_CD -RRB-_-RRB- ,_, oral_JJ hypoglycemics_NNS -LRB-_-LRB- 45_CD -RRB-_-RRB- ,_, cough_NN and_CC cold_JJ preparations_NNS -LRB-_-LRB- 45_CD -RRB-_-RRB- ,_, NSAIDs_NNS -LRB-_-LRB- 38_CD -RRB-_-RRB- ,_, antihyperlipidemics_NNS -LRB-_-LRB- 29_CD -RRB-_-RRB- ,_, antigout_JJ drugs_NNS -LRB-_-LRB- 24_CD -RRB-_-RRB- ,_, oral_JJ contraceptives_NNS -LRB-_-LRB- 18_CD -RRB-_-RRB- ,_, bronchodilators_NNS -LRB-_-LRB- 13_CD -RRB-_-RRB- ,_, insulin_NN -LRB-_-LRB- 10_CD -RRB-_-RRB- ,_, and_CC beta_NN blockers_NNS -LRB-_-LRB- 10_CD -RRB-_-RRB- ._. Laboratory_NNP Test_NNP In_IN clinical_JJ trials_NNS ,_, no_DT clinically_RB relevant_JJ laboratory_NN test_NN abnormalities_NNS were_VBD identified_VBN as_IN causally_RB related_JJ to_TO drug_NN during_IN short-term_JJ treatment_NN with_IN guanfacine_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS No_DT laboratory_NN test_NN abnormalities_NNS related_VBN to_TO the_DT use_NN of_IN guanfacine_NN have_VBP been_VBN identified_VBN ._. An_DT encephalopathic_JJ syndrome_NN -LRB-_-LRB- characterized_VBN by_IN weakness_NN ,_, lethargy_NN ,_, fever_NN ,_, tremulousness_NN and_CC confusion_NN ,_, extrapyramidal_JJ symptoms_NNS ,_, leukocytosis_NN ,_, elevated_JJ serum_NN enzymes_NNS ,_, BUN_NN ,_, and_CC FBS_NN -RRB-_-RRB- followed_VBN by_IN irreversible_JJ brain_NN damage_NN has_VBZ occurred_VBN in_IN a_DT few_JJ patients_NNS treated_VBN with_IN lithium_NN plus_CC HALDOL_NN ._. A_DT causal_JJ relationship_NN between_IN these_DT events_NNS and_CC the_DT concomitant_JJ administration_NN of_IN lithium_NN and_CC HALDOL_NN has_VBZ not_RB been_VBN established_VBN ._. however_RB ,_, patients_NNS receiving_VBG such_JJ combined_JJ therapy_NN should_MD be_VB monitored_VBN closely_RB for_IN early_JJ evidence_NN of_IN neurological_JJ toxicity_NN and_CC treatment_NN discontinued_VBN promptly_RB if_IN such_JJ signs_NNS appear_VBP ._. As_IN with_IN other_JJ antipsychotic_JJ agents_NNS ,_, it_PRP should_MD be_VB noted_VBN that_IN HALDOL_NNP may_MD be_VB capable_JJ of_IN potentiating_VBG CNS_NN depressants_NNS such_JJ as_IN anesthetics_NNS ,_, opiates_NNS ,_, and_CC alcohol_NN ._. In_IN a_DT study_NN of_IN 12_CD schizophrenic_JJ patients_NNS coadministered_VBN oral_JJ haloperidol_NN and_CC rifampin_NN ,_, plasma_NN haloperidol_NN levels_NNS were_VBD decreased_VBN by_IN a_DT mean_NN of_IN 70_CD %_NN and_CC mean_VB scores_NNS on_IN the_DT Brief_JJ Psychiatric_JJ Rating_NNP Scale_NNP were_VBD increased_VBN from_IN baseline_NN ._. In_IN 5_CD other_JJ schizophrenic_JJ patients_NNS treated_VBN with_IN oral_JJ haloperidol_NN and_CC rifampin_NN ,_, discontinuation_NN of_IN rifampin_NN produced_VBD a_DT mean_JJ 3.3-fold_RB increase_VB in_IN haloperidol_NN concentrations_NNS ._. Thus_RB ,_, careful_JJ monitoring_NN of_IN clinical_JJ status_NN is_VBZ warranted_VBN when_WRB rifampin_NN is_VBZ administered_VBN or_CC discontinued_VBN in_IN haloperidol-treated_JJ patients_NNS ._. FLUOTHANE_NN augments_VBZ the_DT action_NN of_IN non-depolarising_JJ muscle_NN relaxants_NNS and_CC the_DT muscle_NN relaxant_NN effects_NNS of_IN aminoglycosides_NNS ._. FLUOTHANE_NN may_MD augment_VB the_DT hypotension_NN caused_VBN by_IN the_DT ganglionic-blocking_NN effect_NN of_IN tubocurarine_NN ._. Caution_NN should_MD be_VB exercised_VBN during_IN the_DT administration_NN of_IN adrenaline_NN to_TO patients_NNS anaesthetised_VBN with_IN FLUOTHANE_NN as_IN arrhythmias_NNS may_MD be_VB precipitated_VBN ._. For_IN this_DT reason_NN the_DT dose_NN of_IN adrenaline_NN should_MD be_VB restricted_JJ and_CC an_DT antiarrhythmic_JJ agent_NN administered_VBN as_IN appropriate_JJ ._. Caution_NN should_MD also_RB be_VB applied_VBN for_IN other_JJ sympathomimetics_NNS ,_, and_CC for_IN aminophylline_NN and_CC theophylline_NN and_CC tricyclic_JJ antidepressants_NNS ,_, which_WDT may_MD also_RB precipitate_VB arrhythmias_NNS ._. Drug_NN Interactions_NNS :_: a._VB Drugs_NNS Enhancing_NN Heparin_NN Effect_NN :_: Oral_JJ anticoagulants_NNS :_: Heparin_NN sodium_NN may_MD prolong_VB the_DT one-stage_JJ prothrombin_NN time_NN ._. Therefore_RB ,_, when_WRB heparin_NN sodium_NN is_VBZ given_VBN with_IN dicumarol_NN or_CC warfarin_NN sodium_NN ,_, a_DT period_NN of_IN at_IN least_JJS 5_CD hours_NNS after_IN the_DT last_JJ intravenous_JJ dose_NN or_CC 24_CD hours_NNS after_IN the_DT last_JJ subcutaneous_JJ dose_NN should_MD elapse_VB before_IN blood_NN is_VBZ drawn_VBN if_IN a_DT valid_JJ prothrombin_NN time_NN is_VBZ to_TO be_VB obtained_VBN ._. Platelet_NN inhibitors_NNS :_: Drugs_NNS such_JJ as_IN acetylsalicylic_JJ acid_NN ,_, dextran_NN ,_, phenylbutazone_NN ,_, ibuprofen_NN ,_, indomethacin_NN ,_, dipyridamole_NN ,_, hydroxychloroquine_NN and_CC others_NNS that_WDT interfere_VBP with_IN platelet-aggregation_JJ reactions_NNS -LRB-_-LRB- the_DT main_JJ hemostatic_JJ defense_NN of_IN heparinized_JJ patients_NNS -RRB-_-RRB- may_MD induce_VB bleeding_NN and_CC should_MD be_VB used_VBN with_IN caution_NN in_IN patients_NNS receiving_VBG heparin_NN sodium_NN ._. The_DT anticoagulant_JJ effect_NN of_IN heparin_NN is_VBZ enhanced_VBN by_IN concurrent_JJ treatment_NN with_IN antithrombin_NN III_CD -LRB-_-LRB- human_JJ -RRB-_-RRB- in_IN patients_NNS with_IN hereditary_JJ antithrombin_NN III_CD deficiency_NN ._. Thus_RB in_IN order_NN to_TO avoid_VB bleeding_NN ,_, reduced_VBD dosage_NN of_IN heparin_NN is_VBZ recommended_VBN during_IN treatment_NN with_IN antithrombin_NN III_CD -LRB-_-LRB- human_JJ -RRB-_-RRB- ._. b._NN Drugs_NNS Decreasing_VBG Heparin_NN Effect_NN :_: Digitalis_NNP ,_, tetracyclines_NNS ,_, nicotine_NN ,_, or_CC antihistamines_NNS may_MD partially_RB counteract_VB the_DT anticoagulant_JJ action_NN of_IN heparin_NN sodium_NN ._. Heparin_NN Sodium_NN Injection_NN should_MD not_RB be_VB mixed_VBN with_IN doxorubicin_NN ,_, droperidol_NN ,_, ciprofloxacin_NN ,_, or_CC mitoxantrone_NN ,_, since_IN it_PRP has_VBZ been_VBN reported_VBN that_IN these_DT drugs_NNS are_VBP incompatible_JJ with_IN heparin_NN and_CC a_DT precipitate_NN may_MD form_VB ._. Drug_NN /_: Laboratory_NNP Tests_NNP Interactions_NNS Hyperaminotransferasemia_NNP :_: Significant_JJ elevations_NNS of_IN aminotransferase_NN -LRB-_-LRB- SGOT_NN -LSB-_-LRB- S-AST_NN -RSB-_-RRB- and_CC SGPT_NN -LSB-_-LRB- S-ALT_NN -RSB-_-RRB- -RRB-_-RRB- levels_NNS have_VBP occurred_VBN in_IN a_DT high_JJ percentage_NN of_IN patients_NNS -LRB-_-LRB- and_CC healthy_JJ subjects_NNS -RRB-_-RRB- who_WP have_VBP received_VBN heparin_NN sodium_NN ._. Since_IN aminotransferase_NN determinations_NNS are_VBP important_JJ in_IN the_DT differential_JJ diagnosis_NN of_IN myocardial_JJ infarction_NN ,_, liver_NN disease_NN and_CC pulmonary_JJ emboli_NNS ,_, rises_VBZ that_IN might_MD be_VB caused_VBN by_IN drugs_NNS -LRB-_-LRB- heparin_NN sodium_NN -RRB-_-RRB- should_MD be_VB interpreted_VBN with_IN caution_NN ._. Opioids_NNS are_VBP strong_JJ central_JJ nervous_JJ system_NN depressants_NNS ,_, but_CC regular_JJ users_NNS develop_VB physiological_JJ tolerance_NN allowing_VBG gradually_RB increased_VBN dosages_NNS ._. In_IN combination_NN with_IN other_JJ central_JJ nervous_JJ system_NN depressants_NNS ,_, heroin_NN may_MD still_RB kill_VB even_RB experienced_JJ users_NNS ,_, particularly_RB if_IN their_PRP$ tolerance_NN to_TO the_DT drug_NN has_VBZ reduced_VBN or_CC the_DT strength_NN of_IN their_PRP$ usual_JJ dose_NN has_VBZ increased_VBN ._. Toxicology_NN studies_NNS of_IN heroin-related_JJ deaths_NNS reveal_VBP frequent_JJ involvement_NN of_IN other_JJ central_JJ nervous_JJ system_NN depressants_NNS ,_, including_VBG alcohol_NN ,_, benzodiazepines_NNS such_JJ as_IN diazepam_NN -LRB-_-LRB- Valium_NN -RRB-_-RRB- ,_, and_CC ,_, to_TO a_DT rising_VBG degree_NN ,_, methadone_NN ._. Ironically_RB ,_, benzodiazepines_NNS are_VBP often_RB used_VBN in_IN the_DT treatment_NN of_IN heroin_NN addiction_NN while_IN they_PRP cause_VBP much_RB more_RBR severe_JJ withdrawal_NN symptoms_NNS ._. Cocaine_NN sometimes_RB proves_VBZ to_TO be_VB fatal_JJ when_WRB used_VBN in_IN combination_NN with_IN heroin_NN ._. No_DT information_NN available_JJ ._. Barbiturates_NNS may_MD decrease_VB the_DT effectiveness_NN of_IN oral_JJ contraceptives_NNS ,_, certain_JJ antibiotics_NNS ,_, quinidine_NN ,_, theophylline_NN ,_, corticosteroids_NNS ,_, anticoagulants_NNS ,_, and_CC beta_NN blockers_NNS ._. MAO_NN inhibitors_NNS should_MD be_VB used_VBN with_IN caution_NN in_IN patients_NNS receiving_VBG hydralazine_NN ._. When_WRB other_JJ potent_JJ parental_JJ antihypertensive_JJ drugs_NNS ,_, such_JJ as_IN diazoxide_NN ,_, are_VBP used_VBN in_IN combination_NN with_IN hydralazine_NN ,_, patients_NNS should_MD be_VB continuously_RB observed_VBN for_IN several_JJ hours_NNS for_IN any_DT excessive_JJ fall_NN in_IN blood_NN pressure_NN ._. Profound_JJ hypotensive_JJ episodes_NNS may_MD occur_VB when_WRB diazoxide_NN infection_NN and_CC hydralazine_NN are_VBP used_VBN concomitantly_RB ._. Beta-blockers_NNS -LRB-_-LRB- metoprolol_NN ,_, propranolol_NN -RRB-_-RRB- serum_NN concentrations_NNS and_CC pharmacologic_JJ effects_NNS may_MD be_VB increased_VBN ._. Monitor_NNP cardiovascular_JJ status_NN ._. Propranolol_NN increases_VBZ hydralazines_NNS serum_NN concentrations_NNS ._. Acebutolol_NNP ,_, atenolol_NN ,_, and_CC nadolol_NN -LRB-_-LRB- low_JJ hepatic_JJ clearance_NN or_CC no_DT first-pass_JJ metabolism_NN -RRB-_-RRB- are_VBP unlikely_JJ to_TO be_VB affected_VBN ._. NSAIDs_NNS may_MD decrease_VB the_DT hemodynamic_JJ effects_NNS of_IN hydralazine_NN ._. avoid_VB use_NN if_IN possible_JJ or_CC closely_RB monitor_VB cardiovascular_JJ status_NN at_IN the_DT end_NN of_IN drug_NN interactions_NNS ._. When_WRB given_VBN concurrently_RB the_DT following_VBG drugs_NNS may_MD interact_VB with_IN thiazide_JJ diuretics_NNS ._. Alcohol_NN ,_, barbiturates_NNS ,_, or_CC narcotics_NNS :_: potentiation_NN of_IN orthostatic_JJ hypotension_NN may_MD occur_VB ._. Antidiabetic_JJ drugs_NNS :_: -LRB-_-LRB- oral_JJ agents_NNS and_CC insulin_NN -RRB-_-RRB- -_: dosage_NN adjustment_NN of_IN the_DT antidiabetic_JJ drug_NN may_MD be_VB required_VBN ._. Other_JJ antihypertensive_JJ drugs_NNS :_: additive_JJ effect_NN or_CC potentiation_NN ._. Cholestyramine_NN and_CC colestipol_NN resins_NNS :_: Absorption_NN of_IN hydrochlorothiazide_NN is_VBZ impaired_JJ in_IN the_DT presence_NN of_IN anionic_JJ exchange_NN resins_NNS ._. Single_JJ doses_NNS of_IN either_CC cholestyramine_NN or_CC colestipol_NN resins_NNS bind_VBP the_DT hydrochlorothiazide_NN and_CC reduce_VB its_PRP$ absorption_NN from_IN the_DT gastrointestinal_JJ tract_NN by_IN up_RB to_TO 85_CD and_CC 43_CD percent_NN ,_, respectively_RB ._. Corticosteroids_NNS ,_, ACTH_NN :_: intensified_VBN electrolyte_NN depletion_NN ,_, particularly_RB hypokalemia_NN ._. Pressor_NNP amines_NNS -LRB-_-LRB- e.g._FW ,_, norepinephrine_NN -RRB-_-RRB- :_: possible_JJ decreased_VBN response_NN to_TO pressor_NN amines_NNS but_CC not_RB sufficient_JJ to_TO preclude_VB their_PRP$ use_NN ._. Skeletal_JJ muscle_NN relaxants_NNS ,_, nondepolarizing_JJ -LRB-_-LRB- e.g._FW ,_, tubocurarine_NN -RRB-_-RRB- :_: possible_JJ increased_VBN responsiveness_NN to_TO the_DT muscle_NN relaxant_NN ._. Lithium_NN :_: generally_RB should_MD not_RB be_VB given_VBN with_IN diuretics_NNS ._. Diuretic_JJ agents_NNS reduce_VB the_DT renal_JJ clearance_NN of_IN lithium_NN and_CC add_VB a_DT high_JJ risk_NN of_IN lithium_NN toxicity_NN ._. Refer_VB to_TO the_DT package_NN insert_NN for_IN lithium_NN preparations_NNS before_IN use_NN of_IN such_JJ preparations_NNS with_IN Hydrochlorothiazide_NN ._. Non-steroidal_JJ Anti-inflammatory_JJ Drugs_NNS :_: In_IN some_DT patients_NNS ,_, the_DT administration_NN of_IN a_DT non-steroidal_JJ anti-inflammatory_JJ agent_NN can_MD reduce_VB the_DT diuretic_JJ ,_, natriuretic_JJ ,_, and_CC antihypertensive_JJ effects_NNS of_IN loop_NN ,_, potassium-sparing_NN and_CC thiazide_JJ diuretics_NNS ._. Therefore_RB ,_, when_WRB Hydrochlorothiazide_NN and_CC non-steroidal_JJ anti-inflammatory_JJ agents_NNS are_VBP used_VBN concomitantly_RB ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB to_TO determine_VB if_IN the_DT desired_VBN effect_NN of_IN the_DT diuretic_JJ is_VBZ obtained_VBN ._. Patients_NNS receiving_VBG other_JJ narcotic_JJ analgesics_NNS ,_, antipsychotics_NNS ,_, antianxiety_JJ agents_NNS ,_, or_CC other_JJ CNS_NN depressants_NNS -LRB-_-LRB- including_VBG alcohol_NN -RRB-_-RRB- concomitantly_RB with_IN hydrocodone_NN and_CC acetaminophen_NN tablets_NNS may_MD exhibit_VB an_DT additive_JJ CNS_NN depression_NN ._. When_WRB combined_VBN therapy_NN is_VBZ contemplated_VBN ,_, the_DT dose_NN of_IN one_CD or_CC both_DT agents_NNS should_MD be_VB reduced_VBN ._. The_DT use_NN of_IN MAO_NN inhibitors_NNS or_CC tricyclic_JJ antidepressants_NNS with_IN hydrocodone_NN preparations_NNS may_MD increase_VB the_DT effect_NN of_IN either_CC the_DT antidepressant_JJ or_CC hydrocodone_NN ._. The_DT concurrent_JJ use_NN of_IN anticholinergics_NNS with_IN hydrocodone_NN may_MD produce_VB paralytic_JJ ileus_NN ._. No_DT information_NN available_JJ ._. Anticoagulants_NNPS ,_, ora_NN ._. -LRB-_-LRB- Effects_NNS may_MD be_VB decreased_VBN when_WRB used_VBN concurrently_RB with_IN thiazide_JJ diuretics_NNS ._. dosage_NN adjustments_NNS may_MD be_VB necessary_JJ ._. -RRB-_-RRB- ._. Antigout_JJ medication_NN ._. -LRB-_-LRB- Thiazide_NNP diuretics_NNS may_MD raise_VB the_DT level_NN of_IN blood_NN uric_JJ acid_NN ._. dosage_NN adjustment_NN of_IN antigout_JJ medications_NNS may_MD be_VB necessary_JJ to_TO control_VB hyperuricemia_NN and_CC gout_NN ._. Antihypertensive_JJ medications_NNS ,_, other_JJ ,_, especially_RB diazoxide_NN ,_, or_CC preanesthetic_JJ and_CC anesthetic_JJ agents_NNS used_VBN in_IN surgery_NN or_CC skeletal-muscle_JJ relaxants_NNS ,_, nondepolarizing_JJ ,_, used_VBN in_IN surger_NN ._. -LRB-_-LRB- Effects_NNS may_MD be_VB potentiated_VBN when_WRB used_VBN concurrently_RB with_IN thiazide_JJ diuretics_NNS ._. dosage_NN adjustments_NNS may_MD be_VB necessary_JJ ._. -RRB-_-RRB- ._. Amphotericin_NN B_NN or_CC Corticosteroids_NNS or_CC Corticotropin_NN -LRB-_-LRB- ACTH_NN ._. -LRB-_-LRB- Concurrent_JJ use_NN with_IN thiazide_JJ diuretics_NNS may_MD intensify_VB electrolyte_NN imbalance_NN ,_, particularly_RB hypokalemia_NN ._. Cardiac_JJ glycoside_NN ._. -LRB-_-LRB- Concurrent_JJ use_NN with_IN thiazide_JJ diuretics_NNS may_MD enhance_VB the_DT possibility_NN of_IN digitalis_NN toxicity_NN associated_VBN with_IN hypokalemia_NN ._. Colestipo_NNP ._. -LRB-_-LRB- May_NNP inhibit_VBP gastrointestinal_JJ absorption_NN of_IN the_DT thiazide_JJ diuretics_NNS ._. administration_NN 1_CD hour_NN before_IN or_CC 4_CD hours_NNS after_IN colestipol_NN is_VBZ recommended_VBN ._. Hypoglycemic_JJ ._. -LRB-_-LRB- Thiazide_NNP diuretics_NNS may_MD raise_VB blood_NN glucose_NN levels_NNS ._. for_IN adult-onset_JJ diabetics_NNS ,_, dosage_NN adjustment_NN of_IN hypoglycemic_JJ medications_NNS may_MD be_VB necessary_JJ during_IN and_CC after_IN thiazide_JJ diuretic_JJ therapy_NN ._. insulin_NN requirements_NNS may_MD be_VB increased_VBN ,_, decreased_VBN ,_, or_CC unchanged_JJ ._. Lithium_NN salt_NN ._. -LRB-_-LRB- Concurrent_JJ use_NN with_IN thiazide_JJ diuretics_NNS is_VBZ not_RB recommended_VBN ,_, as_IN they_PRP may_MD provoke_VB lithium_NN toxicity_NN because_IN of_IN reduced_VBN renal_JJ clearance_NN ._. Methenamin_NNP ._. -LRB-_-LRB- Effectiveness_NN may_MD be_VB decreased_VBN when_WRB used_VBN concurrently_RB with_IN thiazide_JJ diuretics_NNS because_IN of_IN alkalinization_NN of_IN the_DT urine_NN ._. Nonsteroidal_JJ anti-inflammatory_JJ agent_NN ._. -LRB-_-LRB- In_IN some_DT patients_NNS ,_, the_DT steroidal_JJ anti-inflammatory_JJ agent_NN can_MD reduce_VB the_DT diuretic_JJ ,_, natriuretic_JJ ,_, and_CC antihypertensive_JJ effects_NNS of_IN loop_NN ,_, potassium_NN sparing_NN ,_, and_CC thiazide_JJ diuretics_NNS ._. Therefore_RB ,_, when_WRB hydroflumethiazide_NN and_CC nonsteroidal_JJ anti-inflammatory_JJ agents_NNS are_VBP used_VBN concomitantly_RB ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB to_TO determine_VB if_IN the_DT desired_VBN effect_NN of_IN the_DT diuretic_JJ is_VBZ obtained_VBN ._. Norepinephrin_NNP ._. -LRB-_-LRB- Thiazides_NNS may_MD decrease_VB arterial_JJ responsiveness_NN to_TO norepinephrine_NN ._. This_DT diminution_NN is_VBZ not_RB sufficient_JJ to_TO preclude_VB effectiveness_NN of_IN the_DT pressor_NN agent_NN for_IN therapeutic_JJ use_NN ._. -RRB-_-RRB- ._. Tubocurarin_NN ._. -LRB-_-LRB- Thiazide_NN drugs_NNS may_MD increase_VB the_DT responsiveness_NN to_TO tubocurarine_NN ._. DIAGNOSTIC_JJ INTERFERENCE_NN With_IN expected_VBN physiologic_JJ effects_NNS :_: Blood_NN and_CC urine_NN glucose_NN levels_NNS -LRB-_-LRB- usually_RB only_RB in_IN patients_NNS with_IN a_DT predisposition_NN for_IN glucose_NN intolerance_NN -RRB-_-RRB- and_CC Serum_NN bilirubin_NN levels_NNS -LRB-_-LRB- by_IN displacement_NN from_IN albumin_NN binding_NN -RRB-_-RRB- and_CC Serum_NN calcium_NN levels_NNS -LRB-_-LRB- thiazide_JJ diuretics_NNS should_MD be_VB discontinued_VBN before_IN parathyroid-function_NN tests_NNS are_VBP carried_VBN out_RP -RRB-_-RRB- and_CC Serum_NN uric_JJ acid_NN levels_NNS -LRB-_-LRB- may_MD be_VB increased_VBN -RRB-_-RRB- Serum_NN magnesium_NN ,_, potassium_NN ,_, and_CC sodium_NN levels_NNS -LRB-_-LRB- may_MD be_VB decreased_VBN ._. serum_NN magnesium_NN levels_NNS may_MD increase_VB in_IN uremic_JJ patients_NNS -RRB-_-RRB- Serum_NN protein-bound_JJ iodine_NN -LRB-_-LRB- PBI_NN -RRB-_-RRB- levels_NNS -LRB-_-LRB- may_MD be_VB decreased_VBN -RRB-_-RRB- Thiazides_NNS should_MD be_VB discontinued_VBN before_IN carrying_VBG out_RP tests_NNS for_IN parathyroid_JJ function_NN ._. Patients_NNS receiving_VBG other_JJ narcotic_JJ analgesics_NNS ,_, general_JJ anesthetics_NNS ,_, phenothiazines_NNS ,_, tranquilizers_NNS ,_, sedative-hypnotics_NNS ,_, tricyclic_JJ antidepressants_NNS or_CC other_JJ CNS_NN depressants_NNS -LRB-_-LRB- including_VBG alcohol_NN -RRB-_-RRB- concomitantly_RB with_IN DILAUDID_NN may_MD exhibit_VB an_DT additive_JJ CNS_NN depression_NN ._. When_WRB such_JJ combined_JJ therapy_NN is_VBZ contemplated_VBN ,_, the_DT dose_NN of_IN one_CD or_CC both_DT agents_NNS should_MD be_VB reduced_VBN ._. No_DT formal_JJ drug_NN interaction_NN studies_NNS have_VBP been_VBN conducted_VBN with_IN Cyanokit_NN ._. Prospective_JJ studies_NNS on_IN the_DT potential_NN for_IN hydroxyurea_NN to_TO interact_VB with_IN other_JJ drugs_NNS have_VBP not_RB been_VBN performed_VBN ._. Concurrent_JJ use_NN of_IN hydroxyurea_NN and_CC other_JJ myelosuppressive_JJ agents_NNS or_CC radiation_NN therapy_NN may_MD increase_VB the_DT likelihood_NN of_IN bone_NN marrow_NN depression_NN or_CC other_JJ adverse_JJ events_NNS ._. Since_IN hydroxyurea_NN may_MD raise_VB the_DT serum_NN uric_JJ acid_NN level_NN ,_, dosage_NN adjustment_NN of_IN uricosuric_JJ medication_NN may_MD be_VB necessar_JJ ._. THE_DT POTENTIATING_VBG ACTION_NN OF_IN HYDROXYZINE_NNP MUST_NNP BE_VB CONSIDERED_VBN WHEN_WRB THE_DT DRUG_NN IS_VBZ USED_NNP IN_IN CONJUNCTION_NNP WITH_IN CENTRAL_NNP NERVOUS_NNP SYSTEM_NNP DEPRESSANTS_NNP SUCH_NNP AS_NNP NARCOTICS_NNP ,_, NON-NARCOTIC_NN ANALGESICS_NNS AND_CC BARBITURATES_NNS ._. Therefore_RB when_WRB central_JJ nervous_JJ system_NN depressants_NNS are_VBP administered_VBN concomitantly_RB with_IN hydroxyzine_NN their_PRP$ dosage_NN should_MD be_VB reduced_VBN ._. Since_IN drowsiness_NN may_MD occur_VB with_IN use_NN of_IN this_DT drug_NN ,_, patients_NNS should_MD be_VB warned_VBN of_IN this_DT possibility_NN and_CC cautioned_VBD against_IN driving_VBG a_DT car_NN or_CC operating_VBG dangerous_JJ machinery_NN while_IN taking_VBG Atarax_NNP ._. Patients_NNS should_MD be_VB advised_VBN against_IN the_DT simultaneous_JJ use_NN of_IN other_JJ CNS_NNS depressant_NN drugs_NNS ,_, and_CC cautioned_VBD that_IN the_DT effect_NN of_IN alcohol_NN may_MD be_VB increased_VBN ._. Additive_JJ adverse_JJ effects_NNS resulting_VBG from_IN cholinergic_JJ blockade_NN may_MD occur_VB when_WRB LEVSIN_NNP is_VBZ administered_VBN concomitantly_RB with_IN other_JJ antimuscarinics_NNS ,_, amantadine_NN ,_, haloperidol_NN ,_, phenothiazines_NNS ,_, monoamine_NN oxidase_NN -LRB-_-LRB- MAO_NN -RRB-_-RRB- inhibitors_NNS ,_, tricyclic_JJ antidepressants_NNS or_CC some_DT antihistamines_NNS ._. Antacids_NNS may_MD interfere_VB with_IN the_DT absorption_NN of_IN LEVSIN_NNP ._. Administer_VB LEVSIN_NNP before_IN meals_NNS ._. antacids_NNS after_IN meals_NNS ._. Calcium_NN Supplements/Antacid_NN ._. Products_NNPS containing_VBG calcium_NN and_CC other_JJ multivalent_JJ cations_NNS -LRB-_-LRB- such_JJ as_IN aluminum_NN ,_, magnesium_NN ,_, iron_NN -RRB-_-RRB- are_VBP likely_JJ to_TO interfere_VB with_IN absorption_NN of_IN Ibandronate_NN ._. Ibandronate_NN should_MD be_VB taken_VBN at_IN least_JJS 60_CD minutes_NNS before_IN any_DT oral_JJ medications_NNS containing_VBG multivalent_JJ cations_NNS -LRB-_-LRB- including_VBG antacids_NNS ,_, supplements_NNS or_CC vitamins_NNS -RRB-_-RRB- ._. H2_NN Blockers_NNS and_CC Proton_NNP Pump_NN Inhibitors_NNS -LRB-_-LRB- PPIs_NNS ._. Of_IN over_IN 3500_CD patients_NNS enrolled_VBN in_IN the_DT Ibandronate_NNP osteoporosis_NN Treatment_NN and_CC Prevention_NNP Studies_NNPS ,_, 15_CD %_NN used_VBN anti-peptic_JJ agents_NNS -LRB-_-LRB- primarily_RB H2_NN blockers_NNS and_CC PPIs_NNS -RRB-_-RRB- ._. Among_IN these_DT patients_NNS ,_, the_DT incidence_NN of_IN upper_JJ gastrointestinal_JJ adverse_JJ experiences_NNS in_IN the_DT patients_NNS treated_VBN with_IN Ibandronate_NN was_VBD similar_JJ to_TO that_DT in_IN placebo-treated_JJ patients_NNS ._. Similarly_RB ,_, of_IN over_IN 1600_CD patients_NNS enrolled_VBN in_IN a_DT study_NN comparing_VBG once-monthly_JJ with_IN daily_JJ dosing_NN regimens_NNS of_IN ibandronate_NN ,_, 14_CD %_NN of_IN patients_NNS used_VBN anti-peptic_JJ agents_NNS ._. Among_IN these_DT patients_NNS ,_, the_DT incidence_NN of_IN upper_JJ gastrointestinal_JJ adverse_JJ experiences_NNS in_IN the_DT patients_NNS treated_VBN with_IN Ibandronate_NN 150_CD mg_NN once_RB monthly_JJ was_VBD similar_JJ to_TO that_DT in_IN patients_NNS treated_VBN with_IN Ibandronate_JJ 2.5_CD mg_NN once_RB daily_RB ._. Aspirin/Nonsteroidal_JJ Antiinflammatory_JJ Drugs_NNS -LRB-_-LRB- NSAIDs_NNS ._. In_IN the_DT large_JJ ,_, placebo-controlled_JJ osteoporosis_NN Treatment_NN Study_NN ,_, aspirin_NN and_CC nonsteroidal_JJ anti-inflammatory_JJ drugs_NNS were_VBD taken_VBN by_IN 62_CD %_NN of_IN the_DT 2946_CD patients_NNS ._. Among_IN aspirin_NN or_CC NSAID_NN users_NNS ,_, the_DT incidence_NN of_IN upper_JJ gastrointestinal_JJ adverse_JJ events_NNS in_IN patients_NNS treated_VBN with_IN ibandronate_NN 2.5_CD mg_NN daily_JJ -LRB-_-LRB- 28.9_CD %_NN -RRB-_-RRB- was_VBD similar_JJ to_TO that_DT in_IN placebo-treated_JJ patients_NNS -LRB-_-LRB- 30.7_CD %_NN -RRB-_-RRB- ._. Similarly_RB ,_, in_IN the_DT 1-year_JJ monthly_JJ comparison_NN study_NN ,_, aspirin_NN and_CC nonsteroidal_JJ anti-inflammatory_JJ drugs_NNS were_VBD taken_VBN by_IN 39_CD %_NN of_IN the_DT 1602_CD patients_NNS ._. The_DT incidence_NN of_IN upper_JJ gastrointestinal_JJ events_NNS in_IN patients_NNS concomitantly_RB taking_VBG aspirin_NN or_CC NSAIDs_NNS was_VBD similar_JJ in_IN patients_NNS taking_VBG ibandronate_JJ 2.5_CD mg_NN daily_JJ -LRB-_-LRB- 21.7_CD %_NN -RRB-_-RRB- and_CC 150_CD mg_NN once_RB monthly_JJ -LRB-_-LRB- 22.0_CD %_NN -RRB-_-RRB- ._. However_RB ,_, since_IN aspirin_NN ,_, NSAIDs_NNS ,_, and_CC bisphosphonates_NNS are_VBP all_DT associated_VBN with_IN gastrointestinal_JJ irritation_NN ,_, caution_NN should_MD be_VB exercised_VBN in_IN the_DT concomitant_JJ use_NN of_IN aspirin_NN or_CC NSAIDs_NNS with_IN Ibandronate_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS ._. Bisphosphonates_NNS are_VBP known_VBN to_TO interfere_VB with_IN the_DT use_NN of_IN bone-imaging_JJ agents_NNS ._. Specific_JJ studies_NNS with_IN ibandronate_NN have_VBP not_RB been_VBN performed_VBN ._. No_DT formal_JJ drug_NN interaction_NN studies_NNS have_VBP been_VBN performed_VBN with_IN ZEVALIN_NN ._. Due_JJ to_TO the_DT frequent_JJ occurrence_NN of_IN severe_JJ and_CC prolonged_JJ thrombocytopenia_NN ,_, the_DT potential_JJ benefits_NNS of_IN medications_NNS which_WDT interfere_VBP with_IN platelet_NN function_NN and/or_CC anticoagulation_NN should_MD be_VB weighed_VBN against_IN the_DT potential_NN increased_VBD risks_NNS of_IN bleeding_NN and_CC hemorrhage_NN ._. Patients_NNS receiving_VBG medications_NNS that_WDT interfere_VBP with_IN platelet_NN function_NN or_CC coagulation_NN should_MD have_VB more_RBR frequent_JJ laboratory_NN monitoring_NN for_IN thrombocytopenia_NN ._. In_IN addition_NN ,_, the_DT transfusion_NN practices_NNS for_IN such_JJ patients_NNS may_MD need_VB to_TO be_VB modified_VBN given_VBN the_DT increased_VBN risk_NN of_IN bleeding_NN ._. Patients_NNS in_IN clinical_JJ studies_NNS were_VBD prohibited_VBN from_IN receiving_VBG growth_NN factor_NN treatment_NN for_IN 2_CD weeks_NNS prior_RB to_TO the_DT ZEVALIN_NNP therapeutic_JJ regimen_NNS as_RB well_RB as_IN for_IN 2_CD weeks_NNS following_VBG completion_NN of_IN the_DT regimen_NN ._. Coumarin-Type_JJ Anticoagulants_NNPS :_: Several_JJ short-term_JJ controlled_JJ studies_NNS failed_VBD to_TO wshow_VB that_IN ibuprofen_NN significantly_RB affected_VBD prothrombin_NN times_NNS or_CC a_DT variety_NN of_IN other_JJ clotting_NN factors_NNS when_WRB administered_VBN to_TO individuals_NNS on_IN coumarin-type_JJ anticoagulants_NNS ._. However_RB ,_, because_IN bleeding_NN has_VBZ been_VBN reported_VBN when_WRB ibuprofen_NN and_CC other_JJ nonsteroidal_JJ anti-inflammatory_JJ agents_NNS have_VBP been_VBN administered_VBN to_TO patients_NNS on_IN coumarin-type_JJ anticoagulants_NNS ,_, the_DT physician_NN should_MD be_VB cautious_JJ when_WRB administering_VBG ibuprofen_NN to_TO patients_NNS on_IN anticoagulants_NNS ._. Aspirin_NN :_: Animal_NN studies_NNS wshow_VBP that_IN aspirin_NN given_VBN with_IN nonsteroidal_JJ anti-inflammatory_JJ agents_NNS ,_, including_VBG ibuprofen_NN ,_, yields_VBZ a_DT net_JJ decrease_NN in_IN anti-inflammatory_JJ activity_NN with_IN lowered_JJ blood_NN levels_NNS of_IN the_DT non-aspirin_JJ drug_NN ._. Single_JJ dose_NN bioavailability_NN studies_NNS in_IN normal_JJ volunteers_NNS have_VBP failed_VBN to_TO wshow_VB an_DT effect_NN of_IN aspirin_NN on_IN ibuprofen_NN blood_NN levels_NNS ._. Correlative_JJ clinical_JJ studies_NNS have_VBP not_RB been_VBN performed_VBN ._. Methotrexate_NNP :_: Ibuprofen_NNP ,_, as_RB well_RB as_IN other_JJ nonsteroidal_JJ anti-inflammatory_JJ drugs_NNS ,_, probably_RB reduces_VBZ the_DT tubular_JJ secretion_NN of_IN methotrexate_NN based_VBN on_IN in_FW vitro_FW studies_NNS in_IN rabbit_NN kidney_NN slices_NNS ._. This_DT may_MD indicate_VB that_IN ibuprofen_NN could_MD enhance_VB the_DT toxicity_NN of_IN methotrexate_NN ._. Caution_NN should_MD be_VB used_VBN if_IN ibuprofen_NN is_VBZ administered_VBN concomitantly_RB with_IN methotrexate_NN ._. H-2_NN Antagonists_NNS :_: In_IN studies_NNS with_IN human_JJ volunteers_NNS ,_, co-administration_NN of_IN cimetidine_NN or_CC ranitidine_NN with_IN ibuprofen_NN had_VBD no_DT substantive_JJ effect_NN on_IN ibuprofen_NN serum_NN concentrations_NNS ._. Furosemide_NNP :_: Clinical_JJ studies_NNS ,_, as_RB well_RB as_IN random_JJ observations_NNS ,_, have_VBP shown_VBN that_IN ibuprofen_NN can_MD reduce_VB the_DT natriuretic_JJ effect_NN of_IN furosemide_NN and_CC thiazides_NNS in_IN some_DT patients_NNS ._. This_DT response_NN has_VBZ been_VBN attributed_VBN to_TO inhibition_NN of_IN renal_JJ prostaglandin_NN synthesis_NN ._. During_IN concomitant_JJ therapy_NN with_IN ibuprofen_NN ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB for_IN signs_NNS of_IN renal_JJ failure_NN ,_, as_RB well_RB as_IN to_TO assure_VB diuretic_JJ efficacy_NN ._. Lithium_NN :_: Ibuprofen_NN produced_VBD an_DT elevation_NN of_IN plasma_NN lithium_NN levels_NNS and_CC a_DT reduction_NN in_IN renal_JJ lithium_NN clearance_NN in_IN a_DT study_NN of_IN eleven_NNS normal_JJ volunteers_NNS ._. The_DT mean_NN minimum_JJ lithium_NN concentration_NN increased_VBD 15_CD %_NN and_CC the_DT renal_JJ clearance_NN of_IN lithium_NN was_VBD decreased_VBN by_IN 19_CD %_NN during_IN this_DT period_NN of_IN concomitant_JJ drug_NN administration_NN ._. This_DT effect_NN has_VBZ been_VBN attributed_VBN to_TO inhibition_NN of_IN renal_JJ prostaglandin_NN synthesis_NN by_IN ibuprofen_NN ._. Thus_RB ,_, when_WRB ibuprofen_NN and_CC lithium_NN are_VBP administered_VBN concurrently_RB ,_, subjects_NNS should_MD be_VB observed_VBN carefully_RB for_IN signs_NNS of_IN lithium_NN toxicity_NN ._. -LRB-_-LRB- Read_VB circulars_NNS for_IN lithium_NN preparation_NN before_IN use_NN of_IN such_JJ concurrent_JJ therapy_NN -RRB-_-RRB- ._. No_DT specific_JJ pharmacokinetic_JJ or_CC other_JJ formal_JJ drug_NN interaction_NN studies_NNS were_VBD conducted_VBN ._. Digoxin_NNP :_: Supraventricular_JJ arrhythmias_NNS may_MD mask_NN the_DT cardiotoxicity_NN associated_VBN with_IN excessive_JJ digoxin_NN levels_NNS ._. Therefore_RB ,_, it_PRP is_VBZ advisable_JJ to_TO be_VB particularly_RB cautious_JJ in_IN patients_NNS whose_WP$ plasma_NN digoxin_NN levels_NNS are_VBP above_IN or_CC suspected_VBN to_TO be_VB above_IN the_DT usual_JJ therapeutic_JJ range_NN ._. Coadministration_NN of_IN digoxin_NN did_VBD not_RB have_VB effects_NNS on_IN either_CC the_DT safety_NN or_CC efficacy_NN of_IN ibutilide_NN in_IN the_DT clinical_JJ trials_NNS ._. Calcium_NN channel_NN blocking_VBG agents_NNS :_: Coadministration_NN of_IN calcium_NN channel_NN blockers_NNS did_VBD not_RB have_VB any_DT effect_NN on_IN either_CC the_DT safety_NN or_CC efficacy_NN of_IN ibutilide_NN in_IN the_DT clinical_JJ trials_NNS ._. Beta-adrenergic_JJ blocking_VBG agents_NNS :_: Coadministration_NN of_IN beta-adrenergic_JJ blocking_VBG agents_NNS did_VBD not_RB have_VB any_DT effect_NN on_IN either_CC the_DT safety_NN or_CC efficacy_NN of_IN ibutilide_NN in_IN the_DT clinical_JJ trials_NNS ._. General_NNP No_NNP clinical_JJ drug_NN interaction_NN studies_NNS were_VBD performed_VBN ._. No_DT evaluation_NN of_IN EXTRANEALs_NNS effects_NNS on_IN the_DT cytochrome_NN P450_NN system_NN was_VBD conducted_VBN ._. As_IN with_IN other_JJ dialysis_NN solutions_NNS ,_, blood_NN concentrations_NNS of_IN dialyzable_JJ drugs_NNS may_MD be_VB reduced_VBN by_IN dialysis_NN ._. Dosage_NN adjustment_NN of_IN concomitant_JJ medications_NNS may_MD be_VB necessary_JJ ._. In_IN patients_NNS using_VBG cardiac_JJ glycosides_NNS -LRB-_-LRB- digoxin_NN and_CC others_NNS -RRB-_-RRB- ,_, plasma_NN levels_NNS of_IN calcium_NN ,_, potassium_NN and_CC magnesium_NN must_MD be_VB carefully_RB monitored_VBN ._. Insulin_NN :_: A_DT clinical_JJ study_NN in_IN 6_CD insulin-dependent_JJ diabetic_JJ patients_NNS demonstrated_VBD no_DT effect_NN of_IN EXTRANEAL_NN on_IN insulin_NN absorption_NN from_IN the_DT peritoneal_JJ cavity_NN or_CC on_IN insulins_NNS ability_NN to_TO control_VB blood_NN glucose_NN when_WRB insulin_NN was_VBD administered_VBN intraperitoneally_RB with_IN EXTRANEAL_NN ._. However_RB ,_, appropriate_JJ monitoring_NN of_IN blood_NN glucose_NN should_MD be_VB performed_VBN when_WRB initiating_VBG EXTRANEAL_NNP in_IN diabetic_JJ patients_NNS and_CC insulin_NN dosage_NN should_MD be_VB adjusted_VBN if_IN needed_VBN ._. Heparin_NN :_: No_DT human_JJ drug_NN interaction_NN studies_NNS with_IN heparin_NN were_VBD conducted_VBN ._. In_FW vitro_FW studies_NNS demonstrated_VBD no_DT evidence_NN of_IN incompatibility_NN of_IN heparin_NN with_IN EXTRANEAL_NN ._. Antibiotics_NNS :_: No_DT human_JJ drug_NN interaction_NN studies_NNS with_IN antibiotics_NNS were_VBD conducted_VBN ._. In_FW vitro_FW studies_NNS evaluating_VBG the_DT minimum_JJ inhibitory_JJ concentration_NN -LRB-_-LRB- MIC_NN -RRB-_-RRB- of_IN vancomycin_NN ,_, cefazolin_NN ,_, ampicillin_NN ,_, ampicillin/flucoxacillin_NN ,_, ceftazidime_NN ,_, gentamicin_NN ,_, and_CC amphotericin_NN demonstrated_VBD no_DT evidence_NN of_IN incompatibility_NN of_IN these_DT antibiotics_NNS with_IN EXTRANEAL_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS Blood_NN Glucose_NN Blood_NN glucose_NN measurement_NN must_MD be_VB done_VBN with_IN a_DT glucose-specific_JJ method_NN to_TO prevent_VB maltose_NN interference_NN with_IN test_NN results_NNS ._. Since_IN falsely_RB elevated_JJ glucose_NN levels_NNS have_VBP been_VBN observed_VBN with_IN blood_NN glucose_NN monitoring_NN devices_NNS and_CC test_NN strips_NNS that_WDT use_VBP glucose_NN dehydrogenase_NN pyrroloquinolinequinone_NN -LRB-_-LRB- GDH_NN PQQ_NN -RRB-_-RRB- -_: based_VBN methods_NNS ,_, GDH_NN PQQ-based_JJ methods_NNS should_MD not_RB be_VB used_VBN to_TO measure_VB glucose_NN levels_NNS in_IN patients_NNS administered_VBN EXTRANEAL_NNP ._. Serum_NN Amylase_NN An_DT apparent_JJ decrease_NN in_IN serum_NN amylase_NN activity_NN has_VBZ been_VBN observed_VBN in_IN patients_NNS administered_VBN EXTRANEAL_NNP ._. Preliminary_JJ investigations_NNS indicate_VBP that_IN icodextrin_NN and_CC its_PRP$ metabolites_NNS interfere_VBP with_IN enzymatic-based_JJ amylase_NN assays_NNS ,_, resulting_VBG in_IN inaccurately_RB low_JJ values_NNS ._. This_DT should_MD be_VB taken_VBN into_IN account_NN when_WRB evaluating_VBG serum_NN amylase_NN levels_NNS for_IN diagnosis_NN or_CC monitoring_NN of_IN pancreatitis_NN in_IN patients_NNS using_VBG EXTRANEAL_NNP ._. Interactions_NNS may_MD occur_VB between_IN EPA_NNP supplements_NNS and_CC aspirin_NN and_CC other_JJ non-steroidal_JJ anti-inflammatory_JJ drugs_NNS and_CC herbs_NNS such_JJ as_IN garlic_NN -LRB-_-LRB- Allium_NN sativum_NN -RRB-_-RRB- and_CC ginkgo_NN -LRB-_-LRB- Ginkgo_NNP biloba_NN -RRB-_-RRB- ._. Such_JJ interactions_NNS might_MD be_VB manifested_VBN by_IN increased_VBN susceptibility_NN to_TO bruising_VBG ,_, nosebleeds_NNS ,_, hemoptysis_NN ,_, hematemesis_NN ,_, hematuria_NN and_CC blood_NN in_IN the_DT stool_NN ._. Most_JJS who_WP take_VBP EPA_NNP supplements_NNS and_CC the_DT above_JJ drugs_NNS or_CC herbs_NNS do_VBP not_RB suffer_VB from_IN these_DT problems_NNS and_CC if_IN they_PRP occur_VBP ,_, they_PRP are_VBP rare_JJ ._. If_IN they_PRP do_VBP occur_VB ,_, the_DT EPA_NNP dose_NN should_MD be_VB lowered_VBN or_CC discontinued_VBN ._. Conflicting_JJ results_NNS have_VBP been_VBN reported_VBN regarding_VBG the_DT effects_NNS of_IN EPA_NNP supplements_NNS on_IN glycemic_JJ control_NN in_IN non-diabetics_NNS with_IN glucose_NN intolerance_NN ,_, and_CC those_DT with_IN type_NN 2_CD diabetes_NN ._. Some_DT early_JJ studies_NNS indicated_VBD that_IN EPA_NNP supplements_NNS might_MD have_VB detrimental_JJ effects_NNS in_IN those_DT groups_NNS ._. Recent_JJ ,_, better_RBR designed_VBN studies_NNS have_VBP not_RB reported_VBN these_DT adverse_JJ effects_NNS ._. There_EX is_VBZ no_DT evidence_NN that_IN EPA_NNP supplements_NNS have_VBP detrimental_JJ effects_NNS on_IN glucose_NN tolerance_NN ,_, insulin_NN secretion_NN or_CC insulin_NN resistance_NN in_IN non-diabetic_JJ subjects_NNS ._. Diabetics_NNS should_MD discuss_VB the_DT use_NN of_IN these_DT supplements_NNS with_IN their_PRP$ physicians_NNS and_CC note_NN if_IN the_DT supplements_NNS affect_VBP their_PRP$ glycemic_JJ control_NN ._. Diabetics_NNS who_WP take_VBP EPA_NNP supplements_NNS should_MD be_VB monitored_VBN by_IN their_PRP$ physicians_NNS ._. Other_JJ medicines_NNS -_: Although_IN certain_JJ medicines_NNS should_MD not_RB be_VB used_VBN together_RB at_IN all_DT ,_, in_IN other_JJ cases_NNS two_CD different_JJ medicines_NNS may_MD be_VB used_VBN together_RB even_RB if_IN an_DT interaction_NN might_MD occur_VB ._. In_IN these_DT cases_NNS ,_, your_PRP$ doctor_NN may_MD want_VB to_TO change_VB the_DT dose_NN ,_, or_CC other_JJ precautions_NNS may_MD be_VB necessary_JJ ._. When_WRB you_PRP are_VBP using_VBG idoxuridine_NN ,_, it_PRP is_VBZ especially_RB important_JJ that_IN your_PRP$ health_NN care_NN professional_JJ know_VBP if_IN you_PRP are_VBP using_VBG the_DT following_NN :_: Eye_NNP product_NN containing_VBG boric_JJ acid_NN ._. Boric_JJ acid_NN may_MD interact_VB with_IN the_DT idoxuridine_NN preparation_NN causing_VBG a_DT gritty_JJ substance_NN to_TO form_VB or_CC may_MD interact_VB with_IN the_DT preservative_NN in_IN the_DT idoxuridine_NN preparation_NN causing_VBG a_DT toxic_JJ effect_NN in_IN the_DT eye_NN ._. The_DT physician_NN should_MD be_VB alert_JJ for_IN possible_JJ combined_VBN drug_NN actions_NNS ,_, desirable_JJ or_CC undesirable_JJ ,_, involving_VBG ifosfamide_NN even_RB though_IN ifosfamide_NN has_VBZ been_VBN used_VBN successfully_RB concurrently_RB with_IN other_JJ drugs_NNS ,_, including_VBG other_JJ cytotoxic_JJ drugs_NNS ._. In_IN studies_NNS in_IN normal_JJ volunteers_NNS ,_, there_EX was_VBD no_DT pharmacodynamic_JJ interaction_NN between_IN intravenous_JJ iloprost_NN and_CC either_CC nifedipine_NN ,_, diltiazem_NN ,_, or_CC captopril_NN ._. However_RB ,_, iloprost_NN has_VBZ the_DT potential_JJ to_TO increase_VB the_DT hypotensive_JJ effect_NN of_IN vasodilators_NNS and_CC antihypertensive_JJ agents_NNS ._. Since_IN iloprost_NN inhibits_VBZ platelet_NN function_NN ,_, there_EX is_VBZ a_DT potential_NN for_IN increased_VBN risk_NN of_IN bleeding_NN ,_, particularly_RB in_IN patients_NNS maintained_VBN on_IN anticoagulants_NNS ._. During_IN clinical_JJ trials_NNS ,_, iloprost_NN was_VBD used_VBN concurrently_RB with_IN anticoagulants_NNS ,_, diuretics_NNS ,_, cardiac_JJ glycosides_NNS ,_, calcium_NN channel_NN blockers_NNS ,_, analgesics_NNS ,_, antipyretics_NNS ,_, nonsteroidal_JJ antiinflammatories_NNS ,_, corticosteroids_NNS ,_, and_CC other_JJ medications_NNS ._. Intravenous_JJ infusion_NN of_IN iloprost_NN had_VBD no_DT effect_NN on_IN the_DT pharmacokinetics_NNS of_IN digoxin_NN ._. Acetylsalicylic_JJ acid_NN did_VBD not_RB alter_VB the_DT clearance_NN -LRB-_-LRB- pharmacokinetics_NNS -RRB-_-RRB- of_IN iloprost_FW ._. Although_IN clinical_JJ studies_NNS have_VBP not_RB been_VBN conducted_VBN ,_, in_FW vitro_FW studies_NNS of_IN iloprost_JJ indicate_VBP that_IN no_DT relevant_JJ inhibition_NN of_IN cytochrome_NN P450_NN drug_NN metabolism_NN would_MD be_VB expected_VBN ._. Drugs_NNS that_WDT may_MD alter_VB imatinib_JJ plasma_NN concentrations_NNS Drugs_NNS that_WDT may_MD increase_VB imatinib_JJ plasma_NN concentrations_NNS :_: Caution_NN is_VBZ recommended_VBN when_WRB administering_VBG Gleevec_NN with_IN inhibitors_NNS of_IN the_DT CYP3A4_NN family_NN -LRB-_-LRB- e.g._FW ,_, ketoconazole_NN ,_, itraconazole_NN ,_, erythromycin_NN ,_, clarithromycin_NN -RRB-_-RRB- ._. Substances_NNS that_WDT inhibit_VBP the_DT cytochrome_NN P450_NN isoenzyme_NN -LRB-_-LRB- CYP3A4_NN -RRB-_-RRB- activity_NN may_MD decrease_VB metabolism_NN and_CC increase_NN imatinib_NN concentrations_NNS ._. There_EX is_VBZ a_DT significant_JJ increase_NN in_IN exposure_NN to_TO imatinib_NN when_WRB Gleevec_NNP is_VBZ coadministered_VBN with_IN ketoconazole_NN -LRB-_-LRB- CYP3A4_NN inhibitor_NN -RRB-_-RRB- ._. Drugs_NNS that_WDT may_MD decrease_VB imatinib_JJ plasma_NN concentrations_NNS :_: Substances_NNS that_WDT are_VBP inducers_NNS of_IN CYP3A4_NN activity_NN may_MD increase_VB metabolism_NN and_CC decrease_VB imatinib_JJ plasma_NN concentrations_NNS ._. Co-medications_NNS that_WDT induce_VBP CYP3A4_NN -LRB-_-LRB- e.g._FW ,_, dexamethasone_NN ,_, phenytoin_NN ,_, carbamazepine_NN ,_, rifampin_NN ,_, phenobarbital_NN or_CC St._NNP Johns_NNP Wort_NNP -RRB-_-RRB- may_MD significantly_RB reduce_VB exposure_NN to_TO Gleevec_NNP ._. Pretreatment_NN of_IN healthy_JJ volunteers_NNS with_IN multiple_JJ doses_NNS of_IN rifampin_NN followed_VBN by_IN a_DT single_JJ dose_NN of_IN Gleevec_NNP ,_, increased_VBD Gleevec_NNP oral-dose_JJ clearance_NN by_IN 3.8-fold_JJ ,_, which_WDT significantly_RB -LRB-_-LRB- p_NN 0.05_CD -RRB-_-RRB- decreased_VBD mean_NN cmax_NN and_CC AUC_NN -LRB-_-LRB- 0-8_CD -RRB-_-RRB- ._. In_IN patients_NNS where_WRB rifampin_NN or_CC other_JJ CYP3A4_NN inducers_NNS are_VBP indicated_VBN ,_, alternative_JJ therapeutic_JJ agents_NNS with_IN less_JJR enzyme_NN induction_NN potential_NN should_MD be_VB considered_VBN ._. Drugs_NNS that_WDT may_MD have_VB their_PRP$ plasma_NN concentration_NN altered_VBN by_IN Gleevec_NNP Gleevec_NNP increases_VBZ the_DT mean_NN cmax_NN and_CC AUC_NN of_IN simvastatin_NN -LRB-_-LRB- CYP3A4_NN substrate_NN -RRB-_-RRB- 2_LS -_: and_CC 3.5-fold_RB ,_, respectively_RB ,_, suggesting_VBG an_DT inhibition_NN of_IN the_DT CYP3A4_NN by_IN Gleevec_NNP ._. Particular_JJ caution_NN is_VBZ recommended_VBN when_WRB administering_VBG Gleevec_NN with_IN CYP3A4_NN substrates_NNS that_WDT have_VBP a_DT narrow_JJ therapeutic_JJ window_NN -LRB-_-LRB- e.g._FW ,_, cyclosporine_NN or_CC pimozide_NN -RRB-_-RRB- ._. Gleevec_NNP will_MD increase_VB plasmaconcentration_NN of_IN other_JJ CYP3A4_NN metabolized_VBN drugs_NNS -LRB-_-LRB- e.g._FW ,_, triazolo-benzodiazepines_NNS ,_, dihydropyridine_NN calcium_NN channel_NN blockers_NNS ,_, certain_JJ HMG-CoA_NN reductase_NN inhibitors_NNS ,_, etc._FW -RRB-_-RRB- ._. Because_IN warfarin_NN is_VBZ metabolized_VBN by_IN CYP2C9_NN and_CC CYP3A4_NN ,_, patients_NNS who_WP require_VBP anticoagulation_NN should_MD receive_VB low-molecular_JJ weight_NN or_CC standard_JJ heparin_NN ._. in_FW vitro_FW ,_, Gleevec_NN inhibits_VBZ the_DT cytochrome_NN P450_NN isoenzyme_NN CYP2D6_NN activity_NN at_IN similar_JJ concentrations_NNS that_WDT affect_VBP CYP3A4_NN activity_NN ._. Systemic_JJ exposure_NN to_TO substrates_NNS of_IN CYP2D6_NN is_VBZ expected_VBN to_TO be_VB increased_VBN when_WRB coadministered_VBN with_IN Gleevec_NN ._. No_DT specific_JJ studies_NNS have_VBP been_VBN performed_VBN and_CC caution_NN is_VBZ recommended_VBN ._. in_FW vitro_FW ,_, Gleevec_NN inhibits_VBZ acetaminophen_NN O-glucuronidation_NN -LRB-_-LRB- Ki_NN value_NN of_IN 58.5_CD M_NN -RRB-_-RRB- at_IN therapeutic_JJ levels_NNS ._. Systemic_JJ exposure_NN to_TO acetaminophen_NN is_VBZ expected_VBN to_TO be_VB increased_VBN when_WRB coadministered_VBN with_IN Gleevec_NN ._. No_DT specific_JJ studies_NNS in_IN humans_NNS have_VBP been_VBN performed_VBN and_CC caution_NN is_VBZ recommended_VBN ._. In_IN occasional_JJ susceptible_JJ patients_NNS or_CC in_IN those_DT receiving_VBG anticholinergic_JJ drugs_NNS -LRB-_-LRB- including_VBG antiparkinsonism_JJ agents_NNS -RRB-_-RRB- in_IN addition_NN ,_, the_DT atropine-like_JJ effects_NNS may_MD become_VB more_RBR pronounced_JJ -LRB-_-LRB- e.g._FW ,_, paralytic_JJ ileus_NN -RRB-_-RRB- ._. Close_JJ supervision_NN and_CC careful_JJ adjustment_NN of_IN dosage_NN is_VBZ required_VBN when_WRB this_DT drug_NN is_VBZ administered_VBN concomitantly_RB with_IN anticholinergic_JJ drugs_NNS ._. Avoid_VB the_DT use_NN of_IN preparations_NNS such_JJ as_IN decongestants_NNS and_CC local_JJ anesthetics_NNS which_WDT contain_VBP any_DT sympathomimetic_JJ amine_NN -LRB-_-LRB- e.g._FW ,_, epinephrine_NN ,_, norepinephrine_NN -RRB-_-RRB- ,_, since_IN it_PRP has_VBZ been_VBN reported_VBN that_IN tricyclic_JJ antidepressants_NNS can_MD potentiate_VB the_DT effects_NNS of_IN catecholamines_NNS ._. Caution_NN should_MD be_VB exercised_VBN when_WRB imipramine_NN hydrochloride_NN is_VBZ used_VBN with_IN agents_NNS that_WDT lower_JJR blood_NN pressure_NN ._. Imipramine_NN hydrochloride_NN may_MD potentiate_VB the_DT effects_NNS of_IN CNS_NN depressant_NN drugs_NNS ._. The_DT plasma_NN concentration_NN of_IN imipramine_NN may_MD increase_VB when_WRB the_DT drug_NN is_VBZ given_VBN concomitantly_RB with_IN hepatic_JJ enzyme_NN inhibitors_NNS -LRB-_-LRB- e.g._FW ,_, cimetidine_NN ,_, fluoxetine_NN -RRB-_-RRB- and_CC decrease_NN by_IN concomitant_JJ administration_NN of_IN hepatic_JJ enzyme_NN inducers_NNS -LRB-_-LRB- e.g._FW ,_, barbiturates_NNS ,_, phenytoin_NN -RRB-_-RRB- ,_, and_CC adjustment_NN of_IN the_DT dosage_NN of_IN imipramine_NN may_MD therefore_RB be_VB necessary_JJ ._. Drugs_NNS Metabolized_VBN by_IN P450_NN 2D6_NN The_DT biochemical_JJ activity_NN of_IN the_DT drug_NN metabolizing_VBG isozyme_NN cytochrome_NN P450_NN 2D6_NN -LRB-_-LRB- debrisoquin_NN hydroxylase_NN -RRB-_-RRB- is_VBZ reduced_VBN in_IN a_DT subset_NN of_IN the_DT caucasian_JJ population_NN -LRB-_-LRB- about_IN 7_CD to_TO 10_CD %_NN of_IN caucasians_NNS are_VBP so_RB called_VBN poor_JJ metabolizers_NNS -RRB-_-RRB- ;_: ._. reliable_JJ estimates_NNS of_IN the_DT prevalence_NN of_IN reduced_VBN P450_NN 2D6_NN isozyme_NN activity_NN among_IN Asian_JJ ,_, African_JJ and_CC other_JJ populations_NNS are_VBP not_RB yet_RB available_JJ ._. Poor_NNP metabolizers_NNS have_VBP higher_JJR than_IN expected_VBN plasma_NN concentrations_NNS of_IN tricyclic_JJ antidepressants_NNS -LRB-_-LRB- TCAs_NNS -RRB-_-RRB- when_WRB given_VBN usual_JJ doses_NNS ._. Depending_VBG on_IN the_DT fraction_NN of_IN drug_NN metabolized_VBN by_IN P450_NN 2D6_NN ,_, the_DT increase_NN in_IN plasma_NN concentration_NN may_MD be_VB small_JJ ,_, or_CC quite_RB large_JJ -LRB-_-LRB- 8-fold_JJ increase_NN in_IN plasma_NN AUC_NN of_IN the_DT TCA_NNP -RRB-_-RRB- ._. In_IN addition_NN ,_, certain_JJ drugs_NNS inhibit_VBP the_DT activity_NN of_IN this_DT isozyme_NN and_CC make_VB normal_JJ metabolizers_NNS resemble_VBP p.o._NN metabolizers_NNS ._. An_DT individual_NN who_WP is_VBZ stable_JJ on_IN a_DT given_VBN dose_NN of_IN TCA_NNP may_MD become_VB abruptly_RB toxic_JJ when_WRB given_VBN one_CD of_IN these_DT inhibiting_VBG drugs_NNS as_IN concomitant_JJ therapy_NN ._. The_DT drugs_NNS that_WDT inhibit_VBP cytochrome_NN P450_NN 2D6_NN include_VBP some_DT that_WDT are_VBP not_RB metabolized_VBN by_IN the_DT enzyme_NN -LRB-_-LRB- quinidine_NN ._. cimetidine_NN -RRB-_-RRB- and_CC many_JJ that_WDT are_VBP substrates_NNS for_IN P450_NN 2D6_NN -LRB-_-LRB- many_JJ other_JJ antidepressants_NNS ,_, phenothiazines_NNS ,_, and_CC the_DT Type_NN 1C_NN antiarrhythmics_NNS propafenone_NN and_CC flecainide_NN -RRB-_-RRB- ._. While_IN all_PDT the_DT selective_JJ serotonin_NN reuptake_NN inhibitors_NNS -LRB-_-LRB- SSRIs_NNS -RRB-_-RRB- ,_, e._FW g._FW ,_, fluoxetine_NN ,_, sertraline_NN ,_, and_CC paroxetine_NN ,_, inhibit_VBP P450_NN 2D6_NN ,_, they_PRP may_MD vary_VB in_IN the_DT extent_NN of_IN inhibition_NN ._. The_DT extent_NN to_TO which_WDT SSRI-TCA_NNP interactions_NNS may_MD pose_VB clinical_JJ problems_NNS will_MD depend_VB on_IN the_DT degree_NN of_IN inhibition_NN ,_, and_CC the_DT pharmacokinetics_NNS of_IN the_DT SSRI_NNP involved_VBN ._. Nevertheless_RB ,_, caution_NN is_VBZ indicated_VBN in_IN the_DT co-administration_NN of_IN TCA5_NN with_IN any_DT of_IN the_DT SSRIs_NNS and_CC also_RB in_IN switching_NN from_IN one_CD class_NN to_TO the_DT other_JJ ._. Of_IN particular_JJ importance_NN ,_, sufficient_JJ time_NN must_MD elapse_VB before_IN initiating_VBG TCA_NNP treatment_NN in_IN a_DT patient_NN being_VBG withdrawn_VBN from_IN fluoxetine_NN ,_, given_VBN the_DT long_JJ half-life_NN of_IN the_DT parent_NN and_CC active_JJ metabolite_NN -LRB-_-LRB- at_IN least_JJS 5_CD weeks_NNS may_MD be_VB necessary_JJ -RRB-_-RRB- ._. Concomitant_JJ use_NN of_IN tricyclic_JJ antidepressants_NNS with_IN drugs_NNS that_WDT can_MD inhibit_VB cytochrome_NN P450_NN 2D6_NN may_MD require_VB lower_JJR doses_NNS than_IN usually_RB prescribed_VBN for_IN either_CC the_DT tricyclic_JJ antidepressant_JJ or_CC the_DT other_JJ drug_NN ._. Furthermore_RB ,_, whenever_WRB one_CD of_IN these_DT other_JJ drugs_NNS is_VBZ withdrawn_VBN from_IN cotherapy_NN ,_, an_DT increased_VBN dose_NN of_IN tricyclic_JJ antidepressant_JJ may_MD be_VB required_VBN ._. It_PRP is_VBZ desirable_JJ to_TO monitor_VB TCA_NNP plasma_NN levels_NNS whenever_WRB a_DT TCA_NNP is_VBZ going_VBG to_TO be_VB co-administered_VBN with_IN another_DT drug_NN known_VBN to_TO be_VB an_DT inhibitor_NN of_IN P450_NN 2D6_NN ._. No_DT information_NN available_JJ ._. Indinavir_NNP is_VBZ an_DT inhibitor_NN of_IN the_DT cytochrome_NN P450_NN isoform_NN CYP3A4_NN ._. Coadministration_NNP of_IN CRIXIVAN_NNP and_CC drugs_NNS primarily_RB metabolized_VBN by_IN CYP3A4_NN may_MD result_VB in_IN increased_VBN plasma_NN concentrations_NNS of_IN the_DT other_JJ drug_NN ,_, which_WDT could_MD increase_VB or_CC prolong_VB its_PRP$ therapeutic_JJ and_CC adverse_JJ effects_NNS ._. Indinavir_NNP is_VBZ metabolized_VBN by_IN CYP3A4_NN ._. Drugs_NNS that_WDT induce_VBP CYP3A4_NN activity_NN would_MD be_VB expected_VBN to_TO increase_VB the_DT clearance_NN of_IN indinavir_NN ,_, resulting_VBG in_IN lowered_JJ plasma_NN concentrations_NNS of_IN indinavir_NN ._. Coadministration_NNP of_IN CRIXIVAN_NNP and_CC other_JJ drugs_NNS that_WDT inhibit_VBP CYP3A4_NN may_MD decrease_VB the_DT clearance_NN of_IN indinavir_NN and_CC may_MD result_VB in_IN increased_VBN plasma_NN concentrations_NNS of_IN indinavir_NN ._. Table_NNP 8_CD ._. Drugs_NNS That_WDT Should_MD Not_RB Be_VB Coadministered_VBN with_IN CRIXIVA_NN ._. Drug_NN Class_NN :_: Drug_NNP Name_VB Clinical_JJ Comment_NN ._. Antiarrhythmics_NNS :_: amiodaron_NN ._. CONTRAINDICATED_VBN due_JJ to_TO potential_JJ for_IN serious_JJ and/or_CC life-threatening_JJ reactions_NNS such_JJ as_IN cardiac_JJ arrhythmias_NNS ._. Ergot_NNP derivatives_NNS :_: dihydroergotamine_NN ,_, ergonovine_NN ,_, ergotamine_NN ,_, methylergonovin_NN ._. CONTRAINDICATED_VBN due_JJ to_TO potential_JJ for_IN serious_JJ and/or_CC life-threatening_JJ reactions_NNS such_JJ as_IN acute_JJ ergot_NN toxicity_NN characterized_VBN by_IN peripheral_JJ vasospasm_NN and_CC ischemia_NN of_IN the_DT extremities_NNS and_CC other_JJ tissues_NNS ._. Sedative/hypnotics_NNS :_: midazolam_NN ,_, triazola_NN ._. CONTRAINDICATED_VBN due_JJ to_TO potential_JJ for_IN serious_JJ and/or_CC life-threatening_JJ reactions_NNS such_JJ as_IN prolonged_JJ or_CC increased_VBN sedation_NN or_CC respiratory_JJ depression_NN ._. GI_NN motility_NN agents_NNS :_: cisaprid_NN ._. CONTRAINDICATED_VBN due_JJ to_TO potential_JJ for_IN serious_JJ and/or_CC life-threatening_JJ reactions_NNS such_JJ as_IN cardiac_JJ arrhythmias_NNS ._. Neuroleptic_JJ :_: pimozid_NN ._. CONTRAINDICATED_VBN due_JJ to_TO potential_JJ for_IN serious_JJ and/or_CC life-threatening_JJ reactions_NNS such_JJ as_IN cardiac_JJ arrhythmias_NNS ._. Herbal_JJ products_NNS :_: St._NNP John_NNP s_VBZ wort_NN -LRB-_-LRB- Hypericum_NN perforatum_NN -RRB-_-RRB- ._. May_MD lead_VB to_TO loss_NN of_IN virologic_JJ response_NN and_CC possible_JJ resistance_NN to_TO CRIXIVAN_NNP or_CC to_TO the_DT class_NN of_IN protease_NN inhibitors_NNS ._. Antimycobacterial_NNP :_: rifampi_NNS ._. May_MD lead_VB to_TO loss_NN of_IN virologic_JJ response_NN and_CC possible_JJ resistance_NN to_TO CRIXIVAN_NNP or_CC to_TO the_DT class_NN of_IN protease_NN inhibitors_NNS or_CC other_JJ coadministered_VBN antiretroviral_JJ agents_NNS ._. HMG-CoA_NN Reductase_NN inhibitors_NNS :_: lovastatin_NN ,_, simvastati_NN ._. Potential_JJ for_IN serious_JJ reactions_NNS such_JJ as_IN risk_NN of_IN myopathy_NN including_VBG rhabdomyolysis_NN ._. Protease_NN inhibitor_NN :_: atazanavi_NN ._. Both_DT CRIXIVAN_NNP and_CC atazanavir_NN are_VBP associated_VBN with_IN indirect_JJ -LRB-_-LRB- unconjugated_JJ -RRB-_-RRB- hyperbilirubinemia_NN ._. Combinations_NNS of_IN these_DT drugs_NNS have_VBP not_RB been_VBN studied_VBN and_CC coadministration_NN of_IN CRIXIVAN_NNP and_CC atazanavir_NN is_VBZ not_RB recommended_VBN ._. Table_NNP 9_CD ._. Established_VBN and_CC Other_JJ Potentially_RB Significant_JJ Drug_NN Interactions_NNS :_: Alteration_NN in_IN Dose_NN or_CC Regimen_NNP May_NNP Be_VB Recommended_VBN Based_VBN on_IN Drug_NN Interaction_NN Studies_NNS or_CC Predicted_VBN Interaction_NN ._. Drug_NN Name_VB ._. Effect_NN ._. Clinical_JJ Comment_NN ._. HIV_NN Antiviral_JJ Agent_NNP ._. Delavirdin_NNP ._. indinavir_NN concentratio_NN ._. Dose_NN reduction_NN of_IN CRIXIVAN_NNP to_TO 600_CD mg_NN every_DT 8_CD hours_NNS should_MD be_VB considered_VBN when_WRB taking_VBG delavirdine_NN 400_CD mg_NN three_CD times_NNS a_DT day_NN ._. Didanosin_NNP ._. Indinavir_NNP and_CC didanosine_NN formulations_NNS containing_VBG buffer_NN should_MD be_VB administered_VBN at_IN least_JJS one_CD hour_NN apart_RB on_IN an_DT empty_JJ stomach_NN ._. Efaviren_NNP ._. indinavir_NN concentratio_NN ._. The_DT optimal_JJ dose_NN of_IN indinavir_NN ,_, when_WRB given_VBN in_IN combination_NN with_IN efavirenz_NN ,_, is_VBZ not_RB known_VBN ._. Increasing_VBG the_DT indinavir_NN dose_NN to_TO 1000_CD mg_NN every_DT 8_CD hours_NNS does_VBZ not_RB compensate_VB for_IN the_DT increased_VBN indinavir_NN metabolism_NN due_JJ to_TO efavirenz_NN ._. Nelfinavi_NNP ._. indinavir_NN concentratio_NN ._. The_DT appropriate_JJ doses_NNS for_IN this_DT combination_NN ,_, with_IN respect_NN to_TO efficacy_NN and_CC safety_NN ,_, have_VBP not_RB been_VBN established_VBN ._. Nevirapin_NNP ._. indinavir_NN concentratio_NN ._. Indinavir_NNP concentrations_NNS may_MD be_VB decreased_VBN in_IN the_DT presence_NN of_IN nevirapine_NN ._. The_DT appropriate_JJ doses_NNS for_IN this_DT combination_NN ,_, with_IN respect_NN to_TO efficacy_NN and_CC safety_NN ,_, have_VBP not_RB been_VBN established_VBN ._. Ritonavi_NNP ._. indinavir_NN concentration_NN ritonavir_NN concentratio_NN ._. The_DT appropriate_JJ doses_NNS for_IN this_DT combination_NN ,_, with_IN respect_NN to_TO efficacy_NN and_CC safety_NN ,_, have_VBP not_RB been_VBN established_VBN ._. Preliminary_JJ clinical_JJ data_NNS suggest_VBP that_IN the_DT incidence_NN of_IN nephrolithiasis_NN is_VBZ higher_JJR in_IN patients_NNS receiving_VBG indinavir_NN in_IN combination_NN with_IN ritonavir_NN than_IN those_DT receiving_VBG CRIXIVAN_NN 800_CD mg_NN q8h_NN ._. Saquinavi_NNP ._. saquinavir_NN concentratio_NN ._. The_DT appropriate_JJ doses_NNS for_IN this_DT combination_NN ,_, with_IN respect_NN to_TO efficacy_NN and_CC safety_NN ,_, have_VBP not_RB been_VBN established_VBN ._. Other_JJ Agents_NNS ._. Antiarrhythmics_NNS :_: bepridil_NN ,_, lidocaine_NN -LRB-_-LRB- systemic_JJ -RRB-_-RRB- and_CC quinidin_NN ._. antiarrhythmic_JJ agents_NNS concentratio_NN ._. Caution_NN is_VBZ warranted_VBN and_CC therapeutic_JJ concentration_NN monitoring_NN is_VBZ recommended_VBN for_IN antiarrhythmics_NNS when_WRB coadministered_VBN with_IN CRIXIVAN_NNP ._. Anticonvulsants_NNPS :_: carbamazepine_NN ,_, phenobarbital_NN ,_, phenytoi_NN ._. indinavir_NN concentratio_NN ._. Use_NN with_IN caution_NN ._. CRIXIVAN_NNP may_MD not_RB be_VB effective_JJ due_JJ to_TO decreased_VBN indinavir_NN concentrations_NNS in_IN patients_NNS taking_VBG these_DT agents_NNS concomitantly_RB ._. Calcium_NN Channel_NNP Blockers_NNP ,_, Dihydropyridine_NNP :_: e.g._FW ,_, felodipine_NN ,_, nifedipine_NN ,_, nicardipin_NN ._. dihydropyridine_NN calcium_NN channel_NN blockers_NNS concentratio_NN ._. Caution_NN is_VBZ warranted_VBN and_CC clinical_JJ monitoring_NN of_IN patients_NNS is_VBZ recommended_VBN ._. Clarithromyci_NNP ._. clarithromycin_NN concentration_NN indinavir_NN concentratio_NN ._. The_DT appropriate_JJ doses_NNS for_IN this_DT combination_NN ,_, with_IN respect_NN to_TO efficacy_NN and_CC safety_NN ,_, have_VBP not_RB been_VBN established_VBN ._. HMG-CoA_NN Reductase_NNP Inhibitor_NNP :_: atorvastati_NNS ._. atorvastatin_NN concentratio_NN ._. Use_NNP lowest_JJS possible_JJ dose_NN of_IN atorvastatin_NN with_IN careful_JJ monitoring_NN ,_, or_CC consider_VB HMG-CoA_NN reductase_NN inhibitors_NNS that_WDT are_VBP not_RB primarily_RB metabolized_VBN by_IN CYP3A4_NN ,_, such_JJ as_IN pravastatin_NN ,_, fluvastatin_NN ,_, or_CC rosuvastatin_NN in_IN combination_NN with_IN CRIXIVAN_NNP ._. Immunosuppressants_NNS :_: cyclosporine_NN ,_, tacrolimus_NN ,_, sirolimu_NN ._. immunosuppressant_JJ agents_NNS concentratio_NN ._. Plasma_NN concentrations_NNS may_MD be_VB increased_VBN by_IN CRIXIVAN_NNP ._. Itraconazol_NNP ._. indinavir_NN concentratio_NN ._. Dose_NN reduction_NN of_IN CRIXIVAN_NNP to_TO 600_CD mg_NN every_DT 8_CD hours_NNS is_VBZ recommended_VBN when_WRB administering_VBG itraconazole_NN concurrently_RB ._. Ketoconazol_NNP ._. indinavir_NN concentratio_NN ._. 
Dose_NN reduction_NN of_IN CRIXIVAN_NNP to_TO 600_CD mg_NN every_DT 8_CD hours_NNS should_MD be_VB considered_VBN ._. Rifabuti_NNP ._. indinavir_NN concentration_NN rifabutin_NN concentratio_NN ._. Dose_NN reduction_NN of_IN rifabutin_NN to_TO half_PDT the_DT standard_JJ dose_NN and_CC a_DT dose_NN increase_NN of_IN CRIXIVAN_NNP to_TO 1000_CD mg_NN -LRB-_-LRB- three_CD 333-mg_JJ capsules_NNS -RRB-_-RRB- every_DT 8_CD hours_NNS are_VBP recommended_VBN when_WRB rifabutin_NN and_CC CRIXIVAN_NNP are_VBP coadministered_VBN ._. Sildenafi_NNP ._. sildenafil_NN concentratio_NN ._. Sildenafil_NNP dose_NN should_MD not_RB exceed_VB a_DT maximum_NN of_IN 25_CD mg_NN in_IN a_DT 48_CD -_: hour_NN period_NN in_IN patients_NNS receiving_VBG concomitant_JJ indinavir_NN therapy_NN ._. Tadalafi_NNP ._. tadalafil_NN concentratio_NN ._. Tadalafil_NNP dose_NN should_MD not_RB exceed_VB a_DT maximum_NN of_IN 10_CD mg_NN in_IN a_DT 72_CD -_: hour_NN period_NN in_IN patients_NNS receiving_VBG concomitant_JJ indinavir_NN therapy_NN ._. Vardenafi_NNP ._. vardenafil_NN concentratio_NN ._. Vardenafil_NNP dose_NN should_MD not_RB exceed_VB a_DT maximum_NN of_IN 2.5_CD mg_NN in_IN a_DT 24-hour_JJ period_NN in_IN patients_NNS receiving_VBG concomitant_JJ indinavir_NN therapy_NN ._. Note_VB :_: ._. =_JJ increase_NN ;_: ._. =_JJ decrease_NN ._. In_IN normal_JJ volunteers_NNS receiving_VBG indomethacin_NN ,_, the_DT administration_NN of_IN diflunisal_JJ decreased_VBD the_DT renal_JJ clearance_NN and_CC significantly_RB increased_VBD the_DT plasma_NN levels_NNS of_IN indomethacin_NN ._. In_IN some_DT patients_NNS ,_, combined_VBN use_NN of_IN INDOCIN_NNP and_CC diflunisal_NN has_VBZ been_VBN associated_VBN with_IN fatal_JJ gastrointestinal_JJ hemorrhage_NN ._. Therefore_RB ,_, diflunisal_NN and_CC INDOCIN_NN should_MD not_RB be_VB used_VBN concomitantly_RB ._. In_IN a_DT study_NN in_IN normal_JJ volunteers_NNS ,_, it_PRP was_VBD found_VBN that_IN chronic_JJ concurrent_JJ administration_NN of_IN 3.6_CD g_NN of_IN aspirin_NN per_IN day_NN decreases_VBZ indomethacin_NN blood_NN levels_NNS approximately_RB 20_CD %_NN ._. The_DT concomitant_JJ use_NN of_IN INDOCIN_NN with_IN other_JJ NSAIDs_NNS is_VBZ not_RB recommended_VBN due_JJ to_TO the_DT increased_VBN possibility_NN of_IN gastrointestinal_JJ toxicity_NN ,_, with_IN little_JJ or_CC no_DT increase_NN in_IN efficacy_NN ._. Clinical_JJ studies_NNS have_VBP shown_VBN that_IN INDOCIN_NNP does_VBZ not_RB influence_VB the_DT hypoprothrombinemia_NN produced_VBN by_IN anticoagulants_NNS ._. However_RB ,_, when_WRB any_DT additional_JJ drug_NN ,_, including_VBG INDOCIN_NNP ,_, is_VBZ added_VBN to_TO the_DT treatment_NN of_IN patients_NNS on_IN anticoagulant_JJ therapy_NN ,_, the_DT patients_NNS should_MD be_VB observed_VBN for_IN alterations_NNS of_IN the_DT prothrombin_NN time_NN ._. In_IN post-marketing_JJ experience_NN ,_, bleeding_NN has_VBZ been_VBN reported_VBN in_IN patients_NNS on_IN concomitant_JJ treatment_NN with_IN anticoagulants_NNS and_CC INDOCIN_NNP ._. Caution_NN should_MD be_VB exercised_VBN when_WRB INDOCIN_NNP and_CC anticoagulants_NNS are_VBP administered_VBN concomitantly_RB ._. When_WRB INDOCIN_NNP is_VBZ given_VBN to_TO patients_NNS receiving_VBG probenecid_NN ,_, the_DT plasma_NN levels_NNS of_IN indomethacin_NN are_VBP likely_JJ to_TO be_VB increased_VBN ._. Therefore_RB ,_, a_DT lower_JJR total_JJ daily_RB dosage_NN of_IN INDOCIN_NNP may_MD produce_VB a_DT satisfactory_JJ therapeutic_JJ effect_NN ._. When_WRB increases_NNS in_IN the_DT dose_NN of_IN INDOCIN_NNP are_VBP made_VBN ,_, they_PRP should_MD be_VB made_VBN carefully_RB and_CC in_IN small_JJ increments_NNS ._. Caution_NN should_MD be_VB used_VBN if_IN INDOCIN_NNP is_VBZ administered_VBN simultaneously_RB with_IN methotrexate_NN ._. INDOCIN_NNP has_VBZ been_VBN reported_VBN to_TO decrease_VB the_DT tubular_JJ secretion_NN of_IN methotrexate_NN and_CC to_TO potentiate_VB its_PRP$ toxicity_NN ._. Administration_NN of_IN non-steroidal_JJ anti-inflammatory_JJ drugs_NNS concomitantly_RB with_IN cyclosporine_NN has_VBZ been_VBN associated_VBN with_IN an_DT increase_NN in_IN cyclosporine-induced_JJ toxicity_NN ,_, possibly_RB due_JJ to_TO decreased_VBN synthesis_NN of_IN renal_JJ prostacyclin_NN ._. NSAIDs_NNS should_MD be_VB used_VBN with_IN caution_NN in_IN patients_NNS taking_VBG cyclosporine_NN ,_, and_CC renal_JJ function_NN should_MD be_VB carefully_RB monitored_VBN ._. Capsules_NNS INDOCIN_NNP 50_CD mg_NN t.i.d._NN produced_VBD a_DT clinically_RB relevant_JJ elevation_NN of_IN plasma_NN lithium_NN and_CC reduction_NN in_IN renal_JJ lithium_NN clearance_NN in_IN psychiatric_JJ patients_NNS and_CC normal_JJ subjects_NNS with_IN steady_JJ state_NN plasma_NN lithium_NN concentrations_NNS ._. This_DT effect_NN has_VBZ been_VBN attributed_VBN to_TO inhibition_NN of_IN prostaglandin_NN synthesis_NN ._. As_IN a_DT consequence_NN ,_, when_WRB INDOCIN_NNP and_CC lithium_NN are_VBP given_VBN concomitantly_RB ,_, the_DT patient_NN should_MD be_VB carefully_RB observed_VBN for_IN signs_NNS of_IN lithium_NN toxicity_NN ._. -LRB-_-LRB- Read_VB circulars_NNS for_IN lithium_NN preparations_NNS before_IN use_NN of_IN such_JJ concomitant_JJ therapy_NN ._. In_IN addition_NN ,_, the_DT frequency_NN of_IN monitoring_VBG serum_NN lithium_NN concentration_NN should_MD be_VB increased_VBN at_IN the_DT outset_NN of_IN such_JJ combination_NN drug_NN treatment_NN ._. INDOCIN_NNP given_VBN concomitantly_RB with_IN digoxin_NN has_VBZ been_VBN reported_VBN to_TO increase_VB the_DT serum_NN concentration_NN and_CC prolong_VB the_DT half-life_NN of_IN digoxin_NN ._. Therefore_RB ,_, when_WRB INDOCIN_NNP and_CC digoxin_NN are_VBP used_VBN concomitantly_RB ,_, serum_NN digoxin_NN levels_NNS should_MD be_VB closely_RB monitored_VBN ._. In_IN some_DT patients_NNS ,_, the_DT administration_NN of_IN INDOCIN_NNP can_MD reduce_VB the_DT diuretic_JJ ,_, natriuretic_JJ ,_, and_CC antihypertensive_JJ effects_NNS of_IN loop_NN ,_, potassium-sparing_NN ,_, and_CC thiazide_JJ diuretics_NNS ._. Therefore_RB ,_, when_WRB INDOCIN_NNP and_CC INDOCIN_NNP ._. -LRB-_-LRB- Indomethacin_NN -RRB-_-RRB- diuretics_NNS are_VBP used_VBN concomitantly_RB ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB to_TO determine_VB if_IN the_DT desired_VBN effect_NN of_IN the_DT diuretic_JJ is_VBZ obtained_VBN ._. INDOCIN_NNP reduces_VBZ basal_JJ plasma_NN renin_NN activity_NN -LRB-_-LRB- PRA_NNP -RRB-_-RRB- ,_, as_RB well_RB as_IN those_DT elevations_NNS of_IN PRA_NNP induced_VBN by_IN furosemide_NN administration_NN ,_, or_CC salt_NN or_CC volume_NN depletion_NN ._. These_DT facts_NNS should_MD be_VB considered_VBN when_WRB evaluating_VBG plasma_NN renin_NN activity_NN in_IN hypertensive_JJ patients_NNS ._. It_PRP has_VBZ been_VBN reported_VBN that_IN the_DT addition_NN of_IN triamterene_NN to_TO a_DT maintenance_NN schedule_NN of_IN INDOCIN_NNP resulted_VBD in_IN reversible_JJ acute_JJ renal_JJ failure_NN in_IN two_CD of_IN four_CD healthy_JJ volunteers_NNS ._. INDOCIN_NNP and_CC triamterene_NN should_MD not_RB be_VB administered_VBN together_RB ._. INDOCIN_NNP and_CC potassium-sparing_JJ diuretics_NNS each_DT may_MD be_VB associated_VBN with_IN increased_VBN serum_NN potassium_NN levels_NNS ._. The_DT potential_JJ effects_NNS of_IN INDOCIN_NNP and_CC potassium-sparing_JJ diuretics_NNS on_IN potassium_NN kinetics_NNS and_CC renal_JJ function_NN should_MD be_VB considered_VBN when_WRB these_DT agents_NNS are_VBP administered_VBN concurrently_RB ._. Most_JJS of_IN the_DT above_JJ effects_NNS concerning_VBG diuretics_NNS have_VBP been_VBN attributed_VBN ,_, at_IN least_JJS in_IN part_NN ,_, to_TO mechanisms_NNS involving_VBG inhibition_NN of_IN prostaglandin_NN synthesis_NN by_IN INDOCIN_NNP ._. Blunting_VBG of_IN the_DT antihypertensive_JJ effect_NN of_IN beta-adrenoceptor_NN blocking_VBG agents_NNS by_IN non-steroidal_JJ antiinflammatory_JJ drugs_NNS including_VBG INDOCIN_NNP has_VBZ been_VBN reported_VBN ._. Therefore_RB ,_, when_WRB using_VBG these_DT blocking_VBG agents_NNS to_TO treat_VB hypertension_NN ,_, patients_NNS should_MD be_VB observed_VBN carefully_RB in_IN order_NN to_TO confirm_VB that_IN the_DT desired_VBN therapeutic_JJ effect_NN has_VBZ been_VBN obtained_VBN ._. INDOCIN_NNP can_MD reduce_VB the_DT antihypertensive_JJ effects_NNS of_IN captopril_NN and_CC losartan_NN ._. False-negative_JJ results_NNS in_IN the_DT dexamethasone_NN suppression_NN test_NN -LRB-_-LRB- DST_NN -RRB-_-RRB- in_IN patients_NNS being_VBG treated_VBN with_IN INDOCIN_NNP have_VBP been_VBN reported_VBN ._. Thus_RB ,_, results_NNS of_IN the_DT DST_NNP should_MD be_VB interpreted_VBN with_IN caution_NN in_IN these_DT patients_NNS ._. Concurrent_JJ administration_NN of_IN etanercept_NN -LRB-_-LRB- another_DT TNF_NN -_: blocking_VBG agent_NN -RRB-_-RRB- and_CC anakinra_NN -LRB-_-LRB- an_DT interleukin-1_NN antagonist_NN -RRB-_-RRB- has_VBZ been_VBN associated_VBN with_IN an_DT increased_VBN risk_NN of_IN serious_JJ infections_NNS ,_, and_CC increased_VBD risk_NN of_IN neutropenia_NN and_CC no_DT additional_JJ benefit_NN compared_VBN to_TO these_DT medicinal_JJ products_NNS alone_RB ._. Other_JJ TNFa-blocking_JJ agents_NNS -LRB-_-LRB- including_VBG REMICADE_NNP -RRB-_-RRB- used_VBN in_IN combination_NN with_IN anakinra_NN may_MD also_RB result_VB in_IN similar_JJ toxicities_NNS ._. Specific_JJ drug_NN interaction_NN studies_NNS ,_, including_VBG interactions_NNS with_IN MTX_NN ,_, have_VBP not_RB been_VBN conducted_VBN ._. The_DT majority_NN of_IN patients_NNS in_IN rheumatoid_JJ arthritis_NN or_CC Crohn_NN s_NNS disease_NN clinical_JJ studies_NNS received_VBD one_CD or_CC more_JJR concomitant_JJ medications_NNS ._. In_IN rheumatoid_JJ arthritis_NN ,_, concomitant_JJ medications_NNS besides_IN MTX_NN were_VBD nonsteroidal_JJ anti-inflammatory_JJ agents_NNS ,_, folic_JJ acid_NN ,_, corticosteroids_NNS and/or_CC narcotics_NNS ._. Concomitant_JJ Crohn_NN s_NNS disease_NN medications_NNS were_VBD antibiotics_NNS ,_, antivirals_NNS ,_, corticosteroids_NNS ,_, 6-MP/AZA_NN and_CC aminosalicylates_NNS ._. In_IN psoriatic_JJ arthritis_NN clinical_JJ trials_NNS ,_, concomitant_JJ medications_NNS included_VBD MTX_NNP in_IN approximately_RB half_DT of_IN the_DT patients_NNS as_RB well_RB as_IN nonsteroidal_JJ anti-inflammatory_JJ agents_NNS ,_, folic_JJ acid_NN and_CC corticosteroids_NNS ._. Patients_NNS with_IN Crohn_NN s_NNS disease_NN who_WP received_VBD immunosuppressants_NNS tended_VBD to_TO experience_VB fewer_JJR infusion_NN reactions_NNS compared_VBN to_TO patients_NNS on_IN no_DT immunosuppressants_NNS ._. Serum_NN infliximab_NN concentrations_NNS appeared_VBD to_TO be_VB unaffected_JJ by_IN baseline_NN use_NN of_IN medications_NNS for_IN the_DT treatment_NN of_IN Crohn_NN s_NNS disease_NN including_VBG corticosteroids_NNS ,_, antibiotics_NNS -LRB-_-LRB- metronidazole_NN or_CC ciprofloxacin_NN -RRB-_-RRB- and_CC aminosalicylates_NNS ._. A_DT number_NN of_IN substances_NNS affect_VBP glucose_NN metabolism_NN and_CC may_MD require_VB insulin_NN dose_NN adjustment_NN and_CC particularly_RB close_JJ monitoring_NN ._. The_DT following_VBG are_VBP examples_NNS of_IN substances_NNS that_WDT may_MD increase_VB the_DT blood-glucose-lowering_NN effect_NN and_CC susceptibility_NN to_TO hypoglycemia_NN :_: oral_JJ antidiabetes_NNS products_NNS ,_, ACE_NN inhibitors_NNS ,_, disopyramide_NN ,_, fibrates_NNS ,_, fluoxetine_NN ,_, MAO_NN inhibitors_NNS ,_, propoxyphene_NN ,_, salicylates_NNS ,_, somatostatin_NN analog_NN -LRB-_-LRB- e.g._FW ,_, octreotide_NN -RRB-_-RRB- ,_, sulfonamide_NN antibiotics_NNS ._. The_DT following_VBG are_VBP examples_NNS of_IN substances_NNS that_WDT may_MD reduce_VB the_DT blood-glucose-lowering_NN effect_NN of_IN insulin_NN :_: corticosteroids_NNS ,_, danazol_NN ,_, diuretics_NNS ,_, sympathomimetic_JJ agents_NNS -LRB-_-LRB- e.g._FW ,_, epinephrine_NN ,_, albuterol_NN ,_, terbutaline_NN -RRB-_-RRB- ,_, isoniazid_NN ,_, phenothiazine_NN derivatives_NNS ,_, somatropin_NN ,_, thyroid_NN hormones_NNS ,_, estrogens_NNS ,_, progestogens_NNS -LRB-_-LRB- e.g._FW ,_, in_IN oral_JJ contraceptives_NNS -RRB-_-RRB- ._. Beta-blockers_NNS ,_, clonidine_NN ,_, lithium_NN salts_NNS ,_, and_CC alcohol_NN may_MD either_RB potentiate_VB or_CC weaken_VB the_DT blood-glucose-lowering_NN effect_NN of_IN insulin_NN ._. Pentamidine_NNP may_MD cause_VB hypoglycemia_NN ,_, which_WDT may_MD sometimes_RB be_VB followed_VBN by_IN hyperglycemia_NN ._. In_IN addition_NN ,_, under_IN the_DT influence_NN of_IN sympatholytic_JJ medicinal_JJ products_NNS such_JJ as_IN beta-blockers_NNS ,_, clonidine_NN ,_, guanethidine_NN ,_, and_CC reserpine_NN ,_, the_DT signs_NNS of_IN hypoglycemia_NN may_MD be_VB reduced_VBN or_CC absent_JJ ._. A_DT number_NN of_IN substances_NNS affect_VBP glucose_NN metabolism_NN and_CC may_MD require_VB insulin_NN dose_NN adjustment_NN and_CC particularly_RB close_JJ monitoring_NN ._. The_DT following_VBG are_VBP examples_NNS of_IN substances_NNS that_WDT may_MD increase_VB the_DT blood-glucose-lowering_NN effect_NN and_CC susceptibility_NN to_TO hypoglycemia_NN :_: oral_JJ antidiabetic_JJ products_NNS ,_, ACE_NN inhibitors_NNS ,_, disopyramide_NN ,_, fibrates_NNS ,_, fluoxetine_NN ,_, monoamine_NN oxidase_NN -LRB-_-LRB- MAO_NN -RRB-_-RRB- inhibitors_NNS ,_, propoxyphene_NN ,_, salicylates_NNS ,_, somatostatin_NN analog_NN -LRB-_-LRB- e.g._FW ,_, octreotide_NN -RRB-_-RRB- ,_, sulfonamide_NN antibiotics_NNS ._. The_DT following_VBG are_VBP examples_NNS of_IN substances_NNS that_WDT may_MD reduce_VB the_DT blood-glucose-lowering_NN effect_NN :_: corticosteroids_NNS ,_, niacin_NN ,_, danazol_NN ,_, diuretics_NNS ,_, sympathomimetic_JJ agents_NNS -LRB-_-LRB- e.g._FW ,_, epinephrine_NN ,_, salbutamol_NN ,_, terbutaline_NN -RRB-_-RRB- ,_, isoniazid_NN ,_, phenothiazine_NN derivatives_NNS ,_, somatropin_NN ,_, thyroid_NN hormones_NNS ,_, estrogens_NNS ,_, progestogens_NNS -LRB-_-LRB- e.g._FW ,_, in_IN oral_JJ contraceptives_NNS -RRB-_-RRB- ._. Beta-blockers_NNS ,_, clonidine_NN ,_, lithium_NN salts_NNS ,_, and_CC alcohol_NN may_MD either_RB potentiate_VB or_CC weaken_VB the_DT blood-glucose-lowering_NN effect_NN of_IN insulin_NN ._. Pentamidine_NNP may_MD cause_VB hypoglycemia_NN ,_, which_WDT may_MD sometimes_RB be_VB followed_VBN by_IN hyperglycemia_NN ._. In_IN addition_NN ,_, under_IN the_DT influence_NN of_IN sympatholytic_JJ medicinal_JJ products_NNS such_JJ as_IN beta-blockers_NNS ,_, clonidine_NN ,_, guanethidine_NN ,_, and_CC reserpine_NN ,_, the_DT signs_NNS of_IN hypoglycemia_NN may_MD be_VB reduced_VBN or_CC absent_JJ ._. Mixing_NN of_IN Insulin_NN ._. A_DT clinical_JJ study_NN in_IN healthy_JJ male_JJ volunteers_NNS -LRB-_-LRB- n_NN =_JJ 24_CD -RRB-_-RRB- demonstrated_VBD that_IN mixing_VBG NovoLog_NN with_IN NPH_NN human_JJ insulin_NN immediately_RB before_IN injection_NN produced_VBD some_DT attenuation_NN in_IN the_DT peak_NN concentration_NN of_IN NovoLog_NNP ,_, but_CC that_IN the_DT time_NN to_TO peak_NN and_CC the_DT total_JJ bioavailability_NN of_IN NovoLog_NNP were_VBD not_RB significantly_RB affected_VBN ._. If_IN NovoLog_NNP is_VBZ mixed_VBN with_IN NPH_NN human_JJ insulin_NN ,_, NovoLog_NNP should_MD be_VB drawn_VBN into_IN the_DT syringe_NN first_RB ._. The_DT injection_NN should_MD be_VB made_VBN immediately_RB after_IN mixing_VBG ._. Because_IN there_EX are_VBP no_DT data_NNS on_IN the_DT compatibility_NN of_IN NovoLog_NNP and_CC crystalline_JJ zinc_NN insulin_NN preparations_NNS ,_, NovoLog_NNP should_MD not_RB be_VB mixed_VBN with_IN these_DT preparations_NNS ._. The_DT effects_NNS of_IN mixing_VBG NovoLog_NN with_IN insulins_NNS of_IN animal_NN source_NN or_CC insulin_NN preparations_NNS produced_VBN by_IN other_JJ manufacturers_NNS have_VBP not_RB been_VBN studied_VBN ._. Mixtures_NNS should_MD not_RB be_VB administered_VBN intravenously_RB ._. When_WRB used_VBN in_IN external_JJ subcutaneous_JJ infusion_NN pumps_NNS for_IN insulin_NN ,_, NovoLog_NNP should_MD not_RB be_VB mixed_VBN with_IN any_DT other_JJ insulins_NNS or_CC diluent_NN ._. No_DT formal_JJ drug_NN interaction_NN studies_NNS have_VBP been_VBN conducted_VBN with_IN Rebif_NN ._. Due_JJ to_TO its_PRP$ potential_JJ to_TO cause_VB neutropenia_NN and_CC lymphopenia_NN ,_, proper_JJ monitoring_NN of_IN patients_NNS is_VBZ required_VBN if_IN Rebif_NN is_VBZ given_VBN in_IN combination_NN with_IN myelosuppressive_JJ agents_NNS ._. Also_RB ,_, the_DT potential_NN for_IN hepatic_JJ injury_NN should_MD be_VB considered_VBN when_WRB Rebif_NNP is_VBZ used_VBN in_IN combination_NN with_IN other_JJ products_NNS associated_VBN with_IN hepatic_JJ injury_NN ,_, or_CC when_WRB new_JJ agents_NNS are_VBP added_VBN to_TO the_DT regimen_NN of_IN patients_NNS already_RB on_IN Rebif_NNP ._. Interactions_NNS between_IN Betaseron_NNP and_CC other_JJ drugs_NNS have_VBP not_RB been_VBN fully_RB evaluated_VBN ._. Although_IN studies_NNS designed_VBN to_TO examine_VB drug_NN interactions_NNS have_VBP not_RB been_VBN done_VBN ,_, it_PRP was_VBD noted_VBN that_IN corticosteroid_NN or_CC ACTH_NN treatment_NN of_IN relapses_NNS for_IN periods_NNS of_IN up_RB to_TO 28_CD days_NNS has_VBZ been_VBN administered_VBN to_TO patients_NNS -LRB-_-LRB- N_NN =_JJ 180_CD -RRB-_-RRB- receiving_VBG Betaseron_NNP ._. Betaseron_NNP administration_NN to_TO three_CD cancer_NN patients_NNS over_IN a_DT dose_NN range_NN of_IN 0.025_CD mg_NN to_TO 2.2_CD mg_NN led_VBD to_TO a_DT dose-dependent_JJ inhibition_NN of_IN antipyrine_JJ elimination_NN .14_CD The_DT effect_NN of_IN alternate-day_JJ administration_NN of_IN 0.25_CD mg_NN of_IN Betaseron_NNP on_IN drug_NN metabolism_NN in_IN MS_NN patients_NNS is_VBZ unknown_JJ ._. ATROVENT_NNP Inhalation_NNP Aerosol_NNP has_VBZ been_VBN used_VBN concomitantly_RB with_IN other_JJ drugs_NNS ,_, including_VBG sympathomimetic_JJ bronchodilators_NNS ,_, methylxanthines_NNS ,_, and_CC steroids_NNS ,_, commonly_RB used_VBN in_IN the_DT treatment_NN of_IN chronic_JJ obstructive_JJ pulmonary_JJ disease_NN ._. With_IN the_DT exception_NN of_IN albuterol_NN ,_, there_EX are_VBP no_DT formal_JJ studies_NNS fully_RB evaluating_VBG the_DT interaction_NN effects_NNS of_IN ATROVENT_NNP Inhalation_NNP Aerosol_NNP and_CC these_DT drugs_NNS with_IN respect_NN to_TO effectiveness_NN ._. Anticholinergic_JJ agents_NNS :_: Although_IN ipratropium_NN bromide_NN is_VBZ minimally_RB absorbed_VBN into_IN the_DT systemic_JJ circulation_NN ,_, there_EX is_VBZ some_DT potential_JJ for_IN an_DT additive_JJ interaction_NN with_IN concomitantly_RB used_VBN anticholinergic_JJ medications_NNS ._. Caution_NN is_VBZ therefore_RB advised_VBN in_IN the_DT coadministration_NN of_IN ATROVENT_NNP Inhalation_NNP Aerosol_NNP with_IN other_JJ anticholinergic-containing_JJ drugs_NNS ._. No_DT significant_JJ drug-drug_JJ pharmacokinetic_JJ -LRB-_-LRB- or_CC pharmacodynamic_JJ -RRB-_-RRB- interactions_NNS have_VBP been_VBN found_VBN in_IN interaction_NN studies_NNS with_IN hydrochlorothiazide_NN ,_, digoxin_NN ,_, warfarin_NN ,_, and_CC nifedipine_NN ._. In_FW vitro_FW studies_NNS show_VBP significant_JJ inhibition_NN of_IN the_DT formation_NN of_IN oxidized_VBN irbesartan_NN metabolites_NNS with_IN the_DT known_JJ cytochrome_NN CYP_NN 2C9_CD substrates/inhibitors_NNS sulphenazole_NN ,_, tolbutamide_NN and_CC nifedipine_NN ._. However_RB ,_, in_IN clinical_JJ studies_NNS the_DT consequences_NNS of_IN concomitant_JJ irbesartan_NN on_IN the_DT pharmacodynamics_NNS of_IN warfarin_NN were_VBD negligible_JJ ._. Based_VBN on_IN in_FW vitro_FW data_NNS ,_, no_DT interaction_NN would_MD be_VB expected_VBN with_IN drugs_NNS whose_WP$ metabolism_NN is_VBZ dependent_JJ upon_IN cytochrome_NN P450_NN isozymes_NNS 1A1_NN ,_, 1A2_NN ,2_CD A6_NN ,2_CD B6_NN ,2_CD D6_NN ,2_CD E1_NN ,_, or_CC 3A4_NN ._. In_IN separate_JJ studies_NNS of_IN patients_NNS receiving_VBG maintenance_NN doses_NNS of_IN warfarin_NN ,_, hydrochlorothiazide_NN ,_, or_CC digoxin_NN ,_, irbesartan_NN administration_NN for_IN 7_CD days_NNS had_VBD no_DT effect_NN on_IN the_DT pharmacodynamics_NNS of_IN warfarin_NN -LRB-_-LRB- prothrombin_NN time_NN -RRB-_-RRB- or_CC pharmacokinetics_NNS of_IN digoxin_NN ._. The_DT pharmacokinetics_NNS of_IN irbesartan_NN were_VBD not_RB affected_VBN by_IN coadministration_NN of_IN nifedipine_NN or_CC hydrochlorothiazid_NN ._. The_DT adverse_JJ effects_NNS of_IN CAMPTOSAR_NNP ,_, such_JJ as_IN myelosuppression_NN and_CC diarrhea_NN ,_, would_MD be_VB expected_VBN to_TO be_VB exacerbated_VBN by_IN other_JJ antineoplastic_JJ agents_NNS having_VBG similar_JJ adverse_JJ effects_NNS ._. Patients_NNS who_WP have_VBP previously_RB received_VBN pelvic_JJ /_: abdominal_JJ irradiation_NN are_VBP at_IN increased_VBN risk_NN of_IN severe_JJ myelosuppression_NN following_VBG the_DT administration_NN of_IN CAMPTOSAR_NNP ._. The_DT concurrent_JJ administration_NN of_IN CAMPTOSAR_NN with_IN irradiation_NN has_VBZ not_RB been_VBN adequately_RB studied_VBN and_CC is_VBZ not_RB recommended_VBN ._. Lymphocytopenia_NNP has_VBZ been_VBN reported_VBN in_IN patients_NNS receiving_VBG CAMPTOSAR_NNP ,_, and_CC it_PRP is_VBZ possible_JJ that_IN the_DT administration_NN of_IN dexamethasone_NN as_IN antiemetic_JJ prophylaxis_NN may_MD have_VB enhanced_VBN the_DT likelihood_NN of_IN this_DT effect_NN ._. However_RB ,_, serious_JJ opportunistic_JJ infections_NNS have_VBP not_RB been_VBN observed_VBN ,_, and_CC no_DT complications_NNS have_VBP specifically_RB been_VBN attributed_VBN to_TO lymphocytopenia_NN ._. Hyperglycemia_NN has_VBZ also_RB been_VBN reported_VBN in_IN patients_NNS receiving_VBG CAMPTOSAR_NNP ._. Usually_RB ,_, this_DT has_VBZ been_VBN observed_VBN in_IN patients_NNS with_IN a_DT history_NN of_IN diabetes_NN mellitus_NN or_CC evidence_NN of_IN glucose_NN intolerance_NN prior_RB to_TO administration_NN of_IN CAMPTOSAR_NNP ._. It_PRP is_VBZ probable_JJ that_IN dexamethasone_NN ,_, given_VBN as_IN antiemetic_JJ prophylaxis_NN ,_, contributed_VBD to_TO hyperglycemia_NN in_IN some_DT patients_NNS ._. The_DT incidence_NN of_IN akathisia_NN in_IN clinical_JJ trials_NNS of_IN the_DT weekly_JJ dosage_NN schedule_NN was_VBD greater_JJR -LRB-_-LRB- 8.5_CD %_NN ,_, 4/47_CD patients_NNS -RRB-_-RRB- when_WRB prochlorperazine_NN was_VBD administered_VBN on_IN the_DT same_JJ day_NN as_IN CAMPTOSAR_NN than_IN when_WRB these_DT drugs_NNS were_VBD given_VBN on_IN separate_JJ days_NNS -LRB-_-LRB- 1.3_CD %_NN ,_, 1/80_CD patients_NNS -RRB-_-RRB- ._. The_DT 8.5_CD %_NN incidence_NN of_IN akathisia_NN ,_, however_RB ,_, is_VBZ within_IN the_DT range_NN reported_VBD for_IN use_NN of_IN prochlorperazine_NN when_WRB given_VBN as_IN a_DT premedication_NN for_IN other_JJ chemotherapies_NNS ._. It_PRP would_MD be_VB expected_VBN that_IN laxative_NN use_NN during_IN therapy_NN with_IN CAMPTOSAR_NN would_MD worsen_VB the_DT incidence_NN or_CC severity_NN of_IN diarrhea_NN ,_, but_CC this_DT has_VBZ not_RB been_VBN studied_VBN ._. In_IN view_NN of_IN the_DT potential_JJ risk_NN of_IN dehydration_NN secondary_JJ to_TO vomiting_VBG and/or_CC diarrhea_NN induced_VBN by_IN CAMPTOSAR_NNP ,_, the_DT physician_NN may_MD wish_VB to_TO withhold_VB diuretics_NNS during_IN dosing_NN with_IN CAMPTOSAR_NN and_CC ,_, certainly_RB ,_, during_IN periods_NNS of_IN active_JJ vomiting_VBG or_CC diarrhea_NN ._. Drug-Laboratory_JJ Test_NN Interactions_NNS There_EX are_VBP no_DT known_JJ interactions_NNS between_IN CAMPTOSAR_NN and_CC laboratory_NN tests_NNS ._. Isocarboxazid_NN should_MD be_VB administered_VBN with_IN caution_NN to_TO patients_NNS receiving_VBG Antabuse_NN -LRB-_-LRB- disulfiram_NN ,_, Wyeth-Ayerst_NNP Laboratories_NNP -RRB-_-RRB- ._. In_IN a_DT single_JJ study_NN ,_, rats_NNS given_VBN high_JJ intraperitoneal_JJ doses_NNS of_IN an_DT MAO_NNP inhibitor_NN plus_CC disulfiram_NN experienced_VBD severe_JJ toxicity_NN ,_, including_VBG convulsions_NNS and_CC death_NN ._. Concomitant_JJ use_NN of_IN Isocarboxazid_NN and_CC other_JJ psychotropic_JJ agents_NNS is_VBZ generally_RB not_RB recommended_VBN because_IN of_IN possible_JJ potentiating_NN effects_NNS ._. This_DT is_VBZ especially_RB true_JJ in_IN patients_NNS who_WP may_MD subject_VB themselves_PRP to_TO an_DT overdosage_NN of_IN drugs_NNS ._. If_IN combination_NN therapy_NN is_VBZ needed_VBN ,_, careful_JJ consideration_NN should_MD be_VB given_VBN to_TO the_DT pharmacology_NN of_IN all_DT agents_NNS to_TO be_VB used_VBN ._. The_DT monoamine_NN oxidase_NN inhibitory_JJ effects_NNS of_IN Isocarboxazid_NN may_MD persist_VB for_IN a_DT substantial_JJ period_NN after_IN discontinuation_NN of_IN the_DT drug_NN ,_, and_CC this_DT should_MD be_VB borne_VBN in_IN mind_NN when_WRB another_DT drug_NN is_VBZ prescribed_VBN following_VBG Isocarboxazid_NNP ._. To_TO avoid_VB potentiation_NN ,_, the_DT physician_NN wishing_VBG to_TO terminate_VB treatment_NN with_IN Isocarboxazid_NN and_CC begin_VB therapy_NN with_IN another_DT agent_NN should_MD allow_VB for_IN an_DT interval_NN of_IN 10_CD days_NNS ._. May_NNP interact_VBP with_IN the_DT following_NN :_: beta-adrenergic_JJ blocking_VBG agents_NNS -LRB-_-LRB- these_DT medicines_NNS may_MD make_VB your_PRP$ condition_NN worse_JJR and_CC prevent_VB the_DT adrenergic_JJ bronchodilators_NNS from_IN working_VBG properly_RB -RRB-_-RRB- and_CC disopyramide_NN ,_, quinidine_NN ,_, phenothiazines_NNS ,_, and_CC procainamide_NN -LRB-_-LRB- these_DT medicines_NNS may_MD increase_VB the_DT risk_NN of_IN heart_NN problems_NNS -RRB-_-RRB- ._. Isoflurane_NN potentiates_VBZ the_DT muscle_NN relaxant_NN effect_NN of_IN all_DT muscle_NN relaxants_NNS ,_, most_RBS notably_RB nondepolarizing_JJ muscle_NN relaxants_NNS ,_, and_CC MAC_NNP -LRB-_-LRB- minimum_JJ alveolar_JJ concentration_NN -RRB-_-RRB- is_VBZ reduced_VBN by_IN concomitant_JJ administration_NN of_IN N_NN 2O_NN ._. See_VB CLINICAL_NNP PHARMACOLOGY_NNP ._. Food_NNP :_: Isoniazid_NNP should_MD not_RB be_VB administered_VBN with_IN food_NN ._. Studies_NNS have_VBP shown_VBN that_IN the_DT bioavailability_NN of_IN isoniazid_NN is_VBZ reduced_VBN significantly_RB when_WRB administered_VBN with_IN food_NN ._. Acetaminophen_NN :_: A_DT report_NN of_IN severe_JJ acetaminophen_NN toxicity_NN was_VBD reported_VBN in_IN a_DT patient_NN receiving_VBG Isoniazid_NNP ._. It_PRP is_VBZ believed_VBN that_IN the_DT toxicity_NN may_MD have_VB resulted_VBN from_IN a_DT previously_RB unrecognized_JJ interaction_NN between_IN isoniazid_NN and_CC acetaminophen_NN and_CC a_DT molecular_JJ basis_NN for_IN this_DT interaction_NN has_VBZ been_VBN proposed_VBN ._. However_RB ,_, current_JJ evidence_NN suggests_VBZ that_IN isoniazid_NN does_VBZ induce_VB P-450IIE1_NN ,_, a_DT mixed-function_NN oxidase_NN enzyme_NN that_WDT appears_VBZ to_TO generate_VB the_DT toxic_JJ metabolites_NNS ,_, in_IN the_DT liver_NN ._. Furthermore_RB it_PRP has_VBZ been_VBN proposed_VBN that_IN isoniazid_NN resulted_VBD In_IN induction_NN of_IN P-450IIE1_NN in_IN the_DT patients_NNS liver_NN which_WDT ,_, in_IN turn_NN ,_, resulted_VBD in_IN a_DT greater_JJR proportion_NN of_IN the_DT ingested_VBN acetaminophen_NN being_VBG converted_VBN to_TO the_DT toxic_JJ metabolites_NNS ._. Studies_NNS have_VBP demonstrated_VBN that_IN pretreatment_NN with_IN isoniazid_NN potentiates_VBZ a_DT cetaminophen_NN hepatoxicity_NN in_IN rats_NNS ._. Carbamazepine_NNP :_: Isoniazid_NNP is_VBZ known_VBN to_TO slow_VB the_DT metabolism_NN of_IN carbamazepine_NN and_CC increase_VB its_PRP$ serum_NN levels_NNS Carbamazepine_NN levels_NNS should_MD be_VB determined_VBN prior_RB to_TO concurrent_JJ administration_NN with_IN isoniazid_NN ,_, signs_NNS and_CC symptoms_NNS of_IN carbamazepine_NN toxicity_NN should_MD be_VB monitored_VBN closely_RB ,_, and_CC appropriate_JJ dosage_NN adjustment_NN of_IN the_DT anticonvulsant_NN should_MD be_VB made_VBN ._. Ketoconazole_NN :_: Potential_JJ interaction_NN of_IN Ketoconazole_NNP and_CC Isoniazid_NNP may_MD exist_VB ._. Phenytoin_NNP :_: Isoniazid_NNP may_MD increase_VB serum_NN levels_NNS of_IN phenytoin_NN ._. To_TO avoid_VB phenytoin_NN intoxication_NN ,_, appropriate_JJ adjustment_NN of_IN the_DT anticonvulsant_NN should_MD be_VB made_VBN ._. Therophylline_NNP :_: A_NNP recent_JJ study_NN has_VBZ shown_VBN that_IN concomitan_NN administration_NN of_IN isoniazid_NN and_CC theophylline_NN may_MD cause_VB elevated_JJ plasma_NN levels_NNS of_IN theophylline_NN ,_, and_CC in_IN some_DT instances_NNS a_DT slight_JJ decrease_NN in_IN the_DT elimination_NN of_IN isoniazid_NN ._. Since_IN the_DT therapeutic_JJ range_NN of_IN theophylline_NN is_VBZ narrow_JJ theophylline_NN serum_NN levels_NNS should_MD be_VB monitored_VBN closely_RB ,_, and_CC appropriate_JJ dosage_NN adjustments_NNS of_IN theophylline_NN should_MD be_VB made_VBN ._. Valproate_NNP :_: A_NNP recent_JJ case_NN study_NN has_VBZ shown_VBN a_DT possible_JJ increase_NN in_IN the_DT plasma_NN level_NN of_IN valproate_NN when_WRB co_NN administered_VBN with_IN isoniazid_NN ._. Plasma_NN valproate_NN concentration_NN should_MD be_VB monitored_VBN when_WRB isoniazid_NN and_CC valproate_NN are_VBP co_NN administered_VBN ,_, and_CC appropriate_JJ dosage_NN adjustments_NNS of_IN valproate_NN should_MD be_VB made_VBN ._. Isoproterenol_NN hydrochloride_NN injection_NN and_CC epinephrine_NN should_MD not_RB be_VB administered_VBN simultaneously_RB because_IN both_DT drugs_NNS are_VBP direct_JJ cardiac_JJ stimulants_NNS and_CC their_PRP$ combined_JJ effects_NNS may_MD induce_VB serious_JJ arrhythmias_NNS ._. The_DT drugs_NNS may_MD ,_, however_RB ,_, be_VB administered_VBN alternately_RB provided_VBN a_DT proper_JJ interval_NN has_VBZ elapsed_VBN between_IN doses_NNS ._. ISUPREL_NN should_MD be_VB used_VBN with_IN caution_NN ,_, if_IN at_IN all_DT ,_, when_WRB potent_JJ inhalational_JJ anesthetics_NNS such_JJ as_IN halothane_NN are_VBP employed_VBN because_IN of_IN potential_JJ to_TO sensitize_VB the_DT myocardium_NN to_TO effects_NNS of_IN sympathomimetic_JJ amines_NNS ._. The_DT vasodilating_JJ effects_NNS of_IN isosorbide_NN dinitrate_NN may_MD be_VB additive_JJ with_IN those_DT of_IN other_JJ vasodilators_NNS ._. Alcohol_NN ,_, in_IN particular_JJ ,_, has_VBZ been_VBN found_VBN to_TO exhibit_VB additive_JJ effects_NNS of_IN this_DT variety_NN ._. The_DT vasodilating_JJ effects_NNS of_IN isosorbide_NN mononitrate_NN may_MD be_VB additive_JJ with_IN those_DT of_IN other_JJ vasodilators_NNS ._. Alcohol_NN ,_, in_IN particular_JJ ,_, has_VBZ been_VBN found_VBN to_TO exhibit_VB additive_JJ effects_NNS of_IN this_DT variety_NN ._. Marked_JJ symptomatic_JJ orthostatic_JJ hypotension_NN has_VBZ been_VBN reported_VBN when_WRB calcium_NN channel_NN blockers_NNS and_CC organic_JJ nitrates_NNS were_VBD used_VBN in_IN combination_NN ._. Dose_NN adjustments_NNS of_IN either_CC class_NN of_IN agents_NNS may_MD be_VB necessary_JJ ._. Vitamin_NN A_NN :_: Because_IN of_IN the_DT relationship_NN of_IN Accutane_NNP to_TO vitamin_NN A_NN ,_, patients_NNS should_MD be_VB advised_VBN against_IN taking_VBG vitamin_NN supplements_NNS containing_VBG vitamin_NN A_NN to_TO avoid_VB additive_JJ toxic_JJ effect_NN ._. Tetracyclines_NNS :_: Concomitant_JJ treatment_NN with_IN Accutane_NN and_CC tetracyclines_NNS should_MD be_VB avoided_VBN because_IN Accutane_NNP use_NN has_VBZ been_VBN associated_VBN with_IN a_DT number_NN of_IN cases_NNS of_IN pseudotumor_NN cerebri_NN -LRB-_-LRB- benign_JJ intracranial_JJ hypertension_NN -RRB-_-RRB- ,_, some_DT of_IN which_WDT involved_JJ concomitant_JJ use_NN of_IN tetracycline_NN ._. Micro-dosed_JJ Progesterone_NN Preparations_NNS :_: Micro-dosed_JJ progesterone_NN preparations_NNS -LRB-_-LRB- minipills_NNS that_WDT do_VBP not_RB contain_VB an_DT estrogen_NN -RRB-_-RRB- may_MD be_VB an_DT inadequate_JJ method_NN of_IN contraception_NN during_IN Accutane_NN therapy_NN ._. Although_IN other_JJ hormonal_JJ contraceptives_NNS are_VBP highly_RB effective_JJ ,_, there_EX have_VBP been_VBN reports_NNS of_IN pregnancy_NN from_IN women_NNS who_WP have_VBP used_VBN combined_JJ oral_JJ contraceptives_NNS ,_, as_RB well_RB as_IN topical/injectable/implantable_JJ /_: insertable_JJ hormonal_JJ birth_NN control_NN products_NNS ._. These_DT reports_NNS are_VBP more_RBR frequent_JJ for_IN women_NNS who_WP use_VBP only_RB a_DT single_JJ method_NN of_IN contraception_NN ._. It_PRP is_VBZ not_RB known_VBN if_IN hormonal_JJ contraceptives_NNS differ_VBP in_IN their_PRP$ effectiveness_NN when_WRB used_VBN with_IN Accutane_NN ._. Therefore_RB ,_, it_PRP is_VBZ critically_RB important_JJ for_IN women_NNS of_IN childbearing_JJ potential_NN to_TO select_VB and_CC commit_VB to_TO use_VB 2_CD forms_NNS of_IN effective_JJ contraception_NN simultaneously_RB ,_, at_IN least_JJS 1_CD of_IN which_WDT must_MD be_VB a_DT primary_JJ form_NN ,_, unless_IN absolute_JJ abstinence_NN is_VBZ the_DT chosen_VBN method_NN ,_, or_CC the_DT patient_NN has_VBZ undergone_VBN a_DT hysterectomy_NN ._. Phenytoin_NNP :_: Accutane_NNP has_VBZ not_RB been_VBN shown_VBN to_TO alter_VB the_DT pharmacokinetics_NNS of_IN phenytoin_NN in_IN a_DT study_NN in_IN seven_CD healthy_JJ volunteers_NNS ._. These_DT results_NNS are_VBP consistent_JJ with_IN the_DT in_FW vitro_FW finding_NN that_IN neither_CC isotretinoin_NN nor_CC its_PRP$ metabolites_NNS induce_VBP or_CC inhibit_VBP the_DT activity_NN of_IN the_DT CYP_NN 2C9_NN human_JJ hepatic_JJ P450_NN enzyme_NN ._. Phenytoin_NNP is_VBZ known_VBN to_TO cause_VB osteomalacia_NN ._. No_DT formal_JJ clinical_JJ studies_NNS have_VBP been_VBN conducted_VBN to_TO assess_VB if_IN there_EX is_VBZ an_DT interactive_JJ effect_NN on_IN bone_NN loss_NN between_IN phenytoin_NN and_CC Accutane_NN ._. Therefore_RB ,_, caution_NN should_MD be_VB exercised_VBN when_WRB using_VBG these_DT drugs_NNS together_RB ._. Systemic_JJ Corticosteroids_NNS :_: Systemic_JJ corticosteroids_NNS are_VBP known_VBN to_TO cause_VB osteoporosis_NN ._. No_DT formal_JJ clinical_JJ studies_NNS have_VBP been_VBN conducted_VBN to_TO assess_VB if_IN there_EX is_VBZ an_DT interactive_JJ effect_NN on_IN bone_NN loss_NN between_IN systemic_JJ corticosteroids_NNS and_CC Accutane_NNP ._. Therefore_RB ,_, caution_NN should_MD be_VB exercised_VBN when_WRB using_VBG these_DT drugs_NNS together_RB ._. Prescribers_NNS are_VBP advised_VBN to_TO consult_VB the_DT package_NN insert_NN of_IN medication_NN administered_VBN concomitantly_RB with_IN hormonal_JJ contraceptives_NNS ,_, since_IN some_DT medications_NNS may_MD decrease_VB the_DT effectiveness_NN of_IN these_DT birth_NN control_NN products_NNS ._. Accutane_NNP use_NN is_VBZ associated_VBN with_IN depression_NN in_IN some_DT patients_NNS ._. Pregnancies_NNS have_VBP been_VBN reported_VBN by_IN users_NNS of_IN combined_JJ hormonal_JJ contraceptives_NNS who_WP also_RB used_VBD some_DT form_NN of_IN St._NNP Johns_NNP Wort_NNP ._. Laboratory_NNP Tests_NNP Pregnancy_NNP Test_NNP Female_JJ patients_NNS of_IN childbearing_JJ potential_NN must_MD have_VB negative_JJ results_NNS from_IN 2_CD urine_NN or_CC serum_NN pregnancy_NN tests_NNS with_IN a_DT sensitivity_NN of_IN at_IN least_JJS 25_CD mIU/mL_NN before_IN receiving_VBG the_DT initial_JJ Accutane_NN prescription_NN ._. The_DT first_JJ test_NN is_VBZ obtained_VBN by_IN the_DT prescriber_NN when_WRB the_DT decision_NN is_VBZ made_VBN to_TO pursue_VB qualification_NN of_IN the_DT patient_NN for_IN Accutane_NNP -LRB-_-LRB- a_DT screening_NN test_NN -RRB-_-RRB- ._. The_DT second_JJ pregnancy_NN test_NN -LRB-_-LRB- a_DT confirmation_NN test_NN -RRB-_-RRB- should_MD be_VB done_VBN during_IN the_DT first_JJ 5_CD days_NNS of_IN the_DT menstrual_JJ period_NN immediately_RB preceding_VBG the_DT beginning_NN of_IN Accutane_NN therapy_NN ._. For_IN patients_NNS with_IN amenorrhea_NN ,_, the_DT second_JJ test_NN should_MD be_VB done_VBN at_IN least_JJS 11_CD days_NNS after_IN the_DT last_JJ act_NN of_IN unprotected_JJ sexual_JJ intercourse_NN -LRB-_-LRB- without_IN using_VBG 2_CD effective_JJ forms_NNS of_IN contraception_NN -RRB-_-RRB- ._. Each_DT month_NN of_IN therapy_NN ,_, the_DT patient_NN must_MD have_VB a_DT negative_JJ result_NN from_IN a_DT urine_NN or_CC serum_NN pregnancy_NN test_NN ._. A_DT pregnancy_NN test_NN must_MD be_VB repeated_VBN each_DT month_NN prior_RB to_TO the_DT female_JJ patient_NN receiving_VBG each_DT prescription_NN ._. Lipids_NNS :_: Pretreatment_NN and_CC follow-up_JJ blood_NN lipids_NNS should_MD be_VB obtained_VBN under_IN fasting_NN conditions_NNS ._. After_IN consumption_NN of_IN alcohol_NN ,_, at_IN least_JJS 36_CD hours_NNS should_MD elapse_VB before_IN these_DT determinations_NNS are_VBP made_VBN ._. It_PRP is_VBZ recommended_VBN that_IN these_DT tests_NNS be_VB performed_VBN at_IN weekly_JJ or_CC biweekly_JJ intervals_NNS until_IN the_DT lipid_NN response_NN to_TO Accutane_NNP is_VBZ established_VBN ._. The_DT incidence_NN of_IN hypertriglyceridemia_NN is_VBZ 1_CD patient_NN in_IN 4_CD on_IN Accutane_NNP therap_NN ._. Liver_NN Function_NN Tests_NNS :_: Since_IN elevations_NNS of_IN liver_NN enzymes_NNS have_VBP been_VBN observed_VBN during_IN clinical_JJ trials_NNS ,_, and_CC hepatitis_NN has_VBZ been_VBN reported_VBN ,_, pretreatment_NN and_CC follow-up_NN liver_NN function_NN tests_NNS should_MD be_VB performed_VBN at_IN weekly_JJ or_CC biweekly_JJ intervals_NNS until_IN the_DT response_NN to_TO Accutane_NNP has_VBZ been_VBN establishe_NN ._. Glucose_NN :_: Some_DT patients_NNS receiving_VBG Accutane_NNP have_VBP experienced_VBN problems_NNS in_IN the_DT control_NN of_IN their_PRP$ blood_NN sugar_NN ._. In_IN addition_NN ,_, new_JJ cases_NNS of_IN diabetes_NNS have_VBP been_VBN diagnosed_VBN during_IN Accutane_NN therapy_NN ,_, although_IN no_DT causal_JJ relationship_NN has_VBZ been_VBN establishe_NN ._. CPK_NNP :_: Some_DT patients_NNS undergoing_VBG vigorous_JJ physical_JJ activity_NN while_IN on_IN Accutane_NN therapy_NN have_VBP experienced_VBN elevated_JJ CPK_NN levels_NNS ._. however_RB ,_, the_DT clinical_JJ significance_NN is_VBZ unknown_JJ ._. There_EX have_VBP been_VBN rare_JJ postmarketing_VBG reports_NNS of_IN rhabdomyolysis_NN ,_, some_DT associated_VBN with_IN strenuous_JJ physical_JJ activity_NN ._. In_IN a_DT clinical_JJ trial_NN of_IN 217_CD pediatric_JJ patients_NNS -LRB-_-LRB- 12_CD to_TO 17_CD years_NNS -RRB-_-RRB- with_IN severe_JJ recalcitrant_JJ nodular_JJ acne_NN ,_, transient_JJ elevations_NNS in_IN CPK_NNP were_VBD observed_VBN in_IN 12_CD %_NN of_IN patients_NNS ,_, including_VBG those_DT undergoing_VBG strenuous_JJ physical_JJ activity_NN in_IN association_NN with_IN reported_VBN musculoskeletal_JJ adverse_JJ events_NNS such_JJ as_IN back_RB pain_NN ,_, arthralgia_NN ,_, limb_NN injury_NN ,_, or_CC muscle_NN sprain_NN ._. In_IN these_DT patients_NNS ,_, approximately_RB half_NN of_IN the_DT CPK_NN elevations_NNS returned_VBD to_TO normal_JJ within_IN 2_CD weeks_NNS and_CC half_NN returned_VBD to_TO normal_JJ within_IN 4_CD weeks_NNS ._. No_DT cases_NNS of_IN rhabdomyolysis_NN were_VBD reported_VBN in_IN this_DT trial_NN ._. Nitroglycerin_NNP :_: DynaCirc_NNP -LRB-_-LRB- isradipine_NN -RRB-_-RRB- has_VBZ been_VBN safely_RB coadministered_VBN with_IN nitroglycerin_NN ._. Hydrochlorothiazide_NN :_: A_DT study_NN in_IN normal_JJ healthy_JJ volunteers_NNS has_VBZ shown_VBN that_IN concomitant_JJ administration_NN of_IN DynaCirc_NNP -LRB-_-LRB- isradipine_NN -RRB-_-RRB- and_CC hydrochlorothiazide_NN does_VBZ not_RB result_VB in_IN altered_JJ pharmacoktnetics_NNS of_IN either_CC drug_NN ._. In_IN a_DT study_NN in_IN hypertensive_JJ patients_NNS ,_, addition_NN of_IN isradipine_NN to_TO existing_VBG hydrochlorothiazide_NN therapy_NN did_VBD not_RB result_VB in_IN any_DT unexpected_JJ adverse_JJ effects_NNS ,_, and_CC isradipine_NN had_VBD an_DT additional_JJ antihypertensive_JJ effect_NN ._. Propranolol_NN :_: In_IN a_DT single_JJ dose_NN study_NN in_IN normal_JJ volunteers_NNS ,_, coadministration_NN of_IN propranolol_NN had_VBD a_DT small_JJ effect_NN on_IN the_DT rate_NN but_CC no_DT effect_NN on_IN the_DT extent_NN of_IN isradipine_NN bioavailability_NN ._. Significant_JJ increases_NNS In_IN AUC_NN -LRB-_-LRB- 27_CD %_NN -RRB-_-RRB- and_CC Cmax_NN -LRB-_-LRB- 58_CD %_NN -RRB-_-RRB- and_CC decreases_VBZ in_IN tmax_NN -LRB-_-LRB- 23_CD %_NN -RRB-_-RRB- of_IN propranolol_NN were_VBD noted_VBN in_IN this_DT study_NN ._. However_RB ,_, concomitant_JJ administration_NN of_IN 5_CD mg_NN b.i.d._NN isradipine_NN and_CC 40_CD mg_NN b.i.d._NN propranolol_NN to_TO healthy_JJ volunteers_NNS under_IN steady-state_JJ conditions_NNS had_VBD no_DT relevant_JJ effect_NN on_IN either_CC drug_NN s_NNS bioavailability_NN ,_, AUC_NN and_CC Cmax_NN ,_, differences_NNS were_VBD 20_CD %_NN between_IN isradipine_NN given_VBN singly_RB and_CC in_IN combination_NN with_IN propranolol_NN ,_, and_CC between_IN propranolol_NN given_VBN singly_RB and_CC in_IN combination_NN with_IN isradipine_NN ._. Cimetidine_NNP :_: In_IN a_DT study_NN in_IN healthy_JJ volunteers_NNS ,_, a_DT one-week_JJ course_NN of_IN cimetidine_NN at_IN 400_CD mg_NN b.i.d._NN with_IN a_DT single_JJ 5_CD mg_NN dose_NN of_IN isradipine_NN on_IN the_DT sixth_JJ day_NN showed_VBD an_DT increase_NN in_IN isradipine_NN mean_NN peak_JJ plasma_NN concentrations_NNS -LRB-_-LRB- 36_CD %_NN -RRB-_-RRB- and_CC significant_JJ increase_NN in_IN area_NN under_IN the_DT curve_NN -LRB-_-LRB- 50_CD %_NN -RRB-_-RRB- ._. If_IN isradipine_NN therapy_NN is_VBZ initiated_VBN in_IN a_DT patient_NN currently_RB receiving_VBG cimetidine_NN careful_JJ monitoring_NN for_IN adverse_JJ reactions_NNS is_VBZ advised_VBN and_CC downward_JJ dose_NN adjustment_NN may_MD be_VB required_VBN ._. Rifampicin_NNP :_: In_IN a_DT study_NN in_IN healthy_JJ volunteers_NNS ,_, a_DT six-day_JJ course_NN of_IN rifampicin_NN at_IN 600_CD mg/day_NN followed_VBN by_IN a_DT single_JJ 5_CD mg_NN dose_NN of_IN isradipine_NN resulted_VBD in_IN a_DT reduction_NN in_IN isradipine_NN levels_NNS to_TO below_IN detectable_JJ limits_NNS ._. If_IN rifampicin_NN therapy_NN is_VBZ required_VBN ,_, isradipine_NN concentrations_NNS and_CC therapeutic_JJ effects_NNS are_VBP likely_JJ to_TO be_VB markedly_RB reduced_VBN or_CC abolished_VBN as_IN a_DT consequence_NN of_IN increased_VBN metabolism_NN and_CC higher_JJR clearance_NN of_IN isradipine_NN ._. Warfarin_NNP :_: In_IN a_DT study_NN in_IN healthy_JJ volunteers_NNS ,_, no_DT clinically_RB relevant_JJ pharmacokinetic_JJ or_CC pharmacodynamic_JJ interaction_NN between_IN isradipine_NN and_CC racemic_JJ warfarin_NN was_VBD seen_VBN when_WRB two_CD single_JJ oral_JJ doses_NNS of_IN warfarin_NN -LRB-_-LRB- 0.7_CD mg/kg_NN body_NN weight_NN -RRB-_-RRB- were_VBD administered_VBN during_IN 11_CD days_NNS of_IN multipledose_JJ treatment_NN with_IN 5_CD mg_NN b.i.d._NN isradipine_NN ._. Neither_DT racemic_JJ warfarin_NN nor_CC isradipine_NN binding_NN to_TO plasma_NN proteins_NNS in_FW vitro_FW was_VBD altered_VBN by_IN the_DT addition_NN of_IN the_DT other_JJ drug_NN ._. Digoxin_NNP :_: The_DT concomitant_JJ administration_NN of_IN DynaCirc_NNP -LRB-_-LRB- isradipine_NN -RRB-_-RRB- and_CC digoxin_NN in_IN a_DT single-dose_JJ pharmacokinetic_JJ study_NN did_VBD not_RB affect_VB renal_JJ ,_, nonrenal_JJ and_CC total_JJ body_NN clearance_NN of_IN digoxin_NN ._. Fentanyl_NNP Anesthesia_NNP :_: Severe_JJ hypotension_NN has_VBZ been_VBN reported_VBN during_IN fentanyl_NN anesthesia_NN with_IN concomitant_JJ use_NN of_IN a_DT beta_NN blocker_NN and_CC a_DT calcium_NN channel_NN blocker_NN ._. Even_RB though_IN such_JJ interactions_NNS have_VBP not_RB been_VBN seen_VBN in_IN clinical_JJ studies_NNS with_IN DynaCirc_NN -LRB-_-LRB- isradipine_NN -RRB-_-RRB- ,_, an_DT increased_VBN volume_NN of_IN circulating_VBG fluids_NNS might_MD be_VB required_VBN if_IN such_PDT an_DT interaction_NN were_VBD to_TO occur_VB ._. Both_DT itraconazole_NN and_CC its_PRP$ major_JJ metabolite_NN ,_, hydroxyitraconazole_NN ,_, are_VBP inhibitors_NNS of_IN the_DT cytochrome_NN P450_NN 3A4_NN enzyme_NN system_NN ._. Coadministration_NNP of_IN Itraconazole_NNP and_CC drugs_NNS primarily_RB metabolized_VBN by_IN the_DT cytochrome_NN P450_NN 3A4_NN enzyme_NN system_NN may_MD result_VB in_IN increased_VBN plasma_NN concentrations_NNS of_IN the_DT drugs_NNS that_WDT could_MD increase_VB or_CC prolong_VB both_DT therapeutic_JJ and_CC adverse_JJ effects_NNS ._. Therefore_RB ,_, unless_IN otherwise_RB specified_VBN ,_, appropriate_JJ dosage_NN adjustments_NNS may_MD be_VB necessary_JJ ._. Coadministration_NN of_IN terfenadine_NN with_IN Itraconazole_NNP has_VBZ led_VBN to_TO elevated_JJ plasma_NN concentrations_NNS of_IN terfenadine_NN ,_, resulting_VBG in_IN rare_JJ instances_NNS of_IN life_NN -_: threatening_VBG cardiac_JJ dysrhythmias_NNS and_CC one_CD death_NN ._. Another_DT oral_JJ azole_NN antifungal_JJ ,_, ketoconazole_NN ,_, inhibits_VBZ the_DT metabolism_NN of_IN astemizole_NN ,_, resulting_VBG in_IN elevated_JJ plasma_NN concentrations_NNS of_IN astemizole_NN and_CC its_PRP$ active_JJ metabolite_NN desmethylastermizole_NN which_WDT may_MD prolong_VB QT_NNP intervals_NNS ._. In_FW vitro_FW data_NNS suggest_VBP that_IN itraconazole_NN ,_, when_WRB compared_VBN to_TO ketoconazole_NN ,_, has_VBZ a_DT less_RBR pronounced_JJ effect_NN on_IN the_DT biotransformation_NN system_NN responsible_JJ for_IN the_DT metabolism_NN of_IN astemizole_NN ._. Based_VBN on_IN the_DT chemical_NN resemblance_NN of_IN itraconazole_NN and_CC ketoconazole_NN ,_, coadministration_NN of_IN astemizole_NN with_IN itraconazole_NN is_VBZ contraindicated_VBN ._. Human_JJ pharmacokinetics_NNS data_NNS indicate_VBP that_IN oral_JJ ketoconazole_NN potently_RB inhibits_VBZ the_DT metabolism_NN of_IN cisapride_NN resulting_VBG in_IN an_DT eight-fold_JJ increase_NN in_IN the_DT mean_NN AUC_NN of_IN cisapride_NN ._. Data_NNS suggest_VBP that_IN coadministration_NN of_IN oral_JJ ketoconazole_NN and_CC cisapride_NN can_MD result_VB in_IN prolongation_NN of_IN the_DT QT_NNP interval_NN on_IN the_DT ECG_NN ._. In_FW vitro_FW data_NNS suggest_VBP that_IN itraconazole_NN also_RB markedly_RB inhibits_VBZ the_DT biotransformation_NN system_NN mainly_RB responsible_JJ for_IN the_DT metabolism_NN of_IN cisapride_NN ._. therefore_RB concomitant_JJ administration_NN of_IN Itraconazole_NN with_IN cisapride_NN is_VBZ contraindicated_VBN ._. Coadministration_NNP of_IN Itraconazole_NNP with_IN oral_JJ midazolam_NN or_CC triazolam_NN has_VBZ resulted_VBN in_IN elevated_JJ plasma_NN concentrations_NNS of_IN the_DT latter_JJ two_CD drugs_NNS ._. This_DT may_MD potentiate_VB and_CC prolong_VB hypnotic_JJ and_CC sedative_JJ effects_NNS ._. These_DT agents_NNS should_MD not_RB be_VB used_VBN in_IN patients_NNS treated_VBN with_IN Itraconazole_NN ._. If_IN midazolam_NN is_VBZ administered_VBN parenterally_RB ,_, special_JJ precaution_NN is_VBZ required_VBN since_IN the_DT sedative_JJ effect_NN may_MD be_VB prolonged_VBN ._. Coadministration_NNP of_IN Itraconazole_NNP and_CC cyclosporine_NN ,_, tacrolimus_NN or_CC digoxin_NN has_VBZ led_VBN to_TO increased_VBN plasma_NN concentrations_NNS of_IN the_DT latter_JJ three_CD drugs_NNS ._. Cyclosporine_NN ,_, tacrolimus_NN and_CC digoxin_NN concentrations_NNS should_MD be_VB monitored_VBN at_IN the_DT initiation_NN of_IN Itraconazole_NN therapy_NN and_CC frequently_RB thereafter_RB ,_, and_CC the_DT dose_NN of_IN these_DT three_CD drug_NN products_NNS adjusted_VBN appropriately_RB ._. Rhabdomyolysis_NNP has_VBZ been_VBN observed_VBN in_IN patients_NNS receiving_VBG HMG-CoA_NN reductase_NN inhibitors_NNS administered_VBN alone_RB -LRB-_-LRB- at_IN recommended_VBN dosages_NNS -RRB-_-RRB- or_CC concomitantly_RB with_IN immunosuppressive_JJ drugs_NNS including_VBG cyclosporine_NN ._. When_WRB Itraconazole_NNP was_VBD coadministered_VBN with_IN phenytoin_NN ,_, rifampin_NN ,_, or_CC H2antagonists_NNS ,_, reduced_VBN plasma_NN concentrations_NNS of_IN itraconazole_NN were_VBD reported_VBN ._. The_DT physician_NN is_VBZ advised_VBN to_TO monitor_VB the_DT plasma_NN concentrations_NNS of_IN itraconazole_NN when_WRB any_DT of_IN these_DT drugs_NNS is_VBZ taken_VBN concurrently_RB ,_, and_CC to_TO increase_VB the_DT dose_NN of_IN Itraconazole_NNP if_IN necessary_JJ ._. Although_IN no_DT studies_NNS have_VBP been_VBN conducted_VBN ,_, concomitant_JJ administration_NN of_IN Itraconazole_NNP and_CC phenytoin_NN may_MD alter_VB the_DT metabolism_NN of_IN phenytoin_NN ._. therefore_RB ,_, plasma_NN concentrations_NNS of_IN phenytoin_NN should_MD also_RB be_VB monitored_VBN when_WRB it_PRP is_VBZ given_VBN concurrently_RB with_IN Itraconazole_NNP ._. It_PRP has_VBZ been_VBN reported_VBN that_IN Itraconazole_NNP enhances_VBZ the_DT anticoagulant_JJ effect_NN of_IN coumarin-like_JJ drugs_NNS ._. Therefore_RB ,_, prothrombin_NN time_NN should_MD be_VB carefully_RB monitored_VBN in_IN patients_NNS receiving_VBG Itraconazole_NNP and_CC coumarin-like_JJ drugs_NNS simultaneously_RB ._. Plasma_NN concentrations_NNS of_IN azole_JJ antifungal_JJ agents_NNS are_VBP reduced_VBN when_WRB given_VBN concurrently_RB with_IN isoniazid_NN ._. Itraconazole_NNP plasma_NN concentrations_NNS should_MD be_VB monitored_VBN when_WRB Itraconazole_NNP and_CC isoniazid_NN are_VBP coadministered_VBN ._. Severe_JJ hypoglycemia_NN has_VBZ been_VBN reported_VBN in_IN patients_NNS concomitantly_RB receiving_VBG azole_JJ antifungal_JJ agents_NNS and_CC oral_JJ hypoglycemic_JJ agents_NNS ._. Blood_NN glucose_NN concentrations_NNS should_MD be_VB carefully_RB monitored_VBN when_WRB Itraconazole_NNP and_CC oral_JJ hypoglycemic_JJ agents_NNS are_VBP coadministered_VBN ._. Tinnitus_NNP and_CC decreased_VBD hearing_NN have_VBP been_VBN reported_VBN in_IN patients_NNS concomitantly_RB receiving_VBG Itraconazole_NNP and_CC quinidine_NN ._. Edema_NN has_VBZ been_VBN reported_VBN in_IN patients_NNS concomitantly_RB receiving_VBG Itraconazole_NNP and_CC dihydropyridine_NN calcium_NN channel_NN blockers_NNS ._. Appropriate_JJ dosage_NN adjustments_NNS may_MD be_VB necessary_JJ ._. The_DT results_NNS from_IN a_DT study_NN in_IN which_WDT eight_CD HIV-infected_JJ individuals_NNS were_VBD treated_VBN with_IN zidovudine_NN ,_, 8_CD +_CC /_: -_: 0.4_CD mg/kg/day_NN ,_, showed_VBD that_IN the_DT pharmacokinetics_NNS of_IN zidovudine_NN were_VBD not_RB affected_VBN during_IN concomitant_JJ administration_NN of_IN Itraconazole_NNP ,_, 100_CD mg_NN b.i.d._NN ._. In_FW vitro_FW mixing_VBG of_IN an_DT aminoglycoside_NN with_IN beta-lactamtype_JJ antibiotics_NNS -LRB-_-LRB- penicillins_NNS or_CC cephalosporins_NNS -RRB-_-RRB- may_MD result_VB in_IN a_DT significant_JJ mutual_JJ inactivation_NN ._. Even_RB when_WRB an_DT aminoglycoside_NN and_CC a_DT penicillin-type_JJ drug_NN are_VBP administered_VBN separately_RB by_IN different_JJ routes_NNS ,_, a_DT reduction_NN in_IN aminoglycoside_NN serum_NN half-life_NN or_CC serum_NN levels_NNS has_VBZ been_VBN reported_VBN in_IN patients_NNS with_IN impaired_JJ renal_JJ function_NN and_CC in_IN some_DT patients_NNS with_IN normal_JJ renal_JJ function_NN ._. Usually_RB ,_, such_JJ inactivation_NN of_IN the_DT aminoglycoside_NN is_VBZ clinically_RB significant_JJ only_RB in_IN patients_NNS with_IN severely_RB impaired_JJ renal_JJ function_NN ._. See_VB ._. Prolonged_JJ recovery_NN time_NN may_MD occur_VB if_IN barbiturates_NNS and/or_CC narcotics_NNS are_VBP used_VBN concurrently_RB with_IN ketamine_NN ._. Ketamine_NNP is_VBZ clinically_RB compatible_JJ with_IN the_DT commonly_RB used_VBN general_JJ and_CC local_JJ anesthetic_JJ agents_NNS when_WRB an_DT adequate_JJ respiratory_JJ exchange_NN is_VBZ maintained_VBN ._. Ketoconazole_NN is_VBZ a_DT potent_JJ inhibitor_NN of_IN the_DT cytochrome_NN P450_NN 3A4_NN enzyme_NN system_NN ._. Coadministration_NN of_IN NIZORAL_NNP Tablets_NNPS and_CC drugs_NNS primarily_RB metabolized_VBN by_IN the_DT cytochrome_NN P450_NN 3A4_NN enzyme_NN system_NN may_MD result_VB in_IN increased_VBN plasma_NN concentrations_NNS of_IN the_DT drugs_NNS that_WDT could_MD increase_VB or_CC prolong_VB both_DT therapeutic_JJ and_CC adverse_JJ effects_NNS ._. Therefore_RB ,_, unless_IN otherwise_RB specified_VBN ,_, appropriate_JJ dosage_NN adjustments_NNS may_MD be_VB necessary_JJ ._. The_DT following_VBG drug_NN interactions_NNS have_VBP been_VBN identified_VBN involving_VBG NIZORAL_NNP Tablets_NNPS and_CC other_JJ drugs_NNS metabolized_VBN by_IN the_DT cytochrome_NN P450_NN 3A4_NN enzyme_NN system_NN :_: Ketoconazole_NNP tablets_NNS inhibit_VBP the_DT metabolism_NN of_IN terfenadine_NN ,_, resulting_VBG in_IN an_DT increased_VBN plasma_NN concentration_NN of_IN terfenadine_NN and_CC a_DT delay_NN in_IN the_DT elimination_NN of_IN its_PRP$ acid_NN metabolite_NN ._. The_DT increased_VBN plasma_NN concentration_NN of_IN terfenadine_NN or_CC its_PRP$ metabolite_NN may_MD result_VB in_IN prolonged_JJ QT_NN intervals_NNS ._. Pharmacokinetic_JJ data_NNS indicate_VBP that_IN oral_JJ ketoconazole_NN inhibits_VBZ the_DT metabolism_NN of_IN astemizole_NN ,_, resulting_VBG in_IN elevated_JJ plasma_NN levels_NNS of_IN astemizole_NN and_CC its_PRP$ active_JJ metabolite_NN desmethylastemizole_NN which_WDT may_MD prolong_VB QT_NNP intervals_NNS ._. Coadministration_NN of_IN astemizole_NN with_IN ketoconazole_NN tablets_NNS is_VBZ therefore_RB contraindicated_VBN ._. Human_JJ pharmacokinetics_NNS data_NNS indicate_VBP that_IN oral_JJ ketoconazole_NN potently_RB inhibits_VBZ the_DT metabolism_NN of_IN cisapride_NN resulting_VBG in_IN a_DT mean_NN eight-fold_JJ increase_NN in_IN AUC_NN of_IN cisapride_NN ._. Data_NNS suggest_VBP that_IN coadministration_NN of_IN oral_JJ ketoconazole_NN and_CC cisapride_NN can_MD result_VB in_IN prolongation_NN of_IN the_DT QT_NNP interval_NN on_IN the_DT ECG_NN ._. Therefore_RB concomitant_JJ administration_NN of_IN ketoconazole_NN tablets_NNS with_IN cisapride_NN is_VBZ contraindicated_VBN ._. Ketoconazole_NN tablets_NNS may_MD alter_VB the_DT metabolism_NN of_IN cyclosporine_NN ,_, tacrolimus_NN ,_, and_CC methylprednisolone_NN ,_, resulting_VBG in_IN elevated_JJ plasma_NN concentrations_NNS of_IN the_DT latter_JJ drugs_NNS ._. Dosage_NN adjustment_NN may_MD be_VB required_VBN if_IN cyclosporine_NN ,_, tacrolimus_NN ,_, or_CC methylprednisolone_NN are_VBP given_VBN concomitantly_RB with_IN NIZORAL_NNP Tablets_NNPS ._. Coadministration_NN of_IN NIZORAL_NNP Tablets_NNPS with_IN midazolam_NN or_CC triazolam_NN has_VBZ resulted_VBN in_IN elevated_JJ plasma_NN concentrations_NNS of_IN the_DT latter_JJ two_CD drugs_NNS ._. This_DT may_MD potentiate_VB and_CC prolong_VB hypnotic_JJ and_CC sedative_JJ effects_NNS ,_, especially_RB with_IN repeated_VBN dosing_NN or_CC chronic_JJ administration_NN of_IN these_DT agents_NNS ._. These_DT agents_NNS should_MD not_RB be_VB used_VBN in_IN patients_NNS treated_VBN with_IN NIZORAL_NNP Tablets_NNPS ._. If_IN midazolam_NN is_VBZ administered_VBN parenterally_RB ,_, special_JJ precaution_NN is_VBZ required_VBN since_IN the_DT sedative_JJ effect_NN may_MD be_VB prolonged_VBN ._. Rare_JJ cases_NNS of_IN elevated_JJ plasma_NN concentrations_NNS of_IN digoxin_NN have_VBP been_VBN reported_VBN ._. It_PRP is_VBZ not_RB clear_JJ whether_IN this_DT was_VBD due_JJ to_TO the_DT combination_NN of_IN therapy_NN ._. It_PRP is_VBZ ,_, therefore_RB ,_, advisable_JJ to_TO monitor_VB digoxin_NN concentrations_NNS in_IN patients_NNS receiving_VBG ketoconazole_NN ._. When_WRB taken_VBN orally_RB ,_, imidazole_NN compounds_NNS like_IN ketoconazole_NN may_MD enhance_VB the_DT anticoagulant_JJ effect_NN of_IN coumarin-like_JJ drugs_NNS ._. In_IN simultaneous_JJ treatment_NN with_IN imidazole_NN drugs_NNS and_CC coumarin_NN drugs_NNS ,_, the_DT anticoagulant_JJ effect_NN should_MD be_VB carefully_RB titrated_VBN and_CC monitored_VBN ._. Because_IN severe_JJ hypoglycemia_NN has_VBZ been_VBN reported_VBN in_IN patients_NNS concomitantly_RB receiving_VBG oral_JJ miconazole_NN -LRB-_-LRB- an_DT imidazole_NN -RRB-_-RRB- and_CC oral_JJ hypoglycemic_JJ agents_NNS ,_, such_PDT a_DT potential_JJ interaction_NN involving_VBG the_DT latter_JJ agents_NNS when_WRB used_VBN concomitantly_RB with_IN ketoconazole_NN tablets_NNS -LRB-_-LRB- an_DT imidazole_NN -RRB-_-RRB- can_MD not_RB be_VB ruled_VBN out_RP ._. Concomitant_JJ administration_NN of_IN ketoconazole_NN tablets_NNS with_IN phenytoin_NN may_MD alter_VB the_DT metabolism_NN of_IN one_CD or_CC both_DT of_IN the_DT drugs_NNS ._. It_PRP is_VBZ suggested_VBN to_TO monitor_VB both_CC ketoconazole_NN and_CC phenytoin_NN ._. Concomitant_JJ administration_NN of_IN rifampin_NN with_IN ketoconazole_NN tablets_NNS reduces_VBZ the_DT blood_NN levels_NNS of_IN the_DT latter_JJ ._. INH_NN -LRB-_-LRB- Isoniazid_NN -RRB-_-RRB- is_VBZ also_RB reported_VBN to_TO affect_VB ketoconazole_NN concentrations_NNS adversely_RB ._. These_DT drugs_NNS should_MD not_RB be_VB given_VBN concomitantly_RB ._. After_IN the_DT coadministration_NN of_IN 200_CD mg_NN oral_JJ ketoconazole_NN twice_RB daily_RB and_CC one_CD 20_CD mg_NN dose_NN of_IN loratadine_NN to_TO 11_CD subjects_NNS ,_, the_DT AUC_NN and_CC Cmax_NN of_IN loratadine_NN averaged_VBD 302_CD %_NN -LRB-_-LRB- 142_CD S.D._NN -RRB-_-RRB- and_CC 251_CD %_NN -LRB-_-LRB- 68_CD S.D._NN -RRB-_-RRB- ,_, respectively_RB ,_, of_IN those_DT obtained_VBN after_IN co-treatment_NN with_IN placebo_NN ._. The_DT AUC_NN and_CC Cmax_NN of_IN descarboethoxyloratadine_NN ,_, an_DT active_JJ metabolite_NN ,_, averaged_VBD 155_CD %_NN -LRB-_-LRB- 27_CD S.D._NN -RRB-_-RRB- and_CC 141_CD %_NN -LRB-_-LRB- 35_CD S.D._NN -RRB-_-RRB- ,_, respectively_RB ._. However_RB ,_, no_DT related_JJ changes_NNS were_VBD noted_VBN in_IN the_DT QT0_NN on_IN ECG_NN taken_VBN at_IN 2_CD ,_, 6_CD ,_, and_CC 24_CD hours_NNS after_IN the_DT coadministration_NN ._. Also_RB ,_, there_EX were_VBD no_DT clinically_RB significant_JJ differences_NNS in_IN adverse_JJ events_NNS when_WRB loratadine_NN was_VBD administered_VBN with_IN or_CC without_IN ketoconazole_NN ._. Rare_JJ cases_NNS of_IN a_DT disulfiram-like_JJ reaction_NN to_TO alcohol_NN have_VBP been_VBN reported_VBN ._. These_DT experiences_NNS have_VBP been_VBN characterized_VBN by_IN flushing_NN ,_, rash_NN ,_, peripheral_JJ edema_NN ,_, nausea_NN ,_, and_CC headache_NN ._. Symptoms_NNS resolved_VBN within_IN a_DT few_JJ hours_NNS ._. The_DT following_VBG drug_NN interactions_NNS were_VBD studied_VBN with_IN ketoprofen_NN doses_NNS of_IN 200_CD mg/day_NN ._. The_DT possibility_NN of_IN increased_VBN interaction_NN should_MD be_VB kept_VBN in_IN mind_NN when_WRB Orudis_NNP doses_NNS greater_JJR than_IN 50_CD mg_NN as_IN a_DT single_JJ dose_NN or_CC 200_CD mg_NN of_IN ketoprofen_NN per_IN day_NN are_VBP used_VBN concomitantly_RB with_IN highly_RB bound_VBN drugs_NNS ._. 1_LS ._. Antacids_NNS :_: Concomitant_JJ administration_NN of_IN magnesium_NN hydroxide_NN and_CC aluminum_NN hydroxide_NN does_VBZ not_RB interfere_VB with_IN the_DT rate_NN or_CC extent_NN of_IN the_DT absorption_NN of_IN ketoprofen_NN administered_VBN as_IN Orudis_NNP ._. 2_LS ._. Aspirin_NN :_: Ketoprofen_NNP does_VBZ not_RB alter_VB aspirin_NN absorption_NN ._. however_RB ,_, in_IN a_DT study_NN of_IN 12_CD normal_JJ subjects_NNS ,_, concurrent_JJ administration_NN of_IN aspirin_NN decreased_VBD ketoprofen_NN protein_NN binding_NN and_CC increased_VBD ketoprofen_NN plasma_NN clearance_NN from_IN 0.07_CD L/kg/h_NN without_IN aspirin_NN to_TO 0.11_CD L/kg/h_NN with_IN aspirin_NN ._. The_DT clinical_JJ significance_NN of_IN these_DT changes_NNS has_VBZ not_RB been_VBN adequately_RB studied_VBN ._. Therefore_RB ,_, concurrent_JJ use_NN of_IN aspirin_NN and_CC ketoprofen_NN is_VBZ not_RB recommended_VBN ._. 3_LS ._. Diuretic_JJ :_: Hydrochlorothiazide_NN ,_, given_VBN concomitantly_RB with_IN ketoprofen_NN ,_, produces_VBZ a_DT reduction_NN in_IN urinary_JJ potassium_NN and_CC chloride_NN excretion_NN compared_VBN to_TO hydrochlorothiazide_NN alone_RB ._. Patients_NNS taking_VBG diuretics_NNS are_VBP at_IN a_DT greater_JJR risk_NN of_IN developing_VBG renal_JJ failure_NN secondary_JJ to_TO a_DT decrease_NN in_IN renal_JJ blood_NN flow_NN caused_VBN by_IN prostaglandin_NN inhibition_NN ._. 4_LS ._. Digoxin_NNP :_: In_IN a_DT study_NN in_IN 12_CD patients_NNS with_IN congestive_JJ heart_NN failure_NN where_WRB ketoprofen_NN and_CC digoxin_NN were_VBD concomitantly_RB administered_VBN ,_, ketoprofen_NN did_VBD not_RB alter_VB the_DT serum_NN levels_NNS of_IN digoxin_NN ._. 5_CD ._. Warfarin_NNP :_: In_IN a_DT short-term_JJ controlled_JJ study_NN in_IN 14_CD normal_JJ volunteers_NNS ,_, ketoprofen_NN did_VBD not_RB significantly_RB interfere_VB with_IN the_DT effect_NN of_IN warfarin_NN on_IN prothrombin_NN time_NN ._. Bleeding_VBG from_IN a_DT number_NN of_IN sites_NNS may_MD be_VB a_DT complication_NN of_IN warfarin_NN treatment_NN and_CC GI_NN bleeding_VBG a_DT complication_NN of_IN ketoprofen_NN treatment_NN ._. Because_IN prostaglandina_NNS play_VBP an_DT important_JJ role_NN in_IN hemostasis_NN and_CC ketoprofen_NN has_VBZ an_DT effect_NN on_IN platelet_NN function_NN as_RB well_RB ,_, concurent_JJ therapy_NN with_IN ketoprofen_NN and_CC warfarin_NN requires_VBZ close_JJ monitoring_NN of_IN patients_NNS on_IN both_DT drugs_NNS ._. 6_CD ._. Probenecid_NNP :_: Probenecid_NNP increases_VBZ both_DT free_JJ and_CC bound_VBD ketoprofen_NN by_IN reducing_VBG the_DT plasma_NN clearance_NN of_IN ketoprofen_NN to_TO about_IN one-third_NN ,_, as_RB well_RB as_IN decreasing_VBG its_PRP$ protein_NN binding_NN ._. Therefore_RB ,_, the_DT combination_NN of_IN ketoprofen_NN and_CC probenecid_NN is_VBZ not_RB recommended_VBN ._. 7_CD ._. Methotrexate_NNP :_: Ketoprofen_NNP ,_, like_IN other_JJ NSAIDs_NNS ,_, may_MD cause_VB changes_NNS in_IN the_DT elimination_NN of_IN methotrexate_NN leading_VBG to_TO elevated_JJ serum_NN levels_NNS of_IN the_DT drug_NN and_CC increased_VBD toxicity_NN ._. 8_CD ._. Lithium_NN :_: Nonsteroidal_JJ anti-inflammatory_JJ agents_NNS have_VBP been_VBN reported_VBN to_TO increase_VB steadystate_JJ plasma_NN lithium_NN levels_NNS ._. It_PRP is_VBZ recommended_VBN that_IN plasma_NN lithium_NN levels_NNS be_VB monitored_VBN when_WRB ketoprofen_NN is_VBZ coadministered_VBN with_IN lithium_NN ._. DRUG/LABORATORY_NN TEST_NN INTERACTIONS_NNS :_: EFFECT_NN ON_IN BLOOD_NN COAGULATION_NN Ketoprofen_NN decreases_VBZ platelet_NN adhesion_NN and_CC aggregation_NN ._. Therefore_RB ,_, it_PRP can_MD prolong_VB bleeding_JJ time_NN by_IN approximately_RB 3_CD to_TO 4_CD minutes_NNS from_IN baseline_NN values_NNS ._. There_EX is_VBZ no_DT significant_JJ change_NN in_IN platelet_NN count_NN ,_, prothrombin_NN time_NN ,_, partial_JJ thromboplastin_NN time_NN ,_, or_CC thrombin_NN time_NN ._. Ketorolac_NNP is_VBZ highly_RB bound_VBN to_TO human_JJ plasma_NN protein_NN -LRB-_-LRB- mean_NN 99.2_CD %_NN -RRB-_-RRB- ._. Warfarin_NNP ,_, Digoxin_NNP ,_, Salicylate_NNP ,_, and_CC Heparin_NN The_DT in_FW vitro_FW binding_NN of_IN warfarin_NN to_TO plasma_NN proteins_NNS is_VBZ only_RB slightly_RB reduced_VBN by_IN ketorolac_NN tromethamine_NN -LRB-_-LRB- 99.5_CD %_NN control_NN vs_CC 99.3_CD %_NN -RRB-_-RRB- when_WRB ketorolac_JJ plasma_NN concentrations_NNS reach_VBP 5_CD to10_NN m_NN g/mL_NN ._. Ketorolac_NNP does_VBZ not_RB alter_VB digoxin_NN protein_NN binding_NN ._. In_FW vitro_FW studies_NNS indicate_VBP that_IN ,_, at_IN therapeutic_JJ concentrations_NNS of_IN salicylate_NN -LRB-_-LRB- 300_CD m_NN g/mL_NN -RRB-_-RRB- ,_, the_DT binding_NN of_IN ketorolac_NN was_VBD reduced_VBN from_IN approximately_RB 99.2_CD %_NN to_TO 97.5_CD %_NN ,_, representing_VBG a_DT potential_JJ twofold_JJ increase_NN in_IN unbound_JJ ketorolac_NN plasma_NN levels_NNS ._. Therapeutic_JJ concentrations_NNS of_IN digoxin_NN ,_, warfarin_NN ,_, ibuprofen_NN ,_, naproxen_NN ,_, piroxicam_NN ,_, acetaminophen_NN ,_, phenytoin_NN andtolbutamide_NN did_VBD not_RB alter_VB ketorolac_NN tromethamine_NN protein_NN binding_NN ._. In_IN a_DT study_NN involving_VBG 12_CD adult_JJ volunteers_NNS ,_, TORADOLORAL_NN was_VBD coadministered_VBN with_IN a_DT single_JJ dose_NN of_IN 25_CD mg_NN warfarin_NN ,_, causing_VBG no_DT significant_JJ changes_NNS in_IN pharmacokinetics_NNS or_CC pharmacodynamics_NNS of_IN warfarin_NN ._. In_IN another_DT study_NN ,_, TORADOLIV/IM_NN was_VBD given_VBN with_IN two_CD doses_NNS of_IN 5000_CD U_NN of_IN heparin_NN to_TO 11_CD healthy_JJ volunteers_NNS ,_, resulting_VBG in_IN a_DT mean_JJ template_NN bleeding_NN time_NN of_IN 6.4_CD minutes_NNS -LRB-_-LRB- 3.2_CD to_TO 11.4_CD min_NN -RRB-_-RRB- compared_VBN to_TO a_DT mean_NN of_IN 6.0_CD minutes_NNS -LRB-_-LRB- 3.4_CD to_TO 7.5_CD min_NN -RRB-_-RRB- for_IN heparin_NN alone_RB and_CC 5.1_CD minutes_NNS -LRB-_-LRB- 3.5_CD to_TO 8.5_CD min_NN -RRB-_-RRB- for_IN placebo_NN ._. Although_IN these_DT results_NNS do_VBP not_RB indicate_VB a_DT significant_JJ interaction_NN between_IN TORADOL_NNP and_CC warfarin_NN or_CC heparin_NN ,_, the_DT administration_NN of_IN TORADOL_NN to_TO patients_NNS taking_VBG anticoagulants_NNS should_MD be_VB done_VBN extremely_RB cautiously_RB ,_, and_CC patients_NNS should_MD be_VB closely_RB monitored_VBN ._. Furosemide_NNP :_: TORADOL_NNP IV/IM_NNP reduced_VBD the_DT diuretic_JJ response_NN to_TO furosemide_NN in_IN normovolemic_JJ healthy_JJ subjects_NNS by_IN approximately_RB 20_CD %_NN -LRB-_-LRB- mean_NN sodium_NN and_CC urinary_JJ output_NN decreased_VBD 17_CD %_NN -RRB-_-RRB- ._. Probenecid_NNP :_: Concomitant_JJ administration_NN of_IN TORADOL_NNP ORAL_NNP and_CC probenecid_NN resulted_VBD in_IN decreased_VBN clearance_NN of_IN ketorolac_NN and_CC significant_JJ increases_NNS in_IN ketorolac_JJ plasma_NN levels_NNS -LRB-_-LRB- total_JJ AUC_NN increased_VBD approximately_RB threefold_RB from_IN 5.4_CD to_TO 17.8_CD m_NN g/h/mL_NN -RRB-_-RRB- and_CC terminal_JJ half-life_NN increased_VBD approximately_RB twofold_RB from_IN 6.6_CD to_TO 15.1_CD hours_NNS ._. Therefore_RB ,_, concomitant_JJ use_NN of_IN TORADOL_NNP and_CC probenecid_NN is_VBZ contraindicated_VBN ._. Lithium_NN :_: Inhibition_NN of_IN renal_JJ lithium_NN clearance_NN ,_, leading_VBG to_TO an_DT increase_NN in_IN plasma_NN lithium_NN concentration_NN ,_, has_VBZ been_VBN reported_VBN with_IN some_DT prostaglandin_NN synthesis-inhibiting_JJ drugs_NNS ._. The_DT effect_NN of_IN TORADOL_NN on_IN plasma_NN lithium_NN has_VBZ not_RB been_VBN studied_VBN ,_, but_CC cases_NNS of_IN increased_VBN lithium_NN plasma_NN levels_NNS during_IN TORADOL_NN therapy_NN have_VBP been_VBN reported_VBN ._. Methotrexate_NNP :_: Concomitant_JJ administration_NN of_IN methotrexate_NN and_CC some_DT NSAIDs_NNS has_VBZ been_VBN reported_VBN to_TO reduce_VB the_DT clearance_NN of_IN methotrexate_NN ,_, enhancing_VBG the_DT toxicity_NN of_IN methotrexate_NN ._. The_DT effect_NN of_IN TORADOL_NN on_IN methotrexate_NN clearance_NN has_VBZ not_RB been_VBN studied_VBN ._. Nondepolarizing_VBG Muscle_NN Relaxants_NNS :_: In_IN postmarketing_VBG experience_NN there_EX have_VBP been_VBN reports_NNS of_IN a_DT possible_JJ interaction_NN between_IN TORADOLIV/IM_NN and_CC nondepolarizing_JJ muscle_NN relaxants_NNS that_WDT resulted_VBD in_IN apnea_NN ._. The_DT concurrent_JJ use_NN of_IN TORADOL_NN with_IN muscle_NN relaxants_NNS has_VBZ not_RB been_VBN formally_RB studied_VBN ._. ACE_NN Inhibitors_NNS :_: Concomitant_JJ use_NN of_IN ACE_NN inhibitors_NNS may_MD increase_VB the_DT risk_NN of_IN renal_JJ impairment_NN ,_, particularly_RB in_IN volume-depleted_JJ patients_NNS ._. Antiepileptic_JJ Drugs_NNS :_: Sporadic_JJ cases_NNS of_IN seizures_NNS have_VBP been_VBN reported_VBN during_IN concomitant_JJ use_NN of_IN TORADOL_NNP and_CC antiepileptic_JJ drugs_NNS -LRB-_-LRB- phenytoin_NN ,_, carbamazepine_NN -RRB-_-RRB- ._. Psychoactive_JJ Drugs_NNS :_: Hallucinations_NNS have_VBP been_VBN reported_VBN when_WRB TORADOL_NNP was_VBD used_VBN in_IN patients_NNS taking_VBG psychoactive_JJ drugs_NNS -LRB-_-LRB- fluoxetine_NN ,_, thiothixene_NN ,_, alprazolam_NN -RRB-_-RRB- ._. Morphine_NNP :_: TORADOLIV/IM_NN has_VBZ been_VBN administered_VBN concurrently_RB with_IN morphine_NN in_IN several_JJ clinical_JJ trials_NNS of_IN postoperative_JJ pain_NN without_IN evidence_NN of_IN adverse_JJ interactions_NNS ._. Do_VB not_RB mix_VB TORADOL_NN and_CC morphine_NN in_IN the_DT same_JJ syringe_NN ._. There_EX is_VBZ no_DT evidence_NN in_IN animal_NN or_CC human_JJ studies_NNS that_WDT TORADOL_NN induces_VBZ or_CC inhibits_VBZ hepatic_JJ enzymes_NNS capable_JJ of_IN metabolizing_VBG itself_PRP or_CC other_JJ drug_NN ._. Cyclosporine_NN -_: L-arginine_NN may_MD counteract_VB the_DT antinaturetic_JJ effect_NN of_IN cyclosporin_NN ._. Ibuprofen_NN -_: L-arginine_NN may_MD increase_VB the_DT absorption_NN of_IN ibuprofen_NN if_IN taken_VBN concomitantly_RB ._. Organic_NNP nitrates_NNS -_: L-arginine_NN supplements_NNS theoretically_RB may_MD potentiate_VB the_DT effects_NNS of_IN organic_JJ nitrates_NNS if_IN taken_VBN concomitantly_RB ._. Sildenafil_NN citrate_NN -_: Theoretically_RB ,_, L-arginine_JJ supplements_NNS taken_VBN concomitantly_RB with_IN sildenafil_NN citrate_NN ,_, may_MD potentiate_VB the_DT effects_NNS of_IN the_DT drug_NN ._. No_DT drug_NN ,_, nutritional_JJ supplement_NN ,_, food_NN or_CC herb_NN interactions_NNS are_VBP known_VBN ._. Interacts_NNS with_IN valproic_JJ aci_NN ._. No_DT well-known_JJ drug_NN interactions_NNS with_IN glutamic_JJ aci_NN ._. Human_JJ growth_NN hormone_NN -_: Concomitant_JJ use_NN of_IN L-glutamine_NN and_CC human_JJ growth_NN hormone_NN may_MD enhance_VB nutrient_JJ absorption_NN in_IN those_DT with_IN severe_JJ short_JJ bowel_NN syndrome_NN ._. L-glutamine_NN has_VBZ orphan_JJ drug_NN status_NN for_IN this_DT indication_NN ._. Indomethacin_NN -_: Concomitant_JJ use_NN of_IN L-glutamine_NN and_CC indomethacin_NN may_MD ameliorate_VB increased_VBN intestinal_JJ permeability_NN caused_VBN by_IN indomethacin_NN ._. The_DT reported_VBN dose_NN used_VBN for_IN L-glutamine_NN was_VBD 21_CD grams_NNS daily_JJ taken_VBN in_IN divided_VBN doses_NNS three_CD times_NNS a_DT day_NN ._. Further_RB ,_, misoprostol_NN is_VBZ reported_VBN to_TO have_VB a_DT synergistic_JJ effect_NN with_IN this_DT combination_NN in_IN ameliorating_VBG intestinal_JJ permeability_NN ._. Methotrexate_NNP -_: There_EX is_VBZ one_CD report_NN that_IN methotrexate_NN may_MD decrease_VB the_DT possible_JJ effectiveness_NN of_IN supplemental_JJ L-glutamine_NN for_IN chemotherapy-induced_JJ mucositis_NN ._. In_IN another_DT report_NN ,_, nine_CD patients_NNS with_IN breast_NN cancer_NN were_VBD reported_VBN to_TO have_VB decreased_VBN symptoms_NNS of_IN methotrexate-related_JJ toxicity_NN when_WRB given_VBN supplemental_JJ L-glutamine_NN at_IN a_DT dose_NN of_IN 0.5_CD gram/kilogram/day_NN ._. Paclitaxel_NN -_: In_IN one_CD report_NN ,_, L-glutamine_NN at_IN a_DT dose_NN of_IN 10_CD grams_NNS three_CD times_NNS daily_RB ,_, given_VBN 24_CD hours_NNS after_IN receiving_VBG paclitaxel_NN ,_, appeared_VBD to_TO prevent_VB the_DT development_NN of_IN myalgia_NN and_CC arthralgia_NN ,_, adverse_JJ reactions_NNS of_IN paclitaxel_NN ._. Medroxyprogesterone_NNP Acetate_NNP -_: L-histidine_NN was_VBD observed_VBN to_TO enhance_VB -LRB-_-LRB- in_IN tissue_NN culture_NN -RRB-_-RRB- the_DT effect_NN of_IN medroxyprogesterone_NN acetate_NN in_IN reducing_VBG the_DT number_NN of_IN human_JJ breast_NN cancer_NN cells_NNS that_WDT were_VBD in_IN the_DT S_NN phase_NN ._. H1_NN and_CC H2_NN Blockers_NNS -_: Although_IN not_RB reported_VBN ,_, L-histidine_NN ,_, via_IN its_PRP$ metabolism_NN to_TO histamine_NN ,_, might_MD decrease_VB the_DT efficacy_NN of_IN H1_NN and_CC H2_NN blockers_NNS ._. Concomitant_JJ use_NN of_IN calcium_NN supplements_NNS and_CC L-lysine_NN may_MD increase_VB calcium_NN absorptio_NN ._. Acetaminophen_NN and_CC methotrexate_NN -_: L-methionine_NN may_MD decrease_VB hepatic_JJ toxicity_NN in_IN those_DT with_IN acetaminophen_NN overdosage_NN or_CC in_IN those_DT taking_VBG methotrexate_NN ._. Theoretically_RB ,_, it_PRP may_MD decrease_VB hepatic_JJ toxicity_NN in_IN the_DT case_NN of_IN other_JJ potential_JJ hepatotoxic_JJ drugs_NNS ,_, as_RB well_RB ._. Gentamicin_NN -_: Methionine_NN may_MD protect_VB against_IN the_DT ototoxic_JJ effects_NNS of_IN gentamicin_NN ._. Non-selective_JJ monoamine_NN oxidase_NN -LRB-_-LRB- MAO_NN -RRB-_-RRB- inhibitors_NNS -_: including_VBG phenelzine_NN sulfate_NN ,_, tranylcypromine_NN sulfate_NN and_CC pargyline_NN HC1_NN ._. Concomitant_JJ use_NN of_IN L-phenylalanine_NN and_CC non-selective_JJ MAO_NN inhibitors_NNS may_MD cause_VB hypertension_NN ._. Selegiline_NNP -_: L-phenylalanine_NN and_CC the_DT selective_JJ MAO_NNP inhibitor_NN selegiline_NN may_MD have_VB synergistic_JJ antidepressant_JJ activity_NN if_IN used_VBN concomitantly_RB ._. Neuroleptic_JJ Drugs_NNS -_: L-phenylalanine_NN may_MD potentiate_VB the_DT tardive_JJ dyskinesia_NN side_NN reactions_NNS of_IN neuroleptic_JJ drugs_NNS if_IN used_VBN concomitantly_RB with_IN them_PRP ._. Monoamine_NN oxidase_NN -LRB-_-LRB- MAO_NN -RRB-_-RRB- inhibitors_NNS such_JJ as_IN isocarboxazid_NN -LRB-_-LRB- e.g._FW ,_, Marplan_NNP -RRB-_-RRB- ,_, phenelzine_NN -LRB-_-LRB- e.g._FW ,_, Nardil_NNP -RRB-_-RRB- ,_, procarbazine_NN -LRB-_-LRB- e.g._FW ,_, Matulane_NN -RRB-_-RRB- ,_, selegiline_NN -LRB-_-LRB- e.g._FW ,_, Eldepryl_NN -RRB-_-RRB- ,_, and_CC tranylcypromine_NN -LRB-_-LRB- e.g._FW ,_, Parnate_NNP -RRB-_-RRB- :_: Using_VBG these_DT medicines_NNS with_IN L-tryptophan_NN may_MD increase_VB the_DT chance_NN of_IN side_JJ effects_NNS ._. Non-selective_JJ MAO_NN inhibitors_NNS including_VBG tranylcypromine_NN sulfate_NN ,_, phenelzine_NN sulfate_NN ,_, and_CC pargyline_NN HC1_NN :_: Concomitant_JJ use_NN of_IN L-tyrosine_NN and_CC non-selective_JJ MAO_NN inhibitors_NNS may_MD cause_VB hypertension_NN ._. In_IN one_CD survey_NN ,_, 2.3_CD %_NN of_IN patients_NNS taking_VBG labetalol_JJ HCl_NN in_IN combination_NN with_IN tricyclic_JJ antidepressants_NNS experienced_VBD tremor_NN ,_, as_IN compared_VBN to_TO 0.7_CD %_NN reported_VBD to_TO occur_VB with_IN labetalol_NN HCl_NN alone_RB ._. The_DT contribution_NN of_IN each_DT of_IN the_DT treatments_NNS to_TO this_DT adverse_JJ reaction_NN is_VBZ unknown_JJ but_CC the_DT possibility_NN of_IN a_DT drug_NN interaction_NN can_MD not_RB be_VB excluded_VBN ._. Drugs_NNS possessing_VBG beta-blocking_JJ properties_NNS can_MD blunt_VB the_DT bronchodilator_NN effect_NN of_IN beta-receptor_NN agonist_NN drugs_NNS in_IN patients_NNS with_IN bronchospasm_NN ._. therefore_RB ,_, doses_NNS greater_JJR than_IN the_DT normal_JJ antiasthmatic_JJ dose_NN of_IN beta-agonist_JJ bronchodilator_NN drugs_NNS may_MD be_VB required_VBN ._. Cimetidine_NNP has_VBZ been_VBN shown_VBN to_TO increase_VB the_DT bioavailability_NN of_IN labetalol_NN HCl_NN ._. Since_IN this_DT could_MD be_VB explained_VBN either_CC by_IN enhanced_VBN absorption_NN or_CC by_IN an_DT alteration_NN of_IN hepatic_JJ metabolism_NN of_IN labetalol_NN HCl_NN ,_, special_JJ care_NN should_MD be_VB used_VBN in_IN establishing_VBG the_DT dose_NN required_VBN for_IN blood_NN pressure_NN control_NN in_IN such_JJ patients_NNS ._. Synergism_NN has_VBZ been_VBN shown_VBN between_IN halothane_NN anesthesia_NN and_CC intravenously_RB administered_VBN labetalol_NN HCl_NN ._. During_IN controlled_JJ hypotensive_JJ anesthesia_NN using_VBG labetalol_NN HCl_NN in_IN association_NN with_IN halothane_NN ,_, high_JJ concentrations_NNS -LRB-_-LRB- 3_CD %_NN or_CC above_IN -RRB-_-RRB- of_IN halothane_NN should_MD not_RB be_VB used_VBN because_IN the_DT degree_NN of_IN hypotension_NN will_MD be_VB increased_VBN and_CC because_IN of_IN the_DT possibility_NN of_IN a_DT large_JJ reduction_NN in_IN cardiac_JJ output_NN and_CC an_DT increase_NN in_IN central_JJ venous_JJ pressure_NN ._. The_DT anesthesiologist_NN should_MD be_VB informed_VBN when_WRB a_DT patient_NN is_VBZ receiving_VBG labetalol_NN HCl_NN ._. Labetalol_NNP HCl_NN blunts_VBZ the_DT reflex_JJ tachycardia_NN produced_VBN by_IN nitroglycerin_NN without_IN preventing_VBG its_PRP$ hypotensive_JJ effect_NN ._. If_IN labetalol_JJ HCl_NN is_VBZ used_VBN with_IN nitroglycerin_NN in_IN patients_NNS with_IN angina_NN pectoris_NN ,_, additional_JJ antihypertensive_JJ effects_NNS may_MD occur_VB ._. Care_NNP should_MD be_VB taken_VBN if_IN labetalol_NN is_VBZ used_VBN concomitantly_RB with_IN calcium_NN antagonists_NNS of_IN the_DT verapamil_NN type_NN ._. Risk_NN of_IN Anaphylactic_NNP Reaction_NNP While_IN taking_VBG beta-blockers_NNS ,_, patients_NNS with_IN a_DT history_NN of_IN severe_JJ anaphylactic_JJ reaction_NN to_TO a_DT variety_NN of_IN allergens_NNS may_MD be_VB more_RBR reactive_JJ to_TO repeated_VBN challenge_NN ,_, either_CC accidental_JJ ,_, diagnostic_JJ ,_, or_CC therapeutic_JJ ._. Such_JJ patients_NNS may_MD be_VB unresponsive_JJ to_TO the_DT usual_JJ doses_NNS of_IN epinephrine_NN used_VBN to_TO treat_VB allergic_JJ reaction_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS The_DT presence_NN of_IN labetalol_NN metabolites_NNS in_IN the_DT urine_NN may_MD result_VB in_IN falsely_RB elevated_JJ levels_NNS of_IN urinary_JJ catecholamines_NNS ,_, metanephrine_NN ,_, normetanephrine_NN and_CC vanillylmandelic_JJ acid_NN when_WRB measured_VBN by_IN fluorimetric_JJ or_CC photometric_JJ methods_NNS ._. In_IN screening_NN patients_NNS suspected_VBN of_IN having_VBG a_DT pheochromocytoma_NN and_CC being_VBG treated_VBN with_IN labetalol_NN HCl_NN ,_, a_DT specific_JJ method_NN ,_, such_JJ as_IN a_DT high_JJ performance_NN liquid_NN chromatographic_JJ assay_NN with_IN solid_JJ phase_NN extraction_NN -LRB-_-LRB- e.g._FW ,_, J_NNP Chromatogr_NNP 385:241,1987_CD -RRB-_-RRB- should_MD be_VB employed_VBN in_IN determining_VBG levels_NNS of_IN catecholamines_NNS ._. Labetalol_NNP HCl_NN has_VBZ also_RB been_VBN reported_VBN to_TO produce_VB a_DT false_JJ positive_JJ test_NN for_IN amphetamine_NN when_WRB screening_VBG urine_NN for_IN the_DT presence_NN of_IN drugs_NNS using_VBG the_DT commercially_RB available_JJ assay_NN methods_NNS Toxi-Lab_NNP A_NNP -LRB-_-LRB- thin-layer_JJ chromatographic_JJ assay_NN -RRB-_-RRB- and_CC Emit-d.a.u._NN -LRB-_-LRB- radioenzymatic_JJ assay_NN -RRB-_-RRB- ._. When_WRB patients_NNS being_VBG treated_VBN with_IN labetalol_NN have_VBP a_DT positive_JJ urine_NN test_NN for_IN amphetamine_NN using_VBG these_DT techniques_NNS confirmation_NN should_MD be_VB made_VBN by_IN using_VBG more_RBR specific_JJ methods_NNS such_JJ as_IN a_DT gas_NN chromatographic-mass_NN spectrometer_NN technique_NN ._. Results_NNS of_IN preliminary_JJ studies_NNS in_IN humans_NNS and_CC rats_NNS suggest_VBP that_IN nonabsorbable_JJ antacids_NNS given_VBN concurrently_RB with_IN lactulose_NN may_MD inhibit_VB the_DT desired_VBN lactulose-induced_JJ drop_NN in_IN colonic_JJ pH._NN Therefore_RB ,_, a_DT possible_JJ lack_NN of_IN desired_VBN effect_NN of_IN treatment_NN should_MD be_VB taken_VBN into_IN consideration_NN before_IN such_JJ drugs_NNS are_VBP given_VBN concomitantly_RB with_IN lactulose_NN ._. Lamivudine_NN is_VBZ predominantly_RB eliminated_VBN in_IN the_DT urine_NN by_IN active_JJ organic_JJ cationic_JJ secretion_NN ._. The_DT possibility_NN of_IN interactions_NNS with_IN other_JJ drugs_NNS administered_VBN concurrently_RB should_MD be_VB considered_VBN ,_, particularly_RB when_WRB their_PRP$ main_JJ route_NN of_IN elimination_NN is_VBZ active_JJ renal_JJ secretion_NN via_IN the_DT organic_JJ cationic_NN transport_NN system_NN -LRB-_-LRB- e.g._FW ,_, trimethoprim_NN -RRB-_-RRB- ._. No_DT change_NN in_IN dose_NN of_IN either_CC drug_NN is_VBZ recommended_VBN ._. There_EX is_VBZ no_DT information_NN regarding_VBG the_DT effect_NN on_IN lamivudine_NN pharmacokinetics_NNS of_IN higher_JJR doses_NNS of_IN TMP/SMX_NN such_JJ as_IN those_DT used_VBN to_TO treat_VB Pneumocystis_NN carinii_NN pneumonia_NN ._. No_DT data_NNS are_VBP available_JJ regarding_VBG interactions_NNS with_IN other_JJ drugs_NNS that_WDT have_VBP renal_JJ clearance_NN mechanisms_NNS similar_JJ to_TO that_DT of_IN lamivudine_NN ._. Lamivudine_NN and_CC zalcitabine_NN may_MD inhibit_VB the_DT intracellular_JJ phosphorylation_NN of_IN one_CD another_DT ._. Therefore_RB ,_, use_NN of_IN lamivudine_NN in_IN combination_NN with_IN zalcitabine_NN is_VBZ not_RB recommende_NN ._. Lansoprazole_NNP is_VBZ metabolized_VBN through_IN the_DT cytochrome_NN P450_NN system_NN ,_, specifically_RB through_IN the_DT CYP3A_NN and_CC CYP2C19_NN isozymes_NNS ._. Studies_NNS have_VBP shown_VBN that_IN lansoprazole_NN does_VBZ not_RB have_VB clinically_RB significant_JJ interactions_NNS with_IN other_JJ drugs_NNS metabolized_VBN by_IN the_DT cytochrome_NN P450_NN system_NN ,_, such_JJ as_IN warfarin_NN ,_, antipyrine_NN ,_, indomethacin_NN ,_, ibuprofen_NN ,_, phenytoin_NN ,_, propranolol_NN ,_, prednisone_NN ,_, diazepam_NN ,_, clarithromycin_NN ,_, or_CC terfenadine_NN in_IN healthy_JJ subjects_NNS ._. These_DT compounds_NNS are_VBP metabolized_VBN through_IN various_JJ cytochrome_NN P450_NN isozymes_NNS including_VBG CYP1A2_NN ,_, CYP2C9_NN ,_, CYP2C19_NN ,_, CYP2D6_NN ,_, and_CC CYP3A_NN ._. When_WRB lansoprazole_NN was_VBD administered_VBN concomitantly_RB with_IN theophylline_NN -LRB-_-LRB- CYP1A2_NN ,_, CYP3A_NN -RRB-_-RRB- ,_, a_DT minor_JJ increase_NN -LRB-_-LRB- 10_CD %_NN -RRB-_-RRB- in_IN the_DT clearance_NN of_IN theophylline_NN was_VBD seen_VBN ._. Because_IN the_DT small_JJ magnitude_NN and_CC the_DT direction_NN of_IN the_DT effect_NN on_IN theophylline_NN clearance_NN ,_, this_DT interaction_NN is_VBZ unlikely_JJ to_TO be_VB clinical_JJ concern_NN ._. Nonetheless_RB ,_, individual_JJ patients_NNS may_MD require_VB additional_JJ titration_NN of_IN their_PRP$ theophylline_NN dosage_NN when_WRB lansoprazole_NN is_VBZ started_VBN or_CC stopped_VBN to_TO ensure_VB clinically_RB effective_JJ blood_NN levels_NNS ._. Lansoprazole_NNP has_VBZ also_RB been_VBN shown_VBN to_TO have_VB no_DT clinically_RB significant_JJ interaction_NN with_IN amoxicillin_NNP ._. In_IN a_DT single-dose_JJ crossover_NN study_NN examining_VBG lansoprazole_NN 30_CD mg_NN and_CC omeprazole_NN 20_CD mg_NN each_DT administered_VBN alone_RB and_CC concomitantly_RB with_IN sucralfate_NN 1_CD gram_NN ,_, absorption_NN of_IN the_DT proton_NN pump_NN inhibitors_NNS was_VBD delayed_VBN and_CC their_PRP$ bioavailability_NN was_VBD reduced_VBN by_IN 17_CD %_NN and_CC 16_CD %_NN ,_, respectively_RB ,_, when_WRB administered_VBN concomitantly_RB with_IN sucralfate_NN ._. Therefore_RB ,_, proton_NN pump_NN inhibitors_NNS should_MD be_VB taken_VBN at_IN least_JJS 30_CD minutes_NNS prior_RB to_TO sucralfate_NN ._. In_IN clinical_JJ trials_NNS ,_, antacids_NNS were_VBD administered_VBN concomitantly_RB with_IN lansoprazole_NN delayed-release_NN capsules_NNS ._. this_DT did_VBD not_RB interfere_VB with_IN its_PRP$ effect_NN ._. Lansoprazole_NN causes_VBZ a_DT profound_JJ and_CC long_JJ lasting_JJ inhibition_NN of_IN gastric_JJ acid_NN secretion_NN ._. therefore_RB ,_, it_PRP is_VBZ theoretically_RB possible_JJ that_IN lansoprazole_NN may_MD interfere_VB with_IN the_DT absorption_NN of_IN drugs_NNS where_WRB gastric_JJ pH_NN is_VBZ an_DT important_JJ determinant_NN of_IN bioavailability_NN -LRB-_-LRB- e.g._FW ketoconazole_NN ,_, ampicillin_NN esters_NNS ,_, iron_NN salts_NNS ,_, digoxin_NN -RRB-_-RRB- ._. Effects_NNS of_IN Lapatinib_NN on_IN Drug_NN Metabolizing_VBG Enzymes_NNS and_CC Drug_NN Transport_NNP Systems_NNP Lapatinib_NNP inhibits_VBZ CYP3A4_NN and_CC CYP2C8_NN in_FW vitro_FW at_IN clinically_RB relevant_JJ concentrations_NNS ._. Caution_NN should_MD be_VB exercised_VBN and_CC dose_NN reduction_NN of_IN the_DT concomitant_JJ substrate_NN drug_NN should_MD be_VB considered_VBN when_WRB dosing_NN lapatinib_NN concurrently_RB with_IN medications_NNS with_IN narrow_JJ therapeutic_JJ windows_NNS that_WDT are_VBP substrates_NNS of_IN CYP3A4_NN or_CC CYP2C8_NN ._. Lapatinib_NNP did_VBD not_RB significantly_RB inhibit_VB the_DT following_VBG enzymes_NNS in_IN human_JJ liver_NN microsomes_NNS :_: CYP1A2_NN ,_, CYP2C9_NN ,_, CYP2C19_NN ,_, and_CC CYP2D6_NN or_CC UGT_NN enzymes_NNS in_FW vitro_FW ,_, however_RB ,_, the_DT clinical_JJ significance_NN is_VBZ unknown_JJ ._. Lapatinib_NN inhibits_VBZ human_JJ P-glycoprotein_NN ._. If_IN TYKERB_NNP is_VBZ administered_VBN with_IN drugs_NNS that_WDT are_VBP substrates_NNS of_IN Pgp_NNP ,_, increased_VBD concentrations_NNS of_IN the_DT substrate_NN drug_NN are_VBP likely_JJ ,_, and_CC caution_NN should_MD be_VB exercised_VBN ._. Drugs_NNS that_WDT Inhibit_VBP or_CC Induce_VBP Cytochrome_NN P450_NN 3A4_NN Enzymes_NNS Lapatinib_NN undergoes_VBZ extensive_JJ metabolism_NN by_IN CYP3A4_NN ,_, and_CC concomitant_JJ administration_NN of_IN strong_JJ inhibitors_NNS or_CC inducers_NNS of_IN CYP3A4_NN alter_VBP lapatinib_NN concentrations_NNS significantly_RB ._. Dose_NN adjustment_NN of_IN lapatinib_NN should_MD be_VB considered_VBN for_IN patients_NNS who_WP must_MD receive_VB concomitant_JJ strong_JJ inhibitors_NNS or_CC concomitant_JJ strong_JJ inducers_NNS of_IN CYP3A4_NN enzymes_NNS ._. Ketoconazole_NN :_: In_IN healthy_JJ subjects_NNS receiving_VBG ketoconazole_NN ,_, a_DT CYP3A4_NN inhibitor_NN ,_, at_IN 200_CD mg_NN twice_RB daily_RB for_IN 7_CD days_NNS ,_, systemic_JJ exposure_NN -LRB-_-LRB- AUC_NN -RRB-_-RRB- to_TO lapatinib_NN was_VBD increased_VBN to_TO approximately_RB 3.6-fold_RB of_IN control_NN and_CC half-life_NN increased_VBD to_TO 1.7-fold_RB of_IN control_NN ._. Carbamazepine_NNP :_: In_IN healthy_JJ subjects_NNS receiving_VBG the_DT CYP3A4_NN inducer_NN ,_, carbamazepine_NN ,_, at_IN 100_CD mg_NN twice_RB daily_RB for_IN 3_CD days_NNS and_CC 200_CD mg_NN twice_RB daily_RB for_IN 17_CD days_NNS ,_, systemic_JJ exposure_NN -LRB-_-LRB- AUC_NN -RRB-_-RRB- to_TO lapatinib_NN was_VBD decreased_VBN approximately_RB 72_CD %_NN ._. Drugs_NNS that_WDT Inhibit_VBP Drug_NN Transport_NNP Systems_NNP Lapatinib_NNP is_VBZ a_DT substrate_NN of_IN the_DT efflux_NN transporter_NN P-glycoprotein_NN -LRB-_-LRB- Pgp_NN ,_, ABCB1_NN -RRB-_-RRB- ._. If_IN TYKERB_NNP is_VBZ administered_VBN with_IN drugs_NNS that_WDT inhibit_VBP Pgp_NNP ,_, increased_VBD concentrations_NNS of_IN lapatinib_NN are_VBP likely_JJ ,_, and_CC caution_NN should_MD be_VB exercised_VBN ._. Other_JJ Chemotherapy_NNP Agents_NNPS In_IN a_DT separate_JJ study_NN ,_, concomitant_JJ administration_NN of_IN lapatinib_NN with_IN capecitabine_NN did_VBD not_RB meaningfully_RB alter_VB the_DT pharmacokinetics_NNS of_IN either_CC agent_NN -LRB-_-LRB- or_CC the_DT metabolites_NNS of_IN capecitabine_NN -RRB-_-RRB- ._. No_DT formal_JJ drug_NN interaction_NN studies_NNS have_VBP been_VBN conducted_VBN ._. In_FW vitro_FW studies_NNS have_VBP shown_VBN that_IN precipitation_NN occurs_VBZ when_WRB eye_NN drops_VBZ containing_VBG thimerosal_NN are_VBP mixed_VBN with_IN latanoprost_NN ._. If_IN such_JJ drugs_NNS are_VBP used_VBN they_PRP should_MD be_VB administered_VBN with_IN an_DT interval_NN of_IN at_IN least_JJS 5_CD minutes_NNS between_IN applications_NNS ._. Cholestyramine_NNP and_CC Charcoal_NNP Administration_NNP of_IN cholestyramine_NN or_CC activated_VBN charcoal_NN in_IN patients_NNS -LRB-_-LRB- n_NN =_JJ 13_CD -RRB-_-RRB- and_CC volunteers_NNS -LRB-_-LRB- n_NN =_JJ 96_CD -RRB-_-RRB- resulted_VBD in_IN a_DT rapid_JJ and_CC significant_JJ decrease_NN in_IN plasma_NN M1_NN -LRB-_-LRB- the_DT active_JJ metabolite_NN of_IN leflunomide_NN -RRB-_-RRB- concentration_NN ._. Hepatotoxic_JJ Drugs_NNS Increased_VBN side_JJ effects_NNS may_MD occur_VB when_WRB leflunomide_NN is_VBZ given_VBN concomitantly_RB with_IN hepatotoxic_JJ substances_NNS ._. This_DT is_VBZ also_RB to_TO be_VB considered_VBN when_WRB leflunomide_NN treatment_NN is_VBZ followed_VBN by_IN such_JJ drugs_NNS without_IN a_DT drug_NN elimination_NN procedure_NN ._. In_IN a_DT small_JJ -LRB-_-LRB- n_NN =_JJ 30_CD -RRB-_-RRB- combination_NN study_NN of_IN ARAVA_NN with_IN methotrexate_NN ,_, a_DT 2_LS -_: to_TO 3-fold_JJ elevation_NN in_IN liver_NN enzymes_NNS was_VBD seen_VBN in_IN 5_CD of_IN 30_CD patients_NNS ._. All_DT elevations_NNS resolved_VBN ,_, 2_CD with_IN continuation_NN of_IN both_CC drugs_NNS and_CC 3_CD after_IN discontinuation_NN of_IN leflunomide_NN ._. A_DT 3-fold_JJ increase_NN was_VBD seen_VBN in_IN another_DT 5_CD patients_NNS ._. All_DT of_IN these_DT also_RB resolved_VBN ,_, 2_CD with_IN continuation_NN of_IN both_CC drugs_NNS and_CC 3_CD after_IN discontinuation_NN of_IN leflunomide_NN ._. Three_CD patients_NNS met_VBD ACR_NN criteria_NNS for_IN liver_NN biopsy_NN -LRB-_-LRB- 1_CD :_: Roegnik_NNP Grade_NNP I_PRP ,_, 2_CD :_: Roegnik_NNP Grade_NNP IIIa_NN -RRB-_-RRB- ._. No_DT pharmacokinetic_JJ interaction_NN was_VBD identified_VBN ._. NSAIDs_NNS :_: In_IN in_FW vitro_FW studies_NNS ,_, M1_NN was_VBD shown_VBN to_TO cause_VB increases_NNS ranging_VBG from_IN 13_CD -_: 50_CD %_NN in_IN the_DT free_JJ fraction_NN of_IN diclofenac_NN and_CC ibuprofen_NN at_IN concentrations_NNS in_IN the_DT clinical_JJ range_NN ._. The_DT clinical_JJ significance_NN of_IN this_DT finding_NN is_VBZ unknown_JJ ;_: ._. however_RB ,_, there_EX was_VBD extensive_JJ concomitant_JJ use_NN of_IN NSAIDs_NNS in_IN clinical_JJ studies_NNS and_CC no_DT differential_JJ effect_NN was_VBD observed_VBN ._. Tolbutamide_NNP :_: In_IN in_FW vitro_FW studies_NNS ,_, M1_NN was_VBD shown_VBN to_TO cause_VB increases_NNS ranging_VBG from_IN 13_CD -_: 50_CD %_NN in_IN the_DT free_JJ fraction_NN of_IN tolbutamide_NN at_IN concentrations_NNS in_IN the_DT clinical_JJ range_NN ._. The_DT clinical_JJ significance_NN of_IN this_DT finding_NN is_VBZ unknown_JJ ._. Rifampin_NNP :_: Following_VBG concomitant_JJ administration_NN of_IN a_DT single_JJ dose_NN of_IN ARAVA_NNP to_TO subjects_NNS receiving_VBG multiple_JJ doses_NNS of_IN rifampin_NN ,_, M1_NN peak_NN levels_NNS were_VBD increased_VBN -LRB-_-LRB- ~_CD 40_CD %_NN -RRB-_-RRB- over_IN those_DT seen_VBN when_WRB ARAVA_NNP was_VBD given_VBN alone_RB ._. Because_IN of_IN the_DT potential_NN for_IN ARAVA_NN levels_NNS to_TO continue_VB to_TO increase_VB with_IN multiple_JJ dosing_NN ,_, caution_NN should_MD be_VB used_VBN if_IN patients_NNS are_VBP to_TO be_VB receiving_VBG both_DT ARAVA_NN and_CC rifampin_NN ._. Warfarin_NNP :_: Increased_VBN INR_NN -LRB-_-LRB- International_NNP Normalized_NNP Ratio_NNP -RRB-_-RRB- when_WRB ARAVA_NNP and_CC warfarin_NN were_VBD co-administered_VBN has_VBZ been_VBN rarely_RB reported_VBN ._. Results_NNS from_IN human_JJ in_FW vitro_FW metabolism_NN studies_NNS and_CC nonclinical_JJ studies_NNS show_VBP that_IN REVLIMID_NN -LRB-_-LRB- lenalidomide_NN -RRB-_-RRB- is_VBZ neither_DT metabolized_VBN by_IN nor_CC inhibits_VBZ or_CC induces_VBZ the_DT cytochrome_NN P450_NN pathway_NN suggesting_VBG that_IN lenalidomide_NN is_VBZ not_RB likely_JJ to_TO cause_VB or_CC be_VB subject_JJ to_TO P450-based_JJ metabolic_JJ drug_NN interactions_NNS in_IN man_NN ._. Co-administration_NN of_IN multiple_JJ doses_NNS of_IN 10_CD mg_NN of_IN lenalidomide_NN had_VBD no_DT effect_NN on_IN the_DT single_JJ dose_NN pharmacokinetics_NNS of_IN R_NN -_: and_CC S_NN -_: warfarin_NN ._. Co-administration_NN of_IN single_JJ 25-mg_JJ dose_NN warfarin_NN had_VBD no_DT effect_NN on_IN the_DT pharmacokinetics_NNS of_IN total_JJ lenalidomide_NN ._. Expected_VBN changes_NNS in_IN laboratory_NN assessments_NNS of_IN PT_NN and_CC INR_NN were_VBD observed_VBN after_IN warfarin_NN administration_NN ,_, but_CC these_DT changes_NNS were_VBD not_RB affected_VBN by_IN concomitant_JJ lenalidomide_NN administration_NN ._. Concomitant_JJ treatment_NN with_IN thrombolytics_NNS -LRB-_-LRB- eg_FW ,_, rt-PA_NN or_CC streptokinase_NNP -RRB-_-RRB- may_MD :_: -_: increase_VB the_DT risk_NN of_IN bleeding_VBG complications_NNS -_: considerably_RB enhance_VBP the_DT effect_NN of_IN REFLUDAN_NN on_IN aPTT_NN prolongatio_NN ._. Concomitant_JJ treatment_NN with_IN coumarin_NN derivatives_NNS -LRB-_-LRB- vitamin_NN K_NN antagonists_NNS -RRB-_-RRB- and_CC drugs_NNS that_WDT affect_VBP platelet_NN function_NN may_MD also_RB increase_VB the_DT risk_NN of_IN bleeding_NN ._. Clinical_JJ interaction_NN studies_NNS with_IN cimetidine_NN and_CC warfarin_NN indicated_VBD that_IN the_DT coadministration_NN of_IN Femara_NN with_IN these_DT drugs_NNS does_VBZ not_RB result_VB in_IN clinically_RB -_: significant_JJ drug_NN interactions_NNS ._. -LRB-_-LRB- See_VB CLINICAL_NNP PHARMACOLOGY_NNP -RRB-_-RRB- Coadministration_NNP of_IN Femara_NNP and_CC tamoxifen_NN 20_CD mg_NN daily_JJ resulted_VBD in_IN a_DT reduction_NN of_IN letrozole_NN plasma_NN levels_NNS by_IN 38_CD %_NN on_IN average_NN ._. There_EX is_VBZ no_DT clinical_JJ experience_NN to_TO date_NN on_IN the_DT use_NN of_IN Femara_NNP in_IN combination_NN with_IN other_JJ anticancer_JJ agents_NNS ._. Drug/Laboratory_JJ Test-Interactions_NNS None_NN observed_VBN ._. Folic_JJ acid_NN in_IN large_JJ amounts_NNS may_MD counteract_VB the_DT antiepileptic_JJ effect_NN of_IN phenobarbital_NN ,_, phenytoin_NN and_CC primidone_NN ,_, and_CC increase_VB the_DT frequency_NN of_IN seizures_NNS in_IN susceptible_JJ pediatric_JJ patients_NNS ._. Preliminary_JJ animal_NN and_CC human_JJ studies_NNS have_VBP shown_VBN that_IN small_JJ quantities_NNS of_IN systemically_RB administered_VBN leucovorin_NN enter_VBP the_DT CSF_NN primarily_RB as_IN 5-methyltetrahydro-folate_JJ and_CC ,_, in_IN humans_NNS ,_, remain_VBP 1_CD to_TO 3_CD orders_NNS of_IN magnitude_NN lower_JJR than_IN the_DT usual_JJ methotrexate_NN concentrations_NNS following_VBG intrathecal_JJ administration_NN ._. However_RB ,_, high_JJ doses_NNS of_IN leucovorin_NN may_MD reduce_VB the_DT efficacy_NN of_IN intrathecally_RB administered_VBN methotrexate_NN ._. Leucovorin_NNP may_MD enhance_VB the_DT toxicity_NN of_IN 5-fluorouracil_NN ._. ERGAMISOL_NN -LRB-_-LRB- levamisole_NN hydrochloride_NN -RRB-_-RRB- has_VBZ been_VBN reported_VBN to_TO produce_VB ANTABUSE-like_JJ side_JJ effects_NNS when_WRB given_VBN concomitantly_RB with_IN alcohol_NN ._. The_DT physician_NN is_VBZ advised_VBN to_TO monitor_VB plasma_NN levels_NNS of_IN phenytoin_NN and_CC to_TO decrease_VB the_DT dose_NN if_IN necessary_JJ ._. Because_IN of_IN reports_NNS of_IN prolongation_NN of_IN the_DT prothrombin_NN time_NN beyond_IN the_DT therapeutic_JJ range_NN in_IN patients_NNS taking_VBG concurrent_JJ levamisole_NN and_CC warfarin_NN sodium_NN ,_, it_PRP is_VBZ suggested_VBN that_IN the_DT prothrombin_NN time_NN be_VB monitored_VBN carefully_RB ,_, and_CC the_DT dose_NN of_IN warfarin_NN sodium_NN or_CC other_JJ coumarin-like_JJ drugs_NNS should_MD be_VB adjusted_VBN accordingly_RB ,_, in_IN patients_NNS taking_VBG both_CC drugs_NNS ._. in_FW vitro_FW data_NNS on_IN metabolic_JJ interactions_NNS indicate_VBP that_IN Keppra_NNP is_VBZ unlikely_JJ to_TO produce_VB ,_, or_CC be_VB subject_JJ to_TO ,_, pharmacokinetic_JJ interactions_NNS ._. Levetiracetam_NNP and_CC its_PRP$ major_JJ metabolite_NN ,_, at_IN concentrations_NNS well_RB above_IN cmax_NN levels_NNS achieved_VBD within_IN the_DT therapeutic_JJ dose_NN range_NN ,_, are_VBP neither_DT inhibitors_NNS of_IN nor_CC high_JJ affinity_NN substrates_NNS for_IN human_JJ liver_NN cytochrome_NN P450_NN isoforms_NNS ,_, epoxide_NN hydrolase_NN or_CC UDP-glucuronidation_NN enzymes_NNS ._. In_IN addition_NN ,_, levetiracetam_NN does_VBZ not_RB affect_VB the_DT in_FW vitro_FW glucuronidation_NN of_IN valproic_JJ acid_NN ._. Levetiracetam_NN circulates_VBZ largely_RB unbound_JJ -LRB-_-LRB- 10_CD %_NN bound_VBN -RRB-_-RRB- to_TO plasma_NN proteins_NNS ._. clinically_RB significant_JJ interactions_NNS with_IN other_JJ drugs_NNS through_IN competition_NN for_IN protein_NN binding_NN sites_NNS are_VBP therefore_RB unlikely_JJ ._. Potential_JJ pharmacokinetic_JJ interactions_NNS were_VBD assessed_VBN in_IN clinical_JJ pharmacokinetic_JJ studies_NNS -LRB-_-LRB- phenytoin_NN ,_, valproate_NN ,_, oral_JJ contraceptive_NN ,_, digoxin_NN ,_, warfarin_NN ,_, probenecid_NN -RRB-_-RRB- and_CC through_IN pharmacokinetic_JJ screening_NN in_IN the_DT placebo-controlled_JJ clinical_JJ studies_NNS in_IN epilepsy_NN patients_NNS ._. Drug-Drug_NNP Interactions_NNS Between_IN Keppra_NNP And_CC Other_JJ Antiepileptic_JJ Drugs_NNS -LRB-_-LRB- AEDs_NNS -RRB-_-RRB- Phenytoin_NNP Keppra_NNP -LRB-_-LRB- 3000_CD mg_NN daily_JJ -RRB-_-RRB- had_VBD no_DT effect_NN on_IN the_DT pharmacokinetic_JJ disposition_NN of_IN phenytoin_NN in_IN patients_NNS with_IN refractory_JJ epilepsy_NN ._. Pharmacokinetics_NNS of_IN levetiracetam_NN were_VBD also_RB not_RB affected_VBN by_IN phenytoin_NN ._. Valproate_NNP Keppra_NNP -LRB-_-LRB- 1500_CD mg_NN twice_RB daily_RB -RRB-_-RRB- did_VBD not_RB alter_VB the_DT pharmacokinetics_NNS of_IN valproate_NN in_IN healthy_JJ volunteers_NNS ._. Valproate_NNP 500_CD mg_NN twice_RB daily_RB did_VBD not_RB modify_VB the_DT rate_NN or_CC extent_NN of_IN levetiracetam_NN absorption_NN or_CC its_PRP$ plasma_NN clearance_NN or_CC urinary_JJ excretion_NN ._. There_EX also_RB was_VBD no_DT effect_NN on_IN exposure_NN to_TO and_CC the_DT excretion_NN of_IN the_DT primary_JJ metabolite_NN ,_, ucb_NN L057_NN ._. Potential_JJ drug_NN interactions_NNS between_IN Keppra_NNP and_CC other_JJ AEDs_NNS -LRB-_-LRB- carbamazepine_NN ,_, gabapentin_NN ,_, lamotrigine_NN ,_, phenobarbital_NN ,_, phenytoin_NN ,_, primidone_NN and_CC valproate_NN -RRB-_-RRB- were_VBD also_RB assessed_VBN by_IN evaluating_VBG the_DT serum_NN concentrations_NNS of_IN levetiracetam_NN and_CC these_DT AEDs_NNS during_IN placebo-controlled_JJ clinical_JJ studies_NNS ._. These_DT data_NNS indicate_VBP that_IN levetiracetam_NN does_VBZ not_RB influence_VB the_DT plasma_NN concentration_NN of_IN other_JJ AEDs_NNS and_CC that_IN these_DT AEDs_NNS do_VBP not_RB influence_VB the_DT pharmacokinetics_NNS of_IN levetiracetam_NN ._. Effect_NN of_IN AEDs_NNS in_IN Pediatric_NNP Patients_NNPS There_EX was_VBD about_IN a_DT 22_CD %_NN increase_NN of_IN apparent_JJ total_JJ body_NN clearance_NN of_IN levetiracetam_NN when_WRB it_PRP was_VBD co-administered_VBN with_IN enzyme-inducing_JJ AEDs_NNS ._. Dose_NN adjustment_NN is_VBZ not_RB recommended.Levetiracetam_NN had_VBD no_DT effect_NN on_IN plasma_NN concentrations_NNS of_IN carbamazepine_NN ,_, valproate_NN ,_, topiramate_NN ,_, or_CC lamotrigine_NN ._. Other_JJ Drug_NN Interactions_NNS Oral_JJ Contraceptives_NNS Keppra_NN -LRB-_-LRB- 500_CD mg_NN twice_RB daily_RB -RRB-_-RRB- did_VBD not_RB influence_VB the_DT pharmacokinetics_NNS of_IN an_DT oral_JJ contraceptive_NN containing_VBG 0.03_CD mg_NN ethinyl_NN estradiol_NN and_CC 0.15_CD mg_NN levonorgestrel_NN ,_, or_CC of_IN the_DT luteinizing_VBG hormone_NN and_CC progesterone_NN levels_NNS ,_, indicating_VBG that_IN impairment_NN of_IN contraceptive_JJ efficacy_NN is_VBZ unlikely_JJ ._. Coadministration_NN of_IN this_DT oral_JJ contraceptive_NN did_VBD not_RB influence_VB the_DT pharmacokinetics_NNS of_IN levetiracetam_NN ._. Digoxin_NNP Keppra_NNP -LRB-_-LRB- 1000_CD mg_NN twice_RB daily_RB -RRB-_-RRB- did_VBD not_RB influence_VB the_DT pharmacokinetics_NNS and_CC pharmacodynamics_NNS -LRB-_-LRB- ECG_NN -RRB-_-RRB- of_IN digoxin_NN given_VBN as_IN a_DT 0.25_CD mg_NN dose_NN every_DT day_NN ._. Coadministration_NN of_IN digoxin_NN did_VBD not_RB influence_VB the_DT pharmacokinetics_NNS of_IN levetiracetam_NN ._. Warfarin_NNP Keppra_NNP -LRB-_-LRB- 1000_CD mg_NN twice_RB daily_RB -RRB-_-RRB- did_VBD not_RB influence_VB the_DT pharmacokinetics_NNS of_IN R_NN and_CC S_NN warfarin_NN ._. Prothrombin_NNP time_NN was_VBD not_RB affected_VBN by_IN levetiracetam_NN ._. Coadministration_NN of_IN warfarin_NN did_VBD not_RB affect_VB the_DT pharmacokinetics_NNS of_IN levetiracetam_NN ._. Probenecid_NNP :_: Probenecid_NNP ,_, a_DT renal_JJ tubular_JJ secretion_NN blocking_VBG agent_NN ,_, administered_VBN at_IN a_DT dose_NN of_IN 500_CD mg_NN four_CD times_NNS a_DT day_NN ,_, did_VBD not_RB change_VB the_DT pharmacokinetics_NNS of_IN levetiracetam_NN 1000_CD mg_NN twice_RB daily_RB ._. Cssmax_NN of_IN the_DT metabolite_NN ,_, ucb_NN L057_NN ,_, was_VBD approximately_RB doubled_VBN in_IN the_DT presence_NN of_IN probenecid_NN while_IN the_DT fraction_NN of_IN drug_NN excreted_VBD unchanged_JJ in_IN the_DT urine_NN remained_VBD the_DT same_JJ ._. Renal_JJ clearance_NN of_IN ucb_NN L057_NN in_IN the_DT presence_NN of_IN probenecid_NN decreased_VBD 60_CD %_NN ,_, probably_RB related_VBN to_TO competitive_JJ inhibition_NN of_IN tubular_JJ secretion_NN of_IN ucb_NN L057_NN ._. The_DT effect_NN of_IN Keppra_NNP on_IN probenecid_NN was_VBD not_RB studied_VBN ._. Although_IN BETAGAN_NNP used_VBD alone_RB has_VBZ little_JJ or_CC no_DT effect_NN on_IN pupil_NN size_NN ,_, mydriasis_NN resulting_VBG from_IN concomitant_JJ therapy_NN with_IN BETAGAN_NN and_CC epinephrine_NN may_MD occur_VB ._. Close_JJ observation_NN of_IN the_DT patient_NN is_VBZ recommended_VBN when_WRB a_DT beta-blocker_NN is_VBZ administered_VBN to_TO patients_NNS receiving_VBG catecholamine-depleting_JJ drugs_NNS such_JJ as_IN reserpine_NN ,_, because_IN of_IN possible_JJ additive_JJ effects_NNS and_CC the_DT production_NN of_IN hypotension_NN and/or_CC marked_JJ bradycardia_NN ,_, which_WDT may_MD produce_VB vertigo_NN ,_, syncope_NN or_CC postural_JJ hypotension_NN ._. Patients_NNS receiving_VBG beta-adrenergic_JJ blocking_VBG agents_NNS along_IN with_IN either_CC oral_JJ or_CC intravenous_JJ calcium_NN antagonists_NNS should_MD be_VB monitored_VBN for_IN possible_JJ atrioventricular_JJ conduction_NN disturbances_NNS ,_, left_VBD ventricular_JJ failure_NN and_CC hypotension_NN ._. In_IN patients_NNS with_IN impaired_JJ cardiac_JJ function_NN ,_, simultaneous_JJ use_NN should_MD be_VB avoided_VBN altogether_RB ._. The_DT concomitant_JJ use_NN of_IN beta-adrenergic_JJ blocking_VBG agents_NNS with_IN digitalis_NN and_CC calcium_NN antagonists_NNS may_MD have_VB additive_JJ effects_NNS on_IN prolonging_VBG atrioventricular_JJ conduction_NN time_NN ._. Phenothiazine-related_JJ compounds_NNS and_CC beta-adrenergic_JJ blocking_VBG agents_NNS may_MD have_VB additive_JJ hypotensite_JJ effects_NNS due_JJ to_TO the_DT inhibition_NN of_IN each_DT other_JJ s_NNS metabolism_NN ._. Chirocaine_NNP should_MD be_VB used_VBN with_IN caution_NN in_IN patients_NNS receiving_VBG other_JJ local_JJ anesthetics_NNS or_CC agents_NNS structurally_RB related_JJ to_TO amide-type_JJ local_JJ anesthetics_NNS since_IN the_DT toxic_JJ effects_NNS of_IN these_DT drugs_NNS could_MD be_VB additive_JJ ._. In_FW vitro_FW studies_NNS indicate_VBP CYP3A4_NN isoform_NN and_CC CYP1A2_NN isoform_NN mediate_VBP the_DT metabolism_NN of_IN levobupivacaine_NN to_TO desbutyl_NN levobupivacaine_NN and_CC 3-hydroxy_JJ levobupivacaine_NN ,_, respectively_RB ._. Thus_RB agents_NNS likely_JJ to_TO be_VB concomitantly_RB administered_VBN with_IN Chirocaine_NN that_WDT are_VBP metabolized_VBN by_IN this_DT isoenzyme_NN family_NN may_MD potentially_RB interact_VB with_IN Chirocaine_NNP ._. Although_IN no_DT clinical_JJ studies_NNS have_VBP been_VBN conducted_VBN ,_, it_PRP is_VBZ likely_JJ that_IN the_DT metabolism_NN of_IN levobupivacaine_NN may_MD be_VB affected_VBN by_IN the_DT known_JJ CYP3A4_NN inducers_NNS -LRB-_-LRB- such_JJ as_IN phenytoin_NN ,_, phenobarbital_NN ,_, rifampin_NN -RRB-_-RRB- ,_, CYP3A4_NN inhibitors_NNS -LRB-_-LRB- azole_NN antimycotics_NNS e.g._FW ,_, ketoconazole_NN ._. certain_JJ protease_NN inhibitors_NNS e.g._FW ,_, ritanovir_NN ._. macrolide_NN antibiotics_NNS e.g._FW ,_, erythromycin_NN ._. and_CC calcium_NN channel_NN antagonists_NNS e.g._FW ,_, verapamil_NN -RRB-_-RRB- ,_, CYP1A2_NN inducers_NNS -LRB-_-LRB- omeprazole_NN -RRB-_-RRB- and_CC CYP1A2_NN inhibitors_NNS -LRB-_-LRB- furafylline_NN and_CC clarithromycin_NN -RRB-_-RRB- ._. Dosage_NN adjustment_NN may_MD be_VB warranted_VBN when_WRB levobupivacaine_NN is_VBZ concurrently_RB administered_VBN with_IN CYP3A4_NN inhibitors_NNS and_CC CYP1A2_NN inhibitors_NNS as_IN systemic_JJ levobupivacaine_NN levels_NNS may_MD rise_VB resulting_VBG in_IN toxicity_NN ._. Specific_JJ drug_NN interaction_NN studies_NNS have_VBP not_RB been_VBN conducted_VBN with_IN Levofloxacin_NN ._. However_RB ,_, the_DT systemic_JJ administration_NN of_IN some_DT quinolones_NNS has_VBZ been_VBN shown_VBN to_TO elevate_VB plasma_NN concentrations_NNS of_IN theophylline_NN ,_, interfere_VBP with_IN the_DT metabolism_NN of_IN caffeine_NN ,_, and_CC enhance_VBP the_DT effects_NNS of_IN the_DT oral_JJ anticoagulant_JJ warfarin_NN and_CC its_PRP$ derivatives_NNS ,_, and_CC has_VBZ been_VBN associated_VBN with_IN transient_JJ elevations_NNS in_IN serum_NN creatinine_NN in_IN patients_NNS receiving_VBG systemic_JJ cyclosporine_NN concomitantly_RB ._. Interactions_NNS with_IN Other_JJ CNS_NNS Agents_NNS :_: Concurrent_JJ use_NN of_IN Levo-Dromoran_JJ with_IN all_DT central_JJ nervous_JJ system_NN depressants_NNS -LRB-_-LRB- eg_FW ,_, alcohol_NN ,_, sedatives_NNS ,_, hypnotics_NNS ,_, other_JJ opioids_NNS ,_, general_JJ anesthetics_NNS ,_, barbiturates_NNS ,_, tricyclic_JJ antidepressants_NNS ,_, phenothiazines_NNS ,_, tranquilizers_NNS ,_, skeletal_JJ muscle_NN relaxants_NNS and_CC antihistamines_NNS -RRB-_-RRB- may_MD result_VB in_IN additive_JJ central_JJ nervous_JJ system_NN depressant_NN effects_NNS ._. Respiratory_JJ depression_NN ,_, hypotension_NN ,_, and_CC profound_JJ sedation_NN or_CC coma_NN may_MD occur_VB ._. When_WRB such_JJ combined_JJ therapy_NN is_VBZ contemplated_VBN ,_, the_DT dose_NN of_IN one_CD or_CC both_DT agents_NNS should_MD be_VB reduced_VBN ._. Although_IN no_DT interaction_NN between_IN MAO_NNP inhibitors_NNS and_CC Levo-Dromoran_NNP has_VBZ been_VBN observed_VBN ,_, it_PRP is_VBZ not_RB recommended_VBN for_IN use_NN with_IN MAO_NN inhibitors_NNS ._. Most_JJS cases_NNS of_IN serious_JJ or_CC fatal_JJ adverse_JJ events_NNS involving_VBG Levo-Dromoran_NNP reported_VBD to_TO the_DT manufacturer_NN or_CC the_DT FDA_NNP have_VBP involved_VBN either_CC the_DT administration_NN of_IN large_JJ initial_JJ doses_NNS or_CC too_RB frequent_JJ doses_NNS of_IN the_DT drug_NN to_TO nonopioid_JJ tolerant_JJ patients_NNS ,_, or_CC the_DT simultaneous_JJ administration_NN of_IN levorphanol_NN with_IN other_JJ drugs_NNS affecting_VBG respiration_NN ._. The_DT initial_JJ dose_NN of_IN levorphanol_NN should_MD be_VB reduced_VBN by_IN approximately_RB 50_CD %_NN or_CC more_JJR when_WRB it_PRP is_VBZ given_VBN to_TO patients_NNS along_IN with_IN another_DT drug_NN affecting_VBG respiration_NN ._. Interactions_NNS with_IN Mixed_JJ Agonist/Antagonist_NN Opioid_NN Analgesics_NNS :_: Agonist/antagonist_NN analgesics_NNS -LRB-_-LRB- eg_FW ,_, pentazocine_NN ,_, nalbuphine_NN ,_, butorphanol_NN ,_, dezocine_NN and_CC buprenorphine_NN -RRB-_-RRB- should_MD NOT_RB be_VB administered_VBN to_TO a_DT patient_NN who_WP has_VBZ received_VBN or_CC is_VBZ receiving_VBG a_DT course_NN of_IN therapy_NN with_IN a_DT pure_JJ agonist_NN opioid_JJ analgesic_JJ such_JJ as_IN Levo-Dromoran_NNP ._. In_IN opioid-dependent_JJ patients_NNS ,_, mixed_JJ agonist/antagonist_JJ analgesics_NNS may_MD precipitate_VB withdrawal_NN symptoms_NNS ._. No_DT Important_JJ Interactions_NNS To_TO Date_VB Levosimendan_NNP does_VBZ not_RB have_VB clinically_RB important_JJ pharmacokinetic_JJ interactions_NNS with_IN captopril_NN ,_, beta-blockers_NNS ,_, felodipine_NN ,_, digoxin_NN ,_, warfarin_NN ,_, isosorbide_NN mononitrate_NN ,_, carvedilol_NN ,_, ethanol_NN or_CC itraconazole_NN ._. The_DT magnitude_NN and_CC relative_JJ importance_NN of_IN the_DT effects_NNS noted_VBD below_RB are_VBP likely_JJ to_TO be_VB patient_NN specific_JJ and_CC may_MD vary_VB by_IN such_JJ factors_NNS as_IN age_NN ,_, gender_NN ,_, race_NN ,_, intercurrent_JJ illnesses_NNS ,_, dose_NN of_IN either_CC agent_NN ,_, additional_JJ concomitant_JJ medications_NNS ,_, and_CC timing_NN of_IN drug_NN administration_NN ._. Any_DT agent_NN that_WDT alters_VBZ thyroid_NN hormone_NN synthesis_NN ,_, secretion_NN ,_, distribution_NN ,_, effect_NN on_IN target_NN tissues_NNS ,_, metabolism_NN ,_, or_CC elimination_NN may_MD alter_VB the_DT optimal_JJ therapeutic_JJ dose_NN of_IN levothyroxine_NN sodium_NN ._. Levothyroxine_NNP Sodium_NN Absorption_NN :_: The_DT following_VBG agents_NNS may_MD bind_VB and_CC decrease_VB absorption_NN of_IN levothyroxine_NN sodium_NN from_IN the_DT gastrointestinal_JJ tract_NN :_: aluminum_NN hydoxide_NN ,_, cholestyramine_NN resin_NN ,_, colestipol_NN hydrochloride_NN ,_, ferrous_JJ sulfate_NN ,_, sodium_NN polystyrene_NN sulfonate_NN ,_, soybean_NN flour_NN -LRB-_-LRB- e.g._FW ,_, infant_JJ formula_NN -RRB-_-RRB- ,_, sucralfate_NN ._. Binding_NN to_TO Serum_NN Proteins_NNS :_: The_DT following_VBG agents_NNS may_MD either_RB inhibit_VB levothyroxine_NN sodium_NN binding_NN to_TO serum_NN proteins_NNS or_CC alter_VB the_DT concentrations_NNS of_IN serum_NN binding_NN proteins_NNS :_: androgens_NNS and_CC related_JJ anabolic_JJ hormones_NNS ,_, asparaginase_NN ,_, clofibrate_NN ,_, estrogens_NNS and_CC estrogen-containing_JJ compounds_NNS ,_, 5-fluorouracil_NN ,_, furosemide_NN ,_, glucocorticoids_NNS ,_, meclofenamic_JJ acid_NN ,_, mefenamic_JJ acid_NN ,_, methadone_NN ,_, perphenazine_NN ,_, phenylbutazone_NN ,_, phenytoin_NN ,_, salicylates_NNS ,_, tamoxifen_NN ._. Thyroid_NN Physiology_NNP :_: The_DT following_VBG agents_NNS may_MD alter_VB thyroid_NN hormone_NN or_CC TSH_NN levels_NNS ,_, generally_RB by_IN effects_NNS on_IN thyroid_NN hormone_NN synthesis_NN ,_, secretion_NN ,_, distribution_NN ,_, metabolism_NN ,_, hormone_NN action_NN ,_, or_CC elimination_NN ,_, or_CC altered_JJ TSH_NN secretion_NN :_: aminoglutethimide_NN ,_, p-aminosalicylic_JJ acid_NN ,_, amiodarone_NN ,_, androgens_NNS and_CC related_JJ anabolic_JJ hormones_NNS ,_, complex_JJ anions_NNS -LRB-_-LRB- thiocyanate_NN ,_, perchlorate_NN ,_, pertechnetate_NN -RRB-_-RRB- ,_, antithyroid_JJ drugs_NNS ,_, b-adrenergic_JJ blocking_VBG agents_NNS ,_, carbamazepine_NN ,_, chloral_JJ hydrate_NN ,_, diazepam_NN ,_, dopamine_NN and_CC dopamine_NN agonists_NNS ,_, ethionamide_NN ,_, glucocorticoids_NNS ,_, heparin_NN ,_, hepatic_JJ enzyme_NN inducers_NNS ,_, insulin_NN ,_, iodinated_VBN cholestographic_JJ agents_NNS ,_, iodine-containing_JJ compounds_NNS ,_, levodopa_NN ,_, lovastatin_NN ,_, lithium_NN ,_, 6-mercaptopurine_NN ,_, metoclopramide_NN ,_, mitotane_NN ,_, nitroprusside_NN ,_, phenobarbital_NN ,_, phenytoin_NN ,_, resorcinol_NN ,_, rifampin_NN ,_, somatostatin_NN analogs_NNS ,_, sulfonamides_NNS ,_, sulfonylureas_NNS ,_, thiazide_JJ diuretics_NNS ._. Adrenocorticoids_NNP :_: Metabolic_JJ clearance_NN of_IN adrenocorticoids_NNS is_VBZ decreased_VBN in_IN hypothyroid_JJ patients_NNS and_CC increased_VBN in_IN hyperthyroid_JJ patients_NNS ,_, and_CC may_MD therefore_RB change_VB with_IN changing_VBG thyroid_NN status_NN ._. Amiodarone_NNP :_: Amiodarone_NN therapy_NN alone_RB can_MD cause_VB hypothyroidism_NN or_CC hyperthyroidism_NN ._. Anticoagulants_NNS -LRB-_-LRB- Oral_JJ -RRB-_-RRB- :_: The_DT hypoprothrombinemic_JJ effect_NN of_IN anticoagulants_NNS may_MD be_VB potentiated_JJ ,_, apparently_RB by_IN increased_VBN catabloism_NN of_IN vitamin_NN K-dependent_JJ clotting_NN factors_NNS ._. Antidiabetic_JJ Agents_NNS -LRB-_-LRB- Insulin_NN ,_, Sulfonylureas_NNP -RRB-_-RRB- :_: Requirements_NNS for_IN insulin_NN or_CC oral_JJ antidiabetic_JJ agents_NNS may_MD be_VB reduced_VBN in_IN hypothyroid_JJ patients_NNS with_IN diabetes_NN mellitus_NN and_CC may_MD subsequently_RB increase_VB with_IN the_DT initiation_NN of_IN thyroid_NN hormone_NN replacement_NN therapy_NN ._. b-Adrenergic_JJ Blocking_NN Agents_NNS :_: Actions_NNS of_IN some_DT of_IN beta-blocking_JJ agents_NNS may_MD be_VB impaired_JJ when_WRB hypothyroid_JJ patients_NNS become_VBP euthyroid_JJ ._. Cytokines_NNS -LRB-_-LRB- interferon_NN ,_, interleukin_NN -RRB-_-RRB- :_: Cytokines_NNS have_VBP been_VBN reported_VBN to_TO induce_VB both_CC hyperthyroidism_NN and_CC hypothyroidism_NN ._. Digitalis_NNP Glycosides_NNPS :_: Therapeutic_JJ effects_NNS of_IN digitalis_NN glycosides_NNS may_MD be_VB reduced_VBN ._. Serum_NN digitalis_NN levels_NNS may_MD be_VB decreased_VBN in_IN hyperthyroidism_NN or_CC when_WRB a_DT hypothyroid_JJ patient_NN becomes_VBZ euthyroid_JJ ._. Ketamine_NNP :_: Marked_JJ hypertension_NN and_CC tachycardia_NN have_VBP been_VBN reported_VBN in_IN association_NN with_IN concomitant_JJ administration_NN of_IN levothyroxine_NN sodium_NN and_CC ketamine_NN ._. Maprotiline_NNP :_: Risk_NN of_IN cardiac_JJ arrhythmias_NNS may_MD increase_VB ._. Sodium_NN Iodide_NN -LRB-_-LRB- 123I_NN and_CC 131I_NN -RRB-_-RRB- ,_, Sodium_NN Pertechnetate_NN Tc99m_NN :_: Uptake_NNP of_IN radiolabeled_VBN ions_NNS may_MD be_VB decreased_VBN ._. Somatrem/Somatropin_NNP :_: Excessive_JJ concurrent_JJ use_NN of_IN thyroid_NN hormone_NN may_MD accelerate_VB epiphyseal_NN closure_NN ._. Untreated_JJ hypothyroidism_NN may_MD interfere_VB with_IN the_DT growth_NN response_NN to_TO somatrem_NN or_CC somatropin_NN ._. Theophylline_NNP :_: Theophylline_NN clearance_NN may_MD decrease_VB in_IN hypothyroid_JJ patients_NNS and_CC return_NN toward_IN normal_JJ when_WRB a_DT euthyroid_JJ state_NN is_VBZ achieved_VBN ._. Tricyclic_JJ Antidepressants_NNS :_: Concurrent_JJ use_NN may_MD increase_VB the_DT therapeutic_JJ and_CC toxic_JJ effects_NNS of_IN both_DT drugs_NNS ,_, possibly_RB due_JJ to_TO increased_VBN catecholamine_NN sensitivity_NN ._. Onset_NN of_IN action_NN of_IN tricyclics_NNS may_MD be_VB accelerated_VBN ._. Sympathomimetic_JJ Agents_NNS :_: Possible_JJ increased_VBN risk_NN of_IN coronary_JJ insufficiency_NN in_IN patients_NNS with_IN coronary_JJ artery_NN disease_NN ._. The_DT administration_NN of_IN local_JJ anesthetic_JJ solutions_NNS containing_VBG epinephrine_NN or_CC norepinephrine_NN to_TO patients_NNS receiving_VBG monoamine_NN oxidase_NN inhibitors_NNS or_CC tricyclic_JJ antidepressants_NNS may_MD produce_VB severe_JJ ,_, prolonged_JJ hypertension_NN ._. Phenothiazines_NNS and_CC butyrophenones_NNS may_MD reduce_VB or_CC reverse_VB the_DT pressor_NN effect_NN of_IN epinephrine_NN ._. Concurrent_JJ use_NN of_IN these_DT agents_NNS should_MD generally_RB be_VB avoided_VBN ._. In_IN situations_NNS when_WRB concurrent_JJ therapy_NN is_VBZ necessary_JJ ,_, careful_JJ patient_NN monitoring_NN is_VBZ essential_JJ ._. Concurrent_JJ administration_NN of_IN vasopressor_NN drugs_NNS -LRB-_-LRB- for_IN the_DT treatment_NN of_IN hypotension_NN related_JJ to_TO obstetric_JJ blocks_NNS -RRB-_-RRB- and_CC ergot-type_JJ oxytocic_JJ drugs_NNS may_MD cause_VB severe_JJ ,_, persistent_JJ hypertension_NN or_CC cerebrovascular_JJ accidents_NNS ._. Lincomycin_NNP has_VBZ been_VBN shown_VBN to_TO have_VB neuromuscular_JJ blocking_VBG properties_NNS that_WDT may_MD enhance_VB the_DT action_NN of_IN other_JJ neuromuscular_JJ blocking_VBG agents_NNS ._. Therefore_RB ,_, it_PRP should_MD be_VB used_VBN in_IN caution_NN in_IN patients_NNS receiving_VBG such_JJ agents_NNS ._. Antagonism_NN between_IN lincomycin_NN and_CC erythromycin_NN in_FW vitro_FW has_VBZ been_VBN demonstrated_VBN ._. Because_IN of_IN possible_JJ clinical_JJ significance_NN ,_, the_DT two_CD drugs_NNS should_MD not_RB be_VB administered_VBN concurrently_RB ._. Oils_NNS may_MD enhance_VB absorption_NN ._. Therefore_RB ,_, simultaneous_JJ use_NN of_IN creams_NNS ,_, ointments_NNS or_CC oils_NNS should_MD be_VB avoided_VBN ._. Monoamine_NNP Oxidase_NNP Inhibition_NN :_: Linezolid_NN is_VBZ a_DT reversible_JJ ,_, nonselective_JJ inhibitor_NN of_IN monoamine_NN oxidase_NN ._. Therefore_RB ,_, linezolid_NN has_VBZ the_DT potential_NN for_IN interaction_NN with_IN adrenergic_JJ and_CC serotonergic_JJ agents_NNS ._. Adrenergic_JJ Agents_NNS :_: Some_DT individuals_NNS receiving_VBG ZYVOX_NNP may_MD experience_VB a_DT reversible_JJ enhancement_NN of_IN the_DT pressor_NN response_NN to_TO indirect-acting_JJ sympathomimetic_JJ agents_NNS ,_, vasopressor_NN or_CC dopaminergic_JJ agents_NNS ._. Commonly_RB used_VBN drugs_NNS such_JJ as_IN phenylpropanolamine_NN and_CC pseudoephedrine_NN have_VBP been_VBN specifically_RB studied_VBN ._. Initial_JJ doses_NNS of_IN adrenergic_JJ agents_NNS ,_, such_JJ as_IN dopamine_NN or_CC epinephrine_NN ,_, should_MD be_VB reduced_VBN and_CC titrated_VBN to_TO achieve_VB the_DT desired_VBN response_NN ._. Serotonergic_NNP Agents_NNPS :_: Co-administration_NN of_IN linezolid_NN and_CC serotonergic_JJ agents_NNS was_VBD not_RB associated_VBN with_IN serotonin_NN syndrome_NN in_IN Phase_NN 1_CD ,_, 2_CD or_CC 3_CD studies_NNS ._. Spontaneous_JJ reports_NNS of_IN serotonin_NN syndrome_NN associated_VBN with_IN co-administration_NN of_IN ZYVOX_NNP and_CC serotonergic_JJ agents_NNS ,_, including_VBG antidepressants_NNS such_JJ as_IN selective_JJ serotonin_NN reuptake_NN inhibitors_NNS -LRB-_-LRB- SSRIs_NNS -RRB-_-RRB- ,_, have_VBP been_VBN reported_VBN ._. Patients_NNS who_WP are_VBP treated_VBN with_IN ZYVOX_NN and_CC concomitant_JJ serotonergic_JJ agents_NNS should_MD be_VB closely_RB observed_VBN for_IN signs_NNS and_CC symptoms_NNS of_IN serotonin_NN syndrome_NN -LRB-_-LRB- e.g._FW ,_, cognitive_JJ dysfunction_NN ,_, hyperpyrexia_NN ,_, hyperreflexia_NN ,_, incoordination_NN -RRB-_-RRB- ._. If_IN any_DT signs_NNS or_CC symptoms_NNS occur_VBP physicians_NNS should_MD consider_VB discontinuation_NN of_IN either_DT one_CD or_CC both_DT agents_NNS -LRB-_-LRB- ZYVOX_NN or_CC concomitant_JJ serotonergic_JJ agents_NNS -RRB-_-RRB- ._. Drug-Laboratory_JJ Test_NN Interactions_NNS There_EX are_VBP no_DT reported_VBN drug-laboratory_JJ test_NN interactions_NNS ._. Oral_JJ Anticoagulants_NNPS :_: Thyroid_NN hormones_NNS appear_VBP to_TO increase_VB catabolism_NN of_IN vitamin_NN K-dependent_JJ clotting_NN factors_NNS ._. If_IN oral_JJ anticoagulants_NNS are_VBP also_RB being_VBG given_VBN ,_, compensatory_JJ increases_NNS in_IN clotting_NN factor_NN synthesis_NN are_VBP impaired_JJ ._. Patients_NNS stabilized_VBD on_IN oral_JJ anticoagulants_NNS who_WP are_VBP found_VBN to_TO require_VB thyroid_NN replacement_NN therapy_NN should_MD be_VB watched_VBN very_RB closely_RB when_WRB thyroid_NN is_VBZ started_VBN ._. If_IN a_DT patient_NN is_VBZ truly_RB hypothyroid_JJ ,_, it_PRP is_VBZ likely_JJ that_IN a_DT reduction_NN in_IN anticoagulant_JJ dosage_NN will_MD be_VB required_VBN ._. No_DT special_JJ precautions_NNS appear_VBP to_TO be_VB necessary_JJ when_WRB oral_JJ anticoagulant_JJ therapy_NN is_VBZ begun_VBN in_IN a_DT patient_NN already_RB stabilized_VBD on_IN maintenance_NN thyroid_NN replacement_NN therapy_NN ._. Insulin_NN or_CC Oral_JJ Hypoglycemics_NNS :_: Initiating_VBG thyroid_NN replacement_NN therapy_NN may_MD cause_VB increases_NNS in_IN insulin_NN or_CC oral_JJ hypoglycemic_JJ requirements_NNS ._. The_DT effects_NNS seen_VBN are_VBP poorly_RB understood_VBN and_CC depend_VB upon_IN a_DT variety_NN of_IN factors_NNS such_JJ as_IN dose_NN and_CC type_NN of_IN thyroid_NN preparations_NNS and_CC endocrine_JJ status_NN of_IN the_DT patient_NN ._. Patients_NNS receiving_VBG insulin_NN or_CC oral_JJ hypoglycemics_NNS should_MD be_VB closely_RB watched_VBN during_IN initiation_NN of_IN thyroid_NN replacement_NN therapy_NN ._. Cholestyramine_NNP :_: Cholestyramine_NN binds_VBZ both_CC T4_NN and_CC T3_NN in_IN the_DT intestine_NN ,_, thus_RB impairing_VBG absorption_NN of_IN these_DT thyroid_NN hormones_NNS ._. In_FW vitro_FW studies_NNS indicate_VBP that_IN the_DT binding_NN is_VBZ not_RB easily_RB removed_VBN ._. Therefore_RB ,_, 4_CD to_TO 5_CD hours_NNS should_MD elapse_VB between_IN administration_NN of_IN cholestyramine_NN and_CC thyroid_NN hormones_NNS ._. Estrogen_NN ,_, Oral_JJ Contraceptives_NNS :_: Estrogens_NNS tend_VBP to_TO increase_VB serum_NN thyroxine-binding_JJ globulin_NN -LRB-_-LRB- TBg_NN -RRB-_-RRB- ._. In_IN a_DT patient_NN with_IN a_DT nonfunctioning_JJ thyroid_NN gland_NN who_WP is_VBZ receiving_VBG thyroid_NN replacement_NN therapy_NN ,_, free_JJ levothyroxine_NN may_MD be_VB decreased_VBN when_WRB estrogens_NNS are_VBP started_VBN thus_RB increasing_VBG thyroid_NN requirements_NNS ._. However_RB ,_, if_IN the_DT patients_NNS thyroid_NN gland_NN has_VBZ sufficient_JJ function_NN ,_, the_DT decreased_VBN free_JJ thyroxine_NN will_MD result_VB in_IN a_DT compensatory_JJ increase_NN in_IN thyroxine_JJ output_NN by_IN the_DT thyroid_NN ._. Therefore_RB ,_, patients_NNS without_IN a_DT functioning_VBG thyroid_NN gland_NN who_WP are_VBP on_IN thyroid_NN replacement_NN therapy_NN may_MD need_VB to_TO increase_VB their_PRP$ thyroid_NN dose_NN if_IN estrogens_NNS or_CC estrogen-containing_JJ oral_JJ contraceptives_NNS are_VBP given_VBN ._. Tricyclic_JJ Antidepressants_NNS :_: Use_NN of_IN thyroid_NN products_NNS with_IN imipramine_NN and_CC other_JJ tricyclic_JJ antidepressants_NNS may_MD increase_VB receptor_NN sensitivity_NN and_CC enhance_VBP antidepressant_JJ activity_NN transient_JJ cardiac_JJ arrhythmias_NNS have_VBP been_VBN observed_VBN ._. Thyroid_NN hormone_NN activity_NN may_MD also_RB be_VB enhanced_VBN ._. Digitalis_NNP :_: Thyroid_NN preparations_NNS may_MD potentiate_VB the_DT toxic_JJ effects_NNS of_IN digitalis_NN ._. Thyroid_NN hormonal_JJ replacement_NN increases_VBZ metabolic_JJ rate_NN ,_, which_WDT requires_VBZ an_DT increase_NN in_IN digitalis_NN dosage_NN ._. Ketamine_NNP :_: When_WRB administered_VBN to_TO patients_NNS on_IN a_DT thyroid_NN preparation_NN ,_, this_DT parenteral_JJ anesthetic_NN may_MD cause_VB hypertension_NN and_CC tachycardia_NN ._. Use_NN with_IN caution_NN and_CC be_VB prepared_VBN to_TO treat_VB hypertension_NN ,_, if_IN necessary_JJ ._. Vasopressors_NNP :_: Thyroxine_NN increases_VBZ the_DT adrenergic_JJ effect_NN of_IN catecholamines_NNS such_JJ as_IN epinephrine_NN and_CC norepinephrine_NN ._. Therefore_RB ,_, injection_NN of_IN these_DT agents_NNS into_IN patients_NNS receiving_VBG thyroid_NN preparations_NNS increases_VBZ the_DT risk_NN of_IN precipitating_VBG coronary_JJ insufficiency_NN especially_RB in_IN patients_NNS with_IN coronary_JJ artery_NN disease_NN ._. Careful_JJ observation_NN is_VBZ required_VBN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS The_DT following_JJ drugs_NNS or_CC moieties_NNS are_VBP known_VBN to_TO interfere_VB with_IN laboratory_NN tests_NNS performed_VBN in_IN patients_NNS on_IN thyroid_NN hormone_NN therapy_NN :_: androgens_NNS ,_, corticosteroids_NNS ,_, estrogens_NNS ,_, oral_JJ contraceptives_NNS containing_VBG estrogens_NNS ,_, iodine-containing_JJ preparations_NNS and_CC the_DT numerous_JJ preparations_NNS containing_VBG salicylates_NNS ._. -_: Changes_NNS in_IN TBg_NN concentration_NN should_MD be_VB taken_VBN into_IN consideration_NN in_IN the_DT interpretation_NN of_IN T4_NN and_CC T3_NN values_NNS ._. In_IN such_JJ cases_NNS ,_, the_DT unbound_JJ -LRB-_-LRB- free_JJ -RRB-_-RRB- hormone_NN should_MD be_VB measured_VBN ._. Pregnancy_NN estrogens_NNS and_CC estrogen-containing_JJ oral_JJ contraceptives_NNS increase_VBP TBg_NN concentrations_NNS ._. TBg_NN may_MD also_RB be_VB increased_VBN during_IN infectious_JJ hepatitis_NN ._. Decreases_VBZ in_IN TBg_NN concentrations_NNS are_VBP observed_VBN in_IN nephrosis_NN ,_, acromegaly_NN and_CC after_IN androgen_NN or_CC corticosteroid_NN therapy_NN ._. Familial_JJ hyper_NN -_: or_CC hypo-thyroxine-binding-globulinemias_NNS have_VBP been_VBN described_VBN ._. The_DT incidence_NN of_IN TBg_NN deficiency_NN approximates_VBZ 1_CD in_IN 9000_CD ._. The_DT binding_NN of_IN thyroxine_NN by_IN thyroxine-binding_JJ prealbumin_NN -LRB-_-LRB- TBPA_NN -RRB-_-RRB- is_VBZ inhibited_VBN by_IN salicylate_NN ._. -_: Medicinal_JJ or_CC dietary_JJ iodine_NN interferes_VBZ with_IN all_DT in_FW vivo_FW tests_NNS of_IN radio-iodine_NN uptake_NN producing_VBG low_JJ uptakes_NNS which_WDT may_MD not_RB be_VB reflective_JJ of_IN a_DT true_JJ decrease_NN in_IN hormone_NN synthesi_NNS ._. -_: The_DT persistence_NN of_IN clinical_JJ and_CC laboratory_JJ evidence_NN of_IN hypothyroidism_NN in_IN spite_NN of_IN adequate_JJ dosage_NN replacement_NN indicates_VBZ either_CC poor_JJ patient_NN compliance_NN ,_, poor_JJ absorption_NN ,_, excessive_JJ fecal_JJ loss_NN ,_, or_CC inactivity_NN of_IN the_DT preparation_NN ._. Intracellular_JJ resistance_NN to_TO thyroid_NN hormone_NN is_VBZ quite_RB rare_JJ ._. Urinary_JJ acidifying_VBG agents_NNS These_DT agents_NNS -LRB-_-LRB- ammonium_NN chloride_NN ,_, sodium_NN acid_NN phosphate_NN ,_, etc._FW -RRB-_-RRB- increase_VBP the_DT concentration_NN of_IN the_DT ionized_VBN species_NNS of_IN the_DT amphetamine_NN molecule_NN ,_, thereby_RB increasing_VBG urinary_JJ excretion_NN ._. Both_DT groups_NNS of_IN agents_NNS lower_JJR blood_NN levels_NNS and_CC efficacy_NN of_IN amphetamines_NNS ._. Adrenergic_JJ blockers_NNS Adrenergic_JJ blockers_NNS are_VBP inhibited_VBN by_IN amphetamines_NNS ._. Antidepressants_NNS ,_, tricyclic_JJ Amphetamines_NNS may_MD enhance_VB the_DT activity_NN of_IN tricyclic_JJ antidepressants_NNS or_CC sympathomimetic_JJ agents_NNS ._. d-amphetamine_NN with_IN desipramine_NN or_CC protriptyline_NN and_CC possibly_RB other_JJ tricyclics_NNS cause_VBP striking_JJ and_CC sustained_JJ increases_NNS in_IN the_DT concentration_NN of_IN d-amphetamine_NN in_IN the_DT brain_NN ._. cardiovascular_JJ effects_NNS can_MD be_VB potentiated_VBN ._. MAO_NN inhibitors_NNS MAOI_NNP antidepressants_NNS ,_, as_RB well_RB as_IN a_DT metabolite_NN of_IN furazolidone_NN ,_, slow_JJ amphetamine_NN metabolism_NN ._. This_DT slowing_VBG potentiates_VBZ amphetamines_NNS ,_, increasing_VBG their_PRP$ effect_NN on_IN the_DT release_NN of_IN norepinephrine_NN and_CC other_JJ monoamines_NNS from_IN adrenergic_JJ nerve_NN endings_NNS ._. this_DT can_MD cause_VB headaches_NNS and_CC other_JJ signs_NNS of_IN hypertensive_JJ crisis_NN ._. A_DT variety_NN of_IN toxic_JJ neurological_JJ effects_NNS and_CC malignant_JJ hyperpyrexia_NN can_MD occur_VB ,_, sometimes_RB with_IN fatal_JJ results_NNS ._. Antihistamines_NNS :_: Amphetamines_NNS may_MD counteract_VB the_DT sedative_JJ effect_NN of_IN antihistamines_NNS ._. Antihypertensives_NNS :_: Amphetamines_NNS may_MD antagonize_VB the_DT hypotensive_JJ effects_NNS of_IN antihypertensives_NNS ._. Chlorpromazine_NNP :_: Chlorpromazine_NNP blocks_VBZ dopamine_NN and_CC norepinephrine_NN receptors_NNS ,_, thus_RB inhibiting_VBG the_DT central_JJ stimulant_NN effects_NNS of_IN amphetamines_NNS and_CC can_MD be_VB used_VBN to_TO treat_VB amphetamine_NN poisoning_NN ._. Ethosuximide_NNP :_: Amphetamines_NNS may_MD delay_VB intestinal_JJ absorption_NN of_IN ethosuximide_NN ._. Haloperidol_NNP :_: Haloperidol_NNP blocks_VBZ dopamine_NN receptors_NNS ,_, thus_RB inhibiting_VBG the_DT central_JJ stimulant_NN effects_NNS of_IN amphetamines_NNS ._. Lithium_NN carbonate_NN :_: The_DT anorectic_NN and_CC stimulatory_JJ effects_NNS of_IN amphetamines_NNS may_MD be_VB inhibited_VBN by_IN lithium_NN carbonate_NN ._. Meperidine_NNP :_: Amphetamines_NNS potentiate_VBP the_DT analgesic_JJ effect_NN of_IN meperidine_NN ._. Methenamine_NN therapy_NN Urinary_JJ excretion_NN of_IN amphetamines_NNS is_VBZ increased_VBN ,_, and_CC efficacy_NN is_VBZ reduced_VBN by_IN acidifying_VBG agents_NNS used_VBN in_IN methenamine_NN therapy_NN ._. Norepinephrine_NN :_: Amphetamines_NNS enhance_VBP the_DT adrenergic_JJ effect_NN of_IN norepinephrine_NN ._. Phenobarbital_NNP :_: Amphetamines_NNS may_MD delay_VB intestinal_JJ absorption_NN of_IN phenobarbital_NN ._. co-administration_NN of_IN phenobarbital_NN may_MD produce_VB a_DT synergistic_JJ anticonvulsant_JJ action_NN ._. Phenytoin_NNP :_: Amphetamines_NNS may_MD delay_VB intestinal_JJ absorption_NN of_IN phenytoin_NN ._. co-administration_NN of_IN phenytoin_NN may_MD produce_VB a_DT synergistic_JJ anticonvulsant_JJ action_NN ._. Propoxyphene_NNP :_: In_IN cases_NNS of_IN propoxyphene_NN overdosage_NN ,_, amphetamine_NN CNS_NN stimulation_NN is_VBZ potentiated_JJ and_CC fatal_JJ convulsions_NNS can_MD occur_VB ._. Veratrum_NNP alkaloids_NNS :_: Amphetamines_NNS inhibit_VBP the_DT hypotensive_JJ effect_NN of_IN veratrum_NN alkaloids_NNS ._. Drug/Laboratory_JJ Test_NN Interactions_NNS :_: Amphetamines_NNS can_MD cause_VB a_DT significant_JJ elevation_NN in_IN plasma_NN corticosteroid_NN levels_NNS ._. This_DT increase_NN is_VBZ greatest_JJS in_IN the_DT evening_NN ._. Amphetamines_NNS may_MD interfere_VB with_IN urinary_JJ steroid_NN determinations_NNS ._. Hypotension_NN -_: Patients_NNS on_IN Diuretic_JJ Therapy_NN :_: Patients_NNS on_IN diuretics_NNS ,_, and_CC especially_RB those_DT in_IN whom_WP diuretic_JJ therapy_NN was_VBD recently_RB instituted_VBN ,_, may_MD occasionally_RB experience_VB an_DT excessive_JJ reduction_NN of_IN blood_NN pressure_NN after_IN initiation_NN of_IN therapy_NN with_IN PRINIVIL_NN ._. The_DT possibility_NN of_IN hypotensive_JJ effects_NNS with_IN PRINIVIL_NN can_MD be_VB minimized_VBN by_IN either_CC discontinuing_VBG the_DT diuretic_JJ or_CC increasing_VBG the_DT salt_NN intake_NN prior_RB to_TO initiation_NN of_IN treatment_NN with_IN PRINIVIL_NN ._. If_IN it_PRP is_VBZ necessary_JJ to_TO continue_VB the_DT diuretic_JJ ,_, initiate_VB therapy_NN with_IN PRINIVIL_NN at_IN a_DT dose_NN of_IN 5_CD mg_NN daily_RB ,_, and_CC provide_VBP close_JJ medical_JJ supervision_NN after_IN the_DT initial_JJ dose_NN until_IN blood_NN pressure_NN has_VBZ stabilized_VBN ._. When_WRB a_DT diuretic_JJ is_VBZ added_VBN to_TO the_DT therapy_NN of_IN a_DT patient_NN receiving_VBG PRINIVIL_NNP ,_, an_DT additional_JJ antihypertensive_JJ effect_NN is_VBZ usually_RB observed_VBN ._. Studies_NNS with_IN ACE_NN inhibitors_NNS in_IN combination_NN with_IN diuretics_NNS indicate_VBP that_IN the_DT dose_NN of_IN the_DT ACE_NN inhibitor_NN can_MD be_VB reduced_VBN when_WRB it_PRP is_VBZ given_VBN with_IN a_DT diuretic_JJ ._. Non-steroidal_JJ Anti-inflammatory_JJ Agents_NNS :_: In_IN some_DT patients_NNS with_IN compromised_VBN renal_JJ function_NN who_WP are_VBP being_VBG treated_VBN with_IN non-steroidal_JJ anti-inflammatory_JJ drugs_NNS ,_, the_DT co-administration_NN of_IN lisinopril_NN may_MD result_VB in_IN a_DT further_JJ deterioration_NN of_IN renal_JJ function_NN ._. These_DT effects_NNS are_VBP usually_RB reversible_JJ ._. Reports_NNS suggest_VBP that_IN NSAIDs_NNS may_MD diminish_VB the_DT antihypertensive_JJ effect_NN of_IN ACE_NN inhibitors_NNS ,_, including_VBG lisinopril_NN ._. This_DT interaction_NN should_MD be_VB given_VBN consideration_NN in_IN patients_NNS taking_VBG NSAIDs_NNS concomitantly_RB with_IN ACE_NN inhibitors_NNS ._. In_IN a_DT study_NN in_IN 36_CD patients_NNS with_IN mild_JJ to_TO moderate_JJ hypertension_NN where_WRB the_DT antihypertensive_JJ effects_NNS of_IN PRINIVIL_NN alone_RB were_VBD compared_VBN to_TO PRINIVIL_NNP given_VBN concomitantly_RB with_IN indomethacin_NN ,_, the_DT use_NN of_IN indomethacin_NN was_VBD associated_VBN with_IN a_DT reduced_VBN antihypertensive_JJ effect_NN ,_, although_IN the_DT difference_NN between_IN the_DT two_CD regimens_NNS was_VBD not_RB significant_JJ ._. Other_JJ Agents_NNS :_: PRINIVIL_NNP has_VBZ been_VBN used_VBN concomitantly_RB with_IN nitrates_NNS and/or_CC digoxin_NN without_IN evidence_NN of_IN clinically_RB significant_JJ adverse_JJ interactions_NNS ._. This_DT included_VBD post_NN myocardial_JJ infarction_NN patients_NNS who_WP were_VBD receiving_VBG intravenous_JJ or_CC transdermal_JJ nitroglycerin_NN ._. No_DT clinically_RB important_JJ pharmacokinetic_JJ interactions_NNS occurred_VBD when_WRB PRINIVIL_NNP was_VBD used_VBN concomitantly_RB with_IN propranolol_NN or_CC hydrochlorothiazide_NN ._. The_DT presence_NN of_IN food_NN in_IN the_DT stomach_NN does_VBZ not_RB alter_VB the_DT bioavailability_NN of_IN PRINIVIL_NNP ._. Agents_NNS Increasing_VBG Serum_NN Potassium_NN :_: PRINIVIL_NNP attenuates_VBZ potassium_NN loss_NN caused_VBN by_IN thiazide-type_JJ diuretics_NNS ._. Use_NN of_IN PRINIVIL_NN with_IN potassium-sparing_JJ diuretics_NNS -LRB-_-LRB- e.g._FW ,_, spironolactone_NN ,_, triamterene_NN ,_, or_CC amiloride_NN -RRB-_-RRB- ,_, potassium_NN supplements_NNS ,_, or_CC potassium-containing_JJ salt_NN substitutes_NNS may_MD lead_VB to_TO significant_JJ increases_NNS in_IN serum_NN potassium_NN ._. Therefore_RB ,_, if_IN concomitant_JJ use_NN of_IN these_DT agents_NNS is_VBZ indicated_VBN because_IN of_IN demonstrated_VBN hypokalemia_NN ,_, they_PRP should_MD be_VB used_VBN with_IN caution_NN and_CC with_IN frequent_JJ monitoring_NN of_IN serum_NN potassium_NN ._. Potassium_NN sparing_NN agents_NNS should_MD generally_RB not_RB be_VB used_VBN in_IN patients_NNS with_IN heart_NN failure_NN who_WP are_VBP receiving_VBG PRINIVIL_NNP ._. Lithium_NN :_: Lithium_NN toxicity_NN has_VBZ been_VBN reported_VBN in_IN patients_NNS receiving_VBG lithium_NN concomitantly_RB with_IN drugs_NNS which_WDT cause_VBP elimination_NN of_IN sodium_NN ,_, including_VBG ACE_NN inhibitors_NNS ._. Lithium_NN toxicity_NN was_VBD usually_RB reversible_JJ upon_IN discontinuation_NN of_IN lithium_NN and_CC the_DT ACE_NN inhibitor_NN ._. It_PRP is_VBZ recommended_VBN that_IN serum_NN lithium_NN levels_NNS be_VB monitored_VBN frequently_RB if_IN PRINIVIL_NN is_VBZ administered_VBN concomitantly_RB with_IN lithium_NN ._. -_: Lofexidine_NN may_MD enhance_VB the_DT CNS_NN depressive_JJ effects_NNS of_IN alcohol_NN ,_, barbiturates_NNS and_CC other_JJ sedative_NN ._. -_: Lofexidine_NN may_MD enhance_VB the_DT effects_NNS of_IN anti-hypertensive_JJ drug_NN therap_NN ._. -_: Concomitant_JJ use_NN of_IN tricyclic_JJ antidepressants_NNS may_MD reduce_VB the_DT efficacy_NN of_IN lofexidine_NN ._. Theophylline_NNP :_: In_IN three_CD pharmacokinetic_JJ studies_NNS including_VBG 46_CD normal_JJ ,_, healthy_JJ subjects_NNS ,_, theophylline_NN clearance_NN and_CC concentration_NN were_VBD not_RB significantly_RB altered_VBN by_IN the_DT addition_NN of_IN lomefloxacin_NN ._. In_IN clinical_JJ studies_NNS where_WRB patients_NNS were_VBD on_IN chronic_JJ theophylline_NN therapy_NN ,_, lomefloxacin_NN had_VBD no_DT measurable_JJ effect_NN on_IN the_DT mean_JJ distribution_NN of_IN theophylline_NN concentrations_NNS or_CC the_DT mean_NN estimates_NNS of_IN theophylline_NN clearance_NN ._. Though_IN individual_JJ theophylline_NN levels_NNS fluctuated_VBD ,_, there_EX were_VBD no_DT clinically_RB significant_JJ symptoms_NNS of_IN drug_NN inter-action_NN ._. Antacids_NNS and_CC sucralfate_NN :_: Sucralfate_NNP and_CC antacids_NNS containing_VBG magnesium_NN or_CC aluminum_NN ,_, as_RB well_RB as_IN formulations_NNS containing_VBG divalent_JJ and_CC trivalent_JJ cations_NNS such_JJ as_IN Videx_NNP -LRB-_-LRB- didanosine_NN -RRB-_-RRB- ,_, chewable/buffered_JJ tablets_NNS or_CC the_DT pediatric_JJ powder_NN for_IN oral_JJ solution_NN can_MD form_VB chelation_NN complexes_NNS with_IN lomefloxacin_NN and_CC interfere_VB with_IN its_PRP$ bioavailability_NN ._. Sucralfate_NNP administered_VBN 2_CD hours_NNS before_IN lomefloxacin_NN resulted_VBD in_IN a_DT slower_JJR absorption_NN -LRB-_-LRB- mean_NN C_NN max_NN decreased_VBN by_IN 30_CD %_NN and_CC mean_VB T_NN max_NN increased_VBN by_IN 1_CD hour_NN -RRB-_-RRB- and_CC a_DT lesser_JJR extent_NN of_IN absorption_NN -LRB-_-LRB- mean_NN AUC_NN decreased_VBN by_IN approximately_RB 25_CD %_NN -RRB-_-RRB- ._. Magnesium_NN -_: and_CC aluminum-containing_JJ antacids_NNS ,_, administered_VBN concomitantly_RB with_IN lomefloxacin_NN ,_, significantly_RB decreased_VBD the_DT bioavailability_NN -LRB-_-LRB- 48_CD %_NN -RRB-_-RRB- of_IN lomefloxacin_NN ._. Separating_VBG the_DT doses_NNS of_IN antacid_NN and_CC lomefloxacin_NN minimizes_VBZ this_DT decrease_NN in_IN bioavailability_NN ._. therefore_RB ,_, administration_NN of_IN these_DT agents_NNS should_MD precede_VB lomefloxacin_NN dosing_NN by_IN 4_CD hours_NNS or_CC follow_VB lomefloxacin_NN dosing_NN by_IN at_IN least_JJS 2_CD hours_NNS ._. Caffeine_NN :_: Two_CD hundred_CD mg_NN of_IN caffeine_NN -LRB-_-LRB- equivalent_JJ to_TO 1_CD to_TO 3_CD cups_NNS of_IN American_JJ coffee_NN -RRB-_-RRB- was_VBD administered_VBN to_TO 16_CD normal_JJ ,_, healthy_JJ volunteers_NNS who_WP had_VBD achieved_VBN steady-state_JJ blood_NN concentrations_NNS of_IN lomefloxacin_NN after_IN being_VBG dosed_VBN at_IN 400_CD mg_NN qd_NN ._. This_DT did_VBD not_RB result_VB in_IN any_DT statistically_RB or_CC clinically_RB relevant_JJ changes_NNS in_IN the_DT pharmacokinetic_JJ parameters_NNS of_IN either_CC caffeine_NN or_CC its_PRP$ major_JJ metabolite_NN ,_, paraxanthine_NN ._. No_DT data_NNS are_VBP available_JJ on_IN potential_JJ interactions_NNS in_IN individuals_NNS who_WP consume_VBP greater_JJR than_IN 200_CD mg_NN of_IN caffeine_NN per_IN day_NN or_CC in_IN those_DT ,_, such_JJ as_IN the_DT geriatric_JJ population_NN ,_, who_WP are_VBP generally_RB believed_VBN to_TO be_VB more_RBR susceptible_JJ to_TO the_DT development_NN of_IN drug-induced_JJ CNS-related_JJ adverse_JJ effects_NNS ._. Other_JJ quinolones_NNS have_VBP demonstrated_VBN moderate_JJ to_TO marked_JJ interference_NN with_IN the_DT metabolism_NN of_IN caffeine_NN ,_, resulting_VBG in_IN a_DT reduced_VBN clearance_NN ,_, a_DT prolongation_NN of_IN plasma_NN half-life_NN ,_, and_CC an_DT increase_NN in_IN symptoms_NNS that_WDT accompany_VBP high_JJ levels_NNS of_IN caffeine_NN ._. Cimetidine_NNP :_: Cimetidine_NNP has_VBZ been_VBN demonstrated_VBN to_TO interfere_VB with_IN the_DT elimination_NN of_IN other_JJ quinolones_NNS ._. This_DT interference_NN has_VBZ resulted_VBN in_IN significant_JJ increases_NNS in_IN half-life_NN and_CC AUC_NN ._. The_DT interaction_NN between_IN lomefloxacin_NN and_CC cimetidine_NN has_VBZ not_RB been_VBN studied_VBN ._. Cyclosporine_NN :_: Elevated_JJ serum_NN levels_NNS of_IN cyclosporine_NN have_VBP been_VBN reported_VBN with_IN concomitant_JJ use_NN of_IN cyclosporine_NN with_IN other_JJ members_NNS of_IN the_DT quinolone_NN class_NN ._. Interaction_NN between_IN lomefloxacin_NN and_CC cyclosporine_NN has_VBZ not_RB been_VBN studied_VBN ._. Omeprazole_NNP :_: No_NNP clinically_RB significant_JJ changes_NNS in_IN lomefloxacin_NN pharmacokinetics_NNS -LRB-_-LRB- AUC_NN ,_, C_NN max_NN ,_, or_CC T_NN max_NN -RRB-_-RRB- were_VBD observed_VBN when_WRB a_DT single_JJ dose_NN of_IN lomefloxacin_NN 400_CD mg_NN was_VBD given_VBN after_IN multiple_JJ doses_NNS of_IN omeprazole_NN -LRB-_-LRB- 20_CD mg_NN qd_NN -RRB-_-RRB- in_IN 13_CD healthy_JJ volunteers_NNS ._. Changes_NNS in_IN omeprazole_NN pharmacokinetics_NNS were_VBD not_RB studied_VBN ._. Phenytoin_NNP :_: No_NNP significant_JJ differences_NNS were_VBD observed_VBN in_IN mean_JJ phenytoin_NN AUC_NN ,_, C_NN max_NN ,_, C_NN min_NN or_CC T_NN max_NN -LRB-_-LRB- although_IN C_NN max_NN increased_VBN by_IN 11_CD %_NN -RRB-_-RRB- when_WRB extended_VBN phenytoin_NN sodium_NN capsules_NNS -LRB-_-LRB- 100_CD mg_NN tid_NN -RRB-_-RRB- were_VBD coadministered_VBN with_IN lomefloxacin_NN -LRB-_-LRB- 400_CD mg_NN qd_NN -RRB-_-RRB- for_IN five_CD days_NNS in_IN 15_CD healthy_JJ males_NNS ._. Lomefloxacin_NNP is_VBZ unlikely_JJ to_TO have_VB a_DT significant_JJ effect_NN on_IN phenytoin_NN metabolism_NN ._. Probenecid_NNP :_: Probenecid_NNP slows_VBZ the_DT renal_JJ elimination_NN of_IN lome-floxacin_NN ._. An_DT increase_NN of_IN 63_CD %_NN in_IN the_DT mean_NN AUC_NN and_CC increases_NNS of_IN 50_CD %_NN and_CC 4_CD %_NN ,_, respectively_RB ,_, in_IN the_DT mean_JJ T_NN max_NN and_CC mean_VB C_NN max_NN were_VBD noted_VBN in_IN 1_CD study_NN of_IN 6_CD individuals_NNS ._. Terfenadine_NNP :_: No_NNP clinically_RB significant_JJ changes_NNS occurred_VBD in_IN heart_NN rate_NN or_CC corrected_VBN QT_NN intervals_NNS ,_, or_CC in_IN terfenadine_NN metabolite_NN or_CC lomefloxacin_NN pharmacokinetics_NNS ,_, during_IN concurrent_JJ administration_NN of_IN lomefloxacin_NN and_CC terfenadine_NN at_IN steady-state_JJ in_IN 28_CD healthy_JJ males_NNS ._. Warfarin_NNP :_: Quinolones_NNS may_MD enhance_VB the_DT effects_NNS of_IN the_DT oral_JJ anticoagulant_NN ,_, warfarin_NN ,_, or_CC its_PRP$ derivatives_NNS ._. When_WRB these_DT products_NNS are_VBP administered_VBN concomitantly_RB ,_, prothrombin_NN or_CC other_JJ suitable_JJ coagulation_NN tests_NNS should_MD be_VB monitored_VBN closely_RB ._. However_RB ,_, no_DT clinically_RB or_CC statistically_RB significant_JJ differences_NNS in_IN prothrombin_NN time_NN ratio_NN or_CC warfarin_NN enantiomer_NN pharmacokinetics_NNS were_VBD observed_VBN in_IN a_DT small_JJ study_NN of_IN 7_CD healthy_JJ males_NNS who_WP received_VBD both_DT warfarin_NN and_CC lomefloxacin_NN under_IN steady-state_JJ conditions_NNS ._. There_EX was_VBD no_DT evidence_NN in_IN clinical_JJ trials_NNS of_IN drug_NN interactions_NNS with_IN concurrent_JJ medications_NNS ._. Probenecid_NNP :_: As_IN with_IN other_JJ b-lactam_NN antibiotics_NNS ,_, renal_JJ excretion_NN of_IN loracarbef_NN is_VBZ inhibited_VBN by_IN probenecid_NN and_CC resulted_VBD in_IN an_DT approximate_JJ 80_CD %_NN increase_NN in_IN the_DT AUC_NN for_IN loracarbef_NN ._. Loratadine_NN -LRB-_-LRB- 10_CD mg_NN once_RB daily_JJ -RRB-_-RRB- has_VBZ been_VBN coadministered_VBN with_IN therapeutic_JJ doses_NNS of_IN erythromycin_NN ,_, cimetidine_NN ,_, and_CC ketoconazole_NN in_IN controlled_JJ clinical_JJ pharmacology_NN studies_NNS in_IN adult_JJ volunteers_NNS ._. Although_IN increased_VBN plasma_NN concentrations_NNS -LRB-_-LRB- AUC_NN 0-24_CD hrs_NNS -RRB-_-RRB- of_IN loratadine_NN and/or_CC descarboethoxyloratadine_NN were_VBD observed_VBN following_VBG coadministration_NN of_IN loratadine_NN with_IN each_DT of_IN these_DT drugs_NNS in_IN normal_JJ volunteers_NNS -LRB-_-LRB- n_NN =_JJ 24_CD in_IN each_DT study_NN -RRB-_-RRB- ,_, there_EX were_VBD no_DT clinically_RB relevant_JJ changes_NNS in_IN the_DT safety_NN profile_NN of_IN loratadine_NN ,_, as_IN assessed_VBN by_IN electrocardiographic_JJ parameters_NNS ,_, clinical_JJ laboratory_NN tests_NNS ,_, vital_JJ signs_NNS ,_, and_CC adverse_JJ events_NNS ._. There_EX were_VBD no_DT significant_JJ effects_NNS on_IN QTc_NN intervals_NNS ,_, and_CC no_DT reports_NNS of_IN sedation_NN or_CC syncope_NN ._. No_DT effects_NNS on_IN plasma_NN concentrations_NNS of_IN cimetidine_NN or_CC ketoconazole_NN were_VBD observed_VBN ._. Plasma_NN concentrations_NNS -LRB-_-LRB- AUC_NN 0-24_CD hrs_NNS -RRB-_-RRB- of_IN erythromycin_NN decreased_VBD 15_CD %_NN with_IN coadministration_NN of_IN loratadine_NN relative_JJ to_TO that_DT observed_VBN with_IN erythromycin_NN alone_RB ._. The_DT clinical_JJ relevance_NN of_IN this_DT difference_NN is_VBZ unknown_JJ ._. These_DT above_IN findings_NNS are_VBP summarized_VBN in_IN TABLE_NN 1_CD ._. TABLE_NN 1_CD Effects_NNS on_IN Plasma_NN Concentrations_NNS -LRB-_-LRB- AUC_NN 0-24_CD hrs_NNS -RRB-_-RRB- of_IN Loratadine_NN and_CC Descarboethoxyloratadine_NN After_IN 10_CD Days_NNS of_IN Coadministration_NNP -LRB-_-LRB- Loratadine_NNP 10_CD mg_NN -RRB-_-RRB- in_IN Normal_JJ Volunteer_NN ._. Loratadine_NNP Descarboethoxyloratadin_NNP ._. Erythromycin_NN -LRB-_-LRB- 500_CD mg_NN q8h_NN -RRB-_-RRB- +_CC 40_CD %_NN +46_CD ._. Cimetidine_NN -LRB-_-LRB- 300_CD mg_NN qid_NN -RRB-_-RRB- +103_CD %_NN +_CC 6_CD ._. Ketoconazole_NN -LRB-_-LRB- 200_CD mg_NN q12h_NN -RRB-_-RRB- +307_CD %_NN +73_CD ._. There_EX does_VBZ not_RB appear_VB to_TO be_VB an_DT increase_NN in_IN adverse_JJ events_NNS in_IN subjects_NNS who_WP received_VBD oral_JJ contraceptives_NNS and_CC loratadine_NN ._. Tablets_NNS :_: The_DT benzodiazepines_NNS ,_, including_VBG lorazepam_NN ,_, produce_VBP CNS-depressant_JJ effects_NNS when_WRB administered_VBN with_IN such_JJ medications_NNS as_IN barbiturates_NNS or_CC alcohol_NN ._. Injection_NN :_: Lorazepam_NNP injection_NN ,_, like_IN other_JJ injectable_JJ benzodiazepines_NNS ,_, produces_VBZ depression_NN of_IN the_DT central_JJ nervous_JJ system_NN when_WRB administered_VBN with_IN ethyl_NN alcohol_NN ,_, phenothiazines_NNS ,_, barbiturates_NNS ,_, MAO_NN inhibitors_NNS ,_, and_CC other_JJ antidepressants.When_JJ scopolamine_NN is_VBZ used_VBN concomitantly_RB with_IN injectable_JJ lorazepam_NN ,_, an_DT increased_VBN incidence_NN of_IN sedation_NN ,_, hallucinations_NNS ,_, and_CC irrational_JJ behavior_NN has_VBZ been_VBN observed_VBN ._. No_DT significant_JJ drug-drug_JJ pharmacokinetic_JJ interactions_NNS have_VBP been_VBN found_VBN in_IN interaction_NN studies_NNS with_IN hydrochlorothiazide_NN ,_, digoxin_NN ,_, warfarin_NN ,_, cimetidine_NN and_CC phenobarbital_NN ._. Rifampin_NNP ,_, an_DT inducer_NN of_IN drug_NN metabolism_NN ,_, decreased_VBD the_DT concentrations_NNS of_IN losartan_NN and_CC its_PRP$ active_JJ metabolite_NN ._. In_IN humans_NNS ,_, two_CD inhibitors_NNS of_IN P450_NN 3A4_NN have_VBP been_VBN studied_VBN ._. Ketoconazole_NN did_VBD not_RB affect_VB the_DT conversion_NN of_IN losartan_NN to_TO the_DT active_JJ metabolite_NN after_IN intravenous_JJ administration_NN of_IN losartan_NN ,_, and_CC erythromycin_NN had_VBD no_DT clinically_RB significant_JJ effect_NN after_IN oral_JJ administration_NN ._. Fluconazole_NNP ,_, an_DT inhibitor_NN of_IN P450_NN 2C9_NN ,_, decreased_VBD active_JJ metabolite_NN concentration_NN and_CC increased_VBD losartan_NN concentration_NN ._. The_DT pharmacodynamic_JJ consequences_NNS of_IN concomitant_JJ use_NN of_IN losartan_NN and_CC inhibitors_NNS of_IN P450_NN 2C9_NN have_VBP not_RB been_VBN examined_VBN ._. Subjects_NNS who_WP do_VBP not_RB metabolize_VB losartan_NN to_TO active_JJ metabolite_NN have_VBP been_VBN shown_VBN to_TO have_VB a_DT specific_JJ ,_, rare_JJ defect_NN in_IN cytochrome_NN P450_NN 2C9_NN ._. These_DT data_NNS suggest_VBP that_IN the_DT conversion_NN of_IN losartan_NN to_TO its_PRP$ active_JJ metabolite_NN is_VBZ mediated_VBN primarily_RB by_IN P450_NN 2C9_NN and_CC not_RB P450_NN 3A4_NN ._. As_IN with_IN other_JJ drugs_NNS that_WDT block_VBP angiotensin_NN II_CD or_CC its_PRP$ effects_NNS ,_, concomitant_JJ use_NN of_IN potassium-sparing_JJ diuretics_NNS -LRB-_-LRB- e.g._FW ,_, spironolactone_NN ,_, triamterene_NN ,_, amiloride_NN -RRB-_-RRB- ,_, potassium_NN supplements_NNS ,_, or_CC salt_NN substitutes_NNS containing_VBG potassium_NN may_MD lead_VB to_TO increases_NNS in_IN serum_NN potassium_NN ._. As_IN with_IN other_JJ antihypertensive_JJ agents_NNS ,_, the_DT antihypertensive_JJ effect_NN of_IN losartan_NN may_MD be_VB blunted_VBN by_IN the_DT non-steroidal_JJ anti-inflammatory_JJ drug_NN indomethaci_NNS ._. CYP3A4_NN Interactions_NNS ._. Lovastatin_NNP is_VBZ metabolized_VBN by_IN CYP3A4_NN but_CC has_VBZ no_DT CYP3A4_NN inhibitory_JJ activity_NN ._. therefore_RB it_PRP is_VBZ not_RB expected_VBN to_TO affect_VB the_DT plasma_NN concentrations_NNS of_IN other_JJ drugs_NNS metabolized_VBN by_IN CYP3A4_NN ._. Potent_JJ inhibitors_NNS of_IN CYP3A4_NN -LRB-_-LRB- below_IN -RRB-_-RRB- increase_VBP the_DT risk_NN of_IN myopathy_NN by_IN reducing_VBG the_DT elimination_NN of_IN lovastatin_NN ._. Pharmacokinetics_NNS ._. Itraconazole_NNP Ketoconazole_NNP Erythromycin_NNP Clarithromycin_NNP Telithromycin_NNP HIV_NN protease_NN inhibitors_NNS Nefazodone_NNP Cyclosporine_NNP Large_JJ quantities_NNS of_IN grapefruit_NN juice_NN -LRB-_-LRB- 1_CD quart_NN daily_RB ._. Interactions_NNS with_IN lipid-lowering_JJ drugs_NNS that_WDT can_MD cause_VB myopathy_NN when_WRB given_VBN alone_RB ._. The_DT risk_NN of_IN myopathy_NN is_VBZ also_RB increased_VBN by_IN the_DT following_VBG lipid-lowering_JJ drugs_NNS that_WDT are_VBP not_RB potent_JJ CYP3A4_NN inhibitors_NNS ,_, but_CC which_WDT can_MD cause_VB myopathy_NN when_WRB given_VBN alone_RB ._. See_VB WARNINGS_NNP ,_, Myopathy/Rhabdomyolysis_NNP ._. Gemfibrozil_NNP Other_JJ fibrates_NNS Niacin_NNP -LRB-_-LRB- nicotinic_JJ acid_NN -RRB-_-RRB- -LRB-_-LRB- =_JJ 1_CD g/day_NN ._. Other_JJ drug_NN interactions_NNS ._. Danazol_NN :_: The_DT risk_NN of_IN myopathy/rhabdomyolysis_NN is_VBZ increased_VBN by_IN concomitant_JJ administration_NN of_IN danazol_NN particularly_RB with_IN higher_JJR doses_NNS of_IN lovastatin_NN -LRB-_-LRB- see_VB WARNINGS_NNS ,_, Myopathy/Rhabdomyolysis_NN -RRB-_-RRB- ._. Amiodarone_NNP or_CC Verapamil_NNP :_: The_DT risk_NN of_IN myopathy/rhabdomyolysis_NN is_VBZ increased_VBN when_WRB either_CC amiodarone_NN or_CC verapamil_NN is_VBZ used_VBN concomitantly_RB with_IN a_DT closely_RB related_JJ member_NN of_IN the_DT HMG-CoA_NN reductase_NN inhibitor_NN class_NN -LRB-_-LRB- see_VB WARNINGS_NNS ,_, Myopathy/Rhabdomyolysis_NN -RRB-_-RRB- ._. Coumarin_NNP Anticoagulants_NNPS :_: In_IN a_DT small_JJ clinical_JJ trial_NN in_IN which_WDT lovastatin_NN was_VBD administered_VBN to_TO warfarin_NN treated_JJ patients_NNS ,_, no_DT effect_NN on_IN prothrombin_NN time_NN was_VBD detected_VBN ._. However_RB ,_, another_DT HMG-CoA_NN reductase_NN inhibitor_NN has_VBZ been_VBN found_VBN to_TO produce_VB a_DT less_JJR than_IN two-second_JJ increase_NN in_IN prothrombin_NN time_NN in_IN healthy_JJ volunteers_NNS receiving_VBG low_JJ doses_NNS of_IN warfarin_NN ._. Also_RB ,_, bleeding_VBG and/or_CC increased_VBN prothrombin_NN time_NN have_VBP been_VBN reported_VBN in_IN a_DT few_JJ patients_NNS taking_VBG coumarin_NN anticoagulants_NNS concomitantly_RB with_IN lovastatin_NN ._. It_PRP is_VBZ recommended_VBN that_IN in_IN patients_NNS taking_VBG anticoagulants_NNS ,_, prothrombin_NN time_NN be_VB determined_VBN before_IN starting_VBG lovastatin_NN and_CC frequently_RB enough_RB during_IN early_JJ therapy_NN to_TO insure_VB that_IN no_DT significant_JJ alteration_NN of_IN prothrombin_NN time_NN occurs_VBZ ._. Once_RB a_DT stable_JJ prothrombin_NN time_NN has_VBZ been_VBN documented_VBN ,_, prothrombin_NN times_NNS can_MD be_VB monitored_VBN at_IN the_DT intervals_NNS usually_RB recommended_VBN for_IN patients_NNS on_IN coumarin_NN anticoagulants_NNS ._. If_IN the_DT dose_NN of_IN lovastatin_NN is_VBZ changed_VBN ,_, the_DT same_JJ procedure_NN should_MD be_VB repeated_VBN ._. Lovastatin_NN therapy_NN has_VBZ not_RB been_VBN associated_VBN with_IN bleeding_NN or_CC with_IN changes_NNS in_IN prothrombin_NN time_NN in_IN patients_NNS not_RB taking_VBG anticoagulants_NNS ._. Propranolol_NN :_: In_IN normal_JJ volunteers_NNS ,_, there_EX was_VBD no_DT clinically_RB significant_JJ pharmacokinetic_JJ or_CC pharmacodynamic_JJ interaction_NN with_IN concomitant_JJ administration_NN of_IN single_JJ doses_NNS of_IN lovastatin_NN and_CC propranolol_NN ._. Digoxin_NNP :_: In_IN patients_NNS with_IN hypercholesterolemia_NN ,_, concomitant_JJ administration_NN of_IN lovastatin_NN and_CC digoxin_NN resulted_VBD in_IN no_DT effect_NN on_IN digoxin_NN plasma_NN concentrations_NNS ._. Oral_JJ Hypoglycemic_JJ Agents_NNS :_: In_IN pharmacokinetic_JJ studies_NNS of_IN MEVACOR_NN in_IN hypercholesterolemic_JJ noninsulin_NN dependent_JJ diabetic_JJ patients_NNS ,_, there_EX was_VBD no_DT drug_NN interaction_NN with_IN glipizide_NN or_CC with_IN chlorpropamid_NN ._. There_EX have_VBP been_VBN rare_JJ reports_NNS of_IN significant_JJ respiratory_JJ depression_NN ,_, stupor_NN and/or_CC hypotension_NN with_IN the_DT concomitant_JJ use_NN of_IN loxapine_NN and_CC lorazepam_NN ._. The_DT risk_NN of_IN using_VBG loxapine_NN in_IN combination_NN with_IN CNS-active_JJ drugs_NNS has_VBZ not_RB been_VBN systematically_RB evaluated_VBN ._. Therefore_RB ,_, caution_NN is_VBZ advised_VBN if_IN the_DT concomitant_JJ administration_NN of_IN loxapine_NN and_CC CNS-active_JJ drugs_NNS is_VBZ required_VBN ._. The_DT absorption_NN of_IN lymecycline_NN may_MD be_VB affected_VBN by_IN the_DT simultaneous_JJ administration_NN of_IN indigestion_NN remedies_NNS ,_, iron_NN or_CC zinc_NN supplements_NNS ._. Oral_JJ contraceptives_NNS may_MD be_VB less_RBR effective_JJ while_IN you_PRP are_VBP taking_VBG lymecycline_NN ._. Warfarin_NNP :_: Meclofenamate_NNP sodium_NN enhances_VBZ the_DT effect_NN of_IN warfarin_NN ._. Therefore_RB ,_, when_WRB meclofenamate_NN sodium_NN is_VBZ given_VBN to_TO a_DT patient_NN receiving_VBG warfarin_NN ,_, the_DT dosage_NN of_IN warfarin_NN should_MD be_VB reduced_VBN to_TO prevent_VB excessive_JJ prolongation_NN of_IN the_DT prothrombin_NN time_NN ._. Aspirin_NN :_: Concurrent_JJ administration_NN of_IN aspirin_NN may_MD lower_VB meclofenamate_NN sodium_NN plasma_NN levels_NNS ,_, possibly_RB by_IN competing_VBG for_IN protein-binding_JJ sites_NNS ._. The_DT urinary_JJ excretion_NN of_IN meclofenamate_NN sodium_NN is_VBZ unaffected_JJ by_IN aspirin_NN ,_, indicating_VBG no_DT change_NN in_IN meclofenamate_NN sodium_NN absorption_NN ._. Meclofenamate_NN sodium_NN does_VBZ not_RB affect_VB serum_NN salicylate_NN levels_NNS ._. Greater_NNP fecal_JJ blood_NN loss_NN results_VBZ from_IN concomitant_JJ administration_NN of_IN both_CC drugs_NNS than_IN from_IN either_CC drug_NN alone_RB ._. Propoxyphene_NNP :_: The_DT concurrent_JJ administration_NN of_IN propoxyphene_NN hydrochloride_NN does_VBZ not_RB affect_VB the_DT bioavailability_NN of_IN meclofenamate_NN sodium_NN ._. Antacids_NNS :_: Concomitant_JJ administration_NN of_IN aluminum_NN and_CC magnesium_NN hydroxides_NNS does_VBZ not_RB interfere_VB with_IN absorption_NN of_IN meclofenamate_NN sodium_NN ._. Aspirin_NN :_: As_IN with_IN other_JJ NSAIDs_NNS ,_, concomitant_JJ administration_NN of_IN Ponstel_NNP and_CC aspirin_NN is_VBZ not_RB generally_RB recommended_VBN because_IN of_IN the_DT potential_NN of_IN increased_VBN adverse_JJ effects_NNS ._. Methotrexate_NNP :_: NSAIDs_NNS have_VBP been_VBN reported_VBN to_TO competitively_RB inhibit_VB methotrexate_NN accumulation_NN in_IN rabbit_NN kidney_NN slices_NNS ._. This_DT may_MD indicate_VB that_IN they_PRP could_MD enhance_VB the_DT toxicity_NN of_IN methotrexate_NN ._. Caution_NN should_MD be_VB used_VBN when_WRB NSAIDs_NNS are_VBP administered_VBN concomitantly_RB with_IN methotrexate_NN ._. ACE_NN inhibitors_NNS :_: Reports_NNS suggest_VBP that_IN NSAIDs_NNS may_MD diminish_VB the_DT antihypertensive_JJ effect_NN of_IN ACE_NN inhibitors_NNS ._. This_DT interaction_NN should_MD be_VB given_VBN consideration_NN in_IN patients_NNS taking_VBG NSAIDs_NNS concomitantly_RB with_IN ACE_NN inhibitors_NNS ._. Furosemide_NNP :_: Clinical_JJ studies_NNS ,_, as_RB well_RB as_IN post-marketing_JJ observations_NNS ,_, have_VBP shown_VBN that_IN NSAIDs_NNS can_MD reduce_VB the_DT natriuretic_JJ effect_NN of_IN furosemide_NN and_CC thiazides_NNS in_IN some_DT patients_NNS ._. This_DT response_NN has_VBZ been_VBN attributed_VBN to_TO inhibition_NN of_IN renal_JJ prostaglandin_NN synthesis_NN ._. During_IN concomitant_JJ therapy_NN of_IN Ponstel_NN with_IN furosemide_NN ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB for_IN signs_NNS of_IN renal_JJ failure_NN ,_, as_RB well_RB as_IN to_TO assure_VB diuretic_JJ efficacy_NN ._. Lithium_NN :_: NSAIDs_NNS have_VBP produced_VBN an_DT elevation_NN of_IN plasma_NN lithium_NN levels_NNS and_CC a_DT reduction_NN in_IN renal_JJ lithium_NN clearance_NN ._. The_DT mean_NN minimum_JJ lithium_NN concentration_NN increased_VBD 15_CD %_NN and_CC the_DT renal_JJ clearance_NN was_VBD decreased_VBN by_IN approximately_RB 20_CD %_NN ._. These_DT effects_NNS have_VBP been_VBN attributed_VBN to_TO inhibition_NN of_IN renal_JJ prostaglandin_NN synthesis_NN by_IN the_DT NSAID_NN ._. Thus_RB ,_, when_WRB NSAIDs_NNS and_CC lithium_NN are_VBP administered_VBN concurrently_RB ,_, subjects_NNS should_MD be_VB observed_VBN carefully_RB for_IN signs_NNS of_IN lithium_NN toxicity_NN ._. Warfarin_NNP :_: The_DT effects_NNS of_IN warfarin_NN and_CC NSAIDs_NNS on_IN GI_NN bleeding_NN are_VBP synergistic_JJ ,_, such_JJ that_IN users_NNS of_IN both_DT drugs_NNS together_RB have_VBP a_DT risk_NN of_IN serious_JJ GI_NN bleeding_VBG higher_JJR than_IN users_NNS of_IN either_CC drug_NN alone_RB ._. Antacids_NNS :_: In_IN a_DT single_JJ dose_NN study_NN -LRB-_-LRB- n_NN =_JJ 6_CD -RRB-_-RRB- ,_, ingestion_NN of_IN an_DT antacid_NN containing_VBG 1.7-gram_NN of_IN magnesium_NN hydroxide_NN with_IN 500-mg_NN of_IN mefenamic_JJ acid_NN increased_VBD the_DT Cmax_NN and_CC AUC_NN of_IN mefenamic_JJ acid_NN by_IN 125_CD %_NN and_CC 36_CD %_NN ,_, respectively_RB ._. A_DT number_NN of_IN compounds_NNS are_VBP inhibitors_NNS of_IN CYP2C9_NN including_VBG fluconazole_NN ,_, lovastatin_NN and_CC trimethoprim_NN ._. Drug_NN interaction_NN studies_NNS of_IN mefenamic_JJ acid_NN and_CC these_DT compounds_NNS have_VBP not_RB been_VBN conducted_VBN ._. The_DT possibility_NN of_IN altered_JJ safety_NN and_CC efficacy_NN should_MD be_VB considered_VBN when_WRB Ponstel_NNP is_VBZ used_VBN concomitantly_RB with_IN these_DT drugs_NNS ._. Drug-drug_JJ interactions_NNS with_IN Mefloquine_NN have_VBP not_RB been_VBN explored_VBN in_IN detail_NN ._. There_EX is_VBZ one_CD report_NN of_IN cardiopulmonary_JJ arrest_NN ,_, with_IN full_JJ recovery_NN ,_, in_IN a_DT patient_NN who_WP was_VBD taking_VBG a_DT beta_NN blocker_NN -LRB-_-LRB- propranolol_NN -RRB-_-RRB- ._. The_DT effects_NNS of_IN Mefloquineuine_NN on_IN the_DT compromised_VBN cardiovascular_JJ system_NN have_VBP not_RB been_VBN evaluated_VBN ._. The_DT benefits_NNS of_IN Mefloquine_NN therapy_NN should_MD be_VB weighed_VBN against_IN the_DT possibility_NN of_IN adverse_JJ effects_NNS in_IN patients_NNS with_IN cardiac_JJ disease_NN ._. Because_IN of_IN the_DT danger_NN of_IN a_DT potentially_RB fatal_JJ prolongation_NN of_IN the_DT QTc_NN interval_NN ,_, halofantrine_NN must_MD not_RB be_VB given_VBN simultaneously_RB with_IN or_CC subsequent_JJ to_TO Mefloquine_NNP ._. Concomitant_JJ administration_NN of_IN Mefloquine_NNP and_CC other_JJ related_JJ compounds_NNS -LRB-_-LRB- eg_FW ,_, quinine_NN ,_, quinidine_NN and_CC chloroquine_NN -RRB-_-RRB- may_MD produce_VB electrocardiographic_JJ abnormalities_NNS and_CC increase_VB the_DT risk_NN of_IN convulsions_NNS ._. If_IN these_DT drugs_NNS are_VBP to_TO be_VB used_VBN in_IN the_DT initial_JJ treatment_NN of_IN severe_JJ malaria_NN ,_, Mefloquine_NNP administration_NN should_MD be_VB delayed_VBN at_IN least_JJS 12_CD hours_NNS after_IN the_DT last_JJ dose_NN ._. There_EX is_VBZ evidence_NN that_IN the_DT use_NN of_IN halofantrine_NN after_IN Mefloquineuine_NNP causes_VBZ a_DT significant_JJ lengthening_NN of_IN the_DT QTc_NN interval_NN ._. Clinically_RB significant_JJ QTc_NN prolongation_NN has_VBZ not_RB been_VBN found_VBN with_IN Mefloquineuine_NN alone_RB ._. This_DT appears_VBZ to_TO be_VB the_DT only_JJ clinically_RB relevant_JJ interaction_NN of_IN this_DT kind_NN with_IN Mefloquine_NNP ,_, although_IN theoretically_RB ,_, coadministration_NN of_IN other_JJ drugs_NNS known_VBN to_TO alter_VB cardiac_JJ conduction_NN -LRB-_-LRB- eg_FW ,_, anti-arrhythmic_JJ or_CC beta-adrenergic_JJ blocking_VBG agents_NNS ,_, calcium_NN channel_NN blockers_NNS ,_, antihistamines_NNS or_CC H1-blocking_JJ agents_NNS ,_, tricyclic_JJ antidepressants_NNS and_CC phenothiazines_NNS -RRB-_-RRB- might_MD also_RB contribute_VB to_TO a_DT prolongation_NN of_IN the_DT QTc_NN interval_NN ._. There_EX are_VBP no_DT data_NNS that_WDT conclusively_RB establish_VBP whether_IN the_DT concomitant_JJ administration_NN of_IN Mefloquineuine_NN and_CC the_DT above_JJ listed_VBN agents_NNS has_VBZ an_DT effect_NN on_IN cardiac_JJ function_NN ._. In_IN patients_NNS taking_VBG an_DT anticonvulsant_JJ -LRB-_-LRB- eg_FW ,_, valproic_JJ acid_NN ,_, carbamazepine_NN ,_, phenobarbital_NN or_CC phenytoin_NN -RRB-_-RRB- ,_, the_DT concomitant_JJ use_NN of_IN Mefloquine_NNP may_MD reduce_VB seizure_NN control_NN by_IN lowering_VBG the_DT plasma_NN levels_NNS of_IN the_DT anticonvulsant_NN ._. Therefore_RB ,_, patients_NNS concurrently_RB taking_VBG antiseizure_JJ medication_NN and_CC Mefloquine_NN should_MD have_VB the_DT blood_NN level_NN of_IN their_PRP$ antiseizure_JJ medication_NN monitored_VBD and_CC the_DT dosage_NN adjusted_VBN appropriately_RB ._. When_WRB Mefloquine_NNP is_VBZ taken_VBN concurrently_RB with_IN oral_JJ live_JJ typhoid_NN vaccines_NNS ,_, attenuation_NN of_IN immunization_NN can_MD not_RB be_VB excluded_VBN ._. Vaccinations_NNS with_IN attenuated_VBN live_JJ bacteria_NNS should_MD therefore_RB be_VB completed_VBN at_IN least_JJS 3_CD days_NNS before_IN the_DT first_JJ dose_NN of_IN Mefloquine_NNP ._. No_DT other_JJ drug_NN interactions_NNS are_VBP known_VBN ._. Nevertheless_RB ,_, the_DT effects_NNS of_IN Mefloquine_NN on_IN travelers_NNS receiving_VBG comedication_NN ,_, particularly_RB diabetics_NNS or_CC patients_NNS using_VBG anticoagulants_NNS ,_, should_MD be_VB checked_VBN before_IN departure_NN ._. In_IN clinical_JJ trials_NNS ,_, the_DT concomitant_JJ administration_NN of_IN sulfadoxine_NN and_CC pyrimethamine_NN did_VBD not_RB alter_VB the_DT adverse_JJ reaction_NN profile_NN ._. Broad-Spectrum_NNP Antibiotics-Broad-spectrum_NNP antibiotics_NNS may_MD sterilize_VB the_DT bowel_NN and_CC decrease_VB the_DT vitamin_NN K_NN contribution_NN to_TO the_DT body_NN by_IN the_DT intestinal_JJ microflora_NN ._. Cephalosporins-Cephalosporins_NNS containing_VBG side_NN chains_NNS of_IN N-methylthiotetrazole_NN -LRB-_-LRB- cefmenoxime_NN ,_, cefoperazone_NN ,_, cefotetan_NN ,_, cefamandole_NN ,_, latamoxef_NN -RRB-_-RRB- or_CC methylthiadiazole_NN -LRB-_-LRB- cefazolin_NN -RRB-_-RRB- can_MD cause_VB vitamin_NN K_NN deficiency_NN and_CC hypoprothrombinemia_NN ._. These_DT cephalosporins_NNS are_VBP inhibitors_NNS of_IN hepatic_JJ vitamin_NN K_NN epoxide_NN reductase_NN ._. Cholestyramine-Concomitant_JJ intake_NN of_IN cholestyramine_NN and_CC vitamin_NN K_NN may_MD reduce_VB the_DT absorption_NN of_IN vitamin_NN K._NNP Colestipol-Concomitant_NNP intake_NN of_IN colestipol_NN and_CC vitamin_NN K_NN may_MD reduce_VB the_DT absorption_NN of_IN vitamin_NN K._NNP Mineral_NNP Oil-Concomitant_JJ intake_NN of_IN mineral_NN oil_NN and_CC vitamin_NN K_NN may_MD reduce_VB the_DT absorption_NN of_IN vitamin_NN K._NNP Orlistat-Orlistat_NNP may_MD decrease_VB the_DT absorption_NN of_IN vitamin_NN K._NNP Salicylates-Salicylates_NNP in_IN large_JJ doses_NNS may_MD inhibit_VB vitamin_NN K_NN epoxide_NN reductase_NN resulting_VBG in_IN vitamin_NN K_NN deficiency_NN ._. Warfarin-Vitamin_JJ K_NN can_MD antagonize_VB the_DT effect_NN of_IN warfari_NN ._. Nabilone_NN should_MD be_VB administered_VBN with_IN caution_NN to_TO patients_NNS who_WP are_VBP taking_VBG other_JJ psychoactive_JJ drugs_NNS or_CC CNS_NN depressants_NNS ,_, including_VBG alcohol_NN ,_, barbiturates_NNS and_CC narcotic_JJ analgesics_NNS ,_, or_CC to_TO those_DT with_IN a_DT history_NN of_IN psychiatric_JJ disorder_NN -LRB-_-LRB- including_VBG manic-depressive_NN illness_NN and_CC schizophrenia_NN -RRB-_-RRB- ._. Nabilone_NNP has_VBZ been_VBN shown_VBN to_TO have_VB an_DT additive_JJ CNS_NN depressant_NN effect_NN when_WRB given_VBN with_IN either_CC diazepam_NN ,_, secobarbitone_NN sodium_NN ,_, alcohol_NN or_CC codeine_NN ._. In_FW vitro_FW studies_NNS have_VBP shown_VBN that_IN ,_, because_IN of_IN its_PRP$ affinity_NN for_IN protein_NN ,_, 6MNA_NN may_MD displace_VB other_JJ protein-bound_JJ drugs_NNS from_IN their_PRP$ binding_NN site_NN ._. Caution_NN should_MD be_VB exercised_VBN when_WRB administering_VBG nabumetone_NN with_IN warfarin_NN since_IN interactions_NNS have_VBP been_VBN seen_VBN with_IN other_JJ NSAIDs_NNS ._. Concomitant_JJ administration_NN of_IN an_DT aluminum-containing_JJ antacid_NN had_VBD no_DT significant_JJ effect_NN in_IN the_DT bioavailability_NN of_IN 6MNA_NN ._. When_WRB administered_VBN with_IN food_NN or_CC milk_NN ,_, there_EX is_VBZ more_RBR rapid_JJ absorption_NN ;_: ._. however_RB ,_, the_DT total_JJ amount_NN of_IN 6MNA_NN in_IN the_DT plasma_NN is_VBZ unchanged_JJ ._. When_WRB administered_VBN concurrently_RB ,_, the_DT following_VBG drugs_NNS may_MD interact_VB with_IN beta-adrenergic_JJ receptor_NN blocking_VBG agents_NNS :_: Anesthetics_NNS ,_, general_JJ :_: exaggeration_NN of_IN the_DT hypotension_NN induced_VBN by_IN general_JJ anesthetics_NNS ._. Antidiabetic_JJ drugs_NNS -LRB-_-LRB- oral_JJ agents_NNS and_CC insulin_NN -RRB-_-RRB- :_: hypoglycemia_NN or_CC hyperglycemia_NN ._. adjust_VBP dosage_NN of_IN antidiabetic_JJ drug_NN accordingly_RB ._. Catecholamine-depleting_JJ drugs_NNS -LRB-_-LRB- e.g._FW ,_, reserpine_NN -RRB-_-RRB- :_: additive_JJ effect_NN ._. monitor_NN closely_RB for_IN evidence_NN of_IN hypotension_NN and/or_CC excessive_JJ bradycardia_NN -LRB-_-LRB- e.g._FW ,_, vertigo_NN ,_, syncope_NN ,_, postural_JJ hypotension_NN -RRB-_-RRB- ._. Response_NN to_TO Treatment_NN for_IN Anaphylactic_NNP Reaction_NNP :_: While_IN taking_VBG beta-blockers_NNS ,_, patients_NNS with_IN a_DT history_NN of_IN severe_JJ anaphylactic_JJ reaction_NN to_TO a_DT variety_NN of_IN allergens_NNS may_MD be_VB more_RBR reactive_JJ to_TO repeated_VBN challenge_NN ,_, either_CC accidental_JJ ,_, diagnostic_JJ ,_, or_CC therapeutic_JJ ._. Such_JJ patients_NNS may_MD be_VB unresponsive_JJ to_TO the_DT usual_JJ doses_NNS of_IN epinephrine_NN used_VBN to_TO treat_VB allergic_JJ reaction_NN ._. No_DT pharmacokinetic-based_JJ drug-drug_NN interaction_NN studies_NNS have_VBP been_VBN conducted_VBN with_IN SYNAREL_NNP ._. However_RB ,_, because_IN nafarelin_NN acetate_NN is_VBZ a_DT peptide_NN that_WDT is_VBZ primarily_RB degraded_VBN by_IN peptidase_NN and_CC not_RB by_IN cytochrome_NN P-450_NN enzymes_NNS ,_, and_CC the_DT drug_NN is_VBZ only_RB about_RB 80_CD %_NN bound_VBD to_TO plasma_NN proteins_NNS at_IN 4_CD C_NN ,_, drug_NN interactions_NNS would_MD not_RB be_VB expected_VBN to_TO occur_VB ._. Tetracycline_NN ,_, a_DT bacteriostatic_JJ antibiotic_JJ ,_, may_MD antagonize_VB the_DT bactericidal_JJ effect_NN of_IN penicillin_NN and_CC concurrent_JJ use_NN of_IN these_DT drugs_NNS should_MD be_VB avoided_VBN ._. No_DT specific_JJ information_NN available_JJ ._. Elevated_JJ plasma_NN levels_NNS of_IN theophylline_NN have_VBP been_VBN reported_VBN with_IN concomitant_JJ quinolone_NN use_NN ._. There_EX have_VBP been_VBN reports_NNS of_IN theophylline-related_JJ side_JJ effects_NNS in_IN patients_NNS on_IN concomitant_JJ therapy_NN with_IN quinolones_NNS and_CC theophylline_NN ._. Therefore_RB ,_, monitoring_NN of_IN theophylline_NN plasma_NN levels_NNS should_MD be_VB considered_VBN and_CC dosage_NN of_IN theophylline_NN adjusted_VBN ,_, as_IN required_VBN ._. Quinolones_NNS have_VBP been_VBN shown_VBN to_TO interfere_VB with_IN the_DT metabolism_NN of_IN caffeine_NN ._. This_DT may_MD lead_VB to_TO reduced_VBN clearance_NN of_IN caffeine_NN and_CC the_DT prolongation_NN of_IN its_PRP$ plasma_NN half-life_NN ._. Quinolones_NNP ,_, including_VBG nalidixic_JJ acid_NN ,_, may_MD enhance_VB the_DT effects_NNS of_IN the_DT oral_JJ anticoagulant_JJ warfarin_NN or_CC its_PRP$ derivatives_NNS ._. When_WRB these_DT products_NNS are_VBP administered_VBN concomitantly_RB ,_, prothrombin_NN time_NN or_CC other_JJ suitable_JJ coagulation_NN test_NN should_MD be_VB closely_RB monitored_VBN ._. Nitrofurantoin_NN interferes_VBZ with_IN the_DT therapeutic_JJ action_NN of_IN nalidixic_JJ acid_NN ._. Antacids_NNS containing_VBG magnesium_NN ,_, aluminum_NN ,_, or_CC calcium_NN ._. sucralfate_NN or_CC divalent_JJ or_CC trivalent_JJ cations_NNS such_JJ as_IN iron_NN ._. multivitamins_NNS containing_VBG zinc_NN ._. and_CC Videx_NNP ,_, -LRB-_-LRB- Didanosine_NNP -RRB-_-RRB- ,_, chewable/buffered_JJ tablets_NNS or_CC the_DT pediatric_JJ powder_NN for_IN oral_JJ solution_NN may_MD substantially_RB interfere_VB with_IN the_DT absorption_NN of_IN quinolones_NNS ,_, resulting_VBG in_IN systemic_JJ levels_NNS considerably_RB lower_JJR than_IN desired_VBN ._. These_DT agents_NNS should_MD not_RB be_VB taken_VBN within_IN the_DT two_CD hour_NN period_NN before_IN or_CC within_IN the_DT two-hour_JJ period_NN after_IN nalidixic_JJ acid_NN administration_NN ._. Elevated_JJ serum_NN levels_NNS of_IN cyclosporine_NN have_VBP been_VBN reported_VBN with_IN the_DT concomitant_JJ use_NN of_IN some_DT quinolones_NNS and_CC cyclosporine_NN ._. Therefore_RB ,_, cyclosporine_NN serum_NN levels_NNS should_MD be_VB monitored_VBN and_CC appropriate_JJ cyclosporine_NN dosage_NN adjustments_NNS made_VBN when_WRB these_DT drugs_NNS are_VBP used_VBN concomitantly_RB ._. Studies_NNS to_TO evaluate_VB possible_JJ interactions_NNS between_IN REVIA_NNP and_CC drugs_NNS other_JJ than_IN opiates_NNS have_VBP not_RB been_VBN performed_VBN ._. Consequently_RB ,_, caution_NN is_VBZ advised_VBN if_IN the_DT concomitant_JJ administration_NN of_IN REVIA_NNP and_CC other_JJ drugs_NNS is_VBZ required_VBN ._. The_DT safety_NN and_CC efficacy_NN of_IN concomitant_JJ use_NN of_IN REVIA_NNP and_CC disulfiram_NN is_VBZ unknown_JJ ,_, and_CC the_DT concomitant_JJ use_NN of_IN two_CD potentially_RB hepatotoxic_JJ medications_NNS is_VBZ not_RB ordinarily_RB recommended_VBN unless_IN the_DT probable_JJ benefits_NNS outweigh_VBP the_DT known_JJ risks_NNS ._. Lethargy_NN and_CC somnolence_NN have_VBP been_VBN reported_VBN following_VBG doses_NNS of_IN REVIA_NNP and_CC thioridazine_NN ._. Patients_NNS taking_VBG REVIA_NNP may_MD not_RB benefit_VB from_IN opioid_JJ containing_VBG medicines_NNS ,_, such_JJ as_IN cough_NN and_CC cold_JJ preparations_NNS ,_, antidiarrheal_JJ preparations_NNS ,_, and_CC opioid_JJ analgesics_NNS ._. In_IN an_DT emergency_NN situation_NN when_WRB opioid_JJ analgesia_NN must_MD be_VB administered_VBN to_TO a_DT patient_NN receiving_VBG REVIA_NNP ,_, the_DT amount_NN of_IN opioid_NN required_VBN may_MD be_VB greater_JJR than_IN usual_JJ ,_, and_CC the_DT resulting_VBG respiratory_JJ depression_NN may_MD be_VB deeper_JJR and_CC more_RBR prolonged_JJ ._. The_DT use_NN of_IN NSAIDs_NNS in_IN patients_NNS who_WP are_VBP receiving_VBG ACE_NN inhibitors_NNS may_MD potentiate_VB renal_JJ disease_NN states_NNS ._. In_FW vitro_FW studies_NNS have_VBP shown_VBN that_IN naproxen_NN anion_NN ,_, because_IN of_IN its_PRP$ affinity_NN for_IN protein_NN ,_, may_MD displace_VB from_IN their_PRP$ binding_NN sites_NNS other_JJ drugs_NNS which_WDT are_VBP also_RB albumin-bound_JJ ._. Theoretically_RB ,_, the_DT naproxen_NN anion_NN itself_PRP could_MD likewise_RB be_VB displaced_VBN ._. Short-term_JJ controlled_JJ studies_NNS failed_VBD to_TO show_VB that_IN taking_VBG the_DT drug_NN significantly_RB affects_VBZ prothrombin_NN times_NNS when_WRB administered_VBN to_TO individuals_NNS on_IN coumarin-type_JJ anticoagulants_NNS ._. Caution_NN is_VBZ advised_VBN nonetheless_RB ,_, since_IN interactions_NNS have_VBP been_VBN seen_VBN with_IN other_JJ nonsteroidal_JJ agents_NNS of_IN this_DT class_NN ._. Similarly_RB ,_, patients_NNS receiving_VBG the_DT drug_NN and_CC a_DT hydantoin_NN ,_, sulfonamide_NN or_CC sulfonylurea_NN should_MD be_VB observed_VBN for_IN signs_NNS of_IN toxicity_NN to_TO these_DT drugs_NNS ._. Concomitant_JJ administration_NN of_IN naproxen_NN and_CC aspirin_NN is_VBZ not_RB recommended_VBN because_IN naproxen_NN is_VBZ displaced_VBN from_IN its_PRP$ binding_NN sites_NNS during_IN the_DT concomitant_JJ administration_NN of_IN aspirin_NN ,_, resulting_VBG in_IN lower_JJR plasma_NN concentrations_NNS and_CC peak_JJ plasma_NN levels_NNS ._. The_DT natriuretic_JJ effect_NN of_IN furosemide_NN has_VBZ been_VBN reported_VBN to_TO be_VB inhibited_VBN by_IN some_DT drugs_NNS of_IN this_DT class_NN ._. Inhibition_NN of_IN renal_JJ lithium_NN clearance_NN leading_VBG to_TO increases_NNS in_IN plasma_NN lithium_NN concentrations_NNS has_VBZ also_RB been_VBN reported_VBN ._. Naproxen_NN and_CC other_JJ NSAIDs_NNS can_MD reduce_VB the_DT antihypertensive_JJ effect_NN of_IN propranolol_NN and_CC other_JJ beta-blockers_NNS ._. Probenecid_NNP given_VBN concurrently_RB increases_VBZ naproxen_NN anion_NN plasma_NN levels_NNS and_CC extends_VBZ its_PRP$ plasma_NN half-life_NN significantly_RB ._. Caution_NN should_MD be_VB used_VBN if_IN naproxen_NN is_VBZ administered_VBN concomitantly_RB with_IN methotrexate_NN ._. Naproxen_NN ,_, naproxen_NN sodium_NN and_CC other_JJ NSAIDs_NNS have_VBP been_VBN reported_VBN to_TO reduce_VB the_DT tubular_JJ secretion_NN of_IN methotrexate_NN in_IN an_DT animal_NN model_NN ,_, possibly_RB increasing_VBG the_DT toxicity_NN of_IN methotrexate_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS Naproxen_NN may_MD decrease_VB platelet_NN aggregation_NN and_CC prolong_VB bleeding_JJ time_NN ._. This_DT effect_NN should_MD be_VB kept_VBN in_IN mind_NN when_WRB bleeding_VBG times_NNS are_VBP determined_VBN ._. The_DT administration_NN of_IN naproxen_NN may_MD result_VB in_IN increased_VBN urinary_JJ values_NNS for_IN 17-ketogenic_JJ steroids_NNS because_IN of_IN an_DT interaction_NN between_IN the_DT drug_NN and/or_CC its_PRP$ metabolites_NNS with_IN m-dinitrobenzene_NN used_VBN in_IN this_DT assay_NN ._. Although_IN 17-hydroxy-corticosteroid_JJ measurements_NNS -LRB-_-LRB- Porter-Silber_NNP test_NN -RRB-_-RRB- do_VBP not_RB appear_VB to_TO be_VB artifactually_RB altered_VBN ,_, it_PRP is_VBZ suggested_VBN that_IN therapy_NN with_IN naproxen_NN be_VB temporarily_RB discontinued_VBN 72_CD hours_NNS before_IN adrenal_JJ function_NN tests_NNS are_VBP performed_VBN if_IN the_DT Porter-Silber_NNP test_NN is_VBZ to_TO be_VB used_VBN ._. Naproxen_NN may_MD interfere_VB with_IN some_DT urinary_JJ assays_NNS of_IN 5-hydroxy_JJ indoleacetic_JJ acid_NN -LRB-_-LRB- 5HIAA_NN -RRB-_-RRB- ._. Ergot-containing_JJ drugs_NNS have_VBP been_VBN reported_VBN to_TO cause_VB prolonged_JJ vasospastic_JJ reactions_NNS ._. Because_IN there_EX is_VBZ a_DT theoretical_JJ basis_NN that_IN these_DT effects_NNS may_MD be_VB additive_JJ ,_, use_NN of_IN ergotamine-containing_JJ or_CC ergot-type_JJ medications_NNS -LRB-_-LRB- like_IN dihydroergotamine_NN or_CC methysergide_NN -RRB-_-RRB- and_CC naratriptan_NN within_IN 24_CD hours_NNS is_VBZ contraindicated_VBN ._. The_DT administration_NN of_IN naratriptan_NN with_IN other_JJ 5-HT1_NN agonists_NNS has_VBZ not_RB been_VBN evaluated_VBN in_IN migraine_NN patients_NNS ._. Because_IN their_PRP$ vasospastic_JJ effects_NNS may_MD be_VB additive_JJ ,_, coadministration_NN of_IN naratriptan_NN and_CC other_JJ 5-HT1_NN agonists_NNS within_IN 24_CD hours_NNS of_IN each_DT other_JJ is_VBZ not_RB recommended_VBN ._. Selective_JJ serotonin_NN reuptake_NN inhibitors_NNS -LRB-_-LRB- SSRIs_NNS -RRB-_-RRB- -LRB-_-LRB- e.g._FW ,_, fluoxetine_NN ,_, fluvoxamine_NN ,_, paroxetine_NN ,_, sertraline_NN -RRB-_-RRB- have_VBP been_VBN reported_VBN ,_, rarely_RB ,_, to_TO cause_VB weakness_NN ,_, hyperreflexia_NN ,_, and_CC incoordination_NN when_WRB coadministered_VBN with_IN 5-HTv_NN agonists_NNS ._. If_IN concomitant_JJ treatment_NN with_IN naratriptan_NN and_CC an_DT SSRI_NNP is_VBZ clinically_RB warranted_VBN ,_, appropriate_JJ observation_NN of_IN the_DT patient_NN is_VBZ advised_VBN ._. Drug_NN /_: Laboratory_NNP Test_NNP Interactions_NNS AMERGE_NNP Tablets_NNS are_VBP not_RB known_VBN to_TO interfere_VB with_IN commonly_RB employed_VBN clinical_JJ laboratory_NN tests_NNS ._. After_IN multiple_JJ dosing_NN ,_, interferon_NN beta-1a_NN -LRB-_-LRB- AVONEX_NN 30_CD mcg_NN IM_NN once_RB weekly_JJ -RRB-_-RRB- reduced_VBD TYSABRI_NN clearance_NN by_IN approximately_RB 30_CD %_NN ._. The_DT similarity_NN of_IN the_DT TYSABRI_NNP -_: associated_VBN adverse_JJ event_NN profile_NN between_IN Study_NNP 1_CD -LRB-_-LRB- without_IN co-administered_JJ AVONEX_NNP -RRB-_-RRB- and_CC Study_NN 2_CD -LRB-_-LRB- with_IN co-administered_JJ AVONEX_NNP -RRB-_-RRB- indicates_VBZ that_IN this_DT alteration_NN in_IN clearance_NN does_VBZ not_RB necessitate_VB reduction_NN of_IN the_DT TYSABRI_NNP dose_NN to_TO maintain_VB safety_NN ,_, General_NNP -RRB-_-RRB- ._. Results_NNS of_IN studies_NNS in_IN multiple_JJ sclerosis_NN patients_NNS taking_VBG TYSABRI_NNP and_CC concomitant_JJ interferon_NN beta-1a_NN -LRB-_-LRB- AVONEX_NN 30_CD mcg_NN IM_NN once_RB weekly_JJ -RRB-_-RRB- or_CC glatiramer_NN acetate_NN were_VBD inconclusive_JJ with_IN regard_NN to_TO the_DT need_NN for_IN dose_NN adjustment_NN of_IN the_DT beta-interferon_NN or_CC glatiramer_NN acetate_NN ._. In_FW vitro_FW drug_NN metabolism_NN studies_NNS indicate_VBP that_IN Starlix_NNP is_VBZ predominantly_RB metabolized_VBN by_IN the_DT cytochrome_NN P450_NN isozyme_NN CYP2C9_NN -LRB-_-LRB- 70_CD %_NN -RRB-_-RRB- and_CC to_TO a_DT lesser_JJR extent_NN CYP3A4_NN -LRB-_-LRB- 30_CD %_NN -RRB-_-RRB- ._. Starlix_NNP is_VBZ a_DT potential_JJ inhibitor_NN of_IN the_DT CYP2C9_NN isoenzyme_NN in_FW vivo_FW as_IN indicated_VBN by_IN its_PRP$ ability_NN to_TO inhibit_VB the_DT in_FW vitro_FW metabolism_NN of_IN tolbutamide_NN ._. Inhibition_NN of_IN CYP3A4_NN metabolic_JJ reactions_NNS was_VBD not_RB detected_VBN in_IN in_FW vitro_FW experiments_NNS ._. Glyburide_NNP :_: In_IN a_DT randomized_VBN ,_, multiple-dose_JJ crossover_NN study_NN ,_, patients_NNS with_IN Type_NN 2_CD diabetes_NNS were_VBD administered_VBN 120_CD mg_NN Starlix_NN three_CD times_NNS a_DT day_NN before_IN meals_NNS for_IN 1_CD day_NN in_IN combination_NN with_IN glyburide_NN 10_CD mg_NN daily_RB ._. There_EX were_VBD no_DT clinically_RB relevant_JJ alterations_NNS in_IN the_DT pharmacokinetics_NNS of_IN either_CC agent_NN ._. Metformin_NNP :_: When_WRB Starlix_NNP 120_CD mg_NN three_CD times_NNS daily_RB before_IN meals_NNS was_VBD administered_VBN in_IN combination_NN with_IN metformin_NN 500_CD mg_NN three_CD times_NNS daily_JJ to_TO patients_NNS with_IN Type_NN 2_CD diabetes_NN ,_, there_EX were_VBD no_DT clinically_RB relevant_JJ changes_NNS in_IN the_DT pharmacokinetics_NNS of_IN either_CC agent_NN ._. Digoxin_NNP :_: When_WRB Starlix_NNP 120_CD mg_NN before_IN meals_NNS was_VBD administered_VBN in_IN combination_NN with_IN a_DT single_JJ 1-mg_JJ dose_NN of_IN digoxin_NN to_TO healthy_JJ volunteers_NNS ,_, there_EX were_VBD no_DT clinically_RB relevant_JJ changes_NNS in_IN the_DT pharmacokinetics_NNS of_IN either_CC agent_NN ._. Warfarin_NNP :_: When_WRB healthy_JJ subjects_NNS were_VBD administered_VBN Starlix_NNP 120_CD mg_NN three_CD times_NNS daily_RB before_IN meals_NNS for_IN four_CD days_NNS in_IN combination_NN with_IN a_DT single_JJ dose_NN of_IN warfarin_NN 30_CD mg_NN on_IN day_NN 2_CD ,_, there_EX were_VBD no_DT alterations_NNS in_IN the_DT pharmacokinetics_NNS of_IN either_CC agent_NN ._. Prothrombin_NNP time_NN was_VBD not_RB affected_VBN ._. Diclofenac_NNP :_: Administration_NNP of_IN morning_NN and_CC lunch_NN doses_NNS of_IN Starlix_NNP 120_CD mg_NN in_IN combination_NN with_IN a_DT single_JJ 75-mg_JJ dose_NN of_IN diclofenac_NN in_IN healthy_JJ volunteers_NNS resulted_VBD in_IN no_DT significant_JJ changes_NNS to_TO the_DT pharmacokinetics_NNS of_IN either_CC agent_NN ._. Nateglinide_NNP is_VBZ highly_RB bound_VBN to_TO plasma_NN proteins_NNS -LRB-_-LRB- 98_CD %_NN -RRB-_-RRB- ,_, mainly_RB albumin_NN ._. In_FW vitro_FW displacement_NN studies_NNS with_IN highly_RB protein-bound_JJ drugs_NNS such_JJ as_IN furosemide_NN ,_, propranolol_NN ,_, captopril_NN ,_, nicardipine_NN ,_, pravastatin_NN ,_, glyburide_NN ,_, warfarin_NN ,_, phenytoin_NN ,_, acetylsalicylic_JJ acid_NN ,_, tolbutamide_NN ,_, and_CC metformin_NN showed_VBD no_DT influence_NN on_IN the_DT extent_NN of_IN nateglinide_NN protein_NN binding_NN ._. Similarly_RB ,_, nateglinide_NN had_VBD no_DT influence_NN on_IN the_DT serum_NN protein_NN binding_NN of_IN propranolol_NN ,_, glyburide_NN ,_, nicardipine_NN ,_, warfarin_NN ,_, phenytoin_NN ,_, acetylsalicylic_JJ acid_NN ,_, and_CC tolbutamide_NN in_FW vitro_FW ._. However_RB ,_, prudent_JJ evaluation_NN of_IN individual_JJ cases_NNS is_VBZ warranted_VBN in_IN the_DT clinical_JJ setting_NN ._. Certain_JJ drugs_NNS ,_, including_VBG nonsteroidal_JJ anti-inflammatory_JJ agents_NNS -LRB-_-LRB- NSAIDs_NNS -RRB-_-RRB- ,_, salicylates_NNS ,_, monoamine_NN oxidase_NN inhibitors_NNS ,_, and_CC non-selective_JJ beta-adrenergic-blocking_JJ agents_NNS may_MD potentiate_VB the_DT hypoglycemic_JJ action_NN of_IN Starlix_NNP and_CC other_JJ oral_JJ antidiabetic_JJ drugs_NNS ._. Certain_JJ drugs_NNS including_VBG thiazides_NNS ,_, corticosteroids_NNS ,_, thyroid_NN products_NNS ,_, and_CC sympathomimetics_NNS may_MD reduce_VB the_DT hypoglycemic_JJ action_NN of_IN Starlix_NNP and_CC other_JJ oral_JJ antidiabetic_JJ drugs_NNS ._. When_WRB these_DT drugs_NNS are_VBP administered_VBN to_TO or_CC withdrawn_VBN from_IN patients_NNS receiving_VBG Starlix_NNP ,_, the_DT patient_NN should_MD be_VB observed_VBN closely_RB for_IN changes_NNS in_IN glycemic_JJ control_NN ._. In_IN clinical_JJ studies_NNS ,_, Tilade_NNP has_VBZ been_VBN co-administered_VBN with_IN other_JJ anti-asthma_JJ medications_NNS ,_, including_VBG inhaled_VBN and_CC oral_JJ bronchodilators_NNS ,_, and_CC inhaled_VBD corticosteroids_NNS ,_, with_IN no_DT evidence_NN of_IN increased_VBN frequency_NN of_IN adverse_JJ events_NNS or_CC laboratory_NN abnormalities_NNS ._. No_DT formal_JJ drug-drug_JJ interaction_NN studies_NNS ,_, however_RB ,_, have_VBP been_VBN conducted_VBN ._. Nelfinavir_NNP is_VBZ an_DT inhibitor_NN of_IN CYP3A_NN -LRB-_-LRB- cytochrome_NN P450_NN 3A_NN -RRB-_-RRB- ._. Coadministration_NNP of_IN VIRACEPT_NNP and_CC drugs_NNS primarily_RB metabolized_VBN by_IN CYP3A_NN -LRB-_-LRB- e.g._FW ,_, dihydropyridine_NN calcium_NN channel_NN blockers_NNS -RRB-_-RRB- may_MD result_VB in_IN increased_VBN plasma_NN concentrations_NNS of_IN the_DT other_JJ drug_NN that_WDT could_MD increase_VB or_CC prolong_VB both_DT its_PRP$ therapeutic_JJ and_CC adverse_JJ effects_NNS ._. Nelfinavir_NNP is_VBZ metabolized_VBN in_IN proof_NN by_IN C.P.A._NNP Coadministration_NNP of_IN VIRACEPT_NNP and_CC drugs_NNS that_WDT induce_VBP CYP3A_NN may_MD decrease_VB nelfinavir_NN plasma_NN concentrations_NNS and_CC reduce_VB its_PRP$ therapeutic_JJ effect_NN ._. Coadministration_NNP of_IN VIRACEPT_NNP and_CC drugs_NNS that_WDT inhibit_VBP CYP3A_NN may_MD increase_VB nelfinavir_NN plasma_NN concentrations_NNS ._. Based_VBN on_IN known_JJ metabolic_JJ profiles_NNS ,_, clinically_RB significant_JJ drug_NN interactions_NNS are_VBP not_RB expected_VBN between_IN VIRACEPT_NNP and_CC dapsone_NN ,_, trimethoprim/sulfamethoxazole_NN ,_, clarithromycin_NN ,_, erythromycin_NN ,_, itraconazole_NN or_CC fluconazole_NN ._. Drugs_NNS That_WDT Should_MD Not_RB Be_VB Coadministered_JJ With_IN VIRACEPT_NNP Antiarrhythmics_NNPS :_: amiodarone_NN ,_, quinidine_NN Antihistamines_NNS :_: astemizole_NN ,_, terfenadine_NN Antimigraine_NNP :_: ergot_NN derivatives_NNS Antimycobacterial_JJ agents_NNS :_: rifampin_NN Benzodiazepines_NNS midazolam_NN ,_, triazolam_NN GI_NN motility_NN agents_NNS :_: cisaprid_NN ._. Drugs_NNS Which_WDT Require_VBP a_DT Dose_NN Reduction_NN When_WRB Coadminstered_NNP With_IN VIRACEPT_NNP Antimycobacterial_JJ agents_NNS :_: rifabuti_NNS ._. *_SYM This_DT table_NN is_VBZ not_RB all_DT inclusive_JJ **_SYM VIRACEPT_NNP may_MD not_RB be_VB effective_JJ due_JJ to_TO decreased_VBN nelfinavir_NN plasma_NN concentrations_NNS in_IN patients_NNS taking_VBG these_DT agents_NNS concomitantl_NN ._. Antihistamine_NN ._. Terfenadine_NNP :_: Administration_NNP of_IN terfenadine_NN with_IN VIRACEPT_NN resulted_VBD in_IN the_DT appearance_NN of_IN unchanged_JJ terfenadine_NN in_IN plasma_NN ._. therefore_RB ,_, VIRACEPT_NNP should_MD not_RB be_VB administered_VBN concurrently_RB with_IN terfenadine_NN because_IN of_IN the_DT potential_NN for_IN serious_JJ and/or_CC life-threatening_JJ cardiac_JJ arrhythmias_NNS ._. Because_IN a_DT similar_JJ interaction_NN is_VBZ likely_JJ ,_, VIRACEPT_NNP should_MD also_RB not_RB be_VB administered_VBN concurrently_RB with_IN astemizole_NN ._. Anti-HIV_JJ Protease_NN Inhibitor_NN ._. Indinavir_NNP :_: Coadministration_NNP of_IN indinavir_NN with_IN VIRACEPT_NN resulted_VBD in_IN an_DT 83_CD %_NN increase_NN in_IN nelfinavir_NN plasma_NN AUC_NN and_CC a_DT 51_CD %_NN increase_NN in_IN indinavir_NN plasma_NN A.C._NNP Currently_NNP ,_, there_EX are_VBP no_DT safety_NN and_CC efficacy_NN data_NNS available_JJ from_IN the_DT use_NN of_IN this_DT combination_NN ._. Ritonavir_NNP :_: Coadministration_NNP of_IN ritonavir_NN with_IN VIRACEPT_NN resulted_VBD in_IN a_DT 152_CD %_NN increase_NN in_IN nelfinavir_NN plasma_NN AUC_NN and_CC very_RB little_JJ change_NN in_IN ritonavir_NN plasma_NN A.C._NNP Currently_NNP ,_, there_EX are_VBP no_DT safety_NN and_CC efficacy_NN data_NNS available_JJ from_IN the_DT use_NN of_IN this_DT combination_NN ._. Saquinavir_NNP :_: Coadministration_NNP of_IN saquinavir_NN -LRB-_-LRB- using_VBG an_DT experimental_JJ soft-gelatin_JJ capsule_NN formulation_NN of_IN saquinavir_NN 1200mg_NN -RRB-_-RRB- with_IN VIRACEPT_NN resulted_VBD in_IN an_DT 18_CD %_NN increase_NN in_IN nelfinavir_NN plasma_NN AUC_NN and_CC a_DT 4-fold_JJ increase_NN in_IN saquinavir_NN plasma_NN A.C._NNP ._. If_IN used_VBN in_IN combination_NN with_IN saquinavir_NN hard_JJ gelatin_NN capsules_NNS at_IN the_DT recommended_VBN dose_NN of_IN 600_CD mg_NN tid_NN ,_, no_DT dose_NN adjustments_NNS are_VBP needed_VBN ._. Currently_RB ,_, there_EX are_VBP no_DT safety_NN and_CC efficacy_NN data_NNS available_JJ from_IN the_DT use_NN of_IN this_DT combination_NN ._. Antifungal_JJ Agent_NNP ._. Ketoconazole_NN :_: Coadministration_NN of_IN ketoconazole_NN with_IN VIRACEPT_NN resulted_VBD in_IN a_DT 35_CD %_NN increase_NN in_IN nelfinavir_NN plasma_NN A.C._NNP ._. This_DT change_NN was_VBD not_RB considered_VBN clinically_RB significant_JJ and_CC no_DT dose_NN adjustment_NN is_VBZ needed_VBN when_WRB ketoconazole_NN and_CC VIRACEPT_NN are_VBP coadministered_VBN ._. Anti-HIV_JJ Reverse_NN Transcriptase_NNP Inhibitor_NNP ._. Didanosine_NNP :_: It_PRP is_VBZ recommended_VBN that_IN didanosine_NN be_VB administered_VBN on_IN an_DT empty_JJ stomach_NN ._. therefore_RB ,_, nelfinavir_NN should_MD be_VB administered_VBN -LRB-_-LRB- with_IN food_NN -RRB-_-RRB- one_CD hour_NN after_IN or_CC more_JJR than_IN two_CD hours_NNS before_IN didanosine_NN ._. A_DT dose_NN adjustment_NN is_VBZ not_RB needed_VBN when_WRB zidovudine_NN is_VBZ administered_VBN with_IN VIRACEPT_NN ._. Little_JJ or_CC no_DT change_NN in_IN the_DT pharmacokinetics_NNS of_IN either_CC drug_NN was_VBD observed_VBN when_WRB VIRACEPT_NNP was_VBD coadministered_VBN with_IN lamivudine_NN or_CC stavudine_NN ._. Antimycobacterial_JJ Agent_NNP ._. Rifabutin_NNP :_: Coadministration_NNP of_IN rifabutin_NN and_CC VIRACEPT_NN resulted_VBD in_IN a_DT 32_CD %_NN decrease_NN in_IN nelfinavir_NN plasma_NN AUC_NN and_CC a_DT 207_CD %_NN increase_NN in_IN rifabutin_NN plasma_NN A.C._NNP ._. It_PRP is_VBZ recommended_VBN that_IN the_DT dose_NN of_IN rifabutin_NN be_VB reduced_VBN to_TO one-half_NN the_DT usual_JJ dose_NN when_WRB administered_VBN with_IN VIRACEPT_NN ._. Rifampin_NNP :_: Coadministration_NNP of_IN rifampin_NN and_CC VIRACEPT_NN resulted_VBD in_IN an_DT 82_CD %_NN decrease_NN in_IN nelfinavir_NN plasma_NN A.C._NNP VIRACEPT_NNP and_CC rifampin_NN should_MD not_RB be_VB coadministered_VBN ._. Oral_JJ Contraceptive_NN ._. Ethinyl_NNP Estradiol_NNP and_CC Norethindrone_NNP :_: Coadministration_NNP of_IN VIRACEPT_NNP with_IN OVCON-35_NN resulted_VBD in_IN a_DT 47_CD %_NN decrease_NN in_IN ethinyl_NN estradiol_NN and_CC an_DT 18_CD %_NN decrease_NN in_IN norethindrone_NN plasma_NN concentrations_NNS ._. Alternate_JJ or_CC additional_JJ contraceptive_JJ measures_NNS should_MD be_VB used_VBN during_IN therapy_NN with_IN VIRACEP_NN ._. Caution_NN should_MD be_VB taken_VBN in_IN concurrent_JJ or_CC serial_JJ use_NN of_IN other_JJ neurotoxic_JJ and_CC /_: or_CC nephrotoxic_JJ drugs_NNS because_IN of_IN possible_JJ enhancement_NN of_IN the_DT nephrotoxicity_NN and/or_CC ototoxicity_NN of_IN neomycin_NN ._. Caution_NN should_MD also_RB be_VB taken_VBN in_IN concurrent_JJ or_CC serial_JJ use_NN of_IN other_JJ aminoglycosides_NNS and_CC polymyxins_NNS because_IN they_PRP may_MD enhance_VB neomycin_NN s_NNS nephrotoxicity_NN and/or_CC ototoxicity_NN and_CC potentiate_VB neomycin_NN sulfate_NN neuromuscular_JJ blocking_NN effects_NNS ._. Oral_JJ neomycin_NN inhibits_VBZ the_DT gastrointestinal_JJ absorption_NN of_IN penicillin_NN V_NN ,_, oral_JJ vitamin_NN B-12_NN ,_, methotrexate_NN and_CC 5-fluorouracil_NN ._. The_DT gastrointestinal_JJ absorption_NN of_IN digoxin_NN also_RB appears_VBZ to_TO be_VB inhibited_VBN ._. Therefore_RB ,_, digoxin_NN serum_NN levels_NNS should_MD be_VB monitored_VBN ._. Oral_JJ neomycin_NN sulfate_NN may_MD enhance_VB the_DT effect_NN of_IN coumarin_NN in_IN anticoagulants_NNS by_IN decreasing_VBG vitamin_NN K_NN availability_NN ._. Certain_JJ antibiotics_NNS ,_, especially_RB neomycin_NN ,_, streptomycin_NN and_CC kanamycin_NN ,_, have_VBP a_DT mild_JJ but_CC definite_JJ nondepolarizing_JJ blocking_VBG action_NN which_WDT may_MD accentuate_VB neuromuscular_JJ block_NN ._. These_DT antibiotics_NNS should_MD be_VB used_VBN in_IN the_DT myasthenic_JJ patient_NN only_RB where_WRB definitely_RB indicated_VBN ,_, and_CC then_RB careful_JJ adjustment_NN should_MD be_VB made_VBN of_IN adjunctive_JJ anticholinesterase_JJ dosage_NN ._. Local_JJ and_CC some_DT general_JJ anesthetics_NNS ,_, antiarrhythmic_JJ agents_NNS and_CC other_JJ drugs_NNS that_WDT interfere_VBP with_IN neuromuscular_JJ transmission_NN should_MD be_VB used_VBN cautiously_RB ,_, if_IN at_IN all_DT ,_, in_IN patients_NNS with_IN myasthenia_NN gravis_NN ._. the_DT dose_NN of_IN Prostigmin_NNP may_MD have_VB to_TO be_VB increased_VBN accordingly_RB ._. No_DT trials_NNS specifically_RB examining_VBG potential_JJ drug_NN interactions_NNS with_IN Natrecor_NN were_VBD conducted_VBN ,_, although_IN many_JJ concomitant_JJ drugs_NNS were_VBD used_VBN in_IN clinical_JJ trials_NNS ._. No_DT drug_NN interactions_NNS were_VBD detected_VBN except_IN for_IN an_DT increase_NN in_IN symptomatic_JJ hypotension_NN in_IN patients_NNS receiving_VBG oral_JJ ACE_NN inhibitors_NNS ._. The_DT co-administration_NN of_IN Natrecor_NN with_IN IV_CD vasodilators_NNS such_JJ as_IN nitroglycerin_NN ,_, nitroprusside_NN ,_, milrinone_NN ,_, or_CC IV_CD ACE_NN inhibitors_NNS has_VBZ not_RB been_VBN evaluated_VBN -LRB-_-LRB- these_DT drugs_NNS were_VBD not_RB co-administered_VBN with_IN Natrecor_NNP in_IN clinical_JJ trials_NNS -RRB-_-RRB- ._. Netilmicin_NN should_MD not_RB be_VB administered_VBN concomitantly_RB with_IN potent_JJ loop_NN diuretics_NNS such_JJ as_IN furosemide_NN and_CC ethacrynic_JJ acid_NN as_IN the_DT potential_NN for_IN ototoxicity_NN is_VBZ enhanced_VBN by_IN the_DT combination_NN ._. Nevirapine_NNP is_VBZ principally_RB metabolized_VBN by_IN the_DT liver_NN via_IN the_DT cytochrome_NN P450_NN isoenzymes_NNS ,_, 3A4_NN and_CC 2B6_NN ._. Nevirapine_NNP is_VBZ known_VBN to_TO be_VB an_DT inducer_NN of_IN these_DT enzymes_NNS ._. As_IN a_DT result_NN ,_, drugs_NNS that_WDT are_VBP metabolized_VBN by_IN these_DT enzyme_NN systems_NNS may_MD have_VB lower_JJR than_IN expected_VBN plasma_NN levels_NNS when_WRB coadministered_VBN with_IN nevirapine_NN ._. The_DT specific_JJ pharmacokinetic_JJ changes_NNS that_WDT occur_VBP with_IN co-administration_NN of_IN nevirapine_NN and_CC other_JJ drugs_NNS are_VBP listed_VBN in_IN CLINICAL_NNP PHARMACOLOGY_NNP ,_, Table_NNP 1_CD ._. Clinical_JJ comments_NNS about_IN possible_JJ dosage_NN modifications_NNS based_VBN on_IN these_DT pharmacokinetic_JJ changes_NNS are_VBP listed_VBN in_IN Table_NNP 3_CD ._. The_DT data_NNS inTables_NNS 1_CD and_CC 3_CD are_VBP based_VBN on_IN the_DT results_NNS of_IN drug_NN interaction_NN studies_NNS conducted_VBN in_IN HIV-1_NN seropositive_JJ subjects_NNS unless_IN otherwise_RB indicated_VBN ._. In_IN addition_NN to_TO established_VBN drug_NN interactions_NNS ,_, there_EX may_MD be_VB potential_JJ pharmacokinetic_JJ interactions_NNS between_IN nevirapine_NN and_CC other_JJ drug_NN classes_NNS that_WDT are_VBP metabolized_VBN by_IN the_DT cytochrome_NN P450_NN system_NN ._. These_DT potential_JJ drug_NN interactions_NNS are_VBP listed_VBN in_IN Table_NNP 4_CD ._. Although_IN specific_JJ drug_NN interaction_NN studies_NNS in_IN HIV-1_NN seropositive_JJ subjects_NNS have_VBP not_RB been_VBN conducted_VBN for_IN the_DT classes_NNS of_IN drugs_NNS listed_VBN in_IN Table_NNP 4_CD ,_, additional_JJ clinical_JJ monitoring_NN may_MD be_VB warranted_VBN when_WRB co-administering_VBG these_DT drugs_NNS ._. The_DT in_FW vitro_FW interaction_NN between_IN nevirapine_NN and_CC the_DT antithrombotic_JJ agent_NN warfarin_NN is_VBZ complex_NN ._. As_IN a_DT result_NN ,_, when_WRB giving_VBG these_DT drugs_NNS concomitantly_RB ,_, plasma_NN warfarin_NN levels_NNS may_MD change_VB with_IN the_DT potential_NN for_IN increases_NNS in_IN coagulation_NN time_NN ._. When_WRB warfarin_NN is_VBZ co-administered_VBN with_IN nevirapine_NN ,_, anticoagulation_NN levels_NNS should_MD be_VB monitored_VBN frequently_RB ._. Table_NNP 3_CD Established_NNP Drug_NNP Interactions_NNS :_: Alteration_NN in_IN Dose_NN or_CC Regimen_NNP May_NNP Be_VB Recommended_VBN Based_VBN on_IN Drug_NN Interaction_NN Studies_NNS ._. Drug_NN Name_VB ._. Effect_NN on_IN Concentration_NN of_IN Nevirapine_NNP or_CC Concomitant_JJ Dru_NN ._. Clinical_JJ Comment_NN ._. Clarithromyci_NNP ._. Clarithromycin_NNP 14OH_NN -_: clarithromyci_NNS ._. Clarithromycin_NNP exposure_NN was_VBD significantly_RB decreased_VBN by_IN nevirapine_NN ._. however_RB ,_, 14-OH_NN metabolite_NN concentrations_NNS were_VBD increased.Because_JJ clarithromycin_NN active_JJ metabolite_NN has_VBZ reduced_VBN activity_NN against_IN Mycobacteriumavium-intracellulare_JJ complex_NN ,_, overallactivity_NN against_IN this_DT pathogen_NN may_MD bealtered_VB ._. Alternatives_NNP to_TO clarithromycin_NN ,_, such_JJ as_IN azithromycin_NN ,_, should_MD be_VB considered_VBN ._. Efaviren_NNP ._. Efaviren_NNP ._. Appropriate_JJ doses_NNS for_IN this_DT combination_NN are_VBP not_RB established_VBN ._. Ethinyl_NN estradiol_NN and_CC Norethindron_NN ._. Ethinyl_NN estradiol_NN Norethindron_NNP ._. Oral_JJ contraceptives_NNS and_CC other_JJ hormonalmethods_NNS of_IN birth_NN control_NN should_MD not_RB be_VB usedas_JJ the_DT sole_JJ method_NN of_IN contraception_NN inwomen_NN taking_VBG nevirapine_NN ,_, since_IN nevirapinemay_NN lower_JJR the_DT plasma_NN levels_NNS of_IN thesemedications_NNS ._. An_DT alternative_JJ or_CC additional_JJ method_NN of_IN contraception_NN is_VBZ recommended_VBN ._. Fluconazol_NNP ._. Nevirapin_NNP ._. Because_IN of_IN the_DT risk_NN of_IN increased_VBN exposure_NN tonevirapine_NN ,_, caution_NN should_MD be_VB used_VBN inconcomitant_JJ administration_NN ,_, and_CC patients_NNS should_MD be_VB monitored_VBN closely_RB for_IN nevirapine-associated_JJ adverse_JJ events_NNS ._. Indinavi_NNP ._. Indinavi_NNP ._. Appropriate_JJ doses_NNS for_IN this_DT combination_NN arenot_NN established_VBN ,_, but_CC an_DT increase_NN in_IN thedosage_NN of_IN indinavir_NN may_MD be_VB required_VBN ._. Ketoconazol_NNP ._. Ketoconazol_NNP ._. Nevirapine_NNP and_CC ketoconazole_NN should_MD not_RB beadministered_VBN concomitantly_RB becausedecreases_NNS in_IN ketoconazole_NN plasmaconcentrations_NNS may_MD reduce_VB the_DT efficacy_NN of_IN the_DT drug_NN ._. Lopinavir/Ritonavi_NNP ._. Lopinavi_NNP ._. A_DT dose_NN increase_NN of_IN lopinavir/ritonavir_NN to_TO 533/133_CD mg_NN twice_RB daily_RB with_IN food_NN isrecommended_VBN in_IN combination_NN with_IN nevirapine_NN ._. Methadon_NNP ._. Methadonea_NNP ._. Methadone_NN levels_NNS may_MD be_VB decreased_VBN ;_: increased_VBN dosages_NNS may_MD be_VB required_VBN to_TO prevent_VB symptoms_NNS of_IN opiate_JJ withdrawal_NN ._. Methadone_NNP maintained_VBD patients_NNS beginning_VBG nevirapine_NN therapy_NN should_MD be_VB monitored_VBN forevidence_NN of_IN withdrawal_NN and_CC methadone_NN dose_NN should_MD be_VB adjusted_VBN accordingly_RB ._. Nelfinavi_NNP ._. Nelfinavir_NNP M_NN ._. The_DT appropriate_JJ dose_NN for_IN nelfinavir_NN incombination_NN with_IN nevirapine_NN ,_, with_IN respectto_NN safety_NN and_CC efficacy_NN ,_, has_VBZ not_RB been_VBN established_VBN ._. Rifabuti_NNP ._. Rifabuti_NNP ._. Rifabutin_NN and_CC its_PRP$ metabolite_NN concentrationswere_NN moderately_RB increased_VBD ._. Due_JJ to_TO highintersubject_JJ variability_NN ,_, however_RB ,_, somepatients_NNS may_MD experience_VB large_JJ increases_NNS inrifabutin_NN exposure_NN and_CC may_MD be_VB at_IN higher_JJR riskfor_NN rifabutin_NN toxicity_NN ._. Therefore_RB ,_, caution_NN should_MD be_VB used_VBN in_IN concomitant_JJ administration_NN ._. Rifampi_NNP ._. Nevirapin_NNP ._. Nevirapine_NNP and_CC rifampin_NN should_MD not_RB beadministered_VBN concomitantly_RB becausedecreases_NNS in_IN nevirapine_NN plasmaconcentrations_NNS may_MD reduce_VB the_DT efficacy_NN ofthe_NN drug_NN ._. Physicians_NNP needing_VBG to_TO treatpatients_NNS co-infected_VBN with_IN tuberculosis_NN andusing_NN a_DT nevirapine_NN containing_VBG regimen_NN mayuse_NN rifabutin_NN instead_RB ._. Saquinavi_NNP ._. Saquinavi_NNP ._. Appropriate_JJ doses_NNS for_IN this_DT combination_NN arenot_NN established_VBN ,_, but_CC an_DT increase_NN in_IN thedosage_NN of_IN saquinavir_NN may_MD be_VB required_VBN ._. aBased_VBN on_IN reports_NNS of_IN narcotic_JJ withdrawal_NN syndrome_NN in_IN patients_NNS treated_VBN with_IN nevirapine_NN and_CC methadone_NN concurrently_RB ,_, and_CC evidence_NN of_IN decreased_VBN plasma_NN concentrations_NNS of_IN methadone_NN ._. Table_NNP 4_CD Potential_JJ Drug_NN Interactions_NNS :_: Use_NNP With_IN Caution_NN ,_, Dose_NNP Adjustment_NNP of_IN Co-administered_NNP Drug_NNP May_NNP Be_VB Needed_VBN due_JJ to_TO Possible_JJ Decrease_NN in_IN Clinical_JJ Effect_NN ._. Examples_NNS of_IN Drugs_NNS in_IN Which_WDT Plasma_NN Concentrations_NNS May_MD Be_VB Decreased_VBN By_IN Co-administration_NN With_IN Nevirapin_NN ._. Drug_NNP Class_NNP Examples_NNS of_IN Drugs_NNS ._. Antiarrhythmic_JJ ._. Amiodarone_NNP ,_, disopyramide_NN ,_, lidocain_NN ._. Anticonvulsant_NN ._. Carbamazepine_NNP ,_, clonazepam_NN ,_, ethosuximid_NN ._. Antifungal_JJ ._. Itraconazol_NNP ._. Calcium_NN channel_NN blocker_NN ._. Diltiazem_NNP ,_, nifedipine_NN ,_, verapami_NN ._. Cancer_NN chemotherapy_NN ._. Cyclophosphamid_NN ._. Ergot_NNP alkaloid_NN ._. Ergotamin_NNP ._. Immunosuppressant_JJ ._. Cyclosporin_NN ,_, tacrolimus_NN ,_, sirolimu_NN ._. Motility_NN agents_NNS ._. Cisaprid_NNP ._. Opiate_JJ agonist_NN ._. Fentany_NNP ._. Examples_NNS of_IN Drugs_NNS in_IN Which_WDT Plasma_NN Concentrations_NNS May_MD Be_VB Increased_VBN By_IN Co-administration_NN With_IN Nevirapin_NN ._. Antithrombotic_JJ ._. Warfari_NNP ._. Potential_JJ effect_NN on_IN anticoagulation_NN ._. Monitoring_NN of_IN anticoagulation_NN levels_NNS is_VBZ recommended_VBN ._. Fat_NNP redistribution_NN :_: Redistribution/accumulation_NN of_IN body_NN fat_JJ including_VBG central_JJ obesity_NN ,_, dorsocervical_JJ fat_JJ enlargement_NN -LRB-_-LRB- buffalo_NN hump_NN -RRB-_-RRB- ,_, peripheral_JJ wasting_NN ,_, facial_JJ wasting_NN ,_, breast_NN enlargement_NN ,_, and_CC cushingoid_JJ appearance_NN have_VBP been_VBN observed_VBN in_IN patients_NNS receiving_VBG antiretroviral_JJ therapy_NN ._. The_DT mechanism_NN and_CC long-term_JJ consequences_NNS of_IN these_DT events_NNS are_VBP currently_RB unknown_JJ ._. A_DT causal_JJ relationship_NN has_VBZ not_RB been_VBN established_VBN ._. Interactions_NNS for_IN Vitamin_NN B3_NN -LRB-_-LRB- Niacin_NN -RRB-_-RRB- :_: Antihypertensive_JJ Therapy_NN :_: Nicotinic_JJ acid_NN may_MD potentiate_VB the_DT effects_NNS of_IN ganglionic_JJ blocking_VBG agents_NNS and_CC vasoactive_JJ drugs_NNS resulting_VBG in_IN postural_JJ hypotension_NN ._. Aspirin_NN :_: Concomitant_JJ aspirin_NN may_MD decrease_VB the_DT metabolic_JJ clearance_NN of_IN nicotinic_JJ acid_NN ._. The_DT clinical_JJ relevance_NN of_IN this_DT finding_NN is_VBZ unclear_JJ ._. Other_JJ :_: Concomitant_JJ alcohol_NN or_CC hot_JJ drinks_NNS may_MD increase_VB the_DT side_JJ effects_NNS of_IN flushing_NN and_CC pruritus_NN and_CC should_MD be_VB avoided_VBN at_IN the_DT time_NN of_IN drug_NN ingestion_NN ._. Beta-Blockers_NNPS :_: In_IN controlled_JJ clinical_JJ studies_NNS ,_, adrenergic_JJ beta-receptor_NN blockers_NNS have_VBP been_VBN frequently_RB administered_VBN concomitantly_RB with_IN nicardipine_JJ HCl_NN ._. The_DT combination_NN is_VBZ well_RB tolerated_VBN ._. Cimetidine_NNP :_: Cimetidine_NNP increases_VBZ nicardipine_JJ HCl_NN plasma_NN levels_NNS ._. Patients_NNS receiving_VBG the_DT two_CD drugs_NNS concomitantly_RB should_MD be_VB carefully_RB monitored_VBN ._. Digoxin_NNP :_: Some_DT calcium_NN blockers_NNS may_MD increase_VB the_DT concentration_NN of_IN digitalis_NN preparations_NNS in_IN the_DT blood_NN ._. Nicardipine_NNP HCl_NN usually_RB does_VBZ not_RB alter_VB the_DT plasma_NN levels_NNS of_IN digoxin_NN ,_, however_RB ,_, serum_NN digoxin_NN levels_NNS should_MD be_VB evaluated_VBN after_IN concomitant_JJ therapy_NN with_IN nicardipine_JJ HCl_NN is_VBZ initiated_VBN ._. Maalox_NNP *_SYM Coadministration_NNP of_IN Maalox_NNP TC_NNP had_VBD no_DT effect_NN on_IN nicardipine_JJ HCl_NN absorption_NN ._. Even_RB though_IN such_JJ interactions_NNS were_VBD not_RB seen_VBN during_IN clinical_JJ studies_NNS with_IN nicardipine_JJ HCl_NN ,_, an_DT increased_VBN volume_NN of_IN circulating_VBG fluids_NNS might_MD be_VB required_VBN if_IN such_PDT an_DT interaction_NN were_VBD to_TO occur_VB ._. Cyclosporine_NN :_: Concomitant_JJ administration_NN of_IN nicardipine_NN and_CC cyclosporine_NN levels_NNS ._. Plasma_NN concentrations_NNS of_IN cyclosporine_NN should_MD therefore_RB be_VB closely_RB monitored_VBN ,_, and_CC its_PRP$ dosage_NN reduced_VBD accordingly_RB ,_, in_IN patients_NNS treated_VBN with_IN nicardipine_NN ._. When_WRB therapeutic_JJ concentrations_NNS of_IN furosemide_NN ,_, propranolol_NN ,_, dipyridamole_NN ,_, warfarin_NN ,_, quinidine_NN ,_, or_CC naproxen_NN were_VBD added_VBN to_TO human_JJ plasma_NN -LRB-_-LRB- in_FW vitro_FW -RRB-_-RRB- ,_, the_DT plasma_NN protein_NN binding_NN of_IN nicardipine_JJ HCl_NN was_VBD not_RB altered_VBN ._. Physiological_JJ changes_NNS resulting_VBG from_IN smoking_NN cessation_NN ,_, with_IN or_CC without_IN nicotine_NN replacement_NN ,_, may_MD alter_VB the_DT pharmacokinetics_NNS of_IN certain_JJ concomitant_JJ medications_NNS ,_, such_JJ as_IN tricyclic_JJ antidepressants_NNS and_CC theophylline_NN ._. Doses_NNS of_IN these_DT and_CC perhaps_RB other_JJ medications_NNS may_MD need_VB to_TO be_VB adjusted_VBN in_IN patients_NNS who_WP successfully_RB quit_VBD smoking_NN ._. Beta-adrenergic_JJ Blocking_NN Agents_NNS :_: Experience_NN in_IN over_IN 1400_CD patients_NNS in_IN a_DT non-comparative_JJ clinical_JJ trial_NN has_VBZ shown_VBN that_IN concomitant_JJ administration_NN of_IN nifedipine_NN and_CC beta-blocking_NN agents_NNS is_VBZ usually_RB well_RB tolerated_VBD ,_, but_CC there_EX have_VBP been_VBN occasional_JJ literature_NN reports_NNS suggesting_VBG that_IN the_DT combination_NN may_MD increase_VB the_DT likelihood_NN of_IN congestive_JJ heart_NN failure_NN ,_, severe_JJ hypotension_NN or_CC exacerbation_NN of_IN angina_NN ._. Long_NNP Acting_NNP Nitrates_NNPS :_: Nifedipine_NN may_MD be_VB safely_RB co-administered_VBN with_IN nitrates_NNS ,_, but_CC there_EX have_VBP been_VBN no_DT controlled_JJ studies_NNS to_TO evaluate_VB the_DT antianginal_JJ effectiveness_NN of_IN this_DT combination_NN ._. Digitalis_NNP :_: Immediate_NNP Release_NNP Capsules_NNPS :_: Since_IN there_EX have_VBP been_VBN isolated_VBN reports_NNS of_IN patients_NNS with_IN elevated_JJ digoxin_NN levels_NNS ,_, and_CC there_EX is_VBZ a_DT possible_JJ interaction_NN between_IN digoxin_NN and_CC nifedipine_NN ,_, it_PRP is_VBZ recommended_VBN that_IN digoxin_NN levels_NNS be_VB monitored_VBN when_WRB initiating_VBG ,_, adjusting_VBG ,_, and_CC discontinuing_VBG nifedipine_NN to_TO avoid_VB possible_JJ over_IN -_: or_CC under-digitalization_NN ._. Extended_NNP Release_NNP Tablets_NNPS :_: Administration_NN of_IN nifedipine_NN with_IN digoxin_NN increased_VBD digoxin_NN levels_NNS in_IN 9_CD of_IN 12_CD normal_JJ volunteers_NNS ._. The_DT average_JJ increase_NN was_VBD 45_CD %_NN ._. Another_DT investigator_NN found_VBD no_DT increase_NN in_IN digoxin_NN levels_NNS in_IN 13_CD patients_NNS with_IN coronary_JJ artery_NN disease_NN ._. In_IN an_DT uncontrolled_JJ study_NN of_IN over_IN 200_CD patients_NNS with_IN congestive_JJ heart_NN failure_NN during_IN which_WDT digoxin_NN blood_NN levels_NNS were_VBD not_RB measured_VBN ,_, digitalis_NN toxicity_NN was_VBD not_RB observed_VBN ._. Since_IN there_EX have_VBP been_VBN isolated_VBN reports_NNS of_IN patients_NNS with_IN elevated_JJ digoxin_NN levels_NNS ,_, it_PRP is_VBZ recommended_VBN that_IN digoxin_NN levels_NNS be_VB monitored_VBN when_WRB initiating_VBG ,_, adjusting_VBG ,_, and_CC discontinuing_VBG nifedipine_NN to_TO avoid_VB possible_JJ over_IN -_: or_CC under-digitalization_NN ._. Quinidine_NNP :_: Immediate_NNP Release_NNP Capsules_NNPS :_: There_EX have_VBP been_VBN rare_JJ reports_NNS of_IN an_DT interaction_NN between_IN quinidine_NN and_CC nifedipine_NN -LRB-_-LRB- with_IN a_DT decreased_VBN plasma_NN level_NN of_IN quinidine_NN -RRB-_-RRB- ._. Coumarin_NNP Anticoagulants_NNPS :_: There_EX have_VBP been_VBN rare_JJ reports_NNS of_IN increased_VBN prothrombin_NN time_NN in_IN patients_NNS taking_VBG coumarin_NN anticoagulants_NNS to_TO whom_WP nifedipine_NN was_VBD administered_VBN ._. However_RB ,_, the_DT relationship_NN to_TO nifedipine_NN therapy_NN is_VBZ uncertain_JJ ._. Cimetidine_NNP :_: A_NNP study_NN in_IN 6_CD healthy_JJ volunteers_NNS has_VBZ shown_VBN a_DT significant_JJ increase_NN in_IN peak_JJ nifedipine_NN plasma_NN levels_NNS -LRB-_-LRB- 80_CD %_NN -RRB-_-RRB- and_CC area-under-the-curve_NN -LRB-_-LRB- 74_CD %_NN -RRB-_-RRB- after_IN a_DT 1_CD week_NN course_NN of_IN cimetidine_NN at_IN 1000_CD mg_NN per_IN day_NN and_CC nifedipine_NN at_IN 40_CD mg_NN per_IN day_NN ._. Ranitidine_NN produced_VBD smaller_JJR ,_, non-significant_JJ increases_NNS ._. The_DT effect_NN may_MD be_VB mediated_VBN by_IN the_DT known_JJ inhibition_NN of_IN cimetidine_NN on_IN hepatic_JJ cytochrome_NN P-450_NN ,_, the_DT enzyme_NN system_NN probably_RB responsible_JJ for_IN the_DT first-pass_JJ metabolism_NN of_IN nifedipine_NN ._. If_IN nifedipine_NN therapy_NN is_VBZ initiated_VBN in_IN a_DT patient_NN currently_RB receiving_VBG cimetidine_NN ,_, cautious_JJ titration_NN is_VBZ advised_VBN ._. In_FW vitro_FW ,_, nilutamide_NN has_VBZ been_VBN shown_VBN to_TO inhibit_VB the_DT activity_NN of_IN liver_NN cytochrome_NN P-450_NN isoenzymes_NNS and_CC therefore_RB ,_, may_MD reduce_VB the_DT metabolism_NN of_IN compounds_NNS requiring_VBG these_DT systems_NNS ._. Consequently_RB ,_, drugs_NNS with_IN a_DT low_JJ therapeutic_JJ margin_NN ,_, such_JJ as_IN vitamin_NN K_NN antagonists_NNS ,_, phenytoin_NN ,_, and_CC theophylline_NN ,_, could_MD have_VB a_DT delayed_VBN elimination_NN and_CC increases_VBZ in_IN their_PRP$ serum_NN half-life_NN leading_VBG to_TO a_DT toxic_JJ level_NN ._. The_DT dosage_NN of_IN these_DT drugs_NNS or_CC others_NNS with_IN a_DT similar_JJ metabolism_NN may_MD need_VB to_TO be_VB modified_VBN if_IN they_PRP are_VBP administered_VBN concomitantly_RB with_IN nilutamide_NN ._. For_IN example_NN ,_, when_WRB vitamin_NN K_NN antagonists_NNS are_VBP administered_VBN concomitantly_RB with_IN nilutamide_NN ,_, prothrombin_NN time_NN should_MD be_VB carefully_RB monitored_VBN and_CC if_IN necessary_JJ ,_, the_DT dosage_NN of_IN vitamin_NN K_NN antagonists_NNS should_MD be_VB reduced_VBN ._. It_PRP is_VBZ possible_JJ that_IN the_DT cardiovascular_JJ action_NN of_IN other_JJ calcium_NN channel_NN blockers_NNS could_MD be_VB enhanced_VBN by_IN the_DT addition_NN of_IN Nimotop_NNP ._. In_IN Europe_NNP ,_, Nimotop_NNP was_VBD observed_VBN to_TO occasionally_RB intensify_VB the_DT effect_NN of_IN antihypertensive_JJ compounds_NNS taken_VBN concomitantly_RB by_IN patients_NNS suffering_VBG from_IN hypertension_NN ._. this_DT phenomenon_NN was_VBD not_RB observed_VBN in_IN North_JJ American_JJ clinical_JJ trials_NNS ._. A_DT study_NN in_IN eight_CD healthy_JJ volunteers_NNS has_VBZ shown_VBN a_DT 50_CD %_NN increase_NN in_IN mean_JJ peak_JJ nimodipine_NN plasma_NN concentrations_NNS and_CC a_DT 90_CD %_NN increase_NN in_IN mean_JJ area_NN under_IN the_DT curve_NN ,_, after_IN a_DT one_CD week_NN course_NN of_IN cimetidine_NN at_IN 1,000_CD mg/day_NN and_CC nimodipine_NN at_IN 90_CD mg/day_NN ._. This_DT effect_NN may_MD be_VB mediated_VBN by_IN the_DT known_JJ inhibition_NN of_IN hepatic_JJ cytochrome_NN P_NN -_: 450_CD by_IN cimetidine_NN ,_, which_WDT could_MD decrease_VB first_JJ pass_NN metabolism_NN of_IN nimodipine_NN ._. A_DT 30_CD to_TO 45_CD %_NN increase_NN in_IN AUC_NN and_CC Cmax_NN of_IN nisoldipine_NN was_VBD observed_VBN with_IN concomitant_JJ administration_NN of_IN cimetidine_NN 400_CD mg_NN twice_RB daily_RB ._. Ranitidine_NN 150_CD mg_NN twice_RB daily_RB did_VBD not_RB interact_VB significantly_RB with_IN nisoldipine_NN -LRB-_-LRB- AUC_NN was_VBD decreased_VBN by_IN 15-20_CD %_NN -RRB-_-RRB- ._. No_DT pharmacodynamic_JJ effects_NNS of_IN either_CC histamine_NN H2_NN receptor_NN antagonist_NN were_VBD observed_VBN ._. Coadministration_NN of_IN phenytoin_NN with_IN 40_CD mg_NN SULAR_NN tablets_NNS in_IN epileptic_JJ patients_NNS lowered_VBD the_DT nisoldipine_NN plasma_NN concentrations_NNS to_TO undetectable_JJ levels_NNS ._. Coadministration_NN of_IN SULAR_NN with_IN phenytoin_NN or_CC any_DT known_JJ CYP3A4_NN inducer_NN should_MD be_VB avoided_VBN and_CC alternative_JJ antihypertensive_JJ therapy_NN should_MD be_VB considered_VBN ._. Pharmacokinetic_JJ interactions_NNS between_IN nisoldipine_NN and_CC beta-blockers_NNS -LRB-_-LRB- atenolol_NN ,_, propranolol_NN -RRB-_-RRB- were_VBD variable_JJ and_CC not_RB significant_JJ ._. Propranolol_NN attenuated_VBD the_DT heart_NN rate_NN increase_NN following_VBG administration_NN of_IN immediate_JJ release_NN nisoldipine_NN ._. The_DT blood_NN pressure_NN effect_NN of_IN SULAR_NN tended_VBD to_TO be_VB greater_JJR in_IN patients_NNS on_IN atenolol_NN than_IN in_IN patients_NNS on_IN no_DT other_JJ antihypertensive_JJ therapy_NN ._. Quinidine_NN at_IN 648_CD mg_NN bid_NN decreased_VBD the_DT bioavailability_NN -LRB-_-LRB- AUC_NN -RRB-_-RRB- of_IN nisoldipine_NN by_IN 26_CD %_NN ,_, but_CC not_RB the_DT peak_NN concentration_NN ._. The_DT immediate_JJ release_NN ,_, but_CC not_RB the_DT coat-core_JJ formulation_NN of_IN nisoldipine_NN increased_VBN plasma_NN quinidine_NN concentrations_NNS by_IN about_RB 20_CD %_NN ._. This_DT interaction_NN was_VBD not_RB accompanied_VBN by_IN ECG_NN changes_NNS and_CC its_PRP$ clinical_JJ significance_NN is_VBZ not_RB known_VBN ._. No_DT significant_JJ interactions_NNS were_VBD found_VBN between_IN nisoldipine_NN and_CC warfarin_NN or_CC digoxin_NN ._. Tizoxanide_NNP is_VBZ highly_RB bound_VBN to_TO plasma_NN protein_NN -LRB-_-LRB- 99.9_CD %_NN -RRB-_-RRB- ._. Therefore_RB ,_, caution_NN should_MD be_VB used_VBN when_WRB administering_VBG nitazoxanide_NN concurrently_RB with_IN other_JJ highly_RB plasma_NN protein-bound_JJ drugs_NNS with_IN narrow_JJ therapeutic_JJ indices_NNS ,_, as_IN competition_NN for_IN binding_VBG sites_NNS may_MD occur_VB -LRB-_-LRB- e.g._FW ,_, warfarin_NN -RRB-_-RRB- ._. In_FW vitro_FW metabolism_NN studies_NNS have_VBP demonstrated_VBN that_IN tizoxanide_NN has_VBZ no_DT significant_JJ inhibitory_JJ effect_NN on_IN cytochrome_NN P450_NN enzymes_NNS ._. Although_IN no_DT drug-drug_JJ interaction_NN studies_NNS have_VBP been_VBN conducted_VBN in_FW vivo_FW ,_, it_PRP is_VBZ expected_VBN that_IN no_DT significant_JJ interaction_NN would_MD occur_VB when_WRB nitazoxanide_NN is_VBZ co-administered_VBN with_IN drugs_NNS that_WDT either_RB are_VBP metabolized_VBN by_IN or_CC inhibit_VB cytochrome_NN P450_NN enzymes_NNS ._. No_DT formal_JJ drug-interaction_NN studies_NNS have_VBP been_VBN performed_VBN ,_, and_CC a_DT clinically_RB significant_JJ interaction_NN with_IN other_JJ medications_NNS used_VBN in_IN the_DT treatment_NN of_IN hypoxic_JJ respiratory_JJ failure_NN can_MD not_RB be_VB excluded_VBN based_VBN on_IN the_DT available_JJ data_NNS ._. INOmax_NN has_VBZ been_VBN administered_VBN with_IN tolazoline_NN ,_, dopamine_NN ,_, dobutamine_NN ,_, steroids_NNS ,_, surfactant_NN ,_, and_CC high-frequency_VB ventilation_NN ._. Although_IN there_EX are_VBP no_DT study_NN data_NNS to_TO evaluate_VB the_DT possibility_NN ,_, nitric_JJ oxide_NN donor_NN compounds_NNS ,_, including_VBG sodium_NN nitroprusside_NN and_CC nitroglycerin_NN ,_, may_MD have_VB an_DT additive_JJ effect_NN with_IN INOmax_NN on_IN the_DT risk_NN of_IN developing_VBG methemoglobinemia_NN ._. An_DT association_NN between_IN prilocaine_NN and_CC an_DT increased_VBN risk_NN of_IN methaemoglobinaemia_NN ,_, particularly_RB in_IN infants_NNS ,_, has_VBZ specifically_RB been_VBN described_VBN in_IN a_DT literature_NN case_NN report_NN ._. This_DT risk_NN is_VBZ present_JJ whether_IN the_DT drugs_NNS are_VBP administered_VBN as_IN oral_JJ ,_, parenteral_JJ ,_, or_CC topical_JJ formulations_NNS ._. Antacids_NNS containing_VBG magnesium_NN trisilicate_NN ,_, when_WRB administered_VBN concomitantly_RB with_IN nitrofurantoin_NN ,_, reduce_VB both_CC the_DT rate_NN and_CC extent_NN of_IN absorption_NN ._. The_DT mechanism_NN for_IN this_DT interaction_NN probably_RB is_VBZ adsorption_NN of_IN nitrofurantoin_NN onto_IN the_DT surface_NN of_IN magnesium_NN trisilicate_NN ._. Uricosuric_JJ drugs_NNS ,_, such_JJ as_IN probenecid_NN and_CC sulfinpyrazone_NN ,_, can_MD inhibit_VB renal_JJ tubular_JJ secretion_NN of_IN nitrofurantoin_NN ._. The_DT resulting_VBG increase_NN in_IN nitrofurantoin_NN serum_NN levels_NNS may_MD increase_VB toxicity_NN ,_, and_CC the_DT decreased_VBN urinary_JJ levels_NNS could_MD lessen_VB its_PRP$ efficacy_NN as_IN a_DT urinary_JJ tract_NN antibacterial_JJ ._. Drug/Laboratory_JJ Test_NN Interactions_NNS As_IN a_DT result_NN of_IN the_DT presence_NN of_IN nitrofurantoin_NN ,_, a_DT false-positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN may_MD occur_VB ._. This_DT has_VBZ been_VBN observed_VBN with_IN Benedict_NNP s_NNS and_CC Fehling_NN s_NNS solutions_NNS but_CC not_RB with_IN the_DT glucose_NN enzymatic_JJ test_NN ._. The_DT vasodilating_JJ effects_NNS of_IN nitroglycerin_NN may_MD be_VB additive_JJ with_IN those_DT of_IN other_JJ vasodilators_NNS ._. Alcohol_NN ,_, in_IN particular_JJ ,_, has_VBZ been_VBN found_VBN to_TO exhibit_VB additive_JJ effects_NNS of_IN this_DT variety_NN ._. Marked_JJ symptomatic_JJ orthostatic_JJ hypotension_NN has_VBZ been_VBN reported_VBN when_WRB calcium_NN channel_NN blockers_NNS and_CC organic_JJ nitrates_NNS were_VBD used_VBN in_IN combination_NN ._. Dose_NN adjustments_NNS of_IN either_CC class_NN of_IN agents_NNS may_MD be_VB necessary_JJ ._. The_DT hypotensive_JJ effect_NN of_IN sodium_NN nitroprusside_NN is_VBZ augmented_VBN by_IN that_DT of_IN most_RBS other_JJ hypotensive_JJ drugs_NNS ,_, including_VBG ganglionic_JJ blocking_VBG agents_NNS ,_, negative_JJ inotropic_JJ agents_NNS ,_, and_CC inhaled_VBD anesthetics_NNS ._. No_DT interactions_NNS have_VBP been_VBN observed_VBN between_IN nizatidine_NN and_CC theophylline_NN ,_, chlordiazepoxide_NN ,_, lorazepam_NN ,_, lidocaine_NN ,_, phenytoin_NN ,_, and_CC warfarin_NN ._. Nizatidine_NN does_VBZ not_RB inhibit_VB the_DT cytochrome_NN P-450-linked_JJ drug-metabolizing_JJ enzyme_NN system_NN ._. therefore_RB ,_, drug_NN interactions_NNS mediated_VBN by_IN inhibition_NN of_IN hepatic_JJ metabolism_NN are_VBP not_RB expected_VBN to_TO occur_VB ._. In_IN patients_NNS given_VBN very_RB high_JJ doses_NNS -LRB-_-LRB- 3900_CD mg_NN -RRB-_-RRB- of_IN aspirin_NN daily_RB ,_, increases_VBZ in_IN serum_NN salicylate_NN levels_NNS were_VBD seen_VBN when_WRB nizatidine_NN ,_, 150_CD mg_NN b.i.d._NN ,_, was_VBD administered_VBN concurrently_RB ._. The_DT effectiveness_NN of_IN progestin-only_JJ pills_NNS is_VBZ reduced_VBN by_IN hepatic_JJ enzyme-inducing_JJ drugs_NNS such_JJ as_IN the_DT anticonvulsants_NNS phenytoin_NN ,_, carbamazepine_NN ,_, and_CC barbiturates_NNS ,_, and_CC the_DT antituberculosis_NN drug_NN rifampin_NN ._. No_DT significant_JJ interaction_NN has_VBZ been_VBN found_VBN with_IN broad-spectrum_JJ antibiotics_NNS ._. Elevated_JJ plasma_NN levels_NNS of_IN theophylline_NN have_VBP been_VBN reported_VBN with_IN concomitant_JJ quinolone_NN use_NN ._. There_EX have_VBP been_VBN reports_NNS of_IN theophylline-related_JJ side_JJ effects_NNS in_IN patients_NNS on_IN concomitant_JJ therapy_NN with_IN norfloxacin_NN and_CC theophylline_NN ._. Therefore_RB ,_, monitoring_NN of_IN theophylline_NN plasma_NN levels_NNS should_MD be_VB considered_VBN and_CC dosage_NN of_IN theophylline_NN adjusted_VBN as_IN required_VBN ._. Elevated_JJ serum_NN levels_NNS of_IN cyclosporine_NN have_VBP been_VBN reported_VBN with_IN concomitant_JJ use_NN of_IN cyclosporine_NN with_IN norfloxacin_NN ._. Therefore_RB ,_, cyclosporine_NN serum_NN levels_NNS should_MD be_VB monitored_VBN and_CC appropriate_JJ cyclosporine_NN dosage_NN adjustments_NNS made_VBN when_WRB these_DT drugs_NNS are_VBP used_VBN concomitantly_RB ._. Quinolones_NNP ,_, including_VBG norfloxacin_NN ,_, may_MD enhance_VB the_DT effects_NNS of_IN oral_JJ anticoagulants_NNS ,_, including_VBG warfarin_NN or_CC its_PRP$ derivatives_NNS or_CC similar_JJ agents_NNS ._. When_WRB these_DT products_NNS are_VBP administered_VBN concomitantly_RB ,_, prothrombin_NN time_NN or_CC other_JJ suitable_JJ coagulation_NN tests_NNS should_MD be_VB closely_RB monitored_VBN ._. The_DT concomitant_JJ administration_NN of_IN quinolones_NNS including_VBG norfloxacin_NN with_IN glyburide_NN -LRB-_-LRB- a_DT sulfonylurea_NN agent_NN -RRB-_-RRB- has_VBZ ,_, on_IN rare_JJ occasions_NNS ,_, resulted_VBD in_IN severe_JJ hypoglycemia_NN ._. Therefore_RB ,_, monitoring_NN of_IN blood_NN glucose_NN is_VBZ recommended_VBN when_WRB these_DT agents_NNS are_VBP co-administered_JJ ._. Diminished_VBN urinary_JJ excretion_NN of_IN norfloxacin_NN has_VBZ been_VBN reported_VBN during_IN the_DT concomitant_JJ administration_NN of_IN probenecid_NN and_CC norfloxacin_NN ._. The_DT concomitant_JJ use_NN of_IN nitrofurantoin_NN is_VBZ not_RB recommended_VBN since_IN nitrofurantoin_NN may_MD antagonize_VB the_DT antibacterial_JJ effect_NN of_IN Norfloxacin_NNP in_IN the_DT urinary_JJ tract_NN ._. Multivitamins_NNS ,_, or_CC other_JJ products_NNS containing_VBG iron_NN or_CC zinc_NN ,_, antacids_NNS or_CC sucralfate_NN should_MD not_RB be_VB administered_VBN concomitantly_RB with_IN ,_, or_CC within_IN 2_CD hours_NNS of_IN ,_, the_DT administration_NN of_IN norfloxacin_NN ,_, because_IN they_PRP may_MD interfere_VB with_IN absorption_NN resulting_VBG in_IN lower_JJR serum_NN and_CC urine_NN levels_NNS of_IN norfloxacin_NN ._. Videx_NNP -LRB-_-LRB- Didanosine_NNP -RRB-_-RRB- chewable/buffered_VBD tablets_NNS or_CC the_DT pediatric_JJ powder_NN for_IN oral_JJ solution_NN should_MD not_RB be_VB administered_VBN concomitantly_RB with_IN ,_, or_CC within_IN 2_CD hours_NNS of_IN ,_, the_DT administration_NN of_IN norfloxacin_NN ,_, because_IN these_DT products_NNS may_MD interfere_VB with_IN absorption_NN resulting_VBG in_IN lower_JJR serum_NN and_CC urine_NN levels_NNS of_IN norfloxacin_NN ._. Some_DT quinolones_NNS have_VBP also_RB been_VBN shown_VBN to_TO interfere_VB with_IN the_DT metabolism_NN of_IN caffeine_NN ._. This_DT may_MD lead_VB to_TO reduced_VBN clearance_NN of_IN caffeine_NN and_CC a_DT prolongation_NN of_IN its_PRP$ plasma_NN half-life_NN ._. Reduced_VBN efficacy_NN and_CC increased_VBD incidence_NN of_IN breakthrough_NN bleeding_NN and_CC menstrual_JJ irregularities_NNS have_VBP been_VBN associated_VBN with_IN concomitant_JJ use_NN of_IN rifampin_NN ._. A_DT similar_JJ association_NN ,_, though_IN less_JJR marked_JJ ,_, has_VBZ been_VBN suggested_VBN with_IN barbiturates_NNS ,_, phenylbutazone_NN ,_, phenytoin_NN sodium_NN ,_, carbamazepine_NN ,_, griseofulvin_NN ,_, topiramate_NN ,_, and_CC possibly_RB with_IN ampicillin_NN and_CC tetracyclines_NNS 72_CD ._. A_DT possible_JJ interaction_NN has_VBZ been_VBN suggested_VBN with_IN hormonal_JJ contraceptives_NNS and_CC the_DT herbal_JJ supplement_NN St._NNP Johns_NNP Wort_NNP based_VBN on_IN some_DT reports_NNS of_IN oral_JJ contraceptive_JJ users_NNS experiencing_VBG breakthrough_NN bleeding_NN shortly_RB after_IN starting_VBG St._NNP Johns_NNP Wort_NNP ._. Pregnancies_NNS have_VBP been_VBN reported_VBN by_IN users_NNS of_IN combined_JJ hormonal_JJ contraceptives_NNS who_WP also_RB used_VBD some_DT form_NN of_IN St._NNP Johns_NNP Wort_NNP ._. Healthcare_NNP prescribers_NNS are_VBP advised_VBN to_TO consult_VB the_DT package_NN inserts_NNS of_IN medication_NN administered_VBN concomitantly_RB with_IN oral_JJ contraceptives_NNS ._. Steady-state_JJ serum_NN concentrations_NNS of_IN tricyclic_JJ antidepressants_NNS are_VBP reported_VBN to_TO fluctuate_VB significantly_RB when_WRB cimetidine_NN is_VBZ either_CC added_VBN or_CC deleted_VBN from_IN the_DT drug_NN regimen_NN ._. Serious_JJ anticholinergic_JJ symptoms_NNS -LRB-_-LRB- severe_JJ dry_JJ mouth_NN ,_, urinary_JJ retention_NN ,_, blurred_VBD vision_NN -RRB-_-RRB- have_VBP been_VBN associated_VBN with_IN elevations_NNS in_IN the_DT serum_NN levels_NNS of_IN tricyclic_JJ antidepressants_NNS when_WRB cimetidine_NN is_VBZ added_VBN to_TO the_DT drug_NN regimen_NN ._. In_IN addition_NN ,_, higher-than_NN expected_VBD steady-state_JJ serum_NN concentrations_NNS of_IN tricyclic_JJ antidepressants_NNS have_VBP been_VBN observed_VBN when_WRB therapy_NN is_VBZ initiated_VBN in_IN patients_NNS already_RB taking_VBG cimetidine_NN ._. In_IN well-controlled_JJ patients_NNS undergoing_VBG concurrent_JJ therapy_NN with_IN cimetidine_NN ,_, a_DT decrease_NN in_IN the_DT steady-state_JJ serum_NN concentrations_NNS of_IN tricyclic_JJ antidepressants_NNS may_MD occur_VB when_WRB cime-tidine_NN therapy_NN is_VBZ discontinued_VBN ._. The_DT therapeutic_JJ efficacy_NN of_IN tricyclic_JJ antidepressants_NNS may_MD be_VB compromised_VBN in_IN these_DT patients_NNS when_WRB cimetidine_NN is_VBZ discontinued_VBN ._. Several_JJ of_IN the_DT tricyclic_JJ antidepressants_NNS have_VBP been_VBN cited_VBN in_IN these_DT reports_NNS ._. There_EX have_VBP been_VBN greater_JJR than_IN 2-fold_JJ increases_NNS in_IN previously_RB stable_JJ plasma_NN levels_NNS of_IN other_JJ antidepressants_NNS ,_, including_VBG nortriptyline_NN ,_, when_WRB fluoxetine_NN hydrochloride_NN has_VBZ been_VBN administered_VBN in_IN combination_NN with_IN these_DT agents_NNS ._. Fluoxetine_NNP and_CC its_PRP$ active_JJ metabolite_NN ,_, norfluoxe-tine_NN ,_, have_VBP long_JJ half-lives_NNS -LRB-_-LRB- 4_CD to_TO 16_CD days_NNS for_IN norfluoxetine_NN -RRB-_-RRB- ,_, that_WDT may_MD affect_VB strategies_NNS during_IN conversion_NN from_IN one_CD drug_NN to_TO the_DT other_JJ ._. Administration_NN of_IN reserpine_NN during_IN therapy_NN with_IN a_DT tricyclic_JJ antidepressant_JJ has_VBZ been_VBN shown_VBN to_TO produce_VB a_DT stimulating_JJ effect_NN in_IN some_DT depressed_JJ patients_NNS ._. Close_JJ supervision_NN and_CC careful_JJ adjustment_NN of_IN the_DT dosage_NN are_VBP required_VBN when_WRB nortriptyline_NN hydrochloride_NN is_VBZ used_VBN with_IN other_JJ anticholinergic_JJ drugs_NNS or_CC sympathomimetic_JJ drugs_NNS ._. The_DT patient_NN should_MD be_VB informed_VBN that_IN the_DT response_NN to_TO alcohol_NN may_MD be_VB exaggerated_VBN ._. Drugs_NNS Metabolized_VBN by_IN P450IID6_NN A_NN subset_NN -LRB-_-LRB- 3_CD %_NN to_TO 10_CD %_NN -RRB-_-RRB- of_IN the_DT population_NN has_VBZ reduced_VBN activity_NN of_IN certain_JJ drug_NN metabolizing_VBG enzymes_NNS such_JJ as_IN the_DT cytochrome_NN P450_NN isoenzyme_NN P450IID6_NN ._. Such_JJ individuals_NNS are_VBP referred_VBN to_TO as_IN poor_JJ metabolizers_NNS of_IN drugs_NNS such_JJ as_IN debrisoquin_NN ,_, dextromethorphan_NN ,_, and_CC the_DT tricyclic_JJ antidepressants_NNS ._. These_DT individuals_NNS may_MD have_VB higher_JJR than_IN expected_VBN plasma_NN concentrations_NNS of_IN tricyclic_JJ antidepressants_NNS when_WRB given_VBN usual_JJ doses_NNS ._. In_IN addition_NN ,_, certain_JJ drugs_NNS that_WDT are_VBP metabolized_VBN by_IN this_DT isoenzyme_NN ,_, including_VBG many_JJ antidepressants_NNS -LRB-_-LRB- tricyclic_JJ antidepressants_NNS ,_, selective_JJ serotonin_NN reuptake_NN inhibitors_NNS ,_, and_CC others_NNS -RRB-_-RRB- ,_, may_MD inhibit_VB the_DT activity_NN of_IN this_DT isoenzyme_NN ,_, and_CC thus_RB may_MD make_VB normal_JJ metab-olizers_NNS resemble_VBP poor_JJ metabolizers_NNS with_IN regard_NN to_TO concomitant_JJ therapy_NN with_IN other_JJ drugs_NNS metabolized_VBN by_IN this_DT enzyme_NN system_NN ,_, leading_VBG to_TO drug_NN interactions_NNS ._. Concomitant_JJ use_NN of_IN tricyclic_JJ antidepressants_NNS with_IN other_JJ drugs_NNS metabolized_VBN by_IN cytochrome_NN P450IID6_NN may_MD require_VB lower_JJR doses_NNS than_IN usually_RB prescribed_VBN for_IN either_CC the_DT tricyclic_JJ antidepressant_JJ or_CC the_DT other_JJ drug_NN ._. Therefore_RB ,_, co-administration_NN of_IN tricyclic_JJ antidepressants_NNS with_IN other_JJ drugs_NNS that_WDT are_VBP metabolized_VBN by_IN this_DT isoenzyme_NN ,_, including_VBG other_JJ antidepressants_NNS ,_, phenothiazines_NNS ,_, carbamazepine_NN ,_, and_CC Type_NN 1C_NN antiarrhythmics_NNS -LRB-_-LRB- eg_FW ,_, propafenone_NN ,_, flecainide_NN ,_, and_CC encainide_NN -RRB-_-RRB- ,_, or_CC that_IN inhibit_VBP this_DT enzyme_NN -LRB-_-LRB- eg_FW ,_, quinidine_NN -RRB-_-RRB- ,_, should_MD be_VB approached_VBN with_IN caution_NN ._. Oxcarbazepine_NNP can_MD inhibit_VB CYP2C19_NN and_CC induce_VB CYP3A4/5_NN with_IN potentially_RB important_JJ effects_NNS on_IN plasma_NN concentrations_NNS of_IN other_JJ drugs_NNS ._. In_IN addition_NN ,_, several_JJ AED_NN s_NNS that_WDT are_VBP cytochrome_NN P450_NN inducers_NNS can_MD decrease_VB plasma_NN concentrations_NNS of_IN oxcarbazepine_NN and_CC MHD_NN ._. Oxcarbazepine_NN was_VBD evaluated_VBN in_IN human_JJ liver_NN microsomes_NNS to_TO determine_VB its_PRP$ capacity_NN to_TO inhibit_VB the_DT major_JJ cytochrome_NN P450_NN enzymes_NNS responsible_JJ for_IN the_DT metabolism_NN of_IN other_JJ drugs_NNS ._. Results_NNS demonstrate_VBP that_IN oxcarbazepine_NN and_CC its_PRP$ pharmacologically_RB active_JJ 10-monohydroxy_JJ metabolite_NN -LRB-_-LRB- MHD_NN -RRB-_-RRB- have_VBP little_JJ or_CC no_DT capacity_NN to_TO function_VB as_IN inhibitors_NNS for_IN most_JJS of_IN the_DT human_JJ cytochrome_NN P450_NN enzymes_NNS evaluated_VBN -LRB-_-LRB- CYP1A2_NN ,_, CYP2A6_NN ,_, CYP2C9_NN ,_, CYP2D6_NN ,_, CYP2E1_NN ,_, CYP4A9_NN and_CC CYP4A11_NN -RRB-_-RRB- with_IN the_DT exception_NN of_IN CYP2C19_NN and_CC CYP3A4/5_NN ._. Although_IN inhibition_NN of_IN CYP_NN 3A4/5_NN by_IN OXC_NN and_CC MHD_NN did_VBD occur_VB at_IN high_JJ concentrations_NNS ,_, it_PRP is_VBZ not_RB likely_JJ to_TO be_VB of_IN clinical_JJ significance_NN ._. The_DT inhibition_NN of_IN CYP-2C19_NN by_IN OXC_NN and_CC MHD_NN ,_, however_RB ,_, is_VBZ clinically_RB relevant_JJ ._. In_FW vitro_FW ,_, the_DT UDP-glucuronyl_JJ transferase_NN level_NN was_VBD increased_VBN ,_, indicating_VBG induction_NN of_IN this_DT enzyme_NN ._. Increases_NNS of_IN 22_CD %_NN with_IN MHD_NN and_CC 47_CD %_NN with_IN oxcarbazepine_NN were_VBD observed_VBN ._. As_IN MHD_NN ,_, the_DT predominant_JJ plasma_NN substrate_NN ,_, is_VBZ only_RB a_DT weak_JJ inducer_NN of_IN UDP-glucuronyl_JJ transferase_NN ,_, it_PRP is_VBZ unlikely_JJ to_TO have_VB an_DT effect_NN on_IN drugs_NNS that_WDT are_VBP mainly_RB eliminated_VBN by_IN conjugation_NN through_IN UDP-glucuronyl_JJ transferase_NN -LRB-_-LRB- e.g._FW ,_, valproic_JJ acid_NN ,_, lamotrigine_NN -RRB-_-RRB- ._. In_IN addition_NN ,_, oxcarbazepine_NN and_CC MHD_NN induce_VBP a_DT subgroup_NN of_IN the_DT cytochrome_NN P450_NN 3A_NN family_NN -LRB-_-LRB- CYP3A4_NN and_CC CYP3A5_NN -RRB-_-RRB- responsible_JJ for_IN the_DT metabolism_NN of_IN dihydropyridine_NN calcium_NN antagonists_NNS and_CC oral_JJ contraceptives_NNS ,_, resulting_VBG in_IN a_DT lower_JJR plasma_NN concentration_NN of_IN these_DT drugs_NNS ._. As_IN binding_NN of_IN MHD_NN to_TO plasma_NN proteins_NNS is_VBZ low_JJ -LRB-_-LRB- 40_CD %_NN -RRB-_-RRB- ,_, clinically_RB significant_JJ interactions_NNS with_IN other_JJ drugs_NNS through_IN competition_NN for_IN protein_NN binding_NN sites_NNS are_VBP unlikely_JJ ._. Antiepileptic_JJ drugs_NNS :_: Potential_JJ interactions_NNS between_IN Trileptal_JJ and_CC other_JJ AEDs_NNS were_VBD assessed_VBN in_IN clinical_JJ studies_NNS ._. The_DT effect_NN of_IN these_DT interactions_NNS on_IN mean_NN AUCs_NNS and_CC Cmin_NN are_VBP summarized_VBN in_IN Table_NNP 2_CD :_: Table_NNP 2_CD :_: Summary_NNP of_IN AED_NNP interactions_NNS with_IN Trilepta_NN ._. AED_NN Co-administere_NN ._. Dose_NN of_IN AED_NN -LRB-_-LRB- mg/day_NN ._. Trileptal_JJ dose_NN -LRB-_-LRB- mg/day_NN ._. Influence_NN of_IN Trileptal_JJ on_IN AED_NNP Concentration_NN -LRB-_-LRB- Mean_NN change_NN ,_, 90_CD %_NN Confidence_NN Interval_NN ._. Influence_NN of_IN AED_NNP On_IN MHD_NNP Concentration_NN -LRB-_-LRB- Mean_NN change_NN ,_, 90_CD %_NN Confidence_NN Interval_NN ._. Carbamazepin_NNP ._. 400-2000_CD ._. 900_CD ._. nc1_NN 40_CD %_NN decrease_NN -LSB-_-LRB- CI_NN :_: 17_CD %_NN decrease_NN ,_, 57_CD %_NN decrease_NN -RSB-_-RRB- ._. Phenobarbita_NNP ._. 100-150_CD ._. 600-1800_CD ._. 14_CD %_NN increase_NN -LSB-_-LRB- CI_NN :_: 2_CD %_NN increase_NN ,_, 24_CD %_NN increase_NN -RSB-_-RRB- 25_CD %_NN decrease_NN -LSB-_-LRB- CI_NN :_: 12_CD %_NN decrease_NN ,_, 51_CD %_NN decrease_NN -RSB-_-RRB- ._. Phenytoi_NNP ._. 250-500_CD ._. 600-1800_CD ._. nc1_NN ,2_CD 30_CD %_NN decrease_NN -LSB-_-LRB- CI_NN :_: 3_CD %_NN decrease_NN ,_, 48_CD %_NN decrease_NN -RSB-_-RRB- ._. 1200-2400_CD up_IN to_TO 40_CD %_NN increase3_NN -LSB-_-LRB- CI_NN :_: 12_CD %_NN increase_NN ,_, 60_CD %_NN increase_NN -RSB-_-RRB- ._. Valproic_JJ aci_NN ._. 400-2800_CD ._. 600-1800_CD ._. nc1_NN 18_CD %_NN decrease_NN -LSB-_-LRB- CI_NN :_: 13_CD %_NN decrease_NN ,_, 40_CD %_NN decrease_NN -RSB-_-RRB- ._. 1_LS -_: nc_NN denotes_VBZ a_DT mean_JJ change_NN of_IN less_JJR than_IN 10_CD %_NN 2_CD -_: Pediatrics_NNS 3_LS -_: Mean_NN increase_NN in_IN adults_NNS at_IN high_JJ Trileptal_JJ doses_NNS In_FW vivo_FW ,_, the_DT plasma_NN levels_NNS of_IN phenytoin_NN increased_VBN by_IN up_RB to_TO 40_CD %_NN ,_, when_WRB Trileptal_NNP was_VBD given_VBN at_IN doses_NNS above_IN 1200_CD mg/day_NN ._. Therefore_RB ,_, when_WRB using_VBG doses_NNS of_IN Trileptal_JJ greater_JJR than_IN 1200_CD mg/day_NN during_IN adjunctive_JJ therapy_NN ,_, a_DT decrease_NN in_IN the_DT dose_NN of_IN phenytoin_NN may_MD be_VB required_VBN ._. The_DT increase_NN of_IN phenobarbital_JJ level_NN ,_, however_RB ,_, is_VBZ small_JJ -LRB-_-LRB- 15_CD %_NN -RRB-_-RRB- when_WRB given_VBN with_IN Trileptal_JJ ._. Strong_JJ inducers_NNS of_IN cytochrome_NN P450_NN enzymes_NNS -LRB-_-LRB- i.e._FW carbamazepine_FW ,_, phenytoin_NN and_CC phenobarbital_NN -RRB-_-RRB- have_VBP been_VBN shown_VBN to_TO decrease_VB the_DT plasma_NN levels_NNS of_IN MHD_NN -LRB-_-LRB- 29-40_CD %_NN -RRB-_-RRB- ._. No_DT autoinduction_NN has_VBZ been_VBN observed_VBN with_IN Trileptal_JJ ._. Hormonal_JJ contraceptives_NNS Co-administration_NN of_IN Trileptal_JJ with_IN an_DT oral_JJ contraceptive_NN has_VBZ been_VBN shown_VBN to_TO influence_VB the_DT plasma_NN concentrations_NNS of_IN the_DT two_CD hormonal_JJ components_NNS ,_, ethinylestradiol_NN -LRB-_-LRB- EE_NN -RRB-_-RRB- and_CC levonorgestrel_NN -LRB-_-LRB- LNG_NN -RRB-_-RRB- ._. The_DT mean_NN AUC_NN values_NNS of_IN EE_NN were_VBD decreased_VBN by_IN 48_CD %_NN -LSB-_-LRB- 90_CD %_NN CI_NN :_: 22-65_CD -RSB-_-RRB- in_IN one_CD study_NN and_CC 52_CD %_NN -LSB-_-LRB- 90_CD %_NN CI_NN :_: 38-52_CD -RSB-_-RRB- in_IN another_DT study_NN -LSB-_-LRB- 1,2_CD -RSB-_-RRB- ._. The_DT mean_NN AUC_NN values_NNS of_IN LNG_NN were_VBD decreased_VBN by_IN 32_CD %_NN -LSB-_-LRB- 90_CD %_NN CI_NN :_: 20-45_CD -RSB-_-RRB- in_IN one_CD study_NN and_CC 52_CD %_NN -LSB-_-LRB- 90_CD %_NN CI_NN :_: 42-52_CD -RSB-_-RRB- in_IN another_DT study_NN ._. Therefore_RB ,_, concurrent_JJ use_NN of_IN Trileptal_JJ with_IN hormonal_JJ contraceptives_NNS may_MD render_VB these_DT contraceptives_NNS less_RBR effective_JJ ._. Studies_NNS with_IN other_JJ oral_JJ or_CC implant_VB contraceptives_NNS have_VBP not_RB been_VBN conducted_VBN ._. Calcium_NN Antagonists_NNS :_: After_IN repeated_VBN co-administration_NN of_IN Trileptal_NNP ,_, the_DT AUC_NN of_IN felodipine_NN was_VBD lowered_VBN by_IN 28_CD %_NN -LSB-_-LRB- 90_CD %_NN CI_NN :_: 20-33_CD -RSB-_-RRB- ._. Verapamil_NNP produced_VBD a_DT decrease_NN of_IN 20_CD %_NN -LSB-_-LRB- 90_CD %_NN CI_NN :_: 18-27_CD -RSB-_-RRB- of_IN the_DT plasma_NN levels_NNS of_IN MHD_NNP ._. Other_JJ drug_NN interactions_NNS Cimetidine_NNP ,_, erythromycin_NN and_CC dextropropoxyphene_NN had_VBD no_DT effect_NN on_IN the_DT pharmacokinetics_NNS of_IN MHD_NNP ._. Results_NNS with_IN warfarin_NN wshow_NN no_DT evidence_NN of_IN interaction_NN with_IN either_CC single_JJ or_CC repeated_JJ doses_NNS of_IN Trileptal_JJ ._. In_IN a_DT Phase_NN I_PRP trial_NN using_VBG escalating_VBG doses_NNS of_IN TAXOL_NN -LRB-_-LRB- 110-200_CD mg/m2_NN -RRB-_-RRB- and_CC cisplatin_NN -LRB-_-LRB- 50_CD or_CC 75_CD mg/m2_NN -RRB-_-RRB- given_VBN as_IN sequential_JJ infusions_NNS ,_, myelosuppression_NN was_VBD more_RBR profound_JJ when_WRB TAXOL_NNP was_VBD given_VBN after_IN cisplatin_NN than_IN with_IN the_DT alternate_JJ sequence_NN -LRB-_-LRB- ie_FW ,_, TAXOL_NN before_IN cisplatin_NN -RRB-_-RRB- ._. Pharmacokinetic_JJ data_NNS from_IN these_DT patients_NNS demonstrated_VBD a_DT decrease_NN in_IN paclitaxel_NN clearance_NN of_IN approximately_RB 33_CD %_NN when_WRB TAXOL_NNP was_VBD administered_VBN following_VBG cisplatin_NN ._. The_DT metabolism_NN of_IN TAXOL_NN is_VBZ catalyzed_VBN by_IN cytochrome_NN P450_NN isoen-zymes_NNS CYP2C8_NN and_CC CYP3A4_NN ._. In_IN the_DT absence_NN of_IN formal_JJ clinical_JJ drug_NN interaction_NN studies_NNS ,_, caution_NN should_MD be_VB exercised_VBN when_WRB administering_VBG TAXOL_NNP concomitantly_RB with_IN known_JJ substrates_NNS or_CC inhibitors_NNS of_IN the_DT cytochrome_NN P450_NN isoenzymes_NNS CYP2C8_NN and_CC CYP3A4_NN ._. Potential_JJ interactions_NNS between_IN TAXOL_NNP ,_, a_DT substrate_NN of_IN CYP3A4_NN ,_, and_CC protease_NN inhibitors_NNS -LRB-_-LRB- ritonavir_NN ,_, saquinavir_NN ,_, indinavir_NN ,_, and_CC nelfinavir_NN -RRB-_-RRB- ,_, which_WDT are_VBP substrates_NNS and/or_CC inhibitors_NNS of_IN CYP3A4_NN ,_, have_VBP not_RB been_VBN evaluated_VBN in_IN clinical_JJ trials_NNS ._. Reports_NNS in_IN the_DT literature_NN suggest_VBP that_IN plasma_NN levels_NNS of_IN doxorubicin_NN -LRB-_-LRB- and_CC its_PRP$ active_JJ metabolite_NN doxorubicinol_NN -RRB-_-RRB- may_MD be_VB increased_VBN when_WRB paclitaxel_NN and_CC doxorubicin_NN are_VBP used_VBN in_IN combination_NN ._. Hematology_NNP :_: TAXOL_NN therapy_NN should_MD not_RB be_VB administered_VBN to_TO patients_NNS with_IN baseline_NN neutrophil_NN counts_NNS of_IN less_JJR than_IN 1,500_CD cells/mm3_NNS ._. In_IN order_NN to_TO monitor_VB the_DT occurrence_NN of_IN myelotoxicity_NN ,_, it_PRP is_VBZ recommended_VBN that_IN frequent_JJ peripheral_JJ blood_NN cell_NN counts_NNS be_VB performed_VBN on_IN all_DT patients_NNS receiving_VBG TAXOL_NNP ._. Patients_NNS should_MD not_RB be_VB re-treated_JJ with_IN subsequent_JJ cycles_NNS of_IN TAXOL_NN until_IN neutrophils_NNS recover_VBP to_TO a_DT level_NN 1500_CD cells/mm3_NNS and_CC platelets_NNS recover_VBP to_TO a_DT level_NN 100,000_CD cells/mm3_NNS ._. In_IN the_DT case_NN of_IN severe_JJ neutropenia_NN -LRB-_-LRB- 500_CD cells/mm3_NN for_IN seven_CD days_NNS or_CC more_JJR -RRB-_-RRB- during_IN a_DT course_NN of_IN TAXOL_NN therapy_NN ,_, a_DT 20_CD %_NN reduction_NN in_IN dose_NN for_IN subsequent_JJ courses_NNS of_IN therapy_NN is_VBZ recommended_VBN ._. For_IN patients_NNS with_IN advanced_JJ HIV_NN disease_NN and_CC poor-risk_JJ AIDS-related_JJ Kaposi_NN s_NNS sarcoma_NN ,_, TAXOL_NN ,_, at_IN the_DT recommended_VBN dose_NN for_IN this_DT disease_NN ,_, can_MD be_VB initiated_VBN and_CC repeated_VBN if_IN the_DT neutrophil_NN count_NN is_VBZ at_IN least_JJS 1000_CD cells/mm3_NNS ._. Hypersensitivity_NN Reactions_NNS :_: Patients_NNS with_IN a_DT history_NN of_IN severe_JJ hypersensitivity_NN reactions_NNS to_TO products_NNS containing_VBG Cremophor_NNP EL_NNP -LRB-_-LRB- eg_FW ,_, cyclosporin_NN for_IN injection_NN concentrate_NN and_CC teniposide_NN for_IN injection_NN concentrate_NN -RRB-_-RRB- should_MD not_RB be_VB treated_VBN with_IN TAXOL_NN ._. In_IN order_NN to_TO avoid_VB the_DT occurrence_NN of_IN severe_JJ hypersensitivity_NN reactions_NNS ,_, all_DT patients_NNS treated_VBN with_IN TAXOL_NN should_MD be_VB premedicated_VBN with_IN corticosteroids_NNS -LRB-_-LRB- such_JJ as_IN dexamethasone_NN -RRB-_-RRB- ,_, diphen-hydramine_NN and_CC H2_NN antagonists_NNS -LRB-_-LRB- such_JJ as_IN cimetidine_NN or_CC ranitidine_NN -RRB-_-RRB- ._. Minor_JJ symptoms_NNS such_JJ as_IN flushing_NN ,_, skin_NN reactions_NNS ,_, dyspnea_NN ,_, hypotension_NN ,_, or_CC tachycardia_NN do_VBP not_RB require_VB interruption_NN of_IN therapy_NN ._. However_RB ,_, severe_JJ reactions_NNS ,_, such_JJ as_IN hypotension_NN requiring_VBG treatment_NN ,_, dyspnea_NN requiring_VBG bronchodilators_NNS ,_, angioedema_NN ,_, or_CC generalized_VBN urticaria_NN require_VBP immediate_JJ discontinuation_NN of_IN TAXOL_NN and_CC aggressive_JJ symptomatic_JJ therapy_NN ._. Patients_NNS who_WP have_VBP developed_VBN severe_JJ hypersensitivity_NN reactions_NNS should_MD not_RB be_VB rechallenged_VBN with_IN TAXOL_NN ._. Cardiovascular_NNP :_: Hypotension_NN ,_, bradycardia_NN ,_, and_CC hypertension_NN have_VBP been_VBN observed_VBN during_IN administration_NN of_IN TAXOL_NNP ,_, but_CC generally_RB do_VBP not_RB require_VB treatment_NN ._. Occasionally_RB TAXOL_NN infusions_NNS must_MD be_VB interrupted_JJ or_CC discontinued_VBN because_IN of_IN initial_JJ or_CC recurrent_JJ hypertension_NN ._. Frequent_JJ vital_JJ sign_NN monitoring_NN ,_, particularly_RB during_IN the_DT first_JJ hour_NN of_IN TAXOL_NNP infusion_NN ,_, is_VBZ recommended_VBN ._. Continuous_JJ cardiac_JJ monitoring_NN is_VBZ not_RB required_VBN except_IN for_IN patients_NNS with_IN serious_JJ conduction_NN abnormalities_NNS ._. Nervous_JJ System_NN :_: Although_IN the_DT occurrence_NN of_IN peripheral_JJ neuropathy_NN is_VBZ frequent_JJ ,_, the_DT development_NN of_IN severe_JJ symptomatology_NN is_VBZ unusual_JJ and_CC requires_VBZ a_DT dose_NN reduction_NN of_IN 20_CD %_NN for_IN all_DT subsequentcourses_NNS of_IN TAXOL_NN ._. TAXOL_NN contains_VBZ dehydrated_JJ alcohol_NN USP_NN ,_, 396_CD mg/mL_NN ._. consideration_NN should_MD be_VB given_VBN to_TO possible_JJ CNS_NN and_CC other_JJ effects_NNS of_IN alcohol_NN ._. Hepatic_JJ :_: There_EX is_VBZ limited_JJ evidence_NN that_IN the_DT myelotoxicity_NN of_IN TAXOL_NN may_MD be_VB exacerbated_VBN in_IN patients_NNS with_IN serum_NN total_JJ bilirubin_NN 2_CD times_NNS ULN_NNP ._. Extreme_JJ caution_NN should_MD be_VB exercised_VBN when_WRB administering_VBG TAXOL_NN to_TO such_JJ patients_NNS ,_, with_IN dose_NN reduction_NN as_IN recommended_VBN in_IN DOSAGE_NNP AND_CC ADMINISTRATION_NNP ,_, Table_NNP 17_CD ._. InjectionSite_NNP Reaction_NNP :_: Injection_NN site_NN reactions_NNS ,_, including_VBG reactions_NNS secondary_JJ to_TO extravasation_NN ,_, were_VBD usually_RB mild_JJ and_CC consisted_VBD of_IN erythema_NN ,_, tenderness_NN ,_, skin_NN discoloration_NN ,_, or_CC swelling_VBG at_IN the_DT injection_NN site_NN ._. These_DT reactions_NNS have_VBP been_VBN observed_VBN more_RBR frequently_RB with_IN the_DT 24-hour_JJ infusion_NN than_IN with_IN the_DT 3-hour_JJ infusion_NN ._. Recurrence_NN of_IN skin_NN reactions_NNS at_IN a_DT site_NN of_IN previous_JJ extravasation_NN following_VBG administration_NN of_IN TAXOL_NN at_IN a_DT different_JJ site_NN ,_, ie_FW ,_, recall_NN ,_, has_VBZ been_VBN reported_VBN rarely_RB ._. Rare_JJ reports_NNS of_IN more_RBR severe_JJ events_NNS such_JJ as_IN phlebitis_NN ,_, cellulitis_NN ,_, induration_NN ,_, skin_NN exfoliation_NN ,_, necrosis_NN ,_, and_CC fibrosis_NN have_VBP been_VBN received_VBN as_IN part_NN of_IN the_DT continuing_VBG surveillance_NN of_IN TAXOL_NN safety_NN ._. In_IN some_DT cases_NNS the_DT onset_NN of_IN the_DT injection_NN site_NN reaction_NN either_CC occurred_VBD during_IN a_DT prolonged_JJ infusion_NN or_CC was_VBD delayed_VBN by_IN a_DT week_NN to_TO ten_CD days_NNS ._. A_DT specific_JJ treatment_NN for_IN extravasation_NN reactions_NNS is_VBZ unknown_JJ at_IN this_DT time_NN ._. Given_VBN the_DT possibility_NN of_IN extravasation_NN ,_, it_PRP is_VBZ advisable_JJ to_TO closely_RB monitor_VB the_DT infusion_NN site_NN for_IN possible_JJ infiltration_NN during_IN drug_NN administration_NN ._. Treatment_NN with_IN PEGASYS_NN once_RB weekly_JJ for_IN 4_CD weeks_NNS in_IN healthy_JJ subjects_NNS was_VBD associated_VBN with_IN an_DT inhibition_NN of_IN P450_NN 1A2_NN and_CC a_DT 25_CD %_NN increase_NN in_IN theophylline_NN AUC_NN ._. Theophylline_NN serum_NN levels_NNS should_MD be_VB monitored_VBN and_CC appropriate_JJ dose_NN adjustments_NNS considered_VBN for_IN patients_NNS given_VBN both_CC theophylline_NN and_CC PEGASYS_NN ._. There_EX was_VBD no_DT effect_NN on_IN the_DT pharmacokinetics_NNS of_IN representative_JJ drugs_NNS metabolized_VBN by_IN CYP_NN 2C9_NN ,_, CYP_NN 2C19_NN ,_, CYP_NN 2D6_NN or_CC CYP_NN 3A4_NN ._. In_IN patients_NNS with_IN chronic_JJ hepatitis_NN C_NN treated_VBN with_IN PEGASYS_NN in_IN combination_NN with_IN COPEGUS_NNS ,_, PEGASYS_NN treatment_NN did_VBD not_RB affect_VB ribavirin_NNP distribution_NN or_CC clearance_NN ._. Nucleoside_NN Analogues_NNP Didanosine_NNP Co-administration_NN of_IN COPEGUS_NNP and_CC didanosine_NN is_VBZ not_RB recommended_VBN ._. Reports_NNS of_IN fatal_JJ hepatic_JJ failure_NN ,_, as_RB well_RB as_IN peripheral_JJ neuropathy_NN ,_, pancreatitis_NN ,_, and_CC symptomatic_JJ hyperlactatemia/lactic_JJ acidosis_NN have_VBP been_VBN reported_VBN in_IN clinical_JJ trials_NNS ._. Stavudine_NNP and_CC Zidovudine_NNP Ribavirin_NNP can_MD antagonize_VB the_DT in_FW vitro_FW antiviral_JJ activity_NN of_IN stavudine_NN and_CC zidovudine_NN against_IN HIV_NN ._. Therefore_RB ,_, concomitant_JJ use_NN of_IN ribavirin_NNP with_IN either_DT of_IN these_DT drugs_NNS should_MD be_VB avoided_VBN ._. Carcinogenesis_NN ,_, Mutagenesis_NN ,_, Impairment_NN of_IN Fertility_NN Carcinogenesis_NN PEGASYS_NN has_VBZ not_RB been_VBN tested_VBN for_IN its_PRP$ carcinogenic_JJ potential_NN ._. Mutagenesis_NN PEGASYS_NN did_VBD not_RB cause_VB DNA_NN damage_NN when_WRB tested_VBN in_IN the_DT Ames_NNP bacterial_JJ mutagenicity_NN assay_NN and_CC in_IN the_DT in_FW vitro_FW chromosomal_JJ aberration_NN assay_NN in_IN human_JJ lymphocytes_NNS ,_, either_CC in_IN the_DT presence_NN or_CC absence_NN of_IN metabolic_JJ activation_NN ._. Use_NNP With_IN Ribavirin_NNP Ribavirin_NNP is_VBZ genotoxic_JJ and_CC mutagenic_JJ ._. The_DT carcinogenic_JJ potential_NN of_IN ribavirin_NNP has_VBZ not_RB been_VBN fully_RB determined_VBN ._. In_IN a_DT p53_NN -LRB-_-LRB- +_CC /_: -_: -RRB-_-RRB- mouse_NN carcinogenicity_NN study_NN at_IN doses_NNS up_RB to_TO the_DT maximum_NN tolerated_VBD dose_NN of_IN 100_CD mg/kg/day_JJ ribavirin_NNP was_VBD not_RB oncogenic_JJ ._. However_RB ,_, on_IN a_DT body_NN surface_NN area_NN basis_NN ,_, this_DT dose_NN was_VBD 0.5_CD times_NNS maximum_JJ recommended_VBN human_JJ 24-hour_JJ dose_NN of_IN ribavirin_NNP ._. A_DT study_NN in_IN rats_NNS to_TO assess_VB the_DT carcinogenic_JJ potential_NN of_IN ribavirin_NNP is_VBZ ongoing_JJ ._. Mutagenesis_NN Impairment_NN of_IN Fertility_NNP PEGASYS_NNP may_MD impair_VB fertility_NN in_IN women_NNS ._. Prolonged_JJ menstrual_JJ cycles_NNS and/or_CC amenorrhea_NN were_VBD observed_VBN in_IN female_JJ cynomolgus_NN monkeys_NNS given_VBN sc_NN injections_NNS of_IN 600_CD m_NN g/kg/dose_NN -LRB-_-LRB- 7200_CD m_NN g/m2/dose_NN -RRB-_-RRB- of_IN PEGASYS_NN every_DT other_JJ day_NN for_IN one_CD month_NN ,_, at_IN approximately_RB 180_CD times_NNS the_DT recommended_VBN weekly_JJ human_JJ dose_NN for_IN a_DT 60_CD kg_NN person_NN -LRB-_-LRB- based_VBN on_IN body_NN surface_NN area_NN -RRB-_-RRB- ._. Menstrual_JJ cycle_NN irregularities_NNS were_VBD accompanied_VBN by_IN both_CC a_DT decrease_NN and_CC delay_NN in_IN the_DT peak_JJ 17b_NN -_: estradiol_NN and_CC progesterone_NN levels_NNS following_VBG administration_NN of_IN PEGASYS_NNP to_TO female_JJ monkeys_NNS ._. A_DT return_NN to_TO normal_JJ menstrual_JJ rhythm_NN followed_VBD cessation_NN of_IN treatment_NN ._. Every_DT other_JJ day_NN dosing_NN with_IN 100m_NN g/kg_NN -LRB-_-LRB- 1200m_CD g/m2_NN -RRB-_-RRB- PEGASYS_NN -LRB-_-LRB- equivalent_JJ to_TO approximately_RB 30_CD times_NNS the_DT recommended_VBN human_JJ dose_NN -RRB-_-RRB- had_VBD no_DT effects_NNS on_IN cycle_NN duration_NN or_CC reproductive_JJ hormone_NN status_NN ._. The_DT effects_NNS of_IN PEGASYS_NN on_IN male_JJ fertility_NN have_VBP not_RB been_VBN studied_VBN ._. However_RB ,_, no_DT adverse_JJ effects_NNS on_IN fertility_NN were_VBD observed_VBN in_IN male_JJ Rhesus_NNP monkeys_NNS treated_VBN with_IN non-pegylated_JJ interferon_NN alfa-2a_NN for_IN 5_CD months_NNS at_IN doses_NNS up_RB to_TO 25_CD x_CC 106_CD IU/kg/day_NN ._. Pregnancy_NNP Pregnancy_NNP :_: Category_NN C_NN PEGASYS_NN has_VBZ not_RB been_VBN studied_VBN for_IN its_PRP$ teratogenic_JJ effect_NN ._. Non-pegylated_JJ interferon_NN alfa-2a_NN treatment_NN of_IN pregnant_JJ Rhesus_NNP monkeys_NNS at_IN approximately_RB 20_CD to_TO 500_CD times_NNS the_DT human_JJ weekly_JJ dose_NN resulted_VBD in_IN a_DT statistically_RB significant_JJ increase_NN in_IN abortions_NNS ._. No_DT teratogenic_JJ effects_NNS were_VBD seen_VBN in_IN the_DT offspring_NN delivered_VBN at_IN term_NN ._. PEGASYS_NN should_MD be_VB assumed_VBN to_TO have_VB abortifacient_JJ potential_NN ._. There_EX are_VBP no_DT adequate_JJ and_CC well-controlled_JJ studies_NNS of_IN PEGASYS_NNP in_IN pregnant_JJ women_NNS ._. PEGASYS_NNP is_VBZ to_TO be_VB used_VBN during_IN pregnancy_NN only_RB if_IN the_DT potential_JJ benefit_NN justifies_VBZ the_DT potential_JJ risk_NN to_TO the_DT fetus_NN ._. PEGASYS_NNP is_VBZ recommended_VBN for_IN use_NN in_IN women_NNS of_IN childbearing_JJ potential_NN only_RB when_WRB they_PRP are_VBP using_VBG effective_JJ contraception_NN during_IN therapy_NN ._. Pregnancy_NN :_: Category_NN X_NN :_: Use_NNP With_IN Ribavirin_NNP -LRB-_-LRB- see_VB CONTRAINDICATIONS_NNS -RRB-_-RRB- Significant_JJ teratogenic_JJ and/or_CC embryocidal_JJ effects_NNS have_VBP been_VBN demonstrated_VBN in_IN all_DT animal_JJ species_NNS exposed_VBN to_TO ribavirin_NNP ._. COPEGUS_NN therapy_NN is_VBZ contraindicated_VBN in_IN women_NNS who_WP are_VBP pregnant_JJ and_CC in_IN the_DT male_JJ partners_NNS of_IN women_NNS who_WP are_VBP pregnant_JJ ._. If_IN pregnancy_NN occurs_VBZ in_IN a_DT patient_NN or_CC partner_NN of_IN a_DT patient_NN during_IN treatment_NN or_CC during_IN the_DT 6_CD months_NNS after_IN treatment_NN cessation_NN ,_, such_JJ cases_NNS should_MD be_VB reported_VBN to_TO the_DT COPEGUS_NNP Pregnancy_NNP Registry_NNP at_IN 1-800-526-6367_CD ._. Nursing_NNP Mothers_NNP It_PRP is_VBZ not_RB known_VBN whether_IN peginterferon_NN or_CC ribavirin_NNP or_CC its_PRP$ components_NNS are_VBP excreted_VBN in_IN human_JJ milk_NN ._. The_DT effect_NN of_IN orally_RB ingested_VBN peginterferon_NN or_CC ribavirin_NNP from_IN breast_NN milk_NN on_IN the_DT nursing_NN infant_NN has_VBZ not_RB been_VBN evaluated_VBN ._. Because_IN of_IN the_DT potential_NN for_IN adverse_JJ reactions_NNS from_IN the_DT drugs_NNS in_IN nursing_NN infants_NNS ,_, a_DT decision_NN must_MD be_VB made_VBN whether_IN to_TO discontinue_VB nursing_NN or_CC discontinue_VB PEGASYS_NN and_CC COPEGUS_NN treatment_NN ._. Pediatric_NNP Use_NNP The_NNP safety_NN and_CC effectiveness_NN of_IN PEGASYS_NNP ,_, alone_RB or_CC in_IN combination_NN with_IN COPEGUS_NNS in_IN patients_NNS below_IN the_DT age_NN of_IN 18_CD years_NNS have_VBP not_RB been_VBN established_VBN ._. PEGASYS_NN contains_VBZ benzyl_NN alcohol_NN ._. Benzyl_NNP alcohol_NN has_VBZ been_VBN reported_VBN to_TO be_VB associated_VBN with_IN an_DT increased_VBN incidence_NN of_IN neurological_JJ and_CC other_JJ complications_NNS in_IN neonates_NNS and_CC infants_NNS ,_, which_WDT are_VBP sometimes_RB fatal_JJ ._. Geriatric_NNP Use_NNP Younger_NNP patients_NNS have_VBP higher_JJR virologic_JJ response_NN rates_NNS than_IN older_JJR patients_NNS ._. Clinical_JJ studies_NNS of_IN PEGASYS_NN alone_RB or_CC in_IN combination_NN with_IN COPEGUS_NNS did_VBD not_RB include_VB sufficient_JJ numbers_NNS of_IN subjects_NNS aged_JJ 65_CD or_CC over_IN to_TO determine_VB whether_IN they_PRP respond_VBP differently_RB from_IN younger_JJR subjects_NNS ._. Adverse_JJ reactions_NNS related_VBN to_TO alpha_NN interferons_NNS ,_, such_JJ as_IN CNS_NN ,_, cardiac_JJ ,_, and_CC systemic_JJ -LRB-_-LRB- eg_FW ,_, flu-like_JJ -RRB-_-RRB- effects_NNS may_MD be_VB more_RBR severe_JJ in_IN the_DT elderly_JJ and_CC caution_NN should_MD be_VB exercised_VBN in_IN the_DT use_NN of_IN PEGASYS_NNP in_IN this_DT population_NN ._. PEGASYS_NNP and_CC COPEGUS_NNP are_VBP excreted_VBN by_IN the_DT kidney_NN ,_, and_CC the_DT risk_NN of_IN toxic_JJ reactions_NNS to_TO this_DT therapy_NN may_MD be_VB greater_JJR in_IN patients_NNS with_IN impaired_JJ renal_JJ function_NN ._. Because_IN elderly_JJ patients_NNS are_VBP more_RBR likely_JJ to_TO have_VB decreased_VBN renal_JJ function_NN ,_, care_NN should_MD be_VB taken_VBN in_IN dose_NN selection_NN and_CC it_PRP may_MD be_VB useful_JJ to_TO monitor_VB renal_JJ function_NN ._. PEGASYS_NN should_MD be_VB used_VBN with_IN caution_NN in_IN patients_NNS with_IN creatinine_NN clearance_NN 50_CD mL/min_NN and_CC COPEGUS_NN should_MD not_RB be_VB administered_VBN to_TO patients_NNS with_IN creatinine_NN clearance_NN 50_CD mL/mi_NN ._. Aminoglycosides_NNS :_: The_DT mixing_VBG of_IN piperacillin_NN with_IN an_DT aminoglycoside_NN in_FW vitro_FW can_MD result_VB in_IN substantial_JJ inactivation_NN of_IN the_DT aminoglycoside_NN ._. Vecuronium_NNP :_: When_WRB used_VBN in_IN the_DT perioperative_JJ period_NN ,_, piperacillin_NN has_VBZ been_VBN implicated_VBN in_IN the_DT prolongation_NN of_IN the_DT neuromuscular_JJ blockade_NN of_IN vecuronium_NN ._. Caution_NN is_VBZ indicated_VBN when_WRB piperacillin_NN is_VBZ used_VBN perioperatively_RB ._. In_IN one_CD controlled_JJ clinical_JJ study_NN ,_, the_DT ureidopenicillins_NNS ,_, including_VBG piperacillin_NN ,_, were_VBD reported_VBN to_TO prolong_VB the_DT action_NN of_IN vecuronium_NN ._. Due_JJ to_TO their_PRP$ similar_JJ mechanism_NN of_IN action_NN ,_, it_PRP is_VBZ expected_VBN that_IN the_DT neuromuscular_JJ blockade_NN produced_VBN by_IN any_DT of_IN the_DT non-depolarizing_JJ muscle_NN relaxants_NNS could_MD be_VB prolonged_VBN in_IN the_DT presence_NN of_IN piperacillin_NN ._. Probenecid_NNP :_: The_DT oral_JJ combination_NN of_IN probenecid_NN before_IN intramuscular_JJ injection_NN of_IN PIPRACIL_NN produces_VBZ an_DT increase_NN in_IN piperacillin_NN peak_JJ serum_NN level_NN of_IN about_IN 30_CD %_NN ._. Anticoagulants_NNPS :_: Coagulation_NN parameters_NNS should_MD be_VB tested_VBN more_RBR frequently_RB and_CC monitored_VBD regularly_RB during_IN simultaneous_JJ administration_NN of_IN high_JJ doses_NNS of_IN heparin_NN ,_, oral_JJ anticoagulants_NNS ,_, or_CC other_JJ drugs_NNS that_WDT may_MD affect_VB the_DT blood_NN coagulation_NN system_NN or_CC the_DT thrombocyte_NN function_NN ._. Methotrexate_NNP :_: Piperacillin_NNP sodium_NN may_MD reduce_VB the_DT excretion_NN of_IN methotrexate_NN ._. Therefore_RB ,_, serum_NN levels_NNS of_IN methotrexate_NN should_MD be_VB monitored_VBN in_IN patients_NNS to_TO avoid_VB drug_NN toxicity_NN ._. Drug/Laboratory_JJ Test_NN Interactions_NNS As_IN with_IN other_JJ penicillins_NNS ,_, the_DT administration_NN of_IN PIPRACIL_NN may_MD result_VB in_IN a_DT false-positive_JJ reaction_NN for_IN glucose_NN in_IN the_DT urine_NN using_VBG a_DT copper-reduction_NN method_NN ._. It_PRP is_VBZ recommended_VBN that_IN glucose_NN tests_NNS based_VBN on_IN enzymatic_JJ glucose_NN oxidase_NN reactions_NNS be_VB used_VBN ._. There_EX have_VBP been_VBN reports_NNS of_IN positive_JJ test_NN results_NNS using_VBG the_DT Bio-Rad_NNP Laboratories_NNPS Platelia_NNP Aspergillus_NNPS EIA_NN test_NN in_IN patients_NNS receiving_VBG piperacillin/tazobactam_NN injection_NN who_WP were_VBD subsequently_RB found_VBN to_TO be_VB free_JJ of_IN Aspergillus_JJ infection_NN ._. Cross-reactions_NNS with_IN non-Aspergillus_JJ polysaccharides_NNS and_CC polyfuranoses_NNS with_IN the_DT Bio-Rad_NNP Laboratories_NNPS Platelia_NNP Aspergillus_NNPS EIA_NN test_NN have_VBP been_VBN reported_VBN ._. Therefore_RB ,_, positive_JJ test_NN results_VBZ in_IN patients_NNS receiving_VBG piperacillin_NN should_MD be_VB interpreted_VBN cautiously_RB and_CC confirmed_VBN by_IN other_JJ diagnostic_JJ methods_NNS ._. Phenothiazines_NNS -_: Taking_VBG piperazine_NN and_CC a_DT phenothiazine_NN together_RB may_MD increase_VB the_DT risk_NN of_IN convulsions_NNS -LRB-_-LRB- seizures_NNS -RRB-_-RRB- ._. Pyrantel_NN -LRB-_-LRB- e.g._FW ,_, Antiminth_NNP -RRB-_-RRB- -_: Taking_VBG piperazine_NN and_CC pyrantel_NN together_RB may_MD decrease_VB the_DT effects_NNS of_IN piperazine_NN ._. ACE_NN inhibitors_NNS :_: Reports_NNS suggest_VBP that_IN NSAIDs_NNS may_MD diminish_VB the_DT antihypertensive_JJ effect_NN of_IN Angiotensin_NN Converting_VBG Enzyme_NN -LRB-_-LRB- ACE_NN -RRB-_-RRB- inhibitors_NNS ._. In_IN patients_NNS with_IN mild_JJ to_TO moderate_JJ hypertension_NN ,_, administration_NN of_IN 25_CD mg_NN daily_NN of_IN VIOXX_NN with_IN the_DT ACE_NN inhibitor_NN benazepril_NN ,_, 10_CD to_TO 40_CD mg_NN for_IN 4_CD weeks_NNS ,_, was_VBD associated_VBN with_IN an_DT average_JJ increase_NN in_IN mean_JJ arterial_JJ pressure_NN of_IN about_IN 3_CD mm_NN Hg_NN compared_VBN to_TO ACE_NN inhibitor_NN alone_RB ._. This_DT interaction_NN should_MD be_VB given_VBN consideration_NN in_IN patients_NNS taking_VBG VIOXX_NNP concomitantly_RB with_IN ACE_NN inhibitors_NNS ._. Aspirin_NN :_: Concomitant_JJ administration_NN of_IN low-dose_JJ aspirin_NN with_IN VIOXX_NN may_MD result_VB in_IN an_DT increased_VBN rate_NN of_IN GI_NN ulceration_NN or_CC other_JJ complications_NNS ,_, compared_VBN to_TO use_VB of_IN VIOXX_NN alone_RB ._. In_IN a_DT 12-week_JJ endoscopy_NN study_NN conducted_VBN in_IN OA_NN patients_NNS there_EX was_VBD no_DT difference_NN in_IN the_DT cumulative_JJ incidence_NN of_IN endoscopic_JJ gastroduodenal_JJ ulcers_NNS in_IN patients_NNS taking_VBG low-dose_JJ -LRB-_-LRB- 81_CD mg_NN -RRB-_-RRB- enteric_JJ coated_JJ aspirin_NN plus_CC VIOXX_NN 25_CD mg_NN daily_RB ,_, as_IN compared_VBN to_TO those_DT taking_VBG ibuprofen_NN 2400_CD mg_NN daily_JJ alone_RB ._. Patients_NNS taking_VBG low-dose_JJ aspirin_NN plus_CC ibuprofen_NN were_VBD not_RB studied_VBN ._. At_IN steady_JJ state_NN ,_, VIOXX_NNP 50_CD mg_NN once_RB daily_RB had_VBD no_DT effect_NN on_IN the_DT anti-platelet_JJ activity_NN of_IN low-dose_JJ -LRB-_-LRB- 81_CD mg_NN once_RB daily_JJ -RRB-_-RRB- aspirin_NN ,_, as_IN assessed_VBN by_IN ex_FW vivo_FW platelet_NN aggregation_NN and_CC serum_NN TXB2_NN generation_NN in_IN clotting_VBG blood_NN ._. Because_IN of_IN its_PRP$ lack_NN of_IN platelet_NN effects_NNS ,_, VIOXX_NNP is_VBZ not_RB a_DT substitute_NN for_IN aspirin_NN for_IN cardiovascular_JJ prophylaxis_NN ._. Therefore_RB ,_, in_IN patients_NNS taking_VBG VIOXX_NNP ,_, antiplatelet_JJ therapies_NNS should_MD not_RB be_VB discontinued_VBN and_CC should_MD be_VB considered_VBN in_IN patients_NNS with_IN an_DT indication_NN for_IN cardiovascular_JJ prophylaxis_NN ._. Prospective_JJ ,_, long-term_JJ studies_NNS on_IN concomitant_JJ administration_NN of_IN VIOXX_NNP and_CC aspirin_NN have_VBP not_RB been_VBN conducted_VBN ._. Cimetidine_NNP :_: Co-administration_NN with_IN high_JJ doses_NNS of_IN cimetidine_NN -LSB-_-LRB- 800_CD mg_NN twice_RB daily_JJ -RSB-_-RRB- increased_VBD the_DT Cmax_NN of_IN rofecoxib_NN by_IN 21_CD %_NN ,_, the_DT AUC0-120hr_NN by_IN 23_CD %_NN and_CC the_DT t1/2_NN by_IN 15_CD %_NN ._. These_DT small_JJ changes_NNS are_VBP not_RB clinically_RB significant_JJ and_CC no_DT dose_NN adjustment_NN is_VBZ necessary_JJ ._. Digoxin_NNP :_: Rofecoxib_NNP 75_CD mg_NN once_RB daily_RB for_IN 11_CD days_NNS does_VBZ not_RB alter_VB the_DT plasma_NN concentration_NN profile_NN or_CC renal_JJ elimination_NN of_IN digoxin_NN after_IN a_DT single_JJ 0.5_CD mg_NN oral_JJ dose_NN ._. Furosemide_NNP :_: Clinical_JJ studies_NNS ,_, as_RB well_RB as_IN post-marketing_JJ observations_NNS ,_, have_VBP shown_VBN that_IN NSAIDs_NNS can_MD reduce_VB the_DT natriuretic_JJ effect_NN of_IN furosemide_NN and_CC thiazides_NNS in_IN some_DT patients_NNS ._. This_DT response_NN has_VBZ been_VBN attributed_VBN to_TO inhibition_NN of_IN renal_JJ prostaglandin_NN synthesis_NN ._. Ketoconazole_NN :_: Ketoconazole_NN 400_CD mg_NN daily_RB did_VBD not_RB have_VB any_DT clinically_RB important_JJ effect_NN on_IN the_DT pharmacokinetics_NNS of_IN rofecoxib_NN ._. Lithium_NN :_: NSAIDs_NNS have_VBP produced_VBN an_DT elevation_NN of_IN plasma_NN lithium_NN levels_NNS and_CC a_DT reduction_NN in_IN renal_JJ lithium_NN clearance_NN ._. In_IN post-marketing_JJ experience_NN there_EX have_VBP been_VBN reports_NNS of_IN increases_NNS in_IN plasma_NN lithium_NN levels_NNS ._. Thus_RB ,_, when_WRB VIOXX_NNP and_CC lithium_NN are_VBP administered_VBN concurrently_RB ,_, subjects_NNS should_MD be_VB observed_VBN carefully_RB for_IN signs_NNS of_IN lithium_NN toxicity_NN ._. Methotrexate_NNP VIOXX_NNP 12.5_CD ,_, 25_CD ,_, and_CC 50_CD mg_NN ,_, each_DT dose_NN administered_VBN once_RB daily_RB for_IN 7_CD days_NNS ,_, had_VBD no_DT effect_NN on_IN the_DT plasma_NN concentration_NN of_IN methotrexate_NN as_IN measured_VBN by_IN AUC0-24hr_NN in_IN patients_NNS receiving_VBG single_JJ weekly_JJ methotrexate_NN doses_NNS of_IN 7.5_CD to_TO 20_CD mg_NN for_IN rheumatoid_JJ arthritis_NN ._. At_IN higher_JJR than_IN recommended_VBN doses_NNS ,_, VIOXX_NNP 75_CD mg_NN administered_VBN once_RB daily_RB for_IN 10_CD days_NNS increased_VBN plasma_NN concentrations_NNS by_IN 23_CD %_NN as_IN measured_VBN by_IN AUC0-24hr_NN in_IN patients_NNS receiving_VBG methotrexate_NN 7.5_CD to_TO 15_CD mg/week_NN for_IN rheumatoid_JJ arthritis_NN ._. At_IN 24_CD hours_NNS postdose_NN ,_, a_DT similar_JJ proportion_NN of_IN patients_NNS treated_VBN with_IN methotrexate_NN alone_RB -LRB-_-LRB- 94_CD %_NN -RRB-_-RRB- and_CC subsequently_RB treated_VBN with_IN methotrexate_NN co-administered_JJ with_IN 75_CD mg_NN of_IN rofecoxib_NN -LRB-_-LRB- 88_CD %_NN -RRB-_-RRB- had_VBD methotrexate_NN plasma_NN concentrations_NNS below_IN the_DT measurable_JJ limit_NN -LRB-_-LRB- 5_CD ng/mL_NN -RRB-_-RRB- ._. Standard_NNP monitoring_NN of_IN methotrexate-related_JJ toxicity_NN should_MD be_VB continued_VBN if_IN VIOXX_NNP and_CC methotrexate_NN are_VBP administered_VBN concomitantly_RB ._. Oral_JJ Contraceptives_NNS Rofecoxib_NNP did_VBD not_RB have_VB any_DT clinically_RB important_JJ effect_NN on_IN the_DT pharmacokinetics_NNS of_IN ethinyl_NN estradiol_NN and_CC norethindrone_NN ._. Prednisone/prednisolone_NNP :_: Rofecoxib_NNP did_VBD not_RB have_VB any_DT clinically_RB important_JJ effect_NN on_IN the_DT pharmacokinetics_NNS of_IN prednisolone_NN or_CC prednisone_NN ._. Rifampin_NNP :_: Co-administration_NN of_IN VIOXX_NN with_IN rifampin_NN 600_CD mg_NN daily_RB ,_, a_DT potent_JJ inducer_NN of_IN hepatic_JJ metabolism_NN ,_, produced_VBD an_DT approximate_JJ 50_CD %_NN decrease_NN in_IN rofecoxib_NN plasma_NN concentrations_NNS ._. Therefore_RB ,_, a_DT starting_VBG daily_JJ dose_NN of_IN 25_CD mg_NN of_IN VIOXX_NNP should_MD be_VB considered_VBN for_IN the_DT treatment_NN of_IN osteoarthritis_NN when_WRB VIOXX_NNP is_VBZ co-administered_VBN with_IN potent_JJ inducers_NNS of_IN hepatic_JJ metabolism_NN ._. Theophylline_NNP VIOXX_NNP 12.5_CD ,_, 25_CD ,_, and_CC 50_CD mg_NN administered_VBN once_RB daily_RB for_IN 7_CD days_NNS increased_VBN plasma_NN theophylline_NN concentrations_NNS -LRB-_-LRB- AUC_NN -LRB-_-LRB- 0_CD -_: -RRB-_-RRB- -RRB-_-RRB- by_IN 38_CD to_TO 60_CD %_NN in_IN healthy_JJ subjects_NNS administered_VBN a_DT single_JJ 300-mg_JJ dose_NN of_IN theophylline_NN ._. Adequate_JJ monitoring_NN of_IN theophylline_NN plasma_NN concentrations_NNS should_MD be_VB considered_VBN when_WRB therapy_NN with_IN VIOXX_NN is_VBZ initiated_VBN or_CC changed_VBN in_IN patients_NNS receiving_VBG theophylline_NN ._. These_DT data_NNS suggest_VBP that_IN rofecoxib_NN may_MD produce_VB a_DT modest_JJ inhibition_NN of_IN cytochrome_NN P450_NN -LRB-_-LRB- CYP_NN -RRB-_-RRB- 1A2_NN ._. Therefore_RB ,_, there_EX is_VBZ a_DT potential_NN for_IN an_DT interaction_NN with_IN other_JJ drugs_NNS that_WDT are_VBP metabolized_VBN by_IN CYP_NN 1A2_NN -LRB-_-LRB- e.g._FW ,_, amitriptyline_NNP ,_, tacrine_NN ,_, and_CC zileuton_NN -RRB-_-RRB- ._. Warfarin_NNP :_: Anticoagulant_JJ activity_NN should_MD be_VB monitored_VBN ,_, particularly_RB in_IN the_DT first_JJ few_JJ days_NNS after_IN initiating_VBG or_CC changing_VBG VIOXX_NN therapy_NN in_IN patients_NNS receiving_VBG warfarin_NN or_CC similar_JJ agents_NNS ,_, since_IN these_DT patients_NNS are_VBP at_IN an_DT increased_VBN risk_NN of_IN bleeding_VBG complications_NNS ._. In_IN single_JJ and_CC multiple_JJ dose_NN studies_NNS in_IN healthy_JJ subjects_NNS receiving_VBG both_CC warfarin_NN and_CC rofecoxib_NN ,_, prothrombin_NN time_NN -LRB-_-LRB- measured_VBN as_IN INR_NN -RRB-_-RRB- was_VBD increased_VBN by_IN approximately_RB 8_CD %_NN to_TO 11_CD %_NN ._. In_IN post-marketing_JJ experience_NN ,_, bleeding_VBG events_NNS have_VBP been_VBN reported_VBN ,_, predominantly_RB in_IN the_DT elderly_JJ ,_, in_IN association_NN with_IN increases_NNS in_IN prothrombin_NN time_NN in_IN patients_NNS receiving_VBG VIOXX_NNP concurrently_RB with_IN warfarin_NN ._. DRUG_NN INTERACTIONS_NNS ._. Several_JJ drug_NN interaction_NN studies_NNS have_VBP been_VBN completed_VBN with_IN both_CC INVIRASE_NN and_CC FORTOVASE_NN ._. Observations_NNS from_IN drug_NN interaction_NN studies_NNS with_IN FORTOVASE_NN may_MD not_RB be_VB predictive_JJ for_IN INVIRASE_NNP ._. Because_IN ritonavir_NN is_VBZ coadministered_VBN ,_, prescribers_NNS should_MD also_RB refer_VB to_TO the_DT prescribing_VBG information_NN for_IN ritonavir_NN regarding_VBG drug_NN interactions_NNS associated_VBN with_IN this_DT agent_NN ._. The_DT metabolism_NN of_IN saquinavir_NN is_VBZ mediated_VBN by_IN cytochrome_NN P450_NN ,_, with_IN the_DT specific_JJ isoenzyme_NN CYP3A4_NN responsible_JJ for_IN 90_CD %_NN of_IN the_DT hepatic_JJ metabolism_NN ._. Additionally_RB ,_, saquinavir_NN is_VBZ a_DT substrate_NN for_IN P-Glycoprotein_NN -LRB-_-LRB- Pgp_NN -RRB-_-RRB- ._. Therefore_RB ,_, drugs_NNS that_WDT affect_VBP CYP3A4_NN and/or_CC Pgp_NN ,_, may_MD modify_VB the_DT pharmacokinetics_NNS of_IN saquinavir_NN ._. Similarly_RB ,_, saquinavir_NN might_MD also_RB modify_VB the_DT pharmacokinetics_NNS of_IN other_JJ drugs_NNS that_WDT are_VBP substrates_NNS for_IN CYP3A4_NN or_CC Pgp_NN ._. Drugs_NNS that_WDT are_VBP contraindicated_VBN specifically_RB due_JJ to_TO the_DT expected_VBN magnitude_NN of_IN interaction_NN and_CC potential_NN for_IN serious_JJ adverse_JJ events_NNS are_VBP listed_VBN CONTRAINDICATIONS_NNS ._. Additional_JJ drugs_NNS that_WDT are_VBP not_RB recommended_VBN for_IN coadministration_NN with_IN INVIRASE_NN and_CC ritonavir_NN are_VBP included_VBN below_IN ._. These_DT recommendations_NNS are_VBP based_VBN on_IN either_CC drug_NN interaction_NN studies_NNS or_CC predicted_VBN interactions_NNS due_JJ to_TO the_DT expected_VBN magnitude_NN of_IN interaction_NN and_CC potential_NN for_IN serious_JJ events_NNS or_CC loss_NN of_IN efficacy_NN ._. With_IN some_DT agents_NNS ,_, the_DT metabolism_NN may_MD be_VB induced_VBN ,_, resulting_VBG in_IN decreased_VBN concentrations_NNS ._. Drugs_NNS That_WDT Should_MD Not_RB Be_VB Coadministered_JJ With_IN INVIRASE/Ritonavi_NN ._. Drug_NN Class_NN :_: Drug_NNP Name_VB Clinical_JJ Comment_NN ._. Antiarrhythmics_NNS :_: Amiodarone_NNP ,_, bepridil_NN ,_, flecainide_NN ,_, propafenone_NN ,_, quinidine_NN CONTRAINDICATED_NNP due_JJ to_TO potential_JJ for_IN serious_JJ and/or_CC life-threatening_JJ reactions_NNS ._. Antihistamines_NNS :_: astemizole_NN *_NN ,_, terfenadine_NN *_SYM CONTRAINDICATED_NNP due_JJ to_TO potential_JJ for_IN serious_JJ and/or_CC life-threatening_JJ cardiac_JJ arrhythmias_NNS ._. Ergot_NNP Derivatives_NNPS :_: Dihydroergotamine_NN ,_, ergonovine_NN ,_, ergotamine_NN ,_, methylergonovine_NN CONTRAINDICATED_NNP due_JJ to_TO potential_JJ for_IN serious_JJ and_CC life-threatening_JJ reactions_NNS such_JJ as_IN acute_JJ ergot_NN toxicity_NN characterized_VBN by_IN peripheral_JJ vasospasm_NN and_CC ischemia_NN of_IN the_DT extremities_NNS and_CC other_JJ tissues_NNS ._. Antimycobacterial_JJ Agents_NNS :_: rifampin_NN CONTRAINDICATED_NNP since_IN the_DT coadministration_NN of_IN this_DT product_NN with_IN saquinavir_NN in_IN an_DT antiretroviral_JJ regimen_NN reduces_VBZ the_DT plasma_NN concentrations_NNS of_IN saquinavir_NN ._. Garlic_NNP Capsules_NNPS Garlic_NNP capsules_NNS should_MD not_RB be_VB used_VBN while_IN taking_VBG saquinavir_NN -LRB-_-LRB- FORTOVASE_NN -RRB-_-RRB- as_IN the_DT sole_JJ protease_NN inhibitor_NN due_JJ to_TO the_DT risk_NN of_IN decreased_VBN saquinavir_NN plasma_NN concentrations_NNS ._. No_DT data_NNS are_VBP available_JJ for_IN the_DT coadministration_NN of_IN INVIRASE/ritonavir_NN or_CC FORTOVASE/ritonavir_NN and_CC garlic_JJ capsules_NNS ._. GI_NN Motility_NN Agent_NNP :_: cisapride_NN *_SYM CONTRAINDICATED_NNP due_JJ to_TO potential_JJ for_IN serious_JJ and/or_CC life-threatening_JJ reactions_NNS such_JJ as_IN cardiac_JJ arrhythmias_NNS ._. Herbal_NNP Products_NNPS :_: St._NNP John_NNP s_VBZ wort_NN -LRB-_-LRB- hypericum_NN perforatum_NN -RRB-_-RRB- WARNING_NN coadministration_NN may_MD lead_VB to_TO loss_NN of_IN virologic_JJ response_NN and_CC possible_JJ resistance_NN to_TO INVIRASE_NNP or_CC to_TO the_DT class_NN of_IN protease_NN inhibitors_NNS ._. HMG-CoA_NN Reductase_NN Inhibitors_NNS :_: lovastatin_NN ,_, simvastatin_NN WARNING_NNP potential_NN for_IN serious_JJ reactions_NNS such_JJ as_IN risk_NN of_IN myopathy_NN including_VBG rhabdomyolysis_NN ._. Sedatives/Hypnotics_NNS :_: triazolam_NN ,_, midazolam_NN CONTRAINDICATED_NNP due_JJ to_TO potential_JJ for_IN serious_JJ and/or_CC life-threatening_JJ reactions_NNS such_JJ as_IN prolonged_JJ or_CC increased_VBN sedation_NN or_CC respiratory_JJ depression_NN ._. *_SYM No_DT longer_RBR marketed_VBN in_IN the_DT US_NNP ._. Drugs_NNS That_WDT Are_VBP Mainly_RB Metabolized_VBN by_IN CYP3A4_NN ._. Although_IN specific_JJ studies_NNS have_VBP not_RB been_VBN performed_VBN ,_, coadministration_NN with_IN drugs_NNS that_WDT are_VBP mainly_RB metabolized_VBN by_IN CYP3A4_NN -LRB-_-LRB- eg_FW ,_, calcium_NN channel_NN blockers_NNS ,_, dapsone_NN ,_, disopyramide_NN ,_, quinine_NN ,_, amiodarone_NN ,_, quinidine_NN ,_, warfarin_NN ,_, tacrolimus_NN ,_, cyclosporine_NN ,_, ergot_NN derivatives_NNS ,_, pimozide_NN ,_, carbamazepine_NN ,_, fentanyl_NN ,_, alfentanyl_NN ,_, alprazolam_NN ,_, and_CC triazolam_NN -RRB-_-RRB- may_MD have_VB elevated_JJ plasma_NN concentrations_NNS when_WRB coadministered_VBN with_IN saquinavir_NN ._. therefore_RB ,_, these_DT combinations_NNS should_MD be_VB used_VBN with_IN caution_NN ._. Since_IN INVIRASE_NNP is_VBZ coadministered_VBN with_IN ritonavir_NN ,_, the_DT ritonavir_NN label_NN should_MD be_VB reviewed_VBN for_IN additional_JJ drugs_NNS that_WDT should_MD not_RB be_VB coadministered_VBN ._. Inducers_NNS of_IN CYP3A4_NN ._. Coadministration_NN with_IN compounds_NNS that_WDT are_VBP potent_JJ inducers_NNS of_IN CYP3A4_NN -LRB-_-LRB- eg_FW ,_, phenobarbital_JJ ,_, phenytoin_NN ,_, dexamethasone_NN ,_, carbamazepine_NN -RRB-_-RRB- may_MD result_VB in_IN decreased_VBN plasma_NN levels_NNS of_IN saquinavir_NN ._. Sulfacetamide_NN preparations_NNS are_VBP incompatible_JJ with_IN silver_NN preparations_NNS ._. Interations_NNS ._. Sulfapyridine_NN may_MD interact_VB with_IN any_DT of_IN the_DT following_NN :_: -_: Acetaminophen_NN -LRB-_-LRB- e.g._FW ,_, Tylenol_NNP -RRB-_-RRB- -LRB-_-LRB- with_IN long-term_JJ ,_, high-dose_JJ use_NN -RRB-_-RRB- o._SYM -_: Amiodarone_NN -LRB-_-LRB- e.g._FW ,_, Cordarone_NN -RRB-_-RRB- o._SYM -_: Anabolic_JJ steroids_NNS -LRB-_-LRB- nandrolone_NN -LSB-_-LRB- e.g._FW ,_, Anabolin_NNP -RSB-_-RRB- ,_, oxandrolone_NN -LSB-_-LRB- e.g._FW ,_, Anavar_JJ -RSB-_-RRB- ,_, oxymetholone_NN -LSB-_-LRB- e.g._FW ,_, Anadrol_NNP -RSB-_-RRB- ,_, stanozolol_NN -LSB-_-LRB- e.g._FW ,_, Winstrol_NNP -RSB-_-RRB- -RRB-_-RRB- o._SYM -_: Androgens_NNS -LRB-_-LRB- male_JJ hormones_NNS -RRB-_-RRB- o._SYM -_: Antithyroid_JJ agents_NNS -LRB-_-LRB- medicine_NN for_IN overactive_JJ thyroid_NN -RRB-_-RRB- o._SYM -_: Carbamazepine_NN -LRB-_-LRB- e.g._FW ,_, Tegretol_NNP -RRB-_-RRB- o._SYM -_: Carmustine_NN -LRB-_-LRB- e.g._FW ,_, BiCNU_NN -RRB-_-RRB- o._SYM -_: Chloroquine_NN -LRB-_-LRB- e.g._FW ,_, Aralen_NN -RRB-_-RRB- o._SYM -_: Dantrolene_NN -LRB-_-LRB- e.g._FW ,_, Dantrium_NN -RRB-_-RRB- o._SYM -_: Daunorubicin_NN -LRB-_-LRB- e.g._FW ,_, Cerubidine_NN -RRB-_-RRB- o._SYM -_: Disulfiram_NN -LRB-_-LRB- e.g._FW ,_, Antabuse_NN -RRB-_-RRB- o._SYM -_: Divalproex_NN -LRB-_-LRB- e.g._FW ,_, Depakote_NNP -RRB-_-RRB- o._SYM -_: Estrogens_NNS -LRB-_-LRB- female_JJ hormones_NNS -RRB-_-RRB- o._SYM -_: Etretinate_NN -LRB-_-LRB- e.g._FW ,_, Tegison_NN -RRB-_-RRB- o._SYM -_: Gold_NN salts_NNS -LRB-_-LRB- medicine_NN for_IN arthritis_NN -RRB-_-RRB- o._SYM -_: Hydroxychloroquine_NN -LRB-_-LRB- e.g._FW ,_, Plaquenil_NN -RRB-_-RRB- o._SYM -_: Mercaptopurine_NN -LRB-_-LRB- e.g._FW ,_, Purinethol_NN -RRB-_-RRB- o._SYM -_: Naltrexone_NN -LRB-_-LRB- e.g._FW ,_, Trexan_NN -RRB-_-RRB- -LRB-_-LRB- with_IN long-term_JJ ,_, high-dose_JJ use_NN -RRB-_-RRB- o._SYM -_: Oral_JJ contraceptives_NNS -LRB-_-LRB- birth_NN control_NN pills_NNS -RRB-_-RRB- containing_VBG estrogen_NN o._SYM -_: Other_JJ anti-infectives_NNS by_IN mouth_NN or_CC by_IN injection_NN -LRB-_-LRB- medicine_NN for_IN infection_NN -RRB-_-RRB- o._SYM -_: Phenothiazines_NNS -LRB-_-LRB- acetophenazine_NN -LSB-_-LRB- e.g._FW ,_, Tindal_JJ -RSB-_-RRB- ,_, chlorpromazine_NN -LSB-_-LRB- e.g._FW ,_, Thorazine_NN -RSB-_-RRB- ,_, fluphenazine_NN -LSB-_-LRB- e.g._FW ,_, Prolixin_NN -RSB-_-RRB- ,_, mesoridazine_NN -LSB-_-LRB- e.g._FW ,_, Serentil_NN -RSB-_-RRB- ,_, perphenazine_NN -LSB-_-LRB- e.g._FW ,_, Trilafon_NNP -RSB-_-RRB- ,_, prochlorperazine_NN -LSB-_-LRB- e.g._FW ,_, Compazine_NN -RSB-_-RRB- ,_, promazine_NN -LSB-_-LRB- e.g._FW ,_, Sparine_JJ -RSB-_-RRB- ,_, promethazine_NN -LSB-_-LRB- e.g._FW ,_, Phenergan_NN -RSB-_-RRB- ,_, thioridazine_NN -LSB-_-LRB- e.g._FW ,_, Mellaril_NN -RSB-_-RRB- ,_, trifluoperazine_NN -LSB-_-LRB- e.g._FW ,_, Stelazine_NN -RSB-_-RRB- ,_, triflupromazine_NN -LSB-_-LRB- e.g._FW ,_, Vesprin_NN -RSB-_-RRB- ,_, trimeprazine_NN -LSB-_-LRB- e.g._FW ,_, Temaril_NN -RSB-_-RRB- -RRB-_-RRB- o._SYM -_: Plicamycin_NN -LRB-_-LRB- e.g._FW ,_, Mithracin_NN -RRB-_-RRB- o._SYM -_: Valproic_JJ acid_NN -LRB-_-LRB- e.g._FW ,_, Depakene_NN -RRB-_-RRB- Use_NN of_IN sulfapyridine_NN with_IN these_DT medicines_NNS may_MD increase_VB the_DT chance_NN of_IN side_JJ effects_NNS affecting_VBG the_DT live_JJ ._. -_: Acetohydroxamic_JJ acid_NN -LRB-_-LRB- e.g._FW ,_, Lithostat_NN -RRB-_-RRB- o._SYM -_: Dapsone_NN o._SYM -_: Furazolidone_NN -LRB-_-LRB- e.g._FW ,_, Furoxone_NN -RRB-_-RRB- o._SYM -_: Nitrofurantoin_NN -LRB-_-LRB- e.g._FW ,_, Furadantin_NN -RRB-_-RRB- o._SYM -_: Primaquine_NN o._SYM -_: Procainamide_NNP -LRB-_-LRB- e.g._FW ,_, Pronestyl_NNP -RRB-_-RRB- o._SYM -_: Quinidine_NN -LRB-_-LRB- e.g._FW ,_, Quinidex_NNP -RRB-_-RRB- o._SYM -_: Quinine_NN -LRB-_-LRB- e.g._FW ,_, Quinamm_NNP -RRB-_-RRB- o._SYM -_: Sulfoxone_NN -LRB-_-LRB- e.g._FW ,_, Diasone_NN -RRB-_-RRB- o._SYM -_: Vitamin_NN K_NN -LRB-_-LRB- e.g._FW ,_, AquaMEPHYTON_NN ,_, Synkayvite_NN -RRB-_-RRB- Use_NN of_IN sulfapyridine_NN with_IN these_DT medicines_NNS may_MD increase_VB the_DT chance_NN of_IN side_JJ effects_NNS affecting_VBG the_DT bloo_NN ._. -_: Anticoagulants_NNS -LRB-_-LRB- blood_NN thinners_NNS -RRB-_-RRB- o._SYM -_: Ethotoin_NN -LRB-_-LRB- e.g._FW ,_, Peganone_NN -RRB-_-RRB- o._SYM -_: Mephenytoin_NN -LRB-_-LRB- e.g._FW ,_, Mesantoin_NN -RRB-_-RRB- Use_NN of_IN sulfapyridine_NN with_IN these_DT medicines_NNS may_MD increase_VB the_DT chance_NN of_IN side_JJ effects_NNS of_IN these_DT medicine_NN ._. -_: Antidiabetics_NNS ,_, oral_JJ -LRB-_-LRB- diabetes_NN medicine_NN you_PRP take_VBP by_IN mouth_NN -RRB-_-RRB- Use_NN of_IN oral_JJ antidiabetics_NNS with_IN sulfapyridine_NN may_MD increase_VB the_DT chance_NN of_IN side_JJ effects_NNS affecting_VBG the_DT blood_NN and/or_CC the_DT side_JJ effects_NNS or_CC oral_JJ antidiabetic_JJ ._. -_: Methotrexate_NN -LRB-_-LRB- e.g._FW ,_, Mexate_NN -RRB-_-RRB- Use_NN of_IN methotrexate_NN with_IN sulfapyridine_NN may_MD increase_VB the_DT chance_NN of_IN side_JJ effects_NNS affecting_VBG the_DT liver_NN and/or_CC the_DT side_JJ effects_NNS of_IN methotrexat_NN ._. -_: Methyldopa_NN -LRB-_-LRB- e.g._FW ,_, Aldomet_NNP -RRB-_-RRB- Use_NN of_IN methyldopa_NN with_IN sulfapyridine_NN may_MD increase_VB the_DT chance_NN of_IN side_JJ effects_NNS affecting_VBG the_DT liver_NN and/or_CC the_DT bloo_NN ._. -_: Phenytoin_NN -LRB-_-LRB- e.g._FW ,_, Dilantin_NNP -RRB-_-RRB- Use_NN of_IN phenytoin_NN with_IN sulfapyridine_NN may_MD increase_VB the_DT chance_NN of_IN side_JJ effects_NNS affecting_VBG the_DT liver_NN and/or_CC the_DT side_JJ effects_NNS of_IN phenytoi_NN ._. In_IN evaluating_VBG the_DT potential_NN for_IN interactions_NNS among_IN co-administered_JJ antiepilepsy_JJ drugs_NNS -LRB-_-LRB- AEDs_NNS -RRB-_-RRB- ,_, whether_IN or_CC not_RB an_DT AED_NN induces_VBZ or_CC does_VBZ not_RB induce_VB metabolic_JJ enzymes_NNS is_VBZ an_DT important_JJ consideration_NN ._. Phenytoin_NNP ,_, phenobarbital_JJ and_CC carbamazepine_NN are_VBP ge_NN nerally_RB classified_VBN as_IN enzyme_NN inducers_NNS ._. valproate_NN and_CC gabapentin_NN are_VBP not_RB ._. GABITRIL_NNP is_VBZ considered_VBN to_TO be_VB a_DT non-enzyme_JJ inducing_VBG AED_NN ._. The_DT drug_NN interaction_NN data_NNS described_VBN in_IN this_DT section_NN were_VBD obtained_VBN from_IN studies_NNS involving_VBG either_CC healthy_JJ subjects_NNS or_CC patients_NNS with_IN epilepsy_NN ._. Effects_NNS of_IN GABITRIL_NN on_IN other_JJ Antiepilepsy_NNP Drugs_NNS -LRB-_-LRB- AEDs_NNS -RRB-_-RRB- :_: Phenytoin_NNP :_: Tiagabine_NNP had_VBD no_DT effect_NN on_IN the_DT steady-state_JJ plasma_NN concentrations_NNS of_IN phenytoin_NN in_IN patients_NNS with_IN epilepsy_NN ._. Carbamazepine_NNP :_: Tiagabine_NNP had_VBD no_DT effect_NN on_IN the_DT steady-state_JJ plasma_NN concentrations_NNS of_IN carbamazepine_NN or_CC its_PRP$ epoxide_NN metabolite_NN in_IN patients_NNS with_IN epilepsy_NN ._. Valproate_NNP :_: Tiagabine_NNP causes_VBZ a_DT slight_JJ decrease_NN -LRB-_-LRB- about_IN 10_CD %_NN -RRB-_-RRB- in_IN steady-state_JJ valproate_NN concentrations_NNS ._. Phenobarbital_NNP or_CC Primidone_NNP :_: No_NNP formal_JJ pharmacokinetic_JJ studies_NNS have_VBP been_VBN performed_VBN examining_VBG the_DT addition_NN of_IN tiagabine_NN to_TO regimens_NNS containing_VBG phenobarbital_NN or_CC primidone_NN ._. The_DT addition_NN of_IN tiagabine_NN in_IN a_DT limited_JJ number_NN of_IN patients_NNS in_IN three_CD well-controlled_JJ studies_NNS caused_VBD no_DT systematic_JJ changes_NNS in_IN phenobarbital_NN or_CC primidone_NN concentrations_NNS when_WRB compared_VBN to_TO placebo_NN ._. Effects_NNS of_IN other_JJ Antiepilepsy_NNP Drugs_NNS -LRB-_-LRB- AEDs_NNS -RRB-_-RRB- on_IN GABITRIL_NNP :_: Carbamazepine_NNP :_: Population_NNP pharmacokinetic_JJ analyses_NNS indicate_VBP that_IN tiagabine_NN clearance_NN is_VBZ 60_CD %_NN greater_JJR in_IN patients_NNS taking_VBG carbamazepine_NN with_IN or_CC without_IN other_JJ enzyme_NN -_: inducing_VBG AEDs_NNS ._. Phenytoin_NNP :_: Population_NNP pharmacokinetic_JJ analyses_NNS indicate_VBP that_IN tiagabine_NN clearance_NN is_VBZ 60_CD %_NN greater_JJR in_IN patients_NNS taking_VBG phenytoin_NN with_IN or_CC without_IN other_JJ enzyme_NN -_: inducing_VBG AEDs_NNS ._. Phenobarbital_NNP -LRB-_-LRB- Primidone_NNP -RRB-_-RRB- :_: Population_NNP pharmacokinetic_JJ analyses_NNS indicate_VBP that_IN tiagabine_NN clearance_NN is_VBZ 60_CD %_NN greater_JJR in_IN patients_NNS taking_VBG phenobarbital_JJ -LRB-_-LRB- primidone_NN -RRB-_-RRB- with_IN or_CC without_IN other_JJ enzyme-inducing_JJ AEDs_NNS ._. Valproate_NNP :_: The_DT addition_NN of_IN tiagabine_NN to_TO patients_NNS taking_VBG valproate_NN chronically_RB had_VBD no_DT effect_NN on_IN tiagabine_NN pharmacokinetics_NNS ,_, but_CC valproate_NN significantly_RB decreased_VBD tiagabine_NN binding_NN in_FW vitro_FW from_IN 96.3_CD to_TO 94.8_CD %_NN ,_, which_WDT resulted_VBD in_IN an_DT increase_NN of_IN approximately_RB 40_CD %_NN in_IN the_DT free_JJ tiagabine_NN concentration_NN ._. The_DT clinical_JJ relevance_NN of_IN this_DT in_FW vitro_FW finding_NN is_VBZ unknown_JJ ._. Interaction_NN of_IN GABITRIL_NN with_IN Other_JJ Drugs_NNS :_: Cimetidine_NNP :_: Co-administration_NN of_IN cimetidine_NN -LRB-_-LRB- 800_CD mg/day_NN -RRB-_-RRB- to_TO patients_NNS taking_VBG tiagabine_JJ chronically_RB had_VBD no_DT effect_NN on_IN tiagabine_NN pharmacokinetics_NNS ._. Theophylline_NNP :_: A_NNP single_JJ 10_CD mg_NN dose_NN of_IN tiagabine_NN did_VBD not_RB affect_VB the_DT pharmacokinetics_NNS of_IN theophylline_NN at_IN steady_JJ state_NN ._. Warfarin_NNP :_: No_NNP significant_JJ differences_NNS were_VBD observed_VBN in_IN the_DT steady-state_JJ pharmacokinetics_NNS of_IN R-warfarin_NN or_CC S-warfarin_NN with_IN the_DT addition_NN of_IN tiagabine_NN given_VBN as_IN a_DT single_JJ dose_NN ._. Prothrombin_NNP times_NNS were_VBD not_RB affected_VBN by_IN tiagabine_NN ._. Digoxin_NNP :_: Concomitant_JJ administration_NN of_IN tiagabine_NN did_VBD not_RB affect_VB the_DT steady-state_JJ pharmacokinetics_NNS of_IN digoxin_NN or_CC the_DT mean_JJ daily_JJ trough_NN serum_NN level_NN of_IN digoxin_NN ._. Ethanol_NN or_CC Triazolam_NN :_: No_DT significant_JJ differences_NNS were_VBD observed_VBN in_IN the_DT pharmacokinetics_NNS of_IN triazolam_NN -LRB-_-LRB- 0.125_CD mg_NN -RRB-_-RRB- and_CC tiagabine_NN -LRB-_-LRB- 10_CD mg_NN -RRB-_-RRB- when_WRB given_VBN together_RB as_IN a_DT single_JJ dose_NN ._. The_DT pharmacokinetics_NNS of_IN ethanol_NN were_VBD not_RB affected_VBN by_IN multiple-dose_JJ administration_NN of_IN tiagabine_NN ._. Tiagabine_NNP has_VBZ shown_VBN no_DT clinically_RB important_JJ potentiation_NN of_IN the_DT pharmacodynamic_JJ effects_NNS of_IN triazo_NN lam_NN or_CC alcohol_NN ._. Because_IN of_IN the_DT possible_JJ additive_JJ effects_NNS of_IN drugs_NNS that_WDT may_MD depress_VB the_DT nervous_JJ system_NN ,_, ethanol_NN or_CC triazolam_NN should_MD be_VB used_VBN cautiously_RB in_IN combination_NN with_IN tiagabine_NN ._. Oral_JJ Contraceptives_NNS :_: Multiple_JJ dose_NN administration_NN of_IN tiagabine_NN -LRB-_-LRB- 8_CD mg/day_NN monotherapy_NN -RRB-_-RRB- did_VBD not_RB alter_VB the_DT pharmacokinetics_NNS of_IN oral_JJ contraceptives_NNS in_IN healthy_JJ women_NNS of_IN childbearing_JJ age_NN ._. Antipyrine_NNP :_: Antipyrine_NNP pharmacokinetics_NNS were_VBD not_RB significantly_RB different_JJ before_IN and_CC after_IN tiagabine_NN multiple-dose_JJ regimens_NNS ._. This_DT indicates_VBZ that_IN tiagabine_NN does_VBZ not_RB cause_VB induction_NN or_CC inhibition_NN of_IN the_DT hepatic_JJ microsomal_JJ enzyme_NN systems_NNS responsible_JJ for_IN the_DT metabolism_NN of_IN antipyrine_NN ._. Interaction_NN of_IN GABITRIL_NN with_IN Highly_RB Protein_NN Bound_VBN Drugs_NNS :_: In_FW vitro_FW data_NNS showed_VBD that_IN tiagabine_NN is_VBZ 96_CD %_NN bound_VBD to_TO human_JJ plasma_NN protein_NN and_CC therefore_RB has_VBZ the_DT potential_JJ to_TO interact_VB with_IN other_JJ highly_RB protein_NN bound_VBD compounds_NNS ._. Such_PDT an_DT interaction_NN can_MD potentially_RB lead_VB to_TO higher_JJR free_JJ fractions_NNS of_IN either_CC tiagabine_NN or_CC the_DT competing_VBG drug_NN ._. The_DT drug_NN interaction_NN studies_NNS with_IN valdecoxib_NN were_VBD performed_VBN both_CC with_IN valdecoxib_NN and_CC a_DT rapidly_RB hydrolyzed_VBN intravenous_JJ prodrug_NN form_NN ._. The_DT results_NNS from_IN trials_NNS using_VBG the_DT intravenous_JJ prodrug_NN are_VBP reported_VBN in_IN this_DT section_NN as_IN they_PRP relate_VBP to_TO the_DT role_NN of_IN valdecoxib_NN in_IN drug_NN interactions_NNS ._. General_NNP :_: In_IN humans_NNS ,_, valdecoxib_NN metabolism_NN is_VBZ predominantly_RB mediated_VBN via_IN CYP_NN 3A4_NN and_CC 2C9_NN with_IN glucuronidation_NN being_VBG a_DT further_JJ -LRB-_-LRB- 20_CD %_NN -RRB-_-RRB- route_NN of_IN metabolism_NN ._. In_FW vitro_FW studies_NNS indicate_VBP that_IN valdecoxib_NN is_VBZ a_DT moderate_JJ inhibitor_NN of_IN CYP_NN 2C19_NN -LRB-_-LRB- IC50_NN =_JJ 6_CD g/mL_NN or_CC 19_CD M_NN -RRB-_-RRB- and_CC 2C9_NN -LRB-_-LRB- IC50_NN =_JJ 13_CD g/mL_NN or_CC 41_CD M_NN -RRB-_-RRB- ,_, and_CC a_DT weak_JJ inhibitor_NN of_IN CYP_NN 2D6_NN -LRB-_-LRB- IC50_NN =_JJ 31_CD g/mL_NN or_CC 100_CD M_NN -RRB-_-RRB- and_CC 3A4_NN -LRB-_-LRB- IC50_NN =_JJ 44_CD g/mL_NN or_CC 141_CD M_NN -RRB-_-RRB- ._. Aspirin_NN :_: Concomitant_JJ administration_NN of_IN aspirin_NN with_IN valdecoxib_NN may_MD result_VB in_IN an_DT increased_VBN risk_NN of_IN GI_NN ulceration_NN and_CC complications_NNS compared_VBN to_TO valdecoxib_NN alone_RB ._. Because_IN of_IN its_PRP$ lack_NN of_IN anti-platelet_JJ effect_NN valdecoxib_NN is_VBZ not_RB a_DT substitute_NN for_IN aspirin_NN for_IN cardiovascular_JJ prophylaxis_NN ._. In_IN a_DT parallel_JJ group_NN drug_NN interaction_NN study_NN comparing_VBG the_DT intravenous_JJ prodrug_NN form_NN of_IN valdecoxib_NN at_IN 40_CD mg_NN BID_NNP -LRB-_-LRB- n_NN =_JJ 10_CD -RRB-_-RRB- vs_CC placebo_NN -LRB-_-LRB- n_NN =_JJ 9_CD -RRB-_-RRB- ,_, valdecoxib_NN had_VBD no_DT effect_NN on_IN in_FW vitro_FW aspirin-mediated_JJ inhibition_NN of_IN arachidonate_NN -_: or_CC collagen-stimulated_JJ platelet_NN aggregation_NN ._. Methotrexate_NNP :_: Valdecoxib_NNP 10_CD mg_NN BID_NNP did_VBD not_RB show_VB a_DT significant_JJ effect_NN on_IN the_DT plasma_NN exposure_NN or_CC renal_JJ clearance_NN of_IN methotrexate_NN ._. ACE-inhibitors_NNS :_: Reports_NNS suggest_VBP that_IN NSAIDs_NNS may_MD diminish_VB the_DT antihypertensive_JJ effect_NN of_IN ACE-inhibitors_NNS ._. This_DT interaction_NN should_MD be_VB given_VBN consideration_NN in_IN patients_NNS taking_VBG BEXTRA_NNP concomitantly_RB with_IN ACE-inhibitors_NNS ._. Furosemide_NNP :_: Clinical_JJ studies_NNS ,_, as_RB well_RB as_IN post-marketing_JJ observations_NNS ,_, have_VBP shown_VBN that_IN NSAIDs_NNS can_MD reduce_VB the_DT natriuretic_JJ effect_NN of_IN furosemide_NN and_CC thiazides_NNS in_IN some_DT patients_NNS ._. This_DT response_NN has_VBZ been_VBN attributed_VBN to_TO inhibition_NN of_IN renal_JJ prostaglandin_NN synthesis_NN ._. Anticonvulsants_NNS -LRB-_-LRB- Phenytoin_NN -RRB-_-RRB- :_: Steady_JJ state_NN plasma_NN exposure_NN -LRB-_-LRB- AUC_NN -RRB-_-RRB- of_IN valdecoxib_NN -LRB-_-LRB- 40_CD mg_NN BID_NNP for_IN 12_CD days_NNS -RRB-_-RRB- was_VBD decreased_VBN by_IN 27_CD %_NN when_WRB co-administered_VBN with_IN multiple_JJ doses_NNS -LRB-_-LRB- 300_CD mg_NN QD_NN for_IN 12_CD days_NNS -RRB-_-RRB- of_IN phenytoin_NN -LRB-_-LRB- a_DT CYP_NN 3A4_NN inducer_NN -RRB-_-RRB- ._. Patients_NNS already_RB stabilized_VBD on_IN valdecoxib_NN should_MD be_VB closely_RB monitored_VBN for_IN loss_NN of_IN symptom_NN control_NN with_IN phenytoin_NN coadministration_NN ._. Valdecoxib_NNP did_VBD not_RB have_VB a_DT statistically_RB significant_JJ effect_NN on_IN the_DT pharmacokinetics_NNS of_IN phenytoin_NN -LRB-_-LRB- a_DT CYP_NN 2C9_NN and_CC CYP_NN 2C19_NN substrate_NN -RRB-_-RRB- ._. Drug_NN interaction_NN studies_NNS with_IN other_JJ anticonvulsants_NNS have_VBP not_RB been_VBN conducted_VBN ._. Routine_JJ monitoring_NN should_MD be_VB performed_VBN when_WRB therapy_NN with_IN BEXTRA_NN is_VBZ either_CC initiated_VBN or_CC discontinued_VBN in_IN patients_NNS on_IN anticonvulsant_JJ therapy_NN ._. Dextromethorphan_NNP :_: Dextromethorphan_NNP is_VBZ primarily_RB metabolized_VBN by_IN CYP_NN 2D6_NN and_CC to_TO a_DT lesser_JJR extent_NN by_IN 3A4_NN ._. Coadministration_NN with_IN valdecoxib_NN -LRB-_-LRB- 40_CD mg_NN BID_NNP for_IN 7_CD days_NNS -RRB-_-RRB- resulted_VBD in_IN a_DT significant_JJ increase_NN in_IN dextromethorphan_NN plasma_NN levels_NNS suggesting_VBG that_IN ,_, at_IN these_DT doses_NNS ,_, valdecoxib_NN is_VBZ a_DT weak_JJ inhibitor_NN of_IN 2D6_NN ._. Even_RB so_RB dextromethorphan_JJ plasma_NN concentrations_NNS in_IN the_DT presence_NN of_IN high_JJ doses_NNS of_IN valdecoxib_NN were_VBD almost_RB 5-fold_RB lower_JJR than_IN those_DT seen_VBN in_IN CYP_NN 2D6_NN poor_JJ metabolizers_NNS suggesting_VBG that_IN dose_NN adjustment_NN is_VBZ not_RB necessary_JJ ._. Lithium_NN :_: Valdecoxib_NNP 40_CD mg_NN BID_NNP for_IN 7_CD days_NNS produced_VBD significant_JJ decreases_NNS in_IN lithium_NN serum_NN clearance_NN -LRB-_-LRB- 25_CD %_NN -RRB-_-RRB- and_CC renal_JJ clearance_NN -LRB-_-LRB- 30_CD %_NN -RRB-_-RRB- with_IN a_DT 34_CD %_NN higher_JJR serum_NN exposure_NN compared_VBN to_TO lithium_NN alone_RB ._. Lithium_NN serum_NN concentrations_NNS should_MD be_VB monitored_VBN closely_RB when_WRB initiating_VBG or_CC changing_VBG therapy_NN with_IN BEXTRA_NNP in_IN patients_NNS receiving_VBG lithium_NN ._. Lithium_NN carbonate_NN -LRB-_-LRB- 450_CD mg_NN BID_NNP for_IN 7_CD days_NNS -RRB-_-RRB- had_VBD no_DT effect_NN on_IN valdecoxib_NN pharmacokinetics_NNS ._. Warfarin_NNP :_: The_DT effect_NN of_IN valdecoxib_NN on_IN the_DT anticoagulant_JJ effect_NN of_IN warfarin_NN -LRB-_-LRB- 1_CD -_: 8_CD mg/day_NN -RRB-_-RRB- was_VBD studied_VBN in_IN healthy_JJ subjects_NNS by_IN coadministration_NN of_IN BEXTRA_NNP 40_CD mg_NN BID_NNP for_IN 7_CD days_NNS ._. Valdecoxib_NN caused_VBD a_DT statistically_RB significant_JJ increase_NN in_IN plasma_NN exposures_NNS of_IN R-warfarin_NN and_CC S-warfarin_NN -LRB-_-LRB- 12_CD %_NN and_CC 15_CD %_NN ,_, respectively_RB -RRB-_-RRB- ,_, and_CC in_IN the_DT pharmacodynamic_JJ effects_NNS -LRB-_-LRB- prothrombin_NN time_NN ,_, measured_VBN as_IN INR_NN -RRB-_-RRB- of_IN warfarin_NN ._. While_IN mean_NN INR_NN values_NNS were_VBD only_RB slightly_RB increased_VBN with_IN coadministration_NN of_IN valdecoxib_NN ,_, the_DT day-to-day_JJ variability_NN in_IN individual_JJ INR_NN values_NNS was_VBD increased_VBN ._. Anticoagulant_JJ therapy_NN should_MD be_VB monitored_VBN ,_, particularly_RB during_IN the_DT first_JJ few_JJ weeks_NNS ,_, after_IN initiating_VBG therapy_NN with_IN BEXTRA_NNP in_IN patients_NNS receiving_VBG warfarin_NN or_CC similar_JJ agents_NNS ._. Fluconazole_NNP and_CC Ketoconazole_NNP :_: Ketoconazole_NNP and_CC fluconazole_NN are_VBP predominantly_RB CYP_NNP 3A4_NN and_CC 2C9_NN inhibitors_NNS ,_, respectively_RB ._. Concomitant_JJ single_JJ dose_NN administration_NN of_IN valdecoxib_NN 20_CD mg_NN with_IN multiple_JJ doses_NNS of_IN ketoconazole_NN and_CC fluconazole_NN produced_VBD a_DT significant_JJ increase_NN in_IN exposure_NN of_IN valdecoxib_NN ._. Plasma_NN exposure_NN -LRB-_-LRB- AUC_NN -RRB-_-RRB- to_TO valdecoxib_NN was_VBD increased_VBN 62_CD %_NN when_WRB coadministered_VBN with_IN fluconazole_NN and_CC 38_CD %_NN when_WRB coadministered_VBN with_IN ketoconazole_NN ._. Glyburide_NNP :_: Glyburide_NNP is_VBZ a_DT CYP_NN 2C9_NN substrate_NN ._. Coadministration_NN of_IN valdecoxib_NN -LRB-_-LRB- 10_CD mg_NN BID_NNP for_IN 7_CD days_NNS -RRB-_-RRB- with_IN glyburide_NN -LRB-_-LRB- 5_CD mg_NN QD_NN or_CC 10_CD mg_NN BID_NNP -RRB-_-RRB- did_VBD not_RB affect_VB the_DT pharmacokinetics_NNS -LRB-_-LRB- exposure_NN -RRB-_-RRB- of_IN glyburide_NN ._. Coadministration_NN of_IN valdecoxib_NN -LRB-_-LRB- 40_CD mg_NN BID_NNP -LRB-_-LRB- day_NN 1_CD -RRB-_-RRB- and_CC 40_CD mg_NN QD_NN -LRB-_-LRB- days_NNS 2-7_CD -RRB-_-RRB- -RRB-_-RRB- with_IN glyburide_NN -LRB-_-LRB- 5_CD mg_NN QD_NN -RRB-_-RRB- did_VBD not_RB affect_VB either_CC the_DT pharmacokinetics_NNS -LRB-_-LRB- exposure_NN -RRB-_-RRB- or_CC the_DT pharmacodynamics_NNS -LRB-_-LRB- blood_NN glucose_NN and_CC insulin_NN levels_NNS -RRB-_-RRB- of_IN glyburide_NN ._. Coadministration_NN of_IN valdecoxib_NN -LRB-_-LRB- 40_CD mg_NN BID_NNP -LRB-_-LRB- day_NN 1_CD -RRB-_-RRB- and_CC 40_CD mg_NN QD_NN -LRB-_-LRB- days_NNS 2-7_CD -RRB-_-RRB- -RRB-_-RRB- with_IN glyburide_NN -LRB-_-LRB- 10_CD mg_NN glyburide_NN BID_NNP -RRB-_-RRB- resulted_VBD in_IN 21_CD %_NN increase_NN in_IN glyburide_NN AUC0-12_NN and_CC a_DT 16_CD %_NN increase_NN in_IN glyburide_NN Cmax_NN leading_VBG to_TO a_DT 16_CD %_NN decrease_NN in_IN glucose_NN AUC0-24_NN ._. Insulin_NN parameters_NNS were_VBD not_RB affected_VBN ._. Because_IN changes_NNS in_IN glucose_NN concentrations_NNS with_IN valdecoxib_NN coadministration_NN were_VBD within_IN the_DT normal_JJ variability_NN and_CC individual_JJ glucose_NN concentrations_NNS were_VBD above_IN or_CC near_IN 70_CD mg/dL_NN ,_, dose_NN adjustment_NN for_IN glyburide_NN -LRB-_-LRB- 5_CD mg_NN QD_NN and_CC 10_CD mg_NN BID_NNP -RRB-_-RRB- with_IN valdecoxib_NN coadministration_NN -LRB-_-LRB- up_RB to_TO 40_CD mg_NN QD_NN -RRB-_-RRB- is_VBZ not_RB indicated_VBN ._. Coadministration_NN of_IN glyburide_NN with_IN doses_NNS higher_JJR than_IN 40_CD mg_NN valdecoxib_NN -LRB-_-LRB- e.g._FW ,_, 40_CD mg_NN BID_NNP -RRB-_-RRB- have_VBP not_RB been_VBN studied_VBN ._. Omeprazole_NNP :_: Omeprazole_NNP is_VBZ a_DT CYP_NN 3A4_NN substrate_NN and_CC CYP_NN 2C19_NN substrate_NN and_CC inhibitor_NN ._. Valdecoxib_NNP steady_JJ state_NN plasma_NN concentrations_NNS -LRB-_-LRB- 40_CD mg_NN BID_NNP -RRB-_-RRB- were_VBD not_RB affected_VBN significantly_RB with_IN multiple_JJ doses_NNS of_IN omeprazole_NN -LRB-_-LRB- 40_CD mg_NN QD_NN -RRB-_-RRB- ._. Coadministration_NN with_IN valdecoxib_NN increased_VBD exposure_NN of_IN omeprazole_NN -LRB-_-LRB- AUC_NN -RRB-_-RRB- by_IN 46_CD %_NN ._. Drugs_NNS whose_WP$ absorption_NN is_VBZ sensitive_JJ to_TO pH_NN may_MD be_VB negatively_RB impacted_VBN by_IN concomitant_JJ administration_NN of_IN omeprazole_NN and_CC valdecoxib_NN ._. However_RB ,_, because_IN higher_JJR doses_NNS -LRB-_-LRB- up_RB to_TO 360_CD mg_NN QD_NN -RRB-_-RRB- of_IN omeprazole_NN are_VBP tolerated_VBN in_IN Zollinger-Ellison_NN -LRB-_-LRB- ZE_NN -RRB-_-RRB- patients_NNS ,_, no_DT dose_NN adjustment_NN for_IN omeprazole_NN is_VBZ recommended_VBN at_IN current_JJ doses_NNS ._. Coadministration_NN of_IN valdecoxib_NN with_IN doses_NNS higher_JJR than_IN 40_CD mg_NN QD_NN omeprazole_NN has_VBZ not_RB been_VBN studied_VBN ._. Oral_JJ Contraceptives_NNS :_: Valdecoxib_NN -LRB-_-LRB- 40_CD mg_NN BID_NNP -RRB-_-RRB- did_VBD not_RB induce_VB the_DT metabolism_NN of_IN the_DT combination_NN oral_JJ contraceptive_JJ norethindrone/ethinyl_JJ estradiol_NN -LRB-_-LRB- 1_CD mg_NN /_: 35_CD mcg_NN combination_NN ,_, Ortho-Novum_NNP 1/35_CD -RRB-_-RRB- ._. Coadministration_NN of_IN valdecoxib_NN and_CC Ortho-Novum_NNP 1/35_CD increased_VBD the_DT exposure_NN of_IN norethindrone_NN and_CC ethinyl_NN estradiol_NN by_IN 20_CD %_NN and_CC 34_CD %_NN ,_, respectively_RB ._. Although_IN there_EX is_VBZ little_JJ risk_NN for_IN loss_NN of_IN contraceptive_JJ efficacy_NN ,_, the_DT clinical_JJ significance_NN of_IN these_DT increased_VBN exposures_NNS in_IN terms_NNS of_IN safety_NN is_VBZ not_RB known_VBN ._. These_DT increased_VBD exposures_NNS of_IN norethindrone_NN and_CC ethinyl_NN estradiol_NN should_MD be_VB taken_VBN into_IN consideration_NN when_WRB selecting_VBG an_DT oral_JJ contraceptive_NN for_IN women_NNS taking_VBG valdecoxib_NN ._. Diazepam_NN :_: Diazepam_NN -LRB-_-LRB- Valium_NN -RRB-_-RRB- is_VBZ a_DT CYP_NN 3A4_NN and_CC CYP_NN 2C19_NN substrate_NN ._. Plasma_NN exposure_NN of_IN diazepam_NN -LRB-_-LRB- 10_CD mg_NN BID_NNP -RRB-_-RRB- was_VBD increased_VBN by_IN 28_CD %_NN following_VBG administration_NN of_IN valdecoxib_NN -LRB-_-LRB- 40_CD mg_NN BID_NNP -RRB-_-RRB- for_IN 12_CD days_NNS ,_, while_IN plasma_NN exposure_NN of_IN valdecoxib_NN -LRB-_-LRB- 40_CD mg_NN BID_NNP -RRB-_-RRB- was_VBD not_RB substantially_RB increased_VBN following_VBG administration_NN of_IN diazepam_NN -LRB-_-LRB- 10_CD mg_NN BID_NNP -RRB-_-RRB- for_IN 12_CD days_NNS ._. Although_IN the_DT magnitude_NN of_IN changes_NNS in_IN diazepam_NN plasma_NN exposure_NN when_WRB coadministered_VBN with_IN valdecoxib_NN were_VBD not_RB sufficient_JJ to_TO warrant_VB dosage_NN adjustments_NNS ,_, patients_NNS may_MD experience_VB enhanced_VBN sedative_JJ side_JJ effects_NNS caused_VBN by_IN increased_VBN exposure_NN of_IN diazepam_NN under_IN this_DT circumstance_NN ._. Patients_NNS should_MD be_VB cautioned_VBN against_IN engaging_VBG in_IN hazardous_JJ activities_NNS requiring_VBG complete_JJ mental_JJ alertness_NN such_JJ as_IN operating_VBG machinery_NN or_CC driving_VBG a_DT motor_NN vehicle_NN ._. Effect_NN of_IN other_JJ drugs_NNS on_IN Vardenafi_NNP ._. In_FW vitro_FW studies_NNS :_: Studies_NNS in_IN human_JJ liver_NN microsomes_NNS showed_VBD that_IN vardenafil_NN is_VBZ metabolized_VBN primarily_RB by_IN cytochrome_NN P450_NN -LRB-_-LRB- CYP_NN -RRB-_-RRB- isoforms_NNS 3A4/5_NN ,_, and_CC to_TO a_DT lesser_JJR degree_NN by_IN CYP2C9_NN ._. Therefore_RB ,_, inhibitors_NNS of_IN these_DT enzymes_NNS are_VBP expected_VBN to_TO reduce_VB vardenafil_NN clearance_NN ._. In_FW vivo_FW studies_NNS :_: Cytochrome_NN P450_NN Inhibitors_NNS ._. Cimetidine_NN -LRB-_-LRB- 400_CD mg_NN b.i.d._NN -RRB-_-RRB- had_VBD no_DT effect_NN on_IN vardenafil_NN bioavailability_NN -LRB-_-LRB- AUC_NN -RRB-_-RRB- and_CC maximum_NN concentration_NN -LRB-_-LRB- Cmax_NN -RRB-_-RRB- of_IN vardenafil_NN when_WRB co-administered_VBN with_IN 20_CD mg_NN Vardenafil_NNP in_IN healthy_JJ volunteers_NNS ._. Erythromycin_NN -LRB-_-LRB- 500_CD mg_NN t.i.d_NN -RRB-_-RRB- produced_VBD a_DT 4-fold_JJ increase_NN in_IN vardenafil_NN AUC_NN and_CC a_DT 3-fold_JJ increase_NN in_IN Cmax_NNP when_WRB co-administered_VBN with_IN Vardenafil_NNP 5_CD mg_NN in_IN healthy_JJ volunteers_NNS ._. It_PRP is_VBZ recommended_VBN not_RB to_TO exceed_VB a_DT single_JJ 5_CD mg_NN dose_NN of_IN Vardenafil_NNP in_IN a_DT 24-hour_JJ period_NN when_WRB used_VBN in_IN combination_NN with_IN erythromycin_NN ._. Ketoconazole_NN -LRB-_-LRB- 200_CD mg_NN once_RB daily_JJ -RRB-_-RRB- produced_VBD a_DT 10-fold_JJ increase_NN in_IN vardenafil_NN AUC_NN and_CC a_DT 4-fold_JJ increase_NN in_IN Cmax_NNP when_WRB co-administered_VBN with_IN Vardenafil_NNP -LRB-_-LRB- 5_CD mg_NN -RRB-_-RRB- in_IN healthy_JJ volunteers_NNS ._. A_DT 5-mg_JJ Vardenafil_NNP dose_NN should_MD not_RB be_VB exceeded_VBN when_WRB used_VBN in_IN combination_NN with_IN 200_CD mg_NN once_RB daily_JJ ketoconazole_NN ._. Since_IN higher_JJR doses_NNS of_IN ketoconazole_NN -LRB-_-LRB- 400_CD mg_NN daily_JJ -RRB-_-RRB- may_MD result_VB in_IN higher_JJR increases_NNS in_IN Cmax_NN and_CC AUC_NN ,_, a_DT single_JJ 2.5_CD mg_NN dose_NN of_IN Vardenafil_NNP should_MD not_RB be_VB exceeded_VBN in_IN a_DT 24-hour_JJ period_NN when_WRB used_VBN in_IN combination_NN with_IN ketoconazole_NN 400_CD mg_NN daily_RB ._. HIV_NN Protease_NN Inhibitors_NNS :_: Indinavir_NNP -LRB-_-LRB- 800_CD mg_NN t.i.d._NN -RRB-_-RRB- co-administered_JJ with_IN Vardenafil_NNP 10_CD mg_NN resulted_VBD in_IN a_DT 16-fold_JJ increase_NN in_IN vardenafil_NN AUC_NN ,_, a_DT 7-fold_JJ increase_NN in_IN vardenafil_NN Cmax_NN and_CC a_DT 2-fold_JJ increase_NN in_IN vardenafil_NN half-life_NN ._. It_PRP is_VBZ recommended_VBN not_RB to_TO exceed_VB a_DT single_JJ 2.5_CD mg_NN Vardenafil_NNP dose_NN in_IN a_DT 24-hour_JJ period_NN when_WRB used_VBN in_IN combination_NN with_IN indinavir_NN ._. Ritonavir_NNP -LRB-_-LRB- 600_CD mg_NN b.i.d._NN -RRB-_-RRB- co-administered_JJ with_IN Vardenafil_NNP 5_CD mg_NN resulted_VBD in_IN a_DT 49-fold_JJ increase_NN in_IN vardenafil_NN AUC_NN and_CC a_DT 13-fold_RB increase_NN in_IN vardenafil_NN Cmax_NN ._. The_DT interaction_NN is_VBZ a_DT consequence_NN of_IN blocking_VBG hepatic_JJ metabolism_NN of_IN vardenafil_NN by_IN ritonavir_NN ,_, a_DT highly_RB potent_JJ CYP3A4_NN inhibitor_NN ,_, which_WDT also_RB inhibits_VBZ CYP2C9_NN ._. Ritonavir_NNP significantly_RB prolonged_VBD the_DT half-life_NN of_IN vardenafil_NN to_TO 26_CD hours_NNS ._. Consequently_RB ,_, it_PRP is_VBZ recommended_VBN not_RB to_TO exceed_VB a_DT single_JJ 2.5_CD mg_NN Vardenafil_NNP dose_NN in_IN a_DT 72-hour_JJ period_NN when_WRB used_VBN in_IN combination_NN with_IN ritonavir_NN ._. Other_JJ Drug_NN Interactions_NNS :_: No_DT pharmacokinetic_JJ interactions_NNS were_VBD observed_VBN between_IN vardenafil_NN and_CC the_DT following_VBG drugs_NNS :_: glyburide_NN ,_, warfarin_NN ,_, digoxin_NN ,_, Maalox_NNP ,_, and_CC ranitidine_NN ._. In_IN the_DT warfarin_NN study_NN ,_, vardenafil_NN had_VBD no_DT effect_NN on_IN the_DT prothrombin_NN time_NN or_CC other_JJ pharmacodynamic_JJ parameters_NNS ._. Effects_NNS of_IN Vardenafil_NNP on_IN other_JJ drug_NN ._. In_FW vitro_FW studies_NNS :_: Vardenafil_NNP and_CC its_PRP$ metabolites_NNS had_VBD no_DT effect_NN on_IN CYP1A2_NN ,_, 2A6_NN ,_, and_CC 2E1_NN -LRB-_-LRB- Ki_NN 100uM_NN -RRB-_-RRB- ._. Weak_JJ inhibitory_JJ effects_NNS toward_IN other_JJ isoforms_NNS -LRB-_-LRB- CYP2C8_NN ,_, 2C9_NN ,_, 2C19_NN ,_, 2D6_NN ,_, 3A4_NN -RRB-_-RRB- were_VBD found_VBN ,_, but_CC Ki_NN values_NNS were_VBD in_IN excess_NN of_IN plasma_NN concentrations_NNS achieved_VBN following_VBG dosing_NN ._. The_DT most_RBS potent_JJ inhibitory_JJ activity_NN was_VBD observed_VBN for_IN vardenafil_NN metabolite_NN M1_NN ,_, which_WDT had_VBD a_DT Ki_NN of_IN 1.4_CD uM_NN toward_IN CYP3A4_NN ,_, which_WDT is_VBZ about_IN 20_CD times_NNS higher_JJR than_IN the_DT M1_NN Cmax_NN values_NNS after_IN an_DT 80_CD mg_NN Vardenafil_NNP dose_NN ._. In_FW vivo_FW studies_NNS :_: Nitrates_NNS :_: The_DT blood_NN pressure_NN lowering_VBG effects_NNS of_IN sublingual_JJ nitrates_NNS -LRB-_-LRB- 0.4_CD mg_NN -RRB-_-RRB- taken_VBN 1_CD and_CC 4_CD hours_NNS after_IN vardenafil_NN and_CC increases_VBZ in_IN heart_NN rate_NN when_WRB taken_VBN at_IN 1_CD ,_, 4_CD and_CC 8_CD hours_NNS were_VBD potentiated_VBN by_IN a_DT 20_CD mg_NN dose_NN of_IN Vardenafil_NNP in_IN healthy_JJ middle-aged_JJ subjects_NNS ._. These_DT effects_NNS were_VBD not_RB observed_VBN when_WRB Vardenafil_NNP 20_CD mg_NN was_VBD taken_VBN 24_CD hours_NNS before_IN the_DT NTG_NNP ._. Potentiation_NN of_IN the_DT hypotensive_JJ effects_NNS of_IN nitrates_NNS for_IN patients_NNS with_IN ischemic_JJ heart_NN disease_NN has_VBZ not_RB been_VBN evaluated_VBN ,_, and_CC concomitant_JJ use_NN of_IN Vardenafil_NNP and_CC nitrates_NNS is_VBZ contraindicated_VBN ._. Nifedipine_NNP :_: Vardenafil_NNP 20_CD mg_NN ,_, when_WRB co-administered_VBN with_IN slow-release_JJ nifedipine_NN 30_CD mg_NN or_CC 60_CD mg_NN once_RB daily_RB ,_, did_VBD not_RB affect_VB the_DT relative_JJ bioavailability_NN -LRB-_-LRB- AUC_NN -RRB-_-RRB- or_CC maximum_NN concentration_NN -LRB-_-LRB- Cmax_NN -RRB-_-RRB- of_IN nifedipine_NN ,_, a_DT drug_NN that_WDT is_VBZ metabolized_VBN via_IN CYP3A4_NN ._. Nifedipine_NN did_VBD not_RB alter_VB the_DT plasma_NN levels_NNS of_IN Vardenafil_NNP when_WRB taken_VBN in_IN combination_NN ._. In_IN these_DT patients_NNS whose_WP$ hypertension_NN was_VBD controlled_VBN with_IN nifedipine_NN ,_, Vardenafil_NNP 20_CD mg_NN produced_VBD mean_JJ additional_JJ supine_NN systolic/diastolic_JJ blood_NN pressure_NN reductions_NNS of_IN 6/5_CD mm_NN Hg_NN compared_VBN to_TO placebo_NN ._. Alpha-blockers_NNS :_: When_WRB Vardenafil_NNP 10_CD or_CC 20_CD mg_NN was_VBD given_VBN to_TO healthy_JJ volunteers_NNS either_CC simultaneously_RB or_CC 6_CD hours_NNS after_IN a_DT 10_CD mg_NN dose_NN of_IN terazosin_NN ,_, significant_JJ hypotension_NN developed_VBN in_IN a_DT substantial_JJ number_NN of_IN subjects_NNS ._. With_IN simultaneous_JJ dosing_NN of_IN Vardenafil_NNP 10_CD mg_NN and_CC terazosin_NN 10_CD mg_NN ,_, 6_CD of_IN 8_CD subjects_NNS experienced_VBD a_DT standing_NN systolic_JJ blood_NN pressure_NN of_IN less_JJR than_IN 85_CD mm_NN Hg_NN ._. With_IN simultaneous_JJ dosing_NN of_IN Vardenafil_NNP 20_CD mg_NN and_CC terazosin_NN 10_CD mg_NN ,_, 2_CD of_IN 9_CD subjects_NNS experienced_VBD a_DT standing_NN systolic_JJ blood_NN pressure_NN of_IN less_JJR than_IN 85_CD mm_NN Hg_NN ._. When_WRB Vardenafil_NNP dosing_NN was_VBD separated_VBN from_IN terazosin_NN 10_CD mg_NN by_IN 6_CD hours_NNS ,_, 7_CD of_IN 28_CD subjects_NNS who_WP received_VBD 20_CD mg_NN of_IN Vardenafil_NNP experienced_VBD a_DT decrease_NN in_IN standing_VBG systolic_JJ blood_NN pressure_NN below_IN 85_CD mm_NN Hg_NN ._. In_IN a_DT similar_JJ study_NN with_IN tamsulosin_NN in_IN healthy_JJ volunteers_NNS ,_, 1_CD of_IN 24_CD subjects_NNS dosed_JJ with_IN Vardenafil_NNP 20_CD mg_NN and_CC tamsulosin_NN 0.4_CD mg_NN separated_VBN by_IN 6_CD hours_NNS experienced_VBD a_DT standing_NN systolic_JJ blood_NN pressure_NN below_IN 85_CD mm_NN Hg_NN ._. Two_CD of_IN 16_CD subjects_NNS dosed_JJ simultaneously_RB with_IN Vardenafil_NNP 10_CD mg_NN and_CC tamsulosin_NN 0.4_CD mg_NN experienced_VBD a_DT standing_NN systolic_JJ blood_NN pressure_NN below_IN 85_CD mm_NN Hg_NN ._. The_DT administration_NN of_IN lower_JJR doses_NNS of_IN Vardenafil_NN with_IN alpha-blockers_NNS has_VBZ not_RB been_VBN completely_RB evaluated_VBN to_TO determine_VB if_IN they_PRP can_MD be_VB safely_RB administered_VBN together_RB ._. Based_VBN on_IN these_DT data_NNS ,_, Vardenafil_NNP should_MD not_RB be_VB used_VBN in_IN patients_NNS on_IN alpha-blocker_NN therapy_NN ._. Ritonavir_NNP and_CC indinavir_NNP :_: Upon_IN concomitant_JJ administration_NN of_IN 5_CD mg_NN of_IN Vardenafil_NNP with_IN 600_CD mg_NN BID_NNP ritonavir_NN ,_, the_DT Cmax_NNP and_CC AUC_NN of_IN ritonavir_NN were_VBD reduced_VBN by_IN approximately_RB 20_CD %_NN ._. Upon_IN administration_NN of_IN 10_CD mg_NN of_IN Vardenafil_NNP with_IN 800_CD mg_NN TID_NN indinavir_NN ,_, the_DT Cmax_NNP and_CC AUC_NN of_IN indinavir_NN were_VBD reduced_VBN by_IN 40_CD %_NN and_CC 30_CD %_NN ,_, respectively_RB ._. Alcohol_NN :_: Alcohol_NN -LRB-_-LRB- 0.5_CD g/kg_NN body_NN weight_NN :_: approximately_RB 40_CD mL_NN of_IN absolute_JJ alcohol_NN in_IN a_DT 70_CD kg_NN person_NN -RRB-_-RRB- and_CC vardenafil_NN plasma_NN levels_NNS were_VBD not_RB altered_VBN when_WRB dosed_VBN simultaneously_RB ._. Vardenafil_NNP -LRB-_-LRB- 20_CD mg_NN -RRB-_-RRB- did_VBD not_RB potentiate_VB the_DT hypotensive_JJ effects_NNS of_IN alcohol_NN during_IN the_DT 4-hour_JJ observation_NN period_NN in_IN healthy_JJ volunteers_NNS when_WRB administered_VBN with_IN alcohol_NN -LRB-_-LRB- 0.5_CD g/kg_NN body_NN weight_NN -RRB-_-RRB- ._. Aspirin_NN :_: Vardenafil_NNP -LRB-_-LRB- 10_CD mg_NN and_CC 20_CD mg_NN -RRB-_-RRB- did_VBD not_RB potentiate_VB the_DT increase_NN in_IN bleeding_JJ time_NN caused_VBN by_IN aspirin_NN -LRB-_-LRB- two_CD 81_CD mg_NN tablets_NNS -RRB-_-RRB- ._. Other_JJ interactions_NNS :_: Vardenafil_NNP had_VBD no_DT effect_NN on_IN the_DT pharmacodynamics_NNS of_IN glyburide_NN -LRB-_-LRB- glucose_NN and_CC insulin_NN concentrations_NNS -RRB-_-RRB- and_CC warfarin_NN -LRB-_-LRB- prothrombin_NN time_NN or_CC other_JJ pharmacodynamic_JJ parameters_NNS -RRB-_-RRB- ._. Zidovudine_NNP :_: There_EX is_VBZ no_DT significant_JJ pharmacokinetic_JJ interaction_NN between_IN ZDV_NN and_CC zalcitabine_NN which_WDT has_VBZ been_VBN confirmed_VBN clinically_RB ._. Zalcitabine_NNP also_RB has_VBZ no_DT significant_JJ effect_NN on_IN the_DT intracellular_JJ phosphorylation_NN of_IN ZDV_NN ,_, as_IN shown_VBN in_FW vitro_FW in_IN peripheral_JJ blood_NN mononuclear_JJ cells_NNS or_CC in_IN two_CD other_JJ cell_NN lines_NNS -LRB-_-LRB- U937_NN and_CC Molt-4_NN -RRB-_-RRB- ._. In_IN the_DT same_JJ study_NN it_PRP was_VBD shown_VBN that_IN didanosine_NN and_CC stavudine_NN had_VBD no_DT significant_JJ effect_NN on_IN the_DT intracellular_JJ phosphorylation_NN of_IN zalcitabine_NN in_IN peripheral_JJ blood_NN mononuclear_JJ cells_NNS ._. Lamivudine_NNP :_: In_FW vitro_FW studies_NNS in_IN peripheral_JJ blood_NN mononuclear_JJ cells_NNS ,_, U937_NN and_CC Molt-4_NN cells_NNS revealed_VBD that_IN lamivudine_NN significantly_RB inhibited_VBD zalcitabine_NN phosphorylation_NN in_IN a_DT dose_NN dependent_JJ manner_NN ._. Effects_NNS were_VBD already_RB seen_VBN with_IN doses_NNS corresponding_VBG to_TO relevant_JJ plasma_NN levels_NNS in_IN humans_NNS ,_, and_CC the_DT intracellular_JJ phosphorylation_NN of_IN zalcitabine_NN to_TO its_PRP$ three_CD metabolites_NNS -LRB-_-LRB- including_VBG the_DT active_JJ zalcitabine_NN triphosphate_NN metabolite_NN -RRB-_-RRB- was_VBD significantly_RB inhibited_VBN ._. Zalcitabine_NNP inhibited_VBD lamivudine_NN phosphorylation_NN at_IN high_JJ concentration_NN ratios_NNS -LRB-_-LRB- 10_CD and_CC 100_CD -RRB-_-RRB- ._. however_RB ,_, it_PRP is_VBZ considered_VBN to_TO be_VB unlikely_JJ that_IN this_DT decrease_NN of_IN phosphorylated_VBN lamivudine_NN concentration_NN is_VBZ of_IN clinical_JJ significance_NN ,_, as_IN lamivudine_NN is_VBZ a_DT more_RBR efficient_JJ substrate_NN for_IN deoxycytidine_NN kinase_NN than_IN zalcitabine_NN ._. These_DT in_FW vitro_FW studies_NNS suggest_VBP that_IN concomitant_JJ administration_NN of_IN zalcitabine_NN and_CC lamivudine_NN in_IN humans_NNS may_MD result_VB in_IN sub-therapeutic_JJ concentrations_NNS of_IN active_JJ phosphorylated_VBN zalcitabine_NN ,_, which_WDT may_MD lead_VB to_TO a_DT decreased_VBN antiretroviral_JJ effect_NN of_IN zalcitabine_NN ._. It_PRP is_VBZ unknown_JJ how_WRB the_DT effect_NN seen_VBN in_IN these_DT in_FW vitro_FW studies_NNS translates_VBZ into_IN clinical_JJ consequences_NNS ._. Concomitant_JJ use_NN of_IN zalcitabine_NN and_CC lamivudine_NN is_VBZ not_RB recommended_VBN ._. Saquinavir_NNP :_: The_DT combination_NN of_IN HIVID_NNP ,_, saquinavir_NN ,_, and_CC ZDV_NN has_VBZ been_VBN studied_VBN -LRB-_-LRB- as_IN triple_JJ combination_NN -RRB-_-RRB- in_IN adults_NNS ._. Pharmacokinetic_JJ data_NNS suggest_VBP that_IN absorption_NN ,_, metabolism_NN ,_, and_CC elimination_NN of_IN each_DT of_IN these_DT drugs_NNS are_VBP unchanged_JJ when_WRB they_PRP are_VBP used_VBN together_RB ._. Drugs_NNS Associated_VBD With_IN Peripheral_JJ Neuropathy_NN :_: The_DT concomitant_JJ use_NN of_IN HIVID_NN with_IN drugs_NNS that_WDT have_VBP the_DT potential_JJ to_TO cause_VB peripheral_JJ neuropathy_NN should_MD be_VB avoided_VBN where_WRB possible_JJ ._. Drugs_NNS that_WDT have_VBP been_VBN associated_VBN with_IN peripheral_JJ neuropathy_NN include_VBP antiretroviral_JJ nucleoside_NN analogues_NNS ,_, chloramphenicol_NN ,_, cisplatin_NN ,_, dapsone_NN ,_, disulfiram_NN ,_, ethionamide_NN ,_, glutethimide_NN ,_, gold_NN ,_, hydralazine_NN ,_, iodoquinol_NN ,_, isoniazid_NN ,_, metronidazole_NN ,_, nitrofurantoin_NN ,_, phenytoin_NN ,_, ribavirin_NNP ,_, and_CC vincristine_NN ._. Concomitant_JJ use_NN of_IN HIVID_NN with_IN didanosine_NN is_VBZ not_RB recommended_VBN ._. Intravenous_JJ Pentamidine_NN :_: Treatment_NN with_IN HIVID_NN should_MD be_VB interrupted_VBN when_WRB the_DT use_NN of_IN a_DT drug_NN that_WDT has_VBZ the_DT potential_JJ to_TO cause_VB pancreatitis_NN is_VBZ required_VBN ._. Death_NN due_JJ to_TO fulminant_JJ pancreatitis_NN possibly_RB related_JJ to_TO intravenous_JJ pentamidine_NN and_CC HIVID_NN has_VBZ been_VBN reported_VBN ._. If_IN intravenous_JJ pentamidine_NN is_VBZ required_VBN to_TO treat_VB Pneumocystis_NN carinii_NN pneumonia_NN ,_, treatment_NN with_IN HIVID_NN should_MD be_VB interrupted_VBN ._. Amphotericin_NNP ,_, Foscarnet_NNP ,_, and_CC Aminoglycosides_NNS :_: Drugs_NNS such_JJ as_IN amphotericin_NN ,_, foscarnet_NN ,_, and_CC aminoglycosides_NNS may_MD increase_VB the_DT risk_NN of_IN developing_VBG peripheral_JJ neuropathy_NN or_CC other_JJ HIVID-associated_JJ adverse_JJ events_NNS by_IN interfering_VBG with_IN the_DT renal_JJ clearance_NN of_IN zalcitabine_NN -LRB-_-LRB- thereby_RB raising_VBG systemic_JJ exposure_NN -RRB-_-RRB- ._. Patients_NNS who_WP require_VBP the_DT use_NN of_IN one_CD of_IN these_DT drugs_NNS with_IN HIVID_NN should_MD have_VB frequent_JJ clinical_JJ and_CC laboratory_JJ monitoring_NN with_IN dosage_NN adjustment_NN for_IN any_DT significant_JJ change_NN in_IN renal_JJ function_NN ._. Probenecid_NNP or_CC Cimetidine_NNP :_: Concomitant_JJ administration_NN of_IN probenecid_NN or_CC cimetidine_NN decreases_VBZ the_DT elimination_NN of_IN zalcitabine_NN ,_, most_RBS likely_RB by_IN inhibition_NN of_IN renal_JJ tubular_JJ secretion_NN of_IN zalcitabine_NN ._. Patients_NNS receiving_VBG these_DT drugs_NNS in_IN combination_NN with_IN zalcitabine_NN should_MD be_VB monitored_VBN for_IN signs_NNS of_IN toxicity_NN and_CC the_DT dose_NN of_IN zalcitabine_NN reduced_VBN if_IN warranted_VBN ._. Magnesium/Aluminum-containing_JJ Antacid_NNP Products_NNPS :_: Absorption_NN of_IN zalcitabine_NN is_VBZ moderately_RB reduced_VBN -LRB-_-LRB- approximately_RB 25_CD %_NN -RRB-_-RRB- when_WRB coadministered_VBN with_IN magnesium/aluminum-containing_JJ antacid_NN products_NNS ._. The_DT clinical_JJ significance_NN of_IN this_DT reduction_NN is_VBZ not_RB known_VBN ,_, hence_RB zalcitabine_NN is_VBZ not_RB recommended_VBN to_TO be_VB ingested_VBN simultaneously_RB with_IN magnesium/aluminum-containing_JJ antacids_NNS ._. Metoclopramide_NNP :_: Bioavailability_NN is_VBZ mildly_RB reduced_VBN -LRB-_-LRB- approximately_RB 10_CD %_NN -RRB-_-RRB- when_WRB zalcitabine_NN and_CC metoclopramide_NN are_VBP coadministered_VBN ._. Doxorubicin_NN :_: Doxorubicin_NN caused_VBD a_DT decrease_NN in_IN zalcitabine_NN phosphorylation_NN -LRB-_-LRB- 50_CD %_NN inhibition_NN of_IN total_JJ phosphate_NN formation_NN -RRB-_-RRB- in_IN U937/Molt_NN 4_CD cells_NNS ._. Although_IN there_EX may_MD be_VB decreased_VBN zalcitabine_NN activity_NN because_IN of_IN lessened_VBN active_JJ metabolite_NN formation_NN ,_, the_DT clinical_JJ relevance_NN of_IN these_DT in_FW vitro_FW results_NNS are_VBP not_RB known_VBN ._. As_IN with_IN all_DT drugs_NNS ,_, the_DT potential_JJ exists_VBZ for_IN interaction_NN with_IN other_JJ drugs_NNS by_IN a_DT variety_NN of_IN mechanisms_NNS ._. CNS-Active_JJ Drugs_NNS Ethanol_NN :_: Sonata_NNP 10_CD mg_NN potentiated_VBD the_DT CNS-impairing_JJ effects_NNS of_IN ethanol_NN 0.75_CD g/kg_NN on_IN balance_NN testing_NN and_CC reaction_NN time_NN for_IN 1_CD hour_NN after_IN ethanol_NN administration_NN and_CC on_IN the_DT digit_NN symbol_NN substitution_NN test_NN -LRB-_-LRB- DSST_NN -RRB-_-RRB- ,_, symbol_NN copying_NN test_NN ,_, and_CC the_DT variability_NN component_NN of_IN the_DT divided_VBN attention_NN test_NN for_IN 2.5_CD hours_NNS after_IN ethanol_NN administration_NN ._. The_DT potentiation_NN resulted_VBD from_IN a_DT CNS_NN pharmacodynamic_JJ interaction_NN ;_: ._. zaleplon_NN did_VBD not_RB affect_VB the_DT pharmacokinetics_NNS of_IN ethanol_NN ._. Imipramine_NNP :_: Coadministration_NNP of_IN single_JJ doses_NNS of_IN Sonata_NNP 20_CD mg_NN and_CC imipramine_NN 75_CD mg_NN produced_VBD additive_JJ effects_NNS on_IN decreased_VBN alertness_NN and_CC impaired_JJ psychomotor_NN performance_NN for_IN 2_CD to_TO 4_CD hours_NNS after_IN administration_NN ._. The_DT interaction_NN was_VBD pharmacodynamic_JJ with_IN no_DT alteration_NN of_IN the_DT pharmacokinetics_NNS of_IN either_CC drug_NN ._. Paroxetine_NNP :_: Coadministration_NNP of_IN a_DT single_JJ dose_NN of_IN Sonata_NNP 20_CD mg_NN and_CC paroxetine_NN 20_CD mg_NN daily_RB for_IN 7_CD days_NNS did_VBD not_RB produce_VB any_DT interaction_NN on_IN psychomotor_NN performance_NN ._. Additionally_RB ,_, paroxetine_NN did_VBD not_RB alter_VB the_DT pharmacokinetics_NNS of_IN Sonata_NNP ,_, reflecting_VBG the_DT absence_NN of_IN a_DT role_NN of_IN CYP2D6_NN in_IN zaleplon_NN s_NNS metabolism_NN ._. Thioridazine_NNP :_: Coadministration_NNP of_IN single_JJ doses_NNS of_IN Sonata_NNP 20_CD mg_NN and_CC thioridazine_NN 50_CD mg_NN produced_VBD additive_JJ effects_NNS on_IN decreased_VBN alertness_NN and_CC impaired_JJ psychomotor_NN performance_NN for_IN 2_CD to_TO 4_CD hours_NNS after_IN administration_NN ._. The_DT interaction_NN was_VBD pharmacodynamic_JJ with_IN no_DT alteration_NN of_IN the_DT pharmacokinetics_NNS of_IN either_CC drug_NN ._. Venlafaxine_NNP :_: Coadministration_NNP of_IN a_DT single_JJ dose_NN of_IN zaleplon_NN 10_CD mg_NN and_CC multiple_JJ doses_NNS of_IN venlafaxine_NN ER_NN -LRB-_-LRB- extended_JJ release_NN -RRB-_-RRB- 150_CD mg_NN did_VBD not_RB result_VB in_IN any_DT significant_JJ changes_NNS in_IN the_DT pharmacokinetics_NNS of_IN either_CC zaleplon_NN or_CC venlafaxine_NN ._. In_IN addition_NN ,_, there_EX was_VBD no_DT pharmacodynamic_JJ interaction_NN as_IN a_DT result_NN of_IN coadministration_NN of_IN zaleplon_NN and_CC venlafaxine_NN ER_NN ._. Promethazine_NNP :_: Coadministration_NNP of_IN a_DT single_JJ dose_NN of_IN zaleplon_NN and_CC promethazine_NN -LRB-_-LRB- 10_CD and_CC 25_CD mg_NN ,_, respectively_RB -RRB-_-RRB- resulted_VBD in_IN a_DT 15_CD %_NN decrease_NN in_IN maximal_JJ plasma_NN concentrations_NNS of_IN zaleplon_NN ,_, but_CC no_DT change_NN in_IN the_DT area_NN under_IN the_DT plasma_NN concentration-time_NN curve_NN ._. However_RB ,_, the_DT pharmacodynamics_NNS of_IN coadministration_NN of_IN zaleplon_NN and_CC promethazine_NN have_VBP not_RB been_VBN evaluated_VBN ._. Caution_NN should_MD be_VB exercised_VBN when_WRB these_DT 2_CD agents_NNS are_VBP coadministered_VBN ._. Drugs_NNS That_WDT Induce_VBP CYP3A4_NN Rifampin_NNP :_: CYP3A4_NN is_VBZ ordinarily_RB a_DT minor_JJ metabolizing_VBG enzyme_NN of_IN zaleplon_NN ._. Multiple-dose_JJ administration_NN of_IN the_DT potent_JJ CYP3A4_NN inducer_NN rifampin_NN -LRB-_-LRB- 600_CD mg_NN every_DT 24_CD hours_NNS ,_, q24h_NN ,_, for_IN 14_CD days_NNS -RRB-_-RRB- ,_, however_RB ,_, reduced_VBD zaleplon_NN Cmax_NN and_CC AUC_NN by_IN approximately_RB 80_CD %_NN ._. The_DT coadministration_NN of_IN a_DT potent_JJ CYP3A4_NN enzyme_NN inducer_NN ,_, although_IN not_RB posing_VBG a_DT safety_NN concern_NN ,_, thus_RB could_MD lead_VB to_TO ineffectiveness_NN of_IN zaleplon_NN ._. An_DT alternative_JJ non-CYP3A4_NN substrate_NN hypnotic_JJ agent_NN may_MD be_VB considered_VBN in_IN patients_NNS taking_VBG CYP3A4_NN inducers_NNS such_JJ as_IN rifampin_NN ,_, phenytoin_NN ,_, carbamazepine_NN ,_, and_CC phenobarbital_NN ._. Drugs_NNS That_WDT Inhibit_VBP CYP3A4_NN CYP3A4_NN is_VBZ a_DT minor_JJ metabolic_JJ pathway_NN for_IN the_DT elimination_NN of_IN zaleplon_NN because_IN the_DT sum_NN of_IN desethylzaleplon_NN -LRB-_-LRB- formed_VBN via_IN CYP3A4_NN in_FW vitro_FW -RRB-_-RRB- and_CC its_PRP$ metabolites_NNS ,_, 5-oxo-desethylzaleplon_NN and_CC 5-oxo-desethylzaleplon_JJ glucuronide_NN ,_, account_NN for_IN only_RB 9_CD %_NN of_IN the_DT urinary_JJ recovery_NN of_IN a_DT zaleplon_NN dose_NN ._. Coadministration_NN of_IN single_JJ ,_, oral_JJ doses_NNS of_IN zaleplon_NN with_IN erythromycin_NN -LRB-_-LRB- 10_CD mg_NN and_CC 800_CD mg_NN ,_, respectively_RB -RRB-_-RRB- ,_, a_DT strong_JJ ,_, selective_JJ CYP3A4_NN inhibitor_NN produced_VBD a_DT 34_CD %_NN increase_NN in_IN zaleplons_NNS maximal_JJ plasma_NN concentrations_NNS and_CC a_DT 20_CD %_NN increase_NN in_IN the_DT area_NN under_IN the_DT plasma_NN concentration-time_NN curve_NN ._. The_DT magnitude_NN of_IN interaction_NN with_IN multiple_JJ doses_NNS of_IN erythromycin_NN is_VBZ unknown_JJ ._. Other_JJ strong_JJ selective_JJ CYP3A4_NN inhibitors_NNS such_JJ as_IN ketoconazole_NN can_MD also_RB be_VB expected_VBN to_TO increase_VB the_DT exposure_NN of_IN zaleplon_NN ._. A_DT routine_JJ dosage_NN adjustment_NN of_IN zaleplon_NN is_VBZ not_RB considered_VBN necessary_JJ ._. Drugs_NNS That_WDT Inhibit_VBP Aldehyde_NNP Oxidase_NNP The_NNP aldehyde_NN oxidase_NN enzyme_NN system_NN is_VBZ less_RBR well_RB studied_VBN than_IN the_DT cytochrome_NN P450_NN enzyme_NN system_NN ._. Diphenhydramine_NNP :_: Diphenhydramine_NNP is_VBZ reported_VBN to_TO be_VB a_DT weak_JJ inhibitor_NN of_IN aldehyde_NN oxidase_NN in_IN rat_NN liver_NN ,_, but_CC its_PRP$ inhibitory_JJ effects_NNS in_IN human_JJ liver_NN are_VBP not_RB known_VBN ._. There_EX is_VBZ no_DT pharmacokinetic_JJ interaction_NN between_IN zaleplon_NN and_CC diphenhydramine_NN following_VBG the_DT administration_NN of_IN a_DT single_JJ dose_NN -LRB-_-LRB- 10_CD mg_NN and_CC 50_CD mg_NN ,_, respectively_RB -RRB-_-RRB- of_IN each_DT drug_NN ._. However_RB ,_, because_IN both_DT of_IN these_DT compounds_NNS have_VBP CNS_NN effects_NNS ,_, an_DT additive_JJ pharmacodynamic_JJ effect_NN is_VBZ possible_JJ ._. Drugs_NNS That_WDT Inhibit_VBP Both_CC Aldehyde_VBP Oxidase_NN and_CC CYP3A4_NN Cimetidine_NN :_: Cimetidine_NN inhibits_VBZ both_CC aldehyde_NN oxidase_NN -LRB-_-LRB- in_FW vitro_FW -RRB-_-RRB- and_CC CYP3A4_NN -LRB-_-LRB- in_FW vitro_FW and_CC in_FW vivo_FW -RRB-_-RRB- ,_, the_DT primary_JJ and_CC secondary_JJ enzymes_NNS ,_, respectively_RB ,_, responsible_JJ for_IN zaleplon_NN metabolism_NN ._. Concomitant_JJ administration_NN of_IN Sonata_NNP -LRB-_-LRB- 10_CD mg_NN -RRB-_-RRB- and_CC cimetidine_NN -LRB-_-LRB- 800_CD mg_NN -RRB-_-RRB- produced_VBD an_DT 85_CD %_NN increase_NN in_IN the_DT mean_NN Cmax_NN and_CC AUC_NN of_IN zaleplon_NN ._. An_DT initial_JJ dose_NN of_IN 5_CD mg_NN should_MD be_VB given_VBN to_TO patients_NNS who_WP are_VBP concomitantly_RB being_VBG treated_VBN with_IN cimetidine_NN ._. Drugs_NNS Highly_RB Bound_VBN to_TO Plasma_NN Protein_NN Zaleplon_NN is_VBZ not_RB highly_RB bound_VBN to_TO plasma_NN proteins_NNS -LRB-_-LRB- fraction_NN bound_VBN 60_CD %_NN 15_CD %_NN -RRB-_-RRB- ._. therefore_RB ,_, the_DT disposition_NN of_IN zaleplon_NN is_VBZ not_RB expected_VBN to_TO be_VB sensitive_JJ to_TO alterations_NNS in_IN protein_NN binding_NN ._. In_IN addition_NN ,_, administration_NN of_IN Sonata_NNP to_TO a_DT patient_NN taking_VBG another_DT drug_NN that_WDT is_VBZ highly_RB protein_NN bound_VBD should_MD not_RB cause_VB transient_JJ increase_NN in_IN free_JJ concentrations_NNS of_IN the_DT other_JJ drug_NN ._. Drugs_NNS with_IN a_DT Narrow_NNP Therapeutic_JJ Index_NN Digoxin_NN :_: Sonata_NN -LRB-_-LRB- 10_CD mg_NN -RRB-_-RRB- did_VBD not_RB affect_VB the_DT pharmacokinetic_JJ or_CC pharmacodynamic_JJ profile_NN of_IN digoxin_NN -LRB-_-LRB- 0.375_CD mg_NN q24h_NN for_IN 8_CD days_NNS -RRB-_-RRB- ._. Warfarin_NNP :_: Multiple_JJ oral_JJ doses_NNS of_IN Sonata_NN -LRB-_-LRB- 20_CD mg_NN q24h_NN for_IN 13_CD days_NNS -RRB-_-RRB- did_VBD not_RB affect_VB the_DT pharmacokinetics_NNS of_IN warfarin_NN -LRB-_-LRB- R_NN +_CC -RRB-_-RRB- -_: or_CC -LRB-_-LRB- S_NN -_: -RRB-_-RRB- -_: enantiomers_NNS or_CC the_DT pharmacodynamics_NNS -LRB-_-LRB- prothrombin_NN time_NN -RRB-_-RRB- following_VBG a_DT single_JJ 25-mg_JJ oral_JJ dose_NN of_IN warfarin_NN ._. Drugs_NNS That_WDT Alter_VBP Renal_JJ Excretion_NN Ibuprofen_NN :_: Ibuprofen_NN is_VBZ known_VBN to_TO affect_VB renal_JJ function_NN and_CC ,_, consequently_RB ,_, alter_VBP the_DT renal_JJ excretion_NN of_IN other_JJ drugs_NNS ._. There_EX was_VBD no_DT apparent_JJ pharmacokinetic_JJ interaction_NN between_IN zaleplon_NN and_CC ibuprofen_NN following_VBG single_JJ dose_NN administration_NN -LRB-_-LRB- 10_CD mg_NN and_CC 600_CD mg_NN ,_, respectively_RB -RRB-_-RRB- of_IN each_DT drug_NN ._. This_DT was_VBD expected_VBN because_IN zaleplon_NN is_VBZ primarily_RB metabolized_VBN and_CC renal_JJ excretion_NN of_IN unchanged_JJ zaleplon_NN accounts_NNS for_IN less_JJR than_IN 1_CD %_NN of_IN the_DT administered_VBN dose_NN ._. 